include,title,abstract,first_author,year,journal,doi,pubmed_id,authors,pubmed_type,publication_types,mesh,webofscience_id,central_id,openalex_id,title_length,title_word_count,title_sentence_count,abstract_length,abstract_word_count,abstract_sentence_count,language_title,language_abstract
false,irbesartan reduces qt dispersion hypertensive individual,abstract angiotensin type receptor antagonist direct effect autonomic nervous system myocardium hypothesize irbesartan would reduce qt dispersion great degree amlodipine highly selective vasodilator test gather electrocardiographic ecg data multinational multicenter randomize double blind parallel group study compare antihypertensive efficacy irbesartan amlodipine elderly subject mild moderate hypertension subject treat month either drug hydrochlorothiazide atenolol add week blood pressure bp remain uncontrolled ecg obtain randomization month total subject baseline ecg randomize analyze subject complete ecg baseline month treatment baseline characteristic treatment similar apart slight imbalance diastolic bp irbesartan n versus amlodipine n sd versus mm hg p significant difference bp normalization diastolic bp mm hg treatment month irbesartan versus amlodipine versus p find significant reduction qt index irbesartan group qtc dispersion mean millisecond p qtc max millisecond p qtc dispersion correlate change bp reduction qt index amlodipine qtc dispersion millisecond p qtc max millisecond p quite reach statistical significance correlation change qt index change systolic bp conclusion irbesartan improve qt dispersion effect may important prevent sudden cardiac death risk hypertensive subject,Lim PO,1999,Hypertension,https://doi.org/10.1161/01.hyp.33.2.713,10024334,Lim PO; Nys M; Naas AA; Struthers AD; Osbakken M; MacDonald TM,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D017311: Amlodipine; D057911: Angiotensin Receptor Antagonists; D000959: Antihypertensive Agents; D001713: Biphenyl Compounds; D004311: Double-Blind Method; D004562: Electrocardiography; D005260: Female; D006321: Heart; D006801: Humans; D006973: Hypertension; D000077405: Irbesartan; D008297: Male; D011945: Receptors, Angiotensin; D013777: Tetrazoles",,,https://openalex.org/W1972485283,60,7,1,1939,362,13,en,en
false,preterm labor,preterm labor lead cause perinatal morbidity mortality united state characterize cervical effacement dilatation increase uterine irritability week gestation woman history preterm labor great risk strategy reduce incidence preterm labor delivery focus educate physician patient risk preterm labor method detect preterm cervical dilatation method use predict preterm labor include weekly cervical assessment transvaginal ultrasonography detection fetal fibronectin home uterine activity monitoring yet unclear strategy routinely employ present management preterm labor may include use tocolytic agent corticosteroid antibiotic,Weismiller DG,1999,Am Fam Physician,,10029786,Weismiller DG,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review","D005260: Female; D006801: Humans; D007752: Obstetric Labor, Premature; D011247: Pregnancy; D012306: Risk; D012307: Risk Factors; D015149: Tocolytic Agents; D016216: Ultrasonography, Prenatal",,,https://openalex.org/W4299600072,14,3,1,856,137,7,en,en
false,effect angiotensin converting enzyme inhibition compare conventional therapy cardiovascular morbidity mortality hypertension captopril prevention project cappp randomise trial,angiotensin converting enzyme ace inhibitor use decade treat high blood pressure despite lack data randomise intervention trial show treatment affect cardiovascular morbidity mortality captopril prevention project cappp randomised intervention trial compare effect ace inhibition conventional therapy cardiovascular morbidity mortality patient hypertension cappp prospective randomise open trial blinded endpoint evaluation patient enrol health centre sweden finland patient age year measure diastolic blood pressure mm hg two occasion randomly assign captopril conventional antihypertensive treatment diuretic beta blockers analysis intention treat primary endpoint composite fatal non fatal myocardial infarction stroke cardiovascular deaths patient assign captopril assign conventional therapy respectively lose follow primary endpoint event occur patient captopril group per patient years conventional treatment group per patient years relative risk ci p cardiovascular mortality low captopril conventional treatment vs event relative risk p rate fatal non fatal myocardial infarction similar vs fatal non fatal stroke common captopril vs p captopril conventional treatment differ efficacy prevent cardiovascular morbidity mortality difference stroke risk probably due low level blood pressure obtain initially previously treat patient randomise conventional therapy,Hansson L,1999,Lancet,https://doi.org/10.1016/s0140-6736(98)05012-0,10030325,Hansson L; Lindholm LH; Niskanen L; Lanke J; Hedner T; Niklason A; Luomanmäki K; Dahlöf B; de Faire U; Mörlin C; Karlberg BE; Wester PO; Björck JE,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002216: Captopril; D002423: Cause of Death; D002561: Cerebrovascular Disorders; D016001: Confidence Intervals; D004232: Diuretics; D005260: Female; D005500: Follow-Up Studies; D006331: Heart Diseases; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D011446: Prospective Studies; D012307: Risk Factors; D015996: Survival Rate,,,https://openalex.org/W2102979143,202,25,1,1952,322,10,en,en
false,prevalence gingival overgrowth induce calcium channel blocker community based study,background prevalence gingival overgrowth induce chronic medication calcium channel blocker uncertain although several study examine question result conflict previous estimate range study examine prevalence overgrowth induce diltiazem amlodipine estimate respectively method current study aim address problem associate study examine sample patient take one calcium channel blocker draw community based population northeastern england nine hundred eleven subject recruit general medical practice area take nifedipine amlodipine diltiazem addition control subject examine drug demographic data subject record periodontal condition subject assess include plaque index papillary bleeding index photograph anterior gingiva subsequent analysis overgrowth severity result six percent subject take nifedipine see significant overgrowth overgrowth statistically great amount overgrowth see either drug group control population prevalence gingival overgrowth induce amlodipine diltiazem statistically significant compare control group severity overgrowth within nifedipine group find relate amount gingival inflammation also gender subject male time likely develop overgrowth female conclusion prevalence clinically significant overgrowth relate chronic medication calcium channel blocker low e nifedipine male time likely female develop clinically significant overgrowth presence gingival inflammation important cofactor expression effect j periodontol,Ellis JS,1999,J Periodontol,https://doi.org/10.1902/jop.1999.70.1.63,10052772,Ellis JS; Seymour RA; Steele JG; Robertson P; Butler TJ; Thomason JM,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D000704: Analysis of Variance; D002121: Calcium Channel Blockers; D003774: Dental Plaque Index; D004110: Diltiazem; D004305: Dose-Response Relationship, Drug; D004739: England; D005260: Female; D005885: Gingival Hyperplasia; D005891: Gingivitis; D006801: Humans; D016015: Logistic Models; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D010512: Periodontal Index; D015995: Prevalence; D012744: Sex Ratio; D013997: Time Factors",,,https://openalex.org/W2017797465,94,13,1,2122,363,17,en,en
false,effect calcium channel blockade old patient diabetes systolic hypertension,recent report suggest calcium channel blocker may harmful patient diabetes hypertension previously report antihypertensive treatment calcium channel blocker nitrendipine reduce risk cardiovascular event post hoc analysis compare outcome treatment nitrendipine diabetic nondiabetic patients stratification accord center sex presence absence previous cardiovascular complication patient age year systolic blood pressure mm hg diastolic pressure mm hg randomly assign receive active treatment placebo active treatment consist nitrendipine mg per day possible addition substitution enalapril mg per day hydrochlorothiazide mg per day titrate reduce systolic blood pressure least mm hg less mm hg control group match placebo tablet administer similarly randomization patient percent diabetes median follow two year systolic diastolic blood pressure placebo active treatment group differ mm hg respectively among diabetic patient among patient without diabetes systolic diastolic pressure differ mm hg respectively two group adjustment possible confounders active treatment find reduce overall mortality percent death per patient death per patient mortality cardiovascular disease percent cardiovascular event combine percent fatal nonfatal stroke percent cardiac event combine percent group patient diabetes among nondiabetic patient active treatment decrease cardiovascular event combine percent fatal nonfatal stroke percent group patient receive active treatment reduction overall mortality mortality cardiovascular disease cardiovascular event significantly large among diabetic patient among nondiabetic patient p p p respectively nitrendipine based antihypertensive therapy particularly beneficial old patient diabetes isolated systolic hypertension thus finding support hypothesis use long acting calcium channel blocker may harmful diabetic patient,Tuomilehto J,1999,N Engl J Med,https://doi.org/10.1056/nejm199903043400902,10053176,Tuomilehto J; Rastenyte D; Birkenhäger WH; Thijs L; Antikainen R; Bulpitt CJ; Fletcher AE; Forette F; Goldhaber A; Palatini P; Sarti C; Fagard R,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D002318: Cardiovascular Diseases; D048909: Diabetes Complications; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009026: Mortality; D009568: Nitrendipine; D016016: Proportional Hazards Models; D013599: Systole",,,https://openalex.org/W1999904792,93,12,1,2581,433,11,en,en
false,world health organization international society hypertension guideline management hypertension guideline subcommittee,,,1999,J Hypertens,,10067786,,article,"D016431: Guideline; D016428: Journal Article; D017065: Practice Guideline; D013485: Research Support, Non-U.S. Gov't","D000959: Antihypertensive Agents; D001794: Blood Pressure; D006801: Humans; D006973: Hypertension; D007391: International Cooperation; D011788: Quality of Life; D012307: Risk Factors; D012955: Societies, Medical; D016896: Treatment Outcome; D014944: World Health Organization",,,https://openalex.org/W4300047977,140,17,2,0,0,0,en,
false,long acting lacidipine versus short acting nifedipine treatment asymptomatic acute blood pressure increase,compare antihypertensive efficacy safety single administration equipotent dos lacidipine versus nifedipine hypertensive urgency twenty nine asymptomatic essential hypertensive patient nine men woman mean age year baseline diastolic blood pressure dbp mm hg rest min take antihypertensive drug last h randomize single blind fashion receive lacidipine mg lcd patient short acting nifedipine mg nfd patient single dose blood pressure bp heart rate hr take every min first h every h h follow baseline bp value similar two group lcd mm hg vs nfd mm hg p ns drug promote significant reduction systolic blood pressure sbp vs mm hg diastolic blood pressure dbp vs mm hg h however either sbp vs mm hg p dbp vs mm hg p significantly high nfd group h dosing eleven patient lcd group decrease bp baseline value h dose although patient show response nfd group h dose four patient maintain value h one patient treat nfd transient cerebrovascular ischemic attack adverse effect observe lcd group conclude long acting calcium antagonist lacidipine effective short acting nifedipine control bp maintain bp reduction h essential hypertensive patient acute asymptomatic bp increase,Sánchez M,1999,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-199903000-00019,10069685,Sánchez M; Sobrino J; Ribera L; Adrián MJ; Torres M; Coca A,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000959: Antihypertensive Agents; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D003971: Diastole; D004095: Dihydropyridines; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D012016: Reference Values; D016037: Single-Blind Method; D013599: Systole; D016896: Treatment Outcome",,,https://openalex.org/W2315107321,116,14,1,1837,373,9,en,en
false,comparison controlled onset extended release verapamil amlodipine amlodipine plus atenolol exercise performance ambulatory ischemia patient chronic stable angina pectoris,abstract multicenter randomize double blind parallel group placebo lead placebo controlled study compare antianginal anti ischemic effect daily bedtime dosing controlled onset extended release coer verapamil daily morning dosing amlodipine atenolol patient chronic stable angina total patient exercise induced myocardial ischemia evidence coronary artery disease randomize week forced dose titration treatment period coer verapamil mg titrate mg bedtime n amlodipine mg titrate mg day n amlodipine mg titrate mg plus atenolol mg day n placebo n treadmill exercise tolerance testing standard bruce protocol hour ambulatory electrocardiographic holter monitoring perform end placebo lead double blind treatment active treatment significantly improve symptom limited exercise duration time moderate angina p v placebo patient baseline ischemia amlodipine result statistically significant increase total duration ischemic episode compare placebo whereas coer verapamil amlodipine plus atenolol result statistically significant decrease compare placebo amlodipine heart rate onset ischemic episode st product also significantly increase amlodipine p compare either coer amlodipine plus atenolol coer amlodipine alone combination atenolol improve exercise capacity patient angina pectoris coer verapamil monotherapy amlodipine plus atenolol combination therapy effective amlodipine monotherapy decrease ambulatory myocardial ischemia especially hour noon,Frishman WH,1999,Am J Cardiol,https://doi.org/10.1016/s0002-9149(98)00904-7,10073852,Frishman WH; Glasser S; Stone P; Deedwania PC; Johnson M; Fakouhi TD,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D000787: Angina Pectoris; D001262: Atenolol; D002121: Calcium Channel Blockers; D002908: Chronic Disease; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D015716: Electrocardiography, Ambulatory; D005080: Exercise Test; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D016896: Treatment Outcome; D014700: Verapamil",,,https://openalex.org/W1988718127,199,25,1,1914,323,8,en,en
false,correspondence,,Pahor M,1999,Am J Cardiol,https://doi.org/10.1016/s0002-9149(99)00035-1,10080455,Pahor M; Tatti P,article,D016430: Clinical Trial; D016420: Comment; D003160: Comparative Study; D016422: Letter; D016449: Randomized Controlled Trial,"D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D003924: Diabetes Mellitus, Type 2; D004338: Drug Combinations; D004656: Enalapril; D005500: Follow-Up Studies; D017328: Fosinopril; D006331: Heart Diseases; D006801: Humans; D006973: Hypertension; D015737: Nisoldipine; D011446: Prospective Studies; D015203: Reproducibility of Results; D012307: Risk Factors; D016896: Treatment Outcome",,,https://openalex.org/W2463482407,14,1,1,0,0,0,en,
false,diuretic blockers adverse effect year plasma lipid lipoprotein profile men hypertension,concern base report short term adverse effect antihypertensive agent plasma lipid lipoprotein profile plpps complicate therapy hypertension compare long term year effect different antihypertensive drug placebo plpps multicenter randomize double blind parallel group clinical trial u veteran affair medical centers total ambulatory men year old diastolic blood pressure dbps range mm hg take placebo randomize receive placebo antihypertensive drug hydrochlorothiazide atenolol captopril clonidine diltiazem prazosin drug titration patient dbp less mm hg follow year plasma lipid lipoprotein profile determine baseline initial titration year week regimen hydrochlorothiazide increase mg dl mmol l total cholesterol mg dl apolipoprotein b significantly different p decrease mg dl total cholesterol mg dl apob level receive prazosin placebo patient achieve positive dbp control use hydrochlorothiazide responder show adverse change plpps whereas nonresponders exhibit increase triglyceride total cholesterol low density lipoprotein cholesterol level plasma lipid lipoprotein profile change significantly among treatment group year except minor decrease high density lipoprotein level use hydrochlorothiazide clonidine atenolol none antihypertensive drug long term adverse effect plpps therefore may safely prescribe previously report short term adverse effect use hydrochlorothiazide limit nonresponders,Lakshman MR,1999,Arch Intern Med,https://doi.org/10.1001/archinte.159.6.551,10090111,Lakshman MR; Reda DJ; Materson BJ; Cushman WC; Freis ED,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013486: Research Support, U.S. Gov't, Non-P.H.S.","D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D001262: Atenolol; D001786: Blood Glucose; D002216: Captopril; D003000: Clonidine; D004110: Diltiazem; D004232: Diuretics; D004311: Double-Blind Method; D006787: Hospitals, Veterans; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D008055: Lipids; D008074: Lipoproteins; D008297: Male; D008875: Middle Aged; D011188: Potassium; D011224: Prazosin; D013997: Time Factors; D016896: Treatment Outcome; D014481: United States",,,https://openalex.org/W2095656324,128,21,1,1876,305,6,en,en
false,antihypertensive monotherapy nisoldipine cc superior enalapril black patient severe hypertension,single center prospective double blind randomize trial conduct compare efficacy safety calcium channel blocker nisoldipine sustained release coat core formulation cc titrate mg mg daily angiotensin convert enzyme inhibitor enalapril titrate mg daily treatment black south african patient severe hypertension sit diastolic blood pressure dbp mm hg confirm h ambulatory blood pressure monitoring treatment target sit dbp mm hg th week treatment follow month open phase use nisoldipine cc mg daily ninety six patient complete data baseline end double blind open phase include analysis group patient require titration maximal dose double blind medication monotherapy nisoldipine cc enalapril significantly reduce sit h ambulatory blood pressure bp twenty four hour bp nisoldipine cc group decrease mm hg p versus mm hg enalapril group p n profound decrease blood pressure achieve nisoldipine cc accompany significant reduction left ventricular lv mass index observe month treatment g p contrast enalapril effect lv mass g p n antihypertensive effect nisoldipine cc far demonstrate open phase h bp decrease mm hg baseline mm hg end week open phase p effect sustain trough peak ratio systolic diastolic bp regression lv mass reduction h systolic bp mm hg associate great degree regression lv mass index patient treat nisoldipine cc incidence adverse event group low nisoldipine cc enalapril well tolerate incidence significant ventricular arrhythmia also low change treatment conclusion finding suggest nisoldipine cc administer daily could consider suitable first line antihypertensive agent black patient severe hypertension base profound sustain blood pressure lowering effect associate significant regression left ventricular mass low side effect profile,Radevski I,1999,Am J Hypertens,https://doi.org/10.1016/s0895-7061(98)00233-7,10090348,Radevski I; Skudicky D; Candy G; Sathekge S; Strugo V; Sareli P,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000806: Angiotensin-Converting Enzyme Inhibitors; D044383: Black People; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D015150: Echocardiography, Doppler; D015716: Electrocardiography, Ambulatory; D004656: Enalapril; D005260: Female; D005500: Follow-Up Studies; D006339: Heart Rate; D006352: Heart Ventricles; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D015737: Nisoldipine; D011446: Prospective Studies; D012720: Severity of Illness Index; D013019: South Africa; D013318: Stroke Volume; D016896: Treatment Outcome",,,https://openalex.org/W2105973668,116,15,1,2688,491,15,en,en
false,additional efficacy nifedipine diuretic combination depend potency drug administer first sequence administration double blind study salt sensitive black hypertensive,evaluate whether additional antihypertensive efficacy nifedipine thiazide combination depend sequence drug administration whether natriuretic effect thiazide persists co administered nifedipine double blind randomise crossover placebo controlled study salt sensitive hypertensive black patient ssh evaluation antihypertensive h ambulatory monitoring natriuretic effect placebo pl nifedipine gits nif mg hydrochlorothiazide hctz mg give alone combination within two separate therapeutic sequence pl nif nif hctz pl hctz hctz nif month therapeutic regimen nif induce great p reduction h mean arterial pressure map mm hg v pl hctz mm hg association nif hctz induce great p additional reduction map h mm hg produce association hctz nif mm hg nif alone combination modify diuresis natriuresis observe previous treatment whereas hctz alone combination always increase diuresis natriuresis significant negative correlation r p blood pressure bp reduction induce drug administer first nif hctz additional bp reduction obtain association second drug ssh nif gits potent hctz nif modify diuretic natriuretic effect pl hctz great potency nif may explain patient combination hctz nif induce low hypotensive effect association nif hctz independently sequence drug administration low hypotensive effect drug administer first great additional hypotensive effect observe add second drug,Damasceno A,1999,Rev Port Cardiol,,10091520,Damasceno A; Caupers P; Rafik A; Santos A; Polónia J,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000959: Antihypertensive Agents; D044383: Black People; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D004232: Diuretics; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D012965: Sodium Chloride; D049993: Sodium Chloride Symporter Inhibitors",,,https://openalex.org/W1934807845,218,34,2,1981,379,8,en,en
false,clinical neurohormonal effect nicardipine hydrochloride patient severe chronic heart failure receive angiotensin converting enzyme inhibitor therapy,propose worsen heart failure dihydropyridines nicardipine relate activation neuroendocrine system test evaluate patient severe heart failure mean age year new york heart association functional class iii leave ventricular ejection fraction maintenance therapy captopril digoxin diuretic randomize nicardipine mg placebo month double blind protocol following measurement obtain baseline monthly month last follow visit rest exercise radionuclide ventriculography maximal treadmill time minute walk test distance serum norepinephrine aldosterone concentration plasma renin activity follow period worsen heart failure occur patient nicardipine group patient placebo group p maximal treadmill time minute walking distance exercise radionuclide ejection fraction last follow visit change patient deteriorate heart failure placebo nicardipine group compare baseline value study group patient severe heart failure receive therapy digoxin captopril diuretic nicardipine associate worsen heart failure without apparent activation neurohormone however small number patient significant number patient deteriorate follow period definitive conclusion make,Benatar D,1998,Am J Ther,https://doi.org/10.1097/00045391-199801000-00005,10099034,Benatar D; Hall V; Reddy S; Gheorghiade M,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D000450: Aldosterone; D000806: Angiotensin-Converting Enzyme Inhibitors; D002121: Calcium Channel Blockers; D002216: Captopril; D002316: Cardiotonic Agents; D004077: Digoxin; D018450: Disease Progression; D004232: Diuretics; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005080: Exercise Test; D005260: Female; D006333: Heart Failure; D006801: Humans; D008297: Male; D008875: Middle Aged; D009490: Neurosecretory Systems; D009529: Nicardipine; D009638: Norepinephrine; D012083: Renin; D012720: Severity of Illness Index; D013318: Stroke Volume; D016896: Treatment Outcome",,,https://openalex.org/W1973228555,167,19,1,1621,278,7,en,en
false,low dose combination treatment hypertension versus single drug treatmentbisoprolol hydrochlorothiazide versus amlodipine enalapril placebo,assess efficacy safety mg bisoprolol mg hydrochlorothiazide hctz mg amlodipine mg enalapril subject n sit diastolic blood pressure mm hg data two comparative study pool drug titrate diastolic blood pressure mm hg less study double blind randomize parallel dose escalation trial similar design include three active treatment second study also placebo group mean change baseline systolic diastolic blood pressure placebo n mm hg amlodipine n mm hg enalapril n mm hg bisoprolol hctz n overall efficacy analysis document statistically significant decrease sit diastolic blood pressure bisoprolol mg hctz compare placebo amlodipine enalapril significant reduction sit systolic blood pressure bisoprolol mg hctz compare placebo enalapril amlodipine also significant decrease sit heart rate bisoprolol mg hctz beats min compare placebo beats min amlodipine beats min enalapril beats min control rate diastolic blood pressure mm hg bisoprolol mg hctz significantly good placebo enalapril amlodipine patient achieve maintain control bisoprolol mg hctz subject low two dos compare amlodipine enalapril subject percentage patient report least one drug related adverse event week placebo bisoprolol mg hctz amlodipine enalapril significant low dos two drug fixed combination provide good good blood pressure control compare high dos single drug similar tolerability safety,Prisant LM,1998,Am J Ther,https://doi.org/10.1097/00045391-199809000-00007,10099075,Prisant LM; Neutel JM; Papademetriou V; DeQuattro V; Hall WD; Weir MR,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D017311: Amlodipine; D017298: Bisoprolol; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004656: Enalapril; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension",,,https://openalex.org/W2027697161,148,15,1,2106,417,14,en,en
false,baroreflex sensitivity change calcium antagonist therapy elderly subject isolated systolic hypertension,order study effect calcium blocking therapy cardiovascular homeostasis elderly subject isolated systolic hypertension perform randomised double blind placebo controlled crossover study week therapy modified release nifedipine placebo change calcium blocker treatment clinic h blood pressure bp heart rate bp variability baroreflex sensitivity br three method valsalva manoeuvre phenylephrine sodium nitroprusside injection baroreflex non baroreflex mediated reflex tilt cold face stimulus study elderly subject mean age sem year sustain isolated systolic hypertension clinic bp mm hg clinic systolic bp diastolic bp reduce treatment mm hg p diastolic bp mm hg p twenty four hour bp also reduce nifedipine treatment mm hg p clinic h heart rate daytime bp variability unchanged treatment br significantly increase nifedipine therapy three measurement method p degree tilt active treatment subject exhibit great heart rate increase p reduced fall systolic p diastolic bp p thus despite arteriosclerosis reduction large artery compliance describe elderly patient isolated systolic hypertension clinically important improvement clinic ambulatory bp aspect cardiovascular homeostasis achieve calcium channel block therapy,James MA,1999,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1000780,10100056,James MA; Rakicka H; Panerai RB; Potter JF,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000367: Age Factors; D000368: Aged; D017704: Baroreflex; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011336: Probability; D012680: Sensitivity and Specificity; D018709: Statistics, Nonparametric; D013599: Systole",,,https://openalex.org/W2327739018,118,14,1,1672,305,8,en,en
false,systolic hypertension europe syst eur trial phase objective protocol initial progress,systolic hypertension europe syst eur trial prove blood pressure bp lower therapy start nitrendipine reduces risk cardiovascular complication old year patient isolated systolic hypertension systolic bp mm hg diastolic bp mm hg completion syst eur trial february consenting patient eligible enrol phase syst eur trial open follow study aim confirm safety long term antihypertensive therapy base dihydropyridine lower sit systolic bp mm hg target bp first line agent nitrendipine mg day may associate enalapril mg day hydrochlorothiazide mg day add study drug require antihypertensive agent november patient still follow patient proceed non supervised follow die median follow syst eur month last available visit systolic diastolic bp patient formerly randomise placebo n active treatment n decrease mm hg mm hg respectively group bp difference mm hg systolic ci mm hg p mm hg diastolic cl mm mm hg p beginning syst eur goal bp reach former placebo active treatment group last visit proportion respectively moment patient monotherapy nitrendipine take nitrendipine combination study drug end bp control syst eur patient far improve cardiovascular complication adverse event cancer gastro intestinal bleeding monitor validate blinded expert,Gasowski J,1999,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1000769,10100063,Gasowski J; Staessen JA; Celis H; Fagard RH; Thijs L; Birkenhäger WH; Bulpitt CJ; Fletcher AE; Arabidze GG; de Leeuw P; Dollery CT; Duggan J; Kawecka-Jaszcz K; Leonetti G; Nachev C; Safar M; Rodico JL; Rosenfeld J; Seux ML; Tuomilehto J; Webster J; Yodfat Y,article,"D016430: Clinical Trial; D017427: Clinical Trial, Phase II; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D000959: Antihypertensive Agents; D001795: Blood Pressure Determination; D002121: Calcium Channel Blockers; D004095: Dihydropyridines; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D004656: Enalapril; D005060: Europe; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D008297: Male; D009543: Nifedipine; D011379: Prognosis; D015996: Survival Rate; D016896: Treatment Outcome",,,https://openalex.org/W1128729114,100,18,1,1995,394,11,en,en
false,antihypertensive treatment prevention dementia,clinical hypertension research department public health social science geriatrics university uppsala uppsala sweden correspondence request reprint dr lennart hansson clinical hypertension research department public health social science geriatrics university uppsala p box uppsala sweden fax receive november accept november,Hansson L,1999,J Hypertens,https://doi.org/10.1097/00004872-199917030-00001,10100066,Hansson L,article,D016421: Editorial; D016454: Review,D000959: Antihypertensive Agents; D003704: Dementia; D005060: Europe; D006801: Humans; D006973: Hypertension; D016032: Randomized Controlled Trials as Topic,,,https://openalex.org/W2315035482,57,7,1,428,77,5,en,en
false,control study effect angiotensin convert enzyme inhibition versus calcium entry blockade insulin sensitivity overweight hypertensive patient,objective aim study evaluate effect trandolapril angiotensin convert enzyme inhibitor blood pressure forearm blood flow insulin sensitivity comparison nifedipine gastrointestinal therapeutic system patient method multicentre two way parallel group open label comparative study overweight hypertensive patient randomly assign treatment week either trandolapril nifedipine baseline treatment patient undergo oral glucose tolerance test evaluation metabolic profile euglycaemic hyperinsulinaemic clamp test subgroup patient forearm study carry result blood pressure fell second week treatment remain significantly reduce compare baseline treatment group plasma triglyceride level also significantly reduce trandolapril therapy significant change occur metabolic parameter treatment either drug euglycaemic hyperinsulinaemic clamp whole body glucose use similar two treatment group baseline moderate statistically significant increase insulin sensitivity observe trandolapril treatment trandolapril versus mg kg per min nifedipine versus mg kg per min p versus baseline trandolapril versus nifedipine treatment skeletal muscle glucose uptake significantly high trandolapril nifedipine therapy mg min respectively p forearm blood flow similar two treatment group baseline unchanged week therapy skeletal muscle glucose extraction significantly great ace inhibitor treated group nifedipine comparative group trandolapril baseline treatment mg dl nifedipine baseline treatment mg dl p trandolapril versus nifedipine treatment conclusion short term treatment ace inhibition trandolapril able moderately improve insulin sensitivity comparison calcium blockade effect appear independent haemodynamic action drug,Galletti F,1999,J Hypertens,https://doi.org/10.1097/00004872-199917030-00018,10100083,Galletti F; Strazzullo P; Capaldo B; Carretta R; Fabris F; Ferrara LA; Glorioso N; Semplicini A; Mancini M,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D001783: Blood Flow Velocity; D001794: Blood Pressure; D002118: Calcium; D002121: Calcium Channel Blockers; D005260: Female; D005500: Follow-Up Studies; D005542: Forearm; D005947: Glucose; D005951: Glucose Tolerance Test; D006801: Humans; D006973: Hypertension; D007211: Indoles; D007333: Insulin Resistance; D007558: Italy; D008297: Male; D008875: Middle Aged; D018482: Muscle, Skeletal; D009543: Nifedipine; D009765: Obesity; D007703: Peptidyl-Dipeptidase A; D016896: Treatment Outcome",,,https://openalex.org/W2319820844,163,20,1,2307,383,10,en,en
false,efficacy precondition intracoronary diltiazem prevent laser induced spasm,laser energy produce multitude effect result therapeutic tissue ablation complication laser induced spasm li li occur lasing subsequent adjunctive angioplasty intracoronary diltiazem icd partially reverse li occur determine whether pre treatment icd might prevent li laser intervention group lesion study group serve control receive icd procedure group receive mg icd lasing group receive icd lasing second infusion mg icd lasing adjunctive therapy difference clinical characteristic group lesion group complex b c lesion average lesion length mm group procedural success group significant difference among group pre procedure artery stenosis post procedure stenosis laser power use number laser pulse deliver pretreatment icd produce vasodilation minimum lumen diameter mm p well tolerate control patient exhibit incidence li group reduction li lasing p increase li adjunctive therapy incidence li overall group incidence li p conclude pretreatment icd significantly reduce li multiple infusion icd necessary sustain protective effect,McIvor M,1995,J Invasive Cardiol,,10158113,McIvor M; Undemir C; Moses J; Reddinger J; Lawson J,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D015906: Angioplasty, Balloon, Coronary; D017222: Angioplasty, Balloon, Laser-Assisted; D002121: Calcium Channel Blockers; D003329: Coronary Vasospasm; D004110: Diltiazem; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D007261: Infusions, Intra-Arterial; D008297: Male; D008875: Middle Aged; D011292: Premedication; D011859: Radiography; D016896: Treatment Outcome",,,https://openalex.org/W2406071529,91,11,1,1601,302,17,en,en
false,incidence adverse drug reaction adult medical inpatient,study prospective observational study adr occurrence evaluation adult internal medicine inpatient conduct day period clinical pharmacist screen adrs county hospital indianapolis patient information review admission every four day hospitalization discharge adrs occur hospital admission assess causality severity pharmacological type e augment pharmacology versus idiosyncratic reaction affect organ system nurse pharmacist report incident report physician consults patient transfer critical care unit serum drug concentration report additional mean adr identification overall patient experience adr drug exposure result adr patient age great year vs young patient female vs male high risk adr development p length hospital stay long day vs day p drug exposure frequent patient experience adrs p furosemide elicit adrs patient exposure diltiazem enalapril heparin trimterene hydrochlorothiazide combination captopril also frequently implicate adrs classify mild moderate severe organ system commonly affect metabolic hematologic gastrointestinal genitourinary cardiovascular event idiosyncratic reaction adr incidence consistent previous literature many frequently implicated medication new agent severity event less previously report,Bowman L,1994,Can J Hosp Pharm,,10172139,Bowman L; Carlstedt BC; Black CD,article,"D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D016907: Adverse Drug Reaction Reporting Systems; D064420: Drug-Related Side Effects and Adverse Reactions; D006745: Hospital Bed Capacity, 300 to 499; D006766: Hospitals, County; D006801: Humans; D007196: Indiana; D010607: Pharmacy Service, Hospital",,,https://openalex.org/W131874683,64,10,1,1786,327,15,en,en
false,gingival hyperplasia due calcium antagonist,,,1998,Prescrire Int,,10183386,,article,D016428: Journal Article,D002121: Calcium Channel Blockers; D004095: Dihydropyridines; D004110: Diltiazem; D005885: Gingival Hyperplasia; D006801: Humans; D009543: Nifedipine; D014700: Verapamil,,,https://openalex.org/W4300858407,48,7,1,0,0,0,en,
true,incidence cancer postmyocardial infarction patient treat short acting nifedipine diltiazem,background recent report suggest possible link nifedipine diltiazem increase risk cancer patient treat calcium antagonist method total postmyocardial infarction patient divide randomly treat calcium antagonist n nifedipine patient diltiazem patient control calcium antagonist n patient follow month incidence cardiac event well cancer compare among group result thirteen patient control group develop cancer whereas patient nifedipine group odds ratio confidence interval ci patient diltiazem group odds ratio ci develop cancer conclusion diltiazem appear present increase risk cancer incidence cancer slightly high patient receive nifedipine treat calcium antagonist consistent early report however increase statistically significant cancer american cancer society,Kanamasa K,1999,Cancer,https://doi.org/10.1002/(sici)1097-0142(19990315)85:6<1369::aid-cncr21>3.0.co;2-5,10189144,Kanamasa K; Kimura A; Miyataka M; Takenaka T; Ishikawa K,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D002121: Calcium Channel Blockers; D002423: Cause of Death; D004110: Diltiazem; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D009369: Neoplasms; D009543: Nifedipine; D016017: Odds Ratio; D016032: Randomized Controlled Trials as Topic; D012008: Recurrence; D012307: Risk Factors,,,https://openalex.org/W2149078509,108,13,1,1200,227,8,en,en
false,prevalence etiology impotence male hypertensive outpatient,erectile dysfunction impotence high prevalence among male hypertensive patient whether relate mainly specific drug side effect primary pathogenic disorder unknown present study male patient outpatient hypertension clinic answer detailed questionnaire hypertension sexual function patient perceived impotence offer thorough penile evaluation examination perform specialist urology department twenty seven men impotence main cause impotence arterial dysfunction prevalence impotence relate degree secondary organ manifestation reflect world health organization classification iii p intermittent claudication p ischemic heart disease p best determinant respect twelve impotent patient ascribe onset impotence drug initiation variety drug incriminate occurrence drug induced impotence summary result indicate impotence hypertensive men cause mainly penile arterial vascular change probably atherosclerosis drug induced impotence could well result blood pressure reduction specific drug side effect,Jensen J,1999,Am J Hypertens,https://doi.org/10.1016/s0895-7061(98)00225-8,10192229,Jensen J; Lendorf A; Stimpel H; Frost J; Ibsen H; Rosenkilde P,article,D016428: Journal Article,D000328: Adult; D000368: Aged; D000428: Alcohol Drinking; D000553: Ambulatory Care; D000959: Antihypertensive Agents; D007172: Erectile Dysfunction; D006801: Humans; D006973: Hypertension; D007383: Intermittent Claudication; D008297: Male; D008875: Middle Aged; D017202: Myocardial Ischemia; D015995: Prevalence; D012907: Smoking; D011795: Surveys and Questionnaires,,,https://openalex.org/W1997897341,77,11,1,1303,217,12,en,en
false,double blind comparison effect amlodipine enalapril insulin sensitivity hypertensive patient,study compare effect calcium channel blocker amlodipine angiotensin convert enzyme inhibitor enalapril vivo insulin sensitivity patient essential hypertension forty six patient mild moderate hypertension study week single blind placebo phase randomly assign double blind therapy either amlodipine mg day enalapril mg day week group comparable term demographic characteristic degree obesity metabolic parameter arterial blood pressure insulin sensitivity measure baseline week active phase use euglycemic hyperinsulinemic clamp arterial blood pressure decrease similarly group whole body glucose uptake value increase amlodipine mean sem mg kg min p similar tendency observe enalapril mg kg min p trend lower steady state insulin level second clamp compare baseline observe group clamp derived insulin sensitivity index correct steady state insulin level glucose level clamp increase similarly group amlodipine p enalapril p ldl cholesterol decrease amlodipine mean change mg dl p amlodipine enalapril associate increment insulin sensitivity amlodipine provide additional benefit decreased low density lipoprotein cholesterol level,Lender D,1999,Am J Hypertens,https://doi.org/10.1016/s0895-7061(98)00259-3,10192233,Lender D; Arauz-Pacheco C; Breen L; Mora-Mora P; Ramirez LC; Raskin P,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001786: Blood Glucose; D002121: Calcium Channel Blockers; D002784: Cholesterol; D004311: Double-Blind Method; D004656: Enalapril; D005260: Female; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D007333: Insulin Resistance; D008297: Male; D008875: Middle Aged,,,https://openalex.org/W2142834180,116,17,1,1692,301,13,en,en
false,cardiac risk beta agonist,objective report atypical presentation lance adams syndrome presenting severe respiratory depression rather cardiac arrest highlight importance distinguish post hypoxic myoclonic variant background clinician often face difficulty distinguish lance adams syndrome la myoclonic status epilepticus mse similarity two condition frequently result confusion diagnosing managing prognosticate post hypoxic myoclonus patient design methods year old male history pertinent hemophilia b depression opiate alcohol abuse chronic pain find home next empty bottle clonazepam hypoxic oxygen saturation intubate field upon arrival emergency room neurological examination reveal intact corneal reflex gag reflex cough purposeful movement extremity patient exhibit stimulus induced myoclonic jerking last minute despite load valproic acid levetiracetam jerk subsequently cease propofol drip chest x ray confirm interstitial opacity test positive sars cov attempt wean sedation patient exhibit full body myoclonus include face palate inability follow command lack spontaneous movement eeg show biped great hz decide burst suppress treat targeted temperature management day patient successfully wean sedation extubated remain multiple anti seizure medication result patient respond well despite diffuse cerebral anoxic injury regain ability follow command upon discharge residual moderate expressive aphasia post hypoxic action induced myoclonus consistent la conclusion atypical presentation case emphasize importance distinguish la mse guide neurologist aggressively treat la improve outcome particularly since mse historically result mortality rate disclosure dr culpepper nothing disclose dr terpak nothing disclose dr cruz saavedra nothing disclose dr krishnaiengar nothing disclose,Lindmark B,1998,Thorax,https://doi.org/10.1136/thx.53.12.1094,10195086,Lindmark B,article,D016420: Comment; D016422: Letter,"D000318: Adrenergic beta-Agonists; D000368: Aged; D000369: Aged, 80 and over; D006333: Heart Failure; D006801: Humans; D008875: Middle Aged",,,https://openalex.org/W1923760699,32,5,1,2368,402,19,en,en
false,antiischemic effect nicardipine nitroglycerin coronary artery bypass grafting,background assess efficacy continuous infusion nicardipine nitroglycerin reduce incidence severity perioperative myocardial ischemia elective coronary artery bypass grafting procedure prospective randomize control study methods patient receive either nicardipine infusion g kg min n nitroglycerin g kg min n neither medication n aortic occlusion clamp release hour postoperatively myocardial ischemic episode mie consider occur st segment depression elevation least mm least mm depression elevation j lasting least minute use two channel holter monitor results nicardipine significantly decrease duration p mm great minute per hour minute per hour eliminate number p mm great minute per hour zero minute per hour compare control patient minute per hour minute per hour respectively intraoperative postbypass period conclusions result suggest nicardipine lessen severity myocardial ischemia shortly coronary revascularization could consider alternative standard antiischemic therapy,Apostolidou IA,1999,Ann Thorac Surg,https://doi.org/10.1016/s0003-4975(98)01039-x,10197663,Apostolidou IA; Despotis GJ; Hogue CW; Skubas NJ; McCawley CA; Hauptmann EL; Lappas DG,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D001026: Coronary Artery Bypass; D003327: Coronary Disease; D004305: Dose-Response Relationship, Drug; D015716: Electrocardiography, Ambulatory; D005260: Female; D006439: Hemodynamics; D006801: Humans; D007262: Infusions, Intravenous; D008297: Male; D008875: Middle Aged; D017202: Myocardial Ischemia; D009529: Nicardipine; D005996: Nitroglycerin; D011183: Postoperative Complications; D011446: Prospective Studies; D016896: Treatment Outcome; D014665: Vasodilator Agents",,,https://openalex.org/W2021856311,91,11,1,1402,252,6,en,en
false,calcium channel blocker myocardial cerebral ischemia clinician review bench bedside,calcium channel blocker constitute important group drug commonly use treatment cardiovascular cerebrovascular disorder current indication medication include hypertension angina supraventricular arrhythmia prevention coronary cerebral vasospasm although calcium channel blocker originally hold great promise treatment myocardial cerebral ischemia clinical result discourage understanding basic physiological mechanism action drug important practising clinician may explain disappointing result treatment ischemia date paper narrative review clinician viewpoint structure role calcium channel cardiac cerebrovascular tissue well review vitro clinical result calcium channel blockade myocardial cerebral ischemia,Borger MA,1999,Can J Cardiol,,10202197,Borger MA; Weisel RD,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review",D002545: Brain Ischemia; D002121: Calcium Channel Blockers; D015220: Calcium Channels; D005500: Follow-Up Studies; D006801: Humans; D017202: Myocardial Ischemia; D016032: Randomized Controlled Trials as Topic; D012189: Retrospective Studies; D016896: Treatment Outcome,,,https://openalex.org/W2411044431,105,18,1,945,148,5,en,en
false,symptom report elderly patient isolated systolic hypertension baseline data syst eur trial systolic hypertension europe,determine symptomatic well elderly person isolated systolic hypertension well determine placebo run period prior entry systolic hypertension europe syst eur trial people year old average sit blood pressure mm hg symptomatic complaint determine standard interview woman complain symptom men p markedly high prevalence observe woman compare men pain joint hand woman complain men racing heart dry eye blur vision cramp leg sore throat nocturia frequent complaint sex eight symptom increase age one rash tend decline increase systolic pressure woman also report headache unsteadiness blurring vision irregular heart beat racing heart headache increase diastolic pressure observation make adjust age blood sugar body mass index bmi observe men high blood sugar associate mouth ulcer racing heart blur vision cramp leg high bmi associate six symptom low age leave education eight men alcohol consumption relate racing heart smoke wheeze dry cough high level complaint associate female gender increase age blood sugar bmi low age leave education,Bulpitt CJ,1999,Age Ageing,https://doi.org/10.1093/ageing/28.1.15,10203199,Bulpitt CJ; Fletcher AE; Thijs L; Staessen JA; Antikainen R; Davidson C; Fagard R; Gil-Extremera B; Jääskivi M; O'Brien E; Palatini P; Tuomilehto J,article,"D016430: Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D005060: Europe; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011795: Surveys and Questionnaires",,,https://openalex.org/W2145938374,145,21,2,1688,341,9,en,en
false,ambulatory blood pressure profile essential hypertensive treatment new daily nifedipine formulation,antihypertensive efficacy new controlled release preparation nifedipine develop daily administration investigate comparison standard therapy sustained release nifedipine give twice daily randomised open crossover trial twenty two patient mild moderate essential hypertension enrol ambulatory blood pressure monitoring abpm perform wash period week treatment mg controlled release nifedipine daily mg sustained release nifedipine twice daily respectively abpm data evaluate conventional linear analysis rhythm analysis daily twice daily administration nifedipine significantly reduce systolic blood pressure daytime night compare baseline h diastolic blood pressure significantly decrease treatment daily regimen significantly lower diastolic daytime night time mean compare systolic diastolic blood pressure treatment however significant difference obtain nifedipine treatment neither greatly modify circadian blood pressure pattern reflexly increase heart rate conclusion daily application controlled release formulation nifedipine result consistent significant blood pressure reduction daily twice daily medication nifedipine equally effective lower elevate blood pressure,Nold G,1999,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1000787,10204813,Nold G; Herholz C; Sturm M; Hopf R; Lemmer B,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D002940: Circadian Rhythm; D018592: Cross-Over Studies; D004334: Drug Administration Schedule; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D016896: Treatment Outcome",,,https://openalex.org/W1989785590,122,16,1,1546,227,10,en,en
false,isradipine raise glycosylated haemoglobin risk cardiovascular event,adverse outcome associate calcium antagonist appear dose dependent change lipid bilayer composition cell membrane patient diabetes patient might susceptible adverse effect calcium antagonists examine whether impaired glucose metabolism reflect increased concentration glycosylated haemoglobin hba c serum glucose predict adverse cardiovascular event among hypertensive patient allocate isradipine multicenter isradipine diuretic atherosclerosis study midas,Byington RP,1997,Lancet,https://doi.org/10.1016/s0140-6736(05)70455-4,10213554,Byington RP; Craven TE; Furberg CD; Pahor M,article,D016430: Clinical Trial; D003160: Comparative Study; D016422: Letter; D016449: Randomized Controlled Trial,D001161: Arteriosclerosis; D001786: Blood Glucose; D002121: Calcium Channel Blockers; D002318: Cardiovascular Diseases; D002340: Carotid Artery Diseases; D004232: Diuretics; D018149: Glucose Intolerance; D006442: Glycated Hemoglobin; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D017275: Isradipine; D008875: Middle Aged; D012307: Risk Factors; D049993: Sodium Chloride Symporter Inhibitors,,,https://openalex.org/W2123036055,78,11,1,576,83,2,en,en
true,physical symptom distress index,objective examine whether degree stress associate adverse physical side effect correlate overall quality life qol compliance rate determine instrument use assess qol detect difference treatment known central nervous system effect patient method randomize double blind parallel group study evaluate mg controlled onset extend release coer verapamil n mg nifedipine gastrointestinal therapeutic system git n men woman year age stage hypertension battery question evaluate psychological well physical symptom distress index administer week placebo washout baseline week treatment dropout result treatment effectively lower blood pressure significant group difference psychosocial qol difference level physical symptom distress detect treatment p multivariate analysis variance significant univariate treatment effect favor coer verapamil noted pedal edema polyuria rapid heart beat palpitation hive muscle cramp abdominal cramp headache constipation related distress increase significantly p similar extent treatment difference symptom distress tend predict compliance withdrawal nifedipine git group n v coer verapamil group n p conclusion patient assessed physical symptom distress sensitive simple technique evaluate effect antihypertensive medication qol tolerability show ability detect improvement associate coer verapamil depend agent involve physical symptom distress index may closely predict dropout rate traditional psychosocial instrument suggest low dropout rate coer verapamil group thus study treatment effect qol distress physical symptom impact psychosocial factor evaluate,Anderson RB,1999,Arch Intern Med,https://doi.org/10.1001/archinte.159.7.693,10218748,Anderson RB; Hollenberg NK; Williams GH,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D003248: Constipation; D004311: Double-Blind Method; D004487: Edema; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009120: Muscle Cramp; D009543: Nifedipine; D011141: Polyuria; D011788: Quality of Life; D012680: Sensitivity and Specificity; D013315: Stress, Psychological; D011795: Surveys and Questionnaires; D013610: Tachycardia; D014700: Verapamil",,,https://openalex.org/W2017946023,32,4,1,2267,420,11,en,en
false,antianginal efficacy combination felodipine metoprolol mg compare drug alone patient stable effort induced angina pectoris multicenter parallel group study,objective primary objective randomize double blind parallel group trial compare antianginal antiischemic efficacy combination tablet felodipine metoprolol mg daily drug give separately daily patient stable effort induced angina pectoris secondary objective compare tolerability treatment method main criterion inclusion stable effort induced angina pectoris least month enrollment positive bicycle exercise test result patient allocate daily treatment either felodipine metoprolol mg felodipine mg metoprolol mg duration active double blind treatment week primary efficacy variable study time end exercise time onset chest discomfort time mm st depression standardized exercise test result number patient randomize statistically significant improvement time end exercise felodipine metoprolol mg compare metoprolol mg p felodipine mg compare metoprolol mg p however time onset pain time mm st depression significant difference among treatment group high comparable workload st depression less pronounced felodipine metoprolol metoprolol alone p rate pressure product significantly low group receive felodipine metoprolol metoprolol group receive felodipine alone combination metoprolol well tolerate felodipine alone conclusion stable angina pectoris combination felodipine metoprolol mg felodipine mg alone increase exercise time compare metoprolol mg combination tablet metoprolol mg alone show favorable tolerability profile felodipine mg alone heart j,Emanuelsson H,1999,Am Heart J,https://doi.org/10.1016/s0002-8703(99)70409-6,10220634,Emanuelsson H; Egstrup K; Nikus K; Ellström J; Glud T; Pater C; Scheibel M; Tisell A; Tötterman KJ; Forsby M,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005080: Exercise Test; D017079: Exercise Tolerance; D015736: Felodipine; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D008790: Metoprolol; D008875: Middle Aged; D012189: Retrospective Studies; D016896: Treatment Outcome",,,https://openalex.org/W2001164101,195,27,1,2051,334,14,en,en
false,combination therapy felodipine metoprolol compare captopril hydrochlorothiazide,study compare antihypertensive efficacy tolerability combination tablet contain vascular selective calcium antagonist felodipine beta selective adrenergic antagonist metoprolol combination tablet captopril hydrochlorothiazide randomized double blind trial involve patient mild moderate hypertension week placebo patient supine diastolic blood pressure mm hg randomize felodipine metoprolol mg logimax captopril hydrochlorothiazide mg capozide far week mandatory dose increase felodipine metoprolol mg captopril hydrochlorothiazide mg treatment continue another week end study felodipine metoprolol reduced supine blood pressure significantly captopril hydrochlorothiazide mean difference change supine systolic diastolic blood pressure treatment week mm hg respectively favour felodipine metoprolol p stand blood pressure also show trend favour felodipine metoprolol proportion responder similar group treatment well tolerate two patient treat felodipine metoprolol captopril hydrochlorothiazide discontinue treatment due adverse event felodipine metoprolol combination reduce supine blood pressure significantly captopril hydrochlorothiazide maintained tolerability,Klein G,1998,Blood Press,https://doi.org/10.1080/080370598437178,10321444,Klein G,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D002216: Captopril; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D015736: Felodipine; D005260: Female; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D008297: Male; D008790: Metoprolol; D008875: Middle Aged",,,https://openalex.org/W2082062179,98,11,1,1568,231,12,en,en
true,effect long acting versus short acting calcium channel blocker among old survivor acute myocardial infarction,objective recent study highlight potentially harmful effect short acting calcium channel blocker especially dihydropyridine type patient coronary heart disease argue long acting calcium channel blocker safer outcome data exist objective study compare occurrence adverse outcome among recipient long acting versus short acting calcium channel blocker dihydropyridines non dihydropyridines compare separately setting new jersey medicare population design retrospective cohort study use link medicare drug claim data participant old survivor acute myocardial infarction mi occur eligible subject survive least day mi participate medicare drug benefit program prescribe single type either long acting short acting calcium channel blocker within day mi measurement two outcome measure rate cause mortality cardiac rehospitalization use separate cox regression model dihydropyridines nifedipine nicardipine non dihydropyridines diltiazem verapamil examine outcome recipient long acting compare short acting calcium channel blocker result patient eligible study prescribe long acting short acting calcium channel blocker clinical characteristic long acting short acting user comparable year follow death rehospitalizations occur control age sex race indicator disease severity comorbidity relative risk die recipient long acting compare short acting dihydropyridines confidence interval ci cardiac rehospitalization relative risk ci long acting versus short acting non dihydropyridines adjusted relative risk die ci cardiac rehospitalization ci conclusion use long acting dihydropyridine calcium channel blocker acute mi associate substantially low rate cardiac rehospitalization death compare use short acting counterpart data need address possibility long acting compare short acting non dihydropyridines could decrease rehospitalization rate increase mortality j geriatr soc,Gillman MW,1999,J Am Geriatr Soc,https://doi.org/10.1111/j.1532-5415.1999.tb02562.x,10323641,Gillman MW; Ross-Degnan D; McLaughlin TJ; Gao X; Spiegelman D; Hertzmark E; Goldman L; Soumerai SB,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000368: Aged; D002121: Calcium Channel Blockers; D004095: Dihydropyridines; D004110: Diltiazem; D005260: Female; D006801: Humans; D008297: Male; D009203: Myocardial Infarction; D009529: Nicardipine; D009543: Nifedipine; D016016: Proportional Hazards Models; D012189: Retrospective Studies; D012306: Risk; D016019: Survival Analysis; D017741: Survivors; D014700: Verapamil,,,https://openalex.org/W1994930872,120,15,1,2570,416,18,en,en
false,management hypertension pregnancy,hypertension pregnancy single entity comprises summary point antihypertensive treatment well tolerate pregnancy woman need change drug due side effect antihypertensive treatment mild chronic hypertension benefit mother impact perinatal outcome less clear particularly atenolol hypertension presenting later pregnancy even near term available data allow reliable conclusion make benefit risk restricted activity without admission hospital antihypertensive treatment mild moderate hypertension later pregnancy benefit mother impact perinatal outcome may harmful beneficial woman early severe pre eclampsia good perinatal outcome manage expectantly data insufficient estimate risk mother acute severe hypertension later pregnancy parenteral hydralazine drug choice associate maternal perinatal adverse effect drug particularly intravenous labetalol oral sublingual nifedipine antihypertensive treatment give antenatally probably reorder postnatally type hypertension pregnancy differ primarily incidence nature maternal perinatal complication uk confidential inquiry maternal,Magee LA,1999,BMJ,https://doi.org/10.1136/bmj.318.7194.1332,10323823,Magee LA; Ornstein MP; von Dadelszen P,article,D016428: Journal Article; D016454: Review,"D000959: Antihypertensive Agents; D002908: Chronic Disease; D005260: Female; D006801: Humans; D006973: Hypertension; D011247: Pregnancy; D011249: Pregnancy Complications, Cardiovascular; D011644: Puerperal Disorders",,,https://openalex.org/W2058989856,39,5,1,1461,227,2,en,en
false,hypertensive crisis,previewadvances management chronic hypertension make occurrence hypertensive crisis relatively rare however likely primary care physician point encounter patient critically elevate blood pressure dr bale describe type cause hypertensive crisis well appropriate therapy potential complication affect management,Bales A,1999,Postgrad Med,https://doi.org/10.3810/pgm.1999.05.1.735,10335324,Bales A,article,D016428: Journal Article; D016454: Review,"D000208: Acute Disease; D000959: Antihypertensive Agents; D018450: Disease Progression; D004630: Emergencies; D004638: Emergency Treatment; D006801: Humans; D006974: Hypertension, Malignant; D008403: Mass Screening; D012307: Risk Factors",,,https://openalex.org/W2069980278,19,2,1,408,63,3,en,en
false,combination calcium channel blocker adrenoceptor blocker patient exercise induced angina pectoris double blind parallel group comparison different class calcium channel blocker,combination calcium channel blocker beta adrenoceptor blocker effective treatment exercise induced angina pectoris beta adrenoceptor blocker monotherapy ischaemia exercise induced angina precede increase heart rate calcium channel blocker negative chronotropic property may perform good purpose nonchronotropic compounds patient double blind parallel group study compare day treatment amlodipine mg diltiazem mg mibefradil mg add baseline beta adrenoceptor blocker treatment perform exercise testing ett perform bicycle ergometry although none calcium channel blocker improve duration exercise amount workload significantly delay onset mm st segment depression ett p treatment v baseline addition mibefradil low high dose treatment produce long delay low dose different diltiazem amlodipine respectively p high dose different diltiazem amlodipine respectively p effect linearly correlate reduction rate pressure product rpp serious symptom dizziness occur significantly frequently mibefradil p patient mibefradil withdraw trial calcium channel blocker negative chronotropic property provide great delay ischaemia patient exercise induced angina concomitant risk intolerable dizziness attenuate benefit,Van Der Vring JA,1999,Br J Clin Pharmacol,https://doi.org/10.1046/j.1365-2125.1999.00924.x,10336572,Van Der Vring JA; Daniëls MC; Holwerda NJ; Withagen PJ; Schelling A; Cleophas TJ; Hendriks MG,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D017311: Amlodipine; D000787: Angina Pectoris; D001562: Benzimidazoles; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004110: Diltiazem; D004244: Dizziness; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D015444: Exercise; D005080: Exercise Test; D005260: Female; D006339: Heart Rate; D006439: Hemodynamics; D006801: Humans; D008297: Male; D020748: Mibefradil; D008875: Middle Aged; D018570: Risk Assessment; D013764: Tetrahydronaphthalenes",,,https://openalex.org/W1763513677,216,33,1,1646,272,7,en,en
false,retrospective analysis frequency recognition adverse drug reaction mean automatically record laboratory signal,estimate frequency adverse drug reaction adrs identify use automatic signal generate laboratory data al hospitalised patient determine frequency spontaneous recognition adrs attending physician assess potential value al detection adrs laboratory result patient hospitalise nine bed medical ward automatically record period month value exceed defined boundary use al chart every third patient analyse retrospectively regard adverse drug relate reaction causality evaluate well whether adr recognise period hospitalisation chart al patient analyse case drug related adverse reaction probable awareness reaction treating physician evident adrs approximately adrs consider predictable three adrs regard serious adverse drug reaction common often preventable one third adrs could detect al recognise attending physician increased doctor awareness frequency drug relate abnormal laboratory result mean al likely increase recognition rate adrs might help prevent,Tegeder I,1999,Br J Clin Pharmacol,https://doi.org/10.1046/j.1365-2125.1999.00926.x,10336581,Tegeder I; Levy M; Muth-Selbach U; Oelkers R; Neumann F; Dormann H; Azaz-Livshits T; Criegee-Rieck M; Schneider HT; Hahn E; Brune K; Geisslinger G,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000410: Alanine Transaminase; D001219: Aspartate Aminotransferases; D015415: Biomarkers; D016903: Drug Monitoring; D064420: Drug-Related Side Effects and Adverse Reactions; D005260: Female; D006403: Hematologic Tests; D006801: Humans; D007668: Kidney; D007674: Kidney Diseases; D008099: Liver; D008107: Liver Diseases; D008297: Male; D008499: Medical Records; D008875: Middle Aged; D010819: Physician's Role; D012189: Retrospective Studies",,,https://openalex.org/W1802900720,135,18,1,1381,231,10,en,en
false,sustained release nifedipine new indication angina safer drug available,efficacy sustained release osmotic tablet nifedipine symptomatic treatment stable angina poorly document safety nifedipine remain uncertain high dose treatment immediate release preparation increase mortality trial involve coronary patient angina nifedipine use combination betablocker treat patient recent history myocardial infarction unstable angina stable angina inadequate symptom control betablockers effective dihydropyridines also indicate treatment angina e amlodipine felodipine furthermore medium term data amlodipine relatively reassure nifedipine appear little effective sustained release nitrate derivative less safe,,1998,Prescrire Int,,10342920,,article,D003160: Comparative Study; D016428: Journal Article,"D000319: Adrenergic beta-Antagonists; D000787: Angina Pectoris; D000789: Angina, Unstable; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D004095: Dihydropyridines; D004110: Diltiazem; D004341: Drug Evaluation; D005260: Female; D006801: Humans; D007548: Isosorbide Dinitrate; D008297: Male; D009203: Myocardial Infarction; D009543: Nifedipine; D016032: Randomized Controlled Trials as Topic; D016896: Treatment Outcome; D014665: Vasodilator Agents",,,https://openalex.org/W4302587396,80,13,2,829,128,7,en,en
false,hypotension coronary event nifedipine reassessing nifedipine safety,nifedipine administration hypertensive emergency induce neurological cardiac event due abrupt hypotension nifedipine also increase risk coronary event case unstable angina recent myocardial infarction hypertensive emergency potential advantage risk achieve rapid fall arterial pressure assess case case patient coronary heart disease nifedipine contraindicate case recent myocardial infarction unstable angina nifedipine second line choice stable angina combine betablocker,,1998,Prescrire Int,,10342928,,article,D016428: Journal Article; D016454: Review,"D000789: Angina, Unstable; D002121: Calcium Channel Blockers; D000075202: Contraindications; D004341: Drug Evaluation; D005602: France; D006801: Humans; D006973: Hypertension; D007022: Hypotension; D009203: Myocardial Infarction; D009543: Nifedipine; D018579: Patient Selection; D014481: United States",,,https://openalex.org/W4302335376,77,11,1,614,96,5,en,en
false,cyclosporin induced hypertension,blood pressure increase soon administration immunosuppressive regimen use cyclosporin characteristic vascular change lead systemic renal vasoconstriction change blood pressure commonly associate disturbed circadian regulation may promote rapid development target organ injury include intracranial haemorrhage leave ventricular hypertrophy microangiopathic haemolysis mechanisms underlying disorder complex include alter vascular endothelial function vasodilator prostacyclin nitric oxide suppress whereas vasoconstrictor include endothelin increase change kidney include vasoconstriction reduce glomerular filtration sodium retention effective therapy depend upon rigorous blood pressure control administration vasodilating agent attention potential interaction cyclosporin,Taler SJ,1999,Drug Saf,https://doi.org/10.2165/00002018-199920050-00004,10348094,Taler SJ; Textor SC; Canzanello VJ; Schwartz L,article,"D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.; D016454: Review",D000818: Animals; D016572: Cyclosporine; D006801: Humans; D006973: Hypertension; D007166: Immunosuppressive Agents; D015994: Incidence,,,https://openalex.org/W2075025454,32,2,1,919,124,7,en,en
false,meta analysis trial compare blockers calcium antagonist nitrate stable angina,contextwhich drug effective first line treatment stable angina known objectiveto compare relative efficacy tolerability treatment blockers calcium antagonist long acting nitrate patient stable angina data sourceswe identify english language study publish search medline embase database review bibliography identified article locate additional relevant studies study selectionrandomized crossover study compare antianginal drug different class blockers calcium antagonist long acting nitrate last least week review study select report least following outcome cardiac death myocardial infarction study withdrawal due adverse event angina frequency nitroglycerin use exercise duration ninety identified study meet inclusion criteria data extractiontwo independent reviewer extract data select article settle difference consensus outcome data extract third time investigator combine result use odds ratio discrete data mean difference continuous data study calcium antagonist group duration type drug nifedipine v nonnifedipine data synthesisrates cardiac death myocardial infarction significantly different treatment blockers vs calcium antagonist confidence interval ci p ci p episode angina per week blockers calcium antagonist blockers discontinue adverse event less often calcium antagonist ci p difference blockers calcium antagonist striking nifedipine adverse event blockers vs nifedipine ci trial compare nitrate calcium antagonist blockers draw firm conclusion relative efficacy conclusions blockers provide similar clinical outcome associate adverse event calcium antagonist randomized trial patient stable angina,Heidenreich PA,1999,JAMA,https://doi.org/10.1001/jama.281.20.1927,10349897,Heidenreich PA; McDonald KM; Hastie T; Fadel B; Hagan V; Lee BK; Hlatky MA,article,"D003160: Comparative Study; D016428: Journal Article; D017418: Meta-Analysis; D013486: Research Support, U.S. Gov't, Non-P.H.S.; D013487: Research Support, U.S. Gov't, P.H.S.",D000319: Adrenergic beta-Antagonists; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D002986: Clinical Trials as Topic; D006801: Humans; D009566: Nitrates,,,https://openalex.org/W2014750372,97,14,1,2312,376,10,en,en
false,die medikament se anfallsprophylaxe bei symptomatischem paroxysmalem vorhofflimmern flattern,indication treat symptomatic paroxysmal atrial fibrillation discuss controversely successful medical treatment may result reduction symptom improve hemodynamics reduction thromboembolic event however several antiarrhythmic drug also know increase risk proarrhythmic event randomized double blind placebo controlled multicenter trial patient recruit design compare effect two antiarrhythmic drug frequently use germany treatment atrial fibrillation sotalol fixed combination chinidin verapamil cordichin patient symptomatic paroxysmal atrial fibrillation atrial flutter observe period one year occurrence paroxysmal atrial fibrillation document transtelephonic ecg monitoring patient document ecg daily recording mandatory case symptom ecg transmit central data base analysis clinical trial design answer following question average rate spontaneous event symptomatic atrial fibrillation possible reduce frequency symptomatic event chronic antiarrhythmic drug administration long term frequency occurrence severe side effects antiarrhythmic medication primary endpoint define time first recurrence symptomatic arrhythmia reach steady state plasma concentration study medication trial start november plan finish end,Patten M,1999,Z Kardiol,https://doi.org/10.1007/s003920050275,10355069,Patten M; Koch HP; Sonntag F; Lüderitz B; Meinertz T,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D001282: Atrial Flutter; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004338: Drug Combinations; D004554: Electric Countershock; D015716: Electrocardiography, Ambulatory; D005858: Germany; D006801: Humans; D011446: Prospective Studies; D011802: Quinidine; D012008: Recurrence; D013015: Sotalol; D013614: Tachycardia, Paroxysmal; D013686: Telemetry; D016896: Treatment Outcome; D014700: Verapamil",,,https://openalex.org/W2308421811,93,7,1,1627,261,13,de,en
false,die medikament se prophylaxe nach elektronischer kardioversion von chronischem vorhofflimmern,atrial fibrillation af frequent cardiac arrhythmia however despite manifold publication reflect numerous clinical trial treatment af management arrhythmia still controversial discussion daily clinical work well research present study concentrate three major question frequent recurrence af long term follow previous study use occurrence symptom surrogate parameter recurrence af despite expected high rate asymptomatic relapse present study daily transtelephonic ecg transmission enable rhythm monitoring independent symptom frequency af recurrence significantly reduce antiarrhythmic medication direct comparison class iii antiarrhythmic drug still frequently use indication placebo answer question safe long term treatment prevention af recurrence special respect proarrhythmic effect daily transtelephonic ecg transmission enable quantitative qualitative monitoring tachy bradyarrhythmias independent symptom additionally daily analysis ecg measure may detect parameter predict subsequent life threaten arrhythmia study design provide prospective randomised double blind placebo control multicenter parallel group comparison germany czech republic hospital include patient documented chronic af age year eligible electrical cardioversion without concomitant antiarrhythmic drug therapy anticoagulated least three week prior inclusion neither size left atrium duration chronic af exclusion criterion hour successful electrical cardioversion patient randomise either sotalol x mg quinidine verapamil x mg x mg placebo start day cardioversion patient ask record transmit electrocardiogram one minute duration least day use personal transtelephonic ecg record unit tele ecg recorder credit card size case symptom often necessary ecg transmit time regular phone without additional equipment use toll free number custom make computer base fully automate receive centre handle patient call interactively voice control include voice recording patient symptom ecg tracing patient voice message subsequently computer base analyse experienced technician ecg measure store database case af recurrence relevant arrhythmia additional abnormality e g qt prolongation correspondent hospital immediately inform fax case af recurrence subsequent holter record discriminates paroxysmal permanent af study medication end either permanent af third episode paroxysmal af detect month follow regular follow visit perform monthly major endpoint time first recurrence af time death secondary parameter number af recurrence time end medication af relate symptom recruitment start last day end june patient randomise expect end recruitment spring close study spring final result available summer,Fetsch T,1999,Z Kardiol,https://doi.org/10.1007/s003920050276,10355070,Fetsch T; Burschel G; Breithardt G; Engberding R; Koch HP; Lukl J; Trappe HJ; Treese N,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D002908: Chronic Disease; D018153: Czech Republic; D004311: Double-Blind Method; D004338: Drug Combinations; D004554: Electric Countershock; D015716: Electrocardiography, Ambulatory; D005260: Female; D005858: Germany; D006801: Humans; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D011802: Quinidine; D013015: Sotalol; D013686: Telemetry; D014700: Verapamil",,,https://openalex.org/W2042042566,93,9,1,3656,629,32,de,en
false,acc aha acp asim guideline management patient chronic stable angina document approve american college cardiology board trustee march american heart association science advisory coordinate committee march american college physicians american society internal medicine board regent february cite document please use following citation format gibbon rj chatterjee k daley j douglas,table content important medical profession play significant role critically evaluate use diagnostic procedure therapy management prevention disease state rigorous expert analysis available data document relative benefit,Gibbons RJ,1999,J Am Coll Cardiol,https://doi.org/10.1016/s0735-1097(99)00150-3,10362225,Gibbons RJ; Chatterjee K; Daley J; Douglas JS; Fihn SD; Gardin JM; Grunwald MA; Levy D; Lytle BW; O'Rourke RA; Schafer WP; Williams SV; Ritchie JL; Cheitlin MD; Eagle KA; Gardner TJ; Garson A; Russell RO; Ryan TJ; Smith SC,article,D016431: Guideline; D016428: Journal Article; D017065: Practice Guideline,"D000573: American Hospital Association; D000787: Angina Pectoris; D002309: Cardiology; D002637: Chest Pain; D002908: Chronic Disease; D017023: Coronary Angiography; D003937: Diagnosis, Differential; D004452: Echocardiography; D004562: Electrocardiography; D005080: Exercise Test; D006801: Humans; D009204: Myocardial Revascularization; D016896: Treatment Outcome; D014481: United States",,,https://openalex.org/W1991310152,499,78,1,300,48,2,en,en
false,update systolic hypertension europe syst eur trial,homehypertensionvol update systolic hypertension europe syst eur trial free accessotherpdf epubaboutview pdfview epubsections toolsadd favoritesdownload citationstrack citationspermissions shareshare onfacebooktwitterlinked inmendeleyreddit jump tofree accessotherpdf epubupdate systolic hypertension europe syst eur trial jan staessen lutgarde thijs willem h birkenh ger christopher j bulpitt robert fagard behalf syst eur investigator jan staessenjan staessen studieco rdinatiecentrum hypertensie en cardiovasculaire revalidatie eenheid campus gasthuisberg leuven belgium search paper author lutgarde thijslutgarde thijs studieco rdinatiecentrum hypertensie en cardiovasculaire revalidatie eenheid campus gasthuisberg leuven belgium search paper author willem h birkenh gerwillem h birkenh ger studieco rdinatiecentrum hypertensie en cardiovasculaire revalidatie eenheid campus gasthuisberg leuven belgium search paper author christopher j bulpittchristopher j bulpitt studieco rdinatiecentrum hypertensie en cardiovasculaire revalidatie eenheid campus gasthuisberg leuven belgium search paper author robert fagardrobert fagard studieco rdinatiecentrum hypertensie en cardiovasculaire revalidatie eenheid campus gasthuisberg leuven belgium search paper author behalf syst eur investigator behalf syst eur investigator studieco rdinatiecentrum hypertensie en cardiovasculaire revalidatie eenheid campus gasthuisberg leuven belgium search paper author originally published jun https doi org hyp hypertension syst eur trial stop second planned interim analysis predefined stop rules reveal active treatment diminish incidence stroke primary endpoint ethic committee unanimously resolve endpoint occur february pm include final analysis long communication line coordinating office center country make practical implementation recommendation difficult coordinating office strike delicate balance report long awaited outcome result postpone publication great number terminate report form return initial syst eur report placebo patient patient randomize active treatment classify lose follow precede year report reach coordinating office however publication outcome result september effort locate patient continue short letter provide update base final syst eur database number patient lose follow decrease placebo group active treatment group patient respectively double blind follow die supervised open follow non supervised follow number patient years accumulate placebo active treatment group increase respectively great number endpoint available analysis affect conclusion initial syst eur report table fatal non fatal cancer change active treatment ci p bleed episode include cerebral retinal hemorrhage ci p occur similar frequency treatment group patient recruit eastern europe however longer follow western european patient median versus year death versus non fatal cardiovascular endpoint versus notice western european patients number syst eur patient initially report lose follow substantially low instance general practice take part medical research council trial mild hypertension final syst eur database proportion patient lose follow similar hypertension optimal treatment trial stop accord plan event patient follow least years conclusion syst eur experience confirms large multicenter trial terminate early endpoint available main outcome result publish trial researcher encourage continue search unreported endpoint publish final complete analysis however update lead different conclusion unless selective reporting event one treatment group table updated endpoint systolic hypertension europe trialnature endpointrate per patient years number endpoint relative difference rate placebo groupplacebo n active n rate ci pmortalitytotal cardiovascular non cardiovascular non fatal endpointsstroke cardiac endpoints fatal non fatal endpoint combinedstroke cardiac endpoints heart failure myocardial infarction fatal non fatal cardiovascular endpoints non fatal fatal cardiac endpoint include fatal non fatal heart failure fatal non fatal myocardial infarction sudden death footnotescorrespondence jan staessen md phd studieco rdinatiecentrum hypertensie en cardiovasculaire revalidatie eenheid campus gasthuisberg herestraat b leuven belgium reference amery birkenh ger w bulpitt cj clement de leeuw p dollery ct fagard r fletcher forette f leonetti g brien et malley k rodicio jl rosenfeld j staessen j strasser terzoli l thijs l tuomilehto j webster j syst eur multicentre trial treatment isolated systolic hypertension elderly objective protocol organization age milano medlinegoogle scholar staessen ja fagard r thijs l celis h arabidze gg birkenhager wh bulpitt cj de leeuw pw dollery ct fletcher ae forette f leonetti g nachev c brien et rosenfeld j rodicio jl tuomilehto j zanchetti randomise double blind comparison placebo active treatment old patient isolated systolic hypertension systolic hypertension europe syst eur trial investigator lancet crossrefmedlinegoogle scholar medical research council work party mrc trial treatment mild hypertension principal result br med j crossrefmedlinegoogle scholar hansson l zanchetti carruthers sg dahlof b elmfeldt julius menard j rahn kh wedel h westerling effect intensive blood pressure lower low dose aspirin patient hypertension principal result hypertension optimal treatment hot randomise trial hot study group lancet crossrefmedlinegoogle scholar previous back top next figuresreferencesrelateddetailscited lumu w kibirige wesonga r bahendeka effect nurse led lifestyle choice coach intervention systolic blood pressure among type diabetic patient high atherosclerotic cardiovascular risk study protocol cluster randomized trial trial z online publication date dec krasi ska b paluszkiewicz l miciak awicka e krasinski rzymski p tykarski krasi ski z impact acetylsalicylic acid dose bedtime circadian rhythm blood pressure high risk group cardiovascular patients randomize control trial european journal clinical pharmacology online publication date jan wei f asayama k hara hansen li staessen j blood pressure variability versus blood pressure level risk stratification encyclopedia cardiovascular research medicine b gil extremera b jim nez l pez p mediavilla garc j clinical trial pending subject revista cl nica espa ola english edition j rceng online publication date apr gil extremera b jim nez l pez p mediavilla garc j ensayos cl nicos una asignatura pendiente revista cl nica espa ola j rce online publication date apr wei f obsolete blood pressure variability versus blood pressure level risk stratification reference module biomedical science b parson c murad andersen mookadam f labonte h effect antihypertensive treatment incidence stroke cognitive decline elderly meta analysis future cardiology fca online publication date mar asayama k wei f hara hansen li staessen j blood pressure variability elusive harbinger adverse health outcome blood pressure monitoring cardiovascular medicine therapeutic asayama k wei f hara hansen li staessen j prognosis relation blood pressure variability hypertension online publication date jun verdecchia p gentile g angeli f mazzotta g mancia g reboldi g influence blood pressure reduction composite cardiovascular endpoint clinical trial journal hypertension hjh b e e bb online publication date jul coleman j kendall anglo scandinavian cardiac outcome trial blood pressure lower arm journal clinical pharmacy therapeutic j x online publication date aug campbell f dickinson h cook j beyer f eccles mason j method underpin national clinical guideline hypertension describe evidence shortfall bmc health service research online publication date dec staessen j li thijs l wang j blood pressure reduction cardiovascular prevention update include secondary prevention trial hypertension research hypres staessen j thijs l fagard r celis h birkenh ger w bulpitt c de leeuw p fletcher forette f leonetti g mccormack p nachev c brien e rodicio j rosenfeld j sarti c tuomilehto j webster j yodfat zanchetti effect immediate versus delay antihypertensive therapy outcome systolic hypertension europe trial journal hypertension online publication date apr thijs l den hond e nawrot staessen j prevalence pathophysiology treatment isolated systolic hypertension elderly expert review cardiovascular therapy online publication date sep nawrot den hond e thijs l staessen j isolate systolic hypertension risk vascular disease current hypertension report online publication date oct pringle e phillips c thijs l davidson c staessen j de leeuw p jaaskivi nachev c parati g brien e tuomilehto j webster j bulpitt c fagard r systolic blood pressure variability risk factor stroke cardiovascular mortality elderly hypertensive population journal hypertension online publication date dec wang j staessen j benefit antihypertensive pharmacologic therapy blood pressure reduction outcome trial journal clinical hypertension j x online publication date jan zanchetti emerge data calcium channel blocker cohort study clinical cardiology clc online publication date feb staessen j wang j thijs l cardiovascular prevention blood pressure reduction journal hypertension online publication date jun messerli f evolution calcium antagonist past present future clinical cardiology clc online publication date feb weber calcium channel antagonists treatment hypertension american journal cardiovascular drug bulpitt c beckett n fletcher thijs l staessen j dumitrascu forette f leonetti g nachev c tuomilehto j fagard r withdrawal treatment syst eur trial journal hypertension online publication date feb de leeuw p thijs l birkenh ger w voyaki efstratopoulos fagard r leonetti g nachev c petrie j rodicio j rosenfeld j sarti c staessen j prognostic significance renal function elderly patient isolated systolic hypertension result syst eur trial journal american society nephrology asn online publication date sep robertson j critique hypertension treatment trial evaluation journal evaluation clinical practice j x online publication date may celis h fagard r staessen j thijs l risk benefit treatment isolated systolic hypertension elderly evidence systolic hypertension europe trial current opinion cardiology online publication date nov staessen j wang j thijs l cardiovascular protection blood pressure reduction meta analysis lancet x online publication date oct conti c cooper dehoff r invest hypertension trial change clinical practice clinical cardiology clc v v opie l first line drug chronic stable effort angina case new longer acting calcium channel block agent journal american college cardiology online publication date nov schocken epidemiology risk factor heart failure elderly clinic geriatric medicine online publication date aug jackson j merat p unmet need hypertension challenge opportunity current hypertension report z online publication date dec krasi ska b cofta szczepaniak chiche l rzymski p trafas paluszkiewicz l tykarski krasi ski z effect eplerenone circadian blood pressure pattern leave ventricular hypertrophy patient obstructive sleep apnea resistant hypertension randomize control trial journal clinical medicine jcm hara thijs l asayama k jacob l wang j staessen j fuchs f randomise double blind comparison placebo active drug effect risk associate blood pressure variability systolic hypertension europe trial plos one journal pone e verdecchia p angeli f cavallini c gattobigio r gentile g staessen j reboldi g blood pressure reduction renin angiotensin system inhibition prevention congestive heart failure meta analysis european heart journal eurheartj ehn june vol issue advertisement article informationmetrics http doi org hyp manuscript receivedmarch manuscript acceptedapril originally publishedjune pdf download advertisement,Staessen JA,1999,Hypertension,https://doi.org/10.1161/01.hyp.33.6.1476,10373236,Staessen JA; Thijs L; Birkenhäger WH; Bulpitt CJ; Fagard R,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000959: Antihypertensive Agents; D002561: Cerebrovascular Disorders; D005060: Europe; D006333: Heart Failure; D006801: Humans; D006973: Hypertension; D009203: Myocardial Infarction,,,https://openalex.org/W2149877773,62,11,1,16976,3039,66,en,en
false,combination calcium channel blocker beta blocker patient exercise induced angina pectoris double blind parallel group comparison different class calcium channel blocker,combination calcium channel blocker beta blocker effective treatment exercise induced angina pectoris beta blocker monotherapy since ischemia exercise induced angina essentially precede increase heart rate calcium channel blocker negative chronotropic property may perform good purpose nonchronotropic compound patient week double blind parallel group comparison amlodipine mg diltiazem xr mg mibefradil mg treatment add baseline beta blocker treatment perform exercise testing ett perform bicycle ergometry although none calcium channel blocker improve duration exercise amount workload significantly delay onset mm st segment depres sion ett p treatment versus baseline addition mibefradil low high dose treatment produce large delay low dose different diltiazem amlodipine p respectively high continue next page dose different diltiazem amlodipine p respectively effect linearly correlate amount rate pressure product rpp reduction serious symptom dizziness likewise occur significantly frequently mibefradil p lead patient take mibefradil withdraw trial author conclude calcium channel blocker negative chronotropic property provide good delay ischemia patient exercise induced angina concomitant risk intolerable dizziness largely reduce benefit,van der Vring JA,1999,Angiology,https://doi.org/10.1177/000331979905000602,10378820,van der Vring JA; Daniëls MC; Holwerda NJ; Withagen PJ; Schelling A; Cleophas TJ; Hendriks MG,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000293: Adolescent; D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D017311: Amlodipine; D000787: Angina Pectoris; D001562: Benzimidazoles; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004110: Diltiazem; D004244: Dizziness; D004311: Double-Blind Method; D004338: Drug Combinations; D004562: Electrocardiography; D005080: Exercise Test; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D020748: Mibefradil; D008875: Middle Aged; D017202: Myocardial Ischemia; D005082: Physical Exertion; D013764: Tetrahydronaphthalenes; D013997: Time Factors,,,https://openalex.org/W2148913793,199,26,1,1737,308,9,en,en
false,lowering diastolic blood pressure mmhg attempt except type diabetic hypertension optimal treatment hot trial,recently hypertension optimal treatment hot study report study patient diastolic blood pressure mmhg randomly assign target pressure mmhg respectively treat felodipine based antihypertensive regimen three group impressive fall diastolic systolic blood pressure consequence major cardiovascular event primary endpoint study observe difference endpoint score among three group type diabetic patient fare substantially good non diabetic patient likely profit diastolic pressure decrease mmhg remain patient rigorous maintenance present day standard diastolic pressure mmhg advise addition mg aspirin dd result modest significant reduction major cardiovascular event cost increased gastrointestinal bleeding,Wesseling H,1999,Ned Tijdschr Geneeskd,,10389531,Wesseling H,article,D016430: Clinical Trial; D016420: Comment; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D001241: Aspirin; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002318: Cardiovascular Diseases; D003924: Diabetes Mellitus, Type 2; D003971: Diastole; D015736: Felodipine; D005260: Female; D006471: Gastrointestinal Hemorrhage; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009426: Netherlands; D012189: Retrospective Studies; D015996: Survival Rate",,,https://openalex.org/W2399263992,156,33,1,1038,182,6,en,en
false,comparison bisoprolol verapamil hypertension influence left ventricular mass function pilot study,objective study test influence bisoprolol verapamil left ventricular filling hypertensive patient month randomize double blind trial hypertensive patient previously treat beta blockers calcium inhibitor administration placebo day echocardiogram left ventricle record determine left ventricular mass blood flow evaluate pulsed doppler sonography randomization two group one group receive mg bisoprolol mg verapamil lp single dose morning month treatment patient whose blood pressure well control give diuretic echo doppler perform operator day active treatment month subsequent week placebo patient treat single drug reduction blood pressure comparable two treat group significant decrease left ventricular mass leave ventricular filling improve patient receive bisoprolol effect observe immediately first administration throughout month treatment period decline slowly placebo wash effect appear independent alteration heart rate think specific action drug,Gosse P,1999,Therapie,,10394257,Gosse P; Gressin V; Clerson P; Lemetayer P; Clémenty J,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D017298: Bisoprolol; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D015150: Echocardiography, Doppler; D005260: Female; D006352: Heart Ventricles; D006801: Humans; D006973: Hypertension; D017379: Hypertrophy, Left Ventricular; D008297: Male; D008875: Middle Aged; D009929: Organ Size; D010865: Pilot Projects; D016277: Ventricular Function, Left; D014700: Verapamil",,,https://openalex.org/W2277245366,119,20,1,1412,242,10,en,en
false,comparison verapamil versus felodipine heart rate variability hypertensive patient,objective evaluate effect two calcium channel blocker verapamil felodipine heart rate variability hypertensive patient design time frequency domain measure heart rate variability obtain h holter record previously untreated hypertensive patient without left ventricular hypertrophy month verapamil slow release treatment mg daily felodipine extended release treatment mg daily result blood pressure value decrease drug measure heart rate variability comparable baseline two group unchanged felodipine verapamil average rr interval square root mean squared difference adjacent normal rr interval r mssd percentage difference adjacent normal rr interval pnn measure vagal modulation heart rate increase p p p respectively high felodipine coefficient variation measure compensate heart rate effect increase verapamil p high frequency power coefficient component variance represent vagal modulation heart rate increase verapamil ln unit p p finally low high frequency power ratio indicator sympathovagal balance high value suggest sympathetic predominance decrease verapamil p confirm improvement vagal modulation heart rate conclusion hypertensive patient despite comparable anti hypertensive effect verapamil felodipine favourable effect cardiac autonomic control,Petretta M,1999,J Hypertens,https://doi.org/10.1097/00004872-199917050-00016,10403616,Petretta M; Canonico V; Madrid A; Mickiewicz M; Spinelli L; Marciano F; Vetrano A; Signorini A; Bonaduce D,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000368: Aged; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D015736: Felodipine; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D016037: Single-Blind Method; D013997: Time Factors; D014700: Verapamil,,,https://openalex.org/W2316480306,92,12,1,1957,378,9,en,en
false,comparison two strategy intensify antihypertensive treatment low dose combination enalapril felodipine er versus increase dose monotherapy enalapril,compare two popular strategy intensify treatment hypertension double blind randomize prospective parallel group partial crossover study week placebo run baseline week mg enalapril daily patient randomize week treatment either low dose combination therapy mg enalapril mg felodipine er daily lexxel astra merck inc high dose monotherapy mg enalapril daily vasotec merck co inc group randomize combination significantly great reduction sit systolic diastolic blood pressure bp mm hg compare baseline versus mm hg p well great percentage patient achieve either diastolic bp mm hg decline least mm hg responder v p patient originally take mg enalapril cross combination therapy week bp reduction increase response rate loss significant difference compare treat continuously combination entire week great bp lowering efficacy combination independent age gender race significant difference tolerability regimen data support hypothesis patient achieve goal bp reduction low dose antihypertensive agent combination two drug complementary mechanism action effective increase dose first agent j hypertens american journal hypertension ltd,Elliott WJ,1999,Am J Hypertens,https://doi.org/10.1016/s0895-7061(99)00051-5,10411366,Elliott WJ; Montoro R; Smith D; Leibowitz M; Hwang C; Gradman AH; Schleman M; Klibaner M,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004656: Enalapril; D015736: Felodipine; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D016037: Single-Blind Method; D016896: Treatment Outcome",,,https://openalex.org/W2058969331,170,24,1,1693,316,8,en,en
false,prolonged antihypertensive effect amlodipine prospective double blind randomize study,amlodipine calcium antagonist long elimination half life h allow daily dose treatment hypertension randomized double blind study perform assess residual antihypertensive effect amlodipine mg day discontinue therapy previously well controlled mild moderate hypertensive patient blood pressure bp evaluate conventional obp ambulatory blood pressure monitoring abpm amlodipine mg od administer week period significantly reduce obp abpm mean value p whereas change heart rate observe end active treatment period adequately control patient randomize either amlodipine mg od group amlodipine day follow day period placebo double blind treatment phase group p exhibit significant increase bp assess obp abpm compare group conclusion duration action amlodipine extends largely beyond h span patient omit treatment day bp significantly increase,Biston P,1999,Blood Press,https://doi.org/10.1080/080370599438383,10412882,Biston P; Mélot C; Degaute JP; Clement D; Quoidbach A,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000328: Adult; D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D001795: Blood Pressure Determination; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D013997: Time Factors",,,https://openalex.org/W2158627214,92,11,1,1155,210,8,en,en
true,cohort study calcium channel blocker cardiovascular agent prevalence depression,aim report suggest calcium channel blocker may associate increased incidence depression suicide paucity evidence large scale study aim study assess rate depression calcium channel antagonists use data prescription event monitoring study method observational study large cohort patient use lisinopril enalapril ace inhibitor nicardipine type calcium channel blocker diltiazem type calcium channel blocker conduct use prescription event monitoring rate depression different drug rate ratio ci compute result crude overall rate depression treatment per patient month ace inhibitor diltiazem nicardipine respectively use ace inhibitor reference group rate ratio depression diltiazem nicardipine respectively conclusion study support hypothesis calcium channel blocker associate depression consider patient treat general practice uk,Dunn NR,1999,Br J Clin Pharmacol,https://doi.org/10.1046/j.1365-2125.1999.00982.x,10417501,Dunn NR; Freemantle SN; Mann RD,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000806: Angiotensin-Converting Enzyme Inhibitors; D002121: Calcium Channel Blockers; D002317: Cardiovascular Agents; D015331: Cohort Studies; D003866: Depressive Disorder; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D013405: Suicide,,,https://openalex.org/W1535826526,103,16,1,1195,203,8,en,en
false,comparison clinical efficacy adverse effect extended release felodipine slow release diltiazem patient isolated systolic hypertension,isolate systolic hypertension ish risk factor cardiovascular disease extended release felodipine felodipine er show effective treatment ish caucasian however pharmacological property different another calcium blocker diltiazem also effectiveness tolerability adverse reaction two antihypertensive agent ish thoroughly assess chinese sitting blood pressure bp heart rate body weight adverse reaction serum biochemistry assess patient isolated systolic hypertension treat felodipine er slow release diltiazem diltiazem sr week patient give mg felodipine er mg diltiazem sr daily double twice daily necessary five patient felodipine er four diltiazem sr withdraw intolerable side effect ten week patient respond daily dose mg felodipine er daily dose mg diltiazem sr end treatment felodipine er lower mean bp mmhg baseline mmhg whereas diltiazem sr decrease bp mmhg mmhg significant two group heart rate change significantly either group overall two group patient rate adverse reaction vs similar profile adverse effects equivalent dos felodipine er diltiazem sr effective first line monotherapeutic agent treatment ish,Chern MS,1999,Changgeng Yi Xue Za Zhi,,10418209,Chern MS; Lin FC; Wu D,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D002121: Calcium Channel Blockers; D004110: Diltiazem; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged,,,https://openalex.org/W2404832527,163,20,1,1609,291,8,en,en
false,systematic review antihypertensive therapy evidence assist choose first line drug,background available evidence effectiveness specific first line antihypertensive drug lower blood pressure prevent adverse outcome systematically quantify manner would assist clinician choose first line drug method following literature source search medline cochrane library cd rom issue reference previous meta analyses publish select randomize controlled trial least year duration provide morbidity mortality data compare possible first line antihypertensive therapy either another drug therapy drug drug comparison treatment include placebo drug treatment comparison following outcome pool accord trial design drug drug drug treatment comparison drug therapy death stroke coronary artery disease total cardiovascular event withdrawal due adverse effect decrease systolic diastolic blood pressure result trial identify represent patient meet inclusion criterion four drug class evaluate trial thiazide trial beta adrenergic blocker calcium channel blocker angiotensin converting enzyme ace inhibitor drug drug trial compare thiazide beta blockers former associate significantly low rate withdrawal due adverse effect relative risk rr confidence interval ci trial untreated control group low dose thiazide therapy associate significant reduction risk death rr ci stroke rr ci coronary artery disease rr ci cardiovascular event rr ci high dose thiazide therapy beta blocker therapy calcium channel blocker therapy significantly reduce risk death coronary artery disease result total cardiovascular event express term absolute risk reduction low dose thiazide therapy reduce risk ci number need treat nnt approximately year prevent one event drug drug drug treatment comparison trial thiazide significantly good reduce systolic blood pressure drug class interpretation low dose thiazide therapy prescribe first line treatment hypertension confidence risk death coronary artery disease stroke reduce say high dose thiazide therapy beta blockers calcium channel blocker ace inhibitor,Wright JM,1999,CMAJ,,10420860,Wright JM; Lee CH; Chambers GK,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review; D000078182: Systematic Review","D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001581: Benzothiadiazines; D002121: Calcium Channel Blockers; D004232: Diuretics; D019317: Evidence-Based Medicine; D006801: Humans; D006973: Hypertension; D008875: Middle Aged; D049993: Sodium Chloride Symporter Inhibitors; D016896: Treatment Outcome",,,https://openalex.org/W2121926246,104,16,1,2801,495,13,en,en
false,risk benefit assessment therapy premature labour,prematurity lead cause neonatal morbidity mortality yet incidence preterm birth decline despite use multiple pharmacological agent treat preterm labour review literature conclude following beta agonists show prolong gestation hour however agent show decrease neonatal morbidity mortality adverse effect inevitable life threatening proven benefit mother fetus long term therapy data need regard tolerability efficacy calcium antagonist routine clinical use recommend oxytocin antagonist consider investigational drug study need evaluate effectiveness treatment preterm labour furthermore tolerability oxytocin antagonist mother fetus adequately establish indomethacin prostaglandin inhibitor show delay delivery limited number randomised placebo controlled clinical trial sulindac appear promise never evaluate well control trial neonatal adverse effect appear minimal prostaglandin inhibitor long duration treatment short hour gestational age week magnesium sulfate appear inhibit myometrial contractility ineffective prolong gestation prevent preterm birth furthermore magnesium show decrease neonatal morbidity mortality fact investigator show increase infant mortality agent data support adjunctive antimicrobial therapy treatment preterm labour oral maintenance therapy tocolytic agent show decrease rate preterm birth recurrent preterm labour,Higby K,1999,Drug Saf,https://doi.org/10.2165/00002018-199921010-00004,10433352,Higby K; Suiter CR,article,D016428: Journal Article; D016454: Review,"D000818: Animals; D005260: Female; D006801: Humans; D007752: Obstetric Labor, Premature; D011247: Pregnancy; D018570: Risk Assessment",,,https://openalex.org/W2074058415,59,8,1,1916,313,15,en,en
false,density cd labeled langerhans cell normal human gingiva nifedipine immunosuppressive medication induced gingival overgrowth,purpose study compare distribution langerhans cell normal human gingiva nifedipine immunosuppressive medication induced gingival overgrowth mean immunohistochemical study gingival sample collect nifedipine medicated cardiac patient triple medicated azathioprine prednisolone cyclosporin renal transplant recipient generally healthy individual patient group immunosuppression group combined immunosuppression nifedipine group nifedipine group generally healthy control group five microm thick cryostat section stain monoclonal antibody mab cd use avidin biotin enzyme complex abc method number cd labeled cells mm determine area oral epithelium oral sulcular epithelium sulcular epithelium middle connective tissue connective tissue beneath oral epithelium connective tissue beneath sulcular epithelium significance difference group test mean kruskall wallis test significance difference pair result mann whitney u test test numbers cd labeled cell significantly low medicated group control epithelial area p connective tissue beneath sulcular epithelium p significantly cd labeled cell sulcular epithelium nifedipine group medication groups reduced number cd labeled cell find nifedipine induced gingival overgrowth similar reduced number cd labeled cell gingival overgrowth associate immunosuppressive medication,Nurmenniemi PK,1999,J Periodontol,https://doi.org/10.1902/jop.1999.70.7.752,10440636,Nurmenniemi PK; Pernu HE; Knuuttila ML,article,D003160: Comparative Study; D016428: Journal Article,"D000328: Adult; D000893: Anti-Inflammatory Agents; D018949: Antigens, CD1; D001379: Azathioprine; D002121: Calcium Channel Blockers; D002452: Cell Count; D003238: Connective Tissue; D016572: Cyclosporine; D004846: Epithelial Attachment; D004848: Epithelium; D005260: Female; D005881: Gingiva; D019214: Gingival Overgrowth; D006801: Humans; D007124: Immunoenzyme Techniques; D007166: Immunosuppressive Agents; D016030: Kidney Transplantation; D007801: Langerhans Cells; D008297: Male; D009543: Nifedipine; D011239: Prednisolone",,,https://openalex.org/W2001370516,145,18,1,1764,266,6,en,en
false,effect amlodipine enalapril platelet function patient mild moderate hypertension,aim study compare effect amlodipine enalapril platelet aggregation platelet production malondialdehyde patient mild moderate arterial hypertension parallel double blind placebo controlled study carry patient group patient initially patient receive placebo four week amlodipine mg daily enalapril mg daily take day dosage double week diastolic blood pressure mmhg sit position treatment continue week end placebo active phase platelet aggregation test use adenosine diphosphate collagen adrenaline platelet malondialdehyde production test either basal condition mda basal stimulation arachidonic acid pathway add ethylmaleimide mda activated carry blood pressure reduce agent enalapril amlodipine enalapril control hypertensive patient average dosage mg daily amlodipine control patient dosage mg daily platelet aggregation reduce amlodipine adp microm collagen microg ml adrenaline microm p meanwhile enalapril slightly increase platelet aggregation three agent respectively p n malondialdehyde reduce amlodipine p mda basal p mda activated ratio mda basal mda activated p meanwhile enalapril increase mda basal mda activated reduce ratio mda basal mda activated p agent enalapril amlodipine reduce blood pressure amlodipine reduce platelet aggregation platelet production malondialdehyde indicate action arachidonic acid metabolic pathway,Hernández-Hernández R,1999,Int J Clin Pharmacol Ther,,10442506,Hernández-Hernández R; Armas-Padilla MC; Velasco M; Carvajal AR; Armas de Hernández MJ; Guerrero-Pajuelo J; Pacheco B,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D004656: Enalapril; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008315: Malondialdehyde; D008875: Middle Aged; D010974: Platelet Aggregation; D010975: Platelet Aggregation Inhibitors; D010979: Platelet Function Tests,,,https://openalex.org/W175763440,104,16,1,1971,367,10,en,en
false,comparison antihypertensive efficacy tolerability losartan extended release felodipine patient mild moderate hypertension,appropriate control blood pressure show reduce morbidity mortality patient hypertension losartan potassium selective antagonist angiotensin ii type receptor show lower blood pressure patient hypertension purpose study compare efficacy tolerability losartan extended release er felodipine taiwanese patient mild moderate hypertension patient mild moderate hypertension sit diastolic blood pressure mm hg enrol prospective randomize parallel study sit blood pressure heart rate adverse reaction serum biochemistry value assess week placebo week active treatment patient receive mg losartan mg felodipine er daily dosage adjust double initial level week necessary patient randomly allocate receive losartan n felodipine n therapy complete study three patient losartan group four felodipine group withdraw adverse experience lose follow mean reduction sit diastolic blood pressure week significant losartan mm hg respectively felodipine mm hg respectively differ significantly two group losartan er felodipine well tolerate patient however er felodipine group significantly high rate drug related flushing losartan group vs p result indicate daily administration losartan effective well tolerate daily er felodipine blood pressure reduction,Hung MJ,1999,J Formos Med Assoc,,10443063,Hung MJ; Lin FC; Cherng WJ; Wang CH; Hung KC; Hsieh IC; Wen MS; Wu D,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D000704: Analysis of Variance; D000959: Antihypertensive Agents; D003692: Delayed-Action Preparations; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D019808: Losartan; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies,,,https://openalex.org/W2418936151,148,19,1,1804,328,11,en,en
false,diuretic therapy hypertension cancer risk,,Lip GY,1999,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1000867,10449203,Lip GY; Ferner RE,article,D016428: Journal Article; D016454: Review,"D001581: Benzothiadiazines; D002292: Carcinoma, Renal Cell; D004232: Diuretics; D006801: Humans; D006973: Hypertension; D007680: Kidney Neoplasms; D049993: Sodium Chloride Symporter Inhibitors",,,https://openalex.org/W2320621723,49,9,1,0,0,0,en,
false,comparison isosorbide dinitrate aerosol nifedipine treatment hypertensive emergency,background nitric oxide donor use management hypertensive emergency isosorbide dinitrate aerosol isa nitric oxide fast acting donor aim study compare efficacy isa nifedipine treatment method sixty adult patient randomise receive either isa mg nifedipine mg patient give electrocardiogram ecg immediately prior min administer medication blood pressure bp measure every min first min every min period h result blood pressure value patient isa group decrease significantly mmhg p two patient group angor pectoris evidence subepicardial ischaemia see first ecg disappear drug heart rate decrease similarly patient nifedipine group significant decrease bp mm hg p first ecg normal two patient suffer angor pectoris nifedipine subepicardial ischaemia register second ecg heart rate increase group follow period clinically significant side effect case rebound hypertension observe isa group whereas nifedipine group eight patient report headache four others rebound hypertension conclusion result show favourable effect isa treatment,Rubio-Guerra AF,1999,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1000854,10449212,Rubio-Guerra AF; Vargas-Ayala G; Lozano-Nuevo JJ; Narvaez-Rivera JL; Rodriguez-Lopez L,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004562: Electrocardiography; D004632: Emergency Medical Services; D005260: Female; D006801: Humans; D006973: Hypertension; D007548: Isosorbide Dinitrate; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D020030: Nitric Oxide Donors; D016896: Treatment Outcome,,,https://openalex.org/W2142523359,107,13,1,1602,312,14,en,en
false,fixed dose combination v monotherapy hypertension meta analysis evaluation,fixed dose combination antihypertensive therapy receive interest since publication jnc vi report relatively head head comparative study fixed dose combination first line monotherapies hypertension publish objective study conduct meta analysis various first line monotherapies fixed dose combination amlodipine benazepril result meta analysis use compare efficacy safety first line monotherapies amlodipine benazepril meta analysis include study include treatment group cohort study compare nine different monotherapies one combination therapy amlodipine benazepril study placebo controlled active treatment control mean absolute decrease supine diastolic blood pressure bp range mm hg verapamil show great effect captopril least mm hg mm hg respectively study weight sample size atenolol verapamil lisinopril amlodipine benazepril show great bp effect study weight variance amlodipine benazepril atenolol show great bp effect percentage patient control therapy range lisinopril amlodipine benazepril show great percent control overall incidence adverse effect range lisinopril low nifedipine high incidence overall incidence adverse effect result drug discontinuance range amlodipine benazepril low nifedipine high incidence result meta analysis indicate amlodipine benazepril produce average reduction bp low average incidence overall side effect low incidence adverse effect result drug discontinuance fixed dose combination amlodipine benazepril achieves goal effective bp lower minimum significant side effect,Hilleman DE,1999,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1000855,10449213,Hilleman DE; Ryschon KL; Mohiuddin SM; Wurdeman RL,article,"D016428: Journal Article; D017418: Meta-Analysis; D013485: Research Support, Non-U.S. Gov't",D017311: Amlodipine; D000959: Antihypertensive Agents; D001552: Benzazepines; D004338: Drug Combinations; D006801: Humans; D006973: Hypertension; D017706: Lisinopril; D016896: Treatment Outcome; D014700: Verapamil,,,https://openalex.org/W2331732629,81,10,1,2153,333,16,en,en
false,efficacy amlodipine pediatric patient hypertension,design study determine efficacy safety amlodipine give daily pediatric population twenty one patient mean age year either essential n renal n hypertension newly diagnose n poorly control intolerant exist antihypertensive therapy n include patient receive amlodipine daily start mean dose mg kg per day total daily dose amlodipine increase every day mean home blood pressure measurement hbpm th percentile age gender baseline follow repeat h ambulatory blood pressure monitor study abpm perform patient mean hbpm th percentile goal mean titrate dose require control bp mg kg per day year mg kg per day year mg kg per day essential hypertension mg kg per day renal hypertension abpm demonstrate amlodipine provide effective bp control primary therapy essential patient adverse effect include fatigue n headache n facial flushing n dizziness n edema n abdominal pain n chest pain n nausea n vomit n quality life appear improve therapy amlodipine effective daily antihypertensive agent acceptable safety profile high dos amlodipine require young patient monotherapy effective patient essential hypertension,Tallian KB,1999,Pediatr Nephrol,https://doi.org/10.1007/s004670050614,10454779,Tallian KB; Nahata MC; Turman MA; Mahan JD; Hayes JR; Mentser MI,article,D016430: Clinical Trial; D016428: Journal Article,"D000284: Administration, Oral; D000293: Adolescent; D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002648: Child; D005260: Female; D006801: Humans; D006973: Hypertension; D006977: Hypertension, Renal; D008297: Male; D011446: Prospective Studies; D016896: Treatment Outcome",,,https://openalex.org/W2044330276,62,8,1,1613,305,11,en,en
false,comparison intravenous metoprolol verapamil diltiazem attenuation haemodynamic change associate tracheal extubation,change heart rate systolic diastolic mean blood pressure measure extubation asa grade ii patient assess effect diltiazem mg kg verapamil mg kg metoprolol mg kg give bolus min tracheal extubation haemodynamic variable measure increase significantly extubation control diltiazem group compare base line recording p metoprolol effectively block increase heart rate extubation increase blood pressure group less compare control group p verapamil alleviate increase heart rate blood pressure however profound hypotension bradycardia require therapy occur verapamil group reason careful observation necessary use verapamil routine use drug patient coronary artery disease require study,Yörükoğlu D,1999,Eur J Anaesthesiol,https://doi.org/10.1046/j.1365-2346.1999.00516.x,10457878,Yörükoğlu D; Göktug A; Alanoğlu Z; Tulunay M,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000889: Anti-Arrhythmia Agents; D000959: Antihypertensive Agents; D001794: Blood Pressure; D001919: Bradycardia; D003971: Diastole; D004110: Diltiazem; D006339: Heart Rate; D006801: Humans; D007022: Hypotension; D007403: Intervertebral Disc; D007442: Intubation, Intratracheal; D008159: Lumbar Vertebrae; D008790: Metoprolol; D008875: Middle Aged; D013599: Systole; D014665: Vasodilator Agents; D014700: Verapamil",,,https://openalex.org/W2131621192,140,18,1,985,174,6,en,en
false,hypertension diabetic retinopathy story,improve understanding role hypertension pathogenesis diabetic retinopathy present challenge opportunity ophthalmologist diabetic healthcare professional improve patient care around patient type diabetes hypertensive proportion increase age recent report united kingdom prospective diabetes study ukpds focus attention link hypertension sight loss diabetes report type diabetes accord previous observational study type diabetes demonstrate hypertension risk factor diabetic retinopathy beneficial effect tight blood pressure control review summarise recent paper include ukpds report discuss implication management people diabetes diabetes hypertension among common disease developed country frequency disease rise age wisconsin study examine patient type diabetes hypertension define current antihypertensive treatment mean blood pressure year prevalence hypertension baseline year incidence hypertension common type diabetes ukpds newly diagnose patient type diabetes hypertension define repeat blood pressure antihypertensive medication year diagnosis type diabetes incidence hypertension high age match general population type diabetes development diabetic nephropathy may play major role subsequent development hypertension since microalbuminuria present type diabetic subject onset hypertension pathogenesis hypertension,Gillow JT,1999,Br J Ophthalmol,https://doi.org/10.1136/bjo.83.9.1083,10460781,Gillow JT; Gibson JM; Dodson PM,article,D016428: Journal Article; D016454: Review,D000959: Antihypertensive Agents; D003930: Diabetic Retinopathy; D018450: Disease Progression; D006801: Humans; D006973: Hypertension; D011364: Professional Practice,,,https://openalex.org/W2154741382,57,10,1,1944,322,7,en,en
false,acute hypotensive natriuretic hormonal effect nifedipine salt sensitive salt resistant black normotensive hypertensive subject,randomized double blind study compare short term effect nifedipine mg x daily day versus placebo h blood pressure diuresis natriuresis urinary excretion dopamine metabolite plasma renin activity pra plasma aldosterone level black hypertensive ht patient eight salt resistant ht sr salt sensitive ht ss black normotensive nt subject nt sr eight nt ss study randomly high h low salt l diet comparison placebo nifedipine significantly decrease h mean bp group either h ls diet p h great hypotensive effect achieve nt ss mm hg versus nt sr mm hg p ht ss mm hg versus ht sr mm hg p nt ss ht ss nifedipine induce great p bp decrease h mm hg l mm hg respectively whereas nt sr ht sr hypotensive effect differ h l nifedipine versus placebo significantly increase natriuresis fractional excretion sodium group h p ls diet ht ss hypotensive natriuretic effect nifedipine significantly correlate r p nifedipine produce similar increase urinary excretion dopamine l dopa dopac subject correlate hypotensive natriuretic effect nifedipine modify plasma level renin aldosterone except nt ss h nifedipine increase pra level p conclude although nifedipine reduces bp group nt ht l hs diet effect great salt sensitive subject h although ht ss h short term natriuretic response nifedipine may contribute hypotensive effect diuretic natriuretic effect nifedipine necessary expression hypotensive effect moreover unlikely short term effect nifedipine either renal dopaminergic system secretion aldosterone explain nifedipine short term hypotensive diuretic natriuretic effect,Damasceno A,1999,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-199909000-00005,10470991,Damasceno A; Santos A; Pestana M; Serrão P; Caupers P; Soares-da-Silva P; Polónia J,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000450: Aldosterone; D000959: Antihypertensive Agents; D044383: Black People; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003710: Demography; D004232: Diuretics; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D007668: Kidney; D007677: Kidney Function Tests; D008297: Male; D009318: Natriuresis; D009543: Nifedipine; D011954: Receptors, Dopamine; D012083: Renin; D012965: Sodium Chloride",,,https://openalex.org/W2317618511,148,19,1,2284,443,11,en,en
false,pretreatment verapamil patient persistent chronic atrial fibrillation underwent electrical cardioversion,evaluate prospective randomized fashion efficacy pretreatment verapamil v reduce recurrence atrial fibrillation af electrical cardioversion c increase vulnerability af recurrence probably due af induced change electrophysiologic property atrium electrical remodeling seem due intracellular calcium overload one hundred seven patient persistent chronic af underwent external internal c patient receive oral propafenone p mg day three day entire period follow three month first group patient receive p second group adjunct p oral v mg day initiate three day c continue follow finally third group oral v administer three day continue three day electrical c three month follow patient af recurrence mantel haenszel cumulative chi square reach significant level compare af free survival curve group versus group ii group iii chi square respectively p significantly af relapse occur first week cardioversion high incidence group patient group ii patient p group iii patient p six day oral v administration center c day combine p significantly reduce incidence early recurrence af compare p alone,De Simone A,1999,J Am Coll Cardiol,https://doi.org/10.1016/s0735-1097(99)00256-9,10483964,De Simone A; Stabile G; Vitale DF; Turco P; Di Stasio M; Petrazzuoli F; Gasparini M; De Matteis C; Rotunno R; Di Napoli T,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000368: Aged; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D002908: Chronic Disease; D003131: Combined Modality Therapy; D004554: Electric Countershock; D004562: Electrocardiography; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011292: Premedication; D011405: Propafenone; D011446: Prospective Studies; D012008: Recurrence; D016896: Treatment Outcome; D014700: Verapamil,,,https://openalex.org/W2062457536,125,15,1,1607,308,6,en,en
false,effect intensive antihypertensive treatment aspirin low dose hypertensive hot hypertension optimal treatment study,aim hot study hypertension optimal treatment determine optimal diastolic blood pressure decrease assess effect acetyl salicylic acid primary prevention cardiovascular morbidity mortality hypertensive patient hot study open prospective randomise international trial blinded end point study include patient year old mean year country patient france primary hypertension pad mmhg patient randomise target diastolic blood pressure mmhg n mmhg n mmhg n felodipine lp long acting dihydropyridine select first line therapy hypertension drug combine necessary low incidence cardiovascular event observe diastolic blood pressure level mmhg increase risk level even hypertensive patient medical history coronary heart disease stroke diabetic population diastolic blood pressure decrease reduce incidence major cardiovascular event acetyl salicylic acid reduce myocardial infarction risk blood pressure well controlled population,Mallion JM,1999,Arch Mal Coeur Vaiss,,10486668,Mallion JM; Benkritly A; Hansson L; Zanchetti A,article,D016430: Clinical Trial; D004740: English Abstract; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000368: Aged; D000369: Aged, 80 and over; D000959: Antihypertensive Agents; D001241: Aspirin; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005060: Europe; D015736: Felodipine; D006801: Humans; D006973: Hypertension; D008875: Middle Aged",,,https://openalex.org/W593384039,146,27,2,1338,255,9,en,en
false,effect amlodipine exercise induced platelet activation patient affect chronic stable angina,abstract background literature concern exercise induced platelet activation chronic stable angina somewhat confusing reason lie type exercise well methodological problem powerful recently introduce procedure detect platelet activation flow cytometry platelet response activate factor mediate calcium uptake however calcium antagonist effect platelet activity still unclear hypothesis study undertake investigate exercise induced platelet activation treatment amlodipine chronic stable angina method twenty patient chronic stable angina enter study subject underwent symptom limited cycloergometer stress test follow washout period week blood sample collect immediately exercise subject randomize two group patient group group take amlodipine mg day placebo week respectively subsequently undergo second exercise stress test blood sample obtain immediately exercise flow cytometric evaluation platelet activity perform order recognize gmp expression platelet membrane result strenuous exercise induce significant increase platelet activation subject prior therapy significant difference observe platelet activity rest group whereas significant decrease exercise induced platelet activation demonstrate group compare group conclusion data provide evidence favorable effect amlodipine exercise induced platelet activation patient affect chronic stable angina,Sanguigni V,1999,Clin Cardiol,https://doi.org/10.1002/clc.4960220907,10486696,Sanguigni V; Gallù M; Sciarra L; Del Principe D; Menichelli A; Palumbo G; Cannata D; Strano A,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D017311: Amlodipine; D000787: Angina Pectoris; D002118: Calcium; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D015444: Exercise; D005080: Exercise Test; D005260: Female; D005434: Flow Cytometry; D006801: Humans; D008297: Male; D008875: Middle Aged; D015539: Platelet Activation; D018709: Statistics, Nonparametric",,,https://openalex.org/W2055621826,106,14,1,1770,275,14,en,en
false,pharmacovigilance characteristic widely use drug bulgaria,present study analyse registered adverse drug reaction cause use drug bulgaria three year period case assemble spontaneous reporting system operate country describe demographic characteristic patient clinical diagnosis reporting rate per inhabitant drug data antibiotic compare result previous research analyse adverse drug reaction e report receive centre drug safety national drug institute adverse drug reaction type b oedema allergy coma etc predominate number case perforated ulcer melaena cause acetylsalicylic acid considerable frequency adverse drug reaction investigated drug rare accord standard necessary assemble information adverse drug reaction every serious case inform medical doctor pharmacist first step improve pharmacovigilance system bulgaria,Getov I,1999,Cent Eur J Public Health,,10499144,Getov I; Dimitrova Z,article,D016428: Journal Article,"D000293: Adolescent; D000328: Adult; D016907: Adverse Drug Reaction Reporting Systems; D017677: Age Distribution; D000900: Anti-Bacterial Agents; D002031: Bulgaria; D002648: Child; D002675: Child, Preschool; D016903: Drug Monitoring; D064420: Drug-Related Side Effects and Adverse Reactions; D005260: Female; D006801: Humans; D007223: Infant; D007231: Infant, Newborn; D008297: Male; D008875: Middle Aged; D017891: Pharmacoepidemiology; D017678: Sex Distribution",,,https://openalex.org/W2414479305,77,12,1,1067,181,11,en,en
false,atenolol versus amlodipine versus isosorbide mononitrate anginal symptom syndrome x,effect beta blocker atenolol calcium antagonist amlodipine nitrate isosorbide mononitrate anginal symptom patient syndrome x assess crossover double blind randomize trial atenolol find significantly improve chest pain episode suggest preferred drug start pharmacologic treatment patient syndrome x,Lanza GA,1999,Am J Cardiol,https://doi.org/10.1016/s0002-9149(99)00450-6,10513787,Lanza GA; Colonna G; Pasceri V; Maseri A,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000319: Adrenergic beta-Antagonists; D017311: Amlodipine; D000704: Analysis of Variance; D001262: Atenolol; D018592: Cross-Over Studies; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D007548: Isosorbide Dinitrate; D017566: Microvascular Angina; D008875: Middle Aged; D018709: Statistics, Nonparametric; D016896: Treatment Outcome; D014665: Vasodilator Agents",,,https://openalex.org/W2044474620,92,11,1,415,72,2,en,en
false,retract article combine diltiazem lidocaine reduces cardiovascular response tracheal extubation anesthesia emergence hypertensive patient,purpose hypertensive patient exhibit exaggerated cardiovascular response tracheal extubation study undertake compare efficacy combined diltiazem lidocaine drug alone suppress hemodynamic change tracheal extubation method sixty hypertensive patient asa ii define systolic blood pressure mmhg diastolic blood pressure mmhg undergo elective orthopedic surgery receive randomized double blind manner mg x kg diltiazem mg x kg lidocaine mg x kg diltiazem plus mg x kg lidocaine n v tracheal extubation change heart rate hr mean arterial pressure map rate pressure product rpp measure tracheal extubation result hemodynamic change tracheal extubation less patient receive diltiazem plus lidocaine receive diltiazem lidocaine sole medicine rpp combine v diltiazem lidocaine mean sd p conclusion combine diltiazem lidocaine effective prophylaxis diltiazem lidocaine alone attenuate cardiovascular response tracheal extubation emergence anesthesia hypertensive patient,Fujii Y,1999,Can J Anaesth,https://doi.org/10.1007/bf03013130,10522582,Fujii Y; Saitoh Y; Takahashi S; Toyooka H,article,D003160: Comparative Study; D016428: Journal Article; D016441: Retracted Publication,"D000368: Aged; D000762: Anesthesia Recovery Period; D000889: Anti-Arrhythmia Agents; D000959: Antihypertensive Agents; D001794: Blood Pressure; D004110: Diltiazem; D004359: Drug Therapy, Combination; D005260: Female; D006339: Heart Rate; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D007442: Intubation, Intratracheal; D008012: Lidocaine; D008297: Male; D008875: Middle Aged; D019637: Orthopedic Procedures; D011229: Preanesthetic Medication",,,https://openalex.org/W2032197013,157,19,1,1335,245,7,en,en
false,effectiveness nifedipine git combination atenolol chronic stable angina,nifedipine gastrointestinal therapeutic system git daily formulation nifedipine provide stable plasma concentration entire h dose interval two hundred one patient canadian cardiovascular society class ii iii angina mg atenolol yet still experience angina symptom randomize receive either placebo nifedipine git mg day four week treatment change time baseline onset mm st segment depression eligible patient placebo mg day group respectively difference significant p mg day group compare placebo mg day group compare mg day group time onset pain termination exercise show similar prolongation achieve statistical significance one year open label phase study patient exhibit statistically significant improvement time onset st segment depression time anginal pain time termination exercise mean dose mg day nifedipine git adverse event primarily vasodilatory nature study support use nifedipine git patient chronic stable angina inadequately control beta blocker alone,Toal CB,1999,Can J Cardiol,,10523477,Toal CB; Motro M; Baird MG; Klinke P; Sclarowski S; Zilberman A; Marmor A; Kostuk WJ; Lotan C; Weiss A; Erne P; Palant A; Stolero D; Bélanger L; Turpie A,article,"D016430: Clinical Trial; D017427: Clinical Trial, Phase II; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000319: Adrenergic beta-Antagonists; D000368: Aged; D000787: Angina Pectoris; D001262: Atenolol; D002908: Chronic Disease; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D014665: Vasodilator Agents,,,https://openalex.org/W2394978758,87,13,1,1418,244,8,en,en
false,amlodipine lower blood pressure without affect cerebral blood flow measure single photon emission compute tomography elderly hypertensive subject,evaluate effect amlodipine blood pressure cerebral blood flow elderly subject mild moderate hypertension double blind parallel group study patient week placebo run period amlodipine mg match placebo give daily weeks amlodipine significantly reduce blood pressure compare baseline diastolic blood pressure significantly reduce amlodipine compare placebo p p ambulatory blood pressure monitoring show blood pressure control sustain h dosing interval relative regional cerebral blood flow assess use single photon emission compute tomography significantly affect amlodipine three placebo patient amlodipine patient withdraw adverse events amlodipine well tolerated effective antihypertensive agent reduce regional cerebral blood flow elderly hypertensive patient,Pandita-Gunawardena ND,1999,Age Ageing,https://doi.org/10.1093/ageing/28.5.451,10529039,Pandita-Gunawardena ND; Clarke SE,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D001921: Brain; D002560: Cerebrovascular Circulation; D004311: Double-Blind Method; D005260: Female; D006299: Health Services for the Aged; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D015899: Tomography, Emission-Computed, Single-Photon",,,https://openalex.org/W2060497636,161,21,1,979,154,6,en,en
false,nifedipine versus ritodrine suppression preterm labor meta analysis,since large randomized clinical trial compare effectiveness nifedipine ritodrine suppression preterm labor lack perform meta analysis subject search database medline embase use keywords nifedipine ritodrine randomized randomised study score blinding method randomization type analysis intention treat versus par protocol subsequently two two table construct use delay labor hour delay labor beyond week gestation perinatal mortality respiratory distress syndrome admission neonatal intensive care unit end point homogeneity study test breslow day test pool odds ratio calculate case homogeneity could rejected could detect ten study publish incorporate data patient nifedipine reduce risk delivery within hour compare ritodrine difference statistically significant odds ratio confidence interval nifedipine also reduce risk delivery week compare ritodrine difference statistically significant odds ratio confidence interval aware study report long term outcome since study report long term outcome lack choice nifedipine ritodrine base obstetrical short term neonatal outcome perspective nifedipine drug first choice suppression preterm labor,Oei SG,1999,Acta Obstet Gynecol Scand,https://doi.org/10.1034/j.1600-0412.1999.780908.x,10535341,Oei SG; Mol BW; de Kleine MJ; Brölmann HA,article,D003160: Comparative Study; D016428: Journal Article; D017418: Meta-Analysis,"D005260: Female; D006801: Humans; D007226: Infant Mortality; D007231: Infant, Newborn; D009543: Nifedipine; D007752: Obstetric Labor, Premature; D016017: Odds Ratio; D011247: Pregnancy; D016032: Randomized Controlled Trials as Topic; D012127: Respiratory Distress Syndrome, Newborn; D018570: Risk Assessment; D012312: Ritodrine; D015149: Tocolytic Agents; D016896: Treatment Outcome",,,https://openalex.org/W2155574814,77,11,1,1658,281,9,en,en
false,initiation atrial fibrillation ectopic beat originate pulmonary vein,atrial fibrillation af initiate ectopic beat originate atrial great venous tissue study investigate anatomic characteristic electrophysiological property pulmonary vein pvs well possible mechanism response drug ectopic focus assess effect radiofrequency rf ablation af initiate ectopic beat originate pvs seventy nine patient frequent episode paroxysmal af control patient include distal pvs show short effective refractory period erps right superior pvs show high incidence intra pv conduction block leave superior pvs superior leave pvs longer myocardial sleeve inferior right pvs respectively electrophysiological characteristic similar af control patient propranolol verapamil procainamide suppress ectopic beat originate pvs ectopic focus initiate af originate pvs mean rf application completely eliminate ectopic focus month follow period patient free af without antiarrhythmic drug follow transesophageal echocardiogram show ablated pvs focal stenosis one patient mild exertional dyspnea ablation resolve month later patient onset mild exertional dyspnea month ablation electrophysiological characteristic pvs different atrium ectopic beat pvs initiate af beta adrenergic receptor blocker calcium channel blocker sodium channel blocker suppress ectopic beat careful mapping elimination ectopic foci cure paroxysmal af,Chen SA,1999,Circulation,https://doi.org/10.1161/01.cir.100.18.1879,10545432,Chen SA; Hsieh MH; Tai CT; Tsai CF; Prakash VS; Yu WC; Hsu TL; Ding YA; Chang MS,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D018880: Atrial Premature Complexes; D017115: Catheter Ablation; D004562: Electrocardiography; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011342: Procainamide; D011433: Propranolol; D011667: Pulmonary Veins; D016896: Treatment Outcome; D014700: Verapamil",,,https://openalex.org/W2105450637,87,12,1,1801,302,14,en,en
true,calcium channel blocker mortality elderly patient myocardial infarction,although calcium channel blocker useful therapy relieve angina lower blood pressure slow conduction atrial fibrillation grow evidence cast doubt safety patient coronary disease examine association calcium channel blocker therapy hospital discharge mortality population based sample elderly patient hospitalize acute myocardial infarction retrospective cohort study use data medical chart administrative files acute care hospital states medicare patient principal diagnosis acute myocardial infarction consecutively discharge hospital alive month period n mortality day year calcium channel blocker widely prescribe hospital discharge elderly patient myocardial infarction n commonly prescribed diltiazem n nifedipine n amlodipine n verapamil n adjust illness severity concomitant medication use patient prescribe calcium channel blocker hospital discharge increase risk day year mortality exception n treat bepridil bepridil differs calcium channel blocker tendency prolong repolarization association proarrhythmic effect elderly patients identify mortality risk large consecutive sample elderly patient myocardial infarction support need additional prospective trial examine calcium channel blocker therapy ischemic heart disease,Jollis JG,1999,Arch Intern Med,https://doi.org/10.1001/archinte.159.19.2341,10547174,Jollis JG; Simpson RJ; Chowdhury MK; Cascio WE; Crouse JR; Massing MW; Smith SC,article,"D016428: Journal Article; D016448: Multicenter Study; D013487: Research Support, U.S. Gov't, P.H.S.","D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D015764: Bepridil; D002121: Calcium Channel Blockers; D004110: Diltiazem; D005260: Female; D006801: Humans; D016015: Logistic Models; D008297: Male; D009203: Myocardial Infarction; D009543: Nifedipine; D012189: Retrospective Studies; D012720: Severity of Illness Index; D013997: Time Factors; D016896: Treatment Outcome; D014481: United States; D014700: Verapamil",,,https://openalex.org/W2094250001,85,11,1,1738,276,3,en,en
false,sex difference response blood pressure calcium antagonism treatment moderate severe hypertension,pressor response examination clinic setting call white coat effect wce response may confounder investigator use clinic blood pressure measure response antihypertensive therapy study effect pressor response evaluate sex specific effect treatment calcium antagonism blood pressure measure clinic ambulatory blood pressure monitoring abpm untreated hypertensive subject n seat clinic diastolic blood pressure dbp mmhg study day clinic systolic blood pressure sbp ambulatory sbp obtain week placebo month treatment either nifedipine verapamil randomized blind parallel trial placebo woman average sbp mmhg low clinic sbp contrast men average sbp placebo mmhg low clinic sbp significantly great reduction clinic sbp woman men month treatment versus mmhg p however reduction ambulatory sbp month sex versus mmhg study moderate severe hypertensive large wce measure woman markedly diminish treatment account observed sex difference response clinic sbp calcium antagonism contrast abpm equivalent response treatment sex use abpm could valuable mean eliminate wce confounder clinical research,Loeb ED,1999,Blood Press Monit,https://doi.org/10.1097/00126097-199900450-00001,10547639,Loeb ED; Diamond JA; Krakoff LR; Phillips RA,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003971: Diastole; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D009543: Nifedipine; D012727: Sex Characteristics; D016037: Single-Blind Method; D013599: Systole; D014700: Verapamil,,,https://openalex.org/W2060366820,118,16,1,1612,294,9,en,en
false,use calcium antagonist hypertension,prevention treatment hypertension remain major challenge clinician world recently publish sixth report joint national committee prevention detection evaluation treatment high blood pressure jnc vi use evidence based medicine provide guideline aid clinician prevention detection treatment high blood pressure include pharmacological approach calcium antagonist use widely treatment hypertension jnc vi focus specific situation calcium antagonist could consider preferred treatment large number calcium antagonist available variety pharmacodynamic pharmacokinetic action several sustained release formulation drug also available term blood pressure control calcium antagonist effective antihypertensive treatment beta blockers ace inhibitor angiotensin ii receptor blocker black patient dihydropyridine calcium antagonist show reduce morbidity mortality elderly patient isolated systolic hypertension rate lowering calcium antagonist use alternative beta blockers patient coronary artery disease hypertension calcium antagonist use alternative ace inhibitor patient hypertension concomitant diabetes mellitus renal disease dihydropyridine calcium antagonist may useful alternative ace inhibitor patient hypertension systolic heart failure calcium antagonists appear extremely useful patient cyclosporin induced hypertension patient hypertension concomitant raynaud phenomenon migraine rate lowering agent use patient atrial tachyarrhythmias hypertension clinician aware drug drug interaction involve calcium antagonist especially recent problem mibefradil although retrospective study cause controversy regard safety calcium antagonist patient hypertension recent prospective study reveal major safety concern drug,Singh V,1999,Drugs,https://doi.org/10.2165/00003495-199958040-00001,10551431,Singh V; Christiana J; Frishman WH,article,D016428: Journal Article; D016454: Review,D000367: Age Factors; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D003131: Combined Modality Therapy; D004347: Drug Interactions; D006801: Humans; D006973: Hypertension; D007166: Immunosuppressive Agents; D017410: Practice Guidelines as Topic; D044469: Racial Groups,,,https://openalex.org/W2020148100,46,7,1,2240,325,14,en,en
false,hemodynamic effect lomir adalat patient postoperative arterial hypertension,comparison hypotensive effect lomir isradipine adalat nifedipine patient show lomir effective aortocoronary bypass surgery normalization arterial pressure start min lomir infusion follow increase cardiac output decrease peripheral vascular resistance arterial pressure rise lomir infusion discontinue adalat arterial pressure normalize min later therapeutic effect achieve high dose time high recommend cardiac output change cardiac arrhythmia observe patient therefore lomir preferable ca channel blocker treat postoperative arterial hypertension aortocoronary bypass surgery,Eremenko AA,1999,Anesteziol Reanimatol,,10560156,Eremenko AA; Ziuliaeva TP; Bozh'eva LV; Borisov RIu,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article,D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D001026: Coronary Artery Bypass; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D008875: Middle Aged; D009543: Nifedipine; D011183: Postoperative Complications; D013997: Time Factors,,,,99,16,1,796,134,6,en,en
false,comparison effect different long acting delivery system pharmacokinetics pharmacodynamics diltiazem,benzothiazepine calcium channel antagonist diltiazem short acting drug achieve effective h blood pressure control daily dosing rely various extended drug delivery system grow importance result recent report relate use short acting calcium channel antagonists increase cardiovascular morbidity study examine pharmacokinetics result pharmacodynamics two different delivery system load mg diltiazem administer moderately hypertensive patient randomized double blind crossover trial week single blind placebo lead patient clinical diastolic blood pressure mm hg randomize either single dual microbead diltiazem delivery system week period end period subject evaluate h ambulatory blood pressure monitoring subject h inpatient pharmacokinetic analysis separate day follow similar week period subject treat alternative delivery system,Smith DH,1999,Am J Hypertens,https://doi.org/10.1016/s0895-7061(99)00097-7,10560790,Smith DH; Neutel JM; Weber MA,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D018592: Cross-Over Studies; D004110: Diltiazem; D004305: Dose-Response Relationship, Drug; D016503: Drug Delivery Systems; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W1976599248,126,16,1,1121,174,6,en,en
false,use calcium channel blocker pediatric renal transplant recipient,hypertension htn significant problem pediatric renal transplant tp recipient predispose individual development cardiovascular disease graft dysfunction calcium channel blocker ccb consider excellent agent treat post tp htn compare efficacy adverse effect two commonly prescribed ccbs pediatric renal tp population nifedipine procardia p amlodipine norvasc n patient n start ccb systolic sbp diastolic bp dbp change adjunctive antihypertensive medication dos cross period post tp pretreatment pretx sbp mmhg post treatment sbp mmhg patient n p vs pretx p alone n p vs pretx p antihypertensive n p n vs pretx post tp pretreatment dbp mmhg post treatment dbp mmhg patient n p vs pretx p alone n p vs pretx p antihypertensive n p n vs pretx p n equally effective reduce sbp p n dbp p n cyclosporin cya dose p trough level p similar p n treated patient calculate gfr virtually identical p n treated patient p patient parent report high incidence various side effects receive p include headache flushing dizziness leg cramp furthermore report degree gingival hyperplasia treatment p patient report stabilization reduction hypertrophy switch p n conclude ccbs n efficacious drug purpose bp control renal protection pediatric renal tp recipient,Silverstein DM,1999,Pediatr Transplant,https://doi.org/10.1034/j.1399-3046.1999.00056.x,10562973,Silverstein DM; Palmer J; Baluarte HJ; Brass C; Conley SB; Polinsky MS,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article,"D000293: Adolescent; D017311: Amlodipine; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D004359: Drug Therapy, Combination; D005260: Female; D005919: Glomerular Filtration Rate; D006801: Humans; D006973: Hypertension; D007166: Immunosuppressive Agents; D016030: Kidney Transplantation; D008297: Male; D009543: Nifedipine; D012189: Retrospective Studies; D016896: Treatment Outcome",,,https://openalex.org/W2170679291,72,9,1,2011,453,14,en,en
true,randomize double blind comparison calcium antagonist diuretic elderly hypertensive national intervention cooperative study elderly hypertensive study group,although diuretic recommend treatment hypertension decrease diuretic use increase calcium antagonist use necessitate comparison efficacy drug prevent cardiovascular event patient year age systolic blood pressure mm hg diastolic blood pressure mm hg enrol patient randomly assign mg sustained release nicardipine hydrochloride twice daily mg trichlormethiazide daily double dummy method follow year total patient analyze nicardipine group diuretic group blood pressure entry mm hg mm hg respectively decrease mm hg mm hg respectively cardiovascular morbidity rate per person per year similar nicardipine diuretic group respectively p sex age adjusted risk ratio nicardipine group confidence interval p calcium antagonist diuretic group similarly decreased rate cardiovascular event,,1999,Hypertension,,10567194,,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000368: Aged; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004232: Diuretics; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D009529: Nicardipine; D011674: Pulse; D049993: Sodium Chloride Symporter Inhibitors; D014237: Trichlormethiazide,,,https://openalex.org/W4300707695,177,24,2,1159,204,8,en,en
false,prognostic implication ambulatory myocardial ischemia arrhythmia relation ischemia exercise chronic stable angina pectoris angina prognosis study stockholm apsis,prognostic significance ambulatory ischemia alone relation ischemia exercise assess patient men chronic stable angina pectoris take part angina prognosis study stockholm apsis hour ambulatory electrocardiographic registration exercise test baseline n month n double blind treatment metoprolol verapamil ambulatory electrocardiogram analyze ventricular premature complex st segment depression median follow month patient die cardiovascular cv cause nonfatal myocardial infarction underwent revascularization patient cv death episode median v p long median duration v minute p st segment depression patient without event undergone revascularization duration also longer v minute p multivariate cox model include sex history previous myocardial infarction hypertension diabetes duration st segment depression independently predict cv death exercise testing include ambulatory ischemia carry additional prognostic information among patient st segment depression mm exercise treatment give treatment effect ambulatory ischemia add cox model significant impact prognosis find ventricular premature complex carry prognostic information thus patient stable angina pectoris ischemia ambulatory monitoring show independent prognostic importance regard cv death ambulatory electrocardiographic monitoring exercise test provide complementary information among patient marked ischemia exercise treatment reduce ambulatory ischemia short term treatment effect significantly influence prognosis,Forslund L,1999,Am J Cardiol,https://doi.org/10.1016/s0002-9149(99)00526-3,10569322,Forslund L; Hjemdahl P; Held C; Eriksson SV; Björkander I; Rehnqvist N,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D000368: Aged; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D002908: Chronic Disease; D015716: Electrocardiography, Ambulatory; D005080: Exercise Test; D005260: Female; D006801: Humans; D008297: Male; D008790: Metoprolol; D008875: Middle Aged; D017202: Myocardial Ischemia; D011379: Prognosis; D016032: Randomized Controlled Trials as Topic; D016019: Survival Analysis; D014700: Verapamil",,,https://openalex.org/W2023668280,195,30,1,1970,321,12,en,en
false,randomise trial old new antihypertensive drug elderly patient cardiovascular mortality morbidity swedish trial old patient hypertension study,efficacy new antihypertensive drug question compare effect conventional new antihypertensive drug cardiovascular mortality morbidity elderly patients prospective randomise trial patient age year hypertension blood pressure mm hg systolic mm hg diastolic patient randomly assign conventional antihypertensive drug atenolol mg metoprolol mg pindolol mg hydrochlorothiazide mg plus amiloride mg daily new drug enalapril mg lisinopril mg felodipine mg isradipine mg daily assess fatal stroke fatal myocardial infarction fatal cardiovascular disease analysis intention treat blood pressure decrease similarly treatment group primary combined endpoint fatal stroke fatal myocardial infarction fatal cardiovascular disease occur patient conventional drug group event per patient years newer drug group per relative risk ci p combined endpoint fatal non fatal stroke fatal non fatal myocardial infarction cardiovascular mortality occur patient take conventional drug take new drug p old new antihypertensive drug similar prevention cardiovascular mortality major event decrease blood pressure major importance prevention cardiovascular event,Hansson L,1999,Lancet,https://doi.org/10.1016/s0140-6736(99)10327-1,10577635,Hansson L; Lindholm LH; Ekbom T; Dahlöf B; Lanke J; Scherstén B; Wester PO; Hedner T; de Faire U,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D000959: Antihypertensive Agents; D001794: Blood Pressure; D015992: Body Mass Index; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D009203: Myocardial Infarction; D011446: Prospective Studies; D012044: Regression Analysis; D012306: Risk; D020521: Stroke; D013548: Sweden",,,https://openalex.org/W2139805666,174,25,1,1611,282,8,en,en
false,hour blood pressure monitoring diagnosis therapy arterial hypertension,prospective open multicentric study two group b patient essential hypertension use different method blood pressure measurement treatment calcium channel blocker nifidipine git mg fifty one patient follow week result hour blood pressure monitoring visit week know physician group group patient take blood pressure twice per day method measurement show overall decrease blood pressure course therapy mean value medical visit always high average measurement hour monitoring self assessment blood pressure latter two blood pressure value tend agree favorably difference measurement medical visit measurement take home normal activity show measurements doctor office may lead overestimation hypertension without result blood pressure monitor patient group b treat without reason nifedipine git well tolerate nine patient undesired drug effect lead premature halt treatment,Bachmann LM,1999,Praxis (Bern 1994),,10605328,Bachmann LM; Holm D; Vetter W,article,D016430: Clinical Trial; D004740: English Abstract; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D015924: Blood Pressure Monitors; D002121: Calcium Channel Blockers; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011446: Prospective Studies; D016896: Treatment Outcome,,,https://openalex.org/W2420472406,86,14,1,1242,218,9,en,en
false,comparative study ace inhibition angiotensin ii antagonism calcium channel blockade flow mediated vasodilation patient coronary disease banff study,determine effect angiotensin converting enzyme ace inhibition brachial flow mediated vasodilation quinapril ace inhibitor high affinity show improve coronary endothelial dysfunction patient coronary artery disease effectiveness different vasoactive agent improve human endothelial function unknown high resolution ultrasound use assess endothelium dependent brachial artery flow mediated vasodilation fmd patient coronary disease study patient mean age year partial block cross design trial patient randomize one four different drug sequence receive quinapril mg enalapril mg losartan mg amlodipine mg daily patient receive three drug two week washout period treatment primary end point absolute difference fmd eight week study drug compare respective baseline analyze blind fashion mild impairment fmd baseline change fmd baseline significant quinapril p change see losartan p amlodipine p enalapril p significant change nitroglycerin induced dilation occur drug therapy improvement quinapril response see dd ace genotype see id ii genotype respectively p quinapril associate significant improvement fmd response relate presence insertion allele ace genotype,Anderson TJ,2000,J Am Coll Cardiol,https://doi.org/10.1016/s0735-1097(99)00537-9,10636260,Anderson TJ; Elstein E; Haber H; Charbonneau F,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D017311: Amlodipine; D000804: Angiotensin II; D000806: Angiotensin-Converting Enzyme Inhibitors; D001783: Blood Flow Velocity; D002121: Calcium Channel Blockers; D003326: Coronary Circulation; D003327: Coronary Disease; D004359: Drug Therapy, Combination; D004656: Enalapril; D004730: Endothelium, Vascular; D005260: Female; D006801: Humans; D007546: Isoquinolines; D019808: Losartan; D008297: Male; D008875: Middle Aged; D000077583: Quinapril; D044005: Tetrahydroisoquinolines; D014664: Vasodilation",,,https://openalex.org/W2091301735,170,25,1,1741,323,10,en,en
false,use esmolol nicardipine combination blunt hemodynamic change laryngoscopy tracheal intubation,laryngoscopy tracheal intubation lti often provoke undesirable increase blood pressure bp heart rate hr test premise nicardipine nic esmolol esm combination comb would oppose adult surgical patient receive pretreatment randomize iv bolus nic g kg n esm mg kg n comb one half dose n peak bp hr lti compare control cont n pretreatment anesthetic induction standardize iv thiopental mg kg fentanyl g kg succinylcholine mg kg systolic diastolic mean bp hr awake pretreatment baseline similar test group patient treat hypotension bradycardia tachycardia pretreatment anesthetic induction peak hr lti increase versus baseline cont test group differ cont among test group peak sbp dbp increase versus baseline cont esm nic comb peak sbp dbp mbp increase esm versus comb peak dbp esm versus nic compare pretreatment iv induction general anesthesia peak increase bp lti best blunt combination nicardipine esm compare either drug alone single drug combination dos test opposed increase hr implication compare pretreatment iv induction general anesthesia peak increase blood pressure laryngoscopy tracheal intubation best blunt combination nicardipine esmolol compare either drug alone single drug combination dos test opposed increased heart rate,Atlee JL,2000,Anesth Analg,https://doi.org/10.1097/00000539-200002000-00008,10648307,Atlee JL; Dhamee MS; Olund TL; George V,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000769: Anesthesia, Inhalation; D001145: Arrhythmias, Cardiac; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004359: Drug Therapy, Combination; D005260: Female; D006339: Heart Rate; D006439: Hemodynamics; D006801: Humans; D007442: Intubation, Intratracheal; D007828: Laryngoscopy; D008297: Male; D008875: Middle Aged; D009529: Nicardipine; D011183: Postoperative Complications; D011412: Propanolamines",,,https://openalex.org/W2056043930,125,19,1,1764,355,14,en,en
false,efficacy safety calcium channel blocker heart failure focus recent trial second generation dihydropyridines,chronic heart failure chf high morbidity mortality rate despite treatment angiotensin converting enzyme inhibitor diuretic digoxin adjunctive vasodilation calcium channel blockade suggest potentially useful however first generation calcium channel blocker include dihydropyridine nifedipine show disappointing result chf second generation dihydropyridines expect value calcium channel blocker drug one study patient chf medline databank use search study human publish later use dihydropyridines patient chf reference study find subsequently check additional data study patient chf consistent beneficial effect observe regard exercise tolerance functional capacity whereas plasma neurohormone affect hand general worsening chf see second generation dihydropyridines two large study praise v heft iii give estimate long term effect dihydropyridines overall influence mortality rate find note subanalysis praise study suggest patient nonischemic cause chf amlodipine might beneficial effect survival review focus efficacy safety dihydropyridines patient chf report recent trial data support use dihydropyridines primarily give treatment chf result however suggest drug safely give patient left ventricular dysfunction chf need additional treatment angina pectoris hypertension,de Vries RJ,2000,Am Heart J,https://doi.org/10.1067/mhj.2000.101490,10650289,de Vries RJ; van Veldhuisen DJ; Dunselman PH,article,D016428: Journal Article; D016454: Review,"D017311: Amlodipine; D002121: Calcium Channel Blockers; D004095: Dihydropyridines; D005080: Exercise Test; D017079: Exercise Tolerance; D015736: Felodipine; D006333: Heart Failure; D006439: Hemodynamics; D006801: Humans; D016277: Ventricular Function, Left",,,https://openalex.org/W4251018645,128,18,1,1840,305,11,en,en
true,long term effect angiotensin converting enzyme inhibition metabolic control hypertensive type diabetic patient,long term effect angiotensin converting enzyme inhibition metabolic control hypertensive type diabetic patients backgroundin hypertensive type diabetic patient treatment angiotensin converting enzyme ace inhibitor associate low incidence cardiovascular event treat calcium channel blocking agent however long term renal effect ace inhibitor patient remain inconclusive commence placebo controlled double blind randomize study examine anti albuminuric effect enalapril versus nifedipine slow release hypertensive type diabetic patient patient follow mean trial duration year examine determinant include effect ace inhibition clinical outcome patients methodsafter six week placebo controlled run period patient randomize double blind receive nifedipine slow release patient receive enalapril one year analysis confirm superior anti albuminuric effect enalapril nifedipine patient continue previously assign treatment informed consent subdivide normoalbuminuric n microalbuminuric n macroalbuminuric n group base two three hour urinary albumin excretion uae measurement run period renal function show hour uae creatinine clearance ccr regression coefficient yearly plasma creatinine reciprocal cr clinical endpoint define death cardiovascular event renal event need renal replacement therapy doubling baseline plasma creatinine resultsin whole group patient treat enalapril likely revert normoalbuminuric vs develop macroalbuminuria vs compare nifedipine treated patient p microalbuminuric group treatment enalapril n associate p reduction hour uae compare increase nifedipine group n macroalbuminuric patient enalapril treatment n associate stabilization compare decline renal function nifedipine group show cr vs mol p adjustment baseline value compare normoalbuminuric microalbuminuric patient macroalbuminuria low mean ccr vs vs ml min p high frequency clinical event vs vs p multivariate analysis cr r p independently associate baseline hba c p whereas clinical outcome r p independently relate mean low density lipoprotein cholesterol p high density lipoprotein cholesterol p baseline uae p mean ccr treatment p conclusionin prospective cohort analysis involve hypertensive type diabetic patient vary degree albuminuria follow mean duration five year observe importance good metabolic blood pressure control progression albuminuria renal function treatment enalapril associate great reduction albuminuria nifedipine entire patient group especially microalbuminuria macroalbuminuric patient rate deterioration renal function also attenuate treatment enalapril long term effect angiotensin converting enzyme inhibition metabolic control hypertensive type diabetic patient hypertensive type diabetic patient treatment angiotensin converting enzyme ace inhibitor associate low incidence cardiovascular event treat calcium channel blocking agent however long term renal effect ace inhibitor patient remain inconclusive commence placebo controlled double blind randomize study examine anti albuminuric effect enalapril versus nifedipine slow release hypertensive type diabetic patient patient follow mean trial duration year examine determinant include effect ace inhibition clinical outcome patient six week placebo controlled run period patient randomize double blind receive nifedipine slow release patient receive enalapril one year analysis confirm superior anti albuminuric effect enalapril nifedipine patient continue previously assign treatment informed consent subdivide normoalbuminuric n microalbuminuric n macroalbuminuric n group base two three hour urinary albumin excretion uae measurement run period renal function show hour uae creatinine clearance ccr regression coefficient yearly plasma creatinine reciprocal cr clinical endpoint define death cardiovascular event renal event need renal replacement therapy doubling baseline plasma creatinine whole group patient treat enalapril likely revert normoalbuminuric vs develop macroalbuminuria vs compare nifedipine treated patient p microalbuminuric group treatment enalapril n associate p reduction hour uae compare increase nifedipine group n macroalbuminuric patient enalapril treatment n associate stabilization compare decline renal function nifedipine group show cr vs mol p adjustment baseline value compare normoalbuminuric microalbuminuric patient macroalbuminuria low mean ccr vs vs ml min p high frequency clinical event vs vs p multivariate analysis cr r p independently associate baseline hba c p whereas clinical outcome r p independently relate mean low density lipoprotein cholesterol p high density lipoprotein cholesterol p baseline uae p mean ccr treatment p prospective cohort analysis involve hypertensive type diabetic patient vary degree albuminuria follow mean duration five year observe importance good metabolic blood pressure control progression albuminuria renal function treatment enalapril associate great reduction albuminuria nifedipine entire patient group especially microalbuminuria macroalbuminuric patient rate deterioration renal function also attenuate treatment enalapril,Chan JC,2000,Kidney Int,https://doi.org/10.1046/j.1523-1755.2000.00879.x,10652036,Chan JC; Ko GT; Leung DH; Cheung RC; Cheung MY; So WY; Swaminathan R; Nicholls MG; Critchley JA; Cockram CS,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D000419: Albuminuria; D000806: Angiotensin-Converting Enzyme Inhibitors; D003404: Creatinine; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004656: Enalapril; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006949: Hyperlipidemias; D006977: Hypertension, Renal; D007668: Kidney; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D007703: Peptidyl-Dipeptidase A; D011446: Prospective Studies; D012079: Renal Circulation; D016896: Treatment Outcome; D014665: Vasodilator Agents",,,https://openalex.org/W2008168710,124,15,1,7589,1378,34,en,en
false,intravenous nicardipine severe hypertension pre eclampsia effect acute treatment mother foetus,objective assess efficacy lower blood pressure safety mother foetus acute nicardipine therapy severe pre eclampsia design prospective clinical study setting one university hospital obstetric unit patient twenty consecutive adult pre eclamptic patient severe hypertension intervention nicardipine microgram kg per min give intravenously lower mean arterial pressure map least dosage reduce final dosage determine maintain map initial value increase decrease infusion rate mg h measurement result maternal map heart rate hr assess every min h foetal hr fhr record throughout study period assess fischer score gestational age apgar score birth weight capillary filling time duration stay paediatric intensive care unit icu use evaluate short term perinatal outcome decrease map occur within min patient increase hr note two patient severe tachycardia maternal side effect include flushing headache nausea dizziness fhr show transient decrease acceleration episode occurrence deceleration nicardipine related foetal distress occur four infant bear study period well birth good outcome conclusion acute nicardipine therapy induce severe maternal tachycardia severe foetal neonatal adverse effect occur dose scheme require comparison alternative therapeutic option,Aya AG,1999,Intensive Care Med,https://doi.org/10.1007/s001340050100,10654213,Aya AG; Mangin R; Hoffet M; Eledjam JJ,article,D016430: Clinical Trial; D016428: Journal Article,"D000208: Acute Disease; D000328: Adult; D000704: Analysis of Variance; D000959: Antihypertensive Agents; D001794: Blood Pressure; D004334: Drug Administration Schedule; D005260: Female; D006339: Heart Rate; D006340: Heart Rate, Fetal; D006801: Humans; D007275: Injections, Intravenous; D009529: Nicardipine; D011225: Pre-Eclampsia; D011247: Pregnancy; D011256: Pregnancy Outcome; D011446: Prospective Studies; D012720: Severity of Illness Index; D013997: Time Factors",,,https://openalex.org/W2052504550,117,17,1,1667,294,17,en,en
true,sex bias underutilization lipid lowering therapy patient coronary artery disease academic medical center united state canada,efficacy lipid lowering therapy llt well establish patient preexist coronary artery disease cad however limited information available assess extent medication prescribe academic medical centers use llt patient cad prospectively evaluate men woman recruit academic medical center united state canada participate prospective evaluation vascular event norvasc trial prevent assessment llt use year trial evaluate patient receive amlodipine therapy placebo level low density lipoprotein cholesterol ldl c use assess impact llt despite baseline prevalence llt men half patient high level ldl c mmol mg dl subsequent year prevalence elevated ldl c level drop men remain stagnant woman change associate increased llt men woman p ldl c target goal mmol l mg dl attain men woman p study completion ldl c target goal achieve men woman p study highlight relatively low treatment rate hyperlipidemia among patient cad overall woman particular participate clinical trial academic medical center united state canada llt prove reduce future cardiovascular event result suggest intensive effort promote order maximize cad reduction,Miller M,2000,Arch Intern Med,https://doi.org/10.1001/archinte.160.3.343,10668836,Miller M; Byington R; Hunninghake D; Pitt B; Furberg CD,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000046: Academic Medical Centers; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D002170: Canada; D008078: Cholesterol, LDL; D003327: Coronary Disease; D004311: Double-Blind Method; D004363: Drug Utilization; D005260: Female; D006801: Humans; D000960: Hypolipidemic Agents; D008297: Male; D008875: Middle Aged; D018579: Patient Selection; D011287: Prejudice; D011446: Prospective Studies; D035842: Research Subjects; D036302: Therapeutic Human Experimentation; D014481: United States",,,https://openalex.org/W2159148333,156,23,1,1738,344,8,en,en
true,angiotensin converting enzyme inhibitor calcium channel blocker breast cancer,use angiotensin converting enzyme ace inhibitor link decrease risk develop cancer longer term use calcium channel blocker ccbs associate increase risk develop cancer general breast cancer particular using data general practice research database conduct large case control analysis previous exposure ace inhibitor ccbs beta blockers compare postmenopausal woman diagnose incident breast cancer matched control women compared nonusers antihypertensive drug woman use ace inhibitor odds ratio confidence interval ci ccbs ci beta blockers ci year increase decrease risk develop breast cancer adjust smoking body mass index calculate weight kilogram divide square height meter risk breast cancer differ user different ace inhibitor different ccbs dihydropyridines diltiazem hydrochloride verapamil hydrochloride user short acting ci sustained release ci nifedipine preparations finding large case control analysis support hypothesis longer term use ace inhibitor ccbs affect risk develop breast cancer,Meier CR,2000,Arch Intern Med,https://doi.org/10.1001/archinte.160.3.349,10668837,Meier CR; Derby LE; Jick SS; Jick H,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000319: Adrenergic beta-Antagonists; D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D001943: Breast Neoplasms; D002121: Calcium Channel Blockers; D004359: Drug Therapy, Combination; D015914: Estrogen Replacement Therapy; D005260: Female; D006801: Humans; D015994: Incidence; D008875: Middle Aged; D016017: Odds Ratio; D012189: Retrospective Studies; D012307: Risk Factors; D014481: United States",,,https://openalex.org/W2072184670,85,11,1,1497,277,3,en,en
false,effect amlodipine enalapril blood pressure neurohumoral activation hypertensive patient rib disease multiple epiphysal dystrophy,patient rib disease rd form multiple epiphysal dystrophy hypertension frequent often severe accompany relevant cardiac dysfunction study undertake evaluate contribution calcium antagonist amlodipine angiotensin converting enzyme inhibitor enalapril blood pressure regulation study effect neurohormonal activation fifty hypertensive patient rd study placebo run period week patient randomly assign receive either amlodipine mg daily enalapril mg daily months drug significantly lower blood pressure enalapril result activation sympathetic system determine measurement plasma norepinephrine level hand hypotensive effect amlodipine occur increase heart rate level plasma norepinephrine angiotensin ii unclear whether amlodipine may reduce cardiac dysfunction patient rd,Cocco G,2000,Clin Cardiol,https://doi.org/10.1002/clc.4960230208,10676602,Cocco G; Ettlin T; Baumeler HR,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000293: Adolescent; D000328: Adult; D000368: Aged; D017311: Amlodipine; D000804: Angiotensin II; D000806: Angiotensin-Converting Enzyme Inhibitors; D002121: Calcium Channel Blockers; D004656: Enalapril; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D009638: Norepinephrine; D010009: Osteochondrodysplasias,,,https://openalex.org/W2034293994,163,24,1,1051,171,4,en,en
true,evidence regard drug use ventricular rate control,goal determine drug efficacious control ventricular rate patient atrial fibrillation conduct systematic review literature publish may begin search cochrane collaboration central database medline include english language article describe randomize controlled trial drug use heart rate control adult atrial fibrillation abstracts trial review independently member study team review english language abstract non english language publication assess qualitative consistency results forty five article evaluate drug meet criterion review trial verapamil diltiazem heart rate reduce significantly p rest exercise compare placebo equivalent improve exercise tolerance comparison comparison beta blocker placebo beta blocker efficacious control rest heart rate evidence effect drug specific nadolol atenolol prove efficacious comparison demonstrate good heart rate control beta blockers exercise although exercise tolerance compromise comparison trial digoxin administer alone slow rest heart rate placebo significantly slow rate exercise study trial evaluate drug yield insufficient evidence support use drug may yet promising calcium channel blocker verapamil diltiazem select beta blockers efficacious heart rate control rest exercise patient atrial fibrillation without clinically important decrease exercise tolerance digoxin useful rate control exercise less concern,Segal JB,2000,J Fam Pract,,10678340,Segal JB; McNamara RL; Miller MR; Kim N; Goodman SN; Powe NR; Robinson K; Yu D; Bass EB,article,"D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.; D016454: Review; D000078182: Systematic Review",D000319: Adrenergic beta-Antagonists; D000328: Adult; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D015982: Bias; D002121: Calcium Channel Blockers; D004077: Digoxin; D004110: Diltiazem; D019317: Evidence-Based Medicine; D015444: Exercise; D006339: Heart Rate; D006801: Humans; D012107: Research Design; D012146: Rest; D016896: Treatment Outcome; D016276: Ventricular Function; D014700: Verapamil,,,https://openalex.org/W183588017,67,11,1,1931,309,8,en,en
false,amlodipine enalapril dependent leg edema essential hypertension,abstract calcium channel blocker ccbs blunt postural skin vasoconstriction autoregulatory mechanism minimize gravitational increase capillary pressure avoids fluid extravasation stand evaluate dose response relation pharmacological interference dependent edema frequent side effect ccbs antihypertensive treatment skin blood flow laser doppler flowmetry dorsum foot supine limb passively place cm heart level leg weight archimedes principle measure baseline increase dos dihydropyridine amlodipine mg uid week drug withdrawal hypertensive men angiotensin converting enzyme inhibitor may attenuate ankle swell ccbs parameter evaluate accord similar design amlodipine mg uid enalapril mg uid combine n control effect enalapril monotherapy mg uid week evaluate third series patient n amlodipine mg uid increase leg weight without modify postural vasoconstriction percent skin blood flow decrease horizontal dependent position indicate extravascular fluid shift independent postural skin vasoconstriction mg uid however amlodipine blunt postural vasoconstriction increase leg weight far suggest skin blood flow autoregulation limit additional fluid transfer parameter normalize drug withdrawal enalapril per se affect cutaneous vasomotion leg weight reduce amount dependent fluid extravasation ccb despite persistent antagonism postural vasoconstrictor response,Pedrinelli R,2000,Hypertension,https://doi.org/10.1161/01.hyp.35.2.621,10679507,Pedrinelli R; Dell'Omo G; Melillo E; Mariani M,article,D016430: Clinical Trial; D016428: Journal Article,"D000328: Adult; D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D003971: Diastole; D004305: Dose-Response Relationship, Drug; D004487: Edema; D004656: Enalapril; D006801: Humans; D006973: Hypertension; D017078: Laser-Doppler Flowmetry; D007866: Leg; D008297: Male; D008875: Middle Aged; D009929: Organ Size; D012039: Regional Blood Flow; D012867: Skin; D013223: Statistics as Topic; D013599: Systole; D016896: Treatment Outcome",,,https://openalex.org/W2107551489,72,11,1,1802,300,8,en,en
true,effect amlodipine exercise tolerance quality life leave ventricular function patient heart failure leave ventricular systolic dysfunction,preliminary study suggest long acting late generation calcium channel blocker amlodipine favorable effect exercise tolerance safe use heart failure contrast early generation agent goal multicenter study assess effect adjunctive therapy amlodipine addition standard therapy exercise capacity quality life leave ventricular function safety parameter patient heart failure leave ventricular systolic dysfunction two large multicenter trial examine effect amlodipine parameter week period therapy undertake patient mild moderate heart failure leave ventricular systolic dysfunction total patient stable heart failure study randomized double blind placebo controlled prospective design amlodipine dose mg day addition standard therapy patient associate significant difference change exercise tolerance naughton protocol compare placebo trial among patient take amlodipine exercise time increase se second exercise time take placebo increase second p significant significant difference change quality life parameter amlodipine placebo treated patient significant difference symptom score new york heart association classification group leave ventricular function measure ejection fraction improve amlodipine treated patient placebo treated patient p statistically significant excess important adverse event episode worsen heart failure amlodipine treated vs placebo treated patient difference need change background medication groups addition mg amlodipine per day standard therapy patient heart failure associate significant improvement exercise time compare placebo therapy week period increased incidence adverse event data suggest addition amlodipine standard therapy heart failure result additional efficacy per se beyond standard therapy,Udelson JE,2000,Am Heart J,https://doi.org/10.1016/s0002-8703(00)90095-4,10689266,Udelson JE; DeAbate CA; Berk M; Neuberg G; Packer M; Vijay NK; Gorwitt J; Smith WB; Kukin ML; LeJemtel T; Levine TB; Konstam MA,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D017311: Amlodipine; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D005080: Exercise Test; D017079: Exercise Tolerance; D005260: Female; D006333: Heart Failure; D006439: Hemodynamics; D006801: Humans; D008297: Male; D008875: Middle Aged; D011788: Quality of Life; D012720: Severity of Illness Index; D016896: Treatment Outcome; D018487: Ventricular Dysfunction, Left; D016277: Ventricular Function, Left; D016138: Walking",,,https://openalex.org/W2161298778,165,25,1,2361,381,9,en,en
true,bisoprolol nifedipine retard elderly hypertensive patient effect quality life,subject age sustained sit diastolic pressure mm hg randomise regime base bisoprolol n nifedipine retard n week goal diastolic pressure mm hg achieve double blind medication could double mg bisoprolol mg nifedipine retard hydrochlorothiazide mg unblinded could add high dose intention treat analysis subject bisoprolol nifedipine retard treat group provide least baseline second quality life assessment excess symptom observe nifedipine group oedema leg nocturia constipation race heart heart thumping patient report wheeze nifedipine group quality life statistically significant difference two group week however analyse result last available assessment usually week significant p improvement tension anxiety anger hostility vigour activity confusion bewilderment assess profile mood state pom patient receive bisoprolol comparison receive nifedipine retard sickness impact profile objective test cognitive function differ statistically two group quality life maintain good level treatment advantage bisoprolol certain area journal human hypertension,Bulpitt CJ,2000,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1000972,10694836,Bulpitt CJ; Connor M; Schulte M; Fletcher AE,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000318: Adrenergic beta-Agonists; D000339: Affect; D000368: Aged; D000375: Aging; D000959: Antihypertensive Agents; D017298: Bisoprolol; D002121: Calcium Channel Blockers; D003071: Cognition; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011788: Quality of Life,,,https://openalex.org/W2335073246,92,14,1,1550,280,10,en,en
false,comparison effect two modified release preparation nifedipine nifedipine retard mg twice daily nifedipine git mg daily treatment mild moderate hypertension,multicentre randomise double blind cross comparison nifedipine git mg daily nifedipine retard mg twice daily patient mild moderate hypertension conduct treatment result clinically significant trough blood pressure reduction nifedipine git mmhg nifedipine retard mmhg study demonstrate nifedipine git least equivalent nifedipine retard reduction trough diastolic blood pressure one sided low confidence limit mmhg overall incidence adverse event nifedipine git nifedipine retard well incidence headache nifedipine git nifedipine retard peripheral oedema nifedipine git nifedipine retard higher nifedipine retard compare nifedipine git nifedipine git mg daily least equivalent nifedipine retard mg twice daily patient mild moderate hypertension well well tolerate,Kirby BJ,1999,Int J Clin Pract,,10695096,Kirby BJ; Kitchin NR,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D000704: Analysis of Variance; D001795: Blood Pressure Determination; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D016896: Treatment Outcome,,,https://openalex.org/W2410891434,205,35,1,1039,184,5,en,en
false,calcium channel blocker use cyclosporin effect gingival overgrowth,investigate whether choice calcium channel blocker use conjunction cyclosporin affect prevalence gingival overgrowth cohort renal transplant recipient medicate cyclosporin combination either nifedipine amlodipine since transplant take part study inclusion criterion eligible subject receipt kidney transplant least month least teeth receive specialist periodontal treatment age gender current drug regimen dosage record participant alginate impression take arch presence severity gingival overgrowth score plaster models high proportion amlodipine group categorise gingival overgrowth compare nifedipine group chi square p logistic regression analysis use explore relationship presence absence gingival overgrowth dependent variable age gender time since transplant dose cyclosporin centre patient treat calcium channel blocker use independent variable independent predictor gingival overgrowth multivariate analysis whether individual treat amlodipine nifedipine p whether individual young old p within multivariate analysis odds ratio amlodipine associate gingival overgrowth compare nifedipine confidence interval prevalence gingival overgrowth renal transplant recipient maintain cyclosporin nifedipine low treat cyclosporin amlodipine,James JA,2000,J Clin Periodontol,https://doi.org/10.1034/j.1600-051x.2000.027002109.x,10703656,James JA; Marley JJ; Jamal S; Campbell BA; Short CD; Johnson RW; Hull PS; Spratt H; Irwin CR; Boomer S; Maxwell AP; Linden GJ,article,D003160: Comparative Study; D016428: Journal Article,"D000328: Adult; D017311: Amlodipine; D002121: Calcium Channel Blockers; D016572: Cyclosporine; D004359: Drug Therapy, Combination; D005260: Female; D019214: Gingival Overgrowth; D006801: Humans; D007166: Immunosuppressive Agents; D016030: Kidney Transplantation; D008297: Male; D015999: Multivariate Analysis; D009543: Nifedipine; D015995: Prevalence; D011379: Prognosis",,,https://openalex.org/W2140331009,86,13,1,1775,300,7,en,en
false,restenosis clinical outcome patient treat amlodipine angioplasty result coronary angioplasty amlodipine restenosis study capares,intent investigate effect dihydropyridine calcium channel blocker amlodipine restenosis clinical outcome patient undergo percutaneous transluminal coronary angioplasty ptca amlodipine sustain vasodilatory effect relief coronary spasm may reduce luminal loss clinical complication ptca prospective double blind design patient randomize mg amlodipine placebo pretreatment study drug start two week ptca continue four month ptca primary angiographic end point loss minimal lumen diameter mld post ptca follow assess quantitative coronary angiography qca clinical end point death myocardial infarction coronary artery bypass graft surgery repeat ptca major adverse clinical event angioplasty perform patient patient coronary stent implant follow angiography suitable qca analysis patient amlodipine group patient placebo group per protocol group mean loss mld mm amlodipine group versus mm placebo group p need repeat ptca significantly low amlodipine versus placebo group vs patient p relative risk ratio rr confidence interval ci composite incidence clinical event vs patient p rr ci within four month follow period intention treat analysis amlodipine therapy start two week ptca reduce luminal loss incidence repeat ptca composite major adverse clinical event significantly reduce four month follow period ptca amlodipine compare placebo,Jørgensen B,2000,J Am Coll Cardiol,https://doi.org/10.1016/s0735-1097(99)00599-9,10716459,Jørgensen B; Simonsen S; Endresen K; Forfang K; Vatne K; Hansen J; Webb J; Buller C; Goulet G; Erikssen J; Thaulow E,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D017311: Amlodipine; D015906: Angioplasty, Balloon, Coronary; D002121: Calcium Channel Blockers; D017023: Coronary Angiography; D003327: Coronary Disease; D003331: Coronary Vessels; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D055502: Secondary Prevention; D016896: Treatment Outcome",,,https://openalex.org/W2045075493,162,23,1,1931,358,7,en,en
false,blood pressure biofeedback treatment white coat hypertension,objective objective study compare blood pressure bp biofeedback treatment bf effect white coat hypertension essential hypertension method fifteen white coat hypertensive patients essential hypertensive patients randomly assign group b subject group underwent bf week total four session group b visit clinic measure bp later undergo bf result group bps white coat hypertensive essential hypertensive significantly reduce mmhg respectively group b unchanged period later suppress bf bf pulse respiratory rate significantly high elevation diastolic bp due mental stress testing well suppress white coat hypertensive essential hypertensive conclusion treatment effective type hypertension pressor response stress seem important differentiated bf effect,Nakao M,2000,J Psychosom Res,https://doi.org/10.1016/s0022-3999(99)00104-x,10719133,Nakao M; Nomura S; Shimosawa T; Fujita T; Kuboki T,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D001676: Biofeedback, Psychology; D004569: Electroencephalography; D005260: Female; D005712: Galvanic Skin Response; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D013315: Stress, Psychological",,,https://openalex.org/W2076002368,63,7,1,1062,182,8,en,en
false,critical analysis hypertension optimal treatment hot study appear lancet,hot study patient country age year mean age year hypertension diastolic blood pressure mm hg mean value mm hg randomise group different target blood pressure mm hg mm hg mm hg basic treatment felodipin mg q target pressure achieve step initiate either ace inhibitors blockers add third step felodipindose increase mg step dos ace inhibitors blockers double target pressure still achieve diuretic add furthermore half patient group receive either placebo mg acetyl salicylic acid prevent cardiovascular event best benefit show diastolic pressure mm hg reach acetyl salicylic acid show benefit prevent myocardial infarction prevent stroke,Skrabal F,1999,Wien Med Wochenschr,,10721156,Skrabal F,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000319: Adrenergic beta-Antagonists; D000368: Aged; D000369: Aged, 80 and over; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002423: Cause of Death; D004305: Dose-Response Relationship, Drug; D004359: Drug Therapy, Combination; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D016896: Treatment Outcome",,,https://openalex.org/W2403007216,114,25,1,983,187,6,en,en
false,alpha antitrypsin phenotype patient renal arterial fibromuscular dysplasia,fibromuscular dysplasia fmd significant cause renal artery stenosis especially young female rare association fmd alpha antitrypsin alpha deficiency report compare alpha phenotype distribution patient renal arterial fmd publish australian population alpha phenotyping perform isoelectric focus ph ph polyacrylamide gel pim pifm non deficiency allele pims pimz deficiency allele marker follow phenotyping alpha genotyping perform patient confirm presence z allele phenotype distribution allele frequency similar report normal subject two australian population pimm phenotype one pifm seven pims two pimz one pisz suggest alpha deficiency common aetiological factor renal arterial fmd however despite fmd three time less common male female carotid artery dissection rare occurrence male pims deficiency phenotype present internal carotid artery dissection bilateral renal artery fmd far patient pisz deficiency phenotype one two sister fmd severely affected pimm normal phenotype sibling two patient present series together nine cull literature alpha deficiency phenotype fmd suggest chance combination alpha deficiency fmd may predispose severe manifestation fmd,Bofinger A,2000,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1000935,10723113,Bofinger A; Hawley C; Fisher P; Daunt N; Stowasser M; Gordon R,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D005260: Female; D005352: Fibromuscular Dysplasia; D006801: Humans; D008297: Male; D010641: Phenotype; D012077: Renal Artery; D000515: alpha 1-Antitrypsin,,,https://openalex.org/W1978164831,86,9,1,1651,294,9,en,en
false,natural history erythromelalgia,describe demographic presentation outcome patient erythromelalgia rare poorly understood clinical syndrome define triad red hot painful extremities retrospective medical record review follow survey questionnaire large tertiary care medical center patients erythromelalgia examine mayo clinic rochester minn medical record patient analyze follow data consist answer survey questionnaire recent information medical record patient still alive death certificate report death deceased patient obtain patients survival morbidity quality life patient white female male presentation patient mean age year age range year symptom present since childhood patient six patient first degree relative erythromelalgia symptom intermittent patient constant symptom predominantly involve foot patient hand patient kaplan meier survival curve reveal significant decrease survival compare expect person similar age sex p mean follow year range year patient report worsening change improvement complete resolution symptom standard health status questionnaire score one health domain significantly diminish comparison u general population erythromelalgia syndrome significantly increase mortality morbidity compare u general population,Davis MD,2000,Arch Dermatol,https://doi.org/10.1001/archderm.136.3.330,10724194,Davis MD; O'Fallon WM; Rogers RS; Rooke TW,article,D016428: Journal Article,"D000293: Adolescent; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D002648: Child; D002675: Child, Preschool; D004916: Erythromelalgia; D005260: Female; D005500: Follow-Up Studies; D006306: Health Surveys; D006801: Humans; D008297: Male; D008499: Medical Records; D008875: Middle Aged; D009017: Morbidity; D011788: Quality of Life; D012189: Retrospective Studies; D011795: Surveys and Questionnaires; D016019: Survival Analysis",,,https://openalex.org/W2087848923,34,4,1,1868,353,10,en,en
false,effect isradipine dihydropyridine class calcium channel antagonist methamphetamine induced cognitive physiological change human,methamphetamine abuse euphoric effect stimulatory action cognitive function abuse however associate massive hypertension result stroke rupture aneurysm myocardial infarction examine utility isradipine dihydropyridine class calcium channel antagonist treat methamphetamine induced hypertension evaluate effect cognitive function mediate dopaminergic mechanism methamphetamine dose dependently increase vital sign systolic diastolic mean arterial pressure pulse rate parameter isradipine significantly reduce methamphetamine induced increase diastolic mean arterial pressure however potentially beneficial therapeutic effect offset significant reflex rise pulse rate methamphetamine also improve attention accuracy reason ability performance computerized cognitive function task methamphetamine cognitive improving effect alter significantly isradipine isradipine increase false responding rate without significant effect attentional task reason ability performance isradipine appear enhance cognitive function healthy human,Johnson BA,2000,Neuropsychopharmacology,https://doi.org/10.1016/s0893-133x(99)00116-5,10731625,Johnson BA; Ait-Daoud N; Wells LT,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,D000328: Adult; D019969: Amphetamine-Related Disorders; D002121: Calcium Channel Blockers; D002320: Cardiovascular Physiological Phenomena; D003071: Cognition; D018592: Cross-Over Studies; D004095: Dihydropyridines; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D017275: Isradipine; D008297: Male; D008694: Methamphetamine; D008875: Middle Aged; D018697: Nootropic Agents,,,https://openalex.org/W2005522694,149,18,1,1292,190,9,en,en
false,regional racial difference response antihypertensive medication use randomized control trial men hypertension united state,background stroke incidence mortality rate high southeastern region united state call stroke belt compare response antihypertensive medication use patient different u region method short term year efficacy antihypertensive medication hydrochlorothiazide atenolol diltiazem hydrochloride sustained release captopril prazosin hydrochloride clonidine compare u region randomized control trial men hypertension u veteran affair medical center result compare patient outside stroke belt patient inside stroke belt achieve significantly low treatment success rate diastolic blood pressure control year hydrochlorothiazide vs atenolol vs captopril vs clonidine vs difference treatment success rate diltiazem vs prazosin vs control race patient inside stroke belt significantly low treatment success rate hydrochlorothiazide p clonidine p low success rate atenolol approach significance p regardless region black less likely white achieve treatment success atenolol p prazosin p likely diltiazem p trend black reside inside stroke belt low treatment success rate race region group treat captopril p many regional racial difference diet lifestyle characteristic observe adjustment characteristic regression analysis effect reside inside stroke belt remain captopril p clonidine p approach significance hydrochlorothiazide p conclusion hypertension patient reside inside stroke belt respond less use several antihypertensive medication important difference show number characteristic may affect control blood pressure compare patient reside outside stroke belt,Cushman WC,2000,Arch Intern Med,https://doi.org/10.1001/archinte.160.6.825,10737282,Cushman WC; Reda DJ; Perry HM; Williams D; Abdellatif M; Materson BJ,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D001741: Black or African American; D000368: Aged; D000959: Antihypertensive Agents; D044383: Black People; D001794: Blood Pressure; D006787: Hospitals, Veterans; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D012307: Risk Factors; D015144: Southeastern United States; D016896: Treatment Outcome; D014481: United States; D044465: White People",,,https://openalex.org/W2075862502,157,23,1,2310,491,10,en,en
true,felodipine improve leave ventricular emptying patient chronic heart failure v heft iii echocardiographic substudy multicenter reproducibility detect functional change,echocardiographic substudy vasodilator heart failure trial iii v heft iii aim determine felodipine treatment patient heart failure take angiotensin converting enzyme inhibitor favorable effect left ventricular lv structure function earlier v heft trial show hydralazine isosorbide dinitrate improve ejection fraction ef survival whereas enalapril achieve great survival small increase ef would combination potent vasodilator enalapril produce great improvement function survival doppler echocardiographic data collect male heart failure randomize felodipine placebo mean intrasubject difference baseline month month compare intersite intrareader reproducibility measure duplicate recording reading month change ultrasound variable baseline occur either group month felodipine patient achieve great increase ef shorten lv end systolic length increase stroke volume index reproducibility coefficient variation ef end diastolic length stroke volume index echocardiographic substudy show felodipine add heart failure therapy increase ef shorten end systolic length increase stroke volume index change small confirm reproducibility multiple laboratory coordinate useful research tool,Wong M,2000,J Card Fail,https://doi.org/10.1016/s1071-9164(00)00008-7,10746815,Wong M; Germanson T; Taylor WR; Cohen IS; Perry G; Baruch L; Deedwania P; Lopez B; Cohn JN,article,"D016430: Clinical Trial; D017428: Clinical Trial, Phase III; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial","D002121: Calcium Channel Blockers; D002908: Chronic Disease; D018618: Echocardiography, Doppler, Color; D015736: Felodipine; D006333: Heart Failure; D006352: Heart Ventricles; D006801: Humans; D008297: Male; D015588: Observer Variation; D011237: Predictive Value of Tests; D020127: Recovery of Function; D015203: Reproducibility of Results; D015996: Survival Rate; D016277: Ventricular Function, Left",,,https://openalex.org/W2065314153,186,23,1,1562,250,9,en,en
false,calcium channel antagonist controversy symposium congress international society cardiovascular pharmacotherapy march amsterdam,,Rutishauser W,2000,Cardiovasc Drugs Ther,https://doi.org/10.1023/a:1007855508036,10755206,Rutishauser W,article,D016423: Congress,"D002121: Calcium Channel Blockers; D002318: Cardiovascular Diseases; D002986: Clinical Trials as Topic; D005544: Forecasting; D006801: Humans; D009426: Netherlands; D017063: Outcome Assessment, Health Care",,,https://openalex.org/W117213745,161,25,1,0,0,0,en,
false,esophageal motility disorder current concept pathogenesis treatment,current concept esophageal motility disorder summarize primary data source locate via medline cross citation attempt make comprehensive inclusive literature citation discuss instead emphasis place new development diagnosis therapeutic practice pattern control therapeutic trial pathophysiological observation emphasize achalasia rare disease fail low sphincter relaxation aperistalsis diffuse esophageal spasm de equally rare disease define non propagated esophageal contraction nonspecific motility disorder include nutcracker esophagus hypertensive low esophageal sphincter identify manometry ten time prevalent neuromuscular pathology evident achalasia myenteric plexus neuron destruction pharmacological therapy limit efficacy achalasia limited de none nonspecific motility disorder efficacious therapy nonspecific disorder direct associate reflux disease psychiatric disorder pneumatic dilation effective therapy achalasia instance frequently require repeat dilation complicate perforation rate surgical myotomy effective achalasics morbidity thoracotomy major limitation sharply reduce laparoscopic approach conclusion although suggest esophageal motility disorder distinct clinical entity critical review literature support case achalasia disease well define pathophysiology functional disturbance therapy clarity diminish progressively de non specific esophageal motility disorder,Kahrilas PJ,2000,Can J Gastroenterol,https://doi.org/10.1155/2000/389709,10758419,Kahrilas PJ,article,"D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.; D016454: Review",D004106: Dilatation; D015154: Esophageal Motility Disorders; D004943: Esophagogastric Junction; D004947: Esophagus; D006801: Humans; D008365: Manometry; D010528: Peristalsis,,,https://openalex.org/W14920967,77,10,1,1856,288,15,en,en
false,cardiovascular adverse drug reaction associate combined adrenergic calcium entry blocking agent,numerous study show beneficial effect combination therapy beta blockers calcium antagonist patient anginal syndrome hypertension however agent exert negative chronotropic effect combine use may cause bradyarrhythmias resultant symptom cerebral coronary systemic hypoperfusion describe clinical experience patient cardiovascular adverse drug reaction cvadrs combination therapy prospective study include patient cvadrs among admission year period study group include men woman median age year various combination calcium antagonist beta blockers associate cvadrs frequent pharmacologic combination diltiazem plus propranolol cvadrs cause hospital admission patient associate cause nine patient develop hospitalization seven patient cardiac bradyarrhythmias find patient rhythm abnormality resolve within h discontinuation offend drug temporary transvenous pacemaker insertion necessary one patient complete atrioventricular block twenty two patient recover two patient die pump failure associate cvadrs two patient cvadrs contribute patient death cvadrs uncommon elderly patient ischemic heart disease hypertension treat concomitant use calcium antagonist beta adrenergic blocking drug use calcium antagonist plus beta blocker may unpredictably cause serious hemodynamic event mark suppression sinus node activity prolongation atrioventricular conduction patient enhance therapeutic monitoring may warrant calcium antagonist combine beta blockers,Edoute Y,2000,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-200004000-00007,10774785,Edoute Y; Nagachandran P; Svirski B; Ben-Ami H,article,D016430: Clinical Trial; D016428: Journal Article,"D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D001919: Bradycardia; D002121: Calcium Channel Blockers; D002318: Cardiovascular Diseases; D004359: Drug Therapy, Combination; D004594: Electrophysiology; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies",,,https://openalex.org/W2333515379,108,12,1,1915,291,15,en,en
false,antihypertensive efficacy tolerability daily sustained release diltiazem alone combination ramipril hypertension,study assess daily od sustained release sr diltiazem alone combination ramipril essential hypertension fifty patient supine diastolic blood pressure dbp mm hg enter active treatment phase study week placebo run sustained release diltiazem mg od administer week optimally titrate week interval sr diltiazem mg od sr diltiazem mg ramipril mg od achieve supine dbp mm hg week diltiazem monotherapy sr diltiazem mg mg od mean supine dbp reduce mm hg mm hg p mean supine heart rate reduce bpm bpm p diltiazem monotherapy reduce supine dbp mm hg patient combination therapy sr diltiazem mg ramipril mg od receive non responders diltiazem monotherapy reduce supine dbp mm hg patient sinus bradycardia observe one patient sustained release diltiazem alone combination ramipril reduce blood pressure dose related manner well tolerate,Tuteja R,1999,J Assoc Physicians India,,10778687,Tuteja R; Swarup D; Saxena GN; Bhandari S; Sharma P,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article,"D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D003692: Delayed-Action Preparations; D004110: Diltiazem; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D017257: Ramipril",,,https://openalex.org/W2401641514,140,17,1,1254,257,8,en,en
false,comparison efficacy intravenous diltiazem esmolol terminate supraventricular tachycardia,paroxysmal supraventricular tachycardia psvt effectively terminate intravenous administration adenosine verapamil however adenosine expensive injectable verapamil currently scarcely available intravenous diltiazem show useful terminate psvt efficacy esmolol regard evaluate previously hence latter two drug study efficacy terminate psvt prospective randomise crossover study undertake patient present hemodynamically tolerate psvt iccu patient plan trial study prematurely terminate patient enrol due marked superiority diltiazem two sequential dos minute interval either drug administer crossover diltiazem give dose mg kg esmolol dose mg kg diltiazem terminate psvt patient give first drug patient respond esmolol also effectively treat diltiazem thus totally patient respond diltiazem patient respond esmolol p patient respond diltiazem patient second bolus diltiazem work first one fail significant adverse effect seen intravenous diltiazem highly effective safe terminate psvt first bolus ineffective second bolus give minute usually succeed esmolol dose mg kg poor efficacy terminate psvt even bolus administer,Gupta A,1999,J Assoc Physicians India,,10778689,Gupta A; Naik A; Vora A; Lokhandwala Y,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000889: Anti-Arrhythmia Agents; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D004110: Diltiazem; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D004562: Electrocardiography; D005260: Female; D006801: Humans; D007262: Infusions, Intravenous; D008297: Male; D008875: Middle Aged; D011412: Propanolamines; D011446: Prospective Studies; D013617: Tachycardia, Supraventricular; D016896: Treatment Outcome",,,https://openalex.org/W2410410525,104,13,1,1682,284,13,en,en
false,treatment heart failure guide plasma aminoterminal brain natriuretic peptide n bnp concentration,currently objective practical guide intensity drug treatment individual heart failure hypothesise pharmacotherapy guide plasma concentration cardiac peptide aminoterminal brain natriuretic peptide n bnp would produce superior outcome empirical trial based therapy dictate clinical acumen patient impaired systolic function left ventricular ejection fraction symptomatic heart failure new york heart association class ii iv randomise receive treatment guide either plasma n bnp concentration bnp group standardise clinical assessment clinical group follow minimum months median month total cardiovascular event death hospital admission heart failure decompensation bnp group clinical group v p month patient bnp group clinical group experience first cardiovascular event p change left ventricular function quality life renal function adverse event similar groups n bnp guided treatment heart failure reduce total cardiovascular event delay time first event compare intensive clinically guide treatment,Troughton RW,2000,Lancet,https://doi.org/10.1016/s0140-6736(00)02060-2,10791374,Troughton RW; Frampton CM; Yandle TG; Espiner EA; Nicholls MG; Richards AM,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000806: Angiotensin-Converting Enzyme Inhibitors; D015415: Biomarkers; D004077: Digoxin; D004232: Diuretics; D004311: Double-Blind Method; D005260: Female; D005500: Follow-Up Studies; D005665: Furosemide; D006333: Heart Failure; D006801: Humans; D008297: Male; D008875: Middle Aged; D020097: Natriuretic Peptide, Brain; D013997: Time Factors; D014665: Vasodilator Agents; D018487: Ventricular Dysfunction, Left",,,https://openalex.org/W2120561016,106,15,1,1289,214,4,en,en
false,cardiovascular effect melatonin hypertensive patient well control nifedipine hour study,aim melatonin find play role mechanism cardiovascular regulation design present study evaluate whether even ingestion pineal hormone might interfere antihypertensive therapy hypertensive patient well controlled nifedipine monotherapy method forty seven mild moderate essential hypertensive outpatient take nifedipine git mg monotherapy h least month give placebo melatonin mg h week accord double blind cross study end treatment period patient undergo h noninvasive ambulatory blood pressure monitoring abpm usual working day sleep period schedule last h result evening administration melatonin induce increase blood pressure heart rate throughout h period sbp mmhg p dbp mmhg p hr beat min p dbp well hr increase particularly evident morning afternoon hour conclusion hypothesize competition melatonin nifedipine able impair antihypertensive efficacy calcium channel blocker suggest caution uncontrolled use melatonin hypertensive patient pineal hormone might interfere calcium channel blocker therapy consider simply dietary supplement,Lusardi P,2000,Br J Clin Pharmacol,https://doi.org/10.1046/j.1365-2125.2000.00195.x,10792199,Lusardi P; Piazza E; Fogari R,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004347: Drug Interactions; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008550: Melatonin; D008875: Middle Aged; D009543: Nifedipine,,,https://openalex.org/W2114922149,107,15,1,1480,263,7,en,en
false,clinical study month stop study arterial hypertension elderly,demonstration efficacy beta blockers diuretic versus placebo prevent cardiovascular complication elderly hypertensive patient first stop hypertension study swedish group publish end stop hypertension study latter randomise trial show similar population cardiovascular protection recent antihypertensive agent calcium antagonist angiotensin converting enzyme inhibitor similar conventional antihypertensive drug use first study fact degree blood pressure control appear important type antihypertensive drug use conclusion reinforce observation numerous patient rapidly treat one antihypertensive agent reach blood pressure target,Scheen AJ,2000,Rev Med Liege,,10803042,Scheen AJ,article,D004740: English Abstract; D016428: Journal Article,D000319: Adrenergic beta-Antagonists; D000367: Age Factors; D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D002318: Cardiovascular Diseases; D006801: Humans; D006973: Hypertension; D016032: Randomized Controlled Trials as Topic,,,https://openalex.org/W2223175691,88,18,2,868,131,3,en,en
true,progress report nordic diltiazem study nordil outcome study hypertensive patient,nordil nordic diltiazem study nordil prospective randomize open blinded endpoint probe multicenter parallel group morbidity mortality outcome study hypertensive patient design compare intervention strategy base calcium antagonist diltiazem strategy base conventional antihypertensive drug treatment diuretic beta adrenergic blocker patient recruitment start norway sweden september end december male female patient age year essential hypertension randomize paper describe baseline data patient cohort blood pressure achieve two treatment group early part study patient cohort consist male female mean age year respectively concomitant disorder risk factor cohort smoke ischemic heart disease previous myocardial infarction mi previous stroke diabetes mellitus renal impairment difference treatment group respect blood pressure treatment goal target diastolic blood pressure mmhg diastolic blood pressure reduction inclusion pressure treatment group randomize diltiazem based treatment strategy blood pressure mmhg baseline mmhg month follow active treatment group randomize conventional treatment strategy baseline blood pressure randomization mmhg mmhg month active therapy nordil study terminate october final result available mid,Hedner T,1999,Blood Press,https://doi.org/10.1080/080370599439517,10803490,Hedner T,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D015331: Cohort Studies; D004110: Diltiazem; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D012537: Scandinavian and Nordic Countries; D016896: Treatment Outcome,,,https://openalex.org/W2108384165,97,17,1,1784,312,10,en,en
false,prognostic implication result exercise test patient chronic stable angina pectoris treat metoprolol verapamil report angina prognosis study stockholm apsis,aimsto evaluate prognostic implication result exercise testing antianginal treatment among patient chronic stable angina pectoris material method patient anginaprognosis study stockholm apsis men perform evaluable exercise test month double blind treatment metoprolol verapamil median follow month patient suffer cardiovascular death non fatal myocardial infarction resultsprognostic implication result exercise test assess multivariate cox model include sex previous myocardial infarction hypertension diabetes mellitus maximal st segment depression especially mm occur exercise well exercise duration independently predict cardiovascular death similar result obtain combined end point cardiovascular death myocardial infarction among patient positive exercise test baseline verapamil reduce maximal st depression mark edly metoprolol p however treatment give treatment effect st segment depression add cox model impact prognosis could detect either cardiovascular death alone combine myocardial infarction anginal pain carry prognostic information conclusionmarked st segment depression exercise low exercise capacity independently predict adverse outcome patient stable angina pectoris whereas anginal symptom predictive value short term treatment effect ischaemia seem influence prognosis post exercise ischaemia examine carefully evaluate patient stable angina pectoris,Forslund L,2000,Eur Heart J,https://doi.org/10.1053/euhj.1999.1936,10806014,Forslund L; Hjemdahl P; Held C; Björkander I; Eriksson SV; Brodin U; Rehnqvist N,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000319: Adrenergic beta-Antagonists; D000368: Aged; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D002908: Chronic Disease; D005080: Exercise Test; D005260: Female; D006801: Humans; D008297: Male; D008790: Metoprolol; D008875: Middle Aged; D015337: Multicenter Studies as Topic; D011379: Prognosis; D016032: Randomized Controlled Trials as Topic; D012044: Regression Analysis; D014700: Verapamil,,,https://openalex.org/W2166846026,204,32,2,1784,259,4,en,en
false,comparison atenolol amlodipine enalapril hydrochlorothiazide losartan antihypertensive treatment patient obstructive sleep apnea,compare effect atenolol mg amlodipine mg enalapril mg hydrochlorothiazide mg losartan mg give daily oral dos office ambulatory blood pressure bps patient hypertension obstructive sleep apnea osa randomized patient treat sequence two five agent balanced incomplete block design treatment period last wk separate wk washout period change bp baseline study substance compare analysis variance office diastolic bp primary outcome variable effectively lower atenolol four post hoc difference atenolol remain substance statistically significant reduction office systolic daytime ambulatory bp significantly different among five compound however atenolol reduce mean nighttime ambulatory diastolic systolic bp effectively amlodipine enalapril losartan hydrochlorothiazide severity sleep disordered breathing well day significantly influence study compound finding accordance hypothesis overactivity sympathetic nervous system important mechanism behind development maintenance hypertension patient osa,Kraiczi H,2000,Am J Respir Crit Care Med,https://doi.org/10.1164/ajrccm.161.5.9909024,10806134,Kraiczi H; Hedner J; Peker Y; Grote L,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001262: Atenolol; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D004232: Diuretics; D004311: Double-Blind Method; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D019808: Losartan; D008297: Male; D008875: Middle Aged; D016037: Single-Blind Method; D020181: Sleep Apnea, Obstructive; D049993: Sodium Chloride Symporter Inhibitors",,,https://openalex.org/W2135288867,152,21,1,1401,241,9,en,en
false,increase incidence infection verapamil treated kidney transplant recipient,chapter discuss several adrenoceptor antagonist antianginal drugs propranolol gabapentin effective essential tremor gabapentin occasionally cause reversible movement disorder concurrent systemic blocker therapy deleterious effect ocular hypotensive efficacy impact safety topical brimonidine combination timolol brimonidine significantly reduce systolic diastolic blood pressure heart rate compare brimonidine alone surgery standard treatment anal fissure common painful anal disease local application glyceryl trinitrate improves symptom relax internal anal sphincter multicenter randomize placebo controlled doubleblind study glyceryl trinitrate ointment patient least week heal rate similar glyceryl trinitrate placebo adverse event frequent use glyceryl trinitrate isosorbide mononitrate add propranolol appear less well tolerate propranolol alone seven patient withdraw treatment adverse effect four feeling faintness two headache one angina like chest pain compare one atrioventricular block take propranolol alone,Nanni G,2000,Transplant Proc,https://doi.org/10.1016/s0041-1345(00)00886-1,10812109,Nanni G; Panocchia N; Tacchino R; Foco M; Piccioni E; Castagneto M,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article,D000961: Antilymphocyte Serum; D002121: Calcium Channel Blockers; D006084: Graft Rejection; D006801: Humans; D007166: Immunosuppressive Agents; D015994: Incidence; D007239: Infections; D016030: Kidney Transplantation; D014700: Verapamil,,,https://openalex.org/W2002435334,82,9,1,1341,202,7,en,en
false,influence diabetes type hypertension response antihypertensive treatment,aim investigation determine whether presence additional risk factor type hypertension diastolic isolated systolic influence blood pressure bp response treatment international nifedipine git study intervention goal hypertension treatment insight study double blinded outcome comparison calcium channel blockade diuretic high risk patient age year dynamic randomization nifedipine daily hydrochlorothiazide amiloride perform ensure approximately equal number patient group major cardiovascular risk factor patient isolated systolic hypertension also separately randomize atenolol enalapril mandatory second line drug patient complete week titration bp fell mm hg mean sd receive placebo mm hg twenty six percent patient require drug require drug patient diabetes resistant treatment require second third drug frequently patient without diabetes achieve marginally high final bp risk group mm hg age smoking gender hypercholesterolemia leave ventricular hypertrophy exist atherosclerosis little mm hg influence bp end titration except smoke slightly reduce initial response either systolic diastolic bp patient isolated systolic hypertension slightly responsive average treatment finding suggest patient high absolute risk cardiovascular complication hypertension risk factor prevent recommended bp target achieve,Brown MJ,2000,Hypertension,https://doi.org/10.1161/01.hyp.35.5.1038,10818061,Brown MJ; Castaigne A; de Leeuw PW; Mancia G; Palmer CR; Rosenthal T; Ruilope LM,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D000959: Antihypertensive Agents; D001262: Atenolol; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D048909: Diabetes Complications; D003920: Diabetes Mellitus; D003971: Diastole; D004232: Diuretics; D004311: Double-Blind Method; D004656: Enalapril; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D012307: Risk Factors; D013599: Systole",,,https://openalex.org/W2154128260,88,12,1,1838,302,11,en,en
false,evaluation amlodipine lisinopril combination treatment essential hypertension,abstract angiotensin convert enzyme ace inhibitor dihydropyridine calcium antagonist well establish widely use monotherapy patient mild moderate essential hypertension early study combine short act drug class require multiple dosing associate poor compliance availability long act compound allow daily administration avoid inconvenience multiple daily dose decide perform randomised double blind crossover study long acting calcium channel blocker amlodipine long acting ace inhibitor lisinopril give either alone combination essential hypertension twenty four patient diastolic blood pressure dbp mm hg receive amlodipine mg mg lisinopril mg mg combination per prior randomisation schedule supine stand blood pressure heart rate record weekly interval high dos drug individually combination use target supine dbp mm hg achieve significant additional blood pressure lower effect combination compare either amlodipine lisinopril alone five mg amlodipine mg lisinopril monotherapy achieve target blood pressure patient respectively combination mg amlodipine mg lisinopril produce much significant lowering blood pressure high percentage patient individual low dose,Naidu MU,2000,Postgrad Med J,https://doi.org/10.1136/pmj.76.896.350,10824049,Naidu MU; Usha PR; Rao TR; Shobha JC,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006973: Hypertension; D017706: Lisinopril; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2132518773,98,15,1,1580,261,10,en,en
false,effect amlodipine hemodynamic endocrine response mental stress,little know effect antihypertensive drug hemodynamic response mental stress study patient mild moderate hypertension double blind random sequence crossover study compare placebo amlodipine titrate mg daily month treatment subject perform min frustrating cognitive task baseline task amlodipine significantly reduce systolic pressure mm hg v mm hg p diastolic pressure mm hg v mm hg p total peripheral resistance v mm hg l min p elevate baseline norepinephrine level pmol l v pmol l p,Spence JD,2000,Am J Hypertens,https://doi.org/10.1016/s0895-7061(99)00235-6,10826403,Spence JD; Munoz C; Huff MW; Tokmakjian S,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D017311: Amlodipine; D015415: Biomarkers; D002121: Calcium Channel Blockers; D002851: Chromatography, High Pressure Liquid; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004703: Endocrine System; D005260: Female; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D008055: Lipids; D008297: Male; D008875: Middle Aged; D009638: Norepinephrine; D013315: Stress, Psychological",,,https://openalex.org/W2133704811,76,11,1,742,148,4,en,en
false,medical therapy symptom distress cause,background adverse event drug therapy assess measurement feature frequency severity severity turn measure assess distress cause goal relate magnitude distress induce treatment calcium channel block agent change quality life assess psychosocial instrument patient treat calcium channel block agent either hypertension angina pectoris method four hundred seventy five patient angina pectoris randomize double blind treatment ppr physiological pattern release verapamil hydrochloride amlodipine besylate amlodipine atenolol combination placebo addition hypertensive patient randomize either ppr verapamil nifedipine git gastrointestinal system study double blind result significant difference treatment angina pectoris hypertension find regimen overall quality life also fail show significant difference either group group however remarkable concordance find degree distress associate specific symptom change quality life unchanged stable symptom distress associate significant improvement quality life sd improvement erosion symptom distress represent step associate sd change extreme change symptom distress associate substantially large change global quality life conclusion magnitude symptom distress relief associate symptom patient population correlate strongly shift quality life assessment distress associate symptom provide valuable additional information drug therapy,Hollenberg NK,2000,Arch Intern Med,https://doi.org/10.1001/archinte.160.10.1477,10826461,Hollenberg NK; Williams GH; Anderson R,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D016907: Adverse Drug Reaction Reporting Systems; D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D000787: Angina Pectoris; D000959: Antihypertensive Agents; D001262: Atenolol; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011788: Quality of Life; D016896: Treatment Outcome; D014700: Verapamil",,,https://openalex.org/W2164579243,54,10,1,1918,323,14,en,en
false,diltiazem acute myocardial infarction treat thrombolytic agent randomised placebo controlled trial,diltiazem reduces non fatal reinfarction refractory ischaemia non q wave myocardial infarction acute coronary syndrome similar incomplete infarction occur successful reperfusion postulate agent would reduce cardiac event patient acute myocardial infarction treat initially thrombolytic agents clinical application previously unexplored heart rate lowering calcium antagonists prospective randomised double blind sequential trial patient acute myocardial infarction without congestive heart failure first receive thrombolytic agent patient receive either mg oral diltiazem daily placebo initiate within h infarct onset give month trial primary endpoint cumulative first event rate cardiac death non fatal reinfarction refractory ischaemia additional prespecified endpoint include several composite non fatal cardiac event non fatal reinfarction combine refractory ischaemia recurrent ischaemia need myocardial revascularisation diagnosis ischaemia whether refractory recurrent need myocardial revascularisation always base objective electrocardiographical evidence ischaemia either rest exertion trial primary endpoint event occur placebo patient event diltiazem patient hazard ratio ci p non fatal cardiac event diltiazem treatment associate relative decrease combined event rate non fatal reinfarction refractory ischaemia similar decrease composite non fatal endpoint non fatal reinfarction combine recurrent ischaemia non fatal reinfarction combine need myocardial revascularisation need myocardial revascularisation alone significantly reduce major safety issue encountered diltiazem reduce cumulative occurrence cardiac death non fatal reinfarction refractory ischaemia month follow reduce composite endpoint non fatal cardiac event especially need myocardial revascularisation,Boden WE,2000,Lancet,https://doi.org/10.1016/s0140-6736(00)02262-5,10832825,Boden WE; van Gilst WH; Scheldewaert RG; Starkey IR; Carlier MF; Julian DG; Whitehead A; Bertrand ME; Col JJ; Pedersen OL; Lie KI; Santoni JP; Fox KM,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D002121: Calcium Channel Blockers; D004110: Diltiazem; D004311: Double-Blind Method; D005260: Female; D005343: Fibrinolytic Agents; D006801: Humans; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D011446: Prospective Studies,,,https://openalex.org/W2158089084,112,14,1,2369,365,10,en,en
false,prospective randomize comparison antiarrhythmic therapy versus first line radiofrequency ablation patient atrial flutter,despite high success rate radiofrequency rf ablation pharmacologic therapy still consider standard initial therapeutic approach atrial flutter prospectively compare outcome follow patient atrial flutter randomly assign drug therapy rf ablation patients least two episode symptomatic atrial flutter last four month randomize regimen either antiarrhythmic drug therapy first line rf ablation institution therapy end point include recurrence atrial flutter rehospitalization quality life total patient enter study randomize drug therapy rf ablation mean follow month patient receive drug sinus rhythm versus patient undergo rf ablation p patient receive drug required one rehospitalizations whereas post rf ablation patient rehospitalized p follow rf ablation patient develop atrial fibrillation see patient receive medication p sense well pre rf vs post rf p function daily life pre rf vs post rf p improve ablation change significantly patient treat drugs select group patient atrial flutter rf ablation could consider first line therapy due good success rate impact quality life low occurrence atrial fibrillation low need rehospitalization follow,Natale A,2000,J Am Coll Cardiol,https://doi.org/10.1016/s0735-1097(00)00635-5,10841241,Natale A; Newby KH; Pisanó E; Leonelli F; Fanelli R; Potenza D; Beheiry S; Tomassoni G,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D000889: Anti-Arrhythmia Agents; D001282: Atrial Flutter; D017115: Catheter Ablation; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D011446: Prospective Studies; D011788: Quality of Life,,,https://openalex.org/W2040907740,133,15,1,1688,312,6,en,en
false,neonatal poisoning middle anatolia turkey analysis case,study newborn infant follow diagnosis poison erciyes university faculty medicine department pediatrics division neonatology evaluate retrospectively purpose emphasize importance newborn poisoning among general poisoning childhood age infant range min day day forty seven infant poison delivery infant mother preeclampsia eclampsia receive magnesium sulfate nine magnesium sulfate diazepam four magnesium sulfate nifedipine others receive various drug combination aside one mother addison disease use long term dexamethasone pregnancy newborn period five infant inhaled organophosphate insecticide eight ingest corrosive agent four benzalkonium chloride three chlorhexidine gluconate cetrimide infant ammonium four poison overdose digoxin three ingest overdose phenobarbital two receive acepromazine maleate addition infant ingest diphenoxilate hcl atropine sulfate pipenzolate bromid tizanidine hcl follow period infant range hr day day mortality rate death note infant follow poisoning delivery cause death follow sepsis four infant meningitis respiratory distress syndrome necrotizing enterocolitis two infant effect overdose magnesium sulfate diazepam two infant respectively conclusion would like stress newborn infant whose mother receive magnesium sulfate another drug pregnancy delivery closely monitor calculation drug dos carefully teach hospital nurse baby rooms disinfect organophosphate insecticide hospital house infant remove room least hr use drug explain detail mother,Kurtoglu S,2000,J Toxicol Sci,https://doi.org/10.2131/jts.25.115,10845189,Kurtoglu S; Caksen H; Poyrazoglu MH,article,D016428: Journal Article,"D004461: Eclampsia; D005260: Female; D006801: Humans; D007226: Infant Mortality; D007231: Infant, Newborn; D008278: Magnesium Sulfate; D008297: Male; D011041: Poisoning; D011247: Pregnancy; D011248: Pregnancy Complications; D011297: Prenatal Exposure Delayed Effects; D012189: Retrospective Studies; D014421: Turkey",,,https://openalex.org/W2053963933,74,14,2,2196,399,14,en,en
false,antihypertensive drug risk idiopathic aplastic anaemia,aim recent report raise concern nifedipine may associate increase risk aplastic anaemia large population based study evaluate risk idiopathic aplastic anaemia user calcium channel blocker compare antihypertensive drug method study base information derive general practice research database conduct follow study nested case control analysis subject receive antihypertensive drug case people first time diagnosis aplastic anaemia january september risk estimate aplastic anaemia calculate antihypertensive drug nested case control analysis six control match case age sex general practice attend odds ratio compare risk idiopathic aplastic anaemia antihypertensive drug relative nonusers result case newly diagnose idiopathic aplastic anaemia estimate risk aplastic anaemia per user ci calcium channel blocker ci adrenoceptor blocker ci angiotension converting enzyme ace inhibitor ci user antihypertensive drug case control analysis case control odds ratio ci calcium channel blocker ci adrenoceptor blocker ci ace inhibitor ci user antihypertensive drug ci user multiple drug calcium channel blocker compare nonusers conclusion present study suggest use calcium channel blocker associate increase risk aplastic anaemia,Myers MW,2000,Br J Clin Pharmacol,https://doi.org/10.1046/j.1365-2125.2000.00208.x,10848725,Myers MW; Vasilakis C; Kaufman MR; Jick H,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D000741: Anemia, Aplastic; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D016022: Case-Control Studies; D015331: Cohort Studies; D016208: Databases, Factual; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D016017: Odds Ratio; D018570: Risk Assessment; D006113: United Kingdom",,,https://openalex.org/W1949762012,66,9,1,1872,353,12,en,en
false,use calcium salt prevention management verapamil induced hypotension,review available literature use intravenous calcium salt prevention hypotension associate intravenous verapamil medline search june identify pertinent article reference article identify serve additional resources verapamil effective inhibit atrioventricular nodal conduction thereby control ventricular rate patient atrial fibrillation flutter terminate paroxysmal supraventricular tachycardia however hypotension may cause negative inotropic vasodilating effect verapamil vitro animal data suggest calcium pretreatment may minimize effect verapamil cardiac output blood pressure case report suggest intravenous calcium may useful prevention reversal hemodynamic effect verapamil number small clinical trial perform suggest calcium administer prior intravenous verapamil result decreased incidence hypotension common adverse effect intravenous calcium flushing calcium pretreatment prior intravenous calcium channel blocker administration consider patient reduction blood pressure may precipitate hypoperfusion worsen underlying cardiovascular status dose calcium gluconate g ionized calcium mg administer three minute recommend prevent lessen hypotensive effect verapamil without affect antiarrhythmic effect verapamil,Moser LR,2000,Ann Pharmacother,https://doi.org/10.1345/aph.18318,10852091,Moser LR; Smythe MA; Tisdale JE,article,D016428: Journal Article; D016454: Review,"D002121: Calcium Channel Blockers; D002125: Calcium Gluconate; D002986: Clinical Trials as Topic; D006801: Humans; D007022: Hypotension; D007262: Infusions, Intravenous; D014700: Verapamil",,,https://openalex.org/W2109193266,90,13,1,1568,224,7,en,en
false,effect enalapril isradipine alone combination blood pressure renal function echocardiographic parameter mild hypertension,study carry evaluate influence antihypertensive treatment combined low dos enalapril plus isradipine mg daily compare either drug high dose level mg daily double blind three way crossover study balance latin square design subject mean age year essential hypertension leave ventricular mass function evaluate b mode echocardiography renal function glomerular filtration rate gfr serum h urinary na k wash period week treatment supine blood pressure subject give placebo mmhg week treatment systolic diastolic supine blood pressure significantly low mg isradipine plus mg enalapril mmhg mg enalapril mmhg mg isradipine mmhg leave ventricular posterior wall septal thickness significantly similarly reduce group leave ventricular systolic diastolic end diameter significantly change leave ventricular mass lvm significantly reduce e plus group enalapril group gfr significantly alter h urinary na significantly increase enalapril isradipine combination tolerate good either monotherapy observe clinically significant change laboratory variable include blood lipoproteins combination isradipine plus enalapril reduce blood pressure effectively well tolerate drug alone three group show similar change echocardiographic index change renal function,De Rosa ML,2000,Int J Cardiol,https://doi.org/10.1016/s0167-5273(00)00249-7,10854683,De Rosa ML; Maddaluno G; Lionetti F; Di Palma U; Albanese L; Cardace P; Baiano A; Vigorito C,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000704: Analysis of Variance; D000959: Antihypertensive Agents; D001794: Blood Pressure; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004562: Electrocardiography; D004656: Enalapril; D005919: Glomerular Filtration Rate; D006352: Heart Ventricles; D006801: Humans; D006973: Hypertension; D017379: Hypertrophy, Left Ventricular; D017275: Isradipine; D008297: Male; D008875: Middle Aged; D018709: Statistics, Nonparametric",,,https://openalex.org/W2002224139,148,21,1,1706,286,11,en,en
false,efficacy safety new long acting drug combination trandolapril verapamil compare monotherapy primary hypertension,evaluate clinical efficacy safety new antihypertensive drug combination trandolapril verapamil compare monotherapy verapamil trandolapril patient mild moderate primary hypertension multicentre prospective randomize double blind control cross study specific statistical considerations eighteen primary health care centre patient hospital clinic sweden two hundred twenty six outpatient uncomplicated primary hypertension baseline sit diastolic blood pressure bp mmhg week placebo period patient randomize treatment week trandolapril verapamil mg mg drug alone verapamil mg trandolapril mg weeks treatment response blood pressure bp fall rate pressure product three regimen statistical comparison also relation plasma concentration active renin ar adverse event safety also evaluated mean bp fall significantly great combination mmhg p compare trandolapril mmhg verapamil mmhg difference verapamil trandolapril significant rate pressure product decrease significantly combination p trandolapril verapamil alone treatment response trandolapril positively correlate initial ar r treatment well tolerate safe new fix drug combination trandolapril verapamil superior monotherapy either drug alone regard reduction bp rate pressure product combination safely effectively use treatment mild moderate primary hypertension,Karlberg BE,2000,Blood Press,https://doi.org/10.1080/080370500453483,10855738,Karlberg BE; Andrup M; Odén A,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001794: Blood Pressure; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004338: Drug Combinations; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D007211: Indoles; D008297: Male; D008875: Middle Aged; D011237: Predictive Value of Tests; D011446: Prospective Studies; D012083: Renin; D016896: Treatment Outcome; D014665: Vasodilator Agents; D014700: Verapamil",,,https://openalex.org/W2152548271,132,18,1,1792,287,7,en,en
false,clinical trial update optime chf praise hat,abstract summary report presentation make american college cardiology th scientific session anaheim march study particular interest heart failure physician review optime chf outcome prospective trial intravenous milrinone exacerbation chronic heart failure optime chf randomised controlled trial compare h infusion milrinone standard therapy patient recruit year period patient exclude investigator believe clinical condition mandate inotropic therapy patient randomise within h admission acute exacerbation chronic heart failure receive milrinone placebo infision h patient diabetic receive angiotensin convert enzyme inhibitor already beta blocker atrial fibrillation significant difference two group length hospital stay index admission subsequent readmission day hospital following day subjective clinical assessment score also different average admission rate next year one per patient group however significant increase incidence sustained hypotension milrinone group account increased adverse event rate active therapy day mortality group previous trial oral formulation milrinone clearly demonstrate lack benefit milrinone either acute exacerbation stable severe chronic heart failure packer carver jr rodeheffer rj et al effect oral milrinone mortality severe chronic heart failure n engl j med medium sized study milrinone patient mild severity heart failure also suggest adverse impact prognosis presence absence digoxin dibianco r shabetai r kostuk w moran j schlant rc wright r comparison oral milrinone digoxin combination treatment patient chronic heart failure n engl j med whether milrinone even role management haemodyamic crisis require inotropic therapy must also question,Thackray S,2000,Eur J Heart Fail,https://doi.org/10.1016/s1388-9842(00)00080-5,10856736,Thackray S; Witte K; Clark AL; Cleland JG,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000317: Adrenergic alpha-Antagonists; D000319: Adrenergic beta-Antagonists; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D002316: Cardiotonic Agents; D017292: Doxazosin; D006333: Heart Failure; D006801: Humans; D020105: Milrinone; D011725: Pyridines; D016032: Randomized Controlled Trials as Topic; D013841: Thiazepines; D016896: Treatment Outcome,,,https://openalex.org/W2070029274,53,9,1,2375,414,17,en,en
false,cytoprotective property nisoldipine amlodipine oxidative endothelial cell injury,annals new york academy sciencesvolume issue p cytoprotective property nisoldipine amlodipine oxidative endothelial cell injury tong mak correspond author tong mak department physiology experimental medicine george washington university medical center washington c usa address correspondence dr mak eye st nw ross hall room washington dc voice fax e mail itmak gwu edusearch paper authorjingyun zhang jingyun zhang department physiology experimental medicine george washington university medical center washington c usasearch paper authorwilliam b weglicki william b weglicki department physiology experimental medicine george washington university medical center washington c usasearch paper author tong mak correspond author tong mak department physiology experimental medicine george washington university medical center washington c usa address correspondence dr mak eye st nw ross hall room washington dc voice fax e mail itmak gwu edusearch paper authorjingyun zhang jingyun zhang department physiology experimental medicine george washington university medical center washington c usasearch paper authorwilliam b weglicki william b weglicki department physiology experimental medicine george washington university medical center washington c usasearch paper author first publish january http doi org j tb xcitations read full textaboutpdf toolsrequest permissionexport citationadd favoritestrack citation shareshare give accessshare full text accessshare full text accessplease review term condition use check box share full text version article read accept wiley online library term condition useshareable linkuse link share full text version article friend colleague learn copy url share linkshare onfacebooktwitterlinkedinredditwechat cite literature volume issue reactive oxygen specie radiation molecular biology festschrift honor daniel l gilbertjanuary pages relatedinformation,Mak IT,2000,Ann N Y Acad Sci,https://doi.org/10.1111/j.1749-6632.2000.tb06204.x,10863557,Mak IT; Zhang J; Weglicki WB,article,"D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.","D017311: Amlodipine; D000818: Animals; D002121: Calcium Channel Blockers; D002417: Cattle; D002478: Cells, Cultured; D004730: Endothelium, Vascular; D015227: Lipid Peroxidation; D015737: Nisoldipine; D018384: Oxidative Stress",,,https://openalex.org/W1986445058,97,11,1,2517,399,6,en,en
false,maternal neonatal outcome preeclamptic pregnancy potential role factor v leiden mutation methylenetetrahydrofolate reductase,investigate potential perinatal effect factor v leiden mutation methylenetetrahydrofolate reductase c polymorphism preeclamptic women one hundred twenty preeclamptic woman n healthy pregnant control n recruit evaluate frequency leiden methylenetetrahydrofolate reductase mthfr mutation use polymerase chain reaction pcr perinatal outcome record analyze study participant neonates laboratory analysis yield heterozygous carrier factor v leiden mutation among preeclamptic woman heterozygous carrier among healthy control difference two group find statistically significant p relative risk rr confidence interval ci homozygous mthfr mutation find preeclamptic woman healthy control evaluate among preeclamptic woman episode hemolysis elevate liver enzyme low platelet hellp syndrome report factor v leiden mutation negative mutation group difference determine statistically significant p rr ci perinatal indicator collect two group include frequency intrauterine growth retardation birth weight gestational age statistically different perinatal outcome find factor v leiden positive negative preeclamptic woman addition mthfr gene polymorphism appear correlate development preeclampsia although frequency factor v leiden mutation appear significantly high among preeclamptic woman mechanism pathogenesis potential influence perinatal outcome yet well understood relatively high rate hellp syndrome among factor v leiden mutation suggest thrombogene mutation may play significant role hemostatic system activation result suggest role mthfr polymorphism factor folic acid supplementation require extensive analysis control worldwide morbidity mortality associate important maternal condition,Rigó J,2000,Hypertens Pregnancy,https://doi.org/10.1081/prg-100100132,10877984,Rigó J; Nagy B; Fintor L; Tanyi J; Beke A; Karádi I; Papp Z,article,D016428: Journal Article,"D000328: Adult; D005165: Factor V; D005260: Female; D006801: Humans; D007231: Infant, Newborn; D042965: Methylenetetrahydrofolate Reductase (NADPH2); D000587: Oxidoreductases Acting on CH-NH Group Donors; D017354: Point Mutation; D016133: Polymerase Chain Reaction; D011225: Pre-Eclampsia; D011247: Pregnancy; D011256: Pregnancy Outcome",,,https://openalex.org/W2158042435,151,20,1,2360,404,11,en,en
false,evaluation effect fixed combination sustained release verapamil trandolapril versus captopril hydrochlorothiazide metabolic electrolyte parameter patient essential hypertension,objective randomised open active control cross study evaluate effect fixed combination verapamil sr trandolapril compare captopril hydrochlorothiazide serum lipid lipoprotein metabolic electrolyte parameter patient essential hypertension another objective assess efficacy safety combination one hundred hypertensive systolic blood pressure mm hg diastolic blood pressure mm hg evaluate week receive fixed combination verapamil sr mg trandolapril mg vt captopril mg hydro chlorothiazide mg ch give daily lipid lipoprotein assess duplicate consecutive day study complete patient statistically significant difference two combine regimen respect low density lipoprotein ldl cholesterol intention treat population measure end treatment period mmol l vt mmol l ch difference find lipid parameter like total cholesterol triglyceride apolipoproteins b lp high density lipoprotein hdl cholesterol significantly high vt vs p serum potassium decline uric acid glucose increase ch conclusion significant difference find ldl cholesterol lipid parameter exception hdl cholesterol significantly high vt serum potassium decline uric acid glucose increase ch significantly fixed combination well tolerate incidence adverse event high ch fixed combination significantly lower bp journal human hypertension,Cifková R,2000,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1001014,10878692,Cifková R; Nakov R; Novozámská E; Hejl Z; Petrzílková Z; Poledne R; Stávek P; Compagnone D,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000328: Adult; D000368: Aged; D000704: Analysis of Variance; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D002216: Captopril; D016001: Confidence Intervals; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D004338: Drug Combinations; D004573: Electrolytes; D005260: Female; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D007211: Indoles; D008074: Lipoproteins; D008297: Male; D008875: Middle Aged; D016896: Treatment Outcome; D014665: Vasodilator Agents; D014700: Verapamil,,,https://openalex.org/W2320827107,208,22,1,1870,319,15,en,en
false,estudio sobre tolerabilidad efectividad de nicardipino retard en el deterioro cognitivo de origen vascular,nicardipine calcium antagonist previous trial show effective prevention stroke treatment sequela cognitive deterioration vascular origin consider phase iv study primary care level analyze tolerability efficacy retarded action formulation mg nicardipine open prospective multicentric trial patient take part evaluate diagnose vascular type dementia hachinski give treatment nicardipine retard mg day month patient assess montorio daily activity spmsq cognitive function scale first visit one three six month together record side effects patient recruit abandon study problem tolerability drug average improvement see montorio test statistically significant first month reach six month patient start study seriously deteriorate condition show improvement six month spmsq test average improvement also statistically significant first visit six month improvement patient severely deteriorate start study nicardipine retard drug safe effective use treatment mental deterioration vascular origin,González-González JA,2000,Rev Neurol,https://doi.org/10.33588/rn.3008.99225,10893735,González-González JA; Lozano R,article,D016430: Clinical Trial; D004740: English Abstract; D016428: Journal Article; D016448: Multicenter Study,"D000368: Aged; D002121: Calcium Channel Blockers; D003072: Cognition Disorders; D015140: Dementia, Vascular; D018450: Disease Progression; D004361: Drug Tolerance; D005260: Female; D006801: Humans; D008297: Male; D009483: Neuropsychological Tests; D009529: Nicardipine; D011446: Prospective Studies; D012720: Severity of Illness Index; D016896: Treatment Outcome",,,https://openalex.org/W92160321,108,15,1,1510,270,8,es,en
false,effect enalapril nifedipine orthostatic hypotension old hypertensive patient,compare effect enalapril long acting nifedipine orthostatic hypotension old patients prospective double blind cross study outpatient clinic university hospital thirty nine patient age year old systolic blood pressure sbp mm hg diastolic blood pressure dbp mm hg enalapril mg od nifedipine mg od week follow week washout cross second week period supine stand minutes blood pressure record end treatment period baseline sbp mm hg dbp mm hg decline sbp mm hg mm hg minute stand respectively agent cause significant decline supine blood pressure enalapril supine sbp mm hg supine dbp mm hg p drop sbp stand minute mm hg change diastolic value mm hg drop sbp observe three patient patient experience decline mm hg nifedipine supine sbp mm hg supine dbp p nifedipine induce orthostatic decline sbp value mm hg difference supine minute stand value p without change diastolic value orthostatic decline sbp mm hg occur patient drop mm hg six patient cross enalapril nifedipine reproduce hypotensive effect reverse postural effect p nifedipine v enalapril enalapril nifedipine equipotent reduce supine blood pressure level enalapril also reduce number orthostatic episode significantly whereas nifedipine aggravate phenomenon,Slavachevsky I,2000,J Am Geriatr Soc,https://doi.org/10.1111/j.1532-5415.2000.tb04757.x,10894321,Slavachevsky I; Rachmani R; Levi Z; Brosh D; Lidar M; Ravid M,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004656: Enalapril; D006801: Humans; D006973: Hypertension; D007024: Hypotension, Orthostatic; D009543: Nifedipine; D011446: Prospective Studies",,,https://openalex.org/W2038254213,92,12,1,1992,395,12,en,en
false,use metoprolol cr xl maintain sinus rhythm conversion persistent atrial fibrillation,primary objective present study assess efficacy metoprolol cr xl reduce risk relapse cardioversion persistent atrial fibrillation sinus rhythm indirect data study l sotalol provide evidence beta blocking effect compound important maintain sinus rhythm cardioversion atrial fibrillation successful conversion sinus rhythm patient history persistent atrial fibrillation randomly assign treatment metoprolol cr xl placebo two treatment group similar respect pretreatment characteristic patient see outpatient basis record rest electrocardiogram ecg one week one three six month follow whenever felt relapse atrial fibrillation experience adverse event metoprolol cr xl group patient relapse atrial fibrillation compare patient placebo group p heart rate patient relapse atrial fibrillation significantly low metoprolol group beats min placebo group beats min rate adverse event report similar group difference follow time take account result double blind placebo controlled study patient cardioversion persistent atrial fibrillation show metoprolol cr xl effective prevent relapse atrial fibrillation flutter,Kühlkamp V,2000,J Am Coll Cardiol,https://doi.org/10.1016/s0735-1097(00)00693-8,10898425,Kühlkamp V; Schirdewan A; Stangl K; Homberg M; Ploch M; Beck OA,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D058671: Adrenergic beta-1 Receptor Antagonists; D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D001281: Atrial Fibrillation; D004311: Double-Blind Method; D004554: Electric Countershock; D004562: Electrocardiography; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008790: Metoprolol; D008875: Middle Aged; D011446: Prospective Studies; D012449: Safety; D055502: Secondary Prevention; D016896: Treatment Outcome",,,https://openalex.org/W1430322293,101,14,1,1590,262,5,en,en
true,plasma norepinephrine atrial natriuretic peptide heart failure influence felodipine third vasodilator heart failure trial,background reflex activation sympathetic nervous system short acting dihydropyridine calcium channel antagonists report harm hypertensive patient different neurohormonal profile response treatment may influence effectiveness dihydropyridine vasodilator treatment heart failure method four hundred fifty men left ventricular lv systolic dysfunction administer standard heart failure treatment felodipine extend release er placebo vasodilator heart failure trial iii v heft iii plasma norepinephrine pne level atrial natriuretic peptide anp level exercise capacity lv ejection fraction ef cardiac dimension function arrhythmia frequency measure hospital free survival baseline neurohormonal class assess result distribution anp pne level baseline patient heart failure ischemic nonischemic cause virtually identical anp level baseline inversely relate lvef r p exercise duration r p peak oxygen consumption r p directly relate lv r p right ventricular dilatation r p increase anp level baseline month p year p significantly less felodipine er group placebo group pne level differ treatment group hospital free survival directly relate baseline anp p pne level p cause mortality relate baseline pne level p baseline anp level conclusion level anp pne hormone relate lv dysfunction exercise performance hospital free survival heart failure pne level relate cause mortality treatment felodipine er adversely affect survival neurohormone subclass,Smith RF,2000,J Card Fail,https://doi.org/10.1016/s1071-9164(00)90011-3,10908083,Smith RF; Germanson T; Judd D; Wong M; Ziesche S; Anand IS; Taylor WR; Cohn JN,article,"D016430: Clinical Trial; D017428: Clinical Trial, Phase III; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial","D000284: Administration, Oral; D000293: Adolescent; D009320: Atrial Natriuretic Factor; D015415: Biomarkers; D002423: Cause of Death; D015736: Felodipine; D006333: Heart Failure; D006801: Humans; D008297: Male; D009638: Norepinephrine; D011863: Radioimmunoassay; D013318: Stroke Volume; D015996: Survival Rate; D014481: United States; D014665: Vasodilator Agents",,,https://openalex.org/W2094975362,139,20,1,1953,358,12,en,en
false,effect diltiazem retard ambulatory blood pressure heart rate variability patient essential hypertension,background dihydropyridine calcium antagonists increase heart rate due reflex activation sympathetic nervous system although effect less obvious long acting agent objective study effect diltiazem retard long acting nondihydropyridine calcium antagonist h blood pressure heart rate autonomic nerve activity patient essential hypertension design randomize crossover design method thirteen patient five men eight woman age year mean sem administer placebo diltiazem retard mg daily week ambulatory monitoring blood pressure heart rate electrocardiography carry end period use multibiomedical recorder tm autonomic nerve activity evaluate power spectral analysis variability heart rate use high frequency component index parasympathetic nerve activity ratio low frequency component high frequency component index sympathovagal balance result treatment diltiazem retard significantly decrease h average blood pressure heart rate mmhg beats min respectively change daytime night time value comparable diltiazem retard also significantly decrease daytime h low high frequency component ratio versus versus respectively conclusion result indicate diltiazem retard effective daily antihypertensive agent favorable effect heart rate autonomic nervous system,Kawano Y,2000,Blood Press Monit,https://doi.org/10.1097/00126097-200006000-00007,10915232,Kawano Y; Makino Y; Okuda N; Takishita S; Omae T,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D004110: Diltiazem; D004334: Drug Administration Schedule; D016903: Drug Monitoring; D004562: Electrocardiography; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D010275: Parasympathetic Nervous System; D013564: Sympathetic Nervous System; D014630: Vagus Nerve",,,https://openalex.org/W2025175190,123,17,1,1661,274,10,en,en
false,silent myocardial ischaemia elderly,coronary artery disease cad lead cause death disability elderly several recent study show silent myocardial ischaemia smi common manifestation cad especially elderly many elderly patient prior history cad may underlie asymptomatic disease elderly patient know cad might evidence smi result study elderly patient cad also show smi might exist despite antianginal therapy consider adequate symptom control order diagnose residual smi clinician would need perform hour holter monitoring ambulatory set patient perform routine daily activity although number anti ischaemic drug evaluate treatment smi available data suggest beta blocker give alone combination nitrate compound calcium antagonist provide best therapeutic choice long term benefit smi suppression elderly patient establish future study need evaluate clinical benefit therapy give smi elderly,Deedwania PC,2000,Drugs Aging,https://doi.org/10.2165/00002512-200016050-00007,10917075,Deedwania PC,article,D016428: Journal Article; D016454: Review,D000368: Aged; D006801: Humans; D017202: Myocardial Ischemia; D015995: Prevalence; D011379: Prognosis,,,https://openalex.org/W1995543232,42,6,1,1188,207,8,sl,en
false,long term effect diltiazem verapamil mortality cardiac event non q wave acute myocardial infarction without pulmonary congestion post hoc subset analysis multicenter diltiazem postinfarction trial second danish verapamil infarction trial study,main objective retrospective analysis evaluate long term effect heart rate lowering calcium antagonist verapamil diltiazem incidence combined cardiac event cause mortality patient experience non q wave acute myocardial infarction ami also pulmonary congestion addition factor independent association outcome identify non q wave patient die month follow unadjusted mortality rate low patient randomize calcium antagonist therapy placebo vs p non q wave patient die follow old patient survive vs year p factor find independent association cause mortality include diuretic use rr diabetes mellitus rr new york heart association class rr covariate adjust cause mortality risk ratio associate randomization calcium antagonist therapy confidence interval p overall patient die nonfatal reinfarction unadjusted combined event rate low patient randomize calcium antagonist therapy placebo vs p factor find independent association cardiac event include age diabetes rr diuretic use rr previous ami rr addition randomization calcium antagonist group significant independent association reduced cardiac event p covariate adjust event rate rr associate randomization calcium antagonist group confidence interval conclusion heart rate lowering calcium antagonist diltiazem verapamil may play important role reduce long term mortality reinfarction non q wave ami without pulmonary congestion,Gibson RS,2000,Am J Cardiol,https://doi.org/10.1016/s0002-9149(00)00913-9,10922432,Gibson RS; Hansen JF; Messerli F; Schechtman KB; Boden WE,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D002121: Calcium Channel Blockers; D003718: Denmark; D004110: Diltiazem; D004562: Electrocardiography; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D011654: Pulmonary Edema; D012189: Retrospective Studies; D014700: Verapamil,,,https://openalex.org/W1993204002,280,38,1,2013,374,14,en,en
false,effect antihypertensive treatment endpoint diabetic patient randomize systolic hypertension europe syst eur trial,review attempt determine role calcium channel blocker prevent cardiovascular sequela patient hypertension diabetes mellitus data collect three source post hoc analysis subgroup diabetic patient placebo controlled hypertension trial shep syst eur syst china stepped care blood pressure orient trial hot comparative trial primarily focussing metabolic aspect intermediate endpoint abcd facet balance data seem indicate long acting calcium channel blocker score remarkably well prevent cardiovascular complication diabetic hypertensive patient,Birkenhäger WH,2000,J Nephrol,,10928302,Birkenhäger WH; Staessen JA; Gasowski J; de Leeuw PW,article,D003160: Comparative Study; D016428: Journal Article; D016454: Review,D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002318: Cardiovascular Diseases; D003925: Diabetic Angiopathies; D005060: Europe; D006801: Humans; D006973: Hypertension; D011315: Preventive Medicine; D016032: Randomized Controlled Trials as Topic; D013599: Systole,,,https://openalex.org/W2414980519,143,22,1,681,108,3,en,en
false,extended release nifedipine bezoar identify one year discontinuation,report case tablet impaction nifedipine extended release tablet procardia xl discover one year discontinuation drug patient peptic stricture english language reference identify via medline search september bibliographic review pertinent articles extended release nifedipine associate formation medication bezoars case report bezoars concretion undigested material within gastrointestinal gi tract although occur throughout gi tract bezoars frequently locate stomach rarely duodenum report unusual case tablet impaction gastric outlet obstruction duodenal area discover one year patient stop take extended release nifedipine extended release nifedipine associate tablet impaction even long discontinue administration although rare clinician aware potential problem prescribe extended release medication patient risk consider possible etiology refractory epigastric pain weight loss occur,Niezabitowski LM,2000,Ann Pharmacother,https://doi.org/10.1345/aph.19112,10928396,Niezabitowski LM; Nguyen BN; Gums JG,article,D002363: Case Reports; D016428: Journal Article,"D000368: Aged; D001630: Bezoars; D003692: Delayed-Action Preparations; D004380: Duodenal Obstruction; D004386: Duodenum; D016145: Endoscopy, Digestive System; D005260: Female; D006801: Humans; D009543: Nifedipine; D012307: Risk Factors; D013997: Time Factors",,,https://openalex.org/W2034234082,76,8,1,1168,174,5,en,en
false,circadian rhythm sudden death heart failure,purpose study address timing sudden death advanced heart failure patients sudden death catastrophic event cardiovascular disease circadian pattern prominent early think due surge sympathetic stimulation postulate distribution event advanced heart failure chronic sympathetic activation would uniform implicate potential mechanisms analyze data prospective randomize amlodipine survival trial praise sudden death analyze time death h h block uniformity distribution entire cohort prespecified ischemic nonischemic stratum analysis undertake treatment group amlodipine placebo among receive background therapy aspirin warfarin sudden death overall cohort show nonuniform distribution pm peak peak ischemic stratum also show pm peak sudden death within nonischemic stratum uniformly distribute neither amlodipine treatment aspirin warfarin use alter distribution sudden death advanced heart failure show peak suggest circadian sympathetic activation strongly influence event pm peak note likely complex origin affect antiischemic antithrombotic medication,Carson PA,2000,J Am Coll Cardiol,https://doi.org/10.1016/s0735-1097(00)00728-2,10933370,Carson PA; O'Connor CM; Miller AB; Anderson S; Belkin R; Neuberg GW; Wertheimer JH; Frid D; Cropp A; Packer M,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D002121: Calcium Channel Blockers; D002940: Circadian Rhythm; D016757: Death, Sudden, Cardiac; D005260: Female; D006333: Heart Failure; D006801: Humans; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D016032: Randomized Controlled Trials as Topic; D012189: Retrospective Studies",,,https://openalex.org/W177767673,50,8,1,1450,236,8,en,en
false,clinically additive effect doxazosin amlodipine treatment essential hypertension,joint national committee prevention detection evaluation treatment high blood pressure report combination low dos antihypertensive agent different class may provide additional antihypertensive efficacy minimize likelihood dose dependent adverse effect doxazosin amlodipine alone combination compare efficacy reduce blood pressure bp patient predominantly moderate stage hypertension,Nalbantgil S,2000,Am J Hypertens,https://doi.org/10.1016/s0895-7061(99)00279-4,10950401,Nalbantgil S; Nalbantgil I; Onder R,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D017311: Amlodipine; D000959: Antihypertensive Agents; D018592: Cross-Over Studies; D004311: Double-Blind Method; D017292: Doxazosin; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2048583251,102,13,1,487,76,2,en,en
false,verapamil coer mg na hipertens arterial leve moderada em dose nica di ria avaliado pela monitoriza ambulatorial da press arterial,evaluate anti hypertensive effect verapamil coer mg single dose bedtime single therapy mild moderate hypertensives multicentric open placebo control study hypertensive patient old years old follow week blood pressure measure doctor office h ambulatory monitoring abpm observe decrease systolic diastolic blood pressure doctor office th th week abpm show systolic diastolic mean blood pressure heart rate mean hour blood pressure load decrease week treatment addition reduction double product especially morning patient n adverse events therapy verapamil coer mg single dose useful mild moderate hypertensive patient significant pressure decrease office blood pressure measurement abpm hour well show good tolerability,Ortega KC,2000,Arq Bras Cardiol,https://doi.org/10.1590/s0066-782x2000000300009,10951830,Ortega KC; Santello JL; Nobre F; Kohlman Júnior O; Jardim PC; da Costa LS; Rosito GA; Raposo Filho JJ; Oigman W; Mion Júnior D,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D004740: English Abstract; D016428: Journal Article; D016448: Multicenter Study,"D000328: Adult; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D016896: Treatment Outcome; D014700: Verapamil",,,https://openalex.org/W2122645078,149,20,1,1017,176,4,pt,en
false,efficacy divalproex sodium prophylactic treatment child migraine,determine beneficial use divalproex sodium prophylactic treatment migraine children previous study treatment migraine adult show great reduction migraine attack frequency data exist however regard efficacy safety divalproex sodium use child migraine study incidence headache relief patient migraine age year young treat divalproex sodium prophylactically institution july december determine medication dosage use concomitant headache medication possible adverse effects total patient range age year mean age year treat divalproex sodium headache history migraine without aura baseline headache frequency minimum month period one four headache per month divalproex sodium dosage range mg kg day mg kg day patient successfully discontinue abortive medication month treatment headache reduction see patient reduction patient patient become headache free result indicate divalproex sodium effective well tolerated treatment prophylaxis migraine child,Caruso JM,2000,Headache,https://doi.org/10.1046/j.1526-4610.2000.040008672.x,10971664,Caruso JM; Brown WD; Exil G; Gascon GG,article,D016430: Clinical Trial; D016428: Journal Article,D000293: Adolescent; D002648: Child; D005260: Female; D018682: GABA Agents; D006801: Humans; D008297: Male; D008881: Migraine Disorders; D016896: Treatment Outcome; D014635: Valproic Acid,,,https://openalex.org/W2088520962,89,13,1,1366,237,8,en,en
true,randomise trial effect calcium antagonist compare diuretic blockers cardiovascular morbidity mortality hypertension nordic diltiazem nordil study,calcium antagonist first line treatment hypertension effectiveness diltiazem non dihydropyridine calcium antagonist reduce cardiovascular morbidity mortality unclear compare effect diltiazem diuretic beta blockers cardiovascular morbidity mortality hypertensive patients prospective randomise open blind endpoint study enrol patient age year health centre norway sweden diastolic blood pressure mm hg randomly assign patient diltiazem diuretic beta blockers combined primary endpoint fatal non fatal stroke myocardial infarction cardiovascular death analysis intention treat systolic diastolic blood pressure lower effectively diltiazem diuretic beta blocker group reduction v mm hg difference systolic reduction p primary endpoint occur patient diltiazem group diuretic beta blocker group vs event per patient years relative risk ci p fatal non fatal stroke occur patient diltiazem group diuretic beta blocker group vs event per patient years p fatal non fatal myocardial infarction patient vs event per patient years p diltiazem effective treatment base diuretic beta blockers prevent combined primary endpoint stroke myocardial infarction cardiovascular death,Hansson L,2000,Lancet,https://doi.org/10.1016/s0140-6736(00)02526-5,10972367,Hansson L; Hedner T; Lund-Johansen P; Kjeldsen SE; Lindholm LH; Syvertsen JO; Lanke J; de Faire U; Dahlöf B; Karlberg BE,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000319: Adrenergic beta-Antagonists; D000368: Aged; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D002318: Cardiovascular Diseases; D004110: Diltiazem; D004232: Diuretics; D005260: Female; D006801: Humans; D006973: Hypertension; D015993: Life Tables; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D011446: Prospective Studies; D012307: Risk Factors; D016037: Single-Blind Method; D020521: Stroke,,,https://openalex.org/W2118194784,184,27,1,1730,300,8,en,en
true,morbidity mortality patient randomise double blind treatment long acting calcium channel blocker diuretic international nifedipine git study intervention goal hypertension treatment insight,efficacy antihypertensive drug new diuretic beta blockers establish compare effect calcium channel blocker nifedipine daily diuretic combination co amilozide cardiovascular mortality morbidity high risk patient hypertension prospective randomise double blind trial europe israel patient age year hypertension blood pressure mm hg mm hg systolic patient least one additional cardiovascular risk factor randomly assign patient nifedipine mg long acting gastrointestinal transport system git formulation n co amilozide hydrochlorothiazide mg correct plus amiloride mg n dose titration dose doubling addition atenolol mg enalapril mg primary outcome cardiovascular death myocardial infarction heart failure stroke analysis intention treat primary outcome occur patient nifedipine group co amilozide group vs event per patient years relative risk ci p overall mean blood pressure fell mm hg sd mm hg excess withdrawal nifedipine group peripheral oedema v p serious adverse event frequent co amilozide group v p death mainly non vascular nifedipine vs co amilozide p primary event occur patient receive randomise treatment nifedipine co amilozide difference nifedipine daily co amilozide equally effective prevent overall cardiovascular cerebrovascular complication choice drug decide tolerability blood pressure response rather long term safety efficacy,Brown MJ,2000,Lancet,https://doi.org/10.1016/s0140-6736(00)02527-7,10972368,Brown MJ; Palmer CR; Castaigne A; de Leeuw PW; Mancia G; Rosenthal T; Ruilope LM,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D000584: Amiloride; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D002626: Chemistry, Pharmaceutical; D003692: Delayed-Action Preparations; D004232: Diuretics; D004311: Double-Blind Method; D004338: Drug Combinations; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D015993: Life Tables; D008875: Middle Aged; D009543: Nifedipine; D011446: Prospective Studies; D012307: Risk Factors; D016896: Treatment Outcome",,,https://openalex.org/W2109861453,230,33,1,1988,357,12,en,en
false,response antihypertensive therapy old patient sustained nonsustained systolic hypertension,goal present study assess effect antihypertensive therapy clinic cbp ambulatory abp blood pressure ecg voltage incidence stroke cardiovascular event old patient sustained nonsustained systolic hypertension patients year old systolic cbp mm hg diastolic cbp mm hg randomize double blind placebo controlled systolic hypertension europe syst eur trial treatment consist nitrendipine possible addition enalapril hydrochlorothiazide patient enrol ambulatory blood pressure monitor side project classify accord daytime systolic abp subgroup nonsustained hypertension mm hg mild sustain hypertension mm hg moderate sustain hypertension mm hg baseline patient nonsustained hypertension small ecg voltage p follow low incidence stroke p cardiovascular complication p group active treatment reduce abp cbp patient sustained hypertension cbp patient nonsustained hypertension p influence active treatment ecg voltage p incidence stroke p cardiovascular event p favorable placebo patient moderate sustain hypertension patients sustained hypertension high ecg voltage rate cardiovascular complication patient nonsustained hypertension favorable effect active treatment outcome statistically significant patient moderate sustain hypertension,Fagard RH,2000,Circulation,https://doi.org/10.1161/01.cir.102.10.1139,10973843,Fagard RH; Staessen JA; Thijs L; Gasowski J; Bulpitt CJ; Clement D; de Leeuw PW; Dobovisek J; Jääskivi M; Leonetti G; O'Brien E; Palatini P; Parati G; Rodicio JL; Vanhanen H; Webster J,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D000959: Antihypertensive Agents; D002318: Cardiovascular Diseases; D004562: Electrocardiography; D005260: Female; D005500: Follow-Up Studies; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D020521: Stroke; D013599: Systole,,,https://openalex.org/W2102476412,108,13,1,1773,310,7,en,en
false,amlodipine comparable angiotensin converting enzyme inhibitor long term renoprotection hypertensive patient renal dysfunction one year prospective randomize study,unlike angiotensin convert enzyme inhibitor acei long term study show calcium antagonist retard progression renal dysfunction aim prospectively compare effect amlodipine acei enalapril renal function hypertensive patient renal impairment due chronic glomerulonephritis essential hypertension total hypertensive patient serum creatinine cr mg dl randomly allocate treatment either drug year period patient treat acei drop due adverse event whereas patient amlodipine drop data patient available analysis year follow reduction blood pressure comparable amlodipine mm hg acei group serum cr increase sd mg dl amlodipine n difference equivalent acei n creatinine clearance ccr moderate dysfunction group basal cr mg dl change ml min significant amlodipine change similar note acei annual decline ccr amlodipine ml min year acei ml min year comparable tend small annual decline glomerular filtration rate report modification diet renal disease study ml min year serum potassium increase significantly p meq l acei group year prospective study demonstrate effect amlodipine renal function likely acei furthermore amlodipine well tolerate acei hypertensive patient renal dysfunction,Kumagai H,2000,Am J Hypertens,https://doi.org/10.1016/s0895-7061(00)00287-9,10981547,Kumagai H; Hayashi K; Kumamaru H; Saruta T,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000368: Aged; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D002121: Calcium Channel Blockers; D002216: Captopril; D002908: Chronic Disease; D004656: Enalapril; D005260: Female; D005921: Glomerulonephritis; D006801: Humans; D006973: Hypertension; D007668: Kidney; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D013997: Time Factors,,,https://openalex.org/W1996508441,187,24,1,1810,341,12,en,en
false,modulation tear film protein secretion phosphodiesterase inhibitor,double blind randomized clinical study conduct determine whether nicardipine hydrochloride useful treatment dry eye examine effect tear film ocular surface ocular comfort nicardipine hydrochloride isobutyl methylxanthine pilocarpine hydrochloride dissolve artificial tear vehicle apply topically one eye subject separate day ocular physiology ocular comfort tear volume assess trial repeat nicardipine aqueous gel vehicle tear collect assess protein concentration protein profile use electrophoresis mass spectrometry nicardipine induce conjunctival redness symptom dryness irritation change total tear protein concentration volume increase kda protein observe probably due conjunctival vessel dilation leakage albumin adverse symptomatology increase conjunctival redness experience nicardipine make undesirable treatment dry eye,Evans V,2000,Clin Exp Ophthalmol,https://doi.org/10.1046/j.1442-9071.2000.00285.x,10981801,Evans V; Willcox MD; Millar TJ,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D015056: 1-Methyl-3-isobutylxanthine; D000328: Adult; D015153: Blotting, Western; D004311: Double-Blind Method; D015180: Electrophoresis, Gel, Two-Dimensional; D004591: Electrophoresis, Polyacrylamide Gel; D005136: Eye Proteins; D005260: Female; D005782: Gels; D006801: Humans; D007765: Lacrimal Apparatus; D008297: Male; D009529: Nicardipine; D010726: Phosphodiesterase Inhibitors; D010862: Pilocarpine; D012449: Safety; D019032: Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D013666: Tears",,,https://openalex.org/W1994854324,75,9,1,1075,166,9,en,en
false,outcome amlodipine felodipine therapeutic interchange program,journal article outcome amlodipine felodipine therapeutic interchange program get access derrik r lcdr clay pharm derrik r lcdr clay pharm clinical pharmacist pharmacy department portsmouth naval medical center portsmouth va time study assistant division director pharmacy charleston naval hospital cnh charleston sc search work author oxford academic google scholar michael p bourg pharm michael p bourg pharm clinical pharmacist assistant department director pharmacy department cnh address reprint request lt bourg department pharmacy charleston naval hospital river avenue charleston sc chr mpb chr med navy mil search work author oxford academic google scholar david b lawrence pharm bcps david b lawrence pharm bcps clinical education consultant pfizer inc clinical assistant professor college pharmacy medical university south carolina charleston search work author oxford academic google scholar american journal health system pharmacy volume issue september page http doi org ajhp publish september,Clay DR,2000,Am J Health Syst Pharm,https://doi.org/10.1093/ajhp/57.17.1604,10984813,Clay DR; Bourg MP; Lawrence DB,article,D016428: Journal Article,D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D016009: Chi-Square Distribution; D016001: Confidence Intervals; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D015397: Program Evaluation; D012189: Retrospective Studies; D013810: Therapeutic Equivalency; D016896: Treatment Outcome,,,https://openalex.org/W2412144326,71,7,1,1280,219,4,en,en
false,efficacy candesartan cilexetil alone combination amlodipine hydrochlorothiazide moderate severe hypertension,multicenter study evaluate efficacy candesartan cilexetil angiotensin ii type receptor antagonist use alone combination amlodipine combination amlodipine hydrochlorothiazide treatment patient moderate severe essential hypertension week single blind placebo run period patient enter week open label dose titration period candesartan cilexetil dose increase mg daily amlodipine mg daily hydrochlorothiazide mg daily additional medication also add sequentially necessary patient enter final week parallel group double blind randomize placebo controlled withdrawal period candesartan alone total patient recruit week run period placebo tablet mean sit blood pressure bp mm hg end week dose titration maintenance period mean sit bp fell mm hg patient randomize placebo candesartan withdrawn highly significant increase mean systolic diastolic bp mm hg compare patient continue candesartan ancova p conclusion candesartan cilexetil effective bp lowering drug use alone combination amlodipine amlodipine plus hydrochlorothiazide treatment moderate severe essential hypertension drug well tolerate throughout investigation period,MacGregor GA,2000,Hypertension,https://doi.org/10.1161/01.hyp.36.3.454,10988281,MacGregor GA; Viskoper JR; Antonios TF; He FJ,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000450: Aldosterone; D017311: Amlodipine; D000704: Analysis of Variance; D000959: Antihypertensive Agents; D001562: Benzimidazoles; D001713: Biphenyl Compounds; D018660: Blood Pressure Monitoring, Ambulatory; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D007557: Israel; D008297: Male; D008875: Middle Aged; D012083: Renin; D016037: Single-Blind Method; D013777: Tetrazoles; D006113: United Kingdom",,,https://openalex.org/W2151865548,132,15,1,1538,255,10,en,en
false,calcium channel block agent albuminuria diabetic hypertensive patient pilot study,diltiazem tend decrease proteinuria hypertensive diabetic subject comparison amlodipine modify since estimate glomerular pressure identical amlodipine treat diltiazem treated subject difference albuminuria may explain different renal tubular reabsorption rates compare plasma clearance pc technetium label albumin albumin tc obtain serial plasma measurement pc obtain urinary excretion measurement indirectly evaluate tubular reabsorption albumin tc test hypothesis amlodipine decrease renal tubular reabsorption albumin diabetic hypertensive subjects fourteen diabetic hypertensive subject dh average plasma creatinine mmol l normal subject average plasma creatinine mmol l previously assess albumin tc pc eleven dh subject randomize diltiazem mg daily subject amlodipine mg daily subject glomerular filtration glomerular pressure albumin tc pc assess rd th th month study albumin tc pc obtain serial blood draw decrease pc month cc min observe subject treat amlodipine subject diltiazem show pc stability cm min pc obtain urinary excretion amlodipine diltiazem treat subject show pc stability plasma volume amlodipine treat subject decrease diltiazem treat subject decrease pc obtain plasma measurement stability pc base urinary excretion measurement tend identify decrease plasma volume decrease albumin tc tubular reabsorption observe estimate albumin pc tc label albumin measurement still need validate,Lamarre-Cliche M,2000,Arch Mal Coeur Vaiss,,10989730,Lamarre-Cliche M; Lambert R; Van Nguyen P; Cusson J; Wistaff R; Larochelle P,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,D000042: Absorption; D000368: Aged; D000419: Albuminuria; D017311: Amlodipine; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D003404: Creatinine; D048909: Diabetes Complications; D004110: Diltiazem; D005500: Follow-Up Studies; D005919: Glomerular Filtration Rate; D006801: Humans; D006973: Hypertension; D007678: Kidney Glomerulus; D007684: Kidney Tubules; D008875: Middle Aged; D010865: Pilot Projects; D010953: Plasma Volume; D011312: Pressure; D011446: Prospective Studies; D019275: Radiopharmaceuticals; D013668: Technetium Tc 99m Aggregated Albumin,,,https://openalex.org/W1432226529,103,18,2,1910,310,10,en,en
false,commonly encounter prescription medication medical legal death investigation,common prescription medication encounter record normal course death investigation medical examiner office moderate sized jurisdiction urban city tally base data collect death report medication history available death review study common medication briefly discuss particularly adverse effect possible toxicity concern investigation death medication treat cardiovascular disease far commonly encounter common medication regardless category furosemide digoxin nitroglycerin potassium lisinopril warfarin albuterol nifedipine codeine amlodipine,Heninger MM,2000,Am J Forensic Med Pathol,https://doi.org/10.1097/00000433-200009000-00022,10990295,Heninger MM,article,D016428: Journal Article,D001344: Autopsy; D011307: Drug Prescriptions; D005554: Forensic Medicine; D005845: Georgia; D017408: Guidelines as Topic; D006801: Humans,,,https://openalex.org/W2067634187,82,8,1,766,127,5,en,en
false,retrospective evaluation conversion amlodipine alternative calcium channel blocker,evaluate effectiveness safety cost associate formulary conversion amlodipine alternative calcium channel blockers retrospective study veterans affair medical center one hundred patient hypertension receive amlodipine data random sample patient take amlodipine convert formulary calcium channel blocker february october enter excel database evaluation conversion patients require diagnosis hypertension two consecutive clinic visit blood pressure measurement change antihypertensive therapy conversion end point change average systolic blood pressure diastolic blood pressure mean arterial pressure map two clinic visit conversion addition data collect analyze regard adverse drug reaction average dosage alternative calcium channel blocker number additional antihypertensive begin discontinue number dosage change antihypertensive within two visit conversion overall cost impact conversion average systolic blood pressure reduce mm hg conversion ns average diastolic blood pressure significantly reduce mm hg conversion p map q mm hg p five patient change therapy make concurrently time conversion change conversion patient exclude analysis reduction systolic blood pressure conversion significant mm hg p reduction diastolic blood pressure mm hg p map mm hg p patient postconversion change therapy convert diltiazem er nifedipine cc dos felodipine original dose amlodipine overall cost impact conversion net saving year patient converted conversion amlodipine calcium channel blocker result statistically significant reduction diastolic blood pressure map safe well cost effective conversion calcium channel antagonists felodipine less equal dosage felodipine may require dosage titration convert patient amlodipine dosages usually equal felodipine convert calcium channel antagonist need adjustment anticipate,Parra D,2000,Pharmacotherapy,https://doi.org/10.1592/phco.20.13.1072.35022,10999500,Parra D; Beckey NP; Korman L,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D017311: Amlodipine; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004110: Diltiazem; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D009543: Nifedipine; D012189: Retrospective Studies,,,https://openalex.org/W1967373484,96,12,1,2767,476,11,en,en
false,calcium channel blocker ingestion child,limit data exists regard toxicity calcium channel blocker ccbs child purpose study determine frequency range toxicity appropriate observation time assess effective intervention ccb ingestion child year retrospective review ccb ingestion child young year age report one regional poison center undertaken patient coingestants recognize cardiovascular central nervous system cns effect exclude two hundred eighty three patient meet criterion review mean age month patient boy nifedipine verapamil amlodipine commonly ingest seventy five percent ingestion reportedly involve pill symptom occur vomiting cns cardiovascular effect mean time onset symptom regular release sustained release sr ccb preparation hour range hr hour range hr respectively patient clinical effect minor effect moderate effect death major effect reported patient evaluate emergency department receive gastric decontamination usually one dose charcoal calcium chloride give three verapamil sr case five six patient reversal hypotension iv fluid decontamination alone pediatric ccb ingestion involve ingestion small amount drug effect asymptomatic child study group know ingest mg kg verapamil sr mg kg nifedipine sr could monitor home child require evaluation monitoring health care facility observation period regular release sr ccbs hour respectively would appropriate insufficient case symptom draw conclusion optimal therapeutic intervention,Belson MG,2000,Am J Emerg Med,https://doi.org/10.1053/ajem.2000.9264,10999574,Belson MG; Gorman SE; Sullivan K; Geller RJ,article,D016428: Journal Article,"D001711: Biotransformation; D002121: Calcium Channel Blockers; D002648: Child; D002675: Child, Preschool; D003666: Decontamination; D004305: Dose-Response Relationship, Drug; D062787: Drug Overdose; D005260: Female; D006801: Humans; D007223: Infant; D008297: Male; D011039: Poison Control Centers; D012189: Retrospective Studies; D016896: Treatment Outcome; D014481: United States",,,https://openalex.org/W2078514098,46,6,1,2034,370,17,en,en
false,comparative study calcium channel blocker nicardipine combined blocker labetalol control emergence hypertension craniotomy tumor surgery,compare efficacy combination enalaprilat labetalol enalaprilat nicardipine prevent emergence postcraniotomy hypertension prospective randomized open label clinical trial design compare incidence breakthrough hypertension systolic blood pressure sbp mm hg adverse effect hypotension tachycardia bradycardia two drug combination secondarily effect drug sbp mean blood pressure diastolic blood pressure evaluate course study forty two patient receive enalaprilat mg iv dural closure follow either multidose nicardipine mg iv labetalol mg iv maintain sbp mm hg sbp similarly control group marginally small incidence failure adverse effect labetalol blood pressure profile similar group,Kross RA,2000,Anesth Analg,https://doi.org/10.1097/00000539-200010000-00024,11004045,Kross RA; Ferri E; Leung D; Pratila M; Broad C; Veronesi M; Melendez JA,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000317: Adrenergic alpha-Antagonists; D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000704: Analysis of Variance; D000762: Anesthesia Recovery Period; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001794: Blood Pressure; D001919: Bradycardia; D001932: Brain Neoplasms; D002121: Calcium Channel Blockers; D016009: Chi-Square Distribution; D003399: Craniotomy; D015773: Enalaprilat; D005260: Female; D006801: Humans; D006973: Hypertension; D007022: Hypotension; D015994: Incidence; D007741: Labetalol; D008297: Male; D008875: Middle Aged; D009529: Nicardipine; D011446: Prospective Studies; D013610: Tachycardia; D016896: Treatment Outcome,,,https://openalex.org/W2048130686,184,29,1,923,155,7,en,en
true,effect amlodipine progression atherosclerosis occurrence clinical event,result angiographic study suggest calcium channel blocking agent may prevent new coronary lesion formation progression minimal lesion prospective randomize evaluation vascular effect norvasc trial prevent multicenter randomize placebo controlled double masked clinical trial design test whether amlodipine would slow progression early coronary atherosclerosis patient angiographically document coronary artery disease primary outcome average month angiographic change mean minimal diameter segment baseline diameter stenosis secondary hypothesis whether amlodipine would reduce rate atherosclerosis carotid artery assessed b mode ultrasonography measure intimal medial thickness imt rate clinical event also monitor placebo amlodipine group nearly identical average month reduction minimal diameter versus mm respectively p contrast amlodipine significant effect slow month progression carotid artery atherosclerosis placebo group experience mm increase imt whereas mm decrease amlodipine group p treatment difference rate cause mortality major cardiovascular event although amlodipine use associate case unstable angina coronary revascularization amlodipine demonstrable effect angiographic progression coronary atherosclerosis risk major cardiovascular event associate hospitalization unstable angina revascularization,Pitt B,2000,Circulation,https://doi.org/10.1161/01.cir.102.13.1503,11004140,Pitt B; Byington RP; Furberg CD; Hunninghake DB; Mancini GB; Miller ME; Riley W,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D017311: Amlodipine; D002121: Calcium Channel Blockers; D003324: Coronary Artery Disease; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D011859: Radiography,,,https://openalex.org/W2117140855,96,14,1,1753,269,8,en,en
false,intensive medical management ureteral calculus,compare two treatment regimen patient ureteral calculus one regimen control arm use routine drug second regimen treatment arm use routine drug plus uncommonly use drugs february october consecutive patient evaluate symptomatic ureteral calculus thirty five patient randomize control arm receive ketorolac oxycodone acetaminophen combination tablet prochlorperazine suppository thirty five patient randomize treatment arm receive medication plus nifedipine xl prednisone trimethoprim sulfa combination tablet plain acetaminophen stone passage rate work day lose emergency room visit surgical intervention possible side effect drug recorded treatment arm addition nifedipine xl prednisone trimethoprim sulfa plain acetaminophen high versus stone passage rate lose work day mean versus emergency room visit versus surgical intervention versus arm exhibit similar potential drug side effects addition calcium channel block agent steroid antibiotic acetaminophen effect high stone passage rate lose work day emergency room visit surgical intervention,Cooper JT,2000,Urology,https://doi.org/10.1016/s0090-4295(00)00658-0,11018607,Cooper JT; Stack GM; Cooper TP,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000041: Absenteeism; D000082: Acetaminophen; D000892: Anti-Infective Agents, Urinary; D002121: Calcium Channel Blockers; D004359: Drug Therapy, Combination; D006801: Humans; D020910: Ketorolac; D009543: Nifedipine; D010098: Oxycodone; D011241: Prednisone; D011346: Prochlorperazine; D013488: Suppositories; D015662: Trimethoprim, Sulfamethoxazole Drug Combination; D014514: Ureteral Calculi",,,https://openalex.org/W2038694857,48,6,1,1352,227,6,en,en
false,effectiveness nifedipine deflazacort management distal ureter stone,evaluate effectiveness medical therapy watchful wait patient distal ureter stones ninety six patient radiopaque stone locate distal tract ureter stone size cm small involve study patient randomly divide two group group n receive oral treatment mg deflazacort daily maximum day plus mg slow release nifedipine daily maximum week group b n underwent wait watch approach group patient allow use diclofenac demand statistical analysis carry use student test chi square test fisher exact test average stone size mm group mm group b statistically significant difference find stone size stone expulsion observe patient group patient group b average expulsion time day range group day range group b statistically significant difference observe expulsion rate expulsion time p mean amount sodium diclofenac use mg per patient group mg per patient group b p medical treatment prove effective safe demonstrate increase stone expulsion rate decrease expulsion time reduce need analgesic therapy,Porpiglia F,2000,Urology,https://doi.org/10.1016/s0090-4295(00)00732-9,11018608,Porpiglia F; Destefanis P; Fiori C; Fontana D,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000328: Adult; D000368: Aged; D000893: Anti-Inflammatory Agents; D001145: Arrhythmias, Cardiac; D002121: Calcium Channel Blockers; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D007022: Hypotension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011282: Pregnenediones; D011446: Prospective Studies; D014514: Ureteral Calculi",,,https://openalex.org/W1984780926,85,12,1,1476,300,12,en,en
false,pattern amlodipine felodipine use elderly quebec population,assess drug prescription pattern medical resource consumption elderly population quebec receive amlodipine felodipine treatment hypertension sociodemographic clinical drug claim data random sample hypertensive patient year age old least one claim amlodipine felodipine august august extract r gie de l assurance maladie du qu bec ramq database pattern prescription renewal drug switch compliance rate health care resource use establish amlodipine felodipine group long term persistence treatment quantify survival curve analysis amlodipine patient felodipine patient group similar term sex ratio female age mean year average compliance rate amlodipine patient significantly high felodipine patient p switch rate fold high latter group patient initiate treatment felodipine increased rate discontinuation relative risk compare amlodipine patient addition patient least one year follow data likely maintain amlodipine part antihypertensive regimen felodipine adjustment medical resource consumption pattern similar group except increase number specialist visit amlodipine treatment group patients receive amlodipine either monotherapy part multitherapy regimen compliant persistent treatment patient felodipine data suggest amlodipine may provide effective long term hypertension control felodipine two drug therapeutically equivalent,Sheehy O,2000,Can J Cardiol,,11021955,Sheehy O; LeLorier J,article,"D016430: Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D010349: Patient Compliance; D011792: Quebec,,,https://openalex.org/W182813600,74,12,1,1877,318,8,en,en
false,treatment hypertensive child amlodipine,amlodipine long acting dihydropyridine calcium channel block agent administer child age year hypertension secondary hypertension efficacy assess compare pretreatment blood pressure bp follow bp obtain outpatient pediatric nephrology clinic thirty two patient achieve bp control amlodipine alone patient receive amlodipine twice daily eleven patient receive amlodipine suspension mean amlodipine dose mg kg day inverse relationship patient age amlodipine dose follow bp significantly low pretreatment bp systolic bp fell mm hg p diastolic bp fell mm hg p small clinically insignificant increase heart rate beats min beats min p occur amlodipine treatment adverse effect report included dizziness three patient fatigue two patient flush two patient leg edema one patient improve dose reduction conclude amlodipine provide effective bp control without significant adverse effect child hypertension use monotherapy child young child appear require significantly high dos per kilogram body weight old child twice daily dosing may require many child achieve bp control detail pharmacokinetic study need confirm observation,Flynn JT,2000,Am J Hypertens,https://doi.org/10.1016/s0895-7061(00)00278-8,11041159,Flynn JT; Smoyer WE; Bunchman TE,article,D016428: Journal Article,"D000293: Adolescent; D000328: Adult; D000375: Aging; D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002648: Child; D002675: Child, Preschool; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D006973: Hypertension; D007223: Infant; D008297: Male",,,https://openalex.org/W2049587432,50,6,1,1591,294,13,en,en
false,randomized prospective crossover trial amlodipine pediatric hypertension,amlodipine potential advantage child since dissolve liquid preparation long elimination half life allow daily administration objective study compare efficacy compliance amlodipine standard long acting calcium channel blocker felodipine nifedipine hypertensive child randomized prospective crossover study hypertensive child year age renal transplant patient perform electronic monitoring compliance treatment arm day significant difference observe mean systolic sbp diastolic blood pressure dbp amlodipine calcium channel blocker use h blood pressure monitoring significant difference drug treatment period mean day time night time sbp dbp patient compliance similar amlodipine nifedipine felodipine treatment period data suggest amlodipine effective pediatric nephrology patient nifedipine felodipine amlodipine may optimally suit treatment young child present calcium channel blocker administer daily liquid preparation,Rogan JW,2000,Pediatr Nephrol,https://doi.org/10.1007/s004670000400,11045391,Rogan JW; Lyszkiewicz DA; Blowey D; Khattak S; Arbus GS; Koren G,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D002648: Child; D018592: Cross-Over Studies; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D009543: Nifedipine; D010349: Patient Compliance; D011446: Prospective Studies",,,https://openalex.org/W2053287639,80,10,1,1303,209,9,en,en
false,treatment arterial hypertension elderly diltiazem v ramipril,around elderly population suffer arterial hypertension effective antihypertensive treatment therefore required calcium antagonist use treat hypertension owe mechanism action provoke systemic well coronary vasodilatation study author aim evaluate activity tolerability diltiazem compare ramipril group elderly patient suffer essential arterial hypertension control single blind study perform patient randomly assign one two group b consist patient treat respectively mg sustained release diltiazem mg ramipril single daily dose study last month evaluate systolic diastolic pressure heart rate evolution positive patient group patient group b normalisation systolic diastolic value heart rate show persistent fall group expect owe mechanism action diltiazem patient group suspend treatment whereas one patient group b interrupt therapy follow onset persistent cough treatment result similar change systolic diastolic arterial blood pressure light result affirm oral dose mg day sustained release diltiazem find effective well tolerate treatment mild moderate essential arterial hypertension aged,Terranova R,2000,Minerva Cardioangiol,,11048472,Terranova R; Luca S,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000367: Age Factors; D000368: Aged; D000369: Aged, 80 and over; D000959: Antihypertensive Agents; D004110: Diltiazem; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D017257: Ramipril; D016037: Single-Blind Method",,,https://openalex.org/W56113825,77,12,1,1569,268,8,en,en
false,haemodynamic metabolic effect rilmenidine hypertensive patient metabolic syndrome x double blind parallel study versus amlodipine,compare effect rilmenidine amlodipine blood pressure glucose metabolism plasma lipid concentration fibrinolysis parameters four month randomized double blind parallel group study obese hypertensive patient hypertriglyceridaemia mmol l impaired glucose tolerance oms ada include n placebo run period week follow month double blind treatment either rilmenidine amlodipine blood pressure record use mercury sphygmomanometer glucose metabolism evaluate oral glucose tolerance testof patient recruit rilmenidine amlodipine complete month treatment period intention treat analysis show comparable reduction systolic diastolic blood pressure sbp dbp two anti hypertensive treatment rilmenidine mmhg amlodipine mmhg insulin concentration basal condition h standard oral glucose load change significantly treatment group plasma glucose basal condition h standard oral glucose load well area plasma glucose concentration curve tend decrease rilmenidine group increase amlodipine group change parameter significantly different two study group p p p respectively plasminogen activator inhibitor type pai antigen pai activity decrease rilmenidine group statistically significant result demonstrate rilmenidine amlodipine comparable anti hypertensive effect rilmenidine able improve glucose metabolism,De Luca N,2000,J Hypertens,https://doi.org/10.1097/00004872-200018100-00021,11057441,De Luca N; Izzo R; Fontana D; Iovino G; Argenziano L; Vecchione C; Trimarco B,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D001786: Blood Glucose; D001835: Body Weight; D004311: Double-Blind Method; D005260: Female; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D015228: Hypertriglyceridemia; D007328: Insulin; D008297: Male; D008875: Middle Aged; D010080: Oxazoles; D017395: Plasminogen Activator Inhibitor 1; D000077769: Rilmenidine; D010959: Tissue Plasminogen Activator,,,https://openalex.org/W2069661775,149,20,2,1773,288,8,en,en
true,monotherapy amlodipine atenolol versus combination stable angina pectoris,abstract background basic cause angina pectoris imbalance metabolic need myocardium capacity coronary circulation deliver sufficient oxygenate blood satisfy need hypothesis study undertake evaluate whether effect combined amlodipine atenolol therapy patient stable angina pectoris st depression exercise testing h ambulatory electrocardiographic monitoring superior either agent give alone method patient stable angina pectoris st depression exercise ambulatory monitoring randomize receive amlodipine n atenolol n n patient also treat short long acting nitrate design double blind randomize triple arm parallel group study week administration test medication result term time onset st depression mm time onset angina total exercise time maximum achieve workload peak intensity angina amlodipine atenolol alone effective combination ambulatory monitoring atenolol effective amlodipine regard total time number st depression episode effective combined drug conclusion individual patient stable angina pectoris combination beta blocker calcium antagonist necessarily effective either drug give alone,Pehrsson SK,2000,Clin Cardiol,https://doi.org/10.1002/clc.4960231014,11061055,Pehrsson SK; Ringqvist I; Ekdahl S; Karlson BW; Ulvenstam G; Persson S,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D000787: Angina Pectoris; D001262: Atenolol; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D015716: Electrocardiography, Ambulatory; D005080: Exercise Test; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009566: Nitrates",,,https://openalex.org/W2152900885,90,12,1,1517,258,8,en,en
false,combination therapy beta adrenergic blockade amlodipine second line treatment essential hypertension,hypertension beta blockers calcium antagonist drug proved efficacy half patient respond single drug even full dosage second hypotensive agent frequently require obtain adequate blood pressure control combination dihydropyridine calcium antagonist beta blocker justify different mechanism action randomised double blind parallel group study versus placebo perform order assess efficacy atenolol combine amlodipine treatment stage ii essential hypertension control atenolol alone twenty four hour arterial blood pressure monitoring show amlodipine add atenolol produce statistically significant reduction blood pressure value compare placebo patient whose blood pressure control atenolol alone blood pressure circadian rhythm unchanged reduction side effects obtain add dihydropyridine derivate beta blocker confirm effectiveness combination,Mettimano M,2000,Int J Clin Pract,,11070565,Mettimano M; Pichetti F; Fazzari L; Migneco A; Specchia L; Romano Spica V; Savi L,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000319: Adrenergic beta-Antagonists; D000328: Adult; D017311: Amlodipine; D001262: Atenolol; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D016896: Treatment Outcome",,,https://openalex.org/W34990649,115,14,1,1077,164,7,en,en
false,effect indomethacin blood pressure elderly people essential hypertension well control amlodipine enalapril,arthritis hypertension frequent comorbidities elderly hypertensive population nonsteroidal anti inflammatory drug often use relieve pain arthritic patient side effect sodium retention consequent elevation blood pressure bp effect dihydropyridine calcium block drug relatively independent sodium intake whereas angiotensin converting enzyme ace inhibitor effect blunt high sodium diet study compare effect indomethacin placebo elderly patient essential hypertension control amlodipine enalapril indomethacin mg twice daily placebo administer week double blind crossover study patient control amlodipine enalapril response assess ambulatory bp measurement indomethacin raise bp lower pulse rate patient take enalapril little effect patient receive amlodipine difference cause indomethacin two group mm hg increase bp beats min fall pulse people take enalapril addition indomethacin patient take either drug cause rise weight fall plasma renin postulate effect due inhibition prostaglandin synthesis cause sodium retention patient take amlodipine fall plasma renin ameliorate effect sodium retention bp patient take enalapril plasma renin fall translate effect blockage convert enzyme thus full effect sodium retention bp express patient treat indomethacin patient may respond ace inhibitor however major problem patient intermittently take indomethacin nonsteroidal anti inflammatory drug person treat ace inhibitor cause bp go control patient amlodipine would appear preferred choice enalapril,Morgan TO,2000,Am J Hypertens,https://doi.org/10.1016/s0895-7061(00)01204-8,11078175,Morgan TO; Anderson A; Bertram D,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D015746: Abdominal Pain; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D000894: Anti-Inflammatory Agents, Non-Steroidal; D001794: Blood Pressure; D001835: Body Weight; D004311: Double-Blind Method; D004347: Drug Interactions; D004415: Dyspepsia; D004656: Enalapril; D005260: Female; D006801: Humans; D006973: Hypertension; D007213: Indomethacin; D008297: Male; D008875: Middle Aged; D009325: Nausea; D010146: Pain; D012083: Renin",,,https://openalex.org/W2082572643,129,18,1,2039,339,16,en,en
false,effect isradipine enalapril blood pressure salt sensitive hypertensive low high dietary salt intake,large multicenter study test antihypertensive effect isradipine dihydropyridine calcium channel blocker enalapril angiotensin converting enzyme inhibitor salt sensitive hypertensive patient low high salt intake diet week week ad lib salt diet patient sit diastolic blood pressure sdbp mm hg qualify enter week week placebo run low salt diet mmol na day high salt mmol na day add placebo treatment week week patient demonstrate increase sdbp mm hg low high salt diet consider salt sensitive randomize week week double blind treatment period either isradipine mg twice day enalapril mg twice day placebo enter week week placebo washout phase low salt diet mmol na day week low salt diet continue patient restart double blind treatment week week study complete patient screen randomize double blind treatment phase complete study isradipine enalapril decrease sit systolic blood pressure ssbp sdbp high salt diet similar degree whereas enalapril cause great reduction ssbp sdbp isradipine low salt diet mm hg v mm hg mean sem respectively p within drug effect isradipine blood pressure bp higher high low salt diet v mm hg ssbp v mm hg sdbp p enalapril exert similar effect diet salt restriction lower ssbp sdbp low bp achieve drug salt restriction phase,Chrysant SG,2000,Am J Hypertens,https://doi.org/10.1016/s0895-7061(00)01183-3,11078178,Chrysant SG; Weder AB; McCarron DA; Canossa-Terris M; Cohen JD; Gunter PA; Hamilton BP; Lewin AJ; Mennella RF; Kirkegaard LW; Weir MR; Weinberger MH,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000367: Age Factors; D000806: Angiotensin-Converting Enzyme Inhibitors; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D004656: Enalapril; D005260: Female; D018565: Food-Drug Interactions; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D008297: Male; D008875: Middle Aged; D010349: Patient Compliance; D012737: Sex Factors; D017673: Sodium Chloride, Dietary; D013997: Time Factors",,,https://openalex.org/W1978109590,124,18,1,2025,417,10,en,en
false,dofetilide,new antiarrhythmic drug recently recommend approval advisory committee food drug administration fda treatment patient persistent atrial fibrillation dofetilide specific blocker rapid component outward delay rectifier potassium current kr represent first drug relatively pure class iii antiarrhythmic property widely release,Mounsey JP,2000,Circulation,https://doi.org/10.1161/01.cir.102.21.2665,11085972,Mounsey JP; DiMarco JP,article,D016428: Journal Article; D016454: Review,"D000200: Action Potentials; D000284: Administration, Oral; D000818: Animals; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D001282: Atrial Flutter; D018849: Controlled Clinical Trials as Topic; D004195: Disease Models, Animal; D004305: Dose-Response Relationship, Drug; D004562: Electrocardiography; D022062: Electrophysiologic Techniques, Cardiac; D006801: Humans; D010627: Phenethylamines; D011188: Potassium; D026902: Potassium Channel Blockers; D015221: Potassium Channels; D011930: Reaction Time; D013449: Sulfonamides; D016896: Treatment Outcome; D014693: Ventricular Fibrillation",,,https://openalex.org/W77045251,10,1,1,426,67,1,sr,en
false,comparison efficacy side effect combination therapy angiotensin converting enzyme inhibitor benazepril calcium antagonist either nifedipine amlodipine versus high dose calcium antagonist monotherapy systemic hypertension,present multicenter study design evaluate whether patient essential hypertension derive equal benefit use combination therapy calcium antagonist angiotensin converting enzyme ace inhibitor double dose calcium antagonist week washout week single blind placebo run period total patient treat either nifedipine mg study amlodipine mg study daily week patient whose diastolic blood pressure remain mm hg randomize week double blind therapy amlodipine mg benazepril mg amlodipine mg benazepril mg nifedipine mg nifedipine mg study amlodipine mg benazepril mg amlodipine mg benazepril mg amlodipine mg amlodipine mg study dos calcium antagonist ace inhibitor combination therapy lower diastolic pressure much high dose significantly good low dose calcium antagonist monotherapy either nifedipine amlodipine however patient nifedipine high dose monotherapy group amlodipine high dose monotherapy group present form edema contrast incidence edema similar patient treat combination therapy low dose calcium antagonist thus combination therapy calcium antagonist ace inhibitor provide blood pressure control equal high dose calcium antagonist monotherapy significantly dose dependent adverse experience vasodilatory edema,Messerli FH,2000,Am J Cardiol,https://doi.org/10.1016/s0002-9149(00)01199-1,11090788,Messerli FH; Oparil S; Feng Z,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D001552: Benzazepines; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D016037: Single-Blind Method",,,https://openalex.org/W2016342558,250,33,1,1656,279,7,en,en
false,bisoprolol alone combination amlodipine nifedipine treatment chronic stable angina,beta blockers calcium antagonist effective monotherapy stable angina symptom persist two agent commonly co prescribed hope combination add benefit compare monotherapy alone investigate additional efficacy calcium antagonists amlodipine nifedipine add bisoprolol patient stable angina patient randomise multicentre single blind study crossover three treatment consist bisoprolol mg daily bisoprolol plus nifedipine mg twice daily bisoprolol plus amlodipine mg daily exercise test perform end four week study period exercise time onset angina assess total patient centre recruit evaluable efficacy statistically significant difference exercise duration onset angina group combination bisoprolol plus nifedipine least well tolerate summary study suggest little benefit add calcium antagonist bisoprolol treat patient stable angina,Ferguson JD,2000,Int J Clin Pract,,11092108,Ferguson JD; Ormerod O; Lenox-Smith AJ,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000319: Adrenergic beta-Antagonists; D000328: Adult; D017311: Amlodipine; D000704: Analysis of Variance; D000787: Angina Pectoris; D017298: Bisoprolol; D002121: Calcium Channel Blockers; D002908: Chronic Disease; D018592: Cross-Over Studies; D004359: Drug Therapy, Combination; D006801: Humans; D008875: Middle Aged; D009543: Nifedipine; D016037: Single-Blind Method",,,https://openalex.org/W2306355989,107,16,1,1180,193,9,en,en
false,management mild chronic hypertension pregnancy review,conduct systematic review evidence relate management mild chronic hypertension pregnancy include associated risk benefit harm treatment antihypertensive agent nonpharmacologic measure aspirin benefit various monitor strategies using four broad search strategy search english non english language citation electronic database inception february consult relevant textbook reference experts reviewers screen abstract find article meet multiple prespecified patient selection study population design criteria forty six study consistently show chronic hypertension triple risk perinatal mortality odds ratio confidence interval ci double risk placental abruption ci thirteen small randomize controlled trial inadequate power rule rule moderate large benefit antihypertensive treatment possible adverse effect fetal renal failure angiotensin converting enzyme inhibitor use second third trimester growth restriction atenolol use early pregnancy trial show aspirin neither reduces increase perinatal maternal morbidity rule possible small moderate beneficial adverse effect study provide guidance benefit consequence various nonpharmacologic therapy monitor strategies mild chronic hypertension associate increased maternal fetal risk beneficial treatment monitoring regimen clear treatment angiotensin converting enzyme inhibitor best avoid,Ferrer RL,2000,Obstet Gynecol,https://doi.org/10.1016/s0029-7844(00)00938-8,11094241,Ferrer RL; Sibai BM; Mulrow CD; Chiquette E; Stevens KR; Cornell J,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review; D000078182: Systematic Review","D000037: Abruptio Placentae; D000959: Antihypertensive Agents; D002908: Chronic Disease; D005260: Female; D006801: Humans; D006973: Hypertension; D007223: Infant; D007226: Infant Mortality; D018579: Patient Selection; D011247: Pregnancy; D011249: Pregnancy Complications, Cardiovascular; D018570: Risk Assessment",,,https://openalex.org/W2051570900,68,12,1,1769,275,6,en,en
false,rate control versus conversion strategy postoperative atrial fibrillation prospective randomize pilot study,background atrial fibrillation remain frequent complication heart surgery optimal strategy treat condition establish several retrospective study suggest primary rate control strategy may equivalent strategy restore sinus rhythm method fifty patient atrial fibrillation heart surgery randomly assign strategy antiarrhythmic therapy without electrical cardioversion ventricular rate control arm receive anticoagulation heparin overlap warfarin primary end point time conversion sinus rhythm analyze kaplan meier method atrial fibrillation relapse initial conversion monitor hospital month period result significant difference antiarrhythmic conversion strategy n rate control strategy n time conversion sinus rhythm v hour p use cox multivariate analysis control effect age sex blocker usage type surgery antiarrhythmic strategy show trend toward reduce time treatment restoration sinus rhythm p length hospital stay reduce antiarrhythmic arm compare rate control strategy v day p hospital relapse rate antiarrhythmic arm compare rate control strategy p significant difference relapse rate week vs week vs week vs end study patient rate control arm sinus rhythm compare antiarrhythmic arm p conclusion pilot study show little difference rate control strategy strategy restore sinus rhythm regardless strategy patient sinus rhythm month large randomize control study need assess impact restoration sinus rhythm length stay heart j,Lee JK,2000,Am Heart J,https://doi.org/10.1067/mhj.2000.111104,11099990,Lee JK; Klein GJ; Krahn AD; Yee R; Zarnke K; Simpson C; Skanes A; Spindler B,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000368: Aged; D000638: Amiodarone; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D006348: Cardiac Surgical Procedures; D004077: Digoxin; D004333: Drug Administration Routes; D004554: Electric Countershock; D004562: Electrocardiography; D005260: Female; D006339: Heart Rate; D006801: Humans; D007902: Length of Stay; D008297: Male; D010865: Pilot Projects; D011342: Procainamide; D011379: Prognosis; D011405: Propafenone; D011446: Prospective Studies; D012008: Recurrence; D013015: Sotalol,,,https://openalex.org/W2027250725,115,15,1,2123,402,17,en,en
false,therapeutic agent preterm labor tocolytic agent,john hopkins university baltimore maryland correspondence david nagey md phd north wolfe street phipps baltimore md e mail email protect,Hearne AE,2000,Clin Obstet Gynecol,https://doi.org/10.1097/00003081-200012000-00009,11100296,Hearne AE; Nagey DA,article,D016428: Journal Article; D016454: Review,"D005260: Female; D006801: Humans; D007752: Obstetric Labor, Premature; D011247: Pregnancy; D015149: Tocolytic Agents",,,https://openalex.org/W2318463243,53,8,1,178,37,2,en,en
false,blood pressure reduction associate preservation renal function hypertensive patient iga nephropathy year follow,relative importance hypertension progression renal failure well understood recently several study provide evidence antihypertensive therapy enhance renal survival however specific antihypertensive drug regimen effective generate long term effect remain controversial forty nine hypertensive iga nephropathy igan patient year old serum creatinine mg dl proteinuria receive antihypertensive therapy angiotensin converting enzyme inhibitor acei mg benazapril daily calcium channel blocker ccbs mg amlodipine daily year patient blood pressure group one control mmhg increase first drug dose addition second drug group blood pressure patient group control use two option except level mmhg patient within two group select control regard sex age serum creatinine renal protective effect protocol evaluate term reduction creatinine clearance year outline blood pressure control regimens reduction creatinine clearance compared creatinine clearance decrease group patient ml min ml min p hand creatinine clearance remain essentially unchanged patient group ml min ml min although creatinine clearance group almost start study significant difference conclusion study p proteinuria hematuria change significantly throughout study significant difference respect two correspond group significant difference group reference side effects complications data provide evidence reduce blood pressure protective renal effect case mild renal insufficiency hypertension iga nephropathy,Kanno Y,2000,Clin Nephrol,,11105796,Kanno Y; Okada H; Saruta T; Suzuki H,article,D016430: Clinical Trial; D016428: Journal Article,"D000328: Adult; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D001552: Benzazepines; D002121: Calcium Channel Blockers; D003404: Creatinine; D004334: Drug Administration Schedule; D005260: Female; D005500: Follow-Up Studies; D005922: Glomerulonephritis, IGA; D006801: Humans; D006973: Hypertension; D008297: Male",,,https://openalex.org/W2410604121,138,20,1,2157,358,12,en,en
false,wirkung von felodipin bei hypertonen patienten mit leichten hirnleistungsst rungen einer randomisierten doppelblindstudie,cognitive impairment occur frequently hypertensive normotensive individual early sign cognitive impairment predictor dementia late life felodipine capable almost normalize plasma viscosity elevate hypertensive patient thus improve microcirculation aim study evaluate whether hemorheologic property felodipine addition blood pressure lower effect improve cognitive performance hypertensive patients randomized double blind comparison felodipine mg hydrochlorothiazide mg amiloride mg hct amiloride patient year age impaired cognitive function c l test point rest blood pressure value diastolic mmhg systolic mmhg blood pressure measurement evaluation total short term storage capacity beginning week treatment patient felodipine hct amiloride include per protocol analysis blood pressure value beginning week treatment mmhg felodipine systolic p diastolic p amiloride hct systolic p diastolic p short term storage capacity improve bit felodipine treatment p bit amiloride hct treatment p thus cognitive improvement superior felodipine group compare amiloride hct p study pronounced improvement mental performance occur patient treat felodipine since cognitive gain significantly superior amiloride hct treatment must additional blood pressure independent effect felodipine enhance microcirculation whether property possibly counteract development dementia hypertensive evaluate long term study patient,Lehrl S,2000,Dtsch Med Wochenschr,https://doi.org/10.1055/s-2000-8179,11109422,Lehrl S; Grässel E; Eicke C,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D000584: Amiloride; D001809: Blood Viscosity; D001921: Brain; D003072: Cognition Disorders; D003704: Dementia; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D015736: Felodipine; D005260: Female; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D008297: Male; D008833: Microcirculation; D008875: Middle Aged; D009483: Neuropsychological Tests; D016896: Treatment Outcome",,,https://openalex.org/W2424320469,124,13,1,2089,370,12,de,en
false,effect slow release nifedipine hour ambulatory blood pressure ischemic change hour ambulatory electrocardiogram patient severe coronary artery disease,calcium antagonist long use first line drug hypertension angina however deleterious effect also report patient treat calcium antagonist thus evaluate effect slow release twice daily formulation nifedipine patient severe coronary artery disease twenty four hour ambulatory electrocardiography aecg blood pressure monitoring abpm perform simultaneously detect association ischemic episode ecg change blood pressure bp heart rate without nifedipine increase oxygen demand due increase systolic bp heart rate associate ischemic episode without nifedipine nifedipine accompany fall diastolic bp rapid increase heart rate slow release twice daily formulation nifedipine may induce myocardial ischemia heart rate increase decrease coronary blood flow due lower diastolic bp patient severe coronary artery disease daily formulation nifedipine might great value patient,Matsumoto N,2000,Cardiology,https://doi.org/10.1159/000007044,11111143,Matsumoto N; Ideishi M; Sasaguri M; Nii T; Nakashima Y; Arakawa K,article,D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article,"D000368: Aged; D000369: Aged, 80 and over; D000704: Analysis of Variance; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D003327: Coronary Disease; D003692: Delayed-Action Preparations; D015716: Electrocardiography, Ambulatory; D005260: Female; D006339: Heart Rate; D006439: Hemodynamics; D006801: Humans; D008297: Male; D008875: Middle Aged; D017202: Myocardial Ischemia; D009543: Nifedipine; D011336: Probability; D012016: Reference Values; D018570: Risk Assessment; D012720: Severity of Illness Index",,,https://openalex.org/W2081271935,182,24,1,1137,181,7,en,en
false,vatanidipine hydrochloride new long lasting antihypertensive agent,vatanidipine novel dihydropyridine dhp type calcium channel blocker slow onset pharmacological action probably due slow uptake vascular tissue resistance approach calcium channel bind site vatanidipine incorporate vascular tissue easily release even repeat washing thus result long lasting action agent slow onset long lasting hypotensive action observe various experimental hypertensive model clinical trial use human subject essential hypertension indicate vatanidipine exert antihypertensive effect slow onset long duration spite potent hypotensive effect incidence adverse effect vatanidipine administration report low case nitrendipine addition vasodilatory effect vatanidipine efficiently suppress noradrenaline release sympathetic nerve ending thus suggest agent exhibit beneficial effect treatment hypertensive patient reflex activation peripheral sympathetic nerve unfavourable antihypertensive therapy double blind study vatanidipine show reflex tachycardia despite produce potent long lasting hypotensive effect contrast administration nitrendipine animal study vatanidipine exhibit protective effect cerebrovascular lesion mechanism independent hypotensive effect addition renoprotective effect also observe experimental hypertensive model cholesterol fed rabbit vatanidipine exert anti atherosclerotic action probably attributable inhibitory action agent low density lipoprotein oxidation essential hypertensive patient plasma level cholesterol triglyceride decrease vatanidipine treatment thus suggest agent may therapeutic potential prevent vascular disease atherosclerosis take together vatanidipine appear novel useful antihypertensive agent prevent target organ damage reduce cardiovascular morbidity mortality,Matsumura Y,2001,Expert Opin Investig Drugs,https://doi.org/10.1517/13543784.10.1.139,11116287,Matsumura Y; Hayashi K,article,D016428: Journal Article; D016454: Review,D000818: Animals; D000959: Antihypertensive Agents; D001161: Arteriosclerosis; D002121: Calcium Channel Blockers; D002986: Clinical Trials as Topic; D004095: Dihydropyridines; D006801: Humans; D006973: Hypertension; D009568: Nitrendipine,,,https://openalex.org/W2100224348,69,8,1,2241,334,12,en,en
false,effect long term treatment verapamil left ventricular function myocardial blood flow patient dilated cardiomyopathy without overt heart failure,myocardial blood flow mbf abnormality present early stage dilate cardiomyopathy dcm attribute coronary microvascular abnormality favorable effect verapamil coronary microcirculation might indicate use early stage dcm assess safety long term combination therapy verapamil enalapril effect left ventricular function myocardial perfusion compare enalapril alone patient dcm men woman mean age year without overt heart failure nyha class ii baseline month randomized treatment either enalapril mg nine patient group enalapril mg verapamil mg nine patient group leave ventricular function assess rest handgrip bicycle exercise equilibrium radionuclide angiography mean mbf measure rest dipyridamole positron emission tomography pet n ammonia flow tracer baseline two group reduce left ventricular ejection fraction rest far impaired isometric exercise increase peak bicycle exercise mbf similarly reduce two group rest dipyridamole treatment adverse event occur either group month significant difference main study variable either two group within group treatment long term combination therapy verapamil enalapril safe patient dcm without overt heart failure despite favorable effect myocardial perfusion combine treatment prevented deterioration left ventricular function similarly enalapril alone,Neglia D,2000,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-200012000-00009,11117374,Neglia D; Sambuceti G; Giorgetti A; Bartoli M; Salvadori P; Sorace O; Puccini G; L'Abbate A; Parodi O,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D002121: Calcium Channel Blockers; D002302: Cardiac Output; D002311: Cardiomyopathy, Dilated; D003326: Coronary Circulation; D004311: Double-Blind Method; D005080: Exercise Test; D005260: Female; D006321: Heart; D006333: Heart Failure; D006801: Humans; D008297: Male; D008875: Middle Aged; D014055: Tomography, Emission-Computed; D016277: Ventricular Function, Left; D014700: Verapamil",,,https://openalex.org/W1974818453,168,23,1,1768,306,11,en,en
true,rhythm rate control atrial fibrillation pharmacological intervention atrial fibrillation piaf randomised trial,atrial fibrillation commonly encounter sustained cardiac arrhythmia restoration maintenance sinus rhythm believe many physician superior rate control however prospective data compare therapeutic strategies pharmacological intervention atrial fibrillation piaf trial randomised trial patient atrial fibrillation day day duration compare rate group patient rhythm control group b patient group diltiazem use first line therapy amiodarone use group b primary study endpoint improvement symptom relate atrial fibrillation entire observation period year similar proportion patient report improvement symptom group responder month group v responder group b p amiodarone administration result pharmacological restoration sinus rhythm patient walk distance min walk test well group b compare group assessment quality life show difference group incidence hospital admission higher group b v group p adverse drug effect frequently lead change therapy group b patient compare group p respect symptomatic improvement patient atrial fibrillation therapeutic strategy rate versus rhythm control yield similar clinical result overall however exercise tolerance well rhythm control although hospital admission frequent data may serve basis select therapy individual patient,Hohnloser SH,2000,Lancet,https://doi.org/10.1016/s0140-6736(00)03230-x,11117910,Hohnloser SH; Kuck KH; Lilienthal J,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D000638: Amiodarone; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D004110: Diltiazem; D004554: Electric Countershock; D005500: Follow-Up Studies; D006339: Heart Rate; D006760: Hospitalization; D006801: Humans; D008875: Middle Aged; D005082: Physical Exertion; D011788: Quality of Life,,,https://openalex.org/W2124805101,124,18,1,1792,330,11,en,en
true,health outcome associate calcium antagonist compare first line antihypertensive therapy meta analysis randomise control trial,several observational study individual randomised trial hypertension suggest compare drug calcium antagonist may associate high risk coronary event despite similar blood pressure control aim meta analysis compare effect calcium antagonist antihypertensive drug major cardiovascular events undertake meta analysis trial hypertension assess cardiovascular event include least patient randomly assign intermediate acting long acting calcium antagonist antihypertensive drug follow least years nine eligible trial include participant calcium antagonist drug achieve similar control systolic diastolic blood pressure compare patient assign diuretic beta blockers angiotensin converting enzyme inhibitor clonidine n assigned calcium antagonist n significantly high risk acute myocardial infarction odds ratio ci p congestive heart failure p major cardiovascular event p treatment difference within play chance outcome stroke p cause mortality p randomise controlled trial large available database suggest calcium antagonist inferior type antihypertensive drug first line agent reduce risk several major complication hypertension basis data longer acting calcium antagonist recommend first line therapy hypertension,Pahor M,2000,Lancet,https://doi.org/10.1016/s0140-6736(00)03306-7,11130522,Pahor M; Psaty BM; Alderman MH; Applegate WB; Williamson JD; Cavazzini C; Furberg CD,article,D003160: Comparative Study; D016428: Journal Article; D017418: Meta-Analysis,D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003327: Coronary Disease; D003971: Diastole; D005260: Female; D006333: Heart Failure; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D016032: Randomized Controlled Trials as Topic; D020521: Stroke; D013599: Systole; D016896: Treatment Outcome,,,https://openalex.org/W2116620721,158,19,1,1765,282,6,en,en
true,effect ace inhibitor calcium antagonist blood pressure lowering drug result prospectively design overview randomised trial,programme overview randomised trial establish investigate effect angiotensin converting enzyme ace inhibitor calcium antagonist blood pressure lowering drug mortality major cardiovascular morbidity several population patient separate overview trial compare active treatment regimen placebo trial compare intensive less intensive blood pressure lowering strategy trial compare treatment regimen base different drug classes hypothesis investigate trial include outcome study select result participate trial know individual participant data group tabular data provide trial combine standard statistical techniques overview placebo controlled trial ace inhibitor four trial patient mostly coronary heart disease reveal reduction stroke ci coronary heart disease major cardiovascular event overview placebo controlled trial calcium antagonist two trial patient mostly hypertension show reduction stroke major cardiovascular event overview trial compare blood pressure lowering strategy different intensity three trial patient hypertension reduced risk stroke coronary heart disease major cardiovascular event intensive therapy overview compare different antihypertensive regimen eight trial patient hypertension several difference cause specific effect see calcium antagonist based therapy regimen borderline significance strong evidence benefit ace inhibitor calcium antagonist provide overview placebo controlled trial weak evidence difference treatment regimen differ intensity difference treatment regimen base different drug class data continue trial blood pressure lowering drug substantially increase evidence available real difference might exist regimen,Neal B,2000,Lancet,https://doi.org/10.1016/s0140-6736(00)03307-9,11130523,Neal B; MacMahon S; Chapman N; Blood Pressure Lowering Treatment Trialists' Collaboration,article,"D003160: Comparative Study; D016428: Journal Article; D017418: Meta-Analysis; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003327: Coronary Disease; D005260: Female; D006333: Heart Failure; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D016032: Randomized Controlled Trials as Topic; D020521: Stroke; D016896: Treatment Outcome,,,https://openalex.org/W2297753288,153,21,1,2347,382,8,en,en
false,prognostic implication intima media thickness plaque carotid femoral artery patient stable angina pectoris,ultrasonographic assessment intima media thickness plaque carotid artery widely use surrogate marker coronary atherosclerosis prospective evaluation scarce appear lack patient coronary artery disease ultrasonographic evaluation femoral vascular change study prospectively angina prognosis study stockholm apsis patient stable angina pectoris study prospectively double blind treatment verapamil metoprolol ultrasonographic assessment intima media thickness lumen diameter plaque carotid femoral artery evaluate subgroup patient female mean age year relate risk cardiovascular death n non fatal myocardial infarction n revascularization n follow median year univariate cox regression analyse show carotid intima media thickness plaque relate risk cardiovascular death myocardial infarction femoral intima media thickness relate cardiovascular death myocardial infarction well revascularization whereas femoral plaque relate latter adjustment age sex smoking previous cardiovascular disease lipid status carotid intima media thickness fail predict cardiovascular event whereas carotid plaque tend p predict risk cardiovascular death myocardial infarction femoral intima media thickness p plaque p also relate risk revascularization adjustments carotid femoral vascular change differently relate cardiovascular event carotid intima media thickness weak predictor event whereas femoral intima media thickness predict revascularization plaque carotid artery relate cardiovascular death non fatal myocardial infarction whereas plaque femoral artery relate revascularization evaluation plaque provide good prediction assessment intima media thickness patient stable angina,Held C,2001,Eur Heart J,https://doi.org/10.1053/euhj.1999.2006,11133211,Held C; Hjemdahl P; Eriksson SV; Björkander I; Forslund L; Rehnqvist N,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D000787: Angina Pectoris; D001161: Arteriosclerosis; D002339: Carotid Arteries; D002340: Carotid Artery Diseases; D003324: Coronary Artery Disease; D004311: Double-Blind Method; D005260: Female; D005263: Femoral Artery; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D008790: Metoprolol; D008875: Middle Aged; D009203: Myocardial Infarction; D011379: Prognosis; D016016: Proportional Hazards Models; D011446: Prospective Studies; D012307: Risk Factors; D013548: Sweden; D017539: Tunica Intima; D017540: Tunica Media; D014463: Ultrasonography; D014700: Verapamil,,,https://openalex.org/W2040685027,137,19,1,2195,344,10,en,en
false,verapamil increase survival patient anthracycline resistant metastatic breast carcinoma,verapamil ver potent calcium channel blocker find overcome p gp mediated multi drug resistance mdr increase sensitivity cytotoxic anticancer drug refractory myeloma non hodgkin lymphoma value ver treat solid tumor still matter debate perform prospective study patient anthracycline resistant metastatic breast carcinoma mbc assess clinical effect oral ver give association chemotherapy instead retreat patient anthracycline use partially noncross resistant regimen vf combine vindesine vd fluorouracil give continuous infusion fu ci patient randomly assign two cohort one cohort patient treat day cycle involve administration vd mg v bolus day fu ci mg day v day day cohort patient receive vd fu treatment additional oral ver treatment mg day divide dos day day cycle patient treat progression treatment well tolerate side effect could attribute ver detect patient treat ver long overall survival median vs day p high response rate vs p give ver progression free survival pfs also longer difference statistically significant median pfs month ver non ver group respectively p clinical trial demonstrate chemosensitizer ver increase survival mbc patient acquired anthracycline resistance,Belpomme D,2000,Ann Oncol,https://doi.org/10.1023/a:1026556119020,11142488,Belpomme D; Gauthier S; Pujade-Lauraine E; Facchini T; Goudier MJ; Krakowski I; Netter-Pinon G; Frenay M; Gousset C; Marié FN; Benmiloud M; Sturtz F,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D020168: ATP Binding Cassette Transporter, Subfamily B, Member 1; D000284: Administration, Oral; D000368: Aged; D000903: Antibiotics, Antineoplastic; D000971: Antineoplastic Combined Chemotherapy Protocols; D001145: Arrhythmias, Cardiac; D001692: Biological Transport; D001943: Breast Neoplasms; D002121: Calcium Channel Blockers; D015331: Cohort Studies; D018572: Disease-Free Survival; D004334: Drug Administration Schedule; D019008: Drug Resistance, Neoplasm; D005260: Female; D005472: Fluorouracil; D005767: Gastrointestinal Diseases; D006801: Humans; D015993: Life Tables; D008875: Middle Aged; D009363: Neoplasm Proteins; D011446: Prospective Studies; D016019: Survival Analysis; D016896: Treatment Outcome; D014700: Verapamil; D014751: Vindesine",,,https://openalex.org/W2270826964,101,11,1,1754,336,11,en,en
false,cost outcome switch amlodipine felodipine,journal article cost outcome switch amlodipine felodipine get access craig williams pharm craig williams pharm assistant professor pharmacy practice school pharmacy purdue university wishard memorial hospital myers building west tenth street indianapolis cdwilli iupui edu search work author oxford academic google scholar american journal health system pharmacy volume issue december page http doi org ajhp publish december,Williams CD,2000,Am J Health Syst Pharm,https://doi.org/10.1093/ajhp/57.24.2287,11146977,Williams CD,article,D016420: Comment; D016422: Letter,D017311: Amlodipine; D002121: Calcium Channel Blockers; D002318: Cardiovascular Diseases; D015736: Felodipine; D006801: Humans; D016896: Treatment Outcome,,,https://openalex.org/W2395885461,61,9,1,573,92,3,en,en
false,pharmacodynamic pharmacokinetic profile controlled release formulation felodipine metoprolol free fixed combination elderly hypertensive patient,aim aim study study efficacy tolerability felodipine extend release er mg metoprolol control release cr zoc mg give fixed combination logimax free combination elderly age great year hypertensive patient use ambulatory blood pressure bp monitoring secondary aim relate efficacy free fixed combination pharmacokinetic profile method double blind placebo controlled randomise three way crossover multi centre study bp measure h use ambulatory blood pressure monitoring abpm perform last day three treatment phase result mean sit bps measure trough period abpm significantly low free fixed combination metoprolol felodipine placebo mmhg free mmhg fix mmhg placebo mean bps measure h use abpm mmhg mmhg mmhg free fix placebo treatment arm respectively trough peak ratio p systolic bp diastolic bp free fixed combination respectively pharmacokinetic evaluation reveal identical plasma concentration time curve felodipine give free fix combination comparison plasma concentration time curve metoprolol reveal delay release rate fix combination formulation significant difference bp control active treatment note period patient enter study withdrew active phase non drug related reason patient withdraw active treatment due treatment related adverse event frequency adverse event reporting fixed combination felodipine metoprolol similar placebo respectively conclusion result suggest daily dosing either free fixed combination felodipine mg metoprolol mg produce significant sustained reduction systolic diastolic bp similar plasma concentration profile h period,McLay JS,2000,Eur J Clin Pharmacol,https://doi.org/10.1007/s002280000198,11151741,McLay JS; MacDonald TM; Hosie J; Elliott HL; Logimax Group,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002940: Circadian Rhythm; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004338: Drug Combinations; D004359: Drug Therapy, Combination; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008790: Metoprolol; D008875: Middle Aged; D010919: Placebos",,,https://openalex.org/W2168792993,176,21,1,2236,393,14,en,en
false,importance rate control rate regulation improve exercise capacity quality life patient permanent atrial fibrillation normal leave ventricular function randomise control study,objective determine importance rhythm regulation rate control patient permanent atrial fibrillation af normal leave ventricular function patient intervention thirty six patient mixed fast slow ventricular response rate af randomise either bundle ablation hba vvir pacemaker hba group vvi pacemaker atrioventricular modifying drug med group outcome assess one three six month include exercise duration quality life result exercise duration significantly improve baseline group difference outcome group med v hba p n heart rate profile exercise similarly slow group compare baseline quality life significantly improve treatment arm modified karolinska questionnaire kq med v hba p n nottingham health profile nhp med v hba p n however individual symptom score questionnaire improve med group kq med improvedv hba nhp med vhba leave ventricular function equally preserve treatment follow conclusion patient control ventricular response rate either hba vvir pacemaker atrioventricular modifying drug vvi pacemaker lead significant improvement exercise duration quality life rhythm regulation hba confer additional benefit suggest rate control alone necessary successful symptomatic treatment patient permanent af,Levy T,2001,Heart,https://doi.org/10.1136/heart.85.2.171,11156667,Levy T; Walker S; Mason M; Spurrell P; Rex S; Brant S; Paul V,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D002304: Cardiac Pacing, Artificial; D002317: Cardiovascular Agents; D017115: Catheter Ablation; D003131: Combined Modality Therapy; D005080: Exercise Test; D017079: Exercise Tolerance; D005260: Female; D005500: Follow-Up Studies; D006305: Health Status Indicators; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D011788: Quality of Life; D016277: Ventricular Function, Left",,,https://openalex.org/W2115655543,212,31,1,1705,358,11,en,en
true,amlodipine versus slow release metoprolol treatment stable exertional angina pectoris amsa,objectives compare effect amlodipine slow release metoprolol subjective symptom sign ischaemia bicycle ergometric exercise test patient stable angina pectoris design randomized double blind comparison two drug patient documented coronary disease require least three attack angina per week perform symptom limited exercise test significant sign ischaemia ecg results patient complete study amlodipine metoprolol significantly increase total exercise time total workload time onset angina time mm st depression significant difference drug amlodipine significantly efficient metoprolol reduce st depression maximum workload diary data reveal difference patient self rating drug effect conclusions judge suppression subjective symptom performance exercise tolerance test amlodipine represent useful alternative metoprolol monotherapy stable angina pectoris,Midtbø K,2000,Scand Cardiovasc J,https://doi.org/10.1080/140174300750064639,11191937,Midtbø K; Mølstad P; AMSA study group (Amlodipine Metoprolol Stable Angina),article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000319: Adrenergic beta-Antagonists; D000368: Aged; D017311: Amlodipine; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004562: Electrocardiography; D005080: Exercise Test; D005260: Female; D006801: Humans; D008297: Male; D008790: Metoprolol; D008875: Middle Aged; D005082: Physical Exertion,,,https://openalex.org/W2163698074,102,16,1,1103,169,7,en,en
false,treatment hypertension patient year age experience amlodipine,hypertension common finding patient year age contribute cardiovascular morbidity mortality many patient untreated hypertension inadequately control recent randomize controlled study demonstrate benefit treat hypertension elderly study undertake assess efficacy tolerability amlodipine long acting calcium channel blocker elderly year age patient mild moderate hypertension diastolic blood pressure mm hg open label multicenter week general practice study involve patient year age patient malignant secondary hypertension unstable angina exclude experience acute myocardial infarction stroke precede month treat alpha blocker precede month patient assign treatment schedule amlodipine monotherapy combination therapy amlodipine give daily morning evening approximately patient would receive morning dose approximately would receive amlodipine monotherapy paired test use assess significance difference baseline value significance set p total patient receive amlodipine include tolerability analysis patient year patient year include year include efficacy analysis significant reduction p blood pressure note group week treatment equivalence efficacy age group see term reduction blood pressure reduction mm hg patient year age mm hg year age mm hg year age compare baseline therapy successful patient year age patient year age patient year age incidence adverse event similar age group year year year statistically significant difference group tolerability rat good excellent patient significant difference groups daily amlodipine effective treatment mild moderate hypertension patient population demonstrate low frequency adverse event high degree tolerability improve well morning rather even dose appear confer slight advantage,Langdon C,2000,Clin Ther,https://doi.org/10.1016/s0149-2918(00)83045-3,11192138,Langdon C,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D006801: Humans; D006973: Hypertension,,,https://openalex.org/W2160881218,82,13,1,2747,521,13,en,en
false,silent ischemic interval exercise test predictor response drug therapy randomized crossover trial metoprolol versus diltiazem stable angina,method available predict relative antianginal efficacy beta blocker calcium channel antagonist present study undertake assess role silent ischemic interval sii exercise treadmill test ett predictor response therapy metoprolol diltiazem patient stable angina thirty four patient stable angina divide two group depend upon presence absence sii gap least min onset st depression appearance angina ett metoprolol mg twice daily diltiazem mg three time daily randomly assign week patient group patient cross week washout period week antianginal efficacy assess clinical exercise parameters patient sii clinical responder rate well metoprolol diltiazem vs respectively ett metoprolol produce significant improvement total exercise time p time mm st depression p time angina p significant decrease peak rate pressure product p whereas diltiazem significant effect exercise parameter however patient without sii metoprolol diltiazem similar clinical responder rate produce significant increase total exercise time p time mm st depression p time angina p addition metoprolol significant effect peak rate pressure product p silent ischemic interval ett predictor response antianginal therapy stable angina patient sii respond well metoprolol without sii respond equally metoprolol diltiazem,Dwivedi SK,2001,Clin Cardiol,https://doi.org/10.1002/clc.4960240108,11195606,Dwivedi SK; Saran RK; Mittal S; Gupta R; Narain VS; Puri VK,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D004110: Diltiazem; D004562: Electrocardiography; D005080: Exercise Test; D005260: Female; D006801: Humans; D008297: Male; D008790: Metoprolol; D008875: Middle Aged; D017202: Myocardial Ischemia; D011897: Random Allocation,,,https://openalex.org/W2051437311,162,26,1,1833,350,6,en,en
false,fast triglyceride level best reflect coronary risk evidence turkish adult risk factor study,association raise low density lipoprotein cholesterol ldl c level high risk coronary heart disease chd well establish take account guideline coronary prevention relationship risk coronary heart disease chd level fast plasma triglyceride study cohort turkish adult risk factor study representative random sample adult population men woman age year mean plasma lipid lipoprotein measure enzymatic dry method postabsorptive state sample value validate reference laboratory apoliprotein apo b measure turbidimetric immunoassay use commercial kit part cohort blood pressure anthropometric measurement make criterion diagnosis chd base history cardiovascular examination minnesota coding rest electrocardiogram coronary heart disease diagnose subject participant divide four category depend triglyceride level mg dl men woman ii mg dl men woman iii mg dl men woman iv mg dl men woman adjustment age high density lipoprotein hdl low density lipoprotein ldl cholesterol smoking body mass index logistic regression analysis assign chd risk category relative risk men woman combine rise category iii p diminish category iv p woman odds ratio rise gradually p category iii decline category iv men slightly insignificantly equally elevate category iii iv patient chd category iii distinguish category iv study risk parameter suggest high risk chd particularly subject slightly elevate normal cholesterol levels often reflect extreme increase fast triglyceride best modest elevation mg dl serve good marker triglyceride rich lipoprotein particle knowledge may prove value population screening individual risk assessment,Onat A,2001,Clin Cardiol,https://doi.org/10.1002/clc.4960240103,11195622,Onat A; Sansoy V; Yildirim B,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D015331: Cohort Studies; D003327: Coronary Disease; D005215: Fasting; D005260: Female; D006801: Humans; D008074: Lipoproteins; D008297: Male; D008875: Middle Aged; D016017: Odds Ratio; D012307: Risk Factors; D014280: Triglycerides; D014421: Turkey,,,https://openalex.org/W1983530583,111,17,2,2381,447,12,en,en
false,comparison nisoldipine er amlodipine treatment mild moderate hypertension,summary multicentre double blind double dummy randomise trial compare efficacy tolerability nisoldipine extend release mg amlodipine mg patient primary end point treatment comparison change baseline week mean office diastolic blood pressure dbp least square mean reduction systolic bp dbp standard error nisoldipine amlodipine mmhg respectively dbp treatment difference mmhg confidence interval mmhg p tolerability profile similar treatment drug acquisition cost per mmhg dbp reduction low nisoldipine acquisition cost analysis reveal amlodipine expensive nisoldipine treat hypertension summary nisoldipine amlodipine provide clinically equivalent antihypertensive efficacy however nisoldipine economical amlodipine,Whitcomb C,2000,Int J Clin Pract,,11198728,Whitcomb C; Enzmann G; Pershadsingh HA; Johnson R; Ciuryla V; Reisin E,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D001795: Blood Pressure Determination; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D016527: Drug Costs; D005260: Female; D006801: Humans; D006973: Hypertension; D016018: Least-Squares Analysis; D008297: Male; D008875: Middle Aged; D015737: Nisoldipine; D016037: Single-Blind Method; D013810: Therapeutic Equivalency; D016896: Treatment Outcome,,,https://openalex.org/W43513208,96,15,1,1017,172,7,en,en
false,th scientific meeting international society hypertension,approximately delegate attend th scientific meeting international society hypertension chicago usa program consist breakfast workshop oral presentation review lecture invited speaker three debate treatment mild hypertension question whether receptor blocker superior ace inhibitor treatment hypertension value guideline management hypertension one symposium heart failure nearly poster abstract publish supplement journal hypertension volume supplement,Danser AH,2000,Expert Opin Investig Drugs,https://doi.org/10.1517/13543784.9.10.2419,11203289,Danser AH; Schuijt MP,article,D016423: Congress,"D057911: Angiotensin Receptor Antagonists; D000806: Angiotensin-Converting Enzyme Inhibitors; D000818: Animals; D002641: Chicago; D065128: Endothelin Receptor Antagonists; D004791: Enzyme Inhibitors; D006801: Humans; D006973: Hypertension; D007093: Imidazoles; D019001: Nitric Oxide Synthase; D000068557: Olmesartan Medoxomil; D011480: Protease Inhibitors; D044140: Receptor, Angiotensin, Type 1; D044139: Receptor, Angiotensin, Type 2; D012955: Societies, Medical; D013777: Tetrazoles",,,https://openalex.org/W2916471585,68,9,1,644,111,3,en,en
false,new chronotherapeutic oral drug absorption system verapamil optimize blood pressure control morning,novel verapamil chronotherapeutic oral drug absorption system codas verapamil design bedtime dosing controlled onset extended release property evaluate patient mild moderate essential hypertension week double blind placebo controlled trial bedtime dosing pm pm delivery system delay drug release h provide high concentration verapamil noon study result show codas verapamil produce great antihypertensive effect morning period noon also provide effective trough diastolic blood pressure reduction mg significant trough systolic blood pressure reduction achieve mg dos nighttime dose regimen associate excessive blood pressure bp reduction sleeping hour antihypertensive effect generally slightly less h mean reduction codas verapamil provide enhanced bp reduction morning period compare time interval h dosing period,Smith DH,2001,Am J Hypertens,https://doi.org/10.1016/s0895-7061(00)01227-9,11206672,Smith DH; Neutel JM; Weber MA,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000042: Absorption; D000284: Administration, Oral; D000328: Adult; D001794: Blood Pressure; D001795: Blood Pressure Determination; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D019454: Chronotherapy; D003692: Delayed-Action Preparations; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009819: Office Visits; D014700: Verapamil",,,https://openalex.org/W2163430426,113,16,1,1166,189,6,en,en
false,effect short long acting calcium channel blocker relationship blood pressure physical activity,calcium channel blocker widely use antihypertensive drug however controversy use first aim clarify dihydropyridine calcium channel blocker benidipine affect quantitative relationship blood pressure bp physical activity second aim determine whether relationship systolic blood pressure sbp physical activity patient hypertension treat short acting nifedipine long acting benidipine calcium channel blocker study ambulatory bp physical activity measure simultaneously patient hypertension month benidipine study ambulatory bp physical activity measure simultaneously patient hypertension placebo week crossover treatment nifedipine benidipine study difference sbp change cause physical activity pre posttreatment period study sbp significantly relate physical activity placebo benidipine group nifedipine group low bp day time nighttime nifedipine group significantly low benidipine group plasma renin activity ng ml h significantly high nifedipine group placebo benidipine group finding indicate nifedipine might interfere adaptation mechanism bp change physical activity activate renin angiotensin system might cause cardiac event,Kakinoki S,2001,Am J Hypertens,https://doi.org/10.1016/s0895-7061(00)00300-9,11206682,Kakinoki S; Nomura A; Takechi S; Kitabatake A,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D002940: Circadian Rhythm; D018592: Cross-Over Studies; D004095: Dihydropyridines; D015444: Exercise; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D013599: Systole",,,https://openalex.org/W1994456813,123,17,1,1694,288,11,en,en
false,comparative effect mibefradil nifedipine gastrointestinal transport system autonomic function patient mild moderate essential hypertension,background l type dihydropyridine calcium channel blocker ccbs implicate increased cardiovascular event patient hypertension perhaps due adverse effect autonomic nervous system function blockade type calcium channel may limit dysfunction inhibition channel mediated neuroendocrine effect objective design double blind parallel group study compare effect nifedipine gastrointestinal transport system git l type ccb versus mibefradil type ccb function patient mild moderate essential hypertension method sixteen patient male female age year diastolic blood pressure dbp mmhg randomize nifedipine mg daily mibefradil mg daily week nifedipine mg daily mibefradil mg daily week sympathetic nervous system activity snsa assess use norepinephrine kinetics parasympathetic nervous system activity psna assess h holter recording heart rate variability hrv non invasive baroreflex sensitivity br provide integrated assessment result patient group well match baseline achieve dbp low patient treat mibefradil compare nifedipine versus mmhg significant difference snsa br group however root mean square successive difference high frequency power hfp increase mibefradil compare nifedipine treated patient versus p versus ms p respectively furthermore ln hfp ln total power increase week week mibefradil treated group versus p conclusion difference exist effect l type ccbs snsa br however type ccbs increase psna independent achieved change heart rate,Pellizzer AM,2001,J Hypertens,https://doi.org/10.1097/00004872-200102000-00015,11212971,Pellizzer AM; Kamen PW; Esler MD; Lim S; Krum H,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D001341: Autonomic Nervous System; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D004562: Electrocardiography; D005260: Female; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D008297: Male; D020748: Mibefradil; D008875: Middle Aged; D009543: Nifedipine; D009638: Norepinephrine; D011311: Pressoreceptors; D011446: Prospective Studies,,,https://openalex.org/W2067504115,161,20,1,1982,365,13,en,en
false,long term effect amlodipine lisinopril left ventricular mass diastolic function elderly previously untreated hypertensive patient elvera trial,compare effect calcium antagonist amlodipine angiotensin convert enzyme inhibitor lisinopril left ventricular mass diastolic function elderly previously untreated hypertensives double blind randomize parallel group trial effect amlodipine lisinopril left ventricular mass diastolic function e ratio elvera trial rural northern netherlands population screen new diagnose hypertensive subjects study population comprise newly diagnose hypertensive age diastolic blood pressure mmhg systolic blood pressure mmhg patients randomly allocate receive mg amlodipine mg lisinopril years prior year treatment leave ventricular mass index body surface lvmi estimate mode echocardiography accord devereux use penn convention early atrial filling ratio e assess transmitral flow change baseline lvmi e ratio evaluate repeated measurement analysis treatment effect intention treat analysis amlodipine lisinopril lead equivalent reduction systolic diastolic blood pressure end study amlodipine group lead lvmi decrease g confidence interval ci e ratio increase ci lisinopril group lvmi decrease g ci e ratio increase ci statistically significant difference find change lvmi e ratio amlodipine lisinopril long term study elvera trial prove amlodipine lisinopril reduce leave ventricular mass improve diastolic function similar extent elderly newly diagnose hypertensive patient,Terpstra WF,2001,J Hypertens,https://doi.org/10.1097/00004872-200102000-00018,11212974,Terpstra WF; May JF; Smit AJ; de Graeff PA; Havinga TK; van den Veur E; Schuurman FH; Meyboom-de Jong B; Crijns HJ,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D002121: Calcium Channel Blockers; D003971: Diastole; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D017379: Hypertrophy, Left Ventricular; D017706: Lisinopril; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2322157305,167,24,1,1885,319,7,en,en
false,comparison indapamide sr mg amlodipine mg hydrochlorothiazide mg elderly hypertensive patient randomized double blind control study,objective analyse efficacy indapamide sustained release sr mg reduce blood pressure versus amlodipine mg hydrochlorothiazide mg elderly hypertensive patient design double blind randomize week study use three parallel group set european teaching hospital general practice patient randomized patient n include patient isolated systolic hypertension ish mean age year mean systolic diastolic blood pressure sbp dbp mmhg main outcome measure clinic systolic diastolic blood pressure variation result indapamide sr mg demonstrate similar efficacy amlodipine mg well hydrochlorothiazide mg equivalence p mean decrease sbp dbp mmhg mmhg mmhg respectively ish subgroup indapamide sr mg tends great efficacy hydrochlorothiazide mg reduce sbp versus mmhg respectively equivalence p similar result obtain amlodipine mg mmhg equivalence p normalization rate relatively high indapamide sr mg compare amlodipine hydrochlorothiazide especially subgroup isolated systolic hypertensive patient versus amlodipine versus hydrochlorothiazide conclusion indapamide sr mg show similar antihypertensive efficacy amlodipine mg hydrochlorothiazide mg elderly hypertensive patient patient isolated systolic hypertension indapamide sr mg show similar efficacy amlodipine mg great efficacy hydrochlorothiazide mg,Emeriau JP,2001,J Hypertens,https://doi.org/10.1097/00004872-200102000-00023,11212979,Emeriau JP; Knauf H; Pujadas JO; Calvo-Gomez C; Abate G; Leonetti G; Chastang C; European Study Investigators,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D000959: Antihypertensive Agents; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D007190: Indapamide; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2024298544,169,26,1,1785,322,9,en,en
false,efficacy safety hospital self administered single dose oral drug treatment management infrequent well tolerated paroxysmal supraventricular tachycardia,objective test efficacy two drug treatment flecainide f combination diltiazem propranolol p administer single oral dose termination arrhythmic episode background prophylactic drug therapy catheter ablation questionable first line treatment patient infrequent well tolerated episode paroxysmal supraventricular tachycardia svt method among eligible patient screen svt infrequent year well tolerated long lasting episode enrol svt inducible electrophysiological study latter three treatment placebo f p administer random order min svt induction three different day result conversion sinus rhythm occur within h patient placebo f p respectively p conversion time shorter p min placebo min p f min p four patient placebo p f hypotension four p f sinus rate beats min follow svt interruption patient discharge single oral dose effective drug treatment f p time acute test twenty six patient discharge p five f month follow treatment successful p patient f patient arrhythmic episode interrupt hospital within h remain patient failure occur one episode drug ineffectiveness drug unavailability one patient syncope p ingestion follow percentage patient call emergency room assistance significantly reduce compare year enrollment vs p conclusion episodic treatment oral p f assess acute testing appear effective management select patient svt therapeutic strategy minimize need emergency room admission tachycardia recurrence,Alboni P,2001,J Am Coll Cardiol,https://doi.org/10.1016/s0735-1097(00)01128-1,11216977,Alboni P; Tomasi C; Menozzi C; Bottoni N; Paparella N; Fucà G; Brignole M; Cappato R,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000293: Adolescent; D000328: Adult; D000368: Aged; D000553: Ambulatory Care; D000889: Anti-Arrhythmia Agents; D004110: Diltiazem; D004359: Drug Therapy, Combination; D004562: Electrocardiography; D005260: Female; D005424: Flecainide; D006801: Humans; D008297: Male; D008875: Middle Aged; D010359: Patient Readmission; D011433: Propranolol; D012646: Self Administration; D012648: Self Care; D013614: Tachycardia, Paroxysmal; D013617: Tachycardia, Supraventricular; D016896: Treatment Outcome",,,https://openalex.org/W2122609241,176,20,1,2160,416,13,en,en
false,verapamil sr trandolapril combination therapy safe effective hypertensive patient metabolic disorder,summary verapamil sr mg plus trandolapril mg potent antihypertensive combination efficacy safety treatment study fully hypertensive patient metabolic disorder enrol patient mild moderate hypertension least one following disorder diabetes mellitus hypercholesterolaemia mild renal failure sit systolic pressure diastolic blood pressure significantly decrease week treatment blood pressure inadequately control patient progressive decrease blood glucose total cholesterol low density lipoprotein triglyceride level observe study significant change blood urea nitrogen creatinine transaminase level p significant decrease microalbuminuria level significant change glycosylated haemoglobin level diabetic patient verapamil sr plus trandolapril effective drug combination treatment hypertension may use safely patient diabetes mellitus hyperlipidaemia mild renal failure,Aksöyek S,2001,Int J Clin Pract,,11219319,Aksöyek S; Ozer N; Aytemir K; Kes S; Turkish Multicentre Verapamil and Trandolapril Study Group,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study,D000328: Adult; D000419: Albuminuria; D000959: Antihypertensive Agents; D001794: Blood Pressure; D048909: Diabetes Complications; D004338: Drug Combinations; D005260: Female; D006442: Glycated Hemoglobin; D006801: Humans; D006937: Hypercholesterolemia; D006973: Hypertension; D007211: Indoles; D008297: Male; D008659: Metabolic Diseases; D008875: Middle Aged; D011446: Prospective Studies; D051437: Renal Insufficiency; D016896: Treatment Outcome; D014700: Verapamil,,,https://openalex.org/W2470046845,121,16,1,1170,193,10,en,en
false,cardiogenic shock follow single therapeutic oral dose verapamil,cardiogenic shock apnoea appear year old woman history biventricular heart failure follow ingestion single mg verapamil tablet resuscitate artificial ventilation dobutamine norepinephrine calcium gluconate toxicological analysis reveal unexpectedly high plasma verapamil concentration attribute patient liver failure patient advanced heart failure single oral therapeutic dose verapamil may severe toxic effect,Stajer D,2001,Int J Clin Pract,,11219325,Stajer D; Bervar M; Horvat M,article,D002363: Case Reports; D016428: Journal Article,"D000284: Administration, Oral; D000368: Aged; D000889: Anti-Arrhythmia Agents; D001145: Arrhythmias, Cardiac; D005260: Female; D006801: Humans; D012770: Shock, Cardiogenic; D016896: Treatment Outcome; D014700: Verapamil",,,https://openalex.org/W2414456955,71,10,1,514,80,4,en,en
false,blood pressure control patient mild moderate essential hypertension switch nifedipine gastrointestinal therapeutic system git mg nifedipine git mg,nifedipine gastrointestinal therapeutic system git daily formulation nifedipine provide sustained plasma nifedipine concentration throughout hour dosing interval study undertake determine adult patient mild moderate essential hypertension whose blood pressure control month nifedipine git mg could successfully switch mg daily dose continued antihypertensive efficacy randomized double blind parallel group study patient enter week run period continue receive usual antihypertensive medication include nifedipine git mg baseline assessment patient enter week treatment period randomly assign receive nifedipine git mg men woman eligible participate year age receive diagnosis mild moderate essential hypertension sit diastolic blood pressure dbp mm hg exhibit good blood pressure control sit dbp mm hg take nifedipine git mg daily month systolic blood pressure sbp dbp heart rate record baseline week treatment adverse event report patient responder rate define percentage patient whose sit dbp mm hg final study assessment result base intent treat analysis include data patient receive dose postbaseline blood pressure assessment statistical significance set p seventy five patient enter week run period patient randomize treatment twenty four patient receive nifedipine git mg day patient receive nifedipine git mg day group exhibit sustained decrease blood pressure throughout study minor variation statistically significant end point sbp dbp mg group mm hg mm hg respectively change baseline end point sbp dbp differ significantly group end treatment goal dbp mm hg achieve patient receive mg dose patient receive mg dose blood pressure control sit dbp mm hg achieve patient mg group patient mg group commonly report adverse event headache patient discontinue study adverse event overall patient mg group patient mg group experience treatment related adverse event patients whose mild moderate essential hypertension control nifedipine git mg daily may able switch mg daily continued antihypertensive efficacy addition safety economic advantage switch may reasonable alternative patient low body weight adjunct exist antihypertensive therapy,Toal CB,2001,Clin Ther,https://doi.org/10.1016/s0149-2918(01)80032-1,11219482,Toal CB; Canadian Investigators,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine,,,https://openalex.org/W2067160101,178,27,1,3275,599,16,en,en
false,comparative study spirapril quadropril amlodipine efficacy result randomized trial patient mild moderate arterial hypertension,compare non blind randomise parallel study efficiency quadropril amlodipine treatment mild moderate arterial hypertension total patient year include study patient randomise two group patient patient group receive monotherapy quadropril group treat amlodipine treatment duration week group quadropril give fixed dose mg daily initial dose amlodipine mg day case insufficient effect dose elevate mg day efficacy evaluate change blood pressure bp measure rest moreover randomly choose patient h monitoring bp perform start end treatment quadropril group baseline systolic bp reach mm hg diastolic bp mm hg heart rate beats min amlodipine group baseline systolic bp mm hg diastolic bp mm hg heart rate beats min systolic bp decrease end quadropril therapy mm hg diastolic bp mm hg significant change heart rate observe mg amlodipine systolic bp decrease mm hg diastolic bp mm hg heart rate increase beats min therapy mg amlodipine systolic bp decrease mm hg diastolic bp mm hg heart rate increase beats min p hypotensive effect quadropril remain stable effect amlodipine decrease th week therapy p side effect observe significantly often amlodipine group quadropril group main quadropril side effect cough side effect observe amlodipine group edemas tachycardia weakness quadropril amlodipine demonstrate comparable antihypertensive effect although patient amlodipine group dose increase necessary tolerability quadropril well,Shal'nova SA,2000,Ter Arkh,,11220888,Shal'nova SA; Martsevich SIu; Deev AD; Kutishenko NP; Kukushkin SK; Manoshkina EM; Alimova EV; Semenova IuE; Lebedev AV; Koniakhina IP; Zagrebel'nyĭ AV,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D002940: Circadian Rhythm; D004656: Enalapril; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011379: Prognosis; D012449: Safety; D012720: Severity of Illness Index",,,https://openalex.org/W2413102431,155,26,2,2184,414,20,en,en
false,long term efficacy safety profile barnidipine,two multicentre trial investigate efficacy tolerability treatment daily barnidipine patient mild moderate essential hypertension long term efficacy safety barnidipine demonstrate long term multicentre open label study total patient follow first second third year respectively patient receive barnidipine dose titrate achieve sit dbp mmhg decrease sit bdp mmhg necessary another antihypertensive agent add achieve normalisation blood pressure first year normalisation blood pressure achieve patient maintain patient second third year respectively end treatment year patient remain barnidipine monotherapy mg day low incidence adverse event possibly probably relate barnidipine mg day monotherapy report first second year headache peripheral oedema palpitation commonly report third year follow one adverse event ecg abnormality consider possibly relate study medication effective hour control blood pressure barnidipine monotherapy confirm randomised double blind placebo controlled cross study patient patient give week regimen barnidipine mg day placebo office hour ambulatory blood pressure record end treatment phase barnidipine lower blood pressure significantly great extent placebo night day adverse event classify mild moderate adverse event report barnidipine treatment compare placebo barnidipine monotherapy mg day safe effective provide hour control blood pressure furthermore efficacy tolerability barnidipine monotherapy mg day maintain least year,Smilde JG,2000,Int J Clin Pract Suppl,,11221291,Smilde JG,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D016896: Treatment Outcome",,,https://openalex.org/W2402174133,57,9,1,2121,379,17,en,en
false,treatment renal hypertension,recent year conjunction medicamentous treatment renoparenchymatous hypertension particular two problem discuss target blood pressure value renoprotective effect antihypertensive drug prospective study reveal blood pressure reading mm hg significantly retard progression nephropathy whereby patient proteinuria g benefit even low bp reading diabetic nephropathy drug choice inhibitor angiotensin convert enzyme acei already incipient stage also normotensive patient importance acei treatment non diabetic nephropathy confirm recently controlled prospective study aipri rein maximal renoprotective effect acei probably call large dos need normalization bp long term investigation renoprotective effect antagonist angiotensin receptor comparative study acei resp available dihydropyridine blocker calcium channel short term action nifedipine may negative influence progression diabetic nephropathy effect dihydropyridines second generation test prospective study non dihydropyridine calcium channel blocker renoprotective action diabetic nephropathy cca two third patient combine treatment acei diuretic calcium channel blocker necessary antihypertensive drug vasodilatating beta blockers perspectively antagonist endothelin receptor useful,Oksa A,2000,Vnitr Lek,,11227186,Oksa A; Spustová V; Dzúrik R,article,D004740: English Abstract; D016428: Journal Article; D016454: Review,"D000959: Antihypertensive Agents; D001794: Blood Pressure; D006801: Humans; D006977: Hypertension, Renal",,,https://openalex.org/W2415091903,34,7,1,1611,241,11,en,en
false,hypothesis adrenergic receptor blocker weight gain,one argument put forward primary use beta blockers concern adverse metabolic effect unfavorable effect lipid insulin sensitivity another less appreciated potential drawback propensity cause weight gain patient evaluable prospective randomize controlled trial last month body weight higher beta blocker control group end study median difference body weight kg range kg regression analysis suggest beta blockers associate initial weight gain first month thereafter weight gain compare control apparent relationship demographic characteristic change body weight base observation first line use beta blockers obese hypertensive patient review obesity management overweight hypertensive patient may difficult face beta blocker treatment,Sharma AM,2001,Hypertension,https://doi.org/10.1161/01.hyp.37.2.250,11230280,Sharma AM; Pischon T; Hardt S; Kunz I; Luft FC,article,D016428: Journal Article; D016454: Review,D000319: Adrenergic beta-Antagonists; D001835: Body Weight; D006801: Humans; D006973: Hypertension; D015430: Weight Gain,,,https://openalex.org/W2103256591,65,14,1,1053,173,9,en,en
false,proarrhythmia,proarrhythmia define aggravation exist arrhythmia development new arrhythmia secondary antiarrhythmic drug proarrhythmic event include drug induced bradyarrhythmias atrial ventricular proarrhythmias new onset sustain incessant ventricular tachycardia torsade de pointes life threaten article review incidence aggravate factor treatment proarrhythmia,Naccarelli GV,2001,Med Clin North Am,https://doi.org/10.1016/s0025-7125(05)70324-2,11233957,Naccarelli GV; Wolbrette DL; Luck JC,article,D016428: Journal Article; D016454: Review,"D000889: Anti-Arrhythmia Agents; D001145: Arrhythmias, Cardiac; D003937: Diagnosis, Differential; D004562: Electrocardiography; D006339: Heart Rate; D006801: Humans; D011379: Prognosis; D012307: Risk Factors",,,https://openalex.org/W4247432378,13,1,1,435,63,4,sv,en
false,comparative effect amlodipine nifedipine git treatment miss two dos,compare antihypertensive efficacy amlodipine nifedipine gastrointestinal therapeutic system git measure office ambulatory blood pressure monitoring abpm treatment patient miss two doses single blind run week placebo period patient randomly allocate amlodipine mg daily n nifedipine git mg daily n double blind double dummy fashion patient receive active medication week simulate failure compliance patient receive two single blind dos placebo ambulatory blood pressure monitoring carry end run placebo phase first day last day active treatment h last active dose diastolic blood pressure control patient amlodipine nifedipine git reduction blood pressure similar group abpm show significant reduction blood pressure first day nifedipine git group amlodipine group marginal effect peak reduction systolic diastolic blood pressure mmhg h ingestion amlodipine tablet trough reduction mmhg trough peak ratio systolic diastolic blood pressure peak reduction systolic diastolic blood pressure nifedipine git mmhg trough reduction mmhg give trough peak ratio systolic diastolic blood pressure patient receive placebo week active treatment simulate compliance failure amlodipine maintain reduction systolic diastolic blood pressure least h last active dose maintain effect systolic blood pressure diastolic blood pressure contrast nifedipine git effect rapidly lose study phase reduction systolic diastolic blood pressure h last active dose study show amlodipine nifedipine git reduce blood pressure extent chronic treatment case compliance failure miss one two dos amlodipine maintain significant important antihypertensive effect trough peak ratio still h last active dose hand coverage nifedipine git limit h last active dose,Hernández RH,2001,Blood Press Monit,https://doi.org/10.1097/00126097-200102000-00008,11248761,Hernández RH; Armas-Hernández MJ; Chourio JA; Armas-Padilla MC; López L; Alvarez M; Pacheco B,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D001795: Blood Pressure Determination; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D004064: Digestive System; D004311: Double-Blind Method; D016503: Drug Delivery Systems; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D009819: Office Visits; D013810: Therapeutic Equivalency; D013997: Time Factors; D016312: Treatment Refusal",,,https://openalex.org/W2331559760,98,14,1,2475,420,13,en,en
false,comparative effect candesartan cilexetil amlodipine patient mild systemic hypertension,comparative antihypertensive efficacy tolerability angiotensin ii receptor blocker candesartan cilexetil calcium channel blocker amlodipine evaluate week multicenter double blind randomize parallel group forced titration study adult patient woman black mild hypertension stage follow week placebo run period patient sit diastolic blood pressure bp mm hg receive candesartan cilexetil mg n amlodipine mg n daily week double blind treatment patient uptitrated candesartan cilexetil mg amlodipine mg daily significant difference candesartan cilexetil amlodipine regimen reduce bp mean systolic bp diastolic bp reduction mm hg versus mm hg respectively p overall patient candesartan cilexetil amlodipine control diastolic bp mm hg total patient candesartan cilexetil discontinue treatment compare patient amlodipine include versus adverse event versus peripheral edema respectively peripheral edema prespecified primary tolerability end point occur significantly great frequency patient amlodipine mild moderate severe versus patient candesartan cilexetil mild moderate p candesartan cilexetil amlodipine highly effective control bp patient mild hypertension candesartan cilexetil offer significant tolerability advantage respect less risk develop peripheral edema,Kloner RA,2001,Am J Cardiol,https://doi.org/10.1016/s0002-9149(00)01491-0,11249891,"Kloner RA; Weinberger M; Pool JL; Chrysant SG; Prasad R; Harris SM; Zyczynski TM; Leidy NK; Michelson EL; Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators",article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D017311: Amlodipine; D000959: Antihypertensive Agents; D001562: Benzimidazoles; D001713: Biphenyl Compounds; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D004487: Edema; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D017060: Patient Satisfaction; D011355: Prodrugs; D011446: Prospective Studies; D013777: Tetrazoles; D016896: Treatment Outcome,,,https://openalex.org/W2055909650,103,13,1,1778,324,9,en,en
false,nicardipine versus nitroprusside breakthrough hypertension follow carotid endarterectomy,evaluate effectiveness nicardipine nitroprusside breakthrough hypertension follow carotid endarterectomy prospective randomize double blind control effectiveness trial university based surgical intensive care unit asa physical status ii iii iv patient experience breakthrough hypertension time admission intensive care unit icu patients receive either nicardipine n placebo nitroprusside n placebo hour postoperatively load dos nicardipine provide placebo use load patient randomize nitroprusside rapidity variability blood pressure bp control assess first minute nicardipine patient compare nitroprusside treated patient achieve bp control p follow initial control nicardipine nitroprusside treated patient require additional titration infusion maintain blood pressure within targeted range p patient suffer stroke myocardial infarction return operating room bleeding nicardipine administration produce rapid bp control likely relate administration loading dose addition rapid control nicardipine treated patient less variability bp require significantly additional intervention although patient suffer major event study study power sufficiently assess safety,Dorman T,2001,J Clin Anesth,https://doi.org/10.1016/s0952-8180(00)00231-2,11259889,Dorman T; Thompson DA; Breslow MJ; Lipsett PA; Rosenfeld BA,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D004311: Double-Blind Method; D016894: Endarterectomy, Carotid; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D007431: Intraoperative Complications; D008297: Male; D009529: Nicardipine; D009599: Nitroprusside; D011446: Prospective Studies",,,https://openalex.org/W2106249249,95,9,1,1541,251,7,en,en
false,qt interval,effect disease state therapeutic drug qt interval extensively study attempt understand relationship qt risk torsade de pointes sudden cardiac death difference heart rate correction method electrocardiogram lead placement internal eg genetic physiologic external eg food time day factor confound interpretation relationship comprehensive review epidemiologic literature suggest correct qt interval qtc important imprecise marker cardiovascular disease association qtc prolongation mortality identify patient cardiac disease unclear patient without cardiac disease drug related prolongation qtc clearly increase risk torsade de pointes arrhythmia rarely associate qtc less ms also appear noncardiac drug associate qtc prolongation identical proarrhythmic capacity increase exposure via clinically significant drug interaction major contributor liability noncardiac drug induced arrhythmia recognition aforementioned variable conjunction careful qtc measurement assist establish precise benefit risk ratio specific drug therapy arrhythmia risk associate various pathophysiologic genetic state,Bednar MM,2001,Prog Cardiovasc Dis,https://doi.org/10.1053/pcad.2001.21469,11269621,Bednar MM; Harrigan EP; Anziano RJ; Camm AJ; Ruskin JN,article,D016428: Journal Article; D016454: Review,"D000818: Animals; D016757: Death, Sudden, Cardiac; D048909: Diabetes Complications; D003920: Diabetes Mellitus; D004562: Electrocardiography; D014943: Global Health; D006330: Heart Defects, Congenital; D006339: Heart Rate; D006801: Humans; D015994: Incidence; D009765: Obesity; D015995: Prevalence; D011379: Prognosis; D012307: Risk Factors; D015996: Survival Rate; D016171: Torsades de Pointes",,,https://openalex.org/W2088486084,15,3,1,1471,233,7,en,en
false,nifedipine nimodipine competitively inhibit uridine kinase orotidine phosphate decarboxylase theoretical relevance poor outcome stroke,nifedipine nimodipine dihydropyridine calcium channel blocker commonly use antihypertensive antianginal agent patient risk stroke least one stroke trial suggest patient receive calcium channel blocker time acute stroke bad outcome receive antihypertensive medication hypothesize poor outcome may relate blood pressure change instead may mediate competitive inhibition important enzyme pyrimidine synthesis whose product need repair nerve cell membrane acute stroke drug act competitive inhibitor enzymes know synthesize nucleotide uridine phosphate uridine kinase orotidine phosphate decarboxylase nifedipine produce ki value microm uridine kinase microm orotidine phosphate decarboxylase nimodipine produce ki value microm uridine kinase microm orotidine phosphate decarboxylase uridine kinase inhibitor bind tightly physiologic substrate uridine cytidine decarboxylase inhibitor bound less tightly normal physiologic substrate orotidine phosphate additional experiment need determine whether concentration nifedipine nimodipine cytidine uridine orotidine phosphate human brain inhibition would affect stroke outcome,Najarian T,2000,Neurorehabil Neural Repair,https://doi.org/10.1177/154596830001400310,11272481,Najarian T; Traut TW,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013486: Research Support, U.S. Gov't, Non-P.H.S.","D000818: Animals; D001667: Binding, Competitive; D001921: Brain; D002121: Calcium Channel Blockers; D002462: Cell Membrane; D006801: Humans; D009474: Neurons; D009543: Nifedipine; D009553: Nimodipine; D009964: Orotidine-5'-Phosphate Decarboxylase; D010599: Pharmacokinetics; D020127: Recovery of Function; D020521: Stroke; D016896: Treatment Outcome; D014541: Uridine Kinase",,,https://openalex.org/W2114831613,149,18,1,1502,225,9,en,en
false,test effectiveness convert patient long acting antianginal medication quality life angina research trial quart,purpose test hypothesis convert patient stable angina long acting antianginal medication would improve functional status symptom control treatment satisfaction quality life single blind randomize trial patient stable coronary artery disease perform outpatient clinic veteran affair health system outpatient chronic stable angina take least antianginal medication study patient randomize one two treatment optimal adjustment usual antianginal medication conversion solely long acting medication long acting diltiazem nitroglycerin patch atenolol subsequent optimization primary outcome month change seattle angina questionnaire score although difference physical limitation score note patient randomize receive long acting medication improve symptom control month improvement anginal stability v p anginal frequency v p treatment satisfaction month improvement v p good quality life month improvement v p compare patient whose pretrial medication optimize improvement symptom control statistically significant converting patient chronic stable angina long acting antianginal medication result substantial improvement symptom control trend toward good treatment satisfaction quality life,Spertus JA,2001,Am Heart J,https://doi.org/10.1067/mhj.2001.112781,11275919,Spertus JA; Dewhurst T; Dougherty CM; Nichol P,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000319: Adrenergic beta-Antagonists; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D002908: Chronic Disease; D006305: Health Status Indicators; D006801: Humans; D005996: Nitroglycerin; D011446: Prospective Studies; D011788: Quality of Life; D016037: Single-Blind Method,,,https://openalex.org/W2054402060,141,22,1,1561,243,6,en,en
false,postoperative atrial fibrillation old problem cry new solution,j thorac cardiovasc surg,Creswell LL,2001,J Thorac Cardiovasc Surg,https://doi.org/10.1067/mtc.2001.114347,11279402,Creswell LL; Damiano RJ,article,D016420: Comment; D016421: Editorial; D016454: Review,D000367: Age Factors; D001281: Atrial Fibrillation; D001026: Coronary Artery Bypass; D006801: Humans; D011183: Postoperative Complications; D015995: Prevalence; D012307: Risk Factors,,,https://openalex.org/W2052909757,74,11,1,40,7,1,en,en
false,comparison two calcium blocker hemodynamics leave ventricular mass coronary vasodilatory advanced hypertension,dihydropyridine nondihydropyridine calcium channel blocker ccb differ pharmacologic characteristic clinical study distinguish effect ccb monotherapy conduct comprehensive comparison two ccb patient moderate severe hypertension thirty patient pretreatment diastolic blood pressure mm hg randomly assign either nifedipine gits verapamil sr dose titration achieve diastolic blood pressure mm hg decrease mm hg week clinic blood pressure bp h ambulatory bp exercise bp leave ventricular mass systolic diastolic function echocardiography coronary flow reserve split dose thallium imaging adenosine assess baseline end titration month month treatment plasma renin activity atrial natriuretic peptide norepinephrine epinephrine assay drug cause similar reduction clinic h ambulatory bp similar reduction left ventricular mass index compare nifedipine gits verapamil sr produce significantly low resting peak exercise heart rate nifedipine gits elicit low peak exercise systolic bp end titration nifedipine gits produce low plasma atrial natriuretic peptide level longer apparent month plasma norepinephrine low verapamil sr also end titration month month plasma epinephrine plasma renin activity unchanged either drug difference systolic diastolic leave ventricular function coronary flow reserve two treatment daily nifedipine gits verapamil sr equally effective reduction arterial pressure moderate severe hypertension difference hemodynamic profile neurohormonal response consistent preclinical pharmacologic characteristic clinical implication similarity difference remain fully evaluate outcome study,Diamond JA,2001,Am J Hypertens,https://doi.org/10.1016/s0895-7061(00)01267-x,11281234,Diamond JA; Krakoff LR; Goldman A; Coplan N; Gharavi A; Martin K; Goldsmith R; Henzlova MJ; Machac J; Phillips RA,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003326: Coronary Circulation; D003331: Coronary Vessels; D003971: Diastole; D004452: Echocardiography; D005080: Exercise Test; D005260: Female; D006339: Heart Rate; D006352: Heart Ventricles; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D013599: Systole; D014665: Vasodilator Agents; D016277: Ventricular Function, Left; D014700: Verapamil",,,https://openalex.org/W2142083888,125,18,1,2043,326,17,en,en
false,long term effect nifedipine git lisinopril subclinical organ damage patient essential hypertension,background preventing subclinical organ damage currently major issue management patient essential hypertension antihypertensive drug act different pathophysiological mechanism might confer specific target organ protection beyond already provide blood pressure lower effect method thirty one patient essential hypertension randomize receive long term treatment either calcium channel blocker nifedipine git mg day ace inhibitor lisinopril mg day blood pressure leave ventricular mass carotid wall thickness time urinary albumin excretion measure baseline course month treatment result regimen significantly lower mean blood pressure month mmhg lisinopril group nifedipine group overall end organ damage improve persistent blood pressure control however two treatment different specific effect lisinopril induce pronounced reduction left ventricular mass index g p urinary albumin excretion microg min p nifedipine achieve great reduction carotid intima plus medium thickness mm p conclusion blood pressure control help reduce severity organ damage patient essential hypertension different antihypertensive treatment may confer additional specific cardiorenal vascular protection regardless blood pressure control data could useful devise individualize therapeutic strategy high risk hypertensive patient,Pontremoli R,2001,J Nephrol,,11281339,Pontremoli R; Viazzi F; Ravera M; Leoncini G; Berruti V; Bezante GP; Del Sette M; Deferrari G,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000806: Angiotensin-Converting Enzyme Inhibitors; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D005260: Female; D006801: Humans; D006973: Hypertension; D017706: Lisinopril; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D013997: Time Factors,,,https://openalex.org/W194883094,119,18,1,1758,280,11,en,en
false,macrophage lymphocyte subpopulation nifedipine cyclosporin associated human gingival overgrowth,nifedipine cyclosporin csa induce gingival overgrowth drug immunomodulating effect suggest alter immune response associate drug induced gingival overgrowth study evaluate whether difference macrophage lymphocyte subpopulation human nifedipine csa associated gingival overgrowth compare normal gingiva biopsy sample overgrown gingiva obtain nifedipine treated cardiac outpatient csa treated renal transplant recipient include patient also receive nifedipine healthy control individual undergoing dental treatment serial microm thick cryostat section stain mabs cd b pan cd macrophage cd helper inducer cd cytotoxic suppressor use avidin biotin horseradish peroxidase complex method number mab labeled nucleated cell determine area connective tissue beneath sulcular epithelium middle connective tissue connective tissue beneath oral epithelium distribution type cell express percentage mab labeled cell relation total number nucleated cell counting zone significance difference group test mean kruskal wallis test pair result mean mann whitney u test proportion cd labeled cell significantly high connective tissue beneath sulcular epithelium nifedipine group control p medicated group proportion cd labeled cell high counting zone control statistically significantly nifedipine group connective tissue beneath oral epithelium p intergroup difference find respect cd cd labeled cell cd cd ratio significantly low connective tissue beneath sulcular epithelium nifedipine group control p result support idea immune response may alter drug induced gingival overgrowth,Pernu HE,2001,J Periodontol,https://doi.org/10.1902/jop.2001.72.2.160,11288788,Pernu HE; Knuuttila ML,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000911: Antibodies, Monoclonal; D015703: Antigens, CD; D018951: Antigens, CD20; D015214: Antigens, Differentiation, Myelomonocytic; D001402: B-Lymphocytes; D015496: CD4-Positive T-Lymphocytes; D018414: CD8-Positive T-Lymphocytes; D002121: Calcium Channel Blockers; D002452: Cell Count; D003238: Connective Tissue; D016572: Cyclosporine; D004848: Epithelium; D005260: Female; D005881: Gingiva; D019214: Gingival Overgrowth; D006331: Heart Diseases; D006801: Humans; D007124: Immunoenzyme Techniques; D007166: Immunosuppressive Agents; D016030: Kidney Transplantation; D018655: Lymphocyte Count; D016131: Lymphocyte Subsets; D008264: Macrophages; D008297: Male; D009543: Nifedipine; D013223: Statistics as Topic; D018709: Statistics, Nonparametric",,,https://openalex.org/W2010437963,111,12,1,2174,345,11,en,en
false,mitotic activity keratinocytes nifedipine immunosuppressive medication induced gingival overgrowth,purpose study compare mitotic activity basal cell layer normal human gingiva nifedipine immunosuppressive medication induced gingival overgrowth gingival sample collect generally healthy individual nifedipine medicated cardiac patient immunosuppression medicated azathioprine prednisolone cyclosporin organ transplant recipient transplant recipient divide take nifedipine take nifedipine cryostat section stain monoclonal antibody ki use avidin biotin enzyme complex method mitotic activity epithelial cell determine percentage ki label cell relation total number epithelial cell basal layer oral oral sulcular sulcular epithelium mitotic activity significantly high medication group oral epithelium p immunosuppression group sulcular epithelium p control oral sulcular epithelium mitotic activity fairly similar medication group nifedipine group significant negative correlation find duration nifedipine medication percentage ki label cell oral epithelium p result suggest increase epithelial thickness observe nifedipine cyclosporin induced gingival overgrowth associate increased mitotic activity especially oral epithelium,Nurmenniemi PK,2001,J Periodontol,https://doi.org/10.1902/jop.2001.72.2.167,11288789,Nurmenniemi PK; Pernu HE; Knuuttila ML,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D001379: Azathioprine; D002121: Calcium Channel Blockers; D002452: Cell Count; D016572: Cyclosporine; D004847: Epithelial Cells; D004848: Epithelium; D005260: Female; D005881: Gingiva; D019214: Gingival Overgrowth; D005938: Glucocorticoids; D006331: Heart Diseases; D006801: Humans; D007124: Immunoenzyme Techniques; D007166: Immunosuppressive Agents; D015603: Keratinocytes; D019394: Ki-67 Antigen; D008297: Male; D008875: Middle Aged; D008938: Mitosis; D009543: Nifedipine; D016377: Organ Transplantation; D011239: Prednisolone; D013223: Statistics as Topic; D018709: Statistics, Nonparametric",,,https://openalex.org/W1991057166,109,11,1,1537,236,6,en,en
false,follow renal function treated untreated old patient isolated systolic hypertension,background outcome trial provide information renal function old hypertensive patient diuretic blockers mostly use first line drug long term renal effect calcium channel blocker remain unclear objective compare change renal function treat untreated patient isolated systolic hypertension diabetes mellitus proteinuria method perform post hoc analysis double blind placebo controlled systolic hypertension europe syst eur trial active treatment initiate nitrendipine mg day possible addition enalapril mg day hydrochlorothiazide mg day titrate combine reduce sit systolic blood pressure least mmhg less mmhg main outcome measure serum creatinine concentration creatinine clearance calculate formula cockroft gault result serum creatinine concentration time participant randomly allocate study group less mol l mg dl average mol l time last serum creatinine measurement blood pressure difference p two group mmhg intention treat analysis patient years serum creatinine calculated creatinine clearance influence active treatment however patient assign randomly receive active treatment incidence mild renal dysfunction serum creatinine least mmol l decrease p proteinuria p active treatment reduce risk proteinuria diabetic non diabetic patient compare p non proteinuric patient active treatment influence serum creatinine whereas patient proteinuria entry study serum creatinine decrease active treatment p furthermore randomized treatment comparison stratify risk baseline serum creatinine concentration change p patient continue receive monotherapy nitrendipine whereas increase mmol l p patient receive hydrochlorothiazide alone combination study medication p difference trend conclusion old patient isolated systolic hypertension antihypertensive treatment start dihydropyridine calcium channel blocker nitrendipine decrease blood pressure expense renal function prevent development proteinuria especially diabetic patient,Voyaki SM,2001,J Hypertens,https://doi.org/10.1097/00004872-200103000-00020,11288822,Voyaki SM; Staessen JA; Thijs L; Wang JG; Efstratopoulos AD; Birkenhäger WH; de Leeuw PW; Leonetti G; Nachev C; Rodicio JL; Tuomilehto J; Fagard R; Systolic Hypertension in Europe (Syst-Eur) Trial Investigators,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D000959: Antihypertensive Agents; D003404: Creatinine; D048909: Diabetes Complications; D004311: Double-Blind Method; D004656: Enalapril; D005060: Europe; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D007668: Kidney; D008297: Male; D009568: Nitrendipine; D011507: Proteinuria; D013599: Systole,,,https://openalex.org/W2149482089,103,14,1,2699,459,16,en,en
false,efficacy different drug class use initiate antihypertensive treatment black subject,thiazide recommend initiate antihypertensive drug treatment black subjects test efficacy recommendation south african black cohort men woman n age year mean ambulatory daytime diastolic blood pressure mm hg randomize month open label treatment start nifedipine gastrointestinal therapeutic system mg n sustained release verapamil hydrochloride mg n hydrochlorothiazide mg n enalapril maleate mg n target reduce daytime diastolic blood pressure mm hg attain first line drug titrate month medication add regimen receive monotherapy month n patient systolic diastolic decrease daytime blood pressure average mm hg nifedipine mm hg verapamil mm hg hydrochlorothiazide mm hg enalapril month blood pressure patient treat nifedipine control p vs receiving verapamil receiving hydrochlorothiazide receiving enalapril month n patient p continue receive monotherapy nifedipine verapamil hydrochlorothiazide enalapril sustained decrease left ventricular mass p group difference achieve months contrast current recommendation calcium channel blocker effective thiazide initial treatment black subject hypertension treatment start thiazide converting enzyme inhibitor combination therapy likely require control blood pressure reduce left ventricular mass,Sareli P,2001,Arch Intern Med,https://doi.org/10.1001/archinte.161.7.965,11295959,Sareli P; Radevski IV; Valtchanova ZP; Libhaber E; Candy GP; Den Hond E; Libhaber C; Skudicky D; Wang JG; Staessen JA,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D044383: Black People; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003971: Diastole; D004232: Diuretics; D004359: Drug Therapy, Combination; D004656: Enalapril; D005260: Female; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D017379: Hypertrophy, Left Ventricular; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D017410: Practice Guidelines as Topic; D016016: Proportional Hazards Models; D049993: Sodium Chloride Symporter Inhibitors; D013019: South Africa; D013997: Time Factors; D016896: Treatment Outcome; D014665: Vasodilator Agents; D014700: Verapamil",,,https://openalex.org/W2005074656,96,13,1,1908,371,6,en,en
false,clinical feature natural history nonalcoholic steatosis syndrome,nonalcoholic steatohepatitis along form nonalcoholic fatty liver disease chronic liver disease attract increase significance clinicopathologic syndrome originally describe obese diabetic female deny alcohol use hepatic histology consistent alcoholic hepatitis typical patient profile expand recognize occur even normal weight male without overt abnormality carbohydrate metabolism although originally believe benign clinical entity nonalcoholic steatohepatitis recognize cause progressive fibrotic liver disease adverse clinical sequela important emphasize nonalcoholic steatohepatitis best consider one type large spectrum nonalcoholic fatty liver disease consequence insulin resistance range fat alone fat plus inflammation fat plus ballooning degeneration nonalcoholic steatohepatitis latter serious form disease clinical importance nonalcoholic steatohepatitis relate prevalence natural history recent study use different methodology indicate general population prevalence fatty liver nonalcoholic steatohepatitis approximately respectively prevalence rate increase certain subpopulation obesity type ii diabetes great concern recognition cirrhosis liver related death occur approximately patient respectively year period risk factor adverse clinical symptom include patient old age presence diabetes obesity aspartate aminotransferase alanine aminotransferase ratio hepatic histology however number important unresolved issue must clarify true natural history disease fully understood,Falck-Ytter Y,2001,Semin Liver Dis,https://doi.org/10.1055/s-2001-12926,11296693,Falck-Ytter Y; Younossi ZM; Marchesini G; McCullough AJ,article,D016428: Journal Article; D016454: Review,"D002908: Chronic Disease; D003937: Diagnosis, Differential; D018450: Disease Progression; D005234: Fatty Liver; D006801: Humans; D012307: Risk Factors",,,https://openalex.org/W2040538211,73,9,1,1996,316,11,en,en
false,topical diltiazem ointment treatment chronic anal fissure,chronic anal fissure traditionally treat surgically initial enthusiasm chemical sphincterotomy wan poor outcome glyceryl trinitrate ointment study use topical per cent diltiazem ointment investigate alternative method chemical sphincterotomy prospective assessment consecutive patient chronic anal fissure treat per cent topical diltiazem ointment median duration range week performed fifty one patient per cent experience healing fissure month treatment topical diltiazem seventeen patient heal treat week topical diltiazem eight patient subsequently heal diltiazem fifty nine patient complete follow therefore heal diltiazem ointment four patient experience perianal dermatitis one patient experience headache side effects record median range week follow follow completion treatment patient available remain symptom free six seven patient recurrent fissure treat successfully repeat chemical sphincterotomy topical per cent diltiazem ointment use agent chemical sphincterotomy chronic anal fissure offer significant healing rate significant side effect profile may aid compliance treatment early recurrence common usually amenable chemical sphincterotomy,Knight JS,2001,Br J Surg,https://doi.org/10.1046/j.1365-2168.2001.01736.x,11298624,Knight JS; Birks M; Farouk R,article,D016428: Journal Article,"D000287: Administration, Topical; D000293: Adolescent; D000328: Adult; D000368: Aged; D002121: Calcium Channel Blockers; D002648: Child; D002908: Chronic Disease; D004110: Diltiazem; D005260: Female; D005401: Fissure in Ano; D006801: Humans; D008297: Male; D008875: Middle Aged; D009824: Ointments; D011446: Prospective Studies; D016896: Treatment Outcome; D014945: Wound Healing",,,https://openalex.org/W2138824420,67,10,1,1560,249,11,en,en
false,increase dispersion shorten refractoriness cause verapamil chronic atrial fibrillation,objective assess effect ofverapamil atrial fibrillation af cycle length spatial dispersion refractoriness patient chronic af previous study suggest verapamil prevents acute remodel af effect verapamil chronic af unknown electrophysiologic study patient chronic af duration year unipolar electrograms record right atrial free wall right atrial appendage coronary sinus along monophasic action potential recording right atrial appendage mean fibrillatory interval atrial recording site use index local refractoriness dispersion refractoriness calculate standard deviation local mean fibrillatory interval express percentage overall mean fibrillatory interval baseline measurement verapamil mg kg intravenous min infuse measurement repeated administration ofverapamil mean fibrillatory interval shorten mean p right free wall p appendage p coronary sinus monophasic action potential duration decrease p dispersion refractoriness increase patient p strong correlation mean fibrillatory interval action potential duration find verapamil verapamil cause shortening refractoriness increase spatial dispersion refractoriness patient chronic af imply verapamil useful reverse remodel process patient,Ramanna H,2001,J Am Coll Cardiol,https://doi.org/10.1016/s0735-1097(01)01132-9,11300453,Ramanna H; Elvan A; Wittkampf FH; de Bakker JM; Hauer RN; Robles de Medina EO,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D001281: Atrial Fibrillation; D002908: Chronic Disease; D004562: Electrocardiography; D005260: Female; D006325: Heart Atria; D006801: Humans; D007262: Infusions, Intravenous; D008297: Male; D008875: Middle Aged; D017211: Treatment Failure; D014700: Verapamil",,,https://openalex.org/W1982263626,100,12,1,1747,297,9,en,en
false,retrospective analysis compare cost cost effectiveness amlodipine enalapril treatment hypertension,comparison treatment cost cost effectiveness perform retrospectively use patient level data randomize control one year clinical trial amlodipine enalapril treatment mild moderate hypertension unit cost amlodipine enalapril apply daily dosage individual patient calculate total cost average cost per patient treatment group clinical trial intent treat basis efficacy rate use calculate average treatment cost per success blood pressure control although statistically significant amlodipine treatment result high efficacy vs enalapril average cost per amlodipine treated patient consistently low enalapril treated patient week treatment amlodipine result average cost per success per patient compare per enalapril treated patient sensitivity analysis reveal treatment mild moderate hypertension week treatment period amlodipine would remain less costly enalapril decrease cost enalapril would remain cost effective decrease cost enalapril,Doyle J,2001,Manag Care Interface,,11301961,Doyle J; Omvik P; Arikian S; Casciano J; Casciano R; Gonzalez MA; Arocho R,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D017311: Amlodipine; D000959: Antihypertensive Agents; D017281: Cost of Illness; D003362: Cost-Benefit Analysis; D016527: Drug Costs; D004359: Drug Therapy, Combination; D004656: Enalapril; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D012189: Retrospective Studies; D016896: Treatment Outcome; D014481: United States",,,https://openalex.org/W2396694557,129,19,1,1288,217,7,en,en
true,effect pretreatment verapamil early recurrence electrical cardioversion persistent atrial fibrillation randomised study,atrial fibrillation af common arrhythmia increase prevalence patient old years time tend become persistent chronic even underlying structural heart disease present evidence af promotes af emerges fact success rate electrical cardioversion maintenance sinus rhythm highly dependent duration previous af episode possible explanation epidemiological clinical observation apart progressive change cause underlie cardiovascular disease concept electrical remodelling atrium af cause progressive electrophysiological structural change atrium promote initiation perpetuation af phenomenon af beget af first describe goat model atrial electrical remodelling induce af seem develop quickly progressive completely reversible within one week restoration sinus rhythm date many report confirm presence atrial electrical remodelling short long term af rapid atrial pacing animal models human time course appearance reversal atrial electrical remodelling resembles see goat dogs mechanism behind phenomenon yet clarify indication intracellular calcium overload play important role animal human model verapamil administer rapid atrial pacing short episode artificially induce af reduce atrial electrical remodelling contrast pretreatment verapamil result shortening refractory period human animal long last af two study find use calcium antagonist blocker reduces,Bertaglia E,2001,Heart,https://doi.org/10.1136/heart.85.5.578,11303016,Bertaglia E; D'Este D; Zanocco A; Zerbo F; Pascotto P,article,D016430: Clinical Trial; D016422: Letter; D016449: Randomized Controlled Trial,D000368: Aged; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D002121: Calcium Channel Blockers; D004554: Electric Countershock; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D012008: Recurrence; D014700: Verapamil,,,https://openalex.org/W2018029794,144,19,1,1899,312,4,en,en
false,clinical outcome aneurysmal subarachnoid hemorrhage patient treat oral diltiazem limit intensive care management,background aneurysmal subarachnoid hemorrhage sah patient frequently treat prophylactic nimodipine undergo invasive monitoring blood pressure volume status intensive care unit icu set decrease incidence delayed ischemic neurological deficit dind improve functional outcome goal study examine incidence dind poor functional outcome consecutive series sah patient treat different regimen prophylactic oral diltiazem limited use intensive care monitoring method study involve consecutive series aneurysmal sah patient treat senior author admit within hour hemorrhage never receive nimodipine nicardipine functional outcome grade use glasgow outcome scale go result patient identify favorable outcome gos achieve incidence dind hypertensive hypervolemic hemodilutional hhh therapy use patient patient treat dind endovascular mean seven patient poor functional outcome death dind two relate complication hhh therapy result compare contemporary series sah patient manage treatment protocol conclusion functional outcome patient treat regimen oral diltiazem limited use icu monitoring hhh therapy dind compare favorably contemporary series sah patient,Papavasiliou AK,2001,Surg Neurol,https://doi.org/10.1016/s0090-3019(01)00364-0,11311906,Papavasiliou AK; Harbaugh KS; Birkmeyer NJ; Feeney JM; Martin PB; Faccio C; Harbaugh RE,article,"D016430: Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D002545: Brain Ischemia; D004110: Diltiazem; D005260: Female; D006304: Health Status; D006801: Humans; D007362: Intensive Care Units; D002532: Intracranial Aneurysm; D008297: Male; D008875: Middle Aged; D008991: Monitoring, Physiologic; D009422: Nervous System Diseases; D013345: Subarachnoid Hemorrhage; D016896: Treatment Outcome; D014665: Vasodilator Agents",,,https://openalex.org/W2093684793,130,16,1,1576,271,10,en,en
false,pharmacologic therapy persistent pulmonary hypertension newborn,persistent pulmonary hypertension newborn pphn potentially life threatening condition characterize failure pulmonary vascular resistance decrease adequately transition extrauterine life inhale nitric oxide vasodilator act selectively pulmonary circulation revolutionize treatment condition however inhale nitric oxide prove effective patient particularly congenital diaphragmatic hernia meconium aspiration syndrome furthermore large clinical trial inhaled nitric oxide fail demonstrate significant difference mortality nitric oxide treated control infant pphn therapeutic approach pphn limit relative lack specificity pulmonary circulation receive much less attention pharmacologic approach include pulmonary surfactant prostacyclin endothelin antagonist ca channel blocker magnesium sulfate tolazoline exhibit vary degree efficacy lower pulmonary vascular pressure human animal number agent also effective use combination example phosphodiesterase inhibitor report act synergistically inhaled nitric oxide surfactant also appear useful pphn particularly patient congenital diaphragmatic hernia use combination therapy surfactant lavage novel therapy may also effective combination therapy meconium aspiration syndrome study direct define optimal therapy specific clinical setting validation multiple therapeutic modality pphn include inhale nitric oxide allow rational combined vasodilator strategy specific underlying pathophysiology patient,Weinberger B,2001,Pharmacol Ther,https://doi.org/10.1016/s0163-7258(00)00104-2,11316514,Weinberger B; Weiss K; Heck DE; Laskin DL; Laskin JD,article,D016428: Journal Article; D016454: Review,"D000893: Anti-Inflammatory Agents; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D011464: Epoprostenol; D006801: Humans; D007231: Infant, Newborn; D008471: Meconium Aspiration Syndrome; D009569: Nitric Oxide; D010547: Persistent Fetal Circulation Syndrome; D010726: Phosphodiesterase Inhibitors; D011453: Prostaglandins; D014665: Vasodilator Agents",,,https://openalex.org/W2036799356,73,9,1,1909,286,12,en,en
false,chronotherapeutic delivery verapamil obese versus non obese patient essential hypertension,background effect controlled onset extended release coer verapamil haemodynamic parameter obese non obese patient evaluate analysis method data pool three clinical trial evaluate efficacy tolerability coer verapamil hypertensive men woman stage iii randomise coer verapamil mg bedtime placebo week stratify accord body mass index bmi obese kg efficacy assess change baseline blood pressure bp heart rate rate pressure product four time period throughout dosing interval safety tolerability assess monitor adverse event change metabolic laboratory parameter result reduction haemodynamic parameter significantly great follow coer verapamil compare placebo time period haemodynamic effect coer verapamil obese n bmi kg non obese patient n bmi kg similar coer verapamil well tolerate subgroup incidence constipation significantly less obese patient p conclusion coer verapamil effective reduce bp heart rate rate pressure product independently bmi,White WB,2001,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1001137,11317194,White WB; Elliott WJ; Johnson MF; Black HR,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000368: Aged; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D015992: Body Mass Index; D002121: Calcium Channel Blockers; D019454: Chronotherapy; D003692: Delayed-Action Preparations; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009765: Obesity; D014700: Verapamil",,,https://openalex.org/W1986625965,102,12,1,1308,224,9,en,en
false,effect fosinopril sustained release verapamil blood pressure serum catecholamine concentration elderly hypertensive men,randomized double blind placebo controlled clinical trial show elderly hypertensive men study uncomplicated beneficial response either fosinopril verapamil well tolerated reduction systolic blood pressure sbp diastolic blood pressure drp significant adverse drug event sit sbp sit dbp significantly lower fosinopril verapamil sr reduction sbp dbp elderly hypertensive show beneficial finding take importance consider choice medication antihypertensive therapy elderly increase norepinephrine fosinopril treated patient may explain patient treat long term angiotensin converting enzyme inhibitor alone combination diuretic rarely complain orthostatic symptom,Williams LS,2000,Am J Ther,https://doi.org/10.1097/00045391-200007010-00002,11319567,Williams LS; Hill D; Davis J; Lowenthal DT,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D001795: Blood Pressure Determination; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004837: Epinephrine; D017328: Fosinopril; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009638: Norepinephrine; D014700: Verapamil,,,https://openalex.org/W2069593288,137,17,1,922,146,5,en,en
false,improve efficacy safety controlled release diltiazem compare nifedipine may relate negative chronotropic effect,objective study assess safety efficacy long acting preparation two commonly use calcium antagonist particular reference effect heart rate twenty patient chronic stable angina recruit double blind double dummy crossover study controlled release diltiazem diltiazem cr versus sustained release nifedipine nifedipine sr underwent clinical assessment symptom adverse event reporting repeat treadmill exercise test week period main outcome measure heart rate rest exercise incidence angina nitroglycerin use treadmill exercise performance duration time angina time mm st segment depression heart rate equivalent maximal exercise maximal st segment depression adverse event diltiazem cr significantly reduce heart rate rest equivalent exercise incidence angina nitroglycerin use compare nifedipine sr exercise duration time angina time mm st segment depression maximal st segment depression significantly improve diltiazem cr diltiazem cr also cause significantly adverse event nifedipine sr calcium antagonist negative chronotropic effect eg diltiazem cr safe efficacious monotherapy chronic stable angina dihydropyridines eg nifedipine sr even long acting formulation latter use,Basu SK,2000,Am J Ther,https://doi.org/10.1097/00045391-200007010-00004,11319569,Basu SK; Kinsey CD; Miller AJ; Lahiri A,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D003864: Depression, Chemical; D004110: Diltiazem; D004311: Double-Blind Method; D004562: Electrocardiography; D005080: Exercise Test; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D009543: Nifedipine",,,https://openalex.org/W1998810824,134,18,1,1477,237,6,en,en
false,effect chlorthalidone diltiazem myocardial ischemia elderly patient hypertension coronary artery disease,antihypertensive therapy thiazide decrease coronary event elderly patient however influence diuretic myocardial ischemia fully investigate aim study compare effect chlorthalidone diltiazem myocardial ischemia following randomize double blind crossover protocol study elderly hypertensive patient age year myocardial ischemia patient angiographically document coronary artery disease measure patient use hour ambulatory electrocardiogram monitoring exercise testing week period use placebo patient receive chlorthalidone diltiazem weeks treatment lower systolic diastolic blood pressure number ischemic episode ambulatory electrocardiogram recording reduce use chlorthalidone diltiazem compare placebo p total duration ischemic episode reduce treatment compare placebo chlorthalidone min diltiazem min placebo min p elderly hypertensive patient coronary artery disease chlorthalidone reduce myocardial ischemia similarly diltiazem result consistent epidemiological study suggest reduction arterial blood pressure thiazide therapy play important role decrease myocardial ischemia,Serro-Azul JB,2001,Arq Bras Cardiol,https://doi.org/10.1590/s0066-782x2001000400001,11323730,Serro-Azul JB; de Paula RS; Gruppi C; Pinto L; Pierri H; Nussbacher A; Gebara O; Moffa P; Pereira-Barreto AC; Wajngarten M,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002752: Chlorthalidone; D003327: Coronary Disease; D004110: Diltiazem; D004232: Diuretics; D004311: Double-Blind Method; D015716: Electrocardiography, Ambulatory; D005080: Exercise Test; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D017202: Myocardial Ischemia",,,https://openalex.org/W2132661728,128,17,1,1474,221,9,en,en
false,effect acute blood pressure reduction endothelial function brachial artery patient essential hypertension,evaluate effect acute blood pressure reduction endothelium dependent vasodilation peripheral circulation essential hypertensive patients parallel group study endothelial function measure essential hypertensive patient h treatment nifedipine mg n captopril mg n p randomly assigned hypertensive patient evaluate flow mediated endothelium dependent dilation fmd high resolution ultrasound brachial artery compare endothelium independent response glyceryl trinitrate gtn microg l automatic computerized analysis use measure brachial artery diameter end diastolic frame acquire every second study sixty six healthy normotensive subject also evaluate assess presence endothelial dysfunction hypertensive patients hypertensive patient show significantly p low fmd compare healthy control response gtn similar normotensive subject hypertensive patient baseline brachial artery diameter fmd response gtn similar nifedipine captopril treated group nifedipine captopril similarly reduce blood pressure nifedipine increase heart rate acute nifedipine captopril significantly p increase brachial artery diameter fmd response gtn modify nifedipine captopril endothelial dysfunction brachial artery essential hypertensive patient improve acute blood pressure reduction,Ghiadoni L,2001,J Hypertens,https://doi.org/10.1097/00004872-200103001-00005,11327628,Ghiadoni L; Huang Y; Magagna A; Buralli S; Taddei S; Salvetti A,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001794: Blood Pressure; D001916: Brachial Artery; D002121: Calcium Channel Blockers; D002216: Captopril; D003326: Coronary Circulation; D004730: Endothelium, Vascular; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D005996: Nitroglycerin; D012016: Reference Values; D014463: Ultrasonography; D014664: Vasodilation; D014665: Vasodilator Agents",,,https://openalex.org/W2000002665,127,18,1,1656,275,7,en,en
true,risk limb deficiency congenital abnormality child expose utero calcium channel blocker,calcium channel blocker give pregnant rat show increased prevalence digital limb defect safety pregnant woman thus question examine risk malformation follow exposure utero calcium channel blockers conduct nationwide case control study base hungarian case control surveillance congenital abnormality identify case congenital abnormality population control period data drug exposure obtain official questionnaire obligatory prenatal care logbooks among case mother expose calcium channel blocker pregnancy compare control overall prevalence ratio congenital abnormality vary significant increase risk limb deficiency congenital abnormalities data indicate increased prevalence congenital abnormality offspring expose calcium channel blocker utero,Sørensen HT,2001,Acta Obstet Gynecol Scand,https://doi.org/10.1034/j.1600-0412.2001.d01-4.x,11328214,Sørensen HT; Czeizel AE; Rockenbauer M; Steffensen FH; Olsen J,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000014: Abnormalities, Drug-Induced; D000328: Adult; D002121: Calcium Channel Blockers; D016022: Case-Control Studies; D005260: Female; D006801: Humans; D006814: Hungary; D007231: Infant, Newborn; D017880: Limb Deformities, Congenital; D011247: Pregnancy; D011249: Pregnancy Complications, Cardiovascular; D011297: Prenatal Exposure Delayed Effects; D015995: Prevalence; D012307: Risk Factors; D011795: Surveys and Questionnaires",,,https://openalex.org/W2007040049,121,18,1,1067,161,4,en,en
false,amlodipine benazepril fix dose combination therapy hypertension,myocardial infarction stroke heart failure end stage renal disease link inadequate control blood pressure despite overwhelming evidence uncontrolled hypertension responsible sizeable number adverse health related outcome control disease remain considerably suboptimal available data demonstrate order achieve adequate blood pressure control large number patient require therapy one medication fix dose combination antihypertensive therapy many advantage treatment option positive effect blood pressure control rate adherence adverse effect cost identify amlodipine benazepril lotrel novartis fixed dose combination product indicate treatment hypertension although currently recommend first line therapy study confirm combination long acting calcium antagonist angiotensin converting enzyme ace inhibitor possess substantial blood pressure lower capability whereas adverse event tend become frequent increase dos antihypertensive monotherapy rate adverse event attribute amlodipine benazepril clinical trial often correlate rate ascribe placebo amlodipine benazepril capable sustain blood pressure control h period appear minimally affect occasional dose omission unlike old calcium antagonist amlodipine unlikely cause alteration myocardial contractility additionally amlodipine benazepril combination product cost less therapy administer individual component therefore reasonable consider therapy amlodipine benazepril appropriate patient adequate trial antihypertensive monotherapy,Faulkner MA,2001,Expert Opin Pharmacother,https://doi.org/10.1517/14656566.2.1.165,11336577,Faulkner MA; Hilleman DE,article,D003160: Comparative Study; D016428: Journal Article; D016454: Review,D017311: Amlodipine; D000959: Antihypertensive Agents; D001552: Benzazepines; D001794: Blood Pressure; D002986: Clinical Trials as Topic; D004338: Drug Combinations; D006801: Humans; D006973: Hypertension; D016896: Treatment Outcome,,,https://openalex.org/W2134524475,70,8,1,1860,273,12,en,en
false,current status antihypertensive treatment new millennium,short review present historical perspective treatment hypertension highlight current issue look possible future antihypertensive therapy distribution blood pressure within population adopt continuous albeit somewhat skewed distribution constitute hypertension conventionally disease define level blood pressure mmhg accept arbitrary definition infers approximately one quarter adult population u hypertensive significant implication term impact upon public health know treatment hypertension prevent serious consequence cardiovascular disease stroke myocardial infarction mi heart failure renal disease thus important raise blood pressure detected effectively lower level blood pressure reduce conventionally level mmhg use define normotension indication certain circumstance target question also arise whether matter blood pressure treat choice agent may ultimately depend upon presence concomitant condition risk factor recent trial evidence conclude therapy select treat raise blood pressure take account overall cardiovascular risk profile patient,Hardman TC,2001,Expert Opin Pharmacother,https://doi.org/10.1517/14656566.2.5.731,11336618,Hardman TC; Lunnon MW,article,D016421: Editorial; D016454: Review,D000959: Antihypertensive Agents; D002986: Clinical Trials as Topic; D006801: Humans; D006973: Hypertension,,,https://openalex.org/W2103482720,74,11,1,1470,251,12,en,en
false,contemporary management chronic stable angina,chronic stable angina common condition prognosis less benign generally appreciate optimal treatment strategy disorder unclear anti ischaemic agent rigorously test prospectively randomise mortality study evidence base anti ischaemic therapy chronic angina draw upon data borrowed study acute coronary syndrome study chronic angina use surrogate endpoint ambulatory silent ischaemia evidence lead u believe anti ischaemic therapy beta blockers offer mortality benefit chronic angina contrast mortality benefit lipid lower therapy antiplatelet agent well proven angioplasty offer mortality benefit treatment chronic angina although effective medical therapy alone relief symptom patient high order proximal coronary disease coronary bypass surgery offer distinct mortality advantage compare medical treatment alone patient however warrant approach require surgery remain symptomatic despite adequate medical therapy alternative strategy cardiac transplantation transmyocardial laser revascularisation spinal cord stimulation accept subgroup patient treatment chronic angina refractory standard therapy,Staniforth AD,2001,Drugs Aging,https://doi.org/10.2165/00002512-200118020-00004,11346125,Staniforth AD,article,D016428: Journal Article; D016454: Review,D000787: Angina Pectoris; D002908: Chronic Disease; D006801: Humans; D009204: Myocardial Revascularization; D013927: Thrombosis,,,https://openalex.org/W1963666403,48,6,1,1445,227,9,en,en
false,diltiazem treatment alter renal function thoracic surgery,background conflict report effect diltiazem treatment renal function surgical patient seek determine whether diltiazem treatment alters renal function patient undergo major thoracic surgery method prospective study patient schedule elective thoracic surgery receive either iv diltiazem n placebo n immediately operation orally thereafter day effort prevent postoperative atrial arrhythmia serum creatinine bun level compare first postoperative week result patient treat diltiazem similar control subject term age mean sd year vs year respectively baseline serum creatinine bun level prevalence comorbid condition surgical characteristic first postoperative day two group differ term serum creatinine bun level incidence renal failure diltiazem group placebo group difference significant difference length hospitalization mortality rate conclusion patient without renal disease undergo elective thoracic surgery prophylactic diltiazem treatment alter postoperative renal function conflict report effect diltiazem treatment renal function surgical patient seek determine whether diltiazem treatment alters renal function patient undergo major thoracic surgery prospective study patient schedule elective thoracic surgery receive either iv diltiazem n placebo n immediately operation orally thereafter day effort prevent postoperative atrial arrhythmia serum creatinine bun level compare first postoperative week patient treat diltiazem similar control subject term age mean sd year vs year respectively baseline serum creatinine bun level prevalence comorbid condition surgical characteristic first postoperative day two group differ term serum creatinine bun level incidence renal failure diltiazem group placebo group difference significant difference length hospitalization mortality rate patient without renal disease undergo elective thoracic surgery prophylactic diltiazem treatment alter postoperative renal function,Amar D,2001,Chest,https://doi.org/10.1378/chest.119.5.1476,11348956,Amar D; Fleisher M,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D002317: Cardiovascular Agents; D004110: Diltiazem; D005260: Female; D006801: Humans; D007674: Kidney Diseases; D008297: Male; D011013: Pneumonectomy; D011183: Postoperative Complications; D011446: Prospective Studies,,,https://openalex.org/W2014844076,72,10,1,2644,458,18,en,en
false,amlodipin versus nifedipin retard eine randomisierte doppelblindstudie zum vergleich der langzeitwirksamkeit und vertr glichkeit von amlodipin und nifedipin retard der monotherapie der chronisch stabilen angina pectoris,patient method double blind study compare efficacy safety daily amlodipine mg day v twice daily nifedipine mg day patient chronic stable angina pectoris efficacy assess week bicycle exercise test result statistically significant difference find two treatment group end treatment regard ergometry parameter determine maximum st segment deviation maximum workload watt maximum exercise duration time mv st segment depression furthermore two treatment group comparable regard effect reduction anginal attack short act nitrate consumption incidence adverse event lower amlodipine relative nifedipine group vs conclusion result study show daily amlodipine offer comparable antianginal antiischemic efficacy twice daily sustain release nifedipine monotreatment chronic stable angina pectoris give low incidence adverse event amlodipine convenient daily dose regimen however amlodipine may help enhance patient compliance,Sauerbrey-Wullkopf N,2001,Herz,https://doi.org/10.1007/pl00002015,11349617,Sauerbrey-Wullkopf N; Kupper W,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D017311: Amlodipine; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D002908: Chronic Disease; D003627: Data Interpretation, Statistical; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004562: Electrocardiography; D005080: Exercise Test; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D010349: Patient Compliance; D013997: Time Factors; D014665: Vasodilator Agents",,,https://openalex.org/W2469402976,222,26,1,1229,205,7,de,en
false,effect amlodipine baroreflex sympathetic nervous system activity mild moderate hypertension,investigate effect amlodipine baroreflex sensitivity sympathetic system activity patient essential hypertension randomize daily double blind treatment amlodipine mg placebo mg day measurement finapres device allow calculation baroreflex sensitivity blood pressure bp variability adrenergic activity assess via measurement lymphocyte beta adrenoceptors plasma catecholamine concentration compare placebo amlodipine significantly decrease bp significantly alter baroreflex sensitivity spectral analysis finapres data show compare placebo amlodipine decrease variability systolic blood pressure diastolic blood pressure rr interval low frequency band simultaneous change adrenergic function however suggest effect amlodipine mediate via sympathetic nervous system activation,Siché JP,2001,Am J Hypertens,https://doi.org/10.1016/s0895-7061(00)01258-9,11368462,Siché JP; Baguet JP; Fagret D; Trémel F; de Gaudemaris R; Mallion JM,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D017704: Baroreflex; D001794: Blood Pressure; D002395: Catecholamines; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D018343: Receptors, Adrenergic, beta-2; D013564: Sympathetic Nervous System",,,https://openalex.org/W2058780070,108,13,1,982,147,6,en,en
true,effect ramipril v amlodipine renal outcome hypertensive nephrosclerosis subtitle randomize control trial subtitle,incidence end stage renal disease due hypertension increase recent decade optimal strategy treatment hypertension prevent renal failure unknown especially among african americans compare effect angiotensin converting enzyme ace inhibitor ramipril dihydropyridine calcium channel blocker amlodipine beta blocker metoprolol hypertensive renal disease progression interim analysis randomized double blind x factorial trial conduct african american age year hypertensive renal disease glomerular filtration rate gfr ml min per enrol february september report compare ramipril amlodipine group follow discontinuation amlodipine intervention september participants randomly assign receive amlodipine mg n ramipril mg n metoprolol mg n agent add achieve blood pressure goals primary outcome measure rate change gfr main secondary outcome composite index clinical end point reduction gfr ml min per end stage renal disease death among participant urinary protein creatinine ratio correspond approximately proteinuria mg ramipril group se ml min per slow mean decline gfr year p reduce risk clinical end point vs amlodipine group confidence interval ci entire cohort significant difference mean gfr decline baseline year treatment group p however compare amlodipine group adjustment baseline covariates ramipril group reduce risk clinical end point ci slow mean decline gfr month p less proteinuria p ramipril compare amlodipine retard renal disease progression patient hypertensive renal disease proteinuria may offer benefit patient without proteinuria,Agodoa LY,2001,JAMA,https://doi.org/10.1001/jama.285.21.2719,11386927,Agodoa LY; Appel L; Bakris GL; Beck G; Bourgoignie J; Briggs JP; Charleston J; Cheek D; Cleveland W; Douglas JG; Douglas M; Dowie D; Faulkner M; Gabriel A; Gassman J; Greene T; Hall Y; Hebert L; Hiremath L; Jamerson K; Johnson CJ; Kopple J; Kusek J; Lash J; Lea J; Lewis JB; Lipkowitz M; Massry S; Middleton J; Miller ER; Norris K; O'Connor D; Ojo A; Phillips RA; Pogue V; Rahman M; Randall OS; Rostand S; Schulman G; Smith W; Thornley-Brown D; Tisher CC; Toto RD; Wright JT; Xu S; African American Study of Kidney Disease and Hypertension (AASK) Study Group,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000319: Adrenergic beta-Antagonists; D000328: Adult; D001741: Black or African American; D000368: Aged; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D005260: Female; D005919: Glomerular Filtration Rate; D006801: Humans; D006973: Hypertension; D007676: Kidney Failure, Chronic; D008297: Male; D008790: Metoprolol; D008875: Middle Aged; D009400: Nephrosclerosis; D016016: Proportional Hazards Models; D011507: Proteinuria; D017257: Ramipril",,,https://openalex.org/W2147804563,144,29,1,2251,442,4,en,en
true,randomized double blind comparison isradipine spirapril monotherapy combination decline renal function patient chronic renal failure hypertension,treatment hypertension patient chronic renal failure show postpone decline renal function treatment ace inhibitor show superior conventional antihypertensive treatment know ace inhibitor compare treatment calcium channel blocker treatment combination drug aim study evaluate rate decline gfr patient chronic renal failure hypertension treat isradipine spirapril monotherapy combination sixty patient chronic renal failure hypertension enrol study enrollment patient follow prospectively month outpatient clinic usual antihypertensive medication randomize double blinded comparison either spirapril mg daily isradipine mg daily spirapril mg isradipine mg daily randomization patient follow month need dialysis every month month randomization glomerular filtration rate measure cr edta clearance effective renal plasma flow evaluate use renal clearance paraaminohippuric acid blood pressure decline glomerular filtration rate differ group randomization randomization mean decline glomerular filtration rate ml min x month x spirapril group ml min x month x isradipine group ml min x month x combination group p twelve patient group reach end stage renal failure significant difference find respect diastolic p systolic blood pressure p treatment period trend towards good blood pressure control combination group present treatment rate decline renal plasma flow differ significantly group p neither change filtration fraction ff p mean ff p treatment study indicate difference treatment modality favor combined therapy respect rate decline gfr blood pressure control difference insignificant thus treatment might differ unable confirm large variation gfr small sample size,Petersen LJ,2001,Clin Nephrol,,11393383,Petersen LJ; Petersen JR; Talleruphuus U; Møller ML; Ladefoged SD; Mehlsen J; Jensen HA,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D018450: Disease Progression; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004656: Enalapril; D005260: Female; D005919: Glomerular Filtration Rate; D006801: Humans; D006977: Hypertension, Renal; D017275: Isradipine; D007668: Kidney; D007676: Kidney Failure, Chronic; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D017596: Renal Plasma Flow, Effective",,,https://openalex.org/W2406431170,192,29,1,2501,450,11,en,en
false,isradipine improve endothelium dependent vasodilation normotensive coronary artery disease patient hypercholesterolemia,dihydropyridine calcium antagonist isradipine anti atherosclerotic effect animal improve endothelium mediated nitric oxide dependent vasodilation vitro improved endothelial function may beneficial investigate effect patient high likelihood endothelial dysfunction thirty patient two female age year know coronary artery disease elevate mmol l total cholesterol cholesterol mean mmol l cholesterol high density lipoprotein hdl ratio lipid lower therapy participate study endothelial vasodilator function assess double blind randomize administration isradipine mg day placebo months endothelial function assess forearm blood flow fbf venous occlusion plethysmography responses grade brachial artery infusion acetylcholine ach synthase blocker ng monomethyl l arginine l nmma endothelium independent vasodilator sodium nitroprusside snp blood pressure measure either directly brachial arterial sphygmomanometer clinic visits blood pressure unchanged group month isradipine versus mmhg placebo versus mmhg n cholesterol level decrease similarly group isradipine versus mmol l ns placebo versus mmol l p vasodilator response snp decrease fbf response blockade synthesis l nmma unchanged group however isradipine placebo enhance dependent vasodilator response ach p isradipine improve acetylcholine mediated vasodilation hypercholesterolemic patient independent change lipid blood pressure,Bracht C,2001,J Hypertens,https://doi.org/10.1097/00004872-200105000-00010,11393673,Bracht C; Yan XW; Brunner-LaRocca HP; Sütsch G; Amann FW; Kiowski W,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D001794: Blood Pressure; D002784: Cholesterol; D003327: Coronary Disease; D004311: Double-Blind Method; D004730: Endothelium, Vascular; D005542: Forearm; D006801: Humans; D006937: Hypercholesterolemia; D017275: Isradipine; D008297: Male; D008875: Middle Aged; D012016: Reference Values; D014664: Vasodilation; D014665: Vasodilator Agents",,,https://openalex.org/W2334245785,129,12,1,1831,299,6,en,en
false,heart rate lowering calcium antagonist hypertensive post myocardial infarction patient,analyse effect heart rate lowering calcium antagonist hypertensive post myocardial infarction patients three large randomized placebo controlled secondary prevention trial investigate verapamil diltiazem first second danish verapamil infarction trial multicentre diltiazem post infarction trial data total hypertensive post myocardial infarction patient drug placebo pool assess effect blinded therapy mortality event rates treatment heart rate lowering calcium antagonist associate significant reduction event rate versus risk ratio rr confidence interval ci p mortality rate treatment group versus control group rr ci p among subset hypertensive patient without pulmonary congestion reduction mortality rate versus control group rr p significant reduction event rate versus control group rr p patient pulmonary congestion hypertension however calcium antagonist associate increase mortality rr p event rate rr adjustment significant covariates rr mortality treatment versus control group p event rate rr p heart rate lowering calcium antagonist decrease event rate hypertensive post myocardial infarction patient without pulmonary congestion,Messerli FH,2001,J Hypertens,https://doi.org/10.1097/00004872-200105000-00019,11393682,Messerli FH; Hansen JF; Gibson RS; Schechtman KB; Boden WE,article,"D016428: Journal Article; D017418: Meta-Analysis; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D002121: Calcium Channel Blockers; D004110: Diltiazem; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008171: Lung Diseases; D008297: Male; D008875: Middle Aged; D015337: Multicenter Studies as Topic; D009203: Myocardial Infarction; D016032: Randomized Controlled Trials as Topic; D014700: Verapamil,,,https://openalex.org/W1966893077,91,9,1,1639,293,6,en,en
false,prevalence risk gingival enlargement patient treat nifedipine,background gingival enlargement known side effect nifedipine use study conduct determine prevalence risk factor gingival enlargement nifedipinetreated patient method cross sectional study conduct primary care center data patient take nifedipine compare control never receive drug patient examine presence gingival enlargement use different index vertical gingival overgrowth index go point around tooth horizontal mb index interdental area gingival index plaque index probe depth also evaluate result prevalence gingival enlargement significantly high nifedipine treated case control go index versus mb index versus respectively high gingival plaque index observe patient take nifedipine among possible risk factor gingival index show significant association gingival enlargement risk odds ratio gingival enlargement associate nifedipine therapy go index mb index gingival index adjusted respectively subset high nifedipine exposure patient odds ratio gingival enlargement increase go index mb index concordance go mb index show kappa value control patient treat nifedipine conclusion patient take nifedipine high risk gingival enlargement gingivitis act predisposing factor j periodontol,Miranda J,2001,J Periodontol,https://doi.org/10.1902/jop.2001.72.5.605,11394395,Miranda J; Brunet L; Roset P; Berini L; Farré M; Mendieta C,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000704: Analysis of Variance; D002121: Calcium Channel Blockers; D003430: Cross-Sectional Studies; D003774: Dental Plaque Index; D005260: Female; D005881: Gingiva; D019214: Gingival Overgrowth; D005888: Gingival Pocket; D005891: Gingivitis; D006801: Humans; D008297: Male; D008875: Middle Aged; D015999: Multivariate Analysis; D009543: Nifedipine; D016017: Odds Ratio; D010512: Periodontal Index; D015995: Prevalence; D012307: Risk Factors; D013223: Statistics as Topic; D013997: Time Factors; D014665: Vasodilator Agents",,,https://openalex.org/W2160837086,79,11,1,1759,317,15,en,en
false,amiodarone versus diltiazem rate control critically ill patient atrial tachyarrhythmias,objective compare rate lowering effect diltiazem two amiodarone regimen critically ill patient recent onset atrial tachyarrhythmias design prospective randomize control study set medical cardiologic intensive care unit university hospital patient sixty critically ill patient acute physiology chronic health evaluation apache iii score age yr intervention patient atrial fibrillation n atrial flutter n atrial tachycardia n heart rate consistently beats min min randomly assign one three intravenous treatment regimen group receive diltiazem mg bolus follow continuous infusion mg hr hr group receive amiodarone mg bolus group receive amiodarone mg bolus follow mg hr hr measurement main result primary study end point rate reduction within hr secondary study end point heart rate beats min patient consider uncontrolled tachycardia heart rate beats min hr study drug primary study end point achieve patient group respectively p uncontrolled tachycardia frequently observe group patient group respectively p patient achieve tachycardia control diltiazem show significantly well rate reduction p group vs group p time p group vs group p time compare amiodarone group premature drug discontinuation due hypotension require significantly often group group respectively p conclusion sufficient rate control achieve critically ill patient atrial tachyarrhythmias use either diltiazem amiodarone although diltiazem allow significantly good hr heart rate control effect offset significantly high incidence hypotension require discontinuation drug amiodarone may alternative patient severe hemodynamic compromise,Delle Karth G,2001,Crit Care Med,https://doi.org/10.1097/00003246-200106000-00011,11395591,Delle Karth G; Geppert A; Neunteufl T; Priglinger U; Haumer M; Gschwandtner M; Siostrzonek P; Heinz G,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D018806: APACHE; D000368: Aged; D000638: Amiodarone; D000704: Analysis of Variance; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D001282: Atrial Flutter; D002121: Calcium Channel Blockers; D016009: Chi-Square Distribution; D016638: Critical Illness; D004110: Diltiazem; D005260: Female; D006339: Heart Rate; D006801: Humans; D007362: Intensive Care Units; D008297: Male; D011446: Prospective Studies; D016896: Treatment Outcome,,,https://openalex.org/W2025359411,100,13,1,2337,472,15,en,en
false,heart failure prophesy revisit,november ask write article predict status heart failure management katz heart failure prophesy j cardiol c c abstract full text pdf pubmed scopus google scholar past decade see many remarkable case counterintuitive development management clinical syndrome seem useful examine prediction light today understanding heart failure exercise may provide clue regard treatment strategy may emerge next year,Katz AM,2001,Am J Cardiol,https://doi.org/10.1016/s0002-9149(01)01557-0,11397358,Katz AM,article,D016420: Comment; D016421: Editorial,D005544: Forecasting; D005786: Gene Expression Regulation; D006333: Heart Failure; D006801: Humans; D013677: Medical Laboratory Science; D009200: Myocardial Contraction; D014661: Vasoconstriction; D014882: Water-Electrolyte Balance,,,https://openalex.org/W2045161474,43,8,1,589,110,5,en,en
false,tocolysis calcium channel blockers,evaluate use calcium channel blockers ccbs tocolysis review literature retrieve medline database deal fetal toxicity efficacy ccbs compare beta adrenergic agonists data fetal toxicity animal inconsistent teratologic effect observe early pregnancy supratherapeutic dosage usual therapeutic dosage fetal abnormality observe efficacy cbs tocolysis superior beta adrenergic drug allow reduction neonatal morbidity calcium channel blocker well tolerate beta adrenergic agonists published data suggest ccbs could use first line tocolytic agent although use ccbs extremely simple prescribe low risk outpatient,Tsatsaris V,2001,J Gynecol Obstet Biol Reprod (Paris),,11398000,Tsatsaris V; Carbonne B,article,D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016454: Review,D000318: Adrenergic beta-Agonists; D000818: Animals; D002121: Calcium Channel Blockers; D005260: Female; D006801: Humans; D016239: MEDLINE; D009543: Nifedipine; D011247: Pregnancy; D016032: Randomized Controlled Trials as Topic; D015145: Tocolysis; D015149: Tocolytic Agents,,,https://openalex.org/W2419285254,42,6,1,827,128,6,en,en
false,female sexual dysfunction,ideal approach female sexual dysfunction would collaborative effort therapist physician would include complete medical psychosocial evaluation inclusion partner spouse evaluation treatment process despite significant anatomic embryologic parallel men woman multifaceted nature female sexual dysfunction clearly distinct man clinician approach female patient sexual function problem fashion male patient context woman experience sexuality equally important physiologic outcome experience issue determine begin medical therapy determine treatment efficacy,Berman JR,2001,Urol Clin North Am,https://doi.org/10.1016/s0094-0143(05)70148-8,11402591,Berman JR; Goldstein I,article,D016428: Journal Article; D016454: Review,"D000818: Animals; D001143: Arousal; D002987: Clitoris; D004967: Estrogens; D005260: Female; D006801: Humans; D012039: Regional Blood Flow; D012735: Sexual Dysfunction, Physiological; D013739: Testosterone; D014599: Uterus; D014621: Vagina",,,https://openalex.org/W1970037278,25,3,1,792,124,4,en,en
true,rationale design method baseline demography participant anglo scandinavian cardiac outcome trial,objective test primary hypothesis new antihypertensive treatment regimen calcium channel blocker angiotensin convert enzyme inhibitor effective old regimen blocker diuretic primary prevention coronary heart disease chd test second primary hypothesis statin compare placebo far protect chd endpoint hypertensive subject total cholesterol mmol l design prospective randomize open blind endpoint trial double blinded factorial component set patient recruit mainly general practice patient men woman age eligible blood pressure mmhg systolic mmhg diastolic untreated mmhg systolic mmhg diastolic treat randomization intervention patient receive either amlodipine mg perindopril mg atenolol mg bendroflumethiazide mg k therapy require reach blood pressure mmhg systolic mmhg diastolic patient total cholesterol mmol l far randomize receive either atorvastatin mg placebo daily main outcome measure non fatal myocardial infarction mi fatal coronary heart disease chd result men woman initially randomize also randomize lipid lowering limb patient three additional cardiovascular risk factor conclusion study power level detect relative difference chd endpoint calcium channel blocker based regimen blocker based regimen lipid lowering limb study power level detect relative difference chd endpoint group,Sever PS,2001,J Hypertens,https://doi.org/10.1097/00004872-200106000-00020,11403364,Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D000924: Anticholesteremic Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002784: Cholesterol; D002985: Clinical Protocols; D003327: Coronary Disease; D004232: Diuretics; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D012537: Scandinavian and Nordic Countries; D006113: United Kingdom,,,https://openalex.org/W2109547013,115,16,1,1843,329,12,en,en
false,calcium channel blocker nifedipine slow progression coronary calcification hypertensive patient compare diuretic,abstract calcium control numerous event within vessel wall permeability endothelium calcium dependent platelet activation adhesion vascular smooth muscle proliferation migration synthesis fibrous connective tissue double helix computerized tomography noninvasive technique detect measure compare coronary calcification coronary artery use method objective determine whether administration nifedipine daily lieu diuretic high risk hypertensive patient arrest slow progression coronary artery calcification study design side arm insight international nifedipine study intervention goal hypertension therapy aim show efficacy nifedipine daily versus co amilozide hydrochlorothiazide mg amiloride mg high risk hypertensive patient total patient total calcium score onset study undergo annual double helix computerized tomography year analyze efficacy inhibition coronary calcium progression significant nifedipine versus co amilozide group first year versus respectively p significant second year versus respectively p significant third year versus respectively p result point slow progression coronary calcification hypertensive patient nifedipine daily versus co amilozide,Motro M,2001,Hypertension,https://doi.org/10.1161/01.hyp.37.6.1410,11408386,Motro M; Shemesh J,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000584: Amiloride; D002114: Calcinosis; D002121: Calcium Channel Blockers; D009202: Cardiomyopathies; D003324: Coronary Artery Disease; D018450: Disease Progression; D004232: Diuretics; D004311: Double-Blind Method; D004338: Drug Combinations; D005260: Female; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D008137: Longitudinal Studies; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D014057: Tomography, X-Ray Computed",,,https://openalex.org/W2034581851,132,16,1,1573,265,8,en,en
false,emergency room management hypertensive urgency emergency,hypertensive crisis affect upward american year although incidence hypertensive crisis low affect hypertensive adult million adult american suffer hypertension presentation patient severe hypertension emergency room demand immediate evaluation prompt recognition hypertensive emergency urgency prompt institution appropriate therapeutic measure prevent progression target organ damage avoid catastrophic event hypertensive emergency severe elevation blood pressure complicate evidence progressive target organ dysfunction coronary ischemia disorder cerebral function cerebrovascular event pulmonary edema renal failure although therapy parenteral antihypertensive agent may initiate emergency department patient warrant prompt admission intensive care unit continuous monitoring blood pressure assure therapy,Vidt DG,2001,J Clin Hypertens (Greenwich),https://doi.org/10.1111/j.1524-6175.2001.00449.x,11416701,Vidt DG,article,D016428: Journal Article; D016454: Review,D003422: Critical Care; D004632: Emergency Medical Services; D016529: Emergency Nursing; D006801: Humans; D006973: Hypertension; D010346: Patient Care Management,,,https://openalex.org/W1991393575,67,8,1,1038,156,5,en,en
false,prospective comparison four antihypertensive agent daily clinical practice,clinical trial comparison antihypertensive agent seem greatly differ clinical practice one limitation clinical trial absence random distribution target organ damage determine difference response give therapy study design evaluate within condition daily clinical practice capacity four different antihypertensive drug control blood pressure essential hypertensive patient randomly distribute accord assessment target organ damage group mild essential hypertensive year old male send unit routine evaluation therapy hypertension include study randomly allocate four different therapeutic agent atenolol lisinopril nisoldipine losartan patient group week washout previous antihypertensive therapy without previously untreated patient receive one four medication open fashion random distribution perform sex age presence target organ damage include leave ventricular hypertrophy determine echocardiography alteration plaque thicken carotid doppler ultrasonograms presence microalbuminuria mg h efficacy tolerability evaluate week therapy leave ventricular hypertrophy detect patient diastolic dysfunction systolic dysfunction carotid plaque detect subject one plaque medial intimal thickness mm present patient finally exhibit microalbuminuria expected correlation among different component target organ damage find week therapy blood pressure reduction similar group expected goal control diastolic pressure mm hg attain atenolol patient lisinopril nisoldipine losartan severe adverse event observe withdrawal rate atenolol lisinopril nisoldipine losartan conclusion four antihypertensive agent show equal antihypertensive efficacy patient similar degree target organ damage blocker exhibit low tolerability result agreement obtain prospective clinical trial,Campo C,2001,J Clin Hypertens (Greenwich),https://doi.org/10.1111/j.1524-6175.2001.00448.x,11430394,Campo C; Segura J; Fernández ML; Guerrero L; Christiansen H; Ruilope LM,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D001262: Atenolol; D001794: Blood Pressure; D015992: Body Mass Index; D004452: Echocardiography; D005260: Female; D006801: Humans; D006973: Hypertension; D017706: Lisinopril; D019808: Losartan; D008297: Male; D008875: Middle Aged; D015737: Nisoldipine; D015995: Prevalence; D011446: Prospective Studies; D016277: Ventricular Function, Left",,,https://openalex.org/W2137876283,83,11,1,2521,451,19,en,en
false,antihypertensive efficacy amlodipine child chronic kidney disease,adult calcium antagonist amlodipine give day prove attractive addition antihypertensive armamentarium present report describe experience paediatric outpatient boy girl age median year chronic kidney disease patient give amlodipine week part antihypertensive treatment amlodipine arterial pressure mm hg median interquartile range six patient withdraw amlodipine oedema flush headache remain patient amlodipine mg body surface area day significantly decrease arterial pressure mm hg efficacy amlodipine pronounced girl boy change heart rate body weight circulate haemoglobin sodium potassium creatinine note none patient circulate potassium sodium creatinine change mmol l mmol l respectively patient concomitantly treat cyclosporine dosage trough level agent stable throughout trial conclusion present experience paediatric outpatient chronic kidney disease support view amlodipine effective rather well tolerated antihypertensive drug give day,von Vigier RO,2001,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1001203,11439313,von Vigier RO; Franscini LM; Bianda ND; Pfister R; Casaulta Aebischer C; Bianchetti MG,article,D003160: Comparative Study; D016428: Journal Article,"D000293: Adolescent; D000328: Adult; D000367: Age Factors; D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002648: Child; D002669: Child Welfare; D002675: Child, Preschool; D002908: Chronic Disease; D005260: Female; D006339: Heart Rate; D006801: Humans; D006977: Hypertension, Renal; D007223: Infant; D007674: Kidney Diseases; D007678: Kidney Glomerulus; D016014: Linear Models; D008297: Male; D011446: Prospective Studies; D011795: Surveys and Questionnaires; D013810: Therapeutic Equivalency; D016896: Treatment Outcome; D044465: White People",,,https://openalex.org/W1967430575,80,10,1,1404,249,11,en,en
false,current concept treatment hypertension,spite effective drug therapy available hypertensive patient general economic social consideration continue influence low rate detection treatment control hypertension population developing world joint national committee detection evaluation treatment high blood pressure state age adjusted stroke rate rise slightly age adjusted rate decline coronary heart disease appear level furthermore rate incidence end stage renal disease increase hypertension second common cause report also state hypertension control rate improve national health nutrition examination survey nhanes iii phase control disturb trend support need enhance public professional education translate result research improved health,Seedat YK,2001,Cardiovasc J S Afr,,11447499,Seedat YK,article,D016428: Journal Article; D016454: Review,D003906: Developing Countries; D006266: Health Education; D006801: Humans; D006973: Hypertension; D012307: Risk Factors,,,,50,8,1,971,162,5,en,en
false,high altitude illness,term high altitude illness use describe cerebral pulmonary syndrome develop unacclimatized person shortly ascent high altitude acute mountain sickness high altitude cerebral edema refer cerebral abnormality high altitude pulmonary edema pulmonary abnormality million visitor travel high altitude location year acute mountain sickness public health problem economic consequence especially ski industry high altitude pulmonary edema high altitude cerebral edema though uncommon potentially fatal high altitude illness also provide useful model study pathophysiological process hypoxia,Hackett PH,2001,N Engl J Med,https://doi.org/10.1056/nejm200107123450206,11450659,Hackett PH; Roach RC,article,D016428: Journal Article; D016454: Review,"D000086: Acetazolamide; D000532: Altitude Sickness; D001929: Brain Edema; D002121: Calcium Channel Blockers; D003937: Diagnosis, Differential; D004232: Diuretics; D006801: Humans; D009543: Nifedipine; D010100: Oxygen; D011654: Pulmonary Edema; D012307: Risk Factors",,,https://openalex.org/W2748435152,21,2,1,742,114,7,en,en
true,effect verapamil prevention atrial fibrillation patient implant implantable atrial defibrillator,abstract background role verapamil prevention atrial fibrillation af patient recurrent af unknown hypothesis aim study evaluate effect verapamil prevention af patient implant implantable atrial defibrillator iad method effect verapamil mg day total duration af number af recurrence number cardioversions prospectively evaluate randomized crossover fashion week period patient men woman mean age year implant iad result implantable atrial defibrillator successfully convert spontaneous episode af significant difference efficacy cardioversion vs p total duration af vs h p number af episode vs p number cardioversions vs p without treatment verapamil conclusion result present study suggest treatment verapamil significant effect prevention af patient treat iad,Tse HF,2001,Clin Cardiol,https://doi.org/10.1002/clc.4960240717,11450689,Tse HF; Wang Q; Yu CM; Ayers GM; Lau CP,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D017147: Defibrillators, Implantable; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D012008: Recurrence; D014700: Verapamil",,,https://openalex.org/W2092323796,119,16,1,1199,250,6,en,en
false,intravenous magnesium sulfate versus diltiazem paroxysmal atrial fibrillation,background drug currently available acute treatment paroxysmal atrial fibrillation significant limitation assess safety effectiveness intravenous magnesium sulfate versus diltiazem therapy patient prolonged episode paroxysmal atrial fibrillation method prospective randomize trial symptomatic patient present paroxysmal atrial fibrillation give intravenous magnesium sulfate n diltiazem n therapy primary outcome measure effect ventricular rate control proportion patient restore sinus rhythm h initiation treatment result difference baseline characteristic two group form treatment well tolerate adverse clinical event drug similar efficacy reduce ventricular rate first hour treatment p tendency toward decrease infusion time p h respectively p however end h treatment period restoration sinus rhythm observe significantly high proportion patient magnesium group compare diltiazem group patient versus five patient p conclusion magnesium sulfate favorably affect rate control seem promote conversion long last episode paroxysmal atrial fibrillation sinus rhythm represent safe reliable cost effective alternative treatment strategy diltiazem,Chiladakis JA,2001,Int J Cardiol,https://doi.org/10.1016/s0167-5273(01)00450-8,11461753,Chiladakis JA; Stathopoulos C; Davlouros P; Manolis AS,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D002121: Calcium Channel Blockers; D004110: Diltiazem; D005260: Female; D006801: Humans; D007262: Infusions, Intravenous; D008278: Magnesium Sulfate; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D013614: Tachycardia, Paroxysmal",,,https://openalex.org/W2059662721,80,9,1,1568,276,9,en,en
false,daily treatment patient hypertension placebo controlled study amlodipine benazepril v amlodipine benazepril alone,objective compare efficacy tolerability safety daily therapy amlodipine mg benazepril mg v amlodipine mg benazepril mg placebo design randomise double blind placebo controlled parallel group multicentre trial setting twenty two clinical centre include private practice group academic research clinic patient total patient year age essential hypertension screen study randomise treatment amlodipine mg benazepril mg amlodipine mg benazepril mg placebo week result amlodipine mg benazepril mg produce great reduction baseline sit diastolic blood pressure amlodipine mg p benazepril mg p placebo p response rate amlodipine mg benazepril mg treatment group good observe amlodipine mg p benazepril mg p placebo p group significant difference heart rate among four group incidence oedema amlodipine mg benazepril mg group somewhat less amlodipine mg group conclusion therapy amlodipine mg benazepril mg well tolerated superior amlodipine mg benazepril mg placebo reduce sit diastolic blood pressure patient essential hypertension,Pool J,2001,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1001217,11464260,Pool J; Kaihlanen P; Lewis G; Ginsberg D; Oparil S; Glazer R; Messerli FH,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D000959: Antihypertensive Agents; D001552: Benzazepines; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D016896: Treatment Outcome",,,https://openalex.org/W1967578199,141,19,1,1506,286,9,en,en
false,less adrenergic response mental task verapamil compare amlodipine treatment hypertensive subject,compare effect amlodipine verapamil slow release autonomic response min mental arithmetic test mst patient mild moderate hypertension twenty subject receive week verapamil slow release mg amlodipine mg double blind crossover design week placebo heart rate hr blood pressure bp continuously monitor venous plasma catecholamine analyse radioenzymatic assay baroreflex sensitivity br estimate transfer function technique calculation area curve auc use estimate average hr bp catecholamine concentration reactivity mst estimate percent change basal auc paired test perform data mean sem compare verapamil amlodipine increase average noradrenaline na concentration vs pg l respectively p na reactivity vs p average hr vs beats min p hr reactivity vs p bp differ significantly br correlate average baseline hr medication r p conclude adrenergic response mst blunt treatment verapamil compare amlodipine hypertensive patient,Sevre K,2001,Blood Press,https://doi.org/10.1080/08037050152112096,11467760,Sevre K; Lefrandt JD; Eide I; Smit AJ; Rostrup M,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D018663: Adrenergic Agents; D000328: Adult; D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D017704: Baroreflex; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002395: Catecholamines; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D007361: Intelligence Tests; D008297: Male; D008875: Middle Aged; D009638: Norepinephrine; D013315: Stress, Psychological; D014700: Verapamil",,,https://openalex.org/W2135116267,114,15,1,1378,273,13,en,en
true,characteristic hypertensive patient high coronary risk value trial,valsartan orally active selective antagonist angiotensin ii receptor develop treatment hypertension valsartan antihypertensive long term use evaluation value trial cardiovascular event hypertension double blind randomized prospective parallel group study design compare effect valsartan calcium antagonist amlodipine reduction cardiac morbidity mortality patient essential hypertension age year old particularly high risk coronary event enrol patient screen patient country randomize mainly january december hypertensive mean blood pressure mmhg time randomization blind medication population comprise gender men caucasian mean age year mean body mass index kg coronary heart disease high cholesterol type diabetes mellitus smoker randomized participant treat high blood pressure least month screen study randomized population treat goal blood pressure mmhg adherence protocol least patient experience primary cardiac endpoint define clinically evident aborted myocardial infarction hospitalization heart failure death cause coronary heart disease,Kjeldsen SE,2001,Blood Press,https://doi.org/10.1080/08037050152112069,11467764,Kjeldsen SE; Julius S; Brunner H; Hansson L; Henis M; Ekman S; Laragh J; McInnes G; Smith B; Weber M; Zanchetti A,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000368: Aged; D000369: Aged, 80 and over; D000465: Algorithms; D000959: Antihypertensive Agents; D002985: Clinical Protocols; D003327: Coronary Disease; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D012307: Risk Factors; D013777: Tetrazoles; D014633: Valine; D000068756: Valsartan",,,https://openalex.org/W2164485047,85,13,2,1529,267,8,en,en
false,reduction left ventricular mass lisinopril nifedipine hypertensive renal transplant recipient prospective randomize double blind study,cardiovascular disease dominant cause death renal transplant recipient leave ventricular hypertrophy lvh known risk factor renal transplantation persistent hypertension important determinant evolution lvh aim present study compare effect angiotensin convert enzyme ace inhibitor lisinopril calcium channel blocker ccb control release nifedipine treatment posttransplant hypertension focus change lvh one hundred fifty four renal transplant recipient present hypertension diastolic bp mmhg first week transplantation randomize receive double blind mg nifedipine mg lisinopril daily one hundred twenty three patient complete year treatment good quality echocardiographic data available recipient nifedipine lisinopril month posttransplant blood pressure equally well control two group throughout study mean systolic diastolic sd year mmhg nifedipine mmhg lisinopril leave ventricular mass index reduce p group g nifedipine g lisinopril statistically significant difference two treatment group baseline follow hypertensive renal transplant recipient well controlled blood pressure regression left ventricular mass renal transplantation regression left ventricular mass index observe similar extent patient treat lisinopril nifedipine,Midtvedt K,2001,Transplantation,https://doi.org/10.1097/00007890-200107150-00021,11468543,Midtvedt K; Ihlen H; Hartmann A; Bryde P; Bjerkely BL; Foss A; Fauchald P; Holdaas H,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D016572: Cyclosporine; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004452: Echocardiography; D005260: Female; D006321: Heart; D006352: Heart Ventricles; D006801: Humans; D006973: Hypertension; D007166: Immunosuppressive Agents; D016030: Kidney Transplantation; D017706: Lisinopril; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011446: Prospective Studies; D013997: Time Factors,,,https://openalex.org/W1988356420,153,20,1,1736,278,9,en,en
true,verdict verapamil versus digoxin cardioversion trial randomized study role calcium lower maintenance sinus rhythm cardioversion persistent atrial fibrillation,many relapse atrial fibrillation af occur especially first week electrical cardioversion ecv aim present study compare randomized design efficacy verapamil intracellular calcium lower versus digoxin calcium increase maintenance sinus rhythm ecv ninety seven patient persistent af randomize verapamil n digoxin n month month ecv first month ecv patient record heart rhythm use daily transtelephonic monitoring additional antiarrhythmic drug give patient patient verapamil underwent ecv per protocol median previous af duration day verapamil digoxin respectively difference atrial dimension underlie heart disease two group success rate ecv versus p n month versus p n recurrence af median time recurrence day range versus day range p n respectively stand alone intracellular calcium lowering verapamil around ecv enhance cardioversion outcome,Van Noord T,2001,J Cardiovasc Electrophysiol,https://doi.org/10.1046/j.1540-8167.2001.00766.x,11469424,Van Noord T; Van Gelder IC; Tieleman RG; Bosker HA; Tuinenburg AE; Volkers C; Veeger NJ; Crijns HJ,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D002118: Calcium; D002121: Calcium Channel Blockers; D004077: Digoxin; D004554: Electric Countershock; D015716: Electrocardiography, Ambulatory; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D016896: Treatment Outcome; D014700: Verapamil",,,https://openalex.org/W2095967229,195,29,1,1202,238,10,en,en
false,randomized double blind parallel group study compare anti hypertensive effect imidapril nifedipine treatment mild moderate essential hypertension,week multicentre double blind placebo controlled parallel group study compare efficacy angiotensin converting enzyme ace inhibitor imidapril mg day calcium channel blocker nifedipine slow release sr formulation mg twice daily total patient age year mean sit diastolic blood pressure mmhg randomize treatment imidapril n nifedipine sr n efficacy evaluation base intent treat principle study completion difference group respect primary efficacy variable response treatment imidapril nifedipine sr week treatment clinically relevant decrease blood pressure observe group trend towards reduction study end patient imidapril treated group nifedipine group withdraw due adverse event occur treatment study medication versus experienced adverse event versus addition adverse event causally relate imidapril compare nifedipine sr result show imidapril effective treatment essential hypertension well tolerate nifedipine sr,van der Does R,2001,J Int Med Res,https://doi.org/10.1177/147323000102900302,11471852,van der Does R; Euler R,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D007093: Imidazoles; D048289: Imidazolidines; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D010919: Placebos,,,https://openalex.org/W2327021387,177,23,1,1333,242,8,en,en
false,randomized double blind comparison efficacy tolerability daily modified release diltiazem capsule daily amlodipine tablet patient stable angina,randomized double blind parallel group study compare efficacy tolerability daily diltiazem capsule amlodipine tablet patient stable angina run period week patient receive daily diltiazem patient received amlodipine patient receive either diltiazem mg day amlodipine mg day week follow diltiazem mg day amlodipine mg day week standard treadmill exercise testing primary efficacy assessment patient also record incidence angina attack use glyceryl trinitrate spray treatment give significant improvement time onset angina time maximal exercise exception amlodipine mg day treatment give significant increase time mm st segment depression diltiazem mg day give significant decrease rate pressure product significant treatment difference exercise test parameter treatment reduce incidence angina attack use glyceryl trinitrate spray incidence edema significantly less patient receive diltiazem conclusion treatment effective control patient angina diltiazem well tolerate low incidence edema,Chugh SK,2001,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-200109000-00004,11486240,Chugh SK; Digpal K; Hutchinson T; McDonald CJ; Miller AJ; Lahiri A,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D017311: Amlodipine; D000787: Angina Pectoris; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002317: Cardiovascular Agents; D004110: Diltiazem; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D017079: Exercise Tolerance; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D005996: Nitroglycerin; D013997: Time Factors; D016896: Treatment Outcome; D014665: Vasodilator Agents,,,https://openalex.org/W2035987561,186,24,1,1326,223,12,en,en
false,single investigator blind randomise control trial compare effect quinapril nifedipine platelet function patient mild moderate hypertension,effect quinapril nifedipine platelet aggregation vascular endothelial function coagulation system activity compare parallel group investigator blind study carry patient mild moderate hypertension disease receive medication might affect platelet function vascular endothelium coagulation forty patient two group patient control subject recruit patient randomise receive either quinapril nifedipine retard dose escalate control hypertension platelet aggregation study assess serially beta thromboglobulin angiotensin converting enzyme ace von willebrand factor vwf coagulation factor viiic xii fibrinogen measure beginning end week period blood pressure adequately control patient group platelet function impair certain parameter slope reaction adp collagen maximum aggregation collagen patient group compare control treatment improve patient quinapril nifedipine likewise beta thromboglobulin higher patient group fell significantly quinapril group nifedipine measurement endothelial function coagulation normal treatment show alteration study except expected fall plasma ace quinapril group result indicate ace inhibitor quinapril beneficial effect platelet function unlike calcium channel blocker nifedipine,Islim IF,2001,Platelets,https://doi.org/10.1080/09537100120058793,11487379,Islim IF; Bareford D; Beevers DG,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000806: Angiotensin-Converting Enzyme Inhibitors; D001792: Blood Platelets; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004730: Endothelium, Vascular; D005260: Female; D006801: Humans; D006973: Hypertension; D007546: Isoquinolines; D008297: Male; D016555: Matched-Pair Analysis; D008875: Middle Aged; D009543: Nifedipine; D015539: Platelet Activation; D010974: Platelet Aggregation; D010979: Platelet Function Tests; D000077583: Quinapril; D016037: Single-Blind Method; D044005: Tetrahydroisoquinolines; D001620: beta-Thromboglobulin",,,https://openalex.org/W2128454003,172,26,1,1638,260,8,en,en
false,efficacy safety therapeutic interchange high dose calcium channel blocker fixed dose combination amlodipine benazepril patient moderate severe hypertension,recent hypertension trial demonstrate importance achieve goal blood pressure reduce risk target organ damage patient moderate severe hypertension use high dose monotherapy combination drug necessary achieve goal fixed dose combination product may useful patient reduce number daily dos require control blood pressure objective present study evaluate efficacy safety therapeutic interchange high dose calcium channel blocker therapy fixed dose combination amlodipine benazepril lotrel novartis pharmaceutical usa patient moderate severe hypertension total patient switch amlodipine n felodipine n nifedipine gits n amlodipine benazepril twenty eight patient take either beta blocker diuretic addition high dose calcium channel blocker prior switch blood pressure control side effect cost therapeutic interchange evaluate year follow therapeutic interchange sixty six patient successfully switch maintenance blood pressure control without development new dose limiting side effect reason treatment failure therapeutic interchange include loss blood pressure control five patient development new dose limiting side effect four patient side effect include cough three patient rash one patient account difference drug acquisition cost cost relate switch clinic emergency room laboratory test cost saving patient realise first year per patient per year cost saving data indicate therapeutic interchange select high dose calcium channel blocker fixed dose combination amlodipine benazepril successfully accomplish majority patient,Hilleman DE,2001,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1001230,11494095,Hilleman DE; Reyes AP; Wurdeman RL; Faulkner M,article,D003160: Comparative Study; D016428: Journal Article,"D000328: Adult; D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D001552: Benzazepines; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003365: Costs and Cost Analysis; D004305: Dose-Response Relationship, Drug; D004359: Drug Therapy, Combination; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D016896: Treatment Outcome",,,https://openalex.org/W1968696878,190,23,1,2082,342,9,en,en
false,connective tissue growth factor drug induced gingival overgrowth,drug induced gingival overgrowth known side effect certain chemotherapeutic agent use treatment systemic disorder pathogenesis mechanism responsible condition fully understood study assess presence localization connective tissue growth factor ctgf drug induced gingival overgrowth tissue ctgf immunostaining compare section stain transform growth factor tgf beta cd antibody order investigate possible pathogenic mechanisms gingival overgrowth sample obtain patient undergo therapy phenytoin n nifedipine n cyclosporin n control tissue systemically healthy donor n tissue section subject peroxidase immunohistochemistry stain ctgf tgf beta polyclonal primary antibody possible relationship ctgf staining angiogenesis also study use anti cd antibody marker endothelial cell staining analyze computer assisted quantitative semiquantitative methodology defined site sample base location specific landmark include epithelium underlying connective tissues cellular extracellular ctgf content phenytoin gingival overgrowth tissue significantly p high compare gingival overgrowth tissue control high ctgf stain phenytoin gingival overgrowth tissue accompany increased abundance fibroblast connective tissue fiber strong association ctgf stain tgf beta cd staining found data present study show significantly high ctgf stain phenytoin induced gingival overgrowth tissue compare control cyclosporin nifedipine induced gingival overgrowth moreover semiquantitative analysis histologic sample support concept phenytoin overgrowth tissue fibrotic association suggest possible role ctgf promote development fibrotic lesion phenytoin induced gingival overgrowth,Uzel MI,2001,J Periodontol,https://doi.org/10.1902/jop.2001.72.7.921,11495141,Uzel MI; Kantarci A; Hong HH; Uygur C; Sheff MC; Firatli E; Trackman PC,article,"D003160: Comparative Study; D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000906: Antibodies; D000927: Anticonvulsants; D002121: Calcium Channel Blockers; D002352: Carrier Proteins; D004396: Coloring Agents; D003238: Connective Tissue; D055513: Connective Tissue Growth Factor; D016572: Cyclosporine; D004730: Endothelium, Vascular; D004848: Epithelium; D005260: Female; D005347: Fibroblasts; D005355: Fibrosis; D019214: Gingival Overgrowth; D006133: Growth Substances; D006801: Humans; D007091: Image Processing, Computer-Assisted; D017874: Immediate-Early Proteins; D007124: Immunoenzyme Techniques; D007166: Immunosuppressive Agents; D036341: Intercellular Signaling Peptides and Proteins; D007963: Leukocytes, Mononuclear; D008297: Male; D008875: Middle Aged; D008934: Mitogens; D009389: Neovascularization, Pathologic; D009543: Nifedipine; D010672: Phenytoin; D019408: Platelet Endothelial Cell Adhesion Molecule-1; D018709: Statistics, Nonparametric; D016212: Transforming Growth Factor beta; D053773: Transforming Growth Factor beta1",,,https://openalex.org/W2157149444,67,8,1,2131,318,11,en,en
false,antihypertensive drug prescription trend primary health care centre bahrain,determine antihypertensive drug prescribe pattern primary care physician patient uncomplicated essential hypertension identify whether pattern prescription appropriate accordance international guideline pharmacotherapy hypertension estimate impact prescription cost treatment prescription based survey among patient uncomplicated essential hypertension conduct seven total health centre bahrain relevant data study collect use card design chronically ill patients total male female study population monotherapy whereas male female antihypertensive combination therapy among monotherapy category various antihypertensive drug use follow beta blockers angiotensin convert enzyme ace inhibitor calcium channel blocker diuretic alpha methyldopa respect overall utilization pattern beta blockers frequently prescribe diuretic rank second follow ace inhibitor calcium channel blocker alpha methyldopa within class antihypertensive use frequently use individual agent follow among beta blockers use atenolol b among diuretic indapamide hydrochlorothiazide hctz hctz combination triamterene chlorthalidone c among ace inhibitor captopril enalapril lisinopril among calcium channel blocker nifedipine significant age gender related difference prescribe pattern see short acting nifedipine monotherapy inappropriately prescribe significant number patient age year ace inhibitor account approximately two thirds total antihypertensive drug expenditure although drug represent one fifth overall antihypertensive use trend towards excessive use expensive thiazide like diuretic indapamide seem unjustifiable practice particularly study population free diabetic hypertensive patients general pattern antihypertensive utilization appear accordance guideline joint national committee issue trend prescribing antihypertensive favour conventional one beta blocker diuretic introduction new class antihypertensive generally minimal impact prescribing profile almost two thirds patient treat monotherapy disproportionately large percentage antihypertensive drug cost due overt use ace inhibitor indapamide instead thiazide diuretic use short acting calcium channel blocker especially elderly unjustifiable,Jassim al Khaja KA,2001,Pharmacoepidemiol Drug Saf,https://doi.org/10.1002/pds.578,11501335,Jassim al Khaja KA; Sequeira RP; Wahab AW; Mathur VS,article,D016428: Journal Article,"D000293: Adolescent; D000328: Adult; D000367: Age Factors; D000368: Aged; D000369: Aged, 80 and over; D000959: Antihypertensive Agents; D001445: Bahrain; D011307: Drug Prescriptions; D004363: Drug Utilization; D005260: Female; D017408: Guidelines as Topic; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D010821: Physicians, Family",,,https://openalex.org/W2035810543,87,12,1,3064,532,13,en,en
false,comparison hypotensive efficiency tolerability amlodipine enalapril patient essential hypertension,multicentre double blind trial patient mild moderate essential hypertension randomize amlodipine enalapril monotherapy week period placebo dos amlodipine mg daily enalapril mg daily titrate achieve office blood pressure mm hg week therapy drug similarly effective lower blood pressure goal blood pressure achieve patient treat amlodipine enalapril also degree reduction blood pressure similar group compare initial value systolic diastolic blood pressure decrease mm hg amlodipine group mm hg subject receive enalapril however adverse effect especially dry cough frequent enalapril treated patient amlodipine enalapril provide significant blood pressure reduction stage ii hypertension tolerance short term therapy good group however number adverse event significantly low amlodipine treated patient,Gryglas P,2001,Pol Arch Med Wewn,,11505744,Gryglas P,article,D016430: Clinical Trial; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,D000368: Aged; D017311: Amlodipine; D002121: Calcium Channel Blockers; D004656: Enalapril; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies,,,https://openalex.org/W2413641874,128,19,1,1107,179,8,en,en
false,chronic hypertension pregnancy,pregnant woman chronic hypertension risk maternal perinatal morbidity careful assessment management patient pregnancy key reduce maternal fetal complication antihypertensive treatment use woman high risk chronic hypertension whereas drug therapy improve pregnancy outcome woman low risk prophylactic low dose aspirin start early pregnancy woman chronic hypertension effective reduce frequency superimposed preeclampsia avoid,Livingston JC,2001,Obstet Gynecol Clin North Am,https://doi.org/10.1016/s0889-8545(05)70213-8,11512496,Livingston JC; Sibai BM,article,D016428: Journal Article; D016454: Review,"D000328: Adult; D002317: Cardiovascular Agents; D002908: Chronic Disease; D005260: Female; D006801: Humans; D006973: Hypertension; D008875: Middle Aged; D011181: Postnatal Care; D011225: Pre-Eclampsia; D011247: Pregnancy; D011249: Pregnancy Complications, Cardiovascular; D012306: Risk",,,https://openalex.org/W2100574763,33,4,1,571,86,4,en,en
false,adverse drug reaction monitoring digitoxin overdosage elderly,drug related illness everlasting universal problem also important cause admission hospital adverse reaction still grossly underreported medical profession little information available regard frequency type adrs manage hospital since january take part study support german federal institute drug medical device improve spontaneous drug information reporting system germany three german regionalized department clinical pharmacology jena dresden rostock serve pharmacovigilance center collaboration pharmacoepidemiology research group university munich since january regional group jena monitor university clinic internal medicine admission cause adverse drug reaction emergency case patient intensive care unit check adverse drug reaction present result include clinical demographic data concern intoxication especially involve digitoxin patient adr forty patient digitoxin toxicity average age year low body weight kg woman patient digitoxin side effect elevate serum digitoxin level concentration high microg ml relatively high frequency digitoxin intoxication hospital may reflect advanced age low body weight patient patient receive digitoxin regardless age weight sometimes clinical indication physician aware drug high risk use elderly patient use digitoxin assay keep serum level within near therapeutic range diminish incidence overdoses,Hippius M,2001,Int J Clin Pharmacol Ther,https://doi.org/10.5414/cpp39336,11515708,Hippius M; Humaid B; Sicker T; Hoffmann A; Göttler M; Hasford J,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D016907: Adverse Drug Reaction Reporting Systems; D000367: Age Factors; D000368: Aged; D000369: Aged, 80 and over; D000889: Anti-Arrhythmia Agents; D003710: Demography; D004074: Digitoxin; D062787: Drug Overdose; D005260: Female; D005858: Germany; D006760: Hospitalization; D006801: Humans; D008297: Male; D012307: Risk Factors",,,https://openalex.org/W2060062640,70,10,1,1823,301,14,en,en
false,relation drug treatment cancer hypertenslves swedish trial old patient hypertension year prospective randomise control trial,cancer relate hypertension blood pressure antihypertensive drug promote cancer antihypertensive drug protect cancer previously analyse frequency cardiovascular mortality morbidity elderly people participate swedish trial old patient hypertension stop hypertension also look frequency cancer patients randomly assign elderly patient hypertension mean age year median time follow year one three treatment strategy conventional drug diuretic b blockers calcium antagonist ace inhibitor match patient swedish cancer registry compare finding expect value base age sex calendar year specific reference frequency general swedish population also compare number cancer three treatment groups baseline patient previous malignant disease diagnosis closely similar distribution cancer type might see elderly patient follow new case cancer patient frequency cancer differ significantly treatment strategy include cancer individual site standardised incidence ratio sir cancer also close unity ci conventional drug calcium antagonist ace inhibitors difference cancer risk see patient randomly assign conventional drug calcium antagonist ace inhibitor thus general message practising physician attention give get blood pressure risk cancer,Lindholm LH,2001,Lancet,https://doi.org/10.1016/s0140-6736(01)05704-x,11520524,Lindholm LH; Anderson H; Ekbom T; Hansson L; Lanke J; Dahlöf B; de Faire U; Forsén K; Hedner T; Linjer E; Scherstén B; Wester P; Möller T,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D016009: Chi-Square Distribution; D005260: Female; D006801: Humans; D006973: Hypertension; D015994: Incidence; D008297: Male; D009369: Neoplasms; D016012: Poisson Distribution; D015995: Prevalence; D011446: Prospective Studies; D012042: Registries; D012306: Risk; D013548: Sweden,,,https://openalex.org/W2161354300,169,28,1,1810,309,12,en,en
false,incidental retinal phototoxicity associate ingestion photosensitize drug,background report possible correlation incident retinal phototoxicity use photosensitize drug method four patient examine scotoma visual loss incidental exposure strong light source one patient two eye expose standard camera flash one patient one eye brief exposure weld light one patient two eye underwent uncomplicated phacoemulsification intraocular lens implantation fourth patient severe retinal phototoxicity follow secondary intraocular lens implantation four patient undergo thorough assessment include history systemic drug use patient ophthalmologic evaluation include best correct visual acuity etdrs chart fundus examination fluorescein indocyanine green angiography follow year result presentation mean visual acuity range fundus examination disclose yellow gray sub retinal lesion affected eye early phase fluorescein angiography show one multiple hypofluorescent spot surround halo hyperfluorescent window defect late phase spot leak fluorescein dye indocyanine green angiography demonstrate hypofluorescent spot throughout ill defined border hyperfluorescence observe late stage common finding four patient fact take one photosensitizing drug hydrochlorothiazide furosemide allopurinol benzodiazepine three patient full visual recovery month phototoxicity fourth patient remain visual acuity month light exposure despite visual recovery non homogeneous retinal pigment epithelial disturbance persist affected eye conclusion phototoxicity follow incidental light exposure may occur patient take drug photosensitize potential therefore thorough history systemic drug ingestion obtain patient exposure strong light source,Mauget-Faÿsse M,2001,Graefes Arch Clin Exp Ophthalmol,https://doi.org/10.1007/s004170100307,11521694,Mauget-Faÿsse M; Quaranta M; Francoz N; BenEzra D,article,D002363: Case Reports; D016428: Journal Article,D000368: Aged; D000493: Allopurinol; D001569: Benzodiazepines; D005260: Female; D005451: Fluorescein Angiography; D005665: Furosemide; D006801: Humans; D006852: Hydrochlorothiazide; D007208: Indocyanine Green; D008027: Light; D008297: Male; D008875: Middle Aged; D017319: Photosensitizing Agents; D011832: Radiation Injuries; D012160: Retina; D012607: Scotoma; D014792: Visual Acuity,,,https://openalex.org/W1974369348,84,9,1,2145,339,17,en,en
true,effect diltiazem recurrence rate paroxysmal atrial fibrillation,p experimental clinical study demonstrate verapamil may attenuate atrial electrical remodeling induce atrial fibrillation af thereby reduce predisposition toward early recurrence af cardioversion may explain clinical study find treatment calcium antagonist agent cardioversion may reduce incidence immediate early recurrence af however whether calcium antagonist help delay recurrence af patient paroxysmal af unclear therefore prospective study evaluate effect oral diltiazem frequency af patient paroxysmal af undergo atrioventricular junction ablation implantation dual chamber pacemaker study population consist men woman mean age year undergo atrioventricular junction ablation implantation dual chamber pacemaker drug refractory paroxysmal af uncontrolled ventricular rate clinical characteristic list table patient treat amiodarone within month ablation procedure exclude study onset paroxysmal af occur mean month ablation thirteen patient cardiovascular disease patient systemic hypertension mean leave ventricular ejection fraction mean leave atrial diameter echocardiography cm atrioventricular junction ablation successful patient dual chamber rate responsive pacemaker capable mode switching model medtronic inc minneapolis minnesota implant patient pacemaker program low rate limit ppm atrioventricular interval upper rate limit ppm mode switch detection rate program beats min study protocol approve human research committee inform consent obtain patient two day pacemaker implantation patient randomly assign treatment mg day diltiazem treatment diltiazem patient sinus rhythm randomization patient treat antiarrhythmic agent include b blocker mode switch event counter activate use quantitate number arrhythmia recurrence event counter saturation level episode patient examine follow month time pacemaker interrogate event counter clear patient cross alternate therapy another month follow patient examine clinic visit time pacemaker interrogation perform continuous variable express mean sd statistical comparison perform paired test p value consider statistically significant one patient randomly assign receive diltiazem first month study period develop persistent af also case patient randomize receive treatment crossover patient develop persisfrom cardiology division department medicine university hong kong queen mary hospital hong kong china division cardiology department internal medicine university michigan medical center ann arbor michigan study support part nouse arrhythmia research fund ann arbor michigan dr morady address division cardiology b f university michigan medical center east medical center drive ann arbor michigan e mail fmorady umich edu manuscript receive february revise manuscript receive accept april table patient characteristic mode switch event,Tse HF,2001,Am J Cardiol,https://doi.org/10.1016/s0002-9149(01)01743-x,11524073,Tse HF; Lau CP; Wang Q; Pelosi F; Oral H; Knight BP; Strickberger SA; Morady F,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000368: Aged; D001281: Atrial Fibrillation; D017115: Catheter Ablation; D018592: Cross-Over Studies; D004110: Diltiazem; D004334: Drug Administration Schedule; D005260: Female; D005500: Follow-Up Studies; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D010138: Pacemaker, Artificial; D011446: Prospective Studies; D012016: Reference Values; D013614: Tachycardia, Paroxysmal; D016896: Treatment Outcome",,,https://openalex.org/W1986165969,76,11,1,3990,684,33,en,en
false,interaction nonsteroidal anti inflammatory drug intake calcium channel blocker based antihypertensive treatment syst eur trial,assess relationship chronic intake nonsteroidal anti inflammatory drug nsaid outcome particular gastrointestinal bleeding investigate whether effect chronic nsaid intake similar untreated treat elderly hypertensives eligible patient year systolic blood pressure mm hg diastolic blood pressure mm hg randomise active treatment placebo active treatment consist nitrendipine possible addition enalapril hydrochlorothiazide titrate combine reduce sit systolic blood pressure least mm hg mm hg patient never take nsaid n compare patient chronic nsaid intake n define reporting nsaid intake least patient forms tendency towards low mortality relative hazard rate confidence interval ci high incidence bleeding chronic nsaid intake although significant interaction calcium channel blocker ccb based treatment chronic nsaid intake end point chronic nsaid intake tend associate low incidence bleed active treatment compare placebo p value interaction term effect chronic nsaid intake outcome similar patient active treatment base dihydropyridine ccb placebo however chronic nsaid intake might less deleterious effect bleed active treatment compare placebo,Celis H,2001,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1001235,11550107,Celis H; Thijs L; Staessen JA; Birkenhäger WH; Bulpitt CJ; de Leeuw PW; Leonetti G; Nachev C; Tuomilehto J; Fagard RH; Syst-Eur Investigators,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000894: Anti-Inflammatory Agents, Non-Steroidal; D002121: Calcium Channel Blockers; D004347: Drug Interactions; D005260: Female; D005767: Gastrointestinal Diseases; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D012307: Risk Factors; D016896: Treatment Outcome",,,https://openalex.org/W2012224607,145,15,1,1607,288,5,en,en
false,effect long acting ace inhibitor temocapril long acting ca channel blocker amlodipine h ambulatory bp elderly hypertensive patient,prospective randomise cross study compare effect ace inhibitor temocapril calcium channel blocker ccb amlodipine ambulatory blood pressure asymptomatic elderly hypertensive patient mean age year study perform cross fashion week placebo period week treatment temocapril amlodipine hypertensive patient three patient side effect patient whose office bps achieve target bps exclude remain analyse study consist dipper night time reduction systolic bp sbp non dippers reduction baseline significant difference office h daytime bps two group dipper non dippers though office bps daytime bps successfully control level treatment dip group antihypertensive effect strong ccb ace inhibitor night time morning especially non dippers conclude even though office bps control successfully almost level possibility long acting drug differential antihypertensive effect night time morning bps among hypertensive patient different night time bp dip status,Eguchi K,2001,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1001252,11550111,Eguchi K; Kario K; Shimada K,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D002940: Circadian Rhythm; D018592: Cross-Over Studies; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D013841: Thiazepines",,,https://openalex.org/W2031741369,152,24,1,1432,254,6,en,en
false,effect ramipril versus amlodipine renal outcome hypertensive nephrosclerosis,,Vidt DG,2001,Curr Hypertens Rep,https://doi.org/10.1007/s11906-001-0053-3,11551370,Vidt DG,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D003404: Creatinine; D006801: Humans; D006973: Hypertension; D007668: Kidney; D007676: Kidney Failure, Chronic; D009400: Nephrosclerosis; D017257: Ramipril",,,https://openalex.org/W2170072119,90,12,1,0,0,0,en,
false,effect daily angiotensin converting enzyme inhibition calcium channel blockade based antihypertensive treatment regimen left ventricular hypertrophy diastolic filling hypertension,prospective randomize enalapril study evaluate regression ventricular enlargement preserve study design test whether enalapril achieves great leave ventricular lv mass reduction nifedipine gastrointestinal treatment system prognostically meaningful degree population basis g ethnically diverse population men woman essential hypertension increase lv mass screen echocardiography enrol clinical center continent study echocardiography baseline month randomized therapy clinical examination blind echocardiogram reading week study entry intention treat analysis enalapril treated nifedipine treated patient reveal similar reduction systolic diastolic pressure versus mm hg lv mass index versus g p significant treatment difference detect population subset define monotherapy treatment sex age race severity baseline hypertrophy similarly treatment difference change velocity early diastolic atrial phase transmitral blood flow enalapril treated nifedipine treated patient require supplemental treatment hydrochlorothiazide versus p atenolol versus n daily antihypertensive treatment enalapril long acting nifedipine plus adjunctive hydrochlorothiazide atenolol need control blood pressure moderately beneficial statistically indistinguishable effect regression lv hypertrophy,Devereux RB,2001,Circulation,https://doi.org/10.1161/hc3601.095927,11551875,Devereux RB; Palmieri V; Sharpe N; De Quattro V; Bella JN; de Simone G; Walker JF; Hahn RT; Dahlöf B,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000806: Angiotensin-Converting Enzyme Inhibitors; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003971: Diastole; D004311: Double-Blind Method; D004562: Electrocardiography; D004656: Enalapril; D005260: Female; D006352: Heart Ventricles; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D017379: Hypertrophy, Left Ventricular; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011446: Prospective Studies; D016896: Treatment Outcome",,,https://openalex.org/W2097955555,203,22,1,1681,261,5,en,en
false,systematic approach management preterm labor,preterm birth occur delivery account perinatal morbidity mortality although ability obstetric care provider identify woman risk preterm delivery improve overall incidence preterm birth remain unchanged past year preterm birth remain single great challenge physician researchers field maternal fetal medicine st century article review detail current state literature regard etiology pathophysiology prevention treatment premature labor preterm birth good understanding molecular mechanism responsible process labor term preterm improve ability identify manage woman risk premature delivery,Norwitz ER,2001,Semin Perinatol,https://doi.org/10.1053/sper.2001.26417,11561910,Norwitz ER; Robinson JN,article,D016428: Journal Article; D016454: Review,"D000818: Animals; D005260: Female; D006728: Hormones; D006801: Humans; D007743: Labor, Obstetric; D007752: Obstetric Labor, Premature; D011247: Pregnancy; D012307: Risk Factors; D015145: Tocolysis",,,https://openalex.org/W2172172420,56,9,1,827,143,5,en,en
false,prevention strategy circumvent drug resistance cancer chemotherapy,development drug resistance consider major cause failure chemotherapy number type cancer include ovarian breast lung previous research focus approach reverse drug resistance arise use agent make drug resistant tumor sensitive chemotherapy unfortunately approach thus far meet limited clinical success prevalence drug resistance case advanced cancer exist urgent need develop new approach deal problem hypothesize feasibility alternative approach use specific agent prevent development resistance arise initial study examine hypothesis focus ovarian cancer design vitro vivo system resistance develop rapidly exposure tumor cell xenograft melphalan cisplatin use system show two selenium compound selenite selenomethionine able prevent induction resistance furthermore inclusion selenite chemotherapeutic protocol result significant enhancement efficacy cisplatin suppress growth human ovarian tumor xenograft result support idea prevention may useful new approach problem drug resistance cancer chemotherapy,Frenkel GD,2001,Curr Pharm Des,https://doi.org/10.2174/1381612013397186,11562301,Frenkel GD; Caffrey PB,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.; D016454: Review","D000818: Animals; D000970: Antineoplastic Agents; D019008: Drug Resistance, Neoplasm; D006801: Humans; D009369: Neoplasms",,,https://openalex.org/W1922652708,78,10,1,1471,250,10,en,en
false,multicenter randomize double blind study valsartan hydrochlorothiazide combination versus amlodipine patient mild moderate hypertension,objective compare antihypertensive efficacy tolerability daily fixed valsartan hydrochlorothiazide hctz combination amlodipine subject mild moderate hypertension subject set multicentre double blind randomize comparative trial patient sit systolic blood pressure bp mmhg sit diastolic bp mmhg end week placebo wash period randomize valsartan based treatment n amlodipine n method patient receive valsartan mg amlodipine mg week case unsatisfactory blood pressure response treatment could respectively change fixed combination valsartan mg hctz mg amlodipine mg week result treatment approach decrease systolic blood pressure diastolic blood pressure extent rate responder treatment end fourth week titration among valsartan treated patient among amlodipine treated patient ns end study rate responder significantly different two group versus valsartan based treatment slightly low incidence adverse event versus p conclusion result trial demonstrate valsartan hydrochlorothiazide combination amlodipine equally effective lower bp combination well tolerate,Palatini P,2001,J Hypertens,https://doi.org/10.1097/00004872-200109000-00023,11564991,Palatini P; Malacco E; Fogari R; Carretta R; Bonaduce D; Bertocchi F; Mann J; Condorelli M; Italian Collaborative Study Group,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D004311: Double-Blind Method; D004338: Drug Combinations; D005260: Female; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D012720: Severity of Illness Index; D013777: Tetrazoles; D016896: Treatment Outcome; D014633: Valine; D000068756: Valsartan,,,https://openalex.org/W2329929440,154,18,1,1548,272,11,en,en
false,perioperative cardiac complication,although infrequent perioperative cardiac complication source major morbidity mortality population age prevalence cardiovascular disease increase physician refer patient surgery well clinician directly involve perioperative medical care understanding perioperative cardiac complication reduction complication treatment complication essential article summarize approach perioperative hypertension hypotension myocardial ischemia myocardial infarction congestive heart failure,Weitz HH,2001,Med Clin North Am,https://doi.org/10.1016/s0025-7125(05)70370-9,11565492,Weitz HH,article,D016428: Journal Article; D016454: Review,D002318: Cardiovascular Diseases; D006331: Heart Diseases; D006333: Heart Failure; D006801: Humans; D006973: Hypertension; D007022: Hypotension; D007431: Intraoperative Complications; D009203: Myocardial Infarction; D017202: Myocardial Ischemia; D011183: Postoperative Complications,,,https://openalex.org/W2122765407,35,3,1,594,88,4,en,en
false,renoprotective effect angiotensin receptor antagonist irbesartan patient nephropathy due type diabetes,unknown whether either angiotensin ii receptor blocker irbesartan calcium channel blocker amlodipine slow progression nephropathy patient type diabetes independently capacity lower systemic blood pressure randomly assign hypertensive patient nephropathy due type diabetes treatment irbesartan mg daily amlodipine mg daily placebo target blood pressure mm hg less group compare group regard time primary composite end point doubling base line serum creatinine concentration development end stage renal disease death cause also compare regard time secondary cardiovascular composite end point mean duration follow year treatment irbesartan associate risk primary composite end point percent low placebo group p percent low amlodipine group p risk doubling serum creatinine concentration percent lower irbesartan group placebo group p percent lower irbesartan group amlodipine group p treatment irbesartan associate relative risk end stage renal disease percent low group p comparison difference explain difference blood pressure achieve serum creatinine concentration increase percent slowly irbesartan group placebo group p percent slowly amlodipine group p significant difference rate death cause cardiovascular composite end point angiotensin ii receptor blocker irbesartan effective protect progression nephropathy due type diabetes protection independent reduction blood pressure cause,Lewis EJ,2001,N Engl J Med,https://doi.org/10.1056/nejmoa011303,11565517,Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I; Collaborative Study Group,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D017311: Amlodipine; D057911: Angiotensin Receptor Antagonists; D000959: Antihypertensive Agents; D001713: Biphenyl Compounds; D002121: Calcium Channel Blockers; D003404: Creatinine; D003924: Diabetes Mellitus, Type 2; D003928: Diabetic Nephropathies; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D000077405: Irbesartan; D007676: Kidney Failure, Chronic; D008297: Male; D008875: Middle Aged; D016016: Proportional Hazards Models; D013777: Tetrazoles",,,https://openalex.org/W2044773944,123,16,1,2095,363,11,en,en
false,effect losartan renal cardiovascular outcome patient type diabetes nephropathy,diabetic nephropathy lead cause end stage renal disease interruption renin angiotensin system slow progression renal disease patient type diabetes similar data available patient type common form diabetes assess role angiotensin ii receptor antagonist losartan patient type diabetes nephropathy total patient enrol randomized double blind study compare losartan mg daily placebo take addition conventional antihypertensive treatment calcium channel antagonist diuretic alpha blocker beta blockers centrally act agent mean year primary outcome composite doubling base line serum creatinine concentration end stage renal disease death secondary end point include composite morbidity mortality cardiovascular cause proteinuria rate progression renal disease total patient losartan group reach primary end point compare placebo group risk reduction percent p losartan reduce incidence doubling serum creatinine concentration risk reduction percent p end stage renal disease risk reduction percent p effect rate death benefit exceed attributable change blood pressure composite morbidity mortality cardiovascular cause similar two group although rate first hospitalization heart failure significantly low losartan risk reduction percent p level proteinuria decline percent losartan p comparison placebo losartan confer significant renal benefit patient type diabetes nephropathy generally well tolerate,Brenner BM,2001,N Engl J Med,https://doi.org/10.1056/nejmoa011161,11565518,Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Parving HH; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S; RENAAL Study Investigators,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D057911: Angiotensin Receptor Antagonists; D000959: Antihypertensive Agents; D002318: Cardiovascular Diseases; D003401: Creatine; D003404: Creatinine; D003924: Diabetes Mellitus, Type 2; D003928: Diabetic Nephropathies; D018450: Disease Progression; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D007676: Kidney Failure, Chronic; D019808: Losartan; D008297: Male; D008875: Middle Aged; D011507: Proteinuria",,,https://openalex.org/W2056976690,105,16,1,1951,336,9,en,en
false,pharmacological management detrusor instability,urinary incontinence low urinary tract dysfunction remain important cause morbidity affect least woman age year whilst etiology pathophysiology detrusor instability remain elucidate drug therapy remain important management woman irritative symptom urgency frequency urge incontinence number drug develop illustrate point none ideal often systemic adverse effect limit therapeutic usage affect compliance review aim assess current pharmacological management detrusor instability well examine recent progress development new agent may prove efficacious,Robinson D,2001,Int Urogynecol J Pelvic Floor Dysfunct,https://doi.org/10.1007/pl00004037,11569658,Robinson D; Khullar V; Cardozo L,article,D016428: Journal Article; D016454: Review,"D000317: Adrenergic alpha-Antagonists; D000318: Adrenergic beta-Agonists; D000929: Antidepressive Agents, Tricyclic; D002121: Calcium Channel Blockers; D018680: Cholinergic Antagonists; D016861: Cyclooxygenase Inhibitors; D005260: Female; D006801: Humans; D009135: Muscular Diseases; D009498: Neurotoxins; D010276: Parasympatholytics; D015221: Potassium Channels; D014570: Urologic Diseases",,,https://openalex.org/W2077313130,50,5,1,765,124,4,en,en
false,management hypertension general practitioner italian observational study,data patient receive antihypertensive therapy collect general practitioner gps campania italy determine prescription different antihypertensive class use drug concomitant disease investigate main factor influence antihypertensive choice document treatment outcome assess adverse drug reaction adrs gp complete data card consultation produce antihypertensive prescription card collect frequently use antihypertensive angiotensin converting enzyme inhibitor calcium antagonist beta blocker angiotensin ii receptor blocker alpha blocker patient blood pressure reduce reach normotensive level choice antihypertensive treatment influence international guideline clinical diagnosis concomitant disease cost compliance factor adrs often cough edema headache tachycardia occur patient,Mazzeo F,2001,Adv Ther,https://doi.org/10.1007/bf02850300,11571824,Mazzeo F; Motola G; Rossi S; Russo F; Vitelli MR; Capuano A; Rossi F; Filippelli A,article,D016428: Journal Article,D000959: Antihypertensive Agents; D003625: Data Collection; D004363: Drug Utilization; D005194: Family Practice; D005260: Female; D006801: Humans; D006973: Hypertension; D007558: Italy; D008297: Male; D008875: Middle Aged,,,https://openalex.org/W2057599887,83,11,1,1139,228,6,en,en
false,comparison select antihypertensive use conventional vs ambulatory blood pressure detection treatment hypertension,multicenter randomize double blind parallel group study undertake determine effectiveness select antihypertensive doxazosin amlodipine enalapril bendrofluazide maintain hour control blood pressure bp predictive value ambulatory bp versus clinic c bp measurement method detect patient hypertension also evaluate total patient screen diagnose mild moderately hypertensive clinic diastolic bp mm hg mm hg patient coronary heart disease risk factor antihypertensive equally effective control bp h show hour abp measurement incidence adverse event similar treatment group headache common event report patient clinically relevant reduction total cholesterol doxazosin mg dl amlodipine mg dl treatment group comparison enalapril bendrofluazide result abp measurement suggest antihypertensive study effective first line therapy regulation hypertension abp reproducible measure abp may also useful identify patient various type high bp instance white coat hypertension enable accurate screening diagnosis,Ebbs D,2001,Cardiology,https://doi.org/10.1159/000049095,11574740,Ebbs D,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D017311: Amlodipine; D000704: Analysis of Variance; D000959: Antihypertensive Agents; D001539: Bendroflumethiazide; D001794: Blood Pressure; D001795: Blood Pressure Determination; D018660: Blood Pressure Monitoring, Ambulatory; D003971: Diastole; D004311: Double-Blind Method; D017292: Doxazosin; D004656: Enalapril; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D013599: Systole; D016896: Treatment Outcome",,,https://openalex.org/W2066163471,146,21,1,1426,249,8,en,en
false,effective blood pressure treatment improve ldl cholesterol susceptibility oxidation patient essential hypertension,ldl cholesterol particle hypertensive patient exhibit enhanced susceptibility vitro oxidation abnormality thought increase cardiovascular risk test whether blood pressure bp normalization reverse abnormality double blind randomized pharmacological intervention trial clinical research centre subject total nondiabetic normolipidaemic patient essential hypertension bp mmhg normotensive control bp mmhg match gender age obesity glucose tolerance lipid profile intervention anti hypertensive treatment month calcium antagonist randomized combination either ace inhibitor beta blocker lag phase copper induced ldl oxidation cell mediated human umbilical vein endothelium generation malondialdehyde mda ldl vitamin e content ldl baseline hypertensive versus control lag phase short vs min p mda generation high vs nmol l p vitamin e reduce vs microg mg p month bp normalize p vs baseline p ns versus control lag phase prolong min p mda generation reduce nmol l p vitamin e increase microg mg p significant difference randomized groups nondiabetic nonobese normolipidaemic patient essential hypertension ldl susceptibility copper cell mediated oxidation increase bp normalization associate significant improvement full reversal abnormality,Quiñones-Galvan A,2001,J Intern Med,https://doi.org/10.1046/j.1365-2796.2001.00844.x,11576319,Quiñones-Galvan A; Pucciarelli A; Fratta-Pasini A; Garbin U; Franzoni F; Galetta F; Natali A; Cominacini L; Ferrannini E,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000959: Antihypertensive Agents; D001262: Atenolol; D008078: Cholesterol, LDL; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006973: Hypertension; D007211: Indoles; D008297: Male; D008315: Malondialdehyde; D008875: Middle Aged; D009543: Nifedipine; D018384: Oxidative Stress; D017392: Thiobarbituric Acid Reactive Substances; D014700: Verapamil",,,https://openalex.org/W2117370865,127,14,1,1771,326,8,en,en
false,effect long term cyclic iloprost therapy systemic sclerosis raynaud phenomenon randomized control study,iloprost stable prostacyclin analogue show effective short term symptomatic treatment raynaud phenomenon rp secondary systemic sclerosis ssc aim study evaluate effect long term cyclic therapy iloprost comparison nifedipine skin score pulmonary function raynaud severity score patient ssc rp conduct month prospective randomised parallel group blind observer trial compare effect intravenously infuse iloprost ng kg min consecutive day period hours day subsequently hour one day every week conventional vasodilating therapy nifedipine mg day patient ssc rp month iloprost nifedipine reduce skin score iloprost p nifedipine p n iloprost v nifedipine p rp severity score iloprost p vs baseline nifedipine p n carbon monoxide diffuse capacity dlco express predict normal value worsen significantly nifedipine group p remain stable patient treat iloprost iloprost vs nifedipine p ssc patient cyclic intravenous iloprost infusion able control vasospastic disease result suggest might also act disease modifying agent seem improve course disease study principally focus organ involvement natural history disease need confirm result,Scorza R,2001,Clin Exp Rheumatol,,11579708,Scorza R; Caronni M; Mascagni B; Berruti V; Bazzi S; Micallef E; Arpaia G; Sardina M; Origgi L; Vanoli M,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D005260: Female; D006801: Humans; D016285: Iloprost; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011446: Prospective Studies; D011653: Pulmonary Diffusing Capacity; D011658: Pulmonary Fibrosis; D011928: Raynaud Disease; D012595: Scleroderma, Systemic; D016037: Single-Blind Method; D012867: Skin; D012885: Skinfold Thickness; D016896: Treatment Outcome; D014665: Vasodilator Agents",,,https://openalex.org/W22849435,125,20,2,1815,352,6,en,en
false,use risk stratification identify patient unstable angina likeliest benefit invasive versus conservative management strategy,study design determine whether patient characteristic collect presentation identify patient benefit immediate coronary angiography revascularization risk stratification may offer method identify patient unstable angina non q wave myocardial infarction nqmi likeliest benefit invasive management strategies analysis base data randomize control trial enrol patient present unstable angina nqmi randomly assign early invasive early conservative medical management strategy construct risk stratification score patient base adjusted odds ratio clinical variable likely predict adverse outcome stratify trial subject risk score study rate death myocardial infarction mi early invasive management strategy stratum final multivariate model include old age st segment depression presentation history complicate angina presentation elevation baseline creatine kinase mb fraction although patient high risk score increase rate death mi within day day p management strategy early invasive management patient high high risk category associate low rate death mi within day compare conservative management benefit see patient large group patient low low moderate risk category p interaction risk category management assignment risk stratification may effective method identify patient unstable angina nqmi likely benefit early invasive management selective use early invasive management substantial impact reduce morbidity mortality high risk patient may warrant low risk patient,Solomon DH,2001,J Am Coll Cardiol,https://doi.org/10.1016/s0735-1097(01)01503-0,11583866,Solomon DH; Stone PH; Glynn RJ; Ganz DA; Gibson CM; Tracy R; Avorn J,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000368: Aged; D000789: Angina, Unstable; D015906: Angioplasty, Balloon, Coronary; D002097: C-Reactive Protein; D017023: Coronary Angiography; D001026: Coronary Artery Bypass; D005260: Female; D006801: Humans; D016015: Logistic Models; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D011379: Prognosis; D016032: Randomized Controlled Trials as Topic; D018570: Risk Assessment; D019210: Troponin I",,,https://openalex.org/W2171759893,146,20,1,2011,322,6,en,en
true,efficacy tolerability impact quality life long term treatment manidipine amlodipine patient essential hypertension,double blind multicenter trial compare antihypertensive efficacy tolerability impact quality life manidipine amlodipine patient mild moderate essential hypertension patient randomly assign week daily manidipine mg amlodipine mg patient respond treatment week also give enalapril mg study duration main efficacy end point equivalence sit systolic sisbp diastolic sidbp blood pressure reduction two drug week per protocol analysis intention treat itt analysis perform patient least one efficacy determination treatment quality life assess subjective symptom assessment profile ssa p general well schedule gwbs week treatment sisbp reduction week equivalent manidipine mm hg n amlodipine mm hg n corresponding figure sidbp mm hg manidipine mm hg amlodipine large itt population sidbp similarly significantly reduce manidipine mm hg n amlodipine mm hg n similar result observe sisbp stand sbp dbp neither drug change sit stand heart rate compare baseline ssa p score improve manidipine amlodipine gwbs total partial score increase manidipine amlodipine safety profile favor manidipine associate significantly less ankle edema amlodipine study show first time long term treatment long acting calcium channel blocker manidipine effective treatment amlodipine good tolerability profile induces great improvement quality life amlodipine,Zanchetti A,2001,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-200110000-00017,11588535,Zanchetti A; Omboni S; La Commare P; De Cesaris R; Palatini P,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D017311: Amlodipine; D000704: Analysis of Variance; D000959: Antihypertensive Agents; D001794: Blood Pressure; D016009: Chi-Square Distribution; D004095: Dihydropyridines; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009578: Nitrobenzenes; D010879: Piperazines; D011788: Quality of Life; D018709: Statistics, Nonparametric",,,https://openalex.org/W2333690061,146,22,1,1952,359,15,en,en
false,cell involvement cutaneous drug eruption,background frequent side effects drug therapy skin eruption pathomechanism rather unclear objective prospective study investigate cell activation drug specificity different form drug induced exanthema patient method acute drug allergy liver parameter cell subset activation circulation regulation cd hla dr evaluate skin biopsy acute lesion perform recovery causative drug identify lymphocyte transformation ltt scratch patch test result seventeen patient maculo papular exanthema bullous exanthema urticaria causative drug mainly antibiotic anti epileptics anti hypertensives regulation hla dr circulate cd cd cell detect patient mark patient bullous reaction hepatic involvement ltt positive analysed patch test patient show lymphocytic infiltration skin biopsy acute lesion generally cd cell dominate high percentage circulate cd cell find patient bullous skin reaction hepatic involvement conclusion data demonstrate activation drug specificity cell drug induced skin eruption predominant cd cell activation lead severe bullous skin symptom liver involvement predominant activation cd cell elicit mainly maculo papular reaction,Hari Y,2001,Clin Exp Allergy,https://doi.org/10.1046/j.1365-2222.2001.01164.x,11591190,Hari Y; Frutig-Schnyder K; Hurni M; Yawalkar N; Zanni MP; Schnyder B; Kappeler A; von Greyerz S; Braathen LR; Pichler WJ,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000279: Administration, Cutaneous; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D018414: CD8-Positive T-Lymphocytes; D003875: Drug Eruptions; D004342: Drug Hypersensitivity; D005076: Exanthema; D005260: Female; D006801: Humans; D008213: Lymphocyte Activation; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D012680: Sensitivity and Specificity; D012720: Severity of Illness Index; D012867: Skin; D013601: T-Lymphocytes",,,https://openalex.org/W2165715718,46,7,1,1563,258,13,en,en
false,twenty four hour ambulatory blood pressure hypertension optimal treatment hot study,hypertension optimal treatment hot study show antihypertensive treatment reduces diastolic blood pressure well mmhg reduction cardiovascular event particularly myocardial infarction evidence j shaped curve low pressure office measurement however give information blood pressure outside office paper describe hot substudy patient underwent office measurement h ambulatory blood pressure monitoring mean age substudy population year substudy patient treat median period year receive dihydropyridine calcium antagonist felodipine also receive ace inhibitor beta blocker diuretic average h day night ambulatory blood pressure value compute baseline n treatment n patient randomize target office diastolic blood pressure mmhg mmhg mmhg additional analysis include computation trough peak ratio smoothness index ratio average hourly blood pressure reduction treatment standard deviation taking subgroup whole baseline h average blood pressure mmhg significantly markedly low office blood pressure mmhg p office h day night blood pressure significantly reduce treatment small fall ambulatory office pressure group difference office blood pressure small observe overall hot sample group difference h blood pressure even small trough peak ratio smoothness index low high blood pressure target group high low blood pressure target group office ambulatory blood pressure similar group randomize placebo n acetylsalicylic acid n conclusion hot study treatment reduce office also ambulatory blood pressure throughout h reduction less marked ambulatory office blood pressure,Mancia G,2001,J Hypertens,https://doi.org/10.1097/00004872-200110000-00008,11593094,Mancia G; Omboni S; Parati G; Clement DL; Haley WE; Rahman SN; Hoogma RP,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D000369: Aged, 80 and over; D000959: Antihypertensive Agents; D001241: Aspirin; D001794: Blood Pressure; D001795: Blood Pressure Determination; D018660: Blood Pressure Monitoring, Ambulatory; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009819: Office Visits; D010975: Platelet Aggregation Inhibitors",,,https://openalex.org/W2002738846,92,14,1,2293,414,12,en,en
true,random comparison fosinopril nifedipine git patient primary renal disease,investigate random comparison capacity angiotensin convert enzyme inhibitor fosinopril long acting dihydropiridine nifedipine git modify decay renal function patient primary renal disease exhibit progressive increase serum creatinine previous years randomize open label multicenter study minimum follow year total patient include study hypertensive least mg dl increase value serum creatinine month prior enter study initial dos fosinopril nifedipine git mg respectively titration mg perform need obtain expected blood pressure goal mmhg furosemide atenolol doxazosin add second third fourth drug necessary blood pressure control primary end point study appearance double serum creatinine value need enter dialysis programme secondary end points cardiovascular event death change h proteinuria evolution serum creatinine data reflect analysis perform intention treat mean age group male primary glomerulonephritis nephrosclerosis polycystic kidney disease three frequent diagnostic finding year follow patient treat fosinopril receive nifedipine git present primary end point confidence interval p renal survival significantly good fosinopril constitute first step therapy p result seem influence type primary renal disease proteinuria decrease end study mean fosinopril group increase group receive dihydropiridine blood pressure control differ among group diastolic value follow however patient receive acei show systolic blood pressure value mmhg lower patient chronic renal failure hypertension due primary renal disease fosinopril significantly differ nifedipine git capacity slow progressive decay renal function drug also differ capacity lower blood pressure good control particular systolic blood pressure fosinopril arm could contribute relevant manner attainment good outcome acei employ,Marin R,2001,J Hypertens,https://doi.org/10.1097/00004872-200110000-00023,11593109,Marin R; Ruilope LM; Aljama P; Aranda P; Segura J; Diez J; Investigators of the ESPIRAL Study. Efecto del tratamiento antihipertensivo Sobre la Progresión de la Insuficiencia RenAL en pacientes no diabéticos,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D005260: Female; D017328: Fosinopril; D006801: Humans; D006973: Hypertension; D007668: Kidney; D007674: Kidney Diseases; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011446: Prospective Studies,,,https://openalex.org/W2044545030,92,14,1,2658,488,17,en,en
false,guideline management patient atrial fibrillation report american college cardiology american heart association task force practice guideline european society cardiology committee practice guideline policy conference committee develop guideline management patient atrial fibrillation develop collaboration north american society pacing electrophysiology,,Fuster V,2001,Eur Heart J,https://doi.org/10.1053/euhj.2001.2983,11601835,Fuster V; Rydén LE; Asinger RW; Cannom DS; Crijns HJ; Frye RL; Halperin JL; Kay GN; Klein WW; Lévy S; McNamara RL; Prystowsky EN; Wann LS; Wyse DG; American College of Cardiology; American Heart Association; European Society of Cardiology; North American Society of Pacing and Electrophysiology,article,D016431: Guideline; D016428: Journal Article; D017065: Practice Guideline,D001281: Atrial Fibrillation; D004554: Electric Countershock; D004562: Electrocardiography; D005060: Europe; D006325: Heart Atria; D006329: Heart Conduction System; D006801: Humans; D015994: Incidence; D009656: North America; D015995: Prevalence; D011379: Prognosis; D011788: Quality of Life,,,https://openalex.org/W3022495381,452,64,2,0,0,0,en,
false,guideline management patient chronic stable angina treatment,dual aim treat patient chronic stable angina reduce morbidity mortality eliminate angina minimal adverse effect allow patient return normal activity absence contraindication beta blockers recommend initial therapy beta blockers seem equally effective patient serious contraindication beta blockers unacceptable side effect persistent angina calcium antagonist administer long acting dihydropyridine nondihydropyridine agent generally effective beta blockers relieve angina long acting nitrate consider third line therapy nitrate free interval require avoid develop tolerance long acting nitrate seem equally effective patient angina take mg aspirin daily unless contraindication risk factor smoking elevate low density lipoprotein cholesterol level diabetes hypertension treat appropriately coronary revascularization show improve survival patient chronic angina may require control symptom however coronary artery bypass grafting cabg often indicate symptomatic patient left main disease three vessel disease two vessel disease include proximal stenosis left anterior descend coronary artery improve survival percutaneous transluminal coronary angioplasty alternative cabg patient normal leave ventricular function favorable angiographic feature coronary artery bypass grafting initially effective relieve angina medical therapy two procedure yield similar result year eighty percent patient undergo cabg remain angina free year surgery low risk patient percutaneous transluminal coronary angioplasty seem control angina good medical therapy recurrent angina repeat procedure likely cabg patient education important component management long term follow individualize ascertain clinical stability regular interval reassess prognosis warrant,Fihn SD,2001,Ann Intern Med,https://doi.org/10.7326/0003-4819-135-8_part_1-200110160-00014,11601935,Fihn SD; Williams SV; Daley J; Gibbons RJ; American College of Cardiology; American Heart Association; American College of Physicians-American Society of Internal Medicine,article,D016431: Guideline; D016428: Journal Article; D017065: Practice Guideline,"D000319: Adrenergic beta-Antagonists; D000328: Adult; D000465: Algorithms; D000787: Angina Pectoris; D001241: Aspirin; D002121: Calcium Channel Blockers; D002908: Chronic Disease; D000075202: Contraindications; D001026: Coronary Artery Bypass; D016861: Cyclooxygenase Inhibitors; D016757: Death, Sudden, Cardiac; D006801: Humans; D009203: Myocardial Infarction; D009566: Nitrates; D012307: Risk Factors",,,https://openalex.org/W2046592465,79,12,1,2275,346,17,en,en
false,leave ventricular outflow tract obstruction unmask nifedipine therapeutic pitfall management chronic aortic regurgitation,case report illustrate aggravation clinically silent leave ventricular outflow tract obstruction maintenance use nifedipine patient chronic severe aortic regurgitation demonstrate potential limitation vasodilator therapy management patient population recognition clinical scenario imperative decision making patient chronic severe aortic regurgitation rest development symptom leave ventricular dysfunction relation regurgitant volume importance echocardiography detection valvular finding follow patient emphasize,Novaro GM,2001,J Heart Valve Dis,,11603612,Novaro GM; Rodriguez LL,article,D002363: Case Reports; D016428: Journal Article,"D001022: Aortic Valve Insufficiency; D002908: Chronic Disease; D004452: Echocardiography; D006801: Humans; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D014665: Vasodilator Agents; D018487: Ventricular Dysfunction, Left; D014694: Ventricular Outflow Obstruction",,,https://openalex.org/W105560346,139,20,1,675,102,3,en,en
false,effect long acting calcium antagonist amlodipine diltiazem patient stable angina effort comparative randomized control trial,compare effectiveness two long acting calcium antagonist amlodipin diltiazem patient ischemic heart disease ihd stable angina effort sae ihd patient sae enter double blind randomize trial patient receive either amlodipin mg day diltiazem mg twice day week selection effective single dose control drug effectiveness regular intake carry use treadmill test make height drug activity peak effect take next dose end effect patient quit trial frequent anginal attack amlodipin administration drug show positive effect relation exercise tolerance peak effect diltiazem significantly high amlodipin end effect amlodipin increase heart rate rest diltiazem insignificantly decrease amlodipin induced side effect often typical dihydropiridin calcium antagonists amlodipin diltiazem prolonged action pronounce antianginal effect diltiazem effective less toxic,Martsevich SIu,2001,Ter Arkh,,11642080,Martsevich SIu; Sementsov DP; Kutishenko NP; Alimova EV,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,D017311: Amlodipine; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D004110: Diltiazem; D004311: Double-Blind Method; D005080: Exercise Test; D006801: Humans; D008297: Male; D008875: Middle Aged,,,https://openalex.org/W2403714801,153,24,1,1173,201,6,en,en
false,acc aha esc guideline management patient atrial fibrillation executive summary,atrial fibrillation af common sustain cardiac rhythm disturbance increase prevalence population age although often associate heart disease af occurs many patient detectable disease hemodynamic impairment thromboembolic event result significant morbidity mortality cost accordingly american college cardiology acc american heart association aha european society cardiology esc create committee expert establish guideline management arrhythmia committee compose member represent acc aha represent esc north american society pacing electrophysiology naspe representative john hopkins university evidence based practice center represent agency healthcare research quality report atrial fibrillation elderly document review official reviewer nominate acc nominate aha nominate esc well acc clinical electrophysiology committee aha ecg arrhythmia committee naspe reviewer nominate writing committee document approve publication govern body acc aha esc officially endorse naspe guideline review annually task force consider current unless task force revise withdraw distribution committee conduct comprehensive review literature june relevant af use following database pubmed medline embase cochrane library include cochrane database systematic review cochrane control trial registry best evidence search limit english language source human subject atrial fibrillation af supraventricular tachyarrhythmia characterize uncoordinated atrial activation consequent deterioration atrial mechanical function electrocardiogram ecg af,Fuster V,2001,Circulation,https://doi.org/10.1016/s0735-1097(01)01587-x,11673357,Fuster V; Rydén LE; Asinger RW; Cannom DS; Crijns HJ; Frye RL; Halperin JL; Kay GN; Klein WW; Lévy S; McNamara RL; Prystowsky EN; Wann LS; Wyse DG; Gibbons RJ; Antman EM; Alpert JS; Faxon DP; Fuster V; Gregoratos G; Hiratzka LF; Jacobs AK; Russell RO; Smith SC; Klein WW; Alonso-Garcia A; Blomström-Lundqvist C; de Backer G; Flather M; Hradec J; Oto A; Parkhomenko A; Silber S; Torbicki A; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation); North American Society of Pacing and Electrophysiology,article,D016431: Guideline; D016428: Journal Article; D017065: Practice Guideline,"D000368: Aged; D000369: Aged, 80 and over; D000465: Algorithms; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D001282: Atrial Flutter; D015897: Comorbidity; D003937: Diagnosis, Differential; D019468: Disease Management; D004554: Electric Countershock; D004562: Electrocardiography; D005260: Female; D005343: Fibrinolytic Agents; D006801: Humans; D008297: Male; D008875: Middle Aged; D015995: Prevalence; D011379: Prognosis; D044469: Racial Groups; D018570: Risk Assessment; D013610: Tachycardia; D013923: Thromboembolism",,,https://openalex.org/W2119905314,97,13,1,2096,358,12,en,en
false,best treatment slow progression end stage renal disease esrd african american hypertensive nephropathy,,McConaghy JR,2001,J Fam Pract,,11674903,McConaghy JR,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D044383: Black People; D004311: Double-Blind Method; D005260: Female; D005919: Glomerular Filtration Rate; D006801: Humans; D006977: Hypertension, Renal; D007676: Kidney Failure, Chronic; D008297: Male; D008790: Metoprolol; D008875: Middle Aged; D017257: Ramipril",,,https://openalex.org/W2443266550,140,23,1,0,0,0,en,
false,postdischarge adverse drug reaction primary care originate hospital care france,objective describe estimate incidence preventability postdischarge adverse drug reaction adrs detect primary care france design prospective study patient refer hospital participate general practitioner gps gps report case adverse reaction drug institute hospital among patient consult within day discharge setting general practice french region patient patient refer gps private public hospital main outcome measure incidence postdischarge adrs primary care preventability result case postdischarge adr detect consulting patient yield minimal incidence france per admission confidence interval adrs assess serious case main drug class implicate cardiovascular drug adrs oral anticoagulant psychoactive drug antidiabetic opioid analgesic patient experience postdischarge adr old patient experience one median age v year p detect adrs consider preventable case conclusion physician patient aware possible occurrence postdischarge adrs patient information hospital close postdischarge follow patient risk appropriate transmission information hospital physician gps help prevent,Letrilliart L,2001,Drug Saf,https://doi.org/10.2165/00002018-200124100-00006,11676305,Letrilliart L; Hanslik T; Biour M; Fagot JP; Guiguet M; Flahault A,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D016907: Adverse Drug Reaction Reporting Systems; D000367: Age Factors; D000368: Aged; D000369: Aged, 80 and over; D003625: Data Collection; D005260: Female; D005602: France; D006760: Hospitalization; D006801: Humans; D008297: Male; D008875: Middle Aged; D010351: Patient Discharge; D011320: Primary Health Care; D011446: Prospective Studies; D012307: Risk Factors; D012737: Sex Factors; D011795: Surveys and Questionnaires",,,https://openalex.org/W2080361082,93,13,1,1524,274,13,en,en
false,treat hypertension elderly,hypertension highly prevalent elderly individual rapidly grow segment u population epidemiologic study establish increase risk cardiovascular disease associate elevated blood pressure treatment hypertension elderly patient significantly reduce cardiovascular morbidity mortality however antihypertensive therapy often challenge patient population potential metabolic physiologic alteration multiple comorbidities polypharmacy biologic variability drug convenient dose schedule minimal side effect ability impact comorbid condition important consideration treatment hypertension elderly,Schrier RW,2001,Am J Geriatr Cardiol,https://doi.org/10.1111/j.1076-7460.2001.00019.x,11684921,Schrier RW,article,D016428: Journal Article; D016454: Review,"D000367: Age Factors; D000368: Aged; D000369: Aged, 80 and over; D000959: Antihypertensive Agents; D005060: Europe; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D015995: Prevalence; D012307: Risk Factors; D012737: Sex Factors; D014481: United States",,,https://openalex.org/W2117324867,36,5,1,747,107,5,en,en
false,gingival inflammatory infiltrate cardiac patient treat calcium antagonist,abstract objective analyse periodontal inflammatory infiltrates patient cardiac disease patient treat calcium antagonist nifedipine diltiazem compare healthy control group evaluate change inflammatory infiltrate periodontal treatment material method healthy group hg n cardiac group cg n without treatment calcium antagonist nifedipine group ng n diltiazem group dg n analyse biopsy take zone mm upper part interproximal papilla causal periodontal treatment year use haematoxylin eosin staining plasma cell p lymphocytes l histiocytes h polymorphonuclear cell pmn count b lymphocyte evaluate use monoclonal antibody anti cd anti cd ro statistical test use study sample composition anova comparison group student test wilcoxon test comparison visit post hoc test bonferroni result cell compare statistically difference stablished l first visit p last visit p b lymphocyte first visit p last visit p lymphocytes first visit p last visit p visit hg show significant reduction p p l p h p ng l p lymphocytes show difference ng respect b lymphocytes p conclusion nifedipine affect inflammatory infiltrate great number lymphocyte especially b cell fell significantly number periodontal treatment,Bullón P,2001,J Clin Periodontol,https://doi.org/10.1034/j.1600-051x.2001.028010897.x,11686806,Bullón P; Machuca G; Armas JR; Rojas JL; Jiménez G,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000704: Analysis of Variance; D002121: Calcium Channel Blockers; D016022: Case-Control Studies; D016009: Chi-Square Distribution; D004110: Diltiazem; D005260: Female; D005885: Gingival Hyperplasia; D005891: Gingivitis; D006644: Histiocytes; D006801: Humans; D007124: Immunoenzyme Techniques; D008214: Lymphocytes; D008297: Male; D017202: Myocardial Ischemia; D020556: Neutrophil Infiltration; D009504: Neutrophils; D009543: Nifedipine; D010950: Plasma Cells; D018709: Statistics, Nonparametric",,,https://openalex.org/W2079035553,90,12,1,1881,400,10,en,en
true,efficacy tolerability influence quality life nifedipine git versus amlodipine elderly patient mild moderate hypertension,main purpose study compare efficacy tolerability influence quality life qol nifedipine gastrointestinal therapeutic system ni mg day v amlodipine mg day elderly patient mild moderate hypertension randomized double blind parallel group multicenter study week single blind placebo run patient randomize either ni mg mg responder continue dosage additional week non responders titrate mg ni mg blood pressure measure mercury sphygmomanometer efficacy equivalence ni test covariance analysis diastolic blood pressure dbp primary efficacy parameter baseline value take covariate center effect treatment interaction include fixed effect analysis model secondary efficacy variable systolic blood pressure sbp score qol analyze accord model end study overall mean dbps calculate least square mean lsmeans protocol population mmhg ni difference mmhg ci mmhg intention treat itt population lsmeans mmhg ni mmhg difference mmhg ci mmhg sbp lsmeans protocol population mmhg ni mmhg difference mmhg ci correspond value itt population mmhg ni difference mmhg ci mean value qol parameter significantly different total episode adverse event document patient ni dropout group ni ni mg show efficacious safe mg elderly patient mild moderate hypertension qol improve compare baseline significant difference two drug thus confirm positive class effect calcium antagonist,Pessina AC,2001,Blood Press,https://doi.org/10.1080/080370501753182406,11688766,Pessina AC; Boari L; De Dominicis E; Giusti C; Marchesi M; Marelli G; Mattarei M; Mos L; Novo S; Pirrelli A; Santini M; Santonastaso M; Semeraro S; Uslenghi E; Kilama MO,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D006801: Humans; D006973: Hypertension; D008875: Middle Aged; D009543: Nifedipine; D011788: Quality of Life; D013810: Therapeutic Equivalency",,,https://openalex.org/W2098693685,146,22,1,2149,422,9,en,en
false,comparative pharmacokinetics pharmacodynamics amlodipine hypertensive patient without type ii diabetes mellitus,recent clinical trial aim attenuate complication diabetes mellitus generate interest impact drug formulation alter pharmacokinetics pharmacodynamics diabetes specifically propose diabetic state may alter pharmacokinetics several cardiovascular drug include calcium antagonist present study investigate effect diabetes mellitus pharmacokinetics pharmacodynamics amlodipine hypertensive subject without diabetes mellitus determine whether diabetic state alters parameter trial consist week placebo washout phase week titration phase week maintenance phase study patient include hypertensive patient type ii diabetes mellitus nondiabetic hypertensive patient blood sample collect administration amlodipine auc cmax tmax determine acute hour pharmacodynamic response amlodipine assess blood pressure telemetric heart rate measurement significant difference either amlodipine mg auc p mg p mg cmax p mg p mg tmax p mg p mg diabetic nondiabetic hypertensive subject similarly hour pharmacodynamic effect amlodipine systolic blood pressure diastolic blood pressure heart rate differ diabetic nondiabetic subject assess repeated measures analysis variance theoretical basis anticipate diabetes mellitus may provoke important pharmacokinetic pharmacodynamic alteration study provide important database clearly demonstrate diabetic milieu alter pharmacokinetics pharmacodynamics amlodipine,Preston RA,2001,J Clin Pharmacol,https://doi.org/10.1177/00912700122012760,11697754,Preston RA; Chung M; Gaffney M; Alonso A; Baltodano NM; Epstein M,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D019540: Area Under Curve; D001794: Blood Pressure; D003924: Diabetes Mellitus, Type 2; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2021829014,131,16,1,1892,307,10,en,en
false,cutaneous drug reaction case report,skin disorder common adverse reaction attribute drug skin disorder imitate induce aggravate drug help keep date late skin reaction occur new establish drug section journal bring information select adverse drug reaction alert service reaction weekly following case report select late publish world dermatology literature claim first report verify search adisbase proprietary database adis international auckland new zealand medline case report assess seriousness use fda medwatch definition serious patient outcome death life threatening hospitalization disability congenital anomaly require intervention prevent permanent impairment damage,,2001,Am J Clin Dermatol,https://doi.org/10.2165/00128071-200102040-00008,11705254,,article,D002363: Case Reports; D016428: Journal Article,"D000293: Adolescent; D016907: Adverse Drug Reaction Reporting Systems; D000368: Aged; D017311: Amlodipine; D000900: Anti-Bacterial Agents; D000893: Anti-Inflammatory Agents; D000894: Anti-Inflammatory Agents, Non-Steroidal; D000925: Anticoagulants; D000927: Anticonvulsants; D000959: Antihypertensive Agents; D000972: Antineoplastic Agents, Phytogenic; D000971: Antineoplastic Combined Chemotherapy Protocols; D018501: Antirheumatic Agents; D001500: BCG Vaccine; D015313: Cefotetan; D002513: Cephamycins; D003287: Contrast Media; D003545: Cysteine; D003622: Dapsone; D004110: Diltiazem; D004177: Dipyrone; D000077143: Docetaxel; D003875: Drug Eruptions; D020900: Echinacea; D017984: Enoxaparin; D005260: Female; D005632: Fructose; D005936: Glucans; D005947: Glucose; D006052: Gold Sodium Thiomalate; D006801: Humans; D007052: Ibuprofen; D000077607: Icodextrin; D007485: Ioxaglic Acid; D008297: Male; D008875: Middle Aged; D008911: Minocycline; D017239: Paclitaxel; D011247: Pregnancy; D012997: Solvents; D043823: Taxoids; D000077236: Topiramate; D014221: Triamcinolone; D014241: Trichloroethylene",,,https://openalex.org/W4243298127,36,5,1,898,153,6,en,en
false,adverse beneficial effect tocolytic therapy,addition question raise efficacy many tocolytics appropriate concern voice safety potent drug although degree risk adverse effect drug promise strong therapeutic effect accept caution need exercise benefit marginal unproven unfortunately tocolytics notably betamimetics magnesium sulfate find considerable potential adverse maternal cardiovascular respiratory effect although less clearly establish use indomethacin appear associate increased fetal neonatal risk concern magnesium sulfate addition well known maternal effect accumulate evidence show increased frequency adverse outcome fetus neonate lead recommendation abandon use entirely tocolytic give limitation current state knowledge nifedipine would appear among efficacious safer tocolytics available use properly indicate,Pryde PG,2001,Semin Perinatol,https://doi.org/10.1053/sper.2001.27547,11707019,Pryde PG; Besinger RE; Gianopoulos JG; Mittendorf R,article,D016428: Journal Article; D016454: Review,"D000318: Adrenergic beta-Agonists; D002121: Calcium Channel Blockers; D016861: Cyclooxygenase Inhibitors; D005260: Female; D005313: Fetal Death; D005315: Fetal Diseases; D006801: Humans; D008278: Magnesium Sulfate; D007752: Obstetric Labor, Premature; D010121: Oxytocin; D011247: Pregnancy; D016032: Randomized Controlled Trials as Topic; D015149: Tocolytic Agents; D014668: Vasotocin",,,https://openalex.org/W2035970031,51,7,1,1088,176,6,en,en
false,change long acting antianginals provide good symptom control treatment satisfaction quality life,,Maniscalco MM,2001,J Fam Pract,,11711020,Maniscalco MM; Newton W,article,D016428: Journal Article,D000203: Activities of Daily Living; D000318: Adrenergic beta-Agonists; D000368: Aged; D000787: Angina Pectoris; D001262: Atenolol; D003692: Delayed-Action Preparations; D004110: Diltiazem; D019317: Evidence-Based Medicine; D006801: Humans; D008297: Male; D005996: Nitroglycerin; D017060: Patient Satisfaction; D017410: Practice Guidelines as Topic; D011788: Quality of Life; D012107: Research Design; D012720: Severity of Illness Index; D011795: Surveys and Questionnaires; D016896: Treatment Outcome; D014665: Vasodilator Agents,,,https://openalex.org/W2410593798,118,19,1,0,0,0,en,
true,one year study felodipine placebo stage isolated systolic hypertension,substantial number old hypertensive patient stage isolated systolic hypertension systolic blood pressure mm hg diastolic blood pressure mm hg currently data showing drug treatment effective safe beneficial compare effect active treatment compare placebo blood pressure leave ventricular hypertrophy quality life among old stage isolated systolic hypertensive patient randomize double blind parallel group multicenter clinical trial compare felodipine mg daily match placebo perform patient male average age year white hispanic baseline blood pressure mm hg week treatment patient randomize active treatment achieve significantly low blood pressure mm hg extended release felodipine versus mm hg placebo p reduced incidence left ventricular hypertrophy extended release felodipine versus placebo p improved quality life change psychological general well index extended release felodipine versus placebo p versus baseline clinically significant difference treatment tolerability adverse effect stage isolated systolic hypertension effectively safely treat pharmacologically treatment reduce progression high stage hypertension reduce incidence left ventricular hypertrophy improve overall measure quality life large long study need document long term reduction cardiovascular event rate associate treat stage systolic hypertension,Black HR,2001,Hypertension,https://doi.org/10.1161/hy1101.095000,11711508,Black HR; Elliott WJ; Weber MA; Frishman WH; Strom JA; Liebson PR; Hwang CT; Ruff DA; Montoro R; DeQuattro V; Zhang D; Schleman MM; Klibaner MI,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D004311: Double-Blind Method; D004452: Echocardiography; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D017379: Hypertrophy, Left Ventricular; D008297: Male; D008875: Middle Aged; D011788: Quality of Life; D013599: Systole",,,https://openalex.org/W1985434203,82,12,1,1865,321,7,en,en
false,safety controlled onset extended release verapamil middle aged old patient hypertension coronary artery disease,purpose study safety controlled onset extended release coer verapamil patient hypertension coronary artery disease focus elderly patients adverse event data pool double blind multicenter randomize trial include patient hypertension chronic stable angina pectoris patient receive coer verapamil mg daily evening week patient receive placebo receive active comparator agent data analyze accord follow group patient patient hypertension patient angina old patient year old young patient year old adverse event rate compare across treatment group fisher exact test patient combine incidence constipation vs dizziness vs back pain vs higher patient treat coer verapamil placebo patient hypertension back pain vs constipation vs coer verapamil placebo whereas patient angina bradycardia vs dizziness vs constipation vs old patient treat coer verapamil bradycardia constipation dizziness fatigue headache compare young patient treat coer verapamil second third degree atrioventricular block observe administration coer verapamil subgroup data demonstrate coer verapamil acceptable safety profile largely unrelated age patient hypertension coronary artery disease,White WB,2001,Am Heart J,https://doi.org/10.1067/mhj.2001.119127,11717605,White WB; Johnson MF; Anders RJ; Elliott WJ; Black HR,article,"D016428: Journal Article; D017418: Meta-Analysis; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000787: Angina Pectoris; D001416: Back Pain; D003248: Constipation; D003692: Delayed-Action Preparations; D004244: Dizziness; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D014700: Verapamil",,,https://openalex.org/W1996466480,133,16,1,1714,325,7,en,en
false,comparison hour blood pressure profile patient hypertension switch amlodipine nisoldipine,study objective compare hour blood pressure control adverse effect patient essential hypertension switch amlodipine nisoldipine design open label one way crossover study set cardiac clinic patient home patient twenty five patient stage ii essential hypertension stabilize amlodipine least month patient complete study intervention patient underwent hour ambulatory blood pressure monitor receive amlodipine mg day patient switch nisoldipine mg day yrs old mg day yrs old return clinic week interval assess cuff blood pressure heart rate adverse effect compliance adverse effect experience patient low extremity edema commonly report adverse effect four patient two patient discontinue treatment pulmonary edema one chest pain two patient lose follow mean week repeat hour ambulatory monitoring perform evaluate blood pressure control nisoldipine systolic diastolic ambulatory result daytime nighttime total hour calculate amlodipine versus nisoldipine significant difference exist blood pressure parameter p patient complete study except hour diastolic pressure p however latter difference mm hg nisoldipine mm hg amlodipine mm hg conclusion amlodipine nisoldipine similar hour ambulatory blood pressure profile frequency low extremity edema different switch nisoldipine patient take amlodipine,Lenz TL,2001,Pharmacotherapy,https://doi.org/10.1592/phco.21.11.898.34518,11718496,Lenz TL; Wurdeman RL; Hilleman DE,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article,"D000328: Adult; D000368: Aged; D017311: Amlodipine; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D015737: Nisoldipine; D010349: Patient Compliance; D013997: Time Factors",,,https://openalex.org/W1994196784,124,17,1,1839,328,21,en,en
false,beneficial effect diltiazem myocardial reperfusion randomized trial acute myocardial infarction,although experimental model coronary occlusion diltiazem administration show reduce degree stun reperfusion injury majority clinical trial fail demonstrate significant benefit aim study evaluate effect diltiazem administer coronary reperfusion infarct size residual myocardial viability recovery left ventricular function study patient admit within hour onset symptom acute myocardial infarction immediately randomize either intravenous diltiazem mg bolus mg hour day group n placebo group n subsequently treat recombinant tissue type plasminogen activator underwent serial echocardiogram upon admission day post admission low dose dobutamine stress echo discharge month calculate dysfunction score hypokinesia akinesia dyskinesia admission percent reduction dobutamine viability follow recovery lead electrocardiogram continuously monitor day coronary angioplasty perform whenever residual stenosis upon admission difference age sex infarct location size degree st segment elevation time onset symptom dysfunction score creatine kinase peak early patient group incidence recurrent ischemia infarct related vessel patency need coronary angioplasty also similar creatine kinase peak significantly high group v iu l p conversely group residual viability significantly high vs improvement dysfunction score p early recovery regional function significantly great vs discharge p hand delayed recovery significantly different vs time discharge month follow intravenous diltiazem start coronary reperfusion beneficial effect infarct size residual viability recovery regional function confirm large trial preliminary result suggest use diltiazem adjunctive therapy patient acute myocardial infarction undergoing reperfusion,Pizzetti G,2001,Ital Heart J,,11721720,Pizzetti G; Mailhac A; Li Volsi L; Di Marco F; Lu C; Margonato A; Chierchia SL,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D002121: Calcium Channel Blockers; D017023: Coronary Angiography; D004110: Diltiazem; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D025401: Echocardiography, Stress; D005260: Female; D005500: Follow-Up Studies; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D015428: Myocardial Reperfusion Injury; D010960: Plasminogen Activators; D012307: Risk Factors; D015912: Thrombolytic Therapy; D010959: Tissue Plasminogen Activator; D016277: Ventricular Function, Left",,,https://openalex.org/W2411523684,113,16,1,2451,437,11,en,en
false,effect dihydropyridine phenylalkylamine calcium antagonist class autonomic function hypertension vamphyre study,aim present study compare effect long acting dihydropyridine amlodipine nondihydropyridine verapamil autonomic function patient mild moderate hypertension total patient diastolic blood pressure bp mm hg receive week verapamil sustain release mg amlodipine mg prospective randomized double blind cross study week placebo h autonomic balance measure analysis h heart rate variability short term autonomic control bp baroreflex sensitivity measurement plasma norepinephrine sample rest blood pressure equally reduce mm hg mm hg verapamil mm hg amlodipine p low high frequency ratio lf hf reflect sympathovagal balance higher amlodipine verapamil v p baroreflex function improve treatment however baroreflex sensitivity br significantly high verapamil amlodipine v msec mm hg p plasma norepinephrine ne level higher amlodipine verapamil v nmol l p amlodipine induce shift sympathovagal balance measure heart rate variability index plasma ne toward sympathetic predominance compare vagal predominance verapamil short term autonomic control bp assess br effectively improve verapamil amlodipine contrast effect autonomic function suggest nondihydropyridine calcium antagonist verapamil may additional beneficial effect beyond lower bp compare dihydropyridine amlodipine,Lefrandt JD,2001,Am J Hypertens,https://doi.org/10.1016/s0895-7061(01)02218-x,11724204,Lefrandt JD; Heitmann J; Sevre K; Castellano M; Hausberg M; Fallon M; Fluckiger L; Urbigkeit A; Rostrup M; Agabiti-Rosei E; Rahn KH; Murphy M; Zannad F; de Kam PJ; van Roon AM; Smit AJ,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D001341: Autonomic Nervous System; D017704: Baroreflex; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002352: Carrier Proteins; D018592: Cross-Over Studies; D004095: Dihydropyridines; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D012720: Severity of Illness Index; D013251: Steroid Isomerases; D016896: Treatment Outcome; D014700: Verapamil,,,https://openalex.org/W2102654217,136,18,1,1780,312,11,en,en
false,contrast effect verapamil amlodipine cardiovascular stress response hypertension,compare effect two long acting calcium antagonist different type cardiovascular stress response hypertension one hundred forty five patient mild moderate hypertension mean e mean age year receive week phenylalkylamine verapamil sustain release mg dihydropyridine amlodipine mg double blind cross design week placebo blood pressure heart rate plasma noradrenaline monitor min sustained isometric handgrip min cold pressor blood pressure equally reduce drug min handgrip systolic blood pressure heart rate rate pressure product low verapamil compare amlodipine verapamil attenuate increase systolic blood pressure vs mmhg difference ci p rate pressure product vs x mmhg x beat min difference ci p handgrip compare amlodipine similar result observed cold pressor plasma noradrenaline level low verapamil compare amlodipine rest test increase plasma noradrenaline significantly different verapamil effective reduce blood pressure rate pressure product response stress compare amlodipine although plasma noradrenaline low verapamil rest stress increase stress different,Lefrandt JD,2001,Br J Clin Pharmacol,https://doi.org/10.1046/j.0306-5251.2001.01507.x,11736880,Lefrandt JD; Heitmann J; Sevre K; Castellano M; Hausberg M; Fallon M; Urbigkeit A; Rostrup M; Agabiti-Rosei E; Rahn KH; Murphy M; Zannad F; de Kam PJ; Smit AJ,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D017311: Amlodipine; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D004311: Double-Blind Method; D005080: Exercise Test; D005260: Female; D006339: Heart Rate; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009638: Norepinephrine; D019722: Sphygmomanometers; D014700: Verapamil,,,https://openalex.org/W1576015387,98,12,1,1558,279,7,en,en
false,efficacy nifedipine lisinopril treatment hypertension renal transplantation double blind randomise comparative trial,calcium channel blocker angiotensin convert enzyme inhibitors commonly use treatment hypertensive renal transplant recipient purpose study investigate response rate treatment differs drug setting single centre prospective randomised double blinded comparative study address efficacy controlled release nifedipine lisinopril treatment hypertension diastolic blood pressure mmhg cyclosporin csa treated renal transplant recipient perform recipient randomise receive either lisinopril mg daily control release nifedipine mg daily dose double indication number responder diastolic blood pressure mmhg monotherapy address early post transplant phase first month late post transplant phase month renal transplantation patient population one hundred fifty four patient nifedipine lisinopril untreated hypertension diastolic blood pressure mmhg randomise within wk renal transplantation one hundred twenty three patient nifedipine lisinopril complete study fourteen nifedipine treated recipient respond early late post operative phase month renal transplantation eleven lisinopril treated recipient respond early late post transplant phase non responders average kg heavy early phase yr treatment p yr old responder p conclusion result indicate control release nifedipine lisinopril equally efficient treatment post transplant hypertension monotherapy drug show response rate depend time interval transplantation,Midtvedt K,2001,Clin Transplant,https://doi.org/10.1034/j.1399-0012.2001.150611.x,11737121,Midtvedt K; Hartmann A; Holdaas H; Fauchald P,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D000959: Antihypertensive Agents; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D016030: Kidney Transplantation; D017706: Lisinopril; D008297: Male; D009543: Nifedipine; D011183: Postoperative Complications; D011446: Prospective Studies; D014665: Vasodilator Agents,,,https://openalex.org/W1984527042,142,19,1,2008,351,13,en,en
true,double blind parallel group study amlodipine versus long acting nitrate management elderly patient stable angina,ninety seven elderly patient stable angina include week randomize double blind parallel group comparison amlodipine mg isosorbide mononitrate mg daily total exercise time limit angina record together median incidence per week angina attack glyceryl trinitrate consumption safety assess adverse event frequency measurement vital sign laboratory parameter quality life final visit total exercise time significantly great relative baseline amlodipine isosorbide mononitrate final baseline difference vs p statistically significant difference group relation incidence adverse event daily amlodipine provide significantly well control stable angina isosorbide mononitrate elderly population,Hall R,2001,Cardiology,https://doi.org/10.1159/000047392,11740135,Hall R; Chong C,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D000787: Angina Pectoris; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004487: Edema; D005080: Exercise Test; D017079: Exercise Tolerance; D005260: Female; D006261: Headache; D006339: Heart Rate; D006801: Humans; D007548: Isosorbide Dinitrate; D008297: Male; D008875: Middle Aged; D005996: Nitroglycerin; D011788: Quality of Life; D013997: Time Factors; D014665: Vasodilator Agents",,,https://openalex.org/W2066255692,134,19,1,923,147,6,en,en
false,sustained improvement renal graft function two year hypertensive renal transplant recipient treat nifedipine compare lisinopril,treatment posttransplant hypertension still matter debate calcium antagonist may ameliorate renal side effect cyclosporin angiotensin convert enzyme ace inhibitor may effective sustain renal function native chronic renal disease prospectively compare effect controlled release nifedipine lisinopril long term renal function hypertensive kidney transplant patient treat cyclosporin total renal transplant patient present hypertension diastolic blood pressure mmhg first week transplantation randomise receive double blind nifedipine mg lisinopril mg daily total patient complete year treatment nifedipine lisinopril patient complete year double blind treatment nifedipine lisinopril baseline glomerular filtration rate measure mtc diethylene triaminepentaacetate clearance stable phase week inclusion repeat years baseline glomerular filtration rate similar ml min nifedipine ml min lisinopril change glomerular filtration rate baseline statistically significant group year ml min mean treatment difference confidence interval ci ml min p remain statistically significant also year ml min mean difference cis p year glomerular filtration rate average ml min nifedipine group ml min lisinopril group nifedipine lisinopril safe effective treatment hypertension renal transplant patient treat cyclosporin patient receive nifedipine lisinopril improve kidney transplant function period year,Midtvedt K,2001,Transplantation,https://doi.org/10.1097/00007890-200112150-00013,11740389,Midtvedt K; Hartmann A; Foss A; Fauchald P; Nordal KP; Rootwelt K; Holdaas H,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D007166: Immunosuppressive Agents; D007668: Kidney; D016030: Kidney Transplantation; D017706: Lisinopril; D008297: Male; D008875: Middle Aged; D009543: Nifedipine,,,https://openalex.org/W2040921457,154,21,1,1884,298,9,en,en
false,atrial fibrillation cardiac surgery,review epidemiology mechanism complication predictor prevention treatment atrial fibrillation follow cardiac surgery medline search english language report publish search reference relevant papers clinical basic research study atrial fibrillation cardiac surgery relevant clinical information extract select articles atrial fibrillation occur patient cardiac surgery usually second third postoperative day postoperative atrial fibrillation associate increased morbidity mortality long expensive hospital stay prophylactic use beta adrenergic blocker reduce incidence postoperative atrial fibrillation administer cardiac surgery patient without contraindication prophylactic amiodarone atrial overdrive pacing consider patient high risk postoperative atrial fibrillation example patient previous atrial fibrillation mitral valve surgery patient develop atrial fibrillation cardiac surgery strategy rhythm management rate management select patient hemodynamically unstable highly symptomatic contraindication anticoagulation rhythm management electrical cardioversion amiodarone prefer treatment remain patient focus rate control spontaneously revert sinus rhythm within week discharge patient atrial fibrillation persist hour without contraindication receive anticoagulation atrial fibrillation frequently complicate cardiac surgery many case prevent appropriate prophylactic therapy strategy rhythm management symptomatic patient rate management patient usually result reversion sinus rhythm within week discharge,Maisel WH,2001,Ann Intern Med,https://doi.org/10.7326/0003-4819-135-12-200112180-00010,11747385,Maisel WH; Rawn JD; Stevenson WG,article,D016428: Journal Article; D016454: Review,"D000319: Adrenergic beta-Antagonists; D000465: Algorithms; D000638: Amiodarone; D000889: Anti-Arrhythmia Agents; D000925: Anticoagulants; D001281: Atrial Fibrillation; D002304: Cardiac Pacing, Artificial; D001026: Coronary Artery Bypass; D004554: Electric Countershock; D006801: Humans; D007902: Length of Stay; D012307: Risk Factors",,,https://openalex.org/W2096382911,41,5,1,2023,295,10,en,en
false,statin associated myopathy,statin hydroxy methylglutaryl coenzyme reductase inhibitor associate skeletal muscle complaint include clinically important myositis rhabdomyolysis mild serum creatine kinase ck elevation myalgia without elevate ck level muscle weakness muscle cramp persistent myalgia ck elevation statin withdrawal perform literature review provide clinical summary statin associated myopathy discus possible mediating mechanism also update u food drug administration fda report statin associated rhabdomyolysis article statin myopathy identify via pubmed search november article statin clinical trial case series review article identify via pubmed search january adverse event report statin associated rhabdomyolysis also collect fda medwatch database literature review find report muscle problem statin clinical trial extremely rare fda medwatch reporting system list case statin associated rhabdomyolysis report january march cerivastatin commonly implicated statin data available regard frequency less serious event muscle pain weakness may affect patient risk rhabdomyolysis adverse effect statin use exacerbate several factor include compromise hepatic renal function hypothyroidism diabetes concomitant medication medication fibrate gemfibrozil alter statin metabolism increase statin plasma concentration statins injure skeletal muscle clear although recent evidence suggest statins reduce production small regulatory protein important myocyte maintenance,Hamilton-Craig I,2001,Med J Aust,https://doi.org/10.5694/j.1326-5377.2001.tb143683.x,11758079,Hamilton-Craig I,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review",D003402: Creatine Kinase; D004347: Drug Interactions; D016903: Drug Monitoring; D006801: Humans; D019161: Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960: Hypolipidemic Agents; D009135: Muscular Diseases; D011725: Pyridines,,,https://openalex.org/W31982687,26,2,1,1890,296,12,en,en
false,review class iii antiarrhythmic agent atrial fibrillation maintenance normal sinus rhythm,noteworthy shift class class iii antiarrhythmic agent suppression atrial fibrillation occur sotalol amiodarone dofetilide evaluate ability maintain sinus rhythm patient chronic atrial fibrillation agent moderately effective however amiodarone appear efficacious aside common class iii action agent profoundly different pharmacologic pharmacokinetic safety drug interaction profile help guide drug selection amiodarone dofetilide safe patient myocardial infarction heart failure safety commercially available l sotalol patient poorly understood torsades de pointes serious adverse effect sotalol dofetilide risk increase renal dysfunction amiodarone minimal proarrhythmic risk numerous noncardiac toxicity require frequent monitoring overall ideal antiarrhythmic agent exist drug selection highly individualize,Tsikouris JP,2001,Pharmacotherapy,https://doi.org/10.1592/phco.21.20.1514.34484,11765303,Tsikouris JP; Cox CD,article,D016428: Journal Article; D016454: Review,D000638: Amiodarone; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D002986: Clinical Trials as Topic; D004347: Drug Interactions; D006801: Humans; D010627: Phenethylamines; D013015: Sotalol; D013449: Sulfonamides,,,https://openalex.org/W2150951063,103,16,1,1096,176,9,en,en
false,effect two antihypertensive combination metabolic control type diabetic hypertensive patient albuminuria randomised double blind study,objective study compare equal blood pressure bp reduction effect two different combination metabolic control albuminuria type diabetic hypertensive patient albuminuria prospective randomised double blind parallel controlled trial carry spanish hospital total type diabetic patient stable albuminuria bp control monotherapy randomise finish study week single blind placebo period patient randomise verapamil sr trandolapril mg vt enalapril hydroclorothiazide mg eh treatment duration month main outcome measure change bp h albuminuria blood glucose glycated haemoglobin overall bp significantly reduce mm hg mm hg p albuminuria significantly decrease mg h mg h p without significant difference treatment glycated haemoglobin modify vt baseline end treatment increase eh baseline final anova interaction p end study blood glucose mg dl attain vt group improving worsening patient p eh group patient improve worsen p change body weight serum creatinine uric acid potassium cholesterol tryglicerides serum albumin hypertensive type diabetic patient control monotherapy treatment similarly reduce albuminuria combination verapamil trandolapril seem allow good metabolic control enalapril hydroclorothiazide,Fernández R,2001,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1001279,11773987,Fernández R; Puig JG; Rodríguez-Pérez JC; Garrido J; Redon J; TRAVEND Study Group,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000419: Albuminuria; D000704: Analysis of Variance; D000959: Antihypertensive Agents; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004656: Enalapril; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D007211: Indoles; D008297: Male; D008875: Middle Aged; D015999: Multivariate Analysis; D011336: Probability; D011446: Prospective Studies; D013030: Spain; D016896: Treatment Outcome; D014700: Verapamil",,,https://openalex.org/W1990166565,156,21,1,1883,356,12,en,en
false,gender age effect ambulatory blood pressure heart rate response antihypertensive therapy,aim study assess potential difference h antihypertensive response treatment controlled onset extended release coer calcium antagonist verapamil men versus woman old versus young patient hypertension meta analyses perform three prospective randomize double blind placebo controlled trial coer verapamil patient mid stage stage iii essential hypertension trial conduct medical clinic u canada patient mean office diastolic blood pressure bp mm hg consecutive week mean daytime diastolic bp mm hg patient randomize treatment mg day coer verapamil n placebo n change baseline ambulatory bp heart rate coer verapamil compare men versus woman old versus young patient treatment coer verapamil cause significant reduction h early morning systolic diastolic bp subpopulation compare placebo p coer verapamil induce great reduction h systolic v mm hg p diastolic v mm hg p bp woman compare men old patient show great mean reduction h diastolic bp v mm hg p heart rate v beats min p compare young patient side effect similar coer verapamil treatment group gender age significant determinant response coer verapamil antihypertensive effect verapamil great woman men old patient compare young patient j hypertens american journal hypertension ltd,White WB,2001,Am J Hypertens,https://doi.org/10.1016/s0895-7061(01)02203-8,11775133,White WB; Johnson MF; Black HR; Elliott WJ; Sica DA,article,"D016430: Clinical Trial; D016428: Journal Article; D017418: Meta-Analysis; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000367: Age Factors; D000368: Aged; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D012737: Sex Factors; D014700: Verapamil",,,https://openalex.org/W2038630072,108,16,1,1813,330,12,en,en
false,post exercise st segment elevation precede myocardial infarction patient nearly normal coronary artery,,Tsagalou EP,2002,Int J Cardiol,https://doi.org/10.1016/s0167-5273(01)00588-5,11786162,Tsagalou EP; Nanas JN,article,D002363: Case Reports; D016422: Letter,"D000328: Adult; D000788: Angina Pectoris, Variant; D004110: Diltiazem; D004562: Electrocardiography; D005080: Exercise Test; D006801: Humans; D008297: Male; D009203: Myocardial Infarction; D014665: Vasodilator Agents",,,https://openalex.org/W2206150921,117,16,1,0,0,0,en,
true,evidence based evaluation calcium channel blocker hypertension,objective present meta analysis base three recent substantial randomized outcome trial several small trial compare calcium channel blocker ccbs conventional therapy diuretic beta blockers angiotensin converting enzyme ace inhibitors continue uncertainty safety efficacy ccbs treatment hypertension previous meta analyses conflict suggest ccbs increase myocardial infarction mi protect stroke standard procedure meta analysis use analyze three major trial patient another three less study total patients calcium channel blocker strikingly similar risk total cardiovascular mortality major cardiovascular event conventional therapy calcium channel blocker give low risk nonfatal stroke p high risk total mi p chiefly nonfatal perform bonferroni correction multiplicity p value become respectively compare ace inhibitor diabetic patient ccbs substantially high risk nonfatal relative risk rr total mi rr confidence interval p bonferroni correction total cardiovascular mortality rate similar confirm hypothesis ace inhibitor superior ccbs diabetic patient require trial data especially renal end points mortality total cardiovascular major cardiovascular event ccbs apparently similar event see conventional first line therapy diuretic beta blockers stroke reduction balance increased mi diabetic ccbs may less safe ace inhibitor,Opie LH,2002,J Am Coll Cardiol,https://doi.org/10.1016/s0735-1097(01)01728-4,11788225,Opie LH; Schall R,article,"D003160: Comparative Study; D016428: Journal Article; D017418: Meta-Analysis; D013485: Research Support, Non-U.S. Gov't",D000319: Adrenergic beta-Antagonists; D000806: Angiotensin-Converting Enzyme Inhibitors; D002121: Calcium Channel Blockers; D003925: Diabetic Angiopathies; D004232: Diuretics; D019317: Evidence-Based Medicine; D006801: Humans; D006973: Hypertension; D009203: Myocardial Infarction; D016032: Randomized Controlled Trials as Topic; D018570: Risk Assessment; D020521: Stroke,,,https://openalex.org/W2161847205,70,8,1,1829,312,9,en,en
false,sympathetic overactivity cause hypertension chronic renal failure,review current literature sympathetic mediation hypertension chronic renal failure hypertension present vast majority patient chronic renal failure constitute major risk factor excessive cardiovascular morbidity mortality patient population although traditionally hypertension think largely volume dependent increase body literature suggest important sympathetic neural component microneurographic study demonstrate sympathetic overactivity without baroreflex impairment hypertensive chronic hemodialysis patient well less advanced renal insufficiency sympathetic nerve activity find normal hemodialysis patient bilateral nephrectomy lead hypothesis sympathetic overactivity uremia cause neurogenic signal carry renal afferent arise failing kidney hypothesis support rat study show renal deafferentation abrogate hypertension nephrectomy model chronic renal insufficiency addition patient chronic renal insufficiency renin dependent hypertension sympathetic overactivity normalize chronic angiotensin convert enzyme inhibition calcium channel blockade implicate major central neural action angiotensin ii sympathetic overactivity chronic renal failure cause neurohormonal mechanism arise failing kidney future clinical study need determine whether normalization sympathetic activity constitute important therapeutic goal high risk patient population,Augustyniak RA,2002,J Hypertens,https://doi.org/10.1097/00004872-200201000-00002,11791019,Augustyniak RA; Tuncel M; Zhang W; Toto RD; Victor RG,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.; D016454: Review","D000818: Animals; D006801: Humans; D006973: Hypertension; D007676: Kidney Failure, Chronic; D051381: Rats; D013564: Sympathetic Nervous System",,,https://openalex.org/W2319955501,76,11,1,1703,242,7,en,en
false,effect losartan combination quinapril cardiac sympathetic nervous system neurohormonal status essential hypertension,sympathetic nervous renin angiotensin system play important role essential hypertension study aim assess effect losartan combination quinapril cardiac nervous system neurohormonal status essential hypertension randomized comparative study patient mild essential hypertension carry shizuoka general hospital phase hypertensive allocate randomly losartan mg group quinapril mg group phase hypertensive month mg quinapril monotherapy allocate randomly group mg losartan n mg amlodipine n add quinapril treat month patient underwent metaiodobenzylguanidine mibg imaging neurohormonal measurement month treatment monotherapies significantly increase renin activity losartan monotherapy also increase angiotensin ii aii concentration losartan quinapril group washout rate significantly decrease versus p versus p respectively without change heart mediastinum ratio h ratio combined therapy lower blood pressure similar level combination therapy losartan quinapril significantly increase h ratio p decrease washout rate p without affect aii concentration whereas combination therapy amlodipine quinapril therapy affect scintigraphic parameter increase aii concentration usual antihypertensive dose losartan quinapril little suppressive effect cardiac sympathetic activity essential hypertension contrast combination therapy losartan quinapril result high degree inhibition renin angiotensin system could suppress cardiac sympathetic activity effectively,Sakata K,2002,J Hypertens,https://doi.org/10.1097/00004872-200201000-00015,11791032,Sakata K; Yoshida H; Obayashi K; Ishikawa J; Tamekiyo H; Nawada R; Doi O,article,D016430: Clinical Trial; D003160: Comparative Study; D023362: Evaluation Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D019797: 3-Iodobenzylguanidine; D000328: Adult; D000368: Aged; D000804: Angiotensin II; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D004359: Drug Therapy, Combination; D005260: Female; D006321: Heart; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D007546: Isoquinolines; D019808: Losartan; D008297: Male; D008875: Middle Aged; D000077583: Quinapril; D011877: Radionuclide Imaging; D019275: Radiopharmaceuticals; D012083: Renin; D012084: Renin-Angiotensin System; D013564: Sympathetic Nervous System; D044005: Tetrahydroisoquinolines; D016896: Treatment Outcome",,,https://openalex.org/W2316252676,147,20,1,2105,366,9,en,en
false,evaluation safety short acting nifedipine child hypertension,concern regard safety nifedipine emerge report increase risk myocardial infarction associate adult patient receive short acting calcium channel blocker case report adverse event child purpose study investigate effect blood pressure bp incidence adverse event associate nifedipine pediatric population conduct retrospective chart review pediatric patient receive nifedipine record dose administer bp measurement adverse event report within six hour nifedipine dose regardless likelihood event relate nifedipine dose dos nifedipine pediatric patient review systolic bp decrease mean maximum diastolic bp decrease mean maximum adverse event include change neurologic status six case b hypotension two case c oxygen desaturation case neurologic event occur patient acute cns injury patient short acting nifedipine important effective oral antihypertensive agent safely use treatment hypertensive emergency child use caution child acute cns injury,Egger DW,2002,Pediatr Nephrol,https://doi.org/10.1007/s004670200006,11793132,Egger DW; Deming DD; Hamada N; Perkin RM; Sahney S,article,D016428: Journal Article,"D000293: Adolescent; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002648: Child; D002675: Child, Preschool; D004305: Dose-Response Relationship, Drug; D005260: Female; D006801: Humans; D006973: Hypertension; D007022: Hypotension; D007223: Infant; D008297: Male; D009422: Nervous System Diseases; D009543: Nifedipine; D010100: Oxygen; D012189: Retrospective Studies; D012449: Safety",,,https://openalex.org/W2052264803,81,11,1,1378,247,12,en,en
false,autonomic tone cardiovascular risk factor danger chronic fight flight,chronic imbalance autonomic nervous system prevalent potent risk factor adverse cardiovascular event include mortality although widely recognize clinician risk factor easily assess measure resting peak exercise heart rate heart rate recovery exercise heart rate variability factor lead inappropriate activation sympathetic nervous system expect adverse effect measure thus patient outcome factor augment vagal tone tend improve outcome insulin resistance sympathomimetic medication negative psychosocial factor potential affect autonomic function adversely thus cardiovascular prognosis congestive heart failure hypertension also provide important lesson adverse effect sympathetic predominance well illustrate benefit blockers angiotensin converting enzyme inhibitor class drug reduce adrenergic tone intervention exercise improve cardiovascular outcome partially increase vagal activity attenuate sympathetic hyperactivity chronic imbalance autonomic nervous system prevalent potent risk factor adverse cardiovascular event include mortality although widely recognize clinician risk factor easily assess measure resting peak exercise heart rate heart rate recovery exercise heart rate variability factor lead inappropriate activation sympathetic nervous system expect adverse effect measure thus patient outcome factor augment vagal tone tend improve outcome insulin resistance sympathomimetic medication negative psychosocial factor potential affect autonomic function adversely thus cardiovascular prognosis congestive heart failure hypertension also provide important lesson adverse effect sympathetic predominance well illustrate benefit blockers angiotensin converting enzyme inhibitor class drug reduce adrenergic tone intervention exercise improve cardiovascular outcome partially increase vagal activity attenuate sympathetic hyperactivity evolutionary pressure million year adapt sympathetic nervous system major mediator fight flight response adrenergic neurohumoral activation increase heart rate blood pressure cardiac output dilate large muscular artery bronchiole change mean prepare human physical confrontation respond acute hemodynamic collapse respiratory compromise sympathetic nervous system use setting improve person chance survival increase likelihood gene pass next generation appropriate intermittent stimulation sympathetic nervous system produce immediate improvement various symptom mundane fatigue weakness nasal congestion etc serious bronchial constriction hypotension shock additionally exhilaration life mediate adrenergic stimulation commonly refer adrenaline rush conversely reduction sympathetic neurotransmitter dopamine norepinephrine brain produce dysphoria lethargy factor encourage liberal use sympathomimetics long term therapy range prescription counter drug natural supplement illicit illegal drug although agent produce short term beneficial effect many acute situation long term use result tachyphylaxis also exact toll integrity cardiovascular system status autonomic nervous system although often ignore clinician major determinant cardiovascular health prognosis therapy chronically activate sympathetic nervous system diminishes parasympathetic vagal tone increase risk cardiovascular event contrast therapy tip autonomic balance toward parasympathetic dominance decrease sympathetic tone improve prognosis simple axiom explain many observation use guide clinical decision making diagnosis treatment cardiovascular disease article review relationship autonomic tone cardiovascular risk suggest strategy recognize treat risk factor many study establish elevated rest heart rate risk factor cardiovascular disease mortality gillman mw kannel wb belanger agostino rb influence heart rate mortality among person hypertension framingham study heart j abstract full text pdf pubmed google scholar hjalmarson significance reduction heart rate cardiovascular disease clin cardiol ii ii pubmed google scholar astute clinician long recognize paradoxically worrisome nature normal sinus rhythm beats min compare reassuringly abnormal sinus bradycardia beats min example best prognostic marker admit rest electrocardiogram patient suffer acute myocardial infarction mi rest heart rate extensiveness q wave st segment deviation hathaway wr peterson ed wagner gs gusto investigator et al prognostic significance initial electrocardiogram patient acute myocardial infarction jama crossref pubmed scopus google scholar indicator health autonomic system detect routine exercise tolerance test impaired chronotropic response exercise define failure achieve age predicted maximal heart rate abnormality present healthy middle aged adult increase mortality independent finding stress nuclear myocardial perfusion image coronary angiography lauer francis g okin pm pashkow fj snader ce marwick th impair chronotropic response exercise stress test predictor mortality jama crossref pubmed scopus google scholar dresing tj blackstone eh pashkow fj snader ce marwick th lauer usefulness impaired chronotropic response exercise predictor mortality independent severity coronary artery disease j cardiol abstract full text full text pdf pubmed scopus google scholar heart rate recovery exercise mediate primarily vagal tone also show significant prognostic factor study people nishime et al nishime eo cole cr blackstone eh pashkow fj lauer ms heart rate recovery treadmill exercise score predictor mortality patient refer exercise ecg jama crossref pubmed google scholar show failure decrease heart rate beats min first minute exercise note apparently healthy middle aged adult increase mortality fold ensue year figure another large study report relative risk mortality one third healthy adult abnormal heart rate recovery screening treadmill test cole cr foody jm blackstone eh lauer ms heart rate recovery submaximal exercise testing predictor mortality cardiovascularly healthy cohort ann intern med crossref pubmed google scholar intact heart rate variability beat beat variability mediate dynamic autonomic nervous system especially vagal tone baroreflex sensitivity reflex mediated change heart rate response fluctuation preload venous return note postural change characteristic healthy autonomic system potent independent predictor cardiovascular prognosis low heart rate variability associate increased risk coronary heart disease chd mortality dekker jm crow r folsom ar et al low heart rate variability minute rhythm strip predict risk coronary heart disease mortality several cause aric study circulation crossref pubmed google scholar kikallio th h iber k ber l trace investigator et al fractal analysis heart rate dynamic predictor mortality patient depressed leave ventricular function acute myocardial infarction j cardiol abstract full text full text pdf pubmed scopus google scholar well angiographic progression coronary atherosclerosis huikuri hv jokinen v syvanne et al heart rate variability progression coronary atherosclerosis arterioscler thromb vasc biol crossref pubmed google scholar sudden cardiac death fauchier l babuty cosnay p fauchier jp prognostic value heart rate variability sudden death major arrhythmic event patient idiopathic dilate cardiomyopathy j coll cardiol abstract full text full text pdf pubmed scopus google scholar figure data framingham heart study confirm heart rate variability relate risk cause mortality tsuji h venditti jr fj manders es et al reduced heart rate variability mortality risk elderly cohort framingham heart study circulation crossref pubmed google scholar cardiac events tsuji h larson mg venditti jr fj et al impact reduced heart rate variability risk cardiac event framingham heart study circulation crossref pubmed google scholar atrami autonomic tone reflex myocardial infarction study show heart rate variability baroreflex sensitivity independent predictor cardiovascular mortality la rovere mt big jr jt marcus fi mortara schwartz pj atrami autonomic tone reflex myocardial infarction investigator baroreflex sensitivity heart rate variability prediction total cardiac mortality myocardial infarction lancet abstract full text full text pdf pubmed scopus google scholar heart rate variability estimate bedside observe variation heart rate minute deep breathing katz liberty porath ovsyshcher prystowsky en simple bedside test minute heart rate variability deep breathing prognostic index myocardial infarction heart j abstract full text full text pdf pubmed scopus google scholar table table practical clinical indicator abnormal cardiac autonomic function rest heart rate great beats mininability achieve predict maximal heart rate treadmill testingabnormal heart rate recovery failure decrease heart rate beats min first minute peak exercise abnormal heart rate variability failure change heart rate r r interval beats min minute slow deep breath open table new tab simple marker like peak exercise heart rate heart rate variability powerful predictor cardiovascular mortality sign autonomic nervous system disturb strain chronic excessive sympathetic tone dramatic example phenomenon occur extreme condition high altitude mountain climb elite alpinist highly trained athlete sea level resting heart rate less beats min peak exercise heart rate great beats min brisk heart rate recovery within first minute rest within day week climber acclimate progressively high altitude resting heart rate gradually increase peak exercise heart rate decrease heart rate recovery become delayed ponchia noventa bertaglia et al cardiovascular neural regulation prolonged high altitude exposure eur heart j pubmed google scholar farinelli cc kayser b binzoni cerretelli p girardier l autonomic nervous control heart rate altitude eur j appl physiol occup physiol crossref pubmed scopus google scholar altitude great foot term death zone climber ascend level resting heart rate typically increase beats min peak exercise heart rate decrease level thus heart rate recovery nonexistent essentially climber die hypoxia exposure sympathetic nervous system try compensate become less less effective regulation adrenergic receptor face continuous maximal sympathetic stimulation adaptation although less extreme operate normal ambient condition excessive sympathetic stimulation diminished vagal tone marker unhealthy cardiovascular system also part cause adverse event chronic sympathetic hyperactivity increase cardiovascular workload hemodynamic stress predisposes endothelial dysfunction coronary spasm leave ventricular lv hypertrophy serious dysrhythmias metra nodari aloia bontempi l boldi e ca ld rationale use blockers standard treatment heart failure heart j pubmed google scholar increase vagal activity exert protective effect ischemia related dysrhythmias also reduces heart rate blood pressure iellamo f legramante jm massaro raimondi g galante effect residential exercise training baroreflex sensitivity heart rate variability patient coronary artery disease randomized control study circulation crossref pubmed google scholar risk mi sudden cardiac death stroke high first hour awaken morning correlate circadian peak sympathetic activity muller je circadian variation triggering acute coronary events heart j abstract full text full text pdf pubmed google scholar mortality due chd high monday day week employ people willich sn lowel h lewis hormann arntz hr keil u weekly variation acute myocardial infarction increase monday risk working population circulation crossref pubmed google scholar blockers normalize increase risk relate circadian catecholamine peaks peters rw propranolol morning increase sudden cardiac death beta blocker heart attack trial experience j cardiol g gabstract full text pdf pubmed google scholar setting lv dysfunction abnormal autonomic tone sensitive predictor cardiac arrhythmic mortality even document ventricular tachycardia la rovere mt pinna gd hohnloser sh autonomic tone reflex myocardial infarction atrami investigator et al baroreflex sensitivity heart rate variability identification patient risk life threatening arrhythmia implication clinical trials circulation crossref pubmed google scholar major noncardiac surgery associate activation sympathetic nervous system increase chd risk mangano dt hollenberg fegert g study perioperative ischemia spi research group et al perioperative myocardial ischemia patient undergoing noncardiac surgery incidence severity day perioperative period j coll cardiol abstract full text pdf pubmed google scholar blockers normalize perioperative cardiovascular risk mangano dt layug el wallace tateo multicenter study perioperative ischemia research group effect atenolol mortality cardiovascular morbidity noncardiac surgery n engl j med crossref pubmed scopus google scholar poldermans boersma e bax jj dutch echocardiographic cardiac risk evaluation apply stress echocardiography study group et al effect bisoprolol perioperative mortality myocardial infarction high risk patient undergo vascular surgery n engl j med crossref pubmed scopus google scholar rate sudden cardiac death acute mi increase earthquake survivor day week event study patient coincidence wear holter monitor major earthquake taiwan show enhance sympathetic modulation decrease vagal tone within minutes huang jl chiou cw ting ct chen yt chen sa sudden change heart rate variability taiwan earthquake j cardiol abstract full text full text pdf pubmed scopus google scholar interestingly people show worsen autonomic tone take blocker time earthquake animal model blockers decrease stress induced diet induced atherosclerosis recently year randomized placebo controlled trial involve patient low dose metoprolol mg reduce progression carotid atherosclerosis effective statin hedblad b wikstrand j janzon l wedel h berglund g low dose metoprolol cr xl fluvastatin slow progression carotid intima media thickness main result blocker cholesterol lowering asymptomatic plaque study bcaps circulation crossref pubmed google scholar clearly autonomic imbalance much surrogate marker increase chd risk mechanisms whereby traditional risk factor smoking unhealthy diet obesity sedentary lifestyle predispose adverse event multifaceted activation sympathetic nervous system diminished vagal tone appear important final common pathway substantial portion cardiovascular risk conferred grassi g seravalle g calhoun da et al mechanisms responsible sympathetic activation cigarette smoking humans circulation crossref pubmed google scholar factor lead chronic sympathetic activation summarize table table factors contribute chronic sympathetic activation medical condition obesityinsulin resistance diabeteshypertensiondepression anxietycongestive heart failuresleep apneapsychosocial behavioral condition chronic stresssocial isolationhostilitysmokingsleep deprivationunhealthy dietsedentary lifestyleabuse stimulant open table new tab diabetes metabolic syndrome hypertension insulin resistance obesity atherogenic dyslipidemia adversely affect cardiac autonomic function associate increased risk cardiovascular events laakso insulin resistance coronary heart disease curr opin lipidol crossref pubmed google scholar keefe jr jh mile jm harris wh moe rm mccallister bd improve adverse cardiovascular prognosis type diabetes mayo clin proc abstract full text full text pdf pubmed google scholar timar sestier f levy e metabolic syndrome x review j cardiol pubmed google scholar elevate fasting insulin show increase sympathetic activity heart rate anderson ea hoffman rp balon tw sinkey ca mark al hyperinsulinemia produce sympathetic neural activation vasodilation normal humans j clin invest crossref pubmed google scholar festa agostino jr r hale cn mykk nen l haffner sm heart rate relation insulin sensitivity insulin secretion nondiabetic subjects diabetes care crossref pubmed google scholar insulin resistance syndrome also predispose cardiovascular hyper responsiveness sympathetic stimulation show reduce heart rate variability liao sloan rp cascio et al multiple metabolic syndrome associate low heart rate variability atherosclerosis risk community study diabetes care crossref pubmed google scholar recent study show glucose intolerance strong determinant cardiovascular autonomic imbalance compare standard risk factors gerritsen j dekker jm tenvoorde bj et al glucose tolerance determinant cardiovascular autonomic function hoorn study diabetologia crossref pubmed scopus google scholar symptomatic autonomic neuropathy common patient long standing poorly control diabetes associate increased year mortality ewing dj martyn cn young rj clarke bf value cardiovascular autonomic function test year experience diabetes diabetes care crossref pubmed google scholar however chronic hyperinsulinemia even absence type diabetes mellitus associate heighten sympathetic tone decreased vagal tone laitinen vauhkonen ik niskanen lk et al power spectral analysis heart rate variability hyperinsulinemia nondiabetic offspring type diabetic patient evidence possible early autonomic dysfunction insulin resistant subjects diabetes crossref pubmed scopus google scholar emdin gastaldelli muscelli e et al hyperinsulinemia autonomic nervous system dysfunction obesity effect weight loss circulation crossref pubmed google scholar data framingham heart study recently confirm diabetes impaired fasting glucose level associate reduced heart rate variability singh jp larson mg donnell cj et al association hyper glycemia reduced heart rate variability framingham heart study j cardiol abstract full text full text pdf pubmed scopus google scholar diabetic patient fold increased risk sudden death compare nondiabetic patients curb jd rodriguez bl burchfiel cm abbott rd chiu yano k sudden death impair glucose tolerance diabetes japanese american men circulation crossref pubmed google scholar although blockers tend worsen insulin sensitivity decrease mortality diabetic patient partially improve autonomic imbalance risk sudden death jonas reicher reiss h boyko v bezafibrate infarction prevention bip study group et al usefulness blocker therapy patient non insulin dependent diabetes mellitus coronary artery disease j cardiol abstract full text pdf pubmed scopus google scholar illicit powerful sympathomimetic drug like cocaine methamphetamine methylenedioxymethamphet amine also know ecstasy popular produce transient energize euphoric state surprisingly drug markedly increase risk mi stroke cardiomyopathy dysrhythmias adverse cardiovascular effect particularly long term use mittleman mintzer maclure tofler gh sherwood jb muller je triggering myocardial infarction cocaine circulation crossref pubmed google scholar petitti db sidney quesenberry c bernstein stroke cocaine amphetamine use epidemiology crossref pubmed google scholar lester sj baggott welm et al cardiovascular effect methylenedioxymethamphetamine double blind placebo controlled trial ann intern med crossref pubmed google scholar qureshi ai suri mf guterman lr hopkins ln cocaine use likelihood nonfatal myocardial infarction stroke data third national health nutrition examination survey circulation crossref pubmed google scholar legal sympathomimetic medication widely use various condition include weight loss allergy sinus problem asthma chronic lung disease sympathomimetic agent often find counter product include herbal preparation frequently take combination stimulant without supervision two recently publish study release early public health implication renew concern safety nonprescription sympathomimetic medication first study phenylpropanolamine ppa often use decongestant appetite suppressant find increase risk hemorrhagic stroke women kernan wn viscoli cm brass lm et al phenylpropanolamine risk hemorrhagic stroke n engl j med crossref pubmed scopus google scholar accompany editorial estimate many stroke relate use ppa may occur annually united states fleming ga fda regulation risk stroke editorial n engl j med crossref pubmed scopus google scholar result food drug administration recommend product contain ppa remove voluntarily market related study ephedra alkaloid find herbal preparation like huang metabolife use frequently weight loss find associate various adverse cardiovascular central nervous system effect include hypertension stroke mi haller ca benowitz nl adverse cardiovascular central nervous system event associate dietary supplement contain ephedra alkaloids n engl j med crossref pubmed scopus google scholar national football league recently ban ephedra use player die summer training camp ephedra bloodstream ephedra containing drink locker mihoces g ephedrine safe lethal debate intensifies supplement become energy booster choice athletes usa today november c c google scholar although relationship ephedra use death prove case national football league policy intend protect health player study could undertake food drug administration petition public citizen health research group ban counter product contain ephedra data american association poison control center show january february supplement contain ephedra account report adverse event relate nutritional supplement period bergmann cf fda ask ban ephedra products cardiol today november google scholar asthma related mortality increase association liberal use agonists spitzer w suissa ernst p et al use agonists risk death near death asthma n engl j med crossref pubmed google scholar although association remain controversial beasley r pearce n crane j burgess c agonists evidence use increase risk asthma morbidity mortality j allergy clin immunol abstract full text full text pdf pubmed scopus google scholar establish even selective agent cause increase heart rate decrease potassium level increase qtc interval wong c pavord id williams j britton jr tattersfield ae bronchodilator cardiovascular hypokalaemic effect fenoterol salbutamol terbutaline asthma lancet abstract pubmed scopus google scholar agent associate ventricular atrial ectopy newhouse mt chapman kr mccallum al et al cardiovascular safety high dos inhaled fenoterol albuterol acute severe asthma chest crossref pubmed google scholar well increase risk acute cardiovascular mortality suissa hemmelgarn b blais l ernst p bronchodilator acute cardiac death j respir crit care med crossref pubmed google scholar agonists use frequently setting acute upper respiratory tract infection independently associate increase risk mi meier cr jick derby le vasilakis c jick h acute respiratory tract infection risk first time acute myocardial infarction lancet abstract full text full text pdf pubmed scopus google scholar recent case control study show use inhaled agonists associate increase risk mi adjust odds ratio confidence interval patient known cardiovascular disease au dh lemaitre rn curtis jr smith nl psaty bm risk myocardial infarction associate inhaled beta adreno ceptor agonists j respir crit care med crossref pubmed google scholar patient chronic lung disease often use agonist albuterol anticholinergic medication ipratropium concurrently anticholinergic medication increase heart rate decrease heart variability yeragani vk pohl r balon r et al effect imipramine treatment heart rate variabi,Curtis BM,2002,Mayo Clin Proc,https://doi.org/10.4065/77.1.45,11794458,Curtis BM; O'Keefe JH,article,D016428: Journal Article; D016454: Review,D000318: Adrenergic beta-Agonists; D000959: Antihypertensive Agents; D001341: Autonomic Nervous System; D002318: Cardiovascular Diseases; D006329: Heart Conduction System; D006339: Heart Rate; D006801: Humans; D007333: Insulin Resistance; D012307: Risk Factors; D013566: Sympathomimetics,,,https://openalex.org/W2131008517,86,15,1,29863,4732,114,en,en
false,effectiveness nifedipine deflazacort management distal ureter stone,,Clayman RV,2002,J Urol,,11799973,Clayman RV,article,D016428: Journal Article,"D000893: Anti-Inflammatory Agents; D002121: Calcium Channel Blockers; D004359: Drug Therapy, Combination; D006801: Humans; D009543: Nifedipine; D011282: Pregnenediones; D016032: Randomized Controlled Trials as Topic; D016896: Treatment Outcome; D014514: Ureteral Calculi",,,https://openalex.org/W2408394022,86,13,1,0,0,0,en,
false,possible role diltiazem recalcitrant case darier disease,gallant c kenny p oral glucocorticoid complication systemic corticosteroid especially patient need review j acad dermatol prolonged systemic treatment drug may particularly verma kk sirka c khaitan bk generalize severe lichen valuable patient give systemic corticoplanus treat azathioprine acta derm venereol steroid reason however double blind control trial large number patient require klein lr callen jp azathioprine evective steroid spar establish eycacy safety drug patient therapy generalize lichen planus south med j lear jt english jsc erosive generalized lichen planus reference responsive azathioprine clin exp dermatol young ir harris dws cloves gb azathioprine dermato black mm go lichen planus clin exp dermatol logy j acad dermatol tan bb lear jt gawkrodger dj english jsc azathioprine gomes schmidt souteyrand p ohrt c brochier j thiovolet j lichen planus chronic graft versus host reaction dermatology survey current practice uk br j dermatol situ identi cation immunocompetent cell phenotype j cutan pathol snow j l gibson l e pharmacogenetic basis safe evective use azathioprine thiopurine drug derma boyd neldner kh lichen planus j acad dermatol tologic patient j acad dermatol verma kk manchanda pasricha j azathioprine cortico ho vc gupta ak elli cn nickolov bj voorheess jj treatment severe lichen planus cyclosporine j steroid sparing agent treatment dermatitis cause weed parthenium acta derm venereol acad dermatol pigatto pd chiappino g bigardi mozzanica n finzi af verma kk manchanda long term safety toxicity azathioprine patient air borne contact dermatitis ind cyclosporin treatment severe lichen planus br j dermatol j dermatol venereol leprol,Lorentzen H,2001,Acta Derm Venereol,https://doi.org/10.1080/000155501317140205,11800156,Lorentzen H; Svejgaard E,article,D002363: Case Reports; D016422: Letter,D017255: Acitretin; D002317: Cardiovascular Agents; D007644: Darier Disease; D004110: Diltiazem; D005260: Female; D006801: Humans; D007641: Keratolytic Agents; D008875: Middle Aged; D017202: Myocardial Ischemia; D012720: Severity of Illness Index; D016896: Treatment Outcome; D014665: Vasodilator Agents,,,https://openalex.org/W2063389942,69,12,1,2350,493,57,en,en
false,cutaneous drug reaction case report world literature,,,2002,Am J Clin Dermatol,10.2165/00128071-200203010-00007,11817970,,article,D002363: Case Reports; D016428: Journal Article,"D000328: Adult; D016907: Adverse Drug Reaction Reporting Systems; D000368: Aged; D016642: Bupropion; D000068579: Celecoxib; D002750: Chlorquinaldol; D003561: Cytarabine; D017985: Dalteparin; D003622: Dapsone; D003877: Dermatitis, Contact; D004342: Drug Hypersensitivity; D015736: Felodipine; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D010672: Phenytoin; D011247: Pregnancy; D011720: Pyrazoles; D012532: Scabies; D013449: Sulfonamides; D016463: Sweet Syndrome; D014640: Vancomycin",,,,64,11,1,0,0,0,en,
false,treatment heart failure patient diabetes mellitus,patient diabetes mellitus increase morbidity mortality cardiovascular disease coronary artery disease congestive heart failure chf largely responsible increase cardiovascular adverse event patient diabetes review discuss pathophysiology chf mechanism left ventricular lv dysfunction neurohormonal mechanism involve lv dysfunction chf diabetes without hypertension important cause lv dysfunction chf diabetes may responsible metabolic ultrastructural cause lv dysfunction hypertension may responsible marked fibrotic change find experimental induction diabetes animal shed light biochemical ultrastructural change see role insulin reverse metabolic structural change review experimental data limited amount clinical data available therapy chf patient diabetes similar patient without diabetes therapy direct toward use beta blockers angiotensin convert enzyme ace inhibitor morbidity mortality high patient diabetes several study point importance subgroup opportunity make significant clinical impact exist significant opportunity exist reduce morbidity mortality beta blockers ace inhibitor ischaemia chf present however study patient diabetes limit post hoc subgroup analysis rarely predefined subgroup clinical trial involve patient diabetes without hypertension lv dysfunction clearly need future adequately address need high risk subgroup,Lavine SJ,2002,Drugs,https://doi.org/10.2165/00003495-200262020-00004,11817974,Lavine SJ; Gellman SD,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review",D000818: Animals; D009202: Cardiomyopathies; D048909: Diabetes Complications; D006333: Heart Failure; D006801: Humans,,,https://openalex.org/W2092950665,61,9,1,1847,294,12,en,en
false,change renal resistive index urinary albumin excretion hypertensive patient long term treatment lisinopril nifedipine git,increase renal vascular resistance microalbuminuria associate hypertensive target organ damage may predictor hypertensive nephrosclerosis investigate change renal resistive index ri urinary albumin excretion uae group patient primary hypertension long term antihypertensive treatment thirty two patient randomize receive antihypertensive treatment either calcium channel blocker nifedipine git mg day n ace inhibitor lisinopril mg day n alone association diuretic chlortalidone mg day blood pressure renal resistive index u doppler uae mean three nonconsecutive time urinary collection microg min evaluate baseline course month treatment regimen effectively lower blood pressure mean blood pressure baseline mm hg month lisinopril group baseline month nifedipine group p group overall blood pressure decrease associate reduction uae change ri throughout study however despite similar blood pressure reduction two regimen show different specific effect lisinopril associate significant decrease uae baseline month p renal ri baseline month p nifedipine git significantly influence uae baseline month n ri baseline month n effective blood pressure control long period time reduce severity organ damage namely uae maintain renovascular resistance patient essential hypertension different class antihypertensive agent might convey additional specific renal protection beyond blood pressure control data could useful devise individualized therapeutic strategy hypertensive patient increased renal risk,Leoncini G,2002,Nephron,https://doi.org/10.1159/000049038,11818701,Leoncini G; Martinoli C; Viazzi F; Ravera M; Parodi D; Ratto E; Vettoretti S; Tomolillo C; Derchi LE; Deferrari G; Pontremoli R,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000419: Albuminuria; D000806: Angiotensin-Converting Enzyme Inhibitors; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D005260: Female; D006801: Humans; D006977: Hypertension, Renal; D017706: Lisinopril; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D012079: Renal Circulation; D014655: Vascular Resistance",,,https://openalex.org/W2031587261,148,20,1,2185,392,9,en,en
false,persistence antihypertensive efficacy missed dos comparison amlodipine nifedipine gastrointestinal therapeutic system,randomized double blind crossover study antihypertensive efficacy amlodipine nifedipine gastrointestinal therapeutic system git compare follow missed dos design method randomized crossover design patient randomize receive amlodipine mg git formulation nifedipine nifedipine git mg daily week vice versa week treatment period compliance failure simulate patient miss dos medication ambulatory systolic sbp diastolic dbp blood pressure measurement obtained following steady state treatment e perfect compliance difference amlodipine nifedipine git sbp versus mmhg dbp versus mmhg h post dose compliance perfect e one two dos miss dbp maintain significantly low level amlodipine compare nifedipine git h post dose versus mmhg p h post dose versus mmhg p plasma concentration amlodipine well maintain nifedipine git h post dose plasma concentration amlodipine ng ml compare ng ml nifedipine gits short period non compliance antihypertensive efficacy remain predictable amlodipine nifedipine git,Elliott HL,2002,J Hypertens,https://doi.org/10.1097/00004872-200202000-00025,11821720,Elliott HL; Elawad M; Wilkinson R; Singh SP,article,"D016430: Clinical Trial; D003160: Comparative Study; D023362: Evaluation Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002940: Circadian Rhythm; D018592: Cross-Over Studies; D004064: Digestive System; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D013997: Time Factors; D016896: Treatment Outcome",,,https://openalex.org/W2001357735,136,16,1,1517,280,8,en,en
false,withdrawal treatment syst eur trial,investigate reason withdrawal double blind randomized trial reason change treatment within randomized therapeutic group syst eur trial old patient systolic hypertension randomize active placebo treatment reason withdrawal trial examine patient initiated investigator initiated withdrawal addition reason stop first line treatment nitrendipine second line treatment enalapril hydrochlorothiazide corresponding placebo determined total patient withdraw investigator placebo treatment blood pressure high similarly patient initiation corresponding result actively treated patient patient withdraw trial adverse effect treatment however stop take active nitrendipine ankle oedema compare placebo similarly versus three stop due flush forty one stop take enalapril cough eight enalapril placebo stop active nitrendipine enalapril hydrochlorothiazide versus placebo number withdraw trial adverse treatment consequence small comparison cardiovascular benefit nevertheless number stop individual treatment high expect,Bulpitt CJ,2002,J Hypertens,https://doi.org/10.1097/00004872-200202000-00026,11821721,Bulpitt CJ; Beckett NS; Fletcher AE; Thijs L; Staessen JA; Dumitrascu DL; Forette F; Leonetti G; Nachev C; Tuomilehto J; Fagard RH; Syst-Eur investigators,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D004311: Double-Blind Method; D023381: Endpoint Determination; D005060: Europe; D005500: Follow-Up Studies; D006801: Humans; D006973: Hypertension; D013997: Time Factors; D017211: Treatment Failure; D028761: Withholding Treatment,,,https://openalex.org/W2161999537,47,7,1,1558,272,9,en,en
false,amlodipine versus chlorthalidone versus placebo treatment stage isolate systolic hypertension,study compare effect amlodipine calcium channel antagonist chlorthalidone diuretic placebo adult year age stage isolated systolic hypertension ish week placebo run phase patient randomly assign double blind fashion treatment mg amlodipine n mg chlorthalidone n placebo n patient fail meet systolic blood pressure bp reduction goal week dose increase mg amlodipine mg chlorthalidone maintain increase dose week result show mean reduction mean sd sit systolic bp baseline last treatment visit mm hg confidence interval ci mm hg ci mm hg ci amlodipine chlorthalidone placebo treatment group respectively active treatment show significantly great reduction placebo group p significantly different sixty seven percent amlodipine chlorthalidone placebo treated patient reach protocol define systolic bp goal p active treatment group show trend good systolic bp response old patient year secondary efficacy measure include pulse pressure stand systolic diastolic h ambulatory bp also statistically significantly improve active treatment end treatment except chlorthalidone stand diastolic bp adverse event occur study expect well tolerate result study support efficacy safety amlodipine chlorthalidone treatment stage ish week treatment,Grimm RH,2002,Am J Hypertens,https://doi.org/10.1016/s0895-7061(01)02224-5,11824857,Grimm RH; Black H; Rowen R; Lewin A; Shi H; Ghadanfar M; Amlodipine Study Group,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002752: Chlorthalidone; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D010919: Placebos; D016896: Treatment Outcome,,,https://openalex.org/W1975756851,106,14,1,1905,369,10,en,en
false,comparative trial controlled onset extended release verapamil enalapril losartan blood pressure heart rate change,background excess morning risk myocardial infarction stroke may attributable rapid rise blood pressure bp heart rate hour awaken aim randomize double blinded placebo controlled multicenter study compare daily controlled onset extended release coer verapamil enalapril losartan bp heart rate postawakening morning phase well throughout h period,Bakris G,2002,Am J Hypertens,https://doi.org/10.1016/s0895-7061(01)02254-3,11824861,Bakris G; Sica D; Ram V; Fagan T; Vaitkus PT; Anders RJ,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002940: Circadian Rhythm; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004656: Enalapril; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D019808: Losartan; D008297: Male; D008875: Middle Aged; D014665: Vasodilator Agents; D014700: Verapamil,,,https://openalex.org/W2046225374,133,20,1,465,79,2,en,en
true,effect verapamil elderly patient left ventricular diastolic dysfunction cause congestive heart failure,summary fifteen elderly patient normal left ventricular lv systolic function new york heart association functional class ii iii study effect verapamil lv diastolic function assess congestive heart failure chf score treadmill exercise test doppler echocardiography baseline three month treatment period placebo verapamil mg daily separate one week washout period crossover blood pressure heart rate lv ejection fraction lv mass cardiac output unaltered placebo verapamil verapamil treatment significantly improve chf score month p compare baseline placebo exercise time similar baseline min placebo min treatment significantly p increase verapamil min treatment ratio mitral wave duration pulmonary venous atrial systolic reversal duration increase verapamil treatment compare placebo p baseline similar duration isovolumic relaxation time significantly p decrease baseline placebo verapamil result study suggest elderly patient doppler evidence diastolic dysfunction cause chf three month treatment verapamil improve chf increase exercise tolerance improve lv diastolic function,Hung MJ,2002,Int J Clin Pract,,11831838,Hung MJ; Cherng WJ; Kuo LT; Wang CH,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D000369: Aged, 80 and over; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D015150: Echocardiography, Doppler; D005080: Exercise Test; D005260: Female; D006333: Heart Failure; D006801: Humans; D008297: Male; D011897: Random Allocation; D016896: Treatment Outcome; D018487: Ventricular Dysfunction, Left; D016277: Ventricular Function, Left; D014700: Verapamil",,,https://openalex.org/W1627893505,122,18,1,1557,303,8,en,en
false,resolution st segment elevation follow intravenous administration nitroglycerin verapamil,previously describe reperfusion strategy combine thrombolytic drug intravenous nitrate verapamil lee k j horowitz j mckay w j goble j myocardial salvage streptokinase combine nitroglycerin verapamil acute myocardial infarction int j cardiol abstract full text pdf pubmed scopus google scholar arstall beltrame j f mohan p wuttke r esterman j horowitz j incidence adverse event treatment verapamil suspected acute myocardial infarction j cardiol abstract full text pdf pubmed scopus google scholar regimen administer safely arstall beltrame j f mohan p wuttke r esterman j horowitz j incidence adverse event treatment verapamil suspected acute myocardial infarction j cardiol abstract full text pdf pubmed scopus google scholar appear adverse effect day mortality basis risk adjusted comparison sage p r kiosoglous j wuttke r horowitz j early treatment verapamil diltiazem patient acute myocardial infarction safety possible beneficial effect cardiovasc drug ther crossref pubmed scopus google scholar combination agent theoretical advantage interrupt several pathophysiologic process involve infarction hugenholtz p g serruys p w fleckenstein nayler w ca antagonist useful early myocardial ischaemia infarction establish eur heart j pubmed google scholar recent practice initiate therapy nitrate verapamil immediately upon diagnosis st segment elevation begin thrombolytic therapy soon patient suitability assess strategy provide u unique opportunity evaluate evolution electrocardiographic change intravenous nitroglycerin verapamil administration thrombolytic drug thus objective study determine frequency resolution st segment elevation intravenous nitroglycerin verapamil administration thrombolytic eligible patient initiation thrombolytic therapy,Beltrame JF,2002,Am J Cardiol,https://doi.org/10.1016/s0002-9149(01)02268-8,11835928,Beltrame JF; Stewart S; Leslie S; Poropat S; Horowitz JD,article,D016428: Journal Article,"D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D004359: Drug Therapy, Combination; D004562: Electrocardiography; D006329: Heart Conduction System; D006801: Humans; D007262: Infusions, Intravenous; D008875: Middle Aged; D015425: Myocardial Reperfusion; D005996: Nitroglycerin; D011446: Prospective Studies; D014665: Vasodilator Agents; D014700: Verapamil",,,https://openalex.org/W2001260423,102,11,1,2361,394,36,en,en
false,slow infusion calcium channel blocker emergency management supraventricular tachycardia,compare efficacy verapamil diltiazem slow infusion terminate spontaneous supraventricular tachycardia svt emergency department ed patients least year age present ed regular narrow complex tachycardia convert vagal manoeuvre ecg diagnosis svt include haemodynamically unstable exclude patient randomize undergo either verapamil infusion rate mg min maximum mg diltiazem infusion rate mg min maximum mg eighty one patient randomize receive verapamil infusion randomize receive diltiazem infusion difference success rate verapamil diltiazem infusion dose medication require convert svts mg verapamil infusion mg diltiazem infusion one complication group calcium channel blocker infusion safe efficacious terminate spontaneous svt difference success rate verapamil diltiazem infusion,Lim SH,2002,Resuscitation,https://doi.org/10.1016/s0300-9572(01)00459-2,11841884,Lim SH; Anantharaman V; Teo WS,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D002121: Calcium Channel Blockers; D004110: Diltiazem; D004562: Electrocardiography; D004638: Emergency Treatment; D005260: Female; D006801: Humans; D007262: Infusions, Intravenous; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D013617: Tachycardia, Supraventricular; D014700: Verapamil",,,https://openalex.org/W2132207681,101,12,1,1188,205,7,en,en
false,comparative study calcium channel blocker cell proliferation dna collagen synthesis egf receptor cultured gingival fibroblast derive human nifedipine nicardipine nisoldipine responder,previous study indicate fibroblast derive patient reactive nifedipine might susceptible calcium channel blocker nicardipine verapamil diltiazem term cell proliferation dna synthesis collagen synthesis thus present investigation design clarify cross reactivity among dihydropyridine calcium channel blocker nifedipine nicardipine nisoldipine human gingival fibroblast derive seven two one patient develop gingival overgrowth result nifedipine nicardipine nisoldipine medication respectively examine term effect calcium channel blocker nifedipine diltiazem verapamil nicardipine cell proliferation dna synthesis collagen synthesis number epidermal growth factor egf receptor phenytoin use positive control calcium channel blocker phenytoin fibroblast patient reactive nifedipine nicardipine medication give good cell proliferation rate dna synthesis increased number egf receptor compare non drug treated control however case calcium channel blocker test fibroblast patient reactive nisoldipine medication,Matsumoto H,2001,J Oral Sci,https://doi.org/10.2334/josnusd.43.261,11848193,Matsumoto H; Noji I; Akimoto Y; Fujii A,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D000704: Analysis of Variance; D000927: Anticonvulsants; D002121: Calcium Channel Blockers; D018929: Cell Culture Techniques; D002455: Cell Division; D003094: Collagen; D004247: DNA; D004110: Diltiazem; D066246: ErbB Receptors; D005260: Female; D005347: Fibroblasts; D005434: Flow Cytometry; D005881: Gingiva; D019214: Gingival Overgrowth; D006801: Humans; D008297: Male; D008875: Middle Aged; D009529: Nicardipine; D009543: Nifedipine; D015737: Nisoldipine; D010672: Phenytoin; D019275: Radiopharmaceuticals; D013223: Statistics as Topic; D014316: Tritium; D014700: Verapamil,,,https://openalex.org/W2048356388,218,31,1,1289,205,6,en,en
false,delirium intensive care unit help patient,intensive care unit icu represent dynamic interaction patient factor interventional factor complexity situation generate impaired consciousness patient critical care provider face deduce etiology treatment delirium icu many therapeutic agent use icu may precipitate delirium patient may also experience delirium part underlying medical condition withdrawal syndrome delirium tremens particular know cause delirium combination appropriate selection medication awareness delirium side effect patient icu may treat manner minimize clouding consciousness understanding propose pathophysiology various type delirium allow appropriate clinical measure take,Webb JM,2000,Crit Care Nurs Q,https://doi.org/10.1097/00002727-200002000-00006,11852965,Webb JM; Carlton EF; Geehan DM,article,D002363: Case Reports; D016428: Journal Article; D016454: Review,D000430: Alcohol Withdrawal Delirium; D003422: Critical Care; D003693: Delirium; D064420: Drug-Related Side Effects and Adverse Reactions; D006801: Humans; D007239: Infections; D007362: Intensive Care Units; D008297: Male; D008875: Middle Aged; D014883: Water-Electrolyte Imbalance,,,https://openalex.org/W2325042806,64,13,1,884,148,8,en,en
false,relationship treatment induced change left ventricular mass blood pressure black african hypertensive patient result baragwanath trial,background single center study compare extent change conventional ambulatory blood pressure bp predict regression left ventricular mass lvm index response antihypertensive treatment previously untreated treat patient sustained hypertension method results enrol black african patient treatment daytime diastolic bp range mm hg antihypertensive drug titrate combine reduce daytime diastolic bp mm hg echocardiogram obtain baseline follow mean systolic diastolic clinic bp hour bp lvm index similar previously untreated n previously treat n patient average mm hg mm hg g respectively month value decrease p mm hg mm hg g previously untreated patient mm hg mm hg g previously treat patient previously untreated patient regression lvm index correlate similar degree p decrease conventional r p hour r p systolic bp previously treat patient corresponding correlation p p respectively compare hour systolic bp automate oscillometric measurement systolic bp obtain clinic yield similar result conclusions previously untreated patient sustained hypertension follow single center reduction clinic ambulatory systolic pressure response antihypertensive treatment equally predict regression lvm index,Skudicky D,2002,Circulation,https://doi.org/10.1016/s1062-1458(02)00703-1,11854123,Skudicky D; Sareli P; Libhaber E; Candy G; Radevski I; Valtchanova Z; Tshele E; Thijs L; Wang JG; Staessen JA,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000806: Angiotensin-Converting Enzyme Inhibitors; D044383: Black People; D001794: Blood Pressure; D015992: Body Mass Index; D002121: Calcium Channel Blockers; D003971: Diastole; D004232: Diuretics; D004452: Echocardiography; D004656: Enalapril; D005260: Female; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D017379: Hypertrophy, Left Ventricular; D008297: Male; D008750: Methyldopa; D008875: Middle Aged; D009543: Nifedipine; D010349: Patient Compliance; D012044: Regression Analysis; D013019: South Africa; D013599: Systole; D014700: Verapamil",,,https://openalex.org/W2065639036,163,22,2,1721,304,10,en,en
false,effect amlodipine compare atenolol small artery previously untreated essential hypertensive patient,previous retrospective study long term treatment essential hypertensive patient slow release calcium channel blocker result normal resistance artery structure endothelial function occur beta blocker present prospective study previously untreated essential hypertensive patient age year male treat year double blind randomized study long acting calcium channel blocker amlodipine beta blocker atenolol resistance artery lumen diameter microm dissect gluteal subcutaneous biopsy study pressurized myograph blood pressure bp control mm hg identical group last month study year treatment amlodipine media lumen ratio l resistance artery decrease p acetylcholine induced endothelium dependent relaxation tend improve p whereas sodium nitroprusside induced relaxation unchanged patient treat amlodipine beta blocker treated group significant change l acetylcholine induced relaxation conclusion treatment calcium channel blocker amlodipine correct alter resistance artery structure tend improve endothelial function essential hypertensive patient whereas similar good control bp beta blocker atenolol whether vascular protective effect amlodipine result improved outcome hypertension remain demonstrate,Schiffrin EL,2002,Am J Hypertens,https://doi.org/10.1016/s0895-7061(01)02290-7,11863244,Schiffrin EL; Pu Q; Park JB,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000109: Acetylcholine; D000319: Adrenergic beta-Antagonists; D000328: Adult; D017311: Amlodipine; D000959: Antihypertensive Agents; D001158: Arteries; D001262: Atenolol; D002081: Buttocks; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D004730: Endothelium, Vascular; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D012016: Reference Values; D014655: Vascular Resistance; D014664: Vasodilation; D014665: Vasodilator Agents",,,https://openalex.org/W2061107276,115,15,1,1667,279,9,en,en
false,problemas relacionados con la medicaci n como causa del ingreso hospitalario,mediante este estudio se ha pretendido identificar caracterizar los problemasrelacionados con la medicaci n reacciones adversas fracasos terap uticos relacionados con ladosis e intoxicaciones que provocan ingresos en el hospital cl nic de barcelona trav delservicio de urgencias b conocer qu tipo de medicamentos se implicado con frecuencia c identificar los factor que predisponen al ingreso hospitalario por problemas relacionadoscon la medicaci n evaluar cu ntos de estos ingresos se podr haber evitado el estudio ha sido de car cter prospectivo se ha realizado durante los mesescomprendidos entre agosto noviembre de entre enero mayo de duranteestos per odos se han obtenido un total de ingresos correspondientes pacientes el n mero de ingresos debidos problemas relacionados con la medicaci n incluyendolos casos definitivos probables posibles ha sido de de estos casos han correspondido efectos adversos fracasos terap uticos relacionadoscon la dosis fundamentalmente mal cumplimiento siete intoxicaciones si seexcluyen los casos posibles para conseguir una relaci n causal mejor definida el n mero deproblemas relacionados con la medicaci n como causa de ingreso ha sido de siguiendo los criterios de schumock thornton modificados un de los ingresos debidosa problemas relacionados con la medicaci n se ha considerado evitable la mayor de losingresos evitables son debidos al mal cumplimiento seguidos de ausencia de profilaxis monitorizaci seguimiento inapropiado el n mero de ingresos debidos problemas relacionados con la medicaci n eselevado en muchos casos se podr haber evitado goal present study identify characterize drug relatedproblems adverse drug reaction non compliance intentional overdose lead admissionsto hospital hospital cl nic emergency department b know mostfrequently involved medication c identify risk factor hospital admission due drugrelatedproblems determine avoidability admission prospective study carry august november andfrom january may study include admission correspond patient include definitive probable possible case hospital admission drug related one case correspond adverse drug reactions dose related therapeutic failure mainly non compliance correspondedto intentional overdose possible case exclude order achieve abetter define causative relationship drug related admission drop accordingto schumock thornton criterion hospital admission due drug related problemswere consider avoidable avoidable admission due non compliance absence preventive therapy inappropriate monitoring hospital admission due drug related problem frequent often preventable,Martín MT,2002,Med Clin (Barc),https://doi.org/10.1016/s0025-7753(02)72337-3,11864542,Martín MT; Codina C; Tuset M; Carné X; Nogué S; Ribas J,article,"D004740: English Abstract; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D064420: Drug-Related Side Effects and Adverse Reactions; D005260: Female; D006760: Hospitalization; D006801: Humans; D008297: Male; D011446: Prospective Studies,,,https://openalex.org/W2012241936,76,10,1,3128,526,17,es,es
false,angiotensin ii type receptor antagonist losartan cause regression left ventricular hypertrophy end stage renal disease,leave ventricular hypertrophy lvh commonly occur patient end stage renal disease esrd independent risk factor cardiovascular event angiotensin ii type receptor r antagonist may able reverse lvh independent hypotensive effect esrd setting thirty chronically hemodialyzed uremic patient hypertension randomly assign receive r antagonist losartan n angiotensin converting enzyme acd inhibitor enalapril n calcium antagonist amlodipine n leave ventricular mass lvm index measure echocardiography month treatment baseline demographic clinical characteristic differ three group mean baseline lvm index also differ three group month treatment losartan treatment significantly reduce lvm index amlodipine enalapril therapy three group similar decrease mean blood pressure treatment plasma angiotensin ii concentration increase fold losartan treatment contrast plasma angiotension ii concentration change enalapril increase fold amlodipine thus present study indicate losartan effectively regress lvh patient esrd enalapril amlodipine despite comparable depressor effect three drug,Shibasaki Y,2002,Nephron,https://doi.org/10.1159/000049060,11867945,Shibasaki Y; Masaki H; Nishiue T; Nishikawa M; Matsubara H; Iwasaka T,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D000804: Angiotensin II; D057911: Angiotensin Receptor Antagonists; D000959: Antihypertensive Agents; D004452: Echocardiography; D004656: Enalapril; D005260: Female; D006352: Heart Ventricles; D006801: Humans; D006973: Hypertension; D017379: Hypertrophy, Left Ventricular; D007676: Kidney Failure, Chronic; D019808: Losartan; D008297: Male; D008875: Middle Aged; D044140: Receptor, Angiotensin, Type 1; D006435: Renal Dialysis",,,https://openalex.org/W2063266119,129,19,1,1473,258,11,en,en
false,trough peak ratio smoothness index evaluation h blood pressure control hypertension comparative study valsartan hydrochlorothiazide combination amlodipine,objective aim study measure time effect profile daily administered valsartan hydrochlorothiazide combination amlodipine blood pressure use various index derive h ambulatory blood pressure bp monitoring method randomize outpatient uncomplicated mild moderate primary hypertension valsartan hydrochlorothiazide amlodipine eligible analysis week placebo wash period patient randomly allocate treatment either valsartan mg daily amlodipine mg week case unsatisfactory blood pressure response treatment could respectively change fixed combination valsartan mg plus hydrochlorothiazide mg amlodipine mg week trough peak ratio global individualized approach smoothness index e ratio average hourly bp change treatment corresponding standard deviation calculate h ambulatory blood pressure recording make placebo period week week active treatment result regimen effectively lower systolic diastolic ambulatory pressure week week p among responder valsartan hydrochlorothiazide combination great antihypertensive effect night time hour week p responder placebo adjusted mean trough peak ratio valsartan hydrochlorothiazide group n amlodipine group n corresponding global trough peak ratio valsartan hydrochlorothiazide combination amlodipine however group difference individual global trough peak ratio significant smoothness index slightly insignificantly great valsartan hydrochlorothiazide amlodipine responder group whole conclusion valsartan hydrochlorothiazide amlodipine equally effective reduce ambulatory bp valsartan hydrochlorothiazide combination lead homogeneous bp control inter dosing interval trough peak ratio smoothness index reflect finding accurately,Palatini P,2002,Eur J Clin Pharmacol,https://doi.org/10.1007/s00228-001-0393-6,11868797,Palatini P; Malacco E; Di SS; Carretta R; Dorigatti F; Bertocchi F; Mann J,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D004311: Double-Blind Method; D004338: Drug Combinations; D005260: Female; D006339: Heart Rate; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D013777: Tetrazoles; D013997: Time Factors; D014633: Valine; D000068756: Valsartan",,,https://openalex.org/W1976464373,189,26,1,2400,387,15,en,en
false,granuloma annulare like eruption associate use amlodipine,granuloma annulare like drug reaction rarely encountered clinical entity year old caucasian female develop granuloma annulare like reaction day start amlodipine clear within month drug cessation eruption consist multiple erythematous pruritic papule distribute symmetrically lateral aspect leg thigh well palm histology show focal collagen degeneration significant interstitial histiocytic dermal infiltrate suggestive granuloma annulare review previously report case granuloma annulare like drug reaction context recently propose classification drug induced interstitial granulomatous reaction,Lim AC,2002,Australas J Dermatol,https://doi.org/10.1046/j.1440-0960.2002.00547.x,11869204,Lim AC; Hart K; Murrell D,article,D002363: Case Reports; D016428: Journal Article; D016454: Review,"D017311: Amlodipine; D001707: Biopsy, Needle; D002121: Calcium Channel Blockers; D005260: Female; D016460: Granuloma Annulare; D006229: Hand Dermatoses; D006801: Humans; D006973: Hypertension; D007868: Leg Dermatoses; D008875: Middle Aged; D011379: Prognosis; D018570: Risk Assessment; D012720: Severity of Illness Index",,,https://openalex.org/W2032785048,72,10,1,732,104,5,en,en
false,twenty four hour ambulatory blood pressure international nifedipine git study intervention goal hypertension treatment insight,international nifedipine git study intervention goal hypertension treatment insight show mean office blood pressure measurement long term treatment nifedipine git effective diuretic prevent cardiovascular cerebrovascular complication however since office blood pressure measurement reflect limited extent blood pressure outside office side arm insight study patient underwent office measurement h ambulatory blood pressure monitoring also performed study randomize double blind parallel group design week placebo mild moderate essential hypertensive patient randomize nifedipine git mg amiloride hydrochlorothiazide mg year dose titration perform dose doubling addition atenolol mg enalapril mg drug need analysis carry intention treat included computation h day night ambulatory blood pressure heart rate value additional analysis include computation trough peak ratio smoothness index ratio average hourly blood pressure reduction treatment standard deviation total patient recruit valid analysis patient h ambulatory recording baseline treatment treatment office h day night blood pressure significantly similarly reduce treatment office ambulatory heart rate leave unchanged diuretic slightly reduce nifedipine median trough peak ratio always superimposable two treatment group similarly smoothness index systolic diastolic blood pressure comparably high nifedipine diuretic thus demonstrate similar well balanced antihypertensive response drug significant difference observe two treatment group number cardiovascular event nifedipine based diuretics based treatment group insight study long term antihypertensive effect h blood pressure cardiovascular protection nifedipine similar diuretic,Mancia G,2002,J Hypertens,https://doi.org/10.1097/00004872-200203000-00032,11875324,Mancia G; Omboni S; Parati G; Investigators of the INSIGHT ABPM substudy,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000368: Aged; D000369: Aged, 80 and over; D000584: Amiloride; D000959: Antihypertensive Agents; D001795: Blood Pressure Determination; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D002318: Cardiovascular Diseases; D002940: Circadian Rhythm; D004232: Diuretics; D004311: Double-Blind Method; D005260: Female; D006040: Goals; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D009819: Office Visits; D012307: Risk Factors; D049993: Sodium Chloride Symporter Inhibitors; D014665: Vasodilator Agents",,,https://openalex.org/W2330729530,144,21,1,2336,371,11,en,en
false,cross sectional study health related quality life african american chronic renal insufficiency african american study kidney sisease hypertension trial,measure health related quality life hrql use medical outcome study item short form sf cross sectional study african american men woman mild moderate chronic renal insufficiency mean glomerular filtration rate ml min cause hypertension randomization onto african american study kidney disease hypertension aask trial scale contribute physical health summary measure physical component summary pc score mean sd significantly low scale relate mental health mental component summary mc score scale except role physical pc mc significantly high men respectively woman respectively multivariate analysis employment status education level household income body mass index comorbid medical condition year hypertension number antihypertensive drug prescribe exercise status male sex significant independent predictor pc factor predict mc include employment status marital status current smoking age comorbid medical condition male sex entire aask cohort mean score individual scale except mental health pc low mean mc score slightly high value u general population value individual scale sf pc substantially high among aask participant compare african american hemodialysis patient six eight scale low aask cohort compare group racially mixed exclusively african american hypertensive subject conclude physical aspect quality life substantially reduce compare mental component among aask participant number demographic clinical characteristic significantly impact hrql national kidney foundation inc,Kusek JW,2002,Am J Kidney Dis,https://doi.org/10.1053/ajkd.2002.31401,11877570,Kusek JW; Greene P; Wang SR; Beck G; West D; Jamerson K; Agodoa LY; Faulkner M; Level B,article,"D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.","D000293: Adolescent; D000328: Adult; D001741: Black or African American; D000368: Aged; D015897: Comorbidity; D003430: Cross-Sectional Studies; D005260: Female; D006304: Health Status; D006801: Humans; D006973: Hypertension; D007676: Kidney Failure, Chronic; D008297: Male; D008603: Mental Health; D008875: Middle Aged; D015999: Multivariate Analysis; D011788: Quality of Life; D012044: Regression Analysis; D012737: Sex Factors; D012959: Socioeconomic Factors; D011795: Surveys and Questionnaires",,,https://openalex.org/W2029808918,178,25,1,2032,355,10,en,en
false,nifedipine versus terbutaline management preterm labor,international journal gynecology obstetricsvolume issue p brief communication nifedipine versus terbutaline management preterm labor w weerakul w weerakul department obstetrics gynecology ramathibodi hospital mahidol university bangkok thailandsearch paper authora chittacharoen correspond author chittacharoen email protect department obstetrics gynecology ramathibodi hospital mahidol university bangkok thailandcorresponding author tel fax search paper author suthutvoravut suthutvoravut department obstetrics gynecology ramathibodi hospital mahidol university bangkok thailandsearch paper author w weerakul w weerakul department obstetrics gynecology ramathibodi hospital mahidol university bangkok thailandsearch paper authora chittacharoen correspond author chittacharoen email protect department obstetrics gynecology ramathibodi hospital mahidol university bangkok thailandcorresponding author tel fax search paper author suthutvoravut suthutvoravut department obstetrics gynecology ramathibodi hospital mahidol university bangkok thailandsearch paper author first publish march http doi org citations read full textaboutpdf toolsrequest permissionexport citationadd favoritestrack citation shareshare give accessshare full text accessshare full text accessplease review term condition use check box share full text version article read accept wiley online library term condition useshareable linkuse link share full text version article friend colleague learn copy url share linkshare onfacebooktwitterlinkedinredditwechat abstract available article citing literature volume issue march pages relatedinformation,Weerakul W,2002,Int J Gynaecol Obstet,https://doi.org/10.1016/s0020-7292(01)00547-1,11880137,Weerakul W; Chittacharoen A; Suthutvoravut S,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D005260: Female; D006801: Humans; D009543: Nifedipine; D007752: Obstetric Labor, Premature; D011247: Pregnancy; D011256: Pregnancy Outcome; D013726: Terbutaline; D015149: Tocolytic Agents",,,https://openalex.org/W2088192506,60,8,1,2100,307,6,en,en
false,randomised trial compare efficacy safety felodipine plendil nifedipine adalat retard patient mild moderate hypertension,efficacy tolerability felodipine extended release compare nifedipine retard management patient mild moderate hypertension total one hundred thirty three patient screen one hundred twenty one patient enrol week multicentre open randomise rising dose trial receive either felodipine mg daily nifedipine mg twice daily blood pressure measure end dose interval hour hour felodipine nifedipine respectively drug felodipine nifedipine find lower blood pressure significantly compare baseline three week treatment seat blood pressure reduce mmhg systolic diastolic mmhg week felodipine group correspond value nifedipine group mmhg mmhg pulse rate significantly affect either drug percentage patient satisfactory control week treatment felodipine nifedipine significant dose titration necessary end study response rate n n felodipine nifedipine respectively non significant drug metabolically inert derange haematologic biochemical profile patient produce significant weight change pattern side effect similar group tend severe nifedipine necessitate withdrawal two patient group conclusion felodipine er mg mg daily nifedipine retard mg twice daily equally effective medication mild moderate hypertension felodipine well tolerate,Onwubere BJ,2001,West Afr J Med,,11885871,Onwubere BJ; Obodo JO; Oke DA; Okeahialam BN; Danbauchi SS; Mbakwem AC,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D001741: Black or African American; D044383: Black People; D002121: Calcium Channel Blockers; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D009549: Nigeria; D013223: Statistics as Topic,,,https://openalex.org/W56244348,156,26,1,1808,305,13,en,en
false,epidemic primary aldosteronism,,Connell JM,2002,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1001319,11896502,Connell JM,article,D016428: Journal Article,D006801: Humans; D006929: Hyperaldosteronism; D006973: Hypertension; D012084: Renin-Angiotensin System,,,https://openalex.org/W1997572527,46,8,1,0,0,0,en,
false,factor relate occurrence microalbuminuria antihypertensive treatment essential hypertension,objective study assess factor relate occurrence microalbuminuria follow young adult group essential hypertension previously treat normo albuminuric essential hypertensive year old previously treat antihypertensive drug diabetes mellitus include initial evaluation patient treat use nonpharmacological measure n blockers n ace inhibitor n calcium channel blocker n several class n measurement take office blood pressure biochemical profile hour urinary albumin excretion beginning study measure yearly average year follow among patient include develop microalbuminuria progressors patients difference present progressors remain normo albuminuric nonprogressors term age gender body mass index disease duration blood pressure value biochemical profile familial history diabetes hypertension smoke habit presence ekg leave ventricular hypertrophy group low progression rate patient treat ace inhibitor n patients follow diet group n patients blockers group n patients exclude patient treat calcium channel blocker change time different class treatment significant difference incidence microalbuminuria observe among group progressors show high slope fast glucose versus mg p uric acid versus mg p compare slope nonprogressors slope glucose systolic blood pressure time associate independently slope logarithm urinary albumin excretion adjust age gender treatment group cox proportional hazard model progression microalbuminuria show baseline urinary albumin excretion risk ratio rr confidence interval ci slope systolic blood pressure rr ci slope glucose rr ci independently associate development microalbuminuria conclusion group young adult essential hypertension previously treat main factor influence occurrence microalbuminuria antihypertensive treatment value microalbuminuria baseline slope systolic blood pressure fast glucose,Redon J,2002,Hypertension,https://doi.org/10.1161/hy0302.105209,11897766,Redon J; Rovira E; Miralles A; Julve R; Pascual JM,article,D016430: Clinical Trial; D016428: Journal Article,D000319: Adrenergic beta-Antagonists; D000328: Adult; D000419: Albuminuria; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001262: Atenolol; D017298: Bisoprolol; D002121: Calcium Channel Blockers; D004656: Enalapril; D005260: Female; D006801: Humans; D006973: Hypertension; D017706: Lisinopril; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D016016: Proportional Hazards Models; D012044: Regression Analysis; D012307: Risk Factors; D016896: Treatment Outcome,,,https://openalex.org/W2030486736,113,13,1,2785,492,12,en,en
false,hair darken porphyria cutanea tarda,repigmentation grey hair rare describe several clinical setting often report postinflammatory effect several drug chronic arsenic exposure coeliac disease also cite addition darken spontaneous phenomenon report two patient sustained repigmentation hair association porphyria cutanea tarda mechanism repigmentation remain elusive presumably involve recruitment root sheath melanocyte activate form functional hair bulb melanocyte,Shaffrali FC,2002,Br J Dermatol,https://doi.org/10.1046/j.1365-2133.2002.04591.x,11903250,Shaffrali FC; McDonagh AJ; Messenger AG,article,D002363: Case Reports; D016428: Journal Article,D000368: Aged; D005260: Female; D005500: Follow-Up Studies; D006200: Hair Color; D006801: Humans; D017495: Hyperpigmentation; D017119: Porphyria Cutanea Tarda,,,https://openalex.org/W2122552127,41,6,1,592,96,4,en,en
false,double blind placebo controlled crossover comparison five class antihypertensive drug,hypertension guideline recommend initial treatment beta blocker diuretic add drug blood pressure control hypothesize systematic rotation major class antihypertensive drug would demonstrate substantial difference pattern individual patient response suggest rational approach choose best treatment thirty four young hypertensive age median rotate double blind latin square crossover fashion week treatment amlodipine doxazosin lisinopril bisoprolol bendrofluazide placebo blood pressure measure visit best drug define efficacy tolerability repeat end rotation double number patient reach target blood pressure systolic mmhg one drug p five drug represent among best drug six patient blood pressure best drug least mmhg low response best drug highly correlate r previous administration contrast weak correlation response pair drug except angiotensin converting enzyme ace inhibitor beta blocker b calcium blocker c diuretic r p young patient majority patient respond best drug suppress renin system b patients vary reproducibly response initial treatment switch among drug increase efficacy monotherapy result support ab cd scheme choose therapy first drug take one pair uncontrolled patient switch one pair,Deary AJ,2002,J Hypertens,https://doi.org/10.1097/00004872-200204000-00037,11910315,Deary AJ; Schumann AL; Murfet H; Haydock SF; Foo RS; Brown MJ,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000317: Adrenergic alpha-Antagonists; D000319: Adrenergic beta-Antagonists; D000328: Adult; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001539: Bendroflumethiazide; D017298: Bisoprolol; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D004232: Diuretics; D004311: Double-Blind Method; D017292: Doxazosin; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D017706: Lisinopril; D008297: Male; D008875: Middle Aged; D020097: Natriuretic Peptide, Brain; D012084: Renin-Angiotensin System; D049993: Sodium Chloride Symporter Inhibitors",,,https://openalex.org/W2023905894,95,11,1,1782,329,10,en,en
false,prior calcium channel blockade short term survival follow acute myocardial infarction,concern safety calcium channel blocker ccbs acute coronary disease seek determine patient take calcium channel blocker ccbs time admission acute myocardial infarction ami high case fatality compare take beta blockers neither medication clinical drug treatment variable time hospital admission predictive survival day examine community based registry patient age year admit hospital suspected ami perth australia among patient take ccb betablocker alone hospital admission patient take ccbs bad clinical profile take beta blocker alone neither drug control group high unadjusted day mortality versus respectively p significant heterogeneity respect mortality nifedipine diltiazem verapamil use alone beta blocker adjustment factor predictive death day patient take ccb find excess chance death compare control group odds ratio confidence interval ci whereas take beta blocker alone low odds death ci result indicate establish calcium channel blockade associate excess risk death follow ami difference patient take account neither survival advantage see prior beta blocker therapy,Parsons RW,2001,Cardiovasc Drugs Ther,https://doi.org/10.1023/a:1013707503018,11916357,Parsons RW; Hung J; Hanemaaijer I; Jbroadhurst R; Jamrozik K; Hobbs MS,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000319: Adrenergic beta-Antagonists; D001315: Australia; D002121: Calcium Channel Blockers; D004110: Diltiazem; D004347: Drug Interactions; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D009543: Nifedipine; D016017: Odds Ratio; D012189: Retrospective Studies; D015996: Survival Rate; D013997: Time Factors; D016896: Treatment Outcome; D014700: Verapamil,,,https://openalex.org/W1554495529,93,12,1,1678,316,8,en,en
false,antiarrhythmic effect azimilide paroxysmal supraventricular tachycardia efficacy dose response,background azimilide novel classification iii antiarrhythmic agent block ikrand iksand show evidence efficacy patient atrial fibrillation flutter effect paroxysmal supraventricular tachycardia psvt report method result one hundred ninety three patient symptomatic psvt enrol double blind randomize placebo controlled clinical trial almost identical trial design supraventricular arrhythmia sva sva sva sva perform separate stratum study also include stratum patient atrial fibrillation flutter patient receive oral azimilide mg sva sva mg sva mg sva match placebo twice daily day loading period follow daily dosing maintenance period primary outcome variable first recording symptomatic supraventricular arrhythmia either psvt atrial fibrillation atrial flutter record transtelephonic electrocardiographic event recorder duration study day sva sva day sva sva combine analysis result psvt stratum study show dose response relationship prolongation time recurrence p combined mg daily dose hazard ratio placebo azimilide p hazard ratio mg daily dose measure p significant however time recurrence prolong patient receive mg daily combine compare placebo p death case torsades de pointes conclusion trial result suggest significant dose related suppression psvt azimilide low risk serious adverse event heart j,Page RL,2002,Am Heart J,https://doi.org/10.1067/mhj.2002.120969,11923801,Page RL; Connolly SJ; Wilkinson WE; Marcello SR; Schnell DJ; Pritchett EL; Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000889: Anti-Arrhythmia Agents; D004311: Double-Blind Method; D004562: Electrocardiography; D005260: Female; D006801: Humans; D006827: Hydantoins; D007093: Imidazoles; D048289: Imidazolidines; D008297: Male; D008875: Middle Aged; D018579: Patient Selection; D010879: Piperazines; D013614: Tachycardia, Paroxysmal; D013617: Tachycardia, Supraventricular; D013686: Telemetry; D016171: Torsades de Pointes",,,https://openalex.org/W2125177928,106,12,1,1862,339,13,en,en
false,dipyridamole may use safely patient ischaemic heart disease,think patient cerebrovascular disease concurrent ischaemic heart disease dipyridamole co formulated aspirin show increase relative reduction risk second stroke patient prior stroke transient ischaemic attack beyond obtain aspirin alone seek resolve question whether dipyridamole treatment increase risk cardiac adverse event patient co existing ischaemic heart disease published literature periodic safety update report randomise controlled trial antiplatelet agent stroke prevention include dipyridamole cardiovascular indication review analyse early report serious adverse cardiac effect attributable dipyridamole occur patient severe coronary artery disease use dipyridamole stress test adjunct cardiac imaging randomised controlled trial databases show evidence mortality isolated case significant cardiac morbidity attributable dipyridamole recommended oral dos patient ischaemic heart disease conclude patient cerebrovascular mild moderate concomitant ischaemic heart disease may treat safely dipyridamole secondary prevention stroke,Humphreys DM,2002,Int J Clin Pract,,11926699,Humphreys DM; Street J; Schumacher H; Bertrand-Hardy JM; Palluk R,article,D016428: Journal Article; D016454: Review,"D004176: Dipyridamole; D006801: Humans; D002546: Ischemic Attack, Transient; D017202: Myocardial Ischemia; D016032: Randomized Controlled Trials as Topic; D020521: Stroke; D014665: Vasodilator Agents",,,https://openalex.org/W2410712054,72,11,1,1346,199,7,en,en
false,faecal incontinence common treatable,medical journal australiavolume issue p editorial faecal incontinence common treatable michael kamm michael kamm st mark hospital harrow london uk search paper author michael kamm michael kamm st mark hospital harrow london uk search paper author first publish january http doi org j tb xcitations read full textaboutpdf toolsrequest permissionexport citationadd favoritestrack citation shareshare give accessshare full text accessshare full text accessplease review term condition use check box share full text version article read accept wiley online library term condition useshareable linkuse link share full text version article friend colleague learn copy url share linkshare onfacebooktwitterlinkedinredditwechat abstract available article citing literature volume issue january pages relatedinformation,Kamm MA,2002,Med J Aust,https://doi.org/10.5694/j.1326-5377.2002.tb04280.x,11936280,Kamm MA,article,"D016420: Comment; D016421: Editorial; D013485: Research Support, Non-U.S. Gov't",D001315: Australia; D005242: Fecal Incontinence; D006801: Humans; D015995: Prevalence; D012307: Risk Factors,,,https://openalex.org/W2416754511,41,6,1,1068,160,2,en,en
false,nifedipine hydralazine first line agent control hypertension severe preeclampsia,pre eclampsia one serious common complication pregnancy nifedipine calcium channel blocker vasodilator hydralazine use antihypertensive agent condition aim study determine two agent appropriate antihypertensive management severe pre eclampsia one hundred twenty six pre eclamptic patient gestational age week randomize receive either mg nifedipine sublingually mg intravenous hydralazine woman history heart failure woman receive antihypertensive treatment course current pregnancy exclude patient following data record number drug administration time need control blood pressure mean urinary output time interval effective control new hypertensive crisis drug administration relevant adverse effect mother fetus effective control blood pressure achieve treatment arm data analysis indicate significantly drug administration nifedipine arm study time interval new hypertensive crisis follow initial effective control blood pressure significantly longer nifedipine group compare hydralazine effective control blood pressure achieve rapidly multiparous patient receive nifedipine p mean urinary output delivery great nifedipine arm study significant difference two group variable addition neither group serious adverse effect mother fetus nifedipine safe effective hydralazine control blood pressure severe pre eclampsia added advantage cheap widely available latter easily administer,Aali BS,2002,Acta Obstet Gynecol Scand,https://doi.org/10.1034/j.1600-0412.2002.810105.x,11942883,Aali BS; Nejad SS,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000328: Adult; D000959: Antihypertensive Agents; D001794: Blood Pressure; D005260: Female; D006801: Humans; D006830: Hydralazine; D009543: Nifedipine; D011225: Pre-Eclampsia; D011247: Pregnancy; D016037: Single-Blind Method; D014665: Vasodilator Agents,,,https://openalex.org/W1979143133,94,13,1,1970,312,12,en,en
false,randomize clinical trial assess side effects glyceryl trinitrate diltiazem hydrochloride treatment chronic anal fissure,glyceryl trinitrate gtn ointment small middle dot per cent efficacy per cent heal chronic anal fissure headache major side effect diltiazem hydrochloride dtz cream per cent expect side effects prospective double blind randomize two centre trial require least patient group alpha beta institute approval local ethic committee compare incidence side effects primary endpoint per cent gtn ointment per cent dtz cream treatment chronic anal fissure treatment apply perianally twice daily week patient give write informed consent group comparable patient demographic clinical characteristic twelve patient violate protocol withdraw attend follow side effects gtn patient dtz relative risk rr per cent confidence interval c p particular headache occur gtn patient dtz eight rr per cent c p significant difference healing symptomatic improvement rate patient receive gtn dtz dtz cream cause substantially headache gtn ointment significant difference healing improvement chronic anal fissure treatment dtz may preferred first line treatment chronic anal fissure,Kocher HM,2002,Br J Surg,https://doi.org/10.1046/j.0007-1323.2001.02042.x,11952579,Kocher HM; Steward M; Leather AJ; Cullen PT,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D004110: Diltiazem; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D005401: Fissure in Ano; D005500: Follow-Up Studies; D006261: Headache; D006801: Humans; D008297: Male; D008875: Middle Aged; D005996: Nitroglycerin; D009824: Ointments; D010147: Pain Measurement; D011446: Prospective Studies; D016896: Treatment Outcome; D014665: Vasodilator Agents",,,https://openalex.org/W1971773335,144,19,1,1595,311,12,en,en
false,effect calcium channel antagonist diltiazem calcium ionophore cyclosporine induced apoptosis renal tubular cell,calcium channel antagonist report favorable impact cyclosporin csa treated kidney transplant recipient however clear whether direct effect antagonize toxicity csa renal tubular cell study use madin darby canine kidney tubular cell model examine effect diltiazem calcium channel antagonist csa induced apoptosis moreover investigate possible regulation csa cytotoxicity intracellular calcium level effect calcium ionophore csa induced apoptosis also examine find treatment csa alone cause cell death apparently enhance diltiazem g ml accompany severe dna fragmentation activation caspase decreased level bcl caspase inhibitor zvad fmk bcl overexpression capable suppress apoptosis induce synergistic effect diltiazem csa moreover survival rate cell treat csa alone remain however markedly elevate co treatment ng ml rescue cell csa induced apoptosis correlate akt activation bad phosphorylation caspase inactivation take together result suggest report favorable impact diltiazem kidney graft likely direct protection renal tubular cell instead enhance toxicity csa renal tubular cell addition finding raise possibility intracellular calcium level akt pathway may participate regulation csa cytotoxicity,Cheng CH,2002,FEBS Lett,https://doi.org/10.1016/s0014-5793(02)02563-2,11959131,Cheng CH; Hsieh CL; Shu KH; Chen YL; Chen HC,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000818: Animals; D017209: Apoptosis; D000001: Calcimycin; D002118: Calcium; D002121: Calcium Channel Blockers; D053148: Caspase 3; D020169: Caspases; D002478: Cells, Cultured; D016572: Cyclosporine; D053938: DNA Fragmentation; D004268: DNA-Binding Proteins; D004110: Diltiazem; D004285: Dogs; D004789: Enzyme Activation; D015870: Gene Expression; D019254: Genes, bcl-2; D007476: Ionophores; D007684: Kidney Tubules; D050778: NFATC Transcription Factors; D009687: Nuclear Proteins; D014157: Transcription Factors",,,https://openalex.org/W2076277952,134,18,1,1717,307,11,en,en
false,comparaison de la nicardipine et de l isradipine dans l hypertension art rielle observ e apr pontage aorto coronarien,compare efficacy isradipine nicardipine control arterial hypertension follow coronary artery bypass graft cabg clinical prospective randomised study patient asa ii iii mean age year schedule elective cabg include mean arterial pressure map mmhg within first six post operative hour patient include randomly attribute either one group gr n receive nicardipine gr ii n receive isradipine bolus continuous perfusion hr map mpap cvp pcwp ci svri pvri svi record administration drug min first bolus map reach mmhg min continuous perfusion stop perfusion significant change hr cvp pcwp mpap pvri time group significant increase ci group reduction map important gr compare gr ii mainly due significant decrease svri isradipine effective treatment arterial hypertension follow cabg however significant beneficial effect isradipine nicardipine,Madi-Jebara S,2002,Ann Fr Anesth Reanim,https://doi.org/10.1016/s0750-7658(02)00591-9,11963384,Madi-Jebara S; Khater-Rassi D; Yazigi A; Haddad F; Hayek G; Achkouty R; Antakly MC,article,D016430: Clinical Trial; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,D000368: Aged; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D001026: Coronary Artery Bypass; D005260: Female; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D008297: Male; D008875: Middle Aged; D009529: Nicardipine; D011183: Postoperative Complications; D011446: Prospective Studies; D013997: Time Factors,,,https://openalex.org/W2027739324,119,18,1,1309,279,10,fr,en
false,effect chronic calcium channel blockade sympathetic nerve activity hypertension,sympathetic nervous system sn important regulator circulation activity increase hypertension heart failure adversely affect prognosis although certain drug inhibit sn dihydropyridine calcium antagonist may stimulate system phenylalkylamine calcium antagonist verapamil different pharmacological profile therefore test hypothesis whether amlodipine nifedipine verapamil differs effect muscle sympathetic nerve activity msa forty three patient men woman mild moderate hypertension randomly assign drug week blood pressure heart rate msa microneurography measure baseline week treatment calcium antagonists lead similar decrease blood pressure mm hg week p versus baseline significant difference msa group amlodipine msa average bursts min versus baseline nifedipine bursts min versus baseline verapamil bursts min p ns verapamil norepinephrine decrease tend increase one third amlodipine nifedipine p ns thus hypertension slow release form verapamil nifedipine amlodipine exert comparable antihypertensive effect change msa although trend toward decrease msa plasma norepinephrine verapamil,Binggeli C,2002,Hypertension,https://doi.org/10.1161/01.hyp.0000013264.41234.24,11967245,Binggeli C; Corti R; Sudano I; Luscher TF; Noll G,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004837: Epinephrine; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D009132: Muscles; D009543: Nifedipine; D009638: Norepinephrine; D013564: Sympathetic Nervous System; D014700: Verapamil,,,https://openalex.org/W2100907438,89,12,1,1496,264,12,en,en
false,severity hypertension affect improve resistance artery endothelial function angiotensin converting enzyme inhibition,purpose study determine whether difference restoration endothelial function angiotensin converting enzyme inhibition base severity hypertension forearm blood flow fbf measure patient essential hypertension mild n moderate n severe n randomly assign treatment either imidapril amlodipine week double blind fashion reactive hyperemia sublingual administration nitroglycerin imidapril augment fbf response reactive hyperemia week treatment mild moderate hypertensive group severe hypertensive group augmentation fbf response reactive hyperemia induce imidapril significantly great moderate hypertensive group mild hypertensive group amlodipine alter fbf response reactive hyperemia increase fbf sublingually administer nitroglycerin similar group infusion ng monomethyl l arginine nitric oxide synthase inhibitor abolish enhancement reactive hyperemia mild moderate hypertensive group treat imidapril finding suggest effect imidapril endothelial function affect severity hypertension angiotensin converting enzyme inhibitor induced augmentation reactive hyperemia may due increase nitric oxide production,Higashi Y,2002,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-200205000-00007,11973410,Higashi Y; Sasaki S; Nakagawa K; Kimura M; Sasaki S; Noma K; Hara K; Matsuura H; Goto C; Oshima T; Chayama K,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D017311: Amlodipine; D000704: Analysis of Variance; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D004311: Double-Blind Method; D004730: Endothelium, Vascular; D005260: Female; D006801: Humans; D006940: Hyperemia; D006973: Hypertension; D007093: Imidazoles; D048289: Imidazolidines; D008297: Male; D008875: Middle Aged; D007703: Peptidyl-Dipeptidase A; D012039: Regional Blood Flow; D012720: Severity of Illness Index; D014655: Vascular Resistance",,,https://openalex.org/W1984337223,124,13,1,1489,234,8,en,en
false,atrial fibrillation,prevalence incidence atrial fibrillation increase age atrial fibrillation associate high incidence coronary event stroke mortality sinus rhythm fast ventricular rate associate atrial fibrillation may cause tachycardia related cardiomyopathy management atrial fibrillation include treatment underlying cause precipitate factor immediate direct current cardioversion perform person atrial fibrillation associate acute myocardial infarction chest pain due myocardial ischemia hypotension severe heart failure syncope intravenous beta blockers verapamil diltiazem may use immediately slow fast ventricular rate associate atrial fibrillation oral beta blocker verapamil diltiazem give person atrial fibrillation rapid ventricular rate occur rest exercise despite digoxin amiodarone may use selected person symptomatic life threatening atrial fibrillation refractory drug therapy nondrug therapy perform person symptomatic atrial fibrillation rapid ventricular rate slow drug therapy paroxysmal atrial fibrillation associate tachycardia bradycardia syndrome manage permanent pacemaker combination drug permanent pacemaker implant person atrial fibrillation symptom dizziness syncope associate non drug induced ventricular pause long second develop elective direct current cardioversion high success rate low incidence cardiac adverse effect medical cardioversion convert atrial fibrillation sinus rhythm unless transesophageal echocardiography show thrombus left atrial appendage cardioversion oral warfarin give week elective direct current drug cardioversion atrial fibrillation continue least week maintenance sinus rhythm many cardiologist prefer treatment strategy ventricular rate control plus warfarin rather maintain sinus rhythm antiarrhythmic drug especially old patient digoxin use person paroxysmal atrial fibrillation patient chronic paroxysmal atrial fibrillation high risk stroke treat long term warfarin achieve international normalized ratio inr person atrial fibrillation low risk stroke contraindication warfarin receive mg aspirin daily,Aronow WS,2002,Heart Dis,https://doi.org/10.1097/00132580-200203000-00006,11975840,Aronow WS,article,D016428: Journal Article; D016454: Review,"D000367: Age Factors; D000368: Aged; D000369: Aged, 80 and over; D001281: Atrial Fibrillation; D015984: Causality; D004562: Electrocardiography; D005260: Female; D006801: Humans; D015994: Incidence; D008297: Male; D008875: Middle Aged; D015995: Prevalence; D020521: Stroke; D013923: Thromboembolism; D018487: Ventricular Dysfunction, Left",,,https://openalex.org/W4246157165,19,2,1,2676,403,17,es,en
false,arrhythmia sudden death hypertrophic cardiomyopathy,,McKenna WJ,2002,Card Electrophysiol Rev,https://doi.org/10.1023/a:1017966518021,11984011,McKenna WJ; Firoozi S; Sharma S,article,D016428: Journal Article; D016454: Review,"D001145: Arrhythmias, Cardiac; D002312: Cardiomyopathy, Hypertrophic; D016757: Death, Sudden, Cardiac; D006801: Humans; D018570: Risk Assessment",,,https://openalex.org/W149466499,60,8,1,0,0,0,en,
false,class benefit antagonists type diabetes nephropathy,diabetes mellitus reach epidemic proportion many country common cause end stage renal disease esrd angiotensin ii receptor antagonists losartan irbesartan recently evaluate renoprotective agent large clinical trial patient type diabetes nephropathy reduction end point non insulin dependent diabetes mellitus angiotensin ii antagonist renaal study losartan decrease number patient reach primary end point composite measure neuropathy relative risk reduction approximately losartan due reduction doubling creatinine concentration esrd death irbesartan diabetic nephropathy trial idnt beneficial effect irbesartan mainly doubling baseline creatinine concentration risk reduction also reduction onset esrd irbesartan effect mortality beneficial effect occur addition blood pressure control agent antagonist clinical trial suggest may class renoprotective action antagonist although mechanism clear patient type diabetes nephropathy receive either antagonist angiotensin convert enzyme inhibitor ramipril ensure renoprotection,Doggrell SA,2002,Expert Opin Pharmacother,https://doi.org/10.1517/14656566.3.5.625,11996640,Doggrell SA,article,D016428: Journal Article,"D057911: Angiotensin Receptor Antagonists; D000959: Antihypertensive Agents; D001713: Biphenyl Compounds; D002986: Clinical Trials as Topic; D003924: Diabetes Mellitus, Type 2; D003928: Diabetic Nephropathies; D006801: Humans; D000077405: Irbesartan; D007676: Kidney Failure, Chronic; D019808: Losartan; D008875: Middle Aged; D044140: Receptor, Angiotensin, Type 1; D013777: Tetrazoles",,,https://openalex.org/W1979341153,79,18,1,1469,263,9,en,en
false,adverse drug reaction cause admission department internal medicine,assess occurrence pattern adverse drug reaction cause acute hospital admission randomly select patient acutely admit clinic internal medicine swedish university hospital information collect medical record current symptom use drug previous disease result medical investigation test addition standardized interview accord questionnaire carry group expert clinical pharmacology assess data obtain patient case record result interview accord criterion judge probability adverse drug reaction could cause contribute actual admission hospital case include symptom sign judge drug related cause contribute admission eighty two patient altogether symptom classify adverse drug reaction type reaction relationship medication reaction judge certain eight probable possible case common adverse drug reaction cardiovascular twelve patient symptom indicate intoxications prevalence drug related problem cause contribute admission clinic internal medicine high dominate type reaction e reaction principle predictable preventable imply possibility increase drug safety preventive measure,Mjörndal T,2002,Pharmacoepidemiol Drug Saf,https://doi.org/10.1002/pds.667,11998554,Mjörndal T; Boman MD; Hägg S; Bäckström M; Wiholm BE; Wahlin A; Dahlqvist R,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D004358: Drug Therapy; D064420: Drug-Related Side Effects and Adverse Reactions; D005260: Female; D006760: Hospitalization; D006801: Humans; D007388: Internal Medicine; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D013548: Sweden",,,https://openalex.org/W1988304729,85,14,1,1603,278,10,en,en
false,clinical trial report,,Flack JM,2002,Curr Hypertens Rep,https://doi.org/10.1007/s11906-002-0004-7,12003698,Flack JM,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000293: Adolescent; D000328: Adult; D000368: Aged; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D044383: Black People; D002121: Calcium Channel Blockers; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009400: Nephrosclerosis; D011446: Prospective Studies; D017257: Ramipril; D016896: Treatment Outcome,,,https://openalex.org/W2416492499,22,3,1,0,0,0,en,
false,meta analysis randomise controlled trial effectiveness antiarrhythmic agent promote sinus rhythm patient atrial fibrillation,conduct meta analysis randomise control trial estimate effectiveness antiarrhythmic drug promote sinus rhythm patient atrial fibrillation articles identify use comprehensive search english language paper index medline august outcome sinus rhythm death random effect model use model repeated assessment within study different time points emergency department ambulatory clinics patients atrial fibrillation antiarrhythmic agent group accord vaughan williams class sinus rhythm mortality article meet priori criterion inclusion analysis median duration follow one day range mean sd day median proportion patient sinus rhythm follow range range receive active treatment placebo respectively median survival range range compare placebo following drug class associate increased sinus rhythm follow ia treatment difference confidence interval ci ic treatment difference ci iii treatment difference ci class ic drug associate increased sinus rhythm follow compare class iv drug treatment difference ci significant difference mortality drug classes class ia ic iii drug associate increased sinus rhythm follow compare placebo unclear whether antiarrhythmic drug class associate increase decrease mortality,Nichol G,2002,Heart,https://doi.org/10.1136/heart.87.6.535,12010934,Nichol G; McAlister F; Pham B; Laupacis A; Shea B; Green M; Tang A; Wells G,article,"D016428: Journal Article; D017418: Meta-Analysis; D013485: Research Support, Non-U.S. Gov't",D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D006801: Humans; D016032: Randomized Controlled Trials as Topic; D012680: Sensitivity and Specificity; D016019: Survival Analysis; D016896: Treatment Outcome,,,https://openalex.org/W2170313402,154,20,1,1748,329,9,en,en
false,safe calcium antagonist hypertension coronary heart disease,chair internal medicine centro di fisiologia clinica e ipertensione university milan ospedale gerardo dei tintori monza centro auxologico italiano milan italy departments pharmacotherapy cardiology academic medical center university amsterdam amsterdam netherlands,Mancia G,1996,J Hypertens,https://doi.org/10.1097/00004872-199601000-00002,12013485,Mancia G; van Zwieten PA,article,D016421: Editorial,D002121: Calcium Channel Blockers; D003327: Coronary Disease; D005544: Forecasting; D006801: Humans; D006973: Hypertension; D016896: Treatment Outcome; D014481: United States,,,https://openalex.org/W1997649096,76,12,1,320,55,1,en,en
false,topical lidocaine limit autonomic dysreflexia anorectal procedure spinal cord injury prospective double blind study,background aim autonomic dysreflexia common potentially dangerous response patient spinal cord injury acute blood pressure elevation may precipitate rectosigmoid distention anal manipulation topical anesthetic widely recommend minimize incidence severity autonomic dysreflexia although scientific evidence support refute practice study test whether topical lidocaine would prevent limit anorectal procedure associated autonomic dysreflexia patient method enrol patient chronic complete spinal cord injury schedule anoscopy flexible sigmoidoscopy double blind fashion randomize receive either lidocaine jelly n nonmedicated lubricant control n prior procedure measure blood pressure procedure result mean maximal systolic blood pressure increase mmhg lidocaine group vs mmhg control group ns however significant difference anoscopic procedure flexible sigmoidoscopy without anoscopy vs mmhg conclusion topical lidocaine significantly limit prevent autonomic dysreflexia susceptible patient anoscopy flexible sigmoidoscopy cause significant blood pressure elevation anoscopy involve stretching anal sphincter potent stimulus autonomic dysreflexia flexible sigmoidoscopy involve gaseous distention rectosigmoid anal sphincter stretch rectosigmoid distention rather mucosal stimulus likely nociceptive trigger procedure associated autonomic dysreflexia,Cosman BC,2002,Int J Colorectal Dis,https://doi.org/10.1007/s003840100347,12014417,Cosman BC; Vu TT; Plowman BK,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000287: Administration, Topical; D000779: Anesthetics, Local; D020211: Autonomic Dysreflexia; D001794: Blood Pressure; D004311: Double-Blind Method; D005260: Female; D006484: Hemorrhoids; D006801: Humans; D008012: Lidocaine; D008026: Ligation; D008297: Male; D011351: Proctoscopy; D011446: Prospective Studies; D012812: Sigmoidoscopy; D013119: Spinal Cord Injuries",,,https://openalex.org/W2002243414,139,20,1,1765,280,13,en,en
false,effect intravenous amlodipine coronary hemodynamics subject angiographically normal coronary artery,aim current study assess ability amlodipine dilate coronary vessel subject angiographically normal coronary artery normal leave ventricular function ten patient six woman four men mean age year range year enrol coronary flow velocity coronary perfusion pressure invasively measure baseline intracoronary adenosine mg bolus min follow iv amlodipine mg quantitative coronary angiography perform baseline min amlodipine coronary cross sectional area mean coronary flow velocity progressively increase amlodipine administration result average increase coronary flow min individual basis patient one show consistent trend toward progressive coronary vasodilator effect amlodipine time peak effect amlodipine baseline mean coronary flow velocity adenosine first clinical study demonstrate iv administration amlodipine produce powerful coronary vasodilatation subject angiographically normal coronary artery normal ventricular function besides know systemic vasodilating effect coronary vasodilating property amlodipine particularly express microcirculatory level,Neglia D,2002,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-200206000-00014,12021583,Neglia D; Gallopin M; Marraccini P; Simonetti I; Micalizzi M; Macerata A; Marzilli M; L'Abbate A,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D023361: Validation Study","D000241: Adenosine; D000328: Adult; D000368: Aged; D017311: Amlodipine; D000704: Analysis of Variance; D001783: Blood Flow Velocity; D017023: Coronary Angiography; D003331: Coronary Vessels; D005260: Female; D006439: Hemodynamics; D006801: Humans; D007262: Infusions, Intravenous; D008297: Male; D008875: Middle Aged; D014665: Vasodilator Agents",,,https://openalex.org/W2320805495,117,14,1,1416,236,9,en,en
false,subgroup analysis nordil trial,prospective randomize open endpoint blinded nordil trial show risk primary composite endpoint consisting cardiovascular death stroke myocardial infarction similar hypertensive patient receive calcium channel blocker diltiazem compare conventional treatment base diuretic blockers finding agreement recent meta analysis showing antihypertensive drug similar beneficial effect overall cardiovascular prognosis however finding rule possibility new class antihypertensive drug might particularly effective special subgroup patient prevent cause specific endpoint issue journal kjeldsen et al assess whether relative treatment effect nordil trial influence characteristic patient entry gender age level systolic diastolic pressure pulse pressure heart rate subgroup incidence primary composite endpoint similar two treatment group however compare conventional first line treatment diltiazem reduce risk stroke approximately p patient high systolic mmhg diastolic mmhg pulse mmhg pressure contrast risk myocardial infarction high p diltiazem group patient randomize diuretics blockers heart rate entry less beat per minute nevertheless difference treatment effect subgroup significant endpoint average treatment systolic blood pressure approximately mmhg high diltiazem conventional therapy high risk myocardial infarction diltiazem versus conventional therapy subject baseline heart rate median might explain blood pressure difference two treatment group indeed accord recently publish meta regression analysis patient enrol outcome trial mmhg high systolic pressure associate predicted relative risk confidence interval ci significantly p different relative risk observe nordil patient heart rate median ci contrast mmhg gradient systolic pressure two treatment group obviously explain low stroke risk nordil patient diltiazem indeed relative risk stroke accord metaregression analysis ci whereas nordil patient relative risk significantly p low ci stroke secondary endpoint nordil trial therefore chance finding rule hand beneficial effect diltiazem prevention stroke agreement two recently publish meta analyses randomized outcome trial first meta analysis include five trial compare calcium channel blocker based regimen diuretic blocker based therapy patient stroke coronary heart disease event compare old drug class diuretic blockers calcium channel blocker significantly reduce risk stroke additional ci tend increase risk coronary heart disease ci second meta analysis include six trial patient stroke myocardial infarction compare old drug calcium channel blocker provide reduction risk stroke ci less reduction risk myocardial infarction ci result similar overall cardiovascular benefit calcium channel blocker might therefore especially effective stroke prevention interaction treatment effect subgroup significant endpoint may several interpretation finding first could indicate relative difference two treatment group influence sex age severity hypertension fact relative risk stroke significant severe hypertensive patient systolic blood pressure mmhg diastolic blood pressure mmhg pulse pressure mmhg significant less severe hypertensive patient could due low underlying stroke risk latter subgroup mean analysis less severe hypertensive patient less statistical power second nordil trial design test difference randomized first line treatment specific subgroup stroke relative difference two treatment group approximately severe hypertensive patient approximately less severe hypertensive patient nordil trial may insufficient statistical power detect interaction treatment patient characteristic blood pressure level baseline third patient high heart rate risk myocardial infarction may influence blood pressure lowering treatment fourth remain possible diuretic blocker based therapy treatment initiate calcium channel blocker effective high blood pressure level however placebo controlled study moderate severe hypertensive patient find interaction blood pressure level randomization benefit derive active treatment author specify whether number patient treat prevent one cardiovascular complication differ accord patient characteristic entry absolute benefit proportional underlie risk may expect absolute number patient need treat diltiazem prevent one additional stroke much small severe hypertensive patient compare less severe hypertensive patient absolute difference two treatment group could also different old year young year patient woman men indeed two meta analyses outcome trial elderly hypertensive patient show although relative benefit active treatment versus treatment similar men woman young old patient absolute benefit much small low risk group number patient need treat year prevent one fatal non fatal cardiovascular complication men versus woman patient age year old versus age year considerable number nordil patient total population n non insulin dependent diabetes mellitus baseline main mortality morbidity result important subgroup report elsewhere patient type diabetes mellitus risk primary secondary endpoint similar two treatment group initially result might appear contradict combined finding double blind randomize placebo controlled systolic hypertension elderly program shep systolic hypertension europe syst eur trial two study include patient isolated systolic hypertension normal renal function serum creatinine mg dl shep trial treatment start thiazide diuretic chlorthalidone decrease incidence cardiovascular complication extent patient diabetes mellitus ci patient without diabetes mellitus ci however syst eur trial antihypertensive treatment start calcium channel blocker nitrendipine reduce incidence cardiovascular endpoint significantly p diabetic patient ci non diabetic patient ci basis disparate effect two trial additional benefit prevention proteinuria observe diabetic syst eur patient may speculate dihydropiridine derived calcium channel blocker effective thiazide diuretic prevent cardiovascular complication old patient diabetes mellitus normal renal function nordil trial outcome similar diabetic patient randomize diltiazem give conventional therapy remain elucidate syst eur trial dihydropiridine use nordil trial calcium channel blocker different class employ might diabetic patient dihydropyridine derived calcium channel blocker effective prevent cardiovascular complication however blood pressure control may also play important role nordil investigator specify whether blood pressure difference diltiazem conventional therapy group similar diabetic non diabetic patient information appear crucial correct interpretation relative risk finally important know type antihypertensive drug effectively take diabetic patient randomize diltiazem conventional therapy total nordil population limited number patient take thiazide diuretic considerable number patient use antihypertensive drug diuretic blockers although additional benefit diltiazem based therapy versus diuretic blocker based therapy incidence fatal plus non fatal stroke severe hypertensive patient estimate approximately confidence interval compatible difference research therefore perform increase precision estimate possible differential therapeutic effect calcium channel blocker diuretic blockers cause specific cardiovascular complication data also require draw firm conclusion use old new drug class accord patient characteristic meanwhile calcium channel blocker might consider treatment hypertension patient high risk stroke elderly,Thijs L,2002,J Hypertens,https://doi.org/10.1097/00004872-200206000-00018,12023676,Thijs L; Staessen JA; Wang J; Fagard R,article,D016420: Comment; D016421: Editorial,D002121: Calcium Channel Blockers; D004110: Diltiazem; D006801: Humans; D006973: Hypertension; D009203: Myocardial Infarction; D016032: Randomized Controlled Trials as Topic; D012307: Risk Factors; D020521: Stroke; D016896: Treatment Outcome,,,https://openalex.org/W2156911052,37,6,1,10720,1851,57,en,en
true,influence age sex blood pressure principal endpoint nordic diltiazem nordil study,aim nordic diltiazem nordil study compare patient essential hypertension receive calcium antagonist based treatment diltiazem similar patient receive conventional diuretic beta blocker based treatment respect cardiovascular morbidity mortality assess influence age sex severity hypertension heart rate treatment effect sub analysis nordil study prospective randomize open endpoint blinded enrol health centre norway sweden patient age year diastolic blood pressure dbp mmhg systolic blood pressure sbp dbp decrease mmhg diltiazem group mmhg diuretic beta blocker group significant difference sbp p incidence primary endpoint composite cardiovascular death cerebral stroke myocardial infarction similar two treatment fatal non fatal stroke occur patient diltiazem group patient conventional treatment group relative risk rr confidence interval ci p whereas non significant inverse tendency respect myocardial infarction significantly cerebral stroke patient receive diltiazem subgroup baseline sbp mmhg n rr ci p dbp mmhg n rr ci p pulse pressure mmhg n rr ci p myocardial infarction heart rate less beats min n rr ci p however tendency stroke great incidence myocardial infarction present across subgroup result analyse age sex severity hypertension heart rate treatment subgroup interaction analysis statistically significant compared conventional diuretic beta blocker based antihypertensive regimen additional reduction stroke diltiazem treated patient blood pressure pulse pressure great median increase myocardial infarction heart rate less median finding may attributable chance consistency particular stroke finding may also suggest ability diltiazem beyond conventional treatment prevent cerebral stroke hypertensive patient great cardiovascular risk,Kjeldsen SE,2002,J Hypertens,https://doi.org/10.1097/00004872-200206000-00038,12023696,Kjeldsen SE; Hedner T; Syvertsen JO; Lund-Johansen P; Hansson L; Lanke J; Lindholm LH; De Faire U; Dahlöf B; Karlberg BE; NORDIL Study Group,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D000368: Aged; D000375: Aging; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002318: Cardiovascular Diseases; D004110: Diltiazem; D004232: Diuretics; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006973: Hypertension; D015994: Incidence; D008297: Male; D008875: Middle Aged; D015337: Multicenter Studies as Topic; D009203: Myocardial Infarction; D011446: Prospective Studies; D012727: Sex Characteristics; D020521: Stroke; D016019: Survival Analysis",,,https://openalex.org/W2028185271,106,20,1,2623,475,7,en,en
true,effect calcium channel blocker cardiovascular outcome review randomised control trial,choice antihypertensive treatment guide evidence reduction risk cardiovascular cv event therefore improve long term outcome use pre determined criterion ten randomise control trial assess effect calcium channel blocker ccbs cv event patient hypertension identify six enrol relatively small number hypertensive patient whereas four study much large patient small study produce mixed finding especially trial ccbs compare diuretic may reflect methodological limitation impact random error result four large study produce consistent message long acting ccbs nifedipine administer gastro intestinal transport system git formulation nitrendipine diltiazem reduce cv morbidity mortality hypertensive patient one study specifically enrol high risk hypertensive patient nifedipine git effective diuretic therapy reduce cv event four large study sub group analysis show benefit ccbs extend hypertensive patient diabetes available evidence support use long acting ccbs first line treatment option hypertensive patient,De Leeuw PW,2002,Blood Press,https://doi.org/10.1080/08037050211260,12035874,De Leeuw PW; Birkenhäger WH,article,D016428: Journal Article; D016454: Review,"D002121: Calcium Channel Blockers; D002318: Cardiovascular Diseases; D048909: Diabetes Complications; D006801: Humans; D006973: Hypertension; D017063: Outcome Assessment, Health Care; D016032: Randomized Controlled Trials as Topic",,,https://openalex.org/W1984998952,108,16,1,1370,222,7,en,en
false,adverse drug event hospitalized patient treat cardiovascular drug anticoagulant,evaluate incidence serious adverse drug event ade cause cardiovascular drug hospitalization department internal medicine identify patient high risk patient treat cardiovascular drug anticoagulant department november january recruit study hospitalization patient chart review pharmacist clinician occurrence serious ade assess use naranjo algorithm possible doubtful ade counted patient enrol study serious ade compare patient without ade patient ade group old year mean sd vs year p average stay hospital long day vs day p mean urea level high mmol l vs mmol l p frequent background pathology patient ade hypertension atrial fibrillation nine ade group history drug allergy ade record bleed four arrhythmias six orthostatic hypotension six skin necrosis paranoid reaction acute hepatitis acute renal failure four causative drug warfarin account ade beta blockers propafenone amiodarone ca channel blocker nitrate diuretic together accounting ade drug combination implicate ade serious ade develop hospitalized patient take cardiovascular drug high risk old receive multiple drug therapy high urea level warfarin beta blockers drug cause large number adverse effect ade important cause preventable morbidity often serious economic implication special attention give prevention,Zaidenstein R,2002,Pharmacoepidemiol Drug Saf,https://doi.org/10.1002/pds.693,12051123,Zaidenstein R; Eyal S; Efrati S; Akivison L; Michowitz MK; Nagornov V; Golik A,article,D016428: Journal Article,"D016907: Adverse Drug Reaction Reporting Systems; D000368: Aged; D000369: Aged, 80 and over; D000925: Anticoagulants; D002317: Cardiovascular Agents; D005260: Female; D006751: Hospital Information Systems; D006760: Hospitalization; D006801: Humans; D007049: Iatrogenic Disease; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2019513346,97,12,1,2085,419,12,en,en
true,post hoc analysis coronary finding prospective randomized evaluation vascular effect norvasc trial prevent,prospective randomized evaluation vascular effect norvasc trial prevent first prospective double blind randomized trial assess antiatherosclerotic potential calcium antagonist specifically coronary artery segment minimal angiographic disease pitt b byington r p furberg c hunninghake b mancini g b j miller e riley w prevent investigatorseffect amlodipine progression atherosclerosis occurrence clinical event circulation crossref pubmed scopus google scholar although effect calcium antagonist suggest post hoc analysis early trial lichtlen p r hugenholtz p g rafflenbeul w hecker h jost decker j w behalf intact group investigatorsretardation angiographic progression coronary artery disease nifedipine lancet abstract pubmed scopus google scholar water lesperance j francetich causey theroux p chiang k hudon g lemarbre l reitman joyal et al controlled clinical trial assess effect calcium antagonist progression coronary atherosclerosis circulation crossref pubmed scopus google scholar prevent substantiate instead b mode ultrasound analysis subset patient find significant effect amlodipine prevent progression carotid intima medial thickness unanticipated significant reduction prospectively define soft coronary event mainly hospitalization unstable angina need percutaneous coronary intervention note negative coronary angiographic result may consequence less sensitivity ultrasound detect atheromatous change angiography result complicated remodel glagov weisenberg b zarins c k stankunavicius r kolettis g compensatory enlargement human atherosclerotic conronary artery n engl j med crossref pubmed scopus google scholar pasternak g wenaing p j w post j hillen b mali w p borst c paradoxical arterial wall shrinkage may contribute luminal narrowing human atherosclerotic femoral artery circulation crossref pubmed scopus google scholar alternatively vascular effect amlodipine may preferential effect progression atherosclerosis carotid tree different effect coronary bed reason undertake exploratory post hoc analysis goal determine inclusion interim film obtain time clinical event increased power result use segment single statistical model might identify effect amlodipine coronary tree across entire spectrum baseline stenosis,Mancini GB,2002,Am J Cardiol,https://doi.org/10.1016/s0002-9149(02)02357-3,12062738,Mancini GB; Miller ME; Evans GW; Byington R; Furberg CD; Pitt B; PREVENT Study Group. Prospective randomized evaluation of the vascular effects of norvasc,article,D016428: Journal Article,D017311: Amlodipine; D002121: Calcium Channel Blockers; D017023: Coronary Angiography; D003324: Coronary Artery Disease; D003327: Coronary Disease; D023903: Coronary Restenosis; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D011446: Prospective Studies; D016032: Randomized Controlled Trials as Topic; D016896: Treatment Outcome,,,https://openalex.org/W2165004490,136,22,1,2935,493,32,en,en
false,comparison effect diltiazem isosorbide dinitrate digoxin pharmacodynamics kinetics treatment patient chronic ischemic heart failure,evaluate effect arteriolar dilator diltiazem hydrochloride versus venodilator isosorbide dinitrate digoxin kinetics estimate efficacy tolerability vasodilator combine digoxin day therapy patient congestive heart failure secondary ischemic heart disease double blind randomize cross study carry investigate effect arteriolar dilator diltiazem hydrochloride mg day orally versus venodilator isosorbide dinitrate mg day orally digoxin kinetics mg day orally day therapy patient heart failure due ischemic heart disease also effect drug blood pressure heart rate renal function serum electrolyte efficacy tolerability combination digoxin study study carry department medicine main alexandria university hospital alexandria egypt period may may diltiazem cause significant increase digoxin maximum serum concentration without significant change time reach maximum concentration apparent volume distribution total digoxin clearance significantly reduce elimination half life prolong subsequently area time concentration curve steady state digoxin level increase still within therapeutic margin hand isosorbide dinitrate significantly increase digoxin maximum serum concentration without change digoxin pharmacokinetic parameter isosorbide dinitrate diltiazem cause significant reduction supine stand blood pressure drug significantly alter pulse rate renal function serum sodium potassium electrocardiographic pattern patients receive diltiazem display mean increase area plasma concentration time curve increase mean steady state serum digoxin concentration increase peak serum digoxin concentration patient receive isosorbide dinitrate show increase digoxin maximum serum concentration statistically significant change mean steady state digoxin concentration area plasma concentration time curve elimination half life diltiazem phase prolong significant change isosorbide dinitrate netiher diltiazem isosorbide dinitrate significantly alter time reach maximum serum digoxin concentration addition vasodilator diltiazem isosorbid dinitrate digoxin could significantly improve symptom sign heart failure compare digoxin alone well tolerate without fear electrolyte imbalance potentiate digoxin toxicity,Mahgoub AA,2002,Saudi Med J,,12070557,Mahgoub AA; El-Medany AH; Abdulatif AS,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000704: Analysis of Variance; D004077: Digoxin; D004110: Diltiazem; D004311: Double-Blind Method; D004347: Drug Interactions; D004359: Drug Therapy, Combination; D004573: Electrolytes; D004791: Enzyme Inhibitors; D005260: Female; D006207: Half-Life; D006333: Heart Failure; D006439: Hemodynamics; D006801: Humans; D007548: Isosorbide Dinitrate; D008297: Male; D008875: Middle Aged; D017202: Myocardial Ischemia; D014665: Vasodilator Agents",,,https://openalex.org/W1492401012,177,26,1,2871,447,12,en,en
false,medicamentous kidney protection type diabetic patient cheap also economical model calculation swiss health care,impaired renal function occur patient suffer type diabetes diabetic nephropathy become lead cause endstage renal disease reduction blood pressure level around mmhg one effective way slow progression diabetic nephropathy recent meta analyses however emphasize fact ace inhibitor acei non dihydropyridine calcium channel blocker ndhp ccb exert nephro protective effect go beyond effect blood pressure reduction lately confirm prospective trial comparison betablocker atenolol base data demographic swiss population literature data mortality rate type diabetic impaired renal function study true cost antihypertensive calculate cost longterm intervention year antihypertensive middle aged swiss patient type diabetes macro albuminuria whose antihypertensive regimen base either acei lisinopril nd hp ccb verapamil betablocker atenolol atenolol acquisition cost low whereas fast loss renal function time increase mortality rate thus reduce number patient treat nevertheless due fact patient reach uremia dialyze year atenolol based regimen cost million swiss franc turn much expensive lisinopril verapamil based regimen million swiss franc respectively thus low acquisition cost necessarily important determinant overall cost drug therapy,Faller J,2002,Praxis (Bern 1994),10.1024/0369-8394.91.19.836,12071084,Faller J; Hess B,article,D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article,"D000328: Adult; D000959: Antihypertensive Agents; D001262: Atenolol; D017046: Cost Savings; D003362: Cost-Benefit Analysis; D003924: Diabetes Mellitus, Type 2; D003928: Diabetic Nephropathies; D016527: Drug Costs; D005260: Female; D006801: Humans; D007676: Kidney Failure, Chronic; D007677: Kidney Function Tests; D017706: Lisinopril; D008297: Male; D008875: Middle Aged; D018803: Models, Economic; D013557: Switzerland; D014700: Verapamil",,,https://openalex.org/W2050361175,138,25,2,1709,286,8,en,en
false,comparison candesartan felodipine combination treatment elderly patient systolic hypertension,monotherapy frequently cause adequate blood pressure bp reduction goal bp achieve double blind randomize crossover placebo controlled study investigate use factorial design interaction dihydropyridine calcium channel block drug felodipine mg angiotensin type receptor block drug candesartan mg control bp assess h ambulatory monitoring total elderly patient systolic hypertension complete four arm study,Morgan T,2002,Am J Hypertens,https://doi.org/10.1016/s0895-7061(02)02279-3,12074357,Morgan T; Anderson A,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D000959: Antihypertensive Agents; D001562: Benzimidazoles; D001713: Biphenyl Compounds; D018660: Blood Pressure Monitoring, Ambulatory; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D013599: Systole; D013777: Tetrazoles; D016896: Treatment Outcome",,,https://openalex.org/W1966317267,126,19,1,531,91,3,en,en
false,comparative crossover evaluation amlodipine nifedipine git missed dose h blood pressure profile,,Nussinovitch N,2002,Am J Hypertens,https://doi.org/10.1016/s0895-7061(02)02924-2,12074363,Nussinovitch N; Rosenberg G; Peleg E; Rosenthal T,article,D016430: Clinical Trial; D003160: Comparative Study; D016422: Letter; D016449: Randomized Controlled Trial,"D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002940: Circadian Rhythm; D018592: Cross-Over Studies; D004064: Digestive System; D004305: Dose-Response Relationship, Drug; D006801: Humans; D006973: Hypertension; D015999: Multivariate Analysis; D009543: Nifedipine; D010349: Patient Compliance; D016896: Treatment Outcome",,,https://openalex.org/W1970021164,129,20,1,0,0,0,en,
false,effect antihypertensive drug fetus,critical review literature effect antihypertensive drug fetus pregnant woman present survey cover alpha adrenergic receptor agonist beta blockers include topical eye medication alpha beta blocker calcium antagonist diuretic angiotensin converting enzyme ace inhibitor lack data angiotensin ii receptor blocker note although effect consider similar report ace inhibitor therefore avoid analysis literature underscore antihypertensive drug use safely certain stage pregnancy others suspect avoid cost lack placebo controlled study treatment severe hypertension pregnancy due ethical consideration discuss background press need treat woman despite possible deleterious effect antihypertensive drug,Rosenthal T,2002,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1001400,12082488,Rosenthal T; Oparil S,article,D016428: Journal Article; D016454: Review,"D000316: Adrenergic alpha-Agonists; D000319: Adrenergic beta-Antagonists; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D005260: Female; D005333: Fetus; D006801: Humans; D006973: Hypertension; D007741: Labetalol; D008750: Methyldopa; D011247: Pregnancy; D011249: Pregnancy Complications, Cardiovascular",,,https://openalex.org/W2083176293,49,8,1,956,151,5,en,en
false,effect antihypertensive combination arterial pressure albuminuria glycemic control patient type ii diabetic nephropathy randomized study,type ii diabetic patient albuminuria high risk cardiovascular complication intense antihypertensive treatment require often involve use drug combination aim present study compare effect two different renin angiotensin blocking combination blood pressure bp albuminuria glycemic control design prospective randomise control parallel branch perform one endocrinology department spain type ii diabetic patient stable albuminuria mg day include pre inclusion time week patient randomise verapamil sr trandolapril vt losartan hydrochlorothiazide lh mg day duration treatment year evaluated parameter change blood pressure urinary albumin excretion hour glycated hemoglobin plasmatic urea overall bp significantly decrease mmhg mmhg p value treatment vt mmhg baseline mmhg conclusion lh mmhg baseline mmhg conclusion albuminuria significantly decrease mg day mg day parameter show significant difference treatment glycated hemoglobin decrease vt group lh group anova p change adjust baseline value show trend difference treatment p plasmatic urea increase mg dl tv group mg dl mg dl lh group anova p conclusion treatment reduce blood pressure albuminuria similar way type ii diabetic patient verapamil trandolapril combination contributes good carbohydrate metabolism losartan hydroclorothiazide,Goicolea I,2002,Nefrologia,,12085418,Goicolea I; Fernández González R; Piniés J; Garrido J; Martínez JM; Armenteros S; Moreno Carretero E,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D000419: Albuminuria; D057911: Angiotensin Receptor Antagonists; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001786: Blood Glucose; D001794: Blood Pressure; D050260: Carbohydrate Metabolism; D003692: Delayed-Action Preparations; D003924: Diabetes Mellitus, Type 2; D003928: Diabetic Nephropathies; D004232: Diuretics; D004359: Drug Therapy, Combination; D005260: Female; D006442: Glycated Hemoglobin; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D007211: Indoles; D008055: Lipids; D019808: Losartan; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D044140: Receptor, Angiotensin, Type 1; D012084: Renin-Angiotensin System; D049993: Sodium Chloride Symporter Inhibitors; D016896: Treatment Outcome; D014665: Vasodilator Agents; D014700: Verapamil",,,https://openalex.org/W2403423556,164,27,1,2099,377,17,en,en
false,prospective control trial two nifedipine extend release formulation treatment essential hypertension,aim study assess pharmacodynamic equivalence two different slow release formulation nifedipine cas prospective control double blind clinical trial patient essential hypertension sit diastolic blood pressure dbp mmhg undergo initial washout drug free period week randomize receive either mg nifedipine test preparation xl nifecard mg nifedipine reference formulation la six week response treatment assess measure blood pressure bp every two week standard office mercury sphygmomanometry h ambulatory blood pressure monitoring abpm include patient complete trial xl la week therapy dbp decrease mmhg respectively week mean decrease versus end placebo period reach mmhg mmhg end trial dbps low mmhg group measurement within group difference significant p group difference p quite comparable result obtain abpm e g xl group systolic blood pressure end study low mm hg la group mm hg p adverse effect similar group require neither particular intervention withdrawal study drug study comparably effective well tolerated antihypertensive,Pivac N,2002,Arzneimittelforschung,https://doi.org/10.1055/s-0031-1299901,12087923,Pivac N; Naranca M; Vujic-Podlipec D; Bagatin J; Rumboldt Z,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D001835: Body Weight; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004562: Electrocardiography; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011446: Prospective Studies",,,https://openalex.org/W2316731459,119,15,1,1701,356,10,en,en
false,cardiac renal effect standard versus rigorous blood pressure control autosomal dominant polycystic kidney disease,abstract study seek investigate cardiac renal effect rigorous versus standard bp control autosomal dominant polycystic kidney disease adpkd prospective randomize yr study perform examine effect rigorous mmhg versus standard mmhg bp control left ventricular mass index lvmi kidney function hypertensive adpkd patient left ventricular hypertrophy lvmi measure echocardiogram baseline yr renal function assess measure serum creatinine h creatinine clearance every mo yr annually additional yr baseline characteristic comparable two group study average mean arterial pressure mmhg rigorous group mmhg standard group p lvmi decrease standard group rigorous group mixed model longitudinal data analysis reveal rigorous bp control significantly effective decrease lvmi p statistically significant difference renal function two group conclusion leave ventricular hypertrophy major cardiovascular risk factor decrease significantly great extent rigorous standard bp control finding particular clinical importance cardiovascular complication common cause death adpkd patient,Schrier R,2002,J Am Soc Nephrol,https://doi.org/10.1097/01.asn.0000018407.60002.b9,12089368,Schrier R; McFann K; Johnson A; Chapman A; Edelstein C; Brosnahan G; Ecder T; Tison L,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D003404: Creatinine; D004452: Echocardiography; D004656: Enalapril; D005260: Female; D006321: Heart; D006801: Humans; D006973: Hypertension; D017379: Hypertrophy, Left Ventricular; D007668: Kidney; D008137: Longitudinal Studies; D008297: Male; D008875: Middle Aged; D016891: Polycystic Kidney, Autosomal Dominant; D011446: Prospective Studies",,,https://openalex.org/W2165323293,124,16,1,1520,292,11,en,en
true,randomize comparison type versus l type calcium channel blockade exercise duration stable angina result posicor reduction ischemia exercise pride trial,mibefradil type calcium channel antagonist arterial vasodilator negative chronotropic effect know type calcium channel blockade superior l type calcium channel blockade patient stable angina pectoris multicenter randomize double blind trial conduct patient documented coronary disease stable angina compare mg dose diltiazem cd mg dose mibefradil primary end point change time symptom limited exercise termination baseline week secondary efficacy parameter include time onset persistent st segment depression time awareness angina change exercise duration baseline week treatment total patient randomize mibefradil diltiazem cd week increase exercise duration second great mibefradil group p ci second week time development mm st segment depression great second p ci mibefradil time development angina significantly different type calcium channel antagonism mibefradil improve treadmill exercise parameter compare diltiazem patient chronic stable angina investigation development antagonist type calcium channel adverse drug interaction warrant may promise management ischemic heart disease,Lee DS,2002,Am Heart J,https://doi.org/10.1067/mhj.2002.122869,12094189,Lee DS; Goodman S; Dean DM; Lenis J; Ma P; Gervais PB; Langer A; PRIDE Investigators,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D020746: Calcium Channels, L-Type; D020747: Calcium Channels, T-Type; D004110: Diltiazem; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D020748: Mibefradil; D008875: Middle Aged; D017202: Myocardial Ischemia",,,https://openalex.org/W2093469783,184,28,1,1513,247,7,en,en
false,von willebrand factor soluble p selectin target organ damage hypertension,investigate relationship soluble marker platelet endothelial rheological function target organ damage response intensified management population middle age hypertensive patient high risk cardiovascular complication study consecutive patient men mean age year sd along normotensive control free cardiovascular disease patient divide target organ damage tod n free end organ damage plasma level soluble p selectin sp sel marker platelet activation von willebrand factor vwf index endothelial damage dysfunction enzyme linked immunosorbent assay rheological index fibrinogen plasma viscosity hematocrit platelet white cell count measure patient variable far measure month intensified cardiovascular risk management patient tod significantly high vwf sd versus sd iu dl p great proportion smoker versus p statistically significant difference plasma viscosity fibrinogen hematocrit white blood cell count platelet count sp sel subgroup multivariate analysis vwf significant independent predictor tod month intensified management patient enter trial significant reduction systolic blood pressure total cholesterol hematocrit plasma viscosity sp sel vwf p significant change fibrinogen conclusion relationship tod endothelial damage dysfunction hypertension intensified management result improvement hemorheology endothelial platelet function,Spencer CG,2002,Hypertension,https://doi.org/10.1161/01.hyp.0000022061.12297.2e,12105139,"Spencer CG; Gurney D; Blann AD; Beevers DG; Lip GY; ASCOT Steering Committee, Anglo-Scandinavian Cardiac Outcomes Trial",article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D001262: Atenolol; D001539: Bendroflumethiazide; D001794: Blood Pressure; D003430: Cross-Sectional Studies; D004562: Electrocardiography; D005260: Female; D006400: Hematocrit; D018056: Hemorheology; D006801: Humans; D006973: Hypertension; D017379: Hypertrophy, Left Ventricular; D008297: Male; D008875: Middle Aged; D019007: P-Selectin; D020913: Perindopril; D012044: Regression Analysis; D016037: Single-Blind Method; D016896: Treatment Outcome; D014841: von Willebrand Factor",,,https://openalex.org/W2046311507,82,13,1,1815,318,10,en,en
false,effect verapamil secondary cardioversion patient early atrial fibrillation recurrence electrical cardioversion,experimental human study show shortening atrial refractoriness repolarization abnormal adaptation rate called electrical remodeling increase vulnerability recurrent episode atrial fibrillation af wijffels c kirchof c j dorland r alessie af begets af study awake chronically instrumented goat circulation crossref pubmed scopus google scholar daoud e g bogun f goyal r harvey man k c strickberger morady f effect atrial fibrillation atrial refractoriness human circulation crossref pubmed scopus google scholar gotte honeycutt g langberg j j electrical remodeling atrial fibrillation time course mechanism circulation crossref pubmed scopus google scholar intracellular calcium overload seem play pivotal role determine electrical remodeling tieleman r g de langen c j van gelder c de kam p j grandjean j bel k l wijffels c alessie crijns h j verapamil reduces tachycardia induced electrical remodeling atrium circulation crossref pubmed scopus google scholar daoud e g knight b p weiss r behu paladino w goyal r man k c strickberger morady f effect verapamil procainamide atrial fibrillation induced electrical remodeling human circulation crossref pubmed scopus google scholar observation lead worker investigate clinical setting acute daoud e g hummel j agostini r williams kalbfleisch j effect verapamil immediate recurrence atrial fibrillation j cardiovasc electrophysiol crossref pubmed scopus google scholar chronic tieleman r g van gelder c crijns h j de kam p j van den berg p haaksma j van der woude h j alessie early recurrence atrial fibrillation electrical cardioversion result fibrillation induced electrical remodeling atrium j coll cardiol abstract full text full text pdf pubmed scopus google scholar de simone stabile g vitale f turco p di stasio petrazzuoli f gasparini de matteis c rotunno r di napoli pretreatment verapamil patient persistent chronic atrial fibrillation underwent electrical cardioversion j coll cardiol abstract full text full text pdf pubmed scopus google scholar effect calcium lowering agent reduce recurrence af electrical cardioversion data available effect oral calcium lowering drug patient early recurrence af electrical cardioversion study evaluate prospective randomized fashion impact oral pretreatment verapamil patient undergo second cardioversion attempt early recurrence af,De Simone A,2002,Am J Cardiol,https://doi.org/10.1016/s0002-9149(02)02450-5,12106857,De Simone A; Turco P; De Matteis C; La Rocca V; Nocerino P; Greco L; Astarita C; Messina V; Rotunno R; Iaconelli G; Stabile E; Stabile G,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D004359: Drug Therapy, Combination; D004554: Electric Countershock; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D008875: Middle Aged; D011300: Preoperative Care; D011446: Prospective Studies; D012086: Reoperation; D055502: Secondary Prevention; D013997: Time Factors; D016896: Treatment Outcome; D014700: Verapamil",,,https://openalex.org/W2054993263,131,16,1,3015,543,49,en,en
false,prevent drug related morbidity determine valid indicator,objective describe process undertake validate series indicator preventable drug related morbidity originally develop us application uk health care system,Morris CJ,2002,Int J Qual Health Care,https://doi.org/10.1093/oxfordjournals.intqhc.a002610,12108529,Morris CJ; Cantrill JA; Hepler CD; Noyce PR,article,D016428: Journal Article; D023361: Validation Study,"D001291: Attitude of Health Personnel; D003657: Decision Making; D003697: Delphi Technique; D011307: Drug Prescriptions; D004358: Drug Therapy; D064420: Drug-Related Side Effects and Adverse Reactions; D006801: Humans; D008508: Medication Errors; D010595: Pharmacists; D010821: Physicians, Family; D010818: Practice Patterns, Physicians'; D011320: Primary Health Care; D011785: Quality Assurance, Health Care; D019984: Quality Indicators, Health Care; D011795: Surveys and Questionnaires; D016896: Treatment Outcome; D006113: United Kingdom",,,https://openalex.org/W2106271480,63,7,1,210,32,2,en,en
false,effect amlodipine cerebral circulatory value patient essential hypertension,study assess effect calcium channel blocker amlodipine cerebral circulation patient essential hypertension cerebral circulation patient essential hypertension healthy subject assess use rheoplethysmography patient essential hypertension cerebral circulation value also estimated treatment amlodipine mg daily cerebral circulatory parameter hypertensive patient treatment amlodipine different healthy person amlodipine along reduction systemic blood pressure cause attenuation cerebrovascular abnormality decrease spastic sign increase cerebral blood supply patient essential hypertension amlodipine cause reduction cerebral vascular resistance promote improvement arterial blood filling patient essential hypertension change cerebral circulation may secondary increase cardiac output known effect amlodipine,Alizade IG,2001,Anadolu Kardiyol Derg,,12122965,Alizade IG; Karayeva NT,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,"D000328: Adult; D017311: Amlodipine; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D016022: Case-Control Studies; D002536: Cerebral Arteries; D002560: Cerebrovascular Circulation; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D010992: Plethysmography, Impedance; D016896: Treatment Outcome",,,https://openalex.org/W2462641057,97,14,1,1034,143,4,en,en
false,successful blood pressure control african american study kidney disease hypertension,african american study kidney disease hypertension aask ongoing trial evaluate effect blood pressure choice antihypertensive drug rate decline renal function present success aask achieve trial rigorous blood pressure goal extremely challenging patient population aask participant include african american patient hypertension n age year glomerular filtration rate ml min per identified cause renal insufficiency participant randomize goal mean arterial blood pressure map either mm hg usual map goal mm hg less low map goal participant group also randomize double blind regimen contain metoprolol succinate ramipril amlodipine besylate additional agent add require following recommend order furosemide doxazosin mesylate clonidine hydrochloride hydralazine hydrochloride minoxidil need participant randomize low map goal percentage participant achieve blood pressure less mm hg increase baseline month randomization usual map goal participant corresponding percentage increase difference median level map map goal group increase remain approximately mm hg blood pressure reduction similar regardless age sex body mass index education insurance employment status income marital status blood pressure goal set achieve aask participant clearly demonstrate adequate blood pressure control achieve even hypertensive population whose blood pressure difficult control,Wright JT,2002,Arch Intern Med,https://doi.org/10.1001/archinte.162.14.1636,12123409,Wright JT; Agodoa L; Contreras G; Greene T; Douglas JG; Lash J; Randall O; Rogers N; Smith MC; Massry S; African American Study of Kidney Disease and Hypertension Study Group,article,"D016430: Clinical Trial; D003160: Comparative Study; D023362: Evaluation Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000293: Adolescent; D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D044383: Black People; D001794: Blood Pressure; D015331: Cohort Studies; D004311: Double-Blind Method; D005260: Female; D005500: Follow-Up Studies; D005919: Glomerular Filtration Rate; D006801: Humans; D006973: Hypertension; D007674: Kidney Diseases; D008297: Male; D008875: Middle Aged,,,https://openalex.org/W2003209602,98,14,1,1873,334,7,en,en
false,systolic hypertension cardiovascular risk factor,,McInnes GT,2002,Blood Press,https://doi.org/10.1080/080370502760050368,12126259,McInnes GT,article,D016428: Journal Article; D016454: Review,D000959: Antihypertensive Agents; D002318: Cardiovascular Diseases; D006801: Humans; D006973: Hypertension; D012084: Renin-Angiotensin System; D012307: Risk Factors,,,https://openalex.org/W1998114667,53,7,1,0,0,0,en,
false,nebivolol v amlodipine first line treatment essential arterial hypertension elderly,antihypertensive efficacy nebivolol amlodipine tolerability compare multicentre randomize active controlled double blind parallel group trial elderly patient mild moderate essential arterial hypertension one hundred eighty four subject age year screen run phase week randomize either nebivolol mg daily n amlodipine mg daily n period week response rate treatment change sit diastolic blood pressure bp week similar two group low sit systolic bp sbp detect amlodipine week p week p stand bp show change two group sbp low amlodipine week p heart rate low treatment visit nebivolol p incidence adverse event different two group however incidence headache ankle oedema significantly high amlodipine p elderly subject essential hypertension antihypertensive efficacy nebivolol amlodipine similar drug well tolerate although amlodipine accompany high incidence drug related adverse event,Mazza A,2002,Blood Press,https://doi.org/10.1080/080370502760050421,12126265,Mazza A; Gil-Extremera B; Maldonato A; Toutouzas T; Pessina AC,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D000959: Antihypertensive Agents; D001578: Benzopyrans; D001794: Blood Pressure; D004311: Double-Blind Method; D004487: Edema; D004983: Ethanolamines; D006261: Headache; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D000068577: Nebivolol",,,https://openalex.org/W2110121427,97,13,1,1349,254,10,en,en
false,experience intraplaque injection verapamil peyronie disease,examine use intraplaque injection verapamil treatment peyronie disease effect pain curvature indentation sexual function erectile capacity total men underwent treatment intraplaque verapamil injection patient assess objectively dynamic penile duplex ultrasound well subjectively use questionnaire initiation treatment protocol patient also stratify duration disease therapy kelami classification group base pretreatment plaque size severity curvature difference treatment among kelami classification group assessed patient complete treatment objectively measured decrease curvature report subjective decrease curvature followup interview treatment men report increase girth increase rigidity distal plaque improvement sexual function among kelami class curvature objectively measure decrease patient class ii iii respectively significant difference response base duration disease improvement versus improvement disease duration less great year duration respectively mean followup month range reported recurrence penile deformity men initial posttreatment positive response verapamil injection peyronie plaque appear clinically effective treatment option pain curvature contribute subjective improvement sexual function erectile capacity low incidence complication indicate therapy also clinically safe,Levine LA,2002,J Urol,https://doi.org/10.1016/s0022-5347(05)64691-5,12131321,Levine LA; Goldman KE; Greenfield JM,article,D016428: Journal Article,"D000328: Adult; D000368: Aged; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D006801: Humans; D015552: Injections, Intralesional; D008297: Male; D008875: Middle Aged; D010147: Pain Measurement; D010208: Papaverine; D017060: Patient Satisfaction; D010410: Penile Erection; D010411: Penile Induration; D010413: Penis; D011446: Prospective Studies; D012725: Sexual Behavior; D016896: Treatment Outcome; D018616: Ultrasonography, Doppler, Duplex; D014700: Verapamil",,,https://openalex.org/W2114453886,73,11,1,1869,324,9,en,en
false,two case polymorphic ventricular tachycardia induce administration verapamil paroxysmal supraventricular tachycardia,verapamil widely use termination paroxysmal supraventricular tachycardia psvt little proarrhythmic effect describe two case psvt change non sustained polymorphic ventricular tachycardia administration verapamil electrophysiological study reveal atrioventricular nodal reentrant tachycardia first case atrioventricular reentrant tachycardia due conceal left lateral accessory pathway second case catecholamine induced automaticity one possible mechanism vt first case mechanism unknown second case,Shiraishi H,2002,Intern Med,https://doi.org/10.2169/internalmedicine.41.445,12135176,Shiraishi H; Ishibashi K; Urao N; Hyogo M; Tsukamoto M; Keira N; Hirasaki S; Seo Y; Shirayama T; Nakagawa M,article,D002363: Case Reports; D016428: Journal Article,"D000889: Anti-Arrhythmia Agents; D017115: Catheter Ablation; D004562: Electrocardiography; D022062: Electrophysiologic Techniques, Cardiac; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D013617: Tachycardia, Supraventricular; D017180: Tachycardia, Ventricular; D016896: Treatment Outcome; D014700: Verapamil",,,https://openalex.org/W2065069781,140,17,1,616,91,4,en,en
false,differential effect long acting angiotensin convert enzyme inhibitor temocapril long acting calcium antagonist amlodipine ventricular ectopic beat old hypertensive patient,study difference effect long acting angiotensin converting enzyme ace inhibitor temocapril long acting calcium channel blocker amlodipine ventricular ectopic beat veb relation sympathetic nerve activity patient essential hypertension perform h holter electrocardiography ambulatory blood pressure bp monitoring simultaneously examine blood sample baseline temocapril amlodipine treatment period ambulatory bp low amlodipine period temocapril period however number veb significantly increase amlodipine period compare baseline period vs day p temocapril period number veb significantly increase compare baseline period vs day p ambulatory heart rate hr significantly increase amlodipine period compare baseline period h hr vs bpm p daytime hr vs bpm p nocturnal hr vs bpm p plasma norepinephrine ne also significantly increase amlodipine period compare baseline period vs pg ml p however patient receive amlodipine divide high dose group mg day low dose group mg day increase hr plasma ne level find high dose group result indicate amlodipine effective lower bp old hypertensive although may increase veb especially give high dose,Eguchi K,2002,Hypertens Res,https://doi.org/10.1291/hypres.25.329,12135309,Eguchi K; Kario K; Shimada K,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000368: Aged; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D006339: Heart Rate; D006352: Heart Ventricles; D006801: Humans; D006973: Hypertension; D009638: Norepinephrine; D011446: Prospective Studies; D013564: Sympathetic Nervous System; D013841: Thiazepines,,,https://openalex.org/W2013634926,201,29,1,1627,313,9,en,en
false,admission cause adverse drug event internal medicine emergency department hospital longitudinal population based study,objective estimate incidence rate drug related hospitalization drhs longitudinal population based study prospective event assessment design cohort study time trend analysis setting department internal medicine emergency department urban region jena rostock germany serve resident participant patient admit october march patient severe cutaneous reaction exclude main outcome measure incidence drh define symptom diagnosis admission likely likely possibly cause prescription medication accord standardized assessment result incidence drh admission per treated patient confidence interval ci rate high antithrombotics admission per treated patient ci frequent event gastroduodenal lesion bleeding digitalis preparation show linearly increase trend ten quarter p exclusively attributable digitoxin major source digitalis study area incidence drh increase age mean length stay patient drh day cumulative direct cost hospitalization euro million two urban study area annual direct cost germany estimate euro million conclusion drhs considerable public health economic burden longitudinal design observe change population based incidence time approach use public health planning evaluate outcome quality management program design reduce drug induced illness,Schneeweiss S,2002,Eur J Clin Pharmacol,https://doi.org/10.1007/s00228-002-0467-0,12136375,Schneeweiss S; Hasford J; Göttler M; Hoffmann A; Riethling AK; Avorn J,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D002648: Child; D002675: Child, Preschool; D064420: Drug-Related Side Effects and Adverse Reactions; D004636: Emergency Service, Hospital; D005260: Female; D005858: Germany; D006748: Hospital Departments; D006801: Humans; D015994: Incidence; D007223: Infant; D007231: Infant, Newborn; D007388: Internal Medicine; D007902: Length of Stay; D008297: Male; D008875: Middle Aged; D010343: Patient Admission; D011446: Prospective Studies",,,https://openalex.org/W2079842711,139,19,1,1821,312,17,en,en
false,blocker use treatment hypertension elderly,lack benefit potential negative side effect beta blocker overstate especially elderly emphasis lead recommendation investigator agent use management hypertension age group numerous reason recommendation follow use beta blocker elderly hypertensive result reduction stroke congestive heart failure addition emphasize elderly patient likely silent coronary artery disease sustain myocardial infarction abundant evidence beta blocker effective therapy reduce mortality myocardial infarction occur fact clear reduction sudden cardiac death furthermore national statistic document elderly patient prevalence congestive heart failure vary multiple study document beta blocker additive angiotensin converting enzyme inhibitor reduce mortality congestive heart failure thus elderly hypertensive patient may benefit use beta blocker especially evidence ischemic heart disease cardiac arrhythmia congestive heart failure,Prisant LM,2002,J Clin Hypertens (Greenwich),https://doi.org/10.1111/j.1524-6175.2002.01250.x,12147932,Prisant LM,article,D016428: Journal Article; D017418: Meta-Analysis,"D000319: Adrenergic beta-Antagonists; D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D004730: Endothelium, Vascular; D006801: Humans; D006973: Hypertension; D017379: Hypertrophy, Left Ventricular; D011788: Quality of Life",,,https://openalex.org/W2090528144,74,14,1,1295,213,10,en,en
false,calcium channel blocker induce gingival overgrowth,gingival overgrowth occur phenytoin cyclosporin calcium antagonist disfigure painful prevalence gingival overgrowth use calcium antagonist may high prevalence nifedipine may great calcium blocker overgrowth occur times commonly men woman plaque control necessary patient may require gingival surgery,Prisant LM,2002,J Clin Hypertens (Greenwich),https://doi.org/10.1111/j.1524-6175.2002.01095.x,12147940,Prisant LM; Herman W,article,D016428: Journal Article,D002121: Calcium Channel Blockers; D005886: Gingival Hypertrophy; D006801: Humans; D009543: Nifedipine,,,https://openalex.org/W2034989221,51,6,1,429,74,7,en,en
false,microalbuminuria reduction valsartan patient type diabetes mellitus,elevate urine albumin excretion uaer modifiable risk factor renal cardiovascular disease type diabetes blockade renin angiotensin system lower uaer whether effect independent blood pressure bp reduction remain controversial microalbuminuria reduction valsartan marval study design evaluate bp independent effect valsartan uaer type diabetic patient microalbuminuria three hundred thirty two patient type diabetes microalbuminuria without hypertension randomly assign mg valsartan mg amlodipine week target bp mm hg aim dose doubling follow addition bendrofluazide doxazosin whenever need primary end point percent change uaer baseline week uaer week ci baseline valsartan ci baseline amlodipine highly significant group effect p valsartan lower uaer similarly hypertensive normotensive subgroup patient reverse normoalbuminuria valsartan versus p study period bp reduction similar two treatment systolic diastolic mm hg valsartan mm hg amlodipine time point group significant difference bp value either hypertensive normotensive subgroup level attained bp degree bp reduction valsartan lower uaer effectively amlodipine patient type diabetes microalbuminuria include subgroup baseline normotension indicate bp independent antiproteinuric effect valsartan,Viberti G,2002,Circulation,https://doi.org/10.1161/01.cir.0000024416.33113.0a,12163426,Viberti G; Wheeldon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000419: Albuminuria; D017311: Amlodipine; D057911: Angiotensin Receptor Antagonists; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003924: Diabetes Mellitus, Type 2; D003928: Diabetic Nephropathies; D004311: Double-Blind Method; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D013777: Tetrazoles; D014633: Valine; D000068756: Valsartan",,,https://openalex.org/W2118286022,83,11,1,1818,314,10,en,en
false,improvement endothelial function amlodipine vitamin c essential hypertension,background effect antihypertensive agent endothelial function fully evaluate human hypertension data forearm circulation human controversial aim study evaluate endothelial function hypertensive patient investigate whether vitamin c administration benefit endothelial function determine whether treatment calcium antagonist improve endothelial dysfunction hypertensive patient method endothelial function estimate use venous occlusion plethysmography vop hypertensive patient healthy volunteer patient hypertension group treat amlodipine examine change forearm blood flow fbf measure acetylcholine infusion brachial artery also intra arterial vitamin c result forearm blood flow response acetylcholine significantly enhance intra arterial infusion vitamin c hypertensive group antihypertensive treatment co infusion l nmma inhibitor nitric oxide synthase blunt forearm blood flow response acetylcholine treatment amlodipine month hypertensive group endothelium dependent vasorelaxation acetylcholine significantly improve compare pretreatment vitamin c affect improved endothelial function amlodipine treatment conclusion vitamin c acutely amlodipine chronically improve endothelial function hypertensive patient result suggest increase oxidative stress least part may involve decreased endothelial function hypertension,On YK,2002,Korean J Intern Med,https://doi.org/10.3904/kjim.2002.17.2.131,12164090,On YK; Kim CH; Sohn DW; Oh BH; Lee MM; Park YB; Choi YS,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D001205: Ascorbic Acid; D002121: Calcium Channel Blockers; D004730: Endothelium, Vascular; D004791: Enzyme Inhibitors; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D019001: Nitric Oxide Synthase; D014664: Vasodilation; D019323: omega-N-Methylarginine",,,https://openalex.org/W1917326872,89,12,1,1697,259,9,en,en
false,efficacy safety barnidipine compare felodipine treatment hypertension chinese patient,efficacy safety profile barnidipine treatment hypertension evaluate open parallel group study fifty nine chinese patient mild moderate essential hypertension randomize receive either barnidipine felodipine mg daily titrate mg mg daily indicate week drug reduce blood pressure significantly case obtain mark moderate blood pressure reduction mean reduction systolic diastolic blood pressure barnidipine treatment mmhg mmhg felodipine mmhg mmhg respectively significant difference two drug anti hypertensive effect heart rate laboratory measurement incidence adverse event difference patient take felodipine experience palpitation conclude barnidipine similar efficacy similar safety profile felodipine treatment mild moderate essential hypertension chinese patient,Liau CS,2002,J Int Med Res,https://doi.org/10.1177/147323000203000317,12166353,Liau CS; Chien KL; Chao CL; Lee TM,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000368: Aged; D000959: Antihypertensive Agents; D015736: Felodipine; D006801: Humans; D006973: Hypertension; D008875: Middle Aged; D009543: Nifedipine,,,https://openalex.org/W1991386588,112,16,1,1100,179,7,en,en
false,nicardipine hydrochloride injectable phase iv open label clinical trial study anti hypertensive effect safety nicardipine acute aortic dissection,perform multicentre phase iv open label clinical trial examine clinical usefulness continuous infusion nicardipine hydrochloride control hypertension patient acute aortic dissection target blood pressure level reach within min patient min patient min three patient min two patient baseline average systolic diastolic mean arterial blood pressure mmhg mmhg mmhg respectively third day pressure significantly reduce mmhg mmhg mmhg blood pressure discontinuation infusion significantly different measure third day infusion definite adverse effect attributable treatment observe nicardipine hydrochloride effective safe control blood pressure patient acute aortic dissection,Kim KH,2002,J Int Med Res,https://doi.org/10.1177/147323000203000318,12166354,Kim KH; Moon IS; Park JS; Koh YB; Ahn H,article,"D016430: Clinical Trial; D017429: Clinical Trial, Phase IV; D016428: Journal Article; D016448: Multicenter Study; D013485: Research Support, Non-U.S. Gov't",D000959: Antihypertensive Agents; D001019: Aortic Rupture; D001794: Blood Pressure; D006801: Humans; D009529: Nicardipine; D016896: Treatment Outcome,,,https://openalex.org/W2331423403,164,22,1,970,168,5,en,en
false,effect six anti hypertensive medication cognitive performance,describe compare effect six different antihypertensive medication cognitive performance prospective randomize double blind treatment cross university hypertension clinic neuropsychology laboratory ninety eight caucasian men year age mild moderate essential hypertension complete study normotensive men similar socio demographic characteristics six week treatment period atenolol metoprolol hydrochlorothiazide methyldopa enalapril verapamil week placebo baseline wash periods depth neuropsychological assessment several mood questionnaire complete placebo baseline period active treatment period practice effect due repeat neuropsychological testing estimate data collect concurrently normotensive participants antihypertensive treatment lower blood pressure comparably affect mood anxiety small treatment effect note four seven domain cognitive performance irrespective medication type treatment reduce simple motor speed p slow completion two test measure perceptuo motor speed mental flexibility p manual dexterity decline somewhat metoprolol methyldopa p contrast antihypertensive agent favorably affect performance several test require work memory p performance test assess grip strength learning memory attention executive function affected short term treatment standard antihypertensive medication associate small decrement psychomotor performance small improvement work memory without notable drug class difference long term effect await far study,Muldoon MF,2002,J Hypertens,https://doi.org/10.1097/00004872-200208000-00028,12172327,Muldoon MF; Waldstein SR; Ryan CM; Jennings JR; Polefrone JM; Shapiro AP; Manuck SB,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D000959: Antihypertensive Agents; D003071: Cognition; D018592: Cross-Over Studies; D004311: Double-Blind Method; D006801: Humans; D006973: Hypertension; D008297: Male; D008568: Memory; D008875: Middle Aged; D009483: Neuropsychological Tests; D011446: Prospective Studies; D011597: Psychomotor Performance,,,https://openalex.org/W2013863862,69,8,1,1860,266,8,en,en
false,smooth blood pressure control obtain extended release felodipine elderly patient hypertension,objective assess smoothness index si distribution antihypertensive effect extended release er felodipine hour elderly patient hypertension method week washout phase elderly patient mean age year mild moderate hypertension receive week treatment er felodipine mg daily dosage er felodipine double mg day give week non responders sit clinic blood pressure mm hg study open label design placebo control period clinic ambulatory blood pressure measure trough peak p ratio compute divide blood pressure bp change trough hour drug intake change peak adjacent hour maximal bp reduction second eighth hour drug intake si calculate ratio average hourly treatment induced bp change standard deviation result initial week treatment period clinic hour ambulatory bp value high non responders mm hg respectively responder mm hg non responders clinic hour bp value lower far week treatment er felodipine mg day mm hg si high responder systolic diastolic bp low non responders first week treatment period increase non responders additional week treatment er felodipine mg day median p ratio systolic bp diastolic bp responder non responders week treatment variance si p ratio increase non responders double dosage er felodipine er felodipine increase hour heart rate total nine adverse event record six patient patient withdraw study conclusion er felodipine mg day smoothly safely reduce hour ambulatory bp elderly patient hypertension,Antonicelli R,2002,Drugs Aging,https://doi.org/10.2165/00002512-200219070-00007,12182690,Antonicelli R; Omboni S; Giovanni DC; Ansuini R; Mori A; Gesuita R; Parati G; Paciaroni E,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000368: Aged; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D015736: Felodipine; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male",,,https://openalex.org/W130757161,109,13,1,2324,447,16,en,en
false,prognostic significance renal function elderly patient isolated systolic hypertension,several report suggest marker renal function serum creatinine serum uric acid urinary excretion protein may relate cardiovascular complication mortality study analyze data syst eur trial randomized placebo controlled double blind intervention trial elderly patient isolated systolic hypertension purpose evaluate whether serum level creatinine uric acid urinary protein excretion entry relate subsequent morbidity mortality incidence rate total mortality cardiovascular mortality stroke fatal well nonfatal coronary event cardiovascular endpoint calculate quintile serum creatinine serum uric acid category protein excretion none trace overt crude adjust relative hazard rate also determine micro increase serum creatinine micro increase serum uric acid protein excretion category even adjust age gender various covariates serum creatinine significantly associate bad prognosis u shaped relationship serum uric acid total mortality otherwise obvious relationship detect serum uric acid level complication appropriate adjustment make confound variable proteinuria entry significant predictor total mortality cardiovascular endpoint conclude high level serum creatinine trace overt proteinuria associate increased number cardiovascular event high mortality patient isolated systolic hypertension,De Leeuw PW,2002,J Am Soc Nephrol,https://doi.org/10.1097/01.asn.0000027871.86296.92,12191965,De Leeuw PW; Thijs L; Birkenhäger WH; Voyaki SM; Efstratopoulos AD; Fagard RH; Leonetti G; Nachev C; Petrie JC; Rodicio JL; Rosenfeld JJ; Sarti C; Staessen JA; Systolic Hypertension in Europe (Syst-Eur) Trial Investigators,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000959: Antihypertensive Agents; D003404: Creatinine; D004311: Double-Blind Method; D005260: Female; D005919: Glomerular Filtration Rate; D006801: Humans; D006977: Hypertension, Renal; D015994: Incidence; D007668: Kidney; D008297: Male; D008875: Middle Aged; D011237: Predictive Value of Tests; D011379: Prognosis; D011507: Proteinuria; D016019: Survival Analysis; D014527: Uric Acid",,,https://openalex.org/W2108287899,97,12,1,1747,284,9,en,en
false,chronic radiation enteritis,jain gaurav scolapio james wasserman evan floch martin h author information,Jain G,2002,J Clin Gastroenterol,https://doi.org/10.1097/00004836-200209000-00003,12192195,Jain G; Scolapio J; Wasserman E; Floch MH,article,D002363: Case Reports; D016429: Clinical Conference; D016428: Journal Article,"D015746: Abdominal Pain; D000428: Alcohol Drinking; D002908: Chronic Disease; D004751: Enteritis; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D007421: Intestine, Small; D008875: Middle Aged; D010195: Pancreatitis; D010289: Parenteral Nutrition, Total; D011832: Radiation Injuries; D014057: Tomography, X-Ray Computed",,,https://openalex.org/W2316696129,27,3,1,103,26,5,en,ar
false,diltiazem heals glyceryl trinitrate resistant chronic anal fissure,topical diltiazem calcium channel blocker glyceryl trinitrate nitric oxide donor low anal pressure heal two thirds chronic anal fissure study evaluate efficacy diltiazem fissure fail heal glyceryl trinitrate consecutive patient persistent chronic fissure despite treatment percent glyceryl trinitrate ointment underwent anal manometry hour application mg percent diltiazem gel distal anal canal patient apply diltiazem twice daily eight week fissure heal fortnightly review fissure healing assess side effect note patient score symptom pain bleeding irritation use linear visual analog scale initial follow visits patient male median age range year topical percent diltiazem gel lower anal resting pressure percent median cm h p wilcoxon fissure heal percent within week diltiazem patient percent use complete course glyceryl trinitrate g twice daily week percent heal diltiazem remain patient discontinue glyceryl trinitrate prematurely use less headache percent heal diltiazem percent side effect occur four patient percent three report perianal itching continue treatment one developed headache drowsiness mood swing six week treatment stop diltiazem time topical percent diltiazem effective treatment glyceryl trinitrate resistant chronic anal fissure side effect mainly perianal itching may occur percent patient generally tolerate,Jonas M,2002,Dis Colon Rectum,https://doi.org/10.1007/s10350-004-6365-z,12195195,Jonas M; Speake W; Scholefield JH,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000287: Administration, Topical; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D002121: Calcium Channel Blockers; D002908: Chronic Disease; D004110: Diltiazem; D005260: Female; D005401: Fissure in Ano; D005782: Gels; D006801: Humans; D008297: Male; D008875: Middle Aged; D005996: Nitroglycerin; D009824: Ointments; D011446: Prospective Studies; D018709: Statistics, Nonparametric; D016896: Treatment Outcome; D014665: Vasodilator Agents; D014945: Wound Healing",,,https://openalex.org/W1982929529,67,7,1,1873,341,9,en,en
true,relationship antihypertensive treatment regimen change blood pressure risk heart failure hypertensive patient randomly assign doxazosin chlorthalidone analysis antihypertensive lipid lowering treatment prevent heart attack trial,antihypertensive lipid lowering treatment prevent heart attack trial report treatment initiate doxazosin compare chlorthalidone double risk heart failure high risk hypertensive patient relative risk ci patient assign doxazosin therapy mean trial systolic diastolic blood pressure mm hg high patient assign chlorthalidone sixty eight percent former patient latter patient give additional medication achieve target blood pressure less mm hg ascertain influence open label antihypertensive drug subsequent blood pressure relative risk heart failure randomized double blind active controlled clinical trial site united state canada hypertensive patient year age old least one additional risk factor cardiovascular disease chlorthalidone mg doxazosin mg planned follow years data blood pressure medication incident heart failure treat outside hospital hospitalize fatal february december treatment group categorize exposure open label medication monotherapy exposure open label therapy relative risk heart failure doxazosin versus chlorthalidone ci ci respectively adjustment follow systolic diastolic blood pressure overall relative risk ci high risk patient hypertension high risk heart failure take doxazosin compare chlorthalidone attenuate eliminate add antihypertensive drug small observed difference systolic blood pressure explain increase risk,Davis BR,2002,Ann Intern Med,https://doi.org/10.7326/0003-4819-137-5_part_1-200209030-00006,12204014,Davis BR; Cutler JA; Furberg CD; Wright JT; Farber MA; Felicetta JV; Stokes JD; ALLHAT Collaborative Research Group,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000959: Antihypertensive Agents; D001794: Blood Pressure; D002303: Cardiac Output, Low; D002752: Chlorthalidone; D004311: Double-Blind Method; D017292: Doxazosin; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D016016: Proportional Hazards Models; D012307: Risk Factors; D016896: Treatment Outcome",,,https://openalex.org/W2010163342,283,38,1,1934,322,5,en,en
false,short term treatment severe hypertension pregnancy prospective comparison nicardipine labetalol,objective assess efficacy safety nicardipine comparison labetalol initial management severe hypertension pregnancy design randomize prospective study setting obstetric ward teach hospital monastir tunisia patient sixty consecutive pregnant woman admit beyond th week pregnancy severe hypertension intervention patient randomly assign receive intravenously h either labetalol n nicardipine n treatment titrate achieve lowering blood pressure bp measurement maternal bp heart rate measure inclusion repeatedly first hour follow drug administration fetal heart rate record throughout study period main outcome endpoint success rate length time need achieve therapeutic goal rate maternal fetal adverse event dose adjustment also analyze result labetalol nicardipine achieve lowering bp proportion success rate respectively overall nicardipine cause significantly great decrease systolic diastolic bp patient episode hypotension length time achieve bp goal also similar vs min respectively drug well tolerate except moderate tachycardia observe use nicardipine conclusion nicardipine labetalol effective safe initial treatment severe hypertension pregnancy,Elatrous S,2002,Intensive Care Med,https://doi.org/10.1007/s00134-002-1406-3,12209278,Elatrous S; Nouira S; Ouanes Besbes L; Marghli S; Boussarssar M; Sakkouhi M; Abroug F,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000959: Antihypertensive Agents; D005260: Female; D006801: Humans; D006973: Hypertension; D007741: Labetalol; D009529: Nicardipine; D011225: Pre-Eclampsia; D011247: Pregnancy; D011249: Pregnancy Complications, Cardiovascular; D011446: Prospective Studies; D016896: Treatment Outcome; D014416: Tunisia",,,https://openalex.org/W2000764773,109,14,1,1562,272,17,en,en
false,primary pulmonary hypertension cor pulmonale,primary pulmonary hypertension cor pulmonale represent form precapillary pulmonary hypertension due intrinsic lung disease case primary pulmonary hypertension due disease pulmonary vasculature cor pulmonale relate disease pulmonary vasculature airway interstitium patient present sign symptom right ventricular dysfunction low cardiac output include dyspnea chest pain peripheral edema therapy direct underlying disease may include supplemental oxygen disease cause chronic hypoxemia anticoagulation thrombotic disease vasodilator therapy variable efficacy pulmonary vascular disorder postacyclin continuous infusion major advance therapy primary pulmonary hypertension prolong survival delay need lung transplantation bosentan endothelin receptor block agent first oral medication approve therapy pulmonary hypertension,Lehrman S,2002,Cardiol Rev,https://doi.org/10.1097/00045415-200209000-00003,12215190,Lehrman S; Romano P; Frishman W; Rashid A; Dobkin J; Reichel J,article,D016428: Journal Article; D016454: Review,"D006801: Humans; D006976: Hypertension, Pulmonary; D011660: Pulmonary Heart Disease",,,https://openalex.org/W2055591647,48,6,1,1034,156,7,en,en
false,utility computed tomographic renal angiogram management childhood hypertension,purpose study evaluate utility compute tomography ct renal angiogram ctra management childhood hypertension retrospective study child clinical suspicion renovascular disease underwent ctra examination ctra demonstrate surgically correctable etiology hypertension patient renal artery stenosis ra renal pathology patient ctra finding ra confirm catheter angiogram ctra miss ra patient catheter angiogram show beaded narrowing renal artery patient ra resolution hypertension immediately angioplasty surgery one patient diffuse renal artery stenosis ipsilateral multicystic dysplastic kidney patient hypertension resolve spontaneously dysplastic kidney shrunk size seven patient renal etiology hypertension patient hypertension resolve nephrectomy malignant hypertension th patient reflux nephropathy control medically underwent bilateral ureteral reimplantation remain patient renal etiology manage medically find etiology central hypertension patient brain abnormality obesity overweight patient essential hypertension patient thoracic aorta coarctation patient study show except instance ctra could diagnose surgically correctable cause hypertension ctra provide useful information management pediatric hypertension patient,Vade A,2002,Pediatr Nephrol,https://doi.org/10.1007/s00467-002-0921-3,12215828,Vade A; Agrawal R; Lim-Dunham J; Hartoin D,article,D016428: Journal Article,"D000293: Adolescent; D000328: Adult; D002648: Child; D002675: Child, Preschool; D005260: Female; D006801: Humans; D006978: Hypertension, Renovascular; D007223: Infant; D007668: Kidney; D008297: Male; D012077: Renal Artery; D012078: Renal Artery Obstruction; D012189: Retrospective Studies; D014057: Tomography, X-Ray Computed",,,https://openalex.org/W2031189369,91,12,1,1651,270,15,en,en
false,isradipine treatment hypertension child single center experience,many child hypertension particularly new onset hypertension relate glomerulonephritis organ transplantation form secondary hypertension require treatment short acting antihypertensive order quickly achieve blood pressure bp control administer isradipine short acting second generation calcium antagonist child retrospective data collection undertake determine effect isradipine treatment mean age child treat isradipine month mean sd nearly child secondary hypertension initially treat hospital inpatient newly diagnose hypertension mean isradipine dose mg kg per day significant variation dose accord patient age isradipine administer three time per day instance time administer four time per day extemporaneous isradipine suspension use treatment course bp control achieve isradipine alone child remainder receive isradipine combination additional antihypertensive comparison pre treatment bp bp obtain day later demonstrate significant bp reduction isradipine treatment mean reduction mmhg systolic bp mmhg diastolic bp effect isradipine treatment heart rate adverse effect occur treatment course include headache flushing dizziness tachycardia conclude isradipine successfully lower bp hypertensive child secondary form hypertension use isradipine suspension allow infant young child treat readily old child,Flynn JT,2002,Pediatr Nephrol,https://doi.org/10.1007/s00467-002-0939-6,12215829,Flynn JT; Warnick SJ,article,D016430: Clinical Trial; D016428: Journal Article,"D000293: Adolescent; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002648: Child; D002675: Child, Preschool; D006801: Humans; D006973: Hypertension; D007223: Infant; D007231: Infant, Newborn; D017275: Isradipine; D012189: Retrospective Studies",,,https://openalex.org/W2079368183,76,10,1,1790,287,14,en,en
false,medical treatment myocardial ischemia coronary artery disease effect drug regime irregular dosing cape ii trial,circadian anti ischemia program europe cape ii compare efficacy amlodipine diltiazem adizem xl combination amlodipine atenolol diltiazem adizem xl isosorbide mononitrate exercise ambulatory myocardial ischemia regular therapy omission medication optimal medical therapy ischemia suppression impact irregular dose use agent different pharmacologic property establish patient coronary disease patients ischemic episode min st segment depression h electrocardiogram randomize amlodipine mg daily diltiazem adizem xl mg daily week double blind randomize multicountry study second phase atenolol mg add amlodipine isosorbide mononitrate mg diltiazem adizem xl ambulatory monitoring h exercise testing repeat phase treatment h drug free interval monotherapy amlodipine diltiazem adizem xl effective symptom ambulatory exercise ischemia combination therapy reduce ischemia far amlodipine atenolol superior diltiazem adizem xl isosorbide mononitrate amlodipine atenolol significantly superior drug free interval maintenance ischemia reduction amlodipine intrinsically long half life alone together beta blocker likely produce superior ischemia reduction clinical practice patient frequently forget take medication dose irregularly,Deanfield JE,2002,J Am Coll Cardiol,https://doi.org/10.1016/s0735-1097(02)02050-8,12225716,Deanfield JE; Detry JM; Sellier P; Lichtlen PR; Thaulow E; Bultas J; Brennan C; Young ST; Beckerman B; CAPE II Trial Investigators,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D001262: Atenolol; D002121: Calcium Channel Blockers; D002317: Cardiovascular Agents; D003327: Coronary Disease; D004110: Diltiazem; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D004562: Electrocardiography; D005080: Exercise Test; D005260: Female; D006801: Humans; D007547: Isosorbide; D008297: Male; D008875: Middle Aged; D017202: Myocardial Ischemia",,,https://openalex.org/W2137052889,132,22,1,1625,251,5,en,en
false,oxidative stress tgfb kidney transplanted patient cyclosporin induced hypertension effect carvedilol nifedipine,cyclosporin powerful stimulator oxidative stress signaling lead tgfbeta production degradation endothelial dysfunction hypertension post transplant nephropathy carvedilol alpha beta blocker strong antioxidant activity may interfere chain event therefore measure monocyte ecnos tgfbeta heme oxygenase ho mrna level plasma nitrite nitrate nitrotyrosine estimate peroxynitrite total plasma antioxidant power kidney transplanted patient post transplant hypertension treatment carvedilol mg orally month n dihydropyridine calcium channel blocker nifedipine n use comparator antihypertensive drug blood pressure fell similar extent drug carvedilol increase plasma antioxidant power ho mrna reduced nitrotyrosine tgfbeta mrna level observe nifedipine monocyte ec mrna level plasma nitrite nitrate high patient normotensive healthy control group unaffected either treatment conclusion carvedilol reduce oxidative stress correct altered cellular signal mediate oxidative stress csa induced post transplant hypertension therefore may prevent long term complication endothelial dysfunction fibrogenesis post transplant nephropathy decrease degradation production tgfbeta key fibrogenic cytokine activate ho production,Calò L,2002,Clin Nephrol,https://doi.org/10.5414/cnp58103,12227681,Calò L; Giacon B; Davis PA; Pagnin E; Piccin A; Riegler P; Huber W; Antonello A; Semplicini A,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D000328: Adult; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002227: Carbazoles; D000077261: Carvedilol; D016572: Cyclosporine; D004341: Drug Evaluation; D005260: Female; D006419: Heme Oxygenase (Decyclizing); D051547: Heme Oxygenase-1; D006801: Humans; D006973: Hypertension; D007166: Immunosuppressive Agents; D016030: Kidney Transplantation; D008297: Male; D008565: Membrane Proteins; D008875: Middle Aged; D009543: Nifedipine; D009569: Nitric Oxide; D019001: Nitric Oxide Synthase; D052250: Nitric Oxide Synthase Type III; D018384: Oxidative Stress; D011183: Postoperative Complications; D011412: Propanolamines; D012333: RNA, Messenger; D015398: Signal Transduction; D016212: Transforming Growth Factor beta; D016896: Treatment Outcome; D014443: Tyrosine",,,https://openalex.org/W2048270531,133,17,2,1563,245,10,en,en
false,migraine preventive treatment,migraine common episodic headache disorder comprehensive headache treatment plan include acute attack treatment relieve pain impairment long term preventive therapy reduce attack frequency severity duration circumstance might warrant preventive treatment include migraine significantly interfere patient daily routine despite acute treatment ii failure contraindication troublesome side effects acute medication iii overuse acute medication iv special circumstance hemiplegic migraine v frequent headache two week vi patient preference start drug low dose give treatment adequate trial avoid interfering overuse contraindicate drug evaluate therapy sure woman childbearing potential aware potential risk involve patient care maximize compliance consider co morbidity choose drug base proven efficacy patient preference headache profile drug side effects presence absence coexist co morbid disease drug document high efficacy mild moderate adverse event aes include beta blockers amitriptyline divalproex drug low document efficacy mild moderate aes include selective serotonin reuptake inhibitor ssri calcium channel antagonist gabapentin topiramate riboflavin non steroidal anti inflammatory drug,Silberstein SD,2002,Cephalalgia,https://doi.org/10.1046/j.1468-2982.2002.00386.x,12230591,Silberstein SD; Goadsby PJ,article,D016428: Journal Article; D016454: Review,D000700: Analgesics; D002986: Clinical Trials as Topic; D006801: Humans; D008881: Migraine Disorders,,,https://openalex.org/W2028017327,30,4,1,1514,261,13,en,en
false,acute atrial fibrillation,study refer result prospective single centre randomise trial conduct two year emergency department ed valduce hospital como italy hypothesis trial electrical cardioversion ec convert acute atrial fibrillation af sinus rhythm effectively safely intravenous pharmacological cardioversion pc,Freestone B,2002,Clin Evid,https://doi.org/10.7748/en.20.1.15.s7,12230635,Freestone B; Kamath S; Lip G,article,D003160: Comparative Study; D016428: Journal Article; D016454: Review,D000208: Acute Disease; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D004077: Digoxin; D004110: Diltiazem; D004562: Electrocardiography; D005343: Fibrinolytic Agents; D006801: Humans; D011379: Prognosis; D016032: Randomized Controlled Trials as Topic; D013923: Thromboembolism; D013999: Timolol; D016896: Treatment Outcome; D014700: Verapamil,,,https://openalex.org/W2409469309,25,3,1,381,69,2,fr,en
false,management outcome patient atrial fibrillation acute myocardial infarction gusto iii experience,investigate use antiarrhythmic agent electrical cardioversion management patient atrial fibrillation complicate acute myocardial infarction relation day one year mortality prospective study patient atrial fibrillation gusto iii trial study patient receive antiarrhythmic treatment include class antiarrhythmic agent sotalol amiodarone electrical cardioversion attempt sinus rhythm restore patient receive class antiarrhythmic agent receive sotalol receive amiodarone electrical cardioversion adjust baseline characteristic complication occur onset atrial fibrillation difference among treatment group incidence sinus rhythm time discharge deterioration hospital death however use class antiarrhythmic drug sotalol associate low unadjusted day one year mortality adjustment baseline factor pre atrial fibrillation complication odds ratio day one year mortality confidence interval ci ci class agent ci ci sotalol contrast association use amiodarone electrical cardioversion day one year mortality strong trend towards low mortality associate use class antiarrhythmic agent sotalol manage patient atrial fibrillation acute myocardial infarction randomise trial indicate,Wong CK,2002,Heart,https://doi.org/10.1136/heart.88.4.357,12231591,Wong CK; White HD; Wilcox RG; Criger DA; Califf RM; Topol EJ; Ohman EM; GUSTO-III Investigators,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D000638: Amiodarone; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D004554: Electric Countershock; D005260: Female; D006760: Hospitalization; D006801: Humans; D008297: Male; D009203: Myocardial Infarction; D011446: Prospective Studies; D013015: Sotalol; D016896: Treatment Outcome,,,https://openalex.org/W2112841595,120,16,1,1790,322,6,en,en
false,antiplatelet activity semotiadil fumarate,calcium antagonist know exert antiplatelet activity semotiadil fumarate sd new benzothiazine therefore examine antiplatelet activity inhibitory activity adenosine diphosphate adp collagen arachidonic acid aa platelet activate factor paf induced platelet aggregation min incubation concentration range x x x x x examine data compare use diltiazem nifedipine amlodipine identical condition blood eight healthy volunteer four male four female age year eight hypertensive patient four male four female age year semotiadil show dose dependent inhibition platelet aggregation vitro agent examine use various aggregation inducing agent dose dependent inhibitory action comparable compound test antiaggregatory potency order diltiazem semotiadil amlodipine nifedipine incubation period significantly affect antiaggregatory effect difference platelet derive healthy volunteer hypertensive patient note finding indicate potent antiplatelet activity new calcium antagonist semotiadil,Wolfram RM,2002,Thromb Res,https://doi.org/10.1016/s0049-3848(02)00138-x,12297124,Wolfram RM; Kritz H; Oguogho A; Sinzinger H,article,D003160: Comparative Study; D016428: Journal Article,D000244: Adenosine Diphosphate; D000328: Adult; D017311: Amlodipine; D002121: Calcium Channel Blockers; D016022: Case-Control Studies; D003094: Collagen; D004110: Diltiazem; D006801: Humans; D006973: Hypertension; D008875: Middle Aged; D009543: Nifedipine; D010974: Platelet Aggregation; D010975: Platelet Aggregation Inhibitors; D013844: Thiazoles,,,https://openalex.org/W2013850606,44,5,1,1352,243,10,en,en
true,coronary angiographic change patient cardiac event prospective randomized evaluation vascular effect norvasc trial prevent,prospective randomized evaluation vascular effect norvasc trial prevent first prospective double blind randomized trial assess specifically antiatherosclerotic potential calcium antagonist coronary artery segment minimal angiographic disease pitt b byington r p furberg c hunninghake b mancini g b j miller e riley w prevent investigatorseffect amlodipine progression atherosclerosis occurrence clinical event circulation crossref pubmed scopus google scholar unanticipated reduction prospectively defined clinical event mainly hospitalization unstable angina pectoris need percutaneous coronary intervention pci note undertake post hoc analysis assess association angiographic finding clinical event,Mancini GB,2002,Am J Cardiol,https://doi.org/10.1016/s0002-9149(02)02611-5,12356398,Mancini GB; Pitt B,article,D016428: Journal Article,D017311: Amlodipine; D002121: Calcium Channel Blockers; D017023: Coronary Angiography; D003324: Coronary Artery Disease; D018450: Disease Progression; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D015337: Multicenter Studies as Topic; D011446: Prospective Studies; D016032: Randomized Controlled Trials as Topic; D012720: Severity of Illness Index; D016896: Treatment Outcome,,,https://openalex.org/W2089220687,153,23,1,882,139,10,en,en
false,prevention dementia antihypertensive treatment subtitle new evidence systolic hypertension europe syst eur study subtitle,background double blind placebocontrolled systolic hypertension europe syst eur trial end february randomize patient offer active study medication period observation objective refine estimate long term effect antihypertensive therapy incidence dementia methods eligible patient dementia least year old systolic blood pressure entry mm hg diastolic blood pressure mm hg antihypertensive therapy start immediately randomization active treatment group termination doubleblind trial control patients treatment consist nitrendipine mg possible addition enalapril maleate mg hydrochlorothiazide mg add drugs results median follow increase year double blind trial year overall incidence dementia double case alzheimer disease throughout follow sys,Forette F,2002,Arch Intern Med,https://doi.org/10.1001/archinte.162.18.2046,12374512,Forette F; Seux ML; Staessen JA; Thijs L; Babarskiene MR; Babeanu S; Bossini A; Fagard R; Gil-Extremera B; Laks T; Kobalava Z; Sarti C; Tuomilehto J; Vanhanen H; Webster J; Yodfat Y; Birkenhäger WH; Systolic Hypertension in Europe Investigators,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D003704: Dementia; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004656: Enalapril; D005060: Europe; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D015994: Incidence; D008297: Male; D008875: Middle Aged; D009568: Nitrendipine; D013997: Time Factors; D016896: Treatment Outcome",,,https://openalex.org/W2104565625,161,33,1,1073,171,1,en,en
false,new therapeutic surgical approach sporadic hereditary pheochromocytoma,pheochromocytoma rare surgically correctable cause hypertension modern medical blockade significantly improve patient survival morbidity last decade see identification gene responsible several hereditary cause pheochromocytoma evaluation patient demonstrate different catecholamine profile associate different syndrome genetic testing new sensitive catecholamine test allow well early diagnosis affected patient patient small tumor deem nonfunctional traditional method may safely observe function demonstrate laparoscopic surgery supplant use open surgery management tumor adrenocortical sparing surgery may perform use laparoscopy patient hereditary form pheochromocytoma,Walther MM,2002,Ann N Y Acad Sci,https://doi.org/10.1111/j.1749-6632.2002.tb04411.x,12381540,Walther MM,article,"D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.; D016454: Review",D000310: Adrenal Gland Neoplasms; D000315: Adrenalectomy; D000317: Adrenergic alpha-Antagonists; D000319: Adrenergic beta-Antagonists; D002121: Calcium Channel Blockers; D002395: Catecholamines; D006801: Humans; D006973: Hypertension; D010535: Laparoscopy; D010673: Pheochromocytoma,,,https://openalex.org/W1966406043,84,10,1,864,124,8,en,en
false,coagulative fibrinolytic change patient essential hypertension effect sustained release nifedipine,investigate change coagulation fibrinolysis status patient essential hypertension eh observe therapeutic effect sustained release nifedipine ninety nine eh patient divide accord diastolic blood pressure dbp mild group case moderate group case severe group case patient among group choose random receive sustained release nifedipine week twenty healthy subject serve control group plasma dimer dd fibrin monomer fm tissue type plasminogen activator tpa level determine subject enzyme linked immunosorbent assay elisa plasma dd fm level much high tpa level much low hypertensive normal control exacerbate severity disease dbp positively correlate plasma fm level r p patient left ventricular hypertrophy leave ventricular enlargement leave atrial enlargement high level dd fm tpa detect nifedipine treatment produce significant reduction plasma dd fm level along increase tpa level dd mg dl v mg dl fm ng microliter v ng microliter tpa ng ml v ng ml p enhanced coagulative activity lower fibrinolytic activity characterize eh patient nifedipine may correct disorder,Chi DS,2002,Di Yi Jun Yi Da Xue Xue Bao,,12390820,Chi DS; Jin FX; Su YW; Yang SG; Ge B; Wu BM; Hong XS; Yu RS,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D001777: Blood Coagulation; D003692: Delayed-Action Preparations; D005260: Female; D005342: Fibrinolysis; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D014665: Vasodilator Agents",,,https://openalex.org/W2363743447,126,18,1,1483,267,6,en,en
false,biologic molecular mechanism sex difference pharmacokinetics pharmacodynamics pharmacogenetics part,pharmacological difference woman men important clinical consequence several drug high incidence woman drug induced qt prolongation potentially fatal arrhythmia torsades de pointes may reflection long baseline qt interval woman difference cardiovascular disease woman men woman high mortality rate myocardial infarction mi woman also high rate hemorrhagic stroke receive thrombolytic therapy mi difference effectiveness analgesic demonstrate kappa opioids provide pain relief woman men drug may different pharmacokinetics woman men difference phase phase ii enzymes metabolize drug conflict result biological sex difference report major drug metabolize enzyme cytochrome p may relate role p glycoprotein cell membrane transporter report two time higher male liver female report boy need high dose mercaptopurine metabolize thiopurine methyltransferase tpmt tpmt report high male human liver biopsy female verapamil drug angina hypertension different clearance side effect men woman ethnic racial variation also demonstrate drug metabolizing enzyme cyp c c,Anthony M,2002,J Womens Health Gend Based Med,10.1089/152460902760360559,12396893,Anthony M; Berg MJ,article,"D016423: Congress; D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.; D016454: Review","D064420: Drug-Related Side Effects and Adverse Reactions; D005260: Female; D006801: Humans; D008297: Male; D009316: National Institutes of Health (U.S.); D010597: Pharmacogenetics; D010601: Pharmacology, Clinical; D012737: Sex Factors; D014481: United States; D016387: Women's Health",,,,122,18,1,1544,268,12,en,en
false,drug drug interaction elderly,detect frequency potential drug drug interaction ddi outpatient group elderly people european country well describe difference among countries drug use data collect elderly person live european country study population participate control intervention study month investigate impact pharmaceutical care potential ddi study use computerized detection program elderly population use average drug per person least drug combination possibly lead ddi average potential ddi per person almost potential ddi classify avoid accord swedish interaction classification system nearly one third avoid predisposed patient risk subtherapeutic effect result potential ddi common risk adverse reaction furthermore find difference frequency type potential ddi among countries potential ddi common elderly people use many drug part normal drug regimen combination likely negative effect attention must focus detect monitor patient use combination difference potential ddi among country find reason variability need explore study,Björkman IK,2002,Ann Pharmacother,https://doi.org/10.1345/aph.1a484,12398558,Björkman IK; Fastbom J; Schmidt IK; Bernsten CB; Pharmaceutical Care of the Elderly in Europe Research (PEER) Group,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D004347: Drug Interactions; D064420: Drug-Related Side Effects and Adverse Reactions; D005060: Europe; D005260: Female; D005853: Geriatrics; D006801: Humans; D008297: Male; D015337: Multicenter Studies as Topic; D004364: Pharmaceutical Preparations; D015995: Prevalence,,,https://openalex.org/W2132637703,37,5,1,1444,244,9,en,en
false,amlodipine versus angiotensin receptor blocker nonhypertension indication,objective review efficacy safety data amlodipine angiotensin receptor blocker arb focus heart failure angina percutaneous coronary intervention pci renal protection data source medline search december complete use amlodipine angiotensin receptor antagonist losartan valsartan candesartan telmisartan key word english language article identify include study selection data extraction identify article evaluate article representative subject matter review include data synthesis amlodipine arb low blood pressure similar extent amlodipine effective antianginal agent whereas arb however amlodipine effective treatment heart failure arb may useful setting arb also effective preserve renal function may provide protection restenosis patient pci arb may also useful prevent diabetic nondiabetic nephropathy conclusion concomitant disease state consider choose arb amlodipine management hypertension,Kalus JS,2002,Ann Pharmacother,https://doi.org/10.1345/aph.1c102,12398574,Kalus JS; White CM,article,D003160: Comparative Study; D016428: Journal Article; D016454: Review,D017311: Amlodipine; D000787: Angina Pectoris; D057911: Angiotensin Receptor Antagonists; D000959: Antihypertensive Agents; D023903: Coronary Restenosis; D006333: Heart Failure; D006801: Humans; D016032: Randomized Controlled Trials as Topic,,,https://openalex.org/W2121874940,79,7,1,1213,204,11,en,en
false,optimal treatment hypertension african american,treatment hypertension african american special challenge include lack objective trial data base decision differ benefit response patient however adequate control possible goal treat physician article describe current best practice guidance appropriate treatment high blood pressure african american two patient scenario offer insight clinical strategy,Bakris GL,2002,Postgrad Med,https://doi.org/10.3810/pgm.2002.10.1333,12400150,Bakris GL; Ferdinand KC; Douglas JG; Sowers JR,article,D002363: Case Reports; D016428: Journal Article; D016454: Review,"D000319: Adrenergic beta-Antagonists; D001741: Black or African American; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D019985: Benchmarking; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004039: Diet, Sodium-Restricted; D004232: Diuretics; D019317: Evidence-Based Medicine; D006040: Goals; D006801: Humans; D006973: Hypertension; D008019: Life Style; D008297: Male; D008875: Middle Aged; D010347: Patient Care Planning; D017410: Practice Guidelines as Topic; D011320: Primary Health Care; D018570: Risk Assessment; D012307: Risk Factors",,,https://openalex.org/W1598927337,54,7,1,474,76,4,en,en
false,efficacy safety losartan amplodipine combination indian postmarketing surveillance experience,present study conduct among patient enrol doctor evaluate efficacy tolerability combination losartan potassium amlodipine besylate indian patient mild moderate hypertension patient drop patient patient receive daily dosage combination whereas patient receive daily patient receive daily patient receive twice daily dosage combination mean sbp study mm hg baseline day treatment mean sbp significant reduction ie basal end day treatment reduction baseline significant similarly mean dbp mm hg baseline treatment mean dbp significant reduction day treatment reduction baseline end treatment ie day reduction basal significant global evaluation efficacy physician case excellent good response patient fair response detail adverse event report note treatment combination record appropriate section case record form whether consider treatment relate report patient severity adverse event grade point scale mild moderate severe common side effects report oedema foot ankle oedema remain adverse event include cardiovascular event palpitation gastro intestinal event constipation miscellaneous event muscular pain weakness generalise swelling etc cns event include giddiness headache insomnia etc,Gokhale N,2002,J Indian Med Assoc,,12408291,Gokhale N; Shahani S; Pawar D,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study,"D000328: Adult; D000368: Aged; D017311: Amlodipine; D001795: Blood Pressure Determination; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006973: Hypertension; D007194: India; D019808: Losartan; D008297: Male; D008875: Middle Aged; D011358: Product Surveillance, Postmarketing; D016896: Treatment Outcome",,,https://openalex.org/W119829789,105,13,1,1869,345,14,en,en
false,gastrointestinal safety extended release nondeformable oral dosage form oros,background oros osmotic osm dosage form optimise extended release oral administration control rate drug release predetermined time provide constant pattern pulsed delivery profile osm product include prescription medication urology cns cardiovascular indication well counter nasal sinus congestion medication method retrospective study examine u gastrointestinal gi safety data oros dosage form follow nearly two decade use although gi injury obstruction know effect oral medication report suggest extended release product pose great risk gi injury obstruction oral dosage form product incorporate oros technology prescribe expand range patient review gi safety data dosage form thus seem timely appropriate u safety information obtain three source english language literature publish june five major biomedical database postmarketing safety report january june available freedom information act andcommercial safety information obtain directly alza corporation house safety database osm product alza report responsibility u distribution data ims national prescription audit trade mark plus data use estimate cumulative product distribution total total combine number unique gi event determine estimated frequency event result nearly billion osm tablet estimate distribute u incidence clinically significant gi adverse event osm product include intestinal gastric oesophageal irritation injury obstruction report u approximately one case million tablet distribute majority estimate incidence one case million tablet case report patient take procardia xl nifedipine oesophageal low gi obstruction report primarily patient pre existing abnormality disease gi tract among paediatric patient one obstruction report estimated million tablet distribute report gi irritation associate osm product consistent known effect drug substance dosage form conclusion review long term safety experience product use osm controlled release technology yield low incidence clinically significant gi event properly prescribe extended release product provide substantial therapeutic convenience benefit without additional risk,Bass DM,2002,Drug Saf,https://doi.org/10.2165/00002018-200225140-00004,12408733,Bass DM; Prevo M; Waxman DS,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000293: Adolescent; D000328: Adult; D000368: Aged; D002648: Child; D003692: Delayed-Action Preparations; D004363: Drug Utilization; D004935: Esophageal Diseases; D005260: Female; D005767: Gastrointestinal Diseases; D006801: Humans; D008297: Male; D011358: Product Surveillance, Postmarketing; D012189: Retrospective Studies; D018570: Risk Assessment; D014481: United States",,,https://openalex.org/W2189984932,89,17,2,2764,443,16,en,en
false,myocardial sympathetic denervation fatty acid metabolism leave ventricular wall motion vasospastic angina,although various noninvasive method use detect vasospasm none sensitive enough patient sporadic attack abnormal fatty acid metabolism cardiac adrenergic neuronal damage observe ischemic myocardium p iodophenyl r methyl pentadecanoic acid bmipp metaiodobenzylguanidine mibg recently propose useful tracer detection myocardial damage study investigate relationship among coronary vasospastic region abnormal leave ventricular regional wall motion fatty acid metabolism sympathetic nerve function change treatment patient vasospastic angina evaluate patient vasospastic angina clinically document vasospasm group vasospasm induce ergonovine provocation group b control subject chest pain normal coronary artery without ergonovine provocation spasm sixteen patient group reevaluate mo medical treatment territorial region vasospasm induced coronary artery wall motion determine left ventriculography bmipp mibg uptake compared regions exhibit positive reaction ergonovine provocation observe right coronary artery patient left anterior descend artery left circumflex artery provocation occur multiple vessel patient reduction wall motion observe patient sensitivity specificity identification vasospastic angina patient control subject respectively bmipp scintigraphy patient control subject respectively mibg scintigraphy region exhibit reduction left ventricular wall motion bmipp mibg uptake decrease sensitivity specificity determination vasospasm induced coronary artery artery artery respectively bmipp scintigraphy artery artery respectively mibg scintigraphy mo treatment vasospasm reinduced ergonovine provocation patient group reinduced patient group ii improvement decreased bmipp mibg uptake low group respectively group ii respectively p region vasospasm reinduced exhibit decreased bmipp mibg uptake abnormal fatty acid metabolism cardiac sympathetic denervation observe frequently wall motion abnormality vasospastic region patient vasospastic angina bmipp mibg scintigraphy highly accurate noninvasive technique determine presence location vasospasm,Watanabe K,2002,J Nucl Med,,12411551,Watanabe K; Takahashi T; Miyajima S; Hirokawa Y; Tanabe N; Kato K; Kodama M; Aizawa Y; Tazawa S; Inoue M,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D019797: 3-Iodobenzylguanidine; D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D003326: Coronary Circulation; D003329: Coronary Vasospasm; D003331: Coronary Vessels; D004874: Ergonovine; D005227: Fatty Acids; D005260: Female; D006321: Heart; D006801: Humans; D007457: Iodine Radioisotopes; D007462: Iodobenzenes; D008297: Male; D008875: Middle Aged; D009200: Myocardial Contraction; D009206: Myocardium; D015635: Radionuclide Ventriculography; D019275: Radiopharmaceuticals; D013564: Sympathetic Nervous System; D015899: Tomography, Emission-Computed, Single-Photon; D016277: Ventricular Function, Left",,,https://openalex.org/W2099727861,114,17,1,2940,521,14,en,en
false,primary pulmonary hypertension current therapy,cause primary pulmonary hypertension pph remain unknown therapeutic approach disease empirical base pathology pathobiology pulmonary circulation despite inability cure disease therapeutic advance past year contribute improvement quality life prolonged survival pph patient current therapeutic approach pph mostly include limitation physical activity long term anticoagulation vasodilator therapy among test oral vasodilator calcium channel blocker efficient long term therapy improve symptom hemodynamics subset pph patient acutely respond drug acute pulmonary vasodilator response inhalation nitric oxide predict acute chronic response oral calcium channel blocker good understanding pathogenesis pph change focus medical treatment purely chronic vasodilator therapy evaluation agent prostaglandin may reverse proliferation pulmonary vascular cell result regression pulmonary vascular hypertrophy remodel long term treatment intravenous epoprostenol prostaglandin prostacyclin improve exercise capacity hemodynamics survival patient pph functional class nyha iii iv may currently consider gold standard therapy severe patient however response long term epoprostenol therapy may incomplete adverse effect common survival remain unsatisfactory year patient severe pulmonary hypertension refractory medical therapy atrioseptostomy lung transplantation indicate,Sitbon O,2002,Prog Cardiovasc Dis,https://doi.org/10.1053/pcad.2002.128449,12411973,Sitbon O; Humbert M; Simonneau G,article,D016428: Journal Article; D016454: Review,"D000925: Anticoagulants; D002121: Calcium Channel Blockers; D006325: Heart Atria; D006801: Humans; D006976: Hypertension, Pulmonary; D016040: Lung Transplantation; D011453: Prostaglandins; D011651: Pulmonary Artery; D011652: Pulmonary Circulation; D014655: Vascular Resistance; D014665: Vasodilator Agents",,,https://openalex.org/W2035983530,47,6,1,1793,292,9,en,en
false,protective effect anti hypertensive treatment cognitive function essential hypertension,abstract hypertension risk factor stroke may also contribute development vascular cognitive impairment vci vascular dementia vad cognitive complication hypertension influence anti hypertensive treatment underestimate recently paper trial investigate effect anti hypertensive treatment cognitive function evaluate analysis study reveal approximately investigation assess primarily anti hypertensive treatment impaired cognitive function recent study investigate positive effect cognition anti hypertensive medication drug extensively evaluate diuretic beta blockers angiotensin converting enzyme ace inhibitor sartanes ca channel blocker available study confirm elevate diastolic blood pressure pulse pressure isolated systolic hypertension play important role development cognitive impairment randomize placebo controlled trial provide evidence reduction hypertension safely effectively decrease morbidity mortality rate cognitive complication hypertension ca channel blocker ace inhibitor show effective probably good diuretic beta blockers cognitive domain hypertension extensive investigation could contribute establish optimal choice drug dosage treatment cognitive complication hypertension,Amenta F,2002,J Neurol Sci,https://doi.org/10.1016/s0022-510x(02)00281-2,12417374,Amenta F; Mignini F; Rabbia F; Tomassoni D; Veglio F,article,D016428: Journal Article; D016454: Review,D000959: Antihypertensive Agents; D002986: Clinical Trials as Topic; D003072: Cognition Disorders; D006801: Humans; D006973: Hypertension; D008137: Longitudinal Studies,,,https://openalex.org/W2244383043,96,11,1,1566,234,10,en,en
false,new method evaluation safety antiarrhythmic drug,new method preclinical evaluation safety antiarrhythmic drug propose chronic stress class antiarrhythmic preparation increase mortality test animal contrast class ii iv antiarrhythmic agent antioxidant produce significant effect mortality experimental mouse data agree publish result multicenter study,Balashov VP,2002,Bull Exp Biol Med,https://doi.org/10.1023/a:1019842611550,12420078,Balashov VP; Balykova LA; Shuvalova EN; Shevorakova TI; Poderov VN,article,D016428: Journal Article,"D000818: Animals; D000889: Anti-Arrhythmia Agents; D000975: Antioxidants; D002986: Clinical Trials as Topic; D004353: Drug Evaluation, Preclinical; D051379: Mice; D015337: Multicenter Studies as Topic; D013997: Time Factors",,,https://openalex.org/W33248206,62,11,1,376,57,4,en,en
false,atrial fibrillation elderly,although atrial fibrillation widely know general public developed country common arrhythmia incidence increase markedly advance age thus grow proportion elderly individual atrial fibrillation come represent significant medical socioeconomic problem consequence atrial fibrillation great impact risk thromboembolism well know outcome atrial fibrillation less well recognise relationship dementia depression death consequence responsible diminished quality life considerable economic cost atrial fibrillation characterise rapid disorganised atrial activity frequency beats minute ventricle react irregularly may contract rapidly slowly depend health conduction system clinical symptom varied include palpitation syncope dizziness embolic event atrial fibrillation may paroxysmal persistent chronic number attack asymptomatic suspicion confirmation atrial fibrillation necessitates investigation far possible appropriate treatment underlie cause hypertension diabetes mellitus hypoxia hyperthyroidism congestive heart failure evaluation atrial fibrillation cardiac exploration invaluable include electrocardiogram ecg echocardiography aim detect cardiac abnormality direct management elderly patient arbitrarily define aged year management atrial fibrillation varies require individual approach largely depend comorbid condition underlie cardiac disease patient physician preference management essentially base pharmacological treatment also nonpharmacological option two alternative possible restoration maintenance sinus rhythm control ventricular rate leave atrium arrhythmia pharmacological option include antiarrhythmic drug class iii agent beta blockers class ic agent drug adverse effect careful monitoring necessary nonpharmacological approach atrial fibrillation include external internal direct current cardioversion new method catheter ablation specific focus evolve science show successful select group atrial fibrillation patient another serious challenge management chronic atrial fibrillation old individual prevention stroke primary outcome choose appropriate antithrombotic treatment aspirin warfarin several risk stratification scheme validate may helpful determine best antithrombotic choice individual patient,Chatap G,2002,Drugs Aging,https://doi.org/10.2165/00002512-200219110-00002,12428993,Chatap G; Giraud K; Vincent JP,article,D016428: Journal Article; D016454: Review,"D000368: Aged; D000369: Aged, 80 and over; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D004554: Electric Countershock; D005260: Female; D005343: Fibrinolytic Agents; D006349: Heart Valve Diseases; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D016032: Randomized Controlled Trials as Topic; D012214: Rheumatic Heart Disease",,,https://openalex.org/W1968017605,34,5,1,2910,458,20,en,en
false,extent use immediate release formulation calcium channel blocker antihypertensive monotherapy primary care physician multicentric study bahrain,issue cardiovascular safety calcium channel blocker ccbs widely debate view reflex increase sympathetic activity induce immediate release ir short act formulation generally agree ccbs use alone management hypertension determine extent primary care physician prescribe ccbs monotherapy especially immediate release formulation management uncomplicated hypertension diabetic hypertension emphasis upon age patient setting design method retrospective prescription based study carry seven health centre bahrain study involve registered population represent registered individual physician represent primary care physician data collect november january use chronic dispense cards category ccbs third commonly prescribed antihypertensive monotherapy prescription rate uncomplicated hypertension diabetic hypertension elderly patient year age nifedipine formulation extensively prescribed ccbs almost half ccb treated patient ir nifedipine whereas ir diltiazem ir verapamil amlodipine infrequently prescribed prescription ir formulations ccbs monotherapy primary care physician conform recommended guideline view concern safety practice measure change prescribing pattern require,Sequeira RP,2002,J Postgrad Med,,12432188,Sequeira RP; Jassim Al Khaja KA; Mathur VS,article,D016428: Journal Article; D016448: Multicenter Study,"D000328: Adult; D000367: Age Factors; D000368: Aged; D000369: Aged, 80 and over; D000959: Antihypertensive Agents; D001445: Bahrain; D002121: Calcium Channel Blockers; D002626: Chemistry, Pharmaceutical; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D017723: Drug Utilization Review; D005260: Female; D019983: Guideline Adherence; D019538: Health Care Surveys; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011320: Primary Health Care; D012189: Retrospective Studies; D012680: Sensitivity and Specificity; D016896: Treatment Outcome",,,https://openalex.org/W188185894,168,23,1,1649,263,8,en,en
false,year old renal transplant recipient high grade fever progressive shortness breath,,Soman R,2002,J Postgrad Med,,12432193,Soman R; Vaideeswar P; Shah H; Almeida AF,article,D002363: Case Reports; D016428: Journal Article,"D000328: Adult; D000818: Animals; D001344: Autopsy; D001774: Blood Chemical Analysis; D001784: Blood Gas Analysis; D003106: Colon; D018450: Disease Progression; D004417: Dyspnea; D017809: Fatal Outcome; D005334: Fever; D016469: Fungemia; D006084: Graft Rejection; D006801: Humans; D007676: Kidney Failure, Chronic; D007677: Kidney Function Tests; D016030: Kidney Transplantation; D008168: Lung; D008297: Male; D013321: Strongyloides; D013322: Strongyloidiasis",,,https://openalex.org/W1509931586,99,14,1,0,0,0,en,
true,effect blood pressure lower antihypertensive drug class progression hypertensive kidney disease subtitle result aask trial subtitle,hypertension lead cause end stage renal disease esrd united state know treatment prevent progressive decline lead esrd compare effect level blood pressure bp control antihypertensive drug class glomerular filtration rate gfr decline hypertension randomized x factorial trial enrollment february september total african american age year hypertensive renal disease gfr ml min per recruit clinical center throughout united state follow years participants randomly assign mean arterial pressure goal mm hg usual n mm hg less low n initial treatment either beta blocker metoprolol mg n angiotensin converting enzyme inhibitor ramipril mg n dihydropyridine calcium channel blocker amlodipine mg n open label agent add achieve assigned bp goals rate change gfr gfr slope clinical composite outcome reduction gfr ml min per baseline esrd death three primary treatment comparison specify low v usual bp goal ramipril vs metoprolol amlodipine v metoprolol achieved bp average sd mm hg low bp group mm hg usual bp group mean se gfr slope baseline year differ significantly low bp group ml min per per year usual bp group ml min per per year p low bp goal significantly reduce rate clinical composite outcome risk reduction low bp group confidence interval ci p none drug group comparison show consistent significant difference gfr slope however compare metoprolol amlodipine group ramipril group manifest risk reduction clinical composite outcome ci p ci p respectively significant difference clinical composite outcome amlodipine metoprolol groups additional benefit slow progression hypertensive nephrosclerosis observe low bp goal angiotensin converting enzyme inhibitor appear effective beta blockers dihydropyridine calcium channel blocker slow gfr decline,Wright JT,2002,JAMA,https://doi.org/10.1001/jama.288.19.2421,12435255,Wright JT; Bakris G; Greene T; Agodoa LY; Appel LJ; Charleston J; Cheek D; Douglas-Baltimore JG; Gassman J; Glassock R; Hebert L; Jamerson K; Lewis J; Phillips RA; Toto RD; Middleton JP; Rostand SG; African American Study of Kidney Disease and Hypertension Study Group,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000319: Adrenergic beta-Antagonists; D000328: Adult; D001741: Black or African American; D000368: Aged; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D018450: Disease Progression; D005260: Female; D005919: Glomerular Filtration Rate; D006801: Humans; D006973: Hypertension; D007676: Kidney Failure, Chronic; D008297: Male; D008790: Metoprolol; D008875: Middle Aged; D016016: Proportional Hazards Models; D011507: Proteinuria; D017257: Ramipril",,,https://openalex.org/W2120235169,171,34,1,2605,520,8,en,en
false,clinical treatment regimen chronic heart failure review,chronic heart failure chf increase prevalence worldwide particularly elderly accordingly epidemic likely translate major increase healthcare cost systolic heart failure common cause chf presentation although cause vary common single aetiological factor ischaemic heart disease account approximately heart failure presentation research chf pharmacotherapy copious focus principally centre systolic heart failure evidence base pharmacotherapy chf amongst large currently clinical medicine multiple trial establish mortality morbidity benefit pharmacotherapy amongst large scale trial angiotensin converting enzyme inhibitor beta blockers spironolactone provide sound basis evidence based treatment approach chf patient recently research interest increase biomedical engineering study perform biventricular pacing mechanical heart early data biventricular pacing cardiac resynchronisation therapy encourage diastolic heart failure alone account least chf presentation whilst may occur isolation commonly see association systolic heart failure study present broad overview current therapeutic modality management chf particular emphasis pharmacotherapy,Gould PA,2002,Expert Opin Pharmacother,https://doi.org/10.1517/14656566.3.11.1569,12437491,Gould PA; Kaye DM,article,D016428: Journal Article; D016454: Review,"D000319: Adrenergic beta-Antagonists; D000804: Angiotensin II; D057911: Angiotensin Receptor Antagonists; D000806: Angiotensin-Converting Enzyme Inhibitors; D002121: Calcium Channel Blockers; D002316: Cardiotonic Agents; D004077: Digoxin; D004232: Diuretics; D006333: Heart Failure; D006801: Humans; D006830: Hydralazine; D007548: Isosorbide Dinitrate; D010138: Pacemaker, Artificial; D013148: Spironolactone; D014665: Vasodilator Agents",,,https://openalex.org/W2104606169,63,10,1,1512,239,12,en,en
false,rhabdomyolysis due red yeast rice monascus purpureus renal transplant recipient,rhabdomyolysis known complication hepatic methylglutaryl coenzyme reductase hmg coa inhibitor statin therapy posttransplant hyperlipidemia thus monitoring effect indicate report case herbal preparation induced rhabdomyolysis stable renal transplant recipient attribute presence red yeast rice monascus purpureus within mixture condition resolve consumption product cease rice ferment red yeast contain several type mevinic acid include monacolin k identical lovastatin postulate interaction cyclosporine compound cytochrome p system result adverse effect see patient transplant recipient must caution use herbal preparation lower lipid level prevent complication occur,Prasad GV,2002,Transplantation,https://doi.org/10.1097/00007890-200210270-00028,12438974,Prasad GV; Wong T; Meliton G; Bhaloo S,article,D002363: Case Reports; D016428: Journal Article,D000328: Adult; D001688: Biological Products; D016572: Cyclosporine; D003577: Cytochrome P-450 Enzyme System; D019587: Dietary Supplements; D004347: Drug Interactions; D005260: Female; D006801: Humans; D006949: Hyperlipidemias; D007166: Immunosuppressive Agents; D016030: Kidney Transplantation; D008517: Phytotherapy; D012206: Rhabdomyolysis,,,https://openalex.org/W2002289512,89,15,1,897,141,6,en,en
false,improvement insulin sensitivity long acting nifedipine preparation nifedipine cr patient essential hypertension,nifedipine report cause impairment insulin sensitivity recently controlled released formulation nifedipine nifedipine gits report could improve insulin sensitivity evaluate insulin sensitivity two group essential hypertensive subject treatment either long acting nifedipine nifedipine cr adalat cr tablet bayer yakuhin osaka japan n metoprolol n insulin sensitivity evaluate steady state plasma glucose sspg level measure steady state insulin level microu ml use modification sspg method previously reported sspg initially high significantly reduce nifedipine cr treatment mg dl mg dl however sspg significantly alter treatment metoprolol group mg dl mg dl result indicate long acting nifedipine nifedipine cr associate improved insulin sensitivity,Koyama Y,2002,Am J Hypertens,https://doi.org/10.1016/s0895-7061(02)03019-4,12441210,Koyama Y; Kodama K; Suzuki M; Harano Y,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000319: Adrenergic beta-Antagonists; D000368: Aged; D019540: Area Under Curve; D001786: Blood Glucose; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D005230: Fatty Acids, Nonesterified; D005260: Female; D005951: Glucose Tolerance Test; D006801: Humans; D006973: Hypertension; D007328: Insulin; D007333: Insulin Resistance; D007659: Ketones; D008297: Male; D008790: Metoprolol; D008875: Middle Aged; D009543: Nifedipine; D016896: Treatment Outcome",,,https://openalex.org/W2049263276,130,17,1,1031,176,4,en,en
false,tolerability long term treatment lercanidipine versus amlodipine lacidipine elderly hypertensive,irrespective clinical relevance side effect consider negligible problem antihypertensive therapy aim trial evaluate tolerability profile lercanidipine two calcium antagonist amlodipine lacidipine elderly hypertensives multicenter double blind parallel study elderly age year hypertensive randomize lercanidipine mg day n amlodipine mg day n lacidipine mg day n ratio blood pressure bp control unsatisfactory systolic bp diastolic bp mm hg dose double blind medication double step enalapril atenolol plus diuretic need add patient treat average months amlodipine patient significantly p high rate edema early study discontinuation due edema compare lercanidipine lacidipine patient similarly edema related symptom low limb swell heaviness occur significantly p often amlodipine respectively lercanidipine lacidipine edema case occur first month treatment difference evident since begin treatment drug related adverse event differ treatment blood pressure equally effectively reduce three groups two lipophilic dihydropyridine calcium antagonist lercanidipine lacidipine antihypertensive effect comparable amlodipine good tolerability profile,Leonetti G,2002,Am J Hypertens,https://doi.org/10.1016/s0895-7061(02)03000-5,12441211,Leonetti G; Magnani B; Pessina AC; Rappelli A; Trimarco B; Zanchetti A; COHORT Study Group,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D017311: Amlodipine; D002121: Calcium Channel Blockers; D004095: Dihydropyridines; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004487: Edema; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D016491: Peripheral Vascular Diseases; D016896: Treatment Outcome",,,https://openalex.org/W2147784554,112,13,1,1701,323,8,en,en
false,pedal edema dihydropyridine calcium antagonist create equal,,Messerli FH,2002,Am J Hypertens,https://doi.org/10.1016/s0895-7061(02)03087-x,12441226,Messerli FH; Grossman E,article,D016420: Comment; D016421: Editorial,D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D002121: Calcium Channel Blockers; D004487: Edema; D006801: Humans; D006973: Hypertension; D015337: Multicenter Studies as Topic; D016491: Peripheral Vascular Diseases,,,https://openalex.org/W2072231805,73,9,1,0,0,0,en,
false,myocardial ischaemia patient impaired leave ventricular function undergo coronary artery bypass graft milrinone versus nifedipine,myocardial ischaemia infarction major complication immediately coronary artery bypass graft may due incomplete surgical revascularization perioperative anaesthetic management vasospasm arterial graft e g internal mammary artery infusion nifedipine milrinone advocate prevent spasm mammary artery study compare incidence myocardial ischaemia continuous infusion either nifedipine microg kg min milrinone microg kg min patient compromised leave ventricular function schedule elective coronary artery bypass graft institutional review board approval double blinded randomized clinical study enrol adult patient compromised leave ventricular function ejection fraction schedule elective coronary artery bypass grafting write informed consent obtain ischaemia detect holter electrocardiographic monitoring incidence myocardial cell death monitor serial determination creatine kinase mb ck mb troponin new st elevation mv new st depression mv occur five patient milrinone group patient nifedipine group p increase ck mb troponin group twenty four hour postoperatively ck mb p troponin p significantly high nifedipine group perioperative continuous infusion milrinone compare nifedipine result significantly low incidence myocardial ischaemia myocardial cell damage elective coronary artery bypass grafting,Möllhoff T,2002,Eur J Anaesthesiol,https://doi.org/10.1017/s026502150200128x,12442928,Möllhoff T; Schmidt C; Van Aken H; Berendes E; Buerkle H; Marmann P; Reinbold T; Prenger-Berninghoff R; Tjan TD; Scheld HH; Deng MC,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000768: Anesthesia, General; D002121: Calcium Channel Blockers; D001026: Coronary Artery Bypass; D003327: Coronary Disease; D003402: Creatine Kinase; D052279: Creatine Kinase, MB Form; D004311: Double-Blind Method; D005260: Female; D006439: Hemodynamics; D006801: Humans; D007262: Infusions, Intravenous; D007430: Intraoperative Care; D007527: Isoenzymes; D008297: Male; D008875: Middle Aged; D020105: Milrinone; D017202: Myocardial Ischemia; D009543: Nifedipine; D011182: Postoperative Care; D011183: Postoperative Complications; D019210: Troponin I; D014665: Vasodilator Agents; D018487: Ventricular Dysfunction, Left",,,https://openalex.org/W2107599482,145,18,1,1739,291,9,en,en
false,persistence antihypertensive efficacy amlodipine nifedipine git two miss dos randomised double blind comparative trial asian patient,suboptimal management hypertension often result poor patient compliance form missed dos antihypertensive medication multicentre randomise double blind parallel group trial design compare persistence antihypertensive efficacy amlodipine nifedipine gastrointestinal therapeutic system git two missed dos also compare drug overall efficacy safety asian patient mild moderate essential hypertension follow week placebo run period patient randomise receive either amlodipine mg daily increase week necessary mg daily n nifedipine git mg daily increase week necessary mg daily n week placebo substitute day continuous ambulatory blood pressure bp monitoring increase last h mean ambulatory bp day treatment withdrawal significantly less amlodipine nifedipine git v mmhg systolic bp p v mmhg diastolic bp p significant difference two drug mean h ambulatory bp level already evident day withdrawal even though significant difference final day treatment difference safety parameter observe neither drug cause serious severe treatment related adverse event conclusion amlodipine provide great protection nifedipine git loss bp control follow missed dos,Ongtengco I,2002,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1001485,12444542,Ongtengco I; Morales D; Sanderson J; Lu ZR; Beilin LJ; Burke V; Puddey IB; Tanomsup S; Dayi H; Rahardjo P; Zambahari DR; Chen CY; Soenarta AA; Buranakitjaroen P; Tan C; Soon TK; Wu DJ,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D017311: Amlodipine; D000959: Antihypertensive Agents; D001210: Asia, Southeastern; D018660: Blood Pressure Monitoring, Ambulatory; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D006801: Humans; D006973: Hypertension; D009543: Nifedipine",,,https://openalex.org/W2112672576,167,26,1,1645,282,8,en,en
false,metabolic effect combined antihypertensive treatment patient essential hypertension,single drug treatment essential hypertension ht often insufficient normalize blood pressure bp high dos antihypertensive agent adverse effect glucose tolerance gt insulin sensitivity study test whether aggressive bp lower combination treatment influence gt insulin action nonobese body mass index bmi kg normolipidemic patient establish ht mm hg normal gt recruit eleven normotensive mm hg subject match patient anthropometric metabolic variable follow baseline study serum lipid profile oral gt insulin release insulin sensitivity assess insulin clamp technique patient randomize double blind fashion two combination regimen verapamil mg day trandolapril mg day atenolol mg day nifedipine mg day restudied month later blood pressure normalize group decrement mm hg respectively lipid profile gt insulin release insulin sensitivity glucose uptake lipolysis unchanged follow treatment author conclude nonobese normolipidemic glucose tolerant hypertensive patient bp normalization combination therapy feasible cost term undesired effect glucose lipid metabolism insulin sensitivity,Quiñones-Galvan A,2002,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-200212000-00013,12451325,Quiñones-Galvan A; Pucciarelli A; Ciociaro D; Masoni A; Franzoni F; Natali A; Ferrannini E,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000959: Antihypertensive Agents; D001262: Atenolol; D001786: Blood Glucose; D002784: Cholesterol; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005260: Female; D005951: Glucose Tolerance Test; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D007211: Indoles; D007328: Insulin; D000078790: Insulin Secretion; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D014700: Verapamil",,,https://openalex.org/W2002879751,96,11,1,1491,267,8,en,en
false,investigation effect fk tacrolimus cyclosporin gingival overgrowth follow paediatric liver transplantation,summary introduction gingival overgrowth associate immunosuppression follow liver transplantation commonly recognize clinical problem aim study determine incidence gingival overgrowth group child post liver transplantation compare gingival overgrowth child receive fk receive cyclosporin method seventy nine child age month undergo liver transplantation birmingham child hospital october october study gingival overgrowth assess blinded fashion score previously validate manner gingival overgrowth score patient immunosuppressant drug compare result fifty two patient treat cyclosporin treat tacrolimus eighteen child also receive nifedipine also know cause gingival overgrowth consider separately child receive cyclosporin alone exhibit gingival overgrowth compare zero patient receive tacrolimus alone child treat immunosuppression plus nifedipine develop gingival overgrowth however much less mark tacrolimus group conclusion tacrolimus unlike cyclosporin associate gingival overgrowth use immunosuppression follow liver transplantation child may drug choice child,McKaig SJ,2002,Int J Paediatr Dent,https://doi.org/10.1046/j.1365-263x.2002.00397.x,12452980,McKaig SJ; Kelly D; Shaw L,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000704: Analysis of Variance; D002121: Calcium Channel Blockers; D002648: Child; D002675: Child, Preschool; D016572: Cyclosporine; D004311: Double-Blind Method; D005881: Gingiva; D019214: Gingival Overgrowth; D006801: Humans; D007166: Immunosuppressive Agents; D007223: Infant; D016031: Liver Transplantation; D009543: Nifedipine; D011446: Prospective Studies; D018709: Statistics, Nonparametric; D016559: Tacrolimus",,,https://openalex.org/W1891939390,131,18,1,1455,221,15,en,en
false,effect amlodipine fosinopril combination microalbuminuria hypertensive type diabetic patient,aim study compare long term effect amlodipine fosinopril monotherapy combination urinary albumin excretion uae hypertensive diabetic patients select hypertensive patient type diabetes microalbuminuria randomize amlodipine mg day fosinopril mg day amlodipine plus fosinopril mg day month titration period nonresponder patient complain side effect titration period discontinue n remain patient enrol trial treat therapy year every month blood pressure bp heart rate hr uae creatinine clearance glycosylated hemoglobin hba c evaluated combination therapy effective reduce bp either drug alone time study without affect glucose homeostasis three treatment provide significant decrease uae month study period however effect pronounced become evident earlier fosinopril amlodipine monotherapy v month therapy addition combination therapy provide great antialbuminuric effect single drug could due great antihypertensive effect although drug specific effect exclude cardiovascular outcome similar amlodipine fosinopril group low combination group result strengthen rationale use calcium antagonist angiotensin converting enzyme inhibitor combination treatment hypertensive patient type diabetes,Fogari R,2002,Am J Hypertens,https://doi.org/10.1016/s0895-7061(02)03017-0,12460699,Fogari R; Preti P; Zoppi A; Rinaldi A; Corradi L; Pasotti C; Poletti L; Marasi G; Derosa G; Mugellini A; Voglini C; Lazzari P,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000368: Aged; D000419: Albuminuria; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D003924: Diabetes Mellitus, Type 2; D004338: Drug Combinations; D005260: Female; D017328: Fosinopril; D006442: Glycated Hemoglobin; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D016896: Treatment Outcome",,,https://openalex.org/W2104423475,105,13,1,1711,291,8,en,en
false,comparison rate control rhythm control patient atrial fibrillation,two approach treatment atrial fibrillation one cardioversion treatment antiarrhythmic drug maintain sinus rhythm use rate controlling drug allow atrial fibrillation persist approach use anticoagulant drug recommend,Wyse DG,2002,N Engl J Med,https://doi.org/10.1056/nejmoa021328,12466506,Wyse DG; Waldo AL; DiMarco JP; Domanski MJ; Rosenberg Y; Schron EB; Kellen JC; Greene HL; Mickel MC; Dalquist JE; Corley SD; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000319: Adrenergic beta-Antagonists; D000368: Aged; D000638: Amiodarone; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D002121: Calcium Channel Blockers; D017115: Catheter Ablation; D003131: Combined Modality Therapy; D018592: Cross-Over Studies; D004554: Electric Countershock; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D020521: Stroke; D016019: Survival Analysis,,,https://openalex.org/W2110253,84,13,1,312,52,2,en,en
false,comparison rate control rhythm control patient recurrent persistent atrial fibrillation,maintenance sinus rhythm main therapeutic goal patient atrial fibrillation however recurrence atrial fibrillation side effect antiarrhythmic drug offset benefit sinus rhythm hypothesize ventricular rate control inferior maintenance sinus rhythm treatment atrial fibrillation randomly assign patient persistent atrial fibrillation previous electrical cardioversion receive treatment aim rate control rhythm control patient rate control group receive oral anticoagulant drug rate slowing medication patient rhythm control group underwent serial cardioversions receive antiarrhythmic drug oral anticoagulant drug end point composite death cardiovascular cause heart failure thromboembolic complication bleeding implantation pacemaker severe adverse effect drugs mean sd year percent patient rhythm control group sinus rhythm compare percent patient rate control group primary end point occur patient percent rate control group percent rhythm control group percent two sided upper boundary absolute difference primary end point percent prespecified criterion noninferiority percent less distribution various component primary end point similar rate control rhythm control groups rate control inferior rhythm control prevention death morbidity cardiovascular cause may appropriate therapy patient recurrence persistent atrial fibrillation electrical cardioversion,Van Gelder IC,2002,N Engl J Med,https://doi.org/10.1056/nejmoa021375,12466507,Van Gelder IC; Hagens VE; Bosker HA; Kingma JH; Kamp O; Kingma T; Said SA; Darmanata JI; Timmermans AJ; Tijssen JG; Crijns HJ; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000319: Adrenergic beta-Antagonists; D000368: Aged; D000889: Anti-Arrhythmia Agents; D000925: Anticoagulants; D001281: Atrial Fibrillation; D002121: Calcium Channel Blockers; D003131: Combined Modality Therapy; D018572: Disease-Free Survival; D004554: Electric Countershock; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D012008: Recurrence; D012737: Sex Factors,,,https://openalex.org/W1994231358,105,15,1,1834,293,9,en,en
false,drug effect aldosterone plasma renin activity ratio primary aldosteronism,primary aldosteronism specifically treatable potentially curable form secondary hypertension aldosterone plasma renin activity ratio arr routinely use screening test antihypertensive therapy interfere interpretation parameter correct washout period potentially harmful investigate effect therapy atenolol amlodipine doxazosin fosinopril irbesartan arr group patient suspected primary aldosteronism percent change control arr patient take amlodipine atenolol doxazosin fosinopril irbesartan arr change induce atenolol significantly high compare induce drug p arr change induce irbesartan significantly low induce doxazosin p one patient group take amlodipine patient take irbesartan give false negative arr none patient group take fosinopril doxazosin atenolol display false negative arr doxazosin fosinopril use hypertensive patient need undergo aldosterone pra measurement diagnosis primary aldosteronism amlodipine give small percentage false negative diagnosis blockers also interfere diagnosis primary aldosteronism responsible increased rate false positive arrs high rate false negative diagnosis patient undergoing irbesartan treatment require confirmation high number patient,Mulatero P,2002,Hypertension,https://doi.org/10.1161/01.hyp.0000038478.59760.41,12468576,Mulatero P; Rabbia F; Milan A; Paglieri C; Morello F; Chiandussi L; Veglio F,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article,"D000450: Aldosterone; D017311: Amlodipine; D000959: Antihypertensive Agents; D001262: Atenolol; D001713: Biphenyl Compounds; D015986: Confounding Factors, Epidemiologic; D003955: Diagnostic Tests, Routine; D017292: Doxazosin; D005188: False Negative Reactions; D005189: False Positive Reactions; D017328: Fosinopril; D006801: Humans; D006929: Hyperaldosteronism; D006973: Hypertension; D000077405: Irbesartan; D008875: Middle Aged; D011237: Predictive Value of Tests; D012083: Renin; D012084: Renin-Angiotensin System; D012680: Sensitivity and Specificity; D013777: Tetrazoles; D014057: Tomography, X-Ray Computed",,,https://openalex.org/W2125668296,80,10,1,1694,305,11,en,en
false,management patient hypertensive urgency emergency,hypertensive urgency emergency common clinical occurrence hypertensive patient treatment practice vary considerably lack evidence support use one therapeutic agent another paper design review evidence various pharmacotherapeutic regimen management hypertensive urgency emergency term agent ability reach predetermined safe goal blood pressure bps prevent adverse events medline search reference list article retrieve search relevant reference expert field contact identify relevant study cochrane library also search study eligible inclusion review systematic review randomize control trial rcts individual rcts none study systematic review cohort study individual cohort study outcomes research language restriction used none trial include review identify optimal rate bp lower hypertensive emergency urgency definition hypertensive emergency urgency consistent emergency always involve target end organ damage urgency without damage measure outcome uniform study hypertensive emergency hypertensive urgency study represent patient respectively evidence indicate nonsignificant trend toward increase efficacy urapidil compare nitroprusside hypertensive emergency number need treat nnt urapidil achieve target bp confidence interval ci number patient need harm nnh nnt compare nitroprusside several medication efficacious treat hypertensive urgency include nicardipine nnt nicardipine compare plabebo one study ci another ci lacidipine nnt ci lacidipine v nifedipine urapidil nnt urapidil compare enalaprilat nifedipine ci nitroprusside fenoldopam patient reach target bp study study report case cerebral ischemia secondary nifedipine many effective agent exist treatment hypertensive crisis lack large randomize controlled trial many question remain unanswered follow time whether studied agent mortality benefit,Cherney D,2002,J Gen Intern Med,https://doi.org/10.1046/j.1525-1497.2002.20389.x,12472930,Cherney D; Straus S,article,D016428: Journal Article; D016454: Review; D000078182: Systematic Review,"D000959: Antihypertensive Agents; D001795: Blood Pressure Determination; D002986: Clinical Trials as Topic; D016638: Critical Illness; D004630: Emergencies; D004636: Emergency Service, Hospital; D006801: Humans; D006973: Hypertension; D009599: Nitroprusside; D010879: Piperazines; D016032: Randomized Controlled Trials as Topic",,,https://openalex.org/W2023940327,66,8,1,2598,458,13,en,en
false,effect four antihypertensive monotherapies cardiac mass function hypertensive patient left ventricular hypertrophy randomize prospective study,compare effect four antihypertensive drug reportedly different effectiveness reduce myocardial mass randomize double blind prospective study include hypertensive patient left ventricular lv hypertrophy confirm electrocardiographically echocardiographically investigate effect indapamide nicardipine propranolol chlorthalidone arterial blood pressure lv mass function sixty four patient men woman complete month study significant difference antihypertensive effect four medication find average decrease systolic diastolic blood pressure respectively four antihypertensive medication cause pronounced reduction lv mass propranolol group nicardipine group significant difference group patient receive diuretic predominant decrease observe lv mass lv mass index patient treat propranolol thickness lv wall interventricular septum reduce whereas reduction lv mass lv wall interventricular septum thickness find patient treat nicardipine significant correlation change lv mass variable blood pressure systolic diastolic function systolic function improve reversion lv hypertrophy group patient improvement observe index diastolic function early late lv fill velocity ratio improve significantly either clinically relevant side effect observed four antihypertensive monotherapies achieve comparable control hypertension reduction lv hypertrophy,Rakić D,2002,Croat Med J,,12476475,Rakić D; Rumboldt Z; Bagatin J; Polić S,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D002752: Chlorthalidone; D017523: Croatia; D004452: Echocardiography; D005260: Female; D006352: Heart Ventricles; D006801: Humans; D006973: Hypertension; D017379: Hypertrophy, Left Ventricular; D007190: Indapamide; D008297: Male; D008875: Middle Aged; D009529: Nicardipine; D009929: Organ Size; D011433: Propranolol; D011446: Prospective Studies; D016896: Treatment Outcome; D016277: Ventricular Function, Left",,,https://openalex.org/W236125467,165,22,1,1826,290,11,en,en
false,treatment hypertension volume vasoconstriction ace sleeve,control hypertension vascular patient clearly priority however patient often significant co morbidities may influence choice medication decision also may affect cost health plan directives wherever possible monotherapy attempt first although select circumstance combination therapy may appropriate main category drug use initial treatment hypertensive vascular disease diuretic beta adrenergic blocker calcium channel blocker angiotensin converting enzyme ace inhibitor angiotensin receptor blocker arb also less commonly use drug antihypertensive agent roughly equally effective produce good antihypertensive response case antihypertensive especially ace arb also may beneficial effect vascular metabolic system separate blood pressure lower effect suggest may beneficial even blood pressure well maintain agent report cover basic information require vascular surgeon become familiar various medication indication dosage side effect also provide guideline select relevant antihypertensive treatment regimen elderly patient arterial vascular disease,Stanley JC,2002,Semin Vasc Surg,https://doi.org/10.1053/svas.2002.36258,12478497,Stanley JC; Samson RH,article,D016428: Journal Article; D016454: Review,D000319: Adrenergic beta-Antagonists; D000804: Angiotensin II; D057911: Angiotensin Receptor Antagonists; D000806: Angiotensin-Converting Enzyme Inhibitors; D002121: Calcium Channel Blockers; D004232: Diuretics; D006801: Humans; D006973: Hypertension,,,https://openalex.org/W4246399561,81,13,1,1438,248,14,en,en
false,macrophage subpopulation gingival overgrowth induce nifedipine immunosuppressive medication,background immunomodulating effect immunosuppressive nifedipine medication associate druginduced gingival overgrowth aim study report evaluate presence macrophage subpopulation normal human gingiva gingival overgrowth induce nifedipine immunosuppressive medication method gingival sample take nifedipine medicated cardiac outpatient nifedipine group triple medicated organ transplant recipient also take nifedipine immunosuppression plus nifedipine group triple medicated organ transplant recipient immunosuppression group generally healthy individual control group cryostat section stain mabs inflammatory e reparative rm resident f macrophage use avidinbiotin enzyme complex method total number mab labeled cell determine connective tissue beneath sulcular epithelium connective tissue beneath oral epithelium middle connective tissue expression e determine keratinocytes oral epithelium statistic analysis undertaken use chi square test mann whitney u test independent sample test analysis variance analysis covariance result great number inflammatory e positive macrophage find medicate group count zone control group except connective tissue beneath sulcular epithelium immunosuppression group incidence specimen express e antigen throughout oral epithelium significantly high immunosuppression group control group nifedipine group number reparative rm positive macrophage significantly great immunosuppression group connective tissue beneath oral epithelium control group effect markedly associate degree inflammation number resident f positive macrophage low connective tissue beneath sulcular epithelium immunosuppression group high middle connective tissue nifedipine group control group conclusion result show nature drug induced gingival overgrowth differs somewhat immunosuppressive nifedipine medication j periodontol,Nurmenniemi PK,2002,J Periodontol,https://doi.org/10.1902/jop.2002.73.11.1323,12479637,Nurmenniemi PK; Pernu HE; Laukkanen P; Knuuttila ML,article,D016428: Journal Article,"D000328: Adult; D000368: Aged; D000704: Analysis of Variance; D015703: Antigens, CD; D015214: Antigens, Differentiation, Myelomonocytic; D002121: Calcium Channel Blockers; D016022: Case-Control Studies; D016009: Chi-Square Distribution; D005260: Female; D005881: Gingiva; D019214: Gingival Overgrowth; D006801: Humans; D007124: Immunoenzyme Techniques; D016130: Immunophenotyping; D007166: Immunosuppressive Agents; D039841: Leukocyte L1 Antigen Complex; D008264: Macrophages; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011956: Receptors, Cell Surface; D018709: Statistics, Nonparametric",,,https://openalex.org/W2112986841,103,11,1,2393,360,14,en,en
true,major outcome high risk hypertensive patient randomize angiotensin converting enzyme inhibitor calcium channel blocker v diuretic antihypertensive lipid lowering treatment prevent heart attack trial allhat,antihypertensive therapy well establish reduce hypertension related morbidity mortality optimal first step therapy unknown determine whether treatment calcium channel blocker angiotensin converting enzyme inhibitor lower incidence coronary heart disease chd cardiovascular disease cvd event vs treatment diuretic antihypertensive lipid lowering treatment prevent heart attack trial allhat randomize double blind active controlled clinical trial conduct february march total participant age year old hypertension least chd risk factor north american centers participants randomly assign receive chlorthalidone mg n amlodipine mg n lisinopril mg n plan follow approximately years primary outcome combine fatal chd nonfatal myocardial infarction analyze intent treat secondary outcome cause mortality stroke combine chd primary outcome coronary revascularization angina hospitalization combine cvd combine chd stroke treat angina without hospitalization heart failure hf peripheral arterial disease mean follow year primary outcome occur participant difference treatment compare chlorthalidone year rate relative risk rrs ci amlodipine year rate ci lisinopril year rate likewise cause mortality differ group five year systolic blood pressure significantly high amlodipine mm hg p lisinopril mm hg p group compare chlorthalidone year diastolic blood pressure significantly low amlodipine mm hg p amlodipine v chlorthalidone secondary outcome similar except high year rate hf amlodipine vs rr ci lisinopril v chlorthalidone lisinopril high year rate combined cvd vs rr ci stroke vs rr ci hf vs rr ci thiazide type diuretic superior prevent major form cvd less expensive prefer first step antihypertensive therapy,ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial,2002,JAMA,https://doi.org/10.1001/jama.288.23.2981,12479763,ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000368: Aged; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D002318: Cardiovascular Diseases; D002752: Chlorthalidone; D004232: Diuretics; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D017706: Lisinopril; D008297: Male; D008875: Middle Aged; D016016: Proportional Hazards Models; D012307: Risk Factors; D016896: Treatment Outcome,,,https://openalex.org/W2562329777,232,31,1,2556,493,9,en,en
false,dynamic kinetic disposition nisoldipine enantiomer hypertensive patient present type diabetes mellitus,objective nisoldipine n dihydropyridine calcium antagonist market racemic mixture use treatment hypertension present study investigate influence type diabetes mellitus dm enantioselective pharmacokinetic dynamic parameter n method seventeen hypertensive patient nine dm investigate cross study administration rac n coat core tablet mg day placebo day serial blood sample h collect th day h ambulatory blood pressure bp monitoring simultaneously evaluate n enantiomer plasma sample analyse use chiral high performance liquid chromatography combine gas chromatography mass spectrometry enantiomeric ratio differ one evaluate use wilcoxon test result report mean confidence interval lidocaine l test carry vivo marker cyp cyp activity result following difference observe n n enantiomer respectively patient present dm mean range c max ng ml versus ng ml auc ng ml h versus ng ml h cl f l h kg versus l h kg cl f value n low mann whitney test patient dm l h kg versus l h kg observation make n cl f reach l h kg l h kg non diabetic dm group respectively l test result high ratio p plasma l megx concentration min v l dm vs n significantly reduce systolic diastolic bp p wilcoxon test patient investigate relative placebo difference bp reduction observe diabetic non diabetic patient n significantly increase noradrenaline concentration plasma patient group data also demonstrate plasma concentration noradrenaline min n administration low p diabetic mean pmol ml non diabetic patient pmol ml conclusion present data permit u infer type diabetes mellitus alter kinetic disposition n eutomer n distomer presumably due low activity cyp although modify clinical effect bring reduction bp,Marques MP,2002,Eur J Clin Pharmacol,https://doi.org/10.1007/s00228-002-0528-4,12483453,Marques MP; Coelho EB; Dos Santos NA; Geleilete TJ; Lanchote VL,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000959: Antihypertensive Agents; D019540: Area Under Curve; D015415: Biomarkers; D001786: Blood Glucose; D001794: Blood Pressure; D018592: Cross-Over Studies; D019388: Cytochrome P-450 CYP1A2; D051544: Cytochrome P-450 CYP3A; D003577: Cytochrome P-450 Enzyme System; D003692: Delayed-Action Preparations; D003924: Diabetes Mellitus, Type 2; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008012: Lidocaine; D008297: Male; D008875: Middle Aged; D015737: Nisoldipine; D009638: Norepinephrine; D013237: Stereoisomerism",,,https://openalex.org/W2007149752,124,15,1,2660,577,16,en,en
false,strategy treatment noncompliant hypertensive hemodialysis patient,hypertensive hemodialysis patient noncompliant medication benefit pharmacologic advance treatment high blood pressure increase already high risk cardiovascular complication medical staff often become frustrate severe hypertension refuse take medicine home drink excessive fluid miss multiple dialysis session sign dialysis early addition address psychosocial financial educational substance abuse problem contribute noncompliance develop medication strategy serve least interim mean lower blood pressure antihypertensive agent long half lives renal failure lisinopril intrinsically long act transdermal clonidine amlodipine administer dialysis day unit personnel patient would take dose lisinopril amlodipine assure take least dialysis day thrice weekly clonidine patch replace weekly sixteen patient thus treat fail reliably self administer medication significant decline predialysis systolic pressure mm hg mm hg diastolic mm hg mm hg mean pressure mm hg mm hg improvement post dialysis bood pressure mean pressure decline mm hg mm hg many individual erratic blood pressure control intermittently miss dialysis hence unit administered medicine well continue fluid drug abuse patient uniformly excellent acceptance regimen even spontaneously request appreciable adverse effect summary noncompliance address entire medical team dialysis unit administration long acting medicine help many hypertensive dialysis patient would otherwise increase risk severe cardiovascular complication,Ross EA,2002,Int J Artif Organs,https://doi.org/10.1177/039139880202501104,12487393,Ross EA; Pittman TB; Koo LC,article,D003160: Comparative Study; D016428: Journal Article,"D000328: Adult; D000959: Antihypertensive Agents; D001294: Attitude to Health; D001795: Blood Pressure Determination; D005260: Female; D006801: Humans; D006973: Hypertension; D007676: Kidney Failure, Chronic; D008297: Male; D008875: Middle Aged; D010353: Patient Education as Topic; D011336: Probability; D011379: Prognosis; D012189: Retrospective Studies; D018570: Risk Assessment; D015996: Survival Rate; D016896: Treatment Outcome; D016312: Treatment Refusal",,,https://openalex.org/W126112069,77,9,1,2121,366,11,en,en
false,jellyfish envenom syndrome unknown toxic mechanism unproven therapy,medical journal australiavolume issue p bite sting jellyfish envenom syndrome unknown toxic mechanism unproven therapy paul bailey facem paul bailey facem phd scholar department biochemistry emergency medicine university western australia crawley wa search paper authormark little facem mphtm mark little facem mphtm emergency physician also tropical australian stinger research unit cairn qld department biochemistry emergency medicine university western australia crawley wa search paper authorgeorge jelinek md facem george jelinek md facem chairman department professor university western australia crawley wa department emergency medicine sir charles gairdner hospital nedlands wa search paper authorjacqueline wilce bsc phd jacqueline wilce bsc phd research fellow department biochemistry university western australia crawley wa search paper author paul bailey facem paul bailey facem phd scholar department biochemistry emergency medicine university western australia crawley wa search paper authormark little facem mphtm mark little facem mphtm emergency physician also tropical australian stinger research unit cairn qld department biochemistry emergency medicine university western australia crawley wa search paper authorgeorge jelinek md facem george jelinek md facem chairman department professor university western australia crawley wa department emergency medicine sir charles gairdner hospital nedlands wa search paper authorjacqueline wilce bsc phd jacqueline wilce bsc phd research fellow department biochemistry university western australia crawley wa search paper author first publish january http doi org j tb xcitations read full textaboutpdf toolsrequest permissionexport citationadd favoritestrack citation shareshare give accessshare full text accessshare full text accessplease review term condition use check box share full text version article read accept wiley online library term condition useshareable linkuse link share full text version article friend colleague learn copy url share linkshare onfacebooktwitterlinkedinredditwechat cite literature volume issue january pages relatedinformation,Bailey PM,2003,Med J Aust,https://doi.org/10.5694/j.1326-5377.2003.tb05040.x,12492389,Bailey PM; Little M; Jelinek GA; Wilce JA,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review",D000818: Animals; D000959: Antihypertensive Agents; D000997: Antivenins; D001315: Australia; D001733: Bites and Stings; D003064: Cnidarian Venoms; D037462: Cubozoa; D005392: First Aid; D006801: Humans; D011312: Pressure; D013577: Syndrome; D014700: Verapamil,,,https://openalex.org/W1247680957,79,10,1,2644,424,2,en,en
false,effect intracoronary nicorandil administration prevent reflow slow flow phenomenon rotational atherectomy,major limitation rotational atherectomy ra procedure occurrence reflow slow flow phenomenon optimal strategy still evolve recent clinical study demonstrate beneficial effect nicorandil adenosine triphosphate atp sensitive potassium channel opener reflow patient acute myocardial infarction purpose study evaluate effect nicorandil reflow slow flow phenomenon ra procedure sixty one patient undergo ra complex coronary lesion randomly divide group nicorandil cocktail n patient lesion ii verapamil cocktail n patient lesion group drug cocktail mixed pressurized saline infuse fr teflon sheath rotablator system ra procedure nicorandil group drug cocktail consist mg nicorandil mg nitroglycerin u heparin verapamil group drug cocktail consist mg verapamil mg nitroglycerin u heparin baseline procedure characteristic differ group ra perform successfully death q wave myocardial infarction emergency coronary artery bypass surgery occur patient reflow slow flow phenomenon observe lesion verapamil group lesion nicorandil group p untoward complication observe nicorandil infusion data indicate intracoronary continuous infusion nicorandil ra procedure easy safe prevent reflow slow flow phenomenon effectively infusion verapamil,Tsubokawa A,2002,Circ J,https://doi.org/10.1253/circj.66.1119,12499617,Tsubokawa A; Ueda K; Sakamoto H; Iwase T; Tamaki S,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D000787: Angina Pectoris; D017225: Atherectomy, Coronary; D017023: Coronary Angiography; D003326: Coronary Circulation; D023921: Coronary Stenosis; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D017202: Myocardial Ischemia; D020108: Nicorandil; D012008: Recurrence; D014665: Vasodilator Agents; D014700: Verapamil",,,https://openalex.org/W1966217345,124,13,1,1765,310,12,en,en
false,blood pressure response antihypertensive agent relate baseline blood pressure,prevalence white coat hypertension varies approximately per cent among mild hypertensive white coat hypertensive prescribe antihypertensive medication usually decrease clinic blood pressure bp little change hour blood pressure abpm objective study test hypothesis efficacy medication therapy hypertension identical grading severity baseline blood pressure author retrospectively analyse abpm data mild moderate hypertensive patient efficacy decrease blood pressure antihypertensive linear relation baseline blood pressure response antihypertensive agent white coat hypertension minimal significant effect still persist possibility hypotensive adverse event medication case overlook,Sermswan A,2002,J Med Assoc Thai,,12501904,Sermswan A; Uboldejpracharak Y; Suthichaiyakul T; Sukontasarn A; Buranakitcharoen P,article,D016428: Journal Article,D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D020748: Mibefradil; D008875: Middle Aged; D012189: Retrospective Studies; D012720: Severity of Illness Index; D016896: Treatment Outcome,,,https://openalex.org/W2422527436,86,12,1,876,137,6,en,en
false,citalopram induced severe hyponatraemia coma seizure,numerous case report hyponatraemia follow increase use selective serotonin uptake inhibitor ssri adverse effect rarely observe relation citalopram report case severe hyponatraemia associate deep coma seizure atrial fibrillation muscle damage year old woman two dos citalopram review case previously publish literature case spontaneously report australian drug reaction advisory committee adrac data present suggest citalopram well ssri may cause hyponatraemia secondary syndrome inappropriate secretion antidiuretic hormone siadh majority symptomatic case occur elderly patient old year woman polymedication concomitant use another psychotropic drug thiazide diuretic may precipitate augment development hyponatraemia siadh case hyponatraemia associate citalopram detect first month treatment high level suspicion close careful monitoring serum sodium concentration particularly elderly patient especially first month therapy citalopram may reduce incidence serious likely rare adverse effect,Fisher A,2002,Adverse Drug React Toxicol Rev,https://doi.org/10.1007/bf03256195,12503252,Fisher A; Davis M; Croft-Baker J; Purcell P; McLean A,article,D002363: Case Reports; D016428: Journal Article; D016454: Review,"D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D015283: Citalopram; D003128: Coma; D005260: Female; D006801: Humans; D007010: Hyponatremia; D008297: Male; D008875: Middle Aged; D012640: Seizures",,,https://openalex.org/W167639536,61,7,1,1319,217,7,en,en
false,adverse drug event associate hospital admission,increase knowledge base frequency causality avoidability adverse drug event ade cause admission internal medicine occur hospitalization prospective study perform period day epidemiologic data e g age gender medical history drug utilization adverse drug reaction patient hospitalize period collect pharmacy student total patient men woman include study patient mean age sd year mean length stay day renal hepatic insufficiency previous history drug intolerance observe hospitalized patient respectively thirty eight ade occur patient case ade identify reason admission case occur hospitalization case present admission cause admission frequent ade involve neurologic renal hematologic system among ade consider avoidable associate therapeutic error inappropriate administration drug drug interaction dosage error drug stop despite onset ade patient ade stay longer hospital take drug hospital stay p ade observe study avoidable risk benefit ratio administer drug could improve good knowledge patient medical history risk factor ade,Peyriere H,2003,Ann Pharmacother,https://doi.org/10.1345/aph.1c126,12503925,Peyriere H; Cassan S; Floutard E; Riviere S; Blayac JP; Hillaire-Buys D; Le Quellec A; Hansel S,article,D003160: Comparative Study; D016428: Journal Article,"D000328: Adult; D016907: Adverse Drug Reaction Reporting Systems; D000368: Aged; D000369: Aged, 80 and over; D004342: Drug Hypersensitivity; D064420: Drug-Related Side Effects and Adverse Reactions; D005260: Female; D006760: Hospitalization; D006801: Humans; D007902: Length of Stay; D008297: Male; D008508: Medication Errors; D008875: Middle Aged; D010607: Pharmacy Service, Hospital; D011446: Prospective Studies; D012307: Risk Factors",,,https://openalex.org/W2135840157,54,7,1,1651,316,9,en,en
false,calcium channel blocker verapamil cancer risk,rotterdam study report issue european journal cancer prospective population based cohort investigation elderly patient age year followed provide additional useful information use calcium channel blocker ccb risk cancer elderly beiderbeck noll ab sturkenboom mcjm van der linden pd et al verapamil associate increase risk cancer elderly eur j cancer press google scholar incident cancer observe year follow observe among ccb user correspond crude relative risk rr multivariate one confidence interval ci none individual cancer risk significantly relate ccb use skin cancer show significant excess crude rr one multivariate model use since incidence skin cancer largely influence diagnostic attention accuracy levi f franceschi te v c randimbison l la vecchia c trend skin cancer canton vaud br j cancer crossref pubmed scopus google scholar may great subject long term pharmacological treatment general population excess skin cancer incidence probably least part spurious may account observed excess risk cancer incidence calculation rr urinary tract cancer non significant include kidney cancer associate hypertension mclaughlin j k chow w h mandel j et al international renal cell cancer study viii role diuretic anti hypertensive medication hypertension int j cancer crossref pubmed scopus google scholar tavani la vecchia c epidemiology renal cell carcinoma j nephrol google scholar mclaughlin j k lipworth l epidemiologic aspect renal cell cancer semin oncol pubmed google scholar hence underlie condition lead treatment ccb,La Vecchia C,2003,Eur J Cancer,https://doi.org/10.1016/s0959-8049(02)00532-4,12504652,La Vecchia C; Bosetti C,article,"D016420: Comment; D016421: Editorial; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D002121: Calcium Channel Blockers; D006801: Humans; D009369: Neoplasms; D011446: Prospective Studies; D012307: Risk Factors; D014700: Verapamil,,,https://openalex.org/W2103763991,51,8,1,2193,420,25,en,en
true,verapamil associate increase risk cancer elderly rotterdam study,association use calcium channel blocker ccb cancer receive ample attention still controversial study test hypothesis observed association ccb cancer early study could explain residual confounding misclassification exposure use cross sectional data drug use data rotterdam study prospective population based cohort study municipal area ommoord use study population consist cohort participant age year old follow baseline interview period occurrence incident cancer data drug use gather baseline seven community pharmacy serve ommoord region study period january january incident cancer event gather nationwide registry hospitalisation data specialised cancer centre rotterdam region perform three analysis first follow method adjust risk factor early study second analysis include risk factor univariately associate cancer rotterdam study third analysis include exposure ccbs time varying co variates adjust potential confounders relative risk rr cancer associate ccb confidence interval ci first analysis lower ci upon adjustment different co variates second analysis however verapamil significantly associate cancer rrs ci respectively whereas association find ccb study e diltiazem nifedipine significantly increase risk cancer find intermediate daily dos verapamil diltiazem intake antihypertensive beta blocking agent diuretic ace inhibitors associate cancer third analysis exposure ccb time varying co variates risk increase non significant use year less ci use cumulative period year ci however model hazard ratio statistically significantly increase verapamil diltiazem nifedipine basis analysis find increase cancer user diltiazem nifedipine user antihypertensive line early study however find increase risk cancer user verapamil variance conclusion several study think early conclude ccb associate cancer,Beiderbeck-Noll AB,2003,Eur J Cancer,https://doi.org/10.1016/s0959-8049(02)00157-0,12504665,Beiderbeck-Noll AB; Sturkenboom MC; van der Linden PD; Herings RM; Hofman A; Coebergh JW; Leufkens HG; Stricker BH,article,D016428: Journal Article,D000368: Aged; D002121: Calcium Channel Blockers; D002318: Cardiovascular Diseases; D015331: Cohort Studies; D003430: Cross-Sectional Studies; D005260: Female; D006801: Humans; D015994: Incidence; D008297: Male; D008875: Middle Aged; D015999: Multivariate Analysis; D009369: Neoplasms; D009426: Netherlands; D011446: Prospective Studies; D012307: Risk Factors; D014700: Verapamil,,,https://openalex.org/W2164355098,92,16,1,2868,527,20,en,en
false,use sildenafil patient erectile dysfunction relation diabetes mellitus study patient,erectile dysfunction ed seriously impair quality life patient diabetes mellitus dm prone ed due various factor include vasculopathy neuropathy sex hormone abnormality retrospective study involve patient take sildenafil patient dm significantly comorbidities like hypertension ischaemic heart disease also likely medication may affect erectile function include various antihypertensive drug patient dm report success sildenafil compare patient without dm significant number patient dm require high dose sildenafil compare without dm,Ng KK,2002,Singapore Med J,,12507022,Ng KK; Lim HC; Ng FC; Li MK; Consigliere D; Chia SJ; Moorthy P; Munisamy M,article,D016428: Journal Article; D016448: Multicenter Study,"D048909: Diabetes Complications; D003920: Diabetes Mellitus; D006801: Humans; D018783: Impotence, Vasculogenic; D008297: Male; D008875: Middle Aged; D010726: Phosphodiesterase Inhibitors; D010879: Piperazines; D011687: Purines; D012189: Retrospective Studies; D000068677: Sildenafil Citrate; D012846: Singapore; D013450: Sulfones; D014665: Vasodilator Agents",,,https://openalex.org/W2184885059,120,21,1,723,123,7,en,en
false,doxazosin amlodipine decrease insulin resistance patient chronic renal failure prospective randomized controlled study,insulin resistance ir chronic renal failure crf well known randomized controlled study aim compare effect doxazosin amlodipine ir patient crf fifteen patient crf male female mean age year control male female mean age year include patient control family history diabetes mellitus homeostasis model assessment homa calculate marker ir patient group randomly doxazosin n mg day amlodipine n mg day arm baseline biochemical analysis fast serum glucose bun creatinine uric acid cholesterol cholesterol subgroup parameter relate insulin metabolism insulin c peptide homa similar amlodipine doxazosin group difference age gender body mass index among study group follow time week patient crf high homa vs p fast insulin vs iu l p serum triglyceride level vs mg dl p compare control serum hdl cholesterol level significantly low patient crf control vs mg dl p homa significantly decrease doxazosin vs p however difference find amlodipine also fast insulin level decrease week doxazosin therapy vs iu l p change see amlodipine lipid parameter significantly change study period group adverse effect require drug discontinuation observe week period study group conclusion doxazosin decrease ir patient crf whereas amlodipine effect may advantage treatment hypertension group patient prevent long term complication ir,Yildiz A,2002,Clin Nephrol,https://doi.org/10.5414/cnp58405,12508961,Yildiz A; Hursit M; Celik AV; Kayacan SM; Yazici H; Akkaya V; Gürol AO; Karsidag K,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D017311: Amlodipine; D000959: Antihypertensive Agents; D017292: Doxazosin; D005260: Female; D006706: Homeostasis; D006801: Humans; D007333: Insulin Resistance; D007676: Kidney Failure, Chronic; D008297: Male; D008875: Middle Aged; D010865: Pilot Projects; D011446: Prospective Studies; D013997: Time Factors",,,https://openalex.org/W2061622609,141,20,1,2050,410,17,en,en
false,effect candesartan amlodipine renal function electrolyte renal allograft recipient,,Kisters K,2002,Clin Nephrol,https://doi.org/10.5414/cnp58461,12508971,Kisters K; Tokmak F; Kosch M; Barenbrock M; Hausberg M,article,D016422: Letter; D016420: Comment,D017311: Amlodipine; D000959: Antihypertensive Agents; D001562: Benzimidazoles; D001713: Biphenyl Compounds; D006801: Humans; D007668: Kidney; D016030: Kidney Transplantation; D013777: Tetrazoles,,,https://openalex.org/W1964128877,102,14,1,0,0,0,en,
false,efficacy safety daily graded release diltiazem formulation essential hypertension,efficacy safety chronotherapeutic graded release diltiazem hcl extended release grd mg dose administer daily bedtime pm evaluate week randomized double blind comparison placebo grd mg administer daily patient moderate severe essential hypertension assess change baseline end point trough diastolic blood pressure dbp pm pm mean dbp noon grd mg pm grd mg measure ambulatory bp monitoring abpm bedtime dos grd show dose related mean reduction trough dbp significant grd dos mg high bedtime grd mg associate significantly great reduction mean dbp noon compare morning grd mg least square mean treatment difference mm hg p similar dose related significant reduction systolic bp sbp heart rate hr obtain incidence adverse event aes grd group less obtain placebo group mg group show incidence aes similar observe mg group grd dose dependently significantly reduce bp hr h interval daily bedtime dosing great reduction obtain noon circadian bp high compare morning administration dose mg grd safe well tolerate offer far therapeutic option patient severe hypertension require additional bp control,Glasser SP,2003,Am J Hypertens,https://doi.org/10.1016/s0895-7061(02)03153-9,12517683,Glasser SP; Neutel JM; Gana TJ; Albert KS,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000328: Adult; D000959: Antihypertensive Agents; D001794: Blood Pressure; D003692: Delayed-Action Preparations; D004110: Diltiazem; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D016896: Treatment Outcome,,,https://openalex.org/W2045552946,98,13,1,1685,318,7,en,en
false,differential effect daily antihypertensive drug blood pressure leave ventricular mass sympathetic activity nifedipine gits versus felodipine er versus enalapril,recent meta analyses suggest daily dihydropyridines angiotensin converting enzyme inhibitor cause similar decrease left ventricular lv mass comparable decrease blood pressure bp however dihydropyridines felodipine extended release er still increase sympathetic activity may therefore less effective decrease lv mass evaluate effect long term antihypertensive treatment nifedipine gastrointestinal therapeutic system git felodipine er compare enalapril lv mass relative extent bp control assess h ambulatory bp monitoring sympathetic activity assess plasma catecholamine concentration enalapril start mg day felodipine er mg day nifedipine gits mg day daily dos increase mg day mg day mg day respectively office bp remain mmhg great end dosing interval evaluable echocardiogram obtain patient end study week treatment h ambulatory bp monitoring nifedipine gits cause consistent decrease bp throughout h dose interval whereas felodipine er cause marked fall bp day enalapril effect diminish night disappear morning felodipine er significantly increase supine stand plasma noradrenaline similarly six week treatment bp responder decrease systolic bp mmhg great enalapril nifedipine gits cause clear decrease lv mass g whereas felodipine er less effective decrease g p versus enalapril daily dihydropyridines regard one homogeneous class compare felodipine er nifedipine gits exhibit good profile regard h bp control sympathetic activation regression lv mass,Leenen FH,2002,Can J Cardiol,,12518180,Leenen FH; Myers MG; Joyner CD; Toal CB,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000959: Antihypertensive Agents; D015415: Biomarkers; D001794: Blood Pressure; D003627: Data Interpretation, Statistical; D004656: Enalapril; D015736: Felodipine; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D017379: Hypertrophy, Left Ventricular; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D009638: Norepinephrine; D015990: Placebo Effect; D016037: Single-Blind Method",,,https://openalex.org/W49780618,179,23,1,1984,337,6,en,en
false,drug treatment hypertension,hypertension one important preventable cause premature death worldwide benefit antihypertensive drug confirm large evidence base clinical trial medicine many class drug available treatment debate rag whether benefit treatment purely function quality blood pressure control whether type drug use might also powerful determinant outcome key question difference cost old drug thiazide blocker new drug angiotensin convert enzyme ace inhibitor calcium channel blocker substantial meta analysis trial treatment hypertension new drug find ace inhibitor calcium channel blocker likely reduce cardiovascular morbidity mortality order magnitude blocker thiazides analysis insufficient statistical power detect cause specific outcome regard specific drug recently antihypertensive lipid lowering prevent heart attack trial allhat large ever randomise trial antihypertensive treatment reported results design determine whether choice first line treatment hypertension influence cardiovascular outcome importantly trial sufficiently large examine cause specific outcome first hypertension study sufficient power examine combined incidence fatal coronary heart disease non fatal myocardial infarction primary end point allhat randomised double blind control clinical trial conduct centre north america,Williams B,2003,BMJ,https://doi.org/10.1136/bmj.326.7380.61,12521949,Williams B,article,D016420: Comment; D016421: Editorial,"D000368: Aged; D000959: Antihypertensive Agents; D001581: Benzothiadiazines; D004232: Diuretics; D004359: Drug Therapy, Combination; D006801: Humans; D006973: Hypertension; D008875: Middle Aged; D016032: Randomized Controlled Trials as Topic; D049993: Sodium Chloride Symporter Inhibitors",,,https://openalex.org/W1994803148,30,4,1,1754,285,8,en,en
false,angiotensin receptor blocker antihypertensive cardiovascular round medication year,angiotensin receptor blocker part antihypertensive treatment armamentarium since mid period number agent increase greatly number indication drug test randomize controlled clinical trial begin efficacious well tolerated antihypertensive angiotensin receptor blocker show benefit patient diabetes heart failure attributable reduce blood pressure support recently conclude trial expand treatment area agent widen interest applicability across entire cardiovascular continuum number large scale study set report within next year far determine effect angiotensin receptor blocker range cardiovascular indication beyond hypertension,Maggioni AP,2002,Blood Press,https://doi.org/10.1080/080370502321095285,12523675,Maggioni AP; Latini R,article,D016428: Journal Article; D016454: Review,"D057911: Angiotensin Receptor Antagonists; D000806: Angiotensin-Converting Enzyme Inhibitors; D000818: Animals; D000959: Antihypertensive Agents; D002317: Cardiovascular Agents; D002318: Cardiovascular Diseases; D003924: Diabetes Mellitus, Type 2; D006333: Heart Failure; D006801: Humans; D009203: Myocardial Infarction; D012084: Renin-Angiotensin System",,,https://openalex.org/W2086389738,110,14,1,907,136,5,en,en
false,comparison home office blood pressure treated hypertensive nordic diltiazem nordil study,aim nordic diltiazem nordil study compare cardiovascular morbidity mortality calcium antagonist based treatment diltiazem conventional diuretic beta blocker based treatment essential hypertension objective present sub study compare self measured home blood pressure office blood pressure time point study patient blood pressure treat level investigator conceive blood pressure target nordil study prospective randomize open endpoint blinded enrol patient age year health center norway sweden diastolic blood pressure bp mmhg present sub study group n small fairly representative entire study population regard baseline characteristic systolic mmhg p diastolic blood pressure mmhg p significantly low home office pearson correlation coefficient respective office home reading statistically highly significant p moderate strength range r heart rate r r diastolic systolic blood pressure respectively altman plot also give statistical support inconsistency two method measurement pearson correlation coefficient afternoon morning measurement show strong relationship r values blood pressure heart rate altman plot also suggest excellent consistency afternoon morning measurement thus motivate trained hypertensive patient perform home recording blood pressure heart rate precision however difference recording home investigator office suggest degree white coat effect treated hypertensive,Kjeldsen SE,2002,Blood Press,https://doi.org/10.1080/080370502321095348,12523681,Kjeldsen SE; Hedner T; Syvertsen JO; Lund-Johansen P; Hansson L; NORDIL Group. Nordic Diltiazem,article,D003160: Comparative Study; D016428: Journal Article,D000368: Aged; D000959: Antihypertensive Agents; D001795: Blood Pressure Determination; D002986: Clinical Trials as Topic; D004110: Diltiazem; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009664: Norway; D015203: Reproducibility of Results; D013548: Sweden; D013997: Time Factors,,,https://openalex.org/W2090427164,108,18,1,1950,322,11,en,en
false,treatment sporadic hemiplegic migraine calcium channel blocker verapamil,gene mutation within p q type neuronal calcium channel familial hemiplegic migraine fhm suggest therapeutic role calcium channel blockade author previously report abortive therapy fhm iv verapamil author describe four case sporadic hemiplegic migraine shm responsive verapamil administer either orally iv finding indicate verapamil effective therapy shm fhm,Yu W,2003,Neurology,10.1212/01.wnl.0000042051.16284.70,12525732,Yu W; Horowitz SH,article,D002363: Case Reports; D016428: Journal Article,"D000086: Acetazolamide; D000328: Adult; D002121: Calcium Channel Blockers; D005260: Female; D005500: Follow-Up Studies; D006429: Hemiplegia; D006801: Humans; D007024: Hypotension, Orthostatic; D020325: Migraine with Aura; D016896: Treatment Outcome; D014700: Verapamil",,,,81,10,1,448,74,4,en,en
false,antipsychotic qt prolongation,objective evaluate literature relate cardiac qt prolongation use antipsychotic drug method literature search embase medline psychlit perform december reference section retrieved paper scrutinize relevant report result cardiac qtc interval difficult measure precisely accurately appear useful predictor risk dysrhythmia specifically torsade de pointes sudden death less clear drug induced qtc prolongation give rise similar risk data emerge link antipsychotic use increase cardiac mortality many antipsychotic clearly associate qtc prolongation methodological consideration arguably preclude assume antipsychotic free risk qtc prolongation dysrhythmia conclusion available data allow assessment relative absolute risk dysrhythmia sudden death engender antipsychotic caution advise risk dysrhythmia probably reduce careful prescribing antipsychotic low dos simple drug regimen avoid metabolic interaction electrocardiographic monitoring may also help reduce risk review specialist cardiologist may necessary,Taylor DM,2003,Acta Psychiatr Scand,https://doi.org/10.1034/j.1600-0447.2003.02078.x,12534433,Taylor DM,article,D016428: Journal Article; D016454: Review,"D014150: Antipsychotic Agents; D001145: Arrhythmias, Cardiac; D016757: Death, Sudden, Cardiac; D006801: Humans; D008133: Long QT Syndrome; D015203: Reproducibility of Results; D012307: Risk Factors",,,https://openalex.org/W2007239342,34,4,1,1287,201,9,en,en
false,relieve migraine pain sorting option,although triptans major advance treatment migraine optimal approach acute treatment involve combination lifestyle modification nonpharmacologic symptom relief drug therapy,Mannix LK,2003,Cleve Clin J Med,https://doi.org/10.3949/ccjm.70.1.8,12549721,Mannix LK,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review","D018712: Analgesics, Non-Narcotic; D003937: Diagnosis, Differential; D004878: Ergotamine; D020773: Headache Disorders; D006801: Humans; D008881: Migraine Disorders; D004366: Nonprescription Drugs; D010353: Patient Education as Topic; D012017: Referral and Consultation; D017366: Serotonin Receptor Agonists",,,https://openalex.org/W1987183263,53,9,1,210,33,1,en,en
false,effect nifedipine cerivastatin coronary endothelial function patient coronary artery disease,endothelial dysfunction important feature atherosclerosis inhibition hmg coa pathway calcium channel improve endothelial function experimentally forearm circulation thus investigate effect statin calcium antagonist coronary endothelial function patient coronary artery disease cad patient undergo percutaneous coronary intervention center acetylcholine mol l infuse coronary segment without angiographically significant cad change coronary diameter measure quantitative angiography endothelium independent response assess intracoronary adenosine mg ml nitroglycerin microg thereafter patient randomize double blind manner placebo cerivastatin mg nifedipine mg combination study repeat month constricted segment nifedipine cerivastatin reduced vasoconstriction acetylcholine versus placebo p patient take ace inhibitor show small improvement placebo group nifedipine still effect p versus placebo analysis evaluable coronary segment reveal reduction acetylcholine induced vasoconstriction patient receive nifedipine cerivastatin p versus placebo cerivastatin lower ldl cholesterol p encore trial demonstrate multicenter study coronary endothelial function feasible month treatment nifedipine improve coronary endothelial function constricted segment combination nifedipine cerivastatin tend improve endothelial function however reached significance analysis coronary segment,ENCORE Investigators,2003,Circulation,https://doi.org/10.1161/01.cir.0000046488.52939.bf,12551866,ENCORE Investigators,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000109: Acetylcholine; D000328: Adult; D002121: Calcium Channel Blockers; D002784: Cholesterol; D003324: Coronary Artery Disease; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004730: Endothelium, Vascular; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D019161: Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008297: Male; D008875: Middle Aged; D009206: Myocardium; D009543: Nifedipine; D011725: Pyridines; D014661: Vasoconstriction",,,https://openalex.org/W2417878681,111,15,1,1847,310,13,en,en
false,allhat report case information misinformation,announcement result antihypertensive lipid lowering treatment prevent heart attack trial allhat literally front page news large clinical outcome trial hypertension compare diuretic chlorthalidone new agent angiotensin converting enzyme ace inhibitor lisinopril calcium channel blocker ccb amlodipine conclude diuretic superior drug prevent major cardiovascular event allhat author point thiazide like diuretic like chlorthalidone inexpensive double advantage cheap well good drug class right moment publication though expert hypertension surprise result appear conflict data previous carefully conduct clinical trial become possible digest lengthy detail allhat report serious question arise accuracy original claim also propriety announce flamboyant fashion u advocate value diuretic either single agent combination drug feel reassure continue key role hypertension management time important take close look allhat data evaluate validity claim conclusion publish formal report mention accompany press release beginning chief focus study intend coronary event much hat title allhat stand heart attack trial result study show formal primary end point fatal coronary heart disease nonfatal myocardial infarction meaningful difference among drug study event rate chlorthalidone fractionally low point estimate amlodipine lisinopril despite fact systolic blood pressure well control latter two group diuretic group almost unprecedented departure scientific probity author allhat report omit apparently inconvenient fact conclusion noteworthy even new york time initial front page coverage allhat proclaim superiority diuretic felt compel publish formal correction four day later acknowledge primary end point study fact similar among three drug main basis claim chlorthalidone good two drug depend secondary end point notably stroke rate diuretic claim low lisinopril heart failure claim reduce compare lisinopril amlodipine close scrutiny data support claim raise doubt reveal explore far however important look study design issue affect patient management blood pressure control since goal allhat compare effect different antihypertensive agent clinical end point critical achieve equal blood pressure effect three treatment group ensure outcomes benefit three drug class could validly compare intention reinforce quite clearly publication allhat study leader year allhat result announced difference systolic blood pressure mm hg actually slightly high weight patient years treatment exposure favor chlorthalidone lisinopril trivial instead cloud interpretation many allhat clinical outcome recent comprehensive study relationship blood pressure clinical event base observation one million person indicate blood pressure difference closely similar observe allhat could account powerful effect stroke coronary mortality rates reason blood pressure problem allhat easy explain study originally set compare outcomes effect diuretic ccb ace inhibitor blocker discontinue trial discuss far research protocol prohibit use agent class additive treatment require patient whose blood pressure respond adequately primary drug beta blocker agent commonly choose purpose well agent affect adrenergic mechanism main drug could add situation clearly help chlorthalidone addition blocker diuretic provide logical effective blood pressure lowering combination even patient assign amlodipine addition blocker useful lisinopril group add blocker clearly less helpful lowdose diuretic ccb black patient neither ace inhibitor blocker drug choice blood pressure control cause even great shortfall blood pressure control discrepancy shrug accidental unintended result study predictable time study organizer decide attempt multiple comparison single trial rather direct clinically relevant approach separate head head comparison decision may largely drive consideration cost logistics obviously also contrive prevent equal blood pressure effect treatment group essence benefit chlorthalidone put lisinopril disadvantage stroke perhaps feared outcome hypertension compare diuretic stroke event rate treatment amlodipine actually low although advantage ccb statistically significant observe across almost subgroup diverse population include allhat hand chlorthalidone reduce stroke event rate compare ace inhibitor lisinopril herein lie interesting contentious issue allhat start stroke event rate virtually identical diuretic ace inhibitor nonblack patient mean entire overall difference chlorthalidone lisinopril could account dramatic great event rate black patient randomize lisinopril two explanation result african american patient first due treatment selection problem discuss earlier discrepancy mm hg systolic blood pressure favor chlorthalidone difference could explain much even stroke excess high risk patients second fact majority patient require additional therapy finish combination ace inhibitor blocker thus get two drug overlap neurohormonal action might provide additive target organ benefit might expect drug complementary property combine overall claim chlorthalidone superiority two drug prevent clinical end point allhat base predominantly difficult diagnose secondary end point heart failure cardiovascular expert finding come surprise particularly claimed superiority ace inhibitor lisinopril base copious clinical trial evidence well known action circulation regard primary treatment heart failure would expect highly effective prevent condition important question address allhat first clinical trial compare effect heart failure diuretic based treatment treatment base ace inhibitor ccbs hypertensive patient meta analysis carry blood pressure lower treatment trialists collaboration strong authority base prospectively designate clinical trial compare heart failure rate patient treat ace inhibitor treat conventional therapy diuretic blocker total patient group investigator find low event rate ace inhibitor based treatment although difference significant go clearly opposite direction report allhat similar comparison ccbs conventional therapy patient group heart failure event rate time find low diuretic based group though reach statistical significance moreover favor diuretic based treatment point estimate difference substantially low report allhat unexpected difference event rate previous study allhat could possibly explain blood pressure problem allhat also worth consider accuracy diagnosis heart failure difficult diagnosis make even experienced cardiologist participate formal heart failure trial let alone study like allhat conduct large extent community based setting potentially important problem diagnosis heart failure allhat relate mask effect diuretic treatment major fluid dependent clinical sign rale peripheral edema symptom like dyspnea reason heart failure hypertensive patient receive diuretic go unrecognized considerable period allhat majority patient enter study already receive diuretic individual unsuspected heart failure randomize ace inhibitor ccb would risk rapidly lose masking effect previous diuretic manifest heart failure early trial hand patient hidden heart failure randomize powerful diuretic chlorthalidone fluid dependent clinical sign symptom might remain suppressed fact examination kaplan meier curve heart failure event rate chlorthalidone lisinopril show much separation effect take place early stage study situation compare chlorthalidone amlodipine clear mask effect diuretic might play substantial role different event rate two treatment moreover one common side effect ccb peripheral edema relate fluid retention misleadingly suggest appearance heart failure could add possibility misdiagnosis allhat peripheral edema regard key physical finding heart failure rigorous confirmation clinical event carry small sampling patient one final point note heart failure condition high case fatality rate substantial benefit claim chlorthalidone prevent heart failure mention cardiovascular end point result clear trend toward low mortality patient treat diuretic discussed later definitely case view question uncertainty heart failure seem rather soft uncertain secondary end point upon base major justification chlorthalidone overall superiority claim allhat one interesting outcome allhat comparison end point diuretic agent major difference event rate diabetic nondiabetic patient data show specific benefit drug interrupt renin angiotensin system patient diabetic nephropathy expert start recommend drug ace inhibitor use diabetic patient allhat however appear much advantage lisinopril chlorthalidone diabetic compare nondiabetic patient suggest thiazide agent monotherapy could acceptable ace inhibitor monotherapy high risk patient however absence detailed renal data allhat certain apply kidney protection possible though blood pressure difference lisinopril chlorthalidone allhat could influence cardiovascular outcome chlorthalidone favor particularly outcome blood pressure sensitive diabetic patients also forget strong cardiovascular renal benefit diabetic patient occur blocker reninangiotensin system combine diuretic reason despite reassurance allhat physician generally continue employ combination approach diabetic patient hypertension would expect blood glucose concentration rise diuretic either two agent nondiabetic patient enter study year incidence new onset diabetes chlorthalidone group represent increase relative risk compare amlodipine year rate increase relative risk compare lisinopril year incidence difference significant increase new onset diabetes diuretic group translate increased cardiovascular event relatively short period observation follow diagnosis finding prompt recommendation patient risk develop diabetes treat thiazide alone rather regimen base drug interrupt renin angiotensin system mortality definite well important secondary end point allhat yet receive surprisingly little emphasis allhat report press release compare chlorthalidone cause mortality identical lisinopril low amlodipine nonsignificant nonblack patient mortality low lisinopril amlodipine mortality difference favor ccb especially ace inhibitor likely would great blood pressure discrepancy allhat pivotal issue speak directly principal conclusion state allhat report seem inconsistent perhaps almost absurd claim cardiovascular outcome superiority chlorthalidone real meaning drug display life saving attributes effect mortality actually head wrong direction allhat result publication one long study report ever publish also detailed complex take time fully define true meaning data since study final form compare effect three antihypertensive agent may helpful look briefly impact allhat accord allhat author study demonstrate thiazide diuretic superior ace inhibitor ccb cardiovascular protection reason already detail conclusion debatable best even nothing allhat hurt chlorthalidone role integral part hypertension therapy agent strongly consider first step therapy elderly particularly black patient allhat experience also show concern use thiazide diuretic diabetic patient may largely unfounded lisinopril fully equal chlorthalidone primary end point coronary event key secondary end point mortality despite deficiency study design put ace inhibitor blood pressure disadvantage black patient seem well lisinopril nonblack patient although likely use agent combine appropriately drug class diuretic ccbs could also considerable value prevent renal cardiovascular event african american apart controversial heart failure finding advocate ace inhibitor could still argue allhat able disprove notion ace inhibitor use optimal fashion might first line therapy choice many hypertensive patient particularly nonblacks amlodipine perform well allhat heart failure finding need clarification notable amlodipine equal chlorthalidone primary coronary end point actually appear small advantage albeit significant mortality stroke prevention although present allhat report relative cost drug somehow become part publish conclusion doubt thiazide diuretic relatively inexpensive least far cost acquisition concern antihypertensive agent many ace inhibitor include lisinopril well long acting dihydropyridine ccbs also generic well price hypertension aggressive market place several newer brand drug price competitively allow physician reasonable flexibility choose treatment base therapeutic need importantly recognize effective blood pressure control hypertensive patient call logical drug combination typically include drug type examine allhat well class national heart lung blood institute nhlbi responsible organize conduct allhat study write report conclusion since nhlbi also organize hypertension guideline committee forthcoming joint national committee prevention detection evaluation treatment high blood pressure jnc vii appoint member little doubt agenda express allhat report nhlbis press release affect recommendation expert hypertension concern provide best possible treatment diverse hypertension population united state hope fervently committee thoughtfully take account full array available clinical trial data include responsible interpretation allhat write report,Weber MA,2003,J Clin Hypertens (Greenwich),https://doi.org/10.1111/j.1524-6175.2003.02287.x,12556647,Weber MA,article,D016428: Journal Article,"D017311: Amlodipine; D000959: Antihypertensive Agents; D002752: Chlorthalidone; D004359: Drug Therapy, Combination; D006801: Humans; D006973: Hypertension; D000960: Hypolipidemic Agents; D017706: Lisinopril; D009203: Myocardial Infarction; D044469: Racial Groups; D016032: Randomized Controlled Trials as Topic; D012107: Research Design; D020521: Stroke; D016896: Treatment Outcome",,,https://openalex.org/W2015525328,59,10,1,19240,3262,96,en,en
false,amlodipine reduces blood pressure hadache fquency cocaine dependent outpatient,blood pressure headache frequency evaluate normotensive male female cocaine dependent patient n participate placebo controlled double blind trial amlodipine treatment cocaine dependence amlodipine produce significant reduction systolic p diastolic p blood pressure without produce dizziness faintness placebo subject three time frequency headache compare amlodipine treated subject p high frequency headache report cocaine dependent individual significantly reduce amlodipine may reflect improved cerebrovascular tone,Malcolm R,2002,J Psychoactive Drugs,https://doi.org/10.1080/02791072.2002.10399983,12562110,Malcolm R; Liao J; Michel M; Cochran K; Pye W; Yeager D; Halushka PV,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D017311: Amlodipine; D001794: Blood Pressure; D016009: Chi-Square Distribution; D019970: Cocaine-Related Disorders; D004311: Double-Blind Method; D005260: Female; D006261: Headache; D006801: Humans; D008297: Male; D008875: Middle Aged; D010045: Outpatients; D016012: Poisson Distribution,,,https://openalex.org/W2005206085,86,10,1,664,97,4,en,en
false,comparison effect nisoldipine extended release amlodipine patient systemic hypertension chronic stable angina pectoris,efficacy safety nisoldipine extended release er amlodipine compare week multicenter randomize double blind double dummy parallel group titration effect trial patient stage systemic hypertension mm hg diastolic blood pressure bp chronic stable angina pectoris week placebo run period patient n randomly assign active treatment either nisoldipine er mg amlodipine mg daily titrate necessary week achieve diastolic bp mm hg week mean reduction systolic diastolic bp baseline mm hg nisoldipine er mm hg amlodipine p ns p n drug result similar bp responder rate diastolic bp mm hg patient receive nisoldipine er patient amlodipine p n anti ischemic responder rate increase exercise time respectively p n increase exercise time second patient respectively p n also week active therapy similar mean increase total exercise duration second nisoldipine er group second amlodipine group p n neither drug increase heart rate decreased frequency anginal episode adverse event infrequent typically vasodilator related effect include headache peripheral edema occur somewhat high incidence nisoldipine er group thus nisoldipine er amlodipine provide comparable antihypertensive anti ischemic efficacy generally well tolerate,Pepine CJ,2003,Am J Cardiol,https://doi.org/10.1016/s0002-9149(02)03154-5,12565082,Pepine CJ; Cooper-DeHoff RM; Weiss RJ; Koren M; Bittar N; Thadani U; Minkwitz MC; Michelson EL; Hutchinson HG; Comparative Efficacy and Safety of Nisoldipine and Amlodipine (CESNA-II) Study Investigators,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D017311: Amlodipine; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D005080: Exercise Test; D005260: Female; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D015737: Nisoldipine,,,https://openalex.org/W2078444473,142,18,1,1710,326,8,en,en
false,effect angiotensin convert enzyme inhibitor renal function patient membranoproliferative glomerulonephritis mild moderate renal insufficiency,determine effect enalapril angiotensin converting enzyme inhibitor ace progression renal insufficiency primary membranoproliferative glomerulonephritis mild moderate renal insufficiency thirty patient histopathologically prove mpgn hypertension grade ii jnc vi criterion hypertension mild moderate impairment renal function creatinine clearance vary ml min significant albuminuria serum creatinine mg dl initially treat diuretic blockers bring bp mm hg patient randomly divide three group group control group ii nifedipine group iii enalapril group ii iii nifidepine mg day group iii enalapril mg day respectively add addition treatment continue nine month patient follow monthly drug efficacy side effect adverse drug reaction patient complete study end nine month treatment patient control group reveal significant increase serum creatinine mg dl blood urea mg dl hour albuminuria gm decrease creatinine clearance min however enalapril group decrease serum creatinine mg dl blood urea mg dl hour albuminuria gm increase creatinine clearance ml min patient nifedipine show statistically nonsignificant change creatinine clearance blood urea serum creatinine albuminuria increase gm hour p blood pressure well control patient none patient side effect lead withdrawal drug adverse drug reaction noted ace enalapril provide protection progression renal insufficiency patient mpgn hypertension mild moderate renal impairment renoprotective effect ace inhibitor enalapril associate substantial decrease albuminuria,Giri S,2002,J Assoc Physicians India,,12568207,Giri S; Mahajan SK; Sen R; Sharma A,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000704: Analysis of Variance; D000806: Angiotensin-Converting Enzyme Inhibitors; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D004656: Enalapril; D005260: Female; D005500: Follow-Up Studies; D015432: Glomerulonephritis, Membranoproliferative; D006801: Humans; D006973: Hypertension; D007677: Kidney Function Tests; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011336: Probability; D051437: Renal Insufficiency; D012720: Severity of Illness Index; D016896: Treatment Outcome",,,https://openalex.org/W82252233,167,21,1,2310,411,10,en,en
false,effect interferon verapamil dacarbazine treatment advanced malignant melanoma,treatment patient metastatic melanoma either dacarbazine dtic interferon ifn single drug combination result response rate approximately study evaluate activity toxicity follow treatment combination dtic ifn b verapamil vpl thirty patient disseminated metastatic melanoma receive dtic mg day week schedule ifn b miu day week vpl mg three time day throughout cycle either disease progression serious toxicity observe among evaluable patient four complete response cr five partial response pr eight patient stable disease sd overall response rate cr pr two patient cr long term survivor month third still complete remission month fourth cr patient relapse die progressive brain metastasis month among eight patient sd one survive month another month despite one toxic death result suggest treatment regimen well tolerate seem effective dtic alone subset patient controlled randomized study would require determine value add vpl ifn b dtic,Andersson R,2003,Melanoma Res,https://doi.org/10.1097/00008390-200302000-00014,12569290,Andersson R; Ake Hofer P; Riklund-Ahlström K; Henriksson R,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D000971: Antineoplastic Combined Chemotherapy Protocols; D002121: Calcium Channel Blockers; D003606: Dacarbazine; D005260: Female; D006801: Humans; D000077190: Interferon alpha-2; D016898: Interferon-alpha; D008297: Male; D020714: Maximum Tolerated Dose; D008545: Melanoma; D008875: Middle Aged; D009367: Neoplasm Staging; D011877: Radionuclide Imaging; D011994: Recombinant Proteins; D012074: Remission Induction; D012878: Skin Neoplasms; D015996: Survival Rate; D016896: Treatment Outcome; D014604: Uveal Neoplasms; D014700: Verapamil,,,https://openalex.org/W2003155823,98,14,1,1349,259,10,en,en
false,effect isosorbide mononitrate aii inhibition pulse wave reflection hypertension,aortic pulse wave contour isolated systolic hypertension often show prominent reflection peak combine incident wave arise cardiac ejection widen pulse pressure investigate effect extended release nitrate preparation angiotensin ii aii inhibitor aii receptor antagonist ace inhibitor aortic pulse wave contour systemic blood pressure hypertensive subject high augmentation index cause exaggerated pulse wave reflection two double blind randomize placebo controlled crossover study carry total elderly patient systolic hypertension resistant conventional antihypertensive therapy study pharmacodynamic response single dos placebo isosorbide mononitrate eprosartan captopril determine single dose isosorbide mononitrate placebo compare subject treat aii inhibitor baseline blood pressure measure sphygmomanometry pulse wave component applanation tonometry radial artery agent show decrease brachial systolic blood pressure aortic systolic blood pressure aortic pulse pressure qualitative effect aortic pulse wave contour differ augmentation index significantly alter either captopril eprosartan decrease p approximately placebo value isosorbide mononitrate study group propose isosorbide mononitrate correct magnified wave reflection systolic hypertension elderly patient effect distinct exercise either acute chronic aii inhibition,Stokes GS,2003,Hypertension,https://doi.org/10.1161/01.hyp.0000049622.07021.4f,12574098,Stokes GS; Barin ES; Gilfillan KL,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000179: Acrylates; D000368: Aged; D000369: Aged, 80 and over; D057911: Angiotensin Receptor Antagonists; D000806: Angiotensin-Converting Enzyme Inhibitors; D001794: Blood Pressure; D002216: Captopril; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D007093: Imidazoles; D007548: Isosorbide Dinitrate; D008297: Male; D008875: Middle Aged; D011674: Pulse; D013876: Thiophenes; D013997: Time Factors; D014665: Vasodilator Agents",,,https://openalex.org/W2109469972,93,13,1,1724,273,8,en,en
false,plasma level active extracellular matrix metalloproteinases patient essential hypertension antihypertensive treatment,study design test hypothesis plasma concentration matrix metallo proteinase mmp matrix metalloproteinase mmp two enzyme share similar substrate specificity collagen type iv v possibly relate vascular remodelling alter essential hypertension second aim study assess whether chronic antihypertensive treatment calcium channel blocker amlodipine would normalize alteration test hypothesis measure plasma concentration active mmp mmp patient never treated essential hypertension normotensive control subject measurement repeat month treatment calcium channel blocker amlodipine baseline value mmp mmp decrease p respectively hypertensive patient compare normotensives hypertensive patient systemic vascular resistance dyn cm exhibit high value mmp p mmp p hypertensive patient systemic vascular resistance dyn cm treat patient attain nonsignificant increase mmp plasma concentration significant increase mmp plasma concentration p compare respective value treatment conclusion finding suggest plasma concentration active mmp mmp mainly relate vascular extracellular matrix metabolism depress patient essential hypertension month treatment amlodipine normalize mmp mmp plasma concentration hypothesis antihypertensive treatment may modulate collagen metabolism remain determine study,Zervoudaki A,2003,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1001518,12574790,Zervoudaki A; Economou E; Stefanadis C; Pitsavos C; Tsioufis K; Aggeli C; Vasiliadou K; Toutouza M; Toutouzas P,article,D016428: Journal Article,D000328: Adult; D017311: Amlodipine; D000959: Antihypertensive Agents; D004334: Drug Administration Schedule; D004452: Echocardiography; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006973: Hypertension; D008297: Male; D020778: Matrix Metalloproteinase 2; D020780: Matrix Metalloproteinase 9; D008875: Middle Aged; D013997: Time Factors; D014655: Vascular Resistance,,,https://openalex.org/W2051033301,155,20,1,1739,273,10,en,en
false,intensive blood pressure control reduce risk cardiovascular event patient peripheral arterial disease type diabetes,peripheral arterial disease pad diabetes associate high risk ischemic event role intensive blood pressure control pad established appropriate blood pressure control diabetes study follow subject type diabetes year subject normotensive baseline diastolic blood pressure mm hg patient randomize placebo moderate blood pressure control mean blood pressure mm hg last year treatment contrast patient randomize intensive treatment enalapril nisoldipine mean year blood pressure mm hg p compare moderate control pad define ankle brachial index baseline visit diagnose patient patient pad cardiovascular event intensive treatment compare event moderate treatment p adjustment multiple cardiovascular risk factor inverse relationship ankle brachial index cardiovascular event observe moderate treatment p intensive treatment p thus intensive blood pressure control risk event increase even low ankle brachial index value patient without pad pad patient diabetes intensive blood pressure lower mean mm hg result marked reduction cardiovascular event,Mehler PS,2003,Circulation,https://doi.org/10.1161/01.cir.0000049640.46039.52,12578880,Mehler PS; Coll JR; Estacio R; Esler A; Schrier RW; Hiatt WR,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000959: Antihypertensive Agents; D001794: Blood Pressure; D002318: Cardiovascular Diseases; D015331: Cohort Studies; D015897: Comorbidity; D016757: Death, Sudden, Cardiac; D003924: Diabetes Mellitus, Type 2; D004656: Enalapril; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D015737: Nisoldipine; D016017: Odds Ratio; D016491: Peripheral Vascular Diseases; D018570: Risk Assessment; D020521: Stroke; D016896: Treatment Outcome",,,https://openalex.org/W2095230892,139,20,1,1551,278,7,en,en
false,update controversy tocolytic therapy prevention preterm birth,acta obstet gynecol scand acta obstet gynecol scand preterm birth major cause perinatal mortality morbidity developed world contraindication use tocolytics improve neonatal survival rate approximately per day week gestation concomitant reduction morbidity ultimate aim tocolytic therapy prolong pregnancy growth maturation complete even short term delay may enable administration antepartum glucocorticoid reduce hyaline membrane disease arrange transfer center neonatal intensive care facility show reduce neonatal mortality morbidity recently none currently use tocolytics whether license unlicensed develop specifically inhibition preterm labor consequently exhibit various potentially serious side effects result recent licensing oxytocin antagonist atosiban develop treatment preterm labor due high utero specificity obstetrician experience advance option management spontaneous preterm labor,Ingemarsson I,2003,Acta Obstet Gynecol Scand,https://doi.org/10.1034/j.1600-0412.2003.820101.x,12580832,Ingemarsson I; Lamont RF,article,D016428: Journal Article; D016454: Review,"D000318: Adrenergic beta-Agonists; D002121: Calcium Channel Blockers; D016861: Cyclooxygenase Inhibitors; D005260: Female; D006801: Humans; D008278: Magnesium Sulfate; D020030: Nitric Oxide Donors; D007752: Obstetric Labor, Premature; D011247: Pregnancy; D011256: Pregnancy Outcome; D011451: Prostaglandin-Endoperoxide Synthases; D015149: Tocolytic Agents; D014668: Vasotocin",,,https://openalex.org/W2034461416,87,14,1,1234,203,7,en,en
false,basic conceptual practical overview interaction highly prescribe drug,drug interaction frequently result altered activity mechanism responsible drug elimination include drug metabolism mediate select group cytochrome p enzyme cyp cyp cyp c cyp c cyp drug transporter p glycoprotein adverse drug interaction result induction loss therapeutic benefit inhibition increase toxicity excessive effect drug elimination cyps p glycoprotein discuss individually regard characteristic frequently prescribe drug substrate inducer inhibitor important adverse drug event potential important drug interaction predict base property causative agent oral bioavailability mechanism elimination seriousness adverse event interacting agent consequently drug interaction prevent avoid concomitant administration interact substance possibly implement alternative therapeutic strategy furthermore susceptibility adverse event depend interacting substance also patient method drug administration commonly prescribe drug unlikely cause drug interaction involve cyps p glycoprotein also discuss,Dresser GK,2002,Can J Clin Pharmacol,,12584577,Dresser GK; Bailey DG,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review","D020168: ATP Binding Cassette Transporter, Subfamily B, Member 1; D001692: Biological Transport; D065607: Cytochrome P-450 Enzyme Inhibitors; D003577: Cytochrome P-450 Enzyme System; D004347: Drug Interactions; D064420: Drug-Related Side Effects and Adverse Reactions; D006801: Humans; D004364: Pharmaceutical Preparations; D028321: Plant Preparations",,,https://openalex.org/W2416217803,87,13,1,1305,205,8,en,en
false,antihypertensive treatment elderly,,Masotti G,2002,Aging Clin Exp Res,https://doi.org/10.1007/bf03324457,12602564,Masotti G,article,D016421: Editorial; D016454: Review,D000368: Aged; D000375: Aging; D000959: Antihypertensive Agents; D006801: Humans; D006973: Hypertension,,,https://openalex.org/W1976995010,41,5,1,0,0,0,en,
false,treatment scorpion envenom syndrome years experience serotherapy,pathophysiology scorpion envenom syndrome describe emphasis body system commonly affect concept mechanism underlie venom action explain recently discover effect ionic channel discuss protocol treatment scorpion sting base mainly antivenom therapy apply nationwide saudi arabia list drug alternative specify use adjunctive therapy require analysis outcome case al baha region case al qassim region case central specialist hospital central province saudi arabia give impressive result incidence severe venom toxicity follow antivenom administration almost negligible period stay hospital reduce early reaction antivenom administration low expect severity reaction consist mainly skin rash urticaria wheeze bronchial hypersensitivity anaphylaxis victim previously treat antivenom patient show positive skin test might due low protein content antivenom action venom release massive amount catecholamine,Ismail M,2003,Int J Antimicrob Agents,https://doi.org/10.1016/s0924-8579(02)00289-3,12615382,Ismail M,article,D016428: Journal Article,"D018712: Analgesics, Non-Narcotic; D000818: Animals; D000927: Anticonvulsants; D000932: Antiemetics; D000997: Antivenins; D006801: Humans; D007116: Immunization, Passive; D010276: Parasympatholytics; D012529: Saudi Arabia; D065008: Scorpion Stings; D012604: Scorpion Venoms; D012605: Scorpions; D013577: Syndrome; D014665: Vasodilator Agents",,,https://openalex.org/W2022805665,83,11,1,1318,222,10,en,en
false,long term management atrial fibrillation rhythm rate control,atrial fibrillation follow investigation rhythm management affirm investigator comparison rate control rhythm control patient atrial fibrillation n engl j med background atrial fibrillation may produce symptom think due,Kovacs KA,2003,CMAJ,,12615758,Kovacs KA,article,D016428: Journal Article,D000368: Aged; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D006801: Humans; D015337: Multicenter Studies as Topic; D016032: Randomized Controlled Trials as Topic; D016896: Treatment Outcome,,,https://openalex.org/W1830705800,68,11,1,296,49,4,en,en
false,topical nifedipine effective chronic anal fissure,patient study show remarkable improvement lidocaine nifedipine apply twice daily week extremely safe well tolerate effective treatment provide family physician reliable nonsurgical method treat chronic anal fissure,Merenstein D,2003,J Fam Pract,,12620169,Merenstein D; Rosenbaum D,article,D003160: Comparative Study; D016428: Journal Article,"D000287: Administration, Topical; D000779: Anesthetics, Local; D002908: Chronic Disease; D004311: Double-Blind Method; D019317: Evidence-Based Medicine; D005401: Fissure in Ano; D006801: Humans; D008012: Lidocaine; D009543: Nifedipine; D009824: Ointments; D010147: Pain Measurement; D017410: Practice Guidelines as Topic; D016032: Randomized Controlled Trials as Topic; D055502: Secondary Prevention; D016896: Treatment Outcome; D014665: Vasodilator Agents; D014945: Wound Healing",,,https://openalex.org/W149084247,58,9,1,295,48,2,en,en
true,outcome nifedipine git co amilozide hypertensive diabetic nondiabetics intervention goal hypertension insight,investigate impact treatment cardiovascular mortality morbidity assess outcome patient hypertension diabetes receive co amilozide nifedipine international nifedipine git study intervention goal hypertension participant year age hypertension mm hg least one additional cardiovascular risk factor patient receive mg nifedipine daily co amilozide mg hydrochlorothiazide mg amiloride daily dos double target blood pressure mm hg achieve primary composite cardiovascular death myocardial infarction heart failure stroke secondary outcome composite primary outcome include cause mortality death vascular nonvascular cause assess mean intent treat analysis significant difference incidence primary outcome nifedipine treated co amilozide treated patient diabetes baseline n versus relative risk ci p significant benefit nifedipine treated patient see composite secondary outcome versus relative risk ci p among patient without diabetes baseline n significant difference incidence new diabetes nifedipine versus co amilozide p nifedipine git daily effective diuretic therapy reduce cardiovascular complication hypertensive diabetic nifedipine treated patient also less likely diabetes secondary event composite cause mortality death vascular cause death nonvascular cause co amilozide recipient result suggest nifedipine could consider first line therapy hypertensive diabetic,Mancia G,2003,Hypertension,https://doi.org/10.1161/01.hyp.0000057420.27692.ad,12623939,Mancia G; Brown M; Castaigne A; de Leeuw P; Palmer CR; Rosenthal T; Wagener G; Ruilope LM; INSIGHT,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D000584: Amiloride; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002318: Cardiovascular Diseases; D048909: Diabetes Complications; D003920: Diabetes Mellitus; D004232: Diuretics; D004338: Drug Combinations; D005260: Female; D006339: Heart Rate; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D015994: Incidence; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D009937: Organizational Objectives; D016896: Treatment Outcome,,,https://openalex.org/W2150409719,140,21,1,1948,339,11,en,en
false,short versus long term effect different dihydropyridines sympathetic baroreflex function hypertension,antihypertensive treatment dihydropyridines may accompany sympathetic activation data whether common compound similar various phase treatment univocal however untreated essential hypertensive age year mean sem finger blood pressure bp finapres heart rate hr ecg plasma norepinephrine ne high performance liquid chromatography muscle sympathetic nerve traffic msna microneurography measure rest baroreceptor manipulation vasoactive drug placebo run period randomization double blind acute chronic week felodipine mg n lercanidipine mg n acute administration drug induce pronounced bp reduction marked increase hr ne msna week treatment bp reduction similar observe acute administration whereas hr ne msna response markedly attenuate respectively p small residual increase sympathetic activity felodipine group whereas lercanidipine group adrenergic marker return baseline value baroreflex control hr msna markedly impaired respectively acute drug administration recovery complete resetting chronic treatment thus sympathoexcitation induce different dihydropyridines largely limited acute administration drug nevertheless different chronic sympathetic effect indicate dihydropyridines homogeneously affect function acute sympathoexcitation small drugs differential chronic adrenergic effect account baroreflex impairment,Grassi G,2003,Hypertension,https://doi.org/10.1161/01.hyp.0000058003.27729.5a,12623959,Grassi G; Seravalle G; Turri C; Bolla G; Mancia G,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000959: Antihypertensive Agents; D017704: Baroreflex; D001794: Blood Pressure; D004095: Dihydropyridines; D004311: Double-Blind Method; D015736: Felodipine; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D018482: Muscle, Skeletal; D009638: Norepinephrine; D013564: Sympathetic Nervous System; D013997: Time Factors",,,https://openalex.org/W2041483238,115,13,1,1801,317,10,en,en
false,effect benazepril addition amlodipine ankle oedema subcutaneous tissue pressure hypertensive patient,aim study evaluate effect benazepril addition amlodipine antihypertensive treatment ankle foot volume afv pretibial subcutaneous tissue pressure pstp two objective measure ankle oedema total mild moderate essential hypertensive dbp mmhg age year study week placebo period randomize amlodipine mg benazepril mg amlodipine mg plus benazepril mg week accord crossover design end placebo period active treatment period blood pressure afv pstp evaluate afv measure use principle water displacement pstp assess use system subcutaneous pretibial interstitial environment water manometer amlodipine benazepril monotherapy significantly reduce sbp mmhg respectively p v baseline dbp mmhg respectively p reduction increase combination mmhg sbp p mmhg dbp p amlodipine monotherapy significantly increase afv p v baseline pstp p v baseline compare amlodipine alone combination produce less pronounced increase afv p v baseline p vs amlodipine pstp p v baseline p vs amlodipine ankle oedema clinically evident patient amlodipine monotherapy three patient combination result suggest ace inhibitors partially counteract microcirculatory change responsible ca antagonists induced oedema formation,Fogari R,2003,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1001533,12624612,Fogari R; Malamani GD; Zoppi A; Mugellini A; Rinaldi A; Vanasia A; Preti P,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D000842: Ankle; D001552: Benzazepines; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D003935: Diagnostic Techniques, Cardiovascular; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004487: Edema; D005260: Female; D006801: Humans; D006874: Hydrostatic Pressure; D006973: Hypertension; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2030036342,117,16,1,1738,333,14,en,en
false,stenting renal artery compress diaphragm,year old man resistant hypertension increase plasma aldosterone active plasma renin level irregular appearance left kidney outline ultrasound ct scan show stenosis left renal artery push aorta left crus diaphragm angioplasty placement autoexpansible stent carry good result arterial pressure level year patient hospitalised severe hypertension ct scan demonstrate compression stent left crus diaphragm good permeability artery downstream stent radiographic examination show fracture left renal artery stent thus reimplantation left renal artery aorta carry stenosis renal artery fibre crus diaphragm rare cause renovascular hypertension helicoidal angioscanner imaging particularly useful diagnosis present case renal angioplasty stenting complicate fracture stent lead surgery thus renal artery stenosis crus diaphragm diagnose surgical treatment need consider case case basis relation anatomy biological functional data,Baguet JP,2003,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1001528,12624613,Baguet JP; Thony F; Sessa C; Mallion JM,article,D002363: Case Reports; D016428: Journal Article,"D000368: Aged; D017130: Angioplasty; D003964: Diaphragm; D006801: Humans; D006978: Hypertension, Renovascular; D008297: Male; D011475: Prosthesis Failure; D012077: Renal Artery; D012078: Renal Artery Obstruction; D012086: Reoperation; D015607: Stents; D014057: Tomography, X-Ray Computed",,,https://openalex.org/W1996584216,54,9,1,1336,239,10,en,en
false,treatment arrhythmia pregnancy,pregnancy significant change occur hormonal hemodynamic state woman make arrhythmias likely occur palpitation frequently report usually find associate sinus tachycardia incidence paroxysmal supraventricular tachycardia increase pregnancy whereas atrial fibrillation ventricular tachycardia rarely see woman long qt syndrome experience significantly cardiac event postpartum period make beta blocker therapy important time acute treatment arrhythmia pregnant woman much nonpregnant patient however chronic drug therapy pregnancy reserve frequent hemodynamically significant arrhythmia episode,Wolbrette D,2003,Curr Womens Health Rep,,12628083,Wolbrette D,article,D016428: Journal Article; D016454: Review,"D000319: Adrenergic beta-Antagonists; D000889: Anti-Arrhythmia Agents; D001145: Arrhythmias, Cardiac; D001281: Atrial Fibrillation; D017147: Defibrillators, Implantable; D004562: Electrocardiography; D005260: Female; D006801: Humans; D008133: Long QT Syndrome; D011247: Pregnancy; D011249: Pregnancy Complications, Cardiovascular; D012307: Risk Factors; D013617: Tachycardia, Supraventricular",,,https://openalex.org/W2402843889,42,6,1,795,120,6,en,en
false,peyronie disease review,purpose provide current review peyronie disease material method review world peer review literature pathology pathogenesis diagnosis treatment peyronie disease result incidence peyronie disease continuously increase last year however patient need prosthesis surgery sole treatment option early diagnosis improve medical therapy refinement surgical technique good understanding basic science disease conclusion currently patient peyronie disease improvement prognosis experience expansion available therapeutic option,Gholami SS,2003,J Urol,10.1097/01.ju.0000053800.62741.fe,12629334,Gholami SS; Gonzalez-Cadavid NF; Lin CS; Rajfer J; Lue TF,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.; D016454: Review",D002454: Cell Differentiation; D002455: Cell Division; D005347: Fibroblasts; D005786: Gene Expression Regulation; D006801: Humans; D008297: Male; D055435: Myostatin; D020411: Oligonucleotide Array Sequence Analysis; D010411: Penile Induration; D010413: Penis; D017382: Reactive Oxygen Species; D016212: Transforming Growth Factor beta; D053773: Transforming Growth Factor beta1,,,,29,7,1,696,113,5,en,en
false,delay presentation calcium channel antagonist overdose,calcium channel antagonist generally safe therapeutic dosage severe side effect elevated intake increasingly describe typical feature include confusion lethargy hypotension sinus node depression cardiac conduction defect even patient stable presentation preclude possible late development adverse event long acting formulation calcium channel blocker case toxic overdose mg slow release diltiazem present patient stable presentation rapidly become hemodynamically unstable require treatment intravenous calcium temporary pacemaker inotropic support mechanical ventilation successful outcome concise review therapeutic consideration provide,Punukollu G,2003,Am J Ther,https://doi.org/10.1097/00045391-200303000-00009,12629592,Punukollu G; Gowda RM; Khan IA; Dogan OM,article,D002363: Case Reports; D016428: Journal Article,"D001919: Bradycardia; D002121: Calcium Channel Blockers; D002125: Calcium Gluconate; D003692: Delayed-Action Preparations; D004110: Diltiazem; D062787: Drug Overdose; D005260: Female; D006801: Humans; D007022: Hypotension; D000860: Hypoxia; D008875: Middle Aged; D012121: Respiration, Artificial; D013997: Time Factors; D016896: Treatment Outcome",,,https://openalex.org/W2047471094,59,7,1,806,124,5,en,en
false,stroke unit norwegian experience,main aim acute stroke care reduce death disability treatment stroke unit treatment option proven reduce death acute stroke patient stroke unit care also treatment show marked reduction disability general stroke patient also treatment beneficial long term effect survival disability quality life acute hospital norway establish stroke unit recommended stroke unit model non intensive combined unit able focus simultaneously acute care rehabilitation model well evaluate randomised trial achieve best result regard acute stroke care hence one probably conclude stroke unit care norway evidence base,Indredavik B,2003,Cerebrovasc Dis,https://doi.org/10.1159/000068213,12649609,Indredavik B,article,D016428: Journal Article,"D004562: Electrocardiography; D006757: Hospital Units; D006801: Humans; D009664: Norway; D010348: Patient Care Team; D010814: Physical Therapy Department, Hospital; D020521: Stroke; D014057: Tomography, X-Ray Computed; D000078329: Workforce",,,https://openalex.org/W1979880640,39,6,1,821,141,7,en,en
false,esmolol blunt cerebral blood flow velocity increase emergence anesthesia neurosurgical patient,cerebral hyperemia demonstrate emergence anesthesia neurosurgical patient mechanism speculative perform study test hypothesis could attribute sympathetic overactivity thirty neurosurgical patient include prospective randomize double blinded study compare esmolol short acting blocker placebo esmolol mg kg min infuse end anesthesia min extubation cerebral blood flow velocity cbfv mean arterial blood pressure heart rate record anesthesia anesthesia surgery extubation min extubation cardiac output coe estimate use esophageal doppler anesthesia min extubation cbfv coe heart rate significantly low esmolol group mean arterial blood pressure comparable group correlation cbfv coe time point study conclusion esmolol blunt cbfv increase emergence confirm sympathetic overactivity contributes cerebral hyperemia neurosurgical recovery,Grillo P,2003,Anesth Analg,https://doi.org/10.1213/01.ane.0000055647.54957.77,12651674,Grillo P; Bruder N; Auquier P; Pellissier D; Gouin F,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000762: Anesthesia Recovery Period; D001164: Arteriovenous Fistula; D001783: Blood Flow Velocity; D001794: Blood Pressure; D001932: Brain Neoplasms; D002302: Cardiac Output; D002560: Cerebrovascular Circulation; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D002532: Intracranial Aneurysm; D008297: Male; D008875: Middle Aged; D020768: Middle Cerebral Artery; D019635: Neurosurgical Procedures; D011412: Propanolamines,,,https://openalex.org/W1979045400,115,15,1,1190,201,10,en,en
false,antihypertensive medication quality life silent treatment silent killer,hypertension one major killer modern world one great irony disease little immediate effect affected individual quality life qol make treatment difficult medication affect qol negatively either side effect change life style associate chronic drug regimen review describe conceptual background qol measurement look effect qol different antihypertensive treatment available today late addition range antihypertensive drug angiotensin ii receptor blocker may significant step forward treatment ease dose excellent tolerability minimise negative effect patient possible benefit factor sexual function may even improve qol hypertensive patient,Bremner AD,2002,Cardiovasc Drugs Ther,https://doi.org/10.1023/a:1021790112182,12652105,Bremner AD,article,D016428: Journal Article; D016454: Review,"D000959: Antihypertensive Agents; D006801: Humans; D006973: Hypertension; D011788: Quality of Life; D016032: Randomized Controlled Trials as Topic; D012735: Sexual Dysfunction, Physiological",,,https://openalex.org/W2148723073,85,14,1,895,149,4,en,en
false,health economics hypertension optimal treatment hot study cost cost effectiveness intensive blood pressure lower low dose aspirin patient hypertension,abstract j nsson b hansson l st lhammar n stockholm school economics stockholm university uppsala uppsala sweden astrazeneca pharmaceutical de usa health economics hypertension optimal treatment hot study cost cost effectiveness intensive blood pressure lower low dose aspirin patient hypertension j intern med objective investigate marginal cost effectiveness different target reduction blood pressure cost effectiveness add acetylsalicylic acid asa treatment hypertension design patient hypertension randomize three target group blood pressure mmhg patient also randomly assign asa placebo average follow time year direct cost drug visit hospitalization side effects calculate relate clinical outcome set resource utilization data country study pool swedish unit cost apply aggregate resource utilization subject total patient year age mean year diastolic blood pressure mmhg mean mmhg intervention antihypertensive treatment long acting calcium antagonist felodipine give patient additional therapy dose increment four step prescribe reach randomized target blood pressure fifty per cent patient randomize low dose mg daily acetylsalicylic acid main outcome measure direct health care cost major cardiovascular cv event myocardial infarction stroke cv death result average cost drug visit increase intensive treatment increase treatment cost partly fully offset nonsignificant reduction cost cv hospitalization patient diabetes significant difference total cost target group cost avoid major cv event negative base case analysis sek ci sek ci sensitivity analysis patient asa cost slightly significantly high patient placebo estimate cost avoid major cv event vary sek sek wide confidence interval conclusion treatment cost increase target hypertension treatment lower patient diabetes intensive treatment low target cost effective nonsignificant difference event conclusion make patient study furthermore conclusive evidence find regard cost effectiveness add asa treatment hypertension,Jönsson B,2003,J Intern Med,https://doi.org/10.1046/j.1365-2796.2003.01135.x,12653877,Jönsson B; Hansson L; Stålhammar NO,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000959: Antihypertensive Agents; D001241: Aspirin; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003362: Cost-Benefit Analysis; D016757: Death, Sudden, Cardiac; D003925: Diabetic Angiopathies; D004359: Drug Therapy, Combination; D015736: Felodipine; D005260: Female; D017721: Hospital Costs; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D010975: Platelet Aggregation Inhibitors; D020521: Stroke; D016896: Treatment Outcome",,,https://openalex.org/W2008049114,184,27,1,2872,519,33,en,en
false,combination lisinopril nifedipine git increase blood pressure control compare single drug essential hypertensive patient,present study design evaluate effect combination therapy use angiotensin converting enzyme inhibitor lisinopril dihydropyridine calcium antagonist nifedipine git degree homogeneity hour blood pressure reduction essential hypertensive patient week placebo run period patient mean age year essential hypertension clinic diastolic blood pressure mm hg randomize week treatment lisinopril mg nifedipine git mg combination accord multicenter randomize double blind crossover study trough clinic blood pressure hour ambulatory blood pressure measure end run period week treatment addition clinic hour average blood pressure reduction trough peak ratio smoothness index new measure homogeneity blood pressure reduction also calculate although lisinopril nifedipine git produce significant reduction clinic hour average blood pressure value reduction obtain combination significantly p great moreover combination therapy increase p smoothness index compare single drug systolic lisinopril nifedipine git combination diastolic lisinopril nifedipine git combination blood pressure value whereas trough peak ratio value express median systolic lisinopril nifedipine git combination diastolic lisinopril nifedipine git combination blood pressure value significantly increase combination therapy thus antihypertensive treatment combination lisinopril nifedipine git effective balance hour combination component administer alone confirm smoothness index superior trough peak ratio assess homogeneity pharmacologic blood pressure reduction,Taddei S,2003,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-200304000-00010,12658059,Taddei S; Omboni S; Ghiadoni L; Caiazza A; Fogari R; Innocenti P; Porcellati C; Giovannetti R; Corradi L; Mancia G; Salvetti A,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D001794: Blood Pressure; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006973: Hypertension; D017706: Lisinopril; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D018709: Statistics, Nonparametric",,,https://openalex.org/W2039417630,140,18,1,2120,356,7,en,en
false,treatment stable angina low dose diltiazem combination metabolic agent trimetazidine,risk benefit moderate high dos calcium antagonist stable angina uncertain study investigate efficacy acceptability low dose diltiazem combination trimetazidine treatment stable angina day randomize double blind study treatment mg diltiazem combination mg trimetazidine placebo per day compare patient stable angina primary outcome time mm st segment depression duke treadmill score patient treatment group number patient respond trimetazidine compare placebo time mm st segment depression versus p duke treadmill score versus p angina versus p compare placebo improvement trimetazidine mean exercise time mm st segment depression confidence interval p mean duke treadmill score confidence interval p mean anginal attack per week confidence interval p combination low dose diltiazem trimetazidine effective side effects symptomatic control patient stable angina,Manchanda SC,2003,Int J Cardiol,https://doi.org/10.1016/s0167-5273(02)00367-4,12659989,Manchanda SC,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000787: Angina Pectoris; D001053: Apolipoproteins; D004110: Diltiazem; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004562: Electrocardiography; D005080: Exercise Test; D006801: Humans; D008297: Male; D008875: Middle Aged; D017063: Outcome Assessment, Health Care; D014292: Trimetazidine; D014665: Vasodilator Agents",,,https://openalex.org/W2079456378,104,15,1,1308,265,4,en,en
false,cardiovascular outcome irbesartan diabetic nephropathy trial patient type diabetes overt nephropathy,patient diabetes increase risk adverse cardiovascular event angiotensin converting enzyme inhibitor protective type diabetes however definitive study examine use angiotensin receptor blocker patient type diabetes overt nephropathy primary outcome irbesartan diabetic nephropathy trial double serum creatinine level end stage renal disease death cause compare rate cardiovascular event among patient type diabetic nephropathy receive conventional antihypertensive therapy angiotensin receptor blocker irbesartan calcium channel blocker amlodipine placebo randomized double blind placebo controlled trial median follow year time event analysis used center america europe israel australasia adult type diabetic nephropathy hypertension serum creatinine level micromol l mg dl micromol l mg dl woman micromol l mg dl micromol l mg dl men urinary protein excretion rate least mg treatment irbesartan amlodipine placebo time cardiovascular death myocardial infarction congestive heart failure stroke coronary revascularization three group statistically different composite cardiovascular event among component composite trend toward decrease stroke patient receive amlodipine versus receive placebo hazard ratio ci p likewise patient receive amlodipine significantly low rate myocardial infarction compare placebo recipient hazard ratio ci p contrast patient receive irbesartan significantly low incidence congestive heart failure compare placebo recipient hazard ratio ci p amlodipine recipient hazard ratio ci p composite cardiovascular event rate differ patient type diabetes overt nephropathy treat irbesartan amlodipine placebo addition conventional antihypertensive therapy,Berl T,2003,Ann Intern Med,https://doi.org/10.7326/0003-4819-138-7-200304010-00010,12667024,Berl T; Hunsicker LG; Lewis JB; Pfeffer MA; Porush JG; Rouleau JL; Drury PL; Esmatjes E; Hricik D; Parikh CR; Raz I; Vanhille P; Wiegmann TB; Wolfe BM; Locatelli F; Goldhaber SZ; Lewis EJ; Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D017311: Amlodipine; D000804: Angiotensin II; D057911: Angiotensin Receptor Antagonists; D000959: Antihypertensive Agents; D001713: Biphenyl Compounds; D002121: Calcium Channel Blockers; D002318: Cardiovascular Diseases; D003404: Creatinine; D003924: Diabetes Mellitus, Type 2; D003925: Diabetic Angiopathies; D003928: Diabetic Nephropathies; D004311: Double-Blind Method; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006973: Hypertension; D000077405: Irbesartan; D007676: Kidney Failure, Chronic; D008297: Male; D008875: Middle Aged; D010919: Placebos; D012307: Risk Factors; D013777: Tetrazoles; D016896: Treatment Outcome",,,https://openalex.org/W2126045082,123,17,1,2295,391,8,en,en
false,allhat trial diuretic still preferred initial drug high blood pressure,antihypertensive lipid lowering treatment prevent heart attack trial allhat compare four antihypertensive agent patient year old chlorthalidone doxazosin amlodipine lisinopril doxazosin arm terminate early excess congestive heart failure chlorthalidone least equivalent amlodipine lisinopril outcome measure well notably heart failure,Vidt DG,2003,Cleve Clin J Med,https://doi.org/10.3949/ccjm.70.3.263,12678218,Vidt DG,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D001795: Blood Pressure Determination; D002752: Chlorthalidone; D004232: Diuretics; D004305: Dose-Response Relationship, Drug; D017292: Doxazosin; D004334: Drug Administration Schedule; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006973: Hypertension; D017706: Lisinopril; D008297: Male; D008875: Middle Aged; D010349: Patient Compliance; D011336: Probability; D018570: Risk Assessment; D012720: Severity of Illness Index; D016896: Treatment Outcome",,,https://openalex.org/W1988967346,90,16,2,450,74,3,en,en
false,effect selective aldosterone blocker eplerenone versus calcium antagonist amlodipine systolic hypertension,eplerenone highly selective aldosterone blocker development treatment hypertension heart failure assess usefulness old patient systolic hypertension widen pulse pressure compare effect eplerenone amlodipine clinic blood pressure bp pulse pressure subset patient ambulatory bp vascular compliance urinary albumin excretion study involve patient year age randomly assign either eplerenone mg daily amlodipine mg daily double blind titration effect design week therapy reduction clinic systolic bp similar treatment eplerenone mm hg amlodipine mm hg reduction clinic diastolic bp modestly large amlodipine mm hg compare eplerenone mm hg p pulse pressure also reduce similarly baseline treatment group eplerenone mm hg versus amlodipine mm hg p change baseline pulse wave velocity week therapy statistically similar eplerenone amlodipine patient microalbuminuria baseline mg albumin g creatinine eplerenone reduce urinary albumin creatinine ratio compare reduction amlodipine p thus eplerenone effective amlodipine lower systolic bp pulse pressure well pulse wave velocity old patient widened pulse pressure hypertension furthermore eplerenone reduce microalbuminuria great extent amlodipine old patient group,White WB,2003,Hypertension,https://doi.org/10.1161/01.hyp.0000067463.13172.ea,12682082,White WB; Duprez D; St Hillaire R; Krause S; Roniker B; Kuse-Hamilton J; Weber MA,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000368: Aged; D000419: Albuminuria; D017311: Amlodipine; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D003404: Creatinine; D003967: Diarrhea; D004311: Double-Blind Method; D000077545: Eplerenone; D005260: Female; D006261: Headache; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D000451: Mineralocorticoid Receptor Antagonists; D009325: Nausea; D011673: Pulsatile Flow; D013148: Spironolactone; D013599: Systole; D016896: Treatment Outcome",,,https://openalex.org/W2123778248,121,15,1,1709,305,10,en,en
false,effect high dose losartan erythropoietin resistance patient undergoing haemodialysis,patient undergoing haemodialysis hd resistance might develop recombinant human erythropoietin rhuepo use treatment anaemia recently angiotensin converting enzyme ace inhibitor use treat hypertension congestive heart failure hd patient suggest contribute anaemia well inhibit erythropoiesis purpose study investigate whether losartan angiotensin ii atii receptor antagonist cause rhuepo resistance prospective study month compare effect high dose losartan mg day amlodipine mg day rhuepo requirement hypertensive patient receive rhuepo month maintenance hd twenty normotensive rhuepo dependent patient serve control group iron deficiency hyperparathyroidism aluminium intoxication infection inflammation exclude patients mean haemoglobin level find g dl group mean weekly rhuepo dose increase losartan group p v remain constant group significant difference find pth iron status aetiology renal failure groups high dose losartan increase rhuepo requirement reserve dialysis patient hypertension uncontrollable antihypertensive medication,Odabas AR,2003,Panminerva Med,,12682621,Odabas AR; Cetinkaya R; Selcuk Y; Keles S; Bilen H,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D016448: Multicenter Study,"D000328: Adult; D017311: Amlodipine; D000740: Anemia; D057911: Angiotensin Receptor Antagonists; D000959: Antihypertensive Agents; D004305: Dose-Response Relationship, Drug; D004351: Drug Resistance; D004921: Erythropoietin; D005260: Female; D006801: Humans; D006973: Hypertension; D007676: Kidney Failure, Chronic; D019808: Losartan; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D011994: Recombinant Proteins; D006435: Renal Dialysis",,,https://openalex.org/W2400038251,99,14,1,1407,230,7,en,en
false,effect nicardipine clonidine cognitive function electroencephalography hypertensive patient,aim study investigate cognitive electroencephalography eeg short term effect calcium antagonist nicardipine compare placebo clonidine know sedative effect act negative control day elderly hypertensive patient memory complaint nicardipine clonidine compare placebo double blind randomize three way cross control study week placebo run period phase ii clinical study carry patients single research centre fifteen elderly year hypertensive patient without dementia memory complaint include psychomotor performance cognition assess use extensive battery validated psychometric test evaluate attention vigilance body sway memory eeg profile cardiovascular parameter measure blood pressure heart rate detrimental effect nicardipine find attention vigilance body sway memory nicardipine produce significant increase alpha eeg energy may indicate possible alert effect contrast clonidine induce well known deleterious sedative effect psychometric test eeg analysis decrease alpha increase delta theta wave two drug produce equivalent decrease blood pressure steady state conclusion clonidine induce well known sedative effect nicardipine impair central nervous system activity may short term alerting effect elderly hypertensive patient memory complaint study support hypothesis dissociation blood pressure direct drug effect central nervous system,Denolle T,2002,Fundam Clin Pharmacol,https://doi.org/10.1046/j.1472-8206.2002.00110.x,12685512,Denolle T; Sassano P; Allain H; Bentué-Ferrer D; Breton S; Cimarosti I; Ouatara B; Merienne M; Gandon JM,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003000: Clonidine; D003071: Cognition; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004569: Electroencephalography; D005260: Female; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009529: Nicardipine; D011597: Psychomotor Performance,,,https://openalex.org/W2045753938,111,13,1,1779,289,12,en,en
false,randomize comparative double blind study amlodipine vs nicardipine treatment isolated systolic hypertension elderly,day multicenter randomize double blind parallel group study conduct compare efficacy amlodipine day nicardipine two three time day treatment isolated systolic hypertension ish elderly patient n age year ish randomize receive either amlodipine mg day nicardipine mg day titrate necessary mg day mg day respectively day efficacy assess measure office blood pressure bp h ambulatory blood pressure monitoring abpm two treatment substantially comparably reduced office systolic blood pressure sbp pulse pressure pp also produce slight decrease diastolic blood pressure dbp amlodipine reduce sbp assess abpm significantly great extent nicardipine treatment well tolerated sustained effect amlodipine compare nicardipine reflect significantly great antihypertensive activity particularly nocturnal period assess abpm study demonstrate day dose amlodipine effective antihypertensive treatment elderly ish patient,Mounier-Véhier C,2002,Fundam Clin Pharmacol,https://doi.org/10.1046/j.1472-8206.2002.00129.x,12685513,Mounier-Véhier C; Jaboureck O; Emeriau JP; Bernaud C; Clerson P; Carre A,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002940: Circadian Rhythm; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D009529: Nicardipine; D010349: Patient Compliance; D013997: Time Factors",,,https://openalex.org/W2000076755,137,20,1,1224,223,8,en,en
false,relative perioperative bradycardia lead adverse outcome cardiac transplantation,since effect bradycardia cardiac transplantation know test hypothesis perioperative bradycardia would lead increase adverse outcome cardiac transplantation conduct retrospective case control study inclusion criterion heart rate hr less bpm st week transplantation control patient match gender age time since transplantation identify patient perioperative bradycardia undergo cardiac transplantation result demonstrate significant difference donor ischemic time vs p operative surgeon p pretransplant cardiac disease p group bradycardic patient likely pretransplant amiodarone rr p perioperative bradycardia lead increase cellular rejection p vasculopathy p patient prescribe pretransplant amiodarone n trend toward delayed time first rejection episode vs day median p conclusion perioperative bradycardia increase adverse outcome cardiac transplantation associate pretransplant use amiodarone amiodarone may modify recipient immune response delay occurrence rejection,Goldstein DR,2003,Am J Transplant,https://doi.org/10.1034/j.1600-6143.2003.00073.x,12694073,Goldstein DR; Coffey CS; Benza RL; Nanda NC; Bourge RC,article,D016428: Journal Article,D000638: Amiodarone; D000889: Anti-Arrhythmia Agents; D001919: Bradycardia; D016022: Case-Control Studies; D016027: Heart Transplantation; D006801: Humans; D015999: Multivariate Analysis; D012189: Retrospective Studies; D016896: Treatment Outcome,,,https://openalex.org/W2037633665,98,12,1,1393,245,10,en,en
false,non alcoholic fatty liver disease,non alcoholic fatty liver disease clinicopathological condition comprise wide spectrum liver damage range simple steatosis steatohepatitis advanced fibrosis cirrhosis non alcoholic steatohepatitis represent stage within spectrum non alcoholic fatty liver disease define pathologically presence steatosis together necro inflammatory activity true prevalence non alcoholic fatty liver disease unknown estimate affect general population different country diagnosis non alcoholic fatty liver disease base upon convince evidence absent minimal alcohol consumption compatible histological change liver biopsy exclusion liver disease natural history non alcoholic fatty liver disease remain define patient pure steatosis liver biopsy follow relatively benign course whereas patient histological necro inflammatory change fibrosis may progress end stage liver disease initial step treatment non alcoholic fatty liver disease management associated condition obesity diabetes mellitus hyperlipidaemia non alcoholic fatty liver disease patient steatohepatitis fibrosis liver biopsy may benefit investigational pharmacological therapy patient decompensated cirrhosis non alcoholic fatty liver disease may candidate liver transplantation,Alba LM,2003,Aliment Pharmacol Ther,https://doi.org/10.1046/j.1365-2036.2003.01493.x,12694079,Alba LM; Lindor K,article,D016428: Journal Article; D016454: Review,"D000428: Alcohol Drinking; D001706: Biopsy; D015992: Body Mass Index; D003924: Diabetes Mellitus, Type 2; D018450: Disease Progression; D005234: Fatty Liver; D006801: Humans; D006949: Hyperlipidemias; D008107: Liver Diseases; D016031: Liver Transplantation; D009765: Obesity",,,https://openalex.org/W2077344442,33,4,1,1517,221,9,en,en
false,evaluation effect sublingually administer nifedipine captopril via transcranial doppler ultrasonography hypertensive crisis,study design show effect sublingually administer nifedipine captopril middle cerebral arterial blood flow hypertensive crisis emergency department transcranial doppler ultrasonography tcd perform patient fulfil criterion patient give captopril patient give nifedipine mean sd age year respectively patient randomize sublingually administer captopril nifedipine group drug administration tcd repeat initial systolic diastolic blood pressure mmhg captopril group mmhg nifedipine group significant difference antihypertensive effect drug initiation treatment treatment captopril middle cerebral artery mca flow velocity vm pulsatility index pi cm respectively value treatment captopril cm p p respectively treatment nifedipine vm pi cm respectively treatment nifedipine vm cm p pi p treatment captopril pi decrease normal limit group treat nifedipine pi increase pathological value result show reconsider use nifedipine emergency department antihypertensive agent hypertensive attack treatment,Gemici K,2003,Blood Press,,12699135,Gemici K; Baran I; Bakar M; Demircan C; Ozdemir B; Cordan J,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000286: Administration, Sublingual; D000704: Analysis of Variance; D000959: Antihypertensive Agents; D001783: Blood Flow Velocity; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002216: Captopril; D002536: Cerebral Arteries; D003971: Diastole; D004311: Double-Blind Method; D006801: Humans; D006973: Hypertension; D008875: Middle Aged; D009543: Nifedipine; D011446: Prospective Studies; D011673: Pulsatile Flow; D013599: Systole; D013997: Time Factors; D016896: Treatment Outcome; D017585: Ultrasonography, Doppler, Transcranial",,,https://openalex.org/W19796353,151,19,1,1659,298,9,en,en
false,long qt syndrome cause noncardiac drug,numerous medication intend cardiac use include antibiotic histamine blocker antipsychotic medication incidentally block potassium channel myocardial cell prolong qt interval may trigger malignant arrhythmia although odds give patient develop arrhythmia small number patient receive drug enormous patient develop proarrhythmia additional risk factor could easily identify medical history list risk factor include female gender organic heart disease hypokalemia history long qt drug induced arrhythmia patient without risk factor low risk patient neither practical necessary record electrocardiogram therapy initiate important preventive measure avoid concurrent administration drug prolong qt interval administration medication impair metabolism qt prolonging drug perform computerized literature search use key word long qt torsade drug adverse effect drug ventricular arrhythmia search publish report drug induced torsade de pointes reference report also review identify additional publication addition review publish review internet sit deal drug induced arrhythmia original article quote review web site examine critically,Viskin S,2003,Prog Cardiovasc Dis,https://doi.org/10.1053/pcad.2003.00101,12704598,Viskin S; Justo D; Halkin A; Zeltser D,article,D016428: Journal Article; D016454: Review,D000900: Anti-Bacterial Agents; D014150: Antipsychotic Agents; D004347: Drug Interactions; D005260: Female; D006329: Heart Conduction System; D006634: Histamine H1 Antagonists; D006801: Humans; D008133: Long QT Syndrome; D008297: Male; D015221: Potassium Channels; D012307: Risk Factors; D016171: Torsades de Pointes,,,https://openalex.org/W2054195660,43,7,1,1542,253,10,en,en
true,principal result control onset verapamil investigation cardiovascular end point convince trial,background scientific rationale inclusion exclusion criterion baseline characteristic early blood pressure control data regard participant controlled onset verapamil investigation cardiovascular end point convince trial previously publish convince plan large simple trial assess equivalence controlled onset extended release coer verapamil standard therapy prevent cardio,Black HR,2003,JAMA,https://doi.org/10.1001/jama.289.16.2073,12709465,Black HR; Elliott WJ; Grandits G; Grambsch P; Lucente T; White WB; Neaton JD; Grimm RH; Hansson L; Lacourciere Y; Muller J; Sleight P; Weber MA; Williams G; Wittes J; Zanchetti A; Anders RJ; CONVINCE Research Group,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000319: Adrenergic beta-Antagonists; D000368: Aged; D000959: Antihypertensive Agents; D001262: Atenolol; D002121: Calcium Channel Blockers; D002318: Cardiovascular Diseases; D003692: Delayed-Action Preparations; D003920: Diabetes Mellitus; D004232: Diuretics; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D012307: Risk Factors; D012907: Smoking; D049993: Sodium Chloride Symporter Inhibitors; D020521: Stroke; D016019: Survival Analysis; D014665: Vasodilator Agents; D014700: Verapamil,,,https://openalex.org/W2103596506,111,16,1,473,71,2,en,en
false,cardiovascular drug therapy elderly theoretical practical consideration,elderly population expand rapidly throughout world hypertension heart disease cardiovascular disorder prevalent condition among age group consequently clinician spend large proportion practice manage old adult cardiovascular disorder large proportion time devote use pharmacotherapeutic strategy long term management chronic condition physiological change accompany age affect cardiovascular function pharmacokinetics pharmacodynamics many cardiovascular medication alter physiological change interaction change profound effect agent use treat cardiovascular disorder may alter therapeutic outcome several class medication use treat chronic cardiovascular disorder old adult include ace inhibitor angiotensin ii receptor antagonist calcium channel antagonist beta adrenoceptor antagonist beta blockers oral antiarrhythmic agent warfarin drug beta blockers may aggravate decreased cardiac output increase peripheral resistance valuable adjunct many patient congestive heart failure agent reduce angiotensin ii activity may several benefit treat heart failure hypertension successful treatment cardiovascular disorder old adult require choice appropriate agent take consideration complex interaction pharmacokinetics pharmacodynamics disease effect,Williams BR,2003,Drugs Aging,https://doi.org/10.2165/00002512-200320060-00004,12710864,Williams BR; Kim J,article,D016428: Journal Article; D016454: Review,D000319: Adrenergic beta-Antagonists; D000368: Aged; D057911: Angiotensin Receptor Antagonists; D000806: Angiotensin-Converting Enzyme Inhibitors; D000889: Anti-Arrhythmia Agents; D000925: Anticoagulants; D002121: Calcium Channel Blockers; D002318: Cardiovascular Diseases; D006801: Humans; D014859: Warfarin,,,https://openalex.org/W2021258468,84,11,1,1609,232,11,en,en
false,lack improvement treatment hyperlipidemia among patient type diabetes,purpose investigate adequacy treatment hyperlipidemia patient type diabetes assess temporal trend adherence publish guideline method perform post hoc analysis patient enrol appropriate blood pressure control diabetes trial patient fast lipid profile baseline year trial achieve national cholesterol education panel goal hyperlipidemia management primary outcome result percentage patient low density lipoprotein ldl cholesterol level less mg dl n baseline n end year p almost n patient continue ldl cholesterol level great mg dl completion study n patient known coronary artery disease ldl cholesterol level less mg dl baseline n achieve level completion study p conclusion although prevention cardiovascular disease patient diabetes public health priority result suggest hyperlipidemia treat suboptimally,Mehler PS,2003,Am J Med,https://doi.org/10.1016/s0002-9343(02)01566-8,12714127,Mehler PS; Esler A; Estacio RO; MacKenzie TD; Hiatt WR; Schrier RW,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D008078: Cholesterol, LDL; D003324: Coronary Artery Disease; D003924: Diabetes Mellitus, Type 2; D005260: Female; D019983: Guideline Adherence; D006801: Humans; D006949: Hyperlipidemias; D000960: Hypolipidemic Agents; D008297: Male; D008875: Middle Aged; D015999: Multivariate Analysis; D017410: Practice Guidelines as Topic",,,https://openalex.org/W2065012961,90,14,1,1248,243,8,en,en
false,shift trend pharmacologic treatment hypertension nigerian tertiary hospital real world evaluation efficacy safety rationality pharmaco economics old new antihypertensive drug,current prescription pattern essential hypertension efficacy safety tolerability cost effectiveness newer antihypertensive drug evaluate nigerian patient finding compare previous study conduct tertiary hospital year earlier cross sectional evaluation blood pressure bp control hypertension clinic undertake among nigerian patient age year female duration treatment particular drug class combination month initial blood pressure mmhg patient concurrent diabetes mellitus thiazide diuretic alone combination remain commonly prescribed drug patient significant increase prescription calcium channel blocker ccbs p ace inhibitors aceis p slight reduction use methyldopa fixed drug combination p compare previous study fall systolic blood pressure r p ccb r p significantly correlate initial systolic blood pressure age patient achieve normotension bp mmhg ccb monotherapy monotherapy combination therapy aceis methyldopa thiazides normalize bp respectively pulse pressure surrogate marker cardiovascular complication mortality essential hypertension significantly reduce p equally treatment confidence interval range mmhg however hypertensive diabetic ht dm patient n exhibit significant change pulse pressure response treatment adverse drug reaction occur impotence postural dizziness headache pit oedema ccb dry cough acei pharmaco economic comparison drug class reveal every u dollar dollar spend per month percentage treated patient attain normotension ccb acei methyldopa thiazide combination acei ccb preferred treatment hypertensive diabetic nigerian attain bp mmhg result demonstrate shift trend rational efficacious treatment hypertension year period may associate least part intensive continuous education prescribers rational drug use introduction hospital formulary methyldopa still highly efficacious cost effective drug population black ht dm african still constitute subgroup require costlier antihypertensive drug whose bp control suboptimal exhibit poor therapeutic response risk factor pulse pressure constitute continue risk cardiovascular mortality,Adigun AQ,2003,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1001538,12714973,Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA,article,D003160: Comparative Study; D023362: Evaluation Study; D016428: Journal Article,"D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001581: Benzothiadiazines; D001794: Blood Pressure; D015897: Comorbidity; D003362: Cost-Benefit Analysis; D003430: Cross-Sectional Studies; D003971: Diastole; D004232: Diuretics; D004452: Echocardiography; D017850: Economics, Pharmaceutical; D004562: Electrocardiography; D005260: Female; D006339: Heart Rate; D006785: Hospitals, University; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009549: Nigeria; D011237: Predictive Value of Tests; D012307: Risk Factors; D012720: Severity of Illness Index; D049993: Sodium Chloride Symporter Inhibitors; D013599: Systole; D016896: Treatment Outcome",,,https://openalex.org/W1972976017,219,32,1,3033,566,18,en,en
false,different effect antihypertensive drug conduit artery endothelial function,compare effect antihypertensive drug endothelium dependent vasodilation peripheral conduit artery patient essential hypertension prospective randomize parallel group study endothelial function assess hypertensive patient month treatment randomly assign nifedipine git mg n amlodipine mg n atenolol mg n nebivolol mg n telmisartan mg n perindopril mg n necessary hydrochlorothiazide mg add compound evaluate brachial artery flow mediated endothelium dependent dilation high resolution ultrasound compare endothelium independent response glyceryl trinitrate microg brachial artery diameter measure automatic computerized analysis forty healthy subject evaluate control group oxidative stress production evaluate measure plasma malondialdehyde plasma lipoperoxides plasma antioxidant capacity assess ferric reducing antioxidant power hypertensive patient show significantly p low flow mediated dilation compare healthy control subject response glyceryl trinitrate similar control subject patient baseline blood pressure diameter flow mediated dilation response glyceryl trinitrate similar different treatment group treatment similarly reduce blood pressure perindopril increase flow mediate dilation p without modify response glyceryl trinitrate perindopril also telmisartan nifedipine amlodipine reduce oxidative stress increase plasma antioxidant capacity patient essential hypertension ace inhibitor appear compound able improve conduit artery endothelium dependent vasodilation,Ghiadoni L,2003,Hypertension,https://doi.org/10.1161/01.hyp.0000070956.57418.22,12719441,Ghiadoni L; Magagna A; Versari D; Kardasz I; Huang Y; Taddei S; Salvetti A,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D057911: Angiotensin Receptor Antagonists; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001158: Arteries; D001794: Blood Pressure; D001916: Brachial Artery; D002121: Calcium Channel Blockers; D004730: Endothelium, Vascular; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D018384: Oxidative Stress; D044140: Receptor, Angiotensin, Type 1; D016037: Single-Blind Method; D014664: Vasodilation",,,https://openalex.org/W2123861048,81,10,1,1960,325,12,en,en
false,ace inhibitor versus diuretic allhat versus anbp,allhat antihypertensive lipid lowering treatment prevent heart attack trial trial enrol hypertensive patient least one additional risk factor coronary heart disease chd comparison diuretic chlorthalidone calcium channel blocker amlodipine angiotensin converting enzyme ace inhibitor lisinopril throughout study chlorthalidone decrease systolic blood pressure slightly significantly great extent mmhg amlodipine lisinopril significance difference report amlodipine versus chlorthalidone lisinopril versus chlorthalidone primary outcome combined incidence fatal chd nonfatal myocardial infarction finding allhat support use thiazide type diuretic first choice pharmacological therapy risk patient hypertension anbp second australian national blood pressure study also comparison diuretic hydrochlorothiazide ace inhibitor enalapril perform old hypertensive previous cardiovascular event diastolic blood pressure reduction similar group time risk primary outcome cardiovascular event death cause low ace group diuretic group benefit predominantly men thus anbp suggest relatively healthy elderly hypertensive patient ace inhibitor prefer diuretic,Doggrell SA,2003,Expert Opin Pharmacother,https://doi.org/10.1517/14656566.4.5.825,12740004,Doggrell SA,article,D016420: Comment; D016428: Journal Article,,,,https://openalex.org/W2159616176,52,8,1,1507,241,8,en,en
false,anti ischemic property calcium channel blocker,calcium channel blocking agent ccbs calcium antagonist originally introduce counteract myocardial ischemia particular angina pectoris later antihypertensive quality come understood commercially exploit year ago,Opie L,2003,J Am Coll Cardiol,https://doi.org/10.1016/s0735-1097(03)00192-x,12742290,Opie L,article,"D016420: Comment; D016421: Editorial; D013485: Research Support, Non-U.S. Gov't",D002121: Calcium Channel Blockers; D006348: Cardiac Surgical Procedures; D006801: Humans; D009203: Myocardial Infarction; D017202: Myocardial Ischemia; D011183: Postoperative Complications,,,https://openalex.org/W2215520940,52,5,1,296,49,3,en,en
false,eplerenone pharmacia,pharmacia corp formerly gd searle co develop eplerenone aldosterone receptor antagonist potential treatment congestive heart failure systemic hypertension compound register hypertension pharmacia plan submit supplemental nda congestive heart failure first half base positive result phase iii clinical trial,Liew D,2003,Curr Opin Investig Drugs,,12744223,Liew D; Martin J; Krum H,article,D016428: Journal Article; D016454: Review,D000818: Animals; D002986: Clinical Trials as Topic; D000077545: Eplerenone; D006801: Humans; D006973: Hypertension; D000451: Mineralocorticoid Receptor Antagonists; D013148: Spironolactone,,,https://openalex.org/W4301471502,22,4,2,396,66,2,it,en
false,antihypertensive therapy verapamil sr plus trandolapril versus atenolol plus chlorthalidone glycemic control,evidence diuretic beta blocker impair glucose tolerance whereas calcium channel blocker angiotensin convert enzyme blocker lack metabolic effect compare effect combination therapy nondihydropyridine calcium channel blocker plus angiotensin convert enzyme inhibitor beta blocker plus diuretic hemoglobin c hb c patient type diabetes mild moderate hypertension total hypertensive outpatient non insulin treated type diabetes stable antidiabetic therapy least month hba c recruit randomized double blind trial patient treat week fixed combination verapamil sustain release sr plus trandolapril atenolol plus chlorthalidone follow week placebo run period main outcome measure hba c fast plasma glucose fructosamine level well systolic diastolic blood pressure hba c remain stable administration verapamil sr plus trandolapril increase atenolol plus chlorthalidone difference treatment group significant week treatment last visit p mean blood pressure fell mm hg administration verapamil sr plus trandolapril atenolol plus chlorthalidone respectively combination well tolerated hba c parameter short long term glycemic control favorable range antihypertensive treatment verapamil sr plus trandolapril compare atenolol plus chlorthalidone,Holzgreve H,2003,Am J Hypertens,https://doi.org/10.1016/s0895-7061(03)00062-1,12745200,Holzgreve H; Nakov R; Beck K; Janka HU,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001262: Atenolol; D015415: Biomarkers; D001786: Blood Glucose; D001794: Blood Pressure; D002752: Chlorthalidone; D003924: Diabetes Mellitus, Type 2; D003971: Diastole; D004232: Diuretics; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005215: Fasting; D005260: Female; D006442: Glycated Hemoglobin; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D007211: Indoles; D008297: Male; D008875: Middle Aged; D010349: Patient Compliance; D013599: Systole; D016896: Treatment Outcome; D014665: Vasodilator Agents; D014700: Verapamil",,,https://openalex.org/W2074411241,116,14,1,1727,295,6,en,en
false,specialist clinical hypertension critique allhat,,Meltzer JI,2003,Am J Hypertens,https://doi.org/10.1016/s0895-7061(03)00570-3,12745205,Meltzer JI,article,D016421: Editorial; D016454: Review,D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D003324: Coronary Artery Disease; D004232: Diuretics; D006801: Humans; D019161: Hydroxymethylglutaryl-CoA Reductase Inhibitors; D006973: Hypertension; D000960: Hypolipidemic Agents; D009203: Myocardial Infarction,,,https://openalex.org/W2030536173,54,7,1,0,0,0,fr,
false,diarrhoea vomit ace inhibitor important cause acute renal failure,occurrence severe acute renal failure patient develop diarrhoea take angiotensin convert enzyme ace inhibitor lead u undertake retrospective cohort survey determine frequency diarrhoea vomiting associate acute renal failure patient take class drug serum creatinine measure part diagnostic workup consecutive admission acute medical receive unit district general hospital outcome measure presence diarrhoea vomiting whether take ace inhibitor nsaid diuretic time admission also previous initial follow serum creatinine concentration peak serum creatinine case micromol l none required dialysis recover renal function completely receive large volume intravenous fluid cohort study admission serum creatinine micromol l nine regular dialysis patient remain patient take ace inhibitor six give history diarrhoea vomit median creatinine concentration group range micromol l admission micromol l first see hospital micromol l follow withdrawal drug therapy fluid replacement conclusion volume depletion cause acute renal failure patient take ace inhibitor uncommon patient general practitioner aware reversible renal impairment may occur intercurrent illness particularly characterise diarrhoea vomiting,Stirling C,2003,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1001571,12764405,Stirling C; Houston J; Robertson S; Boyle J; Allan A; Norrie J; Isles C,article,"D002363: Case Reports; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D058186: Acute Kidney Injury; D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D015331: Cohort Studies; D003404: Creatinine; D003967: Diarrhea; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D012189: Retrospective Studies; D014839: Vomiting,,,https://openalex.org/W2014455136,83,15,1,1715,296,12,en,en
false,antihypertensive efficacy safety olmesartan medoxomil compare amlodipine mild moderate hypertension,antihypertensive efficacy angiotensin ii receptor blocker olmesartan medoxomil show compare favourably antihypertensive agent randomized double blind study compare antihypertensive efficacy start dose olmesartan medoxomil calcium channel blocker amlodipine besylate amlodipine subject mild moderate hypertension follow week single blind placebo run period subject age year randomize start dose olmesartan medoxomil mg day amlodipine mg day placebo week subject evaluate h ambulatory blood pressure monitoring abpm seat cuff blood pressure bp measurement trough primary end point change baseline mean h diastolic blood pressure dbp abpm week secondary end point include change baseline mean h ambulatory systolic blood pressure sbp week change baseline mean seat trough cuff dbp sbp measurement response control rate dbp mmhg control rate sbp mmhg also calculate olmesartan medoxomil amlodipine produce significantly great reduction ambulatory seat dbp sbp compare placebo mean reduction ambulatory seat bp similar two active agent however olmesartan medoxomil group significantly patient achieve sbp goal mmhg dbp goal mmhg drug well tolerate recommended starting dose although amlodipine associate high incidence oedema reach statistical significance olmesartan medoxomil effective antihypertensive agent bp lowering efficacy start dose similar amlodipine associate patient achieve rigorous bp goal sbp mmhg dbp mmhg,Chrysant SG,2003,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1001577,12764406,Chrysant SG; Marbury TC; Robinson TD,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D017311: Amlodipine; D000959: Antihypertensive Agents; D018660: Blood Pressure Monitoring, Ambulatory; D002940: Circadian Rhythm; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D007093: Imidazoles; D008297: Male; D008875: Middle Aged; D000068557: Olmesartan Medoxomil; D012720: Severity of Illness Index; D013777: Tetrazoles; D013997: Time Factors; D016896: Treatment Outcome",,,https://openalex.org/W2045173804,119,13,1,1970,345,12,en,en
false,restoration nocturnal dip blood pressure associate improvement left ventricular ejection fraction,assess effect amlodipine nifedipine retard h blood pressure bp control nocturnal fall bp significance left ventricular systolic function chinese hypertensive type diabetic patient patient recruit openly randomise amlodipine nifedipine retard ambulatory h bp echocardiogram patient measure year treatment end study reduction systolic bp reduction diastolic bp reduction mean arterial pressure map difference amlodipine nifedipine subject underwent echocardiogram eight become new dippers end study non dippers treatment restore nocturnal fall map treatment patient either non dippers treatment n dipper treatment n dipper treatment non dippers treatment n eight new dippers improve ejection fraction p increased leave ventricular diastolic diameter mm p year treatment calcium antagonist compare subject eight new dippers show significant improvement ejection fraction vs p conclusion amlodipine nifedipine retard effective control h bp chinese hypertensive type diabetic patient restore nocturnal dip bp significantly increase leave ventricular systolic ejection fraction year treatment long act calcium antagonist clinical significance underlying mechanism require study,Ko GT,2003,Int J Cardiol,https://doi.org/10.1016/s0167-5273(02)00450-3,12767538,Ko GT; Chan HC,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D017311: Amlodipine; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D002681: China; D002940: Circadian Rhythm; D003924: Diabetes Mellitus, Type 2; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D020127: Recovery of Function; D013318: Stroke Volume; D016896: Treatment Outcome; D016277: Ventricular Function, Left",,,https://openalex.org/W9375106,116,17,1,1766,309,11,en,en
false,australian intervention randomize control rate atrial fibrillation trial aircraft,australian intervention randomize control rate atrial fibrillation trial multicenter trial atrioventricular junction ablation pacing avjap compare pharmacologic ventricular rate control medication med patient mild moderately symptomatic permanent atrial fibrillation af prospective randomize trial undertake highly symptomatic patient compare avjap pharmacologic method ventricular rate control patient permanent af patient men mean age year five center forty nine patient randomize avjap patient randomize pharmacologic control primary end point cardiac function measure echocardiography exercise tolerance secondary end point ventricular rate control evaluate h ambulatory electrocardiographic monitoring quality life data collect randomization one month six month month post randomization month follow significant difference left ventricular ejection fraction avjap med p ns exercise duration treadmill test avjap min med min p ns however peak ventricular rate low avjap group exercise beats min vs beats min p activity daily life beats min vs beats min p cast quality life questionnaire reveal patient avjap group symptom six month p month p observed relative risk reduction symptom month global subjective semiquantitative measurement quality life use ladder life reveal avjap group report good quality life six month p trial avjap patient mild moderately symptomatic permanent af worsen cardiac function long term follow quality life improve,Weerasooriya R,2003,J Am Coll Cardiol,https://doi.org/10.1016/s0735-1097(03)00338-3,12767649,Weerasooriya R; Davis M; Powell A; Szili-Torok T; Shah C; Whalley D; Kanagaratnam L; Heddle W; Leitch J; Perks A; Ferguson L; Bulsara M,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000203: Activities of Daily Living; D000368: Aged; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D001283: Atrioventricular Node; D017115: Catheter Ablation; D004452: Echocardiography; D015716: Electrocardiography, Ambulatory; D005080: Exercise Test; D005260: Female; D006801: Humans; D008297: Male; D010138: Pacemaker, Artificial; D011788: Quality of Life; D013318: Stroke Volume; D016277: Ventricular Function, Left",,,https://openalex.org/W2098964871,94,14,1,2081,392,12,en,en
false,dilemma immediate preoperative hypertension treat operate postpone surgery,evaluate efficacy complication immediate preoperative reduction arterial blood pressure bp patient well controlled hypertension diastolic blood pressure dbp mmhg arrival operating room prospective randomize large sample study university affiliated bed community hospital patient well controlled hypertension schedule surgery previous myocardial infarction unstable severe angina pectoris renal failure pregnancy induce hypertension leave ventricular hypertrophy previous coronary revascularization aortic stenosis preoperative dysrhythmias conduction defect stroke patients dbp mmhg randomly allocate two group patient control group patient serve study group control group surgery postpone remain hospital bp control study patient receive mg nifedipine intranasally deliver patient observe cardiovascular neurological complication intraoperative period first three postoperative days two group similar age gender type surgery duration anesthesia intraoperative fluid administration statistically significant difference postoperative complication hospitalization time considerable shorter study group control group immediate preoperative reduction dbp intranasal nifedipine safe patient well controlled arterial hypertension present severe severe hypertension patient able avoid unnecessary surgery postponement attendant cost,Weksler N,2003,J Clin Anesth,https://doi.org/10.1016/s0952-8180(03)00035-7,12770652,Weksler N; Klein M; Szendro G; Rozentsveig V; Schily M; Brill S; Tarnopolski A; Ovadia L; Gurman GM,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000281: Administration, Intranasal; D000368: Aged; D000369: Aged, 80 and over; D000959: Antihypertensive Agents; D001071: Appointments and Schedules; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D005260: Female; D006801: Humans; D006973: Hypertension; D007902: Length of Stay; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011446: Prospective Studies; D013514: Surgical Procedures, Operative",,,https://openalex.org/W2090292858,97,17,1,1781,271,6,en,en
false,interaction alcohol drug fatal poisoning,finnish data fatal poisoning due alcohol ethanol single drug statistically analyse retrospect evaluate interaction alcohol drug case low concentration common benzodiazepine present median postmortem blood alcohol concentration bac percent per thousand w w alcohol poisoning significantly low range percent per thousand promazine doxepin amitriptyline propoxyphene find together alcohol levomepromazine temazepam zopiclone present median bac also significantly low percent per thousand citalopram diltiazem exhibit significant effect median bac significantly low case high concentration low concentration drug exclude citalopram suggest positive concentration effect relationship fatal toxicity index ftis calculate relate number death cause drug corresponding sale figure promazine extremely high fti follow levomepromazine propoxyphene doxepin amitriptyline drug relatively low ftis result reflect acute toxicity give drug alcohol combination also manner use abuse drug,Koski A,2003,Hum Exp Toxicol,https://doi.org/10.1191/0960327103ht324oa,12774892,Koski A; Ojanperä I; Vuori E,article,D016428: Journal Article,D000328: Adult; D000368: Aged; D000428: Alcohol Drinking; D001569: Benzodiazepines; D002423: Cause of Death; D004347: Drug Interactions; D062787: Drug Overdose; D000431: Ethanol; D005387: Finland; D006801: Humans; D008297: Male; D008875: Middle Aged; D012189: Retrospective Studies,,,https://openalex.org/W2040960694,52,8,1,1384,238,10,en,en
false,prospective randomize trial diltiazem glyceryltrinitrate ointment treatment chronic anal fissure,abstract objective aim study compare prospectively diltiazem gtn ointment treatment anal fissure patient method outpatient chronic anal fissure patient randomize topical diltiazem ointment patient glyceryltrinitrate gtn ointment twice daily week course treatment patient see three time side effects heal record result heal occur patient treat diltiazem patient cure gtn p treat nitroglycerin ointment develop headache dizzness develop gtn case patient side effects diltiazem conclusion diltiazem glyceryltrinitrate gtn equally effective heal anal fissure former result side effects,Bielecki K,2003,Colorectal Dis,https://doi.org/10.1046/j.1463-1318.2003.00440.x,12780888,Bielecki K; Kolodziejczak M,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000287: Administration, Topical; D000328: Adult; D000368: Aged; D002908: Chronic Disease; D004110: Diltiazem; D005260: Female; D005401: Fissure in Ano; D006801: Humans; D008297: Male; D008875: Middle Aged; D005996: Nitroglycerin; D009824: Ointments; D011446: Prospective Studies; D013997: Time Factors; D014665: Vasodilator Agents; D014945: Wound Healing",,,https://openalex.org/W1970641157,116,16,1,896,158,7,en,en
false,importance von willebrand factor level heart rate change acute coronary syndrome comparison chronic ischemic condition,pathogenesis acute coronary syndrome ac transient myocardial ischemia tmi completely understood therefore author study biological indicator thrombogenesis sympathetic activity study conduct patient acute coronary syndrome patient stable angina pectoris treatment standardize low molecular weight heparin mg aspirin day iib iiia inhibitor oral beta blocker diltiazem mg tid glyceryl trinitrate v patient ac mononitrates orally low molecular weight heparin patient stable angina twenty four hour continuous ecg monitoring st segment analysis perform day admission heart rate analysis perform minute myocardial ischemia period blood sample von willebrand factor vwf determination perform peripheral vein noon pm pm half hour description angina patient ac group transient myocardial ischemia positive n negative n patient stable angina designate control group n detected vwf level different daytime period patient ac significantly high patient stable angina pm pm period vwf level increase significantly high patient tmi patient without tmi noon period detected vwf level decrease significantly tmi group nocturnal ischemia period increase vwf level immediately angina significantly apparent detected change daytime ischemia analysis show heart rate ischemia stable angina episode significantly high tmi silent angina heart rate difference minute ischemia angina group significantly different tmi silent ischemia heart rate time relate ischemia nocturnal period significantly low daytime period heart rate difference ischemia related time ischemia significantly high daytime ischemic attack nocturnal ischemic attack study confirm vwf level indicator thrombogenesis significantly increase patient ac nocturnal ischemia associate thrombogenesis daytime ischemia associate increased sympathetic activity symptomatic ischemia usually associate increased sympathetic activity,Heper G,2003,Angiology,https://doi.org/10.1177/000331970305400304,12785021,Heper G; Bayraktaroğlu M,article,D003160: Comparative Study; D016428: Journal Article,D000208: Acute Disease; D000704: Analysis of Variance; D000787: Angina Pectoris; D016009: Chi-Square Distribution; D002940: Circadian Rhythm; D004562: Electrocardiography; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D017202: Myocardial Ischemia; D014841: von Willebrand Factor,,,https://openalex.org/W2089105464,143,22,1,2722,466,20,en,en
false,role topical diltiazem treatment chronic anal fissure fail glyceryl trinitrate therapy,treatment anal fissure evolve last year development topical treatment aim reduce sphincter hypertonia think improve anal mucosal blood flow promote healing fissure study report use topical diltiazem patient chronic anal fissure fail previous treatment topical glyceryl trinitrate gtn forty seven patient chronic anal fissure previously fail least one course topical gtn recruit prospectively single centre patient instruct apply cm approximately g diltiazem cream anal verge twice daily eight week symptom pain bleeding itching record linear analogue score prior start cream repeat weekly interval patient ask report side effects throughout study period healing fissure assess week treatment forty six patient complete treatment heal fissure ten patient persistent fissure symptomatically improve wish treatment patient remain symptomatic one give repeat course glyceryl trinitrate subsequent healing fissure recruit ongoing study involve injection botulinum toxin internal anal sphincter three refer surgery study show topical diltiazem effective safe treatment chronic anal fissure patient fail topical gtn need sphincterotomy avoid case,Griffin N,2002,Colorectal Dis,https://doi.org/10.1046/j.1463-1318.2002.00376.x,12790914,Griffin N; Acheson AG; Jonas M; Scholefield JH,article,D016428: Journal Article,,,,https://openalex.org/W2041565183,116,18,1,1672,293,10,en,en
false,treatment resistant anal fissure advancement anoplasty,abstract objective primary aim study assess outcome advancement anoplasty treatment chronic anal fissure resistant conventional therapy secondary aim evaluate anal resting pressure patient resistant fissure patient method five year period eight patient male median age year range resistant anal fissure refer centre endure symptom median year range undergone median previous surgical procedure range include lateral sphincterotomy anal dilatation anorectal physiological testing perform patient underwent advancement anoplasty outcome analyse retrospectively result pre operative anorectal physiological testing show significantly lower median maximal anal resting pressure mm h range mm h normal range mm p patient underwent advancement anoplasty median seven month follow range seven eight patient heal fissure asymptomatic median healing time four month range conclusion patient chronic anal fissure resistant conventional therapy may successfully treat advancement anoplasty healing time however may prolong series patient decreased anal resting pressure rather anal hypertonia,Kenefick NJ,2002,Colorectal Dis,https://doi.org/10.1046/j.1463-1318.2002.00373.x,12790921,Kenefick NJ; Gee AS; Durdey P,article,D016428: Journal Article,,,,https://openalex.org/W2080263849,62,8,1,1462,258,13,en,en
false,topical nifedipine vs topical glyceryl trinitrate treatment chronic anal fissure,nifedipine administer orally apply topically effective nonsurgical treatment anal fissure compare efficacy nifedipine vs glyceryl trinitrate chemical sphincterotomy anal fissure prospective double blind trial patient suffer chronic anal fissure randomly equally allocate receive either glyceryl trinitrate nifedipine apply topically perianal region end point study heal within predetermined period month variable assess included demographic data age gender symptom associate fissure duration treatment percentage healing untoward effect treatment pain score duration follow recurrence need complementary mean treatment descriptive data present mean standard deviation quantal data percentage inference analysis perform use student test descriptive data chi squared fisher exact test nominal variables significant difference record regard age gender symptom associate fissure duration treatment heal rate high p nifedipine percent compare glyceryl trinitrate percent treatment side effect headache flush frequent p glyceryl trinitrate percent compare nifedipine percent pain score significantly low p completion treatment group glyceryl trinitrate nifedipine vs respectively differ two group recurrence occur percent patient treat glyceryl trinitrate percent treat nifedipine mean period week week respectively topical application nifedipine management chronic anal fissure effective side effect topical glyceryl trinitrate recurrence frequent drug,Ezri T,2003,Dis Colon Rectum,https://doi.org/10.1007/s10350-004-6660-8,12794583,Ezri T; Susmallian S,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D002121: Calcium Channel Blockers; D002908: Chronic Disease; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D009543: Nifedipine; D005996: Nitroglycerin; D011446: Prospective Studies; D016896: Treatment Outcome; D014665: Vasodilator Agents,,,https://openalex.org/W2007791160,88,12,1,2047,356,11,en,en
false,differential effect antihypertensive agent electrocardiographic voltage result appropriate blood pressure control diabetes abcd trial,serial decline electrocardiographic voltage patient increased leave ventricular mass associate low risk cardiovascular events study patient diabetes mellitus hypertension appropriate blood pressure control diabetes abcd trial patient randomize stratified design receive initial treatment either enalapril nisoldipine either intensive moderate treatment goal measure electrocardiographic index increase leave ventricular mass adjust cornell voltage serially treatment group association change electrocardiographic voltage cardiovascular event define cox proportional hazard analysis year follow decline adjust cornell voltage significantly great patient treat enalapril patient treat nisoldipine repeat measure analysis variance p cox proportional hazard model treatment assignment enalapril v nisoldipine strong predictor cardiovascular event presence coronary disease baseline duration diabetes mellitus change voltage also independent predictor cardiovascular events abcd study enalapril treatment associate low risk myocardial infarction reduction left ventricular mass reflect diminished electrocardiographic voltage may explain effect enalapril study,Havranek EP,2003,Am Heart J,https://doi.org/10.1016/s0002-8703(02)94780-0,12796754,Havranek EP; Esler A; Estacio RO; Mehler PS; Schrier RW; Appropriate Blood Pressure Control in Diabetes Trial,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003924: Diabetes Mellitus, Type 2; D003925: Diabetic Angiopathies; D004311: Double-Blind Method; D004562: Electrocardiography; D004656: Enalapril; D005260: Female; D006801: Humans; D006973: Hypertension; D017379: Hypertrophy, Left Ventricular; D008297: Male; D008875: Middle Aged; D015737: Nisoldipine; D016016: Proportional Hazards Models; D011446: Prospective Studies",,,https://openalex.org/W2052099329,157,22,1,1528,234,6,en,en
false,effect amlodipine ischemia percutaneous transluminal coronary angioplasty secondary result coronary angioplasty amlodipine restenosis capares study,despite successful coronary angioplasty ptca patient may ischemia procedure overall coronary disease luminal renarrowing lesion sit aim study examine effect calcium channel blocker amlodipine post ptca ischemia prospective double blind design patient randomize receive mg amlodipine placebo week angioplasty exercise test hour ambulatory electrocardiography recording perform patient week week early late ptca difference clinical angiographic baseline characteristic treatment group ischemia angina equally distribute ptca difference restenosis find group follow incidence angina significantly low amlodipine group compare placebo group early late ptca p exercise induced ischemia reduce p early p late ptca amlodipine group ischemia ambulatory electrocardiography reduce early late ptca compare placebo p p ischemia angina occur successful ptca significantly reduce amlodipine,Jørgensen B,2003,Am Heart J,https://doi.org/10.1016/s0002-8703(03)00082-6,12796759,Jørgensen B; Thaulow E; Coronary Angioplasty Amlodipine Restenosis Study,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D017311: Amlodipine; D000787: Angina Pectoris; D015906: Angioplasty, Balloon, Coronary; D002121: Calcium Channel Blockers; D017023: Coronary Angiography; D003327: Coronary Disease; D004311: Double-Blind Method; D004562: Electrocardiography; D005080: Exercise Test; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D008875: Middle Aged; D016017: Odds Ratio; D011446: Prospective Studies; D012008: Recurrence; D018709: Statistics, Nonparametric; D015607: Stents",,,https://openalex.org/W2133156136,171,23,1,1339,229,6,en,en
false,braxton hicks contraction alter uteroplacental perfusion,color flow imaging use study effect spontaneous low amplitude uterine contraction braxton hicks flow velocity waveform obtain main uterine artery woman week gestation eight woman abnormal waveform define presence early diastolic notch five woman normal waveform former group three woman chronic hypertension start calcium antagonist nifedipine study contraction monitor external tocography occur frequently group abnormal waveform temporally associate increase impedance blood flow effect occur degree normal abnormal group abnormal group already impaired blood flow intervillous space far diminish result absence forward flow diastole acute reduction flow response frequent impalpable uterine contraction may cause prolonged silent insult uteroplacental perfusion could hasten fetal compromise effect appear abolish patient nifedipine suggest possible therapeutic role drug uteroplacental insufficiency,Bower S,1991,Ultrasound Obstet Gynecol,https://doi.org/10.1046/j.1469-0705.1991.01010046.x,12797102,Bower S; Campbell S; Vyas S; McGirr C,article,D016428: Journal Article,,,,https://openalex.org/W2041996337,61,6,1,1257,208,7,en,en
false,anemia predict mortality severe heart failure,aim examine relationship serum hematocrit hct risk cause mortality among patient severe heart failure hf anemia occur increased frequency severe hf however study examine impact anemia mortality population use prospective cohort design evaluate relationship baseline serum hct mortality among patient left ventricular ef new york heart association functional class iiib iv hf treat angiotensin converting enzyme inhibitor diuretic digitalis mortality ascertain centralized adjudication mean hct range month mean follow death per person years adjustment potential confounders low quintile hct range high risk death hazard ratio confidence interval compare high quintile range within low quintile hct decrease hct associate high risk death p whereas within four high quintiles hct hct associate total mortality evaluation different cause death indicate low hct strongly associate death progressive hf rather sudden death death among patient severe hf anemia significant independent risk factor death progressively high risk increase severity anemia investigation etiology prevention treatment anemia severe hf warrant,Mozaffarian D,2003,J Am Coll Cardiol,https://doi.org/10.1016/s0735-1097(03)00425-x,12798560,Mozaffarian D; Nye R; Levy WC,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013486: Research Support, U.S. Gov't, Non-P.H.S.",D000368: Aged; D017311: Amlodipine; D000740: Anemia; D002121: Calcium Channel Blockers; D002423: Cause of Death; D015331: Cohort Studies; D005260: Female; D005500: Follow-Up Studies; D006333: Heart Failure; D006400: Hematocrit; D006801: Humans; D008297: Male; D008875: Middle Aged; D011237: Predictive Value of Tests; D011446: Prospective Studies; D012307: Risk Factors; D012720: Severity of Illness Index; D012737: Sex Factors; D013318: Stroke Volume; D016019: Survival Analysis; D016896: Treatment Outcome,,,https://openalex.org/W17798182,49,7,1,1671,317,12,en,en
false,expert consensus document management cardiovascular disease pregnancy task force management cardiovascular disease pregnancy european society cardiology,task force management cardiovascular disease pregnancy european society cardiology task force member celia oakley chairperson anne child bernard iung patricia presbitero pilar tornos cpgpc member werner klein chairperson maria angeles alonso garcia carina blomstrom lundqvist guy de backer henry dargie jaap decker marcus flather jaromir hradec gianfranco mazzotta ali oto alexander parkhomenko sigmund silber adam torbicki hans joachim trappe esc staff veronica dean dominique poumeyrol jumeau,Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology,2003,Eur Heart J,https://doi.org/10.1016/s0195-668x(03)00098-8,12800857,Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology,article,D016431: Guideline; D016428: Journal Article; D017065: Practice Guideline,"D009202: Cardiomyopathies; D003327: Coronary Disease; D036861: Delivery, Obstetric; D005104: Expert Testimony; D005260: Female; D005323: Fetal Monitoring; D006801: Humans; D006973: Hypertension; D008429: Maternal Welfare; D017410: Practice Guidelines as Topic; D011247: Pregnancy; D011249: Pregnancy Complications, Cardiovascular; D011295: Prenatal Care; D012307: Risk Factors",,,https://openalex.org/W2185704933,198,27,1,554,96,1,en,en
false,optimal medical management angina,coronary artery disease remain one principal cause disability worldwide common manifestation angina pectoris angina occur due imbalance myocardial oxygen demand supply classically precipitate physical activity emotion eat cold weather define stable frequency severity duration time appearance precipitate factor remain unchanged day treatment patient stable angina target number factor underlie pathophysiology aspirin antiplatelet agent b blockade reduce myocardial oxygen demand additional antianginal drug symptom incompletely control b blockers alone furthermore aggressive treatment risk factor development coronary artery disease confer significant mortality benefit unstable angina define symptom develop rest minimal exertion increase severity duration frequency associate significant mortality consequently early assessment intervention essential prevent worsen ischemia treatment include close patient monitoring administration antiplatelet antithrombotic drug combination b blockers calcium antagonist intravenous nitrate appropriate coronary revascularization consider high risk patient conservative management strategy fail,Noronha B,2003,Curr Cardiol Rep,https://doi.org/10.1007/s11886-003-0060-x,12801442,Noronha B; Duncan E; Byrne JA,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review","D000787: Angina Pectoris; D006801: Humans; D010818: Practice Patterns, Physicians'; D012307: Risk Factors",,,https://openalex.org/W2047641151,36,5,1,1452,226,10,en,en
false,concept pathogenesis treatment chronic anal fissure review literature,chronic anal fissure associate persistent hypertonia spasm internal anal sphincter classic treatment surgical sphincterotomy reduce anal tone eliminate sphincteric spasm however concern raise incidence fecal incontinence surgery therefore pharmacological mean treat chronic anal fissure explored conduct literature review medline database treatment address anomaly high anal pressure several study investigate effect topical glyceryl trinitrate ointment heal rate range therapy limited high incidence moderate severe headache patient comparable result observe injection botulinum toxin anal sphincter minor incontinence flatus soiling report patient pharmacological approach include treatment via calcium channel blockade treatment alpha adrenoceptor antagonist still developmental stage topical glyceryl trinitrate ointment injection botulinum toxin anal sphincter advocate first line treatment chronic anal fissure lateral sphincterotomy offer patient relapse therapeutic failure prior pharmacological treatment,Utzig MJ,2003,Am J Gastroenterol,https://doi.org/10.1111/j.1572-0241.2003.07423.x,12809816,Utzig MJ; Kroesen AJ; Buhr HJ,article,D016428: Journal Article; D016454: Review,"D000287: Administration, Topical; D018726: Anti-Dyskinesia Agents; D001905: Botulinum Toxins; D002121: Calcium Channel Blockers; D002908: Chronic Disease; D002986: Clinical Trials as Topic; D005401: Fissure in Ano; D006801: Humans; D009569: Nitric Oxide; D005996: Nitroglycerin; D016896: Treatment Outcome; D014665: Vasodilator Agents",,,https://openalex.org/W2087524613,89,13,1,1369,214,11,en,en
false,isotretinoin use subsequent depression suicide,grow number reported case depression suicide associate isotretinoin retinoid receptor agonist use patient acne prompt concern among dermatologist patient relative trigger new warning regulator include depression related patient informed consent form establish cause effect relationship useful judiciously consider whether association nature association plausible biological mechanism action validity reliability measure use strength study design hoffmann la roche estimate april approximately million patient worldwide use isotretinoin million patient us medline search january may publish medical literature find documented case isotretinoin associated depression suicide one additional patient commit suicide fourth month isotretinoin treatment patient attempt suicide take overdose isotretinoin u fda adverse event reporting system aers contain almost report isotretinoin approval december november aers contain report u foreign least one report psychiatric event fda aware report suicide u foreign association isotretinoin report positive dechallenge rechallenge present strong signal pointing association isotretinoin depression hoffmann la roche sponsor epidemiological study fail find evidence association isotretinoin depression suicide however design study flaw evidence deem inconclusive study use strong study design reliable valid measure adequate sample size may bring u close answer evidence suggest relationship isotretinoin depression need weigh increase prevalence depression among adolescent young adult psychological impact acne literature contain credible evidence isotretinoin treatment may reduce psychosocial impact acne patient present time known pharmacological mechanism would account psychiatric symptomatology result isotretinoin treatment however retinoid receptor widely distribute brain research need ascertain whether role depression meantime practitioner obvious benefit isotretinoin treat acne encourage continue use however patient relative must inform depressive symptom actively assess visit necessary referral psychiatrist antidepressant therapy discontinuation isotretinoin consider,Hull PR,2003,Am J Clin Dermatol,https://doi.org/10.2165/00128071-200304070-00005,12814338,Hull PR; D'Arcy C,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review","D000152: Acne Vulgaris; D003863: Depression; D003879: Dermatologic Agents; D006801: Humans; D015474: Isotretinoin; D018168: Receptors, Retinoic Acid; D013405: Suicide",,,https://openalex.org/W2072507718,54,7,1,2992,482,16,en,en
false,response six class antihypertensive medication body mass index randomized control trial,blood pressure increase increase body mass index bmi bmi linearly relate blood pressure population study obesity say cause resistance antihypertensive medication compare short term year blood pressure response bmi category weight change hydrochlorothiazide atenolol diltiazem sr captopril clonidine prazosin placebo male veteran drug dos titrate achieve goal diastolic blood pressure mm hg week patient achieve goal blood pressure maintain year bmi predict change systolic diastolic pulse pressure titration drug year obese patient bmi time likely diastolic blood pressure control atenolol normal weight bmi patient p prazosin patient gain weight lb end titration p year p obesity appear cause resistance antihypertensive medication,Materson BJ,2003,J Clin Hypertens (Greenwich),https://doi.org/10.1111/j.1524-6175.2003.02029.x,12826782,Materson BJ; Williams DW; Reda DJ; Cushman WC; Veterans Affairs Cooperative Study Group on Antihypertensive Agents,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D015992: Body Mass Index; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009765: Obesity,,,https://openalex.org/W2019625542,107,16,1,1024,193,9,en,en
false,achieve goal blood pressure patient type diabetes conventional versus fixed dose combination approach,data third national health nutrition examination survey nhanes iii demonstrate people diabetes treat high blood pressure achieve blood pressure goal mm hg recommend sixth report joint national committee prevention detection evaluation treatment high blood pressure jnc vi current study test hypothesis initial therapy fixed dose combination achieve recommended blood pressure goal patient type diabetes faster conventional monotherapy randomized double blind placebo controlled study primary end point achievement blood pressure mm hg participant n hypertension type diabetes receive either amlodipine benazepril mg combination enalapril mg conventional daily week titrate mg day mg day respectively time target blood pressure achieve hydrochlorothiazide hctz mg day add final week target blood pressure still reach time baseline achieve blood pressure mm hg shorter combination group week combination vs week conventional p month participant combination group achieve treatment goal combination vs conventional p data analysis month compare blood pressure control rate fixed dose combination group hctz conventional group receive hctz show even great disparity blood pressure goal achievement combination without hctz vs conventional group hctz p conclude initial therapy fixed dose combination may efficacious conventional monotherapy approach achieve blood pressure goal diabetic patient fixed dose combination approach appear safe current conventional approach,Bakris GL,2003,J Clin Hypertens (Greenwich),https://doi.org/10.1111/j.1524-6175.2002.2041.x,12826783,Bakris GL; Weir MR; Study of Hypertension and the Efficacy of Lotrel in Diabetes (SHIELD) Investigators,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D001552: Benzazepines; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004338: Drug Combinations; D004359: Drug Therapy, Combination; D004656: Enalapril; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D016896: Treatment Outcome",,,https://openalex.org/W2019386940,117,16,1,2008,354,10,en,en
false,refractory hypertension recognition psychiatric comorbidity,year old man long standing anxiety disorder paroxetine paxil diagnose isolated systolic hypertension hydrochlorothiazide hctz initiate patient attribute mouth dryness new medication although blood pressure run mm hg improve mm hg discontinue antihypertensive medication resolution mouth dryness also return high pressure atenolol lead bothersome arm tremor lisinopril long acting nifedipine discontinue due fatigue refer hypertension clinic refractory hypertension due medication intolerance chlorthalidone try discontinue mouth dryness discussion patient psychiatrist attribute mouth dryness probably antihypertensive intolerance underlie anxiety disturbance paroxetine bupropion wellbutrin find nonefficacious institution clonazepam klonopin lead significant reduction multiple chronic somatic complaint include nasal stuffiness ear pain week later hctz successfully reinitiated well tolerate combination lisinopril atenolol extended release nifedipine follow blood pressure mm hg year old woman note persistent systolic blood pressure upper hctz recommend recurrent episode smother sensation palpitation shake ensue patient recall maternal grandmother severe hypertension well panic attack later suffer stroke self taken nurse taken clinic pressure frequently run mm hg patient necessitate several emergency department visit associate panic episode quit job due fear stroke absence panic pressure systolic atenolol add emergency department follow systolic blood pressure go mm hg lead referral hypertension clinic treatment direct panic attack control initiation alprazolam xanax advance mg psychiatric referral home blood pressure discontinue unable tolerate paroxetine several month find group session helpful gradually continue alprazolam hctz mg q follow blood pressure consistently mid mm hg resume work hypertension clinic visit initially weekly scale back every month two case illustrate difficult control hypertension due psychiatric comorbidity hypertension could control treatment psychiatric condition address dry mouth common side effect drug anticholinergic property usually thiazide diuretic communication psychiatrist lead understanding complaint anxiety symptom also reveal patient treat chronic somatification disorder differential diagnosis patient multiple nonspecific drug reaction particularly hypertensive patient include anxiety syndrome second patient develop panic disorder initiation antihypertensive treatment family history hypertension panic attack obtain wide fluctuation blood pressure antihypertensive therapy indicate panic episode significant management issue require primary attention panic disorder hypertensive patient uncommonly appear episode flushing tremble paresthesia sweating dizziness blood pressure measure occurrence usually elevate lead anxiety recurrent episodes often concern regard secondary hypertension pheochromocytoma suboptimal control prompt unnecessary additional testing overly aggressive antihypertensive therapy hypertension significantly associate panic disorder anxiety depression patient take antihypertensive medication experience panic attacks one study patient difficult control hypertension diagnose anxiety related hyperventilation recent survey hypertension patient two drug intolerance find significant association panic attack p anxiety p depression p criterion diagnosis panic attack derive diagnostic statistical manual mental disorder define table occasionally anxiety episode may mark sensation flush precipitate elevate home blood pressure panic disorder may precede diagnosis hypertension far common panic disorder occur follow diagnosis hypertension panic disorder tend make hypertension resistant therapy useful classify medication intolerance either drug specific drug nonspecific drug specific intolerance include edema headache flush dihydropyridine calcium channel blocker cough angiotensin converting enzyme inhibitor fatigue wheeze blocker urinary frequency gout diuretic constipation edema headache nondihydropyridine calcium blockers hypertensive patient nonspecific intolerance five drug show mean high blood pressure mm hg patient recognition treatment panic attack anxiety syndrome underlying psychiatric comorbidity may lead successful antihypertensive therapy,Handler J,2003,J Clin Hypertens (Greenwich),https://doi.org/10.1111/j.1524-6175.2003.02404.x,12826793,Handler J,article,D002363: Case Reports; D016428: Journal Article,D000368: Aged; D000959: Antihypertensive Agents; D001008: Anxiety Disorders; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D016584: Panic Disorder,,,https://openalex.org/W2000086580,63,7,1,5828,921,32,en,en
false,prevention carotid artery thrombosis oral administration glycoprotein iib iiia antagonist crl,study investigate effect glycoprotein iib iiia receptor antagonist crl canine model carotid artery thrombosis carotid artery develop occlusive thrombosis five control animal time occlusion right carotid artery minute leave carotid artery minute single oral dose crl mg kg prevent occlusive thrombosis vessel increase time thrombosis albeit significantly right carotid artery minute leave carotid artery minute initial dose crl follow second oral dose mg kg hour later carotid artery remain patent throughout period electrolytic injury crl reduce thrombus weight treatment protocol ex vivo platelet aggregation arachidonic acid aa adenosine diphosphate adp reduce minute two dos crl single oral dose reduce adp induced response minute significant effect observe aa bleeding time increase minute two oral dos crl minute bleed time unchanged single dose crl result demonstrate oral administration crl prevents carotid artery thrombosis response deep vessel wall injury may potential value characterize extended preclinical clinical study,Hennan JK,2003,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-200307000-00011,12827029,Hennan JK; Willens DE; Driscoll EM; Hong TT; Giboulot T; Lucchesi BR,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000818: Animals; D001760: Bleeding Time; D020212: Carotid Artery Injuries; D002341: Carotid Artery Thrombosis; D004151: Dipeptides; D004285: Dogs; D010974: Platelet Aggregation; D010975: Platelet Aggregation Inhibitors; D019039: Platelet Glycoprotein GPIIb-IIIa Complex; D012039: Regional Blood Flow; D013449: Sulfonamides",,,https://openalex.org/W2312343976,114,14,1,1454,258,10,en,en
false,immunohistochemical analysis th th cytokine profile androgen receptor expression pathogenesis nifedipine induced gingival overgrowth,background numerous study demonstrate gingival overgrowth may associate androgen cytokine expression tissue objective aim study compare expression androgen receptor presenting cell ar cell th th cytokine th interleukin il interferon ifn th il il il expression cell tissue section patient gingival overgrowth material method tissue sample collect patient healthy periodontium h group adult periodontitis p group surgically extract teeth group nifedipine induced gingival overgrowth nigo group clinical periodontal parameter pocket depth pd bleed probe bop plaque control record pcr measure around select sample teeth gingival biopsy far process immunohistochemical stain method expression cell positive ar il ifn il il il count predetermined semiquantitative method result result indicate ar il ifn il il il intensively express nucleus inflammatory cell fibroblast gingival connective tissue strong expression ar il ifn find nigo group ar cells mm gingival fibroblast significantly high nigo group periodontitis group control group p cytokine expression nigo group show trend towards th type expression il p surgically extracted tooth group strong expression th type cytokine il il il p find inflammatory cell comparison il il labeled cell ratio four group descend sequence discover nigo group h group p group group conclusion data support following take nifedipine may elevate expression ar susceptible oral tissue e g gingiva ii cytokine profile cells nigo tissue indicate trend preferentially towards th activity iii elevation ar expression cell prominent th cytokine labeled cell two significant factor pathogenesis nigo,Huang WT,2003,J Periodontal Res,https://doi.org/10.1034/j.1600-0765.2003.00672.x,12828661,Huang WT; Lu HK; Chou HH; Kuo MY,article,D003160: Comparative Study; D016428: Journal Article,"D000328: Adult; D002121: Calcium Channel Blockers; D002467: Cell Nucleus; D003238: Connective Tissue; D005260: Female; D005347: Fibroblasts; D019214: Gingival Overgrowth; D006801: Humans; D007150: Immunohistochemistry; D007371: Interferon-gamma; D016753: Interleukin-10; D018793: Interleukin-13; D007376: Interleukin-2; D015847: Interleukin-4; D007378: Interleukins; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D010512: Periodontal Index; D010518: Periodontitis; D011944: Receptors, Androgen; D018417: Th1 Cells; D018418: Th2 Cells",,,https://openalex.org/W2124950893,152,17,1,2358,463,14,en,en
false,current treatment patient hypertension,plan treatment patient hypertension current guideline emphasise importance risk stratification base blood pressure presence end organ damage cardiovascular risk factor beneficial effect antihypertensive therapy seem link degree blood pressure reduction guideline recommend reduce blood pressure mm hg low target patient young diabetes mellitus without nephropathy non diabetic nephropathy blood pressure reduction achieve several class drug include diuretic beta blockers ace inhibitor angiotensin ii antagonist calcium channel antagonist calcium channel antagonist show reduce risk stroke major cardiovascular event however still controversial whether different treatment regimen base different drug class offer advantage beyond similar degree blood pressure control prevent cardiovascular morbidity mortality international nifedipine git study intervention goal hypertension treatment insight controlled clinical trial aim compare efficacy long acting calcium channel antagonist nifedipine gastrointestinal transport system git versus co amilozide combination diuretic hydrochlorothiazide hctz amiloride morbidity mortality high risk hypertensive patient nifedipine git hctz amiloride equally effective reduce blood pressure risk primary outcome composite death cardiovascular cerebrovascular cause non fatal stroke myocardial infarction heart failure result study indicate may great benefit stroke small benefit coronary artery disease calcium channel antagonist based regimen diuretic beta blocker based regimen however present insufficient evidence recommend specific drug choice base patient risk profile thus choice antihypertensive drug accord efficacy tolerability addition reduction cardiovascular risk two substudies insight show nifedipine git able prevent progression intima medium thickness common carotid artery slow progression coronary calcification clinical significance effect prevention cardiovascular event still remain establish,Taddei S,2003,Drugs,https://doi.org/10.2165/00003495-200363140-00001,12834362,Taddei S; Ghiadoni L; Salvetti A,article,D016428: Journal Article; D016454: Review,D000818: Animals; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002318: Cardiovascular Diseases; D002986: Clinical Trials as Topic; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D009543: Nifedipine,,,https://openalex.org/W2049834264,47,6,1,2536,392,12,en,en
false,safety efficacy sibutramine overweight hispanic patient hypertension,month randomized study evaluate safety efficacy sibutramine overweight hispanic patient hypertension follow week washout confirm diagnosis hypertension antihypertensive medication adjust achieve blood pressure less mm hg institution either sibutramine mg placebo day body mass index excess kg require entry study end weight change kg sibutramine group kg placebo group sibutramine group systolic blood pressure mm hg stabilization mm hg completion trial respective value diastolic blood pressure mm hg placebo blood pressure drop mm hg mm hg timepoints sibutramine group patient report adverse event frequently headache n constipation n dry mouth n placebo group patient adverse event sibutramine safe effective overweight hispanic patient hypertension monitoring blood pressure titration antihypertensive medication necessary,Fanghänel G,2003,Adv Ther,https://doi.org/10.1007/bf02850257,12836810,Fanghänel G; Cortinas L; Sánchez-Reyes L; Gómez-Santos R; Campos-Franco E; Berber A,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000959: Antihypertensive Agents; D001067: Appetite Depressants; D001794: Blood Pressure; D015992: Body Mass Index; D001835: Body Weight; D003503: Cyclobutanes; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008800: Mexico; D008875: Middle Aged; D009765: Obesity; D010919: Placebos; D016896: Treatment Outcome; D015431: Weight Loss,,,https://openalex.org/W2103918479,84,11,1,1308,222,9,en,en
false,effect elevated heart rate precede onset ventricular tachycardia antitachycardia pace effectiveness patient implantable cardioverter defibrillator,incorporation antitachycardia pacing atp implantable cardioverter defibrillator icds provide well tolerated alternative shock atp show effective terminate approximately spontaneous ventricular tachycardia vt episodes although atp routinely use little know predictor atp failure base evaluation stored electrograms aim prospectively follow patient icds analyze parameter affect atp effectiveness one hundred eighteen consecutive patient receive icds standard indication discharge empirical standardized atp therapy program patient within vt zone total spontaneous tachycardia episode occur patient mean follow month among vt diagnose one hundred four fast vt detect ventricular fibrillation zone treat primary shock delivery atp attempt time remain vt episode atp terminate vt successfully atp fail vt finally revert shock vt convert slow vt outside vt zone fifty one slow vt revert spontaneously redetected treat finally primary intention treat basis atp successful vt unsuccessful vt influence vt cycle length atp success rate furthermore atp efficacy similar patient left ventricular ejection fraction daytime nighttime well patient ischemic nonischemic cardiomyopathy fast heart rate immediately precede onset vt vs beats min respectively hazard ratio confidence interval p absence beta blocker therapy vs respectively hazard ratio confidence interval p find cox proportional hazard analysis sole independent predictor atp ineffectiveness icd recipient thus present study identify precede sinus tachycardia reflect increase sympathetic tone lack beta blocker use independent risk factor reduced success atp therapy terminate vt therefore modification sympathetic tone may beneficial patient icds,Kouakam C,2003,Am J Cardiol,https://doi.org/10.1016/s0002-9149(03)00459-4,12842240,Kouakam C; Lauwerier B; Klug D; Jarwe M; Marquié C; Lacroix D; Kacet S,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D002304: Cardiac Pacing, Artificial; D017147: Defibrillators, Implantable; D004562: Electrocardiography; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D016016: Proportional Hazards Models; D011446: Prospective Studies; D012008: Recurrence; D017180: Tachycardia, Ventricular",,,https://openalex.org/W2042002067,173,21,1,2417,438,18,en,en
false,role calcium channel blocker treat hypertension finally define,several large prospective randomize clinical outcome trial show calcium channel blocker effective safe antihypertensive drug compare placebo reduce cardiovascular morbidity mortality treated patient study compare conventional antihypertensive drug demonstrate similar blood pressure lowering effect similar reduction cardiovascular morbidity mortality exception high incidence heart failure fatal myocardial infarction study however consider evidence available today drug consider safe treatment uncomplicated hypertensive patient combination drug also use first line therapy old stroke prone hypertensive patient addition calcium channel blocker indicate good blood pressure control use withhold safety concern,Chrysant GS,2003,Curr Hypertens Rep,https://doi.org/10.1007/s11906-003-0037-6,12844463,Chrysant GS; Chrysant SG,article,D016428: Journal Article; D016454: Review,"D000319: Adrenergic beta-Antagonists; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002318: Cardiovascular Diseases; D004232: Diuretics; D004359: Drug Therapy, Combination; D006801: Humans; D006973: Hypertension; D017063: Outcome Assessment, Health Care; D011446: Prospective Studies; D016032: Randomized Controlled Trials as Topic; D012449: Safety",,,https://openalex.org/W2034700827,87,14,1,973,150,5,en,en
false,levosimendan new dual action drug treatment acute heart failure,levosimendan new agent treatment acute heart failure levosimendan act via complementary mechanism enhance contractility sensitise cardiac myofilaments calcium dilate blood vessel open atp dependent potassium channel contrast traditional inotropes beta agonists phosphodiesterase inhibitor levosimendan raise myocyte calcium level therefore less likely elicit arrhythmia impair diastolic relaxation clinical efficacy levosimendan support four key clinical study include patient hospitalise cardiac decompensation due acutely worsened chronic heart failure heart failure follow myocardial infarction give short term therapy levosimendan enhances cardiac output reduce systemic vascular resistance lower pulmonary capillary wedge pressure day post treatment mortality rate halve decompensated chronic heart failure patient receive levosimendan compare dobutamine advantage sustain day similar survival gain observe among acute failure patient treat levosimendan follow myocardial infarction substantial haemodynamic survival benefit levosimendan well suit part routine management patient acutely decompensated heart failure,Mebazaa A,2003,Int J Clin Pract,,12846347,Mebazaa A; Erhardt L,article,D016428: Journal Article; D016454: Review,"D000208: Acute Disease; D002316: Cardiotonic Agents; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D006333: Heart Failure; D006801: Humans; D006835: Hydrazones; D011724: Pyridazines; D016032: Randomized Controlled Trials as Topic; D000077464: Simendan; D016019: Survival Analysis; D016896: Treatment Outcome",,,https://openalex.org/W1801814366,76,13,1,1392,204,8,en,en
false,preterm delivery overview,preterm delivery lead factor cause neonatal mortality morbidity conduct pubmed literature search obtain update etiology diagnostic problem therapeutic consideration preterm delivery approximately birth premature preterm labor associate preterm rupture membrane cervical incompetence polyhydramnion fetal uterine anomaly infection social factor stress smoking heavy work risk factor diagnosis make patient present symptom clinical finding progressive effacement dilatation cervix biochemical marker preterm delivery minor importance daily clinical work measurement cervix however practical valuable tool predict preterm delivery cervical cerclage useful select case antibiotic may help prevent preterm labor case know etiologic agent e g preterm rupture membrane urinary infection use tocolytic agent beta sympathetic receptor stimulators advocate day evidence long term use beneficial could even harmful fetus calcium channel blocker nifedipine new selective oxytocin receptor antagonist atosiban appear effective beta sympathomimetic drug uterine contraction side effects prostaglandin synthetase inhibitor indomethacin may prevent uterine contraction use prior nd week pregnancy single course corticosteroid treatment two dos mg betamethasone mg dexamethasone important prevention respiratory distress th th week pregnancy multiple dos may harmful avoid case management depend gestation age fetal maturity uterine contraction week gestation indication tocolytic treatment,Haram K,2003,Acta Obstet Gynecol Scand,https://doi.org/10.1034/j.1600-0412.2003.00218.x,12848639,Haram K; Mortensen JH; Wollen AL,article,D016428: Journal Article; D016454: Review,"D005260: Female; D005865: Gestational Age; D006801: Humans; D007752: Obstetric Labor, Premature; D011247: Pregnancy; D011248: Pregnancy Complications; D012307: Risk Factors",,,https://openalex.org/W2100050861,29,5,1,1991,333,18,en,en
false,value trial long term blood pressure trend patient hypertension high cardiovascular risk,valsartan antihypertensive long term use evaluation value study compare cardiovascular outcome eligible patient country randomize valsartan amlodipine based treatment blood pressure bp trend analyze value study patient baseline bp month bp treatment data cohort patient baseline month bp month treatment data available patient n receive antihypertensive therapy baseline baseline bp mm hg treated compare mm hg untreated patient month group indistinguishable bp value month bp decrease mm hg p systolic bp diastolic bp versus baseline month mm hg p v month mm hg month p v month systolic bp control mm hg month increase baseline diastolic bp mm hg combine control mm hg month patient protocol drug monotherapy add hydrochlorothiazide add drug protocol drug nonstandard dos achieve bp control exceed value report publish large scale trial value study execute regular clinical setting patient receive antihypertensive drug baseline explicit bp goal set treatment algorithm provide physician achieve good control rate regular practice,Julius S,2003,Am J Hypertens,https://doi.org/10.1016/s0895-7061(03)00904-x,12850387,Julius S; Kjeldsen SE; Brunner H; Hansson L; Platt F; Ekman S; Laragh JH; McInnes G; Schork AM; Smith B; Weber M; Zanchetti A; VALUE Trial,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000465: Algorithms; D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002318: Cardiovascular Diseases; D015331: Cohort Studies; D004311: Double-Blind Method; D004363: Drug Utilization; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D012306: Risk; D013777: Tetrazoles; D014633: Valine; D000068756: Valsartan,,,https://openalex.org/W2144809272,110,16,1,1676,335,9,en,en
false,diagnosis management gestational hypertension preeclampsia,gestational hypertension preeclampsia common disorder pregnancy majority case develop near term development mild hypertension preeclampsia near term associate minimal maternal neonatal morbidity contrast onset severe gestational hypertension severe preeclampsia week gestation associate significant maternal perinatal complication woman diagnosed gestational hypertension preeclampsia require close evaluation maternal fetal condition duration pregnancy severe disease manage hospital decision delivery expectant management depend fetal gestational age fetal status severity maternal condition time evaluation expectant management possible select group woman severe preeclampsia week gestation steroid effective reduce neonatal mortality morbidity administer severe disease week gestation magnesium sulfate use labor least hour postpartum prevent seizure woman severe disease urgent need conduct randomized trial determine efficacy safety antihypertensive drug woman mild hypertension preeclampsia also need conduct randomized trial determine benefit risk magnesium sulfate labor postpartum woman mild preeclampsia,Sibai BM,2003,Obstet Gynecol,https://doi.org/10.1016/s0029-7844(03)00475-7,12850627,Sibai BM,article,D016428: Journal Article; D016454: Review,"D005260: Female; D005500: Follow-Up Studies; D005865: Gestational Age; D006801: Humans; D006973: Hypertension; D011181: Postnatal Care; D011225: Pre-Eclampsia; D011247: Pregnancy; D011249: Pregnancy Complications, Cardiovascular; D011256: Pregnancy Outcome; D018566: Pregnancy, High-Risk; D011295: Prenatal Care; D018570: Risk Assessment; D012720: Severity of Illness Index; D015996: Survival Rate; D016896: Treatment Outcome",,,https://openalex.org/W2108082438,69,8,1,1549,242,10,en,en
false,result pilot pharmacotherapy quality improvement program use fixed dose combination amlodipine benazepril antihypertensive therapy long term care set,hypertension common old adult age year treatment frequently require multiple medication expensive study measure impact substitute low dose fixed combination therapy use calcium channel blocker ccb amlodipine angiotensin converting enzyme ace inhibitor benazepril high dose ccb monotherapy dual therapy ccb ace inhibitor antihypertensive drug cost incidence adverse event blood pressure control multicenter pilot pharmacotherapy quality improvement program undertake long term care facility set consultant pharmacists review pharmacy record medical chart long term care facility identify old patient diagnosis hypertension either take ccb concomitantly ace inhibitor experienced adverse event high dose ccb therapy eligible patient identify physician contact regard switch fixed dose combination therapy total patient facility switch fixed dose amlodipine benazepril combination therapy woman men mean age year range year mean number comorbidities subsequent month mean blood pressure remain level similar baseline number patient report least drug related adverse event decrease p incidence edema decrease mean per patient cost antihypertensive drug decrease p mean per patient saving u dollar per month patient age year hypertension long term care facility change high dose ccb monotherapy ccb ace inhibitor dual therapy fixed dose combination amlodipine benazepril therapy significantly reduce drug cost incidence adverse event maintain blood pressure control,Sapienza S,2003,Clin Ther,https://doi.org/10.1016/s0149-2918(03)80174-1,12860503,Sapienza S; Sacco P; Floyd K; DiCesare J; Doan QD,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D001552: Benzazepines; D002121: Calcium Channel Blockers; D017046: Cost Savings; D004338: Drug Combinations; D005260: Female; D006801: Humans; D006973: Hypertension; D008134: Long-Term Care; D008297: Male; D008875: Middle Aged; D010865: Pilot Projects; D011785: Quality Assurance, Health Care; D016896: Treatment Outcome",,,https://openalex.org/W2036536272,167,20,1,1957,313,8,en,en
false,symptom distress cause,although increase recognition substantial part cardiovascular central nervous system renal condition induce renin angiotensin aldosterone system activation reflect action aldosterone potential influence therapy design block aldosterone limit fact spironolactone recently aldosterone antagonist available exert substantial array adverse effect seek compare magnitude distress induce widely use calcium channel block agent amlodipine new aldosterone antagonist eplerenone patient treat systolic hypertension total patient old year systolic hypertension randomize either eplerenone mg amlodipine mg titrate maximum mg eplerenone dose mg amlodipine dose patient follow week quality life questionnaire sf health survey validated instrument assess symptom distress symptom distress index administer randomization week start treatment systolic blood pressure response eplerenone amlodipine differ eplerenone mm hg amlodipine mm hg quality life analysis patient randomize eplerenone amlodipine significant treatment group difference symptom distress index detect baseline overall significant treatment effect symptom distress favor eplerenone p indeed symptom distress index show significant worsen distress symptom amlodipine arm none eplerenone arm significant treatment effect favor eplerenone observe symptom ankle swelling weight gain nocturia increased urination shortness breath patient symptom distress also show erosion psychosocial measure quality life p aldosterone antagonist eplerenone substantially well tolerate widely use calcium channel block agent amlodipine comparable reduction systolic blood pressure feature improve therapeutic patient blockade aldosterone effect would helpful,Hollenberg NK,2003,Arch Intern Med,https://doi.org/10.1001/archinte.163.13.1543,12860576,Hollenberg NK; Williams GH; Anderson R; Akhras KS; Bittman RM; Krause SL,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D017311: Amlodipine; D000704: Analysis of Variance; D002121: Calcium Channel Blockers; D000077545: Eplerenone; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D000451: Mineralocorticoid Receptor Antagonists; D011788: Quality of Life; D012084: Renin-Angiotensin System; D013148: Spironolactone; D018709: Statistics, Nonparametric; D016896: Treatment Outcome",,,https://openalex.org/W2166566094,36,6,1,2291,370,11,en,en
false,long term effect nisoldipine progression coronary atherosclerosis occurrence clinical event nicole study,background earlier angiographic study suggest calcium antagonist may prevent formation new coronary lesion progression minimal lesions conversely meta analysis suggest drug may increase cardiovascular mortality morbidity patient coronary heart disease objective investigate whether nisoldipine retard progression coronary atherosclerosis reduce occurrence clinical events design setting nicole study nisoldipine coronary artery disease leuven single centre randomise double blind placebo control trial coronary angiography baseline six month three year follow patients patient undergone successful coronary angioplasty randomise nisoldipine mg daily placebo intention treat per protocol population consist patient respectively results per protocol population nisoldipine treat placebo treat patient n show angiographic progression least one coronary arterial segment define increase diameter stenosis average minimum luminal diameter non dilated lesion decrease mm mm nisoldipine placebo group respectively n respective number new lesion detect n intention treat population rate death stroke acute myocardial infarction similar treatment groups however nisoldipine use associate revascularisation procedure thus percentage patient clinical event low v p conclusions nisoldipine demonstrable effect angiographic progression coronary atherosclerosis risk major cardiovascular event use associate revascularisation procedure,Dens JA,2003,Heart,https://doi.org/10.1136/heart.89.8.887,12860866,Dens JA; Desmet WJ; Coussement P; De Scheerder IK; Kostopoulos K; Kerdsinchai P; Supanantaroek C; Piessens JH,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D002121: Calcium Channel Blockers; D017023: Coronary Angiography; D003324: Coronary Artery Disease; D023921: Coronary Stenosis; D018450: Disease Progression; D004311: Double-Blind Method; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008134: Long-Term Care; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D015737: Nisoldipine; D020521: Stroke,,,https://openalex.org/W2171735087,135,21,1,1951,320,10,en,en
false,comparison blood pressure lowering effect tolerability losartan amlodipine based regimen patient isolated systolic hypertension,elevate systolic blood pressure important risk factor cardiovascular renal disease elevate diastolic blood pressure isolate systolic hypertension ish predominant form hypertension elderly effect angiotensin ii vascular wall endothelium may contribute development ish primary objective study compare effect trough sit systolic blood pressure sisbp regimen losartan selective angiotensin ii receptor antagonist amlodipine based regimen patient ish multicenter prospective randomize double blind parallel group study consist week placebo phase week active treatment phase losartan based regimen consist losartan mg increase need losartan mg hydrochlorothiazide hctz mg week losartan mg hctz mg week achieve target sisbp mm hg amlodipine based regimen consist amlodipine mg increase need amlodipine mg week amlodipine mg hctz mg week primary efficacy measure change trough sisbp baseline week information tolerability study treatment collect visit include investigator patient observation clinical adverse experience caes laboratory adverse experience response symptom questionnaire eight hundred fifty seven patient female randomize treatment losartan group amlodipine group mean age year mean duration hypertension year baseline losartan amlodipine group intent treat population baseline mean sisbp value mm hg respectively week primary end point mean change baseline sisbp mm hg patient receive losartan mm hg patient receive amlodipine estimate least square mean difference mm hg ci indicate losartan effect systolic blood pressure noninferior amlodipine proportion patient respond sisbp mm hg mm hg decrease sisbp baseline comparable group losartan amlodipine incidence caes drug related caes significantly great amlodipine group amlodipine respectively losartan p addition patient amlodipine group discontinue therapy due drug related cae compare patient losartan group vs respectively p lower extremity edema common drug related cae amlodipine group amlodipine losartan p dizziness common drug related cae losartan group losartan amlodipine patient ish losartan amlodipine produce comparable clinically relevant reduction sisbp however losartan well tolerate evidence caes discontinuation compare amlodipine losartan may consider initial treatment ish,Volpe M,2003,Clin Ther,https://doi.org/10.1016/s0149-2918(03)80133-9,12867222,Volpe M; Junren Z; Maxwell T; Rodriguez A; Gamboa R; Gomez-Fernandez P; Ortega-Gonzalez G; Matadamas N; Rodriguez F; Dass B; Kyle C; Clarysse L; Bryce A; Moreno-Heredia E; Germano G; Gilles L; Smith RD; Sanderson JE; CDSP-944 Study Group,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D019808: Losartan; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2082396286,157,19,1,3248,594,15,en,en
false,neurohormone oxidative stress nonischemic cardiomyopathy relationship survival effect treatment amlodipine,purpose study assess effect amlodipine neurohormone oxidative stress nonischemic cardiomyopathy determine relationship baseline posttreatment level marker survival neurohormones oxidative stress important pathophysiology heart failure calcium channel blocker associate poor outcome patient heart failure part due neurohormonal activation contrast amlodipine second generation dihydropyridine favorable clinical profile prospective randomized amlodipine survival evaluation praise trial subset patient nonischemic cardiomyopathy randomize amlodipine mg day placebo blood sample evaluate baseline week week norepinephrine epinephrine angiotensin ii dopamine n terminal pro atrial natriuretic peptide nt pro anp brain natriuretic peptide bnp adrenolutin malondialdehyde difference level neurohormone oxidative stress marker amlodipine placebo group different time nt pro anp bnp decrease week week baseline nt pro anp correlate survival multivariate analysis p strong relationship find reduction bnp week survival hazard ratio ci p relationship find marker oxidative stress survival conclude amlodipine affect circulate neurohormone oxidative stress marker patient nonischemic cardiomyopathy treat angiotensin converting enzyme inhibitor digoxin diuretic addition low circulate nt pro anp reduction bnp time confers good prognosis,Wijeysundera HC,2003,Am Heart J,https://doi.org/10.1016/s0002-8703(03)00171-6,12891198,Wijeysundera HC; Hansen MS; Stanton E; Cropp AS; Hall C; Dhalla NS; Ghali J; Rouleau JL; PRAISE II Investigators,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D017311: Amlodipine; D002121: Calcium Channel Blockers; D002395: Catecholamines; D005260: Female; D006333: Heart Failure; D006801: Humans; D008297: Male; D008875: Middle Aged; D015999: Multivariate Analysis; D018377: Neurotransmitter Agents; D018384: Oxidative Stress; D016019: Survival Analysis,,,https://openalex.org/W2084900070,134,18,1,1823,289,9,en,en
false,irbesartan amlodipine reduce cardiovascular event diabetic patient,add antihypertensive treatment patient diabetes nephropathy neither angiotensin receptor blocker arb irbesartan calcium channel blocker amlodipine reduce overall occurrence cardiovascular event however irbesartan decrease rate heart failure amlodipine reduce rate acute myocardial infarction,Millard PS,2003,J Fam Pract,,12899808,Millard PS,article,D016420: Comment; D016428: Journal Article,,,,https://openalex.org/W2415802221,79,11,1,361,54,2,en,en
false,comparative analysis amlodipine felodipine military outpatient population efficacy outcomes cost consideration,background retrospective study compare efficacy tolerability cost two dihydropyridine calcium channel blocker method chart patient continuous antihypertensive therapy amlodipine felodipine least month review analysis include mean change blood pressure percentage patient achieve blood pressure bp mm hg average dose cost per day two calcium channel blocker average cost additional medication total medication cost per day cost achieve bp control result eighty seven percent amlodipine treated patient achieve bp control compare felodipine treated patient total medication cost achieve bp control per day patient amlodipine compare per day patient felodipine conclusion amlodipine produce bp control great percentage patient felodipine low total cost achieve bp control evaluate total cost antihypertensive treatment cost drug alone misleading,Blivin SJ,2003,Mil Med,https://doi.org/10.1093/milmed/168.7.530,12901461,Blivin SJ; Pippins J; Annis LG; Lyons F,article,D003160: Comparative Study; D016428: Journal Article,"D017311: Amlodipine; D000704: Analysis of Variance; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003363: Cost Control; D016527: Drug Costs; D015736: Felodipine; D005260: Female; D005431: Florida; D006772: Hospitals, Military; D006801: Humans; D006973: Hypertension; D008297: Male; D008485: Medical Audit; D008875: Middle Aged; D008889: Military Personnel; D009326: Naval Medicine; D012189: Retrospective Studies; D018709: Statistics, Nonparametric; D016896: Treatment Outcome",,,https://openalex.org/W141317183,132,20,1,1093,188,7,en,en
false,statin new data secondary prevention diabetes pravastatin simvastatin best assessed statin,efficacy pravastatin simvastatin first show several year ago patient coronary heart disease trial since publish hp trial study patient coronary heart disease cardiovascular condition diabetes simvastatin significantly reduce risk death coronary event stroke compare placebo allhat llt trial patient treated hypertension pravastatin reduce overall mortality prosper trial patient age cardiovascular disease cardiovascular risk factor pravastatin reduce incidence coronary event relative placebo reduce overall mortality pharmacovigilance study suggest difference four statin term potential cause rhabdomyolysis take together trial show statin use extend patient level ldl cholesterol mmol l g l coronary heart disease hypercholesterolaemia history ischaemic stroke lower limb arterial disease statin also prescribe diabetic patient sign cardiovascular disease whose ldl cholesterol exceeds mmol l g l clinical trial data support use pravastatin simvastatin situation dose mg daily plasma creatine phosphokinase assay muscle symptom occur patient particular risk rhabdomyolysis,,2003,Prescrire Int,,12908497,,article,D003160: Comparative Study; D016428: Journal Article,D000368: Aged; D000924: Anticholesteremic Agents; D002986: Clinical Trials as Topic; D003327: Coronary Disease; D003920: Diabetes Mellitus; D004341: Drug Evaluation; D006538: Heptanoic Acids; D006801: Humans; D006973: Hypertension; D017035: Pravastatin; D011758: Pyrroles; D012206: Rhabdomyolysis; D019821: Simvastatin; D020521: Stroke; D016896: Treatment Outcome,,,https://openalex.org/W4301870042,114,18,2,1517,256,10,en,en
false,delirium critical care patient,delirium recognize literature significant problem care treatment critical care patient delirium medical disorder result morbidity mortality patient especially elderly often misdiagnosed inappropriately treat nurse health care professional need depth education delirium validate understandable assessment tool astute clinical observational skill comprehensive aggressive clinical management plan incorporate appropriate pharmacological agent result less morbidity improve long term outcome,Litton KA,2003,Crit Care Nurs Q,https://doi.org/10.1097/00002727-200307000-00005,12930035,Litton KA,article,D016428: Journal Article; D016454: Review,"D000368: Aged; D000430: Alcohol Withdrawal Delirium; D001007: Anxiety; D015897: Comorbidity; D003221: Confusion; D003422: Critical Care; D003693: Delirium; D004496: Education, Continuing; D006801: Humans; D024802: Nurse's Role; D009730: Nursing Assessment; D011618: Psychotic Disorders; D012307: Risk Factors",,,https://openalex.org/W2028687327,37,6,1,639,96,4,en,en
false,calcium channel blocker reduce cardiac morbidity noncardiac surgery meta analysis,brief cardiac complication lead cause death noncardiac surgery despite theoretical benefit calcium channel blocker ccb widely use perioperative setting systematic review assess efficacy ccbs noncardiac surgery medline embase science citation index pubmed reference list search without language restriction randomize control trial rct evaluate ccbs noncardiac surgery two reviewer independently abstract data death myocardial infarction mi ischemia supraventricular tachyarrhythmia svt congestive heart failure chf treatment effect calculate relative risk rr confidence interval ci eleven study patient include ccbs significantly reduce ischemia rr ci p svt rr ci p ccbs associate trend towards reduce death mi post hoc analysis ccbs significantly reduce death mi rr ci p major morbid event mme define death mi chf rr ci p subgroup analysis diltiazem significantly reduce ischemia svt death mi mmes meta analysis show ccbs significantly reduce ischemia svt combine end points setting noncardiac surgery majority benefit attributable diltiazem suggest need evaluation drug large rct implication meta analysis evaluate efficacy calcium channel blockers ccb prevent cardiac complication noncardiac surgery eleven relevant randomize control trial identify overall ccbs reduce major cardiac morbid event benefit attributable diltiazem,Wijeysundera DN,2003,Anesth Analg,https://doi.org/10.1213/01.ane.0000081732.51871.d2,12933374,Wijeysundera DN; Beattie WS,article,D016428: Journal Article; D017418: Meta-Analysis; D016454: Review; D000078182: Systematic Review,"D002121: Calcium Channel Blockers; D006331: Heart Diseases; D006439: Hemodynamics; D006801: Humans; D009203: Myocardial Infarction; D017202: Myocardial Ischemia; D011183: Postoperative Complications; D016032: Randomized Controlled Trials as Topic; D013617: Tachycardia, Supraventricular",,,https://openalex.org/W1981781317,97,13,1,1839,344,16,en,en
false,comparative effect lercanidipine felodipine nifedipine git blood pressure heart rate patient mild moderate arterial hypertension lercanidipine adult lead study,multicenter double blind parallel group study compare effect three dihydropyridine calcium channel blocker lercanidipine felodipine nifedipine gastrointestinal therapeutic system blood pressure heart rate patient mild moderate hypertension diastolic blood pressure mm hg patient randomize week treatment daily dos lercanidipine mg felodipine mg nifedipine gastrointestinal therapeutic system mg week treatment dose double nonresponding patient week significant difference blood pressure observe among three group increase heart rate three group induce stressful condition treatment exacerbate active treatment incidence adverse drug reaction lower lercanidipine nifedipine group felodipine group p particular incidence edema lercanidipine vs felodipine nifedipine,Romito R,2003,J Clin Hypertens (Greenwich),https://doi.org/10.1111/j.1524-6175.2003.01960.x,12939564,Romito R; Pansini MI; Perticone F; Antonelli G; Pitzalis M; Rizzon P,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004095: Dihydropyridines; D004311: Double-Blind Method; D015736: Felodipine; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine,,,https://openalex.org/W2032553750,199,33,1,1072,183,5,en,en
false,comparative assessment duration action amlodipine nifedipine git normotensive subject,study normotensive subject compare duration consistency action amlodipine mg nifedipine git mg assessment attenuation pressor response noradrenaline angiotensin ii drug significantly attenuate pressor response vasoconstrictor h post dose rightward shift fold dose response curve significantly less pharmacokinetic variability amlodipine example intra subject variability amlodipine nifedipine git significant difference pressor dose ratios h post dose amlodipine whereas significant progressive reduction pressor dose ratio nifedipine result suggest drug broadly comparable daily treatment amlodipine displayed less intra inter subject variability provide significantly sustained effect reserve pharmacological activity h post dose,Ueda S,1993,Br J Clin Pharmacol,https://doi.org/10.1111/j.1365-2125.1993.tb00415.x,12959273,Ueda S; Meredith PA; Howie CA; Elliott HL,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D017311: Amlodipine; D000804: Angiotensin II; D000959: Antihypertensive Agents; D001794: Blood Pressure; D018592: Cross-Over Studies; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D009638: Norepinephrine; D014665: Vasodilator Agents",,,https://openalex.org/W2067470304,109,16,1,1045,170,5,en,en
false,comparison acute haemodynamic effect nisoldipine nifedipine treatment atenolol patient coronary artery disease,acute haemodynamic effect intravenous nisoldipine microg kg nifedipine microg kg compare randomised within patient crossover study fifteen male patient stable angina pectoris treat atenolol study undergo routine cardiac catheterisation nisoldipine cause dose related fall systemic vascular resistance maximum associate increase heart rate cardiac index fall mean arterial pressure contrast nifedipine associate significant increase heart rate systemic vascular resistance cardiac index mean arterial pressure remain unaltered dos equivalent effect heart rate microg kg nisoldipine microg kg nifedipine acute dose nisoldipine cause significantly great fall systemic vascular resistance increase cardiac index whilst nifedipine cause great reduction stroke volume index leave ventricular stroke work index result suggest combine atenolol acute dose nisoldipine may complementary haemodynamic profile nifedipine implication finding chronic oral dosing patient impaired leave ventricular function evaluate,Donaldson KM,1993,Br J Clin Pharmacol,https://doi.org/10.1111/j.1365-2125.1993.tb00370.x,12959309,Donaldson KM; Dawkins KD; Waller DG,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D001262: Atenolol; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D006328: Cardiac Catheterization; D002302: Cardiac Output; D003324: Coronary Artery Disease; D018592: Cross-Over Studies; D004305: Dose-Response Relationship, Drug; D004359: Drug Therapy, Combination; D006339: Heart Rate; D006801: Humans; D007262: Infusions, Intravenous; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D015737: Nisoldipine; D016037: Single-Blind Method; D014655: Vascular Resistance",,,https://openalex.org/W2118508057,148,21,1,1332,243,12,en,en
false,antihypertensive efficacy tolerability low dose combination ramipril felodipine er mild moderate essential hypertension,antihypertensive efficacy tolerability low dose combination angiotensin convert enzyme inhibitor ramipril mg extended release formulation dihydropyridine calcium channel antagonist felodipine mg assess double blind double dummy placebo control randomise crossover study patient mean age year range uncomplicated mild moderate hypertension supine diastolic mmhg mmhg week single blind wash placebo four randomise double blind crossover study phase evaluate response week daily treatment placebo monotherapy drug combination noninvasive ambulatory blood pressure monitoring spacelabs perform h end phase mean h ambulatory blood pressure mmhg follow placebo follow monotherapy ramipril mg follow monotherapy felodipine er mg follow combination ramipril mg felodipine er mg active treatment phase significantly reduce mean h ambulatory diastolic pressure comparison placebo antihypertensive efficacy combination additive coadministration ramipril attenuate incidence headache attributable felodipine er,Bainbridge AD,1993,Br J Clin Pharmacol,https://doi.org/10.1111/j.1365-2125.1993.tb00371.x,12959310,Bainbridge AD; Macfadyen RJ; Stark S; Lees KR; Reid JL,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D015736: Felodipine; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D017257: Ramipril",,,https://openalex.org/W2065616454,145,21,1,1390,231,6,en,en
false,treatment hypertension old patient updated look role calcium antagonist,hypertension common adult age year old apart age hypertension powerful predictor cardiovascular end organ damage associated morbidity mortality although diastolic blood pressure regard important risk factor clear systolic blood pressure especially prevalent among old adult good predictor cardiovascular morbidity mortality hypertensive patient blood pressure level control mm hg recommend current guideline control trial demonstrate benefit lower blood pressure hypertensive individual include age year old calcium antagonist dihydropyridine subclass include nifedipine amlodipine felodipine nitrendipine well drug class potent antihypertensive agent may suitable treatment hypertension old adult however antihypertensive agent adverse effect may limit use peripheral edema particularly troublesome dihydropyridines new dihydropyridine calcium antagonist expect approve use soon include lercanidipine lacidipine associate efficacy comparable currently available calcium antagonist low incidence adverse effect especially ankle edema antihypertensive agent improved tolerability profile offer potential improved blood pressure control,Kostis JB,2003,Am J Geriatr Cardiol,https://doi.org/10.1111/j.1076-7460.2003.01722.x,12963858,Kostis JB,article,D016428: Journal Article; D016454: Review,D000368: Aged; D002121: Calcium Channel Blockers; D006801: Humans; D006973: Hypertension; D008875: Middle Aged,,,https://openalex.org/W2095354666,95,16,1,1510,237,9,en,en
false,prolongation qt interval palliative care patient,prolonged qt interval electrocardiogram ecg associate increase risk cardiac arrhythmia sudden death many drug use palliative medicine increase qt interval several license withdraw severely restrict relative importance prolonged qt interval increase palliative medicine physician deal patient long prognosis especially cardiac disease give safety concern aim study determine prevalence prolonged qt interval palliative care patient terminal stage refer specialist service patient prolong qtc two qt ms presence coexistent cardiac disease high level serum alkaline phosphatase appear clinical feature robustly associate prolonged qtc although prolonged qtc relatively common patient refer specialist palliative care service severely prolonged qt rare,Walker G,2003,J Pain Symptom Manage,https://doi.org/10.1016/s0885-3924(03)00313-0,12967735,Walker G; Wilcock A; Carey AM; Manderson C; Weller R; Crosby V,article,D016428: Journal Article,"D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000469: Alkaline Phosphatase; D005260: Female; D006331: Heart Diseases; D006801: Humans; D008133: Long QT Syndrome; D008297: Male; D008875: Middle Aged; D009369: Neoplasms; D010166: Palliative Care; D015995: Prevalence",,,https://openalex.org/W2164525305,59,9,1,1037,176,7,en,en
false,recent development obstetrics,two challenging area antenatal care prematurity pre eclampsia affect one pregnant woman prevalence static recently management option limit improve understanding basic pathophysiology change article describe advance make impact management prematurity pre eclampsia another major concern obstetrics rise number intervention particularly caesarean section without obvious benefit mother baby recent research highlight several simple effective strategy could help influence trend include management previous caesarean section breech presentation appropriate use fetal monitoring epidural labour knowledge valuable clinician come contact pregnant woman article select relevant search english pubmed cochrane collaboration well author experience research reviewing current structure antenatal care develop around detect pre eclampsia detection hypertension proteinuria define sign syndrome key aim frequent surveillance pregnancy pre eclampsia occurs pregnant woman result around maternal death per year worldwide fetus also affect directly placental insufficiency indirectly iatrogenic delivery account infant low birth weight g onset course pre eclampsia unpredictable therefore result enormous use health resource accurate prediction target preventive measure would enormous benefit prediction many biochemical substance principally placental endothelial origin increase pre eclampsia however predictive value detect susceptible woman clinical presentation poor disorder originate,Shennan AH,2003,BMJ,https://doi.org/10.1136/bmj.327.7415.604,12969931,Shennan AH,article,D016428: Journal Article; D016454: Review,"D001946: Breech Presentation; D002585: Cesarean Section; D005260: Female; D006801: Humans; D007752: Obstetric Labor, Premature; D009774: Obstetrics; D011181: Postnatal Care; D011225: Pre-Eclampsia; D011247: Pregnancy; D011248: Pregnancy Complications; D011295: Prenatal Care",,,https://openalex.org/W2067006516,33,4,1,2092,340,18,en,en
false,drug associate acute generalize exanthematic pustulosis,acute generalize exanthematous pustulosis severe eruption usually drug relate causative drug discontinue acute generalize exanthematous pustulosis resolve spontaneously ten day aim study compare drug suspect cause acute generalize exanthematous pustulosis report french pharmacovigilance centre report literature case pustular eruption qualify serious report french pharmacovigilance center january december analyze case diagnosis acute generalize exanthematous pustulosis clearly identify review dermatologist relationship acute generalize exanthematous pustulosis drug exposure examine one u exhaustive review literature also performed review data base reveal case serious acute generalize exanthematous pustulosis lead death case case acute generalize exanthematous pustulosis one drug suspect case main drug involve pristinamycin case amoxicillin clavulanic acid case hydroxychloroquine case combination spiramycin metronidazole case frequent causal drug study literature amoxicillin clavulanic acid pristinamycin hydroxychloroquine ampicillin diltiazem co trimoxazole terbinafine carbamazepine spiramycin metronidazole pristinamycin diltiazem information summary product characteristic regard risk acute generalize exanthematous pustulosis essential discontinue causative drug soon possible pustular eruption occur physician must inform risk add adverse event warning section summary product characteristic drug concerned result show relevance notification side effect physician pharmacovigilance centre lead identification signal public health dissemination warning,Saissi EH,2003,Ann Dermatol Venereol,,13679697,Saissi EH; Beau-Salinas F; Jonville-Béra AP; Lorette G; Autret-Leca E; Centres Régionaux de Pharmacovigilance,article,D003160: Comparative Study; D016428: Journal Article; D016454: Review,"D000208: Acute Disease; D000293: Adolescent; D000328: Adult; D016907: Adverse Drug Reaction Reporting Systems; D000368: Aged; D000369: Aged, 80 and over; D000658: Amoxicillin; D019980: Amoxicillin-Potassium Clavulanate Combination; D000667: Ampicillin; D000900: Anti-Bacterial Agents; D018501: Antirheumatic Agents; D002121: Calcium Channel Blockers; D002220: Carbamazepine; D004110: Diltiazem; D003875: Drug Eruptions; D004359: Drug Therapy, Combination; D005260: Female; D005602: France; D006801: Humans; D006886: Hydroxychloroquine; D008297: Male; D008795: Metronidazole; D008875: Middle Aged; D009281: Naphthalenes; D025762: Pristinamycin; D015572: Spiramycin; D000077291: Terbinafine; D015662: Trimethoprim, Sulfamethoxazole Drug Combination",,,https://openalex.org/W44303660,66,10,1,2182,355,10,en,en
true,relation use antihypertensive medication risk breast carcinoma among woman age year,limit data available regard incidence breast carcinoma among user relatively recently introduce form antihypertensive therapy although suggest woman take calcium channel blocker ccbs increase risk woman take angiotensin converting enzyme ace inhibitor decrease risk currently conclusion drawn population based case control study woman age year conduct western washington state response woman diagnose invasive breast carcinoma compare response woman control group association use different type antihypertensive medication breast carcinoma incidence evaluate use logistic regression overall woman ever use ccbs beta blockers ace inhibitor alter risk breast carcinoma relative woman never use antihypertensive medication although use immediate release ccbs thiazide diuretic potassium sparing diuretic associate modestly increase risk breast carcinoma odds ratio confidence interval ci ci ci respectively absence trend size excess risk increase duration current versus former use agent argue cautious interpretation use particular type antihypertensive medication include immediate release ccbs certain diuretic may increase risk breast carcinoma among old woman additional study warrant clarify potential association cancer,Li CI,2003,Cancer,https://doi.org/10.1002/cncr.11663,14508839,Li CI; Malone KE; Weiss NS; Boudreau DM; Cushing-Haugen KL; Daling JR,article,"D003160: Comparative Study; D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.","D000367: Age Factors; D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001943: Breast Neoplasms; D002121: Calcium Channel Blockers; D018270: Carcinoma, Ductal, Breast; D016022: Case-Control Studies; D016001: Confidence Intervals; D004305: Dose-Response Relationship, Drug; D005260: Female; D006801: Humans; D006973: Hypertension; D015994: Incidence; D016017: Odds Ratio; D011159: Population Surveillance; D011336: Probability; D011379: Prognosis; D012016: Reference Values; D018570: Risk Assessment; D016019: Survival Analysis",,,https://openalex.org/W2004436244,110,16,1,1746,293,7,en,en
false,pulmonary arterial hypertension primary pulmonary hypertension syndrome,broad range disease cause elevation pulmonary pressure pulmonary hypertension focal point cause significant morbidity mortality disorder play secondary less clinically central role others pulmonary arterial hypertension subclass pulmonary hypertension include former type disorder progressive elevation pulmonary pressure right heart failure often cause death classic example group primary pulmonary hypertension review focus various form pulmonary arterial hypertension pathophysiology recent advance treatment life threatening disorder pulmonary hypertension hemodynamic abnormality multiple cause clinical presentation world health organization classification ph detail table system break classification ph five major category pulmonary arterial hypertension b pulmonary venous hypertension c ph associate disorder respiratory system hypoxemia embolic disorder e disorder directly affect vasculature important distinguish various disease include classification various form ph quite separate natural history treatment example treatment ph relate congestive heart failure pulmonary venous hypertension aim improve primary abnormality left ventricular dysfunction volume overload rather attempt dilate pulmonary vessel ph due primary respiratory disease emphysema treat vasodilator oxygen example contrast treatment pah lower pulmonary vascular resistance primary effective treatment current review focus first group classification,Hey JC,2003,Isr Med Assoc J,,14509142,Hey JC; Scharf SM,article,D016428: Journal Article; D016454: Review,"D000959: Antihypertensive Agents; D000077300: Bosentan; D002121: Calcium Channel Blockers; D016232: Endothelins; D011464: Epoprostenol; D006801: Humans; D006976: Hypertension, Pulmonary; D013449: Sulfonamides; D014665: Vasodilator Agents",,,https://openalex.org/W2422069474,78,10,1,1960,319,13,en,en
false,current trend large cell lymphoma,last decade cyclophosphamide doxorubicin vincristine prednisone chop best available standard care aggressive non hodgkin lymphoma nhl base equivalent therapeutic result multiagent chemotherapy accompany low cost less toxicity however patient cure chop new treatment strategy employ include addition rituximab chop elderly patient dose escalation use granulocyte colony stimulating factor overcome multidrug resistance phenotype infusional chemotherapeutic regimen use new agent furthermore international prognostic factor index ipi permit identification subset patient large variation prognosis allow prognosis specific therapy test accumulate evidence clinical behavior certain nhl profile expression certain molecular marker undoubtedly play role development new prognostic model may refine ability identify poor risk patient regardless still significant opportunity improve survival large cell lymphoma,Fisher RI,2003,Leukemia,https://doi.org/10.1038/sj.leu.2403096,14513044,Fisher RI; Shah P,article,D003160: Comparative Study; D016428: Journal Article; D016454: Review,"D000971: Antineoplastic Combined Chemotherapy Protocols; D006801: Humans; D016403: Lymphoma, Large B-Cell, Diffuse; D009367: Neoplasm Staging; D016032: Randomized Controlled Trials as Topic; D016019: Survival Analysis",,,https://openalex.org/W2092993480,37,6,1,1226,195,6,en,en
false,glucagon blocker calcium channel blocker overdose systematic review,glucagon usually accept part standard treatment management patient beta blocker calcium channel blocker overdoses systematic review order evaluate evidence support glucagon use beta blocker calcium channel blocker overdose study evaluate glucagon us identify use cochrane database systematic review cochrane control trial register medline toxline embase search well review medical toxicology textbook reference identified article controlled study human animal study include latter vivo model acute poisoning quality included study assessed search find study human identify animal five study animal model beta blocker overdose include glucagon appear consistently increase heart rate least transiently appear effect mean arterial pressure even though possibly increase cardiac output effect survival rate animal model beta blocker overdose unclear six study animal model calcium channel blocker overdose include glucagon appear increase heart rate cardiac output reverse second third degree av block least transiently appear effect glucagon mean arterial pressure although increase one model glucagon appear effect survival rate included study overdoses blind limit number animal inadequate glucagon regime evidence support use glucagon management patient beta blocker calcium channel blocker overdose limit animal study,Bailey B,2003,J Toxicol Clin Toxicol,https://doi.org/10.1081/clt-120023761,14514004,Bailey B,article,D016428: Journal Article; D016454: Review; D000078182: Systematic Review,"D000319: Adrenergic beta-Antagonists; D000818: Animals; D002121: Calcium Channel Blockers; D002316: Cardiotonic Agents; D004195: Disease Models, Animal; D004285: Dogs; D062787: Drug Overdose; D005934: Glucagon; D006801: Humans; D051381: Rats",,,https://openalex.org/W2138045780,80,12,1,1827,300,10,en,en
false,effect eplerenone enalapril eplerenone enalapril patient essential hypertension leave ventricular hypertrophy,elevate renin angiotensin aldosterone system activity correlate left ventricular hypertrophy lvh cardiovascular risk relative contribution angiotensin ii aldosterone remain unclear study compare lvh regression treatment selective aldosterone blocker eplerenone enalapril combination patient hypertension month double blind randomize study perform patient lvh hypertension receive eplerenone mg daily enalapril mg daily eplerenone mg enalapril mg daily week hydrochlorothiazide mg amlodipine mg add diastolic blood pressure mm hg change left ventricular lv mass assess mri primary end point change blood pressure renin angiotensin aldosterone system hormone albuminuria safety also assess eplerenone significantly reduce lv mass baseline g n similarly enalapril g n p eplerenone enalapril g n effective eplerenone alone p treatment reduce systolic blood pressure diastolic blood pressure baseline eplerenone mm hg enalapril mm hg eplerenone enalapril mm hg p systolic blood pressure compare eplerenone alone cough common enalapril eplerenone p elevate potassium common eplerenone eplerenone effective enalapril lvh regression blood pressure control combination eplerenone enalapril effective reduce lv mass systolic blood pressure eplerenone alone,Pitt B,2003,Circulation,https://doi.org/10.1161/01.cir.0000091405.00772.6e,14517164,Pitt B; Reichek N; Willenbrock R; Zannad F; Phillips RA; Roniker B; Kleiman J; Krause S; Burns D; Williams GH,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D004311: Double-Blind Method; D004357: Drug Synergism; D004359: Drug Therapy, Combination; D004656: Enalapril; D000077545: Eplerenone; D005260: Female; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D017379: Hypertrophy, Left Ventricular; D008279: Magnetic Resonance Imaging; D008297: Male; D008875: Middle Aged; D000451: Mineralocorticoid Receptor Antagonists; D009206: Myocardium; D011188: Potassium; D012084: Renin-Angiotensin System; D013148: Spironolactone; D016896: Treatment Outcome",,,https://openalex.org/W2170880252,131,17,1,1763,296,9,en,en
false,medication sexual function,seem reluctance self report sexual dysfunction clinical interview rate report sexual dysfunction increase information seek aggressively clinical interview relationship specific therapeutic agent however cloud patient perception coexist morbidity data relate sexual dysfunction specific drug anecdotal strong proof casual effect improvement sexual function withdrawal medication adverse sexual effect commonly use medication predict simplified understanding human sexual response physiologic mediator alternative therapeutic agent substitute understand physiologic mechanism careful clinical interview although polypharmacy problem old person case sildenafil use correct drug induced impotence,Thomas DR,2003,Clin Geriatr Med,https://doi.org/10.1016/s0749-0690(02)00101-5,14567007,Thomas DR,article,D016428: Journal Article; D016454: Review,"D064420: Drug-Related Side Effects and Adverse Reactions; D007172: Erectile Dysfunction; D006801: Humans; D007989: Libido; D008297: Male; D012735: Sexual Dysfunction, Physiological",,,https://openalex.org/W2075342975,31,4,1,949,148,8,en,en
false,allhat soft science secondary end point,recent antihypertensive lipid lowering treatment prevent heart attack trial allhat show primary end point coronary heart disease identical chlorthalidone lisinopril amlodipine group yet major conclusion trial thiazide diuretic superior prevent major form cardiovascular disease prefer first line antihypertensive therapy conclusion base solely analysis secondary end point cost evidence dictum use thiazide patient uncomplicated hypertension seventh report joint national committee prevention detection evaluation treatment high blood pressure interpretation allhat broadly adumbrate guideline although diuretic rightfully remain cornerstone antihypertensive therapy remember tell allhat investigator secondary end point soft data form basis main conclusion lead labeling drug class preferred,Messerli FH,2003,Ann Intern Med,https://doi.org/10.7326/0003-4819-139-9-200311040-00012,14597462,Messerli FH,article,D016428: Journal Article,"D000959: Antihypertensive Agents; D001581: Benzothiadiazines; D003627: Data Interpretation, Statistical; D004232: Diuretics; D006801: Humans; D006973: Hypertension; D000960: Hypolipidemic Agents; D049993: Sodium Chloride Symporter Inhibitors",,,https://openalex.org/W1968680893,54,11,1,1106,187,5,en,en
true,calcium antagonist v non calcium antagonist hypertension treatment strategy patient coronary artery disease,despite evidence efficacy antihypertensive agent treat hypertensive patient safety efficacy antihypertensive agent coronary artery disease cad discern subgroup analysis large trials compare mortality morbidity outcome patient hypertension cad treat calcium antagonist strategy ca non calcium antagonist strategy ncas randomized open label blind end point study hypertensive cad patient age year old conduct september february site countries patients randomly assign either ca verapamil sustain release ncas atenolol strategy specify dose additional drug regimen trandolapril hydrochlorothiazide administer achieve blood pressure goal accord guideline sixth report joint national committee prevention detection evaluation treatment high blood pressure jnc vi less mm hg systolic less mm hg diastolic less mm hg systolic less mm hg diastolic diabetes renal impairment present trandolapril also recommend patient heart failure diabetes renal impairment primary first occurrence death cause nonfatal myocardial infarction nonfatal stroke cardiovascular death angina adverse experience hospitalization blood pressure control months month ca group patient take verapamil sustain release take trandolapril take hydrochlorothiazide ncas group patient take atenolol take hydrochlorothiazide take trandolapril follow patient years mean year per patient patient primary outcome event statistically significant difference treatment strategy ca ncas relative risk rr confidence interval ci two year blood pressure control similar group jnc vi blood pressure goal achieve systolic diastolic ca systolic diastolic ncas patient total ca ncas patient achieve systolic blood pressure less mm hg diastolic blood pressure less mm hg verapamil trandolapril based strategy clinically effective atenolol hydrochlorothiazide based strategy hypertensive cad patient,Pepine CJ,2003,JAMA,https://doi.org/10.1001/jama.290.21.2805,14657064,Pepine CJ; Handberg EM; Cooper-DeHoff RM; Marks RG; Kowey P; Messerli FH; Mancia G; Cangiano JL; Garcia-Barreto D; Keltai M; Erdine S; Bristol HA; Kolb HR; Bakris GL; Cohen JD; Parmley WW; INVEST Investigators,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000319: Adrenergic beta-Antagonists; D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001262: Atenolol; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003324: Coronary Artery Disease; D004232: Diuretics; D004359: Drug Therapy, Combination; D005260: Female; D006339: Heart Rate; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D007211: Indoles; D008297: Male; D008875: Middle Aged; D049993: Sodium Chloride Symporter Inhibitors; D016896: Treatment Outcome; D014700: Verapamil",,,https://openalex.org/W1983526026,122,16,1,2654,489,9,en,en
false,effect regular exercise blood pressure leave ventricular hypertrophy african american men severe hypertension,prevalence hypertension cardiovascular complication high african american white intervention control blood pressure population particularly important regular exercise lower blood pressure patient mild moderate hypertension effect patient severe hypertension study examine effect moderately intense exercise blood pressure leave ventricular hypertrophy african american men severe hypertension,Kokkinos PF,1995,N Engl J Med,https://doi.org/10.1056/nejm199511303332204,7477146,Kokkinos PF; Narayan P; Colleran JA; Pittaras A; Notargiacomo A; Reda D; Papademetriou V,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D044383: Black People; D001794: Blood Pressure; D003131: Combined Modality Therapy; D015444: Exercise; D006801: Humans; D006973: Hypertension; D017379: Hypertrophy, Left Ventricular; D007190: Indapamide; D008297: Male; D008875: Middle Aged; D016896: Treatment Outcome; D014700: Verapamil",,,https://openalex.org/W2314843894,127,17,1,520,75,4,en,en
false,epidemiology erectile dysfunction,last two decade significant advance make understanding male sexual dysfunction concomitantly marked increase clinical research activity field male erectile dysfunction lead good evaluation treatment option prevalence incidence dependent definition use diagnostic toll treatment option use standard definition suggest nih consensus conference improve diagnostic treatment option major impact epidemiology ed summary risk factor ed present table still epidemiologic research essential far understand distribution well prevalence ed certain ethnic group chronic condition result surgery trauma study help u improve diagnostic skill well therapeutic option,Benet AE,1995,Urol Clin North Am,https://doi.org/10.1016/s0094-0143(21)00690-x,7483123,Benet AE; Melman A,article,D016428: Journal Article; D016454: Review,D002908: Chronic Disease; D007172: Erectile Dysfunction; D006801: Humans; D007049: Iatrogenic Disease; D008297: Male; D010410: Penile Erection; D011183: Postoperative Complications; D015995: Prevalence; D014481: United States; D014947: Wounds and Injuries,,,https://openalex.org/W33566976,40,5,1,936,161,7,en,en
false,comparaison de effets vasculaires du sulfate de magn sium et de la nicardipine pendant la circulation extracorporelle,tester l hypoth se que le sulfate de magn sium mg habituellement administr pour prot ger le myocarde et r duire l incidence de arythmies en chirurgie cardiaque tait en mesure de contr ler le pouss es hypertensive aussi efficacement que la nicardipine n essai comparatif randomis quarante patient taient r partis en deux groupes en ca de survenue de pouss es hypertensive en cours de cec les patient du groupe n recevaient alors mg kg de nicardipine et ceux du groupe mg mg kg de sulfate de magn sium le protocole anesth sique tait identique et la cec r alis e en normothermie avec un bit de pompe de l min pendant les min suivant l injection des dicaments le variable h modynamiques conventionnelles taient surveill es la n et le mg ont diminu significativement la pam et le ra pendant le neuf minute suivant leur injection cette diminution tait plus importante apr le mg qu apr la n comme le bit de pompe tait maintenu constant apr leur injection cette diminution peut tre attribu e l effet relaxant exerc par des dicaments sur le muscle lisses vasculaires l injection de mg permet de contr ler le pouss es hypertensive en cours de cec aussi efficacement que la n trois gramme de mg ont un effet hypotenseur quivalent celui de mg de n cependant la r p tition de injection de mg n est pa recommand e compte tenu du risque hypermagn mie evaluate hypothesis magnesium sulphate mg usually administer protect myocardium decrease rate arrhythmia cardiac surgery able control hypertensive peak occur cardiopulmonary bypass cpb efficiently nicardipine n randomize controlled trial forty patient allocate two group hypertensive peak occur durlng cpb patient n group give nlcardipine mg kg l mg group receive magneslum sulphate mg kg l anaesthesia technique identical normothermic cpb dow remain constant l min l min followlng n mg administration usual haemodynamic variable monitor n mg decrease significantly map svr min followlng thelr administration decrease marked mg dow pump unchanged injection decrease attribute relax effect agent smooth vascular muscle mg permit treat hypertensive peak occurrlng cpb efficient n three gramme mg hypotensive effect equivalent mg nlcardiplne however repetitive injection mg recommend risk hypermagnesemla,Delhumeau A,1995,Ann Fr Anesth Reanim,https://doi.org/10.1016/s0750-7658(95)70012-0,7486271,Delhumeau A; Granry JC; Cottineau C; Bukowski JG; Corbeau JJ; Moreau X,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D000768: Anesthesia, General; D000959: Antihypertensive Agents; D001794: Blood Pressure; D006348: Cardiac Surgical Procedures; D005112: Extracorporeal Circulation; D006801: Humans; D006973: Hypertension; D007431: Intraoperative Complications; D008278: Magnesium Sulfate; D008875: Middle Aged; D009131: Muscle, Smooth, Vascular; D009529: Nicardipine",,,https://openalex.org/W2016513363,118,16,1,2812,482,19,fr,fr
false,calcium antagonist continue use first line treatment hypertension,thepast year calcium antagonist emerge one attractive widely used class antihypertensive agent attributable several feature include efficacy metabolic neutrality relatively side effect possible protective effect target organ kidney despite attribute number retrospective analysis suggest calcium antagonist may detrimental may promote adverse cardiovascular event first meta analysis effect dihydropyridines outcome include clinical trial suggest adverse trend mortality treated patient vs control patient odds ratio confidence interval ci development subsequent myocardial infarction treated patient vs control patient odds ratio ci recently psaty et al presented,Epstein M,1995,Arch Intern Med,https://doi.org/10.1001/archinte.1995.00430200025006,7487236,Epstein M,article,D016428: Journal Article; D016454: Review,D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D006801: Humans; D006973: Hypertension,,,https://openalex.org/W2067074491,87,12,1,1008,192,4,en,en
false,comparative efficacy two long acting formulation nifedipine treatment hypertension switch study investigator,compare antihypertensive effect incidence side effect two formulation nifedipine prolonged action pa tablet bid gastrointestinal therapeutic system git tablet daily patients controlled hypertension diastolic blood pressure less mmhg nifedipine pa mg n mg n bid enrol open label study consist six week previous nifedipine pa follow six week nifedipine gits therapy nifedipine gits increase mg mg daily patient diastolic blood pressure increase least mmhg compare value six week nifedipine pa blood pressure six week nifedipine pa mg mmhg decrease p conversion nifedipine gits mg mmhg blood pressure value nifedipine pa mg patient unchanged conversion nifedipine gits patient receive nifedipine gits mg patient require titration nifedipine gits mg daily sixteen patient withdraw nifedipine pa five withdrew nifedipine gits mostly reason unrelated drug therapy twenty three patient experienced adverse event nifedipine pa versus patient nifedipine gits therapy patients whose hypertension control nifedipine pa mg bid successfully convert nifedipine gits patient remain normotensive mg daily,Myers MG,1995,Can J Cardiol,,7489530,Myers MG; Toal CB,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000328: Adult; D000368: Aged; D003692: Delayed-Action Preparations; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D010349: Patient Compliance; D013607: Tablets,,,https://openalex.org/W34519052,132,19,2,1478,248,5,en,en
true,comparison effect peak oxygen consumption quality life neurohormone felodipine enalapril patient congestive heart failure,angiotensin converting enzyme ace inhibition currently cornerstone congestive heart failure chf therapy drug tolerate patient patient therapeutic alternative comparable efficacy need felodipine vasoselective dihydropyridine calcium antagonist slow onset action long plasma half life may agent therefore efficacy safety felodipine examine compare enalapril use double blind design study patient left ventricular ejection fraction peak oxygen consumption ml min kg symptom chf despite therapy diuretic digoxin week therapy statistically significant difference peak oxygen consumption felodipine enalapril ml min kg exercise tolerance felodipine second enalapril second quality life parameter affect slightly well felodipine enalapril plasma norepinephrine decrease pg ml enalapril pg ml felodipine p group drug generally well tolerate data suggest felodipine enalapril comparable effect exercise parameter patient chf neurohumoral activation observe either drug,de Vries RJ,1995,Am J Cardiol,https://doi.org/10.1016/s0002-9149(99)80352-x,7503006,de Vries RJ; Queré M; Lok DJ; Sijbring P; Bucx JJ; van Veldhuisen DJ; Dunselman PH,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D000450: Aldosterone; D000806: Angiotensin-Converting Enzyme Inhibitors; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D004656: Enalapril; D017079: Exercise Tolerance; D015736: Felodipine; D005260: Female; D006333: Heart Failure; D006801: Humans; D008297: Male; D008875: Middle Aged; D009638: Norepinephrine; D010101: Oxygen Consumption; D011788: Quality of Life; D012083: Renin; D014665: Vasodilator Agents,,,https://openalex.org/W2055452297,154,24,1,1361,225,11,en,en
false,bepridil improve leave ventricular performance pattients angina pectoris,patient coronary artery disease angina pectoris abnormality left ventricular lv diastolic performance abnormality exist patient rest experience angina presumably secondary abnormality intracellular calcium metabolism twenty three patient chronic exertional angina pectoris participate placebo controlled randomize cross trial bepridil hydrochloride angina frequency nitroglycerin ntg consumption treadmill exercise capacity assess patient underwent first pass radionuclide cineangiography receive placebo bepridil assess lv performance bepridil decrease angina frequency episode per week p ntg consumption tablet per week p total treadmill exercise time time onset angina time mm st segment depression increase significantly bepridil therapy cardiac output co stroke volume sv ejection fraction ef increase rest peak upright bicycle exercise peak ejection rate peak filling rate increase time peak ejection rate time peak fill rate decrease rest peak exercise bepridil therapy addition early diastolic fill fraction increase atrial filling volume decrease bepridil treatment bepridil effective monotherapy treatment patient exertional angina use associate increased exercise capacity decrease angina frequency ntg consumption well improve lv systolic diastolic performance rest peak exercise,Zusman RM,1993,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-199309000-00020,7504141,Zusman RM; Higgins J; Christensen D; Boucher CA,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D015764: Bepridil; D001794: Blood Pressure; D002302: Cardiac Output; D005080: Exercise Test; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D005996: Nitroglycerin; D011875: Radionuclide Angiography; D013318: Stroke Volume; D014655: Vascular Resistance; D016277: Ventricular Function, Left",,,https://openalex.org/W2006625389,80,10,1,1709,283,10,en,en
false,comparative evaluation antihypertensive efficacy daily amlodipine versus nitrendipine hour ambulatory blood pressure monitoring essential hypertension,compare antihypertensive efficacy daily amlodipine versus nitrendipine ntr h ambulatory blood pressure monitoring h abpm patient mild moderate essential hypertension eh week single blind placebo run period patient randomize double blind parallel fashion receive mg ntr mg week dose adjust necessary mg ntr mg continue another week period end placebo period last week treatment patient underwent h abpm initial office bp mean value similar group vs mm hg respectively p n comparable decrease office mean value systolic bp sbp vs mm hg diastolic bp dbp vs mm hg observe nevertheless h abpm mean value differ significantly patient treat ntr regard h sbp vs mm hg p moreover average decrease h sbp vs mm hg p h dbp vs mm hg p higher group change h heart rate hr equivalent daily dosage effective ntr decrease bp assess h abpm,Coca A,1993,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-199310000-00002,7505351,Coca A; Picado MJ; De la Sierra A; Aguilera MT; Sánchez M; Lluch MM; Urbano-Márquez A,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D017311: Amlodipine; D001794: Blood Pressure; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009568: Nitrendipine,,,https://openalex.org/W1974819009,176,20,1,1395,301,8,en,en
false,sotalol,sotalol nonselective beta adrenoceptor antagonist prolong cardiac repolarisation independently antiadrenergic action class iii antiarrhythmic property antiarrhythmic action sotalol appear arise predominantly class iii property drug exhibit broad antiarrhythmic profile conventional beta blockers sotalol effective control paroxysmal supraventricular tachycardia ventricular response atrial fibrillation flutter wolff parkinson white syndrome maintain sinus rhythm cardioversion atrial fibrillation flutter prevent initiation supraventricular tachyarrhythmias follow coronary artery bypass surgery sotalol show promise control nonmalignant life threatening ventricular arrhythmia particularly associate ischaemic heart disease effective suppress complex form ventricular ectopy display superior antiectopic activity propranolol metoprolol acute efficacy sotalol prevent reinduction sustained ventricular tachyarrhythmias suppress spontaneous episode arrhythmia holter monitoring translate long term prophylactic efficacy arrhythmia recurrence approximately patient refractory life threatening ventricular arrhythmia addition sotalol offer advantage class agent reduce cardiac cause mortality high risk population life threatening ventricular arrhythmia adverse effect sotalol primarily relate beta blocking activity class iii property prolong cardiac repolarisation sotalol devoid overt cardiodepressant activity patient mild moderate leave ventricular dysfunction overall arrhythmogenic potential moderately low torsade de pointes may develop conjunction excessive prolongation qt interval due bradycardia hypokalaemia high plasma concentration drug summary sotalol display broad spectrum antiarrhythmic activity haemodynamically well tolerate confers relatively low proarrhythmic risk likely prove particularly appropriate treatment prophylaxis life threatening ventricular tachyarrhythmias,Fitton A,1993,Drugs,https://doi.org/10.2165/00003495-199346040-00007,7506652,Fitton A; Sorkin EM,article,D016428: Journal Article; D016454: Review,"D001145: Arrhythmias, Cardiac; D006801: Humans; D013015: Sotalol; D016896: Treatment Outcome",,,https://openalex.org/W2040968447,7,1,1,2347,324,12,fi,en
false,postinfarct treatment verapamil,danish verapamil infarction trial ii davit ii treatment verapamil mg day improve reinfarction free survival compare administration placebo verapamil appear effectively prevent reinfarction sudden death e sudden event hazard ratio compare placebo confidence limit retrospective analysis data davit ii verapamil treatment patient systemic hypertension prevent reinfarction significantly well placebo verapamil recipient compare placebo recipient reinfarcted p similarly first cardiovascular event e first reinfarction first stroke death prevent effectively verapamil treatment administration placebo verapamil recipient vs placebo recipient first cardiovascular event p,Hansen JF,1993,Drugs,https://doi.org/10.2165/00003495-199300462-00011,7512483,Hansen JF,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D002561: Cerebrovascular Disorders; D016757: Death, Sudden, Cardiac; D003718: Denmark; D004311: Double-Blind Method; D005500: Follow-Up Studies; D006801: Humans; D006973: Hypertension; D009203: Myocardial Infarction; D012008: Recurrence; D012189: Retrospective Studies; D014700: Verapamil",,,https://openalex.org/W107728794,36,4,1,875,146,6,en,en
false,regional oxygen consumption persist dyskinetic canine myocardium,department anesthesiology critical care medicine university pittsburgh pittsburgh pennsylvania u,Buffington CW,1994,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-199407000-00007,7521487,Buffington CW; Strum DP; Watanabe S,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000818: Animals; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002951: Citrates; D003326: Coronary Circulation; D003931: Diacetyl; D004285: Dogs; D006339: Heart Rate; D007261: Infusions, Intra-Arterial; D008012: Lidocaine; D009200: Myocardial Contraction; D017202: Myocardial Ischemia; D010101: Oxygen Consumption; D014700: Verapamil",,,https://openalex.org/W2078791077,68,8,1,115,18,1,en,en
false,effect isradipine nifedipine diastolic function patient left ventricular dysfunction due coronary artery disease,van den toren e wout de vries rob j portegies mireille c blanksma paul k van gilst wiek h hillege han j van veldhuisen dirk j lie kong author information,Wout van den Toren E,1994,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-199406000-00014,7523788,Wout van den Toren E; de Vries RJ; Portegies MC; Blanksma PK; van Gilst WH; Hillege HJ; van Veldhuisen DJ; Lie KI,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D016280: Atrial Function, Right; D002304: Cardiac Pacing, Artificial; D003971: Diastole; D004311: Double-Blind Method; D005260: Female; D006326: Heart Auscultation; D006439: Hemodynamics; D006801: Humans; D017275: Isradipine; D008297: Male; D008875: Middle Aged; D017202: Myocardial Ischemia; D009543: Nifedipine; D013599: Systole; D016277: Ventricular Function, Left",,,https://openalex.org/W2093345186,134,19,1,186,50,2,en,nl
false,felodipine versus placebo stable effort induced angina pectoris patient inadequately control metoprolol dose finding study,compare antianginal antiischemic effect tolerability four different dos felodipine extended release er tablets placebo patient stable effort induced angina pectoris treat beta blocker metoprolol control release cr mg daily seventy five patient enrol study end week single blind period patient perform two exercise test total exercise time vary two test test limit anginal discomfort concomitant st depression least mm patient randomize double blind treatment patient patient receive three following treatment felodipine mg placebo treatment give cross balance incomplete block design three week treatment period exercise test perform h dose intake end treatment period fifty nine patient complete study twelve hour dose administration mg felodipine increase time onset anginal pain average respectively compare placebo p time mm st depression prolong mg p mg p felodipine time end exercise increase p p respectively abstract truncate word,Emanuelsson H,1994,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-199408000-00017,7526065,Emanuelsson H; Ahlström P; Kujacic V; Lundkvist L; Rosenqvist U; Tisell A; Angman K,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D000787: Angina Pectoris; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D015736: Felodipine; D005260: Female; D006801: Humans; D008297: Male; D008790: Metoprolol; D008875: Middle Aged",,,https://openalex.org/W1965507077,139,16,1,1456,289,13,en,en
false,hour efficacy new daily formulation nifedipine,nifedipine git gastro intestinal therapeutic system recently launch long acting formulation nifedipine aim italian nifedipine git study determine duration antihypertensive effect daily nifedipine git outpatient essential hypertension week placebo run period patient mild moderate essential hypertension diastolic bp mm hg randomise receive nifedipine git mg n nifedipine git mg n placebo n daily double blind fashion week end run treatment period ambulatory bp monitoring perform spacelabs device provide regular minute bp reading hour patient least hour valid ambulatory bp data average systolic diastolic bp change treatment nifedipine git mg n nifedipine git mg n placebo n mm hg respectively bp change nifedipine git differ significantly p placebo heart rate significantly alter nifedipine git effect nifedipine git placebo ambulatory bp hour hour last dose evaluate patient complete hour ambulatory bp profile hour dos nifedipine git cause significant p reduction systolic diastolic bp abstract truncate word,Zanchetti A,1994,Drugs,https://doi.org/10.2165/00003495-199400481-00007,7533703,Zanchetti A,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D001794: Blood Pressure; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D013997: Time Factors,,,https://openalex.org/W2011579426,66,10,1,1526,285,10,en,en
false,variation magnesium zinc hypertensive patient receive different treatment,study influence captopril atenolol verapamil serum intraerythrocyte concentration magnesium zinc normotensive control subject men woman age year mean sd year patient untreated mild moderate essential hypertension men woman age year mean sd year ten hypertensive patient treat captopril atenolol verapamil physical examination biochemical analysis serum mg zn participant baseline patient month treatment result compare accord nested design neumann keuls test find significant difference control patient serum intraerythrocyte concentration zn start study although significant decrease serum zn patient p month p treatment regardless drug use decrease think attributable zincuric effect captopril dietary measure intraerythrocyte zn significantly affect antihypertensive treatment serum intraerythrocyte concentration mg significantly low p hypertensive normotensive subject serum mg patient treat verapamil significantly low p treatment captopril atenolol serum mg concentration relate directly serum concentration high density lipoprotein cholesterol r p conclude supplementation mg may benefit patient hypertension,Rubio-Luengo MA,1995,Am J Hypertens,https://doi.org/10.1016/0895-7061(95)00079-5,7546494,Rubio-Luengo MA; Maldonado-Martín A; Gil-Extremera B; González-Gómez L; Luna del Castillo JD,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000959: Antihypertensive Agents; D001262: Atenolol; D001794: Blood Pressure; D002216: Captopril; D008076: Cholesterol, HDL; D004912: Erythrocytes; D005260: Female; D006801: Humans; D006973: Hypertension; D008274: Magnesium; D008297: Male; D008875: Middle Aged; D013997: Time Factors; D014700: Verapamil; D015032: Zinc",,,https://openalex.org/W1983618806,89,12,1,1689,307,10,en,en
false,differential effect felodipine nifedipine h blood pressure leave ventricular mass,dihydropyridine calcium antagonist rapid onset short duration action tend increase sympathetic activity may limit regression left ventricular hypertrophy use treatment hypertension study compare effect shorter acting formulation nifedipine pa longer acting felodipine er h blood pressure leave ventricular mass patient uncomplicated essential hypertension subject randomly allocate receive nifedipine n felodipine n week increase dos sit office diastolic blood pressure dbp mm hg ambulatory blood pressure abp recording echocardiogram perform baseline upon completion study end dosing interval felodipine lower office dbp mm hg compare nifedipine p mean h abp reduce p felodipine mm hg nifedipine mm hg however nifedipine cause apparent biphasic response felodipine reducing p blood pressure early afternoon compare nifedipine left ventricular mass index significantly reduce p felodipine g nifedipine daily administration felodipine achieve consistent control blood pressure compare twice daily nifedipine may associate great reduction left ventricular mass,Myers MG,1995,Am J Hypertens,https://doi.org/10.1016/0895-7061(95)00117-8,7546497,Myers MG; Leenen FH; Tanner J,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000959: Antihypertensive Agents; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D004311: Double-Blind Method; D004452: Echocardiography; D004562: Electrocardiography; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D017379: Hypertrophy, Left Ventricular; D008297: Male; D008875: Middle Aged; D009543: Nifedipine",,,https://openalex.org/W2069363074,99,15,1,1541,289,9,en,en
false,time dependent effect isradipine nocturnal hypertension chronic renal failure,nocturnal hypertension frequently observe chronic renal failure contributes risk target organ damage assess whether antihypertensive therapy may restore nocturnal blood pressure bp fall condition sustained release oral formulation sro isradipine use possible difference response morning v even dose also investigate sixteen hypertensive patient chronic renal failure due parenchymal kidney disease study week single blind placebo runin accord double blind randomize cross design receive mg isradipine sro week separate single blind placebo period week h bp monitoring min interval carry end treatment use spacelabs instrument placebo blunt bp profile observe whereas hr show mean nocturnal fall remain unaltered isradipine isradipine treatment equally effective reduce mean h bp level however evening regimen show pronounced effect night mean nocturnal fall systolic diastolic bp represent corresponding daytime mean morning evening dosing respectively evening administration reset normal synchronization h bp hr profile finding demonstrate antihypertensive treatment may restore nocturnal bp fall renal patient evening regimen isradipine sro seem apt morning regimen obtain therapeutic goal j hypertens,Portaluppi F,1995,Am J Hypertens,https://doi.org/10.1016/0895-7061(95)00124-8,7546498,Portaluppi F; Vergnani L; Manfredini R; degli Uberti EC; Fersini C,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000959: Antihypertensive Agents; D001794: Blood Pressure; D002940: Circadian Rhythm; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D006339: Heart Rate; D006801: Humans; D006977: Hypertension, Renal; D017275: Isradipine; D007676: Kidney Failure, Chronic; D008297: Male; D008875: Middle Aged; D013997: Time Factors",,,https://openalex.org/W1997150388,91,13,1,1673,283,14,en,en
false,change wall motion patient treat unstable angina,background double blind placebo controlled study use anistreplase perform patient unstable angina patient history unstable angina combine typical ecg change without evidence previous recent ongoing myocardial infarction purpose present study analyze relationship patency culprit artery behavior ischemia related regional left ventricular lv wall motion method result entry study patient receive conventional drug therapy iv nitroglycerin therapy oral beta blocking agent calcium antagonist baseline angiography carry within h randomization mean h range h last attack chest pain treatment trial medication withhold case sixty five patient coronary artery disease receive anistreplase u min heparin patient heparin therapy angiography repeat h mean sd range h baseline angiographic study assess change regional myocardial wall motion lv wall divide seven segment ischemia related coronary artery stenosis calculate quantitatively relate quantitatively assessed mean regional leave ventricular ejection fraction rlvef ischemia related segment patient receive trial medication find anistreplase heparin therapy lead significantly p great reduction coronary artery diameter stenosis heparin therapy n mean sd v n mean sd anistreplase heparin therapy relate large significant improvement ischemia related rlvef heparin therapy although latter association statistically significant n mean sd v n mean sd effect change coronary artery stenosis regional lv wall motion also determine paradoxical finding persistently occlude vessel vessel show increase coronary artery stenosis associate great improvement ischemia related rlvef reopened vessel vessel reduction coronary artery stenosis n mean sd v n mean sd v n mean sd v n mean sd n one day last attack chest pain regional lv wall motion still abnormal patient conclusion patient unstable angina lv wall motion improve treated control group follow angiography day later improve coronary arterial anatomy associate less improvement lv contractile function worsening coronary angiographic appearance occur rational explanation result beginning effort elucidate clinical significance stunned hibernate myocardium human double blind placebo controlled study use anistreplase perform patient unstable angina patient history unstable angina combine typical ecg change without evidence previous recent ongoing myocardial infarction purpose present study analyze relationship patency culprit artery behavior ischemia related regional left ventricular lv wall motion entry study patient receive conventional drug therapy iv nitroglycerin therapy oral beta blocking agent calcium antagonist baseline angiography carry within h randomization mean h range h last attack chest pain treatment trial medication withhold case sixty five patient coronary artery disease receive anistreplase u min heparin patient heparin therapy angiography repeat h mean sd range h baseline angiographic study assess change regional myocardial wall motion lv wall divide seven segment ischemia related coronary artery stenosis calculate quantitatively relate quantitatively assessed mean regional leave ventricular ejection fraction rlvef ischemia related segment patient receive trial medication find anistreplase heparin therapy lead significantly p great reduction coronary artery diameter stenosis heparin therapy n mean sd v n mean sd anistreplase heparin therapy relate large significant improvement ischemia related rlvef heparin therapy although latter association statistically significant n mean sd v n mean sd effect change coronary artery stenosis regional lv wall motion also determine paradoxical finding persistently occlude vessel vessel show increase coronary artery stenosis associate great improvement ischemia related rlvef reopened vessel vessel reduction coronary artery stenosis n mean sd v n mean sd v n mean sd v n mean sd n one day last attack chest pain regional lv wall motion still abnormal patient patient unstable angina lv wall motion improve treated control group follow angiography day later improve coronary arterial anatomy associate less improvement lv contractile function worsening coronary angiographic appearance occur rational explanation result beginning effort elucidate clinical significance stunned hibernate myocardium human,de Zwaan C,1995,Chest,https://doi.org/10.1378/chest.108.4.903,7555159,de Zwaan C; Bär FW; Dassen WR; Vermeer F; Wellens HJ,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000368: Aged; D000789: Angina, Unstable; D016255: Anistreplase; D006328: Cardiac Catheterization; D002637: Chest Pain; D016009: Chi-Square Distribution; D017023: Coronary Angiography; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D005343: Fibrinolytic Agents; D006801: Humans; D008297: Male; D008875: Middle Aged; D017682: Myocardial Stunning; D018709: Statistics, Nonparametric; D016277: Ventricular Function, Left",,,https://openalex.org/W1979971847,62,10,1,5965,1047,38,en,en
false,factor determine blood pressure response enalapril nifedipine hypertension associate niddm,examine factor determine blood pressure response enalapril nifedipine monotherapy treatment hypertension associate non insulin dependent diabetes mellitus niddm week placebo baseline period hypertensive niddm patient randomly assign double blindly treatment nifedipine retard slow release n enalapril n daily dosage enalapril increase require mg nifedipine mg week interval week titration period blood pressure h urinary albumin excretion uae biochemical data serum angiotensin converting enzyme ace activity measure week week venous blood also sample baseline plasma atrial natriuretic peptide renin aldosterone serum insulin concentrations week mean daily dose enalapril mg patient receive maximum daily dose mg nifedipine group mean daily drug dose mg receive maximum daily dose mg despite dose dependent fall serum ace activity enalapril group mean arterial pressure map reduce mmhg throughout week titration period compare decline mmhg week respectively nifedipine group p group enalapril group change map week correlate significantly baseline plasma glucose r p aldosterone concentration r p uae r p statistically significant correlation change map baseline plasma renin concentration multivariate analysis baseline renal function glycemic control plasma aldosterone serum insulin concentration independently relate change blood pressure enalapril treated patient statistical association observe nifedipine group hypertensive niddm patient activity renin angiotensin aldosterone system level serum insulin glycemic control renal function proteinuria may important determinant blood pressure response ace inhibition good glycemic control may optimize antihypertensive efficacy concomitant ace inhibitor therapy,Chan JC,1995,Diabetes Care,https://doi.org/10.2337/diacare.18.7.1001,7555530,Chan JC; Nicholls MG; Cheung CK; Law LK; Swaminathan R; Cockram CS,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000419: Albuminuria; D000450: Aldosterone; D000959: Antihypertensive Agents; D009320: Atrial Natriuretic Factor; D001786: Blood Glucose; D001794: Blood Pressure; D003924: Diabetes Mellitus, Type 2; D003925: Diabetic Angiopathies; D004232: Diuretics; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004656: Enalapril; D005665: Furosemide; D006442: Glycated Hemoglobin; D006801: Humans; D006973: Hypertension; D007190: Indapamide; D009543: Nifedipine; D010919: Placebos; D011188: Potassium; D012044: Regression Analysis; D012083: Renin; D012964: Sodium; D013997: Time Factors",,,https://openalex.org/W2052468277,113,15,1,2464,464,11,en,en
false,determination systemic haemodynamic alteration induce slow release nifedipine elderly hypertensive patient use non invasive method double blind cross sectional random study,evaluate systemic haemodynamic alteration induce slow release nifedipine administer elderly hypertensive patient mg twice daily oral route week non invasive chest electrical bio impedance method use detect change stroke volume cardiac output random double blind crossover study show variation measurement make supine stand position delta p delta p mean arterial pressure delta p delta p total peripheral resistance delta p delta p heart rate respectively contrast cardiac output stroke volume measure supine stand position compare placebo period compare conclude slow release nifedipine effective reduce systemic blood pressure level elderly subject phenomenon occur without reduction cardiac output,Ferreira-Filho SR,1995,J Hum Hypertens,,7562881,Ferreira-Filho SR; Dorneles H,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D001795: Blood Pressure Determination; D003430: Cross-Sectional Studies; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D017097: Electric Impedance; D005260: Female; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011187: Posture; D016683: Supine Position,,,https://openalex.org/W2462163909,190,23,1,1051,195,5,en,en
false,acute thrombogenicity arterial prosthesis expose reduce blood flow dog,thrombogenesis consider principal cause early failure arterial graft although antithrombotic drug recommend efficiency low blood flow condition still debate study evaluate ability three drug modify thrombotic property blood consequently influence platelet fibrin deposition luminal surface polyester arterial prosthesis dog receive saline control n heparin u kg n aspirin mg n prostacyclin ng kg min n cm woven loop shaped debakey arterial prosthesis implant substitute infrarenal aorta expose reduce blood flow ml min h parameter blood measure include activate clotting time act platelet aggregation collagen determine treatment blood deposit quantify use labeled platelet labeled fibrinogen act significantly prolong heparin treatment platelet aggregation decrease p heparin treatment almost abolish aspirin prostacyclin treatment compare control group platelet fibrin uptake luminal surface prosthesis reduce significantly heparin respectively despite inhibition platelet aggregation vitro aspirin prostacyclin induce significant change platelet fibrin deposition luminal surface woven polyester arterial prosthesis low blood flow condition condition however thrombin generation subsequent platelet fibrin deposition prevent use heparin anticoagulant therapy,Merhi Y,1995,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-199507000-00001,7564348,Merhi Y; Bernier J; Marois Y; Guidoin R,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000704: Analysis of Variance; D000818: Animals; D000925: Anticoagulants; D001241: Aspirin; D001807: Blood Vessel Prosthesis; D004285: Dogs; D011464: Epoprostenol; D005260: Female; D005337: Fibrin; D006493: Heparin; D008297: Male; D010974: Platelet Aggregation; D010975: Platelet Aggregation Inhibitors; D011091: Polyesters; D012079: Renal Circulation; D013918: Thrombin Time; D013927: Thrombosis",,,https://openalex.org/W2084854724,82,12,1,1769,309,9,en,en
false,clinical efficacy safety daily diltiazem patient stable angina pectoris switch twice daily diltiazem,maintenance angina control assess multicenter three site randomize double blind parallel group study patient stable angina pectoris receive twice daily sustained release sr diltiazem switch equivalent dos daily controlled delivery cd diltiazem diltiazem sr patient switch diltiazem sr diltiazem cd n experience increase time termination p exercise tolerance test ett well improvement time onset angina p ett similar trend observe patient randomize diltiazem sr n suggest training effect therefore equal efficacy diltiazem sr diltiazem cd exercise testing diltiazem sr baseline phase patient experience angina whereas patient experience st segment depression follow transfer diltiazem cd patient respectively remain angina st segment depression free significant change number angina attack nitroglycerin use hemodynamic related parameter observe follow transfer diltiazem cd eleven percent patient receive diltiazem cd experience treatment related adverse event limit headache abdominal pain adverse event lead discontinuation treatment finding suggest patient whose angina control twice daily diltiazem sr safely effectively switch equivalent daily dose daily diltiazem cd,Savard D,1995,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-199507000-00014,7564371,Savard D; Lenis J; Juneau M; Jacob C; Boulet AP,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000368: Aged; D000787: Angina Pectoris; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D004110: Diltiazem; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005080: Exercise Test; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D005996: Nitroglycerin; D014665: Vasodilator Agents,,,https://openalex.org/W2164667816,128,17,1,1631,289,9,en,en
false,three period crossover trial ambulatory blood pressure monitoring evaluate antihypertensive therapy,double blind three period crossover trial use hour ambulatory blood pressure monitoring compare diltiazem control diffusion cd mg placebo patient hypertension n randomly assign one four crossover treatment sequence three treatment period ambulatory blood pressure obtain end week treatment period diltiazem cd significantly decrease diastolic systolic blood pressure bihourly ambulatory blood pressure evaluation p however ambulatory blood pressure monitor data combine one statistical model blood pressure reduction quantifiably similar overall bihourly analysis consistent hour antihypertensive effect diastolic systolic blood pressure relative placebo e parallel blood pressure profile increased precision mean se change diastolic systolic blood pressure across hour dosing interval mm hg mm hg respectively p therefore use crossover design ambulatory blood pressure monitoring show diltiazem cd reduce blood pressure consistently throughout hour dosing interval comparison placebo patient hypertension,Meeves S,1995,Am Heart J,https://doi.org/10.1016/0002-8703(95)90086-1,7572595,Meeves S; Hafner K; Park G; Weber M,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000959: Antihypertensive Agents; D018660: Blood Pressure Monitoring, Ambulatory; D002214: Capsules; D018592: Cross-Over Studies; D004110: Diltiazem; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2138795603,110,12,1,1338,222,7,en,en
false,usefulness heart rale variability predict drug efficacy metoprolol v diltiazem patient stable angina pectoris,investigate whether analysis heart rate hr variability may use predict efficacy drug treatment myocardial ischemia double blind crossover study patient stable angina pectoris proven coronary artery disease myocardial ischemia holter monitoring receive metoprolol controlled release mg daily diltiazem mg time daily placebo run phase treatment period hour holter recording obtain hr variability st segment analysis baseline total duration myocardial ischemia minute mean sd per hour total number episode metoprolol significantly reduce total duration ischemia minute cl total number episode patient low sd normal normal interval baseline sdnn use median value cut value contrast significant treatment effect observe patient high sdnn baseline similar result obtain use base line total power low frequency power use baseline heart rate diltiazem reduce total duration ischemia minute number episode moreover contrast metoprolol efficacy diltiazem relate baseline hr variability conclusion patient reduced hr variability baseline respond treatment metoprolol differential pattern observe diltiazem result therefore suggest analysis hr variability may useful select patient benefit treatment blocker,Brouwer J,1995,Am J Cardiol,https://doi.org/10.1016/s0002-9149(99)80222-7,7572650,Brouwer J; Viersma JW; van Veldhuisen DJ; Man in 't Veld AJ; Sijbring P; Haaksma J; Dijk WA; Lie KI,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000704: Analysis of Variance; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D004110: Diltiazem; D004311: Double-Blind Method; D015716: Electrocardiography, Ambulatory; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008790: Metoprolol; D008875: Middle Aged; D011237: Predictive Value of Tests; D011446: Prospective Studies",,,https://openalex.org/W1976035149,130,20,1,1730,311,12,en,en
false,crossover comparison extended release felodipine prolonged action nifedipine hypertension,crossover design control blood pressure extended release felodipine compare control prolonged action nifedipine child renal hypertension compliance daily felodipine high nifedipine sem v p mean diastolic blood pressure low day felodipine nifedipine v mm hg p similarly blood pressure load percentage day child blood pressure exceed upper limit normal age low felodipine nifedipine v opposite trend night though reach statistical significance data suggest day felodipine effective child hypertension may improved compliance,Moncica I,1995,Arch Dis Child,https://doi.org/10.1136/adc.73.2.154,7574861,Moncica I; Oh PI; ul Qamar I; Scolnik D; Arbus GS; Hebert D; Balfe JW; Koren G,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000959: Antihypertensive Agents; D002648: Child; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D004334: Drug Administration Schedule; D015736: Felodipine; D006801: Humans; D006977: Hypertension, Renal; D009543: Nifedipine; D010349: Patient Compliance",,,https://openalex.org/W2016395844,103,14,1,881,178,7,en,en
false,calcium channel blocker heart rate control atrial fibrillation complicate congestive heart failure,review safety efficacy verapamil diltiazem respect ventricular response atrial fibrillation af setting left ventricular lv systolic dysfunction pertinent article identify medline search english language literature follow manual search bibliography pertinent articles studies select case report control trial review article editorials effects verapamil diltiazem hemodynamics ventricular response af clinical parameter mortality reviewed limit data effect verapamil diltiazem ventricular function patient congestive heart failure vitro diltiazem negative inotropic effect verapamil clinically report hemodynamic clinical deterioration patient significant lv dysfunction give verapamil although patient improve verapamil data concern diltiazem setting af complicate congestive heart failure drug appear exacerbate heart failure although hypotension result chronic af complicate heart failure concern diltiazem may increase mortality option therapy digoxin beta blockers atrioventricular node ablation calcium channel blocker may role acute reduction ventricular response patient af complicate congestive heart failure however safety chronic heart rate control remain prove,Heywood JT,1995,Can J Cardiol,,7585281,Heywood JT,article,D003160: Comparative Study; D016428: Journal Article,"D001281: Atrial Fibrillation; D002121: Calcium Channel Blockers; D002986: Clinical Trials as Topic; D004110: Diltiazem; D005260: Female; D006333: Heart Failure; D006439: Hemodynamics; D006801: Humans; D008297: Male; D015337: Multicenter Studies as Topic; D016032: Randomized Controlled Trials as Topic; D013599: Systole; D018487: Ventricular Dysfunction, Left; D014700: Verapamil",,,https://openalex.org/W2408782388,111,16,1,1571,243,7,en,en
false,antihypertensive efficacy optimally titrate dos daily sustained release diltiazem placebo controlled trial,study assess daily sustained release sr diltiazem essential hypertension patient supine diastolic blood pressure bp mm hg randomize mg diltiazem placebo optimally titrate week interval mg achieve supine diastolic bp mm hg mm hg fall baseline bp measure trough level h dose week dose mg supine diastolic bp significantly reduce mm hg compare placebo mm hg p yield responder diltiazem placebo p titration allow supine diastolic bp normalization diltiazem mm hg compare placebo mm hg p yield responder diltiazem placebo p safety profile similar placebo mg sr diltiazem formulation enable safe close regimen adjustment mild moderate essential hypertension,Ollivier JP,1995,Cardiology,https://doi.org/10.1159/000176927,7585759,Ollivier JP; Wajman A; Stalla-Bourdillon A,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D003692: Delayed-Action Preparations; D004110: Diltiazem; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D016896: Treatment Outcome",,,https://openalex.org/W1968518106,123,14,1,1038,215,8,en,en
false,comparative evaluation antihypertensive efficacy daily sustained release isradipine lacidipine use hour ambulatory blood pressure monitoring,single blind crossover study antihypertensive efficacy two dihydropyridine calcium antagonist sustained release isradipine lacidipine compare use clinic ambulatory blood pressure measurement week placebo wash patient men woman mean age year mild moderate hypertension diastolic blood pressure range mmhg treat mg sustained release isradipine week mg lacidipine week random order medication take daily h clinic ambulatory blood pressure record end placebo treatment period two patient stop isradipine six lacidipine severe adverse effect clinic systolic diastolic blood pressure decrease average mmhg isradipine mmhg lacidipine compare placebo p case without change heart rate mean ambulatory h daytime systolic diastolic blood pressure significantly reduce sustained release isradipine lacidipine p p respectively night systolic blood pressure fell compare placebo p drug whereas reduction diastolic blood pressure statistically significant mean h heart rate remain unchanged blood pressure variability differ significantly two drug either drug placebo antihypertensive effect sustained release isradipine lacidipine similar tolerability isradipine appear great since cause withdrawal,Galderisi M,1995,J Int Med Res,https://doi.org/10.1177/030006059502300403,7589766,Galderisi M; Petrocelli A; Garofalo M; Celentano A; Alfieri A; de Divitiis O,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000959: Antihypertensive Agents; D001794: Blood Pressure; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D004095: Dihydropyridines; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D008297: Male; D008875: Middle Aged; D016037: Single-Blind Method,,,https://openalex.org/W2415363538,164,17,1,1664,281,10,en,en
false,streptokinase induced transient aggravation myocardial injury,examine relationship streptokinase infusion intensity myocardial injury systemic hypotension patient receive streptokinase treatment evolve acute myocardial infarction twenty consecutive patient treat streptokinase evolve acute myocardial infarction receive continuous blood pressure segment monitoring lead electrocardiogram ecg least h commence prior commencement streptokinase infusion aggravation injury manifest episodic increase segment elevation electrocardiogram ecg p mean segment elevation p occur within first min initiation streptokinase infusion hypotension also occur transiently patient mean minimum systolic blood pressure mmhg occur min commencement streptokinase correlation extent aggravation injury hypotension patient show ecg evidence reperfusion reduction elevation reference lead maximal value median min range min conclude streptokinase aggravate injury prior reperfusion although probably via induction hypotension possible effect contribute early hazard thrombolytic therapy,Arstall MA,1995,Int J Cardiol,https://doi.org/10.1016/0167-5273(95)93679-m,7591321,Arstall MA; Stewart S; Haste MA; Horowitz JD,article,D016428: Journal Article,"D000328: Adult; D000368: Aged; D000889: Anti-Arrhythmia Agents; D001794: Blood Pressure; D003326: Coronary Circulation; D004359: Drug Therapy, Combination; D015716: Electrocardiography, Ambulatory; D005260: Female; D005343: Fibrinolytic Agents; D006801: Humans; D007022: Hypotension; D007262: Infusions, Intravenous; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D005996: Nitroglycerin; D011446: Prospective Studies; D012307: Risk Factors; D013300: Streptokinase; D015912: Thrombolytic Therapy; D014665: Vasodilator Agents; D014700: Verapamil",,,https://openalex.org/W1996490416,64,6,1,1413,240,8,en,en
false,alpha blockade calcium antagonism effective well tolerated combination treatment resistant hypertension,objective test whether combination calcium antagonism additive new antihypertensive namely blockers angiotensin convert enzyme ace inhibitor design three way double blind latin square crossover study two group patient essential hypertension three treatment period amlodipine doxazosin study enalapril study b combination amlodipine second drug method treatment take month precede week single blind run period patient receive low dose doxazosin study enalapril study b enable recruitment patient moderate severe hypertension blood pressure foot volume plasma noradrenaline concentration measure end run treatment period result combination blockade calcium antagonism cause fall supine erect blood pressure fall significantly great either drug alone great sum fall take individual drug combination amlodipine ace inhibitor also additive combination amlodipine tolerate well patient conclusion combination blockade calcium antagonism previously study useful resistant hypertensive tolerate p blockade ace inhibitor combination ace inhibition calcium antagonism previously show additive use positive control present study suggest use active drug run period may useful design permit study patient treatment safely withdraw,Brown MJ,1995,J Hypertens,https://doi.org/10.1097/00004872-199506000-00018,7594429,Brown MJ; Dickerson JE,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000317: Adrenergic alpha-Antagonists; D000328: Adult; D000368: Aged; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D004311: Double-Blind Method; D017292: Doxazosin; D004357: Drug Synergism; D004359: Drug Therapy, Combination; D004656: Enalapril; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W1981742720,126,16,1,1754,302,11,en,en
false,spirapril,spirapril non sulfhydryl angiotensin convert enzyme ace inhibitor prodrug convert active metabolite spiraprilat follow oral administration evaluate primarily treatment hypertension dose finding study patient mild severe hypertension spirapril mg daily produce reduction blood pressure approximately mm hg systolic mm hg diastolic hour postdose trough reading end treatment period blood pressure normalisation trough diastolic blood pressure mm hg occur patient end investigation dose response curve spirapril appear flat dos mg daily comparison ace inhibitor limit number study require relative antihypertensive efficacy spirapril fully evaluate however single well control clinical trial spirapril produce similar reduction blood pressure see enalapril captopril give monotherapy combination hydrochlorothiazide spirapril may offer potential advantage calcium antagonist nitrendipine spirapril generally well tolerate produce adverse event profile similar ace inhibitor data small study suggest spirapril use without dosage adjustment patient renal impairment consequence dual renal hepatic clearance mechanism contrast ace inhibitor eliminate predominantly renal mechanism result accumulation active metabolite renal function impair however utility spirapril patient group yet fully determine conflict data regard effect renal function thus spirapril effective antihypertensive agent well tolerate far comparative trial need fully determine efficacy respect ace inhibitor good understanding effect renal function clarify role hypertensive patient renal failure,Noble S,1995,Drugs,https://doi.org/10.2165/00003495-199549050-00008,7601014,Noble S; Sorkin EM,article,D016428: Journal Article; D016454: Review,D000806: Angiotensin-Converting Enzyme Inhibitors; D000818: Animals; D002986: Clinical Trials as Topic; D004656: Enalapril; D006801: Humans; D006973: Hypertension,,,https://openalex.org/W2046691824,9,1,1,2221,375,13,en,en
false,new occupational risk factor chronic renal failure,occupational pollutant may role development chronic renal failure crf epidemiological study cross sectional limited certain renal diagnosis concentrate early transient renal effect case control study examine association crf occupational exposure occupational history men woman crf type compare control match age sex region residence exposure assess degree frequency score independently three industrial hygienist unaware case control status significantly increased risk crf find exposure lead odds ratio ci copper chromium tin mercury weld fume silicon containing compound grain dust oxygenate hydrocarbon frequency various occupational exposure high among patient diabetic nephropathy epidemiological study confirm previously identify risk factor suggest additional occupational exposure experimental evidence may important development crf role grain dust association occupational exposure diabetic nephropathy merit investigation,Nuyts GD,1995,Lancet,https://doi.org/10.1016/s0140-6736(95)92648-8,7603180,Nuyts GD; Van Vlem E; Thys J; De Leersnijder D; D'Haese PC; Elseviers MM; De Broe ME,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000395: Air Pollutants, Occupational; D001530: Belgium; D016022: Case-Control Studies; D002617: Chemical Industry; D003252: Construction Materials; D005260: Female; D006801: Humans; D007676: Kidney Failure, Chronic; D008297: Male; D008669: Metallurgy; D008875: Middle Aged; D016273: Occupational Exposure; D016017: Odds Ratio; D012307: Risk Factors",,,https://openalex.org/W2050951380,55,8,1,1441,260,9,en,en
false,calcium antagonist harmful hypertensive patient,recent report increase risk myocardial infarction hypertensive patient treat calcium antagonist present th annual conference cardiovascular disease epidemiology prevention psaty bm heckhert sr koepsell td et al risk incident myocardial infarction associate anti hypertensive drug therapies reported th annual conference cardiovascular disease epidemiology prevention march hyatt regency hill country resort san antonio texas google scholar march th receive unprecedented medium public attention editorial intend dispel myth clarify misconception offer frame reference render due time fair unbiased judgement hotly debate medical controversy population based case control study design examine association different class antihypertensive drug risk incident myocardial infarction report result preliminary analysis computerized pharmacy record first case prior myocardial infarction control without prior myocardial infarction match age gender year diagnosis subject treat hypertensive patient follow group health cooperative seattle washington major finding study among group patient use two antihypertensive drug calcium antagonist associate significant almost two fold increased risk myocardial infarction relative risk confidence interval compare receive diuretic alone first glance would seem reasonable infer calcium antagonist harmful use antihypertensive drug indeed message million hypertensive patient receive medium coverage report inference would appropriate association calcium antagonist myocardial infarction valid causal nature believe two possible source bias study selection confound bias kleibaum dg kupper morgenstern h epidemiologic research principle quantitative methods new york van nostrand reinhold google scholar first source bias may selection bias potential systematic imbalance case control example inclusion postmyocardial infarction patient case study may inadvertently include sicker patient require medicine calcium antagonist alternatively sick patient may willing participate case control study self selection thus use calcium antagonist may marker sicker patient rather cause increase morbidity observe another source bias confound bias result unknown confounders unmeasured confounders example although author match case control age gender year diagnosis hypertension may occult confound factor patient myocardial infarction congestive heart failure may contribute observed association calcium antagonist myocardial infarction thus confound bias due unknown factor unmeasured factor could potentially invalidate interpretation case control study common strategy minimize confound bias case control study match case control important know confounders university washington study case control frequency match age gender year diagnosis hypertension major limitation match case control study may cause great bias matching variable associate weakly associate risk myocardial infarction systematic imbalance case control artificially introduced kleibaum dg kupper morgenstern h epidemiologic research principle quantitative methods new york van nostrand reinhold google scholar another limitation matching longer possible make inference interaction calcium antagonist match variable vis vis risk myocardial infarction case control artificially matched kleibaum dg kupper morgenstern h epidemiologic research principle quantitative methods new york van nostrand reinhold google scholar thus summary case control study potentially vulnerable introduction selection bias confound bias may invalidate conclusion study limitation study design much less likely problem randomize controlled clinical trial basic difference randomize control trial case control study randomization treatment allocation subject randomized control trial equally likely receive active treatment control thereby minimize selection bias example problem selection bias due great willingness sicker patient participate problem randomized control trial since volunteer participate trial precede occurrence disease interest myocardial infarction moreover since know well unknown unmeasured potential confounders likely distribute equally among treated control subject confound bias minimize randomized controlled trial gold standard advocate scientific community regulatory agency food drug administration judge efficacy safety drug therapy justify public health policy recommendation regard drug therapy thus best way address question role antihypertensive drug risk myocardial infarction perform randomized control clinical trial oppose case control study causality imply judgement cause effect relationship commonly use set criterion aid judgement concern causality first report hill hill ab environment disease association causation proc r soc med pubmed google scholar include magnitude association consistency temporality ie occurrence disease follow exposure treatment dose response relationship specificity biologic plausibility since case control study backward directionality ie patient include study develop disease interest may example clearly address temporal association use calcium antagonist development myocardial infarction university washington study may ask index myocardial infarction occur relation administration calcium antagonist exposure calcium antagonist define computer record calcium antagonist index myocardial infarction particularly important occurrence myocardial infarction may affect decision use calcium antagonist hypertensive patient also two element causality generally difficult assess case control study namely dose response relationship specificity exposure treatment randomize case control study also worth note single study use establish causality observed association judgement concern causality strengthen different study show similar association date randomized control clinical trial effect calcium antagonist death myocardial infarction hypertensive patient nonetheless previous meta analyses calcium antagonist patient acute myocardial infarction suggest excess mortality held ph yusuf furberg cd calcium channel blocker acute myocardial infarction unstable angina overview bmj crossref pubmed scopus google scholar yusuf furberg cd effect calcium channel blocker survival myocardial infarction cardiovasc drug ther crossref pubmed scopus google scholar teo kk yusuf furberg cd effect prophylactic antiarrhythmic drug therapy acute myocardial infarction jama crossref pubmed scopus google scholar however appropriate extrapolate unfavorable result secondary prevention clinical trial calcium antagonist patient myocardial infarction held ph yusuf furberg cd calcium channel blocker acute myocardial infarction unstable angina overview bmj crossref pubmed scopus google scholar yusuf furberg cd effect calcium channel blocker survival myocardial infarction cardiovasc drug ther crossref pubmed scopus google scholar teo kk yusuf furberg cd effect prophylactic antiarrhythmic drug therapy acute myocardial infarction jama crossref pubmed scopus google scholar habib g robert r calcium channel blocker treatment acute myocardial infarction eric r bates ed thrombolysis adjunctive therapy acute myocardial infarction new york marcel dekker google scholar hypertensive patient least two reason first trial use three short acting prototype calcium antagonist nifedipine verapamil diltiazem two nifedipine diltiazem even approve food drug administration treatment hypertension second hemodynamic effect drug ambulatory patient uncomplicated hypertension may quite different effect hospitalized patient acute myocardial infarction therefore available evidence regard association calcium antagonist risk myocardial infarction hypertensive patient limit single case control study limitation university washington study establish clearly causality association calcium antagonist risk myocardial infarction hypertensive patient finally remain number important unanswered question university washington study systematic difference relevant baseline characteristic case control select study subject exclude study subject association increase risk myocardial infarction consistently observe class type calcium antagonist successful match case control age gender year diagnosis potential confounders measure adjust analysis conclusion base issue raise editorial await scrutiny peer review process publication full manuscript university washington academic community cast judgement regard efficacy safety calcium antagonist hypertensive patient believe calcium antagonist consider harmful result ongoing prospective randomize controlled trial antihypertensive drug hypertensive patient allhat complete,Habib GB,1995,Chest,https://doi.org/10.1378/chest.108.1.3,7606987,Habib GB,article,D016421: Editorial,"D002121: Calcium Channel Blockers; D016022: Case-Control Studies; D015986: Confounding Factors, Epidemiologic; D006801: Humans; D006973: Hypertension; D009203: Myocardial Infarction; D016032: Randomized Controlled Trials as Topic; D015983: Selection Bias",,,https://openalex.org/W2073136787,57,8,1,11797,1942,61,en,en
false,diltiazem ten year clinical experience treatment hypertension,diltiazem hydrochloride benzothiazepine derivative calcium channel blocker proven antianginal antihypertensive capability primary mechanism action vasodilatation result diminished vascular resistance improve perfusion various vascular bed target organ antihypertensive efficacy diltiazem various demographic group study compare diuretic beta blockers angiotensin converting enzyme inhibitor calcium channel blocker study show antihypertensive effect diltiazem similar therapy diltiazem adversely affect electrolyte carbohydrate lipid metabolism may beneficial effect heart kidney diltiazem reduce myocardial hypertrophy exert antianginal effect heart coronary vasodilation reduction blood pressure double product diltiazem improve renal perfusion attenuate proteinuria effect may helpful limit progression renal injury overall efficacy tolerability diltiazem well salutary effect heart kidney make important therapeutic consideration patient hypertensive disease,Weir MR,1995,J Clin Pharmacol,https://doi.org/10.1002/j.1552-4604.1995.tb04051.x,7608309,Weir MR,article,D003160: Comparative Study; D016428: Journal Article; D016454: Review,D000959: Antihypertensive Agents; D044383: Black People; D002986: Clinical Trials as Topic; D004110: Diltiazem; D005260: Female; D006321: Heart; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D007668: Kidney; D008297: Male; D011788: Quality of Life; D044465: White People,,,https://openalex.org/W1964513296,76,12,1,1279,188,9,en,en
false,sustain blood pressure control controlled release isradipine isradipine cr,safety efficacy measure peak trough blood pressure reduction new daily controlled release formulation isradipine isradipine cr icr evaluate patient mild moderate essential hypertension nine week trial week placebo washout period patient sit diastolic blood pressure mm hg randomize either icr treatment group placebo randomized patient complete study placebo icr mg icr mg icr mg icr mg peak trough post dose blood pressure response heart rate monitor sitting upright position blood chemistry urinalysis complete blood count electrocardiogram study sit upright blood pressure decrease p mg p daily icr dos peak blood pressure reduction icr dos occur hour post dose maximum peak trough blood pressure response achieve mg dose similar mg icr serious clinical metabolic side effect note except ankle edema dose dependent require discontinuation treatment abstract truncate word,Chrysant SG,1995,J Clin Pharmacol,https://doi.org/10.1002/j.1552-4604.1995.tb04053.x,7608311,Chrysant SG; Cohen M,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000367: Age Factors; D000368: Aged; D001794: Blood Pressure; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D008297: Male; D008875: Middle Aged; D012737: Sex Factors,,,https://openalex.org/W1998064294,83,10,1,1329,255,10,en,en
false,addition zatebradine direct sinus node inhibitor provide great exercise tolerance benefit patient angina take extended release nifedipine result multicenter randomize double blind placebo controlled parallel group study,examine antianginal anti ischemic effect oral zatebradine direct sinus node inhibitor blood pressure lowering negative inotropic effect patient chronic stable angina pectoris take extended release nifedipine heart rate reduction consider important pharmacologic mechanism provide anginal pain relief anti ischemic action patient chronic stable angina suggest benefit sinus node inhibiting drugs single blind placebo run randomize double blind placebo controlled multicenter study patient already receive extended release nifedipine mg day randomize receive zatebradine mg twice day n placebo n subject reproducible treadmill exercise induced angina baseline randomization perform serial exercise test h dose weeks zatebradine reduce rest heart rate week mean sem vs placebo beats min p end comparable stage bruce exercise vs placebo beats min p despite significant effect heart rate rest exercise additional benefit zatebradine placebo baseline measurement total exercise duration time mm st segment depression time onset angina subject take zatebradine also visual disturbance adverse reactions zatebradine seem provide additional antianginal benefit patient already receive nifedipine raise question regard benefit heart rate reduction alone antianginal approach patient chronic stable angina,Frishman WH,1995,J Am Coll Cardiol,https://doi.org/10.1016/0735-1097(95)80000-7,7608428,Frishman WH; Pepine CJ; Weiss RJ; Baiker WM,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000787: Angina Pectoris; D001552: Benzazepines; D001794: Blood Pressure; D002317: Cardiovascular Agents; D002908: Chronic Disease; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005080: Exercise Test; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D016896: Treatment Outcome",,,https://openalex.org/W2002632985,255,37,1,1740,291,4,en,en
false,intravenous administration diltiazem treatment supraventricular tachyarrhythmias,aim study investigate efficacy diltiazem bolus intravenous administration compare disopyramide treatment various type paroxysmal supraventricular tachyarrhythmias fifty patient male female mean age year paroxysmal supraventricular tachyarrhythmia paroxysmal atrial tachycardia paroxysmal atrial fibrillation rapid ventricular response atrial fluttering study diltiazem dose mg kg bw disopyramide dose mg give bolus iv conversion arrhythmia sinus rhythm could achieve initial drug alternate give order administration drug random independent type arrhythmia drug administration detail clinical examination frequent blood pressure bp measurement perform twenty four hour holter monitoring patient start administration antiarrhythmic drug paroxysmal atrial tachycardia diltiazem administration convert arrhythmia sinus rhythm patient disopyramide patient receive drug paroxysmal atrial fibrillation disopyramide convert arrhythmia patient without significant change ventricular response others diltiazem convert arrhythmia though cause significant decrease ventricular response bpm patient important bradycardia bpm atrial fluttering disopyramide convert arrhythmia sinus rhythm patient without significant change ventricular response others diltiazem cause significant decrease ventricular response without conversion sinus rhythm conversion sinus rhythm av junctional rhythm short duration min notice patient short pause sec without initial premature contraction remain disopyramide administration associate side effect diltiazem administration cause small mm hg transient min decrease bp without symptom exception patient bradycardia bp decrease significant mm hg follow intense symptom last six hours diltiazem administration extremely effective conversion paroxysmal atrial tachycardia sinus rhythm addition retard ventricular response patient atrial fibrillation fluttering compare disopyramide effect diltiazem pronounced clinically pertinent,Boudonas G,1995,Acta Cardiol,,7610735,Boudonas G; Lefkos N; Efthymiadis AP; Styliadis IG; Tsapas G,article,D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D001281: Atrial Fibrillation; D001282: Atrial Flutter; D001794: Blood Pressure; D004110: Diltiazem; D004206: Disopyramide; D015716: Electrocardiography, Ambulatory; D005260: Female; D006352: Heart Ventricles; D006801: Humans; D007262: Infusions, Intravenous; D008297: Male; D008875: Middle Aged; D013614: Tachycardia, Paroxysmal; D013617: Tachycardia, Supraventricular",,,https://openalex.org/W90981667,94,11,1,2665,442,15,en,en
false,efficacy safety daily nifedipine administer without food coat core formulation compare gastrointestinal therapeutic system formulation patient mild moderate hypertension,parallel group randomize double blind forced titration multicenter study compare efficacy safety daily nifedipine coat core nif cc daily nifedipine gastrointestinal therapeutic system nif git dose fasting state patient mild moderate essential hypertension formulation show effectively safely low blood pressure placebo controlled trial week placebo run period patient randomize week treatment either nif cc mg daily nif git mg daily period follow forced titration period nifedipine mg daily additional week double blind therapy mg treatment period primary time point statistically significant difference treatment group mean change baseline trough supine diastolic blood pressure primary efficacy variable nif cc patient mm hg nif git patient mm hg p also upper bound treatment difference confidence interval mm hg equivalence define protocol establish mg treatment period change baseline trough supine diastolic blood pressure significant great patient treat nif git patient treat nif cc nif git patient mm hg nif cc patient mm hg p upper bound confidence interval mm hg equivalence claim statistically significant difference note comparison mean hour ambulatory blood pressure monitoring change formulation well tolerate,Glasser SP,1995,Clin Ther,https://doi.org/10.1016/0149-2918(95)80028-x,7614530,Glasser SP; Ripa SR; Allenby KS; Schwartz LA; Commins BM; Jungerwirth S,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D001794: Blood Pressure; D003692: Delayed-Action Preparations; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D005508: Food Deprivation; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine",,,https://openalex.org/W2009614541,214,26,1,1715,299,10,en,en
false,comparison moexipril new ace inhibitor verapamil sr add therapy low dose hydrochlorothiazide hypertensive patient,antihypertensive effect moexipril new angiotensin convert enzyme inhibitor verapamil sr add therapy hydrochlorothiazide hctz investigate patient moderate severe stage ii iii essential hypertension patient treat week mg day hctz whose sit diastolic blood pressure sdbp mm hg inclusive randomize mg day moexipril patient mg day verapamil sr patient addition mg day hctz week treatment sdbp mm hg dose moexipril increase mg day verapamil sr increase mg day patient follow additional week blood chemistry plasma renin activity plasma aldosterone study moexipril verapamil sr safe well tolerate decrease sitting stand blood pressure similarly p study demonstrate addition moexipril verapamil sr low dose hctz effective treatment moderate severe hypertension j hypertens,Chrysant SG,1995,Am J Hypertens,https://doi.org/10.1016/0895-7061(94)00025-7,7619356,Chrysant SG; Fox AA; Stimpel M,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000450: Aldosterone; D000806: Angiotensin-Converting Enzyme Inhibitors; D001794: Blood Pressure; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006339: Heart Rate; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D007546: Isoquinolines; D008297: Male; D008875: Middle Aged; D012083: Renin; D044005: Tetrahydroisoquinolines; D014700: Verapamil",,,https://openalex.org/W2046748438,136,21,1,1140,205,7,en,en
false,twenty four hour efficacy two dose level daily sustained release diltiazem formulation stable angina placebo controlled trial dildurang study group,placebo controlled study assess daily sustained release sr diltiazem mg stable angina patient positive exercise test exercise testing perform baseline day placebo run period repeat day treatment h postdose diltiazem mg produce respectively decrease weekly angina episode placebo decrease p similarly dose level produce decrease nitroglycerin consumption whereas difference obtain placebo p increase time ischaemic threshold significantly superior mg mg diltiazem compare placebo respectively vs p increase time anginal threshold also significantly great diltiazem compare placebo respectively vs p one patient experience worsening angina withdraw study study demonstrate mg sr diltiazem effective give day prophylaxis stable exertional angina daily formulation improve patient compliance comfort,Frances Y,1995,Br J Clin Pharmacol,https://doi.org/10.1111/j.1365-2125.1995.tb04449.x,7619669,Frances Y; Gagey S; Stalla-Bourdillon A,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D000704: Analysis of Variance; D000787: Angina Pectoris; D001794: Blood Pressure; D003692: Delayed-Action Preparations; D004110: Diltiazem; D004311: Double-Blind Method; D004562: Electrocardiography; D005080: Exercise Test; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D005996: Nitroglycerin,,,https://openalex.org/W2004526390,174,28,2,1247,245,13,en,en
false,signal drug induced rash drug recently market united kingdom study prescription event monitoring,study examine skin rash reported event patient use one drug recently release uk market study prescription event monitoring result also compare voluntary report rash possible adverse drug reaction send committee safety medicine csm specific type skin rash e g exfoliative dermatitis exclude rate rash calculate period first month subsequent month first prescription drug despite heterogeneity patient group rate rash nd th month consistent drug probably represent baseline rate rash due variety nonspecific cause rate around per patient per month range per patient per month hand first month first prescription drug rate vary substantially per patient per month diltiazem high first monthly rate rate list drug difference rate test method standard statistical test assume poisson model method base ratio rate period rate similar drug induce rash consider rare abstract truncate word,Kubota K,1995,Int J Clin Pharmacol Ther,,7620692,Kubota K; Kubota N; Pearce GL; Prescott P; Mann RD,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000890: Anti-Infective Agents; D000894: Anti-Inflammatory Agents, Non-Steroidal; D002317: Cardiovascular Agents; D002491: Central Nervous System Agents; D015331: Cohort Studies; D003875: Drug Eruptions; D011307: Drug Prescriptions; D005260: Female; D006633: Histamine Antagonists; D006801: Humans; D008297: Male; D008875: Middle Aged; D011358: Product Surveillance, Postmarketing; D015363: Quinolones; D012867: Skin; D006113: United Kingdom",,,https://openalex.org/W2416719554,128,18,1,1456,295,13,en,en
true,vasodilation related adverse event diltiazem dihydropyridine calcium antagonist study prescription event monitoring,incidence vasodilation related event flush headache dizziness oedema determine total patient treat diltiazem nicardipine isradipine amlodipine study prescription event monitoring event rate express percentage patient experience event six month first prescription rate event newer vasoselective dihydropyridines nicardipine isradipine amlodipine high diltiazem among three dihydropyridines large individual difference rate nicardipine frequency four vasodilation related event similar one another approximately isradipine rate also similar one another approximately twice measure nicardipine study approximately difference may due confound factor publicity adverse drug reaction indication use individual patient dos actually use time event occur amlodipine contrast rate oedema two four time large rate flushing headache dizziness,Kubota K,1995,Eur J Clin Pharmacol,https://doi.org/10.1007/bf00202163,7621840,Kubota K; Pearce GL; Inman WH,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000367: Age Factors; D000368: Aged; D002121: Calcium Channel Blockers; D004095: Dihydropyridines; D004110: Diltiazem; D011307: Drug Prescriptions; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011358: Product Surveillance, Postmarketing; D014664: Vasodilation",,,https://openalex.org/W2035440750,129,13,1,1278,217,8,en,en
true,low dose drug combination therapy alternative first line approach hypertension treatment,investigate concept initial treatment hypertension low dos two antihypertensive different mode action additive effect may achieve control blood pressure minimize dose dependent adverse effect see conventional monotherapy randomize double blind parallel group dose escalation study conduct week placebo washout period men woman diastolic blood pressure mm hg randomly allocate take amlodipine mg enalapril mg low dose combination bisoprolol mg mg hydrochlorothiazide hctz drug administer daily titrate optimal response take total week blood pressure measure hour dose response rate either diastolic blood pressure mm hg decrease diastolic pressure mm hg bisoprolol mg hctz amlodipine enalapril mean decrease systolic diastolic blood pressure baseline mm hg bisoprolol mg hctz amlodipine enalapril respectively mean change enalapril less drug p although daily dosing enalapril maximum dose mg might optimal agent overall adverse event bisoprolol mg hctz amlodipine enalapril p bisoprolol mg hctz v enalapril drug related adverse event significant difference respectively change quality life score measure general well index bisoprolol mg hctz amlodipine enalapril positive change indicate improvement study demonstrate low dose combination therapy bisoprolol mg hctz effective well tolerate thus low dose combination therapy appear rational alternative initiate therapy mild moderate hypertension,Prisant LM,1995,Am Heart J,https://doi.org/10.1016/0002-8703(95)90454-9,7631621,Prisant LM; Weir MR; Papademetriou V; Weber MA; Adegbile IA; Alemayehu D; Lefkowitz MP; Carr AA,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D017311: Amlodipine; D000704: Analysis of Variance; D017298: Bisoprolol; D001794: Blood Pressure; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004656: Enalapril; D005260: Female; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011788: Quality of Life; D014481: United States",,,https://openalex.org/W1982162449,95,12,1,2095,388,11,en,en
false,value combination trimetazidine vastarel mg diltiazem tildiem mg stable effort angina double blind versus placebo multicenter study,trimetazidine cytoprotective anti ischaemic agent whose antianginal efficacy demonstrate monotherapy versus placebo versus reference product combination beta blockers nifedipine coprescription diltiazem previously study objective study evaluate benefit addition trimetazidine mg h diltiazem mg h stable exertional angina insufficiently improve calcium channel blocker alone multicentre double blind placebo controlled study conduct period month inclusion criterion stable angina electrically positive stress test remain positive despite day treatment diltiazem mg h conduct patient randomize two group diltiazem placebo group patient diltiazem trimetazidine group ii patient follow consisted clinical assessment stress test inclusion month two group similar inclusion ergometric parameter except time onset ischaemic threshold mm total duration effort significantly longer placebo group comparison stress test perform sixth month inclusion group ii show ischaemic threshold mm significantly delay minute second trimetazidine group p versus second placebo group ns similarly work perform threshold significantly increase kpm trimetazidine group p versus kpm placebo group p difference two group significant two parameter p p respectively maximum effort total duration total work also increase significantly trimetazidine group second p kpm p respectively versus second kpm placebo group ns double product sbp x hr load watt ratio ischaemic threshold mm reach decrease significantly trimetazidine group p versus placebo group ns difference two group significant p abstract truncate word,Lévy S,1995,Ann Cardiol Angeiol (Paris),,7632029,Lévy S,article,D016430: Clinical Trial; D004740: English Abstract; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000787: Angina Pectoris; D004110: Diltiazem; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D006801: Humans; D008297: Male; D008875: Middle Aged; D005082: Physical Exertion; D014292: Trimetazidine",,,https://openalex.org/W2403503097,165,32,2,2360,443,14,en,en
false,phase ii trial dexverapamil plus vinblastine patient advanced renal cell carcinoma,purpose reduced cardiac toxicity dextro stereoisomer verapamil dexverapamil knoll pharmaceutical whippany nj warrant study potential multidrug resistance mdr reversal agent patient method twenty three patient advanced renal cell carcinoma rcc treat vinblastine dose mg kg intravenous iv bolus injection day every day dexverapamil add subsequent cycle resistance demonstrate dexverapamil treatment begin hour day vinblastine administration give orally every hour dos patient group treat dose mg group b treat mg plus dexamethasone plasma concentration achieve patient correlate vitro effect result toxicity include hypotension asymptomatic bradycardia mild atrioventricular conduction delay although one patient dexverapamil discontinue grade iv congestive heart failure partial complete response mean day serum dexverapamil plus norverapamil plasma concentration ng ml range ng ml group ng ml range ng ml group b time vinblastine administration concentration range reverse vinblastine resistance vitro conclusion advantage dexverapamil mdr reversal agent potential achieve desire blood level substantially less toxicity racemic mixture verapamil base tolerability suitable drug study clinical trial malignancy rcc attempt achieve mdr reversal dose mg give orally every hour dose escalation base individual tolerance represent feasible schedule consider study,Motzer RJ,1995,J Clin Oncol,https://doi.org/10.1200/jco.1995.13.8.1958,7636536,Motzer RJ; Lyn P; Fischer P; Lianes P; Ngo RL; Cordon-Cardo C; O'Brien JP,article,"D016430: Clinical Trial; D017426: Clinical Trial, Phase I; D017427: Clinical Trial, Phase II; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D020168: ATP Binding Cassette Transporter, Subfamily B, Member 1; D000328: Adult; D000368: Aged; D001919: Bradycardia; D002292: Carcinoma, Renal Cell; D018432: Drug Resistance, Multiple; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D007022: Hypotension; D007150: Immunohistochemistry; D007680: Kidney Neoplasms; D008297: Male; D008875: Middle Aged; D013237: Stereoisomerism; D014407: Tumor Cells, Cultured; D014700: Verapamil; D014747: Vinblastine",,,https://openalex.org/W2290583892,98,15,1,1921,328,12,en,en
false,efficacy tolerability amlodipine hydrochlorothiazide nigerian essential hypertension,efficacy safety novel calcium antagonist amlodipine pfizer laboratory new york new york hydrochlorothiazide evaluate compare randomized single blind parallel group study black african essential hypertension twenty nigerian newly diagnose mild moderate essential hypertension randomize receive ascend dos amlodipine mg mg hydrochlorothiazide mg mg blood pressure heart rate measure baseline week therapy amlodipine hydrochlorothiazide significantly reduce supine erect blood pressure supine blood pressure amlodipine fell mean mm hg mm hg thiazide mm hg mm hg however significant difference drug antihypertensive efficacy neither drug induce reflex increase heart rate fall blood pressure agent associate increase plasma urea amlodipine induce change plasma potassium hydrochlorothiazide cause hypokalemia agent well tolerate amlodipine undergo study treatment hypertension black,Ajayi AA,1995,J Natl Med Assoc,,7636894,Ajayi AA; Akintomide AO,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D017311: Amlodipine; D001794: Blood Pressure; D004361: Drug Tolerance; D005260: Female; D006339: Heart Rate; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D007008: Hypokalemia; D008297: Male; D008875: Middle Aged; D009549: Nigeria; D011187: Posture; D011188: Potassium; D012449: Safety; D016037: Single-Blind Method; D016683: Supine Position; D014508: Urea,,,https://openalex.org/W1480198996,109,14,1,1237,216,9,en,en
false,risk myocardial infarction associate antihypertensive drug therapy,assess association first myocardial infarction use antihypertensive agents conduct population based case control study among enrollee group health cooperative puget sound ghc cases hypertensive patient sustain first fatal nonfatal myocardial infarction among woman among men control stratified random sample hypertensive ghc enrollee frequency match case age sex calendar year case control pharmacologically treat hypertension data collection include review ambulatory medical record brief telephone interview consent survivor antihypertensive therapy assess use ghc computerized pharmacy database first analysis include case control initially free cardiovascular disease compare user diuretic alone adjust risk ratio myocardial infarction increase among user calcium channel blocker without diuretic risk ratio confidence interval cl p second analysis restrict case control take either calcium channel blocker beta blocker among subject use calcium channel blocker compare beta blockers associate increase adjusted risk myocardial infarction risk ratio cl p high dos beta blockers associate decreased risk myocardial infarction trend p high dos calcium channel blocker associate increase risk trend p study hypertensive patient use short acting calcium channel blocker especially high dos associate increase risk myocardial infarction ongoing large scale clinical trial assess effect various antihypertensive therapy include calcium channel blocker several important cardiovascular end point result available finding study support current guideline joint national committee detection evaluation treatment high blood pressure recommend diuretic beta blockers first line agent unless contraindicate unacceptable tolerate,Psaty BM,1995,JAMA,https://doi.org/10.1001/jama.1995.03530080036038,7637142,Psaty BM; Heckbert SR; Koepsell TD; Siscovick DS; Raghunathan TE; Weiss NS; Rosendaal FR; Lemaitre RN; Smith NL; Wahl PW,article,"D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.","D000319: Adrenergic beta-Antagonists; D000368: Aged; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D016022: Case-Control Studies; D015986: Confounding Factors, Epidemiologic; D004232: Diuretics; D004305: Dose-Response Relationship, Drug; D005260: Female; D006801: Humans; D006973: Hypertension; D015994: Incidence; D016014: Linear Models; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D012307: Risk Factors; D017741: Survivors",,,https://openalex.org/W2106073810,81,10,1,2410,406,11,en,en
false,nocturnal dosing novel delivery system verapamil systemic hypertension verapamil study group,evaluate efficacy safety novel delivery system physiologic pattern release ppr verapamil administer nocturnally patient stage ii hypertension use ambulatory blood pressure bp monitoring perform multicenter center double blind randomize placebo controlled parallel group trial placebo mg verapamil randomized patient delivery system delay release verapamil hour deliver drug osmotic pumping system approximately hour patient dose p primary end point change baseline trough diastolic bp assess ambulatory bp monitor p week therapy whereas secondary measure include change baseline peak early morning systolic diastolic bp trough clinic bp hour average daytime p nighttime p bp mg verapamil dose achieve statistically significant reduction trough p diastolic bp mm hg respectively reduction peak early morning diastolic bp great mg respectively abstract truncate word,White WB,1995,Am J Cardiol,10.1016/s0002-9149(99)80104-0,7639163,White WB; Anders RJ; MacIntyre JM; Black HR; Sica DA,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D001794: Blood Pressure; D015924: Blood Pressure Monitors; D002940: Circadian Rhythm; D003627: Data Interpretation, Statistical; D003971: Diastole; D004311: Double-Blind Method; D016503: Drug Delivery Systems; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008875: Middle Aged; D010919: Placebos; D011187: Posture; D013599: Systole; D013997: Time Factors; D014700: Verapamil",,,,106,17,2,1383,281,7,en,en
false,change extracellular matrix macromolecule human gingiva treatment drug induce gingival overgrowth,generally agree gingival overgrowth result increase level gingival extracellular macromolecule infiltrate various number inflammatory cell relative amount extracellular matrix macromolecule observe case gingival hyperplasia associate use cyclosporin hydantoin nifedipine compare obtain control group basis histological immunohistochemical investigation tissue section quantification computerized morphometric analysis bfm microcomputer implement transformation mathematical morphology area fraction aa occupy total collagen type iii type iv collagen vessel fibroblast fibronectin elastic fibre estimate compare overall histological aspect drug induced gingival overgrowth similar quantification different extracellular matrix component show difference nifedipine cyclosporin group area occupy fibroblast significantly great healthy gingiva chronic gingivitis area occupy collagen significantly great nifedipine group pathological group fibronectin also strongly express nifedipine group elastic fibre network preserve group,Bonnaure-Mallet M,1995,Arch Oral Biol,https://doi.org/10.1016/0003-9969(94)00187-g,7639642,Bonnaure-Mallet M; Tricot-Doleux S; Godeau GJ,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D003094: Collagen; D016572: Cyclosporine; D004547: Elastic Tissue; D004549: Elastin; D005109: Extracellular Matrix; D016326: Extracellular Matrix Proteins; D005260: Female; D005347: Fibroblasts; D005353: Fibronectins; D005885: Gingival Hyperplasia; D006801: Humans; D006827: Hydantoins; D008297: Male; D018715: Microscopy, Video; D009543: Nifedipine; D009568: Nitrendipine; D012815: Signal Processing, Computer-Assisted; D018709: Statistics, Nonparametric",,,https://openalex.org/W2081077981,119,15,1,1388,211,8,en,en
false,asymptomatic cardiac ischemia pilot acip study impact anti ischemia therapy week rest electrocardiogram exercise test outcome,report asymptomatic cardiac ischemia pilot acip study examines difference magnitude reduction myocardial ischemia determine exercise treadmill test patient randomize three different treatment strategy angina guided medical therapy ischemia guided medical therapy coronary revascularization prospective randomize clinical trial patient exercise electrocardiographic ecg abnormality asymptomatic cardiac ischemia ambulatory ecg monitoring compare impact different treatment strategy include coronary revascularization term reduce myocardial ischemia acip exercise protocol use exercise variable measure include final exercise stage presence exerciseinduced angina ischemia time angina time mm st segment depression number exercise ecg lead abnormality maximal depth st segment depression lead sum st segment depression st hr index rate pressure product time angina time mm st segment depression peak exertion peak exercise time increase min patient assign angina guided ischemiaguided coronary revascularization strategy respectively qualify visit week visit p qualify visit sum exercise induced st segment depression mean sd mm p n three treatment strategy respectively week visit sum exercise induced st segment depression mm p three treatment strategy respectively treatment strategy result significant reduction exercise induced variable myocardial ischemia measure week coronary revascularization significantly reduce extent frequency exercise induced myocardial ischemia compare either medical strategy prognostic impact observation evaluate large scale multicenter clinical trial,Chaitman BR,1995,J Am Coll Cardiol,https://doi.org/10.1016/0735-1097(95)00013-t,7642847,Chaitman BR; Stone PH; Knatterud GL; Forman SA; Sopko G; Bourassa MG; Pratt C; Rogers WJ; Pepine CJ; Conti CR,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.","D000704: Analysis of Variance; D015906: Angioplasty, Balloon, Coronary; D002317: Cardiovascular Agents; D003131: Combined Modality Therapy; D001026: Coronary Artery Bypass; D004359: Drug Therapy, Combination; D015716: Electrocardiography, Ambulatory; D005080: Exercise Test; D005260: Female; D006801: Humans; D008297: Male; D017202: Myocardial Ischemia; D010865: Pilot Projects; D011446: Prospective Studies; D012074: Remission Induction; D012146: Rest; D013997: Time Factors; D016896: Treatment Outcome",,,https://openalex.org/W1983212104,142,21,1,2097,346,10,en,en
false,nifedipine mortality,homecirculationvol nifedipine mortality free accessresearch articledownload epubaboutview epubsections toolsadd favoritesdownload citationstrack citationspermissions shareshare onfacebooktwitterlinked inmendeleyreddit jump tofree accessresearch articledownload epubnifedipine mortality grave defect dossier lionel h opie franz h messerli lionel h opielionel h opie medical research council university cape town south africa l h ochsner clinic new orleans la f h search paper author franz h messerlifranz h messerli medical research council university cape town south africa l h ochsner clinic new orleans la f h search paper author originally published sep https doi org cir circulation approved treatment consider unapproved indication physician must evaluate safety medication value related condition individual patient ask make prudent decision base upon full knowledge available evidence furberg colleagues entitle article nifedipine dose related increase mortality patient coronary heart disease provide valuable service make u think carefully benefit risk ratio calcium antagonists group however tout calcium antagonist unsafe possibly lethal also create great deal uncertainty anxiety among physician patient feel overstate case following attempt show allegation focus short acting nifedipine even correct apply calcium antagonist accusation dose related increase mortality rest biased selection data chosen meta analysis several mechanism suggest propose adverse effect unlikely finally shall argue pharmaceutical company remiss obtain outcome study short acting nifedipine calcium antagonist especially case ischemic heart disease indicted agent short acting nifedipine evidence calcium antagonist scant several aspect furberg paper suggest calcium antagonist general accuse example statement literature review strongly suggest problem may go beyond short acting nifedipine troubling major adverse cardiovascular event link calcium antagonist primarily dihydropyridines clearly unequivocally state furberg et al provide evidence whatsoever adverse effect mortality morbidity agent one important exception exception nimodipine approve use subarachnoid hemorrhage nimodipine give potential cerebroprotective property patient undergo major cardiovascular surgery mortality increased hint calcium antagonist toxic way need firmly set aside real evidence examine meta analysis major argument use furberg et al meta analysis show dose related increase mortality reality confidence limit dos mg significant example mg confidence limit mg thus case must rest data dose mg reason clear furberg et al take short term week mortality data two study muller et al mortality rate nifedipine versus control subject threatened infarct study versus unstable angina study reanalysis use month data allow proposed statistical difference disappear value overall comparison p table recent report yusuf et al suggest statistical multiplicity result overview accept level statistical significance extreme eg p present analysis furberg et al fall far short ambitious goal factor least fold best value could calculate list data p regard study muller et al author indicate number important reservation include unexpected absence mortality placebo patient first week versus expected range logically agent give early stage acute myocardial infarction ami event find patient muller et al especially develop phase may influence extent infarct size subsequent remodeling leave ventricular function long term outlook example isis study even week early treatment blocker atenolol reduce mortality year study muller et al nifedipine alter neither infarct size month follow observation internally consistent logical contrast week data atypical short term follow least consider together longer term data table major case nifedipine group give mg hinge intact study carry lichtlen et al fact mislead include intact group study deal either early phase ami unstable angina intact study one third patient prior ami diagnose ecg abnormality two third mild effort angina include patient coronary angiography show mild degree coronary stenosis patient total coronary occlusion patient group myocardial infarction unstable angina claim legend table article furberg et al ideal meta analysis restrict trial population similar risks thus crucial data case furberg et al mount short acting nifedipine rest whether long short term follow take appropriate patient study muller et al whether include patient intact study grouping ami unstable angina justified whether probability value analysis p calculation p list data furberg et al match requirement another publication value p inherent statistical contradiction attests shakiness meta analysis hardly reassure basis meta analysis furberg et al call regulatory authority consider whether moderate high dos nifedipine capsule exclude approve labeling especially consider increase mortality intact study find drug use experimental nonapproved indication namely retardation progress coronary atherosclerosis mechanism alleged adverse effect short acting nifedipine short acting nifedipine adverse effect yet establish could manifest hypotensive effect fall blood pressure major therapeutic aim treatment hypertension nonetheless benefit turn harm presence coronary artery disease danger excess nifedipine induced hypotension increase myocardial ischemic damage infarct size show experimentally selwyn et al nifedipine give several trial show table article furberg et al appear use without adequate cognizance fact powerful hypotensive agent israeli sprint study sprint ii effect nifedipine blood pressure even report apart hypotension exclusion criterion sprint ii find adverse effect patient initial blood pressure mm hg occur within first week adverse effect excess early hypotension early ami limit calcium antagonist see consensus study intravenous enalaprilat cause hypotension cessation trial nonetheless hypotension explain death nifedipine arm intact trial p r lichtlen personal communication muller et al note increase risk cardiogenic shock likely side effect excess hypotension danger acute hypotension seem marked context potential hemodynamic instability ami rather presence left ventricular hypertrophy cause hypertension hypotension decreased coronary perfusion pressure reflex cardiac acceleration logical explanation proischemic effect calcium antagonists mechanism may explain muller et al data show short acting nifedipine may associate excess early mortality patient ami clearly approved indication nifedipine nonhypotensive proischemic effect short acting nifedipine cause angina well establish hence careful clinician titrate dose upward also advise package insert dose need suppress angina tolerate patient must establish titration excessive dos result hypotension addition role hypotension two factor need consider namely neurohumoral activation see coronary steal existence mechanism mean even patient hypotension avoid proischemic effect could still occur reinforce need dose titration short acting nifedipine introduce repetitive neurohumoral stimulation acute vasodilation induce short acting nifedipine elicit activation autonomic nervous system renin angiotensin cascade report another short acting dihydropyridine felodipine reflex activation think limit regression left ventricular hypertrophy despite blood pressure control hypertensive patients detrimental experience short acting nifedipine use patient congestive heart failure could likewise explain adverse neurohumoral stimulation likely response acute vasodilation baroreflex desensitization may occur short acting nifedipine tablet give long term decrease adrenergic mediated reflexes hypothesis would explain may cluster adverse effect nifedipine within early period initiation therapy proischemic effect risk increased danger early postinfarct period interest recent preliminary data packer yet fully report another dihydropyridine calcium antagonist amlodipine give patient cardiomyopathy already treat diuretic digoxin angiotensin converting enzyme ace inhibition amlodipine neither beneficial harmful effect mortality patient ischemic cardiomyopathy yet reduce mortality dilated cardiomyopathy hypothetically use ace inhibitor lessen neurohumoral activation also long half life constant blood level amlodipine might contribute result postulated proarrhythmic effect proarrhythmic mechanism propose furberg et al seem extremely unlikely view extensive experimental work show calcium antagonist antiarrhythmic effect ischemic reperfusion arrhythmias none study quote furberg et al relate nifedipine none provide convince evidence proarrhythmic effect fact finnish study show clear antiarrhythmic effect ventricular fibrillation reduce nimodipine treated patient versus control subject p furthermore ventricular fibrillation recur nimodipine placebo patient clear benefit nimodipine p second trial concern lidoflazine drug longer use list among calcium antagonist international union pharmacologists negative inotropic effect property great disadvantage rather part basis beneficial effect blockers ischemic heart disease furthermore suggested year ago katz negative inotropic effect may paradoxically explain benefit blockers give long term congestive heart failure experimentally dihydropyridines various effect inotropic state nifedipine amlodipine negative effect yet felodipine small stimulation limit evidence suggest nondihydropyridines verapamil diltiazem therapeutic range closely resemble blockers great negative inotropic effect part mechanism antianginal properties although nifedipine great direct negative inotropic action verapamil diltiazem human ventricular myocardium clinical practice reflex adrenergic activation induce short acting nifedipine often cause increase contractile activity prohemorrhagic effect furberg et al correctly state calcium antagonist various degree antiplatelet effect many agent include aspirin nitrate latter agent inhibit platelet vasodilate calcium antagonists group logically antiplatelet effect verapamil could basis prevention reinfarction davit ii study antiplatelet effect potential double edged sword could explain data becker et al show certain circumstance diltiazem could promote bleed could aspirin study aspect article furberg et al valuable alert u possible new side effect new mode action calcium antagonists nonetheless difficult precise prohemorrhagic effect clinical trial comment furberg et al except concern nimodipine use drug perioperative period clearly contraindicated two study require specific comment proposal calcium antagonist cause cerebrovascular event ace inhibitor treatment hypertension base even abstract rather brief meeting report reality full report glant study press show incidence cerebrovascular event calcium antagonist ace inhibitor group respectively significantly different observation thrombolytic reperfusion associate increased hemorrhage patient treat calcium antagonists must temper caution one obvious explanation eight patient involve hypertension therefore candidate cerebral bleeding also data give article exclude possibility small number patient give calcium antagonist bleed might receive high dose recombinant tissue type plasminogen activator associate increased bleeding eight patient involve three take nifedipine therefore data remain soft interpretation reserve information comparative effect various calcium antagonist platelet coagulation process require balance potentially harmful prohemorrhagic effect versus potentially beneficial antiplatelet effect case diltiazem question settle prospective study currently way threat increased mortality apply calcium antagonists short acting nifedipine present indication data propose adverse effect short acting nifedipine mortality even accept could extrapolate calcium antagonist slow onset action verapamil diltiazem amlodipine truly long acting preparation nifedipine dihydropyridines example importance slow onset long action case nisoldipine short acting form antianginal contrast positive result long acting core coat form used likely explanation slow release form induces less neurohumoral activation hence side effects particular attention pay benefit verapamil postinfarct patient verapamil agent know cause neurohumoral activation rather decrease circulate norepinephrine cardiac store norepinephrine regard postinfarct study verapamil two carefully design series first davit verapamil start soon onset symptom ami within hour late benefit mortality offset early harm reminiscent timing adverse effect nifedipine early ami patient second davit ii therapy initiate later patient overt congestive heart failure require mg furosemide exclude several benefit davit ii particular lessened reinfarction angina decrease development heart failure thus provisional evidence nondihydropyridine agent verapamil reduce circulate norepinephrine levels beneficial effect patient prior myocardial infarction although data still weak require corroboration ideally prospective study davit ii specifically different entry criterion trial concern verapamil include davit may questionable combine davit davit ii fischer hansen et al combine davit ii verapamil trial held yusuf hand seem acceptable combine result diltiazem verapamil use follow non q wave infarct reduction risk cardiac events thus seem prudent consider calcium antagonist create equal prudent clinician expect prudence suggest clinician could continue use calcium antagonist approved indication avoid hypotension side effect carefully evaluate risk benefit ratio use drug nonlicensed indication early postinfarct period blockers contraindicate ischemic heart disease heart rate lowering calcium antagonist choose rather dihydropyridine patient acute phase myocardial infarction calcium antagonist still use frequently fact relatively contraindicate setting justification use dihydropyridines prevent atheroma show intact still unpublished midas data latter isradipine clearly use nimodipine cardiovascular surgery must avoid bleeding risk outweigh cerebroprotective role drug specifically keep benefit subarachnoid hemorrhage cerebral hemorrhage patient ischemic heart disease short acting nifedipine change long acting preparation patient hypertension without clinical angina ischemic heart disease already control short acting nifedipine could leave preparation provide combine blocker ace inhibitor offset expected neurohumoral activation otherwise short acting nifedipine change one slow release long acting preparation amlodipine much favorable trough peak ratio latter type compounds short acting capsular nifedipine might limited indication raynaud phenomenon select case acute blood pressure reduction require patient threat clinical myocardial ischemia case hypertension safety nifedipine retard tablet may ensure stone study publish full recent preliminary report stone study elderly hypertensive patient show highly significant p decrease probability event intention treat analysis nifedipine group compare placebo group specifically decrease terminating event stroke heart failure uremia myocardial infarction angina pectoris severe arrhythmia hospitalization severe illness death decrease event nifedipine significant whether event hypertension related consider substantiate full publication single blind trial carry subject year old treat mean follow month nifedipine tablet give mean dose mg twice daily would provide strong evidence indictment furberg et al least case elderly hypertensive patient data soon come use dihydropyridine calcium antagonist hypertension nitrendipine case syst eur study amlodipine allhat study felodipine hot study case ischemic heart disease mortality data thus far sadly lack calcium antagonists clearly outcome data require case patient angina pectoris encouraging preliminary observation nifedipine retard tablet preparation give good effect hard end point atenolol whereas combination blockers calcium antagonist actually reduce hard end points likewise combination beneficial another preliminary study involve nonrandomized follow patient coronary artery disease use unidentified calcium antagonist beneficial compare treatment data conform good clinical practice combination blocker plus calcium antagonist many positive arguments provide combination undertaken prudently careful attention precaution avoidance excess hypotension future work word another article coauthored furberg meta analyses seldom ever prove specific hypotheses word even though allegation short acting nifedipine view base solid fact despite apparent flaw analysis furberg et al nonetheless proof pudding eating prospective study would answer question bearing mind least two pharmaceutical company make substantial profit sale short acting nifedipine past surely responsibility invest profit proper prospective study mortality end point patient angina pectoris treat dihydropyridine calcium antagonist study already undertake indictment furberg et al would never arise summary would serious deviation fact available even hint calcium antagonist damn situation basis meta analysis kingpin depend whether week month follow prefer two nifedipine group lesson meta analysis infallible rather conform certain demand low probability value p restrict population similar risk clearly need thorough prospective database meta analyses table reanalysis mortality data short acting nifedipine ischemic heart disease include result long term month follow two studies dose rangenifedipinecontrol cip comparison mg mg dmuller eisenberg gerstenblith lichtlen total mg dgottlieb jaffe muller total totals group month muller data totals list furberg paper week muller data recalculate original paper week muller data reference see table furberg et al p value calculate test yates correction studies month follow choose present author week follow table furberg et al daily dose study could mg four nonnifedipine death omit lichtlen data probability value become p mg p final comparison calculated list total furberg et al footnotescorrespondence professor l h opie heart research unit medical research council university cape town medical school observatory cape town south africa franz h messerli md section hypertensive disease ochsner clinic jefferson hwy new orleans la reference opie lh drug heart th ed philadelphia pa wb saunders co iii google scholar furberg cd psaty bm meyer jv nifedipine dose related increase mortality patient coronary heart disease circulation crossrefmedlinegoogle scholar wagenknecht le furberg cd hammon jw legault c troost bt surgical bleeding unexpected effect calcium antagonist br med j crossrefmedlinegoogle scholar muller j morrison j stone ph rude rosner b roberts r pearle dl turi zg schneider jf serfas dh tate c scheiner e sobel hennekens ch braunwald e nifedipine therapy patient threatened acute myocardial infarction randomized double blind placebo controlled comparison circulation crossrefmedlinegoogle scholar muller je turi zg pearle dl schneider jf serfas dh morrison j stone ph rude rosner b sobel tate c scheiner e roberts r hennekens ch braunwald e nifedipine conventional therapy unstable angina pectoris randomized double blind comparison circulation crossrefmedlinegoogle scholar yusuf hold p furberg c update effect calcium antagonist myocardial infarction angina light second danish verapamil infarction trial davit ii recent study j cardiol crossrefmedlinegoogle scholar isis first international study infarct survival collaborative group randomize trial intravenous atenolol among case suspected acute myocardial infarction isis lancet medlinegoogle scholar lichtlen pr hugenholtz pg rafflenbeul w hecker h jost nikutta p decker jw behalf intact group investigator retardation coronary artery disease human calcium channel blocker nifedipine result intact study international nifedipine trial antiatherosclerotic therapy cardiovasc drug ther crossrefmedlinegoogle scholar gonser vetter k noack f meta analyses interventional trial population different risk lancet crossrefgoogle scholar selwyn ap welman e fox k horlock p pratt klein effect nifedipine acute experimental myocardial ischemia infarction dog circ res crossrefmedlinegoogle scholar israeli sprint study group secondary prevention reinfarction israeli nifedipine trial sprint randomize intervention trial nifedipine patient acute myocardial infarction eur heart j crossrefmedlinegoogle scholar sprint study group secondary prevention infarction israeli nifedipine trial sprint ii design method result eur heart j suppl abstract google scholar consensus trial study group effect enalapril mortality severe congestive heart failure result cooperative north scandinavian enalapril survival study consensus n engl j med crossrefmedlinegoogle scholar phillips ra goldman ardeljan eison hb shimabukuro krakoff lr isolated wave abnormality evaluation left ventricular wall motion nifedipine severe hypertension j hypertens crossrefmedlinegoogle scholar baumgart ehring heusch g proischemic action nisoldipine relationship decrease perfusion pressure comparison dipyridamole cardiovasc res crossrefmedlinegoogle scholar egstrup k andersen pe transient myocardial ischemia nifedipine therapy stable angina pectoris relation coronary collateral flow comparison metoprolol j cardiol crossrefmedlinegoogle scholar ruzicka leenen fhh rele,Opie LH,1995,Circulation,https://doi.org/10.1161/01.cir.92.5.1068,7648646,Opie LH; Messerli FH,article,D016420: Comment; D016421: Editorial,"D000787: Angina Pectoris; D001145: Arrhythmias, Cardiac; D001341: Autonomic Nervous System; D002121: Calcium Channel Blockers; D003327: Coronary Disease; D003864: Depression, Chemical; D004305: Dose-Response Relationship, Drug; D005500: Follow-Up Studies; D006470: Hemorrhage; D006801: Humans; D007022: Hypotension; D015201: Meta-Analysis as Topic; D009200: Myocardial Contraction; D009543: Nifedipine; D012084: Renin-Angiotensin System; D018570: Risk Assessment; D013997: Time Factors",,,https://openalex.org/W2009990022,24,3,1,29857,4966,156,en,en
false,calcium antagonist coronary artery disease hypertension,homecirculationvol calcium antagonist coronary artery disease hypertension free accessresearch articledownload epubaboutview epubsections toolsadd favoritesdownload citationstrack citationspermissions shareshare onfacebooktwitterlinked inmendeleyreddit jump tofree accessresearch articledownload epubcalcium antagonist coronary artery disease hypertension time reevaluation salim yusuf salim yusufsalim yusuf division cardiology mcmaster university cardiovascular therapeutic research program hamilton civic hospital research centre hamilton general hospital ontario canada originally published sep https doi org cir circulation calcium antagonist use patient cardiovascular disease decade regulatory authority approve use calcium antagonist individual angina pectoris relieve chest pain hypertension lower blood pressure class among widely use drug treatment cardiovascular condition numerous randomize placebo controlled study demonstrate value agent relieve symptom patient angina action generally associate increased exercise tolerance formal exercise testing however study calcium antagonist use stable angina pectoris clinical manifestation coronary artery disease yet demonstrate convincingly reduction morbidity eg reinfarction stroke mortality part gap information may large long term clinical trial design test question perhaps relief angina per se worthwhile goal therapy symptomatic patient however data accumulate clinical trial conduct last decade raise concern whether calcium antagonists increase morbidity eg worsen unstable angina increase heart failure increase risk infarction mortality data potential adverse effect calcium antagonist obtain patient variety clinical manifestation coronary artery disease include stable angina pectoris unstable angina acute myocardial infarction mi long term use mi heart failure patient various condition often several similarity clinical course common underlying pathophysiological abnormality therefore data obtain broad group patient coronary artery disease widespread clinical applicability far direct evidence potential adverse effect calcium antagonist come meta analysis glasser et al trial calcium antagonist stable angina register u food drug administration fda use stable angina trial design primarily document improvement anginal symptom study individually small provide clear information mortality morbidity however overview trial increase odds adverse outcome composite end point death mi ventricular tachycardia major arrhythmia dropout adverse event unfavorable effect calcium antagonist also see several previous trial mi unstable angina patient particular agent dihydropyridine class associate increase risk death nonfatal mi issue circulation furberg et al demonstrate increase mortality increase dos nifedipine adverse dose response relation provide evidence excess mortality nifedipine likely causal trend toward increase cardiovascular morbidity mortality also observe dihydropyridines nicardipine isradipine albeit small moderate sized study available aware publish large long term trial test effect new dihydropyridines prevent major cardiovascular event patient stable coronary disease angina however reliable information effect new dihydropyridines hypertension congestive heart failure chf available next year well designed large trial progress see table recent data prospective randomized amlodipine survival evaluation praise study indicate clear overall mortality benefit harm use dihydropyridines patient severe chf contrary investigator prior expectation appear little effect large subgroup patient coronary artery disease nominally significant reduction morbidity mortality minority patient coronary artery disease investigator appropriately interpret finding hypothesis generating design new study praise test provocative findings data trial nondihydropyridines demonstrate increased mortality mi rate patient coronary artery disease good left ventricular function unlike dihydropyridines agent diltiazem verapamil increase heart rate possible important clinical difference may exist various subclass calcium antagonist nevertheless share several common pharmacological property convince evidence reduced mortality use nondihydropyridine agent diltiazem verapamil cardiovascular condition unavailable recent long term trial patient stable angina pectoris compare verapamil metoprolol period year similar number major cardiovascular event although study one large trial compare antianginal drug indicate similar effect moderate sized difference eg relative risk verapamil metoprolol still could present however large difference major cardiovascular event eg difference risk probably exclude meta analysis post mi trial suggest diltiazem verapamil reduce risk reinfarction odds ratio ci probably mortality odds ratio ci compare placebo add standard therapy contrast class commonly use anti ischemic agent blockers convince evidence decreased rate mortality reinfarction available large body data present calcium antagonist approve u fda canadian health protection branch secondary prevention use mi dissuade official organizations recent data suggest decrease use patient mi second reason calcium antagonist widely use lower blood pressure bp patient hypertension epidemiological study document elevation bp associate increased risk stroke mi chf renal dysfunction large randomized trial demonstrate clearly diuretic decrease cardiovascular mortality stroke heart failure renal dysfunction extent predict epidemiological study base difference bp observe randomized trials however coronary heart disease risk reduction trial approximately two third predict lead concern shortfall potential benefit expect bp lowering might due adverse metabolic effect diuretic relatively high dos use several trial compare blockers diuretic fail demonstrate superiority blockers prevent major vascular event indicate class agent perhaps equally effective recently data trial low dos diuretic eg mg thiazide per day use indicate far low rate adverse effect previous regimen dose several time higher use similar degree bp stroke reduction apparently large reduction coronary heart disease rate calcium antagonist promote use expectation may superior diuretic adverse metabolic profile however contention test formally large trial result two moderate sized trial dihydropyridines suggest agent may fact inferior diuretics angiotensin converting enzyme inhibitors prevent morbidity despite similar bp reduction raise question appropriateness regulatory agency rely solely bp lowering surrogate outcome result trial available abstract meet report although trial complete year earlier full publication result trial would welcome scientific community absence reliable data large trial compare calcium antagonist diuretic hypertension reasonable base decision result two moderate sized trial extrapolate large trial coronary artery disease although initially group patient coronary artery disease appear distinct hypertension coronary artery disease patient hypertension conversely many hypertensive patient overt occult coronary artery disease therefore may prudent avoid use calcium antagonist first line therapy hypertension unless clear evidence randomize trial establish clinical superiority agent cautious approach support disturb data recent relatively small case control study suggest adverse effect hypertension calcium antagonist compare drugs although case control study likely affect bias result consistent information randomize trial coronary artery disease current place calcium antagonist management patient cardiovascular disease present prudent use drug alternative class agent initial treatment angina hypertension example reasonable consider use nitrate blockers initial treatment relieve angina consider use calcium antagonist symptom persist nitrate blockers contraindicate tolerate revascularization inappropriate calcium antagonist use would prudent use nondihydropyridine agent diltiazem verapamil patient angina also chf poor leave ventricular function amlodipine may relatively safe alternative although long acting preparation may theoretical advantage good evidence reduction major vascular event support use widespread use calcium antagonist await result ongoing trial patient hypertension diuretic blockers initially consider drug choice position consistent guideline fifth joint national committee canadian hypertension society patient left ventricular dysfunction chf type diabetic nephropathy angiotensin converting enzyme inhibitor initial drug choice calcium antagonist reserve use diuretic blockers angiotensin converting enzyme inhibitor use already tolerate contraindicate bp reduction necessary circumstance diltiazem verapamil may prefer dihydropyridine calcium antagonist large trial currently way compare new calcium antagonist diuretic trial demonstrate clear superiority calcium antagonist diuretic remain first line therapy hypertension table major ongoing trial calcium antagonist cardiovascular diseasetrialagentshypothesisprojected patientsprimary end pointcommentshypertensionhotfelodipine mg dos plus ace bb dtest effect dbp lower mm hg cv eventsdbp show small difference group mm hg month small contrast could limit ability show differences stopd vs ace v calcium antagonistseffects three class agent bp target major cv eventsadequate power detect difference class agent may unrealistically optimistic allhatd v amlodipine v lisinopril v doxazosinrelative effect class agent bp target chdhigh power detect relative risk difference arms insightnifedipine git vs amiloride hydrochlorthiaziderelative effect two class agents cv eventsmay adequate power detect plausible differences euro systnitrendipine enalapril hydrochlorthiazideimpact ca antagonist based treatment vs placebo strokesheart failurev heft felodipine vs standard treatmenteffect direct vasodilator add ace dig ex tolerance lv function quality lifeonly moderate power assess clinical outcomes praise amlodipine v placeboeffects patient without chd mortality morbiditymach mabefradil v placebonyha class ii iv use ace dig mortalityhot indicates hypertension optimal treatment ace angiotensin converting enzyme inhibitor bb blocker diuretic cv cardiovascular dbp diastolic blood pressure stop swedish trial old patient hypertension allhat antihypertensive lipid lower heart attack prevention trial bp blood pressure chd coronary heart disease insight international nifedipine study intervention goal hypertension treatment git gastro intestinal therapeutic system euro syst european study systolic hypertension v heft veteran heart failure trial dig digoxin praise prospective randomize amlodipine survival evaluation mach mortality assessment congestive heart failure nyha new york heart association footnotescorrespondence dr salim yusuf hamilton civic hospital research centre hamilton general hospital barton st e hamilton ontario l l x canada email email protect reference holland interuniversity nifedipine metoprolol trial hint research group early treatment unstable angina coronary care unit randomised double blind placebo control comparison recurrent ischemia patient treat nifedipine metoprolol br heart j crossrefmedlinegoogle scholar elkayam u amin j mehra vasquez j weber l rahimtoola sh prospective randomize double blind crossover study compare efficacy safety chronic nifedipine therapy isosorbide dinitrate combination treatment chronic congestive heart failure circulation crossrefmedlinegoogle scholar yusuf hold p furberg c update effect calcium antagonist myocardial infarction angina light second danish verapamil infarction trial davit ii recent study j cardiol crossrefmedlinegoogle scholar israeli sprint study group secondary prevention reinfaraction israeli nifedipine trial sprint randomized intervention trial nifedipine patient acute myocardial infarction eur heart j crossrefmedlinegoogle scholar lichtlen pr hugenholtz pg rafflenbeul w hecker h jost decker jw behalf intact group retardation angiographic progression coronary artery disease nifedipine result international nifedipine trial antiatherosclerotic therapy intact lancet crossrefmedlinegoogle scholar hold ph yusuf calcium antagonist treatment ischemic heart disease myocardial infarction coron artery dis crossrefmedlinegoogle scholar hold ph yusuf furberg cd calcium channel blocker acute myocardial infarction unstable angina overview br med j google scholar multicentre diltiazem postinfarction trial research group effect diltiazem mortality reinfarction myocardial infarction n engl j med crossrefmedlinegoogle scholar glasser sp clark pi lipicky rj hubbard jm yusuf expose patient chronic stable exertional angina placebo period drug trial jama crossrefmedlinegoogle scholar furberg cd psaty bm meyer jv nifedipine dose related increase mortality patient coronary heart disease circulation crossrefmedlinegoogle scholar water lesperance j francetich et al controlled trial assess effect calcium channel blocker upon progression coronary artery atherosclerosis circulation crossrefmedlinegoogle scholar mcclellan k unexpected result midas atherosclerosis inpharma abstract google scholar packer praise trial prospective randomize amlodipine survival evaluation background main result present american college cardiology annual meeting march new orleans la google scholar danish study group verapamil myocardial infarction effect verapamil mortality major event acute myocardial infarction danish verapamil infarction trial ii davit ii j cardiol crossrefmedlinegoogle scholar rehnqvist n hjendahl p bill e bjorkardur eriksson sv forslund l hold c nasman p wallen nh effect metoprolol versus verapamil patient stable angina pectoris angina prognosis study stockholm apsis eur heart j press google scholar yusuf peto r lewis j collins r sleight p betablockade myocardial infarction overview randomized trial prog cardiovasc dis crossrefmedlinegoogle scholar fall el cairn jc dafoe w frasure smith n genest j jr massel peretz tremblay gjl williams wl management post myocardial infarction patient consensus report revision cc guideline j cardiol medlinegoogle scholar rogers participant national registry myocardial infarction treatment myocardial infarction united state observation national registry myocardial infarction circulation crossrefmedlinegoogle scholar montague taylor l martin barnes ackman tsuyuki r wensel r williams r catellier teo k clinical qualityimprovement network investigator practice pattern outcome successfully alter example cardiovascular medicine j cardiol medlinegoogle scholar macmahon peto r cutler j collins r sorlie p neaton j abbott r godwin j dyer stamler j blood pressure stroke coronary heart disease part prolonged difference blood pressure prospective observational study correct regression dilution bias lancet crossrefmedlinegoogle scholar collins r peto r macmahon hebert p fiebach nh eberlein ka et al blood pressure stroke coronary heart disease part short term reduction blood pressure overview randomized drug trial epidemiologic context lancet crossrefmedlinegoogle scholar shep cooperative research group prevention stroke antihypertensive drug treatment old person isolated systolic hypertension final result systolic hypertension elderly program shep jama crossrefmedlinegoogle scholar ferguson jj monomura highlight th annual scientific meeting japanese circulation society circulation google scholar psaty bm heckbert sr koepsell td siscovick lemaitre r smith nl wahl pw wagner eh furberg cd risk incident myocardial infarction associate antihypertensive drug therapy present th annual conference cardiovascular disease epidemiology prevention google scholar joint national committee detection evaluation treatment high blood pressure fifth report joint national committee detection evaluation treatment high blood pressure jnc v arch intern med crossrefmedlinegoogle scholar carruther sg larochelle p haynes rb petrasovits schiffin el report canadian hypertension society consensus conference introduction med assoc j google scholar previous back top next figuresreferencesrelateddetailscited sueta tabata n hokimoto clinical role calcium channel blocker ischemic heart disease hypertension research hr online publication date may son hong choi choi shin kim jung park jung w kim choi park w inhibitory effect bim l type ca channel rat ventricular cell biochemical biophysical research communication j bbrc online publication date jun son choi jung w jo jung park choi sin j shim e kim n han j park w inhibitory effect ca activated k channel activator bm l type ca channel rat ventricular myocytes life science j lfs online publication date aug koh k quon target converge therapeutic pathway overcome hypertension international journal cardiology j ijcard online publication date mar park w kang son kim n ko j kim h ko e kim c han j mitochondrial ca activated k channel activator ns inhibit l type ca channel rat ventricular myocytes biochemical biophysical research communication j bbrc online publication date oct ko j park w earm protein kinase inhibitor staurosporine inhibit l type ca current rabbit atrial myocytes biochemical biophysical research communication j bbrc online publication date apr gao z fain h rapoport n ultrasound enhanced tumor targeting polymeric micellar drug carrier molecular pharmaceutic mp h online publication date jul gibbs w hagemann purify poloxamer sickle cell vaso occlusive crisis annals pharmacotherapy aph online publication date feb braga pfaffenbach g weiss barros bergsten mendes g point prevalence drug prescription elderly non elderly inpatient teaching hospital sao paulo medical journal online publication date apr miri r niknahad h vesal g shafiee synthesis calcium channel antagonist activity nitrooxyalkyl alkyl dihydro dimethyl methyl nitro imidazolyl pyridinedicarboxylates il farmaco x online publication date feb min j meissner wang j morgan j mibefradil improve drenergic responsiveness intracellular ca handling hypertrophied rat myocardium experimental biology medicine online publication date may llhoff schmidt c van aken h berendes e buerkle h marmann p reinbold prenger berninghoff r tjan scheld h deng myocardial ischaemia patient impaired leave ventricular function undergo coronary artery bypass graft milrinone versus nifedipine european journal anaesthesiology online publication date nov stimpel kalziumantagonisten arterielle hypertonie lin wang z fedida influence permeate ion kv channel block nifedipine american journal physiology heart circulatory physiology ajpheart h h h online publication date mar leuranguer v mangoni nargeot j richard inhibition type l type calcium channel mibefradil physiologic pharmacologic base cardiovascular effect journal cardiovascular pharmacology online publication date jun raicu florea deleterious effect nifedipine smooth muscle cell imply alteration intracellular calcium signaling fundamental clinical pharmacology j x online publication date dec erdmann e die medikament se therapie der stabilen angina pectoris pentaerithrityltetranitrat majumdar inui gurwitz j gillman mclaughlin soumerai influence physician specialty adoption relinquishment calcium channel blocker treatment myocardial infarction journal general internal medicine j x online publication date jun kizer j kimmel calcium channel blocker controversy historical perspective important lesson future pharmacotherapies international society pharmacoepidemiology hot topic pharmacoepidemiology drug safety sici aid pds co e online publication date jan gasse c stieber j ring keil u hense h population trend antihypertensive drug use journal clinical epidemiology online publication date jul friesinger g ryan coronary heart disease cardiology clinic x online publication date feb meissner min j haake n hirt simon r dantrolene sodium improve force frequency relationship adrenergic responsiveness fail human myocardium european journal heart failure online publication date jun rosamond w broda g kawalec e rywik pajak cooper l chambless l comparison medical care survival hospitalized patient acute myocardial infarction poland united states atherosclerosis risk community aric study perform collaborative study support national heart lung blood institute contract number n hc n hc n hc n hc n hc n hc n hc warsaw pol monica project support polish state committee scientific research polish ministry health n p grant po cracow pol monica project support polish government grant podo american journal cardiology online publication date apr sapin p muller j trigger acute coronary syndrome management acute coronary syndrome flanagan therapeutic coronary angiogenesis coronary angiogenesis x winten g zeiher koronarinsuffizienz und herzinfarkt therapie innerer krankheiten wood abernethy schwartz j calcium antagonist drug new england journal medicine nejm online publication date nov bailey malcolm j arnold david spence j grapefruit juice drug interaction british journal clinical pharmacology j x online publication date aug hager w davis b riba moye l wun c rouleau j lama g pfeffer absence deleterious effect calcium channel blocker patient left ventricular dysfunction myocardial infarction save study experience american heart journal online publication date mar kritz h sinzinger h fitscha p grady j isradipine lower human arterial low density lipoprotein retention vivo prostaglandin leukotrienes essential fatty acid online publication date nov stelfox h chua g rourke k detsky conflict interest debate calcium channel antagonist new england journal medicine nejm online publication date jan mahon n mckenna w calcium channel b,Yusuf S,1995,Circulation,https://doi.org/10.1161/01.cir.92.5.1079,7648648,Yusuf S,article,D016420: Comment; D016421: Editorial,"D002121: Calcium Channel Blockers; D016022: Case-Control Studies; D003327: Coronary Disease; D004232: Diuretics; D004305: Dose-Response Relationship, Drug; D006801: Humans; D006973: Hypertension; D015201: Meta-Analysis as Topic; D009543: Nifedipine; D016032: Randomized Controlled Trials as Topic",,,https://openalex.org/W2004599322,63,8,1,29865,4999,164,en,en
false,nifedipine,purpose study assess effect dose nifedipine dihydropyridine calcium antagonist increase risk mortality see randomized secondary prevention trial review mechanism adverse effect might occur restrict dose response meta analysis randomize secondary prevention trial nifedipine mortality data available recent trial calcium antagonist formulation also review information possible mechanism action might increase mortality overall use nifedipine associate significant adverse effect total mortality risk ratio ci summary estimate fails draw attention important dose response relationship daily dos mg risk ratio total mortality ci ci ci respectively formal test dose response high dos nifedipine significantly associate increased mortality p mechanism adverse effect know several plausible explanation include establish proischemic effect negative inotropic effect mark hypotension recently report prohemorrhagic effect attribute antiplatelet vasodilatory action calcium antagonist possibly proarrhythmic effects patient coronary disease use short acting nifedipine moderate high dos cause increase total mortality calcium antagonist may similar adverse effect particular dihydropyridine type long term safety data lack calcium antagonist,Furberg CD,1995,Circulation,https://doi.org/10.1161/01.cir.92.5.1326,7648682,Furberg CD; Psaty BM; Meyer JV,article,D016428: Journal Article; D017418: Meta-Analysis,"D000787: Angina Pectoris; D001145: Arrhythmias, Cardiac; D002121: Calcium Channel Blockers; D016001: Confidence Intervals; D003327: Coronary Disease; D003864: Depression, Chemical; D004095: Dihydropyridines; D004305: Dose-Response Relationship, Drug; D006470: Hemorrhage; D006801: Humans; D007022: Hypotension; D009200: Myocardial Contraction; D017202: Myocardial Ischemia; D009543: Nifedipine; D016017: Odds Ratio; D012084: Renin-Angiotensin System; D013564: Sympathetic Nervous System; D013997: Time Factors",,,https://openalex.org/W2092805838,10,1,1,1796,313,9,da,en
false,salutary effect terminalia arjuna patient severe refractory heart failure,twelve patient refractory chronic congestive heart failure class iv nyha relate idiopathic dilate cardiomyopathy patient previous myocardial infarction one patient peripartum cardiomyopathy one patient receive terminalia arjuna indian medicinal plant bark extract mg hourly match placebo week separate week washout period double blind cross design adjuvent maximally tolerable conventional therapy phase clinical laboratory echocardiographic evaluation carry baseline end terminalia arjuna placebo therapy result compare terminalia arjuna compare placebo associate improvement symptom sign heart failure improvement nyha class class iii vs class iv decrease echo left ventricular enddiastolic vs ml p endsystolic volume vs ml p index increase left ventricular stroke volume index vs ml p increase left ventricular ejection fraction vs p long term evaluation open design phase ii wherein phase participant continue terminalia arjuna fixed dosage mg hourly addition flexible diuretic vasodilator digitalis dosage month mean month outpatient basis patient show continued improvement symptom sign effort tolerance nyha class improvement quality life abstract truncate word,Bharani A,1995,Int J Cardiol,https://doi.org/10.1016/0167-5273(95)02320-v,7649665,Bharani A; Ganguly A; Bhargava KD,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D002311: Cardiomyopathy, Dilated; D017024: Chemotherapy, Adjuvant; D002908: Chronic Disease; D003327: Coronary Disease; D018592: Cross-Over Studies; D004077: Digoxin; D004311: Double-Blind Method; D005260: Female; D005665: Furosemide; D006333: Heart Failure; D006334: Heart Function Tests; D006801: Humans; D006973: Hypertension; D007194: India; D008297: Male; D008875: Middle Aged; D010946: Plants, Medicinal; D011788: Quality of Life; D013148: Spironolactone; D016896: Treatment Outcome; D016277: Ventricular Function, Left; D015431: Weight Loss",,,https://openalex.org/W2005060225,85,12,1,1657,309,5,en,en
false,emergent management patient preterm labor,clinician treat ptl realize side effect rarely occur tocolytic medication properly use beneficial effect tocolytic therapy vastly outweigh risk associate use prolongation gestation even short extension utero life day week significantly positively affect neonatal survival long term outcome although opponent tocolytic therapy argue reduction ptb rate occur since introduction argument consider large majority ptbs eligible tocolytic intervention patient clear indication tocolysis could compare treat study substantial beneficial effect tocolytic administration probably would demonstrate base available data consider mgso terbutaline first line tocolytics magnesium use often low side effect profile indomethacin nifedipine reserve difficult refractory preterm labor use interval hour attempt present method decision analysis follow every patient admit obstetric care unit presumptive diagnosis premature labor realize many issue include controversial however hope develop decision tree see fig complete management scheme create lead improve care patient undergoing premature labor,Sullivan CA,1995,Obstet Gynecol Clin North Am,https://doi.org/10.1016/s0889-8545(21)00175-3,7651666,Sullivan CA; Morrison JC,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000318: Adrenergic beta-Agonists; D005260: Female; D006801: Humans; D008278: Magnesium Sulfate; D007752: Obstetric Labor, Premature; D010353: Patient Education as Topic; D017410: Practice Guidelines as Topic; D011247: Pregnancy; D011448: Prostaglandin Antagonists; D012307: Risk Factors; D015145: Tocolysis; D014187: Transportation of Patients",,,https://openalex.org/W2472381624,51,8,1,1600,272,11,en,en
false,amlodipine induce flow pressure independent vasoactive effect brachial artery hypertension,objective study study flow dependent arterial reactivity pressure independent arterial compliance calcium antagonist amlodipine hypertensive men twenty one hypertensive patient randomize receive month treatment placebo n mg amlodipine n day non invasive measurement brachial artery mean blood pressure diameter flow pulsed doppler compliance arterial mechanography logarithmic elastic model obtain drug administration vasoreactivity study mean response brachial artery exclusion hand hyperaemia post ischaemia compare placebo amlodipine reduce mean blood pressure change e mean vs p increase arterial compliance prevailing pressure vs p isobaric pressure vs p significant change increase baseline brachial artery diameter placebo amlodipine observe rest vs p wrist occlusion vs p reactive hyperaemia vs p significant difference amlodipine placebo group observe blood velocity forearm manoeuvre treatment difference observe group brachial flow dependent vasodilation abstract truncate word,Megnien JL,1995,Br J Clin Pharmacol,,7654482,Megnien JL; Levenson J; Del-Pino M; Simon A,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D017311: Amlodipine; D000704: Analysis of Variance; D001783: Blood Flow Velocity; D001794: Blood Pressure; D001916: Brachial Artery; D003187: Compliance; D004311: Double-Blind Method; D005260: Female; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011673: Pulsatile Flow; D012039: Regional Blood Flow; D014664: Vasodilation,,,https://openalex.org/W1917484833,108,15,1,1517,300,14,en,en
false,multicenter comparison adverse reaction profile isradipine enalapril equipotent dos patient essential hypertension,multicenter randomize double blind trial compare safety efficacy dihydropyridine isradipine angiotensin converting enzyme ace inhibitor enalapril give twice daily mild hypertension patient receive either isradipine start mg twice daily enalapril start mg twice daily week dosage increase average sit diastolic blood pressure mm hg significantly great mean reduction systolic blood pressure see week isradipine however end trial patient receive isradipine receive enalapril show decrease least mm hg sit diastolic blood pressure level mm hg possible probable drug related adverse effect report patient show good antihypertensive response isradipine respond enalapril trend low frequency adverse effect isradipine non responders high frequency enalapril non responders pruritus dizziness edema fatigue report often isradipine cough change bowel habit common enalapril relationship pattern adverse effect extent blood pressure reduction may dependent mechanism action drug responder isradipine enalapril show differ pattern similar overall incidence adverse effect,Johnson BF,1995,J Clin Pharmacol,https://doi.org/10.1002/j.1552-4604.1995.tb04092.x,7657848,Johnson BF; Eisner GM; McMahon FG; Jain AK; Rudd P; Sowers JR,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000293: Adolescent; D000328: Adult; D001794: Blood Pressure; D004311: Double-Blind Method; D004656: Enalapril; D005260: Female; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D008297: Male; D008875: Middle Aged; D013810: Therapeutic Equivalency,,,https://openalex.org/W2088552238,141,19,1,1520,276,10,en,en
false,additive effect verapamil enalapril treatment mild moderate hypertension,factorial design apply multicenter double blind placebo controlled trial calcium channel blocker verapamil ace inhibitor enalapril assess hypotensive effect combination compare monotherapy evaluate safety determine effect quality life qol drug alone combination study consist factorial design wherein men woman sit diastolic blood pressure bp mm hg mm hg week placebo washout randomize one six treatment group week active treatment monotherapy mg verapamil mg enalapril reduce systolic diastolic bp similar extent significantly placebo mg verapamil mg enalapril combination additive systolic diastolic blood pressure mg verapamil mg enalapril additive systolic bp total number adverse event report similar six treatment group qol score unchanged baseline different treatment group combination mg verapamil mg enalapril significantly effective reduce bp either drug alone additivity effect link high rate adverse experience deterioration qol thus combination therapy low dos may offer alternative treatment option high dose monotherapy j hypertens doi r,Levine JH,1995,Am J Hypertens,https://doi.org/10.1016/0895-7061(95)00053-r,7662226,Levine JH; Ferdinand KC; Cargo P; Laine H; Lefkowitz M,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000704: Analysis of Variance; D001794: Blood Pressure; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004562: Electrocardiography; D004656: Enalapril; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011788: Quality of Life; D011795: Surveys and Questionnaires; D014700: Verapamil",,,https://openalex.org/W2008002849,93,14,1,1542,277,9,en,en
false,effect different antihypertensive drug plasma fibrinogen hypertensive patient,order evaluate whether treatment different antihypertensive drug would affect plasma fibrinogen level mild moderate essential hypertensive subject male age year randomly treat amlodipine mg atenolol mg hydrochlorothiazide mg lisinopril mg give daily week week treatment blood pressure bp heart rate hr fibrinogen total cholesterol tc hdl c ldl c triglyceride tg plasma glucose plasma uric acid serum creatinine serum potassium evaluate four medication significantly reduce bp value although bp lower effect lisinopril amlodipine atenolol significantly great compare hydrochlorothiazide plasma fibrinogen level unaffected atenolol hydrochlorothiazide amlodipine whereas significantly decrease lisinopril p fibrinogen lower effect evident smoker non smoker atenolol amlodipine significantly affect plasma lipid hydrochlorothiazide increase tc ldl c tg reduced hdl c lisinopril increase hdl c decrease tc ldl c hydrochlorothiazide increase plasma glucose uric acid concentration unaffected drug diuretic also reduce serum potassium result study indicate lisinopril reduces level plasma fibrinogen confirm different antihypertensive drug may elicit different metabolic effect may variously influence overall risk profile hypertensive patient,Fogari R,1995,Br J Clin Pharmacol,https://doi.org/10.1111/j.1365-2125.1995.tb04482.x,7669481,Fogari R; Zoppi A; Malamani GD; Marasi G; Vanasia A; Villa G,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000328: Adult; D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D001262: Atenolol; D001786: Blood Glucose; D001794: Blood Pressure; D002784: Cholesterol; D008076: Cholesterol, HDL; D008078: Cholesterol, LDL; D003404: Creatinine; D005340: Fibrinogen; D006339: Heart Rate; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D017706: Lisinopril; D008297: Male; D008875: Middle Aged; D011188: Potassium; D014280: Triglycerides; D014527: Uric Acid",,,https://openalex.org/W2013439227,90,12,1,1667,296,15,en,en
false,contemporary management atrial fibrillation,incidence atrial fibrillation approximately double every year increment age framingham heart study cohort thus physician face increase patient population atrial fibrillation hypertension observe common associate risk factor sex management patient atrial fibrillation evolve result number published study calcium channel blocker beta blockers emerge preferred choice rate control rather digoxin low dose anticoagulation therapy show beneficial effect primary prevention also secondary prevention thromboembolism thus patient successfully cardioverted anticoagulated contraindication table fall low risk group define patient age without risk factor hypertension diabetes previous stroke patient eligible anticoagulation aspirin therapy patient lone atrial fibrillation high risk thromboembolism general population therefore manage without anticoagulation antiplatelet therapy antiarrhythmic treatment approach cautiously amiodarone low dos effective safe treatment remain controversial,Ukani ZA,1995,Med Clin North Am,https://doi.org/10.1016/s0025-7125(16)30024-4,7674688,Ukani ZA; Ezekowitz MD,article,D016428: Journal Article; D016454: Review,D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D017115: Catheter Ablation; D004554: Electric Countershock; D004617: Embolism; D005260: Female; D006801: Humans; D008297: Male; D018579: Patient Selection; D012307: Risk Factors,,,https://openalex.org/W2315724632,46,5,1,1383,223,9,en,en
false,effect isradipine black patient severe hypertension,fifty consecutive black patient severe hypertension sit diastolic blood pressure mm hg systolic mm hg conventional cuff method treat open label study without placebo active drug control group month long acting preparation isradipine dynacirc sro time serial change h ambulatory blood pressure monitoring abpm leave ventricular lv mass index lv systolic function evaluate mean h abpm reduce mm hg month p reduction bp sustain h dose simultaneous bp measurement use conventional cuff method dinamap significantly different abpm pre posttherapy suggest marked white coat pressor effect lv mass index regress g month p heart rate mean body weight unchanged leave ventricular performance adversely affect cardiac index fractional shortening change insignificantly l min respectively adverse effect tend disappear treatment period clinical laboratory parameter test remain unchanged conclude group patient long acting isradipine show marked sustained antihypertensive action demonstrate h abpm well tolerate associate lv mass regression without adverse effect systolic cardiac function abstract truncate word,Skoularigis J,1994,Am J Hypertens,https://doi.org/10.1093/ajh/7.12.1058,7702799,Skoularigis J; Weinberg J; Strugo V; Davis J; Skudicky D; Zambakides C; Sareli P,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article,"D000328: Adult; D000368: Aged; D044383: Black People; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D003692: Delayed-Action Preparations; D015150: Echocardiography, Doppler; D004562: Electrocardiography; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D008297: Male; D008875: Middle Aged; D016277: Ventricular Function, Left",,,https://openalex.org/W2404817621,68,10,1,1637,307,12,en,en
false,three month efficacy safety daily diltiazem chronic stable angina pectoris,month efficacy safety daily controlled formulation diltiazem mg day assess study patient angina pectoris multicenter study nonrandomized placebo run open label month trial follow week double blind randomized period patient receive placebo minimal change time termination mean change sem second time onset angina second time mm st segment depression second end titration phase end open label study however statistically significant difference end month treatment phase end week randomized placebo phase efficacy parameter second respectively diltiazem significantly decrease frequency anginal attack nitroglycerin use end month treatment phase compare result end randomized double blind placebo phase new unusual adverse event report treatment present result suggest loss efficacy day diltiazem administer long period patient chronic stable angina pectoris,Nadeau C,1995,Am J Cardiol,https://doi.org/10.1016/s0002-9149(99)80615-8,7710563,Nadeau C; Hilton D; Savard D; Morin Y; Baird M; Alexander M; Langer G; Roth D; Boulet AP; Larivière L,article,"D016430: Clinical Trial; D017426: Clinical Trial, Phase I; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D000787: Angina Pectoris; D002908: Chronic Disease; D004110: Diltiazem; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D016896: Treatment Outcome,,,https://openalex.org/W2020803687,89,12,1,1357,245,7,en,en
false,increase vagal activity administration calcium antagonist diltiazem patient coronary heart disease,effect calcium channel blocker diltiazem parasympathetic nervous system study use spectral analysis heart rate variability compare effect beta receptor blocker metoprolol area curve high frequency range f hz control respiratory rate f hz use quantitative index parasympathetic activity twenty four male patient proven coronary artery disease normal leave ventricular function lvef study week chronic treatment diltiazem x mg daily metoprolol x mg daily administration drug twelve patient receive diltiazem patient metoprolol administration diltiazem peripheral systolic blood pressure reduce parasympathetic activity significantly high compare initial measurement effect see metoprolol significant low heart rate present administration relative area high frequency range significantly increase rest diltiazem metoprolol diltiazem metoprolol enhance vagal influence heart thereby lead enhancement barosensitivity respiratory sinus arrhythmia action may contribute beneficial effect drug patient coronary artery disease,Frey AW,1995,Z Kardiol,,7717013,Frey AW; Müller C; Dambacher M; Theisen K,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D001146: Arrhythmia, Sinus; D003327: Coronary Disease; D004110: Diltiazem; D004562: Electrocardiography; D006339: Heart Rate; D006706: Homeostasis; D006801: Humans; D008297: Male; D008790: Metoprolol; D008875: Middle Aged; D010275: Parasympathetic Nervous System; D012815: Signal Processing, Computer-Assisted; D013318: Stroke Volume; D014630: Vagus Nerve; D016277: Ventricular Function, Left",,,https://openalex.org/W2412834427,124,19,1,1447,243,9,en,en
false,safety tolerability losartan potassium angiotensin ii receptor antagonist compare hydrochlorothiazide atenolol felodipne er angiotensin converting enzyme inhibitor treatment systemic hypertension,report present data safety tolerability losartan potassium losartan selective antagonist angiotensin ii receptor approximately hypertensive patient treat double blind clinical trial study headache upper respiratory infection dizziness asthenia fatigue cough clinical adverse experience often report patient treat losartan adverse experience also frequently report patient receive placebo respectively dry cough adverse event report patient treat angiotensin converting enzyme inhibitor patient treat losartan placebo respectively dizziness consider drug related often losartan treated placebo treated patient controlled clinical trial losartan well tolerate antihypertensive agent determine incidence patient report drug related adverse experience rate discontinuation due clinical adverse experience patient receive losartan monotherapy losartan hydrochlorothiazide respectively compare placebo laboratory adverse experience unexpected clinical importance first dose hypotension rarely occur losartan losartan plus hydrochlorothiazide withdrawal effect rebound hypertension observe clinical trial clinically important difference clinical laboratory safety profile demographic subgroup age gender race controlled clinical trial losartan demonstrate excellent tolerability profile,Goldberg AI,1995,Am J Cardiol,https://doi.org/10.1016/s0002-9149(99)80413-5,7717281,Goldberg AI; Dunlay MC; Sweet CS,article,D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article,"D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000804: Angiotensin II; D057911: Angiotensin Receptor Antagonists; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001247: Asthenia; D001262: Atenolol; D001713: Biphenyl Compounds; D003371: Cough; D004244: Dizziness; D004311: Double-Blind Method; D005221: Fatigue; D015736: Felodipine; D005260: Female; D006261: Headache; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D007093: Imidazoles; D019808: Losartan; D008297: Male; D008875: Middle Aged; D010919: Placebos; D012141: Respiratory Tract Infections; D012449: Safety; D013777: Tetrazoles",,,https://openalex.org/W1997980688,232,32,1,1807,309,11,en,en
false,effectiveness enalapril versus nifedipine antagonize blood pressure renal response endothelin human,abstract endothelin infusion human obtain pathophysiological plasma level cause mild hypertension strong renal vasoconstriction sodium retention study whether oral use angiotensin converting enzyme inhibitor enalapril mg bid calcium channel blocker nifedipine mg od could attenuate effect endothelin ng kg per minute minute six healthy volunteer endothelin infusion alone increase plasma endothelin pmol l p blood pressure rise approximately mm hg p renal function change relatively large renal blood flow decrease ml min p glomerular filtration rate ml min p renal vascular resistance increase mm hg min l p sodium excretion decrease mol min p enalapril treatment reduce blood pressure mm hg p prevent hypertensive response endothelin contrast despite renal predilatation endothelin reduce renal blood flow strongly ml min p although maximal renal vascular resistance numerically low mm hg min l endothelin alone p glomerular filtration rate fell ml min p enalapril alter antinatriuretic effect endothelin nifedipine affect blood pressure prevent increase cause endothelin endothelin induced fall renal blood flow ml min p less endothelin infusion alone p maximal renal vascular resistance mm hg min l low experiment p whereas glomerular filtration rate maintain nifedipine increase basal sodium excretion p compensate decrease observe superimpose endothelin infusion conclusion enalapril nifedipine counteract hypertensive effect endothelin nifedipine effective antagonize renal effect endothelin,Kaasjager KA,1995,Hypertension,https://doi.org/10.1161/01.hyp.25.4.620,7721406,Kaasjager KA; Koomans HA; Rabelink TJ,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D001794: Blood Pressure; D004573: Electrolytes; D004656: Enalapril; D016232: Endothelins; D005260: Female; D006801: Humans; D007668: Kidney; D008297: Male; D009543: Nifedipine; D012079: Renal Circulation,,,https://openalex.org/W2063901685,120,17,1,2204,423,13,en,en
false,calcium channel blockade adrenergic blockade affect platelet function fibrinolysis vary degree,effect isradipine atenolol platelet function fibrinolytic activity study male patient mild untreated hypertension week placebo run period volunteer randomize either isradipine mg twice daily atenolol mg daily month period initially receive isradipine receive atenolol vice versa therapy regimen blood draw rest h exercise maximum exercise test platelet activity vivo estimate release b tg pf fibrinolytic activity estimate fast acting inhibitor tissue plasminogen activator usually term pai atenolol isradipine therapy blood pressure bp equally reduce p heart rate hr decrease atenolol treatment change isradipine platelet activity vivo estimate b tg pf decreased irrespective therapy p atenolol placebo therapy exercise result significant increase platelet activity show increase b tg p pf p increase observe isradipine treatment treatment tend improve fibrinolysis show decrease pai h exercise reduce bp isradipine atenolol result similar decrease platelet activity pai level test rest h rest respectively exercise platelet activity increase atenolol treatment change occur isradipine treatment,Gleerup G,1995,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-199501000-00014,7723358,Gleerup G; Mehlsen J; Winther K,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D001262: Atenolol; D001792: Blood Platelets; D001794: Blood Pressure; D018592: Cross-Over Studies; D004311: Double-Blind Method; D015444: Exercise; D005260: Female; D005342: Fibrinolysis; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D008297: Male; D008875: Middle Aged; D017395: Plasminogen Activator Inhibitor 1; D010974: Platelet Aggregation; D011863: Radioimmunoassay; D001620: beta-Thromboglobulin,,,https://openalex.org/W1985055678,119,18,1,1580,282,14,en,en
false,vascular compliance sodium sensitive sodium resistant borderline hypertensive patient,recently demonstrate reduction compliance carotid femoral brachial artery sodium sensitive subject consume regular sodium intake approximately mmol per day compare sodium resistant borderline hypertensive subject normotensive control venous compliance different two borderline hypertensive group slightly less control large artery compliance study use non invasive ultrasound vessel wall movement detector system venous compliance determine mean strain gauge plethysmography borderline hypertensive subject subsequently treat enalapril mg day felodipine mg day placebo six month despite similar reduction blood pressure enalapril induce significant increase muscular femoral brachial artery compliance elastic carotid artery felodipine influence large artery compliance sodium sensitive group effect enalapril muscular artery compliance establish dose dependent increase distension change arterial diameter arterial compliance influence either drug resistant group venous compliance also alter medication conclusion femoral brachial artery compliance sodium sensitive borderline hypertensive subject find low sodium resistant subject improve antihypertensive treatment enalapril felodipine despite similar reduction blood pressure induce drug abstract truncate word,Draaijer P,1995,Kidney Int,https://doi.org/10.1038/ki.1995.20,7731143,Draaijer P; Kool MJ; van Bortel LM; Nieman F; de Leeuw PW; van Hooff JP; Leunissen KM,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D001794: Blood Pressure; D001808: Blood Vessels; D003187: Compliance; D004039: Diet, Sodium-Restricted; D015150: Echocardiography, Doppler; D004656: Enalapril; D015736: Felodipine; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D012084: Renin-Angiotensin System; D014655: Vascular Resistance",,,https://openalex.org/W1998717210,93,9,1,1709,264,10,en,en
false,effect hypertensive agent ventricular geometry function,assess prevalence left ventricular hypertrophy hypertensive patient refer outpatient cardiology unit assess evolution antihypertensive treatment one hundred seven mild moderate hypertensive patient randomize receive either xipamide verapamil atenolol cross sectional echocardiography perform order assess left ventricular mass function mean age year female male ratio mean follow day leave ventricular hypertrophy common decrease antihypertensive treatment leave ventricular mass decrease g g p concentric hypertrophy common geometric pattern decrease treatment xipamide decreased ventricular mass decrease leave ventricular diameter verapamil atenolol decrease leave ventricular thickness mainly septal wall systolic function modify treatment period diastolic function modify xipamide verapamil improve atenolol left ventricular hypertrophy frequent determine echocardiography three drug produce regression left ventricular hypertrophy different way respect left ventricle geometry effect could potential therapeutic implication,Gómez Pajuelo C,1995,Med Clin (Barc),,7731301,Gómez Pajuelo C; Gómez Sánchez MA; Marín Ruiz R; Lombera Romero F; Sanz Julve M; Tascón Pérez J; Sáenz de la Calzada C,article,D016430: Clinical Trial; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D001262: Atenolol; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006973: Hypertension; D017379: Hypertrophy, Left Ventricular; D008297: Male; D008875: Middle Aged; D015995: Prevalence; D016277: Ventricular Function, Left; D014700: Verapamil; D014988: Xipamide",,,https://openalex.org/W2417217652,73,13,1,1378,217,9,en,en
false,evaluation efficacy safety oral nicardipine treatment urgent hypertension multicenter randomize double blind parallel placebo controlled clinical trial,study prospective randomize double blind placebo controlled clinical trial design evaluate safety efficacy oral nicardipine treatment urgent hypertension emergency department patient urgent hypertension patient enrol men woman black white age range year diastolic blood pressure mm hg patient randomly assign receive mg nicardipine placebo blind fashion follow mg open label nicardipine nonresponders responder one two dos nicardipine receive mg nicardipine three time day week discharge emergency department adequate blood pressure reduction define reduction diastolic blood pressure less mm hg least mm hg achieve patient receive mg nicardipine placebo p adequate blood pressure reduction administration open label nicardipine occur nonresponders placebo blood pressure reduction maintain week discharge drug well tolerate significant adverse event occur conclude oral nicardipine safe effective drug initial treatment urgent hypertension,Habib GB,1995,Am Heart J,https://doi.org/10.1016/0002-8703(95)90112-4,7732981,Habib GB; Dunbar LM; Rodrigues R; Neale AC; Friday KJ,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000328: Adult; D000704: Analysis of Variance; D001794: Blood Pressure; D004311: Double-Blind Method; D004630: Emergencies; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009529: Nicardipine; D010919: Placebos; D011446: Prospective Studies",,,https://openalex.org/W1989945517,179,27,1,1321,237,9,en,en
false,sustain blood pressure control controlled release isradipine,efficacy safety different dos new controlled release formulation isradipine isradipine cr icr evaluate patient mild moderate stage essential hypertension placebo controlled study randomized patient complete study placebo mg icr mg icr mg icr mg icr dos icr decrease blood pressure effect great dos mg daily p common clinical side effect mild ankle edema dose dependent occur patient take mg icr dose study show icr long acting effective well tolerate,Chrysant SG,1995,Am J Hypertens,https://doi.org/10.1016/0895-7061(94)00158-8,7734104,Chrysant SG; Cohen M,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D001794: Blood Pressure; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D008297: Male,,,https://openalex.org/W2077696077,67,7,1,717,155,5,en,en
false,invasive hemodynamic evaluation sublingual captopril nifedipine patient arterial hypertension abdominal aortic surgery,objective examine central hemodynamic blood gas response sublingual captopril nifedipine administration patient arterial hypertension abdominal aortic surgery design prospective randomize parallel group clinical study set twenty nine bed medical surgical intensive care unit university hospital patient twenty patient arterial hypertension mean arterial pressure mm hg day abdominal aortic surgery patient bilateral renal artery stenosis identify preoperative angiogram exclude intervention pressure measure use intravascular catheter cardiac output determine thermodilution hr captopril mg n nifedipine mg n administer sublingual route measurement main result captopril administration nifedipine administration decrease mean arterial pressure mm hg sem mm hg respectively pulmonary arterial pressure pulmonary artery occlusion pressure right atrial pressure p variable change heart rate cardiac output significant pao decrease nifedipine torr kpa p captopril torr kpa excessive symptomatic decrease blood pressure observe deterioration renal function observe conclusion sublingual captopril nifedipine equally effective treatment arterial hypertension abdominal aortic surgery nifedipine captopril cause deterioration pulmonary gas exchange crit care med,Leeman M,1995,Crit Care Med,https://doi.org/10.1097/00003246-199505000-00011,7736741,Leeman M; Degaute JP,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000286: Administration, Sublingual; D000368: Aged; D000704: Analysis of Variance; D001012: Aorta, Abdominal; D002216: Captopril; D005260: Female; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011183: Postoperative Complications; D011446: Prospective Studies; D013997: Time Factors",,,https://openalex.org/W2022582118,140,17,1,1800,318,13,en,en
false,calcium channel entry blocker therapy hypertensive patient concomitant renal impairment focus isradipine,treatment hypertension renally impaired patient normalization blood pressure alone may sufficient prevent significant morbidity kidney treatment must reduce pressure renal vasculature otherwise glomerular filtration rate renal plasma flow continue deteriorate isradipine dihydropyridine calcium channel blocker investigate suitable treatment setting isradipine maintain glomerular filtration rate preserve enhance renal plasma flow decrease renal vascular resistance maintain reduce filtration fraction exert sustained natriuretic effect may enable isradipine slow rate progression renal deterioration addition isradipine may decrease proteinuria may decrease glomerular capillary pressure dilate efferent afferent arteriole unlike old calcium channel blocker isradipine exhibit minimal cardiodepressant activity associate negative inotropic effect metabolize liver dosage adjustment may necessary administer patient renal insufficiency isradipine favorable renal effect profile also several property meet requirement patient population extra measure antihypertensive safety require diabetic dialysis patient transplant recipient side effect isradipine usually mild transient occur dose dependent manner,Frishman WH,1994,J Clin Pharmacol,https://doi.org/10.1002/j.1552-4604.1994.tb04727.x,7738211,Frishman WH,article,D003160: Comparative Study; D016428: Journal Article; D016454: Review,D002121: Calcium Channel Blockers; D048909: Diabetes Complications; D005919: Glomerular Filtration Rate; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D007674: Kidney Diseases,,,https://openalex.org/W2080301068,120,16,1,1535,234,9,en,en
false,h anti anginal anti ischaemic effect daily felodipine,effect monotherapy felodipine er mg nifedipine sr mg b compare double blind randomize placebo controlled three way cross trial patient stable exercise induced angina pectoris exercise test perform end dosage interval e h felodipine er h nifedipine sr expected peak time h post dose felodipine nifedipine improve exercise duration respectively p compare placebo end dosing interval time end exercise show statistically significant difference two calcium antagonist onset anginal pain time mm st depression significantly delay felodipine er nifedipine sr respectively p felodipine nifedipine decrease pain score rate pressure product high comparable work load overall tolerability good drug,Schulte KL,1995,Eur Heart J,https://doi.org/10.1093/oxfordjournals.eurheartj.a060881,7744087,Schulte KL,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000328: Adult; D000368: Aged; D000788: Angina Pectoris, Variant; D002940: Circadian Rhythm; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004562: Electrocardiography; D005080: Exercise Test; D015736: Felodipine; D005260: Female; D006439: Hemodynamics; D006801: Humans; D008297: Male; D008875: Middle Aged; D009543: Nifedipine",,,https://openalex.org/W2235164908,71,10,1,999,190,10,en,en
false,effect nonsteroidal anti inflammatory drug blood pressure patient hypertension control verapamil,background nonsteroidal anti inflammatory drug may attenuate antihypertensive effect diuretic blockers angiotensin converting enzyme inhibitor central agonists vasodilator effect antihypertensive efficacy calcium channel blocker inadequately study small number patient appear minimal method three phase randomize double blind placebo controlled multicenter study include patient age year essential hypertension diastolic blood pressure control mm hg less daily verapamil hydrochloride patient receive ibuprofen naproxen placebo matching capsule week blood pressure heart rate weight adverse effect evaluate general linear model confidence interval use compare nonsteroidal anti inflammatory drug treatment group placebo group result significant difference sit stand supine blood pressure note naproxen ibuprofen compare placebo percentage patient treatment group increase mm hg either systolic diastolic blood pressure similar statistically significant increase weight see nonsteroidal anti inflammatory drug therapy change pulse rate significant incidence adverse effect similar across three treatment group conclusion addition naproxen ibuprofen treatment hypertensive patient blood pressure control daily verapamil cause increase blood pressure verapamil may therefore offer considerable advantage maintain control blood pressure patient regularly receive nonsteroidal anti inflammatory drug therapy arch intern med,Houston MC,1995,Arch Intern Med,https://doi.org/10.1001/archinte.1995.00430100075009,7748048,Houston MC; Weir M; Gray J; Ginsberg D; Szeto C; Kaihlenen PM; Sugimoto D; Runde M; Lefkowitz M,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000328: Adult; D000368: Aged; D001794: Blood Pressure; D004311: Double-Blind Method; D004347: Drug Interactions; D005260: Female; D006801: Humans; D006973: Hypertension; D007052: Ibuprofen; D008297: Male; D008875: Middle Aged; D009288: Naproxen; D014700: Verapamil,,,https://openalex.org/W2073613120,124,16,1,1911,316,14,en,en
false,treatment hypertension fixed calcium antagonist diuretic combination observation treatment patient,observational study last month patient essential hypertension treat combination calcium antagonist diuretic aim test efficacy safety drug oft patient already receive anti hypertensive treatment patient also accompany disease treatment begin single daily tablet comprise mg verapamil mg triamterene mg hydrochlorothiazide veratide dose could reduce one half increase two daily indict response blood pressure end month treatment overall group show decrease systolic diastolic blood pressure mmhg breakdown oft patient various age group reveal difference result responder rate vary among patient isolated systolic hypertension response rate form hypertension systolic blood pressure lower course treatment patient develop side effect severe case patient treatment break efficacy safety oft combination preparation investigate confirm doctor office condition decrease diastolic blood pressure marked among smoker among non smokers,Klaus D,1995,Fortschr Med,,7750891,Klaus D,article,D004740: English Abstract; D016428: Journal Article,"D000328: Adult; D000368: Aged; D001794: Blood Pressure; D004305: Dose-Response Relationship, Drug; D004338: Drug Combinations; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011358: Product Surveillance, Postmarketing; D014223: Triamterene; D014700: Verapamil",,,https://openalex.org/W2415791936,128,19,2,1451,259,10,en,en
false,dose ranging study new daily diltiazem formulation patient stable angina,double blind safety efficacy dose ranging study conduct new daily extended release xr diltiazem hydrochloride formulation dilacor xr rh ne poulenc rorer collegeville pa patient chronic stable angina pectoris week placebo lead phase patient randomly assign daily fixed dose treatment group placebo xr diltiazem mg mg mg extended release diltiazem mg mg daily dos significantly improve p total exercise time treadmill exercise tolerance testing week treatment assess hour previous dose increase dos xr diltiazem associate incremental improvement exercise tolerance outpatient function assess frequency anginal attack nitroglycerin use ambulatory electrocardiogram holter scole engineering culver city ca monitoring ischemic event also improve xr diltiazem extended release diltiazem formulation clinically titrate within mg dose range permit effective daily administration treat chronic stable angina,Cutler NR,1995,J Clin Pharmacol,https://doi.org/10.1002/j.1552-4604.1995.tb05010.x,7751431,Cutler NR; Eff J; Fromell G; Brass EP; Archer S; Chrysant SG; Fiddes R,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D002626: Chemistry, Pharmaceutical; D003692: Delayed-Action Preparations; D004110: Diltiazem; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005080: Exercise Test; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W1963781609,93,14,1,1201,198,5,en,en
false,metabolic effect anti hypertensive treatment nifedipine furosemide double blind cross study,evaluate metabolic effect two anti hypertensive agent different action nifedipine mg twice daily furosemide mg twice daily patient untreated essential hypertension perform double blind cross study treatment period month metabolic effect evaluate serum lipoprotein determination intravenous glucose tolerance test hyperinsulinaemic euglycaemic clamp technique nifedipine furosemide reduce blood pressure extent mm hg supine sbp mm hg supine dbp p whereas drug significantly increase level glycolysated haemoglobin hba c p nifedipine p furosemide furosemide increase fast blood glucose mmol l p fast insulin mu l p impair early insulin response v glucose mu l p insulin sensitivity hand significantly impair nifedipine treatment mg kg min p whereas treatment nifedipine change serum lipid furosemide cause increase serum cholesterol mmol l p rise ldl fraction mmol l p insignificant change heart rate induce nifedipine treatment correlate change hba c r p inversely relate change insulin sensitivity r p conclusion furosemide nifedipine cause abnormality glucose metabolism nifedipine group effect glucose metabolism relate occurrence tachycardia suggest sympathetic nerve activation could involve metabolic impairment,Lind L,1995,J Hum Hypertens,,7752176,Lind L; Berne C; Pollare T; Lithell H,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000368: Aged; D000704: Analysis of Variance; D001835: Body Weight; D018592: Cross-Over Studies; D004311: Double-Blind Method; D005260: Female; D005665: Furosemide; D005947: Glucose; D015309: Glucose Clamp Technique; D005951: Glucose Tolerance Test; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008074: Lipoproteins; D008297: Male; D008875: Middle Aged; D009543: Nifedipine,,,https://openalex.org/W192707515,113,16,1,1778,327,10,en,en
false,change dietary salt influence blood pressure hypertensive patient pharmacologically control verapamil salt switching study ss,study change dietary salt influence blood pressure bp pharmacologically control hypertensive patient select large multicenter trial two subgroup patient attain bp control office dbp mm hg week treatment verapamil sr mg daily either unrestricted salt diet high salt patient moderately restricted salt diet low salt patient switch opposite dietary salt regimen continue verapamil week salt switching period office bp ambulatory blood pressure monitoring abpm register salt switching period salt intake check urinary sodium excretion una patient switch high low salt reduced una mm na h p patient switch low high salt increase una mm na h p significant change bp find abpm either group switch high low salt group switch low high salt latter group significant increase observe office dpb sbp short term change salt intake seem little influence bp patient pharmacologically control verapamil,Redón J,1995,J Hum Hypertens,,7752177,Redón J; Lozano JV; de la Figuera M; Rodriguez JC; Garrido J; Alés-Martínez JE; Alvarez-Cantalapiedra I; Velasco-Quintana J,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000704: Analysis of Variance; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D018592: Cross-Over Studies; D004039: Diet, Sodium-Restricted; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D012964: Sodium; D014700: Verapamil",,,https://openalex.org/W53323452,153,22,2,1356,252,8,en,en
false,efficacy safety slow release nicardipine v nifedipine angina,control double blind completely randomize study assess efficacy safety nicardipine nifedipine slow release formulation patient unstable angina thirty patient f include final analysis mean age year sd mean weight kg mean height cm unstable angina nicardipine give daily dosage mg nifedipine mg one month end treatment nicardipine supine systolic diastolic blood pressure sbp dbp drop respectively pm nifedipine reduce sbp dbp respectively pm clinical statistical difference treatment heart rate change appreciably either treatment completion nicardipine treatment patient suffer angina attack compare nifedipine remain patient treat nicardipine present one mild angina attack per day nifedipine patient one moderate angina attack per day untoward effect report nicardipine one patient receive nifedipine present cardiopalmus another complain headache result indicate nicardipine least safe effective nifedipine treatment unstable angina,Villanova C,1994,Minerva Cardioangiol,,7753427,Villanova C; Maddalena F; Rocco CG,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000789: Angina, Unstable; D001794: Blood Pressure; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D009529: Nicardipine; D009543: Nifedipine; D013997: Time Factors",,,https://openalex.org/W2407313700,78,14,1,1464,278,11,en,en
false,pharmacologic management preterm labor,compare tocolytic potency ritodrine nicardipine atosiban use alone dual combination see whether combination drug act via different pathway could improve inhibition uterine contractility study myometrial contractility vitro laboratory physiology lyon france longitudinal myometrial strip non labouring time pregnant wistar rat gestational day strips simultaneously expose ec ec ec dual combination either ritodrine nicardipine ritodrine atosiban nicardipine atosiban n group basal contractile activity contractile activity addition combination measure use min integral activity change express percentage basal min integral activity observed percentage inhibition activity compare expected percentage inhibition additive pharmacological model significant difference occur combination deem simply additive tocolytic effect inhibition activity significantly great compare expected percentage inhibition combination deem synergistic effect changes integral contractile activity response tocolytic combinations ritodrine atosiban inhibited integral activity great extent expect e g use ec observed inhibition v expect inhibition p actual inhibition nicardipine ritodrine vs p n nicardipine atosiban vs p n significantly different expected combination ritodrine plus atosiban exhibit synergistic inhibition myometrial activity thus allow use low concentration drug achieve effect compare drug use alone combination nicardipine plus ritodrine nicardipine plus atosiban achieves additive effect potential decrease side effect beta mimetics cost atosiban use combination clinical practice need evaluate,Monga M,1995,Semin Perinatol,https://doi.org/10.1016/s0146-0005(95)80050-6,7754414,Monga M; Creasy RK,article,D016428: Journal Article; D016454: Review,"D000318: Adrenergic beta-Agonists; D002121: Calcium Channel Blockers; D002986: Clinical Trials as Topic; D016861: Cyclooxygenase Inhibitors; D005260: Female; D006801: Humans; D008278: Magnesium Sulfate; D007752: Obstetric Labor, Premature; D011247: Pregnancy; D012307: Risk Factors; D015149: Tocolytic Agents",,,https://openalex.org/W2040267787,41,5,1,2142,354,12,en,en
false,prospective study effect angiotensin convert enzyme inhibitor beta blockader structure function resistant artery mild essential hypertension,seventeen male untreated mild essential hypertensive patient mean age year agree participate double blind randomized trial test effect treatment cilazapril inhibitor angiotensin convert enzyme comparison treatment atenolol beta blocker structure function subcutaneous resistance artery patient randomize receive either cilazapril mg atenolol mg per day per day blood pressure treatment mmhg group respectively year treatment blood pressure mmhg group patient respectively treatment one year cilazapril result reduction media lumen ratio resistance artery micron lumen diameter dissect subcutaneous gluteal biopsy treatment year later p still slightly significantly large p media lumen ratio resistance artery normotensive control artery patient treat atenolol significant change treatment year treatment active wall tension response endothelin blunt hypertensive patient normalize cilazapril treated patient unchanged take atenolol relaxation response acetylcholine norepinephrine pre contracted artery still significantly reduce one year comparison normotensive patient patient treat atenolol whereas receive cilazapril abstract truncate word,Schiffrin EL,1994,Arch Mal Coeur Vaiss,,7755476,Schiffrin EL; Deng LY; Larochelle P,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D001158: Arteries; D001262: Atenolol; D017315: Cilazapril; D002985: Clinical Protocols; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged,,,https://openalex.org/W2408021185,185,30,1,1732,296,9,en,en
false,effect intensified blood pressure reduction renal function albumin excretion primary hypertensionaddition felodipine ramipril long term treatment blockade,effect intensified blood pressure bp control reduction diastolic bp mm hg renal function urinary albumin excretion uae study men primary hypertension age year treat year beta blockade diuretic hydralazine compare normotensive nt men similar age baseline bl glomerular filtration rate gfr renal plasma flow rpf clearance inulin para aminohippurate uae study thereafter antihypertensive drug except beta blockers withdraw either felodipine mg n ramipril mg n add double blind randomize fashion hydrochlorothiazide add necessary investigation repeat week year double blind treatment bl bp renal vascular resistance rvr significantly high gfr rpf significantly low hypertensive group nt year bp treatment goal reach patient felodipine group two thirds ramipril group spite addition diuretic latter group felodipine group bp gfr rvr year longer differ significantly normal uae fractional albumin clearance increase significantly year treatment felodipine group change ramipril group fractional albumin clearance however differ significantly normal either bl year treatment hypertensive group therefore possible reduce bp improve renal function primary hypertension level significantly different normal treatment felodipine combination beta blockade although regimen increase low uae slightly fractional albumin clearance change less differ significantly normal ramipril beta blocker combination reduce bp less change slightly reduce renal function uae,Siewert-Delle A,1995,Am J Hypertens,https://doi.org/10.1016/0895-7061(94)00174-a,7755939,Siewert-Delle A; Ljungman S; Hartford M; Wikstrand J,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D000368: Aged; D000419: Albuminuria; D001794: Blood Pressure; D004359: Drug Therapy, Combination; D015736: Felodipine; D005500: Follow-Up Studies; D005919: Glomerular Filtration Rate; D006801: Humans; D006973: Hypertension; D007668: Kidney; D008297: Male; D008875: Middle Aged; D017257: Ramipril",,,https://openalex.org/W2092569449,184,23,1,2106,394,14,en,en
false,combine terazosin verapamil therapy essential hypertensionhemodynamic pharmacokinetic interaction,alpha blocker calcium antagonist commonly use treatment hypertension data available concern first dose steady state hemodynamic pharmacokinetic effect drug use combination therapy examine interaction measure supine stand blood pressure bp heart rate hr cardiac index ci h hypertensive patient week placebo first dose week therapy either mg verapamil v twice day mg terazosin titrate weekly mg daily finally add v group vt v add group tv acutely change supine hemodynamics add v v add similar include reduction bp transient increase hr little change ci group experience significant decrease stand blood pressure especially h follow initiation combination therapy despite significant increase stand hr ci stand bp tend low group tv first dose minimum standing systolic bp significantly different group group tv mm hg h group vt mm hg h p four patient group tv two group vt experience symptomatic orthostatic hypotension first dose double agent treatment pharmacokinetic interaction include increase bioavailability v add correlate degree orthostasis week combined therapy orthostatic change bp attenuate symptom improve patient conclude v represent effective combination treatment essential hypertension orthostasis may result initiate combination therapy orthostasis see patient appear due combined vasodilatory effect rather negative ionotropic chronotropic effect,Lenz ML,1995,Am J Hypertens,https://doi.org/10.1016/0895-7061(94)00162-5,7755941,Lenz ML; Pool JL; Laddu AR; Varghese A; Johnston W; Taylor AA,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D001794: Blood Pressure; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011187: Posture; D011224: Prazosin; D014700: Verapamil",,,https://openalex.org/W2135642446,110,11,1,2018,387,10,en,en
false,assessment blood pressure naproxen therapy hypertensive patient treat nicardipine,nonsteroidal antiinflammatory drug nsaid know attenuate antihypertensive effect variety antihypertensive agent include diuretic blockers vasodilator unique mechanism action calcium channel blocker may subject interaction multicenter double blind randomize placebo controlled study design assess effect nsaid therapy blood pressure control stable hypertensive patient treat calcium channel blocker one hundred patient stable blood pressure control mg nicardipine three time day treat mg naproxen twice day placebo week mean diastolic blood pressure estimate mean arterial pressure group change mm hg week study drug treatment none change significantly different baseline two treatment group significantly different body weight placebo treated patient change significantly whereas body weight naproxen treated patient increase significantly kg kg mean p week mean loss kg placebo group mean gain kg naproxen group compare baseline weight neither statistically significant p p respectively result indicate despite significant increase body weight antihypertensive action calcium channel blocker nicardipine significantly affect cotreatment naproxen j hypertens,Klassen DK,1995,Am J Hypertens,https://doi.org/10.1016/0895-7061(94)00164-7,7755942,Klassen DK; Jane LH; Young DY; Peterson CA,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D001794: Blood Pressure; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009288: Naproxen; D009529: Nicardipine; D011446: Prospective Studies",,,https://openalex.org/W2133435549,102,13,1,1647,284,10,en,en
false,efficacy safety daily nifedipine coat core formulation compare gastrointestinal therapeutic system formulation patient mild moderate diastolic hypertension,efficacy safety two sustained release formulation nifedipine coat core system nif cc gastrointestinal therapeutic system nif git examine patient mild moderate essential hypertension week multicenter randomize double blind study coadministration food affect nifedipine pharmacokinetics differ magnitude two formulation evaluate drug safety rigorous circumstance medication give food week placebo lead period eligible patient randomize parallel group treatment period either nif cc nif git mg daily food week follow forced titration nifedipine mg daily additional week final week period half patient receive formulation switch alternate formulation dose mg daily within treatment group four blood pressure variable systolic diastolic measurement trough hour period demonstrate significant reduction p baseline establish placebo lead period formulation every subsequent visit end point compare two formulation mean change baseline hour systolic diastolic blood pressure measurement determine use ambulatory monitoring statistically different dos p mean change trough blood pressure baseline parallel group treatment period statistically significant favor nif git mg mg dos p treatment emergent adverse event rate formulation similar parallel group period exception dizziness high patient receive nif cc formulation well tolerate reduce blood pressure hour dosing interval even coadministered food half patient receive nif git mg daily randomly cross nif cc mg daily significant change either trough hour mean blood pressure measurement p adverse event dropout rate patient receive nif cc mg cross nif git mg daily exhibit significant change diastolic blood pressure p study demonstrate give food nif cc nif git reduce hour mean blood pressure measurement similarly abstract truncate word,Glasser SP,1995,Clin Ther,https://doi.org/10.1016/0149-2918(95)80003-4,7758054,Glasser SP; Jain A; Allenby KS; Shannon T; Pride K; Pettis PP; Schwartz LA; MacCarthy EP,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D018660: Blood Pressure Monitoring, Ambulatory; D002940: Circadian Rhythm; D004032: Diet; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004361: Drug Tolerance; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine",,,https://openalex.org/W2156837143,198,24,1,2558,441,15,en,en
false,cost effect switch calcium channel blocker evidence medicaid claim data,study use medicaid claim data pennsylvania examine cost effect change calcium channel blocker therapy specifically compare procardia xl adalat cc daily dosed extended release form nifedipine available drug interest compare several reason first frequency treatment regimen show important determinant long term compliance calcium channel blocker medication desirable compare drug identical dosing regimen second switch one quite feasible patient third adalat cc price ie average wholesale price less procardia xl result indicate prescription price low patient switch procardia xl adalat cc apparent effect blood pressure control incidence adverse drug reaction nonprescription health care cost potential saving medicaid switch patient procardia xl adalat cc appear large million annually procardia xl treated medicaid patient state pennsylvania study also demonstrate large retrospective database use evaluate economic clinical outcome specific therapy alternative evaluation increasingly relevant third party payer health maintenance organization party involve manage care,Simons WR,1995,Clin Ther,https://doi.org/10.1016/0149-2918(95)80015-8,7758057,Simons WR; Rizzo JA; Stoddard M; Smith ME,article,D003160: Comparative Study; D016428: Journal Article,D015331: Cohort Studies; D003362: Cost-Benefit Analysis; D006801: Humans; D006973: Hypertension; D007345: Insurance Claim Review; D008484: Medicaid; D009543: Nifedipine; D012189: Retrospective Studies; D014481: United States,,,https://openalex.org/W2086931336,95,15,1,1497,244,11,en,en
false,selection medical treatment stable angina pectoris result international multicenter angina exercise image study,objective present study design investigate characteristic anginal symptom exercise test result could predict favorable anti ischemic effect beta adrenergic blocking agent metoprolol calcium antagonist nifedipine patient stable angina pectoris background characteristic anginal symptom result exercise testing consider great importance select medical treatment patient chronic stable angina pectoris however little information available first evaluation may use select best pharmacologic approach individual patient method prospective multicenter study patient stable angina pectoris enrol european center baseline evaluation consist exercise test questionnaire investigate patient anginal symptom patient randomly allocate double blind treatment week either metoprolol controlled release mg daily nifedipine retard mg twice daily accord parallel group design end period exercise test repeat drug intake result metoprolol nifedipine prolong exercise tolerance baseline level improvement great patient receive metoprolol p multivariate analysis reveal low exercise tolerance variable associate favorable effect within treatment group metoprolol effective nifedipine patient low exercise tolerance high rate pressure product rest ischemic threshold none characteristic anginal symptom exercise test result predict great efficacy nifedipine metoprolol conclusion result baseline exercise test characteristic anginal symptom may offer useful information select medical treatment stable angina pectoris,Ardissino D,1995,J Am Coll Cardiol,https://doi.org/10.1016/0735-1097(95)00042-3,7759701,Ardissino D; Savonitto S; Egstrup K; Rasmussen K; Bae EA; Omland T; Schjelderup-Mathiesen PM; Marraccini P; Merlini PA; Wahlqvist I,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000787: Angina Pectoris; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004562: Electrocardiography; D005080: Exercise Test; D017079: Exercise Tolerance; D005260: Female; D006801: Humans; D008297: Male; D008790: Metoprolol; D008875: Middle Aged; D015999: Multivariate Analysis; D009543: Nifedipine; D011237: Predictive Value of Tests; D011446: Prospective Studies; D011795: Surveys and Questionnaires,,,https://openalex.org/W1998936633,128,20,1,2006,320,16,en,en
false,placebo controlled evaluation three dos controlled onset extended release formulation verapamil treatment stable angina pectoris,double blind placebo controlled parallel group multicenter study design evaluate safety efficacy new controlled onset extended release formulation verapamil hydrochloride call physiologic pattern release ppr verapamil study conduct site united state canada overseas see appendix follow week single blind placebo lead period patient chronic stable angina pectoris male female mean age year range randomly assign daily fixed dose treatment group verapamil mg placebo ppr verapamil dos significantly increase p time moderate angina symptom limited exercise duration verapamil mg significantly increase p time mm st segment depression week treatment assess hour previous dose large dos verapamil associate proportionately great improvement exercise tolerance frequency anginal attack also reduce verapamil frequently observed adverse event dizziness headache constipation nausea incidence constipation high within mg treatment group verapamil formulation clinically titrate within mg dose range permit effective oncedaily administration treatment chronic stable angina,Cutler NR,1995,Am J Cardiol,https://doi.org/10.1016/s0002-9149(99)80738-3,7762493,Cutler NR; Anders RJ; Jhee SS; Sramek JJ; Awan NA; Bultas J; Lahiri A; Woroszylska M,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D000704: Analysis of Variance; D000787: Angina Pectoris; D002908: Chronic Disease; D003248: Constipation; D003692: Delayed-Action Preparations; D004244: Dizziness; D005080: Exercise Test; D005260: Female; D006261: Headache; D006801: Humans; D008297: Male; D008875: Middle Aged; D012044: Regression Analysis; D016037: Single-Blind Method; D014700: Verapamil,,,https://openalex.org/W2002407258,152,20,1,1456,255,9,en,en
false,low dose combination antihypertensive therapy additional efficacy without additional adverse effect,,MacConnachie AM,1995,Drug Saf,https://doi.org/10.2165/00002018-199512020-00001,7766339,MacConnachie AM; Maclean D,article,D016428: Journal Article; D016454: Review,"D000317: Adrenergic alpha-Antagonists; D000319: Adrenergic beta-Antagonists; D000806: Angiotensin-Converting Enzyme Inhibitors; D001581: Benzothiadiazines; D002121: Calcium Channel Blockers; D004232: Diuretics; D004359: Drug Therapy, Combination; D006801: Humans; D006973: Hypertension; D049993: Sodium Chloride Symporter Inhibitors",,,https://openalex.org/W2003441364,101,12,1,0,0,0,en,
false,efficacy safety mg sustain release formulation diltiazem administer daily patient stable angina,aim multicentre randomise double blind study compare efficacy safety mg sustain release diltiazem formulation administer daily sr standard diltiazem give three four time daily patient stable angina patient age year reproducible exercise test placebo randomise week treatment sr n n initial dosage mg sr group mg group increase mg daily mg q respectively ergometric parameter always measure end dosing period improve two week week treatment antianginal efficacy rest comparable sr group prolongation total duration exertion respectively p v placebo group intergroup difference dose effect relation find formulation sr formulation give full hour anti ischaemic protection administer daily efficacy safety comparable standard diltiazem q patient stable angina daily administration improve treatment compliance,Trimarco B,1995,Eur J Clin Pharmacol,https://doi.org/10.1007/bf00193700,7768250,Trimarco B; Radzik D; Van Mieghem W; Neveux E; Wajman A; Attali P; Ponsonnaille J,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D003692: Delayed-Action Preparations; D004110: Diltiazem; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2057855372,135,20,1,1314,251,11,en,en
false,comparison efficacy nisoldipine metoprolol isosorbide dinitrate patient stable exertional angina randomized cross placebo controlled study,evaluate acute antianginal effect oral nisoldipine mg metoprolol mg long acting isosorbide dinitrate mg patient stable exertional angina patient perform symptom limited treadmill exercise h administration placebo placebo stage active drug placebo stage patient randomize cross evaluation acute effect single oral dose placebo placebo stage nisoldipine metoprolol long acting isosorbide dinitrate patient developed angina exercise test exercise test terminate onset angina time development mv st segment depression increase three drug compare placebo significantly longer metoprolol isosorbide dinitrate similarly time cease exercise angina also prolong three drug exercise time longer nisoldipine metoprolol compare isosorbide dinitrate significant difference nisoldipine metoprolol conclusion metoprolol nisoldipine effectively prolong exercise compare long acting isosorbide dinitrate patient stable exertional angina,Ogawa H,1995,Int J Cardiol,https://doi.org/10.1016/0167-5273(94)02228-b,7774991,Ogawa H; Yasue H; Nakamura N; Fujii H; Miyagi H; Kikuta K,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000368: Aged; D000787: Angina Pectoris; D001794: Blood Pressure; D018592: Cross-Over Studies; D005080: Exercise Test; D017079: Exercise Tolerance; D005260: Female; D006339: Heart Rate; D006801: Humans; D007548: Isosorbide Dinitrate; D008297: Male; D008790: Metoprolol; D008875: Middle Aged; D015737: Nisoldipine; D005082: Physical Exertion; D012146: Rest; D016896: Treatment Outcome",,,https://openalex.org/W2064532010,169,25,1,1303,221,8,en,en
false,favourable interaction calcium antagonist plus ace inhibitor cardiac haemodynamics treat hypertension rest effort evaluation,aim study evaluate effect verapamil sustain release sr mg enalapril combination blood pressure bp cardiac haemodynamics rest exercise patient moderate essential hypertension seven men woman mean age year week placebo run period patient randomly allocate receive verapamil sr mg daily enalapril mg daily week double blind fashion patient whose diastolic blood pressure dbp still mm hg end period receive verapamil sr plus enalapril additional week end placebo single combined treatment period rest exercise bicycle ergometry haemodynamics evaluate radionuclide ventricular angiography technetium following parameter assess bp heart rate double product systemic vascular resistance svr cardiac output co stroke volume sv ejection fraction ef mean ejection rate mer peak filling rate pfr verapamil sr enalapril monotherapies significantly reduce rest exercise bp p bp normalisation dbp mm hg five patient respectively great bp fall normalisation patient obtain non responders monotherapy treat verapamil sr enalapril p verapamil sr also reduce heart rate rest exercise respectively p abstract truncate word,Di Somma S,1995,J Hum Hypertens,,7783096,Di Somma S; Carotenuto A; de Divitiis M; Paulucci A; Galderisi M; Cuocolo A; de Divitiis O,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D001794: Blood Pressure; D004338: Drug Combinations; D004347: Drug Interactions; D004656: Enalapril; D015444: Exercise; D005260: Female; D006321: Heart; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D012146: Rest; D014700: Verapamil,,,https://openalex.org/W2410103482,142,20,1,1592,319,9,en,en
false,assessment effect two anti hypertensive regimen overall cardiovascular risk,anti hypertensive drug differ effect cardiovascular risk factor date attempt quantitate impact difference twenty five unmedicated patient primary hypertension randomise initial therapy either calcium antagonist felodipine diuretic dos titrate achieve similar level blood pressure bp second drug add need metoprolol prazosin respectively aim determine year whether similar anti hypertensive effect associate difference multivariate index overall cardiovascular risk target supine diastolic blood pressure dbp mm hg require second agent four evaluable patient felodipine group six diuretic group significant rise serum cholesterol fall serum potassium diuretic group felodipine group cardiovascular risk score rank percentile relation age matched general population score fell great degree felodipine patient particularly first month remain low month leave ventricular hypertrophy assess echocardiography another measure cardiovascular risk generally unchanged either regimen equivalent blood pressure level calcium antagonist based regimen great benefit cardiovascular risk particularly first month therapy method may widely applicable assessment anti hypertensive therapy,Jennings GL,1995,J Hum Hypertens,,7783099,Jennings GL; Sudhir K; Laufer E; Korner P; Reid C,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D001794: Blood Pressure; D002318: Cardiovascular Diseases; D002784: Cholesterol; D004232: Diuretics; D004359: Drug Therapy, Combination; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D017379: Hypertrophy, Left Ventricular; D008297: Male; D008790: Metoprolol; D008875: Middle Aged; D011224: Prazosin; D012307: Risk Factors",,,https://openalex.org/W123481140,87,12,1,1582,265,12,en,en
true,placebo control trial felodipine patient mild moderate heart failure uk study group,objective compare effect felodipine placebo patient new york heart association functional class ii iii stable congestive heart failure despite treatment angiotensin convert enzyme inhibitor diuretic digoxin combination three drug patient design patient randomise double blind parallel group study week placebo run oral treatment either felodipine extend release formulation placebo mg twice daily give addition exist background medication week method patient age year either sex chronic congestive heart failure due ischaemic heart disease hypertensive heart disease dilate cardiomyopathy without secondary mitral insufficiency stable precede two month include study treadmill exercise test accord modify naughton protocol perform baseline six week treatment sign symptom heart failure assess every visit physical examination perform leave ventricular ejection fraction measure baseline week result mean sd baseline exercise test time increase felodipine placebo group respectively week last visit change exercise baseline last visit patient give felodipine give placebo p also difference treatment respect efficacy variable death study felodipine n placebo n patient receive felodipine withdraw treatment n receive placebo n common adverse event cite reason withdrawal felodipine placebo group respectively increase need non study heart failure treatment n start new medication change dosage exist treatment patient give felodipine nausea n give placebo patient withdraw study due increase need non study heart failure treatment rapidly stabilise recover conclusion felodipine show benefit patient mild moderate heart failure,Littler WA,1995,Br Heart J,https://doi.org/10.1136/hrt.73.5.428,7786657,Littler WA; Sheridan DJ,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000293: Adolescent; D000328: Adult; D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D004077: Digoxin; D004232: Diuretics; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005080: Exercise Test; D015736: Felodipine; D005260: Female; D006333: Heart Failure; D006801: Humans; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2053901143,103,18,2,2449,458,14,en,en
false,aha president letter,,Smith SC,1995,Circulation,,7788902,Smith SC,article,D016433: News,D002561: Cerebrovascular Disorders; D006331: Heart Diseases; D006801: Humans,,,https://openalex.org/W2992867176,23,5,1,0,0,0,en,
false,hypertension pregnancy,hypertension common potentially serious complication human pregnancy marker underlie maternal disease process aggravate pregnancy directly relate pregnancy pre eclampsia associate increased risk fetal growth retardation severe cause maternal fetal problem risk mother neonate reduce appropriate supervision therapy close monitoring maternal fetal welfare help determine optimum time delivery maternal hypertension control agent consider well tolerate pregnancy follow index pregnancy patient early severe hypertension investigate underlying cause provide clinical resolution acute pregnancy related hypertension investigation usually postpone least month follow delivery,Gallery ED,1995,Drugs,https://doi.org/10.2165/00003495-199549040-00006,7789289,Gallery ED,article,D016428: Journal Article; D016454: Review,"D000959: Antihypertensive Agents; D001795: Blood Pressure Determination; D004461: Eclampsia; D005260: Female; D006801: Humans; D006973: Hypertension; D049590: Postpartum Period; D011225: Pre-Eclampsia; D011247: Pregnancy; D011249: Pregnancy Complications, Cardiovascular; D018566: Pregnancy, High-Risk; D012640: Seizures",,,https://openalex.org/W1997150731,25,3,1,945,153,8,en,en
false,isradipine,since early review drug substantial additional data accumulate regard antihypertensive efficacy isradipine various clinical situation well data clinical effect atherosclerosis recent therapeutic trial confirm efficacy isradipine treatment patient mainly mild moderate hypertension administer orally conventional modified release preparation similar titrated dosage amlodipine felodipine nifedipine diltiazem captopril methyldopa metoprolol prazosin hydrochlorothiazide decrease blood pressure expect isradipine combine another antihypertensive drug patient respond adequately monotherapy initial study show intravenous isradipine effective control hypertension follow coronary artery bypass graft surgery appear useful treatment intraoperative hypertension hypertensive crisis hypertensive disorder pregnancy administer orally intravenously large study multicentre isradipine diuretic atherosclerosis study midas design compare efficacy isradipine hydrochlorothiazide reduce rate progression carotid artery wall thickness measure b mode ultrasound surrogate early atherosclerosis result indicate wall thickness increase significantly less isradipine hydrochlorothiazide month therapy thereafter rate progression remain parallel remainder year trial confirmation antihypertensive efficacy along favourable haemodynamic profile reversal left ventricular hypertrophy minimal effect glucose lipid metabolism preservation quality life good tolerability make isradipine suitable drug treatment patient mild moderate hypertension,Brogden RN,1995,Drugs,https://doi.org/10.2165/00003495-199549040-00009,7789292,Brogden RN; Sorkin EM,article,D016428: Journal Article; D016454: Review,"D006348: Cardiac Surgical Procedures; D002986: Clinical Trials as Topic; D004347: Drug Interactions; D004359: Drug Therapy, Combination; D005260: Female; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D011183: Postoperative Complications; D011247: Pregnancy; D012079: Renal Circulation",,,https://openalex.org/W2009179435,10,1,1,1982,299,8,en,en
false,clinical efficacy force titrate dos diltiazem extended release placebo control study,thirty patient clinical ambulatory essential hypertension treat double blind fashion force titrate dos placebo diltiazem daily od extended release er mg characterize full dose range new formulation incremental dose response effect observe clinic ambulatory blood pressure parameter dos mg significantly decrease clinic diastolic blood pressure whereas systolic blood pressure significantly lower mg dose moreover compare placebo ambulatory blood pressure significantly decrease mg dose level trough peak ratio systolic diastolic blood pressure high dose level mg adverse reaction diltiazem od er generally mild similar observe placebo finding study indicate favorable effect diltiazem od er observe response mg dose level dose escalation force titration study design appear valuable tool obtain rigorous dose response data new antihypertensive agent,Lacourcière Y,1995,Am J Hypertens,https://doi.org/10.1016/0895-7061(94)00199-l,7794578,Lacourcière Y; Poirier L; Lefebvre J; Burford RG,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D003692: Delayed-Action Preparations; D004110: Diltiazem; D004311: Double-Blind Method; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008875: Middle Aged",,,https://openalex.org/W2092131498,98,13,1,1190,200,8,en,en
false,medical treatment reduce total ischemic burden total ischemic burden bisoprolol study tibbs multicenter trial compare bisoprolol nifedipine,objective compare effect bisoprolol transient myocardial ischemia nifedipine patient chronic stable angina background beta adrenergic blocking agent calcium antagonist reduce transient ischemic episode comparison agent make large study method total ischemic burden bisoprolol study tibbs randomized double blind control study two parallel group patient center seven european country stable angina pectoris positive exercise test two transient ischemic episode h holter monitoring central evaluation include patient randomize receive bisoprolol receive nifedipine slow release two treatment phase week h holter monitoring phase phase patient receive either mg bisoprolol daily mg nifedipine slow release phase receive either mg bisoprolol daily mg nifedipine slow release result phase trial week bisoprolol therapy mg daily reduce mean sd number transient ischemic episode h nifedipine mg reduce transient ischemic episode h total duration ischemia reduce min h bisoprolol min h nifedipine reduction statistically significant drug difference bisoprolol nifedipine also significant p bisoprolol reduce heart rate onset episode beats min baseline value beats min p heart rate unchanged nifedipine bisoprolol significantly high responder rate nifedipine doubling dose phase trial small additive effect bisoprolol show marked circadian effect reduce morning peak transient ischemic episode peak time conclusion bisoprolol nifedipine reduce number duration transient ischemic episode patient chronic stable angina bisoprolol significantly effective nifedipine dos test reduce morning peak ischemic activity,von Arnim T,1995,J Am Coll Cardiol,https://doi.org/10.1016/0735-1097(94)00345-q,7798508,von Arnim T,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D017298: Bisoprolol; D004311: Double-Blind Method; D015716: Electrocardiography, Ambulatory; D005060: Europe; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D017202: Myocardial Ischemia; D009543: Nifedipine; D012074: Remission Induction; D013997: Time Factors",,,https://openalex.org/W2027627036,154,24,1,2415,437,21,en,en
true,efficacy safety ofdigoxin alone combination low dosediltiazem orbetaxolol control ventricular rate chronic atrial fibrillation,c hronic atria fibrillation af characterize rapid increase ventricular rate exercise digoxin alone act primarily cause increase vagal tone often fail control exercise induced tachycardia patient af beta adrenergic blockade calcium antagonist tend act preferentially exercise heart rate induce adverse effects detract beneficial effect control heart rate know dose dependent study combination digitalis p adrenergic blockade calcium antagonist chronic af take account adequacy digitalization judge serum leve determination seem mandatory order prove true contribution added p adrenergic blockade calcium antagonist purpose study therefore threefold reevaluate role digitalis maintain adequate heart rate patient chronic af compare effect safety digoxin combination low dose diltiazem betaxolol ventricular rate response blood pressure rate pressure product maximal exercise tolerance exercise patient chronic af study frequency adverse effect use low dose diltiazem betaxolol forty five patient men woman mean age f year range af month define study chronic af include provide informed consent three patient group iii group iv complete study protocol thus result obtain patient,Koh KK,1995,Am J Cardiol,https://doi.org/10.1016/s0002-9149(99)80538-4,7801876,Koh KK; Kwon KS; Park HB; Baik SH; Park SJ; Lee KH; Kim EJ; Kim SH; Cho SK; Kim SS,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D001281: Atrial Fibrillation; D015784: Betaxolol; D002908: Chronic Disease; D004077: Digoxin; D004110: Diltiazem; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D016276: Ventricular Function",,,https://openalex.org/W2059183710,148,19,1,1665,297,10,en,en
false,hypertension elderly trial hyvet,hypertension elderly trial hyvet multicentre open randomise control trial aim trial investigate effect active treatment stroke incidence hypertensive patient age year secondary end points include total cardiovascular mortality morbidity entry criterion include sustained sit systolic blood pressure mm hg plus sustained sit diastolic pressure mm hg also require stand systolic blood pressure least mm hg patient must give informed consent free congestive heart failure require treatment gout renal failure recent cerebral haemorrhage patient randomise groups treatment ii treatment diuretic bendroflumethiazide bendrofluazide iii treatment angiotensin convert enzyme ace inhibitor lisinopril start dosage bendroflumethiazide lisinopril mg day order achieve goal sit systolic diastolic blood pressure mm hg doubling dosage allow furthermore slow release diltiazem mg day increase mg day require may add medication actively treated group drug choose inexpensive appropriate representative therapeutic class patient group total sufficient detect difference cerebrovascular event treatment active treatment alpha beta number also detect difference total mortality cardiovascular mortality pilot phase trial start support british heart foundation centre interested take part contact c j bulpitt author,Bulpitt CJ,1994,Drugs Aging,https://doi.org/10.2165/00002512-199405030-00003,7803945,Bulpitt CJ; Fletcher AE; Amery A; Coope J; Evans JG; Lightowlers S; O'Malley K; Palmer A; Potter J; Sever P,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D016454: Review","D000368: Aged; D000369: Aged, 80 and over; D001539: Bendroflumethiazide; D003692: Delayed-Action Preparations; D004110: Diltiazem; D005500: Follow-Up Studies; D006801: Humans; D006973: Hypertension; D017706: Lisinopril; D008137: Longitudinal Studies; D012107: Research Design; D015996: Survival Rate",,,https://openalex.org/W3013336291,50,10,1,1867,343,16,en,en
false,long term clinical effect nilvadipine patient chronic heart failure double blind placebo controlled study,long term effect calcium channel blocker chronic heart failure disappointing probably reflex sympathetic activation arterial vasodilation however nilvadipine may beneficial treatment chronic heart failure since drug minimal effect sympathetic activation study effect week administration nilvadipine placebo symptom heart failure cardiac function investigate patient mild moderate chronic heart failure double blind trial patient randomly assign either nilvadipine group mg daily placebo group intergroup comparison show significant difference parameter serious adverse effect observe study thus study fail show beneficial effect nilvadipine long term treatment patient chronic heart failure conclude long term administration nilvadipine mg daily neither effective harmful treatment patient chronic heart failure,Hori M,1994,Heart Vessels,https://doi.org/10.1007/bf01745105,7814301,Hori M; Sato H; Karita M; Kodama K; Hoki N; Hayashi T; Naka M; Nanto S; Yamada Y; Kamada T,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D017079: Exercise Tolerance; D005260: Female; D006333: Heart Failure; D006439: Hemodynamics; D006801: Humans; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D013997: Time Factors,,,https://openalex.org/W2017706469,120,16,1,1084,174,8,en,en
false,comparison five antihypertensive monotherapies placebo change left ventricular mass patient receive nutritional hygienic therapy treatment mild hypertension study tomhs,increase leave ventricular mass lvm echocardiography associate increased risk cardiovascular disease thus interest compare effect pharmacological nonpharmacological approach treatment hypertension reduction lvm changes lv structure assess mode echocardiogram double blind placebo controlled clinical trial mild hypertensive participant randomize nutritional hygienic nh intervention plus placebo nh plus one five class antihypertensive agent diuretic chlorthalidone beta blocker acebutolol alpha antagonist doxazosin mesylate calcium antagonist amlodipine maleate angiotensin converting enzyme inhibitor enalapril maleate echocardiogram perform baseline month annually year change blood pressure average mm hg active treatment group mm hg nh group group show significant decrease lvm baseline appear month continue month chlorthalidone group experience great decrease follow visit average decrease g although difference group modest average decrease among group g participant randomize nh intervention mean change lvm similar participant randomize nh intervention plus pharmacological treatment great difference group see month mean decrease range g chlorthalidone group g acebutolol group p compare group within group analysis show change weight urinary sodium excretion systolic bp moderately correlate change lvm statistically significant analyses nh intervention emphasis weight loss reduction dietary sodium effective nh intervention plus pharmacological treatment reduce echocardiographically determine lvm despite small decrease blood pressure nh intervention group possible exception addition diuretic chlorthalidone may modest additional effect reduce lvm,Liebson PR,1995,Circulation,https://doi.org/10.1161/01.cir.91.3.698,7828296,Liebson PR; Grandits GA; Dianzumba S; Prineas RJ; Grimm RH; Neaton JD; Stamler J,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000959: Antihypertensive Agents; D004311: Double-Blind Method; D004452: Echocardiography; D015444: Exercise; D006801: Humans; D006973: Hypertension; D017379: Hypertrophy, Left Ventricular; D008019: Life Style; D008875: Middle Aged; D015431: Weight Loss",,,https://openalex.org/W1967943229,200,28,1,2260,391,10,en,en
false,isradipine versus diltiazem treatment stable effort angina pectoris ergometric evaluation crossover double blind study,evaluate effect isradipine isr diltiazem dil exercise tolerance ischemic st depression patient stable effort angina fourteen patients male female age year mean sd ischemic heart disease reproducible st segment depression two consecutive exercise stress test baseline condition underwent study consist period placebo random isr mg b dil mg b end period multistage treadmill exercise stress test bruce protocol performed drug significantly p increase ischemia time mv st depression compare placebo isr dil without statistical difference two drug p significantly reduce p maximal st depression mv mv isr mv dil systolic blood pressure increase p mm hg mm hg isr mm hg dil similarly heart rate increase bpm bpm isr p bpm dil p n isr dil dosage show important significant anti ischemic effect isr dil,Perticone F,1994,G Ital Cardiol,,7828793,Perticone F; Borelli DA; Maio R; Costa R; Pugliese F; Torchia L; Caristo S; Mattioli PL,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,D000368: Aged; D000787: Angina Pectoris; D018592: Cross-Over Studies; D004110: Diltiazem; D004311: Double-Blind Method; D004562: Electrocardiography; D005080: Exercise Test; D005260: Female; D006801: Humans; D017275: Isradipine; D008297: Male; D008875: Middle Aged,,,https://openalex.org/W2408956550,137,22,1,1375,312,4,en,en
false,effect two different therapeutic approach total cardiovascular mortality cardiovascular study elderly castel,although limited number elderly subject occasionally include population based study study conduct specifically elderly hypertensive practically none population level study hypertensive subject cohort elderly subject intervention consist creation hypertension outpatient clinic auspex complete co operation general practitioner randomize identified hypertensive patient pre established therapeutic drug regimen early follow recording mortality year drug use clonidine n nifedipine n fixed combination atenolol chlorthalidone n subject underwent free therapy personal physician without special intervention normotensive subject overall year follow mortality hypertensive subject receive free therapy receive special care normotensives cardiovascular mortality respectively overall cardiovascular annual cumulative mortality significantly low special therapy free therapy group fixed combination atenolol chlorthalidone reduce mortality normotensives independent cardiovascular risk factor,Casiglia E,1994,Jpn Heart J,https://doi.org/10.1536/ihj.35.589,7830324,Casiglia E; Spolaore P; Mazza A; Ginocchio G; Colangeli G; Onesto C; Di Menza G; Pegoraro L; Ambrosio GB,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D000369: Aged, 80 and over; D001262: Atenolol; D002752: Chlorthalidone; D003000: Clonidine; D004359: Drug Therapy, Combination; D005260: Female; D006331: Heart Diseases; D006801: Humans; D006973: Hypertension; D007558: Italy; D008297: Male; D009543: Nifedipine; D011446: Prospective Studies; D016019: Survival Analysis",,,https://openalex.org/W2039974792,135,22,1,1424,240,9,en,en
false,effect isosorbide dinitrate nicardipine hydrochloride postprandial blood pressure elderly patient stable angina pectoris heal myocardial infarction,,Connelly CM,1995,Am J Cardiol,https://doi.org/10.1016/0002-9149(95)80041-p,7832144,Connelly CM; Waksmonski C; Gagnon MM; Lipsitz LA,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000368: Aged; D000787: Angina Pectoris; D001794: Blood Pressure; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004435: Eating; D005260: Female; D006801: Humans; D007022: Hypotension; D007548: Isosorbide Dinitrate; D008297: Male; D009203: Myocardial Infarction; D009529: Nicardipine,,,https://openalex.org/W2061174216,172,22,1,0,0,0,en,
false,equipotent dos isradipine well tolerate amlodipine patient mild moderate hypertension double blind randomize parallel group study,objective double blind parallel group study compare tolerability isradipine amlodipine specifically side effects know relate use dihydropyridine calcium antagonist total patient mild moderate essential hypertension randomize receive either sustained release sro formulation isradipine n amlodipine n dosage mg daily blood pressure measurement take end dose interval assess antihypertensive efficacy two drug adverse reaction assess two way spontaneously report adverse event record investigate depth severity duration relation study drug outcome b questionnaire use elicit specific adverse reaction know relate use dihydropyridine calcium antagonist evaluate severity duration relation study drug outcome week active treatment isradipine amlodipine reduce mean sit systolic diastolic blood pressure mm hg isradipine mm hg amlodipine difference antihypertensive effect isradipine amlodipine ci difference systolic diastolic blood pressure respectively number patient spontaneously report adverse event significantly high p ci amlodipine isradipine abstract truncate word,Hermans L,1994,Br J Clin Pharmacol,https://doi.org/10.1111/j.1365-2125.1994.tb04363.x,7833223,Hermans L; Deblander A; De Keyser P; Scheys I; Lesaffre E; Westelinck KJ,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D017311: Amlodipine; D000842: Ankle; D001530: Belgium; D001794: Blood Pressure; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004487: Edema; D005260: Female; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D008297: Male; D008875: Middle Aged; D009325: Nausea; D010349: Patient Compliance; D011795: Surveys and Questionnaires; D013810: Therapeutic Equivalency,,,https://openalex.org/W1983271543,165,24,1,1646,301,13,en,en
false,esmolol bolus prevention sympathetic adrenergic reaction follow induction anesthesia,addition laryngoscopy endotracheal intubation stressful intraoperative phase hypertension occurs recovery anaesthesia provoke post operative complication like bleed increased intracranial intraocular pressure furthermore hypertensive reaction result life threatening complication especially patient pre existing cardiovascular disease study effect new short acting beta blocker esmolol give single bolus prevent increase blood pressure heart rate recovery anaesthesia extubation patient hypertension investigate patient method sixty three patient history hypertension period month blood pressure bp mm hg undergo intervertebral disc otolaryngologic eye surgery include study operation perform thiopentone induced isoflurane anaesthesia relaxation atracurium patient assign three group give witnessed oral inform consent study period receive study drug twice turn nitrous oxide b extubation group placebo receive placebo time group ii mg esmolol placebo mg esmolol v b group iii mg esmolol mg esmolol v time medication cardiovascular parameter measure noninvasively period min every minute following h every min result first medication systolic diastolic bp heart rate hr rate pressure product rpp low patient receive mg esmolol group iii group ii second injection blood pressure low two group receive mg esmolol placebo group ii iii mm hg mean min sem change hr ii iii min rpp ii iii similar patient group iii hr drop min none patient bp become instable conclusion sympathoadrenergic reaction recovery anaesthesia extubation treat beta blocking agent therapy without risk long half life effect therapy factor postoperative loss intravascular volume esmolol new short acting cardioselective beta blocker short plasma distribution time elimination half life min thus potential risk beta blockers due half life minimise result study show dangerous increase bp hr increased myocardial oxygen consumption prevent single bolus well double bolus mg esmolol although bradycardia hr min patient might indicate risk cardiac instability systolic bp fall mm hg episode bradycardia short risk patient,Schäffer J,1994,Anaesthesist,10.1007/s001010050114,7840400,Schäffer J; Karg C; Piepenbrock S,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,D000319: Adrenergic beta-Antagonists; D000762: Anesthesia Recovery Period; D001794: Blood Pressure; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011412: Propanolamines; D013564: Sympathetic Nervous System,,,,106,17,1,3266,607,23,en,en
false,fasting postprandial lipid lipoprotein chronic administration antihypertensive drug,evaluate effect various antihypertensive drug fasting postprandial lipid lipoprotein study normolipidemic hypertensive patient men woman age year respectively four week placebo administration lipid lipoprotein measure fasting state every three hour period nine hour intake standardized fat mixed load g follow test patient randomly assign one four treatment group group metoprolol n mg day group ii nicardipine n mg day group iii captopril n mg day end week four treatment fasting postprandial lipid measurement repeat blood pressure mean value significantly p reduce four treatment group find statistically significant lipid lipoprotein change neither fasting postprandial state trend toward low concentration postprandial lipemia treatment observe three group metoprolol nicardipine captopril whereas change observe chlorthalidone group data confirm fast lipid lipoprotein normolipidemic hypertensive patient unfavorably change low dos drug study addition inform postprandial lipemia affect four drug dos use,Granados V,1994,Arch Inst Cardiol Mex,,7840730,Granados V; Ichazo S; Chávez J; Zamora J; Ochoa C; Cardoso G; Posadas C,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000959: Antihypertensive Agents; D004041: Dietary Fats; D004305: Dose-Response Relationship, Drug; D005215: Fasting; D005260: Female; D006801: Humans; D006973: Hypertension; D008055: Lipids; D008074: Lipoproteins; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2413972615,111,16,1,1452,264,8,en,en
false,amiodarone verapamil quinidine treatment patient chronic atrial fibrillation,rapid reliable safe reestablishment sinus rhythm major aim pharmacologic treatment patient chronic atrial fibrillation mainstay therapy arrhythmia quinidine recently amiodarone show noncomparitive study superior class ia agent certain condition patient atrial fibrillation persist week year efficacy safety either quinidine verapamil day quinidine mg day day quinidine mg verapamil mg day amiodarone therapy day amiodarone mg day intravenously day amiodarone mg day orally randomly examine responder continue effective medication month thereafter patient treat fixed regimen quinidine mg day plus verapamil mg day year atrial fibrillation quinidine reduce mean ventricular cycle length quinidine verapamil increase mean cycle length amiodarone p addition quinidine verapamil characteristic rate smoothing effect atrioventricular conduction atrial fibrillation rhythm convert sinus rhythm quinidine patient combination quinidine verapamil patient amiodarone restore sinus rhythm patient overall short duration atrial fibrillation p small left atrial size p predictive successful conversion arrhythmia abstract truncate word,Zehender M,1994,Z Kardiol,,7846938,Zehender M; Meinertz T; Just H,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D000638: Amiodarone; D001281: Atrial Fibrillation; D002908: Chronic Disease; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D015716: Electrocardiography, Ambulatory; D005260: Female; D006801: Humans; D008134: Long-Term Care; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D011802: Quinidine; D016896: Treatment Outcome; D014700: Verapamil",,,https://openalex.org/W145248728,95,14,1,1662,321,12,en,en
false,sotalol quinidine verapamil cordichin chronic atrial fibrillation conversion month follow randomized comparison,atrial fibrillation one common arrhythmia lead least subset patient severe symptom palpitation weakness syncope hemodynamic impairment especially clinical setting left ventricular dysfunction thus many case restauration sinus rhythm indicate negative effect reduced cardiac output quinidine first line drug many year prove highly effective especially combine verapamil grow concern use quinidine class anti arrhythmic agent hint clinical trial increased longterm mortality drug study undertake test efficacy sotalol beta blocker additional strong class iii antiarrhythmic action compare fixed combination quinidine verapamil conversion chronic atrial fibrillation maintenance sinus rhythm medical electrical cardioversion avoid early proarrhythmic effect potassium value range high normal value mval l try obtain patient randomly assign receive either sotalol quinidine verapamil difference group far underlying heart disease duration atrial fibrillation mean day clinical feature include echocardiographic parameter concern dose drug weight related individually adjust drug continue thereafter sinus rhythm could establish time electric cardioversion perform drug continue low dosage thereafter abstract truncate word,Kalusche D,1994,Z Kardiol,,7846939,Kalusche D; Stockinger J; Betz P; Roskamm H,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D001281: Atrial Fibrillation; D003131: Combined Modality Therapy; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D004338: Drug Combinations; D004554: Electric Countershock; D015716: Electrocardiography, Ambulatory; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008134: Long-Term Care; D008297: Male; D008875: Middle Aged; D011802: Quinidine; D013015: Sotalol; D014700: Verapamil",,,https://openalex.org/W263966802,137,22,1,1717,285,11,en,en
false,urinary albumin n acetyl glucosaminidase excretion mild hypertension,renal effect mild hypertension therapy establish since urinary albumin n acetyl beta glucosaminidase excretion reflect renal effect hypertension relate blood pressure cardiovascular risk factor cardiac target organ effect response therapy mild hypertension diastolic blood pressure mm hg participant two clinic treatment mild hypertension study tomhs multicenter randomize double blind control trial participant receive nutritional hygienic therapy one five active drug placebo urinary albumin n acetyl beta glucosaminidase excretion assess prospectively use office spot collection one clinic n retrospectively use overnight collection clinic n relationship determine protein excretion blood pressure age gender race blood glucose cholesterol concentration index body mass leave ventricular mass function baseline treatment effect assess month spot overnight albumin excretion relate positively baseline systolic blood pressure univariate analysis spot albumin excretion relate positively systolic blood pressure age creatinine clearance leave ventricular function overnight albumin excretion relate positively leave ventricular mass female gender multiple regression analysis spot overnight albumin excretion decline significantly active drug therapy n acetyl beta glucosaminidase excretion relate blood pressure decline therapy combined result suggest albumin excretion correlate blood pressure decrease antihypertensive drug therapy associate great leave ventricular function mass well glomerular filtration rate even mild level hypertension,Abraham PA,1994,Am J Hypertens,https://doi.org/10.1093/ajh/7.11.965,7848623,Abraham PA; Mascioli SR; Launer CA; Flack JM; Liebson PR; Svendsen KH; Grandits GA; Opsahl JA; Schoenberger JA; Grimm RH,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000118: Acetylglucosaminidase; D000368: Aged; D000419: Albuminuria; D001794: Blood Pressure; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D007668: Kidney; D008297: Male; D008875: Middle Aged; D012737: Sex Factors,,,https://openalex.org/W2467221888,80,8,1,1939,301,12,en,en
false,multicentre study compare therapeutic efficacy sustained release diltiazem enalapril treatment patient mild moderate hypertension,week study conduct order compare efficacy tolerability twice daily sustained release diltiazem preparation mg daily enalapril mg patient achieve adequate response week monotherapy give combination therapy twice daily diltiazem mg daily enalapril mg patient admit study receive diltiazem receive enalapril patient subsequently receive combination therapy blood pressure reduction patient complete week therapy sit value diltiazem mg mmhg diltiazem mg mmhg enalapril mg mmhg enalapril mg mmhg combination therapy mmhg significant difference incidence level individual symptom see two group diltiazem enalapril group week patient take combination therapy two patient withdraw enalapril group diltiazem group unexpected side effects see study death occur treatment group twice daily sustained release diltiazem mg show effective antihypertensive agent equal efficacy patient acceptability daily enalapril mg combination therapy effectively lower blood pressure patient monotherapy ineffective,Weir RJ,1994,Br J Clin Pract,,7848788,Weir RJ; Lee PS; Clegg DS; Hemingray S; Belgrave GP; Walter E,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000293: Adolescent; D000328: Adult; D000368: Aged; D001794: Blood Pressure; D003692: Delayed-Action Preparations; D004110: Diltiazem; D004656: Enalapril; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D016037: Single-Blind Method,,,https://openalex.org/W2406226592,165,24,1,1492,265,8,en,en
false,postoperative antiarrhythmic effect diltiazem patient undergo coronary bypass grafting,hemodynamic problem result cardiac arrhythmia often occur patient undergo coronary bypass grafting early postoperative period therefore study antiarrhythmic effect calcium channel antagonist diltiazem evaluate coronary bypass grafting forty patient randomly assign either therapy diltiazem nitroglycerin hemodynamic measurement establish swan ganz catheter long term ecg analysis perform preoperatively day operation significantly ventricular arrhythmia lown class iv diltiazem group nitroglycerin group p supraventricular tachycardia significantly often observe nitroglycerin group day p result calcium channel antagonist diltiazem recommend standard adjunct perioperative medication cardiac surgery,el-Sadek M,1994,Cardiology,https://doi.org/10.1159/000176699,7850818,el-Sadek M; Krause E,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D001026: Coronary Artery Bypass; D004110: Diltiazem; D006439: Hemodynamics; D006801: Humans; D008875: Middle Aged; D009211: Myoglobin; D005996: Nitroglycerin; D011182: Postoperative Care; D011300: Preoperative Care; D013617: Tachycardia, Supraventricular; D017180: Tachycardia, Ventricular; D013997: Time Factors",,,https://openalex.org/W2011610262,97,11,1,942,149,7,en,en
false,within patient correlation antihypertensive effect atenolol lisinopril nifedipine,objective investigate whether definable subgroup patient essential hypertension respond specifically particular antihypertensive drug design randomize cross comparison antihypertensive effect mg atenolol per day mg lisinopril per day mg nifedipine retard twice day ambulatory blood pressure monitoring use assess blood pressure level recruitment end treatment period treatment period last week precede week placebo patient seventy two untreated hypertensive patient mean age sd year recruit six general practice hospital outpatient clinic sixty eight patient complete trial main outcome measure assess within patient correlation among blood pressure responses drug explore possible role simple characteristic initial blood pressure plasma renin concentration age identify responder particular drug result systolic diastolic blood pressure fell significantly agent p atenolol reduce lisinopril nifedipine mmhg low degree correlation change blood pressure three drug individual patient drug small percentage non responders initial level systolic blood pressure weakly correlate antihypertensive effect nifedipine r p plasma renin concentration relate effect atenolol r p age predict blood pressure response agent conclusion low level correlation blood pressure change three drug suggest different mechanism may involve aetiology essential hypertension plasma renin concentration initial level systolic blood pressure contribute weakly identification responder three drug,Attwood S,1994,J Hypertens,https://doi.org/10.1097/00004872-199409000-00010,7852749,Attwood S; Bird R; Burch K; Casadei B; Coats A; Conway J; Dawes M; Ebbs D; Farmer A; Robinson J,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000367: Age Factors; D000368: Aged; D001262: Atenolol; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D018592: Cross-Over Studies; D005260: Female; D006801: Humans; D006973: Hypertension; D017706: Lisinopril; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D012083: Renin",,,https://openalex.org/W1970586291,102,12,1,2094,349,14,en,en
false,effect amlodipine atenolol combination myocardial ischemia treadmill exercise ambulatory monitoring,study compare effect amlodipine atenolol combination ischemia treadmill test h ambulatory monitoring know whether anti ischemic drug exert similar effect ischemia ambulatory monitoring exercise treadmill test patient stable coronary artery disease ischemia treadmill test ambulatory monitoring randomize receive amlodipine n atenolol n group undergo counterbalanced crossover evaluation single drug placebo follow evaluation combination amlodipine combination prolong exercise time mv st segment depression respectively p versus atenolol p n ambulatory monitoring frequency ischemic episode decrease amlodipine p n atenolol p combination p vs single drug p vs placebo suppression ischemia exercise testing ambulatory monitoring similar patient without exercise induced angina exercise time angina improve amlodipine p atenolol p combination p vs placebo atenolol amlodipine patient angina total exercise time improve amlodipine p atenolol p n combination p vs placebo either single drug patient without angina therapy significantly improve total exercise time ischemia treadmill test effectively suppress amlodipine whereas ischemia ambulatory monitoring effectively suppress atenolol combination effective either single drug setting,Davies RF,1995,J Am Coll Cardiol,https://doi.org/10.1016/0735-1097(94)00436-t,7860905,Davies RF; Habibi H; Klinke WP; Dessain P; Nadeau C; Phaneuf DC; Lepage S; Raman S; Herbert M; Foris K,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D017311: Amlodipine; D001262: Atenolol; D018592: Cross-Over Studies; D004359: Drug Therapy, Combination; D015716: Electrocardiography, Ambulatory; D005080: Exercise Test; D005260: Female; D006439: Hemodynamics; D006801: Humans; D008297: Male; D008875: Middle Aged; D017202: Myocardial Ischemia; D013997: Time Factors",,,https://openalex.org/W2049145058,127,17,1,1852,351,12,en,en
false,use nifedipine elderly patient essential hypertension patient compliance safety efficacy therapy,aim study evaluate chronic treatment cordafen nifedipine patients year age establish arterial hypertension patients age year subject complete one year study main reason drop outs lack patient compliance severe side effect ineffective monotherapy less severe adverse effect find subject one year therapy hematological biochemical parameter homeostasis deteriorate except increase alkaline phosphatase regular drug intake dose mg daily mean produce significant decrease blood pressure level improvement cardiac function index co nad ef contrast cordafen reduce difference extreme blood pressure value record automatically produce significant regression left ventricular mass cardiac arrhythmia nifedipine mild moderate hypertension elderly patient adequate form monotherapy high motivation treatment age group good drug tolerance may far improve efficacy,Kawecka-Jaszcz K,1994,Pol Tyg Lek,,7862585,Kawecka-Jaszcz K; Kocemba J; Czarnecka D; Grodzicki T; Gryglewska B,article,D016430: Clinical Trial; D004740: English Abstract; D016428: Journal Article,"D000367: Age Factors; D000368: Aged; D000369: Aged, 80 and over; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D010349: Patient Compliance; D016896: Treatment Outcome",,,https://openalex.org/W2411765229,120,21,1,1226,219,9,en,en
false,hypertension optimal treatment hot study patient characteristic randomization risk profile early blood pressure result,hypertension optimal treatment hot study prospective randomize multicenter trial conduct country main aim evaluate relationship three level target diastolic blood pressure mmhg cardiovascular morbidity mortality hypertensive patient addition study examine effect morbidity mortality low dose mg daily acetylsalicylic acid asa aspirin placebo hot study basic antihypertensive treatment initiate calcium antagonist felodipine dose mg daily target blood pressure reach additional antihypertensive therapy either angiotensin convert enzyme ace inhibitor beta adrenoceptor blocking agent give dosage adjustment make accordance set protocol fifth final step diuretic may add inclusion patient stop april time patient randomize woman men average age sd year enrollment patient receive antihypertensive treatment patient enter wash period least week randomization average randomization blood pressure untreated patient mmhg treated patient mmhg august blood pressure data available patient complete month treatment respectively average reduction diastolic blood pressure mmhg month abstract truncate word,Hansson L,1994,Blood Press,https://doi.org/10.3109/08037059409102281,7866597,Hansson L; Zanchetti A,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000319: Adrenergic beta-Antagonists; D017677: Age Distribution; D000368: Aged; D000369: Aged, 80 and over; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001241: Aspirin; D001794: Blood Pressure; D002318: Cardiovascular Diseases; D002784: Cholesterol; D015897: Comorbidity; D003404: Creatinine; D003920: Diabetes Mellitus; D004232: Diuretics; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005060: Europe; D005202: Asia, Eastern; D015736: Felodipine; D005260: Female; D006801: Humans; D006949: Hyperlipidemias; D006973: Hypertension; D007557: Israel; D008173: Lung Diseases, Obstructive; D008297: Male; D008875: Middle Aged; D009656: North America; D011446: Prospective Studies; D011897: Random Allocation; D012107: Research Design; D012307: Risk Factors; D012907: Smoking",,,https://openalex.org/W2000009266,134,20,1,1691,324,16,en,en
false,effect atenolol diltiazem sr exercise pressure load hypertensive patient,abstract effect monotherapy atenolol diltiazem sr blood pressure h blood pressure bp load exercise capacity test patient mild moderate stage ii essential hypertension week single blind placebo therapy patient sit diastolic blood pressure sdbp mmhg randomize atenolol mg day patient diltiazem sr mg b patient double blind parallel study depend sdbp response dose increase mg day atenolol mg b diltiazem sr twenty four hour ambulatory blood pressure measurement exercise tolerance lest bruce protocol end placebo active treatment compare placebo atenolol diltiazem sr significantly decrease heart rate hr sit systolic blood pressure ssbp sdbp ambulatory bp bp load wake sleep hour area bp curve rate pressure product p exercise time ns atenolol exert great effect ambulatory bp hr rate pressure product wake diastolic bp load area h bp curve drug well tolerate cause serious side effect necessitate discontinuation treatment finding indicate monotherapy hypertension atenolol diltiazem sr effective well tolerate decrease h bp load interfere exercise capacity,Chrysant SG,1994,Clin Cardiol,https://doi.org/10.1002/clc.4960171209,7867240,Chrysant SG; Miller E,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D001262: Atenolol; D001794: Blood Pressure; D004110: Diltiazem; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D017079: Exercise Tolerance; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W1994008597,91,13,1,1480,277,10,en,en
false,pharmacokinetic interaction study benazepril amlodipine healthy subject,pharmacokinetic interaction benazepril ace inhibitor amlodipine calcium channel blocker study healthy subject single dos benazepril hydrochloride mg tablet amlodipine besylate tablet equivalent mg amlodipine administer alone combination accord three way latin square randomized cross design serial blood sample collect follow administration determination benazepril active metabolite benazeprilat amlodipine mean value auc h cmax tmax benazepril give combination versus give alone vs ng h ml v ng ml v h mean value auc h cmax tmax benazeprilat benazepril give combination versus give alone vs ng h ml v ng ml v h mean value auc h cmax tmax amlodipine give combination versus give alone vs ng h ml v ng ml v h difference pharmacokinetic parameter combination monotherapy treatment statistically significant base anova result study indicate pharmacokinetic interaction exist two drug,Sun JX,1994,Eur J Clin Pharmacol,https://doi.org/10.1007/bf02570510,7867683,Sun JX; Cipriano A; Chan K; John VA,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D001552: Benzazepines; D018592: Cross-Over Studies; D004347: Drug Interactions; D006801: Humans; D008297: Male; D008875: Middle Aged,,,https://openalex.org/W2024662395,87,10,1,1305,229,5,en,en
false,amlodipine chronic stable angina result multicenter double blind crossover trial,efficacy safety amlodipine mg new long acting calcium antagonist compare placebo patient stable angina pectoris multicenter double blind crossover study trial consist initial week single blind placebo period follow first period week double blind therapy follow week washout period second week double blind period treatment cross twenty four hour holter electrocardiographic monitoring carry patient three center first double blind period amlodipine produce significantly great increase symptom limited exercise duration amlodipine v placebo second change vs respectively p total work amldipine v placebo kilopondmeters change vs respectively p decrease angina attack frequency per week p nitroglycerin consumption tablets wk p compare placebo holter monitoring reveal significant reduction number amlodipine v placebo change vs respectively p absolute total area amlodipine v placebo change vs respectively p duration amlodipine v second change vs respectively p st segment depression treatment amlodipine compare placebo treatment cross change continue favor amlodipine abstract truncate word,Ezekowitz MD,1995,Am Heart J,https://doi.org/10.1016/0002-8703(95)90281-3,7872184,Ezekowitz MD; Hossack K; Mehta JL; Thadani U; Weidler DJ; Kostuk W; Awan N; Grossman W; Bommer W,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D016448: Multicenter Study,"D000328: Adult; D000368: Aged; D017311: Amlodipine; D000787: Angina Pectoris; D002908: Chronic Disease; D018592: Cross-Over Studies; D004311: Double-Blind Method; D015716: Electrocardiography, Ambulatory; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D016037: Single-Blind Method",,,https://openalex.org/W2010251665,90,13,1,1671,313,7,en,en
false,adenosine triphosphate treatment supraventricular paroxysmal tachycardia comparison verapamil,multiple drug option treatment paroxysmal supraventricular tachycardia pst inefficacious vagal stimulus study compare two treatment verapamil versus adenosin triphosphate atp fifty patient pst randomly treat either verapamil mg atp mg basal feature group efficacy safety two drug compare verapamil failure treat atp vice versa characteristic group treatment similar pst episode resolve verapamil use versus atp administration finally patient successfully treat drug adverse effect observe verapamil whereas effect frequent atp use case require specific intervention verapamil atp equally safe effective treatment pst transient minor side effect frequent atp administration,Gil Madre J,1995,Rev Esp Cardiol,,7878283,Gil Madre J; Lázaro Rodríguez S; Sentenac Merchán G; Sepúlveda Berrocal MA; Alises Moraleda JM; Cortés Bermejo S; García de Pedro J; Laín Teres N,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000255: Adenosine Triphosphate; D000328: Adult; D000368: Aged; D000075202: Contraindications; D004341: Drug Evaluation; D005260: Female; D006801: Humans; D007262: Infusions, Intravenous; D008297: Male; D008875: Middle Aged; D012074: Remission Induction; D013614: Tachycardia, Paroxysmal; D013617: Tachycardia, Supraventricular; D014700: Verapamil",,,https://openalex.org/W3141478143,114,17,1,997,176,7,en,en
false,one year experience elderly hypertensive patient isradipine therapy,first report long term use one year isradipine new dihydropyridine calcium channel blocker treatment elderly patient essential hypertension patient complete three month double blind multicentre study compare isradipine hydrochlorothiazide hctz eligible enroll open label continuation study initial baseline patient least year age dbp mmhg mmhg patient titrate necessary every two week isradipine mg mg daily mg mg twice daily maintain sit dbp mmhg hctz mg mg daily could add good bp control total patient complete one year open label phase one hundred fourteen patient receive isradipine monotherapy mean dose mg day receive concomitant hctz therapy one year reduction dbp significant similar among age group race mean change mmhg reduction sbp similar among age group ninety four per cent receive isradipine monotherapy achieve bp control last four month treatment twenty six patient withdrew study adverse reaction one headache two pedal oedema eight problem nondrug related problem four drug ineffective base observation isradipine well tolerated safe effective agent long term bp control elderly patient essential hypertension,Stein GH,1994,J Hum Hypertens,,7884790,Stein GH; Hamilton BP; Hamilton JH; Holtzman JL; Kirkendall WM; Abrams A; Neri G; Culter R; Matthews K,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D017275: Isradipine; D008875: Middle Aged; D010352: Patient Dropouts",,,https://openalex.org/W2432715276,77,11,1,1592,312,12,en,en
false,nsaid antihypertensive agent loss blood pressure control,common patient see primary care physician take nonsteroidal anti inflammatory drug nsaid antihypertensive agent blood pressure control diminish patient physician must evaluate potential interaction two class medication although increase blood pressure secondary nsaid use may mm hg increase may enough justify change medication reason important evaluate interaction two type drug determine clinical significance specific patient,MacFarlane LL,1995,Am Fam Physician,,7887361,MacFarlane LL; Orak DJ; Simpson WM,article,D016428: Journal Article; D016454: Review,"D000894: Anti-Inflammatory Agents, Non-Steroidal; D000959: Antihypertensive Agents; D001794: Blood Pressure; D006801: Humans; D006973: Hypertension",,,https://openalex.org/W2415276732,67,11,1,606,104,4,en,en
false,morning versus even administration nifedipine gastrointestinal therapeutic system management essential hypertension,nifedipine gastrointestinal therapeutic system git recently develop controlled release formulation day dosing evaluate influence morning versus even administration drug randomized double blind cross study include essential hypertensive five patient exclude blood pressure analysis noncompliance three case intolerable side effect two case assess exact duration antihypertensive efficacy noninvasive automatic ambulatory blood pressure monitoring perform placebo period patient give mg nifedipine git either hour twenty four hours systolic diastolic blood pressure profile document sustained antihypertensive effect nifedipine regimen throughout whole period without affect circadian rhythm statistical analysis reveal significant difference morning evening administration two patient stop medication intolerable side effect fatigue muscle cramp respectively two case suffer mild reversible headache provoke discontinuation drug conclusion result document sustained antihypertensive efficacy mg nifedipine git patient moderate essential hypertension time administration impact day nighttime blood pressure control,Greminger P,1994,Clin Investig,https://doi.org/10.1007/bf00190742,7894213,Greminger P; Suter PM; Holm D; Kobelt R; Vetter W,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D018660: Blood Pressure Monitoring, Ambulatory; D002940: Circadian Rhythm; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D010349: Patient Compliance",,,https://openalex.org/W2000107184,131,15,1,1429,211,11,en,en
false,use isoptin sr treatment hypertension,effectiveness hypotensive action tolerance isoptin sr study patient primary arterial hypertension drug use dos mg daily mean dose mg daily blood pressure return normal value patient remain eight case blood pressure normalization achieve side effect occur five patient general worsening wellbeing easy tiring frequently observe result present work indicate isoptin sr effective hypotensive drug useful treatment mild moderate arterial hypertension,Knypl K,1993,Wiad Lek,,7900385,Knypl K; Brym E; Wacławek-Maczkowska J,article,D016430: Clinical Trial; D004740: English Abstract; D016428: Journal Article,D000328: Adult; D003692: Delayed-Action Preparations; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D016896: Treatment Outcome; D014700: Verapamil,,,https://openalex.org/W2401037395,53,11,1,634,112,7,en,en
false,atrial fibrillation atrial flutter,epidemiology pathophysiology diagnosis evaluation treatment atrial fibrillation af atrial flutter afl review recent development controversy approach arrhythmia address af afl arrhythmia frequently encounter clinical practice although occasionally unaware arrhythmia patient usually complain palpitation weakness dyspnea decrease exercise tolerance initial goal therapy control ventricular rate rate control accomplish atrioventricular node blocking agent digoxin calcium channel blocker beta adrenergic blocker along rapid irregular ventricular response detrimental outcome af afl include compromise hemodynamics increased vulnerability thromboembolism cause patient arrhythmia evaluate pharmacologic treatment direct convert rhythm normal sinus rhythm maintain antiarrhythmic drug prove effective case may associate increased mortality effective safe form drug therapy af afl need nonpharmacologic alternative antiarrhythmic medication refractory af afl include radio frequency catheter ablation bundle pacemaker placement surgery patient remain af despite therapy receive long term warfarin treatment drug may use control ventricular response patient af afl terminate prevent arrhythmia prevent thromboembolism nonpharmacologic treatment reserve patient whose arrhythmia poorly control drug,Geraets DR,1993,Clin Pharm,https://doi.org/10.1891/9780826181947.0008,7903069,Geraets DR; Kienzle MG,article,D003160: Comparative Study; D016428: Journal Article; D016454: Review,D000319: Adrenergic beta-Antagonists; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D001282: Atrial Flutter; D002121: Calcium Channel Blockers; D002986: Clinical Trials as Topic; D004077: Digoxin; D004554: Electric Countershock; D006801: Humans,,,https://openalex.org/W2431294349,38,5,1,1726,271,13,en,en
false,pharmacokinetics additional anti ischaemic effectiveness amlodipine daily calcium antagonist acute long term therapy stable angina pectoris patient pre treated beta blocker,journal article pharmacokinetics additional anti ischaemic effectiveness amlodipine daily calcium antagonist acute long term therapy stable angina pectoris patient pre treated beta blocker get access g lehmann g lehmann department cardiology german heart centremunich germany correspondence dr med g nter lehmann german heart centre department cardiology lothstrasse munich germany search work author oxford academic pubmed google scholar g reiniger g reiniger department cardiology german heart centremunich germany search work author oxford academic pubmed google scholar beyerle beyerle department cardiology german heart centremunich germany search work author oxford academic pubmed google scholar w rudolph w rudolph department cardiology german heart centremunich germany search work author oxford academic pubmed google scholar european heart journal volume issue november page http doi org eurheartj publish november article history receive december revision receive may publish november,Lehmann G,1993,Eur Heart J,https://doi.org/10.1093/eurheartj/14.11.1531,7905413,Lehmann G; Reiniger G; Beyerle A; Rudolph W,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000319: Adrenergic beta-Antagonists; D017311: Amlodipine; D000787: Angina Pectoris; D003327: Coronary Disease; D004311: Double-Blind Method; D005080: Exercise Test; D006801: Humans,,,https://openalex.org/W2007730851,213,28,1,1276,208,2,en,en
false,clinical pharmacologic study multidrug resistance reversal vinblastine bepridil,purpose achieve adequate plasma concentration bepridil calcium channel blocker revert multidrug resistance mdr vitro administer combination vinblastine patient advanced colorectal cancer tumor characterize high mdr gene expression study pharmacokinetics drug tolerability antitumor activity relation mdr expression tumor tissue patient method sixteen colorectal cancer patient enter study bepridil administer central venous catheter mg kg bolus minute follow mg kg hour mg kg hour vinblastine mg administer intravenous v bolus hour start bepridil mdr p glycoprotein pgp expression assess tumor sample immunohistochemistry rnase protection assay result bepridil plasma level great mumol l time vinblastine administration patient investigate dose use study bepridil produce qtc prolongation prevent far dose escalation however cardiac toxicity asymptomatic treated patient side effect mild mdr pgp expression positive nine case fifteen patient assessable response one complete remission month duration progression observe respond patient attain complete remission treated progression vinblastine alone conclusion bepridil plasma concentration need vitro modulate mdr could achieve study tolerable toxicity however despite tumor mdr pgp positive response obtain could attribute drug combination mechanism drug resistance mdr probably implicate drug resistance colorectal cancer,Linn SC,1994,J Clin Oncol,https://doi.org/10.1200/jco.1994.12.4.812,7908691,Linn SC; van Kalken CK; van Tellingen O; van der Valk P; van Groeningen CJ; Kuiper CM; Pinedo HM; Giaccone G,article,"D016430: Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D020168: ATP Binding Cassette Transporter, Subfamily B, Member 1; D000328: Adult; D000368: Aged; D000971: Antineoplastic Combined Chemotherapy Protocols; D015764: Bepridil; D002352: Carrier Proteins; D015179: Colorectal Neoplasms; D004351: Drug Resistance; D005260: Female; D015870: Gene Expression; D006801: Humans; D008297: Male; D008562: Membrane Glycoproteins; D008875: Middle Aged; D009363: Neoplasm Proteins; D016896: Treatment Outcome; D014747: Vinblastine",,,https://openalex.org/W2272579234,96,13,1,1896,313,15,en,en
false,calcium channel blockin drug overdose australian series,descriptive case study calcium channel blocking drug ccb overdose hunter region nsw perform analyse hospital morbidity mortality ccb drug overdoses australian population patient admit major hospital within hunter region treat initially gastrointestinal decontamination include use oral activated charcoal management require case include intravenous calcium atropine inotropic support ccb overdoses four patient die non cardiogenic pulmonary oedema occur two case cardiac conduction defect occur case atropine find effective intravenous calcium administer overdose slow release verapamil require prolonged treatment intravenous calcium salt overdose verapamil diltiazem dos great mg carry significant risk death potentially life threaten arrhythmias occur low dos recommend initial management include early effective gastrointestinal decontamination high dose intravenous calcium salt give reverse hypotension bradycardia atropine inotropic support frequently require,Howarth DM,1994,Hum Exp Toxicol,https://doi.org/10.1177/096032719401300304,7909677,Howarth DM; Dawson AH; Smith AJ; Buckley N; Whyte IM,article,D002363: Case Reports; D016428: Journal Article,D000293: Adolescent; D000328: Adult; D000368: Aged; D001315: Australia; D002121: Calcium Channel Blockers; D062787: Drug Overdose; D017809: Fatal Outcome; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged,,,https://openalex.org/W2136207610,59,9,1,1274,198,12,en,en
false,antianginal anti ischemic efficacy immediate release nisoldipine chronic stable angina pectoris,double blind randomize placebo controlled crossover study test peak trough efficacy immediate release nisoldipine mg twice daily add existent beta adrenergic block therapy patient randomize history chronic stable angina receive stable regimen beta blocking agent exercise test induced angina association mm horizontal downsloping st segment depression exercise test reproducibility ambulatory electrocardiographic monitoring hour perform center patient efficacy achieve patient take immediate release nisoldipine placebo sequence take placebo immediate release nisoldipine sequence total exercise time increase compare placebo peak trend see trough time mm st segment depression peak trough ambulatory electrocardiographic parameter also improve adverse effect mild trial confirm immediate release nisoldipine add existent beta blocker therapy active antianginal anti ischemic agent immediate release formulation lose antianginal effect end dose interval hour drug therefore examine new extended release formulation coat core,Glasser SP,1994,Am J Cardiol,https://doi.org/10.1016/0002-9149(94)90175-9,7911271,Glasser SP; Bittar N; Labreche DG; Singh B; Katz R; Schulman P,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D000328: Adult; D000787: Angina Pectoris; D001794: Blood Pressure; D002908: Chronic Disease; D004311: Double-Blind Method; D015716: Electrocardiography, Ambulatory; D005080: Exercise Test; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D017202: Myocardial Ischemia; D015737: Nisoldipine; D010919: Placebos",,,https://openalex.org/W1988865669,105,12,1,1349,214,9,en,en
false,anti ischemia effect gallopamil esmolol intra individual comparison patient coronary heart disease,compare hemodynamic antiischemic metabolic neurohumoral effect intravenous esmolol beta block agent gallopamil verapamil like calcium channel blocker patient angiographically prove cad reproducible st segment depression study rest exercise control condition intravenous bolus injection esmolol mg kg min follow infusion mg kg min gallopamil mg kg min contrast gallopamil esmolol significantly reduce systolic blood pressure vs mm hg heart rate vs min exercise well cardiac output vs l min significantly enhance systemic vascular resistance rest vs dynes cm exercise vs dynes cm hand exercise filling pressure lactate level vs mmol l significantly reduce gallopamil thus significant improvement exercise tolerance esmolol gallopamil base different mechanism action esmolol improve myocardial ischemia appreciably reduce myocardial oxygen consumption whereas gallopamil primarily improve oxygen supply ventricular performance plasma catecholamine atrial natriuretic factor aldosterone level well plasma renin activity identically influence esmolol gallopamil respectively reflex activation sympathetic system occur,Mitrovic V,1994,Z Kardiol,,7915067,Mitrovic V; Oehm E; Minge C; Thürmann P; Schlepper M,article,D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D004740: English Abstract; D016428: Journal Article,"D000319: Adrenergic beta-Antagonists; D000368: Aged; D000450: Aldosterone; D009320: Atrial Natriuretic Factor; D017023: Coronary Angiography; D003326: Coronary Circulation; D003327: Coronary Disease; D004359: Drug Therapy, Combination; D004562: Electrocardiography; D005080: Exercise Test; D005260: Female; D005711: Gallopamil; D006439: Hemodynamics; D006801: Humans; D007262: Infusions, Intravenous; D007773: Lactates; D019344: Lactic Acid; D008297: Male; D008875: Middle Aged; D017202: Myocardial Ischemia; D009638: Norepinephrine; D011412: Propanolamines; D012083: Renin; D016037: Single-Blind Method",,,https://openalex.org/W2400102542,124,19,1,1507,248,6,en,en
false,comparative effect quinapril atenolol verapamil blood pressure forearm hemodynamics handgrip exercise,compare effect angiotensin converting enzyme inhibition quinapril selective blockade atenolol calcium channel blockade verapamil hypertensive subject randomized double blind placebo controlled crossover study antihypertensive agent reduce baseline mean arterial pressure equally modify forearm vascular resistance compare placebo response sustain handgrip exercise quinapril verapamil atenolol attenuate pressor response however verapamil associate exaggerated increase forearm vascular resistance handgrip whereas quinapril alter response compare placebo conclude quinapril verapamil reduce pressor response isometric exercise quantitatively different effect vasoconstrictor response well outside skeletal muscle j hypertens,Cléroux J,1994,Am J Hypertens,https://doi.org/10.1093/ajh/7.6.566,7917158,Cléroux J; Beaulieu M; Kouamé N; Lacourcière Y,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000806: Angiotensin-Converting Enzyme Inhibitors; D001262: Atenolol; D001794: Blood Pressure; D018592: Cross-Over Studies; D004311: Double-Blind Method; D015444: Exercise; D005542: Forearm; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D007546: Isoquinolines; D008875: Middle Aged; D000077583: Quinapril; D044005: Tetrahydroisoquinolines; D014655: Vascular Resistance; D014700: Verapamil,,,https://openalex.org/W2416912063,125,18,1,955,142,6,en,en
false,long acting nicardipine elderly hypertensive patient effect diurnal variation blood pressure,effect long acting nicardipine tablet diurnal variation blood pressure compare standard nicardipine tablet long acting nifedipine tablet hour ambulatory blood pressure monitoring patient hypertension long acting nicardipine decrease systolic blood pressure age group difference anti hypertensive effect compare two drug three drug effect amplitude daily blood pressure variation three drug decrease baseline blood pressure age group compare untreated patient addition change observe decrement baseline blood pressure switch two drug long acting nicardipine long acting nicardipine less effect diurnal blood pressure variation standard nicardipine tablet administer three time daily age group long acting nicardipine also effectively inhibit increase cardiac work result morning rise phenomenon compare standard nicardipine tablet finding suggest long acting nicardipine may useful preparation treatment essential hypertension particularly elderly patient,Harada T,1994,Clin Ther,,7923305,Harada T; Imamura T; Hara K; Sakai A; Fukui J; Kubo S; Fujiwara H; Shikuwa M; Tanioka Y; Yamasa T,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000375: Aging; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002940: Circadian Rhythm; D003692: Delayed-Action Preparations; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009529: Nicardipine; D009543: Nifedipine",,,https://openalex.org/W156173734,105,15,1,1292,198,7,en,en
false,duration extent antianginal effect sustained release formulation nifedipine angina,twenty four patient chronic stable exertional angina pectoris randomize double blind placebo controlled crossover trial assess efficacy durability newly develop sustained release formulation nifedipine nifedipine cc single mg oral dose symptom limited grade treadmill exercise test perform h single administration drug placebo give exercise tolerance h drug compare corresponding placebo value data could analyse patient maximal exercise time time onset angina time mm st segment depression significantly great h nifedipine cc baseline corresponding placebo average maximal exercise time significantly increase h rate pressure product rest peak exercise show significant change h compare placebo p maximal increase exercise tolerance mark h nifedipine cc time plasma drug concentration ng ml thus patient chronic stable exertional angina pectoris nifedipine cc show prolonged improvement exercise tolerance h single oral administration,Yokota M,1994,Eur Heart J,https://doi.org/10.1093/oxfordjournals.eurheartj.a060617,7925519,Yokota M; Saito F; Izawa H; Matsunami T; Yoshida J; Inagaki H; Sotobata I,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000787: Angina Pectoris; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D005080: Exercise Test; D017079: Exercise Tolerance; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D013997: Time Factors,,,https://openalex.org/W2227654656,101,14,1,1369,258,10,en,en
false,comparison efficacy tolerability angiotensin convert enzyme inhibitor lisinopril versus calcium channel antagonist diltiazem sr treatment moderate severe hypertension,one hundred ten patient mean age year moderate severe essential hypertension dbp mmhg randomise eight week double blind treatment lisinopril n diltiazem sr n fourteen patient withdraw therapy six patient withdraw adverse event lisinopril n diltiazem sr n lack bp control lisinopril n diltiazem sr n monotherapies titrate upward lisinopril mg daily diltiazem sr mg twice daily achieve office dbp mmhg hydrochlorothiazide hctz mg daily add monotherapy week patient reach bp goal e non responders four week therapy patient nonresponders eight week therapy patient lisinopril n diltiazem sr n receive hctz week lisinopril diltiazem sr patient meet response criterion mean office dbp decrease baseline mmhg lisinopril patient mmhg diltiazem sr patient week lisinopril effective diltiazem reduce systolic diastolic office bp week p likewise week statistically significant difference detect treatment p systolic diastolic ambulatory bp average hour treatment well tolerate show important antihypertensive efficacy patient moderate severe bp elevation,Weir MR,1994,J Hum Hypertens,,7932518,Weir MR; Fagan T; Chrysant S; Flamenbaum W; Kaihlanen PM; Lueg M; Anzalone D,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D001794: Blood Pressure; D004110: Diltiazem; D004311: Double-Blind Method; D004338: Drug Combinations; D005260: Female; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D017706: Lisinopril; D008297: Male; D008875: Middle Aged,,,https://openalex.org/W2410561379,206,33,1,1540,315,12,en,en
false,long term protective effect calcium antagonist renal function hypertensive renal transplant patient cyclosporine therapy year prospective randomize study,,Morales JM,1994,Transplant Proc,,7940807,Morales JM; Rodriguez-Paternina E; Araque A; Andres A; Hernandez E; Ruilope LM; Rodicio JL,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000704: Analysis of Variance; D000959: Antihypertensive Agents; D002102: Cadaver; D003404: Creatinine; D016572: Cyclosporine; D005260: Female; D005500: Follow-Up Studies; D006085: Graft Survival; D006801: Humans; D006973: Hypertension; D016030: Kidney Transplantation; D008297: Male; D009543: Nifedipine; D011446: Prospective Studies; D015996: Survival Rate; D013997: Time Factors; D014019: Tissue Donors,,,https://openalex.org/W2398882973,175,25,1,0,0,0,en,
false,comparative study long act diltiazem tildiem la sustained release nifedipine nifedipine sr bendrofluazide treatment mild moderate hypertension,therapeutic efficacy long act diltiazem mg od tildiem la compare sustained release nifedipine mg bd bendrofluazide mg od multicentre study patient diagnose mild moderate essential hypertension randomize diltiazem nifedipine sr bendrofluazide group respectively patient enter randomise single investigator blind parallel group multicentre study systolic diastolic blood pressure mm hg mm hg respectively admission visit twenty one general practitioner two hospital physician monitor patient baseline four eight week continuous dosing eight week therapy clinically acceptable control blood pressure see group reduction mm hg mm hg mm hg tildiem nifedipine bendrofluazide group respectively significant difference show bendrofluazide two group diastolic pressure p non significant trend systolic pressure mirror effect significantly high withdrawal cause adverse event see nifedipine follow patient receive nifedipine patient receive diltiazem patient receive bendrofluazide difference withdrawal rate treatment statistically significant p post hoc test reveal diltiazem bendrofluazide statistically significant low withdrawal adverse event nifedipine group p nifedipine associate marginal increase stand apex pulse rate diltiazem la significantly maintain serum potassium level result indicate diltiazem mg effective antihypertensive agent equivalent efficacy nifedipine sr mg superior bendrofluazide nifedipine sr however bad tolerated high withdrawal rate p,Hosie J,1994,Acta Cardiol,,7941918,Hosie J; Nasar MA; Belgrave GP; Walters EG,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000959: Antihypertensive Agents; D001539: Bendroflumethiazide; D001794: Blood Pressure; D003692: Delayed-Action Preparations; D004110: Diltiazem; D004359: Drug Therapy, Combination; D004573: Electrolytes; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D010352: Patient Dropouts",,,https://openalex.org/W173649841,177,30,1,2078,353,13,en,en
false,effect intracoronary felodipine versus nifedipine left ventricular contractility coronary sinus blood flow stable angina pectoris,conclusion intracoronary injection felodipine mg nifedipine mg cause similar coronary vasodilatation although nifedipine impaired myocardial contractility increase lv filling pressure effect observe felodipine probably high vascular selectivity drug reduce mvo possibly increased myocardial efficiency,Koolen JJ,1994,Am J Cardiol,https://doi.org/10.1016/0002-9149(94)90320-4,7942536,Koolen JJ; Van Wezel HB; Piek J; van Liebergen R; Swaan A; Visser CA,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D003326: Coronary Circulation; D003331: Coronary Vessels; D015736: Felodipine; D006801: Humans; D007269: Injections, Intra-Arterial; D008297: Male; D008875: Middle Aged; D009200: Myocardial Contraction; D009543: Nifedipine; D014664: Vasodilation; D016277: Ventricular Function, Left",,,https://openalex.org/W1974517856,143,19,1,400,62,3,en,en
false,inefficacy diltiazem restenosis prevention coronary angioplasty,evaluate efficacy diltiazem prevent restenosis balloon angioplasty ptca eighty nine patient undergone successful ptca divide group g patient receive diltiazem mg tid immediately ptca keep month b patient receive placebo fifty two lesion dilate ga gb patient exclude analysis several reason include necessity diltiazem others calcium channel blocker use heart failure bradicardia av block degree ptca chronic total occlusion ostial lesion ami less day prior ptca patient randomize either active drug placebo double blind fashion restenosis define lesion patient underwent late angiography either month sooner clinically indicated g similar age year v b p n sex v b p n stable angina v b unstable angina v b p n single vessel v b p n multivessel v b p n ptca study patient ga gb p n observe restenosis ga gb p n restenosis rate per lesion ga gb p n diltiazem ineffective prevention restenosis follow ptca,Tanajura LF,1994,Arq Bras Cardiol,,7944997,Tanajura LF; Sousa AG; Feres F; Atallah T; Pinto IM; Centemero MP; Chaves AJ; Mattos LA; Martins HC; Abud RL,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D015906: Angioplasty, Balloon, Coronary; D003327: Coronary Disease; D004110: Diltiazem; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D011446: Prospective Studies; D012008: Recurrence",,,https://openalex.org/W2412680553,78,12,1,1450,359,9,en,en
false,comparison intravenous nicardipine sodium nitroprusside immediate treatment severe hypertension,primary objective study compare antihypertensive efficacy safety intravenously administer nicardipine intravenous nitroprusside snp patient severe hypertension study conduct patient severe hypertension diastolic blood pressure bp mm hg systolic bp mm hg patient randomize receive intravenous nicardipine snp drug administer accord predetermined dosing schedule h period sixty one patient randomize intravenous nicardipine snp pretreatment bp value nicardipine snp group mm hg mm hg respectively therapeutic response diastolic bp mm hg decrease mm hg systolic bp mm hg decrease mm hg achieve patient treat nicardipine patient treat snp mean decrease systolic diastolic bp mm hg mm hg h nicardipine mm hg mm hg h snp mean increase heart rate also similar group nicardipine beats min snp beats min mean number dose adjustment per hour require maintain bp reduction low p nicardipine treated patient time per hour snp treated patient time per hour abstract truncate word,Neutel JM,1994,Am J Hypertens,https://doi.org/10.1093/ajh/7.7.623,7946164,Neutel JM; Smith DH; Wallin D; Cook E; Ram CV; Fletcher E; Maher KE; Turlepaty P; Grandy S; Lee R,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D001794: Blood Pressure; D004305: Dose-Response Relationship, Drug; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D007275: Injections, Intravenous; D008297: Male; D008875: Middle Aged; D009529: Nicardipine; D009599: Nitroprusside; D011446: Prospective Studies; D013997: Time Factors",,,https://openalex.org/W1780078430,114,15,1,1470,295,11,en,en
false,phase trial intrahepatic verapamil doxorubicin regional therapy overcome multidrug resistance,verapamil modulate multidrug resistance vitro level tolerable administer systemically regional strategy drug administration may permit delivery high concentration drug specific area low systemic level colorectal cancer typically express multidrug resistance phenotype phase trial perform determine maximum tolerable dose mtd dose limit toxicity verapamil hepatic artery infusion together doxorubicin patient hepatic metastasis colorectal cancer fourteen patient metastatic colorectal cancer receive hour intrahepatic infusion verapamil six hour start infusion fixed dose doxorubicin mg give also via hepatic artery minute period patient follow cardiac telemetry intensive care setting invasive monitoring use patient receive prior intrahepatic chemotherapy mtd intrahepatic verapamil schedule patient population mg kg hour hypotension dose limiting toxicity major objective response note heavily pretreated patient population dose mg kg hour recommend phase ii trials based estimation normal hepatic artery blood flow estimated concentration verapamil deliver hepatic tumor mg kg hour micrograms ml microm comparable concentration vitro reversal mdr see study demonstrate systemic toxicity mdr reversal agent overcome regional drug delivery establish approach important model system study mdr modulation,Saltz L,1994,Cancer,https://doi.org/10.1002/1097-0142(19941115)74:10<2757::aid-cncr2820741004>3.0.co;2-o,7954234,Saltz L; Murphy B; Kemeny N; Bertino J; Tong W; Keefe D; Tzy-Jun Y; Tao Y; Kelsen D; O'Brien JP,article,"D016430: Clinical Trial; D017426: Clinical Trial, Phase I; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000230: Adenocarcinoma; D000328: Adult; D000368: Aged; D015179: Colorectal Neoplasms; D004317: Doxorubicin; D018432: Drug Resistance, Multiple; D005260: Female; D006499: Hepatic Artery; D006801: Humans; D007261: Infusions, Intra-Arterial; D008113: Liver Neoplasms; D008297: Male; D008875: Middle Aged; D010641: Phenotype; D017211: Treatment Failure; D014700: Verapamil",,,https://openalex.org/W2066390590,108,16,2,1783,291,11,en,en
false,effect enalapril nifedipine carbohydrate lipid metabolism niddm,objective compare effect nifedipine enalapril oncarbohydrate lipoprotein metabolism chinese non insulin dependent diabetes mellitus niddm patient hypertension research design method week double blind run domized study plasma lipid level glycemie control patient treat nifedipine n enalapril n conduct none patient treat insulin diet dosage oral hypoglycemie agent remain unchanged week treatment period result mean arterial pressure reduce nifedipine enalapril vs mmhg p lt similar reduction body mass index plasma triglyceride increase apolipoprotein see treatment hba reduce treatment enalapril nifedipine vs p serum apolipoprotein b apob also decline enalapril nifedipine vs mg dl p conclusion twelve week treatment enalapril hypertensive niddm patient associate great improvement glycemie control great reduction serum apob concentration although reduction blood pressure less nifedipine change cardiovascular risk profile warrant investigation long term,Chan JC,1994,Diabetes Care,https://doi.org/10.2337/diacare.17.8.859,7956631,Chan JC; Yeung VT; Leung DH; Tomlinson B; Nicholls MG; Cockram CS,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D016632: Apolipoprotein A-I; D001055: Apolipoproteins B; D015415: Biomarkers; D001786: Blood Glucose; D001794: Blood Pressure; D002681: China; D002784: Cholesterol; D008076: Cholesterol, HDL; D008078: Cholesterol, LDL; D003404: Creatinine; D003924: Diabetes Mellitus, Type 2; D003930: Diabetic Retinopathy; D004311: Double-Blind Method; D004656: Enalapril; D019270: Fructosamine; D006442: Glycated Hemoglobin; D006595: Hexosamines; D006723: Hong Kong; D006801: Humans; D006973: Hypertension; D008055: Lipids; D009543: Nifedipine; D014280: Triglycerides",,,https://openalex.org/W2036806004,85,13,1,1367,236,8,en,en
false,long term blood pressure reduction patient essential hypertension improve concomitant metabolic disorder,aim aim study investigate occurrence metabolic abnormality patient newly diagnose essential hypertension assess effect blood pressure lower drug therapy respective variable patient result twenty six hypertensive subject female male include study twenty one normotensive subject female male serve control group oral glucose tolerance test hypertensive subject high blood glucose serum insulin level control hypertensive patient also show high triglyceride concentration abdominal pattern body fat distribution addition woman essential hypertension exhibit high free androgen index vs p woman control group month treatment period nifedipine nitrendipine elevated blood pressure hypertensive significantly reduce second glucose tolerance test carry patient blood glucose serum insulin triglyceride concentration significantly low compare pretreatment period metabolic hormonal variable remain unchanged conclusion observation raise question whether long term vasodilatating antihypertensive therapy improve metabolic abnormality find patient essential hypertension,Hauner H,1994,Med Klin (Munich),,7968872,Hauner H; Meissner C,article,D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D004740: English Abstract; D016428: Journal Article,D000328: Adult; D001786: Blood Glucose; D001794: Blood Pressure; D001823: Body Composition; D015992: Body Mass Index; D005260: Female; D005500: Follow-Up Studies; D005951: Glucose Tolerance Test; D006801: Humans; D006973: Hypertension; D007328: Insulin; D008055: Lipids; D008134: Long-Term Care; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D009568: Nitrendipine; D014280: Triglycerides,,,https://openalex.org/W2474654303,123,18,2,1445,235,10,en,en
false,efficacy metoprolol diltiazem treat silent myocardial ischemia,recent study strongly support prognostic importance transient silent ischemia patient silent ischemia high risk cardiac event likely benefit control symptom also treatment direct prevention ischemia efficacy controlled release metoprolol mg daily diltiazem mg time daily assess randomized double blind crossover study patient proven coronary artery disease predominantly asymptomatic myocardial ischemia positive bicycle exercise test result minute asymptomatic st segment depression hour screening ambulatory electrocardiogram ecg beginning end week treatment periods exercise test perform hour ambulatory ecg record active treatment period precede week placebo phase treatment effectively reduce postpone exercise induced st depression reduce total ischemic integral ambulatory ecg metoprolol significantly reduce mean number ischemic episode p vs diltiazem p n mean duration ischemia p vs diltiazem p n compare baseline value metoprolol strongly blunt morning afternoon peak circadian distribution ischemia whereas diltiazem change circadian distribution ischemia,Portegies MC,1994,Am J Cardiol,https://doi.org/10.1016/0002-9149(94)90458-8,7977065,Portegies MC; Sijbring P; Göbel EJ; Viersma JW; Lie KI,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D003692: Delayed-Action Preparations; D004110: Diltiazem; D004334: Drug Administration Schedule; D015716: Electrocardiography, Ambulatory; D005080: Exercise Test; D005260: Female; D006801: Humans; D008297: Male; D008790: Metoprolol; D008875: Middle Aged; D016037: Single-Blind Method; D016896: Treatment Outcome",,,https://openalex.org/W2163902259,75,10,1,1468,253,8,en,en
false,comparison felodipine isosorbide mononitrate adjunct beta blockade patient year age angina pectoris,coronary artery disease increasingly common medical problem elderly relatively study investigate drug therapy focus population assess efficacy safety calcium channel blocker felodipine isosorbide mononitrate ismn adjunct optimal beta blocker therapy elderly patient placebo controlled double blind study conduct patient age year document stress induced angina pectoris myocardial ischemia use latin square design period week exercise testing perform period felodipine mg daily significantly improve time ischemic threshold pain threshold p p respectively v placebo tend increase total exercise time p v placebo contrast ismn mg twice daily significantly affect parameter comparison active treatment arm show overall felodipine effective ismn statistically significant difference time ischemic threshold p regard safety felodipine also well tolerate ismn lead patient discontinue study medication ismn p ismn felodipine conclude elderly patient treat optimal beta blockade felodipine ismn lead additional significant reduction ischemic parameter exercise abstract truncate word,de Vries RJ,1994,Am J Cardiol,https://doi.org/10.1016/0002-9149(94)90548-7,7977090,de Vries RJ; Dunselman PH; van Veldhuisen DJ; van den Heuvel AF; Wielenga RP; Lie KI,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D000368: Aged; D000787: Angina Pectoris; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005080: Exercise Test; D015736: Felodipine; D005260: Female; D006801: Humans; D007548: Isosorbide Dinitrate; D008297: Male; D017202: Myocardial Ischemia; D011446: Prospective Studies; D016896: Treatment Outcome; D014665: Vasodilator Agents",,,https://openalex.org/W2095174258,137,23,1,1534,278,9,en,en
false,intravenous diltiazem treatment patient atrial fibrillation flutter moderate severe congestive heart failure,objective multicenter randomize double blind placebo controlled study determine safety efficacy intravenous diltiazem treatment patient rapid ventricular rate mean sd beats min atrial fibrillation flutter moderate severe congestive heart failure ejection fraction mean sd new york heart association class iii patient class iv patient double blind portion study patient receive either intravenous diltiazem mg kg minute placebo follow minute later diltiazem placebo mg kg minute first dose tolerate ineffective placebo nonresponders give open label intravenous diltiazem similar fashion double blind portion study double blind part study mg kg additional mg kg patient respond diltiazem patient respond placebo p patient mg kg additional mg kg receive placebo double blind period therapeutic response diltiazem open label therapy overall patient therapeutic response intravenous diltiazem heart rate response diltiazem minute bolus infusion consist decrease heart rate baseline patient addition patient also heart rate decrease beats min whereas patient conversion sinus rhythm median time response beginning minute bolus dose diltiazem minute hypotension common adverse event occur patient patient exacerbation congestive heart failure due diltiazem conclusion intravenous diltiazem rapid safe effective acutely lower rapid ventricular rate patient atrial fibrillation flutter moderate severe congestive heart failure,Goldenberg IF,1994,Am J Cardiol,https://doi.org/10.1016/0002-9149(94)90580-0,7977118,Goldenberg IF; Lewis WR; Dias VC; Heywood JT; Pedersen WR,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D001281: Atrial Fibrillation; D001282: Atrial Flutter; D004110: Diltiazem; D004311: Double-Blind Method; D005260: Female; D006333: Heart Failure; D006801: Humans; D007022: Hypotension; D007275: Injections, Intravenous; D008297: Male; D013997: Time Factors",,,https://openalex.org/W2011992070,135,19,1,2061,388,11,en,en
false,comparative double blind study efficacy safety cilazapril compare nifedipine retard treatment mild moderate arterial hypertension,evaluate antihypertensive efficacy safety cilazapril compare nifedipine retard mild moderate hypertension forty randomize patients mild moderate hypertension diastolic pressure dp mmhg placebo day randomize allocate treatment double blind daily cilazapril mg n nifedipine retard mg n four week non responders dp mmhg dosage increase twice b responder maintain week clinical visit perform baseline every two week laboratory test perform placebo run th th week treatment blood pressure bp similar group end placebo cilazapril nifedipine mmhg p dp decrease already second week cilazapril nifedipine mmhg p compare week group end study difference inter group bp normalization obtain patient cilazapril nifedipine group adverse biochemical effect observe group six patient cilazapril nifedipine relate collateral event although difference observe groups cilazapril mg normalized bp mild moderate hypertension patient efficacy similar sustained release nifedipine mg cilazapril adverse effect biochemical parameter low incidence collateral effect,Velasco-Cornejo IF,1994,Arq Bras Cardiol,,7980076,Velasco-Cornejo IF; Mion Júnior D; Martin LC; Tinucci T; Sampaio M; Pascoal IJ; Athanázio-Heliodoro RC; Marcondes M; Franco RJ,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D000806: Angiotensin-Converting Enzyme Inhibitors; D001794: Blood Pressure; D017315: Cilazapril; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D013997: Time Factors; D016896: Treatment Outcome,,,https://openalex.org/W1911929708,168,27,1,1626,304,8,en,en
false,efficacy tolerability extended release felodipine extended release nifedipine patient mild moderate essential hypertension,efficacy tolerability extended release felodipine felodipine er nifedipine gastrointestinal therapeutic system nifedipine git compare multicenter prospective open label clinical trial patient mild moderate uncomplicated essential hypertension sit diastolic blood pressure sidbp mm hg week washout period patient randomize receive felodipine er mg daily nifedipine git mg daily subsequent week titration phase daily felodipine er dose could increase mg nifedipine git dose mg attempt achieve adequate blood pressure response sidbp mm hg mm hg mm hg reduction baseline measure hour dose trough end titration mean daily dos felodipine er nifedipine git mg respectively mean change sit systolic blood pressure sisbp sidbp mm hg respectively reduction significant compare baseline p significant difference treatment group adequate blood pressure response occur felodipine er group nifedipine git group difference significant blood pressure change similar among sex race subgroup high percentage old patient year age young patient year age reach goal sidbp drug patient adequate sidbp response continue receive assigned medication additional week maintenance period reduction sidbp sisbp baseline continue significant treatment group clinically important change heart rate note total patient felodipine er group nifedipine git group withdraw study inadequate blood pressure response least one adverse experience occur felodipine er group nifedipine git group prompt withdrawal patient patient respectively headache edema common adverse experience incidence pattern adverse experience differ significantly treatment result study demonstrate daily felodipine er nifedipine git similarly highly effective generally well tolerate patient essential hypertension,Fagan TC,1994,Clin Ther,,7982251,Fagan TC; Haggert BE; Liss C,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D001794: Blood Pressure; D003692: Delayed-Action Preparations; D004334: Drug Administration Schedule; D004361: Drug Tolerance; D004487: Edema; D015736: Felodipine; D005260: Female; D006261: Headache; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011446: Prospective Studies,,,https://openalex.org/W35510491,146,16,1,2547,458,16,en,en
false,large prospective open label study isradipine patient essential hypertension isradipine investigator group,isradipine dihydropyridine calcium entry blocker previous control blind trial demonstrate safety efficacy isradipine lower blood pressure patient hypertension purpose study reassess safety efficacy large number patient open label long term multicenter trial total patient essential hypertension diastolic blood pressure mm hg receive mg isradipine two divided dos period week mean dose use mg titration week mg mg bid mg mg bid diastolic pressure still mm hg week isradipine treatment systolic blood pressure decrease mm hg mm hg p diastolic pressure mm hg mm hg p monotherapy successful reduce diastolic blood pressure mm hg patient significant adverse effect note patient withdrew study adverse event large long term community based study isradipine effective well tolerate patient,Weiss RJ,1994,Clin Ther,,7982252,Weiss RJ,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000367: Age Factors; D000368: Aged; D044383: Black People; D001794: Blood Pressure; D004334: Drug Administration Schedule; D005260: Female; D006261: Headache; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D012737: Sex Factors; D044465: White People,,,https://openalex.org/W2418932330,129,20,2,1258,250,9,en,en
false,control study new sustained release formulation nifedipine essential hypertensive patient,author study antihypertensive effect tolerability new sustained release formulation nifedipine mg day comparison nifedipine retard mg twice day patient mild moderate primary arterial hypertension treatment significantly lower blood pressure difference daily blood pressure profile steady state two drug determine comparable plasma level nifedipine measure immediately morning dose month treatment new formulation nifedipine still display satisfactory blood pressure control supine stand position change tolerability throughout study conclusion new sustained release formulation nifedipine similar efficacy tolerability conventional treatment nifedipine retard mg twice day,Galletti F,1994,J Clin Pharmacol,https://doi.org/10.1002/j.1552-4604.1994.tb04005.x,7983235,Galletti F; Barba G; Nardecchia A; Strazzullo P; Scagliusi P; Pirrelli A; Mancini M,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D013997: Time Factors,,,https://openalex.org/W2171146266,106,13,1,870,135,5,en,en
false,effect exercise therapy ventricular emptying filling mildly hypertensive patient,leave ventricular lv filling study healthy subject mildly hypertensive patient maximal supine exercise use radionuclide ventriculography addition hypertensive patient effect oral verapamil lisinopril treatment lv filling exercise study rest hypertensive patient compare healthy subject low peak filling rate ratio peak fill peak empty rate first half filling fraction longer isovolumic duration exercise lv filling measure different healthy subject hypertensive patient hypertensive patient rest compare treatment lisinopril prolonged isovolumic duration verapamil effect lv filling maximal exercise compare treatment verapamil shorten time peak fill rate isovolumic duration increase first half filling fraction maximal exercise verapamil effect whereas lisinopril alter exercise lv filling either exercise level thus early abnormal lv filling mildly hypertensive patient influence therapeutic intervention rest exercise hypertens,Clements IP,1994,Am J Hypertens,https://doi.org/10.1093/ajh/7.8.695,7986459,Clements IP; Bailey KR; Zachariah PK,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D001794: Blood Pressure; D002302: Cardiac Output; D004311: Double-Blind Method; D015444: Exercise; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D017706: Lisinopril; D008297: Male; D008875: Middle Aged; D015635: Radionuclide Ventriculography; D016277: Ventricular Function, Left; D014700: Verapamil",,,https://openalex.org/W2404923074,99,14,1,1287,218,7,en,en
false,conventional controlled release diltiazem,diltiazem cr tablets mg b week compare plain tablet mg q healthy male volunteer study pharmacokinetic variable antianginal efficacy also compare patient stable angina pectoris already metoprolol study randomise cross design clinical study double blind pharmacokinetic variable two formulation similar except long tmax h diltiazem cr comparison h plain tablet mean relative bioavailability diltiazem cr comparison plain tablet clinical study show four week diltiazem cr mg b diltiazem plain tablet mg q addition metoprolol significant decrease weekly anginal attack attacks week number nitroglycerin tablet consume tablets week increase maximum workload w diltiazem cr plain diltiazem tablet respectively compare placebo five patient angina free diltiazem treatment difference anti anginal efficacy two preparation see conclude cr mg b appear bioequivalent plain diltiazem tablet mg q,Brorson L,1994,Eur J Clin Pharmacol,https://doi.org/10.1007/bf00193483,7988629,Brorson L; Arvill A; Löfdahl P; Jörgensen E; Fraser T; Larsson H; Olsson AM; Olsson SO,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D001682: Biological Availability; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D004110: Diltiazem; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D006801: Humans; D008297: Male; D008790: Metoprolol; D008875: Middle Aged",,,https://openalex.org/W2331379398,45,5,1,1336,239,14,en,en
false,comparison lisinopril nifedipine treatment mild moderate hypertension,lisinopril compare slow release nifedipine week double blind randomize parallel group study involve patient mild moderate hypertension sit systolic diastolic blood pressure reduce mmhg lisinopril nifedipine week monotherapy week great proportion patient take lisinopril control sit diastolic blood pressure mm hg take nifedipine result take lisinopril take nifedipine require additional therapy hydrochlorothiazide addition hydrochlorothiazide result similar response rate lisinopril nifedipine group respectively rate reporting adverse event consider drug related rate withdrawal similar treatment cough often report lisinopril headache sweating hot flush nifedipine conclude daily titrated dos lisinopril produce well control blood pressure twice daily titrated dos nifedipine,Rogstad B,1994,Eur J Clin Pharmacol,https://doi.org/10.1007/bf00196102,7995312,Rogstad B,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000293: Adolescent; D000328: Adult; D000368: Aged; D005260: Female; D006801: Humans; D006973: Hypertension; D017706: Lisinopril; D008297: Male; D008875: Middle Aged; D009543: Nifedipine,,,https://openalex.org/W2885009455,91,14,1,1131,184,8,en,en
false,lisinopril nifedipine neutral effect lipid,randomized double blind parallel group multicentre study norway patient mild moderate hypertension mean blood pressure mm hg treat either lisinopril mg nifedipine mg effect blood lipid evaluate complete result laboratory analysis give patient week run placebo period antihypertensive treatment give next week treatment lisinopril change lipid total cholesterol hdl cholesterol triglyceride ratio hdl cholesterol hdl nifedipine corresponding value cholesterol hdl cholesterol triglyceride ratio none change statistically significant lisinopril nifedipine lower blood pressure significantly mm hg lisonopril p systolic diastolic pressure mm hg nifedipine p respectively drug well tolerate conclusion neither lisinopril nifedipine negative impact lipid level,Gisholt K,1994,Tidsskr Nor Laegeforen,,7998047,Gisholt K; Bratland B; Dahlöf B; Os I; Syvertsen JO; Tretli S,article,"D016430: Clinical Trial; D004740: English Abstract; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D008055: Lipids; D017706: Lisinopril; D008297: Male; D008875: Middle Aged; D009543: Nifedipine,,,https://openalex.org/W2345583452,59,11,1,1164,206,9,en,en
false,double blind comparison amlodipine hydrochlorothiazide patient mild moderate hypertension,abstract final analysis study week patient randomize receive amlodipine attain blood pressure control amlodipine alone compare patient allocate hydrochlorothiazide hctz neither amlodipine hctz produce clinically significant change pulse rate electrocardiogram amlodipine treatment appear produce clinically significant change blood lipid hctz however produce increase total plasma cholesterol mg dl incidence side effect rate patient withdrawal amlodipine hctz group comparable expect hctz therapy cause well recognized biochemical alteration cholesterol potassium level whereas amlodipine metabolically neutral,Ram CV,1994,Clin Cardiol,https://doi.org/10.1002/clc.4960170506,8004839,Ram CV; Ames RP; Applegate WB; Burris JF; Davidov ME; Mroczek WJ,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000328: Adult; D000368: Aged; D017311: Amlodipine; D001262: Atenolol; D001794: Blood Pressure; D002784: Cholesterol; D008076: Cholesterol, HDL; D008078: Cholesterol, LDL; D015243: Cholesterol, VLDL; D004311: Double-Blind Method; D004338: Drug Combinations; D004562: Electrocardiography; D005260: Female; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011674: Pulse; D012449: Safety; D016037: Single-Blind Method; D014280: Triglycerides",,,https://openalex.org/W2037105419,108,13,1,800,129,5,en,en
false,antihypertensive efficacy tolerability different drug regimen isolated systolic hypertension elderly,pharmacological treatment mainly base diuretic isolated systolic hypertension ish recently show reduce risk stroke coronary heart disease elderly purpose study compare antihypertensive effect tolerability different drug regimen elderly subject ish systolic blood pressure sbp mmhg diastolic blood pressure dbp mmhg multicentre randomize control open trial plan general practice set four widely use treatment schedule test hydrochlorothiazide mg plus amiloride mg h nifedipine slow release mg n atenolol mg atenolol mg plus chlorthalidone mg c baseline evaluation patient female mean age year randomize follow month month drug dosage double systolic blood pressure goal sbp mmhg sbp reduction least mmhg reach ninety four subject present contraindication beta blockers rd th month visit treatment group except show significant reduction sbp compare control group dbp show significant reduction group time end follow percentage hypertensive reach bp goal control group h n c abstract truncate word,Avanzini F,1994,Eur Heart J,https://doi.org/10.1093/oxfordjournals.eurheartj.a060477,8005121,Avanzini F; Alli C; Bettelli G; Corso R; Colombo F; Mariotti G; Radice M; Torri V; Tognoni G,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D000584: Amiloride; D000959: Antihypertensive Agents; D001262: Atenolol; D001794: Blood Pressure; D002752: Chlorthalidone; D003692: Delayed-Action Preparations; D004338: Drug Combinations; D004359: Drug Therapy, Combination; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D008297: Male; D009543: Nifedipine; D017060: Patient Satisfaction; D016896: Treatment Outcome",,,https://openalex.org/W1735740492,118,15,1,1512,302,10,en,en
false,prognostic significance post infarction angina pectoris effect verapamil incidence angina pectoris prognosis,prognostic sign angina pectoris effect intervention verapamil incidence angina pectoris study patient recover myocardial infarction include danish verapamil infarction trial ii second week admission patient double blindly randomize treatment verapamil mg day placebo treatment continue month discharge angina pectoris report patient randomize verapamil randomized placebo n one month discharge significantly increase prevalance angina pectoris report verapamil p placebo group p one month prevalence angina pectoris p month overall incidence angina pectoris p sigificant low verapamil group compare placebo stable angina pectoris first month follow significant predictor major event e death reinfarction hazard ratio confidence limit verapamil significantly reduce incidence angina pectoris daily activity thereby number patient high risk beneficial effect verapamil reduce major event patient recover myocardial infarction likely due abolish myocardial ischaemia,Jespersen CM,1994,Eur Heart J,https://doi.org/10.1093/oxfordjournals.eurheartj.a060486,8005130,Jespersen CM; Hansen JF; Mortensen LS,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D003718: Denmark; D004311: Double-Blind Method; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D011379: Prognosis; D012008: Recurrence; D015996: Survival Rate; D014700: Verapamil,,,https://openalex.org/W2247463310,140,20,1,1424,257,9,en,en
false,asymptomatic cardiac ischemia pilot acip study design randomized clinical trial baseline data implication long term outcome trial,primary objective asymptomatic cardiac ischemia pilot compare week efficacy three treatment strategy suppress cardiac ischemia assess feasibility prognosis trial patient asymptomatic cardiac ischemia cardiac ischemia associate increased morbidity mortality however cardiac ischemia asymptomatic although therapeutic strategy range medication revascularization use treat ischemia prospective study evaluate different treatment strategy reported patients angiographically document coronary artery disease ischemia exercise ambulatory electrocardiogram ecg clinical unit randomize receive angina guided medical therapy angina guided plus ambulatory ecg ischemia guided medical therapy revascularization coronary angioplasty bypass surgery patient also randomize receive either diltiazem plus isosorbide dinitrate atenolol plus nifedipine possible anti ischemic medication adjustment control angina blind medication adjust medical therapy group eliminate ischemia ischemia guided group primary outcome absence ischemia week follow schedule year total patient screen ambulatory ecg monitoring asymptomatic ischemia enrol study patient men year old two ischemic episode early positive exercise test multivessel disease design baseline data pilot study ischemia treatment strategy describe,Pepine CJ,1994,J Am Coll Cardiol,https://doi.org/10.1016/0735-1097(94)90534-7,8006249,Pepine CJ; Geller NL; Knatterud GL; Bourassa MG; Chaitman BR; Davies RF; Day P; Deanfield JE; Goldberg AD; McMahon RP,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.","D000368: Aged; D000787: Angina Pectoris; D001262: Atenolol; D004110: Diltiazem; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D007548: Isosorbide Dinitrate; D008297: Male; D008875: Middle Aged; D017202: Myocardial Ischemia; D009204: Myocardial Revascularization; D009543: Nifedipine; D010865: Pilot Projects; D012107: Research Design; D013997: Time Factors; D016896: Treatment Outcome; D014481: United States",,,https://openalex.org/W1990859472,153,26,1,1703,265,7,en,en
false,effect treatment strategy suppress ischemia patient coronary artery disease week result asymptomatic cardiac ischemia pilot acip study,objective asymptomatic cardiac ischemia pilot acip study initiate determine feasibility large trial evaluate effect treatment ischemia outcome mortality myocardial infarction study design examine effect medical treatment control angina compare treatment strategy guide ambulatory electrocardiographic ecg ischemia coronary anatomy background treatment suppress ischemia asymptomatic symptomatic evaluate large prospective randomized trial undertake trial issue recruitment treatment strategy must address method enrol patient coronary artery disease suitable revascularization ischemia stress test asymptomatic ischemia ambulatory ecg patient assign randomly one three treatment strategy angina guided medical strategy titration anti ischemic medication relieve angina angina guided strategy angina guided plus ambulatory ecg ischemia guided medical strategy titration anti ischemic medication eliminate angina ambulatory ecg ischemia ischemia guided strategy revascularization angioplasty bypass surgery revascularization strategy result ambulatory ecg ischemia longer present week visit patient assign angina guided strategy patient assign ischemia guided strategy patient assign revascularization strategy strategy reduce median number episode total duration st segment depression follow ambulatory ecg monitoring revascularization effective strategy treadmill test result concordant ambulatory ecg monitoring lor patient two medical strategy angina control low moderate dos anti ischemic medication majority patient revascularization strategy require medication angina conclusion pilot study demonstrate cardiac ischemia suppress patient either low moderate dos medication revascularization large trial feasible,Knatterud GL,1994,J Am Coll Cardiol,https://doi.org/10.1016/0735-1097(94)90535-5,8006252,Knatterud GL; Bourassa MG; Pepine CJ; Geller NL; Sopko G; Chaitman BR; Pratt C; Stone PH; Davies RF; Rogers WJ,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000368: Aged; D001262: Atenolol; D003327: Coronary Disease; D004110: Diltiazem; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D007548: Isosorbide Dinitrate; D008297: Male; D008875: Middle Aged; D017202: Myocardial Ischemia; D009204: Myocardial Revascularization; D009543: Nifedipine; D010865: Pilot Projects; D013997: Time Factors; D016896: Treatment Outcome; D014481: United States",,,https://openalex.org/W1982723174,166,26,1,2280,366,16,en,en
false,comparison nisoldipine diltiazem treatment effort angina pectoris,order evaluate benefit calcium antagonist medium term treatment patient effort stable angina pectoris treat nisoldipine comparison diltiazem twenty patient stable effort angina complete double blind placebo control trial compare twice daily nisoldipine per diltiazem three time daily per day wash placebo drug period ergometer stress test perform exercise tolerance angina frequency nitrate consumption side effect evaluated result show drug significantly increase exercise tolerance exercise duration sec placebo sec nisoldipine p sec diltiazem p effort angina episode decrease placebo nisoldipine diltiazem drug reduce rate pressure product submaximal exercise comparison placebo difference peak exercise placebo drug period drug similarly reduce nitrate consumption weekly effort angina attack patient refer serious side effects nisoldipine like diltiazem effective drug treatment stable effort angina moreover therapeutic effect nisoldipine medium term treatment probably relate decrease oxygen consumption,de Caprio L,1994,G Ital Cardiol,,8013763,de Caprio L; Sestito M; Pandolfi E; Santamaria F; di Palma A; Lombardi L; Voza A; De Rosa ML; Cicatiello AM; Rengo F,article,D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000328: Adult; D000787: Angina Pectoris; D004110: Diltiazem; D004311: Double-Blind Method; D004562: Electrocardiography; D005080: Exercise Test; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D015737: Nisoldipine; D005996: Nitroglycerin",,,https://openalex.org/W2415472249,85,15,1,1382,223,10,en,en
false,dose response evaluation daily therapy new formulation diltiazem stable angina pectoris,diltiazem hydrochloride daily capsule formulation dcd recently approve united state treatment mild moderate hypertension chronic stable angina pectoris trial evaluate dose response dcd patient chronic stable angina pectoris multicenter randomize double blind parallel design trial effect tolerability daily therapy placebo dcd mg evaluate hour dose follow week therapy patient reproducible stable exertional angina pectoris significant linear dose trend p present across treatment group primary end point time exercise termination hour dosing using standard brace treadmill excercise test significant linear dose trend also see time mm st segment depression hour dose similar effect exercise parameter also see hour dose linear dose trend p note relative overall anginal attack daily activity anginal attack exercise p overall frequency treatment related adverse effect dose related occur patient treat dcd placebo respectively dose mg day improvement exercise tolerance achieve without associated increase rate treatment related adverse event compare placebo result study suggest mg dcd would start dose careful titration mg day individual patient maximal therapeutic efficacy,Thadani U,1994,Am J Cardiol,https://doi.org/10.1016/0002-9149(94)90483-9,8017316,Thadani U; Glasser S; Bittar N; Beach CL,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000704: Analysis of Variance; D000787: Angina Pectoris; D004110: Diltiazem; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004562: Electrocardiography; D017079: Exercise Tolerance; D005260: Female; D006439: Hemodynamics; D006801: Humans; D008297: Male; D016896: Treatment Outcome",,,https://openalex.org/W1980999608,109,15,1,1675,294,10,en,en
false,use confidence interval describe precision trough peak ratio diltiazem cd treatment hypertension,daily diltiazem hydrochloride cardizem cd diltiazem cd mg evaluate safety efficacy relationship peak trough antihypertensive ejects multicenter placebo controlled parallel design trial week placebo baseline period patient essential hypertension randomize receive placebo diltiazem cd week treatment period diltiazem cd mg lower supine diastolic systolic blood pressure trough significantly placebo mm hg vs mm hg p mm hg vs mm hg p respectively supine blood pressure also measure hourly hour dose assess peak effect trough peak ratio use large residual drug effect mm hg hour peak hour residual drug effect mm hg trough trough peak ratio estimate low one sided confidence limit precision trough peak ratio estimate low confidence limit establish trough peak ratio statistically statistically significant difference supine dbp note peak effect hour indicate plateau peak antihypertensive effect hour post dose diltiazem cd therapy well tolerate serious treatment related adverse event report trial patient discontinue trial due treatment related adverse event trial demonstrate diltiazem cd mg safe effective therapy administer daily treatment essential hypertension,Meeves SG,1994,J Clin Pharmacol,https://doi.org/10.1002/j.1552-4604.1994.tb03991.x,8021331,Meeves SG; Park GD,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D001794: Blood Pressure; D016001: Confidence Intervals; D004110: Diltiazem; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged,,,https://openalex.org/W2018122219,129,20,1,1664,295,9,en,en
false,short term effect felodipine hypertensive type ii diabetic male sulfonylurea treatment,abstract objective study effect blood pressure glucose homeostasis felodipine calcium antagonist design double blind randomize cross study compare felodipine er placebo setting university centre diabetic care malm sweden subject seventeen hypertensive type ii diabetic male oral sulfonylurea glibenclamide treatment intervention four week treatment period separate week wash period felodipine mg daily give main outcome measure blood pressure heart rate hba c response oral glucose tolerance test glucose insulin c peptide measure randomization end double blind treatment period result blood pressure significantly reduce felodipine treatment heart rate slightly increase felodipine influence insulin c peptide level significant change glucose level increase hba c conclusion study demonstrate felodipine effective agent type ii diabetic patient glibenclamide treatment effect hba c noteworthy even clinical significance short term control long term study diabetic patient need fully evaluate antihypertensive agent,Kjellström T,1994,J Intern Med,https://doi.org/10.1111/j.1365-2796.1994.tb01119.x,8021573,Kjellström T; Blychert E; Lindgärde F,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D001786: Blood Glucose; D001794: Blood Pressure; D002096: C-Peptide; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D015736: Felodipine; D006339: Heart Rate; D006441: Hemoglobin A; D006801: Humans; D006973: Hypertension; D007328: Insulin; D008297: Male; D008875: Middle Aged; D013453: Sulfonylurea Compounds; D013997: Time Factors",,,https://openalex.org/W2009674481,97,13,1,1299,211,23,en,en
false,effect long acting propranolol verapamil blood pressure platelet function metabolic rheological property hypertension,newly develop antihypertensive drug long acting beta blocker propranolol sustained release calcium antagonist verapamil compare antihypertensive platelet function rheological property metabolic effect trial double blind randomised placebo controlled cross study thirty patient mild moderate hypertension receive propranolol mg verapamil mg daily two separate ten week course ten week treatment drug significantly reduce sbp dbp beta thromboglobulin beta tg concentration reflect status platelet activation vivo significantly decrease propranolol vs ng ml verapamil vs ng ml treatment platelet aggregation induce adp collagen arachidonic acid adrenaline production thromboxane b txb ketoprostaglandin f alpha keto pgf alpha platelet cyclic adenosine monophosphate c amp concentration affect significant alteration rheological parameter plasma whole blood viscosity fibrinogen level red cell deformability find high cholesterol low density lipoprotein cholesterol ldl c level observe propranolol treatment verapamil treatment side effects mild tolerate patient withdraw study conclusion propranolol verapamil generally effective antihypertensive well rheologically safe drug compare metabolic effect serum lipid verapamil may good choice drug possess tendency inhibit platelet property desirable hypertension treatment,Ding YA,1994,J Hum Hypertens,,8021907,Ding YA; Chou TC; Lin KC,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D001783: Blood Flow Velocity; D001792: Blood Platelets; D001794: Blood Pressure; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004907: Erythrocyte Deformability; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D010974: Platelet Aggregation; D010978: Platelet Factor 4; D011433: Propranolol; D013929: Thromboxane B2; D013997: Time Factors; D014700: Verapamil; D001620: beta-Thromboglobulin",,,https://openalex.org/W2412724851,140,20,1,1778,283,11,en,en
false,double blind crossover study daily nifedipine coat core essential hypertension,nineteen patient essential hypertension regular treatment nifedipine tablet mg twice daily whose dbp mmhg least two occasion two week apart enter double blind randomise crossover study three week treatment nifedipine coat core new formulation either mg one daily mg daily dose bp plasma nifedipine level measure two four six hour dose pattern bp response dos similar h period however great bp lower effect achieve mg compare mg bp lower effect dos less h last dose compare peak effect plasma nifedipine level significantly associate bp lower effect group whole e high nifedipine level low bp significantly less hour compare peak nifedipine coat core formulation effective lower bp patient essential hypertension mg dose effective mg dose induce high nifedipine level associate great bp lower effect however maximum bp lower effect maintain hour,Missouris CG,1994,J Hum Hypertens,,8021910,Missouris CG; Cappuccio FP; Markandu ND; Singer DR; MacGregor GA,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000328: Adult; D000368: Aged; D001794: Blood Pressure; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D013997: Time Factors",,,https://openalex.org/W2399977284,90,13,1,1260,235,10,en,en
false,new preparation nifedipine sublingual application hypertensive urgency,new preparation nifedipine sublingual application hypertensive urgency investigate prospective study patient admit emergency department persistent elevation systolic blood pressure sbp great mm hg diastolic blood pressure dbp great mm hg receive nifedipine mg sublin gual sprayer second dose administrate fifteen minute later adequate response define stable reduction sbp mm hg dbp mm hg occur patient respond first nifedipine appli cation respond second dose nonresponders treat urapidil overall mean sbp mm hg mean dbp mm hg treatment significant antihypertensive effect note within fifteen minute nifedipine spray p maximum antihypertensive effect sbp sixty minute mm hg dbp one hundred twenty minute mm hg average reduction sbp dbp first dose responder n significant antihypertensive effect note within fifteen minute sbp decline minimum mm hg sixty minute dbp minimum mm hg one hundred twenty minute second dose responder n significant antihypertensive effect note within thirty minute sbp decline minimum mm hg sixty minute dbp minimum mm hg one hundred twenty minute treatment sublin gual nifedipine spray author could observe clinically significant side effect overall heart rate decrease significantly beat per minute minimum beat per minute one hundred twenty minute author conclude sublingual nifedipine spray application offer new highly effective safe convenient method treat patient hypertensive urgency,Kürkciyan I,1994,Angiology,https://doi.org/10.1177/000331979404500706,8024162,Kürkciyan I; Sterz F; Roden M; Heinz G; Hirschl MM; Müllner M; Laggner AN,article,D016428: Journal Article,"D000286: Administration, Sublingual; D000328: Adult; D000336: Aerosols; D000368: Aged; D001794: Blood Pressure; D004630: Emergencies; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011446: Prospective Studies",,,https://openalex.org/W2054395636,84,11,1,2113,416,14,en,en
true,effect antihypertensive medication quality life elderly hypertensive woman,impact antihypertensive medication quality life elderly hypertensive woman rarely systematically evaluate large clinical trial use drug new generation pharmaceutic preparation carry multicenter randomize double blind clinical trial hypertensive woman age year assess effect atenolol enalapril isradipine measure quality life week period patient mild moderate hypertension hydrochlorothiazide add treatment monotherapy inadequate lower blood pressure conclusion trial three drug group differ degree reduction diastolic blood pressure supplementation hydrochlorothiazide week trial linear trend analysis show difference treatment group change baseline quality life measure well physical status emotional status cognitive functioning social role participation regard physical side effect week find general difference atenolol enalapril isradipine group measure change distress symptom except enalapril patient worsen distress cough p atenolol patient worsen distress dry mouth p center three medication datively new addition armamentarium blood pressure control finding underline increase opportunity physician select drug control blood pressure maintain quality life elderly hypertensive woman j hypertens,Croog SH,1994,Am J Hypertens,https://doi.org/10.1093/ajh/7.4.329,8031548,Croog SH; Elias MF; Colton T; Baume RM; Leiblum SR; Jenkins CD; Perry HM; Hall WD,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D000959: Antihypertensive Agents; D001262: Atenolol; D001794: Blood Pressure; D004311: Double-Blind Method; D004656: Enalapril; D005260: Female; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D011788: Quality of Life; D013997: Time Factors",,,https://openalex.org/W2077393379,88,12,1,1696,277,9,en,en
true,long term double blind comparative study quality life treatment amlodipine enalapril mild moderate hypertensive patient multicentre study,efficacy tolerability impact quality life amlodipine enalapril compare multicentre double blind general practice study mild moderate hypertensive week active treatment period amlodipine mg daily enalapril mg daily find similarly effective lower blood pressure adversely affect quality life parameter however enalapril group compare amlodipine group require addition hydrochlorothiazide blood pressure control p diastolic blood pressure normalise reduce mmhg patient amlodipine patient enalapril side effects general mild little clinical significance major side effects record class typical ace inhibitor calcium antagonist namely cough enalapril oedema amlodipine respectively tolerability good patient amlodipine enalapril withdraw study due side effects definitely relate treatment amlodipine monotherapy produce slightly beneficial effect blood lipid concentration drug reduce calculated year risk coronary heart disease conclude calcium antagonist amlodipine compare favourably ace inhibitor enalapril term antihypertensive efficacy tolerability impact quality life,Omvik P,1994,Br J Clin Pract Suppl,,8031705,Omvik P; Thaulow E; Herland OB; Eide I; Midha R; Turner RR,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D017311: Amlodipine; D004311: Double-Blind Method; D004656: Enalapril; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011788: Quality of Life,,,https://openalex.org/W2408907824,173,28,1,1485,261,9,en,en
false,treatment hypertensive emergency,objective present efficacy tolerability new oral dosage form calcium antagonist nitrendipine compare nifedipine capsule patient hypertensive emergency design multicenter randomize double blind clinical study setting study centre hospital germany patient patient year acutely elevate blood pressure systolic mmhg diastolic mmhg without concomitant clinical symptom intervention double blind treatment mg nifedipine mg nitrendipine nifedipine administer capsule nitrendipine give small plastic tube vial contain ml alcoholic solution every patient receive addition test medication placebo correspond product patient insufficient treatment min give either additional capsule mg nifedipine vial contain mg nitrendipine accord group maintain double dummy procedure measurement result blood pressure heart rate measure repeatedly h min begin treatment channel rest ecg record min administration blood pressure fall significantly mmhg mmhg nifedipine mmhg mmhg nitrendipine nifedipine patient nitrendipine patient already reach blood pressure value mmhg min group patient still limit end observation period h tolerability good group conclusion new dosage form nitrendipine vial ml alcoholic solution represent alternative treatment hypertensive emergency,Rohr G,1994,Intensive Care Med,https://doi.org/10.1007/bf01708963,8046120,Rohr G; Reimnitz P; Blanke P,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000328: Adult; D000368: Aged; D002214: Capsules; D016009: Chi-Square Distribution; D004311: Double-Blind Method; D004630: Emergencies; D005260: Female; D005858: Germany; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D009568: Nitrendipine; D013997: Time Factors",,,https://openalex.org/W2335759768,35,4,1,1876,317,12,en,en
false,addition pentoxifylline plus nifedipine chemotherapy patient cisplatin resistant cancer lung site,eight evaluable patient cisplatin resistant non small cell lung cancer patient small cell lung cancer patient breast ovarian cancer patient enter study determine whether addition nifedipine plus pentoxifylline cisplatin based chemotherapy would result increased chemotherapy efficacy patient respond treatment myelosuppression may augment nifedipine pentoxifylline median granulocyte nadir l two patient develop febrile neutropenia nifedipine pentoxifylline stop two evaluable patient due hypotension three additional inevaluable patient withdraw study due nifedipine pentoxifylline toxicity receive chemotherapy indication type chemotherapy toxicity increase addition nifedipine pentoxifylline major problem strategy follow protocol patient whose tumor fail respond cisplatin based regimen often ill tolerate additional cisplatin particularly accompany nifedipine associated hypotension,Stewart DJ,1994,Am J Clin Oncol,https://doi.org/10.1097/00000421-199408000-00006,8048393,Stewart DJ; Evans WK; Logan D,article,D016428: Journal Article,D000971: Antineoplastic Combined Chemotherapy Protocols; D001943: Breast Neoplasms; D002945: Cisplatin; D004341: Drug Evaluation; D004351: Drug Resistance; D005260: Female; D006801: Humans; D007022: Hypotension; D008175: Lung Neoplasms; D008297: Male; D009503: Neutropenia; D009543: Nifedipine; D010051: Ovarian Neoplasms; D010431: Pentoxifylline,,,https://openalex.org/W2031708956,131,18,1,1175,180,7,en,en
false,nifedipine asymptomatic patient severe aortic regurgitation normal leave ventricular function,vasodilator therapy nifedipine reduces leave ventricular volume mass increase ejection fraction asymptomatic patient severe aortic regurgitation,Scognamiglio R,1994,N Engl J Med,https://doi.org/10.1056/nejm199409153311101,8058074,Scognamiglio R; Rahimtoola SH; Fasoli G; Nistri S; Dalla Volta S,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D001022: Aortic Valve Insufficiency; D002908: Chronic Disease; D004077: Digoxin; D005260: Female; D005500: Follow-Up Studies; D006350: Heart Valve Prosthesis; D006801: Humans; D008297: Male; D009543: Nifedipine; D013318: Stroke Volume; D016277: Ventricular Function, Left",,,https://openalex.org/W2333744553,105,13,1,171,23,1,en,en
false,nicardipine versus metoprolol treatment hypertension pregnancy randomized comparative trial,compare effect treatment nicardipine metoprolol patient hypertension pregnancy one hundred pregnant patient mild moderate hypertension follow centre hospitalier intercommunal de cr teil france randomly allocate treatment either nicardipine metoprolol change maternal blood pressure bp laboratory index umbilical doppler velocimetry neonatal outcome compare mean student test chi test analysis variance nicardipine decrease maternal systolic diastolic bp metoprolol p umbilical artery resistance low nicardipine treated patient p plasma uric acid creatinine concentration increase less markedly nicardipine group p p respectively incidence cesarean delivery fetal distress low nicardipine group p trend toward high birth weight nicardipine group significant difference neonatal outcome nicardipine effective metoprolol decrease maternal bp neonatal outcome significantly different,Jannet D,1994,Obstet Gynecol,https://doi.org/10.1016/0020-7292(95)90977-v,8058230,Jannet D; Carbonne B; Sebban E; Milliez J,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D001724: Birth Weight; D001794: Blood Pressure; D002585: Cesarean Section; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D006973: Hypertension; D007231: Infant, Newborn; D008790: Metoprolol; D009529: Nicardipine; D011225: Pre-Eclampsia; D011247: Pregnancy; D011249: Pregnancy Complications, Cardiovascular; D011256: Pregnancy Outcome",,,https://openalex.org/W75299216,111,15,1,1169,193,6,en,en
false,hypertension current management strategy,hypertension affect million person united state common reason office visit prescription report review epidemiology diagnosis treatment condition provide special attention concomitant risk factor issue adherence literature search perform use medline file date back key word hypertension antihypertensive agent patient compliance cardiovascular risk factor isolate systolic hypertension jnc additional reference access cross referencing bibliography article obtain search effective therapeutic pharmacologic nonpharmacologic management hypertension include stage reclassify fifth report joint national committee jnc v greatly reduce mortality patient despite extensive national effort percent hypertensive patient remain unknown percent hypertension adequately control additional cardiovascular risk factor compound risk adverse outcome adversely affect treatment jnc v recommendation regard equally effective pharmacologic agent flexible controversial favorable cardioprotective effect angiotensin converting enzyme inhibitor calcium channel blocker alpha blocker alpha beta blockers often make appropriate choice diuretic beta blockers practical technique improve patient adherence treatment regimen also important begin diagnosis hypertension make,Sutherland J,1994,J Am Board Fam Pract,,8059624,Sutherland J; Castle C; Friedman R,article,D016428: Journal Article; D016454: Review,D000293: Adolescent; D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002423: Cause of Death; D000075202: Contraindications; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D012307: Risk Factors,,,https://openalex.org/W1794460138,44,6,1,1626,247,9,en,en
false,nifedipine versus captopril management moderate hypertension black ratients,efficacy nifedipine mg twice daily captopril mg twice daily assess week single blind randomize trial moderately hypertensive black patient mean h diastolic blood pressure bp mm hg mm hg nifedipine captopril administer monotherapy increase dosage diuretic add week patient fail reach target bp h mean diastolic bp mm hg monotherapy week monotherapy mean h ambulatory bp reduce mm hg p nifedipine group remain essentially unchanged captopril group leave ventricular lv mass index also reduce significantly p nifedipine group cardiac index fractional shortening change marginally addition diuretic captopril group patient result significant fall bp patient nifedipine group require addition diuretic overall incidence side effect similar treatment addition diuretic captopril group follow adverse change serum sodium p urea p creatinine p level conclude nifedipine monotherapy offer effective safe firstline antihypertensive treatment black patient moderate hypertension captopril alone fail control bp combination captopril diuretic although effective control bp compare captopril alone associate significant adverse metabolic effect j hypertens,Skoularigis J,1994,Am J Hypertens,https://doi.org/10.1093/ajh/7.5.440,8060578,Skoularigis J; Eitzman L; Davis J; Strugo V; Sareli P,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D044383: Black People; D001794: Blood Pressure; D002216: Captopril; D004452: Echocardiography; D006801: Humans; D006973: Hypertension; D008875: Middle Aged; D009543: Nifedipine,,,https://openalex.org/W2286701326,88,12,1,1742,335,10,en,en
false,comparison effect nicardipine trichlormethiazide insulin sensitivity hypertensive patient,perform randomize crossover study compare effect nicardipine trichlormethiazide insulin sensitivity untreated essential hypertensive patient treat either nicardipine trichlormethiazide week treat alternative drug week insulin sensitivity determine hyperinsulinemic euglycemic clamp technique nicardipine adverse effect insulin sensitivity trichlormethiazide decrease insulin sensitivity index nicardipine adverse effect insulin sensitivity prefer patient proven metabolic abnormality,Kageyama S,1994,Am J Hypertens,https://doi.org/10.1093/ajh/7.5.474,8060584,Kageyama S; Yamamoto J; Mimura A; Ishibashi K; Sakurai T; Yokota K; Isogai Y; Fujita T,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D001794: Blood Pressure; D004573: Electrolytes; D015309: Glucose Clamp Technique; D005951: Glucose Tolerance Test; D006801: Humans; D006973: Hypertension; D007333: Insulin Resistance; D008055: Lipids; D008297: Male; D008875: Middle Aged; D009529: Nicardipine; D014237: Trichlormethiazide,,,https://openalex.org/W2271209526,107,13,1,686,105,6,en,en
false,blood pressure control diltiazem xr novel extended release formulation diltiazem hcl mature elderly hypertensive patient,safety efficacy extended release form diltiazem hcl diltiazem xr patient year old mild moderate essential hypertension examine multi center double blind randomize placebo controlled parallel group study involve patient supine diastolic blood pressure dbp mm hg mm hg patient randomize daily dose diltiazem xr mg placebo patient receive diltiazem xr receive placebo week dose double mg patient whose supine dbp mm hg treatment continue another week diltiazem xr consistently reduce blood pressure bp study population end point mean reduction supine dbp mm hg diltiazem xr group mm hg placebo group p subgroup analysis confirm efficacy diltiazem xr men woman patient age year patient year old non black patient bp value supine systolic stand diastolic stand systolic also significantly reduce patient treat diltiazem xr bp reduction supine dbp mm hg mm hg achieve patient receive diltiazem xr compare patient receive placebo decrease apical heart rate minimal similar group significant difference note adverse event diltiazem xr placebo group patient diltiazem xr group placebo group adverse experience respectively least one adverse event physical examination finding laboratory value clinically unremarkable comparable diltiazem xr placebo group diltiazem xr give daily dos mg mg safe effective lower blood pressure mature elderly patient mild moderate hypertension,Fiddes R,1994,Clin Ther,,8062317,Fiddes R; Heym H; Hilty W; Lewin AJ; Codispoti J; McNally C; Stokes A; Gilderman L,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000368: Aged; D044383: Black People; D001794: Blood Pressure; D003692: Delayed-Action Preparations; D004110: Diltiazem; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D012449: Safety",,,https://openalex.org/W158646827,141,22,1,1995,377,12,en,en
false,effect verapamil nitrendipine left ventricular mass function systolic diastolic arterial hypertension,evaluate effect two calcium antagonist verapamil nitrendipine regression left ventricular mass function systolic diastolic echocardiography doppler treat hypertensive subjects hypertensive subject study randomized placebo control prospective double blind trial verapamil mg day administer nitrendipine mg day active drug therapy phase month rest effort tensional evaluation echo doppler perform placebo phase month evaluate leave ventricular structure septal posterior wall thickness diameter mass function systolic diastolic tensional control rest effort similar drug heart rate decrease verapamil leave ventricular mass index decrease verapamil nitrendipine due reduction wall thickness verapamil g nitrendipine g p leave ventricular systolic function modify follow drug verapamil group leave ventricular diastolic function parameter improve e e age p verapamil nitrendipine exerts similar tensional control rest effort leave ventricular mass regression improvement diastolic function parameter verapamil group probably due bradycardia,González-Juanatey JR,1994,Rev Esp Cardiol,,8066309,González-Juanatey JR; García-Acuña JM; Calvo Gómez C; Amaro Cendón A; Fernández-López JA; Gil de la Peña M,article,D016430: Clinical Trial; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D004311: Double-Blind Method; D015150: Echocardiography, Doppler; D005500: Follow-Up Studies; D006352: Heart Ventricles; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009200: Myocardial Contraction; D009568: Nitrendipine; D016277: Ventricular Function, Left; D014700: Verapamil",,,https://openalex.org/W2472859118,131,23,1,1584,273,8,en,en
false,quality life cost effectiveness treatment hypertension,large result different study quality life hypertension suggest among beta blockers nonselective beta blocker propranolol negative effect well associate depression side effects finding diuretic comparatively mainly observe adverse impact sexual function one broaden treatment scenario include mortality morbidity evidence beneficial impact prove beta blockers diuretic primary aim antihypertensive drug therapy give reduction cardiovascular risk factor aim regard quality life quality life maintain new guideline management mild hypertension issue united state highlight danger relax concern risk reduction cost favour surrogate end points even though may carry great significance individual patient,Wiklund I,1994,J Clin Pharm Ther,https://doi.org/10.1111/j.1365-2710.1994.tb01116.x,8071397,Wiklund I,article,D016428: Journal Article; D016454: Review,D000959: Antihypertensive Agents; D002986: Clinical Trials as Topic; D003362: Cost-Benefit Analysis; D006801: Humans; D006973: Hypertension; D011788: Quality of Life; D016896: Treatment Outcome,,,https://openalex.org/W1998758995,71,10,1,978,161,5,en,en
false,intracellular ionic consequence dietary salt load essential hypertension relation blood pressure effect calcium channel blockade,study ionic basis salt sensitivity hypertension f p na nuclear magnetic resonance technique use measure cytosolic free calcium cai ph phi free magnesium mgi sodium nai erythrocyte essential hypertensive subject n individual study mo low unav meq high unav meq salt diet concomitant administration nifedipine mg placebo tablet mo diet salt load elevate cai nai suppress mgi phi change occur predominantly salt sensitive subject n nifedipine blunt pressor response salt load delta diastolic bp high low salt v placebo vs mmhg p reverse salt induced ionic change lower cai elevate mgi phi regardless definition salt sensitivity continuous relationship observe pressure response salt loading level cai r p nai r p phi r p salt induced change mgi r p altogether result emphasize reciprocal coordinate nature intracellular ionic change response dietary salt loading calcium channel blockade essential hypertension suggest salt sensitivity mediate cellular calcium accumulation extracellular space association magnesium depletion acidification lastly interpretation intracellular ion measurement future require concurrent assessment dietary salt intake,Resnick LM,1994,J Clin Invest,https://doi.org/10.1172/jci117445,8083368,Resnick LM; Gupta RK; DiFabio B; Barbagallo M; Mann S; Marion R; Laragh JH,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000704: Analysis of Variance; D001794: Blood Pressure; D002118: Calcium; D004573: Electrolytes; D004912: Erythrocytes; D005260: Female; D006801: Humans; D006863: Hydrogen-Ion Concentration; D006973: Hypertension; D008274: Magnesium; D009682: Magnetic Resonance Spectroscopy; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D016037: Single-Blind Method; D012964: Sodium; D012982: Sodium, Dietary",,,https://openalex.org/W2015190627,151,22,2,1654,325,9,en,en
false,comparative metabolism h glucosamine fibroblast population expose cyclosporine,c yclosporine nifedipine therapy produce gingival overgrowth many patient neither mechanism underlie undesirable side effect possibility synergism drug know although many renal transplant patient receive drug study compare rate h glucosamine utilization three group fibroblast untreated gingival fibroblast fibroblast gingival overgrowth tissue patient receive cyclosporine nifedipine normal gingival fibroblast expose cyclosporine vitro significant difference rate deposition h glucosamine extracellular matrix group gingival fibroblast demonstrate suggest increase rate deposition proteoglycans gingival extracellular matrix fibroblast far investigate biologic mechanism gingival overgrowth j periodontol,Zebrowski EJ,1994,J Periodontol,https://doi.org/10.1902/jop.1994.65.6.565,8083787,Zebrowski EJ; Pylypas SP; Odlum O; Johnson RB,article,"D002363: Case Reports; D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D002452: Cell Count; D002478: Cells, Cultured; D002908: Chronic Disease; D016572: Cyclosporine; D005109: Extracellular Matrix; D005347: Fibroblasts; D005881: Gingiva; D005885: Gingival Hyperplasia; D005944: Glucosamine; D006801: Humans; D016030: Kidney Transplantation; D008297: Male; D009543: Nifedipine; D011509: Proteoglycans; D014316: Tritium",,,https://openalex.org/W2086721874,101,17,1,948,139,5,en,en
false,effect nilvadipine nifedipine induced edema low leg result double blind randomized comparative study,evaluation effect nilvadipine nifedipine induced lower leg edema multicenter randomize double blind study outpatient suffer essential hypertension diastolic blood pressure adjust mmhg nifedipine simultaneous lower leg edema first phase wash placebo b second phase slow release nifedipine mg b third phase slow release nifedipine mg b nilvadipine mg morning placebo evening lower leg volume blood pressure heart rate weight laboratory investigation undesired effect assessment effectiveness tolerability physician subjective patient assessment patients treat nilvadipine immediately follow nifedipine therapy show significant decrease lower leg volume compare continue receive nifedipine half patient receive nilvadipine nifedipine induced lower leg edema disappear completely difference see two substance term effectiveness tolerability,Vollmuth M,1994,Fortschr Med,,8088691,Vollmuth M; Schmitt W,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000368: Aged; D000959: Antihypertensive Agents; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004487: Edema; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine",,,https://openalex.org/W2418092749,125,21,2,1057,160,6,en,en
false,double blind placebo controlled trial sustained release diltiazem patient angina sustained release diltiazem study group,efficacy new sustained release formulation diltiazem examine placebo controlled double blind trial patient stable angina dos mg bid mg bid mg bid mg bid compare placebo patient hour hour dose diltiazem dos mg bid mg bid statistically superior placebo respect increase total exercise time treadmill exercise time hour postdose increase placebo sec sec ns mg bid sec sec p mg bid sec sec p hour postdose treadmill exercise time placebo increase sec sec ns mg bid sec sec p mg bid sec sec p time onset angina also increase mg bid dose hour postdose sec sec p hour postdose sec sec p sustained release diltiazem effective safe treat patient chronic stable angina,Weiss RJ,1993,Clin Ther,,8111804,Weiss RJ; Hicks D; Bittar N; Bowers J; Shah A,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000787: Angina Pectoris; D003692: Delayed-Action Preparations; D004110: Diltiazem; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005080: Exercise Test; D005260: Female; D006801: Humans; D008297: Male,,,https://openalex.org/W2442979133,137,18,2,1296,279,7,en,en
false,efficacy safety enalapril versus extended release nifedipine treatment mild moderate essential hypertension multicenter week study multicenter cooperative study group,antihypertensive effect tolerability single daily dos enalapril extended release nifedipine nifedipine er compare open label randomize parallel group week treatment study involve men woman mean age year follow week washout period mean sd blood pressure level mmhg enalapril group n mmhg nifedipine er group n begin mg daily enalapril mg daily nifedipine er dosage titrate every week week maximum mg enalapril mg nifedipine er treatment goal satisfactory response low trough sit diastolic blood pressure mmhg least mmhg level mmhg mean daily dose mg enalapril mg nifedipine er three quarter treatment group achieve satisfactory response mean reduction trough sit blood pressure level end week treatment mmhg enalapril mmhg nifedipine er difference treatment significant change systolic blood pressure p however enalapril well tolerate nifedipine er number patient adverse experience withdrawal study adverse experience significantly low enalapril nifedipine er p incidence abnormal laboratory finding small consider clinical importance either group data suggest enalapril nifedipine er approximately equal efficacy daily antihypertensive treatment enalapril well tolerate,Leon AS,1993,Clin Ther,,8111807,Leon AS,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D003692: Delayed-Action Preparations; D004334: Drug Administration Schedule; D004656: Enalapril; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D013997: Time Factors,,,https://openalex.org/W295291,195,26,2,1772,320,11,en,en
false,efficacy safety daily nifedipine coat core treatment mild moderate hypertension adalat cc cooperative study group,efficacy safety daily nifedipine coat core new extended release formulation examine patient essential hypertension week multicenter randomize double blind placebo controlled parallel group study mean net reduction trough supine diastolic blood pressure endpoint mmhg mmhg mmhg mg day nifedipine respectively reduction statistically significant compare placebo trough peak ratio supine diastolic blood pressure change follow mg day dos respectively adverse event generally mild moderate reflect vasodilatory property drug eg headache edema report adverse event decrease treatment progress nifedipine coat core tablet provide good control blood pressure entire hour dosing interval well tolerate majority patient study,Feig PU,1993,Clin Ther,,8111816,Feig PU; Gibson L; Mac Carthy EP; Pettis PP; Schwartz L,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D001794: Blood Pressure; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006207: Half-Life; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D016037: Single-Blind Method; D013607: Tablets,,,https://openalex.org/W2419374439,144,21,2,1001,176,7,en,en
false,safety efficacy daily nifedipine coat core combination atenolol hypertensive patient adalat cc cooperative study group,efficacy safety daily nifedipine coat core add regimen atenolol atn mg day compare atn placebo patient essential hypertension week multicenter randomize double blind placebo controlled parallel group study mean net reduction atn effect subtract supine diastolic blood pressure endpoint mmhg mmhg mmhg mg day nifedipine coat core respectively mmhg atn placebo beyond first week double blind therapy reduction produce nifedipine coat core combine atn statistically significant p compare atn placebo ambulatory blood pressure monitoring trough peak ratio change diastolic blood pressure mg day dos respectively adverse event generally mild moderate reflect vasodilatory property nifedipine eg edema headache nifedipine coat core combine atn patient control atn alone significant antihypertensive activity entire hour dosing interval well tolerate majority patient study,Mac Carthy EP,1993,Clin Ther,,8111817,Mac Carthy EP; Pettis PP; Gibson L; Schwartz L; Feig PU,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D001262: Atenolol; D001794: Blood Pressure; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D016037: Single-Blind Method; D013607: Tablets",,,https://openalex.org/W2432405488,148,22,2,1234,221,6,en,en
false,safety placebo controlled trial vasospastic angina,,Savonitto S,1994,J Am Coll Cardiol,https://doi.org/10.1016/0735-1097(94)90783-8,8113575,Savonitto S; Ardissino D,article,D016430: Clinical Trial; D016420: Comment; D016422: Letter; D016449: Randomized Controlled Trial,"D017311: Amlodipine; D000788: Angina Pectoris, Variant; D004311: Double-Blind Method; D006801: Humans; D016032: Randomized Controlled Trials as Topic; D012449: Safety",,,https://openalex.org/W2089895131,57,7,1,0,0,0,en,
false,pharmacokinetics dynamic response plain slow release isradipine formulation moderately hypertensive patient,abstract pharmacokinetic variable antihypertensive effect calcium antagonist isradipine investigate hypertensive patient isradipine give orally parallel group design plain slow release formulation dos mg twice daily mg daily respectively isradipine concentration serum measure sensitive ria method first dose week treatment pharmacokinetics concentration effect relationship first dose week treatment compare difference pharmacokinetics observe single multiple dosing data accordance result study healthy volunteer rate extent bioavailability differs two isradipine formulation antihypertensive efficacy two formulation similar mmhg significant time dependent increase e max mmhg mmhg week treatment observe,Christensen HR,1993,Pharmacol Toxicol,https://doi.org/10.1111/j.1600-0773.1993.tb00585.x,8115311,Christensen HR; Simonsen K; Kampmann JP,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D001794: Blood Pressure; D003692: Delayed-Action Preparations; D004305: Dose-Response Relationship, Drug; D005260: Female; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D008297: Male; D008954: Models, Biological",,,https://openalex.org/W2069841413,123,15,1,1018,166,8,en,en
true,post marketing surveillance lisinopril general practice uk,summary total patient patient treat lisinopril nifedipine respectively post marketing surveillance study conduct general practice uk patient follow month lisinopril patient hypertension small number heart failure nifedipine patient uncomplicated hypertension cardiovascular disease without hypertension lisinopril nifedipine equally effective reduce blood pressure study hypertensive patient assign lisinopril died compare patient assign nifedipine lisinopril patient compare patient nifedipine group withdraw adverse event cough malaise fatigue nausea vomiting frequent cause withdrawal lisinopril nifedipine conversely headache pallor flushing oedema palpitation cause frequent withdrawal nifedipine anaemia often encounter nifedipine treatment lisinopril hypertensive patient frequency first dose hypotension similar treatment serious event occur patient give lisinopril nifedipine respectively lisinopril well tolerate heart failure patient patient die incidence serious adverse event report pattern anticipate patient dizziness giddiness dyspnoea cough nausea vomiting frequent cause withdrawal incidence first dose hypotension low overall survey find adverse event already recognise controlled clinical trial show lisinopril effective well tolerated treatment hypertension heart failure,Fallowfield JM,1993,Br J Clin Pract,,8117550,Fallowfield JM; Blenkinsopp J; Raza A; Fowkes AG; Higgins TJ; Bridgman KM,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D016448: Multicenter Study,"D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D005194: Family Practice; D005260: Female; D006333: Heart Failure; D006801: Humans; D006973: Hypertension; D017706: Lisinopril; D008297: Male; D008875: Middle Aged; D017202: Myocardial Ischemia; D009543: Nifedipine; D011358: Product Surveillance, Postmarketing; D006113: United Kingdom",,,https://openalex.org/W197138820,71,10,1,1874,319,13,en,en
false,calcium antagonists really useful cerebral aneurysmal surgery retrospective study,patient one several cerebral arterial aneurysm surgically treat department since perform surgery early possible soon subarachnoid hemorrhage diagnosis confirm compute tomography unconfirmed lumbar puncture assume patient may aneurysm patient treat vascular volume expansion maintenance central venous pressure cm h albumin ringer lactate necessary albumin supplement calcium antagonist nimodipine patient nicardipine patient two month discharge patient examine neurosurgeon day subject neuropsychological evaluation computed tomographic scan brain month consultation working position family activities questionnaire issue patient result study basis postoperative mortality second month compute tomographic scan ischemia neuropsychological evaluation return work show significant difference group without calcium antagonist nimodipine nicardipine subgroup,Mercier P,1994,Neurosurgery,https://doi.org/10.1227/00006123-199409000-00037,8121567,Mercier P; Alhayek G; Rizk T; Fournier D; Menei P; Guy G,article,D003160: Comparative Study; D016428: Journal Article,"D000203: Activities of Daily Living; D000328: Adult; D000368: Aged; D002545: Brain Ischemia; D002121: Calcium Channel Blockers; D002533: Cerebral Angiography; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D002532: Intracranial Aneurysm; D002546: Ischemic Attack, Transient; D008297: Male; D008875: Middle Aged; D009483: Neuropsychological Tests; D009529: Nicardipine; D009553: Nimodipine; D011183: Postoperative Complications; D011292: Premedication; D011300: Preoperative Care; D012050: Rehabilitation, Vocational; D012189: Retrospective Studies; D013345: Subarachnoid Hemorrhage; D015996: Survival Rate",,,https://openalex.org/W2001714132,95,14,2,1290,220,7,en,en
false,nicardipine heart failure distinguish acute beneficial chronic effect,concern negative inotropic effect limit use calcium blocker patient congestive heart failure nicardipine second generation dihydropyridine calcium channel blocker demonstrate positive hemodynamic effect short term therapy patient congestive heart failure prolong use calcium channel blocker remain contraindicate patient congestive heart failure due potential activation renin angiotensin system however acute intravenous nicardipine administration important clinical application management surgical hypertension hypertensive emergency nicardipine may safely use indication even presence congestive heart failure,Sy J,1993,Minerva Cardioangiol,,8127455,Sy J; Vitarelli A; Gheorghiade M,article,D003160: Comparative Study; D016428: Journal Article; D016454: Review,"D000208: Acute Disease; D002121: Calcium Channel Blockers; D002908: Chronic Disease; D004280: Dobutamine; D004298: Dopamine; D004305: Dose-Response Relationship, Drug; D005260: Female; D006333: Heart Failure; D006439: Hemodynamics; D006801: Humans; D007275: Injections, Intravenous; D008297: Male; D009529: Nicardipine; D012084: Renin-Angiotensin System; D013997: Time Factors",,,https://openalex.org/W108383451,91,14,1,754,109,5,en,en
false,placebo necessary clinical trial ambulatory blood pressure,placebo slight effect ambulatory blood pressure abp author suggest use placebo necessary study drug effect abp demonstrate even placebo effect small use placebo group still necessary effect one daily dose mg atenolol mg slow released nifedipine investigate patient office dbp mmhg receive double blind protocol either group n placebo group p n ambulatory bp abp hr measure spacelabs diasys system h one month treatment group comparable treatment month treatment abp significantly low group compare p group whole day p p effect important h p hr significantly low group daytime h night h whole group placebo effect significant however abp decrease placebo subject high initial pressure result analysis without data placebo group lead overestimation effect drug,Chau NP,1993,Arch Mal Coeur Vaiss,,8129540,Chau NP; Chanudet X; Mestivier D; Nguyen G,article,D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D004740: English Abstract; D016428: Journal Article,D000328: Adult; D000368: Aged; D001262: Atenolol; D001794: Blood Pressure; D015924: Blood Pressure Monitors; D002986: Clinical Trials as Topic; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D010919: Placebos,,,https://openalex.org/W2408969561,73,15,2,1254,270,13,en,en
false,treatment arterial hypertension surgery abdominal aorta comparison captopril nifedipine administrate sublingually,treatment high blood pressure abdominal aortic surgery require adynamic ileus use intravenously sublingually sl administer drug hemodynamic response captopril mg sl n nifedipine mg sl n study hour patient mean age year arterial hypertension mean blood pressure pa mmhg day abdominal aortic surgery patient bilateral renal artery stenosis identify preoperative angiogram exclude systemic arterial pressure pulmonary vascular pressure measure use femoral catheter pulmonary artery catheter respectively cardiac output q determine thermodilution table see text captopril nifedipine significantly decrease pulmonary artery pressure pulmonary artery occlusion pressure right atrial pressure deterioration renal function observe conclusion captopril nifedipine sl effective well tolerate treatment high blood pressure abdominal aortic surgery,Leeman M,1993,Arch Mal Coeur Vaiss,,8129541,Leeman M; Degaute JP,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000286: Administration, Sublingual; D000368: Aged; D017544: Aortic Aneurysm, Abdominal; D002216: Captopril; D004341: Drug Evaluation; D006801: Humans; D006973: Hypertension; D008875: Middle Aged; D009543: Nifedipine; D011183: Postoperative Complications",,,https://openalex.org/W2414142342,141,21,1,1084,189,8,en,en
false,verapamil nifedipine combination treatment hypertension,author examine efficacy safety combination verapamil nifedipine control hypertension retrospective analysis blood pressure obtain patient historically document essential hypertension receive verapamil nifedipine patient moderate severe hypertension uncontrolled prescribed regimen two separate class drug control define ability maintain blood pressure provide dos verapamil max mg day nifedipine max mg day twenty nine black white age range year mean duration therapy year control failure provide verapamil nifedipine three discontinue side effect reversible hepatitis rash serious adverse event e chf arrhythmia manageable ankle edema see patient verapamil nifedipine combination dihydropyridine non dihydropyridine calcium antagonist effective safe group patient difficult manage hypertension,Kaesemeyer WH,1994,J Clin Pharmacol,https://doi.org/10.1002/j.1552-4604.1994.tb03965.x,8132851,Kaesemeyer WH; Carr AA; Bottini PB; Prisant LM,article,D016428: Journal Article,"D000293: Adolescent; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D001794: Blood Pressure; D004359: Drug Therapy, Combination; D004487: Edema; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D012189: Retrospective Studies; D014700: Verapamil",,,https://openalex.org/W2149561964,73,10,1,1233,238,12,en,en
false,use self measured blood pressure determination assess dynamic drug compliance study amlodipine day morning versus evening,test whether time administration influence therapeutic response calcium antagonist take day also dynamic drug compliance impact blood pressure control investigated twenty outpatient mild moderate hypertension include randomized placebo controlled open study crossover design patient receive mg amlodipine either morning evening two consecutive week treatment periods blood pressure take casual measurement ambulatory h monitoring spacelabs self measurement home perform semi automatic oscillometric device whole study period compliance assess use medication event monitoring system mem neither casual ambulatory day night time reading detect significant difference morning evening administration however self measurement document significantly great blood pressure reduction morning even administration mem show different compliance day ambulatory monitoring drug regimens compare whole treatment period number day missed medication thus significantly high evening dose regimen difference self measured blood pressure two regimen lose day missed medication remove statistical analysis time day amlodipine administration influence efficacy h blood pressure control furthermore use self measurement mem may provide useful additional information pharmacodynamic impact different dose pattern hypertensive patient,Mengden T,1993,J Hypertens,https://doi.org/10.1097/00004872-199312000-00013,8133022,Mengden T; Binswanger B; Spühler T; Weisser B; Vetter W,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D001794: Blood Pressure; D001795: Blood Pressure Determination; D004334: Drug Administration Schedule; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D008991: Monitoring, Physiologic; D010349: Patient Compliance; D012646: Self Administration; D012648: Self Care",,,https://openalex.org/W1992694553,157,25,1,1741,262,9,en,en
false,hemodynamic effect diaminopyridine swine model verapamil toxicity,study hypothesis diaminopyridine dap may reverse hemodynamic effect severe verapamil toxicity design nonblinded acute animal preparation intervention eighteen chloralose anesthetized instrumented swine poison verapamil mg kg hr five minute mg kg hr systolic blood pressure mm hg achieve heart rate lead ii ecg mean arterial pressure leave ventricular dp dt max cardiac index monitor nine control animal receive ml kg min infusion normal saline nine treatment animal receive similar volume mg kg min dap systolic blood pressure reach mm hg elapsed time minute death result verapamil toxicity produce animal follow average dose mg kg verapamil result diminished mean arterial pressure dp dt max cardiac index heart rate average value baseline value respectively transient atrioventricular dissociation note case dap treatment average dose mg kg result significant increase mean arterial pressure dp dt max cardiac index heart rate baseline value respectively mortality unchanged group dap treatment complicate muscle twitching tachycardia rate hypertension diastolic blood pressure mm hg case conclusion although dap reverse hypotensive negative inotropic effect verapamil toxicity fail improve survival result several complication include muscle twitching tachycardia hypertension study hypothesis diaminopyridine dap may reverse hemodynamic effect severe verapamil toxicity design nonblinded acute animal preparation intervention eighteen chloralose anesthetized instrumented swine poison verapamil mg kg hr five minute mg kg hr systolic blood pressure mm hg achieve heart rate lead ii ecg mean arterial pressure leave ventricular dp dt max cardiac index monitor nine control animal receive ml kg min infusion normal saline nine treatment animal receive similar volume mg kg min dap systolic blood pressure reach mm hg elapsed time minute death result verapamil toxicity produce animal follow average dose mg kg verapamil result diminished mean arterial pressure dp dt max cardiac index heart rate average value baseline value respectively transient atrioventricular dissociation note case dap treatment average dose mg kg result significant increase mean arterial pressure dp dt max cardiac index heart rate baseline value respectively mortality unchanged group dap treatment complicate muscle twitching tachycardia rate hypertension diastolic blood pressure mm hg case conclusion although dap reverse hypotensive negative inotropic effect verapamil toxicity fail improve survival result several complication include muscle twitching tachycardia hypertension,Plewa MC,1994,Ann Emerg Med,https://doi.org/10.1016/s0196-0644(94)70069-9,8135425,Plewa MC; Martin TG; Menegazzi JJ; Seaberg DC; Wolfson AB,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D015761: 4-Aminopyridine; D000077770: Amifampridine; D000818: Animals; D004195: Disease Models, Animal; D004305: Dose-Response Relationship, Drug; D005260: Female; D006439: Hemodynamics; D011041: Poisoning; D015221: Potassium Channels; D013552: Swine; D014700: Verapamil",,,https://openalex.org/W2001723888,81,11,1,3511,638,22,en,en
false,calcium antagonist induced gingival hyperplasia,brief reports april calcium antagonist induced gingival hyperplasiaruth steele pharmd arthur schuna rph ronald schreiber mdruth steele pharmdfrom william middleton memorial veteran hospital madison wisconsin search paper author arthur schuna rphfrom william middleton memorial veteran hospital madison wisconsin search paper author ronald schreiber mdfrom william middleton memorial veteran hospital madison wisconsin search paper authorauthor article disclosure informationhttps doi org sectionsaboutfull textpdf toolsadd favoritesdownload citationstrack citationspermissions sharefacebooktwitterlinkedinredditemail use calcium antagonist associate gingival tissue overgrowth report prevalence vary follow nifedipine diltiazem verapamil study determine prevalence gingival overgrowth patient whose know risk factor ingestion calcium antagonist identify difference prevalence among patient receive diltiazem verapamil nifedipine methodsour evaluator blinded case control cross sectional study hypertension general medicine geriatric outpatient clinic veteran affair hospital madison wisconsin november references ramon behar kishon engelberg gingival hyperplasia cause nifedipine preliminary report int j cardiol google scholar shaftic aa widdup abate jacknowitz ai nifedipine induced gingival hyperplasia drug intell clin pharm google scholar fattore l stablein bredfeldt g semla moran doherty greenberg jm gingival hyperplasia side effect nifedipine diltiazem special care dentistry google scholar physician desk reference th ed new jersey medical economics co google scholar miller c damm dd incidence verapamil induced gingival hyperplasia dental population j periodontol google scholar angelopoulos ap goaz pw incidence diphenylhydantoin gingival hyperplasia oral surg oral med oral pathol google scholar seymour ra calcium channel blocker gingival overgrowth br dent j google scholar hancock rh swan rh nifedipine induced gingival overgrowth report case treat control plaque j clin periodontol google scholar heijl l sundin nitrendipine induced gingival overgrowth dog j periodontol google scholar slavin j taylor j cyclosporin nifedipine gingival hyperplasia letter lancet google scholar author article disclosure informationaffiliations william middleton memorial veteran hospital madison wisconsin corresponding author ruth steele pharmd department pharmacy cook county hospital west polk suite chicago il acknowledgments author thank john tsunehiro dd william rick dd greg paprocki dd department dentistry william middleton memorial veteran hospital technical support department veteran affair research service editorial assistance previousarticlenextarticle advertisement figuresreferencesrelateddetails metric cite byassociations toothbrushing behaviour risk vascular nonvascular disease chinese adultsadverse effect medication periodontal tissuesdrug discovery periodontitisgingival fibromatosis clinical molecular therapeutic issuescalcium antagonist calcium channel blocker diltiazem une hyperplasie gingivale inhabituellepattern gingival overgrowth among patient antihypertensive pharmacotherapy nairobi hospital kenyatwo case drug induced gingival overgrowth improve periodontal initial therapydrug induced gingival overgrowth study french pharmacovigilance databasegingival enlargementthe oral cavity lipsdiltiazemgingival hyperplasia associate administration amlodipine dog degenerative valvular disease hypertension practice towards year referencespharmacologic therapeutic consideration hypertension therapy calcium channel blocker focus verapamilpathologie buccodentaire et sa prise en charge chez les insuffisants r naux chroniqueseffect phenytoin collagen accumulation human gingival fibroblast expose tnf alphain vitrofelodipine influenced gingival enlargement uncontrolled type diabetic patientprevalence risk gingival overgrowth patient treat diltiazem verapamilon relation nitric oxide nifedipine induced gingival hyperplasia impaired submandibular gland function rat vivocalcium antagonistsgingival enlargement child treat antiepilepticscathepsin l key molecule pathogenesis drug induced cell disease mediated gingival overgrowthcalcium channel blocker induce gingival overgrowthdrug induced gingival hyperplasia transplant recipientsprevalence risk gingival enlargement patient treat anticonvulsant drugsprevalence risk gingival enlargement patient treat nifedipinekalziumantagonistenthe role drug pathogenesis gingival overgrowth collective review current conceptsmedically induced gingival hyperplasianifedipine induced gingival overgrowth rat brief review experimental studysystolic hypertension elderlyprevalence amlodipine related gingival hyperplasiametabolism phenytoin gingiva normal human possible role reactive metabolities phenytoin initiation gingival hyperplasia effect phenytoin plasma high density lipoprotein cholesterol level men low level high density lipoprotein cholesterol adrenoceptor antagonist antianginal drugsdiltiazem nifedipine verapamilcalcium antagonist calcium channel blocker april volume issue page keywordscalciumcalcium antagonist therapydrug regulationdrugshemorrhagehospital medicinehygieneinflammationmouthoutpatient clinic issue publish april copyrightcopyright american college physician right reserved pdf downloadloading,Steele RM,1994,Ann Intern Med,https://doi.org/10.7326/0003-4819-120-8-199404150-00006,8135450,Steele RM; Schuna AA; Schreiber RT,article,D016430: Clinical Trial; D016428: Journal Article,D000328: Adult; D000368: Aged; D002121: Calcium Channel Blockers; D003430: Cross-Sectional Studies; D004110: Diltiazem; D005885: Gingival Hyperplasia; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D016037: Single-Blind Method; D014700: Verapamil,,,https://openalex.org/W2065605784,47,4,1,6550,962,52,en,en
false,comparison effect nifedipine verapamil exercise performance patient mild moderate hypertension,twenty four patient complete double blind randomize clinical trial compare effect nifedipine git n verapamil sr v blood pressure bp control exercise performance week placebo phase subject measurement vo max maximal workload endurance time randomize either n mg day v mg day retested bps stabilize rest n lower systolic bp mm hg p compare baseline diastolic bp mm hg p v lower sbp mm hg p dbp mm hg p neither drug affect rest heart rate v significantly decrease rest epinephrine p tendency v reduce norepinephrine p dopamine p n tend increase plasma renin activity p graded cycle ergometry n compare placebo significantly lower dbp exercise level p significant effect heart rate hr sbp heart rate pressure product hrpp pulse pressure pp significantly increase p noticeable high exercise level compare placebo v cause marked reduction exercise hr p pronounced high level sbp p dbp p mean arterial pressure map p hrpp p abstract truncate word,Halperin AK,1993,Am J Hypertens,https://doi.org/10.1093/ajh/6.12.1025,8136093,Halperin AK; Icenogle MV; Kapsner CO; Chick TW; Roehnert J; Murata GH,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D004311: Double-Blind Method; D005080: Exercise Test; D006439: Hemodynamics; D006728: Hormones; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D005082: Physical Exertion; D014700: Verapamil,,,https://openalex.org/W2406620263,126,19,1,1425,334,12,en,en
false,calcium antagonist treatment diabetes associated hypertension,hypertensive diabetic strict blood pressure control may decrease incidence cardiovascular diabetic complication long term experience use calcium antagonist still limit metabolic renal effect long term month therapy amlodipine mg daily study hypertensive patient uncomplicated diabetes mellitus compare patient essential hypertension week placebo phase diabetic essential hypertensive patient differ mean blood pressure v mm hg body weight creatinine clearance microalbumin excretion c peptide lipid level serum fructosamine higher diabetic group amlodipine cause significant long lasting decrease arterial pressure modify creatinine clearance microalbumin excretion serum lipid level diabetic index diabetic control insulin glucose response oral glucose tolerance test unchanged whereas essential hypertension insulin response glucose load decrease p amlodipine exert comparable long lasting antihypertensive effect hypertensive diabetic patient essential hypertension despite significant decrease arterial pressure change urinary microalbumin excretion lipid metabolism quality diabetic control insulin response glucose load affect unfavorably,Zanetti-Elshater F,1994,Am J Hypertens,https://doi.org/10.1093/ajh/7.1.36,8136109,Zanetti-Elshater F; Pingitore R; Beretta-Piccoli C; Riesen W; Heinen G,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article,D000328: Adult; D000368: Aged; D000419: Albuminuria; D017311: Amlodipine; D001786: Blood Glucose; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D048909: Diabetes Complications; D003920: Diabetes Mellitus; D005260: Female; D006801: Humans; D006973: Hypertension; D007328: Insulin; D008297: Male; D008875: Middle Aged; D012084: Renin-Angiotensin System,,,https://openalex.org/W2462166651,69,7,1,1533,255,9,en,en
false,verapamil treatment coronary angioplasty patient high risk recurrent stenosis,objective evaluate efficacy high dose verapamil treatment mg twice daily prevention angiographic restenosis primary successful coronary angioplasty patient high risk recurrent obstruction design placebo control double blind trial patient stable angina pectoris patient unstable angina non q wave infarction treat mg aspirin mg dipyridamole twice daily randomise verapamil group control group follow angiography perform month angioplasty sooner sign recurrent ischaemia develop setting university department cardiology patient consecutive patient undergo coronary angioplasty beginning april end march meet selection criterion include presence least one six predefined risk factor restenosis time coronary angioplasty patient unstable angina non q wave infarction stable angina pectoris result patient verapamil group control patient follow angiogram available restenosis rate low verapamil group placebo group odds ratio confidence interval ci p patient follow angiogram available take verapamil take placebo comply trial day mean sd remain patient restenosis rate verapamil group placebo group odds ratio ci p patient unstable angina non q wave infarction restenosis rate significantly influence verapamil verapamil v placebo odds ratio ci p patient stable angina pectoris restenosis rate drop placebo verapamil odds ratio ci p conclusion observed beneficial effect high dose verapamil treatment angiographic restenosis rate patient stable angina pectoris increase risk recurrent obstruction require confirmation prospective study,Hoberg E,1994,Br Heart J,https://doi.org/10.1136/hrt.71.3.254,8142195,Hoberg E; Dietz R; Frees U; Katus HA; Rauch B; Schömig A; Schuler G; Schwarz F; Tillmanns H; Niebauer J,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D015906: Angioplasty, Balloon, Coronary; D001241: Aspirin; D017023: Coronary Angiography; D003327: Coronary Disease; D004176: Dipyridamole; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D012008: Recurrence; D012307: Risk Factors; D014700: Verapamil",,,https://openalex.org/W1972179323,94,14,1,2346,445,13,en,en
false,experience amlodipine norvasc management arterial hypertension,author report result therapy amlodipine patient mild moderate hypertension diastolic pressure mmhg amlodopine administer dose either mg day week none patient history congestive heart failure eleven patient men year age average age year significant decrease systolic blood pressure mm hg diastolic blood pressure mm hg heart rate remain beat per minute one patient experience palpitation two complain mild transient giddiness therapy,Rodríguez N,1993,Rev Med Panama,,8146352,Rodríguez N; Domínguez B,article,D004740: English Abstract; D016428: Journal Article,D000328: Adult; D000368: Aged; D017311: Amlodipine; D001794: Blood Pressure; D002908: Chronic Disease; D004341: Drug Evaluation; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged,,,https://openalex.org/W122032734,82,15,1,716,143,7,en,en
false,effect nisoldipine diltiazem systolic diastolic function left ventricle patient coronary heart disease,objective background calcium channel blocker negative inotropic effect protract relaxation normal myocardium effect may vary patient coronary artery disease cad different kind calcium antagonist present study therefore compare hemodynamic effect intravenously give equihypotensive dosage diltiazem nisoldipine n patient cad method result group contain patient administration bolus micrograms kg micrograms kg n respectively follow continuous infusion micrograms kg min micrograms kg min n respectively mean arterial pressure reduce n mm hg atrial pacing perform patient avoid reflectory heart rate effect pulmonary artery pressure decrease slightly drug whereas cardiac index increase use n l min x l min x significant change maximal rate rise left ventricular pressure dp dt max index inotropy detect n parameter diastolic function time constant ventricular relaxation tau maximum rate left ventricular isovolumic pressure decline dp dt min also indicate unequivocal drug effect doppler echocardiography mitral valve flow perform simultaneously invasive pressure measurement flow propagation derive color mode correlate significantly tau slightly improve abstract truncate word,Fehske W,1994,Z Kardiol,,8147070,Fehske W; Niedeggen A; Omran H; Pizzulli L; Manz M; Lüderitz B,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D003327: Coronary Disease; D003971: Diastole; D004110: Diltiazem; D015150: Echocardiography, Doppler; D005080: Exercise Test; D005260: Female; D006439: Hemodynamics; D006801: Humans; D007262: Infusions, Intravenous; D008297: Male; D008875: Middle Aged; D015737: Nisoldipine; D013599: Systole; D016277: Ventricular Function, Left",,,https://openalex.org/W2400178603,135,23,1,1664,296,10,en,en
false,antihypertensive efficacy slow release nifedipine tablet formulation give daily patient mild moderate hypertension placebo controlled double blind parallel group trial,double blind randomize parallel group multi center study antihypertensive efficacy slow release tablet contain mg nifedipine aprical long cas investigate two weeks wash previous antihypertensive medication two weeks placebo run period patient gender diastolic blood pressure mmhg receive either nifedipine placebo week blood pressure measure end dose interval rest semi automatic auscultatory device control measurement record use standard cuff sphygmomanometer primary efficacy criterion drop diastolic blood pressure dbp measure semi automatically week therapy patient randomize nifedipine placebo patient complete protocol nifedipine placebo however patient bp measurement record appropriately semi automatic device nifedipine placebo nifedipine group blood pressure fell mmhg mmhg blood pressure placebo determine mmhg treatment mmhg end study heart rate affect treatment confidence interval difference mean fall dbp range mmhg point estimator mmhg end study patient nifedipine patient placebo dbp mmhg decrease dbp mmhg abstract truncate word,Harder S,1994,Arzneimittelforschung,,8147945,Harder S; Rietbrock S; Thürmann P,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000368: Aged; D001794: Blood Pressure; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine,,,https://openalex.org/W2462151943,195,27,2,1648,317,14,en,en
false,effect tissue plasminogen activator comparison early invasive conservative strategy unstable angina non q wave myocardial infarction result timi iiib trial thrombolysis myocardial ischemia,although coronary thrombosis play critical role pathogenesis unstable angina non q wave myocardial infarction nqmi effect thrombolytic therapy disorder clear also role routine early coronary arteriography follow revascularization established patients n see within hour ischemic chest discomfort rest consider represent unstable angina nqmi randomize use x factorial design compare tpa versus placebo initial therapy early invasive strategy early coronary arteriography follow revascularization anatomy suitable versus early conservative strategy coronary arteriography follow revascularization initial medical therapy fail patient treat bed rest anti ischemic medication aspirin heparin primary end point tpa placebo comparison death myocardial infarction failure initial therapy week occur tpa treated patient placebo treated patient p n fatal nonfatal myocardial infarction randomization reinfarction nqmi patient occur frequently tpa treated patient placebo treated patient p kaplan meier estimate four intracranial hemorrhage occur tpa treated group versus none placebo treated group p end point comparison two strategy death myocardial infarction unsatisfactory symptom limited exercise stress test week occur patient assign early conservative strategy patient assign early invasive strategy p n latter average length initial hospitalization incidence rehospitalization within week day rehospitalization significantly lower overall trial patient unstable angina nqmi manage low rate mortality myocardial infarction reinfarction time week visit result achieve use either early conservative early invasive strategy latter resulting reduced incidence day hospitalization rehospitalization use antianginal drug addition thrombolytic agent beneficial may harmful,,1994,Circulation,https://doi.org/10.1161/01.cir.89.4.1545,8149520,,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.","D000789: Angina, Unstable; D015906: Angioplasty, Balloon, Coronary; D006328: Cardiac Catheterization; D017023: Coronary Angiography; D005260: Female; D006801: Humans; D007902: Length of Stay; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D009204: Myocardial Revascularization; D016016: Proportional Hazards Models; D012008: Recurrence; D015912: Thrombolytic Therapy; D013997: Time Factors; D010959: Tissue Plasminogen Activator",,,https://openalex.org/W2537589444,228,34,3,2409,422,10,en,en
false,long term open evaluation amlodipine v hydrochlorothiazide patient essential hypertension,long term efficacy safety amlodipine mg daily compare hydrochlorothiazide hctz mg daily patient mild moderate hypertension study randomized open label parallel comparison week duration patient randomize ratio amlodipine n hctz n atenolol add week monotherapy inadequate week mean reduction supine stand systolic diastolic blood pressure value amlodipine find mmhg mmhg respectively compare mmhg mmhg treatment hctz percentage patient respond treatment week amlodipine hctz addition atenolol patient adequately control monotherapy produce additional mean reduction supine stand systolic diastolic pressure amlodipine atenolol group hctz atenolol group incidence adverse effect amlodipine hctz week overall six patient discontinue side effect receive amlodipine monotherapy one hctz monotherapy group none discontinue side effect combination therapy laboratory test abnormality report amlodipine treated patient compare patient hctz antihypertensive effect amlodipine hydrochlorothiazide appear comparable maintain long term therapy,Adolphe AB,1993,Int J Clin Pharmacol Res,,8150546,Adolphe AB; Vlachakis ND; Rofman BA; Brescia D; Zellner SR,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D017311: Amlodipine; D001794: Blood Pressure; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D008297: Male",,,https://openalex.org/W114969519,103,13,1,1593,273,11,en,en
false,effect vasopressin nicardipine hemodynamics liver function patient cirrhosis comparison vasopressin alone,effect combination vasopressin calcium channel blocker nicardipine portohepatic hemodynamics liver function compare effect vasopressin alone patient portal hypertension nine patient receive units min vasopressin patient receive dose vasopressin plus mg min nicardipine min vasopressin plus nicardipine induce significant reduction free portal venous pressure portal venous pressure gradient effect similar change vasopressin alone vs free portal venous pressure vs portal venous pressure gradient vasopressin decrease hepatic blood flow p intrinsic clearance indocyanine green p contrast two parameter significantly change vasopressin plus nicardipine respectively result suggest addition nicardipine improves hepatic impairment induce vasopressin cause reduction portal pressure,Iwao T,1993,J Hepatol,https://doi.org/10.1016/s0168-8278(05)80542-2,8151095,Iwao T; Toyonaga A; Ikegami M; Oho K; Sumino M; Sakaki M; Shigemori H; Nakayama M; Sasaki E; Tanikawa K,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D004359: Drug Therapy, Combination; D005260: Female; D006439: Hemodynamics; D006801: Humans; D006975: Hypertension, Portal; D008099: Liver; D008103: Liver Cirrhosis; D008297: Male; D008875: Middle Aged; D009529: Nicardipine; D013152: Splanchnic Circulation; D014667: Vasopressins",,,https://openalex.org/W1988007231,135,19,1,1088,191,7,en,en
false,double blind comparison amlodipine nifedipine retard treatment mild moderate hypertension,efficacy safety profile amlodipine mg daily nifedipine retard mg twice daily compare hypertensive patient sit dbp mmhg eight week treatment randomised double blind parallel group study bp measure hour daily dose amlodipine hour dose nifedipine retard baseline sit bps mmhg mmhg significantly reduce p mmhg mmhg end treatment response mean daily dos amlodipine mg nifedipine retard mg clinically significant change heart rate either treatment three patient amlodipine group five patient nifedipine retard group could consider analysis total number adverse event consider relate possibly relate treatment vs well number patient experience event vs similar amlodipine nifedipine retard treat group respectively great incidence headache response nifedipine retard oedema response amlodipine five patient treatment group discontinue therapy due event overall result show daily amlodipine equivalent twice daily nifedipine retard management mild moderate hypertension,Lorimer AR,1994,J Hum Hypertens,,8151609,Lorimer AR; Anderson JA; Laher MS; Davies J; Lazarus JH; Taylor SH; Sanghera S,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D000375: Aging; D017311: Amlodipine; D001794: Blood Pressure; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine,,,https://openalex.org/W84577353,110,16,1,1419,251,8,en,en
false,efficacy flecainide patient supraventricular arrhythmia respiratory insufficiency,objective evaluation efficacy intravenous flecainide revert supraventricular arrhythmia sinus rhythm patient respiratory insufficiency design comparative randomize prospective trial setting icu university hospital patient patient acute respiratory insufficiency acute exacerbation chronic respiratory insufficiency supraventricular arrhythmia intravenous flecainide administer patient group mg kg min continuous perfusion mg kg h intravenous verapamil administer patient group b mg kg min continuous perfusion mg kg min h measurement result category patient arrhythmia group atrial fibrillation af case atrial flutter afl multifocal atrial tachycardia mat supraventricular tachycardia svt group b af case afl mat svt case flecainide revert arrhythmia sinus rhythm case revert initial bolus verapamil revert case p significant secondary adverse effect detect conclusion intravenous flecainide effective antiarrhythmic drug treat acute supraventricular arrhythmia patient respiratory insufficiency,Barranco F,1994,Intensive Care Med,https://doi.org/10.1007/bf02425054,8163757,Barranco F; Sanchez M; Rodriguez J; Guerrero M,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000208: Acute Disease; D000368: Aged; D000369: Aged, 80 and over; D001145: Arrhythmias, Cardiac; D016009: Chi-Square Distribution; D004562: Electrocardiography; D005260: Female; D005424: Flecainide; D006801: Humans; D007262: Infusions, Intravenous; D008173: Lung Diseases, Obstructive; D008297: Male; D008875: Middle Aged; D012131: Respiratory Insufficiency; D014700: Verapamil",,,https://openalex.org/W2054935293,98,11,1,1372,250,12,en,en
false,comparative study efficacy tolerability bepridil diltiazem unstable angina patient,bepridil use rarely unstable angina since long half life could imply delayed action loading dose could deal disadvantage order confirm hypothesis randomised trial undertaken involve day comparison bepridil dose mg day loading dose mg mg diltiazem mg day patient men woman mean age suffer unstable angina confirm ecg symptomatic event show reversible st depression continuous hour ecg record obtain patient inclusion error patient provide evaluable data bepridil diltiazem include continuous ecg mortality bepridil v diltiazem premature treatment termination therapeutic inefficacy bepridil v diltiazem myocardial infarction bepridil v diltiazem adverse event bepridil v diltiazem patient request bepridil similar group efficacy regard angina similar recurrence bepridil diltiazem first hour persist without difference beyond hour result treatment adjustment concern nitrate identical group among patient evaluable continuous ecg bepridil diltiazem n recurrent ischemic episode bepridil diltiazem clinically silent total number total duration maximum amplitude st depression similar group abstract truncate word,Bory M,1994,Ann Cardiol Angeiol (Paris),,8172482,Bory M; Quilliet L,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000368: Aged; D000789: Angina, Unstable; D015764: Bepridil; D001794: Blood Pressure; D017023: Coronary Angiography; D004110: Diltiazem; D004341: Drug Evaluation; D004562: Electrocardiography; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2408599749,112,20,2,1694,326,11,en,en
false,improve antihypertensive efficacy felodipine metoprolol extended release tablet compare drug alone,double blind randomise three way crossover latin square design multicentre study aim compare efficacy tolerability fixed combination felodipine metoprolol individual component monotherapy total patient supine diastolic blood pressure mmhg treat fixed combination felodipine plus metoprolol mg fm felodipine mg f metoprolol mg week treatment extended release formulation administer daily blood pressure measure h dose dose titration perform week diastolic blood pressure mmhg week active treatment mean supine blood pressure mmhg fm f respectively mean difference systolic diastolic blood pressure mmhg p p mmhg p p mmhg p p fm v f fm v f v respectively blood pressure control supine diastolic blood pressure mmhg week achieve significantly great proportion patient treatment fm f control respective treatment fm patient take high dose week treatment corresponding figure f respectively thirteen patient control fm abstract truncate word,Dahlöf B,1993,Blood Press Suppl,,8173689,Dahlöf B; Jönsson L; Borgholst O; Ekblad G; Engstrand C; Grundestam I; Lindh A,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D001835: Body Weight; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004338: Drug Combinations; D004562: Electrocardiography; D015736: Felodipine; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008790: Metoprolol; D008875: Middle Aged,,,https://openalex.org/W2281593419,118,14,1,1583,321,11,en,en
false,antihypertensive therapy circadian blood pressure profile retrospective analysis utilise cumulative sum,result previous study effect antihypertensive agent circadian blood pressure pattern inconclusive possibly due lack simple objective universally accept method quantify circadian blood pressure profile order investigate difference effect antihypertensive drug circadian change utilise recently describe modified cumulative sum technique quantify circadian alteration magnitude cam cam simply calculate difference crest trough blood pressure mean blood pressure h period high low sustain pressure respectively record h ambulatory blood pressure monitoring perform year period subject either medication treatment single first line antihypertensive agent examine retrospectively sample n stratify trough diastolic blood pressure age sex randomly select follow group subject medication subject treat bendrofluazide atenolol class calcium channel blocker captopril alone untreated subject bendrofluazide class calcium channel blocker similar circadian pattern subject atenolol therapy systolic cam se diastolic cam se attenuate circadian change p compare untreated group captopril exhibit markedly increase systolic diastolic circadian blood pressure swing differ atenolol treat group p abstract truncate word,Stanton A,1993,Blood Press,https://doi.org/10.3109/08037059309077170,8173698,Stanton A; Atkins N; O'Brien E; O'Malley K,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002940: Circadian Rhythm; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D012189: Retrospective Studies,,,https://openalex.org/W2116265947,114,14,1,1746,301,8,en,en
false,nordic diltiazem study nordil prospective intervention trial calcium antagonist therapy hypertension,nordil nordic diltiazem intervention study start september trial prospective randomize open blinded endpoint probe multicenter parallel group study conduct norway sweden study design evaluate potential preventive effect diltiazem compare conventional antihypertensive drug treatment primary endpoint cardiovascular mortality define fatal acute myocardial infarction fatal acute cerebrovascular disease stroke sudden death fatal cardiovascular disease well cardiovascular morbidity define myocardial infarction cerebrovascular disease stroke secondary endpoint total mortality development deterioration ischaemic heart disease congestive heart failure atrial fibrillation transient ischaemic attack diabetes mellitus renal insufficiency male female patient age primary hypertension randomly allocate therapy start either diltiazem mg daily conventional treatment diuretic beta adrenergic blocker add therapy conventional treatment group exclude type calcium antagonist goal treatment target diastolic blood pressure mmhg diastolic blood pressure reduction nordil study allow detection difference cardiovascular mortality two group power significance level two sided test total patient recruit primary health care center hospital base hypertension unit patient treat average period year,,1993,Blood Press,https://doi.org/10.3109/08037059309077174,8173702,,article,D016428: Journal Article; D016454: Review,D000368: Aged; D004110: Diltiazem; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D016032: Randomized Controlled Trials as Topic,,,https://openalex.org/W2056242350,118,19,2,1673,272,11,en,en
false,comparison amlodipine nifedipine retard preparation treatment arterial hypertension,efficacy acceptability amlodipine mg sustained release nifedipine mg b compare multicenter double blind clinical trial two week placebo period essential hypertensive sex age year diastolic blood pressure mmhg randomly allocate either amlodipine mg daily group nifedipine mg twice daily group b respect blood pressure response initial dose double two week significant difference blood pressure record baseline end placebo period demonstrate significant reduction systolic diastolic blood pressure supine position observe already two day start treatment group decrease mm hg p group b mm hg p similar change blood pressure observe standing position well end study overall reduction supine diastolic blood pressure group versus group b p standing position amlodipine decrease diastolic blood pressure nifedipine p furthermore amlodipine decrease stand diastolic blood pressure great extent versus p nifedipine abstract truncate word,Pivac N,1993,Lijec Vjesn,,8176999,Pivac N; Dobovisek J; Bagatin J; Gros Furek V; Rumboldt Z; Janezić A; Kveder R; Sjerobabski V; Simunić M; Sardelić S,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D017311: Amlodipine; D001794: Blood Pressure; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine,,,https://openalex.org/W82813214,107,17,1,1536,304,13,en,en
false,twenty four hour profile anti hypertensive action isradipine essential hypertension,isradipine mg twice daily placebo administer week untreated essential hypertensive double blind random order crossover study end phase patient assess h continuous intra arterial blood pressure monitoring surface electrocardiography measurement endogenous creatinine clearance serum biochemistry plasma renin activity arterial pressure significantly reduce isradipine mean reduction systolic blood pressure mmhg diastolic pressure mmhg h significant change heart rate endogenous creatinine clearance serum biochemistry plasma renin activity,Low CJ,1993,Blood Press,https://doi.org/10.3109/08037059309077528,8193733,Low CJ; Foy SG; Chaudhary H; Crozier IG; Baskaranathan S; Ikram H,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D001794: Blood Pressure; D002940: Circadian Rhythm; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D008297: Male; D008875: Middle Aged,,,https://openalex.org/W2021227402,96,12,1,692,111,3,en,en
false,clinical assessment gingival hyperplasia patient treat nifedipine,gingival hyperplasia cause use nifedipine extensively report paper gingiva patient suffer cardiopathy treat nifedipine compare patient cardiac disorder treat calcium antagonist treatment group patient nifedipine produce gingival hyperplasia although patient treat calcium antagonist also mild hyperplasia hyperplasia first appear interproximal area observation may important early detection direct correlation degree hyperplasia bacterial plaque score study influence administration time dose nifedipine degree hyperplasia statistically significant difference find,Bullon P,1994,J Clin Periodontol,https://doi.org/10.1111/j.1600-051x.1994.tb00314.x,8195441,Bullon P; Machuca G; Martinez-Sahuquillo A; Rios JV; Rojas J; Lacalle JR,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D003774: Dental Plaque Index; D004305: Dose-Response Relationship, Drug; D005260: Female; D005884: Gingival Hemorrhage; D005885: Gingival Hyperplasia; D006801: Humans; D008297: Male; D017202: Myocardial Ischemia; D009543: Nifedipine; D009910: Oral Hygiene; D013997: Time Factors",,,https://openalex.org/W2053065370,79,10,1,848,135,6,en,en
false,effect bepridil silent myocardial ischemia eicosanoid metabolism chronic stable angina pectoris heal myocardial infarction,investigate effect bepridil silent myocardial ischemia eicosanoid metabolism patient chronic stable angina underwent exercise treadmill test hour ambulatory electrocardiographic monitor week bepridil administration mg day fast venous level thromboxane b keto prostaglandin f leukotriene c measure radioimmunoassay bepridil decrease heart rate response daily activity ambulatory monitoring significantly p reduce median frequency duration silent myocardial ischemic episode events hour minutes hour respectively bepridil significantly decrease blood pressure heart rate product peak exercise significantly prolong mean exercise tolerance time second bepridil also significantly decrease plasma level thromboxane b leukotriene c rest result suggest bepridil may reduce silent myocardial ischemic episode either reduction cardiac oxygen demand daily activity exercise stress control coronary systemic vasomotor tone drug also salutary effect eicosanoid metabolism efficacy silent myocardial ischemic episode may relate,Takase B,1994,Am J Cardiol,https://doi.org/10.1016/0002-9149(94)90284-4,8198031,Takase B; Kurita A; Hikita H; Uehata A; Nishioka T; Maruyama T; Mizuno K; Nakamura H; Kanda Y,article,D016430: Clinical Trial; D016428: Journal Article,"D015121: 6-Ketoprostaglandin F1 alpha; D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D001095: Arachidonic Acids; D015764: Bepridil; D002908: Chronic Disease; D015716: Electrocardiography, Ambulatory; D005080: Exercise Test; D005260: Female; D006339: Heart Rate; D006801: Humans; D017997: Leukotriene C4; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D017202: Myocardial Ischemia; D011863: Radioimmunoassay; D016037: Single-Blind Method; D013929: Thromboxane B2",,,https://openalex.org/W2063444516,148,20,1,1354,212,7,en,en
false,felodipine metoprolol combination compare placebo isolated systolic hypertension elderly,study compare placebo efficacy tolerability optimised dos felodipine mg daily metoprolol mg daily combination subject year isolated systolic hypertension study employ randomised double blind crossover design allocation treatment order within subject latin square subject single blind run placebo phase four randomise treatment phase six week duration dose titration step three week necessary twenty eight subject enter randomised phase study twenty one complete four phase male female age median range year end felodipine metoprolol phase systolic diastolic pressure reduce hour postdose compare placebo phase p blood pressure reduction felodipine mmhg great metoprolol mmhg p immediately predose hour postdose persisting reduction supine systolic blood pressure mmhg felodipine p significant effect metoprolol measurement time two drug combination additive effect blood pressure increase reported symptom active treatment phase four subject withdraw randomised phase probable drug related adverse event six subject require dosage reduction felodipine combination phase abstract truncate word,Wing LM,1994,Blood Press,https://doi.org/10.3109/08037059409101526,8199723,Wing LM; Russell AE; Tonkin AL; Bune AJ; West MJ; Chalmers JP,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D001794: Blood Pressure; D004311: Double-Blind Method; D004338: Drug Combinations; D015736: Felodipine; D005260: Female; D006339: Heart Rate; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D008297: Male; D008790: Metoprolol; D008875: Middle Aged; D010919: Placebos; D013599: Systole",,,https://openalex.org/W1980547742,115,16,1,1612,284,10,en,en
false,mono combination therapy felodipine enalapril elderly patient systolic hypertension,use randomised double blind crossover design latin square allocation treatment subject male female ages year systolic hypertension investigate efficacy tolerability daily felodipine extended release mg enalapril mg combination compare placebo four treatment phase week duration phase dos titrate achieve predose clinic supine systolic blood pressure mmhg predetermine maximum dose felodipine combination phase predose supine stand systolic diastolic pressure significantly reduce compare placebo phase decrease supine pressure respectively predose supine diastolic pressure significantly reduce mmhg compare placebo enalapril phase combination effect two drug predose blood pressure additive increase report symptom felodipine combination phase compare placebo enalapril phase thus elderly subject systolic hypertension felodipine effectively reduce blood pressure throughout dose interval vasodilator adverse effect contrast enalapril well tolerate less effective reduce blood pressure throughout whole dose interval,Wing LM,1994,Blood Press,https://doi.org/10.3109/08037059409101527,8199724,Wing LM; Russell AE; Tonkin AL; Watts RW; Bune AJ; West MJ; Chalmers JP,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D001794: Blood Pressure; D004338: Drug Combinations; D004656: Enalapril; D015736: Felodipine; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D013599: Systole",,,https://openalex.org/W2106079532,105,14,1,1396,231,8,en,en
false,effect calcium antagonist renal hemodynamics progression nondiabetic chronic renal disease,recent year substantial investigative attention focus therapeutic regimen could retard progression chronic renal insufficiency emphasis place effect antihypertensive treatment renal hemodynamics preservation renal function suggest class antihypertensive agent may confer great renoprotective effect especially agent low glomerular capillary pressure conversely virtue ability preferentially dilate afferent arteriole calcium antagonist theoretically could favor increase glomerular capillary pressure thereby accelerate decline renal function review survey literature critically conclude patient essential hypertension patient chronic renal insufficiency calcium antagonist effectively reduce systemic blood pressure maintain glomerular filtration rate effective renal plasma flow preliminary result long term study suggest calcium antagonist may even attenuate decline renal function patient chronic renal failure majority study human however nonrandomized short duration confound investigative difficulty preclude definite conclusion whether calcium antagonist renoprotective effect although possibility calcium antagonist may retard progression renal disease remain ascertain available evidence indicate calcium antagonist may use patient renal functional impairment without exacerbate renal function,ter Wee PM,1994,Arch Intern Med,https://doi.org/10.1001/archinte.1994.00420110021004,8203987,ter Wee PM; De Micheli AG; Epstein M,article,D016428: Journal Article; D016454: Review,"D000818: Animals; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002986: Clinical Trials as Topic; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D007668: Kidney; D007676: Kidney Failure, Chronic; D012079: Renal Circulation",,,https://openalex.org/W2148748683,105,14,1,1656,238,8,en,en
false,effect isradipine cyclosporin related hypertension,evidence calcium antagonist may beneficial effect cyclosporin cya induced hypertension organ transplantation double blind control trial consecutive non diabetic first kidney transplant recipient randomize receive either isradipine dihydropyridine calcium antagonist placebo significant difference age weight gender warm cold ischaemic period original renal disease treatment group treatment start intravenously h transplantation procedure subsequently continue orally month immunosuppressive treatment include oral cya day short course anti lymphocyte immunoglobulin hypertension treat oral labetolol combination guanfacine necessary antihypertensive medication prescribe significantly often vs patient p placebo group stand systolic blood pressure significantly low isradipine group stand diastolic systolic diastolic sit blood pressure similar group month patient mean serum creatinine significantly low isradipine placebo vs mumol l p isradipine significantly high dose cya need achieve adequate plasma level vs mg kg day p conclude isradipine effective antihypertensive agent kidney transplantation may influence cya metabolism furthermore isradipine appear ameliorate cya induced nephropathy,van den Dorpel MA,1994,Blood Press Suppl,,8205301,van den Dorpel MA; Zietse R; Ijzermans JN; Schalekamp MA; Weimar W,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D001794: Blood Pressure; D016572: Cyclosporine; D004311: Double-Blind Method; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D016030: Kidney Transplantation; D011182: Postoperative Care; D011446: Prospective Studies,,,https://openalex.org/W2429410139,59,8,1,1662,271,13,en,en
false,comparison isradipine felodipine australian patient hypertension focus ankle oedema,aim study compare tolerability efficacy isradipine felodipine treatment mild moderate hypertension week placebo period patient enter randomize double blind multicentre study week duration patient receive either isradipine n felodipine n mg twice daily doubling dose addition enalapril mg daily permit dbp mmhg week respectively isradipine monotherapy reduce bp mmhg baseline mmhg week p felodipine alone reduce bp baseline p follow addition enalapril patient isradipine group bp far reduce mmhg week p addition enalapril felodipine group far reduce bp mmhg week p difference bp find group monotherapy however isradipine group significantly low dbp felodipine group conclusion study p ci mmhg similar incidence headache flushing dizziness tachycardia report group however incidence ankle oedema significantly low isradipine group p overall ankle oedema report often female patient associate increase weight abstract truncate word,Hammond JJ,1993,Blood Press,https://doi.org/10.3109/08037059309077552,8205314,Hammond JJ; Cutler SA,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000328: Adult; D000368: Aged; D000842: Ankle; D001794: Blood Pressure; D004311: Double-Blind Method; D004361: Drug Tolerance; D004487: Edema; D004656: Enalapril; D015736: Felodipine; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D008055: Lipids; D008297: Male; D008875: Middle Aged,,,https://openalex.org/W1987959961,105,16,1,1561,315,13,en,en
false,amiodarone development ards lung surgery,evaluation amiodarone prophylactic treatment supraventricular tachyarrhythmias pulmonary surgery stop high incidence adult respiratory distress syndrome ards pneumonectomy retrospective analysis case resection pulmonary neoplasm hospital indicate amiodarone may implicate development ards lung surgery,Van Mieghem W,1994,Chest,https://doi.org/10.1378/chest.105.6.1642,8205854,Van Mieghem W; Coolen L; Malysse I; Lacquet LM; Deneffe GJ; Demedts MG,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D000638: Amiodarone; D001281: Atrial Fibrillation; D006801: Humans; D015994: Incidence; D008875: Middle Aged; D011013: Pneumonectomy; D011183: Postoperative Complications; D011446: Prospective Studies; D012128: Respiratory Distress Syndrome; D012189: Retrospective Studies; D014700: Verapamil,,,https://openalex.org/W2140140153,57,9,1,429,65,2,en,en
false,comparison cilazapril nifedipine retard ambulatory blood pressure metabolic rheological platelet function hypertensive patient,week randomise double blind study total patient sit dbp mmhg enrol comparison antihypertensive metabolic antiplatelet effect drug cilazapril nifedipine retard two week placebo treatment give either cilazapril mg daily nifedipine retard mg twice daily administer four week treatment patient sit dbp mmhg give double initial dos next six week others maintain initial dos patient receive drug report adverse effect every week blood take metabolic rheological platelet function test ambulatory bp heart rate record start fourth tenth week study end trial significant decrease sbp dbp cilazapril group mmhg systolic p mmhg diastolic p nifedipine group also significant decrease sbp dbp mmhg systolic p mmhg diastolic p significant increase heart rate beats minute p significant change biochemical metabolic parameter two group abstract truncate word,Ding YA,1994,J Hum Hypertens,,8207740,Ding YA; Law HW; Chou TC,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D001792: Blood Platelets; D001794: Blood Pressure; D017315: Cilazapril; D003692: Delayed-Action Preparations; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D012212: Rheology; D013997: Time Factors",,,https://openalex.org/W2405308715,147,21,1,1430,294,10,en,en
false,effect verapamil reinfarction cardiovascular event patient arterial hypertension include danish verapamil infarction trial ii danish study group verapamil myocardial infarction,increased incidence reinfarction cardiovascular event report patient hypertension recover acute myocardial infarction study effect intervention verapamil development myocardial infarction cardiovascular event patient hypertension enrol danish verapamil infarction trial ii second week index infarct patient randomly assign treatment verapamil mg per day n placebo n followed month mean month month first reinfarction rate verapamil placebo treat patient hazard ratio confidence limit p first cardiovascular event rate verapamil placebo group hazard ratio confidence limit p retrospective analysis patient hypertension include danish verapamil infarction trial ii intervention verapamil reduce cardiovascular event primarily due substantial reduction reinfarctions,Jespersen CM,1994,J Hum Hypertens,,8207744,Jespersen CM; Hansen JF,article,"D016430: Clinical Trial; D017427: Clinical Trial, Phase II; D016428: Journal Article; D016449: Randomized Controlled Trial",D000368: Aged; D001794: Blood Pressure; D002319: Cardiovascular System; D003718: Denmark; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D012189: Retrospective Studies; D014700: Verapamil,,,https://openalex.org/W2395323984,216,32,2,1126,196,6,en,en
false,ace inhibition versus calcium antagonism treatment mild moderate hypertension multicentre study ireland netherlands lisinopril nifedipine study group,summary efficacy lisinopril mg daily compare nifedipine tablet mg twice daily multicentre double blind randomize parallel group study week duration involve patient mild moderate hypertension group randomize lisinopril nifedipine significantly different respect demographic variable analysis pool data centre demonstrate significantly great fall lying stand systolic blood pressure sbp lisinopril nifedipine treatment difference treatment mmhg p mmhg p lie stand sbp respectively however difference may account slightly high mean sbp lisinopril treatment group compare nifedipine group end placebo run period treatment lower lie stand diastolic blood pressure dbp extent response rate two treatment effect two drug heart rate indistinguishable six lisinopril nifedipine treated patient withdraw randomize treatment p nineteen per cent lisinopril patient report adverse event compare nifedipine patient relative risk adverse event lisinopril compare nifedipine confidence limit difference approach statistical significance p lisinopril produce great reduction lying stand sbp nifedipine associate equivalent reduction dbp lisinopril may good tolerate nifedipine,Hart W,1993,Postgrad Med J,https://doi.org/10.1136/pgmj.69.812.450,8208641,Hart W; Clarke RJ,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000293: Adolescent; D000328: Adult; D000368: Aged; D001794: Blood Pressure; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D017706: Lisinopril; D008297: Male; D008875: Middle Aged; D009543: Nifedipine,,,https://openalex.org/W2149028768,166,22,2,1748,295,11,en,en
false,comparison sublingual captopril nifedipine prazosin hypertensive emergency hemodialysis,hypertensive emergency hemodialysis require immediate therapy usually parenteral drug administration however sublingual medication may potential special condition sublingual captopril mg nifedipine mg prazosin mg prescribe determine effectiveness safety medication treatment hypertensive emergency hemodialysis blood pressure heart rate measure continuously min postdose response rate captopril nifedipine prazosin significant hypotensive effect sublingual captopril nifedipine occur min continue min reduction systolic blood pressure occur earlier nifedipine captopril vs min significant difference heart rate note side effect captopril group flushing tachycardia headache observe patient nifedipine group conclude sublingual captopril nifedipine effective captopril seem less side effect nifedipine may excellent alternative sublingual nifedipine urgent treatment hypertensive emergency hemodialysis prazosin recommended low response rate,Wu SG,1993,Nephron,https://doi.org/10.1159/000187489,8247194,Wu SG; Lin SL; Shiao WY; Huang HW; Lin CF; Yang YH,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000286: Administration, Sublingual; D000328: Adult; D000368: Aged; D001794: Blood Pressure; D002216: Captopril; D002626: Chemistry, Pharmaceutical; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011224: Prazosin; D006435: Renal Dialysis",,,https://openalex.org/W2022904745,107,13,1,1328,222,10,en,en
false,antihypertensive action nicardipine retard hour effect stress,thirty six patient male female age year old mean age suffer slight moderate arterial hypertension monitor four week day placebo treatment double blind random study patient treat nicardipine retard mg twice day whereas receive placebo twice day sphigomanometric control carry two four week show significant reduction arterial pressure patient receive active treatment hour patient monitoring arterial pressure carry use spacelabs show reduction systolic diastolic arterial pressure throughout day subject treat calcium antagonists compare placebo group normal physiological hour trend arterial pressure always take account pressure response cold pressor test mental arithmetic test isometric dynamic effort test measure use cycloergometer modify anti hypertensive treatment thus confirm preservation normal physiological behaviour daily activity significant change heart rate drug well tolerate,De Cesaris R,1993,Minerva Med,,8247308,De Cesaris R; Ranieri G; Andriani A; Filitti V; Bonfantino MV; Lamontanara G; Ferrieri A,article,D016430: Clinical Trial; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D015924: Blood Pressure Monitors; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D005080: Exercise Test; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D008991: Monitoring, Physiologic; D009200: Myocardial Contraction; D009529: Nicardipine; D011187: Posture",,,https://openalex.org/W2396627535,85,16,1,1241,206,7,en,en
false,assessment glucose tolerance hypertensive subject treat amlodipine,author study side effect amlodipine glucose metabolism carry oral glucose tolerance test day treatment group subject normal glucose tolerance significant variation average plasma glucose insulin level observe nevertheless case amlodipine therapy decrease glucose plasma level find,Panuccio D,1993,Clin Ter,,8258265,Panuccio D; Romani A; Trabatti MR; Romanelli R; Nardi R,article,D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article,D017311: Amlodipine; D001786: Blood Glucose; D004341: Drug Evaluation; D005260: Female; D005951: Glucose Tolerance Test; D006801: Humans; D006973: Hypertension; D007328: Insulin; D008297: Male; D008875: Middle Aged; D013997: Time Factors,,,https://openalex.org/W2400067880,87,14,1,402,70,3,en,en
false,atenolol versus fixed combination atenolol nifedipine stable angina pectoris,one hundred fourteen patient male chronic stable angina positive exercise test week atenolol alone randomize receive either atenolol alone fixed combination atenolol nifedipine slow release formulation week double blind cross manner exercise stress testing bruce protocol end treatment period demonstrate time onset pain occurrence mm st segment depression improve significantly p p respectively whilst fix combination compare atenolol alone order achieve sufficient sensitivity analysis exercise time novel statistical method base survival analysis use maximum st segment depression mm less p fixed combination incidence withdrawal adverse effect similar treatment,Foale RA,1993,Eur Heart J,https://doi.org/10.1093/eurheartj/14.10.1369,8262084,Foale RA,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D001262: Atenolol; D001794: Blood Pressure; D003327: Coronary Disease; D003692: Delayed-Action Preparations; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004562: Electrocardiography; D005080: Exercise Test; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D005996: Nitroglycerin",,,https://openalex.org/W1991849898,90,13,1,918,161,5,en,en
false,acute effect nicardipine vascular reactivity oxygen patient respiratory insufficiency pulmonary hypertension,pulmonary vascular response inhalation various concentration oxygen fio study basal condition nicardipine patient pulmonary hypertension secondary chronic bronchitis hemodynamic data blood gas measure inhalation gas mixture hypoxia fio normoxia fio hyperoxia fio gas mixture administer minute initially infusion placebo nicardipine give steady plasma concentration ng ml obtain continuous v infusion mg kg hour basal condition placebo heart rate cardiac output pulmonary hypertension increase decrease concentration inhaled oxygen systemic blood pressure unchanged hypoxia decrease hyperoxia nicardipine increase heart rate cardiac output reduce blood pressure every inhaled oxygen mixture blood pressure independent fio reduction observe hyperoxia placebo longer occur nicardipine however pulmonary hypertension unaffected dosage use study nicardipine modify systemic vascular response oxygen pulmonary vascular response vasodilation induce much great systemic pulmonary circulation relation absence significant pulmonary vasodilation change blood gas due possible pulmonary shunting effect observe dosage nicardipine ineffective reduce pulmonary hypertension however systemic hypotensive action may use patient respiratory failure due chronic bronchitis without deleterious effect blood gas,Saadjian A,1993,Arch Mal Coeur Vaiss,,8274062,Saadjian A; Philip-Joët F; Paganelli F; Saadjian M; Lévy S,article,D016430: Clinical Trial; D004740: English Abstract; D016428: Journal Article; D016454: Review,"D001784: Blood Gas Analysis; D002985: Clinical Protocols; D006439: Hemodynamics; D006801: Humans; D006976: Hypertension, Pulmonary; D008297: Male; D009529: Nicardipine; D010100: Oxygen; D012131: Respiratory Insufficiency; D014666: Vasomotor System",,,https://openalex.org/W2407340636,138,21,1,1795,297,15,en,en
false,comparison nifedipine gastrointestinal therapeutic system atenolol antianginal efficacy exercise hemodynamic response stable angina pectoris,gastrointestinal therapeutic system git nifedipine develop provide daily dosing predictable relatively constant plasma concentration study compare antianginal efficacy nifedipine git day receptor blocker atenolol seventeen patient documented coronary artery disease stable stress induced angina pectoris study week single blind placebo baseline phase week randomized double blind active drug crossover efficacy phase use bicycle exercise test ambulatory electrocardiographic recording patient exercise significantly longer nifedipine git second atenolol second placebo second nifedipine git reduce systolic blood pressure stage exercise compare placebo heart rate tend increase nifedipine therapy difference rate pressure product placebo nifedipine git period contrast atenolol reduce heart rate systolic blood pressure rate pressure product exercise compare placebo whereas leave ventricular ejection fraction radionuclide angiocardiography increase exercise maximal increase small atenolol placebo nifedipine net increase left ventricular ejection fraction end exercise great nifedipine placebo atenolol ambulatory electrocardiogram show small number ischemic event neither nifedipine git atenolol reduce number ischemic event total duration st segment deviation significantly conclude nifedipine git effective antianginal agent atenolol hemodynamic effect agent differ leave ventricular ejection fraction increase nifedipine atenolol bicycle excercise,Wallace WA,1994,Am J Cardiol,https://doi.org/10.1016/0002-9149(94)90721-8,8279372,Wallace WA; Wellington KL; Chess MA; Liang CS,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000704: Analysis of Variance; D000787: Angina Pectoris; D001262: Atenolol; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D016503: Drug Delivery Systems; D015716: Electrocardiography, Ambulatory; D005080: Exercise Test; D005260: Female; D006439: Hemodynamics; D006801: Humans; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011875: Radionuclide Angiography; D016037: Single-Blind Method; D016896: Treatment Outcome; D016277: Ventricular Function, Left",,,https://openalex.org/W2062454953,160,19,1,1941,303,12,en,en
false,characteristic radiofrequency ablation therapy intermediate septal accessory pathway,fourteen patient intermediate septal accessory pathway identify among consecutive patient wolff parkinson white syndrome electrophysiologic study radiofrequency ablation therapy nine woman men mean age year rest electrocardiogram show ventricular preexcitation patient normal pr interval anterograde retrograde mapping study reveal accessory pathway para hisian patient paranodal accessory pathway successfully ablate patient para hisian paranodal damage para hisian treatment patient complicate transient atrioventricular av block intermittent second degree av block another permanent complete av block require implantation permanent pacemaker six patient underwent follow electrophysiologic study day ablation none induction tachycardia even isoproterenol infusion conclude radiofrequency ablation therapy intermediate septal accessory pathway feasible however success rate modest whereas complication heart block complete right bundle branch block high thus procedure reserve patient life threatening troublesome symptomatic tachyarrhythmias,Yeh SJ,1994,Am J Cardiol,https://doi.org/10.1016/0002-9149(94)90726-9,8279377,Yeh SJ; Wang CC; Wen MS; Lin FC; Koo CC; Lo YS; Wu D,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000293: Adolescent; D000328: Adult; D017115: Catheter Ablation; D004562: Electrocardiography; D004594: Electrophysiology; D005260: Female; D006327: Heart Block; D006801: Humans; D008297: Male; D008875: Middle Aged; D016896: Treatment Outcome; D014927: Wolff-Parkinson-White Syndrome,,,https://openalex.org/W2050281503,92,10,1,1402,234,10,en,en
false,monotherapy mild moderate hypertension double blind comparative study amlodipine versus enalapril,double blind multicenter study involve patient mild moderate essential hypertension perform compare efficacy tolerability amlodipine enalapril follow placebo controlled run phase treatment initiate daily dose mg amlodipine enalapril second week treatment daily dose enalapril increase mg two week treatment amlodipine dose increase mg enalapril dose mg diastolic seat blood pressure exceed mmhg mean systolic diastolic blood pressure decrease amlodipine group respectively mmhg mmhg enalapril group mmhg mmhg reduction blood pressure statistically significant group p difference blood pressure lower effect two treatment statistically significant target blood pressure diastolic bp seat mmhg achieve patient amlodipine group patient enalapril group neither group experience severe adverse reaction side effect see patient amlodipine group enalapril group,Mehmel HC,1993,Fortschr Med,,8282290,Mehmel HC; Görne RC,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D017311: Amlodipine; D001794: Blood Pressure; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004656: Enalapril; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2461522660,108,17,2,1314,241,7,en,en
false,effect metoprolol diltiazem total ischaemic burden patient chronic stable angina randomized control trial,conduct randomise control trial study effect metoprolol diltiazem total ischaemic burden sum symptomatic silent myocardial ischaemia patient stable angina pectoris one hundred thirty four complete study protocol sixty eight patient receive metoprolol mg twice daily n mg twice daily n receive diltiazem mg three time daily n mg three time daily n drug give week primary outcome variable frequency duration total ischaemic burden silent symptomatic myocardial ischaemia measure h holter monitoring reduction duration frequency total ischaemic burden metoprolol respectively significantly high diltiazem respectively p p frequency duration silent myocardial ischaemia constitute total ischaemic burden two group show similar result however reduction frequency symptomatic myocardial ischaemia significantly great metoprolol diltiazem difference reduction duration symptomatic ischaemia insignificant vs p whether great reduction total ischaemic burden metoprolol compare diltiazem implication prognosis patient chronic stable angina remain establish,Ahuja RC,1993,Int J Cardiol,https://doi.org/10.1016/0167-5273(93)90115-w,8288408,Ahuja RC; Sinha N; Kumar RR; Saran RK,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000787: Angina Pectoris; D004110: Diltiazem; D015716: Electrocardiography, Ambulatory; D005080: Exercise Test; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008790: Metoprolol; D008875: Middle Aged; D017202: Myocardial Ischemia",,,https://openalex.org/W2027583135,134,21,1,1496,281,10,en,en
false,investigation therapeutic mechanism atenolol diltiazem patient variable threshold angina,effect beta adrenoreceptor calcium channel blocking agent balance myocardial oxygen supply demand study patient woman men age mean year variable threshold angina exercise test perform therapy begin hour ambulatory ecg monitoring perform week long acting nitrate therapy third week random assignment either atenolol diltiazem third week crossover exercise test positive except one patient take diltiazem exercise time mv st change minute therapy minute nitrate minute diltiazem minute atenolol rate pressure product mv st change therapy nitrate diltiazem respectively fell beats min mm hg atenolol p significant difference number anginal attack nitroglycerin consumption per week heart rate onset st segment change exercise test ambulatory ecg monitoring significantly low atenolol diltiazem treatment atenolol diltiazem similar efficacy increase nonischemic exercise duration patient variable threshold angina act primarily slow rest heart rate abstract truncate word,Nadazdin A,1994,Am Heart J,https://doi.org/10.1016/0002-8703(94)90118-x,8296698,Nadazdin A; Davies GJ,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D000788: Angina Pectoris, Variant; D001262: Atenolol; D001794: Blood Pressure; D017023: Coronary Angiography; D004110: Diltiazem; D004311: Double-Blind Method; D015716: Electrocardiography, Ambulatory; D005080: Exercise Test; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D017202: Myocardial Ischemia; D009566: Nitrates; D005996: Nitroglycerin; D010101: Oxygen Consumption",,,https://openalex.org/W1996742106,108,13,1,1520,273,9,en,en
false,safety compatibility betaxolol hydrochloride combine diltiazem nifedipine therapy stable angina pectoris,compare placebo add betaxolol mg every day nifedipine mg day divided dos diltiazem mg day divided dos week treatment period patient stable angina pectoris significantly p lengthen time onset moderate angina exercise tolerance test treatment time point median increase time onset moderate angina final exercise tolerance test end point compare baseline minute betaxolol placebo group respectively p betaxolol v placebo time onset mm st segment depression increase significantly p betaxolol compare placebo treatment time point median increase p minute respectively end point duration exercise also increase significantly p third week treatment end point median minute respectively p generally comparable result find within diltiazem n nifedipine n subgroup although nifedipine group small detect statistically significant difference betaxolol placebo treatment rest systolic blood pressure heart rate rate pressure product measure angina occur end exercise also influence significantly p betaxolol addition serious adverse effect associate betaxolol treatment syncope see patient,Glasser SP,1994,Am J Cardiol,https://doi.org/10.1016/0002-9149(94)90221-6,8296748,Glasser SP; Friedman R; Talibi T; Smith LK; Weir EK,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000787: Angina Pectoris; D015784: Betaxolol; D002908: Chronic Disease; D004110: Diltiazem; D004311: Double-Blind Method; D004347: Drug Interactions; D004359: Drug Therapy, Combination; D005260: Female; D006439: Hemodynamics; D006801: Humans; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D005082: Physical Exertion; D013223: Statistics as Topic; D013575: Syncope; D013997: Time Factors",,,https://openalex.org/W2168715873,123,16,1,1562,293,7,en,en
false,acute liver injury associate nonsteroidal anti inflammatory drug role risk factor,hospitalization acute liver injury absence viral infection well defined pathologic finding could cause rare study include outpatient hospitalize patient acute liver injury estimate risk clinically important acute liver injury associate use nonsteroidal anti inflammatory drug nsaid study role certain risk factors retrospective cohort study secondary case control analysis study include general practitioner practice england wale period october august total person receive million prescription one nsaid follow estimate risk newly diagnose acute liver injury case acute liver injury incidence acute liver injury per nsaid user per nsaid prescription none case fatal outcome sulindac nsaid substantially great risk overall nsaid group user nsaid rheumatoid arthritis fold increased risk acute liver injury compare nsaid treated patient osteoarthritis concomitant exposure hepatotoxic medication also increase risk transient minor increase liver test value useful predictor diagnosed nsaid associated acute liver injury although nsaid find associate acute liver injury small number person risk sufficiently small minimal concern nsaid,García Rodríguez LA,1994,Arch Intern Med,https://doi.org/10.1001/archinte.1994.00420030117012,8297198,García Rodríguez LA; Williams R; Derby LE; Dean AD; Jick H,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000208: Acute Disease; D000293: Adolescent; D000328: Adult; D017677: Age Distribution; D000368: Aged; D000894: Anti-Inflammatory Agents, Non-Steroidal; D016022: Case-Control Studies; D056486: Chemical and Drug Induced Liver Injury; D005260: Female; D006801: Humans; D008111: Liver Function Tests; D016015: Logistic Models; D008297: Male; D008875: Middle Aged; D012189: Retrospective Studies; D012307: Risk Factors; D017678: Sex Distribution",,,https://openalex.org/W2111411689,100,14,1,1632,271,10,en,en
false,angiotensin convert enzyme inhibition chronic stable angina effect myocardial ischaemia comparison nifedipine,determine anti ischaemic effect new angiotensin convert enzyme inhibitor benazepril compare nifedipine alone combination chronic stable angina cause coronary artery disease placebo control double blind latin square design regional cardiology service mixed urban rural population patient stable exertional angina produce least mm st segment depression exercise test bruce protocol patient complete four phase trial patient treat placebo benazepril mg twice daily nifedipine retard mg twice daily combination benazepril nifedipine dos random order period two weeks total duration exercise increase treatment exercise time development mm st segment depression significantly change benazepril alone combination nifedipine increase nifedipine min min confidence interval ci p significant relation increase duration exercise rest renin concentration r p myocardial ischaemia daily activity assess ambulatory electrocardiographic monitoring reduce benazepril benazepril nifedipine combination significant total ischaemic burden min v min ci min p maximal depth st segment depression mm v mm ci p combination maximal st segment depth benazepril monotherapy mm v mm ci p benazepril significantly alter circadian rhythm cardiac ischaemia abolish peak ischaemic period p benazepril angiotensin convert enzyme inhibitor modest anti ischaemic effect effort angina effect pronounce nifedipine anti ischaemic action noticeable asymptomatic ischaemia daily activity whereas nifedipine little effect aspect myocardial ischaemia combination benazepril nifedipine reduce ischaemia daily activity,Ikram H,1994,Br Heart J,https://doi.org/10.1136/hrt.71.1.30,8297690,Ikram H; Low CJ; Shirlaw TM; Foy SG; Crozier IG; Richards AM; Khurmi NS; Horsburgh RJ,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D000806: Angiotensin-Converting Enzyme Inhibitors; D001552: Benzazepines; D002908: Chronic Disease; D003327: Coronary Disease; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D015716: Electrocardiography, Ambulatory; D005080: Exercise Test; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D017202: Myocardial Ischemia; D009543: Nifedipine",,,https://openalex.org/W2127015685,130,18,1,2319,432,9,en,en
false,einflu von angiotensin converting enzym hemmern auf die proteinurie bei chronischer glomerulonephritis,effect two angiotensin converting enzyme ace inhibitor lisinopril captopril proteinuria renal haemodynamics investigate hypertensive men woman mean age year proteinuria g h due chronic glomerulonephritis impaired renal function glomerular filtration rate ml min randomized double blind cross trial patient receive time six week either lisinopril mg sometimes increase mg week captopril twice daily mg sometimes increase twice mg week initially individual treatment phase placebo phase week follow measure protein excretion include fractional clearance albumin igg plasma renin activity renal haemodynamics protein excretion significantly reduce either drug placebo g lisinopril g captopril g albumin excretion fractional albumin clearance significantly decrease lisinopril p captopril plasma renin activity increase lisinopril captopril placebo ng ml h lisinopril ng ml h p captopril ng ml h p renal haemodynamics slightly influence either drug captopril significantly decrease filtration fraction presence chronic glomerulonephritis renal failure result influence renin angiotensin aldosterone system ace inhibitor addition know action renal haemodynamics independent effect load barrier basal membrane kidney,Erley CM,1994,Dtsch Med Wochenschr,https://doi.org/10.1055/s-2008-1058666,8299527,Erley CM; Komini E; Nicaeus T; Braun N; Wolf S; Risler T,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D002216: Captopril; D002908: Chronic Disease; D004311: Double-Blind Method; D005260: Female; D005921: Glomerulonephritis; D006801: Humans; D017706: Lisinopril; D008297: Male; D008875: Middle Aged; D011507: Proteinuria,,,https://openalex.org/W2043254310,103,9,1,1746,317,9,de,en
false,effect amlodipine renal haemodynamics mild moderate hypertensive patient,study efficacy safety short term amlodipine administration renal haemodynamics evaluate mild moderate hypertensive subject final goal evaluate whether reduced blood pressure induce treatment associate maintenance renal function run period placebo hypertensive patient without cardiac renal disease randomly allocate double blind week control study amlodipine mg day patient placebo patient renal haemodynamic measurement include effective renal plasma flow erpf glomerular filtration rate gfr radionuclide study use hippuran mtc method describe schlegel gate respectively addition effective renal blood flow erbf erpf ht filtration fraction ff gfr erpf renal vascular resistance rvr mbp x erbf calculate plasma renin activity pra serum aldosterone ald urinary excretion sodium nau evaluate end amlodipine administration significant decrease p sbp dbp mbp baseline value observe significant decrease p rvr significant increase p erpf erbf nau also find without relevant change gfr ff pra ald significant variation clinical renal measurement observe placebo group relevant side effect observe either group conclusion amlodipine effective lower blood pressure mild moderate hypertension exert favourable effect renal haemodynamics function,Licata G,1993,Eur J Clin Pharmacol,https://doi.org/10.1007/bf00265946,8299661,Licata G; Scaglione R; Ganguzza A; Parrinello G; Costa R; Merlino G; Corrao S; Amato P,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D017311: Amlodipine; D004311: Double-Blind Method; D005260: Female; D005919: Glomerular Filtration Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D017597: Renal Blood Flow, Effective; D012083: Renin; D014563: Urodynamics; D014655: Vascular Resistance",,,https://openalex.org/W2322745539,86,12,1,1650,301,11,en,en
false,slow release nicardipine treatment arterial hypertension comparative study vs ace inhibitor,anti hypertensive activity influence form stress slow release nicardipoine captopril compare use randomized protocol thirty six patient mean age year suffer slight moderate arterial hypertension treat either mg nicardipine retard twice day b captopril dose mg b week significant reduction observe arterial pressure orthostatism clinostatism follow treatment comparison placebo period group treat slow release nicardipine show great statistically significant reduction arterial pressure significant change heart rate report use either drug non invasive patient monitoring arterial pressure perform use spacelabs show significant reduction arterial pressure use drug conservation normal circadian rhythm arterial pressure pressure response cold pressor test cpt mental arithmetic test dynamic isometric effort positive drug thus reveal degree protection offer treatment use two substance overall term two drug well tolerate,De Cesaris R,1993,Minerva Cardioangiol,,8302442,De Cesaris R; Ranieri G; Bonfantino V; Adriani A; Filitti V; Ferrieri A,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D003692: Delayed-Action Preparations; D004341: Drug Evaluation; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009529: Nicardipine,,,https://openalex.org/W2438460389,109,18,1,1268,216,9,en,en
false,efficacy safety atenolol enalapril isradipine elderly hypertensive woman,trial design evaluate efficacy safety three different class antihypertensive agent elderly women trial three phase week placebo week titration week maintenance white woman year old sit diastolic blood pressure dbps mm hg treat placebo evaluate history physical examination laboratory study quality life interview double blind randomization low dose atenolol enalapril isradipine dose increase stepwise hydrochlorothiazide add need achieve goal dbp less mm hg great mm hg baseline maintenance patient goal step patient uncontrolled dbp maximum dosage remove study pretreatment baseline blood pressure randomize participant average mm hg treat previously hypertension diabetes mellitus smoke consume alcohol patient complete trial average decrease blood pressure treatment mm hg antihypertensive efficacy similar monotherapy drug regimen patient receive atenolol enalapril isradipine respectively achieve dbp goal patient complete trial leave symptom uncontrolled dbp important unexpected drug induced change symptom blood chemistry note symptom frequency differ little among three dosage level become maximal second visit dosage level three drug lower dbp comparably none produce alarming effect thirteen percent patient leave study symptom,Perry HM,1994,Am J Med,https://doi.org/10.1016/0002-9343(94)90118-x,8304366,Perry HM; Hall WD; Benz JR; Bartels DW; Kostis JB; Townsend RR; Due DL; Peng A; Sirgo M,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D001262: Atenolol; D001794: Blood Pressure; D004311: Double-Blind Method; D004656: Enalapril; D005260: Female; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D017275: Isradipine; D008875: Middle Aged; D011188: Potassium; D011446: Prospective Studies,,,https://openalex.org/W2010830316,88,14,1,1842,329,10,en,en
false,cardiac protection heart surgery intervention preventive drug administration extracorporeal circulation study troponin parameter perioperative myocardial damage,present study design test prophylactic intravenous nifedipine nitroglycerine could reduce myocardial damage cardiopulmonary bypass patient schedule elective coronary artery bypass graft divide random three group group control group nifedipine microgram kg min group nitroglycerine micrograms kg min infusion period reach beginning anaesthesia crossclamp aorta myocardial damage estimate troponin tnt ck mb st segment analysis ecg tnt cardiospecific protein contractile apparatus striated muscle cell tnt levels might provide sensitive marker small amount cardiac muscle necrosis test elisa one step sandwich assay streptavidin technology criterion ischemia st segment analysis accord smith et al st depression mm baseline st elevation mm baseline j point ms statistical interpretation one two factorial analysis variance include multivariate analysis variance correlation two variable test regression analysis level p take indicate statistical significance biometrical data circulation data data cardiopulmonary bypass without significant difference among group table start normal value ng ml tnt significantly rise group immediately cardiopulmonary bypass remain elevate forth day operation value microgram ml figure abstract truncate word,Knothe C,1993,Herz,,8307554,Knothe C; Boldt J; Zickmann B; Ballesteros M; Häufler G; Bruns F; Hempelmann G,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D015415: Biomarkers; D002315: Cardiopulmonary Bypass; D001026: Coronary Artery Bypass; D003402: Creatine Kinase; D004305: Dose-Response Relationship, Drug; D004562: Electrocardiography; D005260: Female; D006801: Humans; D007527: Isoenzymes; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D009543: Nifedipine; D005996: Nitroglycerin; D011183: Postoperative Complications; D011292: Premedication; D014336: Troponin; D020107: Troponin T; D016277: Ventricular Function, Left",,,https://openalex.org/W2345370291,196,28,2,1690,288,14,en,en
false,sublingual nifedipine captopril hypertensive urgency emergency,fifty two patient severe hypertension diastolic blood pressure mmhg without acute complication treat sublingual nifedipine mg sublingual captopril mg randomized prospective patient study careful clinical monitoring drug safe effective rapidly lower blood pressure nifedipine appear superior captopril early onset action great magnitude response long duration action significant side effect observe either two group,Dadkar VN,1993,Indian Heart J,,8314271,Dadkar VN; Karnik ND; Izar M; Sharma SR; Gandhi YP; Narawane NM; Vyawahare SS; Sudhakar S; Gore AG; Kapadia NM,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000286: Administration, Sublingual; D000293: Adolescent; D000328: Adult; D000368: Aged; D001794: Blood Pressure; D002216: Captopril; D003971: Diastole; D004630: Emergencies; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011446: Prospective Studies",,,https://openalex.org/W180349243,78,10,1,561,95,4,en,en
false,antianginal antiischemic efficacy monotherapy extended release nisoldipine coat core chronic stable angina,double blind randomize placebo controlled study conduct test peak trough antianginal antiischemic monotherapy efficacy safety new extended release formulation nisoldipine nisoldipine coat core bayer corporation mg mg mg daily compare placebo study patient history chronic stable angina pectoris exercise induced angina association st segment depression exercise test reproducibility patient enrol study result valid safety analysis efficacy analysis statistically significant improvement total exercise time peak trough patient take mg mg nisoldipine compare patient take placebo group take mg good group take mg second respectively trough result similar secondary endpoint time onset angina time mm st segment depression correlation evident plasma nisoldipine level total exercise duration headache peripheral edema frequently report adverse event dose relate discontinuation due adverse event patient randomize mg nisoldipine group death occur patient receive active nisoldipine therapy therapy extended release formulation nisoldipine effective daily treatment chronic stable angina pectoris represent one dihydropyridine calcium channel antagonists show efficacy administer monotherapy patient angina,Glasser SP,1995,J Clin Pharmacol,https://doi.org/10.1002/j.1552-4604.1995.tb04120.x,8522634,Glasser SP; Ripa S; Garland WT; Weiss R; Nademanee K; Singh S; Bittar N,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D002908: Chronic Disease; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D005080: Exercise Test; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D017202: Myocardial Ischemia; D015737: Nisoldipine",,,https://openalex.org/W2073067259,118,16,1,1694,284,11,en,en
false,moexipril treatment mild moderate essential hypertension comparison sustained release verapamil,compare contrast antihypertensive efficacy angiotensin converting enzyme ace inhibitor calcium antagonist patient essential hypertension randomly assign receive moexipril verapamil respectively end first week active therapy sit diastolic blood pressure decrease mmhg patient receive moexipril mmhg patient receive verapamil week treatment period complete patient receive moexipril patient receive verapamil mean decrease sit diastolic blood pressure mmhg mmhg observe respective intent treat moexipril verapamil group dos mg mg daily moexipril antihypertensive effect comparable sustained release verapamil dos mg mg daily,Abernethy DR,1995,J Clin Pharmacol,https://doi.org/10.1002/j.1552-4604.1995.tb04122.x,8522636,Abernethy DR; Fox AA; Stimpel M,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000806: Angiotensin-Converting Enzyme Inhibitors; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D006973: Hypertension; D007546: Isoquinolines; D008297: Male; D008875: Middle Aged; D011355: Prodrugs; D044005: Tetrahydroisoquinolines; D014700: Verapamil",,,https://openalex.org/W2048844715,114,15,1,883,147,5,en,en
false,office ambulatory blood pressure comparison amlodipine felodipine er danish multicentre group,anti hypertensive efficacy safety extended release er felodipine mg amlodipine mg daily compare patient mild moderate essential hypertension double blind double dummy randomise comparative study total patient allocate week double blind treatment either felodipine er n amlodipine n anti hypertensive effect evaluate measure office blood pressure bp baseline week together h ambulatory blood pressure monitoring abpm baseline day treatment end study mean office bp change baseline week mmhg felodipine er mean daily dose mg mm hg amlodipine mean daily dose mg bp reduction significant p respect time difference treatment group significant mean ambulatory bp change baseline end study mmhg felodipine er mm hg amlodipine significant p fall ambulatory sbp significantly great p patient treat amlodipine compare felodipine er whereas difference group respect ambulatory dbp drgs well tolerate withdrawl rate equally distribute abstract truncate word,Høegholm A,1995,J Hum Hypertens,,8523374,Høegholm A; Wiinberg N; Rasmussen E; Nielsen PE,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D017311: Amlodipine; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D003971: Diastole; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009819: Office Visits; D013599: Systole; D016896: Treatment Outcome",,,https://openalex.org/W2464249014,114,18,2,1551,320,9,en,en
false,comparison amlodipine quinapril ambulatory blood pressure platelet function hypertension,effect calcium channel blocker ccb amlodipine mg day angiotensin converting enzyme ace inhibitor quinapril mg day ambulatory blood pressure abp rheological platelet function hypertension compare randomised double blind placebo controlled cross study study precede week placebo run period total duration study week casual h abp plasma renin activity pra plasma aldosterone pa concentration well metabolic platelet function determine end drug therapy total patient complete study casual bp significantly reduce amlodipine quinapril treatment change heart rate regard h abp amlodipine produce fall mm hg p sbp dbp quinapril also cause reduction mm hg p sbp dbp neither amlodipine quinapril produce significant change heart rate level keto prostaglandin fl alpha keto pgfl alpha increase pg ml p significant change thromboxane b txb note amlodipine treatment pra increase ng ml h p quinapril treatment biochemical parameter unchanged abstract truncate word,Ding YA,1995,J Hum Hypertens,,8523379,Ding YA; Chang SM; Chou TC,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000450: Aldosterone; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001792: Blood Platelets; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D007546: Isoquinolines; D008297: Male; D008875: Middle Aged; D000077583: Quinapril; D012083: Renin; D044005: Tetrahydroisoquinolines; D016896: Treatment Outcome",,,https://openalex.org/W105683178,106,15,1,1510,293,12,en,en
false,initial result hot study switzerland hypertension optimal treatment,hot study hypertension optimal treatment international clinical study primary prevention cardiovascular event hypertensive patient worldwide aim recognition optimal diastolic blood pressure value mmhg order maximize possible benefit antihypertensive therapy addition hot study investigate whether low dos aspirin mg day able reduce occurrence severe cardiovascular event switzerland total patient enrol study antihypertensive therapy initiate felodipine plendil mg day vasoelective calcium antagonist could reduce diastolic blood pressure value mg hg respectively one two one three patient within first three month nine six patient respectively ten reduction diastolic blood pressure value mmhg reach within one year combination felodipine antihypertensive drug ace inhibitor beta blocker diuretic,Waeber B,1995,Praxis (Bern 1994),,8533005,Waeber B; Roth D,article,"D016430: Clinical Trial; D004740: English Abstract; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D000368: Aged; D000369: Aged, 80 and over; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies",,,https://openalex.org/W2398595190,83,15,1,1086,196,8,en,en
false,effect felodipine metoprolol combination blood pressure rest exercise volume regulatory hormone hypertensive patient,effect blood pressure bp heart rate hr rest bicycle exercise vascular selective calcium antagonist felodipine cardio selective beta blocker metoprolol two drug combination assess double blind three way cross study comprise patient essential mild moderate hypertension three treatment regimen give patient randomised order week week placebo run period felodipine mg daily metoprolol mg daily combination felodipine mg plus metoprolol mg daily effective antihypertensive treatment rest exercise two drug seem additive effect effect bp combination great either drug give monotherapy mean sit bp mmhg randomisation week placebo treatment mmhg respectively week treatment felodipine metoprolol combination maximal exercise capacity similar irrespective treatment regimen normal response exercise bp hr maintain active treatment change observe volume regulatory hormone pra aldosterone anp consistent direct tubular natriuretic diuretic effect felodipine beta blocker attenuated release renin treatment regimen well tolerate adverse event report usually mild transient,Gordon RD,1995,Blood Press,https://doi.org/10.3109/08037059509077611,8535552,Gordon RD; Klemm SA; Tunny TJ; Wicks JR; Elmfeldt DB,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000450: Aldosterone; D009320: Atrial Natriuretic Factor; D001794: Blood Pressure; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D015444: Exercise; D005080: Exercise Test; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008790: Metoprolol; D008875: Middle Aged; D012083: Renin",,,https://openalex.org/W2118254548,160,24,1,1527,259,8,en,en
false,hypertension optimal treatment hot study month data blood pressure tolerability special reference age gender,hypertension optimal treatment hot study ongoing prospective randomize multicenter trial conduct country two main aim evaluate relationship three level target diastolic blood pressure mmhg incidence cardiovascular morbidity mortality hypertensive patient effect morbidity mortality low dose mg daily acetylsalicylic acid asa aspirin compare placebo altogether patient recruit randomize one year data available patient report blood pressure achieve tolerability available data month follow patient special reference give subgroup elderly patient year n compare young patient year n average target group mmhg diastolic blood pressure reach mmhg target group mmhg reach mmhg target group mmhg reach mmhg percentage patient obtain target blood pressure target group mmhg target group mmhg target group mmhg month follow elderly subgroup year age percentage patient target high target group respectively month antihypertensive treatment initiate calcium antagonist felodipine dose mg daily target blood pressure reach additional antihypertensive therapy either angiotensin convert enzyme ace inhibitor beta adrenoceptor blocking agent give far dose adjustment make accordance set protocol fifth final step diuretic may add side effect relatively large multinational series intensively treat hypertensive patient ankle edema coughing young elderly patient respectively exceed frequency patient still take baseline therapy felodipine one year one year data present indicate possible fulfill primary aim hot study,Hansson L,1995,Blood Press,https://doi.org/10.3109/08037059509077613,8535554,Hansson L; Zanchetti A,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000367: Age Factors; D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D016032: Randomized Controlled Trials as Topic; D012737: Sex Factors,,,https://openalex.org/W2045717943,138,24,2,2377,478,15,en,en
false,proarrhythmia class iii antiarrhythmic drug definition electrophysiologic mechanism incidence predispose factor clinical implication,proarrhythmia class iii antiarrhythmic agent antiarrhythmic drug induce unexpected sometimes fatal reaction either produce new symptomatic arrhythmia aggravate exist arrhythmia definition proarrhythmia change since control clinical study show dichotomy arrhythmia suppression mortality nature proarrhythmia reaction link electrophysiologic effect various antiarrhythmic drug whereas class agent without accompany effect repolarization generally produce ventricular tachycardia often incessant fibrillation class iii agent typically produce torsades de pointes may deteriorate ventricular fibrillation precise mechanism torsades de pointes fully elucidate although early afterdepolarization increase spatial temporal dispersion repolarization likely possibility proarrhythmic risk low amiodarone probably relate drug complex electrophysiologic profile incidence torsades sotalol increase dose baseline value qt interval incidence sotalol pure class iii agent remain unclear prospective randomize placebo controlled study evaluate way fact sotalol increase mortality postinfarction patient suggest may possibly common property pure class iii compound ongoing clinical trial various class iii agent likely provide critical information important therapeutic issue,Hohnloser SH,1995,J Cardiovasc Electrophysiol,https://doi.org/10.1111/j.1540-8167.1995.tb00368.x,8548113,Hohnloser SH; Singh BN,article,D016428: Journal Article; D016454: Review,"D000638: Amiodarone; D000889: Anti-Arrhythmia Agents; D001145: Arrhythmias, Cardiac; D004594: Electrophysiology; D005544: Forecasting; D006801: Humans; D015994: Incidence; D013015: Sotalol; D009626: Terminology as Topic",,,https://openalex.org/W2034573541,159,26,1,1622,242,12,en,en
false,hypertension elderly h ambulatory blood pressure result placebo controlled trial,calcium channel blocker increasingly use treat hypertension elderly patient assess effect low dose long acting verapamil blood pressure bp quality life qol elderly patient verapamil mg placebo give daily week patient age year week placebo wash period patient sit dbp mm hg mean daytime pm ambulatory dbp mm hg enter study twenty four hour bp monitoring well qol self assessment digit span testing cognitive function perform end placebo wash double blind treatment period patient treat verapamil show significant decrease mean whole day bp treat placebo show small increase bp treatment difference two group sbp dbp statistically significant p significant difference also see h period divide daytime night time reading qol digit span test score unchanged baseline verapamil treated patient different placebo treated group result study demonstrate consistent significant decrease bp throughout h period adverse effect qol cognitive function formulation verapamil elderly hypertensive patient,Neutel JM,1995,J Hum Hypertens,,8551485,Neutel JM; Smith DH; Lefkowitz MP; Cargo P; Alemayehu D; Weber MA,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D011788: Quality of Life; D016896: Treatment Outcome; D014700: Verapamil",,,https://openalex.org/W2419325796,100,16,1,1439,254,9,en,en
false,randomise double blind parallel study anti hypertensive efficacy safety losartan potassium compare felodipine er elderly patient mild moderate hypertension,study investigate anti hypertensive efficacy tolerability daily losartan potassium mg titrate mg angiotensin ii receptor antagonist compare daily felodipine extend release er mg titrate mg calcium channel blocker week therapy elderly hypertensive patient follow week single blind placebo baseline period qualify patient randomly allocate week double blind treatment losartan potassium felodipine er week patient h post dose sit diastolic blood pressure mm hg dose double remain week week great bp response felodipine er losartan potassium elderly patient mild moderate hypertension however week therapy losartan potassium reduce bp effectively felodipine er difference mean bp reduction anti hypertensive response category treatment group study treatment well tolerate felodipine er associate numerically high incidence headache oedema incidence asthenia numerically high losartan treated patient,Chan JC,1995,J Hum Hypertens,,8551492,Chan JC; Critchley JA; Lappe JT; Raskin SJ; Snavely D; Goldberg AI; Sweet CS,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000368: Aged; D000369: Aged, 80 and over; D000959: Antihypertensive Agents; D001713: Biphenyl Compounds; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D007093: Imidazoles; D019808: Losartan; D008297: Male; D013777: Tetrazoles; D016896: Treatment Outcome",,,https://openalex.org/W2400973035,191,28,1,1241,211,6,en,en
false,randomise double blind trial intravenous diltiazem versus glyceryl trinitrate unstable angina pectoris,effect dihydropyridines patient unstable angina discourage find effect non dihydropyridine like calcium channel blocker diltiazem randomised double blind trial conduct compare diltiazem glyceryl trinitrate give intravenously patient unstable angina endpoint refractory angina myocardial infarction individually composite endpoint refractory angina alone together myocardial infarction occur significantly less commonly diltiazem group patient trial drug number refractory angina diltiazem group versus glyceryl trinitrate group relative risk p number refractory angina myocardial infarction versus relative risk p h number refractory angina versus relative risk p refractory angina myocardial infarction versus,Göbel EJ,1995,Lancet,https://doi.org/10.1016/s0140-6736(95)92837-5,8551821,Göbel EJ; Hautvast RW; van Gilst WH; Spanjaard JN; Hillege HL; DeJongste MJ; Molhoek GP; Lie KI,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000789: Angina, Unstable; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004110: Diltiazem; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D007262: Infusions, Intravenous; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D005996: Nitroglycerin",,,https://openalex.org/W2027759368,111,14,1,1045,196,6,en,en
false,calcium antagonist content justify headline,international journal clinical practicevolume issue p editorial calcium antagonist content justify headline graham jackson graham jackson editorsearch paper author graham jackson graham jackson editorsearch paper author first publish november http doi org j tb xcitations read full textaboutpdf toolsrequest permissionexport citationadd favoritestrack citation shareshare give accessshare full text accessshare full text accessplease review term condition use check box share full text version article read accept wiley online library term condition useshareable linkuse link share full text version article friend colleague learn copy url abstract available article citing literature volume issue november december pages relatedinformation,Jackson G,1995,Br J Clin Pract,,8554947,Jackson G,article,D016421: Editorial,D002121: Calcium Channel Blockers; D000075202: Contraindications; D003327: Coronary Disease; D006801: Humans; D015201: Meta-Analysis as Topic; D009203: Myocardial Infarction; D009543: Nifedipine; D011643: Publishing; D012189: Retrospective Studies,,,https://openalex.org/W2401349005,67,11,1,999,140,2,en,en
false,calcium antagonist safe,recent study generate storm controversy member nih committee calcium channel blocker give perspective,Gifford RW,1995,Cleve Clin J Med,https://doi.org/10.3949/ccjm.62.6.348,8556804,Gifford RW,article,D016421: Editorial,D002121: Calcium Channel Blockers; D002986: Clinical Trials as Topic; D004341: Drug Evaluation; D006801: Humans; D006973: Hypertension; D012307: Risk Factors,,,https://openalex.org/W2333074194,29,5,1,134,22,2,en,en
false,combination therapy metoprolol nifedipine versus monotherapy patient stable angina pectoris result international multicenter angina exercise image study,study design investigate whether combination therapy metoprolol nifedipine provide great anti ischemic effect monotherapy individual patient stable angina pectoris combination therapy beta adrenergic blocking agent reduce myocardial oxygen consumption dihydropyridine calcium antagonist increase coronary blood flow logical approach treatment stable angina pectoris however clear whether individual patient combined therapy effective monotherapy two hundred eighty patient stable angina pectoris enrol double blind trial european center patient randomize week metoprolol controlled release mg daily nifedipine retard mg twice daily week placebo alternative drug add week exercise test perform week week metoprolol nifedipine increase mean exercise time mm st segment depression comparison week p metoprolol effective nifedipine p week group randomize combination therapy increase time mm st segment depression p vs placebo analysis result individual patient reveal patient add nifedipine metoprolol patient p add metoprolol nifedipine showed increase exercise tolerance great th percentile distribution change observe corresponding monotherapy placebo group however among patient additive effect observe patient treat metoprolol nifedipine treat nifedipine metoprolol mean additive anti ischemic effect show combination therapy metoprolol nifedipine patient stable angina pectoris result additive effect individual patient rather may attribute recruitment second drug patient respond monotherapy,Savonitto S,1996,J Am Coll Cardiol,https://doi.org/10.1016/0735-1097(95)00489-0,8557899,Savonitto S; Ardissiono D; Egstrup K; Rasmussen K; Bae EA; Omland T; Schjelderup-Mathiesen PM; Marraccini P; Wahlqvist I; Merlini PA; Rehnqvist N,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004562: Electrocardiography; D005080: Exercise Test; D017079: Exercise Tolerance; D005260: Female; D006801: Humans; D008297: Male; D008790: Metoprolol; D008875: Middle Aged; D009543: Nifedipine",,,https://openalex.org/W2075509392,180,25,1,2180,389,8,en,en
false,diltiazem versus intravenous nitroglycerin treatment unstable angina pectoris randomized study,prognosis unstable angina pectoris relate admission ekg change prompt symptom control aim study compare clinical effect intravenous diltiazem dtz nitroglycerin ntg patient unstable angina pectoris study patient admit hospital history rest angina within last hour associate ekg evidence ischemia subject receive intravenous heparin oral aspirin randomly assign receive intravenous dtz receive intravenous ntg group similar baseline feature endpoint treatment recurrence angina myocardial infarction death hospitalization secondary side effect treatment dtz compare ntg result significant reduction recurrent angina respectively p number angina episode per patient respectively p low need dose increment control symptom patient respectively p common side effect observe cephalea ntg patient asymptomatic sinus bradicardia dtz patient group one patient myocardial infarction one patient die conclude intravenous dtz reduce myocardial ischemia great extent ntg safely use patient unstable angina pectoris,Castro P,1995,Rev Med Chil,,8560112,Castro P; Corbalán R; Vergara I; Kunstmann S,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D000704: Analysis of Variance; D000789: Angina, Unstable; D000925: Anticoagulants; D001241: Aspirin; D001794: Blood Pressure; D002317: Cardiovascular Agents; D004110: Diltiazem; D005260: Female; D006493: Heparin; D006801: Humans; D007275: Injections, Intravenous; D008297: Male; D008875: Middle Aged; D005996: Nitroglycerin; D010975: Platelet Aggregation Inhibitors; D011446: Prospective Studies; D014665: Vasodilator Agents",,,https://openalex.org/W107488107,110,18,2,1435,264,9,en,en
false,comparison antispastic effect bi tildiem mg tildiem mg,diltiazem tildiem mg calcium channel blocker demonstrated efficacy safety treatment stable angina pectoris spastic angina sustained release formulation diltiazem allow two daily dos bi tildiem mg already market france treatment stable angina therefore interesting evaluate efficacy safety form administer two daily dos coronary spasm versus classical formulation tildiem mg give daily dose e mg three divided dos per day conduct single centre randomize double blind cross clinical study twelve patient eleven men one woman age year present angina normal coronary artery spasm document positive methylergonovine methergin test divide two group six patient receive either tildiem follow bi tildiem bi tildiem follow tildiem characteristic two group comparable time selection visit methylergonovine test use assess efficacy two treatment improve tildiem bi tildiem compare placebo test p without significant difference tildiem bi tildiem improvement obtain patient respectively deterioration test observe tildiem bi tildiem compare placebo coronary symptom blood diltiazem level similar tildiem bi tildiem result confirm safety bi tildiem single adverse effect attribute treatment episode mild insomnia serious adverse effect observe none patient discontinue study efficacy safety tildiem bi tildiem comparable treatment spastic angina,Yvorra S,1995,Ann Cardiol Angeiol (Paris),,8561443,Yvorra S; Desfossez L; Panagides D; De La Garoullaye A; Bory M,article,"D016430: Clinical Trial; D017427: Clinical Trial, Phase II; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial","D000284: Administration, Oral; D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D003329: Coronary Vasospasm; D018592: Cross-Over Studies; D004110: Diltiazem; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008755: Methylergonovine; D008875: Middle Aged; D013607: Tablets",,,https://openalex.org/W167481628,77,15,1,1889,334,14,en,en
false,comparison efficacy safety nifedipine coat core versus amlodipine treatment patient mild moderate essential hypertension,antihypertensive efficacy safety daily nifedipine coat core compare daily amlodipine multicenter prospective double blind randomize parallel group study titration base response study consist week single blind placebo run period follow week double blind treatment period double blind treatment begin nifedipine coat core mg amlodipine mg week double blind therapy patient trough seat diastolic blood pressure dbp mm hg receive increase dose nifedipine coat core mg amlodipine mg total patient receive study medication private practice medical center ambulatory blood pressure monitoring abpm perform six medical center nifedipine coat core amlodipine patient data patient valid primary efficacy analysis treatment group well match respect baseline demographic disease characteristic study period nifedipine coat core patient remain original mg dose study medication compare amlodipine patient remain mg starting dose mean trough blood pressure baseline mm hg nifedipine coat core patient compare mm hg amlodipine patient mean trough blood pressure end point mm hg mm hg nifedipine coat core amlodipine group respectively equivalence two treatment group demonstrate base difference amlodipine nifedipine coat core change baseline trough seat dbp confidence interval systolic blood pressure hour abpm data support equivalent antihypertensive efficacy two treatment drug well tolerate similar safety profile nineteen patient amlodipine group experience least one adverse event compare nifedipine coat core group amlodipine patient tend toward late occurrence adverse event plus great number event particularly edema gastrointestinal symptom patient nifedipine coat core group n amlodipine group n discontinue treatment adverse event abstract truncate word,Zidek W,1995,Clin Ther,https://doi.org/10.1016/0149-2918(95)80045-x,8565032,Zidek W; Spiecker C; Knaup G; Steindl L; Breuer HW,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011446: Prospective Studies; D013608: Tablets, Enteric-Coated",,,https://openalex.org/W2131705789,153,20,1,2434,408,17,en,en
false,quality blood pressure control general practice hot study french research group hot hypertension optimal treatment,previous investigation french league hypertension show hypertensive age year age year bp control treatment bp mmhg international prospective randomise hot study aim assess optimal diastolic bp dbp level active antihypertensive treatment reduce best cardiovascular morbidity mortality study going completion inclusion bp measurement perform oscillometric method international bp device hestia enrollment hypertensive treat mean bp level mmhg mmhg n randomisation two week treatment withdrawal bp mmhg six month later treatment bp mmhg mean decrease mmhg compare value previous treatment depend randomisation group define different dbp objective patient bp normalisation dbp mmhg one year treatment five explanation may propose good bp control observe study compare result inclusion reflect general practice fact patient free participate inform may improve compliance patient follow reinforce first week protocol base treatment initiation dihydropyridine long duration action felodipine bp objective rigorously define dbp mmhg depend randomisation group whereas general practice physician may smooth objective mainly aim improve tolerability large use bi therapy conclusion ambitious aim bp control dbp mmhg study induce treatment intensification good bp control,Raveau-Landon C,1995,Arch Mal Coeur Vaiss,,8572869,Raveau-Landon C,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002986: Clinical Trials as Topic; D004359: Drug Therapy, Combination; D005194: Family Practice; D005260: Female; D005602: France; D006306: Health Surveys; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D011785: Quality Assurance, Health Care; D012307: Risk Factors",,,https://openalex.org/W2428204167,137,26,2,2022,386,11,en,en
false,antihypertensive treatment verapamil amlodipine,many biological psychological factor induce haemodynamic extra cardiovascular functional change mediate autonomic nervous system pharmacological blood pressure reduction neurovegetative stimulus change arousal sympathetic nervous system evaluate effect two calcium channel blocker verapamil amlodipine administer monotherapies upon sympathetic stress response randomized mild moderate essential hypertensive mmhg patient perform four stress test mental arithmetic colour word stroop cold pressor handgrip extracardiovascular haemodynamic function assess non invasively every heart beat baseline stress recovery phase sympathetic response evaluate compute area curve value x time measure psychophysiological session session repeat run placebo treatment one month treatment baseline blood pressure significantly reduce patient treat amlodipine mmhg p verapamil mmhg p emotional arousal frontalis muscular contraction skin conductance unchanged cutaneous vascular response reduce p patient treat verapamil change systolic diastolic blood pressure detectable amlodipine increase heart rate response p contrast verapamil reduce heart rate p without depress cardiac output response increase amlodipine p total vascular resistance significantly p reduce treatment consequently functional cardiac load express pressure rate product cardiac power significantly enhance amlodipine reduce verapamil conclusion abnormal sympathetic stress response characterize hypertensive patient might affect choice medication verapamil particular moderate emotional arousal vasoconstrictive response reduced cardiac load without lower cardiac output demand contrast patient treat amlodipine cardiac output response increase pattern reverse functional cardiac load also increase,Nazzaro P,1995,Eur Heart J,https://doi.org/10.1093/oxfordjournals.eurheartj.a061086,8582392,Nazzaro P; Manzari M; Merlo M; Triggiani R; Scarano AM; Lasciarrea A; Pirrelli A,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D017311: Amlodipine; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D013312: Stress, Physiological; D013315: Stress, Psychological; D016896: Treatment Outcome; D014700: Verapamil",,,https://openalex.org/W2430884699,56,6,1,2388,397,15,en,en
false,gingival overgrowth induce nifedipine cyclosporin clinical morphometric study image analysis,study develop quantitative method digital image analysis evaluate degree gingival overgrowth go compare go kidney transplant patient treat cyclosporin csa n csa nifedipine n group healthy control n method reproducible reliable finding show significant difference papillary gingival surface control transplant patient treat go inducer gingival overgrowth index also differ significantly control patient group p kruskal wallis test administration calcium channel blocker nifedipine potentiate adverse effect csa comparison morphometric finding reveal significant difference patient treat csa alone csa nifedipine papillary area dental area go index p mann whitney u test conclude method image analysis develop useful assess degree go,O'Valle F,1995,J Clin Periodontol,https://doi.org/10.1111/j.1600-051x.1995.tb00810.x,8583014,O'Valle F; Mesa F; Aneiros J; Gómez-Morales M; Lucena MA; Ramírez C; Revelles F; Moreno E; Navarro N; Caballero T,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D002121: Calcium Channel Blockers; D016022: Case-Control Studies; D016572: Cyclosporine; D004357: Drug Synergism; D005260: Female; D005500: Follow-Up Studies; D005881: Gingiva; D005885: Gingival Hyperplasia; D006801: Humans; D007091: Image Processing, Computer-Assisted; D007166: Immunosuppressive Agents; D016030: Kidney Transplantation; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D015588: Observer Variation; D010512: Periodontal Index; D010781: Photography; D015203: Reproducibility of Results; D012815: Signal Processing, Computer-Assisted",,,https://openalex.org/W1551134559,112,16,2,1009,179,6,en,en
false,effect amlodipine left ventricular mass amlodipine cardiovascular community trial,summary part amlodipine cardiovascular community trial acct large multicenter study design assess effect calcium channel blocker amlodipine besylate norvasc monotherapy treatment mild moderate hypertension seek determine effect amlodipine regression left ventricular lv hypertrophy lvh study begin week placebo run period baseline antihypertensive drug discontinue amlodipine administer mg day week titration efficacy period patient achieve goal diastolic blood pressure dbp mm hg decrease dbp mm hg enter week maintenance phase option continue long term therapy thereafter echocardiogram obtain subset patient end baseline period patient lvh baseline echocardiogram repeat end week therapy week week patient continue long term therapy thirty seven percent hypertensive patient screen lvh baseline lvh detect echocardiogram black high incidence lvh compare white p patient lvh likely high baseline systolic bp sbp dbp sit sbp dbp decrease significantly mean mm hg baseline mm hg amlodipine therapy week p amlodipine treatment produce mean decrease g lv mass index p week treatment mean decrease g lv mass week p compare baseline difference degree lv mass regression men woman old young patient trend ward less regression black g compare white g week,Kloner RA,1995,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-199509000-00018,8583790,Kloner RA; Sowers JR; DiBona GF; Gaffney M; Wein M,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D000704: Analysis of Variance; D044383: Black People; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004452: Echocardiography; D005260: Female; D006352: Heart Ventricles; D006801: Humans; D006973: Hypertension; D017379: Hypertrophy, Left Ventricular; D008297: Male; D008875: Middle Aged; D009929: Organ Size; D044465: White People",,,https://openalex.org/W2074250591,94,13,1,1932,377,12,en,en
true,randomized comparison effect four antihypertensive monotherapies subjective quality life previously untreated asymptomatic patient field trial general practice,assess equivalence four antihypertensive treatment patient mild moderate hypertension compare effect drug subjective quality life clinical safety patient age year untreated hypertension randomly allocate receive combination two diuretic altizide spironolactone beta blocker bisoprolol calcium antagonist verapamil angiotensin converting enzyme ace inhibitor enalapril follow last year composite outcome following measure use define success attendance month visit least nine supine dbp measurement study median supine dbp mmhg reduction least mmhg compare baseline value failure define one criterion fulfil equivalence conclude confidence interval success rate differ two group less clinical safety subjective quality life also assessed statistically significant difference change dbp systolic blood pressure observe group success rate diuretic beta blocker calcium antagonist ace inhibitor group respectively equivalence treatment could conclude although analysis large equivalence interval show comparison indicate equivalence significant improvement satisfaction observe certain item subjective quality life month calcium antagonist treatment group significant difference response clinical safety questionnaire observe month follow calcium antagonist beta blocker group difference longer significant months result provide evidence basis efficacy blood pressure lower ability increase short term year safety quality life favour particular treatment among studied drug newly diagnose patient mild moderate hypertension,Boissel JP,1995,J Hypertens,https://doi.org/10.1097/00004872-199509000-00018,8586825,Boissel JP; Collet JP; Lion L; Ducruet T; Moleur P; Luciani J; Milon H; Madonna O; Gillet J; Gerini P,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000319: Adrenergic beta-Antagonists; D000328: Adult; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D004232: Diuretics; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011788: Quality of Life; D012189: Retrospective Studies; D011795: Surveys and Questionnaires; D016896: Treatment Outcome,,,https://openalex.org/W1987963638,189,27,1,2140,351,9,en,en
false,hypertension non insulin dependent diabetes,effect angiotensin converting enzyme lisinopril compare calcium antagonist nifedipine non insulin dependent diabetic hypertensive patient week period patient respectively lisinopril slow release nifedipine produce similar reduction blood pressure systolic diastolic mmhg supine mmhg standing lisinopril mmhg supine mmhg stand nifedipine fast post prandial plasma glucose glycosylated haemoglobin plasma lipid appear unaffected either agent also patient lisinopril nifedipine present microalbuminuria drug induce reduction albumin excretion rate aer geometric mean x tolerance factor reduction aer among microalbuminuric patient lisinopril x micrograms min great though significantly observe nifedipine x micrograms min moreover lisinopril appear well tolerate nifedipine study population microalbuminuria important risk factor cardiovascular mortality non insulin dependent diabetic patient well general population extent reduction aer could ameliorate diabetic patient present unknown finally lisinopril nifedipine show similar antihypertensive effect patient associate significant difference plasma glucose insulin lipid concentration clinical consequence insignificant difference aer remain unclear,Crepaldi G,1995,Acta Diabetol,https://doi.org/10.1007/bf00838494,8590792,Crepaldi G; Carraro A; Brocco E; Adezati L; Andreani D; Bompiani G; Brunetti P; Fedele D; Giorgino R; Giustina G,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000419: Albuminuria; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001786: Blood Glucose; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003924: Diabetes Mellitus, Type 2; D003925: Diabetic Angiopathies; D004311: Double-Blind Method; D005260: Female; D006442: Glycated Hemoglobin; D006801: Humans; D006973: Hypertension; D007328: Insulin; D017706: Lisinopril; D008297: Male; D008875: Middle Aged; D009543: Nifedipine",,,https://openalex.org/W2941182404,47,4,1,1656,264,11,en,en
false,ritodrine nifedipine tocolytic agent preliminary comparison,effectiveness tocolytic agent betamimetic drug treatment preterm labor remain controversial effectiveness efficancy ritodrine yet convincingly prove major concern marked side effect beta mimetics calcium channel blocker nifedipine use tocolysis shortly introduction clinical practice consider probable good alternative ritodrine efficacy nifedipine versus ritodrine treatment preterm labor assess retrospective study patient receive intravenous ritodrine oral nifedipine endpoint use postponement delivery maternal side effect perinatal outcome result retrospective study suggest nifedipine successful postpone delivery ritodrine maternal side effect seem occur frequently serious patient treat ritodrine compare nifedipine perinatal outcome seem well nifedipine group ritodrine group promise data small prospective study result retrospective study warrant far large prospective study definitive place nifedipine treatment premature labor result trial available advocate use nifedipine case preterm labor especially patient diabetes mellitus rupture membrane cardiac disease multiple pregnancy order avoid characteristic side effect beta mimetics,van Dijk KG,1995,J Perinat Med,,8606348,van Dijk KG; Dekker GA; van Geijn HP,article,D003160: Comparative Study; D016428: Journal Article,"D005260: Female; D006801: Humans; D009543: Nifedipine; D007752: Obstetric Labor, Premature; D011247: Pregnancy; D012189: Retrospective Studies; D012312: Ritodrine; D015149: Tocolytic Agents; D017211: Treatment Failure",,,https://openalex.org/W2340014296,71,11,1,1567,251,12,en,en
false,twenty four hour blood pressure monitor treatment extended release felodipine versus slow release nifedipine,lack comparative study nifedipine felodipine use h blood pressure bp monitoring patient lead present study evaluate antihypertensive efficacy side effect treatment slow release sr nifedipine mg twice daily extended release er felodipine mg daily double blind study subject randomly assign one two treatment group week nifedipine sr mg twice daily follow week felodipine er mg daily even match placebo vice versa twenty four hour ambulatory bp monitoring show significant difference systolic bp sbp day significant difference diastolic bp dbp throughout h although frequency dbp recording mm hg great nifedipine felodipine treatment common side effect flush palpitation headache ankle edema adverse effect lipid profile glucose level,Carroll J,1995,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-199512000-00018,8606536,Carroll J; Shamiss A; Zevin D; Levi J; Rosenthal T,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000328: Adult; D000368: Aged; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine",,,https://openalex.org/W2044950360,123,12,1,1039,199,5,en,en
false,verapamil prophylactic treatment atrial fibrillation lung operation,atrial fibrillation frequently occur arrhythmia thoracic operation preventive strategy complication extensively evaluate cardiac operations perform prospective open randomize study compare intravenous verapamil placebo patient pneumonectomy lobectomy university hospital leuven verapamil administer bolus mg minute follow minute infusion mg min mg min day patient continuously monitor postoperative intensive care unit atrial fibrillation occur patient receive placebo patient receive verapamil difference significant verapamil infusion interrupt patient bradycardia hypotension tolerate continuous intravenous verapamil infusion show modest prophylactic efficacy occurrence atrial fibrillation lung operation dose employ verapamil infusion accompany high incidence side effect necessitate interruption therapy,Van Mieghem W,1996,Ann Thorac Surg,https://doi.org/10.1016/0003-4975(96)00073-2,8607661,Van Mieghem W; Tits G; Demuynck K; Lacquet L; Deneffe G; Tjandra-Maga T; Demedts M,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000638: Amiodarone; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D001919: Bradycardia; D006801: Humans; D007022: Hypotension; D015994: Incidence; D008875: Middle Aged; D011013: Pneumonectomy; D011183: Postoperative Complications; D011446: Prospective Studies; D012128: Respiratory Distress Syndrome; D014700: Verapamil,,,https://openalex.org/W1988650800,81,10,1,1162,179,6,en,en
false,effect gemfibrozil lopid hyperlipidemia acitretin treated patient result double blind cross study,hyperlipidemia common side effect oral retinoid treatment sometimes interferes long term therapy evaluate safety efficacy lipid lowering drug gemfibrozil retinoid associated hyperlipidemia study clinical response plasma lipoprotein level acitretin treated mg kg patient mainly suffer psoriasis gemfibrozil placebo give double blind cross fashion patient week acitretin therapy dietary advice exhibit hyperlipidemia triglyceride level baseline mmol l serum triglyceride remain high mmol l placebo treatment reduce week gemfibrozil treatment p total cholesterol level decrease slightly p gemfibrozil treatment ldl hdl ratio change significantly untoward effect gemfibrozil acitretin dose response clinical side effects note gemfibrozil thus appear useful patient prone retinoid induced hyperlipidemia unresponsive dietary treatment acitretin dose reduction,Vahlquist C,1995,Acta Derm Venereol,https://doi.org/10.2340/0001555575377380,8615057,Vahlquist C; Olsson AG; Lindholm A; Vahlquist A,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D017255: Acitretin; D000328: Adult; D000368: Aged; D002784: Cholesterol; D008076: Cholesterol, HDL; D008078: Cholesterol, LDL; D018592: Cross-Over Studies; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D015248: Gemfibrozil; D006801: Humans; D006949: Hyperlipidemias; D000960: Hypolipidemic Agents; D007641: Keratolytic Agents; D008074: Lipoproteins; D008079: Lipoproteins, VLDL; D008297: Male; D008875: Middle Aged; D010919: Placebos; D011565: Psoriasis; D014280: Triglycerides",,,https://openalex.org/W149473924,123,19,2,1163,184,7,en,en
false,long term effect plasma lipid diet drug treat hypertension,compare long term plasma lipid change among antihypertensive treatment intervention stage mild hypertension multicenter randomize double blind parallel group clinical trial four academic clinical research unit united states total men woman age year stage diastolic hypertension diastolic blood pressure mm hg recruit person screen communities participant randomize treatment group placebo beta blocker acebutolol calcium antagonist amlodipine diuretic chlorthalidone alpha antagonist doxazosin angiotensin converting enzyme inhibitor enalapril group receive intensive lifestyle counseling achieve weight loss dietary sodium alcohol reduction increase physical activity change plasma total cholesterol high density lipoprotein hdl cholesterol low density lipoprotein ldl cholesterol triglyceride baseline annual visit years mean change plasma lipid favorable group degree weight loss fat modified diet exercise significantly relate favorable lipid change significant difference p among group average change follow lipid observe decrease plasma total cholesterol ldl cholesterol great doxazosin acebutolol plasma total cholesterol mmol l mg dl respectively less chlorthalidone placebo mmol l mg dl respectively decrease triglyceride great doxazosin enalapril least acebutolol increase hdl cholesterol great enalapril doxazosin least acebutolol significant relative increase plasma total cholesterol chlorthalidone compare placebo month longer present month beyond mean plasma total cholesterol chlorthalidone group fell baseline analysis participant continue receive chlorthalidone throughout year follow indicate due solely increase percentage participant change discontinue use medication follow weight loss fat modified diet plus increased exercise produce favorable long term effect blood pressure plasma lipid fraction adult stage hypertension blood pressure reduction enhance similar degree addition drug one class antihypertensive medication drug differ quantitatively influence degree long term favorable effect blood lipid obtain nutritional hygienic treatment,Grimm RH,1996,JAMA,https://doi.org/10.1001/jama.1996.03530440029033,8622245,Grimm RH; Flack JM; Grandits GA; Elmer PJ; Neaton JD; Cutler JA; Lewis C; McDonald R; Schoenberger J; Stamler J,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000070: Acebutolol; D000317: Adrenergic alpha-Antagonists; D000319: Adrenergic beta-Antagonists; D000368: Aged; D017311: Amlodipine; D000704: Analysis of Variance; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D002752: Chlorthalidone; D002784: Cholesterol; D018752: Diet, Fat-Restricted; D004038: Diet, Reducing; D004039: Diet, Sodium-Restricted; D004232: Diuretics; D004311: Double-Blind Method; D017292: Doxazosin; D004656: Enalapril; D015444: Exercise; D005260: Female; D015438: Health Behavior; D006801: Humans; D006973: Hypertension; D016014: Linear Models; D008055: Lipids; D008137: Longitudinal Studies; D008297: Male; D008875: Middle Aged; D014280: Triglycerides; D015431: Weight Loss",,,https://openalex.org/W2027812010,74,12,1,2773,460,10,en,en
false,comparison amlodipine benazepril monotherapy amlodipine plus benazepril patient systemic hypertension randomized double blind placebo controlled parallel group study,single blind run randomize double blind parallel group placebo controlled comparison trial conduct assess safety efficacy low dose amlodipine mg daily low dose benazepril mg daily combination two drug dos use daily patient n mild moderate stage ii systemic hypertension monotherapy regimen show significantly reduce systolic diastolic blood pressure compare baseline placebo value combination regimen show superior lower systolic diastolic blood pressure compare either monotherapy regimens combination therapy also result great percentage patient successful clinical response mean sit diastolic blood pressure amlodipine benazepril regimen also show associate similar incidence adverse experience active monotherapy placebo regimen although group give combination therapy appear low incidence edema group give amlodipine alone low dose amlodipine mg plus benazepril mg provide great blood pressure lowering efficacy either monotherapy excellent safety profile,Frishman WH,1995,J Clin Pharmacol,https://doi.org/10.1002/j.1552-4604.1995.tb04027.x,8626878,Frishman WH; RAM CV; McMahon FG; Chrysant SG; Graff A; Kupiec JW; Hsu H,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001552: Benzazepines; D002121: Calcium Channel Blockers; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2040463508,190,25,1,1286,210,5,en,en
false,echocardiography acute myocardial infarction today tomorrow,,Firoozan S,1996,Indian Heart J,,8631565,Firoozan S; Kaul S,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D016454: Review","D000818: Animals; D015150: Echocardiography, Doppler; D006439: Hemodynamics; D006801: Humans; D009203: Myocardial Infarction; D015425: Myocardial Reperfusion",,,https://openalex.org/W2407293096,68,10,1,0,0,0,en,
false,effectiveness safety diltiazem lisinopril treatment hypertension heart transplantation result prospective randomized multicenter trial,purpose study determine effectiveness safety diltiazem lisinopril treatment hypertension heart transplantation systemic hypertension common heart transplantation date randomized prospective multicenter treatment trials members cardiac transplant research database group develop implement prospective randomized multicenter trial effectiveness safety diltiazem lisinopril treatment hypertension cyclosporine treated patient heart transplantation one hundred sixteen patient hypertension blood pressure mm hg heart transplantation randomize month treatment diltiazem treated patient responder diastolic blood pressure mm hg nonresponders diastolic blood pressure mm hg withdraw study lisinopril treated patient responder nonresponders withdraw difference baseline characteristic percent responder two group systolic pressure decrease mm hg mean sem diltiazem treated responder mm hg lisinopril treated responder p diastolic pressure decrease mm hg diltiazem treated responder mm hg lisinopril treated responder p total reported adverse event lead withdrawal patient study drug related side effect consider minor resolve discontinuation drug result indicate diltiazem lisinopril safe treatment hypertension heart transplantation although titrate monotherapy either drug control condition patient,Brozena SC,1996,J Am Coll Cardiol,https://doi.org/10.1016/0735-1097(96)00057-5,8636558,Brozena SC; Johnson MR; Ventura H; Hobbs R; Miller L; Olivari MT; Clemson B; Bourge R; Quigg R; Mills RM; Naftel D,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D016572: Cyclosporine; D004110: Diltiazem; D005260: Female; D016027: Heart Transplantation; D006801: Humans; D006973: Hypertension; D007166: Immunosuppressive Agents; D017706: Lisinopril; D008297: Male; D008875: Middle Aged; D011183: Postoperative Complications; D011446: Prospective Studies; D016896: Treatment Outcome,,,https://openalex.org/W1992903405,163,22,1,2004,357,8,en,en
false,ambulatory blood pressure leave ventricular change antihypertensive treatment,grandi anna bignotti massimo gaudio giovanni zanzi paolo guasti luigina venco achilla author information,Grandi AM,1995,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-199511000-00010,8637188,Grandi AM; Bignotti M; Gaudio G; Zanzi P; Guasti L; Venco A,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D005260: Female; D006801: Humans; D006973: Hypertension; D017379: Hypertrophy, Left Ventricular; D007211: Indoles; D017275: Isradipine; D008297: Male; D008875: Middle Aged; D020913: Perindopril",,,https://openalex.org/W2009146643,88,10,1,118,26,1,en,en
false,felodipine alternative expensive calcium antagonist mild moderate hypertension,study therapeutic substitution less expensive equally effective antihypertensive agent assessed patient outcome medication patient hypertension change daily diltiazem hydrochloride cardizem cd nifedipine procardia xl felodipine plendil titration final dose base home office blood pressure measurement assess subsequent follow clinic visit self administered questionnaire measure different aspect well symptom change medication eighty percent cohort switch successfully felodipine office systolic diastolic pressure improve medication change systolic mm hg versus mm hg diastolic mm hg versus mm hg statistically significant difference find among symptom measure yearly saving potential institution estimate,Landry FJ,1996,South Med J,https://doi.org/10.1097/00007611-199606000-00004,8638195,Landry FJ; Horwhat JD; Tomich D; Pinski L,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004110: Diltiazem; D016527: Drug Costs; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011446: Prospective Studies; D016896: Treatment Outcome,,,https://openalex.org/W200966644,99,14,1,945,154,8,en,en
false,correction nifedipine meta analysis,,Furberg CD,1996,Circulation,,8641044,Furberg CD; Psaty BM,article,D016422: Letter,"D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D003327: Coronary Disease; D004305: Dose-Response Relationship, Drug; D006801: Humans; D006973: Hypertension; D015201: Meta-Analysis as Topic; D009543: Nifedipine; D016032: Randomized Controlled Trials as Topic; D012306: Risk; D016896: Treatment Outcome",,,https://openalex.org/W2470742685,44,6,1,0,0,0,en,
true,rationale design third vasodilator heart failure trial v heft iii felodipine adjunctive therapy enalapril loop diuretic without digoxin chronic congestive heart failure,therapy angiotensin converting enzyme inhibitor nonselective vasodilator hydralazine isosorbide dinitrate become accepted treatment patient symptomatic chronic congestive heart failure chf demonstrate large clinical trial ameliorate symptom improve exercise performance reduce cardiac mortality nevertheless management patient chf remain therapeutic challenge second vasodilator heart failure trial v heft ii show average year mortality enalapril significantly low hydralazine isosorbide dinitrate somewhat surprisingly nonspecific vasodilator produce significantly improvement exercise performance leave ventricular function data suggest improvement symptom hemodynamics survival may afford use single class vasodilator therapy might optimize combine use different agent report describe rationale design v heft iii multicenter prospective randomize double blind placebo controlled trial compare effect chronic oral extended release felodipine felodipine er mg twice daily add stable regimen enalapril loop diuretic without digoxin exercise performance morbidity mortality patient new york heart association functional class ii iii chf follow minimum week felodipine second generation dihydropyridine calcium antagonist high degree vascular selectivity dos use study exert systemic arterial effect decrease peripheral vascular resistance without produce negative inotropic effect result v heft iii may shed important light role additive vasodilator therapy management patient chf,Boden WE,1996,Am J Cardiol,https://doi.org/10.1016/s0002-9149(96)00136-1,8644661,Boden WE; Ziesche S; Carson PE; Conrad CH; Syat D; Cohn JN,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000806: Angiotensin-Converting Enzyme Inhibitors; D002121: Calcium Channel Blockers; D002316: Cardiotonic Agents; D002908: Chronic Disease; D004077: Digoxin; D004232: Diuretics; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004656: Enalapril; D005080: Exercise Test; D015736: Felodipine; D006333: Heart Failure; D006439: Hemodynamics; D006801: Humans; D011446: Prospective Studies; D011788: Quality of Life; D012107: Research Design; D016896: Treatment Outcome; D014665: Vasodilator Agents",,,https://openalex.org/W2042735910,204,32,1,1911,308,7,en,en
false,effect nifedipine chlordiazepoxide alcohol withdrawal syndrome,aim study evaluate efficacy tolerability dhp calcium channel antagonist nifedipine human aws comparison conventional treatment chlordiazepoxide fifty nine hospitalize alcoholic sex diagnosis aws accord dsm iii r criterion treat week monotherapy nifedipine cordafen polfa mg chlordiazepoxide elenium polfa mg evaluation aws symptom perform baseline day use sandowal wang scale original scale item design measure depth dependence wgu velocity dependence syndrome appearance wwo result show group similar regard wgu wwo treatment drug cause improvement aws symptom day last till end hospitalization nifedipine well tolerate side effect observe report group multidimensional analysis perform use original computer program patient divide subgroup comparison mean value improvement index drug subgroup patient accord wgu criterion reveal nifedipine effective rd th day group group resp accord wwo criterion improvement index significantly high rd th day two group whereas one group chlordiazepoxide nifedipine action equal propose method group multidimensional analysis enable u compare effectiveness different kind aws treatment useful aid choose best drug treatment new patient,Samochowiec J,1996,Psychiatr Pol,,8650291,Samochowiec J; Fabiańczyk K; Reszczyński R; Czopek I; Pełka-Wysiecka J; Horodnicki JM,article,D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article,D000328: Adult; D014151: Anti-Anxiety Agents; D002707: Chlordiazepoxide; D000431: Ethanol; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D013375: Substance Withdrawal Syndrome; D015149: Tocolytic Agents,,,https://openalex.org/W2464211798,79,13,1,1694,290,14,en,en
false,sex age related antihypertensive effect amlodipine,community based study assess whether age sex racial difference response amlodipine mg daily patient mild moderate essential hypertension prospective open label trial week placebo period week upward drug titration efficacy period week drug maintenance period evaluable patient mean age year men woman white black year old end titration efficacy phase mean sd blood pressure bp decrease mm hg p amlodipine produce goal bp response sit diastolic bp mm hg mm hg decrease patient overall bp response great woman men p great year old year old p however similar white black vs respectively p n sex difference bp response could fully explain difference age weight dose mg kg race baseline bp compliance difference among woman base use hormone replacement therapy amlodipine well tolerate mild moderate edema common adverse effect thus amlodipine effective safe day monotherapy treatment mild moderate hypertension community based population woman great bp response amlodipine,Kloner RA,1996,Am J Cardiol,https://doi.org/10.1016/s0002-9149(97)89205-3,8651122,Kloner RA; Sowers JR; DiBona GF; Gaffney M; Wein M,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000367: Age Factors; D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D000959: Antihypertensive Agents; D044383: Black People; D001794: Blood Pressure; D001835: Body Weight; D004361: Drug Tolerance; D004487: Edema; D015914: Estrogen Replacement Therapy; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D010349: Patient Compliance; D010919: Placebos; D011446: Prospective Studies; D012737: Sex Factors; D044465: White People",,,https://openalex.org/W2014773670,59,7,1,1556,340,10,en,en
false,gingival overgrowth renal transplant patient administer cyclosporin mixture capsule form longitudinal study,cyclosporin csa induced gingival overgrowth longitudinally study adult renal transplant patient randomly assign administer csa orally mixture capsule form year csa therapy mixture capsule patient exhibit gingival overgrowth mixture patient gingival overgrowth present already month csa therapy month mixture patient exhibit increased number site gingival overgrowth region upper front low molar compare capsule patient addition relative increase gingival width interdental papilla maxillary central incisor mandibular first molars measure buccolingually stone cast also high mixture patient capsule patient stepwise multiple logistic regression analysis use nifedipine total csa dose administer first posttransplant month predictor associate gingival overgrowth study suggest concomitant administration nifedipine renal transplant patient avoid change mixture form csa capsule form consider order minimize development csa induced gingival overgrowth,Wondimu B,1996,Clin Transplant,,8652903,Wondimu B; Sandberg J; Modéer T,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D002121: Calcium Channel Blockers; D002214: Capsules; D016572: Cyclosporine; D005260: Female; D005881: Gingiva; D006801: Humans; D007166: Immunosuppressive Agents; D016030: Kidney Transplantation; D008137: Longitudinal Studies; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011897: Random Allocation,,,https://openalex.org/W2411749722,128,20,2,1303,216,6,en,en
false,clinical equivalence two tablet formulation felodipine,objective study perform assess whether new formulation felodipine extend release fer tablets mm diameter similar presently use mm diameter fer formulation respect antihypertensive effect tolerability patient essential hypertension randomised double blind placebo control three way cross study design use patient twenty four patient supine diastolic blood pressure dbp mmhg week placebo run period give fer mg mm tablet fer mg mm tablet placebo randomised order tablet give daily double blind treatment period last two week method twenty four hour ambulatory blood pressure monitoring perform end treatment period primary effect variable mean dbp hour nineteen patient hour blood pressure data valid analysis use analysis variance patient treatment period carry factor result formulation fer mg tablet significantly reduce mean hour dbp compare placebo mm tablet result average mmhg low mean hour dbp placebo however significant difference two different fer formulation fer formulation well tolerate similar placebo respect conclusion fer mg tablet formulation mm diameter give daily clinically equivalent respect antihypertensive effect tolerability patient mild moderate essential hypertension,McGrath BP,1995,Eur J Clin Pharmacol,https://doi.org/10.1007/bf00192375,8665991,McGrath BP; Watts RW; Elmfeldt DB,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D002121: Calcium Channel Blockers; D002626: Chemistry, Pharmaceutical; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D016683: Supine Position; D013810: Therapeutic Equivalency",,,https://openalex.org/W2036323196,61,8,1,1652,288,12,en,en
false,stress induced hemodynamic hemostatic change patient systemic hypertension effect verapamil,stress induced hemodynamic hemostatic response may acutely trigger atherosclerotic plaque disruption thrombosis lead myocardial infarction study design evaluate response three stressor determine daily sustain release verapamil verelan modify response study patient mild moderate hypertension randomized double blind placebo controlled crossover trial week therapy patient evaluate follow assumption upright posture mental stress cold pressor test placebo stressor produce increase systolic pressure mmhg p heart rate beats min p platelet aggregability adenosine diphosphate threshold concentration fell microm p epinephrine microm p verapamil lower systolic pressure baseline mmhg p stress mmhg p alter absolute increase stress verapamil platelet reactivity increase stress post stress response epinephrine reduce high threshold concentration compare placebo vs microm p verapamil also reduce response collagen increase lag time baseline stress vs p conclude verapamil blunt potentially harmful stress induced hemodynamic hemostatic change study require determine whether effect translate low incidence acute cardiovascular event,Gebara OC,1996,Clin Cardiol,https://doi.org/10.1002/clc.4960190313,8674257,Gebara OC; Jimenez AH; McKenna C; Mittleman MA; Xu P; Lipinska I; Muller JE; Tofler GH,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000244: Adenosine Diphosphate; D000328: Adult; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003094: Collagen; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004837: Epinephrine; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D010919: Placebos; D015539: Platelet Activation; D010974: Platelet Aggregation; D011187: Posture; D013312: Stress, Physiological; D013315: Stress, Psychological; D014665: Vasodilator Agents; D014700: Verapamil",,,https://openalex.org/W1992745139,109,14,1,1743,327,10,en,en
false,comparison nifedipine alone diltiazem verapamil hypertension,receptor bind study suggest combination calcium channel blocker may result either enhance diminished pharmacological effect clinical data hypertension incomplete study compare blood pressure reduction use nifedipine alone nifedipine plus diltiazem nifedipine plus verapamil determine whether combination alter nifedipine pharmacokinetics determination baseline blood pressure subject essential hypertension men woman mean age year receive mg open label sustain release nifedipine week still hypertensive n randomize double blind receive either additional sustain release diltiazem sustain release verapamil mg week crossed final week study medication daily extended release formulation blood pressure nifedipine plasma concentration measure final day treatment overall combination lower mean systolic diastolic pressure nifedipine alone mean supine diastolic pressure significantly low hour versus mm hg p hour versus mm hg p nifedipine plus diltiazem nifedipine plus verapamil mean nifedipine concentration inversely correlate mean blood pressure mean nifedipine area curve value great diltiazem verapamil versus ng h ml p great nifedipine alone ng h ml nifedipine plus diltiazem great antihypertensive effect nifedipine plus verapamil diltiazem cause great increase nifedipine plasma concentration verapamil data suggest combined calcium channel blocker result additive antihypertensive effect perhaps pharmacokinetic interaction,Saseen JJ,1996,Hypertension,https://doi.org/10.1161/01.hyp.28.1.109,8675249,Saseen JJ; Carter BL; Brown TE; Elliott WJ; Black HR,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003627: Data Interpretation, Statistical; D004110: Diltiazem; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D013997: Time Factors; D014700: Verapamil",,,https://openalex.org/W2079737282,78,11,1,1935,316,14,en,en
false,trial use nifedipine prevent relapse affective schizoaffective psychosis,nifedipine apply secondary prophylaxis affective phasic disorder patient affective schizoaffective psychosis treat nifedipine year mostly year dose mg daily usually mg clear prophylactic effect nifedipine observe case duration affective phase reduce frequency decrease compare control group positive therapeutic effect pronounced manic disorder transition disturbance subclinical ambulant level preventive effect drug clear affective schizoaffective psychosis respectively well expressed bipolar monopolar patient low frequency side effects occur positive characteristic nifedipine treatment especially long term therapy,Snedkova LV,1996,Zh Nevrol Psikhiatr Im S S Korsakova,,8677723,Snedkova LV,article,D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D004740: English Abstract; D016428: Journal Article,"D000328: Adult; D000341: Affective Disorders, Psychotic; D000368: Aged; D002908: Chronic Disease; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011618: Psychotic Disorders; D011619: Psychotropic Drugs; D012008: Recurrence; D013997: Time Factors",,,https://openalex.org/W2395187296,102,18,1,960,175,7,en,en
false,pointer recent multicentre trial use ambulatory monitoring place placebo perspective,journal article pointer recent multicentre trial use ambulatory monitoring place placebo perspective get access mulcahy mulcahy cardiology department adelaide meath hospitalsdublin ireland correspondence david mulcahy md mrcpi fesc consultant cardiologist adelaide hospital peter street dublin ireland search work author oxford academic pubmed google scholar european heart journal volume issue december page http doi org oxfordjournals eurheartj publish december,Mulcahy D,1995,Eur Heart J,https://doi.org/10.1093/oxfordjournals.eurheartj.a060821,8682000,Mulcahy D,article,D016430: Clinical Trial; D016420: Comment; D003160: Comparative Study; D016421: Editorial; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000319: Adrenergic beta-Antagonists; D017311: Amlodipine; D000787: Angina Pectoris; D001262: Atenolol; D003327: Coronary Disease; D004359: Drug Therapy, Combination; D015716: Electrocardiography, Ambulatory; D006801: Humans; D015990: Placebo Effect; D014665: Vasodilator Agents",,,https://openalex.org/W2285470397,100,13,1,582,92,1,en,en
true,total ischaemic burden european trial tibet effect ischaemia treatment atenolol nifedipine sr combination outcome patient chronic stable angina,study relationship presence absence ischaemic event holter monitoring occurrence hard hard soft endpoint randomize double blind parallel group study atenolol nifedipine combination ambulatory monitor treatment week randomized treatment prospective follow year average europe men woman diagnosis chronic stable angina consider surgery hard endpoint cardiac death nonfatal myocardial infarction unstable angina soft endpoint coronary artery bypass surgery coronary angioplasty treatment failure study show evidence association presence frequency total duration ischaemic event holter monitoring either treatment main outcome measure non significant trend low rate hard endpoint group receive combination therapy compliance measure withdrawal trial medication clearly poor nifedipine group similar withdrawal rate atenolol combination therapy groups recording ischaemic event h holter monitoring fail predict hard hard soft endpoint patient chronic stable angina,Dargie HJ,1996,Eur Heart J,https://doi.org/10.1093/oxfordjournals.eurheartj.a014668,8682116,Dargie HJ; Ford I; Fox KM,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D001262: Atenolol; D002121: Calcium Channel Blockers; D003327: Coronary Disease; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D015716: Electrocardiography, Ambulatory; D005060: Europe; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011446: Prospective Studies; D015996: Survival Rate; D016896: Treatment Outcome",,,https://openalex.org/W2210576597,182,30,1,1299,201,3,en,en
true,effect metoprolol v verapamil patient stable angina pectoris angina prognosis study stockholm apsis,study long term treatment effect metoprolol verapamil combined cardiovascular end point psychological variable patient stable angina pectoris randomized double blind double dummy trial study include patient year age stable angina pectoris mean age patient year woman exclusion criterion myocardial infarction within previous year contraindication beta blockers calcium antagonist patient follow month median year total patient year patient treat either metoprolol seloken zoc mg verapamil isoptin retard b acetylsalicylic acid ace inhibitor lipid lower drug long act nitrate allow study death non fatal cardiovascular event include acute myocardial infarction incapacitate unstable angina cerebrovascular peripheral vascular event psychological variable reflect quality life e psychosomatic symptom sleep disturbance evaluation overall life satisfaction combined cardiovascular event differ occur metoprolol verapamil treat patient respectively total mortality metoprolol verapamil treat patient respectively cardiovascular mortality group non fatal cardiovascular event occur metoprolol verapamil treated patient respectively psychosomatic symptom sleep disturbance significantly improve treatment group magnitude change small differ treatment life satisfaction change either drug withdrawal due side effect occur respectively long term study indicate drug well tolerate difference show effect mortality cardiovascular end point measure quality life,Rehnqvist N,1996,Eur Heart J,https://doi.org/10.1093/oxfordjournals.eurheartj.a014695,8682134,Rehnqvist N; Hjemdahl P; Billing E; Björkander I; Eriksson SV; Forslund L; Held C; Näsman P; Wallén NH,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008790: Metoprolol; D008875: Middle Aged; D011379: Prognosis; D011788: Quality of Life; D015996: Survival Rate; D013548: Sweden; D016896: Treatment Outcome; D014700: Verapamil,,,https://openalex.org/W2043076806,123,21,1,2021,322,15,en,en
false,total ischaemic burden european trial tibet effect atenolol nifedipine sr combination exercise test total ischaemic burden patient stable angina,determine effect atenolol nifedipine combination exercise parameter ambulatory ischaemic activity patient mild chronic stable angina multicentre multinational study involve patient centre nine countries placebo washout follow double blind parallel group study compare atenolol mg bd nifedipine sr mg bd combination patient underwent maximal exercise test use either bicycle n treadmill n h ambulatory st segment monitoring outside hospital environment end placebo washout period week active therapy medication alone combination cause significant improvement exercise parameter significant reduction ischaemic activity daily activity compare placebo however significant difference group measured ischaemic parameter although combination therapy result great fall rest systolic diastolic blood pressure either treatment alone management mild chronic stable angina appear little advantage gain use combination therapy ischaemia reduction,Fox KM,1996,Eur Heart J,https://doi.org/10.1093/oxfordjournals.eurheartj.a014699,8682138,Fox KM; Mulcahy D; Findlay I; Ford I; Dargie HJ,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D001262: Atenolol; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D004562: Electrocardiography; D015716: Electrocardiography, Ambulatory; D005060: Europe; D005080: Exercise Test; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009543: Nifedipine",,,https://openalex.org/W2126638897,194,34,1,1243,192,3,en,en
false,comparison nifedipine daily adalat la isosorbide mononitrate daily isosorbide dinitrate twice daily patient chronic stable angina,efficacy nifedipine gastrointestinal therapeutic system git mg isosorbide dinitrate mg b isosorbide mononitrate slow release mg assess six week double blind parallel group study patient stable angina chronic beta blocker treatment patient enter study eligible valid case analysis efficacy safety analysis nifedipine git significantly good isosorbide dinitrate p prolong time mm st segment depression time maximum st segment depression time occurrence angina total exercise duration addition reduce number angina attack glyceryl trinitrate consumption six week therapy nifedipine git also significantly good isosorbide mononitrate p prolong time occurrence angina time mm st segment depression six week therapy incidence headache considerably high isosorbide dinitrate isosorbide mononitrate group respectively nifedipine git group p main reason withdrawal study isosorbide dinitrate isosorbide mononitrate nifedipine git peripheral oedema common patient treat nifedipine git compare nitrate group p result withdrawal one patient treat nifedipine git study suggest efficacy tolerability nifedipine git superior long act nitrate second line therapy beta blockade treatment chronic stable angina,Walker JM,1996,Int J Cardiol,https://doi.org/10.1016/0167-5273(95)02531-6,8682597,Walker JM; Curry PV; Bailey AE; Steare SE,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004562: Electrocardiography; D005080: Exercise Test; D005260: Female; D006339: Heart Rate; D006801: Humans; D007548: Isosorbide Dinitrate; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D016896: Treatment Outcome; D014665: Vasodilator Agents",,,https://openalex.org/W2075967653,161,27,1,1730,312,8,en,en
false,assessment efficacy lomir treat hypertension patient early period aortocoronary bypass operation,author assess efficacy safety intravenous lomir use treat arterial hypertension coronary patient early aortocoronary shunting following parameter monitor systolic diastolic mean arterial pressure ecg pressure pulmonary artery blood gas minute volume obtain thermodilution intravenous lomir find highly effective hypotensive agent patient early period aortocoronary shunting well tolerate patient infusion easy monitor involve virtually side effect lomir improve coronary bloodstream virtually influence heart rate atrioventricular conduction pump function heart,Tskhovrebov SV,1996,Anesteziol Reanimatol,,8686946,Tskhovrebov SV; Poplavskaia LM,article,D004740: English Abstract; D016428: Journal Article,"D000328: Adult; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D001026: Coronary Artery Bypass; D004341: Drug Evaluation; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D007262: Infusions, Intravenous; D017275: Isradipine; D008297: Male; D008875: Middle Aged; D011183: Postoperative Complications; D013997: Time Factors",,,https://openalex.org/W2409931355,136,23,1,741,121,4,en,en
false,effect dihydropyridine calcium antagonist albuminuria patient diabetes,present study design assess effect two different dyhydropyridine calcium antagonist dhpcas proteinuria patient noninsulin dependent diabetes mellitus niddm hypothesis similar level blood pressure reduction two different dhpcas produce similar degree proteinuria reduction test prospective randomized study patient niddm hypertension proteinuria renal insufficiency give either isradipine n nifedipine xl n month week washout period patient cross drug observe additional month drug titrate lower arterial pressure mmhg patient also instruct follow low sodium diet initial visit blood pressure hour urine value creatinine clearance albuminuria proteinuria sodium assess monthly end initial crossover treatment period significant reduction level albuminuria baseline either drug sodium excretion meq l drug test result study support concept dhpcas reduce proteinuria patient type ii diabetes failure reduce albuminuria proteinuria occur despite adequate blood pressure reduction effort dietary sodium restriction,Abbott K,1996,J Clin Pharmacol,https://doi.org/10.1002/j.1552-4604.1996.tb04199.x,8690823,Abbott K; Smith A; Bakris GL,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000419: Albuminuria; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D003924: Diabetes Mellitus, Type 2; D004039: Diet, Sodium-Restricted; D005260: Female; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D008297: Male; D009543: Nifedipine; D011446: Prospective Studies",,,https://openalex.org/W1985549796,87,11,1,1395,242,11,en,en
true,age severe adverse drug reaction cause nifedipine verapamil,association age risk severe adverse drug reaction sadrs study hospitalized patient take nifedipine verapamil respectively nifedipine cause hypotension n tachycardia n acute renal failure n total sadr rate verapamil cause hypotension n bradycardia n atrioventricular block n total sadr rate mean age patient without sadrsr nifedipine year respectively p verapamil year respectively sex length stay comorbidity polypharmacy intake slow release preparation daily dosage new intake calcium antagonist examine potential confounders age sadr association adjust potential confounders age signficantly independently associate sadrs cause nifedipine sadrs cause verapamil ci year increase respectively although nifedipine verapamil significantly different rate sadrs age related gradient find nifedipine,Pahor M,1996,J Clin Epidemiol,https://doi.org/10.1016/0895-4356(96)00056-x,8699214,Pahor M; Manto A; Pedone C; Carosella L; Guralnik JM; Carbonin P,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000367: Age Factors; D000368: Aged; D000369: Aged, 80 and over; D002121: Calcium Channel Blockers; D015897: Comorbidity; D015986: Confounding Factors, Epidemiologic; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D012307: Risk Factors; D014700: Verapamil",,,https://openalex.org/W2032977120,72,11,1,1204,242,7,en,en
false,comparison antihypertensive effect nicardipine nitroglycerin perioperative hypertension,compare efficacy intravenous iv nicardipine nitroglycerin treatment patient perioperative hypertension forty patient perioperative hypertension randomly divide two group treat intravenous calcium entry blocker nicardipine vasodilator nitroglycerin haemodynamic measurement include mean arterial pulmonary arterial pressure central venous pulmonary capillary wedge pressure cardiac output record peripheral pulmonary vascular resistance calculated medication effective reduce blood pressure control haemodynamics maintenance continuous iv infusion nicardipine control hypertension rapidly nitroglycerin nicardipine min nitroglycerin min p without significant alteration heart rate total frequency dose adjustment require achieve therapeutic response significantly less nicardipine treated group nicardipine nitroglycerin p incidence hypotensive episode infusion observe group nicardipine nitroglycerin p intravenous nicardipine effective nitroglycerin treatment perioperative hypertension specific advantage identify stable dose response effect less hypotensive tachycardial effect use iv nicardipine treatment hypertensive patient,Chen TL,1995,Acta Anaesthesiol Sin,,8705151,Chen TL; Sun WZ; Cheng YJ; Lee TS; Lin SY; Lin CJ,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000368: Aged; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D005260: Female; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009529: Nicardipine; D005996: Nitroglycerin; D014665: Vasodilator Agents,,,https://openalex.org/W135220819,104,12,1,1532,234,6,en,en
false,calcium antagonist lithium preventive treatment manic depressive disorder,recent advance knowledge calcium role intracellular regulator allow broaden understanding possible pathophysiologic mechanism affective disorder hypothesis emerge bipolar illness arise disorder calcium regulated function give hypothesis author propose describe common profile action different mood stabilizers neural mechanism hypothesize explain various psychopharmacological treatment bipolar illness involve function critically control calcium moreover every instance known action lithium calcium dependent process could account lithium prophylactic result similarity exist action lithium calcium antagonist like verapamil nimodipine consideration hypothesis emerge calcium antagonist could alternative pharmacological agent maintenance treatment bipolar illness calcium antagonist find useful indication number investigator give safety relative lack side effect calcium channel block agent potential efficacy mood disorder conclude calcium antagonist may alternative choice prophylactic treatment bipolar illness especially patient treat lithium carbamazepine evidence use verapamil mg day time study suggest association lithium calcium antagonist result effective lithium alone calcium antagonist alone reduction episode affective disorder however concomitant administration calcium channel antagonist lithium present adverse interaction lithium toxicity cardiovascular accident probably synergistic toxic effect therefore author advise care monitor patient receive combination medication,Sarfati Y,1996,Encephale,,8706625,Sarfati Y; Spadone C; Vanelle JM; Lôo H,article,D004740: English Abstract; D016428: Journal Article; D016454: Review,"D018692: Antimanic Agents; D001714: Bipolar Disorder; D002121: Calcium Channel Blockers; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D006801: Humans; D008094: Lithium; D009553: Nimodipine; D016896: Treatment Outcome; D014700: Verapamil",,,https://openalex.org/W2293539944,87,13,1,1978,302,12,en,en
false,efficacy tolerability felodipine nifedipine stable angina refractory beta blocker therapy,medical therapy stable angina contemplates beta blockers first line combination dihydropyridines beta blocking drug enhance effectiveness single therapy nifedipine usual formulation ar burden unsatisfactory tolerability main reason study new dihydropyridines compare efficacy tolerability felodipine er mg nifedipine ar mg b patient stable angina pectoris refractory beta blocker therapy initial patient entirely evaluable study design double blind double dummy random cross placebo control patient show reproducible threshold ischemia exercise test constancy beta blocker therapy give placebo week one active drug placebo one week follow cross period week efficacy tolerability treatment evaluate clinical observation rest exercise radionuclide angiography end individual study decide blindly drug seem preferable consider symptom undesired collateral effect result exercise procedures efficacy angina active treatment different patient suffer undesired side effect nifedipine felodipine leave ventricular ejection fraction lvef rest e placebo felodipine nifedipine p n significant reduction rest lv function decrease lvef observe patient felodipine nifedipine group patient show improvement lvef exercise lvef decrease placebo nifedipine increase felodipine p vs placebo end study felodipine blindly judged superior nifedipine patient nifedipine superior case clear difference p patient stable angina refractory beta blockers addition felodipine nifedipine similar antiischemic effect however felodipine show well result lvef response exercise less side effect lead frequent blind choice felodipine versus nifedipine add beta blocker therapy,Mazzotta G,1996,G Ital Cardiol,,8707025,Mazzotta G; Falcidieno M; Ravera E; Vecchio C,article,D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D004740: English Abstract; D016428: Journal Article,D000319: Adrenergic beta-Antagonists; D000368: Aged; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D004311: Double-Blind Method; D015736: Felodipine; D006801: Humans; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D010919: Placebos; D013318: Stroke Volume; D014665: Vasodilator Agents,,,https://openalex.org/W82140395,109,17,1,2478,455,16,en,en
true,comparison enalapril versus nifedipine decrease left ventricular hypertrophy systemic hypertension preserve trial,preserve prospective randomize enalapril study evaluate regression ventricular enlargement study design provide definitive test ability enalapril achieve great left ventricular lv mass reduction nifedipine git gastrointestinal treatment system degree would prognostically meaningful population basis g achieve goal ethnically diverse population men woman essential hypertension increase lv mass screen echocardiography enrol clinical center continent study echocardiography baseline month randomize therapy blind reading echocardiogram central laboratory provide systematic information treatment effect lv structure wall motion doppler blood flow study power least test primary hypothesis enalapril induce great normalization lv mass diastolic filling nifedipine year echocardiographic trial study population follow year test hypothesis reduction lv mass independent blood pressure lowering associate reduction risk morbid fatal cardiovascular event,Devereux RB,1996,Am J Cardiol,https://doi.org/10.1016/s0002-9149(96)00228-7,8712120,Devereux RB; Dahlof B; Levy D; Pfeffer MA,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000959: Antihypertensive Agents; D004311: Double-Blind Method; D004452: Echocardiography; D004656: Enalapril; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006973: Hypertension; D017379: Hypertrophy, Left Ventricular; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011379: Prognosis; D012107: Research Design; D013997: Time Factors; D016277: Ventricular Function, Left",,,https://openalex.org/W2055132277,128,18,1,1282,212,5,en,en
false,trend determinant calcium antagonist usage acute myocardial infarction gissi experience,last decade several clinical trial patient recover acute myocardial infarction ami evaluate role calcium antagonist affect patient prognosis result disparate evidence possible harm effect benefit depend agent use evaluate evidence trial influence pattern prescription calcium antagonist assess important determinant use agent patient ami analyze retrospectively prescription calcium antagonist discharge patient recover ami enrol large randomize clinical trial gruppo italiano per lo studio della sopravvivenza nell infarto gissi gissi gissi last year progressive decrease prescription calcium antagonist evident gissi gissi gissi p presence post ami angina history hypertension occurrence reinfarction associate high usage calcium antagonist whereas use blocker discharge major independent negative determinant use calcium antagonist secondary prevention ami e without specific clinical indication use decrease approximately data indicate usage calcium antagonist gissi study strongly affect result large multicenter trial evaluate calcium antagonist agent prescribe patient ami almost exclusively presence specific indication systemic hypertension angina,Zuanetti G,1996,Am J Cardiol,https://doi.org/10.1016/s0002-9149(96)90388-4,8712135,Zuanetti G; Latini R; Avanzini F; Franzosi MG; Maggioni AP; Colombo F; Nicolis E; Mauri F,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D002121: Calcium Channel Blockers; D004363: Drug Utilization; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D010818: Practice Patterns, Physicians'; D016032: Randomized Controlled Trials as Topic; D012189: Retrospective Studies",,,https://openalex.org/W2123234419,108,16,1,1704,295,9,en,en
false,comparison effect amlodipine diltiazem hour blood pressure plasma catecholamine leave ventricular mass,patient mild moderate essential hypertension high normal left ventricular lv mass effect treatment month amlodipine mg every morning versus diltiazem sustained release sr mg twice daily hour blood pressure bp plasma catecholamine echocardiographic estimate lv mass function evaluate amlodipine diltiazem cause stable persistent bp reduction hour evidence peak effect similar decrease diastolic bp amlodipine cause significantly large decrease systolic bp amlodipine decrease bp lower total peripheral resistance whereas diltiazem cause small decrease total peripheral resistance cardiac index calcium antagonist cause modest significant decrease supine stand plasma catecholamine lv wall thickness lv mass decrease significantly month follow diltiazem g amlodipine patient take amlodipine decrease lv mass correlate significantly decrease plasma norepinephrine contrast rapid acting calcium antagonist amlodipine diltiazem sr cause smooth bp control appropriate decrease lv mass without activation sympathetic nervous system,Leenen FH,1996,Am J Cardiol,,8712143,Leenen FH; Fourney A,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002395: Catecholamines; D004110: Diltiazem; D005260: Female; D006339: Heart Rate; D006352: Heart Ventricles; D006801: Humans; D017379: Hypertrophy, Left Ventricular; D008297: Male; D008875: Middle Aged; D016277: Ventricular Function, Left",,,https://openalex.org/W2098479310,130,21,1,1346,227,8,en,en
false,twenty four hour antihypertensive efficacy felodipine mg extended release italian inter university study,summary assess h antihypertensive efficacy extended release er mg formulation dihydropyridine felodipine mild moderate essential hypertension world health organization stage ii thirty patient men woman age year mean year participate double blind randomize cross study felodipine mg er versus placebo ambulatory daytime diastolic blood pressure dbp mm hg end week run period necessary enter week treatment phase twenty nine patient complete treatment phase twenty two underwent day single blind placebo follow assess residual drug effect patient underwent ambulatory bp monitoring abpm spacelabs recorder recorder program make automatic bp heart rate hr measurement every min throughout h felodipine mg er significantly p reduce ambulatory systolic bp sbp dbp value throughout h day p night p period influencing average ambulatory hr value trough peak p ratio calculate average ambulatory bp value measure h interval second day abpm new drug administration trough noon h interval first day abpm peak bp lowering effect sbp dbp respectively individual p calculation post hoc selection nonresponders give superimposable result consistency judge mean median confidence interval ci however wide variability individual p ratio suggest method mean evaluate duration action antihypertensive drug abpm long acting bp lowering drug effect clearly show abpm perform follow sbp dbp average value h day night period still reduce felodipine mg er effectively reduce bp patient mild moderate hypertension show prolonged duration antihypertensive action beyond time next dose,Pannarale G,1996,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-199602000-00012,8720425,Pannarale G; Puddu PE; Monti F; Irace L; Bentivoglio M; Collauto F; Barsotti A; Corea L; Trevi G; Campa PP; Jacono A,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D013997: Time Factors",,,https://openalex.org/W2324403952,115,13,1,2190,403,12,en,en
false,antihypertensive drug glucose metabolism comparison diuretic felodipine new calcium antagonist add beta blocker non diabetic hypertensive woman,felodipine vascular selective antihypertensive calcium antagonist compare hydrochlorothiazide diuretic respect glucose tolerance open crossover study perform comprise non diabetic hypertensive woman age range year woman continue take beta blocker basal therapy treatment period last three month blood pressure similar irrespective treatment blood glucose value significantly different oral glucose tolerance test serum insulin level glucose administration low patient treat felodipine take hydrochlorothiazide possible explanation observation may increased insulin release consequence treatment diuretic order maintain normal blood glucose level glucose tolerance test felodipine appear preferable hydrochlorothiazide addition beta blocker hypertensive patient glucose metabolism point view,Bengtsson C,1994,Scott Med J,https://doi.org/10.1177/003693309403900304,8720766,Bengtsson C; Lapidus L,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D000368: Aged; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D004232: Diuretics; D004359: Drug Therapy, Combination; D015736: Felodipine; D005260: Female; D005947: Glucose; D005951: Glucose Tolerance Test; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D007328: Insulin; D008875: Middle Aged; D049993: Sodium Chloride Symporter Inhibitors; D016896: Treatment Outcome",,,https://openalex.org/W29504699,184,28,1,1030,160,9,en,en
false,clinical outcome mandatory formulary switch dihydropyridine calcium channel blocker therapy veteran administration medical center,recently change antihypertensive therapy similar property make base primarily cost saving hospital formulary assess blood pressure bp control adverse side effect associate switch patient nifedipine git felodipine veteran administration medical center vamc prospectively study physician record patient reported side effect medical record patient questionnaire hypertensive patient year men nonblack coronary disease undergo forced switch therapy period patient visits chart review physician unaware study conduct minimum month two visit therapy require patient inclusion mean dos nifedipine git felodipine use mg day mg day respectively use supplemental antihypertensive agent similar calcium channel blocker group systolic bps heart rate similar patient take two drug diastolic bp modestly low patient take felodipine mm hg felodipine mm hg nifedipine p difference incidence side effect patient reported provider reported two antihypertensive therapy data demonstrate hypertensive population follow vamc mandatory switching stable dihydropyridine calcium channel blocker therapy result significant change short term month bp control adverse side effect different base physician patient report source information,Gustin G,1996,Am J Hypertens,https://doi.org/10.1016/0895-7061(95)00358-4,8722433,Gustin G; White WB; Taylor S; Daragjati C,article,"D003160: Comparative Study; D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.","D000368: Aged; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003237: Connecticut; D015736: Felodipine; D005260: Female; D005572: Formularies, Hospital as Topic; D006339: Heart Rate; D006787: Hospitals, Veterans; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D017060: Patient Satisfaction; D011446: Prospective Studies; D011795: Surveys and Questionnaires; D016896: Treatment Outcome",,,https://openalex.org/W1978501852,145,20,1,1738,303,9,en,en
false,rationale design antihypertensive lipid lower treatment prevent heart attack trial allhat,newer type antihypertensive agent currently costly purchase average good good diuretic reduce coronary heart disease incidence progression lower ldl cholesterol moderately hypercholesterolemic old individual reduce incidence cardiovascular disease total mortality important medical practice public health question address antihypertensive lipid lower treatment prevent heart attack trial allhat randomize double blind trial high risk hypertensive patient allhat design determine whether combined incidence fatal coronary heart disease chd nonfatal myocardial infarction differs person randomize diuretic chlorthalidone treatment three alternative treatment calcium antagonist amlodipine angiotensin convert enzyme inhibitor lisinopril alpha adrenergic blocker doxazosin allhat also contain randomized open label lipid lowering trial design determine whether lower ldl cholesterol moderately hypercholesterolemic patient subset hydroxymethylglutaryl coenzyme hmg coa reductase inhibitor pravastatin reduce cause mortality compare control group receive usual care allhat main eligibility criterion age old systolic diastolic hypertension one additional risk factor heart attack eg evidence atherosclerotic disease type ii diabetes lipid lowering trial participant must ldl cholesterol mg dl mg dl known chd triglyceride level mg dl mean duration treatment follow plan year feature rationale design objective treatment program study organization allhat describe article,Davis BR,1996,Am J Hypertens,https://doi.org/10.1016/0895-7061(96)00037-4,8722437,Davis BR; Cutler JA; Gordon DJ; Furberg CD; Wright JT; Cushman WC; Grimm RH; LaRosa J; Whelton PK; Perry HM; Alderman MH; Ford CE; Oparil S; Francis C; Proschan M; Pressel S; Black HR; Hawkins CM,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013487: Research Support, U.S. Gov't, P.H.S.","D000959: Antihypertensive Agents; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006937: Hypercholesterolemia; D006973: Hypertension; D000960: Hypolipidemic Agents; D008297: Male; D008875: Middle Aged; D009026: Mortality; D017202: Myocardial Ischemia; D017063: Outcome Assessment, Health Care; D018401: Sample Size",,,https://openalex.org/W2166089332,113,18,1,1962,329,9,en,en
false,treat treat hospital paroxysmal supraventricular tachycardia question,academic emergency medicinevolume issue p free access treat treat hospital paroxysmal supraventricular tachycardia question marianne gausche md correspond author marianne gausche md ucla school medicine harbor ucla medical center torrance ca department emergency medicine department emergency medicine harbor ucla medical center west carson street box torrance ca fax e mail email protect search paper author marianne gausche md correspond author marianne gausche md ucla school medicine harbor ucla medical center torrance ca department emergency medicine department emergency medicine harbor ucla medical center west carson street box torrance ca fax e mail email protect search paper author first publish june http doi org j tb xcitations aboutpdf toolsrequest permissionexport citationadd favoritestrack citation shareshare give accessshare full text accessshare full text accessplease review term condition use check box share full text version article read accept wiley online library term condition useshareable linkuse link share full text version article friend colleague learn copy url share linkshare onemailfacebooktwitterlinkedinredditwechat reference brady wj debehnke dj wickman lindbeck g treatment hospital supraventricular tachycardia adenosine v verapamil acad emerg med mccabe jl adhar gc menagazzi jj et intravenous adenosine prehospital treatment paroxysmal supraventricular tachycardia ann emerg med gausche persse de sugarman et al adenosine prehospital treatment paroxysmal supraventricular tachycardia ann emerg med furlong r gerhardt rt farber p et al intravenous adenosine first line prehospital management narrow complex tachycardia em personnel without direct physician control j emerg med lozano mcintosh b giordano lm effect adenosine management supraventricular tachycardia urban paramedic ann emerg med shaw lc eitel dr walton sl et al prehospital use intravenous verapamil j emerg med madsen cd pointer je lynch tg comparison adenosine verapamil treatment supraventricular tachycardia prehospital setting ann emerg med dimarco jp mile w akhtar et al adenosine paroxysmal supraventricular tachycardia dose ranging comparison verapamil ann intern med cite literature volume issue june pages referencesrelatedinformation,Gausche M,1996,Acad Emerg Med,https://doi.org/10.1111/j.1553-2712.1996.tb03464.x,8727625,Gausche M,article,D016420: Comment; D003160: Comparative Study; D016421: Editorial,"D000241: Adenosine; D000553: Ambulatory Care; D000889: Anti-Arrhythmia Agents; D004562: Electrocardiography; D006801: Humans; D013617: Tachycardia, Supraventricular; D016896: Treatment Outcome; D014700: Verapamil",,,https://openalex.org/W1979902208,104,17,1,2939,526,37,en,en
false,treatment hospital supraventricular tachycardia adenosine v verapamil,compare use adenosine use verapamil hospital therapy supraventricular tachycardia svt period prospective adenosine use march february compare historical control period verapamil use march february svt data obtain svt patient treat metropolitan fire department based paramedic system serve population approximately million person standard drug protocol use patient outcome e conversion rate complication recurrence monitored adenosine treatment period patient svt receive adenosine convert sinus rhythm sr vagal maneuver vm result restoration sr patient patient receive adenosine non svt rhythm sinus tachycardia atrial fibrilation wide complex tachycardia wct ventricular tachycardia non svt rhythm convert sr none patient experience adverse effect twenty five patient hemodynamically unstable systolic blood pressure mm hg receive drug convert sr patient required electrical cardioversion four patient experienced adverse effect relate adenosine chest pain dyspnea prolonged bradycardia ventricular tachycardia verapamil period patient svt receive verapamil p compare adenosine period convert sr p two patient receive verapamil wct neither convert sr experience cardiovascular collapse vm result restoration sr patient p sixteen patient hemodynamically unstable receive drug p convert sr patient required electrical cardioversion p four patient experienced adverse effect relate verapamil hypotension ventricular tachycardia ventricular fibrillation recurrence svt note adenosine patient verapamil patient hospital setting adenosine patient verapamil patient ed arrival necessitate additional therapy p recurrence rate type additional therapy respectively hospital diagnosis outcome ed disposition similar groups adenosine verapamil equally successful convert hospital svt patient similar etiology responsible svt recurrence svt occur similar rate medication rhythm misidentification remain common issue hospital cardiac care emergency medical service system,Brady WJ,1996,Acad Emerg Med,https://doi.org/10.1111/j.1553-2712.1996.tb03467.x,8727628,Brady WJ; DeBehnke DJ; Wickman LL; Lindbeck G,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000241: Adenosine; D000328: Adult; D000368: Aged; D000488: Allied Health Personnel; D000553: Ambulatory Care; D000889: Anti-Arrhythmia Agents; D003131: Combined Modality Therapy; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D004554: Electric Countershock; D015716: Electrocardiography, Ambulatory; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D012008: Recurrence; D013617: Tachycardia, Supraventricular; D014700: Verapamil",,,https://openalex.org/W2093797920,81,9,1,2724,489,16,en,en
false,prediction patient response antihypertensive drug use genetic polymorphism investigation renin angiotensin system gene,objective investigate whether polymorphism angiotensinogen agt gene insertion deletion polymorphism angiotensin converting enzyme ace gene predict blood pressure response different antihypertensive agent design sixty three patient untreated essential hypertension randomly assign placebocontrolled crossover comparison atenolol mg daily lisinopril mg daily nifedipine sr mg twice daily effect blood pressure assess ambulatory blood pressure monitoring abpm patient placebo controlled abpm data available treatment single agent atenolol mg daily case lisinopril mg daily case change systolic diastolic blood pressure achieve agent analyse association genotype agt ace gene locus method polymerase chain reaction pcr amplification genomic dna individual use identify polymorphism ace gene polymorphism agt gene detect tf digestion pcr product result significant association response drug either agt ace polymorphism conclusion large variability individual observed blood pressure response agent attribute polymorphism analyse ace agt locus,Dudley C,1996,J Hypertens,https://doi.org/10.1097/00004872-199602000-00016,8728305,Dudley C; Keavney B; Casadei B; Conway J; Bird R; Ratcliffe P,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000483: Alleles; D000704: Analysis of Variance; D000808: Angiotensinogen; D000959: Antihypertensive Agents; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D018592: Cross-Over Studies; D004247: DNA; D005260: Female; D005838: Genotype; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D007703: Peptidyl-Dipeptidase A; D016133: Polymerase Chain Reaction; D011110: Polymorphism, Genetic; D012084: Renin-Angiotensin System",,,https://openalex.org/W2028756148,134,16,1,1464,246,7,en,en
true,high salt intake cause hyperfiltration patient essential hypertension,animal model salt dependent hypertension hyperfiltration associate fast decline renal function evidence hypertensive man increase creatinine clearance marker early hypertensive nephropathy study influence salt intake glomerular filtration rate gfr creatinine clearance patient mild hypertension patient study random order accord crossover design habitual salt intake high salt intake ie habitual mmol day low salt intake habitual mmol day protein calcium potassium intake fix across three study period control group form seven healthy subject high salt intake cause significant p increase h mean arterial pressure map expected suppression plasma renin activity pra plasma aldosterone seven patient classify salt sensitive gfr significantly high p high salt intake ml min habitual ml min low salt intake ml min aggregate urinary salt excretion significantly relate gfr p correlation analysis repeated observation slope relationship predict mmol day increase salt intake associate ml min rise gfr relationship gfr h urinary salt salt sensitive patient differ salt resistant patient gfr response salt loading largely independent renin aldosterone system change arterial pressure gfr observe healthy subject fixed protein intake change salt intake physiological range associate important gfr variation mild hypertensive long hyperfiltration mild hypertension predictor renal function deterioration high salt intake independent effect arterial pressure could factor contribute nephronic obsolescence patient essential hypertension,Mallamaci F,1996,J Hum Hypertens,,8733032,Mallamaci F; Leonardis D; Bellizzi V; Zoccali C,article,D016428: Journal Article,"D000328: Adult; D000368: Aged; D004573: Electrolytes; D005919: Glomerular Filtration Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D012982: Sodium, Dietary",,,https://openalex.org/W140430390,84,12,1,2109,378,14,en,en
false,great reduction urinary albumin excretion hypertensive type ii diabetic patient incipient nephropathy lisinopril nifedipine,double blind randomise parallel group multicentre multinational study compare effect month treatment lisinopril mg daily nifedipine retard tablet mg twice daily male age year post menopausal female age year history clinically stable type ii diabetes month microalbuminuria early diabetic nephropathy urinary albumin excretion uae rate range micrograms min sit diastolic blood pressure dbp mm hg korotkoff phase v inclusive entry week placebo treatment aim treatment achieve reduction sit dbp mm hg h last dose lisinopril hour last dose nifedipine evaluate effect treatment uae month effect two treatment ambulatory blood pressure bp also evaluate subset patient management diabetes oral hypoglycaemic drug diet insulin alone combination permit median uae fell lisinopril range micrograms min baseline micrograms min month nifedipine median uae fell range micrograms min baseline micrograms min month estimated median difference effect two treatment micrograms min p month treatment produce similar fall sit bp mm hg mean mm hg lisinopril mm hg mm hg nifedipine ambulatory bp assess subset patient use area bp time curve auc comparison effect two treatment show treatment difference creatinine clearance glycaemic control hba c lipid profile change significantly either treatment frequency withdrawal adverse event similar treatment conclude lisinopril significantly beneficial effect uae nifedipine despite similar effect bp glycaemic control type ii diabetic patient hypertension,Agardh CD,1996,J Hum Hypertens,,8733038,Agardh CD; Garcia-Puig J; Charbonnel B; Angelkort B; Barnett AH,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000328: Adult; D000368: Aged; D000419: Albuminuria; D003924: Diabetes Mellitus, Type 2; D003928: Diabetic Nephropathies; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D017706: Lisinopril; D008297: Male; D008875: Middle Aged; D009543: Nifedipine",,,https://openalex.org/W1824174105,149,21,1,2292,427,14,en,en
false,study efficacy felodipine give twice daily management elderly hypertensive patient,use medication give daily clinical practice may lead inadequate control blood pressure bp h medication frequently titrate time peak effect twenty three patient age complete study receive placebo felodipine mg daily felodipine mg hourly felodipine mg daily randomized double blind crossover design bp response assess clinic h medication h ambulatory monitoring trough peak ratio define fall bp rd th hour post dose divide fall bp rd th hour post dose bp fell three regime clinic bps differ low placebo peak bp response ambulatory bp monitor record similar dose great percentage effect maintain prior morning dose mg hourly mg daily felodipine mg daily reduces bp people effect persist h however dose use bp measure prior dose drug ensure h control maintain felodipine mg daily felodipine mg b equally effective maintain control significant advantage use twice daily regime felodipine mg daily high dos use bp titrate post dose knowledge effect still present prior next dose drug thus daily felodipine extend release er mg use effectively maintain bp control h clinical practice elderly patient felodipine er mg daily adequate regime,Morgan T,1996,J Hum Hypertens,,8733039,Morgan T; Morgan O; Anderson A,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D015736: Felodipine; D006801: Humans; D006973: Hypertension",,,https://openalex.org/W185420170,115,20,1,1780,343,12,en,en
false,decrease blood viscosity serum level erythropoietin anti hypertensive treatment amlodipine metoprolol result cross study,increased viscosity blood hypertensive patient assume risk factor development cardiovascular disease aim present study elucidate whether anti hypertensive treatment impact blood rheology twenty patient previously untreated hypertension consecutively attend outpatient hypertension clinic include prospective open cross study patient randomly select treatment amlodipine metoprolol anti hypertensive therapy switch month haemorheological haemodynamic variable measure rotational viscometry impedance cardiography respectively fifteen patient could evaluate amlodipine metoprolol treatment respectively mean blood pressure bp decrease mm hg amlodipine mm hg metoprolol therapy amlodipine treatment total peripheral resistance index decrease whereas metoprolol treatment accompany decrease cardiac index decrease whole blood viscosity haematocrit serum erythropoietin find amlodipine well metoprolol treatment amlodipine plasma viscosity decrease erythrocyte deformability increase majority patient plasma fibrinogen decrease metoprolol treatment despite difference haemodynamic mechanism underlie decrease bp amlodipine metoprolol exert beneficial effect blood viscosity haemodilution decrease serum erythropoietin may factor underlie decrease blood viscosity,Linde T,1996,J Hum Hypertens,,8733040,Linde T; Sandhagen B; Hägg A; Mörlin C; Danielson BG,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D017311: Amlodipine; D001772: Blood Cell Count; D001774: Blood Chemical Analysis; D001809: Blood Viscosity; D018592: Cross-Over Studies; D004921: Erythropoietin; D005260: Female; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D008297: Male; D008790: Metoprolol; D008875: Middle Aged,,,https://openalex.org/W17607991,156,22,1,1720,265,14,en,en
false,calcium antagonism perspective new data diltiazem unstable angina,,van Gilst WH,1996,Eur Heart J,https://doi.org/10.1093/oxfordjournals.eurheartj.a014892,8733072,van Gilst WH; Lie KI,article,D016421: Editorial,"D000789: Angina, Unstable; D002121: Calcium Channel Blockers; D002986: Clinical Trials as Topic; D004110: Diltiazem; D006801: Humans; D016896: Treatment Outcome",,,https://openalex.org/W2314395938,75,12,1,0,0,0,en,
false,evaluation amlodipine stable effort angina comparison diltiazem term efficacy tolerability maintenance anti ischemic action hour last dose,patient enrol multicentre randomize open study assess efficacy amlodipine stable effort angina preselected patient submit one week placebo wash period nitrate molsidomine authorize patient randomize receive either mg amlodipine morning dose mg diltiazem three divided dos two week dosage able increase accord clinical efficacy mg amlodipine single dose mg diltiazem four divided dos antianginal efficacy two treatment essentially evaluate term result stress test st conduct end second week fourth week active treatment hour last dose drug result patient scrupulously comply protocol show amlodipine diltiazem correct improve st parameter time onset amplitude st depression duration st work perform anti ischaemic action amlodipine maintain least hour last dose therefore provide good security cover entire hour period good compliance tolerate dose omission several hour,Marchand X,1996,Ann Cardiol Angeiol (Paris),,8734139,Marchand X; Tibi T; Bernaud C; Morand P,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D017311: Amlodipine; D000787: Angina Pectoris; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004110: Diltiazem; D005080: Exercise Test; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D005082: Physical Exertion; D014665: Vasodilator Agents,,,https://openalex.org/W2403816984,186,32,2,1285,234,7,en,en
false,anti ischaemic efficacy l propionylcarnitine promising novel metabolic approach ischaemia,l propionylcarnitine naturally occur derivative l carnitine essential mitochondrial fatty acid transport high energy phosphate exchange acutely reduce myocardial ischaemia improve ischaemia induced cardiac dysfunction follow intravenous administration randomized crossover study design compare long term anti ischaemic effect oral l propionylcarnitine diltiazem patient stable exercise induced angina week washout phase anti anginal medication week single blind placebo period patient include study receive mg l propionylcarnitine daily week diltiazem mg daily week follow mg daily week cross treatment week washout period three patient l propionylcarnitine two diltiazem discontinue treatment result comparable exercise duration mean sem time mv st depression increase time mv st depression baseline l propionylcarnitine diltiazem respectively diltiazem decrease rate pressure product rest exercise l propionylcarnitine compound significantly reduce st depression maximal exercise l propionylcarnitine v diltiazem p diltiazem vs l propionylcarnitine diltiazem increase time onset angina contrast significant change occur l propionylcarnitine study anginal attack reduce nitroglycerin consumption decrease l propionylcarnitine diltiazem respectively thus l propionylcarnitine high dose diltiazem result anti ischaemic effect decrease anginal attack daily life although effect diltiazem exercise induced ischaemia appear pronounced l propionylcarnitine novel metabolic approach ischaemia warrant far development,Bartels GL,1996,Eur Heart J,https://doi.org/10.1093/oxfordjournals.eurheartj.a014874,8737216,Bartels GL; Remme WJ; Holwerda KJ; Kruijssen DA,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D001794: Blood Pressure; D002316: Cardiotonic Agents; D002317: Cardiovascular Agents; D002331: Carnitine; D018592: Cross-Over Studies; D004110: Diltiazem; D004311: Double-Blind Method; D015716: Electrocardiography, Ambulatory; D005080: Exercise Test; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D016896: Treatment Outcome",,,https://openalex.org/W2005398415,101,13,1,2079,348,12,en,en
false,comparison bid tid regimen improve compliance improved antihypertensive effect,objective compare compliance antihypertensive treatment administer either twice daily three time daily two formulation antihypertensive treatment use nicardipine regular tablet slow release tablet b bioequivalent daily dosage use study study design open control parallel design study centralise randomise allocation treatment group tid group nicardipine mg tablet three time daily month bid group capsule slow release sr nicardipine mg twice daily month patient hypertensive patient investigate general practitioner compliance nicardipine assess mean standardised interview patient questionnaire investigator result compliance slightly high bid tid group patient first group declare compliance compare second group statistically significant relationship show compliance nicardipine decrease blood pressure three month therapy however significant difference notice two group patient absolute decrease blood pressure treatment period mm hg tid group compare mm hg bid group conclusion difference compliance bioequivalent bid tid formulation active agent show hypertensive patient however difference large enough lead difference either number controlled patient decrease blood pressure reduce number daily dos automatically lead great efficacy treatment,Boissel JP,1996,Eur J Clin Pharmacol,https://doi.org/10.1007/s002280050070,8739813,Boissel JP; Meillard O; Perrin-Fayolle E; Ducruet T; Alamercery Y; Sassano P; Benghozi R,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009529: Nicardipine; D010349: Patient Compliance; D016312: Treatment Refusal,,,https://openalex.org/W2068382479,104,16,1,1825,328,14,en,en
false,cardiac function improvement hour isradipine sro patient chronic stable angina double blind randomized study,recently show isradipine calcium antagonist dihydropyridine group reduce ischemia improve ventricular function rest exercise hour single oral dose patient chronic stable angina present study evaluate effect long act slow release oral sro isradipine mg compare placebo coronary patient stable chronic angina randomize double blind fashion following parameter obtain rest submaximal exercise left right ventricular lv rv ejection fraction ef peak filling rate pfr edv assess gated radionuclide angiography clinical symptom electrocardiogram ecg st segment depression mm systolic diastolic blood pressure sbp dbp mm hg patient give two oral dos either isradipine placebo one day parameter reassess rest n equivalent exercise hour later hour last administration drug result isradipine n show rest significant increase lvef pfr respectively decrease dbp exercise significant increase lvef tot decrease st segment depression tot significant change observe placebo patient conclude even hour oral administration isradipine sro maintain beneficial effect rest lv systolic diastolic function pressure exercise ecg sign ischemia improvement lv ejection fraction,Doat M,1996,Acta Cardiol,,8742912,Doat M; Hacot JP; Pavin D; Righetti A,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D005080: Exercise Test; D017079: Exercise Tolerance; D005260: Female; D015637: Gated Blood-Pool Imaging; D006321: Heart; D006801: Humans; D017275: Isradipine; D008297: Male; D008875: Middle Aged; D013318: Stroke Volume; D016896: Treatment Outcome; D016276: Ventricular Function,,,https://openalex.org/W2414677273,131,20,1,1745,350,8,en,en
true,comparative study efficacy safety low dose diltiazem betaxolol combination digoxin control ventricular rate chronic atrial fibrillation randomize crossover study,background combination therapy low dose diltiazem bexatolol digoxin useful adjunct achieve heart rate control minimal side effect study include patient impaired leave ventricular function evaluate whether beneficial effect medication maintain followup period objective purpose study three fold compare efficacy digoxin low dose diltiazem digoxin low dose betaxolol randomize crossover study evaluate whether beneficial effect medication maintain month evaluate safety combination therapy patient impaired leave ventricular function method prospective randomize crossover study patient chronic atrial fibrillation af include patient left ventricular dysfunction enrollment patient evaluate heart rate blood pressure rate pressure product maximal exercise tolerance rest symptom limited treadmill test medication week medication digoxin mg daily diltiazem mg twice daily week digoxin betaxolol mg daily perform h ambulatory electrocardiogram ecg patient end phase treatment repeat symptom limited treadmill test like method patient month medication result ventricular rate significantly reduce digoxin low dose betaxolol therapy rest exercise mean e beats min respectively comparison digoxin low dose diltiazem therapy p rate pressure product significantly less digoxin low dose betaxolol rest exercise mmhg min digoxin low dose diltiazem therapy p exercise capacity significantly improve digoxin low dose betaxolol mets digoxin low dose diltiazem comparison control state p month evaluation significant difference week month result h ambulatory ecg show finding treadmill test although side effect occur frequently digoxin low dose betaxolol therapy minimal patient withdraw medication worsening left ventricular dysfunction observe conclusion study suggest combination therapy low dose betaxolol digoxin superior low dose diltiazem digoxin control ventricular rate reduce ratepressure product effect control ventricular rate reduce rate pressure product improve excercise capacity well maintain even month medication combination therapy,Koh KK,1995,Int J Cardiol,https://doi.org/10.1016/0167-5273(95)02480-k,8749878,Koh KK; Song JH; Kwon KS; Park HB; Baik SH; Park YS; In HH; Moon TH; Park GS; Cho SK,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D015784: Betaxolol; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002908: Chronic Disease; D018592: Cross-Over Studies; D004077: Digoxin; D004110: Diltiazem; D004359: Drug Therapy, Combination; D017079: Exercise Tolerance; D005260: Female; D006339: Heart Rate; D006439: Hemodynamics; D006801: Humans; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D018487: Ventricular Dysfunction, Left",,,https://openalex.org/W2001561006,190,27,1,3006,556,16,en,en
false,antianginal effect conventional controlled release diltiazem stable angina pectoris,two preparation diltiazem control release cr give twice day b plain give time day q compare multicentre double blind crossover study patient stable angina pectoris therapeutic efficacy assess maximal exercise test patient recording nitroglycerine consumption angina attack significant difference cr plain tablet see efficacy variable maximal workload significantly increase w placebo w cr tablet w plain tablet anginal attacks week significantly decrease placebo cr tablet plain tablet consumption nitroglycerine tablets week significantly decrease placebo cr plain tablets respectively number seriousness adverse event differ group result imply diltiazem cr b equally potent safe conventional diltiazem q control stable angina pectoris,Boman K,1995,Eur J Clin Pharmacol,https://doi.org/10.1007/bf00192354,8751017,Boman K; Saetre H; Karlsson LG; Ritter B; Marsell R; Wingman H; Lövheim O; Michaeli EW; Löfdahl P; Olsson SO,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000368: Aged; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D004110: Diltiazem; D004311: Double-Blind Method; D005080: Exercise Test; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D016037: Single-Blind Method,,,https://openalex.org/W2027723540,93,12,1,1072,191,12,en,en
false,czech slovak spirapril intervention study cassis,randomized double blind placebo active controlled multicentre study spirapril new angiotensin converting enzyme inhibitor acei conduct patient chronic congestive heart failure chf nyha class ii iv placebo run period week patient randomly assign one five treatment group placebo n spirapril mg n spirapril mg n spirapril mg n enalapril mg n primary objective assess change exercise tolerance secondary objective assessment cardiovascular sign symptom quality life ejection fraction chest x ray finding exercise tolerance increase group however statistically significant difference find group statistically significant reduction mortality pooled spirapril group compare placebo trend reduction serious cardiovascular adverse event well duration hospitalization effect improvement lung congestion appear dose dependent patient moderate severe heart failure combination first generation calcium channel blocker unfavourable effect exercise capacity clinical parameter spirapril might effective alternative enalapril treatment patient chf role exercise tolerance test establish efficacy aceis chf widespread use nifedipine chf question,Widimský J,1995,Eur J Clin Pharmacol,https://doi.org/10.1007/bf00192366,8751029,Widimský J; Kremer HJ; Jerie P; Uhlír O,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000806: Angiotensin-Converting Enzyme Inhibitors; D018153: Czech Republic; D004311: Double-Blind Method; D004656: Enalapril; D005080: Exercise Test; D017079: Exercise Tolerance; D005260: Female; D006333: Heart Failure; D006801: Humans; D008297: Male; D008875: Middle Aged; D011355: Prodrugs; D018154: Slovakia,,,https://openalex.org/W1993371098,54,9,1,1548,274,9,en,en
false,prognostic significance transient ischemic episode response treatment show improve prognosis result total ischemic burden bisoprolol study tibbs follow,objective total ischemic burden bisoprolol study tibbs follow examine cardiac event rate relation translent ischemia treatment background nuclear whether transient ischemia ambulatory electrocardiogram prognostic implication stable angina whether medical treatment improve prognosis method tibbs trial week randomize control comparison effect bisoprolol nifedipine transient ischemic episode patient stable angina pectoris patient screen could follow rate cardiac noncardiac death nonfatal acute myocardial infarction hospital admission unstable angina need coronary artery bypass graft surgery percutaneous transluminal coronary angioplasty record result total event occur patient patient six episode event rate compare patient two six episode patient less two episode p hard event death acute myocardial infarction hospital admission unstable angina pectoris frequent patient two ischemic episode vs p patient response rate transient ischemic episode tibbs trial event rate year compare non responder p patient receive bisoprolol tibbs trial low event rate year patient randomize nifedipine p conclusion patient stable angina pectoris frequent episode transient ischemia marker increased event rate response medical treatment reduce event rate great reduction ischemia bisoprolol nifedipine tibbs trial translate animproved outcome year,Von Arnim T,1996,J Am Coll Cardiol,https://doi.org/10.1016/0735-1097(96)00122-2,8752790,Von Arnim T,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D017298: Bisoprolol; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D018572: Disease-Free Survival; D004311: Double-Blind Method; D015716: Electrocardiography, Ambulatory; D005500: Follow-Up Studies; D006801: Humans; D017202: Myocardial Ischemia; D009543: Nifedipine; D018579: Patient Selection; D011379: Prognosis; D013997: Time Factors",,,https://openalex.org/W2158598053,174,25,1,1946,356,18,en,en
false,nifedipine scare hypertension fact fiction,,Gambhir DS,1996,Indian Heart J,,8755005,Gambhir DS,article,D016421: Editorial,D002121: Calcium Channel Blockers; D002986: Clinical Trials as Topic; D006801: Humans; D006973: Hypertension; D009543: Nifedipine,,,https://openalex.org/W2472493767,54,10,1,0,0,0,en,
true,calcium channel blockade incidence cancer aged population,calcium channel blocker alter apoptosis mechanism destruction cancer cell examine whether long term use calcium channel blocker associate increase risk cancer carry prospective cohort study people age year live three region massachusetts iowa connecticut usa take calcium channel blocker n compare participant n incidence cancer assess survey hospital discharge diagnosis cause death outcome validate cancer registry one region available demographic variable disability cigarette smoking alcohol consumption blood pressure body mass index use drug hospital admission cause comorbidity assess possible confound factors hazard ratio cancer associate calcium channel blocker person years event compare take calcium channel blocker person years event ci p adjustment confound factor significant dose response gradient find hazard ratio associate verapamil diltiazem nifedipine differ significantly result remain unchanged community specific analysis association calcium channel blocker cancer find common cancers calcium channel blocker associate general increase risk cancer study population suggest common mechanism observational finding confirm study,Pahor M,1996,Lancet,https://doi.org/10.1016/s0140-6736(96)04277-8,8757150,Pahor M; Guralnik JM; Ferrucci L; Corti MC; Salive ME; Cerhan JR; Wallace RB; Havlik RJ,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000368: Aged; D000369: Aged, 80 and over; D002121: Calcium Channel Blockers; D015986: Confounding Factors, Epidemiologic; D004305: Dose-Response Relationship, Drug; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D015999: Multivariate Analysis; D009369: Neoplasms; D011446: Prospective Studies; D012042: Registries; D012307: Risk Factors; D014481: United States",,,https://openalex.org/W1971027475,68,9,1,1717,283,11,en,en
false,calcium antagonist cause cancer,,Kaplan NM,1996,Lancet,https://doi.org/10.1016/s0140-6736(96)24034-6,8757160,Kaplan NM,article,D016420: Comment; D016422: Letter,D000368: Aged; D001943: Breast Neoplasms; D002121: Calcium Channel Blockers; D016022: Case-Control Studies; D005260: Female; D006801: Humans; D009369: Neoplasms,,,https://openalex.org/W2154189241,36,6,1,0,0,0,en,
false,multiple drug allergy syndrome matched control retrospective study patient allergic penicillin,skin test reaction side chain penicillin determinant j allergy clin immunol saxon beall gn rohr et al immediate hypersensitivity reaction beta lactam antibiotic ann intern med thoborn r johnson je iii cluft le study epidemiology adverse drug reaction iv relationship cephalothin penicillin allergy jama igea jm fraj j darila et al allergy cefazolin study vivo cross reactivity beta lactams ann allergy,Khoury L,1996,J Allergy Clin Immunol,https://doi.org/10.1016/s0091-6749(96)70172-0,8757225,Khoury L; Warrington R,article,D003160: Comparative Study; D016428: Journal Article,"D016022: Case-Control Studies; D005260: Female; D006801: Humans; D006969: Hypersensitivity, Immediate; D008297: Male; D018777: Multiple Chemical Sensitivity; D010406: Penicillins; D012223: Rhinitis, Vasomotor; D012882: Skin Tests",,,https://openalex.org/W1965916118,108,15,1,556,115,16,en,en
true,diltiazem improve cardiac function exercise capacity patient idiopathic dilate cardiomyopathy,background evidence arise calcium antagonist idiopathic dilate cardiomyopathy idc may beneficial effect virus induced cardiopathology alcohol toxicity microcirculatory disorder impaired calcium cycling possibly involve pathogenesis disease thus effect adjunct diltiazem mg tid standard treatment investigate method result diltiazem dilate cardiomyopathy didi trial randomized double blind placebo controlled multicenter trial patient receive diltiazem receive placebo idc diagnose coronary angiography catheterization left side heart left ventricular ejection fraction mean effect adjunct diltiazem treatment transplant listing free survival hemodynamics exercise capacity subjective status investigate month study period patient drop study patient finish study protocol twenty seven patient die listing heart transplantation placebo group diltiazem group transplant listing free survival rate diltiazem placebo recipient p month diltiazem significantly increase cardiac index rest p workload p systolic diastolic pressure p p stroke volume index p stroke work index p decrease pulmonary artery pressure workload p heart rate p diltiazem also increase exercise capacity p subjective well p adverse reaction minor evenly distribute group except increase pq interval diltiazem group conclusion patient idc adjunct therapy diltiazem improves cardiac function exercise capacity subjective status without deleterious effect transplant listing free survival,Figulla HR,1996,Circulation,https://doi.org/10.1161/01.cir.94.3.346,8759075,Figulla HR; Gietzen F; Zeymer U; Raiber M; Hegselmann J; Soballa R; Hilgers R,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D002121: Calcium Channel Blockers; D002311: Cardiomyopathy, Dilated; D004110: Diltiazem; D005260: Female; D006304: Health Status; D006321: Heart; D016027: Heart Transplantation; D006801: Humans; D008297: Male; D008875: Middle Aged; D005082: Physical Exertion; D016019: Survival Analysis",,,https://openalex.org/W2031850393,108,13,1,2023,360,11,en,en
false,trough peak ratio nifedipine gastrointestinal therapeutic system nifedipine retard essential hypertensive patient italian multi centre study,evaluate antihypertensive effect nifedipine gastrointestinal therapeutic system retard term trough peak ratio efficacy according double blind randomize crossover design patient mild moderate essential hypertension month placebo washout receive mg day nifedipine gastrointestinal therapeutic system mg nifedipine retard twice day corresponding placebo month end treatment period blood pressure measure use mercury sphygmomanometer trough h last dosing peak effect identify maximum decrement induce three randomize treatment respect value end placebo washout period h interval trough peak ratio systolic diastolic blood pressure calculate group ratio individual ratio decrement induce nifedipine gastrointestinal therapeutic system retard correct induce randomized placebo patient define responder randomize treatment diastolic blood pressure trough time reduce least mmhg relative corresponding time end placebo washout nifedipine gastrointestinal therapeutic system retard significantly reduce blood pressure similar extent trough peak systolic diastolic group trough peak ratio responder nifedipine gastrointestinal therapeutic system n respectively responder nifedipine retard n respectively percentage patient trough peak ratio systolic trough peak ratio diastolic trough peak ratio nifedipine formulations data show mg day nifedipine gastrointestinal therapeutic system mg nifedipine retard twice day favourable trough peak ratio efficacy give monotherapy essential hypertensive patient,Salvetti A,1996,J Hypertens,https://doi.org/10.1097/00004872-199605000-00017,8762211,Salvetti A; Virdis A; Taddei S; Ambrosoli S; Caiazza A; Gandolfi E; del Prato C; Saba G; nello Ceccarelli C; Buoninconti R; Spadari G; Kilama MO,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine,,,https://openalex.org/W2036648650,156,22,1,2035,343,7,en,en
false,metabolic neutrality combined verapamil trandolapril treatment contrast beta blocker low dose chlortalidone treatment hypertensive type diabetes,objective investigate metabolic antihypertensive albuminuria modifying effect heart rate modulating calcium antagonist angiotensin convert enzyme inhibitor combination compare p blockerlow dose diuretic combination non insulin dependent diabetic hypertensive design prospective randomize double blind study subject method twenty four diabetic diastolic blood pressure mm hg without azotemia plasma creatinine level mol l evaluate week receive placebo week receive treatment either combined slow release verapamil retard formulation trandolapril mean maintenance dos mg daily atenolol chlortalidone mg daily insulin sensitivity minimal model method bergman additional metabolic variable clinic blood pressure ambulatory blood pressure profile renal index assess end placebo active treatment phase result compare placebo two therapy produce similar decrease mean supine clinic blood pressure versus means sem upright clinic blood pressure versus ambulatory daytime blood pressure versus however although verapamil trandolapril combination find metabolically neutral atenolol chlortalidone combination aggravate insulin resistance insulin sensitivity index x min per u per ml increase serum triglyceride level decrease high density lipoprotein cholesterol plasma potassium level although therapy tend reduce h albuminuria significant verapamil trandolapril treatment conclusion effect antihypertensive drug include diuretic blockers cardiovascular morbidity mortality non insulin dependent diabetic patient know rational treatment selection presently base surrogate end points therefore triad metabolic neutrality antihypertensive antiproteinuric efficacy support combine verapamil trandolapril potentially valuable therapy hypertension accompany diabetes mellitus,Schneider M,1996,J Hypertens,https://doi.org/10.1097/00004872-199605000-00018,8762212,Schneider M; Lerch M; Papiri M; Buechel P; Boehlen L; Shaw S; Risen W; Weidmann P,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D050260: Carbohydrate Metabolism; D002752: Chlorthalidone; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006973: Hypertension; D007211: Indoles; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D014700: Verapamil",,,https://openalex.org/W2022839328,158,17,1,2250,340,9,en,en
false,double blind randomize comparative study two antihypertensive combination enalapril hydrochlorothiazide versus enalapril nifedipine hypertensive patient resistant monotherapy,combination two antihypertensive drug recommend mild moderate hypertension control sequential monotherapy aim study compare efficacy safety combination enalapril mg hydrochlorothiazide mg enalapril mg nifedipine sl mg x two hundred forty four hypertensive patient control dpb mmhg single dose enalapril mg h receive week one two combine therapy randomized double blind trial efficacy amplitude two group dbp mmhg enalapril hydrochlorothiazide vs mmhg enalapril nifedipine side effect less frequent enalapril hydrochlorothiazide group per cent v per cent p,Frances Y,1996,Therapie,,8762218,Frances Y; Lafay V; Madona O; Chastang C; Souchet T; Chazelle F,article,"D016430: Clinical Trial; D017427: Clinical Trial, Phase II; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial","D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D004311: Double-Blind Method; D004351: Drug Resistance; D004359: Drug Therapy, Combination; D004361: Drug Tolerance; D004656: Enalapril; D005260: Female; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine",,,https://openalex.org/W208158969,194,23,2,790,140,5,en,en
false,equivalent effect nicardipine captopril urinary albumin excretion type non insulin dependent diabetic subject mild moderate hypertension,test calcium antagonist convert enzyme inhibitor act similarly urinary albumin excretion type non insulin dependent diabetic subject hypertension week double blind randomize parallel multicentre study perform patient allocate nicardipine mg slow release form n captopril mg n twice daily efficacy drug similar urinary albumin excretion westlake test p however blood pressure low nicardipine captopril p antialbuminuric effect nicardipine relate hypotensive effect case captopril two drug tolerate equally thus nicardipine captopril week equally effective urinary albumin excretion type non insulin dependent diabetic subject hypertension mechanism anti albuminuric effect may different,Bouhanick B,1996,Therapie,,8762219,Bouhanick B,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000419: Albuminuria; D000704: Analysis of Variance; D000806: Angiotensin-Converting Enzyme Inhibitors; D002121: Calcium Channel Blockers; D002216: Captopril; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009529: Nicardipine",,,https://openalex.org/W2442596331,163,23,1,960,171,5,en,en
false,antihypertensive effect adverse effect isradipine patient sever hypertension result open multicenter study,antihypertensive efficacy tolerability isradipine patient severe hypertension results open multicenter study open multicentre study patient mean age year severe hypertension diastolic blood pressure mmhg treat seven week calcium antagonist dihydropyridine type isradipine cas lomir necessary metoprolol enalapril add regimen inclusion active treatment phase responsiveness patient single administration isradipine mg compare placebo preexist antihypertensive therapy patient maintain study period blood pressure record automatic device week period blood pressure decrease mmhg mmhg group isradipine monotherapy n combination group n show significant reduction systolic diastolic blood pressure diastolic blood pressure response define decline mmhg note monotherapy combination group patient whole blood pressure normalize participant nineteen patient experience adverse event rat mild moderate therapy withdraw one patient due ankle edema frequent adverse event headache,Burger KJ,1996,Arzneimittelforschung,,8767350,Burger KJ; Dehner R,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D004740: English Abstract; D016428: Journal Article; D016448: Multicenter Study,D000328: Adult; D000368: Aged; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D008297: Male; D008875: Middle Aged,,,https://openalex.org/W2414669836,134,22,2,1442,261,13,en,en
false,effectiveness depot diltiazem stable effort angina double blind study compare placebo,antianginal efficacy slow release sr diltiazem change ergometric parameter treatment evaluate patient stable effort angina forty eight patient documented ischemic cardiopathy study study design double blind randomise cross versus placebo day run period pharmacological washout patient randomise treatment diltiazem sr mgs bid placebo week follow crossover treatment concomitant antianginal therapy except sublingual nitro glycerine allow trial exercise test perform run period end week treatment diltiazem administration exercise duration increase significantly comparison placebo vs p similarly time onset angina time ischemic threshold increase comparison placebo vs p vs p respectively significant change heart rate blood pressure double product ischemic threshold peak exercise detected sr diltiazem effective well tolerate treatment patient stable angina,Baldi N,1996,G Ital Cardiol,,8767776,Baldi N; Guiducci U; Piccitto R,article,D016430: Clinical Trial; D004740: English Abstract; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D004110: Diltiazem; D004311: Double-Blind Method; D005080: Exercise Test; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged,,,https://openalex.org/W2415489036,103,18,1,1284,217,7,en,en
false,final outcome result multicenter isradipine diuretic atherosclerosis study midas randomized control trial,objective compare rate progression mean maximum intimal medial thickness imt carotid artery use quantitative b mode ultrasound imaging antihypertensive therapy isradipine v hydrochlorothiazide design randomize double blind positive controlled trial setting nine medical center clinic population total patient baseline mean sd systolic diastolic blood pressure sbp dbp respectively mm hg age year maximum imt mm intervention twice daily dos isradipine mg hydrochlorothiazide mg main outcome measure primary end point rate progression mean maximum imt carotid focal point year result difference rate progression mean maximum imt isradipine hydrochlorothiazide year p high incidence major vascular event eg myocardial infarction stroke congestive heart failure angina sudden death isradipine n v hydrochlorothiazide n p significant increase nonmajor vascular event procedure eg transient ischemic attack dysrhythmia aortic valve replacement femoral popliteal bypass graft isradipine n v hydrochlorothiazide n p month mean dbp decrease mm hg group mean sbp decrease mm hg hydrochlorothiazide mm hg isradipine p difference sbp group persist throughout study explain increased incidence vascular event patient treat isradipine conclusion rate progression mean maximum imt carotid artery surrogate end point study differ treatment group increased incidence vascular event patient receive isradipine compare hydrochlorothiazide concern study,Borhani NO,1996,JAMA,,8769587,Borhani NO; Mercuri M; Borhani PA; Buckalew VM; Canossa-Terris M; Carr AA; Kappagoda T; Rocco MV; Schnaper HW; Sowers JR; Bond MG,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D000959: Antihypertensive Agents; D001161: Arteriosclerosis; D002339: Carotid Arteries; D003971: Diastole; D018450: Disease Progression; D004232: Diuretics; D004311: Double-Blind Method; D004656: Enalapril; D005260: Female; D006801: Humans; D006852: Hydrochlorothiazide; D017275: Isradipine; D016013: Likelihood Functions; D008297: Male; D008875: Middle Aged; D012044: Regression Analysis; D049993: Sodium Chloride Symporter Inhibitors; D013599: Systole; D016896: Treatment Outcome; D017539: Tunica Intima; D014463: Ultrasonography; D014665: Vasodilator Agents,,,https://openalex.org/W2136406291,121,18,2,2055,382,11,en,en
false,nifedipine migraine tension headache randomised double blind crossover study,nifedipine evaluate prophylaxis patient migraine tension headache use double blind cross design random allocation drug placebo group duration trial month week run period week wash oat period separate two treatment period week satisfactory response obtain migraineurs p patient tension headache p n minor side effect observe patient nifedipine useful agent management migraine reduce frequency severity pain drug recommend tension headache,Shukla R,1995,J Assoc Physicians India,,8773038,Shukla R; Garg RK; Nag D; Ahuja RC,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D008297: Male; D008881: Migraine Disorders; D009543: Nifedipine; D018781: Tension-Type Headache; D013997: Time Factors,,,https://openalex.org/W2397597026,87,14,1,666,126,5,en,en
false,randomise controlled trial methyldopa isradipine preeclampsia effect uteroplacental fetal hemodynamics,prospective randomise control study woman admit preeclampsia third trimester mean arterial blood pressure decrease mmhg confidence interval mmhg methyldopa group mmhg confidence interval mmhg isradipine group maternal heart rate decrease beat per min confidence interval bpm methyldopa treatment beat per min confidence interval isradipine treatment pulsatility index maternal fetal vessel affect either two drug birth weight placental weight neonatal outcome similar uneventful hypotensive effect similar methyldopa isradipine except reduced maternal heart rate methyldopa fetal uteroplacental hemodynamics alter treatment preeclampsia methyldopa isradipine,Montan S,1996,J Perinat Med,https://doi.org/10.1515/jpme.1996.24.2.177,8773944,Montan S; Anandakumar C; Arulkumaran S; Ingemarsson I; Ratnam S,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000959: Antihypertensive Agents; D001794: Blood Pressure; D005260: Female; D005865: Gestational Age; D006339: Heart Rate; D006340: Heart Rate, Fetal; D006801: Humans; D017275: Isradipine; D008750: Methyldopa; D011225: Pre-Eclampsia; D011247: Pregnancy; D011256: Pregnancy Outcome; D011446: Prospective Studies; D011673: Pulsatile Flow",,,https://openalex.org/W2082756400,123,16,1,959,168,7,en,en
true,long term prevention atrial fibrillation coronary artery bypass surgery comparison quinidine verapimil amiodarone maintain sinus rhythm,evaluate necessity efficacy quinidine fumarate verapimil amiodarone prophylaxis sinus rhythm maintenance patient experience atrial fibrillation coronary artery bypass surgery prospective randomize placebo controlled study examine patient atrial fibrillation occur restore sinus rhythm pharmacological therapy direct current cardioversion immediately postoperative period coronary artery pass surgery significant difference perioperative characteristic among patient randomly separate four group course discharge group n patient receive antiarrhythmic drug quinidine fumarate give group n verapimil group n amiodarone group n patient monitor six time day postoperative period hour holter monitoring routine examination recurrent atrial fibrillation usually develop within day discharge atrial fibrillation occur one patient group two group atrial fibrillation asymptomatic occur slow ventricular response group side effect occur patient give quinidine patient give amiodarone patient give verapimil significant difference maintenance sinus rhythm among four group suggest long term prevention atrial fibrillation patient coronary artery bypass grafting necessary postdischarge period,Yilmaz AT,1996,J Card Surg,https://doi.org/10.1111/j.1540-8191.1996.tb00010.x,8775337,Yilmaz AT; Demírkiliç U; Arslan M; Kurulay E; Ozal E; Tatar H; Oztürk O,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000368: Aged; D000638: Amiodarone; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D001026: Coronary Artery Bypass; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011183: Postoperative Complications; D011446: Prospective Studies; D011802: Quinidine; D014700: Verapamil,,,https://openalex.org/W2157265290,160,23,1,1658,285,8,en,en
true,acute hemodynamic long term clinical effect isradipine patient coronary artery disease chronic heart failure double blind placebo controlled study,assess acute hemodynamic long term clinical effect isradipine calcium antagonist dihydropyridine class perform double blind placebo controlled parallel study patient coronary artery disease cad stable chronic heart failure chf mean age year leave ventricular ejection fraction lvef patient treat diuretic digoxin clinically stable sinus rhythm acute hemodynamic study show intravenous isradipine increase cardiac index stroke volume index p systemic vascular resistance mean arterial pressure decrease p fill pressure heart rate affect patient complete week study patient placebo death side effects patient isradipine mg time daily drop week peak oxygen consumption vo lvef echocardiographic index clinical parameter unaffected treatment repeat invasive hemodynamic measurement show initial improvement isradipine present anymore conclusion despite beneficial acute hemodynamic effect isradipine favorable clinical influence prolonged treatment patient mild moderate chf,van den Toren EW,1996,Int J Cardiol,https://doi.org/10.1016/0167-5273(95)02506-5,8776276,van den Toren EW; van Veldhuisen DJ; van Bruggen A; van den Broek SA; van Gilst WH; Lie KI,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D002121: Calcium Channel Blockers; D002303: Cardiac Output, Low; D002908: Chronic Disease; D003327: Coronary Disease; D004311: Double-Blind Method; D005260: Female; D006439: Hemodynamics; D006801: Humans; D017275: Isradipine; D008297: Male; D008875: Middle Aged; D017211: Treatment Failure",,,https://openalex.org/W1976555251,171,24,2,1376,259,10,en,en
false,comparison nifedipine git hydrochlorothiazide management elderly patient stage iii diastolic hypertension,randomized double blind parallel study perform compare effect nifedipine gastrointestinal therapeutic system git hydrochlorothiazide hctz management elderly hypertensive eighteen patient mean age year stage iii diastolic hypertension sit diastolic bp mm hg include treatment group follow week placebo washout phase patient receive either nifedipine git hctz titrate week achieve goal diastolic blood pressure less mm hg patient continue medication week maintenance phase treatment effect systolic diastolic blood pressure assess serum electrolytes lipid blood urea nitrogen creatinine measure treatment posttreatment change renal cardiovascular function well leave ventricular mass evaluate result show significant reduction systolic diastolic blood pressure drug treatment difference find although goal blood pressure achieve rapidly nifedipine git v day p bun significantly increase diuretic therapy p serum potassium fell great degree hctz meq l v meq l nifedipine git statistically significant change left ventricular mass ejection fraction glomerular filtration rate renal blood flow see therapy either drug however time peak lv diastolic fill rate decrease nifedipine git msec increase hctz msec treatment difference approach statistical significance p adverse side effect treatment report nifedipine git patient patient treat hctz treatment difference statistically significant conclude nifedipine git hctz monotherapy provide significant blood pressure reduction old hypertensive stage iii diastolic hypertension drug well tolerate significant adverse effect renal cardiovascular function short term therapy,Dey HM,1996,Am J Hypertens,https://doi.org/10.1016/0895-7061(96)00168-9,8783785,Dey HM; Soufer R; Hoffer P; Wackers FJ; Black HR,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D000959: Antihypertensive Agents; D001794: Blood Pressure; D001810: Blood Volume; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011446: Prospective Studies; D012079: Renal Circulation; D016277: Ventricular Function, Left",,,https://openalex.org/W2170874280,131,17,1,2216,385,16,en,en
false,ace inhibitor elderly patient hypertension,angiotensin convert enzyme ace inhibitor emerge class antihypertensive vasodilatatory agent first choice treatment elderly patient hypertension normotensive patient congestive heart failure post anterior myocardial infarction diabetes mellitus evidence microangiopathy also benefit continuous ace inhibition long term use ace inhibitor associate improved survival reduced cardiovascular cerebral renal morbidity patient elderly atherosclerotic patient agent provide good control systolic diastolic blood pressure peripheral resistance remarkable preservation vital organ perfusion infrequent adverse effect use monotherapy effectiveness ace inhibitor limited however advantage use combination drug notably thiazide diuretic nitrate calcium antagonist renal function thus preserve leave heart hypertrophy prevent major difference various ace inhibitor choice drug largely matter personal preference,Ravid M,1996,Drugs Aging,https://doi.org/10.2165/00002512-199608010-00006,8785466,Ravid M; Ravid D,article,D016428: Journal Article; D016454: Review,D000319: Adrenergic beta-Antagonists; D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D004232: Diuretics; D006801: Humans; D006973: Hypertension,,,https://openalex.org/W2201309519,52,7,1,1175,182,8,en,en
false,new antiherpesvirus agent,large number agent development treatment herpes virus infection herpes simplex virus type hsv hsv varicella zoster virus vzv cytomegalovirus cmv epstein barr virus ebv ten apparently reach clinical development aciclovir approve treatment hsv infection year ago remain important reliable antiviral agent recent approval country valaciclovir vzv infection famciclovir hsv vzv infection demonstrate rapidity change field intravenous ganciclovir foscarnet approve treatment cmv infection immunocompromised patient five antiherpetic drug current clinical development nucleoside analogue prodrugs another phosphorylated nucleoside nucleotide four nucleoside agents penciclovir famciclovir valaciclovir lobucavir develop management hsv vzv infection valaciclovir also develop prevention cmv infection famciclovir lobucavir treatment hepatitis b virus infection oral ganciclovir lobucavir isi cidofovir develop suppression cmv infection immunocompromised patient sorivudine study vzv infection n docosanol development hsv infection cidofovir develop hsv cmv infection well treatment viral disease traditionally adverse effect associate anti cmv compound difficult manage acceptable clinically severity underlying infection lack safer therapeutic alternative general toxicity issue continue problematic anti cmv arena although new agent improve situation extent contrast safety anti hsv compound traditionally excellent establish safety standard must meet new agent enter field,Alrabiah FA,1996,Drugs,https://doi.org/10.2165/00003495-199652010-00002,8799682,Alrabiah FA; Sacks SL,article,D016428: Journal Article; D016454: Review,D000998: Antiviral Agents; D001682: Biological Availability; D002986: Clinical Trials as Topic; D006566: Herpesviridae Infections; D006801: Humans; D011355: Prodrugs,,,https://openalex.org/W2027210619,26,3,1,2073,343,13,en,en
true,effect amlodipine morbidity mortality severe chronic heart failure,previous study show calcium channel blocker increase morbidity mortality patient chronic heart failure study effect new calcium channel blocker amlodipine patient severe chronic heart failure,Packer M,1996,N Engl J Med,https://doi.org/10.1056/nejm199610103351504,8813041,Packer M; O'Connor CM; Ghali JK; Pressler ML; Carson PE; Belkin RN; Miller AB; Neuberg GW; Frid D; Wertheimer JH; Cropp AB; DeMets DL,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D017311: Amlodipine; D002121: Calcium Channel Blockers; D002311: Cardiomyopathy, Dilated; D002908: Chronic Disease; D004311: Double-Blind Method; D005260: Female; D006333: Heart Failure; D006801: Humans; D008297: Male; D008875: Middle Aged; D017202: Myocardial Ischemia; D016019: Survival Analysis; D016896: Treatment Outcome",,,https://openalex.org/W2318480619,79,12,1,245,38,2,en,en
false,efficacy safety low dose propranolol versus diltiazem prophylaxis supraventricular tachyarrhythmia coronary artery bypass grafting,supraventricular tachyarrhythmias svt complicate postoperative management coronary bypass surgery patient though prophylactic treatment beta adrenergic block agent calcium antagonist diltiazem use prevention post operative svt study yet perform prospective comparison efficacy therapies investigate prophylactic effect either calcium antagonist diltiazem mg kg per h v beta adrenergic blocking agent propranolol mg every h postoperatively randomize prospectively consecutive patient three group third one serving control group anti arrhythmic medication start procedure continue rd postoperative day preoperative condition three group concern age extent coronary heart disease ventricular function heart related medication difference intraoperative parameter postoperative enzyme pattern diltiazem ineffective prevent svt incidence exactly control group propranolol reduce occurrence svt significantly p furthermore patient treat diltiazem need positive inotropic support often first hour surgery patient control group vs p perioperative administration low dose propranolol consider safe effective drug prophylaxis avoid occurrence svt bypass surgery,Babin-Ebell J,1996,Eur J Cardiothorac Surg,https://doi.org/10.1016/s1010-7940(96)80107-2,8817135,Babin-Ebell J; Keith PR; Elert O,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000889: Anti-Arrhythmia Agents; D002121: Calcium Channel Blockers; D001026: Coronary Artery Bypass; D004110: Diltiazem; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D015716: Electrocardiography, Ambulatory; D005260: Female; D006439: Hemodynamics; D006801: Humans; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D011183: Postoperative Complications; D011433: Propranolol; D011446: Prospective Studies; D013617: Tachycardia, Supraventricular; D016896: Treatment Outcome",,,https://openalex.org/W2136272170,153,19,1,1575,260,8,en,en
false,calcium channel blocker dock innocent guilty,several study recently publish raise doubt long term safety calcium channel blocker ccb include retrospective case control study hypertension meta analyses small scale study unstable angina myocardial infarction mi report primarily concern use short act dihydropyridine nifedipine despite wide medium coverage report result mean irrefutable nature study open several criticism calcium channel blocker currently evaluate large scale prospective randomise control study result unlikely available within next year meanwhile consensus view seem short act dihydropyridines general avoid place management unstable angina post mi setting stable angina long act dihydropyridines generally use conjunction beta blocker hypertensive patient long act dihydropyridines may use alternative antihypertensive agent patient first line agent diuretic beta blockers poorly tolerate contra indicated ineffective,Mackay JA,1996,J Hum Hypertens,,8817399,Mackay JA; Sever PS,article,D016428: Journal Article,D002121: Calcium Channel Blockers; D016022: Case-Control Studies; D002986: Clinical Trials as Topic; D006801: Humans; D015201: Meta-Analysis as Topic; D009203: Myocardial Infarction; D009543: Nifedipine; D012189: Retrospective Studies; D012307: Risk Factors,,,https://openalex.org/W2419819179,57,11,1,1284,211,8,en,en
false,nifedipine captopril exert divergent effect heart rate variability patient acute episode hypertension,acute change heart rate variability hrv depict alteration autonomic influence cardiovascular system often precede ventricular arrhythmia aim study assess effect sublingual mg nifedipine n mg captopril n hrv consecutive patient admit hospital due severe hypertension hrv calculate line cardiac cycle min drug administration baseline systolic blood pressure sbp mm hg diastolic blood pressure dbp mm hg agent cause similar reduction blood pressure bp nifedipine reduce variance p high frequency hf component p increase lf hf ratio p heart rate p captopril exert different effect variance hf component increase p p respectively lf hf low high frequency ratio decrease p together heart rate conclude captopril contrast nifedipine increase hrv decrease lf hf ratio therefore good choice hypertensive patient might prone dangerous arrhythmia,Wolk R,1996,J Hum Hypertens,,8817407,Wolk R; Kulakowski P; Ceremuzynski L,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,"D000208: Acute Disease; D000286: Administration, Sublingual; D000328: Adult; D000368: Aged; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004632: Emergency Medical Services; D005260: Female; D006339: Heart Rate; D006760: Hospitalization; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine",,,https://openalex.org/W2471111749,123,18,1,1289,275,9,en,en
false,calcium antagonist elderly,calcium antagonist effective lower blood pressure relieve anginal symptom improve exercise tolerance old young patient coronary artery disease verapamil diltiazem effective slow ventricular response rate supraventricular arrhythmia old young patient although belong least distinct chemical class moderate decrease clearance calcium antagonists occur age clinical trial drug use dosage old young patient confound analysis sensitivity old compare young patient great reduction blood pressure usually occur old compare young patient receive dosage calcium antagonist similarly dosage require reduce blood pressure certain level usually low old compare young patient drug acquisition cost generally high calcium antagonist beta blockers diuretic compare young patient great heart rate suppression may see old patient treat verapamil diltiazem conversely heart rate increase usually see dihydropyridines calcium antagonist show provide long term benefit decrease morbidity mortality elderly patient hypertension verapamil dihydropyridines decrease mortality myocardial infarction patient without congestive heart failure calcium antagonist show beneficial treatment acute stroke adverse effect postural hypotension may frequent elderly compare young patient addition elderly great risk drug interaction calcium antagonist due high likelihood receive drug,Schwartz JB,1996,Drugs Aging,https://doi.org/10.2165/00002512-199609010-00003,8818583,Schwartz JB,article,"D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.; D016454: Review",D000368: Aged; D000375: Aging; D002121: Calcium Channel Blockers; D002986: Clinical Trials as Topic; D003327: Coronary Disease; D004347: Drug Interactions; D006801: Humans; D006973: Hypertension; D018570: Risk Assessment,,,https://openalex.org/W2049911447,34,5,1,1863,292,12,en,en
false,efficacy tolerability quality life losartan alone hydrochlorothiazide versus nifedipine git patient essential hypertension,randomized double masked parallel group multicenter clinical trial conduct compare efficacy tolerability effect quality life associate angiotensin ii receptor antagonist losartan alone hydrochlorothiazide hctz dihydropyridine calcium channel blocker nifedipine gastrointestinal therapeutic system git patient whose sit diastolic blood pressure measurement mm hg inclusive receive placebo patient randomize receive either losartan nifedipine git double masked double dummy fashion week placebo washout period establish baseline untreated blood pressure measurement follow week active treatment period patient receive losartan n initially give mg day qd could titrate losartan hctz mg mg qd week follow losartan hctz mg mg qd week necessary patient nifedipine git group n receive mg qd could titrate mg qd week follow mg qd week medication titrate upward necessary achieve sit trough diastolic blood pressure mm hg efficacy tolerability quality life score assess week therapy trough sit diastolic blood pressure reduction week therapy clinically comparable losartan mm hg respectively nifedipine git mm hg respectively mean reduction sit diastolic blood pressure week losartan group mm hg low confidence interval mm hg low mm hg high mean reduction sit diastolic blood pressure nifedipine git group similarly reduction systolic blood pressure two treatment group comparable time point percentage patient reach goal trough sit diastolic blood pressure comparable two treatment group patient losartan regimen patient nifedipine git regimen reach goal patient report adverse event two group patient receive losartan receive nifedipine git significantly edema nifedipine git group vs p fourteen patient nifedipine git group withdraw due adverse event eight edema six patient losartan group withdraw due adverse event none patient edema significant difference patient reported quality life symptom bother inventory respect edema nifedipine git therapy cause significantly bother due edema patient regardless whether symptom present baseline vs p statistically significant difference bother due symptom inventory note note incidence patient reported symptom bother due edema nifedipine git group incidence physician reported drug related edema difference point need improved physician patient communication regard adverse effect impact patient quality life conclusion regimen losartan compare regimen nifedipine git provide comparable efficacy respect edema superior tolerability less bother patient therapy dropout,Weir MR,1996,Clin Ther,https://doi.org/10.1016/s0149-2918(96)80022-1,8829017,Weir MR; Elkins M; Liss C; Vrecenak AJ; Barr E; Edelman JM,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000959: Antihypertensive Agents; D001713: Biphenyl Compounds; D002121: Calcium Channel Blockers; D004232: Diuretics; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D007093: Imidazoles; D019808: Losartan; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011788: Quality of Life; D049993: Sodium Chloride Symporter Inhibitors; D013777: Tetrazoles",,,https://openalex.org/W1980483149,154,24,1,3598,652,18,en,en
false,nisoldipine versus isosorbide dinitrate coronary heart disease result double masked study,efficacy tolerability twice daily dose mg nisoldipine versus mg sustained release isosorbide dinitrate isdn compare randomized double masked study patient day treatment period mean time take bicycle ergometry appearance st segment depression least mv compare rest value increase second second nisoldipine group second second isdn group mean value end treatment calculate use analysis covariance second group difference two treatment group statistically significant mean st segment depression individually maximal workload decrease mv mv nisoldipine group mv mv isdn group mean total duration exercise increase second second nisoldipine group second second isdn group nisoldipine group patient report adverse event consider possibly probably relate test medication isdn group patient report adverse event although anti ischemic effect two treatment comparable nisoldipine descriptively superior isdn term tolerability,Heublein B,1996,Clin Ther,https://doi.org/10.1016/s0149-2918(96)80025-7,8829020,Heublein B; Amende I; Blanke PM; Baunack-Frost AR; Breuer HW,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000368: Aged; D001699: Biometry; D003327: Coronary Disease; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D005080: Exercise Test; D005260: Female; D006801: Humans; D007548: Isosorbide Dinitrate; D008297: Male; D008875: Middle Aged; D015737: Nisoldipine; D014665: Vasodilator Agents,,,https://openalex.org/W2151343606,99,14,1,1476,266,8,en,en
false,treatment hypertension associate stable angina pectoris favourable interaction new metoprolol formulation oros nifedipine,double blind within patient crossover study evaluate effect new formulation metoprolol blood pressure bp myocardial ischemia twenty outpatient mild moderate essential arterial hypertension chronic stable angina pectoris positive exercise test week baseline placebo period randomize receive long acting metoprolol oros mg nifedipine sr mg b combination sequence x latin square design two patient withdraw study adverse event metoprolol rise bp nifedipine nifedipine metoprolol combination significantly reduce weekly number angina attack nitroglycerin consumption respect baseline total number ischemic event hour ecg monitoring significantly decrease treatment respect baseline twenty four hour mean systolic diastolic bp reduce nifedipine alone metoprolol alone combination two drug lead decrease systolic diastolic bp duration silent ischemic episode significantly reduce nifedipine combination metoprolol hand hour symptomatic attacks patient significantly reduce beta blocker combination nifedipine metoprolol alone administer nifedipine cause decrease respect placebo baseline hour mean heart rate hr reduce increase hr systolic bp onset st depression symptomatic ischemic episode effort time time st mm treadmill significantly increase treatment nifedipine alone metoprolol alone combination combination effective individual therapy st depression peak exercise significantly reduce treatment slope correlation st segment variation systolic bp hr rate pressure product exercise significantly decrease treatment respect placebo baseline combination therapy nifedipine alone metoprolol alone conclusion base result favourable interaction metoprolol oros nifedipine give concomitantly likely due good control respect individual therapy pathogenetic mechanism myocardia ischemia bp hr increase exercise symptomatic ischemic episode control beta blocker coronary vasoconstriction silent ischemia prevent calcium antagonist,Di Somma S,1996,Cardiologia,,8831181,Di Somma S; de Divitiis M; Bertocchi F; Carotenuto A; Cudemo G; Petitto M; Napodano M; de Divitiis O,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000787: Angina Pectoris; D000959: Antihypertensive Agents; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D002908: Chronic Disease; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004357: Drug Synergism; D015716: Electrocardiography, Ambulatory; D005080: Exercise Test; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008790: Metoprolol; D008875: Middle Aged; D009543: Nifedipine; D005996: Nitroglycerin; D012044: Regression Analysis; D014665: Vasodilator Agents",,,https://openalex.org/W2184047539,146,21,1,2676,439,14,en,en
false,possible role medullasin nifedipine induced human gingival overgrowth,order clarify possible pathophysiological role medullasin neutrophil elastase like proteinase nifedipine nf induced gingival overgrowth distribution medullasin positive cell immunostained specimen patient nf induced gingival overgrowth chronic marginal gingivitis compare three different biopsy area twenty gingival biopsy obtain five patient gingival overgrowth biopsy another five patient chronic marginal gingivitis marginal gingivitis group mean percentage positive cell vicinity pocket epithelium zone significantly high area connective tissue mid portion zone ii adjacent oral epithelium zone iii p gingival overgrowth group contrary positive cell significantly increase zone ii compare zone iii p medullasin positive cell zone ii iii overgrowth group infiltrate extensively gingivitis group p indicate participation enzyme mechanism nf induced gingival overgrowth observation suggest medullasin may play part nf induced overgrowth host defence immunoregulation possibly cytotoxically,Kunimatsu K,1996,Arch Oral Biol,https://doi.org/10.1016/0003-9969(95)00108-5,8833599,Kunimatsu K; Ozaki Y; Aoki Y; Kato I,article,D003160: Comparative Study; D016428: Journal Article,"D000328: Adult; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D002908: Chronic Disease; D004396: Coloring Agents; D003238: Connective Tissue; D003602: Cytotoxicity, Immunologic; D004846: Epithelial Attachment; D004848: Epithelium; D005881: Gingiva; D019214: Gingival Overgrowth; D005888: Gingival Pocket; D005891: Gingivitis; D006801: Humans; D007150: Immunohistochemistry; D008875: Middle Aged; D009543: Nifedipine; D012697: Serine Endopeptidases",,,https://openalex.org/W2008009358,76,9,1,1345,225,6,en,en
false,persistence anti hypertensive effect miss dos calcium antagonist long amlodipine v short diltiazem elimination half life,calcium antagonist long v short elimination half life may show marked difference antihypertensive effect short interruption therapy missed dos present study evaluate blood pressure lower effect amlodipine v diltiazem active maintenance treatment active treatment interrupt day placebo use double blind randomized design single blind placebo run period hypertensive patient randomize amlodipine mg daily diltiazem mg twice daily week dos increase mg daily mg twice daily necessary control diastolic blood pressure week active treatment blisterpacks contain day placebo twenty four hour blood pressure monitoring perform end run period week active v interrupt therapy active therapy amlodipine n lower day systolic blood pressure mmhg diastolic blood pressure mmhg change heart rate second day interrupt therapy response still present diltiazem n lower day systolic blood pressure mmhg diastolic blood pressure mmhg heart rate beat min response disappear second day interrupted therapy conclude amlodipine diltiazem fairly similar lower blood pressure efficacy point view however short period noncompliance blood pressure control persist markedly well agent long v one short elimination half life,Leenen FH,1996,Br J Clin Pharmacol,https://doi.org/10.1111/j.1365-2125.1996.tb00164.x,8838433,Leenen FH; Fourney A; Notman G; Tanner J,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D004110: Diltiazem; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006207: Half-Life; D006801: Humans; D008297: Male; D008875: Middle Aged; D010919: Placebos",,,https://openalex.org/W2113760076,155,30,1,1714,309,16,en,en
false,evaluation gingival periodontal condition follow causal periodontal treatment patient treat nifedipine diltiazem,abstract establish phenytoin cyclosporin calcium antagonist produce gingival overgrowth know condition may respond causal periodontal treatment order find longitudinal study carry year compare group patient give nifedipine ng n another group give diltiazem dg n others one comprise cardiopathic patient take calcium antagonists cg n contained patient medically healthy moderate periodontitis hg n basal visit examine instruct oral hygiene give causal periodontal treatment see month hygiene instruction reinforce see last time month examine group ng dg basal visit show large gum size group hg cg statistically significant final visit difference remain interproximal level number patient gingival overgrowth taking average group hg minimal value much high group cg dg ng basal visit final visit difference remain group dg ng probe pocket depth reduction much great group hg cg dg ng basically due great gaining clinical attachment level site pocket depth improve mm hg cg dg ng site attachment gain mm hg cg dg ng amount plaque bleeding probing similar group basal visit decrease throughout study especially basal nd visit group hg cg demonstrate patient take nifedipine diltiazem show large gum size response causal periodontal treatment poor healthy cardiac group,Bullon P,1996,J Clin Periodontol,https://doi.org/10.1111/j.1600-051x.1996.tb00589.x,8841897,Bullon P; Machuca G; Martinez-Sahuquillo A; Rios JV; Velasco E; Rojas J; Lacalle JR,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000704: Analysis of Variance; D002121: Calcium Channel Blockers; D016009: Chi-Square Distribution; D017742: Dental Care for Chronically Ill; D003774: Dental Plaque Index; D004110: Diltiazem; D005260: Female; D005500: Follow-Up Studies; D019214: Gingival Overgrowth; D006801: Humans; D008297: Male; D017202: Myocardial Ischemia; D009543: Nifedipine; D017063: Outcome Assessment, Health Care; D010510: Periodontal Diseases; D010512: Periodontal Index; D018709: Statistics, Nonparametric",,,https://openalex.org/W1969643541,150,24,1,2125,446,16,en,en
false,diltiazem different dos study dose response study daily diltiazem therapy hypertension,objective evaluate dose related efficacy tolerance profile mg diltiazem slow release daily od dos emphasis mg dose study randomize double blinded week parallel two branched cross design single blind run period week placebo week mg diltiazem od branch include six week active treatment period mg tablet one two tablet od participant men postmenopausal woman age year uncomplicated primary hypertension stag ii supine diastolic blood pressure mm hg absence antihypertensive medication total patient various clinic participate study include intention treat analysis patient include per protocol analysis criterion evaluation blood pressure heart rate response rate well plasma diltiazem metabolite concentration morning dose well patient adverse event record electrocardiogram standard laboratory test obtain analysis variance use statistical calculation supine blood pressure response rate per protocol analysis placebo mg mg mg mg diltiazem od intention treat analysis similar per protocol analysis small statistically significant decrease heart rate dos diltiazem od compare placebo linear relationship exist dose plasma concentration diltiazem metabolite well dose response relationship diltiazem od dose range mg generally well tolerate differently perceive placebo treatment except ankle edema study show od diltiazem significantly superior placebo mild moderate hypertension effect large enough clinically valuable also show linear dose response relationship diltiazem mg,Nilsson P,1996,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-199604000-00003,8847861,Nilsson P; Lindholm LH; Hedner T,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D001794: Blood Pressure; D003692: Delayed-Action Preparations; D004110: Diltiazem; D004305: Dose-Response Relationship, Drug; D004562: Electrocardiography; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D010919: Placebos",,,https://openalex.org/W2327513282,106,13,1,2287,418,17,en,en
false,bezoars implicate drug avoidance strategy,wide variety drug combination drug potential form bezoars majority patient present bezoars clear predisposing factor article highlight drug group drug implicate bezoar formation although bezoars rare important clinician aware possibility development particularly susceptible individual bezoars often develop elderly serious coexistent disease may difficult diagnose recourse laparotomy frequently require treat result associate significant morbidity mortality,Thompson KC,1996,Drug Saf,https://doi.org/10.2165/00002018-199614020-00003,8852523,Thompson KC; Iredale JP,article,D003160: Comparative Study; D016428: Journal Article; D016454: Review,D001630: Bezoars; D002400: Cathartics; D004064: Digestive System; D006635: Histamine H2 Antagonists; D006801: Humans; D007813: Laparotomy; D012307: Risk Factors,,,https://openalex.org/W2058463767,49,6,1,705,121,7,pl,en
false,relative efficacy tolerability lacidipine amlodipine patient mild moderate hypertension randomized double blind study,calcium channel blocker increasingly use treatment hypertension new calcium channel blocker dihydropyridine group long elimination half lives permit daily dosage generally well tolerate parent compound study efficacy safety lacidipine amlodipine compare patient mild moderate hypertension attend hypertension outpatient clinic teaching hospital randomized double blind cross trial dose titration lacidipine amlodipine significantly reduce systolic blood pressure sbp mm hg respectively diastolic bp dbp mm hg respectively h postdose significant difference antihypertensive effect incidence adverse event ae lacidipine amlodipine incidence withdrawal study due side effect lacidipine amlodipine result suggest lacidipine well tolerated effective amlodipine daily antihypertensive agent,Lau CP,1996,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-199608000-00021,8856491,Lau CP; Cheung BM,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D004095: Dihydropyridines; D004311: Double-Blind Method; D005260: Female; D006207: Half-Life; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011674: Pulse,,,https://openalex.org/W2154802933,143,18,1,1164,198,8,en,en
false,comparison daily twice daily nisoldipine monotherapy essential hypertension,twenty four patient complete dose range study effect nisoldipine monotherapy treatment hypertension randomize double blind study consist two crossover phase twice daily treatment compare first treatment phase total daily dose nisoldipine mg increase mg second phase trough blood pressure measurement make h postdose first phase blood pressure value follow treatment nisoldipine mg twice daily significantly low mg daily however daily dose increase mg significant difference two treatment regimen also significant difference nisoldipine mg twice daily mg twice daily result mg daily significantly low mg daily four patient withdraw study adverse event one placebo three nisoldipine therapy percent percent patient report adverse event nisoldipine treatment majority adverse event report mild require treatment withdrawal nisoldipine twice daily appear effective well tolerate daily treatment h blood pressure control,Davidsson GK,1996,Control Clin Trials,https://doi.org/10.1016/s0197-2456(96)80003-1,8860064,Davidsson GK; Edwards JS; Davidson C,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D015737: Nisoldipine; D016896: Treatment Outcome",,,https://openalex.org/W1990274021,93,13,1,1374,232,10,en,en
false,verapamil,verapamil well prove efficacy treatment patient hypertension early study indicate efficacy treatment coronary artery disease efficacy verapamil relative placebo patient stable angina pectoris confirm drug least effective nifedipine propranolol metoprolol similar efficacy bepridil nicardipine administer conventional sustained release formulation verapamil first calcium antagonist show double blind study significantly reduce mortality reinfarction rate acute myocardial infarction patient without heart failure patient reduction mortality achieve verapamil similar report beta adrenoceptor antagonist suggest verapamil may suitable alternative beta blockers secondary prevention patient intolerant drug recurrence stenosis patient successfully undergo percutaneous transluminal coronary angioplasty ptca limit usefulness procedure verapamil recently show significantly reduce rate restenosis patient stable angina risk recurrence although initial result require confirmation verapamil therefore effective treatment patient stable angina pectoris appear alternative beta blockers selected patient late start secondary prevention acute myocardial infarction potential role prevent recurrent stenosis ptca initial result confirm,Brogden RN,1996,Drugs,https://doi.org/10.2165/00003495-199651050-00007,8861548,Brogden RN; Benfield P,article,D016428: Journal Article; D016454: Review,D000787: Angina Pectoris; D000818: Animals; D002121: Calcium Channel Blockers; D003327: Coronary Disease; D006801: Humans; D009203: Myocardial Infarction; D014665: Vasodilator Agents; D014700: Verapamil,,,https://openalex.org/W2030911789,9,1,1,1618,249,7,hr,en
true,quality life normotensives compare hypertensive men treat isradipine methyldopa monotherapy combination captopril lomir mct il study,quality life qol measure assess multi center double blind case controlled trial year duration total hypertensive male patient randomly assign monotherapies either isradipine methyldopa placebo normotension achieve captopril add qol assessment hypertensive normotensives include self structured scale measure subjective perception qol severity desirability controllability recent critical life event semantic memory physical dysfunction sleep disorder sexual difficulty depression work related stress overall withdrawal rate trial mainly due lack efficacy adverse experience baseline end trial normotensives compare hypertensive patient significantly good score qol measure patient treat combination isradipine captopril report favorable change subjective measure qol p semantic memory p patient treat monotherapies methyldopa combination captopril statistically significant difference among treatment change index qol qol measurement normotensives rat well hypertensives patient treat long term therapy combination isradipine captopril show improvement self structured qol measure semantic memory compare patient treat either methyldopa placebo,Yodfat Y,1996,J Hum Hypertens,,8867566,Yodfat Y; Bar-On D; Amir M; Cristal N,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000704: Analysis of Variance; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D002216: Captopril; D016022: Case-Control Studies; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D008297: Male; D008750: Methyldopa; D008875: Middle Aged; D011788: Quality of Life; D016896: Treatment Outcome",,,https://openalex.org/W2256709615,172,26,1,1578,260,10,en,en
false,long term survival myocardial infarction relationship thrombolysis discharge medication result augsburg myocardial infarction follow study,large number randomized clinical trial show thrombolysis long term treatment beta blockers antiplatelet drug angiotensin convert enzyme inhibitor improve survival acute myocardial infarction ami however calcium channel blocker nifedipine diltiazem verapamil either benefit positive effect report subgroup recent study raise concern safety drug class especially patient coronary heart disease study long term survival median follow time year non diabetic patient population based ami registry augsburg germany age year survive first q wave acute myocardial infarction least day impact thrombolysis prescribed medication discharge beta blockers antiplatelet drug calcium channel blocker long term survival analyse use cox proportional hazard model control age sex concomitant cardiac drug use thrombolysis risk ratio rr confidence interval ci long term beta blockade rr ci antiplatelet drug use rr ci associate considerable reduction total mortality use calcium channel blocker associate reduction total mortality rr ci separate analysis nifedipine rr ci diltiazem rr ci show increase risk death associate latter use patient beta blockers rr reference prescription calcium channel blocker consistently associate increase total mortality nifedipine without beta blockers rr ci diltiazem without beta blockers rr ci result observational study demonstrate benefit thrombolysis beta adrenergic blockade antiplatelet drug use long term survival acute myocardial infarction patient calcium channel blocker use appear associate increase risk death data support need controlled trial address issue specifically,Koenig W,1996,Eur Heart J,https://doi.org/10.1093/oxfordjournals.eurheartj.a015037,8869861,Koenig W; Löwel H; Lewis M; Hörmann A,article,D003160: Comparative Study; D016428: Journal Article,D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D002121: Calcium Channel Blockers; D004562: Electrocardiography; D005260: Female; D005343: Fibrinolytic Agents; D005500: Follow-Up Studies; D005858: Germany; D006801: Humans; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D010975: Platelet Aggregation Inhibitors; D012189: Retrospective Studies; D012307: Risk Factors; D015996: Survival Rate; D015912: Thrombolytic Therapy,,,https://openalex.org/W2000578790,178,23,1,2259,400,12,en,en
false,review ultraviolet nm irradiation therapy systemic lupus erythematosus,ultraviolet uv wavelength find effective mitigate sign symp tom disease activity systemic lupus erythematosus sle study uncon troll rigorously assess effectiveness safety daily low dose uv irradiation therapeutic agent disorder enrol woman sle week two phase study initial six week prospective double blind placebo controlled phase patient divide two group group expose kj uv nm irradiation within sunbed five day week three week group b expose equal amount time visible light great nm placebo group cross exposure source three week second phase week patient physician unblinded patient irradiate progressively decrease level uv twenty five patient complete six week placebo controlled phase study eighteen patient participate entire week group systemic lupus activ ity measure slam score improve significantly three week five day week uv irradiation p regress baseline three week placebo irra diation improvement recur progress six week three day week uv irradiation p group b patient respond negligibly three week visible light sharply uv group maximally six week three day week uv p twice weekly uv irradiation slam score worsen slightly patient decrease drug use anti double stranded dna antibody anti dsdna decrease significantly p anti nuclear antibody non significantly side effect negligible visible light significant effect conclusion low dose uv irradiation effectively comfortably without apparent toxicity diminish sign symptom disease activity sle,McGrath H,1996,Lupus,https://doi.org/10.1177/096120339600500405,8869897,McGrath H; Martínez-Osuna P; Lee FA,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000368: Aged; D000974: Antibodies, Antinuclear; D018592: Cross-Over Studies; D004247: DNA; D004110: Diltiazem; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008180: Lupus Erythematosus, Systemic; D008875: Middle Aged; D010787: Photosensitivity Disorders; D011446: Prospective Studies; D011838: Radiation-Sensitizing Agents; D011879: Radiotherapy Dosage; D012449: Safety; D012720: Severity of Illness Index; D016896: Treatment Outcome; D014467: Ultraviolet Therapy",,,https://openalex.org/W2025595817,88,13,1,2110,373,15,en,en
false,comparison antihypertensive effectiveness combination moexipril sustained release verapamil low dose hydrochlorothiazide,antihypertensive effectiveness moexipril new angiotensin converting enzyme ace inhibitor sustained release verapamil verapamil sr combination low dose hydrochlorothiazide investigate patient moderate severe stage ii iii essential hypertension patient treat week hydrochlorothiazide mg day patient sit diastolic blood pressure sdbp mmhg randomly assign receive either moexipril mg day n verapamil sr mg day n addition hydrochlorothiazide mg day week treatment dos moexipril verapamil sr increase mg day respectively patient sdbp mmhg patient evaluate additional week electrocardiogram blood chemistry blood count urinalysis plasma renin activity plasma aldosterone level monitor study moexipril verapamil sr combination low dose hydrochlorothiazide result decreased blood pressure sitting stand position correlation blood pressure response baseline plasma renin activity demonstrate result study indicate moexipril verapamil sr produce additive hypertensive effect add low dose hydrochlorothiazide combination well tolerate patient result serious clinical metabolic side effect,Chrysant SG,1996,J Clin Pharmacol,https://doi.org/10.1002/j.1552-4604.1996.tb04238.x,8877673,Chrysant SG; Stimpel M,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D000367: Age Factors; D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D004232: Diuretics; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006439: Hemodynamics; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D007546: Isoquinolines; D008297: Male; D008875: Middle Aged; D049993: Sodium Chloride Symporter Inhibitors; D044005: Tetrahydroisoquinolines; D014700: Verapamil",,,https://openalex.org/W2081265616,145,17,1,1484,245,9,en,en
true,antihypertensive therapy quality life influence blood pressure reduction adverse event prior antihypertensive therapy,quality life important attribute antihypertensive therapy previous study address importance patient prior pharmacotherapy quality life may serve basis reference new therapy previous study compare commonly used quality life instrument consistency investigate whether improvement worsening quality life correlate adverse event blood pressure reduction two hundred eighteen hypertensive patient diastolic blood pressure mm hg week placebo washout period enrol randomized double blind parallel group dose escalation trial compare effect amlodipine mg bisoprolol mg hydrochlorothiazide hctz enalapril mg blood pressure adverse event quality life three quality life instrument general well index vital sign quality life zung self rating depression scale administer original therapy placebo washout week optimally titrate clinical trial pharmacotherapy result demonstrate removal prior therapy detectable influence subsequent evaluation quality life three quality life instrument consistent change observe three therapy trend toward good quality life amlodipine bisoprolol hctz adverse event systolic diastolic blood pressure reduction correlate directly change quality life,Weir MR,1996,Am J Hypertens,https://doi.org/10.1016/s0895-7061(96)00116-1,8879341,Weir MR; Prisant LM; Papademetriou V; Weber MA; Adegbile IA; Alemayehu D; Lefkowitz MP,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D017311: Amlodipine; D000704: Analysis of Variance; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D017298: Bisoprolol; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D004656: Enalapril; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011788: Quality of Life,,,https://openalex.org/W2083824966,134,19,1,1571,267,8,en,en
false,efficacy tolerability effect quality life losartan alone hydrochlorothiazide versus amlodipine alone hydrochlorothiazide patient essential hypertension,randomized double masked parallel group multicenter clinical trial conduct compare efficacy tolerability effect quality life associate treatment regimen include angiotensin ii receptor antagonist losartan hydrochlorothiazide hctz add need regimen include dihydropyridine calcium channel blocker amlodipine hctz add need trial include patient whose sit diastolic blood pressure sidbp measurement mm hg inclusive placebo baseline patient randomize receive either losartan amlodipine double masked double dummy fashion week placebo washout period follow week active treatment period patient losartan arm n initially give mg oral po losartan day qd medication could titrate mg losartan mg hctz po qd week follow mg losartan plus mg hctz po qd week necessary patient amlodipine group n receive mg amlodipine po qd could titrate mg po qd week follow mg plus mg hctz po qd week medication titrate upward necessary achieve trough sidbp mm hg efficacy tolerability quality life score assess week therapy regimen trough sidbp reduction week therapy clinically comparable losartan group mm hg respectively amlodipine group mm hg respectively similar reduction systolic blood pressure also see treatment group percentage patient reach goal sidbp define trough sidbp mm hg sidbp mm hg mm hg drop placebo baseline comparable two group patient losartan group patient amlodipine group reach goal significantly patient amlodipine group drug related adverse experience vs particular drug related edema common patient receive amlodipine regimen receive losartan regimen vs patient amlodipine arm report significantly bother due edema regardless whether edema present baseline patient losartan arm vs although overall quality life different two treatment group study demonstrate regimen losartan hctz add need compare regimen amlodipine hctz add needed provide comparable efficacy superior tolerability less bother patient respect edema,Oparil S,1996,Clin Ther,https://doi.org/10.1016/s0149-2918(96)80212-8,8879890,Oparil S; Barr E; Elkins M; Liss C; Vrecenak A; Edelman J,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D017311: Amlodipine; D000959: Antihypertensive Agents; D001713: Biphenyl Compounds; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004361: Drug Tolerance; D005260: Female; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D007093: Imidazoles; D019808: Losartan; D008297: Male; D008875: Middle Aged; D011788: Quality of Life; D013777: Tetrazoles",,,https://openalex.org/W2086214954,196,31,1,2732,511,15,en,en
false,double blind parallel comparative multicentre study new combination diltiazem hydrochlorothiazide individual component patient mild moderate hypertension,objective compare antihypertensive efficacy tolerability new combination preparation diltiazem mg hydrochlorothiazide mg individual constituent patient mild moderate hypertension design multi centre double blind randomised parallel group study patient seventy one patient essential hypertension recruit study treatment following completion placebo run period patient fulfil prerandomisation criterion enter week treatment period patient randomise receive either combination preparation mg h mg diltiazem mg hydrochlorthiazide mg dosage increase three patient attain target blood pressure bp control week outcome measure response treatment assess change baseline clinic h ambulatory bp result proportion patient achieve target bp reduction rest supine diastolic blood pressure dbp mm hg reduction mm hg baseline combination group diltiazem group hydrochlorothiazide group respective figure reduction supine dbp baseline mm hg mm hg mm hg similar treatment order appear throughout efficacy variable bp control throughout h dose interval demonstrate ambulatory bp monitoring treatment well tolerate conclusion study provide clear evidence efficacy combination therapy diltiazem hydrochlorothiazide management patient hypertension,Manning G,1996,J Hum Hypertens,,8880557,Manning G; Joy A; Mathias CJ; McDonald CJ; Millar-Craig MW,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000328: Adult; D000368: Aged; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D003971: Diastole; D004110: Diltiazem; D004232: Diuretics; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D008875: Middle Aged; D049993: Sodium Chloride Symporter Inhibitors; D016683: Supine Position; D013599: Systole",,,https://openalex.org/W2412890265,186,26,1,1689,293,13,en,en
true,felodipine addition beta adrenergic blockade angina pectoris multicentre randomize placebo controlled trial,journal article felodipine addition beta adrenergic blockade angina pectoris multicentre randomize placebo controlled trial get access p k r nnevik p k r nnevik search work author oxford academic pubmed google scholar b silke b silke correspondence dr per k r nnevik department heart disease haukeland hospital n bergen norway search work author oxford academic pubmed google scholar stergaard stergaard investigator participate study list appendix search work author oxford academic pubmed google scholar european heart journal volume issue november page http doi org oxfordjournals eurheartj publish november article history accept january publish november,Rønnevik PK,1995,Eur Heart J,https://doi.org/10.1093/oxfordjournals.eurheartj.a060774,8881845,Rønnevik PK; Silke B; Ostergaard O,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D015736: Felodipine; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D010352: Patient Dropouts; D010919: Placebos; D011788: Quality of Life; D013997: Time Factors",,,https://openalex.org/W2224971400,122,15,1,879,144,2,en,en
false,safety finasteride use benign prostatic hypertrophy non interventional observational cohort study patient,examine safety finasteride use general medical practice treat benign prostatic hypertrophy bph information collect patient include observational cohort study conduct use prescription event monitoring finasteride report effective patient opinion efficacy record impotence ejaculatory failure report patient decrease libido gynaecomastia related condition impotence frequent reason stop treatment finasteride commonly report adverse reaction drug patient include elderly cohort involve study die none death attribute finasteride impotence ejaculatory failure decrease libido gynaecomastia small proportion patient associate use finasteride result study strongly suggest drug acceptably safe use accordance current prescribing information,Wilton L,1996,Br J Urol,https://doi.org/10.1046/j.1464-410x.1996.00091.x,8881946,Wilton L; Pearce G; Edet E; Freemantle S; Stephens MD; Mann RD,article,D016428: Journal Article,"D000293: Adolescent; D000328: Adult; D000368: Aged; D015331: Cohort Studies; D004542: Ejaculation; D004791: Enzyme Inhibitors; D007172: Erectile Dysfunction; D018120: Finasteride; D006177: Gynecomastia; D006201: Hair Diseases; D006801: Humans; D007989: Libido; D008297: Male; D008875: Middle Aged; D011358: Product Surveillance, Postmarketing; D011470: Prostatic Hyperplasia; D014555: Urination Disorders",,,https://openalex.org/W2162405033,130,19,1,1092,182,5,en,en
false,comparative review adverse effect calcium antagonist,large number drug within currently class calcium antagonist common medical use treatment hypertension ischaemic heart disease reported adverse effect profile drug varies tend hold true drug class typify adverse reaction report nifedipine amlodipine dihydropyridines diltiazem benzothiazepines verapamil phenylalkylamines minor adverse effect flushing headache ankle oedema palpitation constipation uncommon frequently require cessation treatment great concern affect wide common first line use calcium antagonist yet unresolved issue reportedly great risk myocardial infarction death follow use short acting nifedipine patient history hypertension myocardial infarction angina issue fully resolve would seem prudent limit use agent risk patient await result prospective study final conclusion make,Dougall HT,1996,Drug Saf,https://doi.org/10.2165/00002018-199615020-00002,8884161,Dougall HT; McLay J,article,D003160: Comparative Study; D016428: Journal Article; D016454: Review,"D001145: Arrhythmias, Cardiac; D002121: Calcium Channel Blockers; D002319: Cardiovascular System; D004700: Endocrine System Diseases; D005767: Gastrointestinal Diseases; D006402: Hematologic Diseases; D006801: Humans; D007674: Kidney Diseases; D009203: Myocardial Infarction; D009543: Nifedipine; D012871: Skin Diseases",,,https://openalex.org/W2030435316,66,10,1,1108,186,5,en,en
false,comparison two formulation nifedipine hour ambulatory blood pressure monitoring,study objective determine one commercial extended release formulation nifedipine adalat cc effective another procardia xl control blood pressure hour design open label randomize crossover study setting university affiliated family medicine clinic patient fifteen patient stage primary hypertension intervention procardia xl adalat cc day titrate achieve blood pressure control effective dose continue week wash week reinstituted study drug measurement main result twenty four hour ambulatory blood pressure record conclusion treatment phase treatment phase compare mean hour blood pressure mean daytime p mean nighttime blood pressure mean blood pressure load percentage blood pressure measurement mm hg daytime mm hg nighttime thirteen patient complete study statistically significant difference see mean hour blood pressure mm hg procardia xl vs mm hg adalat cc daytime nighttime blood pressure blood pressure load two patient experience clinically significant adverse effect take adalat cc conclusion patient primary hypertension adalat cc effective procardia xl control blood pressure hour blood pressure heart rate adverse effect monitor week exchange adalat cc procardia xl,Granberry MC,1996,Pharmacotherapy,,8888089,Granberry MC; Gardner SF; Schneider EF; Carter IR,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine",,,,97,13,1,1562,267,13,en,en
false,chronopharmacologic consideration treat patient hypertension review,recognition existence circadian variation exacerbation cardiovascular disease may relevance clinical use cardioactive agent physiologic rational chronobiology cardiac disease exists provide basis examine efficacy agent manage cardiac disease use hour ambulatory blood pressure monitoring abpm device advance ability describe interplay chronobiologic rhythm pharmacodynamic response antihypertensive medication review summarize study evaluate use various antihypertensive medication context use hour blood pressure monitoring device study describe attempt increase awareness chronobiology potential implication design chronotherapeutic regimen,Straka RJ,1996,J Clin Pharmacol,https://doi.org/10.1002/j.1552-4604.1996.tb04250.x,8889897,Straka RJ; Benson SR,article,D003160: Comparative Study; D016428: Journal Article; D016454: Review,D018674: Adrenergic Antagonists; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D019454: Chronotherapy; D006801: Humans; D006973: Hypertension,,,https://openalex.org/W1969106268,88,11,1,834,122,5,en,en
false,shanghai trial nifedipine elderly,assess effectiveness nifedipine treatment elderly hypertensives single blind trial conduct direction shanghai institute hypertension subject age year alternatively allocate either nifedipine placebo week placebo run period mean follow month clinical event risk modification analyse collaboration university montreal seventy four patient severe hypertension reallocate active nifedipine treatment placebo run cox proportional hazard model accounting covariates demonstrate highly significant decrease probability event original treatment assignment analysis indicate event occur placebo nifedipine group similar significance achieve actual treatment changes exclude exclude reallocate subject analyse significant reduction relative risk observe stroke severe arrhythmia overall decrease confidence interval nifedipine treatment diminish number severe clinical outcome elderly hypertensive significantly,Gong L,1996,J Hypertens,https://doi.org/10.1097/00004872-199610000-00013,8906524,Gong L; Zhang W; Zhu Y; Zhu J; Kong D; Pagé V; Ghadirian P; LeLorier J; Hamet P,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D001145: Arrhythmias, Cardiac; D002121: Calcium Channel Blockers; D002561: Cerebrovascular Disorders; D015331: Cohort Studies; D006801: Humans; D006973: Hypertension; D008875: Middle Aged; D009543: Nifedipine; D016016: Proportional Hazards Models; D016037: Single-Blind Method",,,https://openalex.org/W2416538760,43,7,1,1230,181,5,en,en
false,prescribing practice management headache newfoundland labrador,assess impact sumatriptan clinical practice undertake retrospective analysis government newfoundland labrador prescription drug program data base consecutive patient prescribe sumatriptan number dos drug prescribe range prescription per patient month mean number dos analgesic drug prescribe sumatriptan therapy per month initiation sumatriptan per month prescribing multiple analgesic common receive three different analgesic twenty two patient prescribed medication indicate prophylaxis migraine concomitantly drug indicate symptomatic treatment twenty four patient prescribe medication capable induce migraine conclude sumatriptan major impact outcome patient judge use analgesic simple explanation many patient suffer analgesic induced headache rather migraine addition conclude deficiency prescribe practice include number quantity choice analgesic use analgesic concomitantly drug indicate migraine prophylaxis use drug capable induce migraine research require validate finding,Furlong S,1996,Headache,https://doi.org/10.1046/j.1526-4610.1996.3609542.x,8916562,Furlong S; Pryse-Phillips W; Crowley M; Turner CJ,article,D016428: Journal Article,"D000700: Analgesics; D015331: Cohort Studies; D011307: Drug Prescriptions; D006261: Headache; D006801: Humans; D008881: Migraine Disorders; D009523: Newfoundland and Labrador; D010818: Practice Patterns, Physicians'; D012189: Retrospective Studies; D017366: Serotonin Receptor Agonists; D018170: Sumatriptan; D016896: Treatment Outcome",,,https://openalex.org/W2131101452,81,11,1,1436,236,10,en,en
false,clinical evaluation serum amlodipine level patient angina pectoris,serum amlodipine level determine patient vasospastic angina patient divide two group group n receive amlodipine mg single daily administration group b n receive mg give single daily administration first day mg th day serum amlodipine concentration group take day reach steady state around ng ml level group b ng ml day result optimal dosage amlodipine treatment angina pectoris mg initial day follow mg thereafter,Watanabe K,1996,Gen Pharmacol,https://doi.org/10.1016/0306-3623(95)02022-5,8919632,Watanabe K; Ochiai Y; Washizuka T; Inomata T; Miyakita Y; Shiba M; Izumi T; Shibata A; Qu YL; Nagatomo T,article,D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article,D000368: Aged; D017311: Amlodipine; D000787: Angina Pectoris; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged,,,https://openalex.org/W2067284436,78,11,1,613,127,5,en,en
false,calcium channel blocker debate true lie,,Leor J,1996,Cardiovasc Drugs Ther,https://doi.org/10.1007/bf00051105,8924054,Leor J; Battler A,article,D016421: Editorial,D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D006801: Humans; D006973: Hypertension; D009200: Myocardial Contraction; D009203: Myocardial Infarction; D017202: Myocardial Ischemia; D009543: Nifedipine; D012307: Risk Factors,,,https://openalex.org/W1980244185,42,8,1,0,0,0,en,
false,comparative antihypertensive action mg delayed action nifedipine either mg atenolol study treatment patient mild moderately severe arterial hypertension,present double blind randomize placebo controlled study untreated patient year mild moderate hypertension include day placebo period treat combination mg retard nifedipine mg atenolol six week group start mg group b mg atenolol casual sit blood pressure measure automatically every second week routine laboratory parameter side effect evaluate end placebo verum period blood pressure two group comparable placebo reduce mmhg group mmhg group b p vs placebo six week second treatment period verum blood pressure far reduce combination equally efficient also female elder subgroup year characterize high systolic blood pressure response rate combination mg atenolol respectively heart rate significantly reduce group mg atenolol laboratory parameter alter treatment frequency severeness side effect equal group conclude patient mild moderate uncomplicated hypertension combination mg retard nifedipine mg atenolol equally efficient combination mg atenolol,Kraft K,1996,Praxis (Bern 1994),,8927880,Kraft K; Schiessl S; Vetter H,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D000959: Antihypertensive Agents; D001262: Atenolol; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine",,,https://openalex.org/W2412928077,197,33,2,1461,264,12,en,en
true,comparison therapeutic effect beta blocking agent bisoprolol calcium blocking agent diltiazem patient heart failure due dilate cardiomyopathy,beta blocking agent reduce mortality improve symptom patient dilate cardiomyopathy dcm report diltiazem calcium blocking agent also effective patient prospectively compare effect beta blocking agent bisoprolol calcium blocking agent diltiazem patient male female age dcm patient new york heart association functional class iii class iv randomly assign group bisoprolol administer first drug patient diltiazem administer cross bisoprolol also perform patient end study among patient give bisoprolol show good response efficacy rate contrast patient receive diltiazem show good response efficacy rate among patient nyha class iii treat bisoprolol respond treat diltiazem respond p among patient class iv respond bisoprolol respond diltiazem significant result suggest diltiazem iike bisoprolol beneficial effect patient dcm great effect class iii patient however conclude diltiazem usually use second choice improve heart failure dcm first medication contraindication beta blocking agent jpn circ j,Suwa M,1996,Jpn Circ J,https://doi.org/10.1253/jcj.60.767,8933239,Suwa M; Ito T; Otake Y; Moriguchi A; Hirota Y; Kawamura K,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D017298: Bisoprolol; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002311: Cardiomyopathy, Dilated; D018592: Cross-Over Studies; D004110: Diltiazem; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D009638: Norepinephrine; D011446: Prospective Studies; D016277: Ventricular Function, Left",,,https://openalex.org/W2058452337,177,24,1,1586,324,14,en,en
false,multicenter comparative study felodipine er nifedipine oros treatment mild moderate arterial hypertension,compare efficacy tolerance felodipine er nifedipine oros daily treatment mild moderate uncomplicated arterial hypertension ah multicentric open randomize paralled trial select patient uncomplicated mild moderate essential ah diastolic blood pressure dbp mmhg anti hypertensive medication patient receive placebo two week period would take either mg day felodipine mg day nifedipine oros daily randomized fashion patient underwent laboratory test electrocardiogram ecg begining end study heart rate blood pressure bp measurement nearly hour last active drug dose completed study patient felodipine group nifedipine group compare baseline average systolic bp dbp decrease mmhg mmhg mmhg respectively end treatment felodipine group mmhg mmhg mmhg respectively nifedipine group p diferences adequate bp response treatment dbp normalization reduction mmhg baseline occur patient felodipine group nifedipine group ns side effect occur approximately case similar group usually moderate transient responsible withdrawal study two case felodipine group three case nifedipine group felodipine er nifedipine oros similarly effective generally well tolerate patient mild moderate essential hypertension,Batlouni M,1996,Arq Bras Cardiol,,8935693,Batlouni M; Leite Luna R; Castro I; Silveira Sbissa A; Armaganijan D; Chaves Junior Hde C; Nobre F; Pereira da Cunha C,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D000704: Analysis of Variance; D016009: Chi-Square Distribution; D004361: Drug Tolerance; D015736: Felodipine; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine,,,https://openalex.org/W21488639,128,17,1,1896,351,8,en,en
false,increase renal dopamine production induce nifedipine hypertensive patient double blind v placebo study,dopamine synthetized excrete kidney amine exert natriuretic diuretic effect inhibition sodium reabsorption kidney convolute tubule objective study verify change dopamine urinary excretion induce nifedipine lp treatment hypertensive patient twenty four patient essential hypertension stag include double blind placebo control study twelve patient receive nifedipine average daily dose mg day week patient receive placebo time period significant change detect upon nifedipine treatment neither plasma biochemical hematological parameter systolic blood pressure sbp diastolic blood pressure dbp significantly reduce pretreatment value mmhg mmhg respectively end treatment value mmhg mmhg p placebo treatment modify sbp dbp urinary dopamine excretion increase micrograms h prior treatment micrograms h treatment p confidence interval difference urinary volume nifedipine treated patient increase ml h ml h post treatment p significant change observe urinary noradrenaline adrenaline excretion nifedipine placebo treated patient analysis fluorescent light excitation emission spectrum nm nm dopamine extract patient urine submit nifedipine treatment reveal interference compare chemically pure dopamine conclude nifedipine treatment hypertensive patient increase kidney dopamine production turn exert natriuretic diuretic effect besides well know vasodilator property,Romero-Vecchione E,1995,Arch Inst Cardiol Mex,,8948688,Romero-Vecchione E; Vásquez J; Velasco M; Morales E; Davoli MA; Arocha I,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D004740: English Abstract; D016428: Journal Article,D000328: Adult; D004298: Dopamine; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D007668: Kidney; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D014665: Vasodilator Agents,,,https://openalex.org/W2417830435,118,20,2,1929,324,13,en,en
false,short long term clinical tolerance hypertensive treatment hot study hypertension optimal treatment,international prospective randomize hot study aim determine optimal bp level treatment order reduce cardiovascular morbidity mortality define randomization level obtain dbp mmhg treatment start felodipine mg day necessary bitherapy prescribe necessary tritherapy patient include bp randomization mmhg year treatment possible search influence clinical tolerance sex age bp goal geographic area time treatment percentage patient side effect bp goal treatment type time different geographic area following ne northern europe norway switzerland belgium hungary sweden denmark finland netherlands uk germany austria se southern europe italy spain greece table see text target bp age n nearly influence clinical tolerance side effect report physician numerous treatment start longeur terme due therapeutic modification physician good acceptation drug patient real disappearance side effect report side effect frequent southern europe france northern europe frequent among woman men incidence side effect proportional number prescribed drug time number antihypertensive drug appear important factor,Mallion JM,1996,Arch Mal Coeur Vaiss,,8949385,Mallion JM; Pehrsson NG; Raveau-Landon C; Boutelant S; Ménard J,article,D016430: Clinical Trial; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000367: Age Factors; D000959: Antihypertensive Agents; D001794: Blood Pressure; D004359: Drug Therapy, Combination; D004361: Drug Tolerance; D005060: Europe; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D015337: Multicenter Studies as Topic; D011446: Prospective Studies; D012737: Sex Factors",,,https://openalex.org/W2248049650,121,20,1,1593,305,11,en,en
true,low dosage felodipine er daily monotherapy elderly hypertensive patient effect ambulatory blood pressure quality life,objective establish efficacy h ambulatory casual blood pressure bp reduction tolerability daily felodipine extend release er mg felodipine er mg monotherapy design randomise double blind placebo control week parallel study set general practice centre gps region university maastricht netherlands subject total subject age year primary hypertension screen men woman casual diastolic bp mm hg systolic bp less mm hg enter study main outcome measure casual h ambulatory bp subjective symptom assessment ssa questionnaire week therapy result correlation placebo response mean casual systolic diastolic bp sbp dbp reduction mm hg ns mm hg p felodipine er mg respectively use h ambulatory bp measurement reduction mm hg ns mm hg p respectively significant difference sbp dbp find night time felodipine placebo felodipine er mg lower bp load significantly daytime night time felodipine er mg dbp daytime significant difference number responder placebo v felodipine er mg er mg felodipine dosage placebo comparable low number adverse event result ssa conclusion daytime felodipine er mg mg effective bp lowering elderly hypertensive patient however felodipine er mg effective reduce bp night time felodipine er mg significant reduce effect bp load day night time felodipine er er significant effect responder rate appear study compare placebo contrast felodipine er mg er form felodipine mg bp lower effect night time elderly patient assess effectivity night time felodipine er mg individual patient recommendable measure bp end dose interval,van Ree JW,1996,J Hum Hypertens,,8953207,van Ree JW; van der Pol GA,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011788: Quality of Life",,,https://openalex.org/W2417339754,145,24,1,2345,461,17,en,en
false,effect verapamil prevalence severity cyclosporine induced gingival overgrowth renal allograft recipient,cyclosporine csa verapamil two agent use renal transplantation suspect induce gingival overgrowth study conduct investigate effect verapamil severity prevalence csa induced gingival overgrowth fifty one renal transplant recipient total group use csa group prescribe csa verapamil group b evaluate various periodontal pharmacological parameter statistically significant difference find age sex plaque index gingival index calculus index probe depth csa oral dose csa whole blood level duration csa therapy azathioprine dose prednisolone dose although prevalence gingival overgrowth pronounced csa verapamil group compare csa group vs difference statistically significant similarly severity gingival overgrowth although manifest csa verapamil group csa patient vs significantly different gingival overgrowth score main group csa csa verapamil group find positively correlate periodontal probe depth r r r respectively gingival index r r r respectively csa oral dose whole blood level duration csa therapy find correlate gingival overgrowth either group likewise dose verapamil duration verapamil therapy correlate gingival overgrowth group b study indicate verapamil prescribe calcium channel blocker renal transplant patient augment effect severity prevalence csa induced gingival overgrowth,Cebeci I,1996,J Periodontol,https://doi.org/10.1902/jop.1996.67.11.1201,8959570,Cebeci I; Kantarci A; Firatli E; Carin M; Tuncer O,article,D016428: Journal Article,"D000328: Adult; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D016009: Chi-Square Distribution; D016572: Cyclosporine; D004338: Drug Combinations; D005260: Female; D005885: Gingival Hyperplasia; D006801: Humans; D007166: Immunosuppressive Agents; D016030: Kidney Transplantation; D008297: Male; D010512: Periodontal Index; D018709: Statistics, Nonparametric; D014700: Verapamil",,,https://openalex.org/W2000593592,128,17,1,1828,342,10,en,en
false,hypertension diabetes study iv therapeutic requirement maintain tight blood pressure control,report efficacy therapy year follow non insulin dependent diabetic patient prospective randomise control study therapy mild hypertension patient recruit antihypertensive therapy systolic blood pressure mmhg diastolic mmhg therapy systolic blood pressure mmhg diastolic mmhg mean blood pressure entry study mmhg mean age year allocate tight control aim systolic diastolic mmhg less tight control aim systolic diastolic mmhg tight control group allocate primary therapy either beta blocker atenolol antiotensin convert enzyme inhibitor captopril addition agent require year mean blood pressure tight control group significantly low vs mmhg p difference see allocate atenolol captopril proportion patient require three antihypertensive therapy maintain tight control allocate atenolol captopril increase respectively year respectively year whereas less tight control group year respectively required three therapy difference incidence side effect hypoglycaemic episode allocate atenolol captopril allocate atenolol increase body weight mean kg compare kg allocate captopril p allocation atenolol also associate small increase triglyceride decrease ldl hdl cholesterol uncertain clinical relevance study continue determine whether improved blood pressure control obtain beneficial maintain health patient decrease incidence major clinical complication principally myocardial infarction stroke microvascular complication severe retinopathy require photocoagulation deterioration renal function,,1996,Diabetologia,https://doi.org/10.1007/s001250050614,8960842,,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000319: Adrenergic beta-Antagonists; D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001262: Atenolol; D001794: Blood Pressure; D002216: Captopril; D015331: Cohort Studies; D003924: Diabetes Mellitus, Type 2; D004573: Electrolytes; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006973: Hypertension; D007003: Hypoglycemia; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D013997: Time Factors",,,https://openalex.org/W2069628693,100,14,2,2242,396,11,en,en
true,appropriate blood pressure control niddm abcd trial,abcd appropriate blood pressure control diabetes trial large prospective randomized clinical trial patient non insulin dependent diabetes mellitus niddm design compare effect intensive blood pressure control moderate control prevention progression diabetic nephropathy retinopathy cardiovascular disease neuropathy niddm secondary objective determine equivalency effect calcium channel blocker nisoldipine angiotensin converting enzyme inhibitor enalapril first line antihypertensive agent prevention progression diabetic vascular complication study consist two study population age year hypertensive patient diastolic blood pressure mmhg time randomization normotensive patient diastolic blood pressure mmhg time randomization study duration year schedule end may patient randomize receive either intensive antihypertensive drug therapy moderate antihypertensive drug therapy patient also randomize nisoldipine enalapril open label medication add blood pressure control necessary primary outcome measure glomerular filtration rate assess h creatinine clearance secondary outcome measure urinary albumin excretion leave ventricular hypertrophy retinopathy neuropathy cardiovascular morbidity mortality also evaluate give data show impact hypertension complication niddm abcd trial design determine intensive antihypertensive therapy efficacious moderate antihypertensive therapy outcome diabetic complication niddm,Schrier RW,1996,Diabetologia,https://doi.org/10.1007/s001250050629,8960857,Schrier RW; Estacio RO; Jeffers B,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000419: Albuminuria; D000806: Angiotensin-Converting Enzyme Inhibitors; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002318: Cardiovascular Diseases; D015331: Cohort Studies; D003924: Diabetes Mellitus, Type 2; D003928: Diabetic Nephropathies; D003929: Diabetic Neuropathies; D003930: Diabetic Retinopathy; D004656: Enalapril; D015444: Exercise; D005260: Female; D005919: Glomerular Filtration Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D015737: Nisoldipine; D011446: Prospective Studies; D012727: Sex Characteristics",,,https://openalex.org/W1964395315,56,10,1,1822,284,10,en,en
false,effect treatment trapidil compare nifedipine physical emotional cognitive exercise tolerance patient coronary heart disease,present study carry investigate exercise test result outcome quality life administration trapidil cas rocornal nifedipine cas patient coronary heart disease characteristic life quality combination result exercise test consider great importance select medical treatment patient chronic stable angina pectoris however little information available first evaluation may use select best pharmacological approach individual patient prospective multicentre study patient stable angina enrol centre due protocol violation drop outs patient evaluate tolerability patient evaluate efficacy baseline evaluation consist exercise test question investigating patient anginal symptom several psychometric testing patient randomly allocate double blind treatment week either trapidil mg nifedipine mg accord parallel group design week exercise test psychometric testing repeat trapidil nifedipine prolong exercise tolerance trapidil vs nifedipine increase total exercise baseline level trapidil vs nifedipine use mann whitney u test sb rating scale physician assessment reveal comparable improvement life quality trapidil vs nifedipine treatment addition patient question show significant reduction angina attack nitroglycerin consumption none characteristic anginal symptom exercise test give evidence significant difference nifedipine trapidil drug demonstrate similar safety profile adverse event aes trapidil nifedipine four patient trapidil group one nifedipine group discontinue clinical trial aes result baseline exercise test rating questionnaire may offer useful information select medical treatment stable angina pectoris,Assmann I,1996,Arzneimittelforschung,,8967905,Assmann I; Lehrl S; Burkard G; Strösser W,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000368: Aged; D003071: Cognition; D003327: Coronary Disease; D004311: Double-Blind Method; D004562: Electrocardiography; D004644: Emotions; D015444: Exercise; D005080: Exercise Test; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011594: Psychometrics; D011788: Quality of Life; D014192: Trapidil; D014665: Vasodilator Agents,,,https://openalex.org/W2407033294,160,26,1,2251,370,15,en,en
false,novel delivery system verapamil design achieve maximal blood pressure control early morning,risk cardiovascular event appear great early morning period time adequate blood pressure bp control appear desirable study controlled onset extended release system coer deliver verapamil manner design achieve maximal level drug early morning surge bp compare placebo ninety five patient mild moderate hypertension study group patient mean age year men woman randomize take verapamil coer mg pm subject mean age year men woman randomize take placebo ambulatory bp monitoring perform week initial placebo period repeat week treatment verapamil placebo verapamil coer result significant p decrease mean whole day systolic diastolic bp mm hg baseline mm hg compare placebo mm hg baseline mm hg noon verapamil coer result change systolic diastolic bp mm hg significantly p great change occur placebo mm hg period last hour dosing interval pm pm verapamil coer cause significantly great p decrease bp mm hg placebo mm hg data demonstrate coer system administer late evening achieve maximal bp reduction early morning hour moreover bp reduction sustain throughout hour period,Neutel JM,1996,Am Heart J,https://doi.org/10.1016/s0002-8703(96)90464-0,8969572,Neutel JM; Alderman M; Anders RJ; Weber MA,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002940: Circadian Rhythm; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D016503: Drug Delivery Systems; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D014700: Verapamil",,,https://openalex.org/W2134530239,111,16,1,1701,321,10,en,en
false,effect bunazosin atenolol serum lipid apolipoproteins randomised trial,effect bunazosin atenolol serum lipid lipoprotein month treatment compare multicentric double blind randomised trial total patient mild moderate essential hypertension hospital germany poland include study eighty seven treat alpha receptor blocker bunazosin number beta blocker atenolol systolic diastolic blood pressure decrease significantly group whereas atenolol decrease pulse rate bunazosin group hdl cholesterol significantly increase month treatment whereas analysed parameter remain unchanged atenolol group total cholesterol ldl cholesterol total triglyceride apolipoprotein e vldl cholesterol vldl triglycerides significantly increase month therapy significant difference bunazosin atenolol total cholesterol hdl cholesterol ldl cholesterol vldl cholesterol triglyceride vldl triglycerides apolipoprotein b level consequence significant difference atherogenic index group conclude bunazosin favorable treatment high blood pressure coronary risk negatively influence show atenolol,Schmitz G,1996,Blood Press,https://doi.org/10.3109/08037059609078074,8973753,Schmitz G; Stumpe KO; Herrmann W; Weidinger G,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000317: Adrenergic alpha-Antagonists; D000328: Adult; D000959: Antihypertensive Agents; D001053: Apolipoproteins; D001262: Atenolol; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D008055: Lipids; D008297: Male; D008875: Middle Aged; D011799: Quinazolines; D016896: Treatment Outcome,,,https://openalex.org/W2118085902,91,14,1,1348,206,9,en,en
false,hyperprolactinaemia verapamil prevalence potential association hypogonadism men,objective verapamil associate hyperprolactinaemia population based study objective determine prevalence degree hyperprolactinaemia associate verapamil clinical setting design observation cross sectional longitudinal component setting urban teaching hospital satellite patient clinic patient male patients exclude take drug know raise prl renal failure know primary hypothyroidism eligible subject control subject draw eligible patients take verapamil measurement serum prl level frequency persistent hyperprolactinaemia total testosterone level result prolactin level obtain subject verapamil response rate control proportion individual hyperprolactinaemia prl mu l verapamil control group respectively p test mean sd serum prl level mu l verapamil control group respectively p independent test patient previously determine elevate prl level follow data obtain one find pituitary adenoma exclude analysis fifteen still verapamil group continue hyperprolactinaemic patient verapamil discontinue group normal prl level continue verapamil use associate persistent hyperprolactinaemia odds ratio p sd serum testosterone level follow significantly low group nmol l group nmol l p independent test conclusion prevalence hyperprolactinaemia associate verapamil use study male patients cl persistence hyperprolactinaemia verapamil continue group return normal prl level verapamil discontinue group confirm verapamil causal role development hyperprolactinaemia low testosterone level common group testosterone level low patient verapamil data suggest screen hyperprolactinaemia consider male patient take verapamil,Romeo JH,1996,Clin Endocrinol (Oxf),https://doi.org/10.1046/j.1365-2265.1996.00859.x,8977754,Romeo JH; Dombrowski R; Kwak YS; Fuehrer S; Aron DC,article,"D016428: Journal Article; D013486: Research Support, U.S. Gov't, Non-P.H.S.","D000368: Aged; D002121: Calcium Channel Blockers; D003430: Cross-Sectional Studies; D006801: Humans; D006966: Hyperprolactinemia; D008137: Longitudinal Studies; D008297: Male; D008875: Middle Aged; D010044: Outpatient Clinics, Hospital; D015995: Prevalence; D013739: Testosterone; D014700: Verapamil",,,https://openalex.org/W2005371095,103,18,1,2438,438,18,en,en
false,effectiveness verapamil quinidine versus digoxin quinidine emergency department treatment paroxysmal atrial fibrillation,determine relative effectiveness verapamil quinidine sequential combination versus digoxin quinidine emergency department treatment paroxysmal atrial fibrillation paf prospective double blind randomize control trial involve patient age year new onset hour atrial fibrillation present community based urban hospital annual ed census exclusion criterion include ventricular response rate low high beats minute allergy study drug hypotension evidence end organ hypoperfusion conduction abnormality consent patient randomly assign receive rapid digitalization mg hour v verapamil sequential mg boluses mg ventricular rate control beats minute oral quinidine mg initiate repeat every hour conversion normal sinus rhythm nsr occur g quinidine administer adverse effect supervene heart rate blood pressure cardiac rhythm time conversion adverse effect documented forty four patient receive study drug three withdraw leave verapamil quinidine ver q group digoxin quinidine dig q group sixteen patient ver q group dig q group convert nsr within hour p mean time conversion sd minute ver q minute dig q patient p n twelve ver q patient dig q patient discharge ed p minor adverse effect common ver q group mortality significant morbidity occurred sequential combination verapamil quinidine dos study effective treatment paf superior digoxin quinidine digoxin longer consider treatment choice uncomplicated paf,Innes GD,1997,Ann Emerg Med,https://doi.org/10.1016/s0196-0644(97)70318-4,8998091,Innes GD; Vertesi L; Dillon EC; Metcalfe C,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D004077: Digoxin; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004632: Emergency Medical Services; D004636: Emergency Service, Hospital; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D011802: Quinidine; D013614: Tachycardia, Paroxysmal; D016896: Treatment Outcome; D014700: Verapamil",,,https://openalex.org/W2079438910,133,14,1,1986,364,13,en,en
false,antihypertensive effect amlodipine hydrochlorothiazide elderly patient ambulatory hypertension,recent study authority advocate use low dose thiazide diuretic first line treatment agent elderly hypertensive however recommendation base solely blood pressure bp measure clinic objective present week double blind study compare effect hydrochlorothiazide hctz amlodipine aml elderly patient confirmed ambulatory hypertension week placebo washout period men woman patient mean age year clinic sit diastolic bp mm hg daytime ambulatory diastolic bp mm hg randomize double blind receive aml mg n hctz mg n daily week monotherapy patient clinic diastolic bp remain mm hg give combination therapy agent amlodipine monotherapy induce significant reduction clinic mean h daytime sleep systolic diastolic bps whereas clinic bp decrease significantly patient treat hctz monotherapy moreover versus patient aml hctz monotherapies achieve adequate bp control end week treatment period combination therapy hctz group result statistically significant reduction clinic well h daytime sleep ambulatory bps similar observe aml monotherapy group conclusion administration aml monotherapy induce significant reduction clinic ambulatory bps elderly patient whereas clinic bp significantly decrease hctz monotherapy moreover addition aml hctz patient inadequately control monotherapy permit statistically significant decrement clinic well ambulatory bp consequently result present study suggest use hctz dos mg daily inadequate ambulatory bp control elderly despite official recommendation j hypertens,Lacourcière Y,1995,Am J Hypertens,https://doi.org/10.1016/0895-7061(95)00362-2,8998248,Lacourcière Y; Poirier L; Lefebvre J; Archambault F; Cléroux J; Boileau G,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002940: Circadian Rhythm; D004359: Drug Therapy, Combination; D005260: Female; D006339: Heart Rate; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D008297: Male; D016037: Single-Blind Method",,,https://openalex.org/W2054234263,112,13,1,2050,357,12,en,en
false,treatment non insulin dependent diabetic hypertensive patient ca channel blocker associate increased platelet sensitivity insulin,insulin influence platelet function reduce platelet responsiveness vasoactive agonist hypertension insulin related inhibitory effect blunt aim study determine whether platelet sensitivity insulin affect week antihypertensive treatment calcium channel blocker eleven patient essential hypertension non insulin dependent diabetes treat either isradipine diltiazem platelet free calcium concentration measure spectrofluorometrically nonstimulated angiotensin ii nmol l stimulated platelet pre exposed insulin microu ml platelet study therapy week treatment systolic blood pressure mean arterial pressure decrease significantly treatment calcium channel blocker equally decrease fast serum insulin level pmol l therapy pmol l therapy result calcium channel antagonist similar pool pretreatment phase insulin pre incubation effect angiotensin ii stimulated intracellular free calcium response angiotensin ii similar absence nmol l presence insulin nmol l treatment calcium channel blocker insulin significantly p reduce angiotensin ii induced rise intracellular free calcium nmol l absence insulin nmol l presence insulin whether effect due specifically calcium channel blocker whether result lowering blood pressure remain unclear serum insulin level positively correlate angiotensin ii stimulated increase intracellular free calcium platelet pre exposed insulin r p suggest increase level insulin resistance inhibitory effect insulin reduce study show treatment non insulin dependent diabetic hypertensive patient calcium channel blocker reduce hyperinsulinemia increase sensitivity platelet inhibitory effect insulin angiotensin ii stimulated calcium response,Touyz RM,1995,Am J Hypertens,https://doi.org/10.1016/0895-7061(95)00249-9,8998256,Touyz RM; Schiffrin EL,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000804: Angiotensin II; D000959: Antihypertensive Agents; D001792: Blood Platelets; D001794: Blood Pressure; D002118: Calcium; D002121: Calcium Channel Blockers; D003924: Diabetes Mellitus, Type 2; D004110: Diltiazem; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D007004: Hypoglycemic Agents; D007328: Insulin; D007333: Insulin Resistance; D017275: Isradipine; D008297: Male; D008875: Middle Aged; D014662: Vasoconstrictor Agents",,,https://openalex.org/W1971345003,154,19,1,2249,347,14,en,en
false,treatment patient essential hypertension amlodipine mg benazepril mg compare amlodipine mg benazepril mg placebo,multicenter double masked randomize parallel group study compare efficacy tolerability safety amlodipine mg benazepril mg amlodipine mg benazepril mg placebo patient essential hypertension placebo run period patient white randomize treatment group take medication daily week blood pressure measure week treatment hour period dose patient wear noninvasive blood pressure monitor hour randomization final visit investigator record adverse experience randomization study week obtain specimen laboratory testing randomization study week three hundred seven patient evaluate efficacy tolerability safety end point last postrandomization measurement patient reduction mean sit diastolic blood pressure amlodipine mg benazepril mg treatment statistically significantly great comparative therapy result hour monitoring show amlodipine benazepril treatment unlike monotherapy maintain hourly mean diastolic blood pressure mm hg responder rate observe amlodipine mg benazepril mg versus amlodipine benazepril placebo respectively difference amlodipine benazepril treatment group comparative single agent treatment group statistically significant drug related adverse event occur patient amlodipine benazepril group patient amlodipine benazepril placebo group respectively edema occur less often amlodipine benazepril group amlodipine group overall daily therapy amlodipine mg benazepril mg provide antihypertensive effect statistically clinically superior amlodipine mg alone benazepril mg alone placebo well tolerate associate less edema amlodipine treatment,Kuschnir E,1996,Clin Ther,https://doi.org/10.1016/s0149-2918(96)80076-2,9001838,Kuschnir E; Acuña E; Sevilla D; Vasquez J; Bendersky M; Resk J; Glazer R,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D001552: Benzazepines; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D002214: Capsules; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D012449: Safety; D016896: Treatment Outcome",,,https://openalex.org/W2010811270,144,24,1,2187,368,13,en,en
false,evaluation enalapril diltiazem er hypertensive patient coexist renal dysfunction enalapril diltiazem er hypertensive renal disease group,enalapril long acting diltiazem show effectively lower blood pressure bp hypertensive patient furthermore clinical study two agent provide beneficial renal effect patient administer long term basis combination enalapril diltiazem er evaluate patient stage hypertension coexist renal disease trial use multicenter randomize double blind parallel group design study consist week double blind phase follow month open label extension phase combination enalapril diltiazem er show reduce bp follow short term long term treatment phase patient renal group creatinine clearance crcl ml min decrease mm hg week month therapy respectively renal group ii crcl ml min similar decrease mm hg time point adverse event phase associate respective monotherapies reduction crcl coincident decrease proteinuria note renal group combination enalapril diltiazem er lower bp generally well tolerate patient combination two agent improve management hypertensive patient,Hricik DE,1996,J Hum Hypertens,,9004108,Hricik DE; Levine BS; Adrogue HJ; Weinberg MS; Goldstein R,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D001794: Blood Pressure; D003404: Creatinine; D003692: Delayed-Action Preparations; D004110: Diltiazem; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004656: Enalapril; D005260: Female; D006801: Humans; D006973: Hypertension; D007674: Kidney Diseases; D008297: Male; D008875: Middle Aged; D011507: Proteinuria",,,https://openalex.org/W112000884,156,20,2,1381,233,12,en,en
false,blood pressure metabolic response moderate sodium restriction isradipine treated hypertensive patient,multicenter randomize control clinical trial assess influence sodium chloride intake antihypertensive effect calcium channel blocker isradipine participant uncomplicated hypertension control isradipine enter week sodium restricted mmol h period participant urinary sodium level mmol h n randomize placebo sodium chloride mmol h week cross alternative treatment additional week mean baseline systolic blood pressure mm hg mean sd open label isradipine treatment systolic blood pressure ad libitum sodium chloride restriction mm hg respectively double blind sodium chloride restriction supplementation mm hg p urinary sodium excretion value open label isradipine ad libitum versus restrict versus mmol h double blind restrict versus supplement sodium excretion v mmol h p change urinary sodium excretion predictive variation blood pressure urinary sodium excretion sodium restriction correlate directly hdl cholesterol p inversely total cholesterol hdl cholesterol p despite decrease total saturate fat intake p sodium restriction associate significant reduction p virtually macronutrients electrolyte thus adverse impact overall nutrition antihypertensive action isradipine enhance dietary sodium chloride restriction lipoprotein profile least favorable sodium chloride restriction,McCarron DA,1997,Am J Hypertens,https://doi.org/10.1016/s0895-7061(96)00295-6,9008250,McCarron DA; Weder AB; Egan BM; Krishna GG; Morris CD; Cohen M; Oparil S,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000959: Antihypertensive Agents; D001794: Blood Pressure; D005260: Female; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D008297: Male; D008875: Middle Aged; D017673: Sodium Chloride, Dietary",,,https://openalex.org/W2068738649,113,13,1,1836,315,10,en,en
false,nifedipine gastrointestinal therapeutic system versus atenolol stable angina pectoris,gastrointestinal therapeutic system formulation nifedipine enable daily dosing result predictable relatively constant plasma concentration evaluate efficacy safety formulation compare blocker atenolol conduct double blind randomise multi centre study male patient documented exercise induce angina pectoris week treatment nifedipine mg improved time onset mv st segment depression time onset pain total exercise time atenolol mg comparable effect time onset mv st segment depression improve time onset pain total exercise time group analysis reveal statistically significant difference exercise parameter atenolol nifedipine significantly reduce heart rate systolic blood pressure rest exercise p group indicate different mode action drug regard safety drug generally well tolerate significantly p vasodilation relate side effect nifedipine data demonstrate gastrointestinal therapeutic system formulation nifedipine atenolol daily monotherapy equally effective safe different effect exercise parameter,de Vries RJ,1996,Int J Cardiol,https://doi.org/10.1016/s0167-5273(96)02806-9,9013266,de Vries RJ; van den Heuvel AF; Lok DJ; Claessens RJ; Bernink PJ; Pasteuning WH; Kingma JH; Dunselman PH,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000319: Adrenergic beta-Antagonists; D000368: Aged; D000787: Angina Pectoris; D001262: Atenolol; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004562: Electrocardiography; D005080: Exercise Test; D017079: Exercise Tolerance; D006801: Humans; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D005996: Nitroglycerin; D016896: Treatment Outcome; D014665: Vasodilator Agents",,,https://openalex.org/W2119183667,88,10,1,1513,273,7,en,en
false,long term effectiveness enalapril plus extended release diltiazem essential hypertension,study objective evaluate efficacy safety new combination product enalapril diltiazem er administer long term design open label titration response treatment last week week double blind phase setting medical clinic private academic sector patient patient men caucasian mean age yr essential hypertension sit diastolic blood pressure mm hg enrol complete trial intervention patient receive either dosage enalapril diltiazem er give double blind phase prescribe enalapril mg diltiazem er mg day dosage increase blood pressure control maximum enalapril diltiazem er mg day measurement main result combination therapy decrease sit blood pressure mm hg overall patient achieve sit diastolic blood pressure mm hg end study evidence tolerance agent antihypertensive effect common drug related adverse event cough headache dizziness asthenia fatigue conclusion combination effectively manage essential hypertension administer long term basis generally well tolerate improve compliance management hypertension,Applegate W,1997,Pharmacotherapy,,9017770,Applegate W; Cohen JD; Wolfson P; Davis A; Green S,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D004110: Diltiazem; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004656: Enalapril; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D016896: Treatment Outcome",,,https://openalex.org/W1752132702,94,10,1,1430,247,19,en,en
false,pharmacologic conversion atrial fibrillation atrial flutter normal sinus rhythm role ibutilide,pharmacotherapy journal human pharmacology drug therapyvolume issue p free access pharmacologic conversion atrial fibrillation atrial flutter normal sinus rhythm role ibutilide michael katcher michael katcher new england cardiac arrhythmia center new england medical center tufts university school medicine boston massachusetts search paper authorn mark estes iii correspond author n mark estes iii new england cardiac arrhythmia center new england medical center tufts university school medicine boston massachusetts new england cardiac arrhythmia center new england medical center washington street boston search paper author michael katcher michael katcher new england cardiac arrhythmia center new england medical center tufts university school medicine boston massachusetts search paper authorn mark estes iii correspond author n mark estes iii new england cardiac arrhythmia center new england medical center tufts university school medicine boston massachusetts new england cardiac arrhythmia center new england medical center washington street boston search paper author first publish january http doi org j tb xaboutpdf toolsrequest permissionexport citationadd favoritestrack citation shareshare give accessshare full text accessshare full text accessplease review term condition use check box share full text version article read accept wiley online library term condition useshareable linkuse link share full text version article friend colleague learn copy url share linkshare onemailfacebooktwitterlinkedinredditwechat reference kannel wb wolf pa epidemiology atrial fibrillation rh falk pt podrid ed atrial fibrillation mechanism management new york raven press kannel wb abbott rd savage dd mcnamara pm epidemiologic feature chronic atrial fibrillation framingham study n engl j med wolf pa abbott rd kannel wb atrial fibrillation major contributor stroke elderly framingham study arch intern med stroke prevention atrial fibrillation investigator warfarin versus aspirin prevention thromboembolism atrial fibrillation stroke prevention atrial fibrillation ii study lancet van gelder ic crijns hj blanksma pk et al time course hemodynamic change improvement exercise tolerance cardioversion chronic atrial fibrillation unassociated cardiac valve disease j cardiol coplen se antman em berlin ja hewitt hp chalmers tc efficacy safety quinidine therapy maintenance sinus rhythm cardioversion meta analysis randomize control trial circulation flaker gc blackshear jl mcbride r kronmal ra halpern jl hart rg antiarrhythmic drug therapy cardiac mortality atrial fibrillation j coll cardiol laupacis albers g dunn feinberg w antithrombotic therapy atrial fibrillation third accp concensus conference antithrombotic therapy chest suppl desilva ra graboys tb podrid pj lown b cardioversion defibrillation heart j man wj silverman di katz se et al temporal dependence return atrial mechanical function mode cardioversion atrial fibrillation sinus rhythm j cardiol ellenbogen ka stambler b wood et al efficacy intravenous ibutilide rapid termination atrial fibrillation flutter dose response study j coll cardiol anonymous pharmacy therapeutic review preliminary evaluation amiodarone intravenous formulary cropp j antal eg talbert rl ibutilide new class iii antiarrhythmic agent pharmacotherapy volgman stambler b kappagoda c et al comparison intravenous ibutilide versus procainamide rapid termination atrial fibrillation flutter abstr pace anonymous corvert injection ibutilide fumarate comprehensive review data file pharmacia upjohn kalamazoo mi february fenster pe comess ka marsh r katzenberg c hager wd conversion atrial fibrillation sinus rhythm acute intravenous procainamide infusion heart j madrid ah moro c marin huerta e mestre j novo l costa comparison flecainide procainamide cardioversion atrial fibrillation eur heart j stambler b wood ellenbogen ka comparative efficacy intravenous ibutilide versus procainamide enhance termination atrial flutter atrial overdrive pacing j cardiol pharmacia upjohn corvert ibutilide fumarate injection package insert kalamazoo mi volume issue january february pages referencesrelatedinformation,Katcher MS,1997,Pharmacotherapy,,9017781,Katcher MS; Estes NA,article,D016421: Editorial,D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D001282: Atrial Flutter; D002986: Clinical Trials as Topic; D006801: Humans; D013449: Sulfonamides,,,https://openalex.org/W1566770392,112,17,1,5316,969,68,en,en
false,antihypertensive efficacy novel calcium antagonist mibefradil comparison nifedipine git moderate severe hypertensive ambulatory hypertension,mibefradil novel calcium antagonist block selectively type calcium channel double blind force titration study design compare effect mibefradil mg nifedipine git mg monotherapies combine lisinopril mg moderate severe hypertensive men woman confirmed ambulatory hypertension incremental dose response effect observe clinic ambulatory blood pressure parameter treatment mibefradil nifedipine git alone combine lisinopril maximal dosage patient treat mibefradil experience great p reduction clinic ambulatory diastolic blood pressure well great response rate v trough peak ratio systolic diastolic blood pressure dose level significant decrease baseline heart rate observe mibefradil mg alone combine lisinopril patient experience clinically significant atrioventricular conduction abnormality adverse event relate vasodilation prevalent nifedipine git group consequently result present study demonstrate novel calcium channel blocker mibefradil either alone combination lisinopril effective reduce clinic h blood pressure decrease heart rate well tolerate patient moderate severe hypertension,Lacourcière Y,1997,Am J Hypertens,https://doi.org/10.1016/s0895-7061(96)00322-6,9037327,Lacourcière Y; Poirier L; Lefebvre J; Archambault F; Dalle Ave S; Ward C; Lindberg E,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D001562: Benzimidazoles; D001794: Blood Pressure; D001835: Body Weight; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D017706: Lisinopril; D008297: Male; D020748: Mibefradil; D008875: Middle Aged; D009543: Nifedipine; D013764: Tetrahydronaphthalenes",,,https://openalex.org/W2163367728,172,22,1,1482,246,8,en,en
false,calcium antagonist useful additional therapy treatment resistant hypertension comparison felodipine er nifedipine retard h ambulatory blood pressure monitoring,compare efficacy tolerability felodipine extend release er mg f mg f daily nifedipine retard mg n mg n twice daily additional therapy patient remain hypertensive despite treatment ace inhibitor beta blocker diuretic multicentre double blind parallel study men woman age supine diastolic blood pressure mmhg randomise treatment f f n n week optional doubling dose week blood pressure measure office week h ambulatory monitoring abpm week spontaneously report adverse event subjective symptom assessment questionnaire use side effect profiling mean office systolic diastolic blood pressure clinically relevantly reduce treatment group week mmhg f f n n respectively week f mmhg f mmhg n mmhg n mmhg statistically significant difference group low dose felodipine f least effective week abpm show consistent h reduction blood pressure mmhg respectively h felodipine er mg group nifedipine group statistically significant difference group find office responder appear identical ambulatory one vice versa adverse event mostly oedema flush headache dose related felodipine er nifedipine retard effective add drug patient monotherapy resistant hypertension blood pressure lowering effect dose dependent tolerability inversely relate efficacy result emphasize benefit combine two agent low dos,Dees A,1997,Neth J Med,https://doi.org/10.1016/s0300-2977(96)00077-0,9038037,Dees A; Kremer Hovinga T; Breed JG; Verstappen VM; Puister SM; Meems L,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D004361: Drug Tolerance; D015736: Felodipine; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D016896: Treatment Outcome",,,https://openalex.org/W2053584356,180,25,1,1972,361,10,en,en
false,long term effect sexual function five antihypertensive drug nutritional hygienic treatment hypertensive men woman,problem sexual function long standing concern treatment hypertension may influence choice treatment regimen decision discontinue drug treatment mild hypertension study tomhs provide excellent opportunity examination sexual function effect treatment sexual function men woman stage diastolic hypertension number drug class study double blind study design long term follow tomhs double blind randomize control trial hypertensive individual men woman age year treat placebo one five active drug acebutolol amlodipine maleate chlorthalidone doxazosin maleate enalapril maleate participant receive intensive lifestyle counseling regard weight loss dietary sodium reduction alcohol reduction current drinker increase physical activity sexual function ascertain physician interview baseline annually follow baseline men woman report problem sexual function men problem obtain maintain erection woman report problem orgasm erection problem men baseline positively relate age systolic pressure previous antihypertensive drug use incidence erection dysfunction follow men month respectively relate type antihypertensive therapy participant randomize chlorthalidone report significantly high incidence erection problem month participant randomize placebo versus p incidence rate month similar among treatment group month nonsignificant difference chlorthalidone placebo group incidence low doxazosin group significantly different placebo group incidence acebutolol amlodipine enalapril group similar placebo group many case erection dysfunction require withdrawal medication disappearance erection problem among men problem baseline common group great doxazosin group incidence report sexual problem woman low treatment group conclusion long term incidence erection problem treated hypertensive men relatively low high chlorthalidone treatment effect erection dysfunction chlorthalidone appear relatively early often tolerable new occurrence year unlikely rate report sexual problem hypertensive woman low appear differ type drug similar incidence rate erection dysfunction placebo active drug group caution routine attribution erection problem antihypertensive medication,Grimm RH,1997,Hypertension,https://doi.org/10.1161/01.hyp.29.1.8,9039073,Grimm RH; Grandits GA; Prineas RJ; McDonald RH; Lewis CE; Flack JM; Yunis C; Svendsen K; Liebson PR; Elmer PJ,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000070: Acebutolol; D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D002752: Chlorthalidone; D004311: Double-Blind Method; D017292: Doxazosin; D004656: Enalapril; D005260: Female; D006801: Humans; D006973: Hypertension; D007989: Libido; D008297: Male; D008875: Middle Aged; D009948: Orgasm; D010410: Penile Erection; D012735: Sexual Dysfunction, Physiological",,,https://openalex.org/W2009763073,132,18,1,3013,502,20,en,en
false,quinine induced hearing loss guinea pig affect ca channel antagonist verapamil,well document quinine induces reversible hearing loss tinnitus purpose study induce quinine hearing loss investigate verapamil ca channel antagonist l type might affect response pigment guinea pig n anaesthetize atropine hypnorm midazolam permit spontaneous respiration electrode platinum place round window short msec tone pulse khz present external ear typical deflection n wave determine hearing threshold quinine hydrochloride mg kg verapamil mg kg give intravenously quinine induce significant reversible hearing loss mean db hearing loss affect verapamil give quinine verapamil often cause acute cardiac arrest particularly combination verapamil follow quinine induced death animal conclude verapamil quinine vivo interaction regard hearing ability,Jäger W,1997,Acta Otolaryngol,https://doi.org/10.3109/00016489709117990,9039480,Jäger W; Idrizbegovic E; Karlsson KK; Alván G,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000818: Animals; D001309: Auditory Threshold; D002121: Calcium Channel Blockers; D003645: Death, Sudden; D004195: Disease Models, Animal; D004347: Drug Interactions; D006168: Guinea Pigs; D006311: Hearing Disorders; D006323: Heart Arrest; D006801: Humans; D011803: Quinine; D014012: Tinnitus; D014700: Verapamil",,,https://openalex.org/W1972414665,113,23,1,1049,183,11,en,en
false,safety calcium channel blocker,calcium channel blocker widely use effective treatment hypertension angina several study raise question safety suggest calcium channel blocker increase rate myocardial infarction mi death particularly patient heart disease review study uncover serious methodological shortcoming find restrict short acting drug frequently high dos use inappropriately one study base old data regard short acting nifedipine never indicate patient suffer mi unstable angina case control study short acting verapamil diltiazem nifedipine suggest increase mi rate confound high rate diabetes preexist heart disease patient treat calcium channel blocker third study report significantly decrease survival patient take short acting nifedipine case report blood pressure control study alert u limitation short acting calcium channel blocker necessity consider side effect neurohormonal stimulation number recent better controlled study confirm increase risk calcium channel blocker appropriately employ calcium channel blocker still consider first line therapy appropriately select patient hypertension angina,,1997,Med Lett Drugs Ther,,9040648,,article,D016428: Journal Article,D002121: Calcium Channel Blockers; D006333: Heart Failure; D006801: Humans; D006973: Hypertension; D009203: Myocardial Infarction,,,https://openalex.org/W175020486,35,5,1,1499,225,8,en,en
false,haemostatic marker inflammatory parameter lipid male female patient angina prognosis study stockholm apsis comparison healthy control,investigate haemostatic marker especially fibrinolysis inflammatory parameter lipid patient stable angina pectoris special attention pay difference male female patient reactivity exercise diurnal variation certain parameters eight hundred nine patient female match healthy control group n patient sign disturbed fibrinolysis elevate plasma level tissue plasminogen activator tpa antigen plasminogen activator inhibitor pai activity rest attenuated response tpa antigen activity exercise elevated level fibrinogen white blood cell count orosomucoid find suggest increased inflammatory activity well disturbed lipid profile high triglyceride low hdl cholesterol level among control female patient high hdl cholesterol low triglyceride level male patient high platelet count sign enhanced platelet activity beta thromboglobulin excretion addition female patient low white blood cell count suggest less inflammatory activity patients stable angina pectoris sign markedly disturb fibrinolysis rest response exercise well sign enhanced inflammatory activity dyslipidemia observed sex difference suggest male patient stable angina pectoris may lipid related disease whereas may dependent platelet function female,Held C,1997,J Intern Med,https://doi.org/10.1046/j.1365-2796.1997.84102000.x,9042095,Held C; Hjemdahl P; Rehnqvist N; Wallén NH; Forslund L; Björkander I; Angelin B; Wiman B,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000787: Angina Pectoris; D015415: Biomarkers; D016022: Case-Control Studies; D002940: Circadian Rhythm; D004837: Epinephrine; D005080: Exercise Test; D005260: Female; D005340: Fibrinogen; D005342: Fibrinolysis; D006487: Hemostasis; D006801: Humans; D007249: Inflammation; D007958: Leukocyte Count; D008055: Lipids; D008297: Male; D008875: Middle Aged; D009961: Orosomucoid; D017395: Plasminogen Activator Inhibitor 1; D010976: Platelet Count; D011379: Prognosis; D011446: Prospective Studies; D016032: Randomized Controlled Trials as Topic; D012737: Sex Factors; D013548: Sweden; D010959: Tissue Plasminogen Activator,,,https://openalex.org/W2083580266,170,28,2,1564,253,6,en,en
false,doppler flow echocardiography functional cardiac insufficiency assessment nisoldipine therapy result defiant ii study,multicentre double blind placebo controlled trial conduct patient randomize day myocardial infarction study effect nisoldipine coat core nisoldipine cc exercise month secondary endpoint include exercise induced ischaemia leave ventricular function measure doppler echocardiography adverse cardiac event clinical outcome patients reduce left ventricular ejection fraction heart failure exercise time different two group nisoldipine cc prolonged time mm st deviation p effect nisoldipine cc cm early peak velocity p isovolumic relaxation time p effect left ventricular volume ejection fraction trend towards reduce mortality one death nisoldipine cc group vs seven placebo group p combined end point mortality cardiac event p peripheral oedema occur patient assign nisoldipine cc two assign placebo p difference non cardiac events nisoldipine cc improve exercise time increase time mm st deviation improve diastolic leave ventricular function safe well tolerate post infarction patient impaired leave ventricular function,,1997,Eur Heart J,https://doi.org/10.1093/oxfordjournals.eurheartj.a015115,9049513,,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D015150: Echocardiography, Doppler; D004562: Electrocardiography; D005080: Exercise Test; D005260: Female; D006333: Heart Failure; D006801: Humans; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D015737: Nisoldipine; D015996: Survival Rate; D016896: Treatment Outcome; D016277: Ventricular Function, Left",,,https://openalex.org/W4232147792,137,19,1,1399,243,10,en,en
false,unnecessary controversy lack knowledge,,Fischer-Hansen J,1997,Eur Heart J,https://doi.org/10.1093/oxfordjournals.eurheartj.a015101,9049531,Fischer-Hansen J,article,D016430: Clinical Trial; D016420: Comment; D003160: Comparative Study; D016422: Letter; D016449: Randomized Controlled Trial,"D002121: Calcium Channel Blockers; D002423: Cause of Death; D004110: Diltiazem; D006801: Humans; D012307: Risk Factors; D015996: Survival Rate; D018487: Ventricular Dysfunction, Left; D014700: Verapamil",,,https://openalex.org/W2035630359,49,8,1,0,0,0,en,
false,combine enalapril felodipine extend release er systemic hypertension,multicenter placebo controlled double blind trial factorial design evaluate safety efficacy combination treatment angiotensin converting enzyme inhibitor enalapril vascular selective calcium antagonist felodipine extend release er patient essential hypertension week single blind placebo baseline period patient sit diastolic blood pressure bps range mm hg receive placebo enalapril mg felodipine er mg combination week double blind treatment period dos enalapril felodipine er statistically significant p additive effect reduce systolic diastolic bp trough peak ratio combination range enalapril mg felodipine er mg enalapril mg felodipine er mg consistent effective bp control dose day patient age year demonstrate great reduction diastolic bp combination enalapril felodipine er associate less drug induced peripheral edema compare felodipine er monotherapy serious drug related adverse effect observe study trial combination enalapril felodipine er effectively lower bp generally well tolerate excellent safety profile use treatment hypertension efficacy safety tolerability combination treatment enalapril felodipine extend release er evaluate patient essential hypertension multicenter factorial design study combination significant additive blood pressure lowering effect compare monotherapies wide range dos generally well tolerate associate low incidence drug related peripheral edema high dos felodipine er monotherapy,Gradman AH,1997,Am J Cardiol,https://doi.org/10.1016/s0002-9149(96)00781-3,9052345,Gradman AH; Cutler NR; Davis PJ; Robbins JA; Weiss RJ; Wood BC,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004656: Enalapril; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2100478740,81,12,1,1975,334,10,en,en
false,effect calcium channel blockade progression diabetic nephropathy african american,blockers know slow progression diabetic nephropathy lower arterial pressure moreover individual diabetic nephropathy antihypertensive agent provide sustain reduction proteinuria slow rate decline renal function compare agent without antiproteinuric effect examine whether differential effect proteinuria affect progression diabetic nephropathy conduct randomize study compare effect heart rate lowering calcium channel blocker sustained release verapamil blocker atenolol progression diabetic renal disease primary end point study change creatinine clearance slope thirty four african american follow inclusion criterion randomize one two group serum creatinine great mg dl proteinuria great mg long year history non insulin dependent diabetes mellitus hypertension exclusion renal disease goal blood pressure less mm hg subject receive loop diuretic second line agent help achieve blood pressure goal twenty four hour urinary protein sodium excretion well creatinine clearance measure month interval blood pressure measure every month mean follow month calcium channel blocker group demonstrate slow rate decline creatinine clearance versus ml min per year per p great reduction proteinuria compare atenolol group additionally great proportion atenolol group increase serum creatinine compare verapamil group versus p group difference could explain difference blood pressure control data support concept antihypertensive agent persistently maintain reduction arterial pressure proteinuria slow progression diabetic renal disease african american great extent agent without effect,Bakris GL,1997,Hypertension,https://doi.org/10.1161/01.hyp.29.3.744,9052890,Bakris GL; Mangrum A; Copley JB; Vicknair N; Sadler R,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D000368: Aged; D001262: Atenolol; D044383: Black People; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003404: Creatinine; D003692: Delayed-Action Preparations; D003924: Diabetes Mellitus, Type 2; D003928: Diabetic Nephropathies; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011897: Random Allocation; D014700: Verapamil",,,https://openalex.org/W2153701973,103,15,1,2181,358,13,en,en
false,calcium channel blocker blunt postural cutaneous vasoconstriction hypertensive patient,aim work test whether calcium channel blocker interfere skin vasoconstrictor reflex minimize postural increase capillary pressure avoid fluid extravasation eventually subcutaneous edema study conduct untreated mild moderate essential hypertensive drug either calcium channel blocker give week accord crossover sequence randomized design skin blood flow measure laser doppler flowmetry two skin area dorsum foot arteriovenous anastomosis poorly represent plantar surface great toe anastomosis predominant determination obtain foot heart level place passively cm heart level percent flow change horizontal dependent position measure postural vasoconstriction two dihydropyridine derivative amlodipine mg uid nifedipine mg uid verapamil mg bid chemically unrelated compound diminish similar extent postural fall skin blood flow dorsum foot blockade alpha adrenergic subtype angiotensin ii receptor doxazosin mg uid losartan mg uid respectively exert effect postural skin blood flow response plantar surface great toe unmodified pharmacological trial thus calcium channel blocker different chemical origin antagonize postural skin vasoconstriction dorsum foot data indicate alter postural capillary blood flow regulation since arteriovenous anastomosis anatomically absent site effect independent either alpha adrenoceptor angiotensin ii receptor antagonism interference skin postural vasoconstrictor mechanism may result net filtration fluid extravascular compartment mechanism might explain yet unknown pathogenesis ankle edema treatment calcium antagonist,Iabichella ML,1997,Hypertension,https://doi.org/10.1161/01.hyp.29.3.751,9052891,Iabichella ML; Dell'Omo G; Melillo E; Pedrinelli R,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D005260: Female; D005528: Foot; D006801: Humans; D006973: Hypertension; D017078: Laser-Doppler Flowmetry; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011187: Posture; D011897: Random Allocation; D012867: Skin; D014661: Vasoconstriction; D014700: Verapamil,,,https://openalex.org/W2126245220,91,10,1,2051,342,11,en,en
false,efficacy tolerability nisoldipine coat core formulation treatment essential hypertension south african multicenter anchor study,double blind placebo controlled multicenter trial undertake assess antihypertensive efficacy tolerability controlled release coat core cc tablet formulation second generation dihydropyridine calcium channel antagonist nisoldipine patient mild moderate essential hypertension two exclude main efficacy analysis rest randomize one four treatment group receive either placebo nisoldipine cc dos mg daily week follow week placebo run period blood pressure measurement supine stand diastolic systolic take trough plasma level h previous dose week interval throughout study adverse event laboratory parameter plasma lipid glucose level thyroid function monitor three dos nisoldipine cc lower blood pressure compare placebo h dose endpoint week mean change supine blood pressure baseline systolic diastolic mm hg group assign placebo nisoldipine cc mg respectively response rate nisoldipine cc mg respectively twenty four hour ambulatory blood pressure monitoring show nisoldipine cc effectively control blood pressure throughout dosing interval change heart rate see three dos nisoldipine cc h dosing interval nisoldipine cc least effective black patient white generally adverse event increase except peripheral edema rate placebo respectively receive nisoldipine cc mg daily clinically significant change blood lipid blood glucose thyroid function conclusion daily nisoldipine cc dos mg effective well tolerated antihypertensive agent provide h control blood pressure without increase heart rate,Opie LH,1997,Am J Hypertens,https://doi.org/10.1016/s0895-7061(96)00384-6,9056681,Opie LH; Müller FO; Myburgh DP; Rosendorff C; Sareli P; Seedat YK; Weich DJ; Luus HG,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D015737: Nisoldipine; D011446: Prospective Studies; D044469: Racial Groups; D013608: Tablets, Enteric-Coated",,,https://openalex.org/W2013426128,148,19,1,2140,393,13,en,en
false,antihypertensive anti albuminuric effect losartan potassium felodipine chinese elderly hypertensive patient without imon lnsulin dependent diabetes mellitus,week placebo baseline period chinese elderly hypertensive patient randomize double blind week treatment either losartan potassium n angiotensin ii antagonist receptor felodipine n calcium channel block agent patient coexist non insulin dependent diabetes mellitus week mean reduction confidence interval mean arterial pressure similar group losartan range mm hg felodipine range mm hg whole group hour urinary albumin excretion reduce losartan compare change felodipine treated group p analysis variance diabetic group losartan treatment reduce urinary albumin excretion compare felodipine treated group non diabetic patient urinary albumin excretion fell losartan treated group increase felodipine treated group p repeated measures analysis variance plasma sodium increase similar extent group fast plasma triglyceride level decline p within group losartan significantly reduce felodipine treated group comparable reduction blood pressure great reduction albuminuria see losartan felodipine treatment chinese hypertensive patient without non insulin dependent diabetes mellitus long term study require examine whether antiproteinuric effect losartan translate renoprotection,Chan JC,1997,Am J Nephrol,https://doi.org/10.1159/000169075,9057957,Chan JC; Critchley JA; Tomlinson B; Chan TY; Cockram CS,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000419: Albuminuria; D057911: Angiotensin Receptor Antagonists; D000959: Antihypertensive Agents; D001713: Biphenyl Compounds; D002121: Calcium Channel Blockers; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D015736: Felodipine; D005260: Female; D006723: Hong Kong; D006801: Humans; D006973: Hypertension; D007093: Imidazoles; D019808: Losartan; D008297: Male; D013777: Tetrazoles",,,https://openalex.org/W2033011961,180,20,1,1667,299,10,en,en
false,analysis risk associate calcium channel blockade,calcium channel antagonist widely prescribe obstetrics gynecology blood pressure control tocolysis concern recently arise regard safety agent several study find short acting form calcium channel blocker associate increased cardiovascular mortality malignancy gastrointestinal bleeding recent meta analysis find significant increase risk mortality patient treat short acting form nifedipine another subgroup analysis observational study old hypertensive patient find significantly increase risk cancer gastrointestinal hemorrhage patient prescribed calcium channel blocker vitro small human vitro series report potential cardiac toxicity pregnant woman treat concomitantly calcium channel blocker magnesium sulfate additional data available suggest calcium channel blocker use obstetrics gynecology long acting variety prescribe concurrent use calcium channel blocker magnesium sulfate undertake cautiously potential synergistic depression cardiac function,Davis WB,1997,Obstet Gynecol Surv,https://doi.org/10.1097/00006254-199703000-00023,9061722,Davis WB; Wells SR; Kuller JA; Thorp JM,article,D016428: Journal Article; D016454: Review,D002121: Calcium Channel Blockers; D004347: Drug Interactions; D005260: Female; D006471: Gastrointestinal Hemorrhage; D006331: Heart Diseases; D006801: Humans; D008278: Magnesium Sulfate; D009369: Neoplasms; D009543: Nifedipine; D011247: Pregnancy; D011248: Pregnancy Complications; D015149: Tocolytic Agents,,,https://openalex.org/W1990755937,62,9,1,1227,180,8,en,en
false,pharmacoepidemiology ace inhibitor induce cough,,Tomlinson B,1997,Drug Saf,https://doi.org/10.2165/00002018-199716020-00006,9067125,Tomlinson B; Young RP; Chan JC; Chan TY; Critchley JA,article,D016420: Comment; D016422: Letter,D000806: Angiotensin-Converting Enzyme Inhibitors; D003371: Cough; D006723: Hong Kong; D006801: Humans; D015994: Incidence,,,https://openalex.org/W219701883,53,9,2,0,0,0,en,
true,cardiac event rate acute myocardial infarction patient treat verapamil trandolapril versus trandolapril alone,angiotensin converting enzyme ace inhibitor improve survival patient congestive heart failure chf acute myocardial infarction ami mortality may high year verapamil prevents cardiac event ami patient without chf hypothesize postinfarct patient chf already prescribe diuretic ace inhibitor additional treatment verapamil may reduce cardiac event rate multicenter double blind study patient chf receive diuretic treatment consecutively randomize treatment trandolapril mg day month mg day follow month n trandolapril mentioned plus verapamil mg day month mg day month n trial medication start day ami patient follow month end point trandolapril trandolapril verapamil group death reinfarction unstable angina readmission chf month first cardiac event rate trandolapril treated patient trandolapril verapamil treated patient hazard ratio confidence interval p data suggest verapamil reduces cardiac event rate post ami patient chf add ace inhibitor diuretic double blind randomize study safety efficacy treatment verapamil versus placebo test postinfarct patient congestive heart failure treatment diuretic angiotensin converting enzyme inhibitor month cardiac event rate significantly low verapamil treated placebo treated patient,Hansen JF,1997,Am J Cardiol,https://doi.org/10.1016/s0002-9149(96)00860-0,9070551,Hansen JF; Hagerup L; Sigurd B; Pedersen F; Mellemgaard K; Pedersen-Bjergaard O; Mortensen LS,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D002121: Calcium Channel Blockers; D003718: Denmark; D004232: Diuretics; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006333: Heart Failure; D006801: Humans; D007211: Indoles; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D012008: Recurrence; D013997: Time Factors; D014700: Verapamil",,,https://openalex.org/W2085258016,131,17,1,1722,299,11,en,en
true,relationship quality life measure long term lifestyle drug treatment treatment mild hypertension study,objective compare antihypertensive drug placebo change quality life ql assess relationship lifestyle factor change lifestyle factor ql participant stage diastolic hypertension method treatment mild hypertension study tomhs randomized double blind placebocontrolled clinical trial minimum participant follow year conduct hypertension screening treatment academic center united state cohort consist men woman hypertension age year diastolic blood pressure less mm hg informed consent obtain participant nature procedure fully explain sustain nutritional hygienic intervention administer participant reduce weight reduce dietary sodium alcohol intake increase physical activity participant randomize take acebutolol n amlodipine maleate n chlorthalidone n doxazosin mesylate n enalapril maleate n placebo n change ql index assess base item questionnaire general health energy fatigue mental health general functioning satisfaction physical ability social functioning social contact result baseline high ql associate old age physical activity low obesity level male gender non african american race high educational level improvement ql observe randomized group include placebo group follow great improvement observe acebutolol chlorthalidone group evident throughout follow amount weight loss increase physical activity level attained blood pressure control follow relate great improvement ql conclusion patient stage hypertension antihypertensive treatment agent use tomhs impair ql diuretic chlorthalidone cardioselective blocker acebutolol appear improve ql success lifestyle change affect weight loss increase physical activity relate great improvement ql show intervention addition contribute blood pressure control positive effect general well individual arch intern med,Grimm RH,1997,Arch Intern Med,https://doi.org/10.1001/archinte.1997.00440270080007,9080918,Grimm RH; Grandits GA; Cutler JA; Stewart AL; McDonald RH; Svendsen K; Prineas RJ; Liebson PR,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000368: Aged; D000428: Alcohol Drinking; D000959: Antihypertensive Agents; D004311: Double-Blind Method; D015444: Exercise; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006973: Hypertension; D008019: Life Style; D008297: Male; D008875: Middle Aged; D011788: Quality of Life; D012982: Sodium, Dietary; D011795: Surveys and Questionnaires; D015431: Weight Loss",,,https://openalex.org/W2068875560,127,17,1,2537,477,17,en,en
false,site specific variation metabolism human fibroblast expose nifedipine vitro,nifedipine induces overgrowth gingival tissue patient however collagenous tissue body overgrow purpose study compare effect serial dilution nifedipine vitro metabolism fibroblast derive normal gingiva nifedipine induced hyper plastic gingiva knee capsular ligament dermis data suggest nifedipine affect metabolism fibroblast derive gingiva also connective tissue thus nifedipine responder cell present tissue gingiva inverse relationship vivo tissue level il beta vitro responsiveness nifedipine fibroblast derive tissue nifedipine induced overgrowth connective tissue gingiva probably occur either relatively slow rate collagenous protein synthesis resident fibroblast alteration collagen deposition resorption within susceptible tissue produce nifedipine collagenase synthesis,Henderson JS,1997,J Oral Pathol Med,https://doi.org/10.1111/j.1600-0714.1997.tb00002.x,9082044,Henderson JS; Flynn JC; Tucci MA; Tsao AK; Zebrowski EJ; Odlum O; Johnson RB,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000704: Analysis of Variance; D002121: Calcium Channel Blockers; D002478: Cells, Cultured; D003094: Collagen; D003238: Connective Tissue; D003239: Connective Tissue Cells; D016326: Extracellular Matrix Proteins; D005260: Female; D005347: Fibroblasts; D005881: Gingiva; D019214: Gingival Overgrowth; D006801: Humans; D007375: Interleukin-1; D007719: Knee Joint; D008023: Ligaments, Articular; D008297: Male; D009543: Nifedipine; D009928: Organ Specificity; D012867: Skin",,,https://openalex.org/W2009453574,90,12,1,1078,164,10,en,en
false,overview safety felodipine base clinical trial patient hypertension,clinical study least week duration felodipine patient hypertension include safety analysis major finding felodipine increase mortality incidence major cardiovascular event data indicate favorable effect,Welin L,1997,Am J Cardiol,https://doi.org/10.1016/s0002-9149(97)00034-9,9104926,Welin L; Elvelin L; Niklasson A; Olsson G; Elmfeldt D,article,D016428: Journal Article,"D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D002561: Cerebrovascular Disorders; D004311: Double-Blind Method; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D011358: Product Surveillance, Postmarketing; D011446: Prospective Studies; D016032: Randomized Controlled Trials as Topic",,,https://openalex.org/W2136763181,91,14,1,293,49,2,en,en
false,isradipine prevention cyclosporine induced hypertension allogeneic bone marrow transplant recipient,hypertension nephrotoxicity frequently occur patient receive cyclosporine therapy bone marrow transplantation bmt isradipine calcium channel entry blocker use successfully cyclosporine induced hypertension thirty leukemic patient receive cyclosporine bmt randomize receive isradipine mg kg hr commencement cyclosporine therapy day bmt placebo placebo isradipine group well match difference find isradipine placebo group level blood pressure renal function marrow engraftment mortality hypertension incidence surprisingly low week hospital discharge day bmt differ groups isradipine harm immunohematopoietic reconstitution bmt therefore may use setting although previously report incidence hypertension exaggerate,Bursztyn M,1997,Transplantation,https://doi.org/10.1097/00007890-199704150-00025,9112363,Bursztyn M; Zelig O; Or R; Nagler A,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000959: Antihypertensive Agents; D016026: Bone Marrow Transplantation; D016572: Cyclosporine; D005260: Female; D006801: Humans; D006973: Hypertension; D007166: Immunosuppressive Agents; D017275: Isradipine; D008297: Male; D010865: Pilot Projects; D014184: Transplantation, Homologous",,,https://openalex.org/W1974133559,114,13,1,994,158,4,en,en
false,asymptomatic cardiac ischemia pilot acip study two year follow,background patient ischemia stress testing ambulatory ecg monitoring increase risk cardiac event know whether prognosis improve aggressive treatment anti ischemic drug revascularization method result asymptomatic cardiac ischemia pilot study randomize patient coronary anatomy suitable revascularization three treatment strategy angina guided drug therapy n angina plus ischemia guided drug therapy n revascularization angioplasty bypass surgery n two year randomization total mortality angina guided strategy ischemia guided strategy revascularization strategy p rate death myocardial infarction angina guided strategy ischemia guided strategy revascularization strategy p rate death myocardial infarction recurrent cardiac hospitalization angina guided strategy ischemia guided strategy revascularization strategy p pairwise test reveal significant difference revascularization angina guided strategy comparison conclusion strategy initial revascularization appear improve prognosis population compare angina guided medical therapy large long term study need confirm benefit adequately test potential aggressive drug therapy,Davies RF,1997,Circulation,https://doi.org/10.1161/01.cir.95.8.2037,9133513,Davies RF; Goldberg AD; Forman S; Pepine CJ; Knatterud GL; Geller N; Sopko G; Pratt C; Deanfield J; Conti CR,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000319: Adrenergic beta-Antagonists; D000368: Aged; D015906: Angioplasty, Balloon, Coronary; D001262: Atenolol; D002121: Calcium Channel Blockers; D002315: Cardiopulmonary Bypass; D002318: Cardiovascular Diseases; D015897: Comorbidity; D004110: Diltiazem; D004359: Drug Therapy, Combination; D015716: Electrocardiography, Ambulatory; D005080: Exercise Test; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D007548: Isosorbide Dinitrate; D015993: Life Tables; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D017202: Myocardial Ischemia; D009204: Myocardial Revascularization; D009543: Nifedipine; D010865: Pilot Projects; D011379: Prognosis; D012307: Risk Factors; D016019: Survival Analysis; D016896: Treatment Outcome; D014665: Vasodilator Agents",,,https://openalex.org/W2053327848,67,10,1,1581,265,8,en,en
false,effect diltiazem versus digoxin dysrhythmias cardiac function pneumonectomy,prospective study design determine whether diltiazem superior digoxin prophylaxis supraventricular dysrhythmias svd pneumonectomy extrapleural pneumonectomy epp assess influence drug perioperative cardiac function seventy consecutive patient without previous svd randomly allocate immediately pneumonectomy epp receive diltiazem n digoxin n diltiazem treated patient receive slow intravenous load dose mg follow mg intravenously every hour hour mg orally daily month digoxin treated patient receive mg intravenous loading first hour mg orally daily month concurrent prospective cohort patient without previous svd participate study underwent pneumonectomy epp without prophylaxis serve comparison group svd occurrence serial doppler echocardiogram perform assess cardiac function patient continuously monitor holter recorder day data analyze intent treat patient undergo standard intrapericardial pneumonectomy diltiazem prevent overall incidence postoperative svd compare digoxin patient versus patient respectively p epp patient include analysis diltiazem decrease incidence svd patient patient compare digoxin p digoxin treated patient similar incidence svd concurrent control patient two treat group differ right leave atrial size leave ventricular ejection fraction right heart pressure patient combined svd develop significantly old year versus year p longer median hospital stay versus day p compare svd develop respectively subset patient undergo epp great incidence atrial fibrillation electrocardiographic change suggestive postoperative pericarditis pneumonectomy patients diltiazem safe effective digoxin reduce overall incidence svd standard intrapericardial pneumonectomy digoxin therapy effect incidence postoperative svd recommend prophylaxis svd dysrhythmias pneumonectomy epp occur old patient associate great length hospital stay,Amar D,1997,Ann Thorac Surg,https://doi.org/10.1016/s0003-4975(97)80354-2,9146330,Amar D; Roistacher N; Burt ME; Rusch VW; Bains MS; Leung DH; Downey RJ; Ginsberg RJ,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D000889: Anti-Arrhythmia Agents; D001145: Arrhythmias, Cardiac; D002121: Calcium Channel Blockers; D004077: Digoxin; D004110: Diltiazem; D015150: Echocardiography, Doppler; D005260: Female; D006321: Heart; D006801: Humans; D008175: Lung Neoplasms; D008297: Male; D008875: Middle Aged; D010997: Pleural Neoplasms; D011013: Pneumonectomy; D011446: Prospective Studies; D016896: Treatment Outcome; D017725: Ventricular Pressure",,,https://openalex.org/W1976838830,92,12,1,2685,472,13,en,en
true,cancer risk user calcium channel blocker,ca channel blocker may cause cancer inhibit apoptosis reduce intracellular ca certain tissue recent finding suggest drug user increase risk cancer general colon cancer particular conduct study one danish county patient receive least one prescription ca channel blocker january december patient identify record national health insurance program refund part price drug cancer occurrence rate determine use file danish cancer registry compare county specific incidence rate various category cancer follow period year cancer observe among user ca channel blocker compare expect yield age sex standardized incidence ratio sir confidence interval indication excess risk subgroup likely long term user user specific drug sir colon cancer site priori interest confidence interval basis case although result reassure lack association could reflect relatively short follow registration prescription database continue monitoring cancer risk plan,Olsen JH,1997,Hypertension,https://doi.org/10.1161/01.hyp.29.5.1091,9149671,Olsen JH; Sørensen HT; Friis S; McLaughlin JK; Steffensen FH; Nielsen GL; Andersen M; Fraumeni JF; Olsen J,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D002121: Calcium Channel Blockers; D015331: Cohort Studies; D003718: Denmark; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009369: Neoplasms; D012307: Risk Factors",,,https://openalex.org/W2113928275,48,8,1,1398,253,10,en,en
false,felodipine amlodipine stable angina pectoris result randomized double blind crossover trial,randomized double blind crossover study test antiischemic antianginal efficacy felodipine extended release mg versus amlodipine mg daily fifty two patient documented exercise induced angina pectoris myocardial ischemia h electrocardiographic monitoring include study forty seven patient complete week treatment period whereas five patient withdraw study mean number ischemic episodes h reduce baseline amlodipine felodipine total duration ischemic episode decrease min h min min amlodipine felodipine respectively variable p p treatment treatment p compare baseline eighteen patient receive amlodipine patient receive felodipine show st segment depression treatment maximal st depression reduce average mm mm amlodipine felodipine respectively p treatment p compare baseline mean heart rate remain unchanged compare baseline anginal attack reduce week baseline week amlodipine week felodipine p treatment p vs baseline accordingly nitrate consumption reduce capsule per week amlodipine felodipine respectively p treatment p compare baseline adverse reaction infrequent distribute similarly two treatment conclude drug effectively reduce ischemic episode anginal attack well tolerate patient stable angina pectoris evidence two regimen different antiischemic antianginal property,Koenig W,1997,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-199704000-00014,9156363,Koenig W; Höher M,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D000787: Angina Pectoris; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D015716: Electrocardiography, Ambulatory; D015736: Felodipine; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D017202: Myocardial Ischemia; D011446: Prospective Studies; D016896: Treatment Outcome",,,https://openalex.org/W2027934743,105,15,1,1953,329,12,en,en
false,effect verapamil sr trandolapril fixed combination h blood pressure veratran study,veratran study investigate antihypertensive efficacy verapamil sustain release sr mg trandolapril mg fixed combination h period week placebo run period patient age year mean sd essential hypertension clinic diastolic blood pressure mm hg randomize verapamil trandolapril fixed combination placebo week accord multicenter double blind parallel group study design clinic semiautomatic blood pressure trough h ambulatory blood pressure measure end run period week treatment patient include efficacy analysis run clinic semiautomatic blood pressure reduce verapamil trandolapril combine verapamil trandolapril significantly placebo reduction obtain combination significantly great obtain verapamil alone twenty four hour average blood pressure modify placebo reduce mm hg systolic diastolic verapamil mm hg trandolapril mm hg combination two drug difference effect combination combination component instance statistically significant verapamil trandolapril combination effective also day average blood pressure superior monotherapies trough peak ratio antihypertensive effect well twenty four hour heart rate slightly significantly reduce verapamil reduction manifest group take verapamil plus trandolapril thus antihypertensive treatment fixed verapamil sr trandolapril combination effective balance hour effect combination component administer alone,Veratran Study Group,1997,Am J Hypertens,https://doi.org/10.1016/s0895-7061(96)00486-4,9160758,Veratran Study Group,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006973: Hypertension; D007211: Indoles; D008297: Male; D008875: Middle Aged; D014700: Verapamil",,,https://openalex.org/W3164134185,108,18,1,1912,314,10,en,en
false,effect isradipine spirapril monotherapy combine therapy blood pressure renal hemodynamics natriuresis urinary kallikrein hypertensive nephropathy,cross double blind study essential hypertensive patient stage ii iii glomerular filtration rate gfr ml min submit week placebo follow week isradipine sro mg spirapril sp mg isradipine plus spirapril sp study evaluate effect drug gfr mtc dtpa effective renal plasma flow erpf orthoiodohippurate urinary sodium excretion unav urinary kallikrein excretion ukal urinary albumin excretion uae plasma renin activity pra three protocol significantly reduce mean blood pressure v mm hg v mm hg v mm hg sp sp respectively erpf gfr change unav increase significantly v meq min sp v meq min ukal increase significantly sp uae decrease significantly sp pra increase significantly v ng ml h sp v ng ml h sp v ng ml min conclusion sp sp effective reduce blood pressure keep renal function stable sp significantly decrease uae enhance ukal may play role natriuresis observe sp j hypertens american journal hypertension ltd,Maccariello ER,1997,Am J Hypertens,https://doi.org/10.1016/s0895-7061(97)00029-0,9160765,Maccariello ER; Genelhu de Abreu Fagundes V; Francischetti EA,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,"D000368: Aged; D000419: Albuminuria; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004656: Enalapril; D005260: Female; D005919: Glomerular Filtration Rate; D006801: Humans; D006977: Hypertension, Renal; D017275: Isradipine; D007610: Kallikreins; D007674: Kidney Diseases; D008297: Male; D008875: Middle Aged; D009318: Natriuresis; D012079: Renal Circulation; D017596: Renal Plasma Flow, Effective; D016037: Single-Blind Method",,,https://openalex.org/W1965284810,178,26,1,1411,310,12,en,en
false,calcium channel blocker hypertension dissect evidence adverse effect,safety drug treatment hypertension see relation efficacy come mean blood pressure bp reduction improvement hard end point include mortality information safety come variety source ascending hierarchy follow case control study cohort study randomize control trial rcts metaanalyses base good rcts case metaanalyses definite criterion acceptability establish evaluation case control cohort study remain subjective despite reserve data source propose case control study point risk acute myocardial infarction therapy short acting calcium channel blocker ccbs balance another good recent study large cohort study israel elderly population well designed cohort study strongly suggest short acting nifedipine link increase mortality specific link may high dose initial bp less mm hg however initial bp available unspecified number patient risk use short acting verapamil beta blockade difference attribute least part low catecholamine profile verapamil marked rapid adrenergic activation short acting nifedipine could also explain adverse effect find agent give patient acute coronary syndrome chronic use long acting dihydropyridine dhp ccbs evidence suggest little catecholamine activation case amlodipine even decrease plasma catecholamine level difference may explain expected regression left ventricular hypertrophy obtain long short acting dhps present result several large randomize controlled trial long acting ccbs await meantime decision make use ccb preferential choice use non dhp hypertension clinical ischemia postinfarct hypertension long acting ccb control left ventricular hypertrophy dhp amlodipine associate depression myocardial function,Opie LH,1997,Am J Hypertens,https://doi.org/10.1016/s0895-7061(96)00508-0,9160770,Opie LH,article,D016428: Journal Article; D016454: Review,D002121: Calcium Channel Blockers; D002395: Catecholamines; D002561: Cerebrovascular Disorders; D004341: Drug Evaluation; D006471: Gastrointestinal Hemorrhage; D006801: Humans; D006973: Hypertension; D009203: Myocardial Infarction; D017202: Myocardial Ischemia; D009369: Neoplasms; D009543: Nifedipine; D016896: Treatment Outcome; D014700: Verapamil,,,https://openalex.org/W2083881398,85,11,1,2390,411,12,en,en
false,nifedipine interaction tacrolimus liver transplant recipient,examine possible drug interaction nifedipine tacrolimus liver transplant recipients retrospective study compare two group liver transplant recipient starting time comparison transplant one group n consist hypertensive patient treat nifedipine group n receive nifedipine two group compare year effect nifedipine tacrolimus measure term tacrolimus whole blood trough concentration daily tacrolimus dosage cumulative tacrolimus dosage month patient chart review regard concurrent medication could affect metabolism tacrolimus eventually affect tacrolimus concentration dosages require information retrieve medical records statistically significant difference daily dosage requirement tacrolimus p p p day nifedipine nifedipine group tacrolimus daily dosage nifedipine group decrease month respectively compare dosage nifedipine group statistically significant difference cumulative dosage tacrolimus observe p p day nifedipine nifedipine group cumulative dosage reduction month respectively nifedipine group compare nifedipine group nifedipine decrease daily cumulative dosage requirement tacrolimus interaction observe nifedipine tacrolimus first report human clinically important result drug interaction recommend blood concentration tacrolimus monitor coadministration drug tacrolimus dosage adjust accordingly,Seifeldin RA,1997,Ann Pharmacother,https://doi.org/10.1177/106002809703100508,9161650,Seifeldin RA; Marcos-Alvarez A; Gordon FD; Lewis WD; Jenkins RL,article,"D016430: Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D002121: Calcium Channel Blockers; D003404: Creatinine; D004347: Drug Interactions; D005260: Female; D006801: Humans; D006973: Hypertension; D007166: Immunosuppressive Agents; D008111: Liver Function Tests; D016031: Liver Transplantation; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D012189: Retrospective Studies; D016559: Tacrolimus,,,https://openalex.org/W2203261309,69,8,1,1983,343,10,en,en
false,example phase iv trial involve several physician aim answer scientific question eol,aim trial test hypothesis reduced number dos improves compliance current medical practice compliance twice day dosage compare compliance three dos day two bioequivalent presentation nicardipine use regular presentation slow release b trial control randomize open two parallel group group one tablet regular nicardipine mg three time day three month b group one capsule slow release nicardipine twice day three month general practitioner randomize hypertensive patient primary criterion document per cent case end trial remain per cent comprise treatment withdrawal per cent patient lose follow per cent primary criterion study compliance assess self questionnaire fill patient standardise interview physician compliance slightly well b group group p remain pill count also use failure random sample investigator make site visit discordant data infrequent limit date visit difficulty site visit mostly due rather frequent lack source record,Boissel JP,1996,Therapie,,9164003,Boissel JP; Meillard O; Perrin-Fayolle E; Ducruet T; Alamercery Y; Sassano P; Benghozi R,article,"D016430: Clinical Trial; D017429: Clinical Trial, Phase IV; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000959: Antihypertensive Agents; D003187: Compliance; D004334: Drug Administration Schedule; D005194: Family Practice; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009529: Nicardipine; D011795: Surveys and Questionnaires,,,https://openalex.org/W2399897588,110,21,1,1379,267,18,en,en
false,effect sustained release verapamil morning systemic arterial pressure surge daily activity patient systemic hypertension,placebo controlled study subject systemic hypertension sustained release verapamil reduce morning surge systolic pressure mm hg p diastolic pressure mm hg p heart rate beats min p blunting morning hemodynamic surge may mechanism verapamil could reduce risk plaque disruption acute coronary event morning,Rosito GA,1997,Am J Cardiol,https://doi.org/10.1016/s0002-9149(97)00093-3,9164897,Rosito GA; Gebara OC; McKenna CA; Solomon HS; Muller JE; Tofler GH,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000704: Analysis of Variance; D001794: Blood Pressure; D002940: Circadian Rhythm; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D005583: Fourier Analysis; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D008991: Monitoring, Physiologic; D014700: Verapamil",,,https://openalex.org/W2051045771,146,19,1,428,82,2,en,en
false,effect aerobic training exaggerated blood pressure response exercise african american severe systemic hypertension treat indapamide verapamil enalapril,hypertensive patient likely exaggerated blood pressure bp response physical exertion moderate aerobic exercise add medical antihypertensive therapy patient severe hypertension excessive elevation bp physical exertion attenuate even modest reduction bp rest,Kokkinos PF,1997,Am J Cardiol,https://doi.org/10.1016/s0002-9149(97)00158-6,9165176,Kokkinos PF; Narayan P; Fletcher RD; Tsagadopoulos D; Papademetriou V,article,D016428: Journal Article,"D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D044383: Black People; D001794: Blood Pressure; D003131: Combined Modality Therapy; D004359: Drug Therapy, Combination; D004656: Enalapril; D005081: Exercise Therapy; D006801: Humans; D006973: Hypertension; D007190: Indapamide; D008297: Male; D008875: Middle Aged; D014700: Verapamil",,,https://openalex.org/W2007853756,181,24,1,337,53,2,en,en
false,short acting nifedipine diltiazem reduce incidence cardiac event patient healed myocardial infarction,background administration calcium antagonist patient healed myocardial infarction controversial treatment study conduct elucidate effect short acting nifedipine diltiazem cardiac event patient healed myocardial infarction method result controlled clinical open trial patient healed myocardial infarction carry patient include receive calcium antagonist receive short acting nifedipine mg receive short acting diltiazem mg primary end point cardiac event define fatal nonfatal recurrent myocardial infarction death congestive heart failure sudden death hospitalization worsen angina congestive heart failure premature ventricular contraction cardiac event occur patient calcium antagonist group calcium antagonist group odds ratio ci demonstrate calcium antagonist reduce incidence cardiac event subgroup analysis reveal beneficial effect drug reduce cardiac event patient complication hypertension angina pectoris conclusion study show use short acting nifedipine diltiazem postmyocardial infarction population associate high cardiac event rate strong adverse trend reach statistical significance,Ishikawa K,1997,Circulation,https://doi.org/10.1161/01.cir.95.10.2368,9170398,Ishikawa K; Nakai S; Takenaka T; Kanamasa K; Hama J; Ogawa I; Yamamoto T; Oyaizu M; Kimura A; Yamamoto K; Yabushita H; Katori R,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,D000368: Aged; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D004110: Diltiazem; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D015999: Multivariate Analysis; D009203: Myocardial Infarction; D009543: Nifedipine; D012008: Recurrence; D016019: Survival Analysis,,,https://openalex.org/W2093009820,129,18,1,1546,249,8,en,en
false,fibrinolytic variable cardiovascular prognosisin patient stable angina pectoris treat verapamil metoprolol,background disturb fibrinolytic function may influence progression coronary atherosclerosis contribute thrombotic cardiovascular cv event method result angina prognosis study stockholm apsis patient stable angina pectoris study prospectively double blind treatment metoprolol verapamil various measure fibrinolytic function study patient median follow time year patient years patient suffer cv death nonfatal myocardial infarction mi underwent revascularization plasma level tissue plasminogen activator tpa activity antigen ag plasminogen activator inhibitor pai activity rest tpa response exercise determine baseline month treatment relate subsequent fatal nonfatal cv event univariate cox regression analysis reveal elevated level tpa ag rest p high pai activity p low tpa ag response exercise p associate increased risk subsequent cv death adjustment baseline risk factor tpa ag independently predict cv death mi addition pai activity independently predict cv death mi male patient verapamil treatment associate decrease tpa ag level metoprolol treatment increase p treatment difference conclusion plasma tpa ag level rest among male patient pai activity well independently predict subsequent cv death mi patient stable angina pectoris impaired fibrinolytic reactivity exercise novel factor relate cv prognosis effect verapamil metoprolol treatment fibrinolytic function importantly influence cv prognosis,Held C,1997,Circulation,https://doi.org/10.1161/01.cir.95.10.2380,9170400,Held C; Hjemdahl P; Rehnqvist N; Wallén NH; Björkander I; Eriksson SV; Forslund L; Wiman B,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000319: Adrenergic beta-Antagonists; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D002319: Cardiovascular System; D005260: Female; D005342: Fibrinolysis; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D008790: Metoprolol; D008875: Middle Aged; D011379: Prognosis; D016896: Treatment Outcome; D014700: Verapamil,,,https://openalex.org/W2146753829,127,15,1,1855,328,12,en,en
true,carvedilol versus verapamil chronic stable angina multicentre trial,objective multicentre double blind parallel group study anti anginal anti ischaemic efficacy week therapy vasodilating beta adrenoceptor blocker carvedilol mg b compare verapamil mg method week placebo run period patient require two treadmill exercise test modify bruce protocol differing regard total exercise time tet patient enrol randomize complete study accord protocol result primary variable tet analyse use cox proportional hazard model take account censor value due patient stop exercise test reason angina forty three per cent patient allocate carvedilol verapamil stop angina final visit difference tet group risk ratio favour carvedilol ci tet increase baseline final visit carvedilol group verapamil group result time angina time mm st segment depression similar compare verapamil carvedilol significantly reduce hr systolic bp rate pressure product peak exercise analysis h holter monitor data show great reduction hr pvc carvedilol lown grade improve group adverse event report serious adverse event patient take carvedilol serious adverse event take verapamil conclusion carvedilol least effective verapamil management chronic stable angina demonstrate favourable adverse event profile,Hauf-Zachariou U,1997,Eur J Clin Pharmacol,https://doi.org/10.1007/s002280050256,9174677,Hauf-Zachariou U; Blackwood RA; Gunawardena KA; O'Donnell JG; Garnham S; Pfarr E,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000319: Adrenergic beta-Antagonists; D000368: Aged; D000787: Angina Pectoris; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002227: Carbazoles; D000077261: Carvedilol; D002908: Chronic Disease; D004311: Double-Blind Method; D015716: Electrocardiography, Ambulatory; D005080: Exercise Test; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D005996: Nitroglycerin; D011412: Propanolamines; D014665: Vasodilator Agents; D014700: Verapamil",,,https://openalex.org/W2054176065,73,11,1,1785,326,14,en,en
false,blood pressure reduction tolerability felodipine er old young hypertensive patient,objective evaluate compare blood pressure reduction tolerability felodipine er extended release young old patient design multicenter double blind placebo controlled parallel group study setting nineteen study site approximately half site academic medical center half private primary care practice patient non hospitalized free living patient young year old year patient age range sit diastolic blood pressure sdbp mm hg high stage low stage placebo patient volunteer study intervention week single blind placebo baseline period patient sdbp mm hg randomize treatment felodipine er mg qd placebo ratio felodipine placebo dose felodipine er increase mg qd week mg qd week sdbp great mm hg measurement main outcome measure change sdbp secondary outcome measure change sit systolic blood pressure ssbp percent responder define sdbp less mm hg mm hg reduction measurement include heart rate weight routine laboratory value self reported adverse event result week felodipine er reduce blood pressure old subject n mm hg young patient n reduction mm hg reduction significantly different placebo p reduction diastolic systolic blood pressure significantly great old young patient p p respectively percentage patient report clinical adverse experience similar felodipine er placebo treatment group incidence side effect similar old young patient discontinuation occur felodipine treated patient placebo treated patient old patient require low dos felodipine er achieve equivalent blood pressure control conclusion felodipine er effective lower blood pressure well tolerate young old people,Fagan TC,1997,J Am Geriatr Soc,https://doi.org/10.1111/j.1532-5415.1997.tb01475.x,9180665,Fagan TC,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D004361: Drug Tolerance; D015736: Felodipine; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008875: Middle Aged; D010919: Placebos; D016896: Treatment Outcome,,,https://openalex.org/W2003109958,101,14,1,2281,435,19,en,en
false,effect calcium antagonist risk coronary heart disease cancer bleeding,effect calciuim antagonist risk coronary heart disease cancer bleeding,,1997,Blood Press,https://doi.org/10.3109/08037059709061929,9181251,,article,D016428: Journal Article; D016454: Review,D002121: Calcium Channel Blockers; D003327: Coronary Disease; D006470: Hemorrhage; D006801: Humans; D009369: Neoplasms; D012307: Risk Factors,,,https://openalex.org/W567316860,90,15,1,91,15,1,en,en
false,lack effect diuretic add diltiazem,,MacGregor GA,1997,J Hum Hypertens,,9185031,MacGregor GA; Cappuccio FP,article,D016420: Comment; D003160: Comparative Study; D016422: Letter,"D000959: Antihypertensive Agents; D002986: Clinical Trials as Topic; D003627: Data Interpretation, Statistical; D004110: Diltiazem; D004232: Diuretics; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D012107: Research Design; D049993: Sodium Chloride Symporter Inhibitors; D016896: Treatment Outcome",,,https://openalex.org/W2472854566,48,10,1,0,0,0,en,
false,comparison two long acting vasoselective calcium antagonist pulmonary hypertension secondary copd,study objective patient pulmonary hypertension ph common copd may predict mortality disorder compare pulmonary vasodilator effect dose response characteristic tolerability two calcium channel blocker amlodipine extended release er felodipine patient seven men age sd year clinically stable copd ph drugs give equal single daily oral dos mg increase weekly week randomized investigator blinded crossover manner week wash period two treatments doppler measurement pulmonary hemodynamics make seventh day treatment drug dose lung function arterial blood gas adverse event also monitor weekly dose dependent decline pulmonary artery pressure pap observe drug dose mg produce significant decrease pap compare baseline amlodipine felodipine er additional decrease pap observe mg mg similar drug reach statistical significance compare mg dose related decrease pulmonary vascular resistance increase oxygen delivery amlodipine felodipine er lung function blood gas value stable throughout side effect headache ankle edema less frequent amlodipine treatment p amlodipine felodipine er give single daily oral dose mg effective pulmonary vasodilator copd patient ph dose response characteristic similar amlodipine treatment associate side effect,Sajkov D,1997,Chest,https://doi.org/10.1378/chest.111.6.1622,9187185,Sajkov D; Wang T; Frith PA; Bune AJ; Alpers JA; McEvoy RD,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D017311: Amlodipine; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D004305: Dose-Response Relationship, Drug; D015736: Felodipine; D005260: Female; D006439: Hemodynamics; D006801: Humans; D006976: Hypertension, Pulmonary; D008173: Lung Diseases, Obstructive; D008297: Male; D008875: Middle Aged; D018579: Patient Selection; D016037: Single-Blind Method; D014665: Vasodilator Agents",,,https://openalex.org/W2125683388,109,14,1,1710,304,9,en,en
false,determine optimum dose intravenous administration nicardipine treatment acute heart failure,nicardipine potent arteriolar vasodilator negligible negative inotropic effect although intravenous administration drug report effective treatment heart failure optimal dose route clear study design determine optimum dose intravenous infusion nicardipine treatment heart failure trial nicardipine administer intravenously dose microgram kg per min patient acute heart failure dose increase microgram kg per min case marked improvement h trial nicardipine administer double blind manner patient different rate infusion h group n group n group n micrograms kg per min neither heart rate mean right atrial pressure change group favorable hemodynamic effect evident group begin min start infusion increase cardiac index control vs h infusion l min per group vs group vs group vs p compare control decrease diastolic pulmonary artery pressure group vs group vs group vs mmhg p decrease systolic pressure great group group vs group vs group vs mmhg p compare control p group intravenous drip infusion nicardipine effective treatment heart failure induce increase cardiac output decrease pulmonary artery wedge pressure optimal dose study microgram kg per min,Hirota Y,1997,Jpn Circ J,https://doi.org/10.1253/jcj.61.367,9192235,Hirota Y; Kawai C; Hori R; Okumura K; Kinoshita M; Kumada T; Ogawa H; Kawamura K; Kusukawa R,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000208: Acute Disease; D000368: Aged; D002121: Calcium Channel Blockers; D002303: Cardiac Output, Low; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006439: Hemodynamics; D006801: Humans; D007262: Infusions, Intravenous; D008297: Male; D008875: Middle Aged; D009529: Nicardipine; D014665: Vasodilator Agents",,,https://openalex.org/W2023162019,118,17,1,1906,413,10,en,en
false,short term antihypertensive medication exacerbate sleep disordered breathing newly diagnose hypertensive patient,speculate time various antihypertensive medication may deleterious effect respiration sleep thereby enhance apparent association hypertension sleep apnea hypopnea sah however data support contention present study use double blind randomize cross design contrast effect week treatment methyldopa combination hydrochlorothiazide amiloride amlodipine combined diuretic group newly diagnose patient primary hypertension night polysomnography perform initiation therapy baseline end two treatment period respiratory variable fail reveal significant difference treatment baseline two different treatment regimen two treatment regimen achieve similar reduction blood pressure prevalence sah treatment comparable prevalence similar group drawn population receive various antihypertensive medication finding study agreement previous report use class antihypertensive drug also fail detect tendency increase nocturnal respiratory disturbance index assessment period week short j hypertens american journal hypertension ltd,Bartel PR,1997,Am J Hypertens,https://doi.org/10.1016/s0895-7061(96)00507-9,9194510,Bartel PR; Loock M; Becker P; Robinson E; van der Meyden C; Rossouw S,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D017311: Amlodipine; D000959: Antihypertensive Agents; D018592: Cross-Over Studies; D004311: Double-Blind Method; D006801: Humans; D006973: Hypertension; D008750: Methyldopa; D012891: Sleep Apnea Syndromes,,,https://openalex.org/W2055431030,126,13,1,1483,238,9,en,en
false,effect gallopamil myocardial microperfusion patient stable effort angina randomized cross double blind placebo controlled trial,evaluate efficacy safety daily administration gallopamil mg day effect myocardial perfusion medium term randomize double blind cross placebo controlled trial study patient male female mean age year stable effort angina angiographically document coronary artery disease reversible perfusion defect exercise thallium myocardial scintigraphy least one segment left ventricle week single blind placebo run period patient underwent least exercise test hour holter ecg recording patient treat either placebo gallopamil mg day end period patient cross alternate regimen phase double blind treatment placebo gallopamil patient underwent exercise test hour holter ecg record thallium myocardial scintigraphy weekly angina frequency trinitroglycerin tnt consumption safety also evaluate patient drop study major side effect number total ischemic symptomatic event record hour ecg monitoring weekly angina frequency tnt consumption significantly reduce gallopamil treatment gallopamil administration exercise duration significantly increase run placebo gallopamil p st segment depression significantly reduce run mm placebo mm gallopamil mm p heart rate systolic blood pressure rate pressure product unchanged rest submaximal peak exercise qualitative quantitative evaluation myocardial perfusion myocardial uptake percentage thallium ischemic zone significantly improve gallopamil treatment finding demonstrate gallopamil improve myocardial perfusion reduce myocardial oxygen consumption,Acanfora D,1997,Cardiology,https://doi.org/10.1159/000177359,9197430,Acanfora D; Vitale DF; Rengo C; Iannuzzi GL; Furgi G; Picone C; Rossi M; Trojano L; Rengo F,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D017023: Coronary Angiography; D003326: Coronary Circulation; D018592: Cross-Over Studies; D004311: Double-Blind Method; D015716: Electrocardiography, Ambulatory; D005080: Exercise Test; D005260: Female; D005500: Follow-Up Studies; D005711: Gallopamil; D006439: Hemodynamics; D006801: Humans; D008297: Male; D008875: Middle Aged; D011877: Radionuclide Imaging; D012449: Safety; D013794: Thallium Radioisotopes; D016896: Treatment Outcome",,,https://openalex.org/W1968037804,153,22,1,2065,350,13,en,en
false,restrospective study poison tehran,examine cause mortality poison tehran poisoning case refer loghman hakim hospital tehran six month evaluate retrospectively overall female male ratio poisoning occur age range child adult oral ingestion common route intoxication child boy high frequency poisoning girl case child refer hospital pm adult refer hospital little diurnal variation poison presentation adult drug common cause intoxication benzodiazepine frequent follow antidepressant analgesic pesticide opiate intoxication also commonly observe child drug hydrocarbon frequent cause poison pesticide poisoning often fatal follow barbiturate opiates organophosphate insecticide responsible total pesticide poisoning case death attribute suicide majority poison case adult occur intentionally child accidentally,Abdollahi M,1997,J Toxicol Clin Toxicol,https://doi.org/10.3109/15563659709043371,9204099,Abdollahi M; Jalali N; Sabzevari O; Hoseini R; Ghanea T,article,D016428: Journal Article,"D000293: Adolescent; D000328: Adult; D017677: Age Distribution; D002423: Cause of Death; D002491: Central Nervous System Agents; D002648: Child; D002675: Child, Preschool; D005260: Female; D006801: Humans; D007492: Iran; D008297: Male; D010575: Pesticides; D011041: Poisoning; D012189: Retrospective Studies",,,https://openalex.org/W2098068687,45,7,1,1295,243,13,en,en
false,coronary vasodilatory capacity flow reserve normal myocardium supply bypass graft late surgery,coronary artery bypass surgery use widely treat myocardial ischemia however blood flow flow reserve normally perfuse myocardium subtend bypass graft evaluate late surgery also unknown whether pharmacologic vasodilation evokes comparable myocardial flow response arterial venous conduit myocardial blood flow quantify rest dipyridamole hyperemia use n ammonia positron emission tomography pet patient year bypass surgery healthy volunteer blood flow analyze territory subtend bypass graft normal wall motion normal perfusion myocardial blood flow rest differ patient control vs ml g min similar normal myocardium subtend saphenous vein n internal mammary artery graft n vs ml g min however hyperemic response normal myocardium supply bypass graft less control vs ml g min p difference territory supply venous arterial conduit observe vs ml g min normal myocardium subtend bypass graft exhibit low flow reserve control vs p myocardial flow reserve almost identical region supply venous arterial graft vs similar reduction vasodilatory capacity together normal pet polar map finding dipyridamole argue flow limit stenosis venous arterial bypass conduit late revascularization rather nonobstructive proliferative fibrointimal change bypass conduit atherosclerosis native resistance vessel might account finding,Campisi R,1997,Am J Cardiol,https://doi.org/10.1016/s0002-9149(97)00278-6,9205015,Campisi R; Czernin J; Karpman HL; Schelbert HR,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013486: Research Support, U.S. Gov't, Non-P.H.S.; D013487: Research Support, U.S. Gov't, P.H.S.","D000368: Aged; D017023: Coronary Angiography; D001026: Coronary Artery Bypass; D003326: Coronary Circulation; D004176: Dipyridamole; D004452: Echocardiography; D005260: Female; D006321: Heart; D006439: Hemodynamics; D006801: Humans; D007091: Image Processing, Computer-Assisted; D008297: Male; D008875: Middle Aged; D012016: Reference Values; D014055: Tomography, Emission-Computed; D014655: Vascular Resistance; D014664: Vasodilation",,,https://openalex.org/W2075505067,113,16,1,1918,332,12,en,en
false,therapy old patient isolated systolic hypertension fourth progress report syst eur trial,syst eur trial multicentre randomize double blind placebo control therapeutical trial patient least year old isolated systolic hypertension scope investigate effect modern antihypertensive drug treatment morbidity mortality assess possible adverse effect drug use patient recruit country western eastern europe israel three run visit month apart sit systolic blood pressure sbp single blind placebo treatment average mm hg diastolic blood pressure dbp low mm hg stratification sex presence cardiovascular complication patient randomize either active treatment placebo active treatment consist nitrendipine mg day possible addition enalapril mg day hydrochlorothiazide mg day titrate combine reduce sit sbp least mm hg mm hg match placebo employ similarly present progress report base data receive coordinate office march time subject randomize total patient follow least year double blind treatment patient least year baseline bp similar treatment group average mm hg accord per protocol analysis year bp fell p average mm hg active treatment group mm hg placebo group year bp mm hg lower p active treatment placebo year percentage patient reach goal bp placebo group active treatment group year percentage respectively,Antikainen R,1997,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1000452,9205931,Antikainen R; Tuomilehto J; Thijs L; Vanhanen H; Sarti C; Birkenhäger W; Arabidze G; Fagard R; Grigorow M; Jankulova K; Jääskivi M; Kohonen-Jalonen P; Laks T; Lazebnic L; Mantova S; Nachev C; Kermova P; Vänskä O; Yodfat Y; Bulpitt CJ; Staessen JA,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000959: Antihypertensive Agents; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004656: Enalapril; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D008875: Middle Aged; D009568: Nitrendipine; D016896: Treatment Outcome",,,https://openalex.org/W2136258012,105,16,1,1897,352,15,en,en
false,role cytokine mechanism action amlodipine praise heart failure trial,objective seek determine whether beneficial effect amlodipine heart failure may mediate reduction tumor necrosis factor alpha tnf alpha interleukin il level postulate tnf alpha il level may also predictive value patient congestive heart failure chf background molecular mechanism progression chf may involve cytokine overexpression effect amlodipine cytokine level patient chf unknown method prospective randomized amlodipine survival evaluation praise trial use enzyme linked immunosorbent assay measure plasma level tnf alpha patient il patient new york heart association functional class iii iv randomize receive amlodipine mg day placebo blood sample obtain cytokine measurement baseline week enrollment result baseline amlodipine placebo group differ demographic cytokine level mean sd plasma level tnf alpha pg ml il pg ml baseline level elevate time respectively compare normal subject p level tnf alpha change significantly week period p however il level significantly low week patient treat amlodipine versus placebo p wilcoxon signed rank test adverse event chf death occurred commonly patient high il level conclusion amlodipine lower plasma il level patient chf beneficial effect amlodipine chf may due reduction cytokine il j coll cardiol,Mohler ER,1997,J Am Coll Cardiol,https://doi.org/10.1016/s0735-1097(97)00145-9,9207618,Mohler ER; Sorensen LC; Ghali JK; Schocken DD; Willis PW; Bowers JA; Cropp AB; Pressler ML,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000368: Aged; D017311: Amlodipine; D000704: Analysis of Variance; D002121: Calcium Channel Blockers; D004797: Enzyme-Linked Immunosorbent Assay; D005260: Female; D006333: Heart Failure; D006801: Humans; D015850: Interleukin-6; D008297: Male; D008875: Middle Aged; D011237: Predictive Value of Tests; D011379: Prognosis; D011446: Prospective Studies; D014409: Tumor Necrosis Factor-alpha,,,https://openalex.org/W2066109249,90,16,1,1789,322,20,en,en
false,postabsorption concentration peak brand name generic verapamil double blind crossover study elderly hypertensive patient,pharmacokinetic action bioequivalence cardiovascular effect two verapamil product study randomized double blind crossover study eight elderly hypertensive patient median age year range year give brand name generic immediate release verapamil mg twice daily dos day blood pressure heart rate p r interval serum concentration r verapamil norverapamil measure multiple time patient last day therapy median blood pressure decrease generic verapamil brand name drug large difference occur hour mmhg versus mmhg p respectively pharmacokinetic parameter different two product p however generic product compare brand name drug mean area concentration time curve time hour ratio ci r total verapamil seventy concentration peak brand name drug generic drug appear hour median percentage increase peak compare previous concentration brand name generic drug respectively fifty peak associate stereospecific concentration peak norverapamil temporally meal finding suggest whereas two verapamil product may bioequivalent food drug administration criterion observed difference effect clinically significant elderly population multiple concentration peak absorption observe patient verapamil product perhaps relate enterohepatic recirculation,Saseen JJ,1997,J Clin Pharmacol,https://doi.org/10.1002/j.1552-4604.1997.tb04331.x,9208360,Saseen JJ; Porter JA; Barnette DJ; Bauman JL; Zajac EJ; Carter BL,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D004311: Double-Blind Method; D005260: Female; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D014700: Verapamil,,,https://openalex.org/W2116781222,138,18,1,1857,328,10,en,en
false,comment comparison nifedipine daily adalat la isosorbide mononitrate daily isosorbide dinitrate twice daily patient stable angina,paper walker et al international journal cardiology several unclear point would like point reader hope author clarify also hope letter could serve example report clinical trial paper,Nyberg G,1997,Int J Cardiol,https://doi.org/10.1016/s0167-5273(97)00064-8,9209948,Nyberg G,article,D016422: Letter; D016420: Comment,D000787: Angina Pectoris; D003692: Delayed-Action Preparations; D006801: Humans; D007548: Isosorbide Dinitrate; D009543: Nifedipine; D014665: Vasodilator Agents,,,https://openalex.org/W1965643405,166,29,1,307,62,4,en,en
false,editorial,c alcium antagonist widely use antihy pertensive agent use increase dramatically last decade show leader al issue journal wide appeal attribute several feature include antihypertensive efficacy metabolic neutrality clean side effect profile one accept surrogate end point lower blood pressure goal antihypertensive treatment calcium antagonist could consider ideal agents however drug class longitudinal study document efficacy prevent stroke myocardial infarction mi congestive heart failure death lack unfortunately finding widely publicize news medium cause anxiety even panic among patient discontinue antihypertensive drug altogether physician whose office inundate phone call frustrate complete lack information although panic unnecessary unfortunate principal question raise study however imperfect whether calcium antagonist promote adverse cardiovascular eventsdeserves consideration study leader et al issue another pebble mosaic suggest calcium antagonist associate increase risk myocardial infarction mortality may even superior diuretic beta blockers several prospective study report calcium antagonist exert beneficial effect,Grossman E,1997,Am J Med,https://doi.org/10.1016/s0002-9343(96)00400-7,9217563,Grossman E; Messerli FH,article,D016420: Comment; D016421: Editorial,D002121: Calcium Channel Blockers; D002318: Cardiovascular Diseases; D006801: Humans; D009203: Myocardial Infarction; D012307: Risk Factors,,,https://openalex.org/W2419048171,9,1,1,1571,251,2,es,en
false,diltiazem calcium antagonist partly attenuate effect dextroamphetamine healthy volunteer,calcium antagonist previously show effective treatment mania present study use dextroamphetamine administer human model mania determine whether calcium antagonist diltiazem would prevent dextroamphetamine induced change may help determine whether diltiazem likely useful treatment mania ten healthy volunteer enrol double blind placebo controlled balance crossover study subject receive either oral diltiazem mg placebo placebo dcxtroamphetamine mg diltiazem dextroamphetamine placebo alone subjective sleep change measure use visual analogue scale attentiveness visual reaction time measure repeatedly diastolic systolic blood pressure result show dextroamphelamine alone produce number subjective change cardiovascular change change reaction time diltiazem significantly attenuate cardiovascular change subjective reaction time change hypothesize finding may represent effect diltiazem noradrenergic neurotransmission result tentatively supportive suggestion diltiazem may clinically useful treatment mania another calcium channel antagonist verapamil,Fabian JE,1997,Int Clin Psychopharmacol,https://doi.org/10.1097/00004850-199703000-00007,9219047,Fabian JE; Silverstone PH,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D001143: Arousal; D001288: Attention; D001714: Bipolar Disorder; D002121: Calcium Channel Blockers; D000697: Central Nervous System Stimulants; D018592: Cross-Over Studies; D003913: Dextroamphetamine; D004110: Diltiazem; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male,,,https://openalex.org/W2030688706,105,15,1,1354,210,11,en,en
false,nifedipine gastrointestinal therapeutic system versus nifedipine coat core comparison efficacy via hour ambulatory blood pressure monitoring,objective assess comparable efficacy adverse effect profile two extended release preparation nifedipine gastrointestinal therapeutic system git coat core cc patient mild moderate hypertension design single institution single blind prospective study setting dwight david eisenhower army medical center fort gordon ga patient ninety one patient take nifedipine git sole antihypertensive agent randomize receive either git cc week hour ambulatory blood pressure monitoring conduct adverse effect questionnaire administer patient cross treatment arm monitoring repeat week measurement mean blood pressure heart rate percentage reading exceed mm hg systolic mm hg diastolic compare hour period additionally mean blood pressure hour interval drug administration heart rate first hour dosage interval compare result ninety one patient enrol complete study patient include efficacy analysis statistically significant difference p show last hour systolic blood pressure however difference small mm hg git vs mm hg cc difference percentage reading exceed mm hg systolic mm hg diastolic neither dosage treatment order effect result adverse effect report great frequency cc therapy cc vs git p generally transient discontinuation drug necessary patient cc cycle conclusion git cc demonstrate clinically equivalent antihypertensive efficacy study population cc product may high rate adverse effect drug discontinuation uncommon patient take git formulation nifedipine sole antihypertensive agent safely switch cc preparation without clinically important sacrifice blood pressure control major increase adverse effect might lead drug discontinuation result study extrapolate patient poorly control hypertension condition treat nifedipine military medical center cost controlled institution reason contemplate switch clearly economic estimate patient institution receive git preparation annual cost current market cost direct switch would lead annual saving institution patient currently take git nifedipine product cc nifedipine offer adequate blood pressure control cost effective,Defina LF,1997,Ann Pharmacother,https://doi.org/10.1177/106002809703100701,9220037,Defina LF; Bookstaver DA; Goldfinger MP; Coffey TA,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000704: Analysis of Variance; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D016009: Chi-Square Distribution; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D016503: Drug Delivery Systems; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011446: Prospective Studies; D011897: Random Allocation; D016037: Single-Blind Method; D011795: Surveys and Questionnaires",,,https://openalex.org/W2218226010,147,17,1,2923,510,23,en,en
false,selective prescribing suicidal patient little thought decrease risk future morbidity mortality,,Rynn KO,1997,Ann Pharmacother,https://doi.org/10.1177/106002809703100722,9220060,Rynn KO; Graf SE; Paloucek FP,article,D016420: Comment; D016428: Journal Article,"D000293: Adolescent; D000328: Adult; D002648: Child; D002675: Child, Preschool; D062787: Drug Overdose; D011307: Drug Prescriptions; D006801: Humans; D011041: Poisoning; D010818: Practice Patterns, Physicians'; D000092864: Suicide Prevention",,,https://openalex.org/W2282033609,116,18,1,0,0,0,en,
false,prognostic significance angina pectoris experience first month follow acute myocardial infarction,abstract background angina pectoris accompany transient st segment change hospital phase acute myocardial infarction ami well establish marker subsequent cardiac death reinfarction hypothesis study undertake record prognostic significance angina pectoris experience first month follow discharge ami method patient include placebo arm danish verapamil infarction trial ii follow month coronary care unit denmark patient randomize placebo still study treatment month discharge patient report chest pain first month follow discharge result patient angina pectoris significantly increase risk reinfarction hazard confidence limit cl increase mortality risk however reach borderline statistical significance hazard cl patient subdivide accord angina pectoris heart failure one risk marker significantly increase mortality p reinfarction p rate compare patient free angina pectoris heart failure conclusion patient postinfarction angina pectoris significantly increase morbidity risk,Jespersen CM,1997,Clin Cardiol,https://doi.org/10.1002/clc.4960200708,9220178,Jespersen CM,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D016009: Chi-Square Distribution; D016001: Confidence Intervals; D004311: Double-Blind Method; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D015994: Incidence; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D011379: Prognosis; D016016: Proportional Hazards Models; D012008: Recurrence; D012044: Regression Analysis; D012307: Risk Factors; D015996: Survival Rate; D014700: Verapamil,,,https://openalex.org/W1999000407,119,15,1,1403,244,8,en,en
true,safety nifedipine patient hypertension,abstract objective compare cardiovascular event rate patient mild moderate hypertension receive nifedipine active drug control perform medlar search use mesh heading hypertension text word nifedipine identify article publish august english french german italian spanish language involve human subject computerized search supplement manual search article bibliography review citation reveal randomize control clinical trial meet protocol criterion article extract independently two doctor blind author institution treatment regimen use structure pretested extraction form difference opinion resolve consensus fourteen event occur exposure nifedipine event exposure active drug control unadjusted odds ratio nifedipine versus control confidence interval ci definitive event death nonfatal myocardial infarction stroke revascularization procedure ci event definitive plus increase angina odds ratio nifedipine monotherapy sustained extended release exposure nonsignificantly high definitive event odds ratio ci odds ratio ci respectively odds ratio nifedipine combination another drug significantly low definitive event odds ratio ci odds ratio ci respectively difference odds ratio nifedipine monotherapy combine therapy statistically significant p definitive event p event result support safety sustained extended release nifedipine treatment mild moderate hypertension use combination drug,Stason WB,1997,Hypertension,https://doi.org/10.1161/01.hyp.30.1.7,9231814,Stason WB; Schmid CH; Niedzwiecki D; Whiting GW; Caubet JF; Luo D; Ross SD; Chalmers TC,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D017418: Meta-Analysis; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D004232: Diuretics; D004359: Drug Therapy, Combination; D006801: Humans; D006973: Hypertension; D008523: MEDLARS; D008875: Middle Aged; D009543: Nifedipine; D016017: Odds Ratio; D012449: Safety; D013997: Time Factors; D014481: United States; D014665: Vasodilator Agents",,,https://openalex.org/W2114631850,50,7,1,2050,366,12,en,en
false,additive effect diltiazem lisinopril treatment elderly patient mild moderate hypertension,multicenter double blind placebo controlled trial multifactorial design conduct evaluate safety efficacy calcium channel blocker diltiazem sustained release preparation angiotensin convert enzyme inhibitor lisinopril treatment elderly chinese patient mild moderate hypertension addition hypotensive effect combination drug compare monotherapy give daily effect quality life also evaluate study consist x multifactorial design woman men sit diastolic pressure mm hg mm hg week placebo washout phase randomize one six treatment group week active treatment monotherapy diltiazem mg produce increase reduction systolic diastolic blood pressure compare placebo lisinopril mg effect intermediate diltiazem dose combination diltiazem mg lisinopril mg diltiazem mg lisinopril mg show increased efficacy reduce systolic diastolic blood pressure compare drug dos use monotherapy effect combination less predict additive model although total number adverse event report similar active treatment group compare placebo lisinopril induced cough common incidence rechallenge premature drug withdrawal necessary four patient receive lisinopril due intractable cough combination diltiazem mg lisinopril mg significantly effective reduce blood pressure either drug alone additive effect result high rate adverse effect impairment quality life thus combination therapy agent well tolerate result increased efficacy elderly patient,Chan P,1997,Am J Hypertens,https://doi.org/10.1016/s0895-7061(96)00060-x,9234828,Chan P; Lin CN; Tomlinson B; Lin TH; Lee YS,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D000369: Aged, 80 and over; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D004110: Diltiazem; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004357: Drug Synergism; D005260: Female; D006801: Humans; D006973: Hypertension; D017706: Lisinopril; D008297: Male; D008875: Middle Aged; D010349: Patient Compliance; D011788: Quality of Life",,,https://openalex.org/W2050157559,116,15,1,1987,332,10,en,en
false,nifedipine ritodrine management preterm labor randomized multicenter trial,compare efficacy nifedipine ritodrine management preterm labor one hundred eighty five singleton pregnancy preterm labor assign randomly either ritodrine intravenously n nifedipine orally n principal outcome assess delay delivery ritodrine discontinue patient severe maternal side effect result exclude analysis woman ritodrine group deliver within hour versus p within hour versus p within week versus p within week versus p compare receive nifedipine significantly maternal side effect nifedipine group apgar score umbilical artery vein ph similar group number admission neonatal intensive care unit nicu nifedipine group significantly low ritodrine group versus p nifedipine comparison ritodrine management preterm labor significantly associate longer postponement delivery maternal side effect admission nicu,Papatsonis DN,1997,Obstet Gynecol,https://doi.org/10.1016/s0029-7844(97)00182-8,9241299,Papatsonis DN; Van Geijn HP; Adèr HJ; Lange FM; Bleker OP; Dekker GA,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000328: Adult; D005260: Female; D005322: Fetal Membranes, Premature Rupture; D006801: Humans; D007262: Infusions, Intravenous; D009543: Nifedipine; D007752: Obstetric Labor, Premature; D011247: Pregnancy; D011256: Pregnancy Outcome; D012312: Ritodrine; D013997: Time Factors; D015145: Tocolysis; D015149: Tocolytic Agents; D016896: Treatment Outcome",,,https://openalex.org/W2164938074,91,14,1,1229,235,9,en,en
false,effectiveness tolerability bisoprolol vs nifedipine uremic patient ischemic cardiopathy dialysis treatment,effect bisoprolol transient myocardial ischemia compare nifedipine patient coronary artery disease end stage renal failure maintain haemodialysis also evaluate tolerability drug sixty patient male female mean age year renal failure maintain haemodialysis coronary artery disease four significant episode transient myocardial ischemia min hour holter monitoring include study cardiovascular drug discontinue day hour ambulatory ecg monitoring exception sublingual nitrate allow relief anginal attack patient randomize receive either bisoprolol nifedipine week day wash period cross receive either bisoprolol nifedipine week statistical analysis carry use student test p value consider significant bisoprolol nifedipine reduce number duration transient ischemic episode well total ischemic burden reduction statistically significant antianginal drug bisoprolol effective silent ischemia p also reduce heart rate p nifedipine raise p drug reduce systolic diastolic blood pressure circadian variation transient ischemic episode show two peak hour peak reduce bisoprolol nifedipine bring clear overall reduction number episode circadian pattern unchanged study patient take bisoprolol patient take nifedipine drug adverse effect one withdraw treatment conclusion bisoprolol seem useful nifedipine effect transient ischemic episode greatly superior nifedipine effective also silent ischemia drug show good tolerability patient bisoprolol reduce two daily peak ischemic episode frequency protective role towards mortality due coronary artery disease,Cice G,1997,Cardiologia,,9244644,Cice G; Di Benedetto A; Tagliamonte E; Ferrara L; Sorice P; Iacono A,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,D000319: Adrenergic beta-Antagonists; D017298: Bisoprolol; D002121: Calcium Channel Blockers; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D017202: Myocardial Ischemia; D009543: Nifedipine; D006435: Renal Dialysis; D014511: Uremia,,,https://openalex.org/W2408978336,129,19,1,2254,392,21,en,en
false,randomised double blind trial compare mibefradil amlodipine two long acting calcium antagonist similar efficacy different tolerability profile,objective compare efficacy tolerability mibefradil amlodipine patient uncomplicated mild moderate essential hypertension design double blind randomise parallel group multicentre trial method patient receive mg mibefradil mg amlodipine week follow forced titration mg mibefradil mg amlodipine additional week patient enter week withdrawal period either therapy switch placebo result statistically equivalent reduction trough sit diastolic blood pressure sdbp observe week daily treatment mg mibefradil mm hg mg amlodipine mm hg number patient normalised sdbp mm hg increase mibefradil group amlodipine group approximately group patient mibefradil amlodipine withdrawal period significantly large decrease sdbp placebo patient mibefradil decrease heart rate bpm patient amlodipine change heart rate however cessation amlodipine associate decrease heart rate conclusion mibefradil effective amlodipine reduce bp compound effective treatment hypertension,Viskoper RJ,1997,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1000453,9249234,Viskoper RJ; Bernink PJ; Schelling A; Ribeiro AB; Kantola IM; Wilkins MR; Kobrin I,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D017311: Amlodipine; D001562: Benzimidazoles; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D020748: Mibefradil; D008875: Middle Aged; D013764: Tetrahydronaphthalenes,,,https://openalex.org/W1966980453,163,21,1,1366,242,10,en,en
false,regression nifedipine induced gingival hyperplasia follow switch class calcium channel blocker isradipine,patient nifedipine induced gingival hyperplasia gh often require continued calcium channel blocker therapy switch diltiazem verapamil describe however drug different chemical class present therapeutic limitation patient purpose study evaluate effect nifedipine induced gh switch dihydropyridine derivative low incidence gh fourteen patient nifedipine induced gh give medical exam periodontal exam following parameter assess probe depth pd gingival margin gm gingival thickness gt plaque index pi gingival index gi intraoral photograph study model gingival biopsy histological examination take follow baseline measure patient randomize continue treatment nifedipine equivalent dose isradipine single blind fashion biweekly periodontal parameter take week end week patient elect receive week open label isradipine therapy biweekly examination continue open label phase isradipine treatment arm show mean decrease pd mm week p measure parameter gm gt pi gi significantly change compare either baseline alternate treatment arm clinically patient treat isradipine exhibit decrease hyperplasia patient treat nifedipine demonstrate increase hyperplasia significant difference p combine open label data patient switch therapy isradipine exhibit increase gm increase recession mm baseline week p patient treat isradipine exhibit increase gingival overgrowth patient exhibit adequate control hypertension conclude hypertensive patient nifedipine induced gh switch hypertensive therapy isradipine may result regression gh couple aggressive oral hygiene treatment drug may provide reasonable option patient require dihydropyridine treatment,Westbrook P,1997,J Periodontol,https://doi.org/10.1902/jop.1997.68.7.645,9249636,Westbrook P; Bednarczyk EM; Carlson M; Sheehan H; Bissada NF,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D001706: Biopsy; D002121: Calcium Channel Blockers; D003774: Dental Plaque Index; D005069: Evaluation Studies as Topic; D005260: Female; D005500: Follow-Up Studies; D005881: Gingiva; D005885: Gingival Hyperplasia; D005888: Gingival Pocket; D005889: Gingival Recession; D006801: Humans; D006973: Hypertension; D015994: Incidence; D017275: Isradipine; D008297: Male; D008875: Middle Aged; D003765: Models, Dental; D009543: Nifedipine; D009910: Oral Hygiene; D010512: Periodontal Index; D010781: Photography; D012074: Remission Induction; D016037: Single-Blind Method",,,https://openalex.org/W2059631518,122,16,1,2203,388,17,en,en
false,prevalence amlodipine related gingival hyperplasia,calcium channel blocker know contribute gingival hyperplasia vast majority report discus patient take drug nifedipine past year new calcium channel blocker amlodipine use increase frequency date six case publish indicate amlodipine may also promote gingival hyperplasia however data report regard prevalence phenomenon purpose study examine large group patient take amlodipine determine prevalence gingival hyperplasia one hundred fifty dentate patient take amlodipine mg per day least month volunteer undergo screening examination gingival hyperplasia mild hyperplasia clinical crown find five patients prevalence significantly less p rate report patient take nifedipine significantly different rate previously report control group cardiac patient take calcium channel blocker result group patient indicate amlodipine mg per day induce gingival hyperplasia,Jorgensen MG,1997,J Periodontol,https://doi.org/10.1902/jop.1997.68.7.676,9249639,Jorgensen MG,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D002121: Calcium Channel Blockers; D003774: Dental Plaque Index; D005260: Female; D005885: Gingival Hyperplasia; D006801: Humans; D007256: Information Systems; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D010349: Patient Compliance; D015995: Prevalence; D012907: Smoking; D013997: Time Factors",,,https://openalex.org/W1983034326,53,5,1,1195,205,9,en,en
false,antianginal response daily diltiazem cd patient receive concomitant beta blockers long acting nitrate diltiazem cd study group,determine safety efficacy diltiazem cd mg administer day patient chronic stable angina inadequately control p blockers long acting nitrate multicenter randomize double blind placebo controlled parallel group trial medical clinic private academic sectors patient complete week double blind treatment period patient receive either diltiazem cd mg placebo day combination exist antianginal therapy time termination exercise tolerance testing hour dose increase significantly diltiazem cd group sec compare placebo group sec p time onset angina exercise test also increase vs sec respectively p time moderate angina vs sec respectively p rate total angina attack angina attack exertion significantly reduce diltiazem cd group versus placebo p significant reduction systolic diastolic blood pressure heart rate blood pressure product measure rest submaximum exercise exercise termination observe diltiazem cd treated patient compare placebo p frequency treatment related adverse event identical two group diltiazem cd mg day effective safe beneficial initial dosage add exist antianginal therapy,Heller GV,1997,Pharmacotherapy,,9250554,Heller GV; Sridharan M; Morse J; Glasser S; Beach CL,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D004110: Diltiazem; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004562: Electrocardiography; D005080: Exercise Test; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D009566: Nitrates; D014665: Vasodilator Agents",,,https://openalex.org/W1890462776,153,23,2,1494,249,6,en,en
false,comparison two formulation nifedipine hour ambulatory blood pressure monitoring,study objective determine one commercial extended release formulation nifedipine adalat cc effective another procardia xl control blood pressure hour design open label randomize crossover study set university affiliated family medicine clinic patient fifteen patient stage primary hypertension intervention procardia xl adalat cc day titrate achieve blood pressure control effective dose continue week wash week reinstituted study drug measurement main result twenty four hour ambulatory blood pressure record conclusion treatment phase treatment phase compare mean hour blood pressure mean daytime p mean nighttime blood pressure mean blood pressure load percentage blood pressure measurement mm hg daytime mm hg nighttime thirteen patient complete study statistically significant difference see mean hour blood pressure mm hg procardia xl vs mm hg adalat cc daytime nighttime blood pressure blood pressure load two patient experience clinically significant adverse effect take adalat cc conclusion patient primary hypertension adalat cc effective procardia xl control blood pressure hour blood pressure heart rate adverse effect monitor week exchange adalat cc procardia xl,Lucas BD,1997,Pharmacotherapy,,9250574,Lucas BD; Hilleman DE; Wurdeman RL,article,D016430: Clinical Trial; D016420: Comment; D003160: Comparative Study; D016428: Journal Article,"D000368: Aged; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D014665: Vasodilator Agents",,,https://openalex.org/W1944132425,96,12,1,1569,271,20,en,en
false,effect barnidipine hydrochloride autonomic nervous system difference short long acting component calcium antagonist,short acting calcium antagonist deleterious effect prognosis patient myocardial ischemia possibly cause overactivation sympathetic nerve due vasodilatation negative inotropism coronary steal however considerable debate whether long acting calcium antagonist well short acting calcium antagonist effect barnidipine hcl newly developed calcium antagonist short long acting particle study evaluate change autonomic tone due barnidipine short long acting effect calcium antagonist evaluate eleven patient primary hypertension underwent hour ambulatory electrocardiogram blood pressure monitoring treatment barnidipine heart rate blood pressure compare medication heart rate variability analyze marquette high frequency power hf parameter vagal tone ratio low frequency power lf parameter sympathetic tone obtain twenty four hour average blood pressure decrease significantly day nocturnal hypotension observe heart rate increase hf decrease peak short long acting component lf hf increase peak short acting component short acting particle barnidipine deleterious effect autonomic tone overactivation sympathetic tone suppression vagal tone long acting particle barnidipine suppress vagal tone finding suggest short acting calcium antagonist may cause arrhythmia deterioration coronary ischemia,Soejima K,1997,J Cardiol,,9253691,Soejima K; Akaishi M; Oyamada K; Mitamura H; Ogawa S,article,D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article,"D001341: Autonomic Nervous System; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D015716: Electrocardiography, Ambulatory; D005260: Female; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D009543: Nifedipine",,,https://openalex.org/W2416255071,146,22,1,1718,269,16,en,en
false,intravenous infusion nifedipine alternative prevention hypertension eye surgery local anesthesia,order control critical rise blood pressure peri operative period elderly hypertensive patient effectiveness continuous intravenous infusion nifedipine study double blind study patient n undergo eye surgery local anesthesia divide randomly three group patient find sbp dbp mmhg previous day surgery well patient receive anti hypertensive treatment regimen last week surgery select five min perform local anesthesia continuous infusion nifedipine two different rate mg h mg h administer group b respectively whereas group c receive placebo sbp dbp hr record every min hour statistically significant difference among profile three group find control group high sbp dbp none group show significant change hr conclusion intravenous infusion nifedipine dose mg h seem control hypertensive phase blood pressure without drop unduly low level risk undesirable side effect elderly hypertensive patient perioperative period,Nastou H,1997,Acta Anaesthesiol Belg,,9259871,Nastou H; Sarros G; Nastos A; Saleh M,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D000369: Aged, 80 and over; D000772: Anesthesia, Local; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D007262: Infusions, Intravenous; D007431: Intraoperative Complications; D008297: Male; D009543: Nifedipine; D013508: Ophthalmologic Surgical Procedures",,,https://openalex.org/W2397884015,125,19,1,1298,233,10,en,en
false,comparison clinical efficacy adverse effect extended release felodipine atenolol patient mild moderate essential hypertension,essential hypertension risk factor cardiovascular disease atenolol cardio selective beta blocker show safe effective antihypertensive agent extended release form felodipine felodipine er vascular selective dihydropyridine calcium blocker extensively use caucasian however effectiveness tolerability adverse side effect assess chinese populations sitting blood pressure bp heart rate body weight adverse reaction serum biochemistry assess patient mild moderate essential hypertension treat either felodipine er patient atenolol patient week patient prescribe mg felodipine er mg atenolol daily daily dosage double twice daily necessary six patient receive felodipine er receive atenolol withdrew treatment intolerable side effect within ten week patient respond total daily dosage mg felodipine er daily dose mg atenolol end treatment mean bp felodipine er group decrease mmhg baseline mmhg bp atenolol group drop mmhg mmhg ns two group heart rate decline atenolol group change patient receive felodipine er overall patient felodipine er group high rate adverse reaction vs p patient felodipine er group experience symptom hypotension equivalent dos felodipine er atenolol effective first line monotherapeutic agent treatment mild moderate essential hypertension,Chern MS,1997,Changgeng Yi Xue Za Zhi,,9260367,Chern MS; Lin FC; Wu D,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D001262: Atenolol; D002121: Calcium Channel Blockers; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged,,,https://openalex.org/W2413546458,159,21,1,1812,321,9,en,en
false,challenge concept use calcium channel blocker cause reversible male infertility,objective study retrospectively evaluate vitro fertilization ivf non ivf cycle male partner take calcium channel blocker either confirm refute previous data another centre suggest drug cause severe reversible subfertility problem male drug find inhibit expression mannose ligand binding receptor thus prevent spermatozoon attach zona pellucida postulate cause failed fertilization base one case defect return normal achieve stop drug however couple undergo cycle ivf see fertilization occur data present demonstrate fertilization patient ivf take calcium channel blocker subsequent pregnancy rate per transfer also five non ivf patient conceive correction various female factor failure six patient conceive could explain confound factor especially oligoasthenozoospermia take consideration data suggest poor fertilization mannose ligand bind receptor abnormality demonstrate propose possibility defect associate calcium channel blocker may associate cryptic factor cause poor fertilization accord hypothesis calcium channel blocker might cause problem mannose expression also adversely affect factor deficient non drug related abnormality mannose ligand binding expression find,Katsoff D,1997,Hum Reprod,https://doi.org/10.1093/humrep/12.7.1480,9262281,Katsoff D; Check JH,article,D016428: Journal Article,"D002121: Calcium Channel Blockers; D004110: Diltiazem; D004624: Embryo Transfer; D005260: Female; D005307: Fertilization in Vitro; D006801: Humans; D007248: Infertility, Male; D008297: Male; D009845: Oligospermia; D011247: Pregnancy; D012189: Retrospective Studies; D014700: Verapamil",,,https://openalex.org/W2136725143,102,16,1,1694,273,9,en,en
false,danish multicenter randomize study invasive versus conservative treatment patient inducible ischemia thrombolysis acute myocardial infarction danami,background aim danish trial acute myocardial infarction danami study compare invasive strategy percutaneous transluminal coronary angioplasty ptca coronary artery bypass grafting cabg conservative strategy patient inducible myocardial ischemia receive thrombolytic treatment first acute myocardial infarction ami method result patient randomize invasive strategy ptca perform cabg week ami patient conservative treatment group revascularized month ami patient follow year primary end point mortality reinfarction admission unstable angina year follow median mortality invasive treatment group conservative treatment group significant invasive treatment associate low incidence ami versus p low incidence admission unstable angina versus p percentage patient primary end point year year versus year p invasive conservative treatment group respectively month stable angina pectoris present patient invasive treatment group conservative treatment group conclusion invasive treatment post ami patient inducible ischemia result reduction incidence reinfarction admission due unstable angina low prevalence stable angina conclude patient inducible ischemia discharge receive treatment thrombolytic drug first ami refer coronary arteriography revascularized accordingly,Madsen JK,1997,Circulation,https://doi.org/10.1161/01.cir.96.3.748,9264478,Madsen JK; Grande P; Saunamäki K; Thayssen P; Kassis E; Eriksen U; Rasmussen K; Haunsø S; Nielsen TT; Haghfelt T; Fritz-Hansen P; Hjelms E; Paulsen PK; Alstrup P; Arendrup H; Niebuhr-Jørgensen U; Andersen LI,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000789: Angina, Unstable; D015906: Angioplasty, Balloon, Coronary; D001026: Coronary Artery Bypass; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D017202: Myocardial Ischemia; D012008: Recurrence; D016019: Survival Analysis; D015912: Thrombolytic Therapy",,,https://openalex.org/W2016493598,172,23,1,1942,371,11,en,en
true,effect calcium antagonist felodipine supplementary vasodilator therapy patient chronic heart failure treat enalapril,despite therapy diuretic ace inhibitor digoxin morbidity mortality heart failure remain high might respond favorably additional vasodilator male patient n chronic heart failure cardiac dysfunction impaired exercise performance optimal current therapy enalapril diuretic randomly assign double blind treatment felodipine extend release mg bid placebo month average month felodipine significantly reduce blood pressure month increase ejection fraction versus unit placebo group p reduced plasma atrial natriuretic peptide level versus pg ml placebo group p improve exercise tolerance quality life need hospitalization long term follow favorable effect ejection fraction atrial peptide persist felodipine prevent worsen exercise tolerance quality life felodipine placebo group mortality versus respectively hospitalization versus rate similar high incidence peripheral edema apparent side effect felodipine therapy felodipine exert well tolerated additional sustain vasodilator effect patient heart failure treat enalapril possible long term benefit trend good exercise tolerance less depression quality life second year treatment drug appear safe clearly efficacious patient heart failure,Cohn JN,1997,Circulation,https://doi.org/10.1161/01.cir.96.3.856,9264493,Cohn JN; Ziesche S; Smith R; Anand I; Dunkman WB; Loeb H; Cintron G; Boden W; Baruch L; Rochin P; Loss L,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013486: Research Support, U.S. Gov't, Non-P.H.S.",D000328: Adult; D000806: Angiotensin-Converting Enzyme Inhibitors; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D004656: Enalapril; D015736: Felodipine; D006333: Heart Failure; D006439: Hemodynamics; D006728: Hormones; D006760: Hospitalization; D006801: Humans; D008297: Male; D008875: Middle Aged; D010807: Physical Endurance; D011788: Quality of Life; D013318: Stroke Volume; D014665: Vasodilator Agents,,,https://openalex.org/W1983494586,142,19,1,1614,280,5,en,en
false,effect amlodipine norepinephrine kinetics baroreflex function patient congestive heart failure,background use calcium channel block drug controversial heart failure partly concern neurohormonal stimulation preliminary data suggest new agent amlodipine may useful syndrome suppression sympathetic activity either directly sensitized baroreflex function could contribute factor clinical use drug objective assess effect short term amlodipine therapy baseline measure sympathetic activity baroreflex function patient chronic stable congestive heart failure chf method seven patient chronic chf new york heart association functional class ii iii moderate severe reduction left ventricular systolic function study patient underwent baroreflex test head tilt head tilt head tilt phenylephrine infusion heart rate mean arterial pressure forearm blood flow resistance plasma norepinephrine ne kinetics assess baseline baroreflex perturbation three occasion control test day placebo amlodipine therapy result plasma ne ne spillover significantly increase amlodipine administration compare control placebo test pg ml v pg ml three subject plasma ne level essentially unchanged whereas four rise markedly pg ml control vs pg ml difference response variable baroreflex perturbation amlodipine administration compare control placebo test one subject tolerate head tilt couple phenylephrine administration control placebo test become markedly short breath intervention amlodipine administration plasma ne level patient rise markedly receive amlodipine appropriately suppress baroreflex loading maneuver conclusion short term therapy amlodipine suppress sympathetic activity alter efferent response baroreflex perturbation patient stable chronic chf significant increase plasma ne ne spillover abnormal response baroreflex stimulation possible administration drug relevance finding study large number patient require study heart j,Goldsmith SR,1997,Am Heart J,https://doi.org/10.1016/s0002-8703(97)70101-7,9266778,Goldsmith SR,article,"D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D017311: Amlodipine; D017704: Baroreflex; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002316: Cardiotonic Agents; D002908: Chronic Disease; D004525: Efferent Pathways; D005542: Forearm; D018475: Head-Down Tilt; D006333: Heart Failure; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D018377: Neurotransmitter Agents; D009638: Norepinephrine; D010656: Phenylephrine; D010919: Placebos; D019275: Radiopharmaceuticals; D012039: Regional Blood Flow; D012131: Respiratory Insufficiency; D013566: Sympathomimetics; D018667: Tilt-Table Test; D014316: Tritium; D014655: Vascular Resistance; D018487: Ventricular Dysfunction, Left",,,https://openalex.org/W2143192352,113,15,1,2481,403,16,en,en
false,fix combination benazepril low dose amlodipine treatment mild moderate essential hypertension evaluation hour noninvasive ambulatory blood pressure monitoring,antihypertensive efficacy tolerability fixed combination benazepril mg low dose amlodipine mg assess patient mean age year uncomplicated mild moderate essential hypertension supine diastolic blood pressure dbp mm hg week washout take placebo patient randomize receive fixed combination placebo administer daily week accord double blind crossover design patient check end washout period every week thereafter visit h ambulatory bp monitoring abpm perform noninvasive device spacelabs casual bp mercury sphygmomanometer heart rate hr body weight also measure fixed combination significantly reduce systolic sbp dbp value throughout h compare placebo without affect normal bp circadian variability antihypertensive effect fixed combination could observe similar extent day night still significant h dose hr body weight affect treatment fixed combination benazepril mg amlodipine mg well tolerate patient withdraw study side effect,Fogari R,1997,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-199708000-00005,9269944,Fogari R; Zoppi A; Lusardi P; Mugellini A; Preti P; Motolese M,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001552: Benzazepines; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D004311: Double-Blind Method; D004338: Drug Combinations; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2071421034,187,25,1,1331,250,8,en,en
false,nifedipine captopril metoprolol nifedipine metoprolol hypertensive crisis non intensive care setting,case severe hypertension dbp mm hg without acute complication efficacy safety sl nifedipine mg nif sl captopril mg cap iv metoprolol mg meet sl nif iv meet study inpatient trial maximum mean percent reduction sbp dbp nif cap meet nif meet respectively safe dbp mm hg kaplan achieve percent patient statistically significant fall dbp observe minute regimen except cap minute mild side effect observe palpitation flushing nif n taste disturbance cap n heaviness head cap n giddiness meet n nif meet n trial data suggest hypertensive crisis manage without intensive care facility four regimen imply significant cost containment,Karnik ND,1996,J Assoc Physicians India,,9282610,Karnik ND; Bhatt AD; Trivedi TH; Dadkar VN; Kapadia NM; Vaidya AB; Khokhani RC,article,D016430: Clinical Trial; D003160: Comparative Study; D018848: Controlled Clinical Trial; D016428: Journal Article,"D000208: Acute Disease; D000293: Adolescent; D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002216: Captopril; D003362: Cost-Benefit Analysis; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008790: Metoprolol; D008875: Middle Aged; D009543: Nifedipine; D012449: Safety; D016896: Treatment Outcome; D014665: Vasodilator Agents",,,https://openalex.org/W70946881,118,17,1,969,224,6,en,en
false,calcium channel blocker evidence based review,calcium channel blocker widely use treatment cardiovascular disease proper therapeutic role controversial nevertheless drug class evaluate many controlled clinical trial adequate size duration different patient population although many important question remain unanswered trial clarify drug use general benefit calcium channel blocker control angina hypertension much clearly document long term effect hard end points mortality long term data sorely need particularly hypertension increase risk dihydropyridine calcium channel blocker clearly see across several study patient coronary disease coronary patient heart failure deleterious effect nifedipine diltiazem verapamil outweigh possible benefit long acting formulation new calcium channel blocker may share adverse effect old drug class however long term safety yet document understanding limitation calcium channel blocker base upon clinical trial evidence often lead practitioner choose drug another class efficacy clearly proven,Waters D,1997,Can J Cardiol,,9284842,Waters D,article,"D016430: Clinical Trial; D017427: Clinical Trial, Phase II; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D016454: Review",D000806: Angiotensin-Converting Enzyme Inhibitors; D002121: Calcium Channel Blockers; D004110: Diltiazem; D006801: Humans; D009203: Myocardial Infarction; D009543: Nifedipine; D014700: Verapamil,,,https://openalex.org/W2210244012,51,8,1,1363,222,9,en,en
false,effect morning versus even dosing diltiazem myocardial ischemia detect ambulatory electrocardiographic monitoring chronic stable angina pectoris,myocardial ischemia occur frequently daily life circadian pattern similar report myocardial infarction sudden death increase risk myocardial ischemia morning hour suggest administration anti ischemic medication bedtime may effective traditional morning dosing randomized double blind placebo controlled crossover study evaluate effect mg day diltiazem give either p myocardial ischemia use ambulatory electrocardiographic monitoring patient chronic stable angina minute ischemia per hour treatment diltiazem duration number myocardial ischemic episode reduce minute p episode p respectively duration number myocardial ischemic episode daytime p hour also reduce minute p episode p respectively significant difference p dosing morning ischemia noon consider separately daytime ischemia also significantly reduce p dosing regimen difference regimen result study show p dosing long acting diltiazem equally effective suppress episode ambulatory myocardial ischemia time,Deedwania PC,1997,Am J Cardiol,https://doi.org/10.1016/s0002-9149(97)00389-5,9285652,Deedwania PC; Pool PE; Thadani U; Eff J,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000704: Analysis of Variance; D000787: Angina Pectoris; D002908: Chronic Disease; D002940: Circadian Rhythm; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D004110: Diltiazem; D004311: Double-Blind Method; D015716: Electrocardiography, Ambulatory; D006801: Humans; D017202: Myocardial Ischemia; D014665: Vasodilator Agents",,,https://openalex.org/W2136252536,164,21,1,1527,276,8,en,en
false,effect controlled onset extended release verapamil nocturnal blood pressure dipper versus nondippers,approximately patient systemic hypertension hour blood pressure bp profile characterize blunted absent nocturnal decline pressure evaluate effect chronotherapeutic delivery system controlled onset extended release coer verapamil hydrochloride placebo hypertensive patient accord circadian bp pattern week prospective multicenter randomize double blind clinical trial patient stratify dipper decline bp period p compare hour p nondippers decline bp nighttime daytime placebo subtracted bp similarly decrease dipper nondippers coer verapamil nighttime placebo increase nocturnal bp dipper baseline nocturnal bp mm hg mm hg reduce bp mm hg nondippers baseline nocturnal bp mm hg p n group control age gender ethnicity regression mean observe placebo dos coer verapamil reduce nocturnal bp nondippers dipper mm hg p systolic bp p diastolic bp additionally significant dose related reduction systolic diastolic nocturnal bp r p systolic bp r p diastolic bp observe coer verapamil control baseline covariates data demonstrate nocturnal bp decrease great extent nondipper hypertensive dipper hypertensive follow treatment coer verapamil hcl,White WB,1997,Am J Cardiol,https://doi.org/10.1016/s0002-9149(97)00397-4,9285660,White WB; Mehrotra DV; Black HR; Fakouhi TD,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000959: Antihypertensive Agents; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002940: Circadian Rhythm; D015986: Confounding Factors, Epidemiologic; D003692: Delayed-Action Preparations; D003971: Diastole; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D012044: Regression Analysis; D013599: Systole; D016896: Treatment Outcome; D014700: Verapamil",,,https://openalex.org/W2012196372,110,14,1,1688,310,8,en,en
false,randomise double blind comparison placebo active treatment old patient isolated systolic hypertension,background isolate systolic hypertension occur people age year old european work party high blood pressure elderly investigate whether active treatment could reduce cardiovascular complication isolated systolic hypertension fatal non fatal stroke combine primary endpoint method patient year initially start masked placebo three run visit month apart average sit systolic blood pressure mm hg diastolic blood pressure low mm hg stratification centre sex previous cardiovascular complication patient randomly assign nitrendipine mg daily possible addition enalapril mg daily hydrochlorothiazide mg daily match placebo patient withdraw double blind treatment still follow compare occurrence major endpoint intention treat finding median year follow sit systolic diastolic blood pressure fall mm hg mm hg placebo group n mm hg mm hg active treatment group n group difference systolic mm hg ci diastolic mm hg active treatment reduce total rate stroke endpoint per patient years reduction p non fatal stroke decrease p active treatment group fatal non fatal cardiac endpoint include sudden death decline p non fatal cardiac endpoint decrease p fatal non fatal cardiovascular endpoint p cardiovascular mortality slightly low active treatment p cause mortality influence p interpretation among elderly patient isolated systolic hypertension antihypertensive drug treatment start nitrendipine reduces rate cardiovascular complication treatment patient year type regimen may prevent stroke major cardiovascular endpoint,Staessen JA,1997,Lancet,https://doi.org/10.1016/s0140-6736(97)05381-6,9297994,Staessen JA; Fagard R; Thijs L; Celis H; Arabidze GG; Birkenhäger WH; Bulpitt CJ; de Leeuw PW; Dollery CT; Fletcher AE; Forette F; Leonetti G; Nachev C; O'Brien ET; Rosenfeld J; Rodicio JL; Tuomilehto J; Zanchetti A,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002561: Cerebrovascular Disorders; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004656: Enalapril; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D008297: Male; D009017: Morbidity; D009568: Nitrendipine; D013997: Time Factors",,,https://openalex.org/W2114634962,121,15,1,2185,392,17,en,en
false,physical performance preserve regression left ventricular hypertrophy,reversal left ventricular hypertrophy show improve left ventricular diastolic function elderly patient hypertension little know whether affect physical performance leave ventricular mass cardiac function rest submaximal exercise physical performance assess elderly patient hypertension left ventricular hypertrophy normal systolic function month therapy amlodipine hydrochlorothiazide blood pressure control achieve amlodipine patient hydrochlorothiazide seven combination drug leave ventricular mass index similarly reduce approximately approximately g month treatment group systolic function maintain three treatment regimen whereas similar decrease time peak fill rate increase first third filling fraction occur rest submaximal exercise month far month therapy exercise capacity significantly change group whole individual change peak oxygen uptake end treatment correlate significantly decrease time peak fill rate submaximal exercise r p conclude long term blood pressure control amlodipine hydrochlorothiazide associate significant reduction left ventricular mass improve diastolic function elderly patient hypertension left ventricular hypertrophy despite reduction left ventricular mass leave ventricular systolic function physical performance well preserve submaximal exercise,Lacourcière Y,1997,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-199709000-00017,9300324,Lacourcière Y; Poirier L; Cléroux J,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D015444: Exercise; D005260: Female; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D017379: Hypertrophy, Left Ventricular; D008297: Male; D016277: Ventricular Function, Left",,,https://openalex.org/W2318339683,82,10,1,1782,280,8,en,en
false,long term antianginal antiischemic effect mibefradil novel type calcium channel blocker multicenter double blind placebo controlled randomized comparison sustained release diltiazem,study compare efficacy safety tolerability mibefradil sustained release diltiazem patient chronic stable angina pectoris week statistically equivalent mean increase exercise tolerance test ett duration minute observe group similar improvement time onset angina time persistent mm st segment depression also observe drug large reduction heart rate blood pressure rate pressure product observe stage ett among patient treat mibefradil drug associate least reduction baseline anginal frequency nitroglycerin consumption patient maintain mibefradil withdrawal period significant increase three ett variable week compare placebo effectiveness mibefradil comparable sustained release diltiazem treat chronic stable angina pectoris although mibefradil provide great reduction heart rate cardiac workload,Davies GJ,1997,Am Heart J,https://doi.org/10.1016/s0002-8703(97)70128-5,9313601,Davies GJ; Kobrin I; Caspi A; Reisin LH; de Albuquerque DC; Armagnijan D; Coelho OR; Schneeweiss A,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D001562: Benzimidazoles; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D004110: Diltiazem; D004311: Double-Blind Method; D005080: Exercise Test; D005260: Female; D006439: Hemodynamics; D006801: Humans; D008297: Male; D020748: Mibefradil; D008875: Middle Aged; D005996: Nitroglycerin; D011446: Prospective Studies; D013764: Tetrahydronaphthalenes,,,https://openalex.org/W2115522997,207,27,1,1055,169,7,en,en
false,salt blood pressure responses calcium antagonism hypertensive patient,since salt intake may affect blood pressure response antihypertensive drug individual salt sensitivity status may important consideration selection medication purpose single blind study assess impact salt sensitivity antihypertensive effect isradipine total evaluable hypertensive patient white black year age mean year randomize low salt diet mean hour urine sodium mmol high salt diet mean hour urine sodium mmol week follow crossover diet week washout period diet regimen patient receive placebo week follow optimal titration isradipine mg bid blood pressure control last week high salt diet salt sensitive hypertensive mean arterial blood pressure increase mm hg n exhibit systolic diastolic blood pressure change mm hg mm hg week isradipine treatment whereas low salt diet blood pressure change mm hg mm hg non salt sensitive patient n exhibit systolic diastolic blood pressure change mm hg mm hg high salt diet mm hg mm hg low salt diet treatment isradipine absolute blood pressure attain salt sensitive non salt sensitive patient almost identical isradipine therapy despite variation dietary salt although slightly high dos isradipine require salt sensitive group consequently isradipine perhaps calcium antagonist general manifest robust blood pressure lowering effect setting high sodium intake effect however appear largely confine individual salt sensitive,Weir MR,1997,Hypertension,https://doi.org/10.1161/01.hyp.30.3.422,9314427,Weir MR; Hall PS; Behrens MT; Flack JM,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D004039: Diet, Sodium-Restricted; D004351: Drug Resistance; D005260: Female; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D008297: Male; D008875: Middle Aged; D016037: Single-Blind Method; D012965: Sodium Chloride",,,https://openalex.org/W2023281555,80,11,1,1936,334,9,en,en
false,efficacy captopril nifedipine black white patient hypertensive crisis,examine antihypertensive efficacy sublingual oral single dos captopril mg nifedipine capsules mg white patient black patient hypertensive crisis single oral dose slow acting preparation nifedipine retard mg another black patient blood pressure bp assess min interval h administration h bp fall induce drug still significantly low baseline placebo value hypotensive effect nifedipine capsules establish rapidly captopril white black patient nifedipine retard black patient consider area curve bp value h treatment overall hypotensive effect nifedipine capsules similar captopril white patient significantly pronounced captopril nifedipine retard black patient white patient similar maximal drop bp mean e obtain nifedipine capsules mm hg captopril mm hg black patient maximal drop bp nifedipine capsules mm hg great p captopril mm hg similar nifedipine retard mm hg however contrast nifedipine capsules captopril nifedipine retard produce slow drop bp time peak drop bp nifedipine capsules captopril occur within first h whereas nifedipine retard occur h administration patient report side effect nifedipine retard compare two preparation conclude single dos captopril nifedipine reduces bp least h white black patient hypertensive crisis nifedipine potent captopril black patient slow release form nifedipine retard effectively safely lower bp achieve rapid enough effect without critical rapid fall bp occur nifedipine capsules,Damasceno A,1997,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1000428,9322826,Damasceno A; Ferreira B; Patel S; Sevene E; Polónia J,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000328: Adult; D000806: Angiotensin-Converting Enzyme Inhibitors; D044383: Black People; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002216: Captopril; D003692: Delayed-Action Preparations; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D009543: Nifedipine; D012449: Safety; D016896: Treatment Outcome; D044465: White People",,,https://openalex.org/W2069786835,89,13,1,2139,373,13,en,en
false,treatment severe hypertension trandolapril verapamil hydrochlorothiazide,multiple drug regimen consist trandolapril verapamil hydrochlorothiazide hctz sequentially add open label evaluation patient severe hypertension ninety patient white black patient titrate one drug follow week maintenance period statistically significant p mean decrease supine diastolic blood pressure dbp mm hg trandolapril mm hg trandolapril verapamil tv combination mm hg hydrochlorothiazide add combination decrease bp observe tv combination therapy plus hctz significantly p great decrease observe tv combination significantly p great decrease observe trandolapril monotherapy clinical responder rate trandolapril monotherapy trandolapril verapamil combination therapy triple therapy respectively black white patient similar response rate black patient appear benefit addition hctz black patient achieve post treatment supine dbp mm hg compare white patient study demonstrate addition verapamil trandolapril additive effect bp maintain throughout day,Punzi HA,1997,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1000439,9322827,Punzi HA; Novrit BA,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004232: Diuretics; D004357: Drug Synergism; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D007211: Indoles; D008297: Male; D008875: Middle Aged; D012449: Safety; D016037: Single-Blind Method; D049993: Sodium Chloride Symporter Inhibitors; D016896: Treatment Outcome; D014700: Verapamil",,,https://openalex.org/W2071929209,90,12,1,1387,254,8,en,en
false,long term effect angiotensin converting enzyme inhibitor calcium antagonist right leave ventricle essential hypertension,compare effect chronic antihypertensive treatment left right ventricular structure function patient mild moderate never treated hypertension randomize receive fosinopril mg daily amlodipine mg daily month baseline subsequently end third sixth twelfth month patient undergo integrate echocardiographic study noninvasive ambulatory blood pressure monitoring drug significantly reduce blood pressure casual monitor p leave ventricular mass index gm p amlodipine gm p fosinopril decrease left ventricular mass essentially cause reduction ventricular thickness free right ventricular wall thickness also lower group consistently amlodipine mm p without increase plasma natriuretic peptide insulin concentration heart rate treatment decrease ventricular mass associate impairment systolic function whereas trend toward improvement doppler echocardiographic index biventricular diastolic function observe conclusion amlodipine fosinopril induce similar qualitative effect anatomy function ventricle clinical meaning observation must define mean adequately size prospective trial,Lombardo M,1997,Am Heart J,https://doi.org/10.1016/s0002-8703(97)70095-4,9327716,Lombardo M; Alli C; Broccolino M; Ferrari S; Montemurro L; Zaini G; Zanni D,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001795: Blood Pressure Determination; D002121: Calcium Channel Blockers; D004452: Echocardiography; D005260: Female; D017328: Fosinopril; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009206: Myocardium; D011446: Prospective Studies; D016276: Ventricular Function,,,https://openalex.org/W2105080549,144,18,1,1534,268,8,en,en
false,combine therapy benazepril amlodipine treatment hypertension inadequately control ace inhibitor alone,multicenter randomize double blind placebo controlled study evaluate efficacy tolerability combination benazepril mg amlodipine mg daily compare benazepril mg monotherapy patient hypertension inadequately control angiotensin converting enzyme ace inhibitor monotherapy week placebo week single blind benazepril mg daily run period patient men woman age year mean year mean diastolic blood pressure dbp mm hg end benazepril run period randomize receive one following treatment daily week benazepril mg plus placebo bz b benazepril mg plus amlodipine mg bz aml c benazepril mg plus amlodipine mg bz aml patient admit trial end placebo run benazepril run period end week treatment period sit stand blood pressure bp heart rate hr body weight measure h intake trial medication bz aml bz aml combination show well antihypertensive activity bz monotherapy terminal visit demonstrate h postdosing sit stand systolic bp sbp dbp value statistically low combination therapy bz b success rate statistically high combination bz aml bz aml group compare bz group tolerability good three treatment group significant abnormal laboratory data detect difference efficacy safety tolerability bz aml bz aml group,Fogari R,1997,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-199710000-00014,9335410,Fogari R; Corea L; Cardoni O; Cosmi F; Porcellati C; Innocenti P; Provvidenza M; Timio M; Bentivoglio M; Bertocchi F; Zoppi A,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000328: Adult; D000368: Aged; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001552: Benzazepines; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D010919: Placebos",,,https://openalex.org/W2074267034,130,18,1,1882,367,7,en,en
false,prehospital use intravenous diltiazem cardizem lyo ject treatment rapid atrial fibrillation,present study complete establish epidemiological database define prehospital rapid atrial fibrillation raf intervention give patient hope develop recommendation treatment protocol review paramedic run report low volume urban emergency medical service em system person present raf data collect included vital signs ventricular rate patient age ambulance field time patient chief complaint prehospital intervention efficacy intervention additional cardiac rhythm iatrogenic complication patient past medical history neither intravenous iv diltiazem electrical cardioversion use within month period study symptomatic supportive care consist observation intervention nitroglycerine furosemide aspirin morphine iv fluid bolus therapy account prehospital treatment paramedic document improvement patient case occur raf result severe hemodynamic instability inappropriate use point estimate pe unmet need pe care note data present study suggest give similar em system characteristic prehospital raf infrequently encounter predominantly hemodynamically stable cardiac arrhythmia readily treatable symptomatic supportive care cautious observation prehospital application adult advanced cardiac life support guideline utilize iv diltiazem electrical cardioversion treatment raf may unnecessary j emerg med copyright w b saunders company,Abarbanell NR,1997,Am J Emerg Med,https://doi.org/10.1016/s0735-6757(97)90170-4,9337374,Abarbanell NR; Marcotte MA,article,D002363: Case Reports; D016422: Letter,"D000368: Aged; D000369: Aged, 80 and over; D001281: Atrial Fibrillation; D002121: Calcium Channel Blockers; D002317: Cardiovascular Agents; D004110: Diltiazem; D004356: Drug Storage; D004632: Emergency Medical Services; D006801: Humans; D008297: Male; D012034: Refrigeration",,,https://openalex.org/W2128089029,106,16,1,1756,308,13,en,en
false,use calcium channel blocker breast carcinoma risk postmenopausal woman,background use calcium channel blocker elderly population recently report associate incidence cancer cardiovascular health study multisite observational cohort study provide opportunity investigate epidemiologic association use calcium channel blocker breast carcinoma risk woman age year method standard questionnaire clinical procedure administer four study site annually drug usage assess medication inventory hospitalization incident invasive breast carcinoma case identify use international classification diseases clinical modification code time dependent cox proportional hazard regression model use assess association incident breast carcinoma use specific antihypertensive medication include calcium channel blocker result adjusted cox proportional hazard model elevated risk breast carcinoma associate use calcium channel blocker hazard ratio hr confidence interval ci association persist comparison group user antihypertensive medication association use antihypertensive medication incident breast carcinoma find association enhance assessment high dose baseline hr ci calcium channel blocker combine estrogen use hr ci association find strong use estrogen immediate release calcium channel blocker hr ci conclusion although number case limit observational study association find use calcium channel blocker incident invasive breast carcinoma warrant investigation site specific carcinoma include outcome ongoing plan long term clinical trial use calcium channel blocker cancer american cancer society,Fitzpatrick AL,1997,Cancer,https://doi.org/10.1002/(sici)1097-0142(19971015)80:8<1438::aid-cncr11>3.0.co;2-6,9338468,Fitzpatrick AL; Daling JR; Furberg CD; Kronmal RA; Weissfeld JL,article,"D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.",D000367: Age Factors; D000368: Aged; D001943: Breast Neoplasms; D002121: Calcium Channel Blockers; D015331: Cohort Studies; D004967: Estrogens; D005260: Female; D006801: Humans; D017698: Postmenopause; D016016: Proportional Hazards Models; D012307: Risk Factors,,,https://openalex.org/W2028294998,81,12,1,2117,343,14,en,en
true,rationale design baseline characteristic prospective randomized evaluation vascular effect norvasc trial prevent,prospective randomized evaluation vascular effect norvasc trial first angiographic clinical trial design test whether agent slow even reverse progression early coronary atherosclerosis patient documented disease addition subset patient undergo carotid ultrasound examination provide unique opportunity assess correlate disease progression arterial bed,Byington RP,1997,Am J Cardiol,https://doi.org/10.1016/s0002-9149(97)00611-5,9352986,Byington RP; Miller ME; Herrington D; Riley W; Pitt B; Furberg CD; Hunninghake DB; Mancini GB,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D017311: Amlodipine; D017023: Coronary Angiography; D003324: Coronary Artery Disease; D003327: Coronary Disease; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D015337: Multicenter Studies as Topic; D011446: Prospective Studies; D016032: Randomized Controlled Trials as Topic; D012107: Research Design,,,https://openalex.org/W2076531736,139,22,1,448,70,2,en,en
false,efficacy mibefradil compare amlodipine suppress exercise induced daily silent ischemia,background mibefradil new benzimidazolyl substituted tetraline derivative calcium antagonist vasodilatory activity combine ability lower heart rate without negative inotropic effect well long duration action make promising anti ischemic agent method result three hundred nine patient coronary artery disease stable angina pectoris positive exercise test randomize receive mibefradil mg amlodipine mg placebo anti ischemic effect mibefradil exercise test silent ischemia parameter assess dos mg mibefradil increase exercise duration second respectively p increase time onset angina second respectively p increase time mm st depression second respectively p comparison mg dose amlodipine significantly improve time onset angina treatment effect second p mibefradil mg mg decrease number episode silent ischemia treatment effect respectively p duration silent ischemia treatment effect minute p minute p respectively decrease number episode silent ischemia also statistically significant group receive mg amlodipine p conclusion daily dos mg mibefradil effective improve exercise tolerance reduce ischemic episode ambulatory monitoring patient coronary artery disease,Tzivoni D,1997,Circulation,https://doi.org/10.1161/01.cir.96.8.2557,9355894,Tzivoni D; Kadr H; Braat S; Rutsch W; Ramires JA; Kobrin I,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D017311: Amlodipine; D000787: Angina Pectoris; D001562: Benzimidazoles; D004311: Double-Blind Method; D015716: Electrocardiography, Ambulatory; D015444: Exercise; D005080: Exercise Test; D005260: Female; D006339: Heart Rate; D006439: Hemodynamics; D006801: Humans; D008297: Male; D020748: Mibefradil; D008875: Middle Aged; D017202: Myocardial Ischemia; D005996: Nitroglycerin; D011446: Prospective Studies; D013764: Tetrahydronaphthalenes; D014665: Vasodilator Agents",,,https://openalex.org/W2074231791,105,13,1,1685,316,9,en,en
false,assessment atrioventricular junction ablation dddr mode switching pacemaker versus pharmacological treatment patient severely symptomatic paroxysmal atrial fibrillation,purpose study evaluate effect av junction ablation pacemaker implantation quality life specific symptom patient paroxysmal atrial fibrillation af control drugs perform multicenter randomize month evaluation clinical effect av junction ablation dddr mode switching pacemaker abl pm versus pharmacological treatment patient intolerable recurrent paroxysmal af three episode previous month control three antiarrhythmic drug completion study patient drug group withdraw severity symptom patient assign abl pm group ablation procedure fail end month patient abl pm group complete study show comparison drug group low score living heart failure questionnaire p palpitation p effort dyspnea p exercise intolerance score p easy fatigue p score rest dyspnea chest discomfort nyha functional classification also low respectively abl pm group although significantly end study palpitation longer present abl pm group drug group p af document visit abl pm group examination drug group p chronic af develop two group respectively p patient paroxysmal af control pharmacological therapy abl pm treatment highly effective superior drug therapy control symptom improve quality life discontinuation drug therapy expose patient recurrence paroxysmal af risk develop permanent af,Brignole M,1997,Circulation,https://doi.org/10.1161/01.cir.96.8.2617,9355902,Brignole M; Gianfranchi L; Menozzi C; Alboni P; Musso G; Bongiorni MG; Gasparini M; Raviele A; Lolli G; Paparella N; Acquarone S,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000368: Aged; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D001283: Atrioventricular Node; D017115: Catheter Ablation; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D010043: Outcome and Process Assessment, Health Care; D010138: Pacemaker, Artificial; D011446: Prospective Studies; D011788: Quality of Life",,,https://openalex.org/W2075135210,184,20,1,1965,388,7,en,en
false,hypertension optimal treatment hot study month data blood pressure tolerability,hypertension optimal treatment hot study ongoing prospective randomize multicentre trial conduct country two main aim study first evaluate relationship three level target diastolic blood pressure mmhg incidence cardiovascular morbidity mortality hypertensive patient second determine effect morbidity mortality low dose mg daily acetylsalicylic acid asa aspirin compare placebo altogether patient recruit randomize two year data available patient report blood pressure achieve tolerability available data month follow patient special emphasis give subgroup elderly patient year n compare young patient year n average patient mmhg diastolic blood pressure target group reach mmhg mmhg target group patient reach mmhg mmhg target group patient reach mmhg percentage achieve target blood pressure target group month follow mmhg target group mmhg target group mmhg target group elderly subgroup year age percentage patient achieve target month high target group namely mmhg group mmhg group mmhg group antihypertensive treatment initiate calcium antagonist felodipine dose mg daily target blood pressure reach additional antihypertensive therapy either angiotensin convert enzyme ace inhibitor beta adrenoceptor blocking agent give far dose adjustment make accordance set protocol fifth final step diuretic could add relatively side effect large multinational study hypertensive patient ankle oedema cough exceed frequency ankle oedema young elderly cough young elderly two year patient still take baseline therapy felodipine month data present indicate possible fulfil primary aim hot study,Hansson L,1997,Blood Press,https://doi.org/10.3109/08037059709062088,9360003,Hansson L; Zanchetti A,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000368: Aged; D000959: Antihypertensive Agents; D001241: Aspirin; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002318: Cardiovascular Diseases; D016861: Cyclooxygenase Inhibitors; D004305: Dose-Response Relationship, Drug; D004359: Drug Therapy, Combination; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009017: Morbidity; D011446: Prospective Studies; D012621: Seasons",,,https://openalex.org/W2087153968,96,16,1,2529,517,18,en,en
false,calcium antagonism abolish antipressor action vasopressin v receptor antagonism,previous study demonstrate vasopressin v receptor antagonism lower arterial pressure black action v receptor blockade may mediate various mechanism include change intracellular calcium flux study undertake test hypothesis inhibition calcium entry may attenuate reduction arterial pressure observe v receptor blockade sixteen hypertensive patient white black examine antihypertensive therapy stop week follow three baseline blood pressure measurement patient give intravenous bolus injection v receptor antagonist blood pressure monitor every min period h subject randomize either mg clonidine twice daily mg diltiazem cd daily period day previous experiment repeat patient cross drug additional day experiment repeat significant reduction baseline mean arterial pressure among black white delta mm hg black versus delta mm hg white p presence clonidine similar reduction arterial pressure group p reduction follow v receptor blockade black delta mm hg black versus delta mm hg white p conversely presence diltiazem cd reduction arterial pressure either group follow v receptor antagonist conclude calcium channel blockade abolish blood pressure lower response v receptor blockade black,Bakris GL,1997,Am J Hypertens,https://doi.org/10.1016/s0895-7061(97)00216-1,9370387,Bakris GL; Kusmirek SL; Smith AC; Gavras I; Gavras H,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000368: Aged; D065092: Antidiuretic Hormone Receptor Antagonists; D000959: Antihypertensive Agents; D044383: Black People; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D013564: Sympathetic Nervous System; D044465: White People,,,https://openalex.org/W2083995922,91,13,1,1714,305,12,en,en
false,antihypertensive renal effect isradipine essential hypertension focus renin system activity,calcium antagonist know exert various effect kidney might modulate antihypertensive potential study evaluate renal effect along efficacy isradipine two subgroup patient mild moderate essential hyper tension eh define accord plasma renin activity pra twenty six patient randomly assign receive week treatment slow release isradipine mg placebo assessment pra relate concurrent hour sodium excretion use define patient high medium n low renin profile n urinary albumin excretion uae serum creatinine glomerular filtration rate gfr endogenous creatinine clearance measure blood pressure bp decrease isradipine great low pra group compare high medium pra group p normalization bp achieve low renin patient compare high medium pra group bp reduction placebo group statistically significant isradipine placebo induced significant reduction uae p decrease similar pra group treatment cause significant change gfr pra urinary sodium creatinine excretion serum aldosterone creatinine concentration decrease bp whole isradipine treat group inversely correlate pretreatment serum creatinine well basal urinary creatinine excretion conclusion antihypertensive effect isradipine pronounced low renin eh patient despite similar effect renal function uae pra group,Allikmets K,1997,Angiology,https://doi.org/10.1177/000331979704801107,9373050,Allikmets K; Parik T; Teesalu R,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D005260: Female; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D008297: Male; D012083: Renin,,,https://openalex.org/W2323942275,106,15,1,1674,297,11,en,en
false,pattern compliance versus twice daily antihypertensive drug therapy primary care randomized clinical trial use electronic monitoring,evaluate pattern compliance versus twice daily administration antihypertensive therapy primary outcome measure relevance partial compliance blood pressure control secondary outcome measure multicentre nonblinded parallel group randomize design nonacademic primary care practice across canada patients mild essential hypertension diastolic blood pressure mmhg either sex woman age year average year one hundred ninety eight patient randomize active treatment patient discontinue study side effects four week placebo run period patient randomize amlodipine mg day diltiazem slow release formulation sr mg twice daily dos increase mg mg achieve sit diastolic blood pressure mmhg less week active treatment compliance assess pill count medication event monitoring system mem assess percentage prescribed dos take percentage day correct dose take percentage prescribe dos take time blood pressure control determine office blood pressure measurement percentage prescribe dos take either pill count mem show high degree compliance similar two treatment however parameter compliance significantly well versus twice daily therapy partial compliance less pill count lead less blood pressure control short acting diltiazem affect blood pressure control long acting amlodipine side effect profile differ two treatments within constraint clinical trial hypertensive patient primary care show high degree overall compliance twice daily pill taking pattern pill taking erratic twice versus daily medication particularly men result suggest negative consequence partial compliance blood pressure control offset choose agent duration action well beyond dose interval,Leenen FH,1997,Can J Cardiol,,9374947,Leenen FH; Wilson TW; Bolli P; Larochelle P; Myers M; Handa SP; Boileau G; Tanner J,article,"D016430: Clinical Trial; D017427: Clinical Trial, Phase II; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D016454: Review","D000293: Adolescent; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D000959: Antihypertensive Agents; D002170: Canada; D004110: Diltiazem; D004305: Dose-Response Relationship, Drug; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D008991: Monitoring, Physiologic; D010349: Patient Compliance; D011320: Primary Health Care",,,https://openalex.org/W202756716,155,23,1,2160,358,7,en,en
false,efficacy low dose nifedipine git mg patient mild moderate hypertension,nifedipine gastrointestinal therapeutic system git day formulation nifedipine provide stable plasma concentration entire h dose interval antihypertensive efficacy new mg formulation evaluate patient centre across country two week placebo washout mild moderate hypertensive patient randomize double blind parallel design four week placebo nifedipine git mg daily treatment change office blood pressure bp note group ambulatory bp also monitor baseline four week placebo nifedipine therapy subgroup patient five centre four week treatment office bp placebo group decrease mmhg compare mmhg nifedipine git group systolic diastolic bp significantly decrease p p systolic diastolic respectively nifedipine git heart rate significantly differ group baseline four week treatment percentage responder define sit diastolic bp less mmhg decrease baseline mmhg nifedipine git versus placebo p daytime average diastolic blood pressure mmhg nifedipine git mg group compare mmhg placebo group p maximum antihypertensive effect nifedipine ambulatory monitoring similar reduction bp observe office end dosing interval frequency spontaneously report adverse event similar nifedipine git placebo result indicate mg nifedipine git efficacious decrease bp good h control incidence adverse event similar placebo treated patient,Toal CB,1997,Can J Cardiol,,9374948,Toal CB,article,"D016430: Clinical Trial; D017427: Clinical Trial, Phase II; D016428: Journal Article; D016449: Randomized Controlled Trial",D000328: Adult; D000959: Antihypertensive Agents; D004064: Digestive System; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine,,,https://openalex.org/W167095492,94,19,1,1967,356,13,en,en
false,comparative study assess efficacy adverse effect amlodipine nifedipine retard patient stable exertional angina hypertension,purpose study compare antianginal hypotensive efficacy tolerability week treatment amlodipine take daily nifedipine take twice daily patient stable exertional angina pectoris mild moderate hypertension follow week placebo run period patient randomize receive amlodipine mg daily patient receive nifedipine mg twice daily week treatment phase antianginal efficacy assess angina diares investigator patient global evaluation treadmill exercise test placebo run period week therapy amlodipine significantly reduce weekly anginal attack consumption glyceryl trinitrate tablet effect pronounced compare efficacy nifedipine exercise tolerance also improve markedly amlodipine nifedipine treatment amlodipine treatment result significant increase total exercise time increase exercise time angina onset increase time st segment depression decrease st segment depression decrease total duration st segment depression decrease duration pain patient treat nifedipine favourable effect significant decrease total duration st segment depression without significant change examined parameter drug decrease blood pressure significant change heart rate serious adverse event occur patient therapy amlodipine well nifedipine result study demonstrate amlodipine markedly well anti anginal efficacy nifedipine respect parameter examine however drug show comparable antihypertensive action well tolerate angina patient good anti anginal hypotensive efficacy safety amiodipine daily dosage regimen make drug excellent choice treatment hypertensive patient severe coronary artery disease,Witkowska M,1997,Przegl Lek,,9380807,Witkowska M; Tracz W; Kubler G; Negrusz-Kawecka M; Hlawaty M; Olszowska M; Salamon P,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,D000368: Aged; D017311: Amlodipine; D000787: Angina Pectoris; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004334: Drug Administration Schedule; D005080: Exercise Test; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D005996: Nitroglycerin; D014665: Vasodilator Agents,,,https://openalex.org/W2462527674,158,25,1,2102,328,13,en,en
false,reliable unbiased assessment effect calcium antagonist,clinical trial research unit department medicine university auckland new zealand clinical trial service unit epidemiological study unit nuffield department clinical medicine university oxford uk northern medical research foundation royal north shore hospital university sydney australia requests reprint dr stephen macmahon clinical trial research unit department medicine university auckland private bag auckland new zealand receive august accept september,MacMahon S,1997,J Hypertens,https://doi.org/10.1097/00004872-199715110-00002,9383167,MacMahon S; Collins R; Chalmers J,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D002121: Calcium Channel Blockers; D003327: Coronary Disease; D006801: Humans; D006973: Hypertension,,,https://openalex.org/W2314169030,70,10,1,548,91,3,en,en
false,main result losartan versus amlodipine loa study drug tolerability psychological general well,compare two losartan regimen without hydrochlorothiazide amlodipine treat mild moderate hypertension regard blood pressure lowering effect drug tolerability quality life week randomize double blind parallel group multi centre study week placebo patient diastolic blood pressure dbp range mmhg allocate randomly administer mg losartan increase mg dbp mmhg week mg losartan plus mg hydrochlorothiazide condition mg amlodipine increase mg condition tolerability treatment quality life evaluate spontaneous reporting active questioning psychological general well pgwb index total hypertensive mainly refer primary health care mean age year men administration mg losartan plus hydrochlorothiazide necessary mg amlodipine mg necessary lower blood pressure well good mg losartan mg necessary incidence discomfort swollen ankle increase amlodipine losartan treatment opposite find dizziness upon stand incidence drug related adverse event number patient withdraw therapy high amlodipine losartan treatment pgwb index week indicate improvement baseline occur domain losartan group whereas remain unchanged amlodipine group losartan amlodipine effective lower blood pressure tolerate well administration mg losartan plus mg hydrochlorothiazide necessary mg amlodipine mg necessary lower blood pressure equally well good mg losartan mg necessary drug related adverse effect withdrawal study common amlodipine group clinical significance improvement pgwb index losartan need study,Dahlöf B,1997,J Hypertens,https://doi.org/10.1097/00004872-199715110-00018,9383183,Dahlöf B; Lindholm LH; Carney S; Pentikäinen PJ; Ostergren J,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D019808: Losartan; D008297: Male; D008875: Middle Aged; D011788: Quality of Life,,,https://openalex.org/W2027706040,116,18,1,2207,386,10,en,en
false,clinical result verapamil hypertension atherosclerosis study,verapamil hypertension atherosclerosis study vhas prospective randomized study objective compare long term effect verapamil chlorthalidone blood pressure clinical safety progression regression carotid wall lesion member large population hypertensive patients week placebo run period hypertensive patient men woman age year blood pressure mmhg mean sd assign randomly administer either mg sustained release verapamil n mg chlorthalidone n day year study design double blind first month open thereafter mg day captopril add treatment non responding patient subsequently patient respond combine therapy switch therapy choose treating doctor free therapy blood pressure sit subject heart rate standard clinical safety profile electrocardiogram laboratory test adverse event cardiovascular event death assess regularly throughout study year systolic diastolic blood pressure reduce significantly member treatment group verapamil chlorthalidone analysis variance p patient add captopril treatment constitute verapamil chlorthalidone group patient group respectively administer free therapy normalization diastolic blood pressure mmhg mmhg decrease achieve verapamil chlorthalidone group decrease heart rate occur member verapamil group decrease total serum cholesterol mg dl p total cholesterol high density lipoprotein cholesterol ratio p note verapamil group whereas significantly great rate hyperuricemia plasma urate mg dl versus hypokalemia serum k mmol l versus observe chlorthalidone group p versus verapamil adverse event report patient treat verapamil treat chlorthalidone frequent adverse event constipation member verapamil group asthenia member chlorthalidone group total drop verapamil chlorthalidone group occurrence cardiovascular event similar treatment event verapamil chlorthalidone n similar antihypertensive efficacy tolerabilities cardiovascular event rate observe verapamil chlorthalidone however treatment chlorthalidone associate significantly high incidence hyperuricemia hypokalemia treatment verapamil,Rosei EA,1997,J Hypertens,https://doi.org/10.1097/00004872-199715110-00019,9383184,Rosei EA; Dal Palù C; Leonetti G; Magnani B; Pessina A; Zanchetti A,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D001161: Arteriosclerosis; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002752: Chlorthalidone; D004311: Double-Blind Method; D004562: Electrocardiography; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D014700: Verapamil,,,https://openalex.org/W2320639211,75,10,1,3164,579,13,en,en
false,nifedipine gastrointestinal therapeutic system git hypertensive patient primary care setting result extended release adalat canadian trial exact,nifedipine gastrointestinal therapeutic system git extended release dosage formulation provide sustained blood concentration nifedipine hour week postmarketing surveillance study effectiveness patient tolerability nifedipine git mg conduct office canadian general practitioner september march total patient previously newly diagnose mild moderate essential hypertension sit diastolic blood pressure mm hg include week treatment period complete patient patient receive nifedipine git mg initially dose could titrate upward mg week patient enter report one adverse event three frequently occur adverse event headache peripheral edema dizziness frequency adverse event high first week decrease subsequently overall incidence adverse event patient receive mg nifedipine git receive mg adverse event cause study discontinuation patient overall health status patient measure sf questionnaire comparable previously report healthy individual baseline mean se systolic diastolic blood pressure value patient mm hg final blood pressure reading week treatment mg group mm hg mg group mm hg significantly decrease baseline week mg dose sufficient maintain blood pressure patient patient require mg subgroup analysis reveal similar response patient receive blood pressure medication study initiation response also independent age type previous antihypertensive therapy general medical practice mg mg dos nifedipine git effective well tolerate minimal negative effect overall health status treated individual,Toal CB,1997,Clin Ther,https://doi.org/10.1016/s0149-2918(97)80046-x,9385481,Toal CB; Mahon WA; Barnes C; Burelle D,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article,"D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000959: Antihypertensive Agents; D001794: Blood Pressure; D003692: Delayed-Action Preparations; D004487: Edema; D005260: Female; D006261: Headache; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011320: Primary Health Care; D011358: Product Surveillance, Postmarketing",,,https://openalex.org/W1976042053,168,27,1,2274,404,15,en,en
false,comparative antihypertensive effectiveness daily mibefradil diltiazem cd,multicenter double masked randomize forced titration parallel group trial design determine whether could confirm result previous trial demonstrate significantly great antihypertensive effect mibefradil compare diltiazem cd two hundred thirty nine patient uncomplicated mild moderate essential hypertension baseline sit diastolic blood pressure sdbp mm hg randomize receive daily treatment mibefradil mg n diltiazem cd mg n week treatment patient underwent forced titration mibefradil mg diltiazem cd mg additional week week active treatment mean reduction baseline trough sdbp significantly great mibefradil diltiazem cd mm hg v mm hg respectively addition significantly patient receive mibefradil decrease sdbp mm hg decrease mm hg week patient receive diltiazem cd vs respectively tolerability mibefradil diltiazem cd comparable similar percentage patient group report least one adverse event vs respectively consider least remotely relate study drug result study confirm previous trial daily treatment mibefradil mg significantly effective diltiazem cd mg lower diastolic systolic blood pressure drug well tolerate,Bittar N,1997,Clin Ther,https://doi.org/10.1016/s0149-2918(97)80048-3,9385483,Bittar N,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000959: Antihypertensive Agents; D001562: Benzimidazoles; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004110: Diltiazem; D004244: Dizziness; D004311: Double-Blind Method; D004487: Edema; D005260: Female; D006261: Headache; D006801: Humans; D006973: Hypertension; D008297: Male; D020748: Mibefradil; D008875: Middle Aged; D013764: Tetrahydronaphthalenes,,,https://openalex.org/W2088191572,84,9,1,1610,287,9,en,en
false,comparison isradipine enalapril effect regional carotid circulation patient hypertension unilateral internal carotid artery stenosis,randomize double blind placebo controlled study aim detect cerebrovascular effect isradipine enalapril patient moderate hypertension depend presence grade unilateral stenosis internal carotid artery ica evaluate carotid vascular resistance use doppler analysis regional cerebral blood flow rcbf use xe clearance technique single mg oral dose isradipine enalapril placebo effect randomly consecutively test patient essential hypertension subdivide three group without carotid occlusive lesion moderate severe unilateral asymptomatic ica stenosis difference age gender antihypertensive effect drug three subgroup three major variant cerebrovascular drug effect observe absence change variant decrease carotid vascular resistance increase rcbf elimination side side asymmetry variant ii increase carotid vascular resistance reduction rcbf ipsilaterally ica stenosis increase side side asymmetry variant iii frequency variant iii significantly high patient severe ica stenosis enalapril produce variant cerebrovascular effect patient examine variant iii observe patient severe ica stenosis isradipine produce variant cerebrovascular effect much less frequently enalapril drug variant ii typical patient without ica stenosis moderate ica stenosis patient severe ica stenosis however isradipine produce reduction cerebral perfusion presumably presence ica stenosis especially increase risk cerebrovascular disorder antihypertensive therapy patient severe ica stenosis treatment enalapril appear safe isradipine,Akopov SE,1997,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-199711000-00005,9388037,Akopov SE; Simonian NA,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D016893: Carotid Stenosis; D002560: Cerebrovascular Circulation; D004656: Enalapril; D005260: Female; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D008297: Male; D008875: Middle Aged; D011875: Radionuclide Angiography; D018608: Ultrasonography, Doppler; D014655: Vascular Resistance",,,https://openalex.org/W2312556688,157,20,1,2025,334,12,en,en
false,effect long term treatment left ventricular hypertrophy patient essential hypertension relation change neurohumoral factor,study compare effect year monotherapy calcium channel antagonist nilvadipine nil angiotensin converting enzyme ace inhibitor temocapril tem new vasodilator cadralazine cad left ventricular lv hypertrophy essential hypertension furthermore elucidate mechanism responsible regression lv hypertrophy treatment lv mass index lvmi echocardiography plasma renin activity pra aldosterone pac norepinephrine atrial natriuretic peptide anp concentration measure treatment thirty six patient randomly assign nil tem cad group blood pressure bp treatment mm hg mean sd nil tem cad group respectively bp low treatment three test drug placebo period difference bp reduction among three group lvmi nil tem reduce g g p p respectively whereas cad group increase g p cad group pac decrease anp increase significantly change lvmi correlate bp tem anp patient data indicate lv volume overload well lv pressure overload may contribute lv hypertrophy monotherapy cad desirable point view lv mass reduction essential hypertension,Ueno H,1997,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-199711000-00015,9388047,Ueno H; Takata M; Tomita S; Oh-hashi S; Yasumoto K; Inoue H,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000450: Aldosterone; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D009320: Atrial Natriuretic Factor; D002121: Calcium Channel Blockers; D004452: Echocardiography; D005260: Female; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D017379: Hypertrophy, Left Ventricular; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D009638: Norepinephrine; D011724: Pyridazines; D012083: Renin; D013841: Thiazepines; D014665: Vasodilator Agents",,,https://openalex.org/W2333626505,151,21,1,1583,331,9,en,en
false,cardiovascular prognosis relation apolipoproteins lipid parameter patient stable angina pectoris treat verapamil metoprolol,relationship apolipoproteins lipid parameter cardiovascular cv prognosis evaluate angina prognosis study stockholm apsis patient stable angina pectoris lipid variable obtain patient baseline one month double blind treatment metoprolol verapamil evaluate treatment effect lipid variable median follow time year patient year patient suffer cv death suffer non fatal myocardial infarction mi underwent revascularization apolipoprotein apo high density lipoprotein cholesterol triglyceride predictor cv death non fatal mi univariate analysis apo remain independent predictor multivariate analysis lipid variable except low density lipoprotein cholesterol relate risk revascularization univariate analysis apo apo b independent predictor event triglyceride weakly independently associate prognosis verapamil metoprolol differential short term effect lipid shift towards atherogenic profile metoprolol treat patient however significant impact treatment give treatment effect risk cv event result present study suggest apolipoprotein level good predictor cv event lipid parameter patient stable angina pectoris,Held C,1997,Atherosclerosis,https://doi.org/10.1016/s0021-9150(97)00147-0,9395279,Held C; Hjemdahl P; Rehnqvist N; Björkander I; Forslund L; Brodin U; Berglund L; Angelin B,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000787: Angina Pectoris; D001053: Apolipoproteins; D002319: Cardiovascular System; D002784: Cholesterol; D008076: Cholesterol, HDL; D008078: Cholesterol, LDL; D004311: Double-Blind Method; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008055: Lipids; D008297: Male; D008790: Metoprolol; D008875: Middle Aged; D011379: Prognosis; D016016: Proportional Hazards Models; D011446: Prospective Studies; D018570: Risk Assessment; D013548: Sweden; D013997: Time Factors; D016896: Treatment Outcome; D014700: Verapamil",,,https://openalex.org/W74165581,159,21,1,1545,256,9,en,en
false,correspondence,,Lewan RB,1997,Obstet Gynecol,https://doi.org/10.1016/s0029-7844(97)00574-7,9397125,Lewan RB; Flynn CA,article,D016422: Letter; D016420: Comment,"D015982: Bias; D005260: Female; D006801: Humans; D009543: Nifedipine; D007752: Obstetric Labor, Premature; D011247: Pregnancy; D012107: Research Design; D012312: Ritodrine; D015149: Tocolytic Agents",,,https://openalex.org/W2495182794,14,1,1,0,0,0,en,
false,comparison amlodipine long acting diltiazem treatment mild moderate hypertension,comparative effect day calcium channel antagonists amlodipine long acting diltiazem assess parallel design investigator blinded multicenter trial patient diastolic blood pressure range mm hg treatment patient randomize one two drug titrate week interval mg amlodipine mg long acting diltiazem week treatment period drug significantly reduce resting sit stand h ambulatory systolic diastolic pressure amlodipine cause significantly great reduction sit stand systolic pressure stand diastolic pressure h ambulatory systolic diastolic pressure versus diltiazem sit systolic pressure reduce se baseline mm hg amlodipine treatment mm hg diltiazem sit diastolic pressure reduce mm hg amlodipine mm hg diltiazem reduction stand systolic pressure treatment mm hg amlodipine v mm hg diltiazem p reduction stand diastolic pressure mm hg amlodipine v mm hg diltiazem p heart rate change significantly either drug study two subject group drop adverse experience although agent well tolerate reduce blood pressure consistently week test period amlodipine effective diltiazem reduce systolic diastolic blood pressure target pressure mm hg systolic mm hg diastolic range dos widely use clinical practice,Horwitz LD,1997,Am J Hypertens,https://doi.org/10.1016/s0895-7061(97)00264-1,9397246,Horwitz LD; Weinberger HD; Clegg L,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D004110: Diltiazem; D004311: Double-Blind Method; D004562: Electrocardiography; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D010349: Patient Compliance; D010352: Patient Dropouts",,,https://openalex.org/W2021839082,100,14,1,1871,328,10,en,en
false,equivalent reduction proteinuria hypertensive either nifedipine git enalapril disparate effect neurohormone ambulatory blood pressure influence salt,objective compare efficacy two class antihypertensive therapy ambulatory blood pressure control proteinuria patient hypertension furthermore determine effect interaction therapy neurohormonal activation patient ambient sodium intake outcome method sustained release nifedipine nifedipine gastrointestinal therapeutic system git mg day compare double blind sequential randomize placebo controlled trial enalapril mg day regard office hour blood pressure control plasma renin activity noradrenaline adrenaline level hour urinary protein sodium elderly nondiabetic hypertensive patient week trial result nifedipine git enalapril control ambulatory blood pressure day peak effect nifedipine git control ambulatory blood pressure early morning surge night time well nifedipine git increase plasma renin activity noradrenaline respectively compare change produce enalapril nifedipine git enalapril reduce proteinuria patient increase level proteinuria proportional high ambient sodium intake r p effect accentuate nifedipine git therapy compare enalapril conclusion nifedipine git superior enalapril control ambulatory blood pressure equivalent reduce proteinuria disparate effect neural activation duration action raise protein excretion appear associate raised sodium intake apparent especially nifedipine xl therapy,DeQuattro V,1997,Cardiology,https://doi.org/10.1159/000177505,9397292,DeQuattro V; Lee DP,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D002395: Catecholamines; D003404: Creatinine; D004311: Double-Blind Method; D004656: Enalapril; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D009543: Nifedipine; D011507: Proteinuria; D012083: Renin; D012964: Sodium; D017673: Sodium Chloride, Dietary",,,https://openalex.org/W2044517793,183,26,1,1769,284,13,en,en
false,effect amlodipine patient chronic heart failure,role calcium antagonist patient ischemic heart failure currently unclear examine effect amlodipine exercise capacity central regional hemodynamics patient mild moderate chronic heart failure single center double blind randomized placebo controlled trial take least mg furosemide daily angiotensin converting enzyme inhibitor ischemic heart disease common cause heart failure patient symptom limiting angina mean treadmill exercise capacity patient take amlodipine increase second confidence interval second placebo group mean difference change treatment second p active treatment amlodipine affect self paced corridor walk time similarly significant effect cardiac output oxygen uptake heart rate mean arterial pressure rest exercise calf renal blood flow also unchanged treatment lack significant effect demonstrate data suggest limited role amlodipine patient ischemic cardiomyopathy although may prove beneficial nonischemic disease data require amlodipine recommend patient chronic heart failure,Walsh JT,1997,Am Heart J,https://doi.org/10.1016/s0002-8703(97)80010-5,9398099,Walsh JT; Andrews R; Curtis S; Evans A; Cowley AJ,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D017311: Amlodipine; D002121: Calcium Channel Blockers; D002908: Chronic Disease; D004311: Double-Blind Method; D005080: Exercise Test; D017079: Exercise Tolerance; D005260: Female; D006333: Heart Failure; D006439: Hemodynamics; D006801: Humans; D008297: Male; D008875: Middle Aged; D010101: Oxygen Consumption; D011446: Prospective Studies; D016896: Treatment Outcome,,,https://openalex.org/W2104431749,60,9,1,1388,234,10,en,en
false,systematic review meta analysis incidence cancer randomize control trial verapamil,conduct systematic review publish randomize control trial assess risk cancer death patient receive verapamil hypertension angina pectoris cardiac arrhythmia meta analysis compare risk new cancer cancer death death perform thirty nine trial comprise patient eligible study duration range days year mean wks nine trial patient week duration long cancer cancer death ci verapamil versus active control ci verapamil versus placebo death ci verapamil versus active control ci verapamil versus placebo sensitivity analysis trial week duration long give similar result statistically significant increase risk cancer death verapamil compare active control placebo,Dong EW,1997,Pharmacotherapy,,9399603,Dong EW; Connelly JE; Borden SP; Yorzyk W; Passov DG; Kupelnick B; Luo D; Ross SD,article,"D016428: Journal Article; D017418: Meta-Analysis; D013485: Research Support, Non-U.S. Gov't; D000078182: Systematic Review",D002121: Calcium Channel Blockers; D006801: Humans; D009369: Neoplasms; D016032: Randomized Controlled Trials as Topic; D014700: Verapamil,,,https://openalex.org/W1487407525,110,17,1,1012,190,9,en,en
false,comparison intravenous diltiazem verapamil acute treatment atrial fibrillation atrial flutter,study objective compare efficacy safety intravenous diltiazem verapamil control ventricular rate patient atrial fibrillation flutter evaluate effect agent left ventricular systolic function design prospective randomize double blind crossover study set university affiliated hospital veteran administration hospital patient seventeen men atrial fibrillation flutter ventricular rate beats minute high systolic blood pressure mm hg great intervention patient receive two intravenous bolus either diltiazem verapamil follow hour continuous infusion therapeutic response achieve phase washout period patient respond cross receive drug similar fashion phase ii measurement main result end infusion patient ejection fraction assess gated angiography men initially randomize successfully complete phase ii patient baseline mean sd ventricular rate treatment intravenous diltiazem verapamil beats minute respectively ns minute initial bolus dose mean ventricular rate decrease beats minute diltiazem group compare beats minute receive verapamil p mean ventricular rate beats minute maintain hour continuous infusion diltiazem verapamil respectively ns completion bolus dose continuous infusion significant difference blood pressure group mean ejection fraction diltiazem verapamil group respectively ns patient mean maximum percentage decrease blood pressure significantly different group however three patient develop symptomatic hypotension randomize receive verapamil initially conclusion intravenous diltiazem verapamil comparable term efficacy effect systolic function patient rapid atrial fibrillation flutter however hypotension may limit therapy verapamil patient,Phillips BG,1997,Pharmacotherapy,,9399606,Phillips BG; Gandhi AJ; Sanoski CA; Just VL; Bauman JL,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D001281: Atrial Fibrillation; D001282: Atrial Flutter; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D004110: Diltiazem; D004311: Double-Blind Method; D004562: Electrocardiography; D006439: Hemodynamics; D006801: Humans; D007275: Injections, Intravenous; D008297: Male; D011446: Prospective Studies; D016277: Ventricular Function, Left; D014700: Verapamil",,,https://openalex.org/W1622359208,115,16,1,2385,416,24,en,en
false,long acting diltiazem cd safe effective hypertensive mexican american population,evaluate safety effectiveness diltiazem cd reduce blood pressure mexican american patient mild moderate hypertension randomized double blind placebo controlled trial twelve clinical site united states patients baseline diastolic blood pressure mm hg patients treat average daily dose diltiazem cd mg patient placebo patient achieve trough diastolic blood pressure mm hg diltiazem cd significantly reduce mean diastolic blood pressure compare placebo versus mm hg respectively p diastolic blood pressure mm hg reduction mm hg achieve diltiazem cd versus placebo recipient systolic blood pressure heart rate also reduce diltiazem cd adverse event mild similar frequency diltiazem cd placebo diltiazem cd safe effective hypertensive mexican american diastolic blood pressure reduction compare non hispanic white patient,Herrera CR,1997,Pharmacotherapy,,9399608,Herrera CR; Lewin A; Fiddes R; Friedman J; Linn W; Baker T; Balanoff D; Beach CL,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D004110: Diltiazem; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D008297: Male; D017058: Mexican Americans; D008875: Middle Aged,,,https://openalex.org/W2140991504,92,12,1,1096,186,4,en,en
false,prognostic significance myocardial ischemia detect ambulatory electrocardiography exercise treadmill test electrocardiogram rest predict cardiac event one year asymptomatic cardiac ischemia pilot acip study,myocardial ischemia identify ambulatory electrocardiography aecg exercise treadmill test ett lead electrocardiogram rest associate adverse prognosis effect improve ischemic manifestation treatment outcome unknown asymptomatic cardiac ischemia pilot acip study national heart lung blood institute fund study determine feasibility conduct large scale prognosis study assess effect treatment strategy angina guided strategy aecg ischemia guided strategy revascularization strategy reduce manifestation ischemia indicate aecg ett study cohort database study consist randomized patient perform aecg ett lead electrocardiogram rest qualifying week visit effect modify ischemia treatment incidence cardiac event death myocardial infarction coronary revascularization procedure hospitalization ischemic event year examine medical treatment group n association number ambulatory electrocardiographic ischemic episode qualify visit combined cardiac event year p aecg ischemia guided patient trend associate great reduction number ambulatory electrocardiographic ischemia episode reduced incidence combined cardiac event r p revascularization strategy patient association absent medical treatment patient exercise duration baseline ett inversely associate adverse prognosis p medical treatment strategy slightly improve exercise time exercise duration remain prognostic significance revascularization group strategy patient association absent thus myocardial ischemia detect aecg abnormal ett independently associate adverse cardiac outcome patient subsequently treat medically,Stone PH,1997,Am J Cardiol,https://doi.org/10.1016/s0002-9149(97)00706-6,9399710,Stone PH; Chaitman BR; Forman S; Andrews TC; Bittner V; Bourassa MG; Davies RF; Deanfield JE; Frishman W; Goldberg AD; MacCallum G; Ouyang P; Pepine CJ; Pratt CM; Sharaf B; Steingart R; Knatterud GL; Sopko G; Conti CR,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D004562: Electrocardiography; D015716: Electrocardiography, Ambulatory; D005080: Exercise Test; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008297: Male; D008875: Middle Aged; D015999: Multivariate Analysis; D017202: Myocardial Ischemia; D009204: Myocardial Revascularization; D010865: Pilot Projects; D011237: Predictive Value of Tests; D011379: Prognosis; D012146: Rest; D014665: Vasodilator Agents",,,https://openalex.org/W2113492921,241,36,1,2126,348,11,en,en
false,addition felodipine metoprolol vs replacement metoprolol felodipine patient angina pectoris despite adequate beta blockade result felodipine er metoprolol cr angina femina study,study aim compare addition felodipine metoprolol replacement metoprolol felodipine continuation metoprolol patient angina pectoris despite optimal beta blockade study double blind parallel randomized control comprise patient outpatient cardiology clinic netherlands patient angina positive bicycle exercise test despite optimal beta blockade rest heart rate beats min randomization three treatment group continuation metoprolol control addition felodipine metoprolol replacement metoprolol felodipine exercise test repeat week main outcome measure exercise result week compare baseline group comparison change vs control significant difference exercise duration onset chest pain v control addition felodipine increase time mm st depression confidence interval decrease st depression high comparable work load mm confidence interval maximal st depression mm confidence interval exercise result replacement metoprolol felodipine different control apart significant increase rate pressure product significantly patient experienced adverse event felodipine monotherapy group combination metoprolol felodipine prefer felodipine monotherapy patient sign symptom myocardial ischaemia despite optimal beta blockade,Dunselman P,1997,Eur Heart J,https://doi.org/10.1093/oxfordjournals.eurheartj.a015170,9402450,Dunselman P; Liem AH; Verdel G; Kragten H; Bosma A; Bernink P,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D004562: Electrocardiography; D005080: Exercise Test; D015736: Felodipine; D005260: Female; D006801: Humans; D008297: Male; D008790: Metoprolol; D008875: Middle Aged",,,https://openalex.org/W2331704258,216,34,1,1658,273,9,en,en
false,twenty four hour blood pressure monitor treatment extended release felodipine versus slow release nifedipine elderly patient mild moderate hypertension randomized double blind cross study,objective double blind placebo controlled randomize study design compare antihypertensive effect tolerability extended release felodipine slow release nifedipine retard elderly hypertensive patient method thirty patient sex mean age year mild moderate essential hypertension recruit hypertension outpatient clinic week placebo period felodipine extended release felodipine er mg daily nifedipine slow release retard nifedipine sr mg twice daily placebo administer patient week accord x latin square design end treatment period patient underwent h noninvasive blood pressure monitoring result patient complete trial serious adverse experience report comparison placebo felodipine nifedipine decrease mean h diastolic blood pressure mmhg respectively significant difference two drug mean h systolic blood pressure also decrease felodipine nifedipine difference two drug drug reduce blood pressure variability lower h mean standard deviation mean hourly blood pressure value trough peak ratio felodipine systolic diastolic blood pressure conclusion felodipine er daily lower blood pressure elderly hypertensive effective nifedipine sr twice daily high trough peak ratio suggest dose dose interval felodipine provide adequate therapeutic coverage,Bonaduce D,1997,Eur J Clin Pharmacol,https://doi.org/10.1007/s002280050344,9403278,Bonaduce D; Canonico V; Petretta M; Forgione L; Ianniciello A; Cavallaro V; Bertocchi F; Rengo F,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D009543: Nifedipine",,,https://openalex.org/W2047126149,224,28,1,1660,273,11,en,en
false,drug induced chest pain myocardial infarction report national centre review literature,objective analyse report drug induced myocardial infarction chest pain send national reporting centre review drug suspect exhibit adverse event mechanism involve method year period total report adverse reaction drug receive netherlands centre monitoring adverse reaction drug report concern drug induced chest pain myocardial infarction exclude report causal relationship unlikely poorly document report report case overdosage report analyse result report drug induced chest pain report drug induced myocardial infarction total report concerned female frequently report suspect drug antimigraine drug sumatriptan report concern myocardial infarction calcium antagonist nifedipin report myocardial infarction nicotine report patch chew gum concern myocardial infarction report fatal outcome conclusion several drug produce chest pain myocardial ischaemia important recognise drug potential cause especially patient normal coronary artery,Ottervanger JP,1997,Eur J Clin Pharmacol,https://doi.org/10.1007/s002280050346,9403280,Ottervanger JP; Wilson JH; Stricker BH,article,D016428: Journal Article; D016454: Review,D016907: Adverse Drug Reaction Reporting Systems; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D005260: Female; D006801: Humans; D008297: Male; D009203: Myocardial Infarction; D009426: Netherlands; D009543: Nifedipine; D018170: Sumatriptan; D014662: Vasoconstrictor Agents,,,https://openalex.org/W1985212398,108,17,2,1392,254,11,en,en
false,combination treatment trimetazidine diltiazem stable angina pectoris,summary fear learning defensive behavior need finely balance allow animal return normal behavior termination threat indicating sensory cue nevertheless circuit underlie balancing largely unknown investigate role direct r indirect adora pathway neuron amygdala striatal transition zone astria fear learning vivo ca image reveal fear learning increase response r astria neuron auditory c give animal move adora neuron fear learning also induce differential activity freezing movement albeit little influence c vivo optogenetic silencing training day show plasticity r astria neuron contribute auditory cued fear memory whereas adora neuron suppress learn freeze c present circuit trace experiment identify cortical input structure astria recording optogenetically evoked epscs corresponding projection reveal different form long term plasticity synapsis onto r adora astria neuron take together direct indirect pathway neuron astria show differential sign vivo ex vivo plasticity fear learning balance defensive behavior presence absence aversively motivated sensory cue,Manchanda SC,1997,Heart,https://doi.org/10.1136/hrt.78.4.353,9404250,Manchanda SC; Krishnaswami S,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D004110: Diltiazem; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004562: Electrocardiography; D005080: Exercise Test; D006801: Humans; D008297: Male; D008875: Middle Aged; D014292: Trimetazidine; D014665: Vasodilator Agents",,,https://openalex.org/W2101685570,80,10,1,1462,262,8,en,en
false,long term clinical tolerance antihypertensive treatment hot study groupe fran ais de l etude hot,objective hot study international prospective randomised study determine optimal level blood pressure treatment link low cardiovascular mortality morbidity target diastolic blood pressure mmhg determine randomisation order reach target blood pressure strategy treatment determine st step felodipine long acting dihydropyridine next step blood pressure reduction enough propose addition different therapeutic class increase drug dose available data year patient follow allow u evaluate incidence reported side effect accord target blood pressure assign randomisation number hypertension drug use reach target percentage patient least one side effect month follow respectively target group dbp mmhg versus target group dbp mmhg versus target group dbp mmhg versus overall tolerability influence target diastolic blood pressure depend number hypertension drug use month patient monotherapy bitherapy tritherapy incidence side effect decrease st year slow third month first year influence region incidence side effect south european country describe side effect france north european country seem link perception side effect high rate conclusion result confirm possibility reach targeted blood pressure use predetermined strategy without increase dramatically incidence side effect,Mallion JM,1997,Arch Mal Coeur Vaiss,,9404429,Mallion JM; Dahan R; Boutelant S; Benkritly A; Baguet JP; Noir-Clerc M,article,D016430: Clinical Trial; D004740: English Abstract; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000959: Antihypertensive Agents; D001241: Aspirin; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002318: Cardiovascular Diseases; D004359: Drug Therapy, Combination; D004361: Drug Tolerance; D005060: Europe; D015736: Felodipine; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006973: Hypertension; D008297: Male; D011446: Prospective Studies",,,https://openalex.org/W2409551335,114,19,2,1970,370,11,fr,en
true,risk serious adverse event hypertensive patient receive isradipine meta analysis,meta analysis perform compare risk serious adverse event associate use formulation isradipine use monotherapy hypertension active drug placebo control eligible study total publish unpublished randomise controlled trial involve subject treatment exposure isradipine isradipine sustained release active drug placebo mortality cardiovascular outcome serious incident illness cancer withdrawal seek seventy five per cent isradipine exposure standard release formulation sustained release formulation overall isradipine therapy show difference risk major adverse event withdrawal compare active control placebo odds ratio ci ci major adverse event include angina fatal non fatal myocardial infarction stroke overall mortality isradipine sustain release could compare placebo base available data show low risk withdrawal ci similar trend observe major adverse event ci publish unpublished randomise controlled trial analyse separate meta analyses later combine sensitivity analysis risk show difference group conclusion find evidence increase risk serious adverse event patient receive isradipine monotherapy hypertension,Ross SD,1997,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1000532,9416985,Ross SD; Kupelnick B; Kumashiro M; Arellano FM; Mohanty N; Allen IE,article,D016428: Journal Article; D017418: Meta-Analysis,D000959: Antihypertensive Agents; D005260: Female; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D008297: Male; D008875: Middle Aged; D016032: Randomized Controlled Trials as Topic; D012307: Risk Factors; D012680: Sensitivity and Specificity,,,https://openalex.org/W2082043920,93,13,1,1611,277,9,en,en
false,relationship change left ventricular mass clinic ambulatory blood pressure response antihypertensive therapy,analyse relationship change left ventricular mass response month antihypertensive therapy change conventional automated measurement clinic blood pressure average h ambulatory blood pressure daytime night time blood pressures placebo run period patient essential hypertension world health organization stag ii treat month one combination two first line antihypertensive drugs investigations include echocardiography conventional automate clinic blood pressure measurement ambulatory blood pressure monitoring daytime night time blood pressure assess accord two clock time dependent two clock time independent method wide narrow approach technique fifty four patient complete month treatment period leave ventricular mass adjust sex body size correlate significantly systolic diastolic clinic blood pressure r r p antihypertensive therapy r p r p change left ventricular mass significantly relate change blood pressure correlation coefficient amount p p conventional automated measurement clinic systolic blood pressure respectively p average h systolic blood pressure r value n n p respectively diastolic blood pressure average h blood pressure add p p variance change mass explain term conventional automated measurement clinic systolic blood pressure respectively p p diastolic blood pressure change daytime night time blood pressure predict change left ventricular mass significantly p similar extent irrespective analytical method treatment induced change left ventricular mass significantly relate change clinic h daytime night time blood pressure change h ambulatory blood pressure add variance change left ventricular mass explain term clinic blood pressure data,Fagard RH,1997,J Hypertens,https://doi.org/10.1097/00004872-199715120-00018,9431857,Fagard RH; Staessen JA; Thijs L,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000959: Antihypertensive Agents; D001794: Blood Pressure; D001795: Blood Pressure Determination; D004452: Echocardiography; D006321: Heart; D006352: Heart Ventricles; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D017706: Lisinopril; D008875: Middle Aged; D018670: Monitoring, Ambulatory; D009819: Office Visits",,,https://openalex.org/W2007247821,138,19,1,2388,425,7,en,en
false,comparison treatment supraventricular tachycardia valsalva maneuver carotid sinus massage,abstract study objective compare efficacy valsalva maneuver carotid sinus massage csm terminate paroxysmal supraventricular tachycardia svt ed method prospective randomized case study perform ed tertiary care institution patient least year age regular narrow complex tachycardia ecg diagnosis svt patient regular narrow complex tachycardia randomly assign undergo either valsalva maneuver csm tachycardia terminate method choose randomization alternative method vagal maneuver use tachycardia convert method vagal stimulation patient would undergo either synchronized electrical cardioversion pharmacologic method conversion discretion treating physician depend patient hemodynamic status result one hundred forty eight instance svt study sixty two patient underwent valsalva maneuver first conversion success rate eighty six underwent csm first conversion success rate carotid sinus massage use case svt conversion achieve valsalva maneuver conversion occur case success rate case svt initial csm achieve conversion conversion occur valsalva maneuver success rate valsalva maneuver csm achieve conversion total instance svt success rate conclusion vagal maneuver efficacious terminate one quarter spontaneous svt case detectable difference efficacy valsalva maneuver csm lim sh anantharaman v teo w goh pp tan ath comparison treatment supraventricular tachycardia valsalva maneuver carotid sinus massage ann emerg med january,Lim SH,1998,Ann Emerg Med,https://doi.org/10.1016/s0196-0644(98)70277-x,9437338,Lim SH; Anantharaman V; Teo WS; Goh PP; Tan AT,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D002346: Carotid Sinus; D004554: Electric Countershock; D004562: Electrocardiography; D004638: Emergency Treatment; D005260: Female; D006801: Humans; D008297: Male; D008405: Massage; D008875: Middle Aged; D011446: Prospective Studies; D013617: Tachycardia, Supraventricular; D014636: Valsalva Maneuver",,,https://openalex.org/W2067245155,102,13,1,2020,391,17,en,en
false,malignant hypertension hypertensive emergency,hypertensive emergency urgency important cause morbidity mortality malignant hypertension hypertensive urgency characterize grade iii iv retinopathy widespread endothelial damage control bp essential treatment disorder effect hypertension target organ function need balance risk excessive bp lower hypertensive emergency bp lower within minute parenteral agent prevent critical end organ damage hypertensive urgency bp lower slowly several hour often oral agent avoid detrimental fall bp absolute indication treatment optimal therapy depend underlying condition,Kitiyakara C,1998,J Am Soc Nephrol,https://doi.org/10.1681/asn.v91133,9440098,Kitiyakara C; Guzman NJ,article,D016428: Journal Article; D016454: Review,"D001794: Blood Pressure; D004630: Emergencies; D006801: Humans; D006974: Hypertension, Malignant",,,https://openalex.org/W2100731991,52,6,1,755,121,7,en,en
false,comparative efficacy tolerability two long acting calcium antagonist mibefradil amlodipine essential hypertension,previous forced titration trial mibefradil mg qd effective amlodipine mg qd reduce sit diastolic blood pressure sdbp produce significantly less leg edema amlodipine mg qd present multicenter double masked randomize parallel design trial perform assess reproducibility result use flexible titration design follow week single masked placebo run period patient trough sdbp mm hg hour postdose randomize receive daily treatment mibefradil mg n amlodipine mg n patient whose trough sdbp great mm hg week double masked therapy dosage titrate upward mibefradil mg amlodipine mg remainder week active treatment period great proportion amlodipine treated patient mibefradil treated patient require titration high dose despite difference statistically equivalent reduction trough sdbp observe week treatment mg mibefradil qd mm hg mg amlodipine qd mm hg sdbp normalize mm hg week patient treat mibefradil receive amlodipine tolerability profile mibefradil superior amlodipine significantly patient p reporting leg edema mibefradil treatment amlodipine treatment result study confirm previous trial daily treatment mibefradil mg week effective week daily treatment amlodipine mg reduce sdbp associate significantly low incidence leg edema,Karch FE,1997,Clin Ther,https://doi.org/10.1016/s0149-2918(97)80011-2,9444446,Karch FE; Pordy R; Benz JR; Carr A; Lunde NM; Marbury T; Tarro JN,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D017311: Amlodipine; D000959: Antihypertensive Agents; D001562: Benzimidazoles; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D020748: Mibefradil; D008875: Middle Aged; D013764: Tetrahydronaphthalenes; D013997: Time Factors,,,https://openalex.org/W2037799667,130,17,1,1887,359,10,en,en
false,der einflu von diltiazem auf die konzentration von cyclosporin metaboliten bei mit sandimmun und neoral behandelten nierentransplantierten patienten,background diltiazem reduce cyclosporine dose require blood level therapeutic target range effect diltiazem pharmacokinetic disposition cyclosporine oral neoral application unknown unclear whether diltiazem cyclosporine interaction affect galenic cyclosporine formulation patient method fifty one stable renal allograft patient female male enrol prospective randomized double blind study patient assign treatment group diltiazem n nifedipine ii n without calcium channel blocker iii n nine patient group receive sandimmun patient neoral blood concentration cyclosporine metabolite measure use hplc week treatment group different respect age gender distribution serum creatinine concentration cyclosporine dos adjust basis blood level result cyclosporine dose require achieve target blood level significantly low group compare group ii group iii p although cyclosporine blood concentration group therapeutic range blood level group show much low variability blood concentration metabolite group significantly high group ii iii dose correction p significantly low group group ii iii p average dose blood concentration cyclosporine different patient receive neoral compare receive sandimmun within group patient group blood concentration metabolite significantly high sandimmun application neoral difference metabolite concentration detect within group compare patient take sandimmun neoral incidence acute rejection low group group ii iii conclusion diltiazem significantly reduce necessary dose cyclosporine compare group ii iii blood concentration stable patient group diltiazem increase blood concentration patient treat sandimmun large extent patient take neoral additional pharmacokinetic difference cyclosporine application different sandimmun neoral find,Sperschneider H,1997,Med Klin (Munich),https://doi.org/10.1007/bf03044784,9446006,Sperschneider H; Wagner C; Korn A; Christians U,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D001711: Biotransformation; D002121: Calcium Channel Blockers; D016572: Cyclosporine; D004110: Diltiazem; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D007166: Immunosuppressive Agents; D016030: Kidney Transplantation; D008297: Male; D008657: Metabolic Clearance Rate; D008875: Middle Aged; D009543: Nifedipine; D011446: Prospective Studies; D013329: Structure-Activity Relationship",,,https://openalex.org/W11933480,151,17,1,2609,465,18,de,en
false,nifedipine retard versus nifedipine capsules therapy hypertensive crisis black patient,randomized parallel group placebo controlled study compare short term hypotensive efficacy safety single administration nifedipine retard mg tablet two administration h apart nifedipine capsule mg black patient respectively acute severe hypertension group similar pretreatment blood pressure bp value blood pressure record min interval h use automated device first h treatment nifedipine capsule induce faster great hypotensive effect nifedipine retard associate increase heart rate h treatment nifedipine capsule decrease bp level mm hg significantly low reach nifedipine retard mm hg p preparation induce similar maximal bp decrease placebo value peak decrease bp occur significantly later nifedipine retard min administration nifedipine capsule min p four hour administration hypotensive effect nifedipine capsule blunt second administration necessary whereas nifedipine retard reduce bp slowly continuously h smoothly flush headache frequently find nifedipine capsule conclude black patient hypertensive crisis nifedipine capsule produce abrupt decrease bp may potentially harmful thus patient suitable treatment nifedipine nifedipine retard preferable effectively reduce bp h achieve rapid enough effect without critical short term decrease bp,Damasceno A,1998,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-199801000-00022,9456291,Damasceno A; Sevene E; Patel S; Polónia J,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000328: Adult; D044383: Black People; D001794: Blood Pressure; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D009543: Nifedipine; D014665: Vasodilator Agents",,,https://openalex.org/W1969045591,101,12,1,1776,310,10,en,en
false,calcium antagonist cancer,recent publication raise concern possible link calcium antagonist therapy development cancer comparison methodology result study study association calcium antagonist therapy cancer apparent suggest association likely due selection bias chance clinical biochemical study produce consistent plausible mechanism causative link calcium antagonist development cancer far prospective data available long term morbidity mortality trial use calcium antagonist cardiovascular disease value establish safety drug,Howes LG,1998,Drug Saf,https://doi.org/10.2165/00002018-199818010-00001,9466084,Howes LG; Edwards CT,article,D016428: Journal Article; D016454: Review,"D000818: Animals; D002121: Calcium Channel Blockers; D006801: Humans; D009369: Neoplasms; D009374: Neoplasms, Experimental",,,https://openalex.org/W2083815538,30,4,1,759,118,4,en,en
false,pro haemorrhagic effect calcium antagonist comparison isradipine atenolol ex vivo platelet function hypertensive subject,suggest long term treatment calcium antagonist drug might inhibit platelet function lead anti atheromatous effect however recent data also suggest effect might increase mortality due increase incidence gastrointestinal bleeding identify subject general practice uncomplicated mild moderate hypertension compare effect calcium antagonist isradipine beta blocker atenolol platelet function plasma beta thromboglobulin level fibrinolysis serum lipid randomised double blind parallel group study careful evaluation exclude concomitant aspirin use subject eligible enter study isradipine atenolol produce comparable clinically significant fall blood pressure mm hg mm hg respectively neither drug produce detectable effect ex vivo platelet aggregation platelet retention thromboxane generation adrenaline collagen adenosine di phosphate platelet activate factor however decrease plasma beta thromboglobulin level observe reach statistical significance p week treatment isradipine atenolol group reduction isradipine compare follow atenolol treatment euglobulin clot lysis time alter either drug serum cholesterol concentration also unaltered drug treatment therapeutic dos calcium antagonist isradipine may produce minor indirect effect platelet function several week treatment however doubtful clinical importance may simply reflect effect lowered blood pressure platelet function,Smith A,1997,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1000449,9468004,Smith A; McPherson J; Taylor M; Mason A; Carney S; Gillies A,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000319: Adrenergic beta-Antagonists; D000328: Adult; D001262: Atenolol; D001792: Blood Platelets; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D005260: Female; D006470: Hemorrhage; D006801: Humans; D006973: Hypertension; D017275: Isradipine; D008297: Male; D008875: Middle Aged; D001620: beta-Thromboglobulin,,,https://openalex.org/W1988632908,142,20,1,1842,299,11,en,en
false,reduction left ventricular mass antihypertensive treatment improve exercise performance essential hypertension,test hypothesis reduction left ventricular mass long term antihypertensive treatment possibly associate improvement diastolic function would increase exercise performance patient essential hypertension design placebo run period patient essential hypertension world health organization stage ii assign randomly month double blind treatment either diuretic hydrochlorothiazide plus triamterene converting enzyme inhibitor trandolapril calcium antagonist amlodipine could add month require good blood pressure control investigations include clinic ambulatory blood pressure measurement leave ventricular imaging transmitral doppler echocardiography grade maximal exercise test bicycle ergometer respiratory gas analysis six month antihypertensive therapy cause significant p reduction blood pressure clinic pressure left ventricular mass without convince evidence improved diastolic function affect exercise performance peak oxygen uptake influence clinic exercise ambulatory blood pressure peak oxygen uptake similar two treatment arm leave ventricular wall thickness decrease great extent trandolapril group p month p month regression left ventricular mass cause month antihypertensive therapy improve exercise performance patient essential hypertension,Fagard RH,1997,J Hypertens,https://doi.org/10.1097/00004872-199715030-00013,9468459,Fagard RH; Lijnen PJ,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000959: Antihypertensive Agents; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D003971: Diastole; D004311: Double-Blind Method; D004452: Echocardiography; D005080: Exercise Test; D005260: Female; D006321: Heart; D006352: Heart Ventricles; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D005082: Physical Exertion",,,https://openalex.org/W2329322180,128,16,1,1607,251,3,en,en
false,effect calcium antagonist risk coronary heart disease cancer bleeding ad hoc subcommittee liaison committee world health organisation international society hypertension,,,1997,J Hypertens,,9469785,,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D002121: Calcium Channel Blockers; D016022: Case-Control Studies; D003327: Coronary Disease; D006470: Hemorrhage; D006801: Humans; D009369: Neoplasms; D016032: Randomized Controlled Trials as Topic; D012306: Risk,,,,216,35,2,0,0,0,en,
false,treatment diastolic dysfunction hypertensive patient without left ventricular hypertrophy,aim study evaluate influence verapamil sr mg v combination amiloride mg hydrochlorothiazide mg ah diastolic dysfunction hypertensive patient without left ventricular hypertrophy lvh twenty six hypertensive patient diastolic dysfunction normal systolic function without lvh include week washout period randomise month v ah treatment one blinded treatment echocardiographist baseline week assessed doppler echocardiography v ah satisfactorily control blood pressure v improved diastolic function show tendency reduce peak increase peak e ratio significant reduction deceleration time week v significantly reduce wall thickness comparison ah result need confirm large scale study,Molinero E,1998,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1000544,9482129,Molinero E; Murga N; Sagastagoitia JD; Fernández R; Garrido J,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000584: Amiloride; D000889: Anti-Arrhythmia Agents; D000959: Antihypertensive Agents; D004232: Diuretics; D004359: Drug Therapy, Combination; D015150: Echocardiography, Doppler; D005260: Female; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D018754: Ventricular Dysfunction; D014700: Verapamil",,,https://openalex.org/W1966714209,96,11,1,910,158,6,en,en
false,antianginal efficacy hour exercise hemodynamic effect daily sustained release mg diltiazem mg verapamil stable angina pectoris,antianginal efficacy mg sustain release verapamil daily dos mg diltiazem study normotensive patient chronic stable angina pectoris use randomize double blind crossover design patient receive blinded therapy verapamil placebo diltiazem placebo six week sustained release diltiazem srd long term phase three week two week placebo baseline period symptom limited bicycle exercise longer verapamil diltiazem placebo baseline p verapamil diltiazem reduce weekly rate anginal attack placebo verapamil diltiazem p antianginal effect two agent probably mediate reduction myocardial oxygen demand submaximal exercise addition diltiazem appear provide symptomatic relief reduce weekly number anginal attack significantly verapamil therefore daily administration simplify treatment schedule improve patient compliance,De Rosa ML,1998,Int J Cardiol,https://doi.org/10.1016/s0167-5273(97)00261-1,9482142,De Rosa ML; Giordano A; Melfi M; Della Guardia D; Ciaburri F; Rengo F,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000368: Aged; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D004110: Diltiazem; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004562: Electrocardiography; D015444: Exercise; D005260: Female; D005500: Follow-Up Studies; D006439: Hemodynamics; D006801: Humans; D008297: Male; D008875: Middle Aged; D017202: Myocardial Ischemia; D005996: Nitroglycerin; D012449: Safety; D016896: Treatment Outcome; D014665: Vasodilator Agents; D014700: Verapamil",,,https://openalex.org/W2087745238,163,24,1,1168,190,7,en,en
false,comparison effect controlled onset extend release verapamil bedtime nifedipine gastrointestinal therapeutic system arise early morning blood pressure heart rate heart rate blood pressure product list study investigator appear appendix,assess differential effect chronotherapeutic agent controlled onset extend release coer verapamil administer bedtime versus conventional homeostatic therapy nifedipine gastrointestinal therapeutic system git take morning early morning hour blood pressure bp heart rate hr hr systolic bp product study multicenter n randomize double blind prospective clinical trial week treatment period dose titration perform study investigator base systolic diastolic bp value doctor office ambulatory bp monitoring perform placebo baseline week stable double blind therapy end study twenty four hour bp profile study hypertensive patient change bp hr slope rate rise bp hr hr systolic bp product hour hour hour awaken evaluate study power show equivalence regimen predefined difference treatment group mean change baseline early morning bp mm hg systolic mm hg diastolic change early morning bp fell within definition equivalence treatment strategy mm hg coer verapamil mm hg nifedipine git change early morning hr rate pressure product significantly great follow coer verapamil therapy versus nifedipine git hr beats minute v beats minute p hr systolic bp product beats min mm hg v beats min mm hg respectively p change ambulatory bp demonstrate clinically similar reduction awake period nifedipine git lower systolic bp great extent coer verapamil sleep v mm hg p coer verapamil nifedipine git equivalent effect mm hg early morning bp addition extended release calcium antagonist effectively lower hour bp however coer verapamil great effect nifedipine git early morning hemodynamics hr hr systolic bp product rate rise bp hr less effect sleep due intrinsic pharmacologic property chronotherapeutic delivery system,White WB,1998,Am J Cardiol,https://doi.org/10.1016/s0002-9149(97)00935-1,9485131,White WB; Black HR; Weber MA; Elliott WJ; Bryzinski B; Fakouhi TD,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000704: Analysis of Variance; D001794: Blood Pressure; D019454: Chronotherapy; D003692: Delayed-Action Preparations; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D018670: Monitoring, Ambulatory; D009543: Nifedipine; D014700: Verapamil",,,https://openalex.org/W1974456030,286,43,1,2346,422,13,en,en
true,effect nisoldipine compare enalapril cardiovascular outcome patient non insulin dependent diabetes hypertension,recently report use calcium channel blocker hypertension may associate increase risk cardiovascular complication issue remain controversial study incidence complication patient non insulin dependent diabetes mellitus hypertension randomly assign treatment either calcium channel blocker nisoldipine angiotensin converting enzyme inhibitor enalapril part large study appropriate blood pressure control diabetes abcd trial prospective randomize blind trial compare effect moderate control blood pressure target diastolic pressure mm hg intensive control blood pressure diastolic pressure mm hg incidence progression complication diabetes study also compare nisoldipine enalapril first line antihypertensive agent term prevention progression complication diabetes current study analyze data secondary end point incidence myocardial infarction subgroup patient abcd trial hypertension analysis patient trial hypertension base line diastolic blood pressure mm hg show similar control blood pressure blood glucose lipid concentration smoke behavior nisoldipine group patient enalapril group patient throughout five year follow use multiple logistic regression model adjustment cardiac risk factor find nisoldipine associate high incidence fatal nonfatal myocardial infarction total enalapril total risk ratio percent confidence interval population patient diabetes hypertension find significantly high incidence fatal nonfatal myocardial infarction among assign therapy calcium channel blocker nisoldipine among assign receive enalapril since finding base secondary end point require confirmation,Estacio RO,1998,N Engl J Med,https://doi.org/10.1056/nejm199803053381003,9486993,Estacio RO; Jeffers BW; Hiatt WR; Biggerstaff SL; Gifford N; Schrier RW,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000328: Adult; D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D002121: Calcium Channel Blockers; D002318: Cardiovascular Diseases; D003924: Diabetes Mellitus, Type 2; D004311: Double-Blind Method; D004656: Enalapril; D005260: Female; D006801: Humans; D006973: Hypertension; D016015: Logistic Models; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D015737: Nisoldipine; D011446: Prospective Studies; D016896: Treatment Outcome",,,https://openalex.org/W2312999996,144,18,1,2186,361,6,en,en
false,natriuretic effect nifedipine gastrointestinal therapeutic system remain despite presence mild moderate renal failure,calcium channel blocker facilitate renal excretion sodium effect maintain chronic administration drug however unknown whether natriuretic effect remain despite presence decreased renal function compare natriuretic capacity nifedipine gastrointestinal therapeutic system git lisinopril patient mild moderate chronic renal failure open label randomize comparative study conduct compare natriuretic capacity nifedipine git lisinopril presence mild moderate renal failure creatinine clearance ml min wash period week intravenous saline infusion ml kg body weight isotonic saline h perform repeat week active therapy two sex age matched group hypertensive patient n include study renal failure diagnose secondary nephrosclerosis patients significant increase renal capacity excrete sodium load observe patient receive nifedipine git n take lisinopril n drug control blood pressure similar extent change observe body weight glomerular filtration rate renal plasma flow measure inulin paraaminohippurate clearance significant drop observe urinary albumin excretion lisinopril nifedipine heart rate higher nifedipine group natriuretic capacity nifedipine git remain despite presence mild moderate chronic renal failure effect take place absence change renal hemodynamics suggest cause direct tubular effect,Campo C,1997,J Hypertens,https://doi.org/10.1097/00004872-199715120-00093,9488243,Campo C; Garcia-Vallejo O; Barrios V; Lahera V; Manero M; Esteban E; Rodicio JL; Ruilope LM,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000328: Adult; D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D005260: Female; D005919: Glomerular Filtration Rate; D006801: Humans; D006973: Hypertension; D007676: Kidney Failure, Chronic; D017706: Lisinopril; D008297: Male; D008875: Middle Aged; D009318: Natriuresis; D009543: Nifedipine; D011446: Prospective Studies; D012964: Sodium; D016896: Treatment Outcome",,,https://openalex.org/W1969635871,135,16,1,1764,291,10,en,en
false,comparative efficacy tolerability nisoldipine coat core hydrochlorothiazide mild moderate hypertension,study compare efficacy tolerability nisoldipine coat core cc mg hydrochlorothiazide hctz mg patient mild moderate essential hypertension receive either nisoldipine cc mg hctz mg treatment titrate two weekly interval necessary primary efficacy endpoint defined reduction diastolic blood pressure dbp response rate similar nisoldipine cc hctz treated group respectively secondary efficacy endpoint reduction diastolic systolic blood pressure sbp treatment endpoint change baseline sbp mmhg nisoldipine cc group mmhg hctz group drug well tolerate adverse event generally minor typical antihypertensive agent drug related adverse event great nisoldipine cc hctz treated patient respectively nisoldipine cc show demonstrate antihypertensive efficacy similar hctz treatment mild moderate hypertension,Fodor JG,1997,Int J Clin Pract,,9489083,Fodor JG,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D000959: Antihypertensive Agents; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D015737: Nisoldipine",,,https://openalex.org/W2410796693,120,14,1,1119,195,12,en,en
false,controversy use calcium antagonist treatment coronary disease hypertension,calcium antagonist widely use therapy hypertension angina pectoris advantage good efficacy relatively dangerous side effect first lack bad metabolic effect hypokalemia hyperuricemia hyperinsulinemia hyperlipoproteinemia contrast beta blockers diuretic decline mortality myocardial infarction stroke similar information concern calcium antagonist two meta analysis unexpectedly suggest preparation calcium antagonist increase mortality myocardial infarction stroke paper discuss possible pathogenetic harmful mechanism pay attention class calcium antagonist time action particular drug short act nifedipine formulation withdraw chronic hypertension angina pectoris therapy ongoing multicenter trial several european country usa decide usefulness calcium antagonist preparation,Głuszek J,1997,Przegl Lek,,9501678,Głuszek J; Pawlaczyk-Gabriel K,article,D004740: English Abstract; D016428: Journal Article; D016454: Review,D002121: Calcium Channel Blockers; D002561: Cerebrovascular Disorders; D002986: Clinical Trials as Topic; D003327: Coronary Disease; D006801: Humans; D006973: Hypertension; D009203: Myocardial Infarction; D009543: Nifedipine,,,https://openalex.org/W2414625767,97,15,1,1025,154,7,en,en
false,comparison fixed combination enalapril diltiazem er monotherapies stage essential hypertension,safety efficacy two fixed dose combination enalapril diltiazem extend release formation er e compare monotherapies placebo patient stage hypertension trial design multicenter randomize double blind placebo control parallel group week treatment phase follow week open label phase total patient sit diastolic blood pressure sidbp mm hg randomly assign enalapril mg diltiazem er mg diltiazem er mg enalapril mg diltiazem er mg e enalapril mg diltiazem er mg e placebo open label phase patient receive fixed combination titrate need control sidbp mm hg efficacy determine trough h postdose sit blood pressure measurement week end open label part study safety evaluate base patient symptom clinical laboratory electrocardiogram ecg,Cushman WC,1998,Am J Hypertens,https://doi.org/10.1016/s0895-7061(97)00372-5,9504446,Cushman WC; Cohen JD; Jones RP; Marbury TC; Rhoades RB; Smith LK,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D004110: Diltiazem; D004311: Double-Blind Method; D004338: Drug Combinations; D004656: Enalapril; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D017063: Outcome Assessment, Health Care",,,https://openalex.org/W2012547472,124,18,1,1035,204,6,en,en
false,effect chronic exercise blood pressure dahl salt sensitive rat,test hypothesis daily exercise would reduce directly measure arterial blood pressure bp sympathetic nervous system support bp conscious unrestrained female dahl salt sensitive rat consume nacl dahl jr inbred rat assign daily exercise ex sedentary sed treatment condition n group week age rat ex group house cage attached run wheel week exercise rat run km day least wks treatment rat group place nacl diet week produce sodium induced hypertension rat continue either exercise daily remain sedentary additional week consume high sodium diet carotid jugular catheter implant measurement conscious rest unrestrained rat two separate day daily wheel run exercise week alter bp hr dahl jr rat consume nacl diet however acute arterial depressor response ganglionic blockade less ex rat furthermore great alpha adrenergic phenylephrine induced pressor response observe ex group ganglionic blockade finding suggest overall rest sympathetic neural activity cardiac beta adrenergic responsiveness sympathetic activity reduce model hypertension daily wheel run exercise,Overton JM,1998,Am J Hypertens,https://doi.org/10.1016/s0895-7061(97)00308-7,9504453,Overton JM; VanNess JM; Takata HJ,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000316: Adrenergic alpha-Agonists; D000818: Animals; D001794: Blood Pressure; D005260: Female; D006973: Hypertension; D009929: Organ Size; D010656: Phenylephrine; D010805: Physical Conditioning, Animal; D051381: Rats; D012982: Sodium, Dietary",,,https://openalex.org/W2147997092,73,11,1,1455,257,11,en,en
false,use calcium channel blocker hypertension,past year number subclass calcium channel blocker increase one four three class single clinically approve compound verapamil diltiazem mibefradil fourth class dihydropyridines contain numerous compound agent effective lower blood pressure short term study side effect trouble patient infrequent long term study hypertensive patient limited short acting agent nifedipine associate increase cardiovascular risk study agent also probably create compliance problem hypertensive patient need multiple daily dos unpleasant side effect e g ankle edema palpitation flush therefore useful indicate treatment hypertensive patient data suggest long acting dihydropyridines nondihydropyridine calcium channel blocker share fate indeed several line evidence suggest opposite cardioprotective effect however definitive information require completion several long term trial include allhat convince hot insight nordil finally important reflect lesson learn controversy associate potential risk calcium channel blocker first disagreement common one use case controlled study reflective poor precision method use statistically relevant one study may hold true another may clinical relevance particularly relative risk less investigator need temper enthusiasm reflect reality second cut edge science probably relatively little agreement correct among equally competent scientist bias position recognize admit colleague infer disagree unstated secondary agenda bring personal financial reward government accolade inappropriate counterproductive third randomized clinical trial despite imperfection still best tool establish common ground controversial issue finally may seem best public health perspective may best interest individual patient possibility physician constantly consider example public health benefit occur patient remain hypertensive fail take medication matter medication,Conlin PR,1998,Adv Intern Med,,9506192,Conlin PR; Williams GH,article,D016428: Journal Article; D016454: Review,D000959: Antihypertensive Agents; D001562: Benzimidazoles; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D016022: Case-Control Studies; D002986: Clinical Trials as Topic; D004095: Dihydropyridines; D004110: Diltiazem; D006331: Heart Diseases; D006801: Humans; D006973: Hypertension; D008137: Longitudinal Studies; D020748: Mibefradil; D009543: Nifedipine; D011634: Public Health; D016032: Randomized Controlled Trials as Topic; D012307: Risk Factors; D013764: Tetrahydronaphthalenes; D014665: Vasodilator Agents; D014700: Verapamil,,,https://openalex.org/W151071739,48,8,1,2660,441,21,en,en
false,evaluation enalapril combine diltiazem er patient stage essential hypertension,enalapril combine extended release formulation diltiazem evaluate week multicenter trial patient stage essential hypertension patient randomize daily therapy enalapril mg plus diltiazem er mg mg dosage could titrate antihypertensive agent add blood pressure control efficacy assess sit blood pressure trough hour postdose overall decrease mmhg patient respond enalapril diltiazem er alone reduction mmhg patient achieve trough sit diastolic blood pressure mmhg common drug related adverse experience headache dizziness rash asthenidfatigue daily fixed combination enalapril diltiazem er generally well tolerated effective give alone antihypertensive stage hypertension,Gavras H,1998,Clin Exp Hypertens,https://doi.org/10.3109/10641969809053205,9507787,Gavras H; Chrysant SG; Niederman AL; Marbury TC; Goldstein R; Conradi E,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000959: Antihypertensive Agents; D004110: Diltiazem; D018450: Disease Progression; D004359: Drug Therapy, Combination; D004656: Enalapril; D005069: Evaluation Studies as Topic; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W1989467431,100,14,1,945,151,9,en,en
false,nifedipine git versus diltiazem chronic stable angina randomised multicentre study,order compare efficacy nifedipine gastrointestinal therapeutic system git diltiazem patient chronic stable angina study parallel group randomised trial accord result two exercise tolerance test etts perform placebo run patient divide fixed threshold group variability time mm st segment depression variable threshold group higher efficacy assess compare time mm st depression bicycle ett week treatment adjust baseline value adjusted mean min nifedipine git min diltiazem difference min low confidence limit within stated interval equivalence result confirm intention treat analysis comparable result obtain fix variable threshold group incidence side effect nifedipine git diltiazem nifedipine git diltiazem find equally effective increase exercise tolerance chronic stable angina patient,Zanolla L,1997,Br J Clin Pract Suppl,,9519505,Zanolla L; Franceschini L; Rossi L; Ochan M; Amigoni S; Zardini P,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D002908: Chronic Disease; D004110: Diltiazem; D004311: Double-Blind Method; D005080: Exercise Test; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009543: Nifedipine,,,https://openalex.org/W175525459,90,14,1,1188,211,7,en,en
true,calcium channel block agent risk cancer patient coronary heart disease study support boehringer mannheim ltd mannheim germany,objective analysis seek estimate risk ratio cancer incidence cancer related mortality associate use calcium channel block agent ccbs large group patient chronic coronary heart disease chd background recent publication contend use short acting ccbs may double risk cancer incidence possibly increase mortality hypertensive patient method cancer incidence data obtain patient screen bezafibrate infarction prevention bip study one half treat time screen ccbs mean follow period year cause specific mortality available september mean follow year statistical power detect odds ratio give cancer incidence rate nonusers ccbs power decline decline odds ratio respectively result incident cancer case occur among user among nonusers ccbs adjustment age gender smoking odds ratio estimate cancer combine confidence interval ci ccb user relative nonusers adjusted risk ratio cause mortality age gender smoking pertinent prognostic clinical characteristic estimate ci adjusted risk ratio cancer related mortality ci conclusion patient chd treat ccbs exhibit similar risk cancer incidence total cancer related mortality compare nonusers ccbs analysis provide certain assurance ccb use middle aged elderly patient chd associate meaningful difference cancer incidence related mortality,Braun S,1998,J Am Coll Cardiol,https://doi.org/10.1016/s0735-1097(98)00008-4,9525550,Braun S; Boyko V; Behar S; Reicher-Reiss H; Laniado S; Kaplinsky E; Goldbourt U,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D002121: Calcium Channel Blockers; D002423: Cause of Death; D016001: Confidence Intervals; D003327: Coronary Disease; D004110: Diltiazem; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009369: Neoplasms; D009543: Nifedipine; D016017: Odds Ratio; D012307: Risk Factors; D014700: Verapamil,,,https://openalex.org/W1538185747,165,26,1,1893,346,17,en,en
false,evaluation change sympathetic nerve activity heart rate essential hypertensive patient induce amlodipine nifedipine,compare effect amlodipine nifedipine heart rate parameter sympathetic nerve activity acute chronic treatment period order elucidate influence cardiovascular outcome randomize single blind study perform h ambulatory electrocardiography blood pressure monitoring essential hypertensive inpatient plasma urinary catecholamine level measure control pretreatment period first day acute period week chronic period administration amlodipine short acting nifedipine slow releasing formulation low frequency high frequency power spectral density low frequency high frequency ratio obtain heart rate power spectral analysis blood pressure significantly similarly reduce administration amlodipine short acting nifedipine slow releasing nifedipine chronic period total qrs count per h remain constant chronic period administration slow releasing nifedipine increase administration nifedipine decrease administration amlodipine administration amlodipine decrease plasma urinary norepinephrine level chronic period whereas level significantly increase administration short acting nifedipine change administration slow release nifedipine although low frequency high frequency ratio increase significantly administration short acting nifedipine slightly administration slow releasing nifedipine administration amlodipine reduce acute chronic periods administration amlodipine induce increase sympathetic nerve activity essential hypertensive patient chronic period suggest beneficial effect essential hypertension expect long term administration administration slow releasing nifedipine induces milder reflex sympathetic activation short acting nifedipine,Hamada T,1998,J Hypertens,https://doi.org/10.1097/00004872-199816010-00016,9533424,Hamada T; Watanabe M; Kaneda T; Ohtahara A; Kinugawa T; Hisatome I; Fujimoto Y; Yoshida A; Shigemasa C,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002940: Circadian Rhythm; D003692: Delayed-Action Preparations; D004837: Epinephrine; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D009638: Norepinephrine; D016037: Single-Blind Method; D013564: Sympathetic Nervous System,,,https://openalex.org/W2081491508,138,19,1,2110,293,7,en,en
true,calcium channel blocker risk cancer,recent epidemiologic study raise concern calcium channel blocker use may increase risk cancer overall several specific cancers assess whether calcium channel blocker use increase risk cancer overall specific cancers case control drug surveillance study base data collect hospitals baltimore md new york ny philadelphia pa total patient age year incident cancer various site control age year admit nonmalignant conditions incident cancer overall specific cancers calcium channel blocker use unrelated risk cancer overall relative risk rr confidence interval ci use significantly associate increased risk individual cancer include previously implicate except cancer kidney rr ci recent use use year use individual calcium channel blocker drug also associate cancer incidence use beta blockers angiotensin converting enzyme inhibitor generally unrelated cancer overall individual cancer associate kidney cancer rr ci rr ci respectively present study suggest use calcium channel blocker unrelated increase overall risk cancer individual cancer except kidney cancer associate hypertension drug treat hypertension previous study,Rosenberg L,1998,JAMA,https://doi.org/10.1001/jama.279.13.1000,9533498,Rosenberg L; Rao RS; Palmer JR; Strom BL; Stolley PD; Zauber AG; Warshauer ME; Shapiro S,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D000368: Aged; D002121: Calcium Channel Blockers; D016022: Case-Control Studies; D005260: Female; D006801: Humans; D015994: Incidence; D016015: Logistic Models; D008297: Male; D008875: Middle Aged; D015999: Multivariate Analysis; D009369: Neoplasms; D012306: Risk,,,https://openalex.org/W2038118918,47,8,1,1580,284,4,en,en
false,hypertension optimal treatment hot study,hypertension optimal treatment study prospective trial conduct country aim evaluate relationship three level target office diastolic blood pressure bp mm hg cardiovascular morbidity mortality hypertensive patient examine effect cardiovascular morbidity mortality mg aspirin daily versus placebo total patient year age randomize end april treatment initiate felodipine mg daily additional therapy give accordance set protocol present substudy patient perform nine country aim compare home office bp representative subsample hot population titration treatment complete clarify whether separation target group could expand office setting difference office home measurement diastolic bp mm hg sd confidence interval p systolic bp mm hg sd confidence interval p significant group differences home bp mm hg versus mm hg versus diastolic bp f anova p mm hg systolic bp f p thus office home bps measure semiautomatic device comparable treated hypertensive subject hot study separation target group base office reading prevail home,Kjeldsen SE,1998,Hypertension,https://doi.org/10.1161/01.hyp.31.4.1014,9535429,Kjeldsen SE; Hedner T; Jamerson K; Julius S; Haley WE; Zabalgoitia M; Butt AR; Rahman SN; Hansson L,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D000704: Analysis of Variance; D000959: Antihypertensive Agents; D001794: Blood Pressure; D001795: Blood Pressure Determination; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies",,,https://openalex.org/W2043697045,42,7,1,1650,339,8,en,en
false,amlodipine patient stable angina pectoris treat beta blockers double blind comparison placebo,order assess additional anti ischaemic effect amlodipine aml coronary artery disease cad treat beta blockers patient cad verify angiogram stable angina randomize receive mg day aml placebo increase mg day week baseline recording h ambulatory ecg blood pressure echocardiography bicycle exercise test repeat treatment week week reduction ambulatory ischaemia significantly great aml placebo exercise test time mv st segment depression total exercise time remain unaltered blood pressure reduce mg aml total variability low frequency component heart rate reduce dos clinical significance possible unfavourable change autonomic modulation heart cad patient know,Rossinen J,1998,Scand Cardiovasc J,https://doi.org/10.1080/14017439850140337,9536505,Rossinen J; Partanen J; Nieminen MS,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000319: Adrenergic beta-Antagonists; D017311: Amlodipine; D000787: Angina Pectoris; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D017023: Coronary Angiography; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D018619: Echocardiography, Doppler, Pulsed; D015716: Electrocardiography, Ambulatory; D005080: Exercise Test; D005260: Female; D005500: Follow-Up Studies; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D014665: Vasodilator Agents",,,https://openalex.org/W2104026968,115,15,1,927,162,7,en,en
false,comparison anti ischemic effect bepridil diltiazem evaluate exercise test patient coronary disease multicenter study groupe investigateurs,bepridil cordium calcium channel blocker demonstrate effective preventive treatment angina controlled trial compare bepridil diltiazem tildiem reference calcium channel blocker objective study evaluate efficacy safety bepridil stable coronary patient patient f mean age year documented coronary artery disease positive stress test day placebo include double blind randomization receive bepridil mg day ion dos diltiazem mg day dos day stress test perform condition inclusion anti ischaemic efficacy two drug comparable total work increase kpm kpm bepridil p kpm kpm p diltiazem intergroup difference duration effort significantly prolong min min bepridil p min min diltiazem p intergroup difference time onset min st depression increase significantly two stress test min min bepridil p min min diltiazem p significant difference two group clinical safety two product comparable electrocardiogram qt interval significantly prolong bepridil msec msec p reflect cellular impregnation drug,Sellier P,1997,Ann Cardiol Angeiol (Paris),,9538375,Sellier P; Quilliet L,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D015764: Bepridil; D002121: Calcium Channel Blockers; D003327: Coronary Disease; D004110: Diltiazem; D004311: Double-Blind Method; D005080: Exercise Test; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D014665: Vasodilator Agents,,,https://openalex.org/W2432929796,170,27,3,1803,362,12,en,en
false,effect lisinopril nifedipine progression overt albuminuria iddm patient incipient nephropathy normal blood pressure,intervention trial renal function iddm patient microalbuminuria adopt rate decline glomerular filtration rate gfr outcome measure however normotensive iddm patient show change gfr follow period year thus present study use cumulative incidence progression albuminuria albumin excretion rate aer micrograms min primary endpoint yearly increase aer rate baseline secondary end point renal function ninety two normotensive iddm patient underwent double blind double dummy treatment either lisinopril slow release nifedipine comparison placebo ten patient discontinue study year follow period year follow period placebo treated lisinopril treated nifedipine treated patient progress clinical albuminuria fisher exact test p time event analysis indicate reduction risk progression macroalbuminuria ci patient lisinopril p ci patient nifedipine p adjustment mean blood pressure glycated hemoglobin baseline aer comparison patient placebo baseline aer micrograms min range progressors micrograms min range nonprogressors n percentage patient show yearly increase aer baseline value significantly low lisinopril group p nifedipine group placebo group lisinopril group significantly low blood pressure value follow either nifedipine p placebo p group data show lisinopril nifedipine effective delay occurrence macroalbuminuria normotensive iddm patient overt proteinuria strongly predict end stage renal failure treatment appear capable prevent complication normotensive iddm patient however lisinopril appear powerful slow course nephropathy,Crepaldi G,1998,Diabetes Care,https://doi.org/10.2337/diacare.21.1.104,9538979,Crepaldi G; Carta Q; Deferrari G; Mangili R; Navalesi R; Santeusanio F; Spalluto A; Vanasia A; Villa GM; Nosadini R,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000419: Albuminuria; D000806: Angiotensin-Converting Enzyme Inhibitors; D001794: Blood Pressure; D003404: Creatinine; D003922: Diabetes Mellitus, Type 1; D003928: Diabetic Nephropathies; D018450: Disease Progression; D004311: Double-Blind Method; D004562: Electrocardiography; D005260: Female; D005919: Glomerular Filtration Rate; D006442: Glycated Hemoglobin; D006801: Humans; D007558: Italy; D017706: Lisinopril; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011188: Potassium; D012907: Smoking; D013997: Time Factors; D014665: Vasodilator Agents",,,https://openalex.org/W1987340119,146,21,1,2333,440,10,en,en
false,epidural verapamil reduces analgesic consumption low abdominal surgery,double blind study administer lumbar epidural bupivacaine bupivacaine plus verapamil investigate possible role calcium channel blocker verapamil postoperative pain one hundred patient asa physical class ii schedule low abdominal surgery randomly assign one four group group receive ml epidural bupivacaine inject min incision follow ml epidural normal saline min incision group receive ml epidural normal saline inject incision follow ml epidural bupivacaine min incision group receive ml epidural bupivacaine plus mg verapamil inject incision follow ml epidural normal saline min incision group receive drug group reverse order pain mood numeric rating score sedation score prince henry score patient controlled cumulative postoperative analgesic consumption incidence side effect assessed h operation group cumulative postoperative analgesic consumption group significantly low p group h surgery difference pain mood sedation score incidence side effect among four group conclude epidural verapamil decrease postoperative pain possibly interfere normal sensory processing prevent establishment central sensitization implication calcium play important role pain physiology spinal cord level examine effect bupivacaine plus verapamil calcium channel blocker bupivacaine alone demonstrate combination administer epidurally result less postoperative analgesic consumption bupivacaine alone anesth analg,Choe H,1998,Anesth Analg,https://doi.org/10.1097/00000539-199804000-00020,9539602,Choe H; Kim JS; Ko SH; Kim DC; Han YJ; Song HS,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000005: Abdomen; D000328: Adult; D000339: Affect; D015360: Analgesia, Epidural; D016058: Analgesia, Patient-Controlled; D000700: Analgesics; D000701: Analgesics, Opioid; D000704: Analysis of Variance; D000779: Anesthetics, Local; D002045: Bupivacaine; D002121: Calcium Channel Blockers; D016009: Chi-Square Distribution; D003243: Consciousness; D004311: Double-Blind Method; D005500: Follow-Up Studies; D006801: Humans; D015994: Incidence; D007268: Injections, Epidural; D008875: Middle Aged; D009020: Morphine; D010149: Pain, Postoperative; D011292: Premedication; D012677: Sensation; D012965: Sodium Chloride; D013116: Spinal Cord; D014700: Verapamil",,,https://openalex.org/W1991369673,78,9,1,1939,345,14,en,en
false,comparison safety efficacy mibefradil nifedipine sr patient renal disease hypertension,antihypertensive efficacy safety mibefradil nifedipine sr compare patient chronic renal failure mild moderate hypertension multicenter double blind randomize parallel design study treatment week significantly great decrease sit diastolic blood pressure sdbp see mibefradil nifedipine sr mmhg v mmhg respectively p significantly great number mibefradil treated patient achieve normalization sdbp week vs p change renal function parameter incidence adverse event similar group population week treatment mibefradil effective nifedipine sr lower blood pressure similar effect renal function parameter,Woittiez AJ,1998,Clin Nephrol,,9543597,Woittiez AJ; Huysmans FT; Bailey R; Robson RA; Mion Júnior D; Villa G; Kobrin I,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D001562: Benzimidazoles; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D007668: Kidney; D007676: Kidney Failure, Chronic; D008297: Male; D020748: Mibefradil; D008875: Middle Aged; D009543: Nifedipine; D013764: Tetrahydronaphthalenes",,,https://openalex.org/W2471224006,120,20,1,840,145,5,en,en
false,effect verapamil trandolapril treatment hypertension,combination angiotensin convert enzyme inhibitor calcium antagonist become common way treat patient essential hypertension respond insufficiently monotherapy double blind randomize parallel placebo controlled multicenter outpatient study evaluate antihypertensive efficacy safety calcium antagonist verapamil sr angiotensin convert enzyme inhibitor trandolapril patient mild moderate stage ii essential hypertension six hundred thirty one patient enrol week study week single blind placebo phase patient receive one following daily dosage regimen double blind fashion week placebo mg trandolapril mg verapamil sr combination mg trandolapril mg verapamil sr trough sit diastolic blood pressure lower mm hg mm hg mm hg placebo trandolapril verapamil sr combination group respectively combination group sit diastolic blood pressure significantly lower p mm hg trandolapril group mm hg verapamil sr group analysis trough peak ratio sit diastolic blood pressure reveal value mg trandolapril combination group respectively end point overall incidence adverse reaction similar treatment group study combination angiotensin convert enzyme inhibitor calcium antagonist well tolerate effective either agent administer alone treatment mild moderate essential hypertension,Messerli F,1998,Am J Hypertens,https://doi.org/10.1016/s0895-7061(97)00466-4,9544873,Messerli F; Frishman WH; Elliott WJ,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D004338: Drug Combinations; D005260: Female; D006801: Humans; D006973: Hypertension; D007211: Indoles; D008297: Male; D008875: Middle Aged; D016037: Single-Blind Method; D016896: Treatment Outcome; D014700: Verapamil,,,https://openalex.org/W2011039011,70,10,1,1748,295,8,en,en
false,placebo controlled comparison diltiazem amlodipine monotherapy essential hypertension use h ambulatory monitoring,thirty patient female median age year mild moderate hypertension sit diastolic blood pressure mmhg consecutive week participate study efficacy tolerability daily diltiazem control delivery mg mg amlodipine mg compare placebo use clinic h ambulatory blood pressure measurement accutraker ii study conduct general practice set use randomized double blind crossover design latin square allocation treatment order within subject phase dos titrate achieve predose clinic sit diastolic blood pressure mmhg three patient withdraw take amlodipine take placebo number patient receive high dose phase follow placebo diltiazem amlodipine end phase mean clinic sit blood pressure follow placebo diltiazem amlodipine end phase mean h ambulatory blood pressure follow placebo diltiazem amlodipine clinic ambulatory blood pressure therefore significantly reduce p active phase compare placebo systolic blood pressure also significantly low amlodipine compare diltiazem heart rate increase amlodipine drug well tolerate adverse event predictable agent amlodipine cause vasodilator side effect thus amlodipine diltiazem daily effective reduce blood pressure amlodipine potent diltiazem reduce systolic blood pressure cause vasodilator side effect,Watts RW,1998,Blood Press,https://doi.org/10.1080/080370598437538,9551874,Watts RW; Wing LM,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004110: Diltiazem; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D015716: Electrocardiography, Ambulatory; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009206: Myocardium; D009929: Organ Size",,,https://openalex.org/W2105521482,130,15,1,1748,285,12,en,en
false,calcium channel antagonist morbidity mortality evidence,recent study show association use calcium channel antagonists treatment hypertension increase risk myocardial infarction gastrointestinal hemorrhage cancer interpretation result study application clinical practice require understanding study design constraint conflict result limitation extrapolate study finding dosage strength formulation agent within calcium channel antagonist class review critique study provide background information controversial subject use calcium channel antagonists treatment hypertension despite limitation study clinician may want select class agent include diuretic beta blocker first line therapy morbidity mortality effect relate use calcium channel antagonist clearly know,Straka RJ,1998,Am Fam Physician,,9556644,Straka RJ; Swanson AL; Parra D,article,D016428: Journal Article; D016454: Review,"D000286: Administration, Sublingual; D000368: Aged; D002121: Calcium Channel Blockers; D006471: Gastrointestinal Hemorrhage; D006801: Humans; D006973: Hypertension; D015994: Incidence; D009203: Myocardial Infarction; D009369: Neoplasms; D009543: Nifedipine; D018570: Risk Assessment; D015996: Survival Rate",,,https://openalex.org/W2470741995,74,13,1,962,145,4,en,en
false,study pose new question calcium channel blocker,journal article study pose new question calcium channel blocker get access american journal health system pharmacy volume issue april page http doi org ajhp publish april,Jeffers ER,1998,Am J Health Syst Pharm,https://doi.org/10.1093/ajhp/55.8.762,9568234,Jeffers ER,article,D016433: News,D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D048909: Diabetes Complications; D006801: Humans; D006973: Hypertension; D015737: Nisoldipine,,,https://openalex.org/W2411731847,56,7,1,235,38,1,en,en
false,calcium channel blocker heart failure,considerable effort make last year evaluate safety efficacy calcium channel blocker ccbs treatment patient chronic congestive heart failure chf available study provide strong evidence potential detrimental effect first generation calcium antagonist patient chf indicate need great caution drug use patient significant depression left ventricular systolic function number second generation ccb demonstrate strong vasodilatory effect favorable hemodynamic action fail show similar improvement exercise capacity morbidity mortality moreover drug nicardipine nisoldipine result detrimental effect patient therefore consider safe use patient moderate severe heart failure available information v heft iii study demonstrate lack unfavorable effect felodipine exercise tolerance patient chronic heart failure although mortality rate similar felodipine placebo group relatively small number patient study clear conclusion draw regard effect felodipine mortality patient chf encouraging signal regard potential role ccb treatment chronic heart failure provide recently complete praise study prospective large scale study demonstrate safety amlodipine long acting dihydropyridine derivative use patient heart failure due coronary artery disease furthermore study demonstrate substantial reduction mortality patient chf due nonischemic cardiomyopathy provide strong indication potential therapeutic benefit amlodipine add standard chf therapy patient population clear explanation available present time regard reason deleterious effect demonstrate dihydropyridines contrasting benefit see amlodipine finally information regard safety efficacy dihydropyridines become available next year praise ii study ongoing provide information regard therapeutic role amlodipine patient nonischemic dilate cardiomyopathy mach study evaluate effect mibefradil predominant type channel blocker ideal activity profile morbidity mortality patient chronic chf,Elkayam U,1998,Cardiology,https://doi.org/10.1159/000047278,9570428,Elkayam U,article,D003160: Comparative Study; D016428: Journal Article; D016454: Review,D002121: Calcium Channel Blockers; D015220: Calcium Channels; D002908: Chronic Disease; D006333: Heart Failure; D006439: Hemodynamics; D006801: Humans; D012449: Safety; D016896: Treatment Outcome,,,https://openalex.org/W2041600410,41,6,1,2614,415,13,en,en
true,outcome result fosinopril versus amlodipine cardiovascular event randomize trial facet patient hypertension niddm,ace inhibitor calcium antagonist may favorably affect serum lipid glucose metabolism primary aim fosinopril versus amlodipine cardiovascular event randomize trial facet compare effect fosinopril amlodipine serum lipid diabetes control niddm patient hypertension prospectively define cardiovascular event assess secondary outcomes inclusion criterion include diagnosis niddm hypertension systolic blood pressure mmhg diastolic blood pressure mmhg exclusion criterion include history coronary heart disease stroke serum creatinine mg dl albuminuria micrograms min use lipid lowering drug aspirin antihypertensive agent beta blockers diuretic total hypertensive diabetic randomly assign open label fosinopril mg day amlodipine mg day follow year blood pressure control study drug added treatment effective lower blood pressure end follow two group significant difference total serum cholesterol hdl cholesterol hba c fast serum glucose plasma insulin patient receive fosinopril significantly low risk combined outcome acute myocardial infarction stroke hospitalize angina receive amlodipine vs hazard ratio ci fosinopril amlodipine similar effect biochemical measure patient randomize fosinopril significantly low risk major vascular event compare patient randomize amlodipine,Tatti P,1998,Diabetes Care,https://doi.org/10.2337/diacare.21.4.597,9571349,Tatti P; Pahor M; Byington RP; Di Mauro P; Guarisco R; Strollo G; Strollo F,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001786: Blood Glucose; D001794: Blood Pressure; D015992: Body Mass Index; D002121: Calcium Channel Blockers; D008076: Cholesterol, HDL; D003924: Diabetes Mellitus, Type 2; D003925: Diabetic Angiopathies; D005260: Female; D005340: Fibrinogen; D005500: Follow-Up Studies; D017328: Fosinopril; D006442: Glycated Hemoglobin; D006801: Humans; D006973: Hypertension; D008055: Lipids; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D013997: Time Factors",,,https://openalex.org/W2138119952,138,20,1,1732,286,8,en,en
false,interventional study diltiazem dilated cardiomyopathy report multiple centre clinical trial china,aim study determine interventional effect diltiazem autoantibody mediate myocardial damage dilate cardiomyopathy dcm patient dcm hospital include multiple centre clinical trial january november use diltiazem placebo base background therapy heart failure patient randomly divide group single blind trial follow observation average month treatment heart function patient diltiazem group recover grade ii occur patient placebo group heart thorax ratio decrease left ventricular end diastolic dimension lvedd mm mm left ventricular ejection fraction ef increase p diltiazem group n parameter significantly change placebo group n mortality diltiazem group placebo group p analysis also show lvedd reduce ef obviously elevate patient dcm lvedd mm parameter n improve patient lvedd mm study suggest diltiazem safe effective treatment dcm action mechanism might intervention antibody mediated myocardial damage protection myocardium diltiazem suitable treatment early stage dcm,Liao YH,1998,Int J Cardiol,https://doi.org/10.1016/s0167-5273(97)00310-0,9579813,Liao YH,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D001323: Autoantibodies; D002311: Cardiomyopathy, Dilated; D002317: Cardiovascular Agents; D002681: China; D004110: Diltiazem; D005260: Female; D005500: Follow-Up Studies; D006334: Heart Function Tests; D006801: Humans; D008297: Male; D008875: Middle Aged; D000226: Mitochondrial ADP, ATP Translocases; D012016: Reference Values; D012984: Software; D015996: Survival Rate; D016896: Treatment Outcome",,,https://openalex.org/W152841347,112,17,1,1556,290,10,en,en
false,clinical histological comparative study effect nifedipine phenytion human gingiva,ten patient manifest gingival enlargement choose study five patient treat mg nifedipine per day treatment angina pectoris five patient treat phenytion anticonvulsant drug clinical histological data show nefidipine induce gingival hyperplasia close similarity induce phenytion despite difference target tissue,Shoieb MA,1993,Egypt Dent J,,9588123,Shoieb MA; Fathy LM; Abu-el-Dahab O; el-Sherbiny MM,article,D003160: Comparative Study; D016428: Journal Article,D000927: Anticonvulsants; D001706: Biopsy; D002121: Calcium Channel Blockers; D005881: Gingiva; D005885: Gingival Hyperplasia; D006801: Humans; D009543: Nifedipine; D010672: Phenytoin; D013997: Time Factors,,,https://openalex.org/W2421611056,105,17,1,432,69,3,en,en
false,randomized double blind comparison intravenous diltiazem digoxin atrial fibrillation coronary artery bypass surgery,atrial fibrillation af coronary bypass graft surgery may result hypotension heart failure symptom embolic complication prolongation length hospital stay lohs purpose study determine whether intravenous diltiazem effective digoxin ventricular rate control af coronary artery bypass graft surgery secondary end point determine whether ventricular rate control diltiazem reduces postoperative lohs compare digoxin patients af ventricular rate beats min within day coronary artery bypass graft surgery randomly assign receive intravenous therapy diltiazem n digoxin n efficacy measure ambulatory electrocardiography holter monitoring safety assess clinical monitoring electrocardiographic recording lohs measure day surgery data analyze intention treat principle randomly assign patient addition separate intention treat analysis perform exclude patient spontaneously convert sinus rhythm analysis randomly assign patient receive diltiazem achieve ventricular rate control decrease pretreatment ventricular rate mean median minute compare median minute patient receive digoxin p hour proportion patient achieve rate control significantly high patient treat diltiazem vs p similarly hour response rate associate diltiazem high digoxin group vs p however response rate associate diltiazem digoxin hour significantly different hour conversion sinus rhythm occur patient receive diltiazem patient receive digoxin p result analysis patient remain af similar present difference diltiazem treated digoxin treated group postoperative lohs vs day respectively p ventricular rate control occur rapidly intravenous diltiazem digoxin af coronary artery bypass graft surgery however hour response rate duration postoperative hospital stay associate two drug similar,Tisdale JE,1998,Am Heart J,https://doi.org/10.1016/s0002-8703(98)70031-6,9588402,Tisdale JE; Padhi ID; Goldberg AD; Silverman NA; Webb CR; Higgins RS; Paone G; Frank DM; Borzak S,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D001026: Coronary Artery Bypass; D004077: Digoxin; D004110: Diltiazem; D004311: Double-Blind Method; D015716: Electrocardiography, Ambulatory; D005260: Female; D006339: Heart Rate; D006801: Humans; D007262: Infusions, Intravenous; D008297: Male; D008875: Middle Aged; D011183: Postoperative Complications; D016896: Treatment Outcome; D014665: Vasodilator Agents",,,https://openalex.org/W2133523844,135,18,1,2527,453,16,en,en
true,value addition amlodipine atenolol patient angina pectoris despite adequate beta blockade,anginal patient remain symptomatic despite optimally dose beta blockade may also give dihydropyridine calcium antagonist treatment regimen examine double blind parallel randomize control study patient angina positive bicycle exercise test despite optimal beta blockade atenolol heart rate rest beats min patient randomize atenolol placebo control atenolol amlodipine main outcome measurement exercise tolerance week compare baseline week significant difference time mv st segment depression time chest pain time end exercise observe number patient chest pain exercise decrease significantly amlodipine group p v control subgroup patient early minute onset chest pain baseline show significant increase time chest pain amlodipine p v control amlodipine group st depression rate pressure product submaximum comparable workload decrease mm p v control beats min x mm hg p v control number patient group adverse event different addition amlodipine treatment patient myocardial ischemia despite optimal beta blockade well tolerate may lead improvement symptomatic anginal patient rapid onset exercise induced ischemia,Dunselman PH,1998,Am J Cardiol,https://doi.org/10.1016/s0002-9149(97)00877-1,9591892,Dunselman PH; van Kempen LH; Bouwens LH; Holwerda KJ; Herweijer AH; Bernink PJ,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D000787: Angina Pectoris; D001262: Atenolol; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D004562: Electrocardiography; D005080: Exercise Test; D017079: Exercise Tolerance; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D012449: Safety; D016896: Treatment Outcome",,,https://openalex.org/W2110765303,111,17,1,1537,276,10,en,en
true,amlodipine versus diltiazem additional antianginal treatment atenololfn fn study sponsor grant pfizer ltd sandwich kent united kingdom,antianginal efficacy tolerability amlodipine diltiazem compare double blind randomized trial patient angina resistant atenolol alone amlodipine diltiazem significantly reduce frequency angina attack p glyceryl trinitrate consumption p p holter monitoring treatment reduce overall frequency ambulatory myocardial ischemia although change reach statistical significance exercise test parameter total exercise time time angina time st depression maximum st depression tend improve treatment change achieve statistical significance relative baseline drug generally well tolerate adverse event occur patient amlodipine group patient diltiazem group patient take diltiazem report almost twice many adverse event patient take amlodipine quality life assess total nottingham health profile score significantly different treatment addition either daily amlodipine twice daily sustained release diltiazem improve symptom patient angina resistant atenolol alone diltiazem associate frequent serious adverse event,Knight CJ,1998,Am J Cardiol,https://doi.org/10.1016/s0002-9149(97)00893-x,9591893,Knight CJ; Fox KM,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D000787: Angina Pectoris; D001262: Atenolol; D002121: Calcium Channel Blockers; D017023: Coronary Angiography; D004110: Diltiazem; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D015716: Electrocardiography, Ambulatory; D005080: Exercise Test; D005260: Female; D005500: Follow-Up Studies; D006439: Hemodynamics; D006801: Humans; D008297: Male; D008875: Middle Aged; D012449: Safety; D016896: Treatment Outcome",,,https://openalex.org/W2063996790,165,26,1,1373,233,8,en,en
false,safety long acting dihydropyridine calcium channel blocker hypertensive patient,issue raise recently concern safety calcium channel blocker ccbs prompt analysis occurrence cardiovascular event death pfizer inc hypertension clinical trial database amlodipine norvasc nifedipine gastrointestinal therapeutic system git formulation procardia xl prospectively defined analysis data comparative noncomparative trial amlodipine nifedipine git conduct outcome measure include cardiovascular noncardiovascular death adverse cardiovascular event include new worsened angina myocardial infarction mi serious arrhythmia stroke congestive heart failure bleed among amlodipine treated patient n incidence rate cause death mi new worsened angina patient years exposure respectively among comparative trial alone n cause death rate patient years comparable non ccb agent significantly less ccbs patient years p although difference rate represent death among nifedipine gits treated patient n rate cause death patient years mi patient years new worsened angina patient years incidence rate mi cardiac event low hypertension trial differ among treatment group either amlodipine nifedipine git comparative analysis clinical trial database analyze signal suggest excessive risk death cardiovascular event hypertensive patient treat amlodipine nifedipine git,Kloner RA,1998,Am J Cardiol,https://doi.org/10.1016/s0002-9149(97)00868-0,9591899,Kloner RA; Vetrovec GW; Materson BJ; Levenstein M,article,D003160: Comparative Study; D016428: Journal Article; D017418: Meta-Analysis,D017311: Amlodipine; D002121: Calcium Channel Blockers; D002423: Cause of Death; D002561: Cerebrovascular Disorders; D002986: Clinical Trials as Topic; D003692: Delayed-Action Preparations; D005260: Female; D005500: Follow-Up Studies; D006333: Heart Failure; D006470: Hemorrhage; D006801: Humans; D006973: Hypertension; D015994: Incidence; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D009543: Nifedipine; D011446: Prospective Studies; D012449: Safety; D015996: Survival Rate; D016896: Treatment Outcome; D014481: United States,,,https://openalex.org/W1974149808,87,10,1,1774,289,8,en,en
false,intravenous diltiazem acute renal failure cardiac operation,perioperative administration intravenous diltiazem patient undergo cardiac procedure show decrease incidence ischemia arrhythmia however adopt practice cardiac surgery program perceive increased incidence postoperative renal dysfunction direct record review postoperative renal function conduct consecutive patient undergoing cardiac operation time period adoption prophylactic intravenous diltiazem mg kg h hour two group compare use chi two sample test risk development postoperative renal failure model logistic regression diltiazem treated patient n similar control patient n term age versus year p ejection fraction versus p baseline serum creatinine level versus mg dl p prevalence comorbid condition surgical characteristic prevalence left main coronary artery disease low diltiazem group control group versus p day postoperative period average peak serum creatinine level higher diltiazem group mg dl mean standard deviation control group mg dl p incidence acute renal failure require dialysis diltiazem group versus control group p difference length hospitalization mortality risk acute renal failure strongly associate intravenous diltiazem adjust odds ratio aor p age aor per year p baseline serum creatinine aor per mg dl p presence left main coronary disease aor p presence cerebrovascular disease aor p retrospective analysis suggest prophylactic use intravenous diltiazem patient undergoing cardiac operation associate increased renal dysfunction study risk benefit intravenous diltiazem setting undertake,Young EW,1998,Ann Thorac Surg,https://doi.org/10.1016/s0003-4975(98)00157-x,9594859,Young EW; Diab A; Kirsh MM,article,"D003160: Comparative Study; D016428: Journal Article; D013486: Research Support, U.S. Gov't, Non-P.H.S.","D058186: Acute Kidney Injury; D000367: Age Factors; D001145: Arrhythmias, Cardiac; D002121: Calcium Channel Blockers; D002561: Cerebrovascular Disorders; D016009: Chi-Square Distribution; D001026: Coronary Artery Bypass; D003327: Coronary Disease; D003404: Creatinine; D004110: Diltiazem; D005260: Female; D006801: Humans; D015994: Incidence; D007262: Infusions, Intravenous; D007430: Intraoperative Care; D016015: Logistic Models; D008297: Male; D008875: Middle Aged; D017202: Myocardial Ischemia; D016017: Odds Ratio; D015995: Prevalence; D006435: Renal Dialysis; D012189: Retrospective Studies; D012307: Risk Factors; D013318: Stroke Volume; D014665: Vasodilator Agents",,,https://openalex.org/W2082623104,70,9,1,2200,409,10,en,en
false,amlodipine randomized blind clinical trial cat systemic hypertension,efficacy amlodipine aml test hypertensive cat placebo controlled randomize blind clinical trial five cat randomize receive mg aml daily cat receive placebo pla daily average systolic blood pressure sbp record doppler method day mm hg aml group mm hg pla group day cat receive aml significantly low average daily sbp mm hg sbp pla group unchanged mm hg day cat receive pla one cat receive aml cross group inadequate response blood pressure decrease adequately cat day day pla day aml treatment code break cat subsequently administer mg aml daily cat require mg aml daily kg kg weigh significantly cat respond mg aml daily kg average daily sbp record cat complete study significantly low week treatment mm hg compare day mm hg three cat euthanized completion study cat responder aml day sbps measure hour aml administration similar average daily sbp suggest aml effectively control sbp hour period aml show effective daily antihypertensive agent administer cat dosage mg kg sid,Snyder PS,1998,J Vet Intern Med,https://doi.org/10.1111/j.1939-1676.1998.tb02111.x,9595376,Snyder PS,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D017311: Amlodipine; D000818: Animals; D000959: Antihypertensive Agents; D001794: Blood Pressure; D001835: Body Weight; D002371: Cat Diseases; D002415: Cats; D004311: Double-Blind Method; D006973: Hypertension; D010919: Placebos; D013997: Time Factors,,,https://openalex.org/W1977872872,85,14,1,1599,331,13,en,en
false,direct medical cost coronary artery disease united state study support part parke davis division warner lambert company morris plain new jersey pfizer inc new york new york,generate current incidence based estimate direct medical cost coronary artery disease cad united state markov model economic cost cad related medical care develop risk initial subsequent cad event sudden cad death fatal nonfatal acute myocardial infarction ami unstable angina stable angina estimate use new framingham heart study risk equation population risk profile derive national survey data cost assume related treatment initial subsequent cad event event related follow care nonevent related respectively cost estimate derive primarily national public use database first year direct medical cost treat cad event estimate fatal ami nonfatal ami stable angina unstable angina sudden cad death nonevent related direct cost cad treatment estimate annually annual incidence cad united state estimate case first year cost treatment total billion five year cumulative cost dollar patient initially free cad estimate billion billion respectively patient cad cost estimate billion billion respectively direct medical cost cad create large economic burden united state health care system,Russell MW,1998,Am J Cardiol,https://doi.org/10.1016/s0002-9149(98)00136-2,9605051,Russell MW; Huse DM; Drowns S; Hamel EC; Hartz SC,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D003327: Coronary Disease; D017281: Cost of Illness; D003365: Costs and Cost Analysis; D005260: Female; D017048: Health Care Costs; D006801: Humans; D008297: Male; D008875: Middle Aged; D014481: United States",,,https://openalex.org/W2050977476,222,43,1,1521,275,9,en,en
false,replace short acting nifedipine alternative medication large health maintenance organization,response recent evidence safety calcium channel blocker group health cooperative puget sound ghc large health maintenance organization implement plan april reevaluate medication patient take short acting nifedipine follow intervention patient take short acting nifedipine discontinue use switch daily felodipine present physician patient recent evidence safety short acting nifedipine large health maintenance organization able motivate broad scale change safer alternative drug therapy j hypertens american journal hypertension ltd,Kaplan RC,1998,Am J Hypertens,https://doi.org/10.1016/s0895-7061(97)00494-9,9607386,Kaplan RC; Psaty BM; Kriesel D; Heckbert SR; Smith NL; Gillett C; Golston AG,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000368: Aged; D002121: Calcium Channel Blockers; D015331: Cohort Studies; D003692: Delayed-Action Preparations; D004363: Drug Utilization; D015736: Felodipine; D005260: Female; D005500: Follow-Up Studies; D006279: Health Maintenance Organizations; D006801: Humans; D006973: Hypertension; D008297: Male; D009543: Nifedipine; D019233: Retreatment; D012449: Safety,,,https://openalex.org/W1991336434,105,12,1,724,117,4,en,en
false,compliance antihypertensive efficacy amlodipine compare nifedipine slow release,poor compliance principal cause treatment failure hypertensive patient daily dose improves compliance h antihypertensive activity provide compliance efficacy safety amlodipine nifedipine slow release sr compare patient mild moderate essential hypertension recruit among center france week washout period patient randomize week amlodipine mg daily n mg nifedipine sr twice daily n compliance calculate electronic drug monitoring efficacy measure ambulatory casual bp recording patient receive amlodipine demonstrate good compliance patient receive nifedipine sr respect compliance index total number dos take divide total number dos prescribe express percentage v p day correct number dos take v p prescribed dos take schedule v p absolute relative therapeutic coverage high patient receive amlodipine nifedipine sr p mean sbp dbp decrease equally group although amlodipine offer well bp control compare nifedipine sr specific time day patient high nocturnal sbp amlodipine nifedipine sr p adverse event treatment withdrawal occur less frequently amlodipine treated patient nifedipine sr treated patient amlodipine mg daily provide improved compliance good h bp control adverse event mg nifedipine sr twice daily patient mild moderate hypertension,Mounier-Vehier C,1998,Am J Hypertens,https://doi.org/10.1016/s0895-7061(97)00485-8,9607387,Mounier-Vehier C; Bernaud C; Carré A; Lequeuche B; Hotton JM; Charpentier JC,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000328: Adult; D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D010349: Patient Compliance; D016896: Treatment Outcome",,,https://openalex.org/W1964491414,92,10,1,1772,323,12,en,en
false,potassium channel blocking action nifedipine cause morbidity high dos,homecirculationvol potassium channel blocking action nifedipine cause morbidity high dos free accessletterpdf epubaboutview pdfview epubsections toolsadd favoritesdownload citationstrack citationspermissions shareshare onfacebooktwitterlinked inmendeleyreddit jump tofree accessletterpdf epubpotassium channel blocking action nifedipine cause morbidity high dos xue zhang david fedida xue zhangxue zhang department physiology queen university kingston ontario canada david fedidadavid fedida department physiology queen university kingston ontario canada originally published may https doi org cir circulation editor last year use nifedipine especially short acting form come increase scrutiny wide use almost two decade control angina pectoris hypertension associate dose dependent manner unfavorable side effect like increase negative inotropy hypotension proarrhythmia study increase mortality although conclusion without controversy adverse action short acting nifedipine acute situation patient hypertension preexist coronary heart disease accepted one important finding wave inversion asymptomatic would like highlight possible underlying mechanism base sensitivity myocardial potassium ion channel calcium channel antagonist first generation drug nifedipine verapamil diltiazem block calcium channel myocardium relatively high affinity kd nmol l three also block myocardial potassium channel mammalian ventricular myocytes kds mol l clone channels plateau phase cardiac action potential normally terminate repolarizing outward potassium flux block prolong action potential cause dispersion refractoriness channel differ regional distribution across myocardial wall lead instability rest potential ventricular muscle interestingly one prominent effect expect wave inversion relate preferential block epicardial potassium current responsible short epicardial action potential instability plateau rest potential combination raise catecholamine level may predispose generation early late afterdepolarizations give rise important ventricular arrhythmias one particular potassium current ikur rapidly activate delay rectifier present clone human heart hkv particularly important determine plateau duration human cardiac action potential data exist show hkv block three type ca antagonist describe block hkv verapamil detail suggest mechanism open channel block inner pore diltiazem nifedipine block hkv recent data suggest nifedipine also open channel blocker act predominantly external pore hkv channels threshold effect nifedipine hkv nmol l whereas sublingual oral nifedipine give single dos show reach concentration nmol l well within range cause significant potassium channel blockade vitro furthermore concentration may well increase significant renal impairment hypoperfusion occurs due high resistance nature cardiac action potential plateau significant change duration could occur minor block current seem reasonable suggest situation nifedipine give acutely high dose compromised myocardium catecholamine level high stress acute infarction potassium channel block nifedipine could exacerbate likelihood serious arrhythmia reference grossman e messerli fh grodzicki kowey p moratorium place sublingual nifedipine capsule give hypertensive emergency pseudoemergencies jama crossrefmedlinegoogle scholar marwick c fda give calcium channel blocker clean bill health warns short acting nifedipine hazard jama crossrefmedlinegoogle scholar furberg cd psaty bm meyer jv nifedipine dose related increase mortality patient coronary heart disease circulation crossrefmedlinegoogle scholar yusuf f calcium antagonist coronary artery disease hypertension circulation crossrefmedlinegoogle scholar epstein calcium antagonist still appropriate first line antihypertensive agent j hypertens crossrefmedlinegoogle scholar phillips ra goldman ardeljan eison hb shimabukuro krakoff lr isolated wave abnormality evaluation left ventricular wall motion nifedipine severe hypertension j hypertens crossrefmedlinegoogle scholar charnet p ouadid h richard nargeot j electrophysiological analysis action nifedipine nicardipine myocardial fiber fundam clin pharmacol crossrefmedlinegoogle scholar rampe wible b fedida dage rc brown verapamil block rapidly activate delay rectifier k channel clone human heart mol pharmacol medlinegoogle scholar zhang x anderson jw fedida characterization nifedipine block human heart delay rectifier hkv j pharmacol exp ther medlinegoogle scholar liu w gintant ga antzelevitch c ionic base electrophysiological distinction among epicardial midmyocardial endocardial myocytes free wall canine leave ventricle circ res crossrefmedlinegoogle scholar january ct riddle jm early afterdepolarizations mechanism induction block role l type ca current circ res google scholar wang z fermini b nattel sustain depolarization induced outward current human atrial myocytes evidence novel delay rectifier k current similar kv cloned channel current circ res crossrefmedlinegoogle scholar fedida wible b wang z fermini b faust f nattel brown identity novel delay rectifier current human heart cloned k channel current circ res crossrefmedlinegoogle scholar mcallister rgj kinetics dynamic nifedipine oral sublingual dos j med suppl google scholar taburet singlas e colin j banzet thibonnier corvol p pharmacokinetic study nifedipine tablet correlation antihypertensive effect hypertension suppl ii ii ii google scholar eletters eletters relate article recently publish journal forum provide unpublished data comment review appropriate use tone language comment peer reviewed acceptable comment post journal website comment publish issue index pubmed comment long word post online reference limit author article cite comment invite reply appropriate comment feedback aha asa scientific statement guideline direct aha asa manuscript oversight committee via correspondence page sign submit response article previous back top next figuresreferencesrelateddetailscited goldspink lu v bill l larraufie p tolhurst g gribble f reimann f mechanistic insight detection free fatty bile acid ileal glucagon like peptide secreting cell molecular metabolism j molmet online publication date jan li g wang j liao p bartels p zhang h yu liang poh k yu c jiang f yong wong hu z huang h zhang g galupo bian j ponniah trasti see k foo r hoppe u herzig soong exclusion alternative exon ca v calcium channel heart proarrhythmogenic proceeding national academy science pnas online publication date may matza flavell r role ca v channel ahnak cell beauty beast immunological review j x x online publication date sep bett g rasmusson r modification k channel drug interaction ancillary subunit journal physiology jphysiol online publication date feb robertson b pharmacology voltage gated k channels potassium channel cardiovascular biology zhang miller paterson w oppose role k cl channel maintenance opossum lower esophageal sphincter tone american journal physiology gastrointestinal liver physiology ajpgi g g g online publication date dec may vol issue advertisement article information metric copyright american heart associationhttps doi org cir originally publishedmay pdf download advertisement,Zhang X,1998,Circulation,https://doi.org/10.1161/01.cir.97.20.2098,9610546,Zhang X; Fedida D,article,D016422: Letter,D002121: Calcium Channel Blockers; D006801: Humans; D009543: Nifedipine; D026902: Potassium Channel Blockers,,,https://openalex.org/W2081145125,86,14,1,9775,1588,55,en,en
false,cinnarizine induced parkinsonism ten year later,abstract retrospective study carry investigate evolution patient diagnose cinnarizineinduced parkinsonism cip past year total case cip find among patient druginduced parkinsonism dip cip dip significantly frequent woman clinical difference cip dip find patient completely recover cinnarizine withdrawal month eleven patient later develop parkinson disease four previously recover five patient tardive dyskinesia cip account high proportion dip refer neurologist population cinnarizine widely prescribe symptom typically resolve drug withdrawal although complete recovery may take year,Martí-Massó JF,1998,Mov Disord,https://doi.org/10.1002/mds.870130313,9613736,Martí-Massó JF; Poza JJ,article,D016428: Journal Article,"D000368: Aged; D002936: Cinnarizine; D004244: Dizziness; D004409: Dyskinesia, Drug-Induced; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D008134: Long-Term Care; D008297: Male; D009460: Neurologic Examination; D010302: Parkinson Disease, Secondary; D012189: Retrospective Studies; D013030: Spain; D013375: Substance Withdrawal Syndrome; D014715: Vertebrobasilar Insufficiency",,,https://openalex.org/W1534658073,49,6,1,847,145,9,en,en
false,comparative effect felodipine er amlodipine nifedipine git h blood pressure control trough peak ratio mild moderate ambulatory hypertension forced titration study,evaluate h antihypertensive efficacy duration action felodipine extend release er comparison two long act dihydropyridine calcium antagonist amlodipine nifedipine gastrointestinal therapeutic system git patient mild moderate essential hypertension substantiate ambulatory blood pressure bp monitoring randomized force titration parallel group study clinic bp measure every patient visit h ambulatory bp monitor baseline end dose titration period single centre hypertension research unit quebec city quebec patient enrol study eighty four eligible patient randomize complete study include final efficacy analysis following two four week washout period baseline patient randomly allocate receive felodipine er mg amlodipine mg nifedipine git mg four week low dose study patient daily dose double felodipine er mg amlodipine mg nifedipine git mg four week high dose significant p similar change baseline clinic bp observe treatment group low high dos ambulatory bp profile show comparable blood pressure reduction felodipine er amlodipine trend towards less reduction nifedipine git h daytime night time period bp load similarly reduce three treatment trough peak ratio p calculate h ambulatory bp curve accord two different approach diastolic systolic bp respectively global approach produce p felodipine er mg felodipine er mg amlodipine mg amlodipine mg nifedipine git mg nifedipine git mg p individual approach felodipine er mg felodipine er mg amlodipine mg amlodipine mg nifedipine git mg nifedipine git mg evidence study difference among felodipine er amlodipine nifedipine git lower ambulatory clinic bp treatment base ambulatory bp may preferable treatment guide p ambulatory bp firmly establish predictor cardiovascular risk furthermore consensus calculate p different method calculation may give divergent result,Lefebvre J,1998,Can J Cardiol,,9627524,Lefebvre J; Poirier L; Archambault F; Jewell D; Reed CV; Lacourcière Y,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D017311: Amlodipine; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D002940: Circadian Rhythm; D003692: Delayed-Action Preparations; D015736: Felodipine; D005260: Female; D005500: Follow-Up Studies; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D010045: Outpatients; D016896: Treatment Outcome",,,https://openalex.org/W147103854,196,33,1,2676,490,9,en,en
false,effect intensive blood pressure lowering low dose aspirin patient hypertension principal result hypertension optimal treatment hot randomise trial,background despite treatment often high incidence cardiovascular complication patient hypertension normotensive individual inadequate reduction blood pressure likely cause optimum target blood pressure know impact acetylsalicylic acid aspirin never investigate patient hypertension aim assess optimum target diastolic blood pressure potential benefit low dose acetylsalicylic acid treatment hypertension method patient country age year mean year hypertension diastolic blood pressure mm hg mm hg mean mm hg randomly assign target diastolic blood pressure patient allocate target pressure mm hg mm hg mm hg felodipine give baseline therapy addition agent accord five step regimen addition patient randomly assign mg day acetylsalicylic acid bamycor astra patient assign placebo finding diastolic blood pressure reduce mm hg mm hg mm hg mm hg mm hg mm hg target group respectively low incidence major cardiovascular event occur mean achieve diastolic blood pressure mm hg low risk cardiovascular mortality occur mm hg reduction blood pressure safe patient diabetes mellitus reduction major cardiovascular event target group mm hg compare target group mm hg p trend acetylsalicylic acid reduce major cardiovascular event p myocardial infarction p effect stroke seven fatal bleeds acetylsalicylic acid group eight placebo group versus non fatal major bleeds two group respectively p interpretation intensive lowering blood pressure patient hypertension associate low rate cardiovascular event hot study show benefit lower diastolic blood pressure mm hg acetylsalicylic acid significantly reduce major cardiovascular event great benefit see myocardial infarction effect incidence stroke fatal bleeds non fatal major bleeds twice common,Hansson L,1998,Lancet,https://doi.org/10.1016/s0140-6736(98)04311-6,9635947,Hansson L; Zanchetti A; Carruthers SG; Dahlöf B; Elmfeldt D; Julius S; Ménard J; Rahn KH; Wedel H; Westerling S,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D000894: Anti-Inflammatory Agents, Non-Steroidal; D000959: Antihypertensive Agents; D001241: Aspirin; D001794: Blood Pressure; D002318: Cardiovascular Diseases; D004359: Drug Therapy, Combination; D004562: Electrocardiography; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2137408480,175,25,1,2513,457,18,en,en
false,intravesical instillation trospium chloride oxybutynin verapamil relaxation bladder detrusor muscle placebo control randomize clinical test,therapy detrusor hyperactivity anticholinergic agent often follow adverse drug reaction intravesical application may interesting alternative randomised single blind placebo controlled mono centre clinical trial carry patient urgency urge incontinence due intravesical administration oxybutynin cas n trospium chloride cas n respectively significant increase maximum bladder capacity decrease detrusor pressure accompany increase residual urine find comparison placebo urodynamical investigation improvement uninhibited bladder contraction occur lead high filling volume verapamil cas n marked change efficacy variable find compare placebo patient complete study assess regard efficacy safety adverse event mark change vital sign report immediate onset effect lack adverse drug reaction suggest treatment topical oxybutynin trospium chloride effective alternative patient intolerable side effect orally treat addition intravesical administration may indicate patient bladder spasm due indwell catheter order increase bladder capacity percutaneous cystostomy,Fröhlich G,1998,Arzneimittelforschung,,9638316,Fröhlich G; Burmeister S; Wiedemann A; Bulitta M,article,D016430: Clinical Trial; D003160: Comparative Study; D004740: English Abstract; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D001561: Benzilates; D002121: Calcium Channel Blockers; D005260: Female; D006801: Humans; D007267: Injections; D008297: Male; D008333: Mandelic Acids; D009126: Muscle Relaxation; D009130: Muscle, Smooth; D009662: Nortropanes; D010276: Parasympatholytics; D016037: Single-Blind Method; D001743: Urinary Bladder; D014563: Urodynamics; D014700: Verapamil",,,https://openalex.org/W72147436,169,27,2,1426,231,10,en,en
false,calcium antagonist real concern safety,summarycalcium antagonist widely use treatment arterial hypertension ischemic heart disease last year controversial article editorial publish concern potential risk calcium antagonist regard mortality cancer haemorrhage information mainly derive case control study major concern observational study treatment outcome large potential systematic error affect result however overview controlled trial calcium antagonist provide clear evidence effect calcium antagonist mortality risk cancer risk bleeding,Duprez DA,1998,Acta Clin Belg,https://doi.org/10.1080/17843286.1998.11754144,9639942,Duprez DA; De Buyzere ML; Clement DL,article,D016428: Journal Article; D016454: Review,D015982: Bias; D002121: Calcium Channel Blockers; D003257: Consumer Product Safety; D006470: Hemorrhage; D006801: Humans; D006973: Hypertension; D009203: Myocardial Infarction; D017202: Myocardial Ischemia; D009369: Neoplasms; D012107: Research Design; D012307: Risk Factors,,,https://openalex.org/W2397062148,58,11,1,691,111,5,en,en
false,nifedipine acute myocardial infarction sola dosis facit venenum dose determine harm,,Messerli FH,1998,Cardiovasc Drugs Ther,https://doi.org/10.1023/a:1007770825097,9652872,Messerli FH,article,D016420: Comment; D016421: Editorial,D002121: Calcium Channel Blockers; D006801: Humans; D009203: Myocardial Infarction; D009543: Nifedipine; D012008: Recurrence; D018570: Risk Assessment,,,https://openalex.org/W2189646932,106,18,1,0,0,0,en,
false,effect amlodipine lisinopril left ventricular mass diastolic function previously untreated patient mild moderate diastolic hypertension,aim study compare effect two long acting antihypertensive agent calcium antagonist amlodipine ace inhibitor lisinopril left ventricular mass diastolic filling patient mild moderate diastolic hypertension primary care centre year prospective double blind randomize parallel group comparative study patient year age untreated hypertension elevated diastolic blood pressure mmhg three occasion twice first visit second third visit recruit population survey week placebo run patient randomize dosage amlodipine mg lisinopril mg titrate basis effect blood pressure fifty nine patient complete study period primary endpoint leave ventricular mass index early atrial peak fill velocity office ambulatory blood pressure echocardiographic measurement consider secondary decrease blood pressure equal treatment regimens statistically significant decrease left ventricular mass index treatment group observe g ci amlodipine group g ci lisinopril group high baseline value left ventricular mass treatment decrease treatment early atrial peak fill velocity change significantly within treatment group ci amlodipine group ci lisinopril group however analysis time measurement early peak show significant change treatment group significant difference primary secondary endpoint treatment group find twelve patient complete study seven amlodipine five lisinopril basically due adverse event effect amlodipine lisinopril left ventricular mass early atrial filling peak velocity year treatment patient previously untreated mild moderate hypertension similar study recommend particularly large sample size follow long duration,Beltman FW,1998,Blood Press,https://doi.org/10.1080/080370598437484,9657538,Beltman FW; Heesen WF; Smit AJ; May JF; de Graeff PA; Havinga TK; Schuurman FH; van der Veur E; Lie KI; Meyboom-de Jong B,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D005260: Female; D006352: Heart Ventricles; D006801: Humans; D006973: Hypertension; D017706: Lisinopril; D008297: Male; D008875: Middle Aged,,,https://openalex.org/W2128743126,162,22,1,2328,407,16,en,en
false,effect amlodipine versus felodipine extend release hour ambulatory blood pressure hypertension,amlodipine felodipine calcium antagonist dihydropyridine type elimination half life amlodipine long felodipine study whether different elimination rate drug reflect different duration blood pressure bp control compare amlodipine felodipine extend release er conventional clinic bp h drug intake h ambulatory bp monitoring abpm special reference nighttime morning blood pressure two hundred sixteen patient primary hypertension supine diastolic bp mm hg randomize receive amlodipine felodipine er multicenter study start dose drug mg target clinic diastolic bp mm hg achieve week dose increase mg twenty four hour abpm perform subject take placebo medication randomization week undergo active treatment significantly patient respond week treatment amlodipine compare felodipine p abpm daytime similar treatment nighttime systolic p diastolic p bp effectively reduce amlodipine felodipine week achieve target pressure amlodipine felodipine p difference amlodipine seem effective felodipine drug compare dose regard effect clinic bp h dose ambulatory bp night long elimination half life amlodipine compare felodipine probable reason finding,Ostergren J,1998,Am J Hypertens,https://doi.org/10.1016/s0895-7061(98)00032-6,9657628,Ostergren J; Isaksson H; Brodin U; Schwan A; Ohman KP,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2016788066,108,14,1,1750,325,11,en,en
false,distinct vasodilation without reflex neurohormonal activation induce barnidipine hypertensive patient,barnidipine new dihydropyridine calcium antagonist strong long lasting vasodilatory effect order assess haemodynamic profile antihypertensive effect barnidipine randomize double blind study barnidipine v nitrendipine perform patient mild moderate essential hypertension follow initial week placebo period patient whose sit diastolic blood pressure sidbp mm hg whose sit systolic blood pressure mm hg randomize ratio receive either barnidipine mg nitrendipine mg daily week double blind period subsequently patient sidbp less mm hg continue second week period monotherapy patient sidbp mm hg receive double dose antihypertensive treatment next week two dimensional b mode echocardiography doppler flowmetry perform end placebo active treatment phase barnidipine nitrendipine reduce blood pressure degree barnidipine mm hg p nitrendipine mm hg p result peripheral vasodilation accompany reflex neurohormonal activation moreover group receive barnidipine significant decrease plasma noradrenaline observe patient supine position pg ml p upright pg ml p,Argenziano L,1998,Blood Press Suppl,https://doi.org/10.1080/080370598438546,9660521,Argenziano L; Izzo R; Iovino G; De Luca N; Parrella L; Morisco C; Trimarco B,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D009568: Nitrendipine; D012018: Reflex; D013564: Sympathetic Nervous System; D014664: Vasodilation,,,https://openalex.org/W2108604849,111,14,1,1688,317,8,en,en
false,diversity intensity adverse event treatment hypertension barnidipine,abstractcalcium antagonist caas divide three structural class typically represent verapamil diltiazem nifedipine group principal type adverse effect drug relate pharmacological action calcium channel blockade namely vasodilation include dizziness flushing palpitation peripheral oedema clinical safety new dihydropyridine caa barnidipine assess clinical trial include patient treat one dos barnidipine dose mg adverse event barnidipine mild moderate intensity commonly type occur early phase treatment incidence serious adverse event rate withdrawal low hence barnidipine likely well tolerate general clinical use,van der Velden JW,1998,Blood Press Suppl,https://doi.org/10.1080/080370598438573,9660524,van der Velden JW; Beudeker HJ; Nishi M,article,D016428: Journal Article,D000368: Aged; D002121: Calcium Channel Blockers; D006801: Humans; D006973: Hypertension; D009543: Nifedipine; D016896: Treatment Outcome,,,https://openalex.org/W2096237895,91,13,1,871,157,6,en,en
false,life threatening interaction mibefradil blockers dihydropyridine calcium channel blocker,mibefradil type l type calcium channel blocker ccb release united state management hypertension chronic stable angina postmarketing surveillance reveal potential serious interaction mibefradil beta blockers digoxin verapamil diltiazem especially elderly patient manufacturer voluntarily withdraw mibefradil june describe case cardiogenic shock patient take mibefradil beta blockers begin take dihydropyridine ccbs one case result death survive episode cardiogenic shock intensive support heart rate blood pressure physician prepare switch patient medication mibefradil antihypertensive agent aware potentially life threatening drug drug interaction,Mullins ME,1998,JAMA,https://doi.org/10.1001/jama.280.2.157,9669789,Mullins ME; Horowitz BZ; Linden DH; Smith GW; Norton RL; Stump J,article,D002363: Case Reports; D016428: Journal Article,"D000319: Adrenergic beta-Antagonists; D000368: Aged; D001562: Benzimidazoles; D002121: Calcium Channel Blockers; D051544: Cytochrome P-450 CYP3A; D065607: Cytochrome P-450 Enzyme Inhibitors; D004095: Dihydropyridines; D004347: Drug Interactions; D005260: Female; D006207: Half-Life; D006801: Humans; D020748: Mibefradil; D006899: Mixed Function Oxygenases; D012770: Shock, Cardiogenic; D012849: Sinoatrial Node; D013764: Tetrahydronaphthalenes",,,https://openalex.org/W2064102714,103,11,1,850,131,6,en,en
false,angiotensin converting enzyme inhibition calcium antagonism improve response renal vasculature l arginine patient essential hypertension,endothelial function show impair patient essential hypertension purpose present study determine whether antihypertensive drug therapy improve impaired endothelium dependent renal vasorelaxation essential hypertensive patient without atherosclerosis evaluate effect intravenous infusion l arginine mg kg give minute systemic renal hemodynamics patient mild moderate essential hypertension randomly assign treatment either angiotensin converting enzyme inhibitor imidapril calcium antagonist amlodipine week double blind fashion week decrease blood pressure similar imidapril n amlodipine n group increase renal plasma flow also similar group l arginine induced renovascular relaxation increase imidapril renal plasma flow renal vascular resistance p respectively amlodipine urinary excretion nitrite nitrate response l arginine significantly increase imidapril p remain unchanged amlodipine finding suggest angiotensin converting enzyme inhibition improve impaired endothelium dependent renovascular relaxation patient essential hypertension due increase nitric oxide production reduction blood pressure calcium antagonist play major role potentiation l arginine nitric oxide mediated effect,Higashi Y,1998,Hypertension,https://doi.org/10.1161/01.hyp.32.1.16,9674632,Higashi Y; Oshima T; Sasaki S; Nakano Y; Kambe M; Matsuura H; Kajiyama G,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000368: Aged; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001120: Arginine; D002121: Calcium Channel Blockers; D003627: Data Interpretation, Statistical; D004311: Double-Blind Method; D004730: Endothelium, Vascular; D005260: Female; D006801: Humans; D006973: Hypertension; D007093: Imidazoles; D048289: Imidazolidines; D007262: Infusions, Intravenous; D007668: Kidney; D008297: Male; D008875: Middle Aged; D009566: Nitrates; D009569: Nitric Oxide; D009573: Nitrites; D012079: Renal Circulation; D013997: Time Factors; D014655: Vascular Resistance",,,https://openalex.org/W2169961082,180,30,1,1635,254,8,en,en
false,effect single drug therapy reduction left atrial size mild moderate hypertension,cardiac effect hypertension include increase left ventricular lv mass lv hypertrophy well increase leave atrial size predictor stroke atrial fibrillation although literature reduction lv mass antihypertensive therapy extensive little information available effect treatment left atrial size patients mild moderate hypertension diastolic blood pressure mm hg randomly allocate treatment atenolol captopril clonidine diltiazem hydrochlorothiazide prazosin double masked trial two dimensional targeted mode echocardiography use assess left atrial size lv mass baseline week year longitudinal analysis examine change left atrial size baseline study statistically adjust age race pretreatment leave atrial size lv mass serial measurement systolic blood pressure body weight urinary sodium excretion physical activity score without adjustment covariates hydrochlorothiazide associate decrease left atrial size baseline week mm p year mm p year mm p adjustment effect covariates patient normal left atrial size great reduction mm left atrial size year hydrochlorothiazide drug patient left atrial enlargement leave atrial size decrease significantly hydrochlorothiazide atenolol clonidine diltiazem year treatment year however reduction year great hydrochlorothiazide captopril prazosin antihypertensive drug differ effect left atrial size hydrochlorothiazide associate great overall reduction left atrial size drug effective treatment hypertension reduction left atrial size therapy part independent factor know influence left atrial size include lv mass reduction lv mass treatment clinical benefit reduce leave atrial size antihypertensive treatment remain determine,Gottdiener JS,1998,Circulation,https://doi.org/10.1161/01.cir.98.2.140,9679720,Gottdiener JS; Reda DJ; Williams DW; Materson BJ; Cushman W; Anderson RJ,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013486: Research Support, U.S. Gov't, Non-P.H.S.",D000368: Aged; D000959: Antihypertensive Agents; D004311: Double-Blind Method; D004452: Echocardiography; D006325: Heart Atria; D006801: Humans; D006973: Hypertension; D008137: Longitudinal Studies; D008297: Male; D008875: Middle Aged,,,https://openalex.org/W2036890726,95,15,1,2218,379,11,en,en
true,rationale design controlled onset verapamil investigation cardiovascular endpoint convince trial,control onset verapamil investigation cardiovascular endpoint convince trial randomized prospective double blind parallel group two arm actively control multicenter international year clinical trial involve patient convince compare incidence fatal nonfatal myocardial infarction mi fatal nonfatal stroke cardiovascular disease related death two antihypertensive treatment regimen one treatment arm begin control onset extended release coer verapamil major antihypertensive effect hour administration arm standard care soc begin either hydrochlorothiazide hctz atenolol one preselected investigator individual patient prior randomization secondary objective include comparison regimen component primary endpoint separately death hospitalization relate cardiovascular disease efficacy lower blood pressure goal primary event occur noon cause mortality withdrawal blind therapy cancer hospitalization due bleed patient may enrol hypertensive least year age establish second risk factor cardiovascular disease initial medication include coer verapamil mg hctz mg atenolol mg initial dos double blood pressure bp reach goal systolic bp mm diastolic bp mm hg bp control high dose initial medication hctz add coer verapamil soc choice initially select add soc arm ace inhibitor recommend although nearly open label medication allow third step patient whose bp adequately control contraindication one two soc medication patient take two set tablet daily one morning one evening although patient switch establish antihypertensive medication randomize treatment untreated patient stage iii hypertension sbp dbp mm hg eligible outcome monitor independent data safety monitoring board enrollment begin third quarter follow complete third quarter,Black HR,1998,Control Clin Trials,https://doi.org/10.1016/s0197-2456(98)00013-0,9683312,Black HR; Elliott WJ; Neaton JD; Grandits G; Grambsch P; Grimm RH; Hansson L; Lacoucière Y; Muller J; Sleight P; Weber MA; White WB; Williams G; Wittes J; Zanchetti A; Fakouhi TD,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D000959: Antihypertensive Agents; D001262: Atenolol; D002318: Cardiovascular Diseases; D002561: Cerebrovascular Disorders; D004311: Double-Blind Method; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D008875: Middle Aged; D009203: Myocardial Infarction; D014700: Verapamil,,,https://openalex.org/W1993486615,114,16,1,2437,426,14,en,en
false,manage migraine,important advance management migraine headache since last review subject formal diagnostic criterion introduce lead reliable assessment prevalence migraine affect attendance efficiency work addition use ht agonist become establish article discuss change alter management migraine adult,,1998,Drug Ther Bull,https://doi.org/10.1136/dtb.1998.36641,9684422,,article,D016428: Journal Article; D016454: Review,D000328: Adult; D000700: Analgesics; D006801: Humans; D008881: Migraine Disorders; D017366: Serotonin Receptor Agonists,,,https://openalex.org/W4234851192,17,2,1,460,82,4,en,en
false,withdrawal effect antianginal therapy,compare effect abrupt cessation nifedipine isosorbide dinitrate therapy patient stable angina pectoris eighteen male study patient receive isosorbide dinitrate nifedipine continuously week randomised cross technique exercise treadmill test perform treatment period beginning treatment week initiation treatment first eighth day drug withdrawal end treatment antianginal effect agent attenuate versus acute administration abrupt cessation isosorbide dinitrate cause tendency towards decrease exercise tolerance versus pre treatment level alternatively abrupt cessation nifedipine result substantial deterioration exercise tolerance statistically significant h last dose administration number anginal attack increase two patient cessation isosorbide dinitrate eight patient cessation nifedipine patient rest angina episode appear stop isosorbide dinitrate however stop nifedipine rest angina episode appear three patient conclude withdrawal phenomenon nifedipine much pronounced isosorbide dinitrate may emerge first day drug cessation phenomenon may evident even patient nifedipine effect attenuate due development tolerance,Martsevich SYu,1998,Int J Cardiol,https://doi.org/10.1016/s0167-5273(98)00020-5,9688432,Martsevich SYu; Koutishenko N; Metelitsa VI,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000328: Adult; D000787: Angina Pectoris; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D005080: Exercise Test; D017079: Exercise Tolerance; D006801: Humans; D007548: Isosorbide Dinitrate; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D016037: Single-Blind Method; D013375: Substance Withdrawal Syndrome,,,https://openalex.org/W773552,42,6,1,1513,240,11,en,en
false,prospective randomized trial nifedipine vs ritodrine threatened preterm labor,objective compare tocolytic efficacy maternal tolerance nifedipine ritodrine management threatened preterm labor method prospective randomize study singleton pregnancy preterm labor week gestation capacity delay delivery h day week fetal weight reach g outcome variable assess doppler ultrasound study perform fetal umbilical artery control result significant difference find delay delivery significantly maternal side effects find nifedipine group doppler ultrasound result similar group conclusion nifedipine valid well tolerated alternative among tocolytic drug apparently significantly alter fetal vascular blood flow,García-Velasco JA,1998,Int J Gynaecol Obstet,https://doi.org/10.1016/s0020-7292(98)00053-8,9688484,García-Velasco JA; González González A,article,D002363: Case Reports; D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000033: Abortion, Threatened; D000328: Adult; D001034: Apgar Score; D001786: Blood Glucose; D005260: Female; D005333: Fetus; D005865: Gestational Age; D006439: Hemodynamics; D006801: Humans; D007231: Infant, Newborn; D007262: Infusions, Intravenous; D009543: Nifedipine; D007752: Obstetric Labor, Premature; D011247: Pregnancy; D011256: Pregnancy Outcome; D011446: Prospective Studies; D012039: Regional Blood Flow; D012312: Ritodrine; D015149: Tocolytic Agents; D018617: Ultrasonography, Doppler, Pulsed; D016216: Ultrasonography, Prenatal; D014469: Umbilical Arteries",,,https://openalex.org/W1975144724,87,13,1,857,141,7,en,en
false,comparison antihypertensive efficacy safety felodipine iv nifedipine iv patient hypertensive crisis emergency respond oral nifedipine,objective clinical definition hypertensive emergency excessively high blood pressure presence symptom indicate end organ damage equally high blood pressure without symptom call hypertensive crisis patient hypertensive crisis emergency need prompt effective specific therapy controlled reduction blood pressure method perform randomize double blind multi centre study compare safety efficacy tolerability intravenous v infusion two dihydropyridine calcium channel blocker either nifedipine felodipine patient diagnose hypertensive emergency hypertensive crisis react adequately diastolic blood pressure mmhg mg nifedipine po result drug lower blood pressure adequately patient well tolerate one patient withdraw excessive decrease blood pressure conclusion patient excessively high blood pressure react oral nifedipine treat equally effectively felodipine nifedipine iv felodipine easy handle lack light sensitivity,Risler T,1998,Eur J Clin Pharmacol,https://doi.org/10.1007/s002280050462,9696952,Risler T; Bohm R; Wetzchewald D; Nast HP; Koch HH; Stein G; Erley CM,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000959: Antihypertensive Agents; D001794: Blood Pressure; D004311: Double-Blind Method; D004630: Emergencies; D015736: Felodipine; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D007275: Injections, Intravenous; D008297: Male; D008875: Middle Aged; D009543: Nifedipine",,,https://openalex.org/W2050130494,175,26,1,1240,212,9,en,en
false,comparison hour blood pressure heart rate autonomic nerve activity hypertensive patient treat cilnidipine nifedipine retard,compare effect cilnidipine nifedipine retard h blood pressure bp heart rate hr autonomic nerve activity patient essential hypertension cilnidipine novel unique dihydropyridine calcium antagonist l type n type voltage dependent calcium channel blocking action fourteen hypertensive outpatient four men woman age year mean sem enrol study ambulatory bp electrocardiogram monitor h interval min portable recorder week drug free period week treatment period cilnidipine mg daily week treatment period nifedipine retard mg twice daily order three period randomize autonomic nerve activity evaluate power spectral analysis hr variability use high frequency hf component index parasympathetic nerve activity ratio low frequency lf component hf component lf hf index sympathovagal balance cilnidipine nifedipine retard significantly reduce h bp patient similar extent cilnidipine mm hg nifedipine retard mm hg cilnidipine change h average hr whereas nifedipine retard significantly increase beats min p nifedipine retard significantly increase lf hf ratio daytime nighttime change limit daytime treatment period cilnidipine result suggest cilnidipine effective daily antihypertensive agent less influence autonomic nervous system hr nifedipine retard,Minami J,1998,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-199808000-00023,9700998,Minami J; Ishimitsu T; Kawano Y; Numabe A; Matsuoka H,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D017776: Autonomic Pathways; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D004095: Dihydropyridines; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine,,,https://openalex.org/W2017326295,149,22,1,1779,319,11,en,en
false,difference amlodipine lisinopril control clinic twenty four hour ambulatory blood pressure,anti hypertensive efficacy daily amlodipine mg lisinopril mg compare term clinic ambulatory blood pressure bp control observer blind two period crossover study follow week placebo run period patient underwent two active treatment phase last week separate week washout period sixty patient supine diastolic bp mm hg include irrespective whether receive previous anti hypertensive medication amlodipine reduce supine systolic diastolic clinic bp significantly lisinopril v mm hg p p h post dose clinic stand diastolic bp also significantly reduce amlodipine compare lisinopril p drug produce control mean ambulatory bp relative baseline h amlodipine show consistent control bp h period contrast lisinopril exert great effect daytime,Lorimer AR,1998,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1000620,9705044,Lorimer AR; Lyons D; Fowler G; Petrie JC; Rothman MT,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000293: Adolescent; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D000959: Antihypertensive Agents; D001794: Blood Pressure; D018660: Blood Pressure Monitoring, Ambulatory; D002940: Circadian Rhythm; D018592: Cross-Over Studies; D005260: Female; D006801: Humans; D006973: Hypertension; D017706: Lisinopril; D008297: Male; D008875: Middle Aged; D016037: Single-Blind Method; D016896: Treatment Outcome",,,https://openalex.org/W2057343910,114,15,1,1057,178,6,en,en
false,surgical treatment cyclosporine nifedipine induced gingival enlargement gingivectomy versus periodontal flap,purpose study compare probe depth resolution achieve gingivectomy periodontal flap technique treatment cyclosporine nifedipine induced gingival enlargement ten kidney transplant patient receive cyclosporine nifedipine least month participate study five patient randomly assign gingivectomy group patient periodontal flap group anterior segment oral cavity canine canine surgically treat clinical measurement include probe depth plaque index gingival sulcus index take baseline week month year result show probe depth similar group first week study significantly shallow periodontal flap group compare gingivectomy group month mm versus mm respectively year mm versus mm respectively within limitation study suggest pocket reduction achieve periodontal flap may sustain long period time gingivectomy technique treatment cyclosporine nifedipine induced gingival enlargement,Pilloni A,1998,J Periodontol,https://doi.org/10.1902/jop.1998.69.7.791,9706857,Pilloni A; Camargo PM; Carere M; Carranza FA,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,D000293: Adolescent; D000328: Adult; D002121: Calcium Channel Blockers; D002648: Child; D016572: Cyclosporine; D005260: Female; D005885: Gingival Hyperplasia; D005890: Gingivectomy; D006801: Humans; D007166: Immunosuppressive Agents; D016030: Kidney Transplantation; D008297: Male; D009543: Nifedipine; D010512: Periodontal Index; D010514: Periodontal Pocket; D013524: Surgical Flaps,,,https://openalex.org/W2024803553,119,14,1,1273,221,7,en,en
false,retract article calcium channel blocker attenuate cardiovascular response tracheal extubation hypertensive patient,purpose hypertensive patient exhibit exaggerated cardiovascular response tracheal extubation study undertake examine inhibitory effect calcium channel blocker nicardipine diltiazem haemodynamic change tracheal extubation method sixty hypertensive patient asa physical status ii undergo elective orthopaedic upper low extremity surgery receive randomized double blind manner micrograms kg nicardipine mg kg diltiazem saline control n v tracheal extubation change heart rate hr mean arterial pressure map rate pressure product rpp measure tracheal extubation result hr map rpp increase tracheal extubation control group p increase haemodynamic variable attenuate nicardipine diltiazem inhibitory effect diltiazem cardiovascular response tracheal extubation great nicardipine hr vs rpp vs mean sd p conclusion compare nicardipine administration diltiazem produce great attenuate circulatory response tracheal extubation hypertensive patient,Fujii Y,1998,Can J Anaesth,https://doi.org/10.1007/bf03012096,9717598,Fujii Y; Kihara S; Takahashi S; Tanaka H; Toyooka H,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D016441: Retracted Publication,"D000328: Adult; D000368: Aged; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004110: Diltiazem; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006439: Hemodynamics; D006801: Humans; D006973: Hypertension; D007442: Intubation, Intratracheal; D008297: Male; D008875: Middle Aged; D009529: Nicardipine; D019637: Orthopedic Procedures",,,https://openalex.org/W3027959097,126,15,1,1307,227,9,en,en
false,randomize double blind crossover study investigate effect amlodipine isosorbide mononitrate time course severity exercise induced myocardial stunning,myocardial stunning may cause prolonged left ventricular dysfunction exercise induced ischemia attenuate calcium antagonist animal model assess effect human perform randomize double blind crossover study compare calcium antagonist amlodipine mg daily versus isosorbide mononitrate ismn mg daily postexercise stunning twenty four men chronic stable angina normal leave ventricular function underwent serial quantitative exercise stress echocardiography week treatment assess degree postexercise stun simultaneous sestamibi single photon emission compute tomography perfusion scan peak stress quantify ischemic burden exercise time p maximum st depression p sestamibi single photon emission compute tomography score p unchanged treatment stun occur often ismn amlodipine versus global segmental stress echocardiography parameter stun attenuate patient take amlodipine compare ismn shorten fraction ejection fraction less impaired minute exercise patient receive amlodipine versus p versus p similarly isovolumic relaxation period less prolonged amlodipine versus p despite comparable level ischemia amlodipine attenuate stun compare ismn beneficial effect may relate prevention calcium overload implicate pathogenesis stunning,Rinaldi CA,1998,Circulation,https://doi.org/10.1161/01.cir.98.8.749,9727544,Rinaldi CA; Linka AZ; Masani ND; Avery PG; Jones E; Saunders H; Hall RJ,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D017311: Amlodipine; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D018592: Cross-Over Studies; D004311: Double-Blind Method; D004452: Echocardiography; D005080: Exercise Test; D006801: Humans; D007548: Isosorbide Dinitrate; D008297: Male; D008875: Middle Aged; D017682: Myocardial Stunning; D015899: Tomography, Emission-Computed, Single-Photon",,,https://openalex.org/W2004036329,180,24,1,1674,262,7,en,en
false,inhale nitric oxide screening agent safely identify responder oral calcium channel blocker primary pulmonary hypertension,subset patient primary pulmonary hypertension pph high dos oral calcium channel blocker ccb produce sustained clinical haemodynamic improvement however significant side effects report acute test ccb therefore identify accurately patient may benefit long term ccb therapy need safe potent short acting vasodilator aim study compare acute response inhale nitric oxide oral high dos ccb consecutive patient pph significant acute vasodilator response define fall mean pulmonary artery pressure total pulmonary resistance ten patient respond acutely nine respond acutely ccb without complication patient fail respond ccb nonresponders nine serious adverse event observe ccb clinical baseline haemodynamic feature predict acute vasodilator response long term oral treatment ccb restrict nine acute responder sustained clinical haemodynamic improvement observe six patient primary pulmonary hypertension acute response rate high dos calcium channel blocker low serious adverse reaction high dos calcium channel blocker acute test frequently observe nonresponders conclude nitric oxide may use screening agent safely identify patient primary pulmonary hypertension respond acutely calcium channel blocker may benefit long term treatment agent,Sitbon O,1998,Eur Respir J,https://doi.org/10.1183/09031936.98.12020265,9727772,Sitbon O; Humbert M; Jagot JL; Taravella O; Fartoukh M; Parent F; Herve P; Simonneau G,article,D003160: Comparative Study; D016428: Journal Article,"D000280: Administration, Inhalation; D000284: Administration, Oral; D002121: Calcium Channel Blockers; D004110: Diltiazem; D004305: Dose-Response Relationship, Drug; D005260: Female; D006801: Humans; D006976: Hypertension, Pulmonary; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D009569: Nitric Oxide; D011446: Prospective Studies; D011669: Pulmonary Wedge Pressure; D013997: Time Factors; D014655: Vascular Resistance",,,https://openalex.org/W2118073788,142,19,1,1696,292,13,en,en
false,amlodipine daily systemic hypertension,unlabelled calcium channel blocker nifedipine widely use child systemic hypertension however short duration action three four daily dos standard preparation require amlodipine daily calcium channel blocker structurally relate nifedipine excellent bioavailability long elimination half time show reduce blood pressure adult information available use amlodipine childhood effect amlodipine daily mg therefore assess paediatric patient hypertension amlodipine withdraw five patient experience oedema flushing remain patient blood pressure significantly reduce week amlodipine average mm hg far decrease week mm hg heart rate body weight unchanged eight patient concomitantly treat cyclosporine blood level agent stable throughout study thus require dose adjustment conclusion study illustrate antihypertensive property amlodipine daily paediatric hypertension amlodipine appear particularly indicate patient concomitantly treat cyclosporine,Pfammatter JP,1998,Eur J Pediatr,https://doi.org/10.1007/s004310050897,9727842,Pfammatter JP; Clericetti-Affolter C; Truttmann AC; Busch K; Laux-End R; Bianchetti MG,article,D016428: Journal Article,"D000293: Adolescent; D000328: Adult; D017311: Amlodipine; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D002648: Child; D002675: Child, Preschool; D016572: Cyclosporine; D004305: Dose-Response Relationship, Drug; D004334: Drug Administration Schedule; D004359: Drug Therapy, Combination; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006973: Hypertension; D016030: Kidney Transplantation; D008297: Male; D011183: Postoperative Complications",,,https://openalex.org/W2052759325,46,5,1,1284,210,10,en,en
false,metformin old drug treatment diabetes new drug protection endothelium,anti diabetic oral hypoglycaemic agent metformin first use clinically today first choice gold standard drug treatment type diabetes polycystic ovary disease particular importance treatment diabetes metformin affords protection diabetes induced vascular disease addition retrospective analysis suggest treatment metformin provide therapeutic benefit patient several form cancer despite almost year clinical use precise cellular mode action metformin remain controversial direct indirect role adenosine monophosphate amp activated protein kinase ampk fuel gauge cell infer many study evidence activation ampk may result mild inhibitory effect metformin mitochondrial complex turn would raise amp activate ampk discrepancy however concentration metformin use vitro study versus therapeutic level suggest caution apply extend inference derive cell based study therapeutic benefit see patient conceivably effect may least partially independent ampk mitochondrial respiration reflect direct effect either metformin minor yet unidentified putative metabolite metformin target protein signalling cascade review critically evaluate data study investigate pharmacokinetic property cellular clinical basis oral hypoglycaemic insulin sensitising vascular protective effect metformin,UK Prospective Diabetes Study Group,1998,BMJ,https://doi.org/10.1159/000381643,9732337,UK Prospective Diabetes Study Group,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000319: Adrenergic beta-Antagonists; D000419: Albuminuria; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001262: Atenolol; D001786: Blood Glucose; D002216: Captopril; D002561: Cerebrovascular Disorders; D003924: Diabetes Mellitus, Type 2; D003925: Diabetic Angiopathies; D003930: Diabetic Retinopathy; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006973: Hypertension; D007003: Hypoglycemia; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D010349: Patient Compliance; D016491: Peripheral Vascular Diseases; D011446: Prospective Studies; D011507: Proteinuria; D014792: Visual Acuity; D015430: Weight Gain",,,https://openalex.org/W1545732697,105,20,1,1703,284,8,en,en
false,efficacy atenolol captopril reduce risk macrovascular microvascular complication type diabetes ukpds uk prospective diabetes study group,determine whether tight control blood pressure either beta blocker angiotensin converting enzyme inhibitor specific advantage disadvantage prevent macrovascular microvascular complication type diabetes randomised control trial compare angiotensin convert enzyme inhibitor captopril beta blocker atenolol patient type diabetes aim blood pressure mm hg hospital base clinic england scotland northern ireland hypertensive patient type diabetes mean age year mean blood pressure mm hg patient allocate tight control blood pressure allocate captopril atenolol patient allocate less tight control blood pressure predefined clinical end point fatal non fatal relate diabetes death relate diabetes cause mortality surrogate measure microvascular macrovascular disease include urinary albumin excretion retinopathy assess retinal photography captopril atenolol equally effective reduce blood pressure mean mm hg mm hg respectively similar proportion patient require three antihypertensive treatment patient captopril group atenolol group take allocated treatment last clinic visit allocate captopril allocate atenolol take drug p captopril atenolol equally effective reduce risk macrovascular end point similar proportion patient two group show deterioration retinopathy two grade nine year captopril group atenolol group developed clinical grade albuminuria mg l proportion patient hypoglycaemic attack different group mean weight gain atenolol group great kg v kg blood pressure lower captopril atenolol similarly effective reduce incidence diabetic complication study provide evidence either drug specific beneficial deleterious effect suggest blood pressure reduction may important treatment use,UK Prospective Diabetes Study Group,1998,BMJ,,9732338,UK Prospective Diabetes Study Group,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.","D000319: Adrenergic beta-Antagonists; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001262: Atenolol; D002216: Captopril; D002561: Cerebrovascular Disorders; D003924: Diabetes Mellitus, Type 2; D003925: Diabetic Angiopathies; D003930: Diabetic Retinopathy; D005500: Follow-Up Studies; D006442: Glycated Hemoglobin; D006801: Humans; D006973: Hypertension; D007003: Hypoglycemia; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D010349: Patient Compliance; D016491: Peripheral Vascular Diseases; D011446: Prospective Studies; D016896: Treatment Outcome; D014792: Visual Acuity; D015430: Weight Gain",,,https://openalex.org/W4298211110,167,27,2,2361,405,9,en,en
false,assessment atrioventricular junction ablation vvir pacemaker versus pharmacological treatment patient heart failure chronic atrial fibrillation,background uncontrolled study suggest atrioventricular junction ablation pacemaker implantation beneficial effect quality life patient chronic atrial fibrillation af method result perform multicenter control randomize month evaluation clinical effect atrioventricular junction ablation vvir pacemaker abl pm versus pharmacological drug treatment patient chronic last month af clinically manifest heart failure heart rate bpm standard ecg record rest stable clinical condition different day completion study withdrawal occur patient drug group patient abl pm group end month abl pm patient complete study show low score palpitation p effort dyspnea p drug group low score although significant also observe exercise intolerance easy fatigue chest discomfort live heart failure questionnaire new york heart association functional classification activity scale intrapatient comparison enrollment month show abl pm group variable except easy fatigue improve significantly however improvement also observe drug group difference group significant palpitation p effort dyspnea p exercise intolerance p easy fatigue p chest discomfort p cardiac performance evaluate mean standard echocardiogram exercise test differ significantly group remain stable time conclusion patient heart failure chronic af abl pm treatment effective superior drug therapy control symptom although efficacy appear less observe uncontrolled study improvement also expect medically treated patient cardiac performance modify treatment,Brignole M,1998,Circulation,https://doi.org/10.1161/01.cir.98.10.953,9737514,Brignole M; Menozzi C; Gianfranchi L; Musso G; Mureddu R; Bottoni N; Lolli G,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000368: Aged; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D001283: Atrioventricular Node; D017115: Catheter Ablation; D002637: Chest Pain; D004417: Dyspnea; D015716: Electrocardiography, Ambulatory; D017079: Exercise Tolerance; D005260: Female; D006333: Heart Failure; D006339: Heart Rate; D006801: Humans; D008297: Male; D010138: Pacemaker, Artificial; D018579: Patient Selection; D011788: Quality of Life",,,https://openalex.org/W2109788838,163,20,1,2202,408,10,en,en
false,use calcium antagonist link cancer,animal vitro study several calcium antagonist show block apoptosis program cell death natural cellular defence cancer basis study hypothesise calcium antagonist may function cancer promoter might cause cancer human association use calcium antagonist cancer address recently independent epidemiological study four study cohort case control find significantly high risk cancer among user certain calcium antagonist compare either non users user antihypertensive agent study fail find support association study limitation vary type significance emerge pattern investigation include following feature strength association appear dependent daily dosage range association user low dosage fold possibly high increase risk user high dosage ii time lag appearance association appear least year iii association high risk cancer find primarily verapamil relationship report diltiazem iv highly consistent association show specific cancer sit histological type data preferably long term randomised clinical trial require firm conclusion draw,Pahor M,1998,Drugs Aging,https://doi.org/10.2165/00002512-199813020-00002,9739499,Pahor M; Furberg CD,article,D003160: Comparative Study; D016428: Journal Article; D016454: Review,"D000367: Age Factors; D000368: Aged; D000959: Antihypertensive Agents; D017209: Apoptosis; D002121: Calcium Channel Blockers; D016022: Case-Control Studies; D015331: Cohort Studies; D004305: Dose-Response Relationship, Drug; D005260: Female; D006801: Humans; D008297: Male; D009369: Neoplasms; D012307: Risk Factors",,,https://openalex.org/W55808841,56,11,1,1558,276,8,en,en
false,ventricular arrhythmia elderly,sudden cardiac death scd remain significant medical problem account death annually united states incidence scd increase advance age cardiovascular disease prevalent elderly case scd metabolic substrate myocardial ischemia underlie coronary artery disease hypertension hypertrophy result ventricular tachycardia vt ventricular fibrillation vf underlying substrate scd common elderly high prevalence coronary artery disease hypertension well physiologic change myocardium advance age also predispose electrical instability although established principle evaluation management cardiac arrhythmia apply age group management elderly patient especially challenging increased risk interventional pharmacologic therapy alter pharmacokinetics drug sometimes unclear long term benefit old patient,Tresch DD,1998,Emerg Med Clin North Am,https://doi.org/10.1016/s0733-8627(05)70022-5,9739779,Tresch DD; Thakur RK,article,D016428: Journal Article; D016454: Review,"D000368: Aged; D000369: Aged, 80 and over; D000638: Amiodarone; D015906: Angioplasty, Balloon, Coronary; D000889: Anti-Arrhythmia Agents; D001026: Coronary Artery Bypass; D017147: Defibrillators, Implantable; D006334: Heart Function Tests; D006801: Humans; D008875: Middle Aged; D017180: Tachycardia, Ventricular; D014693: Ventricular Fibrillation; D018879: Ventricular Premature Complexes",,,https://openalex.org/W2089594224,38,5,1,1085,172,2,en,en
false,long term follow early intervention intravenous diltiazem intravenous nitroglycerin unstable angina pectoris,aimsin double blind randomized trial unstable angina show intravenous diltiazem reduce ischaemic event first h inclusion well intravenous nitroglycerin present study perform establish long term prognosis randomized patient respect initial treatment assignment method resultsone year follow data ischaemic end points anti ischaemic medication recorded results available randomize patients one hundred sixty seven primary endpoint event record occur first h follow survival analysis show event free survival significantly well diltiazem group nitroglycerin group p incidence rate h one year cardiac death respectively trend anti ischaemic medication higher nitroglycerin group beta blockers trend become significant month p conclusionthese result show initial benefit obtain early treatment intravenous diltiazem preserve first year initial hospitalization despite high risk cardiac event population overall mortality month inclusion low,Göbel EJ,1998,Eur Heart J,https://doi.org/10.1053/euhj.1998.0874,9740342,Göbel EJ; van Gilst WH; de Kam PJ; ter Napel MG; Molhoek GP; Lie KI,article,D016428: Journal Article,"D000789: Angina, Unstable; D002121: Calcium Channel Blockers; D004110: Diltiazem; D018572: Disease-Free Survival; D004311: Double-Blind Method; D005500: Follow-Up Studies; D006801: Humans; D007262: Infusions, Intravenous; D005996: Nitroglycerin; D011379: Prognosis; D016032: Randomized Controlled Trials as Topic; D016896: Treatment Outcome; D014665: Vasodilator Agents",,,https://openalex.org/W1982948421,129,15,1,1355,216,3,en,en
false,intravenous diltiazem acute myocardial infarction,study define pilot investigation usefulness safety intravenous diltiazem adjunctive therapy tissue plasminogen activator acute myocardial infarction follow oral therapy weeks experimental study document calcium antagonist protect myocardial cell damage cause coronary artery occlusion reperfusion yet benefit conclusively demonstrate acute myocardial infarction ami humans pilot study patient ami treat tissue type plasminogen activator pa randomize double blind intravenous diltiazem placebo h follow oral therapy week primary objective detect effect index regional leave ventricular function perfusion patient also closely monitor clinical event coronary artery patency index infarct size left ventricular function creatine kinase elevation q wave score global regional left ventricular function coronary artery patency h significantly different diltiazem placebo group great improvement observe regional perfusion function diltiazem likely explain initial large defect diltiazem compare placebo reduce rate death reinfarction recurrent ischemia day p prevent need urgent intervention rate death myocardial infarction reduce p benefit could explain difference baseline characteristic age site extent infarction time inclusion concomitant therapy heart rate blood pressure reduce throughout study active diltiazem treatment side effect diltiazem bradycardia hypotension require transient permanent discontinuation study drug patient vs patient placebo protective effect clinical event relate early postinfarction ischemia reinfarction suggest study diltiazem administer intravenously pa follow oral therapy month effect coronary artery patency leave ventricular function perfusion,Théroux P,1998,J Am Coll Cardiol,https://doi.org/10.1016/s0735-1097(98)00281-2,9741502,Théroux P; Grégoire J; Chin C; Pelletier G; de Guise P; Juneau M,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000284: Administration, Oral; D000328: Adult; D000368: Aged; D002121: Calcium Channel Blockers; D003326: Coronary Circulation; D004110: Diltiazem; D004311: Double-Blind Method; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D007262: Infusions, Intravenous; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction; D015428: Myocardial Reperfusion Injury; D010865: Pilot Projects; D012008: Recurrence; D015996: Survival Rate; D015912: Thrombolytic Therapy; D010959: Tissue Plasminogen Activator; D016277: Ventricular Function, Left",,,https://openalex.org/W2136303393,52,6,1,2286,375,9,en,en
false,comparison nisoldipine coat core felodipine treatment mild moderate hypertension,efficacy safety nisoldipine cc felodipine compare multicentre randomise double blind trial patient mild moderate hypertension n follow two week placebo run period patient randomise week active treatment nisoldipine coat core cc mg felodipine mg daily week high proportion patient nisoldipine cc group low dose therapy vs p proportion treatment responder nisoldipine cc felodipine mean change baseline systolic diastolic blood pressure mmhg nisoldipine cc mmhg felodipine common adverse event include peripheral oedema headache neither treatment affected heart rate thus nisoldipine cc felodipine provide comparable antihypertensive efficacy adverse effect drug relate vasodilator property common class,Hoglund C,1998,Int J Clin Pract,,9744143,Hoglund C; Hutchinson HG,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D004311: Double-Blind Method; D004487: Edema; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D015737: Nisoldipine; D016896: Treatment Outcome; D014717: Vertigo,,,https://openalex.org/W87356177,102,13,1,1015,178,8,en,en
false,fatal aplastic anaemia associate nifedipine,although risk benefit ratio question nifedipine still use treatment hypertension angina suggest nifedipine may associate risk aplastic anaemia,Laporte JR,1998,Lancet,https://doi.org/10.1016/s0140-6736(98)24034-7,9746025,Laporte JR; Ibáñez L; Ballarín E; Pérez E; Vidal X,article,D016422: Letter,"D000368: Aged; D000741: Anemia, Aplastic; D002121: Calcium Channel Blockers; D016022: Case-Control Studies; D005260: Female; D006801: Humans; D015994: Incidence; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D012307: Risk Factors",,,https://openalex.org/W2161974756,49,6,1,200,34,2,en,en
false,comparison effect amlodipine lisinopril proteinuria nondiabetic renal failure double blind randomize prospective study,double blind randomize controlled study long week duration compare antiproteinuric potential long acting dihydropyridine calcium channel blocker angiotensin convert enzyme ace inhibitor lack therefore perform study patient nondiabetic renal disease proteinuria week wash period patient use medication know affect proteinuria patient randomize double blind fashion receive either calcium channel blocker amlodipine amlo mg ace inhibitor lisinopril li mg throughout week study period blood pressure creatinine clearance proteinuria measure every week addition device measure blood pressure renal hemodynamic study perform start end study systolic blood pressure fell li group sem mm hg p mm hg amlo group diastolic blood pressure fell mm hg li group mm hg amlo group renal hemodynamics affect amlodipine treatment whereas fall glomerular filtration rate gfr see lisinopril treated patient ml min p amlodipine significantly affect proteinuria lisinopril induce decline protein creatinine ratio maximal effect reach week therapy g mmol p conclusion could demonstrate antiproteinuric effect long acting dihydropyridine calcium channel blocker amlodipine whereas therapy ace inhibitor lisinopril result decrease proteinuria amlodipine affect renal hemodynamics whereas lisinopril induce fall gfr j hypertens american journal hypertension ltd,Janssen JJ,1998,Am J Hypertens,https://doi.org/10.1016/s0895-7061(98)00129-0,9752892,Janssen JJ; Gans RO; van der Meulen J; Pijpers R; ter Wee PM,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000328: Adult; D000368: Aged; D017311: Amlodipine; D000806: Angiotensin-Converting Enzyme Inhibitors; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D017706: Lisinopril; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D011507: Proteinuria; D051437: Renal Insufficiency,,,https://openalex.org/W2010313240,150,21,1,1962,369,12,en,en
false,reduction cardiovascular structural change nifedipine git essential hypertensive patient,abstractthe aim study evaluate effect calcium antagonist nifedipine git double blind randomize comparison diuretic hydrochlorothiazide hctz reduction left ventricular lv mass minimal vascular resistance group essential hypertensive left ventricular hypertrophy lvh effect blood pressure echocardiographic lv functional parameter also analyse two month randomized treatment nifedipine git hctz diastolic blood pressure mmhg combination two drug give continue week mode guided echocardiography use measure lv mass index lvmi accord penn convention minimal vascular resistance measure forearm arterial pressure maximal blood flow use strain gauge plethysmography examination perform week treatment change lvmi analyse week week patient receive monotherapy accord protocol analysis also end treatment patient take nifedipine hctz monotherapy combination two drug intention treat analysis nifedipine hctz significantly reduce systolic diastolic blood pressure p without significant difference two drug treatment heart rate significantly modify either treatment progressive decrease lvmi observe week treatment nifedipine monotherapy anova p decrease lvmi hctz treatment progress far week anova p significant reduction minimal vascular resistance observe patient treat nifedipine git monotherapy anova p hctz group anova p comparison change forearm minimal vascular resistance consider baseline value could demonstrate great effect nifedipine monotherapy compare hctz monotherapy conclusion group hypertensive patient lvh treatment week nifedipine git alone combination hctz induce significant reduction lvmi forearm vascular structural change evaluate minimal vascular resistance decrease minimal vascular resistance significantly great patient treat nifedipine monotherapy compare give hctz,Agabiti-Rosei E,1998,Blood Press,https://doi.org/10.1080/080370598437376,9758086,Agabiti-Rosei E; Zulli R; Muiesan ML; Salvetti M; Rizzoni D; Corbellini C; Monteduro C,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D004232: Diuretics; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006352: Heart Ventricles; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D017379: Hypertrophy, Left Ventricular; D008297: Male; D008875: Middle Aged; D009206: Myocardium; D009543: Nifedipine; D009929: Organ Size; D049993: Sodium Chloride Symporter Inhibitors; D014655: Vascular Resistance; D016277: Ventricular Function, Left; D020257: Ventricular Remodeling",,,https://openalex.org/W2163691183,100,12,1,2496,443,16,en,en
false,valsartan antihypertensive long term use evaluation value trial cardiovascular event hypertension rationale design,essential hypertension major public health issue although number treated hypertensive patient increase treated patient blood pressure level control benefit treat hypertension prove cardiovascular morbidity mortality rate remain high ideal antihypertensive drug normalize blood pressure level also reduce associated cardiovascular morbidity mortality rate role angiotensin ii systemic hypertension complication recently redefine potent trophic effect angiotensin ii blood vessel cardiac cell well demonstrate especially role angiotensin ii left ventricular hypertrophy vascular hypertrophy endothelial dysfunction congestive heart failure ongoing mortality morbidity trial systemic hypertension value valsartan antihypertensive long term use evaluation one compare angiotensin ii antagonist valsartan third generation calcium channel blocker amlodipine main hypothesis value trial equivalent decrease blood pressure valsartan effective amlodipine decrease cardiac mortality morbidity value prospective multinational multicentre double blind randomize active controlled arm parallel group comparison response dependent dose titration scheme value involve patient country follow year patient experience primary endpoint population include value consist hypertensive men woman age year old relatively high risk sustain cardiovascular event high risk profile define take account age gender list cardiovascular risk factor disease factor risk factor cigarette smoking hypercholesterolaemia diabetes mellitus uncomplicated leave ventricular hypertrophy proteinuria high serum creatinine disease factor include documented history myocardial infarction peripheral vascular disease stroke transient ischaemic attack presence left ventricular hypertrophy strain ecg unique feature value assessment predictive power cardiovascular risk factor scale large population treated hypertensive patient trial start september,Mann J,1998,Blood Press,https://doi.org/10.1080/080370598437394,9758088,Mann J; Julius S,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000368: Aged; D017311: Amlodipine; D000804: Angiotensin II; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D002318: Cardiovascular Diseases; D004305: Dose-Response Relationship, Drug; D004311: Double-Blind Method; D005260: Female; D006801: Humans; D006973: Hypertension; D017379: Hypertrophy, Left Ventricular; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D012107: Research Design; D012307: Risk Factors; D013777: Tetrazoles; D016896: Treatment Outcome; D014633: Valine; D000068756: Valsartan",,,https://openalex.org/W2150174446,132,19,2,2480,401,16,en,en
false,frequency hospitalization exposure know drug drug interaction medicaid population,matched pair case control analysis medicaid claim perform determine risk hospitalization associate drug drug interaction patient hospitalize control randomly match base contemporaneous eligibility medicaid benefit odds ratio hospitalization patient expose know drug drug interaction compare patient expose one interacting agent confidence interval overlap odds ratio consider significantly increase odds ratio significantly increase many interacting drug pair associate commonly recognize interaction well less widely recognize one cimetidine interaction achieve significance theophylline medicaid population exposure number drug drug interaction associate significantly increase risk hospitalization,Hamilton RA,1998,Pharmacotherapy,,9758323,Hamilton RA; Briceland LL; Andritz MH,article,D003160: Comparative Study; D016428: Journal Article,"D000293: Adolescent; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D016022: Case-Control Studies; D002648: Child; D002675: Child, Preschool; D004347: Drug Interactions; D064420: Drug-Related Side Effects and Adverse Reactions; D005260: Female; D006760: Hospitalization; D006801: Humans; D007049: Iatrogenic Disease; D008297: Male; D008484: Medicaid; D008875: Middle Aged; D009518: New York; D014481: United States",,,https://openalex.org/W1491526239,100,13,1,943,138,8,en,en
false,constipation adverse effect drug use nursing home patient overestimate risk,investigate whether result case control cross sectional study suggest association laxative use drug use could confirm cohort study nursing home patients prospective cohort study nursing home patient age year perform estimate incidence relative risk constipation associate drug use study conduct prescription sequence analysis resident detailed pharmacy record data morbidity mobility use drug accord summary product characteristic spc literature adverse drug effect moderately strongly constipate property associate relative risk ci occurrence constipation exposure time use drug mildly moderately constipate effect associate laxative use rr ci stratification level age gender type nursing psychogeriatric somatic morbidity number medication take mobility show confound effect variable outcome measurement variable act effect modifier effect age number medication take relative risk nonlinear although association drug exhibit moderately strongly constipate effect occurrence constipation find risk high see previous study high prevalence constipation nursing home patient partly due adverse drug effect,van Dijk KN,1998,Br J Clin Pharmacol,https://doi.org/10.1046/j.1365-2125.1998.00777.x,9764967,van Dijk KN; de Vries CS; van den Berg PB; Dijkema AM; Brouwers JR; de Jong-van den Berg LT,article,D016428: Journal Article,"D000368: Aged; D000369: Aged, 80 and over; D002400: Cathartics; D015331: Cohort Studies; D003248: Constipation; D064420: Drug-Related Side Effects and Adverse Reactions; D005260: Female; D006707: Homes for the Aged; D006801: Humans; D008297: Male; D009735: Nursing Homes; D011446: Prospective Studies; D012307: Risk Factors",,,https://openalex.org/W1534348323,93,16,1,1585,265,7,en,en
false,diltiazem maintenance tocolysis preterm labor comparison rifedipine randomized trial,objective study compare safety efficacy maintenance tocolysis oral diltiazem oral nifedipine achieve week gestation successful intravenous tocolysis magnesium sulfate woman preterm labor week gestation randomly assign nifedipine mg orally every hr diltiazem mg orally every hr primary outcome percentage patient achieve week gestation maternal cardiovascular alteration neonatal outcome also assess sixty nine patient available final analysis less patient diltiazem compare nifedipine achieve week vs p gestational age delivery also less patient receive diltiazem week vs week p day gain utero randomization delivery diltiazem compare nifedipine however difference statistically significant day vs day p maternal blood pressure pulse tocolysis differ significantly group despite theoretical advantage diltiazem tocolysis maintenance tocolysis diltiazem offer benefit nifedipine achieve week gestation cardiovascular alteration either drug normotensive pregnant patient appear minimal j matern fetal med wiley liss inc,El-Sayed YY,1998,J Matern Fetal Med,https://doi.org/10.1002/(sici)1520-6661(199809/10)7:5<217::aid-mfm1>3.0.co;2-p,9775988,El-Sayed YY; Holbrook RH; Gibson R; Chitkara U; Druzin ML; Baba D,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000653: Amniotic Fluid; D002543: Cerebral Hemorrhage; D004110: Diltiazem; D005260: Female; D005865: Gestational Age; D006801: Humans; D007231: Infant, Newborn; D017078: Laser-Doppler Flowmetry; D009543: Nifedipine; D007752: Obstetric Labor, Premature; D011247: Pregnancy; D011446: Prospective Studies; D012127: Respiratory Distress Syndrome, Newborn; D015145: Tocolysis; D014469: Umbilical Arteries",,,https://openalex.org/W2003815951,100,15,1,1474,258,14,en,en
false,comparison efficacy dihydropyridine calcium channel blocker african american patient hypertension,hypertension prevalent disease among african american successful treatment rate low since calcium channel blocker well tolerated efficacious african american undertake study compare efficacy safety tolerability commonly prescribed calcium channel blocker amlodipine besylate norvasc nifedipine coat core cc adalat cc nifedipine gastrointestinal therapeutic system git procardia xl one hundred ninety two hypertensive patient across study center randomly assign double blind monotherapy amlodipine besylate mg nifedipine cc mg nifedipine git mg week patient achieve therapeutic response week dose double next week primary end point comparison average reduction week minus baseline hour ambulatory diastolic blood pressure dbp secondary end point include comparison average hour ambulatory systolic blood pressure sbp office sbp dbp reduction responder rate safety tolerability one hundred sixty three patient evaluable efficacy week significant difference average hour ambulatory dbp mm hg respectively sbp mm hg respectively reduction average office sbp dbp reduce comparable degree mm hg p mm hg p respectively responder rate dbp reduce mm hg similar p discontinuation rate adverse event frequency distribute similarly across treatment groups efficacy safety tolerability dihydropyridine calcium channel blocker equivalent african american stage hypertension,Hall WD,1998,Arch Intern Med,https://doi.org/10.1001/archinte.158.18.2029,9778203,Hall WD; Reed JW; Flack JM; Yunis C; Preisser J,article,"D016430: Clinical Trial; D017429: Clinical Trial, Phase IV; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000328: Adult; D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D044383: Black People; D001794: Blood Pressure; D001835: Body Weight; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D012720: Severity of Illness Index; D013997: Time Factors; D016896: Treatment Outcome,,,https://openalex.org/W2118292702,117,15,1,1827,338,9,en,en
true,effect amlodipine mode death among patient advanced heart failure praise trial,investigation calcium antagonist patient advanced heart failure raise concern increase risk worsen heart failure heart failure death assess effect amlodipine cause specific mortality patient enrol randomized double blind placebo controlled trial total patient new york heart association class iiib iv heart failure randomize receive amlodipine placebo along angiotensin converting enzyme inhibitor diuretic digitalis median month follow patient die cardiovascular death account fatality sudden death due pump failure attribute myocardial infarction cardiovascular cause amlodipine treatment result great relative reduction sudden death pump failure death overall patient classify etiology heart failure ischemic nonischemic cause specific mortality differ significantly treatment group ischemic stratum nonischemic stratum however sudden death pump failure death reduce respectively amlodipine thus add digitalis diuretic angiotensin converting enzyme inhibitor patient advanced heart failure amlodipine appear effect cause specific mortality ischemic cardiomyopathy pump failure sudden death appear decrease nonischemic heart failure patient treat amlodipine,O'Connor CM,1998,Am J Cardiol,https://doi.org/10.1016/s0002-9149(98)00496-2,9781971,O'Connor CM; Carson PE; Miller AB; Pressler ML; Belkin RN; Neuberg GW; Frid DJ; Cropp AB; Anderson S; Wertheimer JH; DeMets DL,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D017311: Amlodipine; D002121: Calcium Channel Blockers; D002423: Cause of Death; D003645: Death, Sudden; D016757: Death, Sudden, Cardiac; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005500: Follow-Up Studies; D006333: Heart Failure; D006801: Humans; D012307: Risk Factors; D016019: Survival Analysis; D013997: Time Factors",,,https://openalex.org/W1969963476,100,17,1,1619,276,9,en,en
false,calcium channel blocker prevention noise trauma otologic surgery,one hundred patient test prior otologic ear surgery prospective randomize double blind study assess perioperative efficiacy calcium channel blocker diltiazem prevent acoustical trauma middle ear surgery patient randomly divide therapy group diltiazem control group placebo bone conduction hear threshold examine preoperatively follow day month postoperatively frequency dependent change postoperative bone conduction number patient various degree postoperative hearing loss group statistically analyze result indicate small postoperative hearing loss ear surgery group tendency good result therapy group find statistically significant despite favorable result animal trial utilize different kind noise prophylactic application diltiazem study human need determine role calcium antagonist drug prophylaxis treatment acoustical trauma,Maurer J,1998,J La State Med Soc,,9785750,Maurer J; Mann WJ; Amedee RG,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000293: Adolescent; D000328: Adult; D000368: Aged; D002121: Calcium Channel Blockers; D004110: Diltiazem; D004311: Double-Blind Method; D005260: Female; D006317: Hearing Loss, Noise-Induced; D006801: Humans; D008297: Male; D008875: Middle Aged; D011183: Postoperative Complications; D011292: Premedication; D011446: Prospective Studies; D016896: Treatment Outcome; D014433: Tympanoplasty",,,https://openalex.org/W2413943855,76,12,1,1132,182,7,en,en
false,nimodipine monotherapy carbamazepine augmentation patient refractory recurrent affective illness,patient treatment refractory affective illness show moderate mark response blind nimodipine monotherapy compare placebo clinical global impression scale fourteen inadequately responsive patient unipolar bipolar bp treat blind addition carbamazepine carbamazepine augmentation nimodipine convert four partial responder robust responder patient show excellent response nimodipine carbamazepine combination include individual patient pattern rapid cycling ultradian cycling recurrent brief depression one bp type ii depression verapamil blindly substitute nimodipine two bp patient fail maintain improvement respond nimodipine remain well blind transition another dihydropyridine l type calcium channel blocker ccb isradipine mechanistic implication response dihydropyridine l type ccb nimodipine alone combination carbamazepine discuss,Pazzaglia PJ,1998,J Clin Psychopharmacol,https://doi.org/10.1097/00004714-199810000-00009,9790159,Pazzaglia PJ; Post RM; Ketter TA; Callahan AM; Marangell LB; Frye MA; George MS; Kimbrell TA; Leverich GS; Cora-Locatelli G; Luckenbaugh D,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D018692: Antimanic Agents; D001714: Bipolar Disorder; D002121: Calcium Channel Blockers; D002220: Carbamazepine; D003866: Depressive Disorder; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D017275: Isradipine; D008297: Male; D008875: Middle Aged; D009553: Nimodipine; D011569: Psychiatric Status Rating Scales; D016896: Treatment Outcome",,,https://openalex.org/W1978473122,109,12,1,1075,169,6,en,en
false,quality life elderly patient isolated systolic hypertension,objective describe measure quality life elderly patient isolated systolic hypertension entry placebo controlled randomized trial antihypertensive treatment investigate factor associate design cross sectional analysis entry randomize control trial set patient attend hypertension clinic general practitioner surgery centre european country patient six hundred thirty one patient age year sit systolic blood pressure run phase mmhg sit diastolic blood pressure mmhg stand systolic blood pressure mmhg main outcome measure cognitive function test reitan trail make b brief assessment index measure depressed mood four subscales sickness impact profile ambulation social interaction sleep rest housework result poor quality life generally associate increase age previous treatment antihypertensive drug presence cardiovascular complication among woman high diastolic blood pressure high consumption alcohol high body mass index conclusion entry trial considerable heterogeneity patient term measure quality life cognitive performance remain determine whether influence subsequent quality life randomized treatment,Fletcher AE,1998,J Hypertens,https://doi.org/10.1097/00004872-199816080-00006,9794714,Fletcher AE; Bulpitt CJ; Tuomilehto J; Browne J; Bossini A; Kawecka-Jaszcz K; Kivinen P; O'Brien E; Staessen J; Thijs L; Vänskä O; Vanhanen H,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D016448: Multicenter Study,D000367: Age Factors; D000368: Aged; D000704: Analysis of Variance; D000959: Antihypertensive Agents; D003071: Cognition; D003430: Cross-Sectional Studies; D005060: Europe; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011788: Quality of Life; D012044: Regression Analysis; D013599: Systole,,,https://openalex.org/W2412293343,71,10,1,1465,236,8,en,en
false,correlate cognitive status old patient isolated systolic hypertension,objective assess cognitive function correlate dementia free cohort old patient isolated systolic hypertension design cross sectional data randomization period european trial elderly systolic hypertension syst eur vascular dementia project set sixteen european country israel participant study patient age year mean main outcome measure mini mental state examination mmse spearman correlation mmse score demographic data blood pressure result mmse successfully complete woman men baseline blood pressure average mmhg mean sd median age education patient school stop year men woman consume alcohol median intake g day respectively median mmse score range maximum score attain subject fifty nine patient mmse score less mmse score decrease advance age r p men woman positively correlate level education r r p woman adjustment age level education score correlate negatively systolic blood pressure r p positively intake alcohol r p conclusion cohort elderly patient isolated systolic hypertension baseline cognitive function measure term mmse score high probably due selective recruitment patient clinically demented blood pressure weak contributor cognitive status compare age level education baseline cognitive function woman negatively independently correlate systolic blood pressure,Seux ML,1998,J Hypertens,https://doi.org/10.1097/00004872-199816070-00009,9794736,Seux ML; Thijs L; Forette F; Staessen JA; Birkenhäger WH; Bulpitt CJ; Girerd X; Jääskivi M; Vanhanen H; Kivinen P; Yodfat Y; Vänskä O; Antikainen R; Laks T; Webster JR; Hakamäki T; Lehtomäki E; Lilov E; Grigorov M; Janculova K; Halonen K; Kohonen-Jalonen P; Kermowa R; Nachev C; Tuomilehto J,article,"D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D003071: Cognition; D015331: Cohort Studies; D003430: Cross-Sectional Studies; D015140: Dementia, Vascular; D005060: Europe; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D012307: Risk Factors; D013599: Systole",,,https://openalex.org/W2095377585,82,11,1,1863,356,18,en,en
false,antihypertensive effect amlodipine compare nifedipine retard patient mild moderate essential hypertension,present study undertake evaluate efficacy safety amlodipine hypertension treatment comparison nifedipine retard examine patient arterial blood pressure approximately mmhg mm hg beginning trial randomized double blind parallel group trial include two group patient patient first group give active amlodipine nifedipine retard placebo week second group give active nifedipine retard amlodipine placebo statistical analysis make use paired student test chi square test anova test end point observe significant decrease arterial blood pressure treatment drug treatment nifedipine retard increase mean heart rate patient amlodipine therapy comparison nifedipine retard change heart rate treated patient safety parameter sgot sgtp creatinine others laboratory norm ranges amlodipine prove effective safe better tolerated therapeutical alternative hypertension management nifedipine retard,Kalina Z,1998,Boll Chim Farm,,9795483,Kalina Z; Okopień B; Madej A; Tokarz D; Maślankiewicz A; Szwed Z; Gross-Furek V; Herman ZS,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000293: Adolescent; D000328: Adult; D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine,,,https://openalex.org/W2336954201,128,17,1,1162,180,7,en,en
false,calcium channel blocker cancer incidence cancer mortality cohort u woman nurse health study,study suggest use calcium channel blocker may increase risk cancer possible association use calcium channel blocker cancer incidence cancer mortality address use data nurse health study study total female nurse report regularly take least cardiovascular medication diuretic beta blockers calcium channel blocker angiotensin converting enzyme ace inhibitor cancer incidence cancer death ascertain year follow woman newly diagnose cancer woman die cancer woman report use calcium channel blocker increase risk newly diagnose cancer compare take cardiovascular drug relative risk ci relative risk die cancer associate self reported use calcium channel blocker ci relative risk adjust following self reported factor age weight height cholesterol level systolic diastolic blood pressure smoking alcohol intake physical activity menopausal status postmenopausal hormone use aspirin use history diabetes cancer stroke myocardial infarction coronary artery bypass graft percutaneous transluminal coronary angioplasty angina hypertension regard site specific cancer incidence mortality lung cancer incidence somewhat increased rr ci data suggest important increase overall cancer incidence cancer mortality relate self reported use calcium channel blocker,Michels KB,1998,Cancer,,9806660,Michels KB; Rosner BA; Walker AM; Stampfer MJ; Manson JE; Colditz GA; Hennekens CH; Willett WC,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D013487: Research Support, U.S. Gov't, P.H.S.",D000319: Adrenergic beta-Antagonists; D000328: Adult; D000806: Angiotensin-Converting Enzyme Inhibitors; D017209: Apoptosis; D002121: Calcium Channel Blockers; D004232: Diuretics; D005260: Female; D006801: Humans; D015994: Incidence; D008875: Middle Aged; D009369: Neoplasms; D009726: Nurses; D016272: Occupational Health; D012307: Risk Factors; D011795: Surveys and Questionnaires; D014481: United States,,,https://openalex.org/W2155530651,117,23,1,1697,285,7,en,en
false,intensive medical therapy versus coronary angioplasty suppression myocardial ischemia survivor acute myocardial infarction,patient inducible ischemia acute myocardial infarction ami generally undergo coronary angiography intent revascularize whether approach superior intensive treatment anti ischemic medication unknown perform prospective randomize pilot study compare intensive medical therapy coronary angioplasty ptca suppression myocardial ischemia stable survivor ami myocardial ischemia quantify adenosine tl tomography spect perform day ami patient baseline large total ischemic leave ventricular perfusion defect size pd spect repeat day therapy optimize total stress induced pd comparably reduce medical therapy p ptca p reduction ischemic pd also similar p ns group cardiac event occur patient month patient remain clinically stable great reduction ischemic pd recurrent cardiac event p event free survival superior patient significant reduction pd compare p small pilot study intensive medical therapy ptca comparable suppress ischemia stable patient ami sequential image adenosine spect track change pd anti ischemic therapy thereby predict subsequent outcome corroboration preliminary finding large cardiac event trial warrant,Dakik HA,1998,Circulation,https://doi.org/10.1161/01.cir.98.19.2017,9808599,Dakik HA; Kleiman NS; Farmer JA; He ZX; Wendt JA; Pratt CM; Verani MS; Mahmarian JJ,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000319: Adrenergic beta-Antagonists; D000328: Adult; D015906: Angioplasty, Balloon, Coronary; D004110: Diltiazem; D005260: Female; D006801: Humans; D007548: Isosorbide Dinitrate; D008297: Male; D008790: Metoprolol; D008875: Middle Aged; D009203: Myocardial Infarction; D017202: Myocardial Ischemia; D010865: Pilot Projects; D011446: Prospective Studies; D015899: Tomography, Emission-Computed, Single-Photon; D014665: Vasodilator Agents",,,https://openalex.org/W2107290181,136,17,1,1690,308,12,en,en
true,rationale design international verapamil sr trandolapril study invest internet based randomized trial coronary artery disease patient hypertension,objective primary objective international verapamil sr trandolapril study invest compare risk adverse outcome cause mortality nonfatal myocardial infarction mi nonfatal stroke hypertensive patient coronary artery disease cad treat either calcium antagonist based noncalcium antagonist based strategy background treatment recommendation hypertension include initial therapy diuretic beta adrenergic blocking agent reduction morbidity mortality document randomized trial less expect epidemiologic data reason recent attention focus calcium antagonist angiotensin converting enzyme inhibitor agent reduce blood pressure outcome data large randomize trial lack case control data dominate short acting dihydropyridines suggest increase risk cardiovascular event study methodologic limitation differentiate among calcium antagonist type formulation several study differentiate among calcium antagonist type overview publish randomized trial show increase risk verapamil suggestion benefit cad patient method total cad patient hypertension randomize primary care sit receive either calcium antagonist based verapamil beta blocker diuretic based atenolol hydrochlorothiazide antihypertensive care strategy study use novel electronic paper less system direct screen data entry randomization drug distribution mail pharmacy link coordination center via internet result contract negotiation united state international site ongoing patient enrol predominantly elderly age year old men either abnormal coronary angiogram prior mi addition hypertension cad elderly age patient one associated condition diabetes dyslipidemia smoking cerebral peripheral vascular disease etc contribute increase risk adverse outcome diabetes noninsulin dependent use protocol strategy target blood pressure accord jnc vi reach fourth visit expect require multiple antihypertensive drug conclusion design baseline characteristic initial patient recruit prospective randomize international multicenter study compare two therapeutic strategy control hypertension cad patient describe,Pepine CJ,1998,J Am Coll Cardiol,https://doi.org/10.1016/s0735-1097(98)00423-9,9809930,Pepine CJ; Handberg-Thurmond E; Marks RG; Conlon M; Cooper-DeHoff R; Volkers P; Zellig P,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D017023: Coronary Angiography; D003327: Coronary Disease; D004359: Drug Therapy, Combination; D005260: Female; D005500: Follow-Up Studies; D006801: Humans; D006973: Hypertension; D007211: Indoles; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D012107: Research Design; D016896: Treatment Outcome; D014700: Verapamil",,,https://openalex.org/W2057386253,172,24,1,2721,442,20,en,en
false,study losartan alone hydrochlorothiazide v nifedipine git elderly patient diastolic hypertension,conduct randomised double blind parallel design study compare efficacy tolerability angiotensin ii receptor antagonist losartan alone low dose hydrochlorothiazide hctz dihydropyridine calcium channel blocker nifedipine git gastro intestinal therapeutic system elderly patient year old diastolic blood pressure dbp mm hg placebo wash period patient randomly assign receive either losartan mg nifedipine git mg patient evaluate week interval week treatment period patient receive losartan hctz mg add increase mg reduce dbp mm hg patient receive nifedipine git dose increase mg mg reduce dbp mm hg efficacy tolerability quality life assess week regimen patient treat losartan regimen n reduction trough sit dbp mm hg week therapy respectively patient receive nifedipine git regimen n dbp reduction mm hg respectively significant difference dbp response treatment group except week p similar reduction systolic bp sbp two treatment group observe time point percentage patient two treatment group reach goal dbp mm hg dbp mm hg reduction baseline mm hg comparable losartan regimen nifedipine git regimen significantly adverse event report patient receive nifedipine git compare losartan regimen vs p patient reported symptom inventory also show swollen ankle bothersome significantly patient treat nifedipine git regimen compare losartan regimen vs p thus elderly patient diastolic hypertension regimen losartan alone hctz similar efficacy regimen nifedipine git great tolerability less symptom bother due swell ankle,Conlin PR,1998,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1000687,9819017,Conlin PR; Elkins M; Liss C; Vrecenak AJ; Barr E; Edelman JM,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000375: Aging; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D003971: Diastole; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D019808: Losartan; D008297: Male; D009543: Nifedipine; D016896: Treatment Outcome",,,https://openalex.org/W2033922465,121,18,1,2264,439,14,en,en
false,team study study effectiveness tolerance treatment essential hypertension fixed combination trandolapril verapamil,team trial investigate effectiveness tolerance fixed combination ace inhibitor calcium channel blocker mg trandolapril mg verapamil retard preparation tarka open multicentre prospective study treatment moderately severe hypertension diastolic pressure end two week wash period mm hg trial comprise patient treat first four week monotherapy mg trandolapril four week patient attain normal blood pressure proceed trandolapril treatment hypertensive patient attain normal diastolic pressure level treat another four week fixed combination trandolapril verapamil sr four week treatment trandolapril patient diastolic blood pressure less mm hg fixed combination trandolapril verapamil sr reduce diastolic blood pressure less mm hg patient resistant treatment mg trandolapril another patient reduce diastolic blood pressure mm hg two month treatment patient normal blood pressure due trandolapril another patient treat combination trandolapril verapamil sr e total patient originally suffer moderately severe hypertension attain normal diastolic blood pressure mean decrease diastolic pressure two month treatment mm hg non respondents trandolapril monotherapy mm hg respondent mean decrease systolic pressure non respondents respondent trandolapril treatment mm hg mm hg resp fixed combination trandolapril verapamil effective associate minimum undesirable effect incidence headache decline significantly combination preparation useful also preparation cardio nephroprotective effect affect lipid carbohydrate metabolism treatment fixed combination trandolapril verapamil sr indicate moderately severe hypertension respond monotherapy particular associate diabetes hyperlipoproteinaemia ischaemic heart disease leave ventricular hypertrophy,Widimský J,1998,Vnitr Lek,,9820054,Widimský J; Dzúrik R,article,D016430: Clinical Trial; D004740: English Abstract; D016428: Journal Article; D016448: Multicenter Study,D000328: Adult; D000806: Angiotensin-Converting Enzyme Inhibitors; D000959: Antihypertensive Agents; D001794: Blood Pressure; D004338: Drug Combinations; D005260: Female; D006801: Humans; D006973: Hypertension; D007211: Indoles; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D014700: Verapamil,,,https://openalex.org/W2470247582,155,27,1,2430,416,13,en,en
false,adrenergic blockade accelerate conversion postoperative supraventricular tachyarrhythmias,background postoperative supraventricular tachyarrhythmia common complication surgery chemical cardioversion often ineffective ventricular rate control remain principal goal therapy author hypothesize patient supraventricular tachyarrhythmia major noncardiac surgery receive intravenous beta adrenergic blockade ventricular rate control would experience conversion sinus rhythm rate differs receive intravenous calcium channel blockade method rate conversion sinus rhythm h treatment examine case postoperative supraventricular tachyarrhythmia adenosine administration patient remain supraventricular tachyarrhythmia prospectively randomize receive either intravenous diltiazem intravenous esmolol ventricular rate control unblinded load infusion rate adjust achieve equivalent degree ventricular rate control result patient similar regard age apache iii score patient group atrial fibrillation esmolol diltiazem none experience stable conversion adenosine patient randomize receive esmolol experience rate conversion sinus rhythm within h treatment compare patient randomize receive diltiazem intention treat p odds ratio confidence interval h therapy number patient convert sinus rhythm increase group esmolol diltiazem rate conversion longer differ significantly ventricular rate supraventricular tachyarrhythmia begin h rate control therapy similar two treatment group hospital mortality rate length stay intensive care unit significantly influence treatment group conclusion among adenosine resistant patient intensive care unit atrial fibrillation noncardiac surgery intravenous esmolol produce rapid h conversion sinus rhythm intravenous diltiazem,Balser JR,1998,Anesthesiology,https://doi.org/10.1097/00000542-199811000-00004,9821992,Balser JR; Martinez EA; Winters BD; Perdue PW; Clarke AW; Huang W; Tomaselli GF; Dorman T; Campbell K; Lipsett P; Breslow MJ; Rosenfeld BA,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D000368: Aged; D002121: Calcium Channel Blockers; D003422: Critical Care; D004110: Diltiazem; D004311: Double-Blind Method; D004562: Electrocardiography; D005260: Female; D006339: Heart Rate; D006801: Humans; D007275: Injections, Intravenous; D008297: Male; D011183: Postoperative Complications; D011412: Propanolamines; D013617: Tachycardia, Supraventricular; D013997: Time Factors",,,https://openalex.org/W2063051761,96,8,1,2188,353,13,en,en
true,modulation ventricular rate permanent atrial fibrillation randomize crossover study effect slow release formulation gallopamil diltiazem verapamil,abstract background management permanent atrial fibrillation paf consist primarily long term anticoagulation either aspirin warfarin prevent systemic embolization modulation ventricular rate vr improve cardiac function prolong ventricular diastolic filling time hypothesis effect slow release formulation gallopamil mg b diltiazem mg bid verapamil mg b vr evaluate patient paf without organic heart disease method patient treatment administer randomly compare oral digoxin assess h holter monitoring daily life min walk ing test result significant difference mean minimum vr record h holter monitoring among four treatment peak heart rate record min walk test digoxin treatment beats min significantly reduce gallopamil beats min p diltiazem beats min p verapamil beats min p significant difference peak vr walking test among three calcium antagonist pause observe patient receive digoxin max patient receive diltiazem max p n period bradycardia beats min observe patient digoxin treatment patient treatment gallopamil diltiazem verapamil p n conclusion gallopamil diltiazem verapamil superior digoxin control vr mild exercise patient paf without organic heart disease reduction peak vr obtainable without slowing rest vr however gallopamil appear least effective calcium blocker control rest exercise vr thus advantage calcium blocker use clinical setting,Botto GL,1998,Clin Cardiol,https://doi.org/10.1002/clc.4960211110,9825197,Botto GL; Bonini W; Broffoni T,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000284: Administration, Oral; D000368: Aged; D000889: Anti-Arrhythmia Agents; D001281: Atrial Fibrillation; D002121: Calcium Channel Blockers; D002316: Cardiotonic Agents; D018592: Cross-Over Studies; D003692: Delayed-Action Preparations; D004077: Digoxin; D004110: Diltiazem; D015716: Electrocardiography, Ambulatory; D005260: Female; D005711: Gallopamil; D006339: Heart Rate; D006801: Humans; D008297: Male; D008875: Middle Aged; D014700: Verapamil",,,https://openalex.org/W2072235496,175,26,1,2057,406,15,en,en
false,retract article diltiazem lidocaine combination attenuation cardiovascular response tracheal intubation hypertensive patient,purpose hypertensive patient prone haemodynamic change laryngoscopy tracheal intubation study undertake compare efficacy combination diltiazem lidocaine drug alone suppress cardiovascular response tracheal intubation method sixty hypertensive patient asa ii define systolic blood pressure mmhg diastolic blood pressure mmhg world health organization undergo elective surgery receive randomized double blind manner mg kg diltiazem mg kg lidocaine mg kg diltiazem plus mg kg lidocaine v n initiation laryngoscopy anaesthesia induce mg kg thiopentone v tracheal intubation facilitate mg kg succinylcholine v precurarization mg kg vecuronium v change heart rate hr mean arterial pressure map rate pressure product rpp measure immediate min tracheal intubation result inhibitory effect diltiazem lidocaine combination cardiovascular response tracheal intubation great diltiazem lidocaine sole medicine rpp combination vs diltiazem lidocaine mean sd p conclusion prophylactic therapy diltiazem lidocaine combination effective diltiazem lidocaine alone attenuate cardiovascular change associate tracheal intubation hypertensive patient,Fujii Y,1998,Can J Anaesth,https://doi.org/10.1007/bf03012299,9836028,Fujii Y; Saitoh Y; Takahashi S; Toyooka H,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D016441: Retracted Publication,"D000368: Aged; D018686: Anesthetics, Intravenous; D000889: Anti-Arrhythmia Agents; D000959: Antihypertensive Agents; D001794: Blood Pressure; D004110: Diltiazem; D004311: Double-Blind Method; D004338: Drug Combinations; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D007275: Injections, Intravenous; D007442: Intubation, Intratracheal; D007828: Laryngoscopy; D008012: Lidocaine; D008297: Male; D008875: Middle Aged; D009467: Neuromuscular Depolarizing Agents; D003473: Neuromuscular Nondepolarizing Agents; D013390: Succinylcholine; D013874: Thiopental; D014673: Vecuronium Bromide",,,https://openalex.org/W1976086238,146,17,1,1602,275,9,en,en
false,calcium channel blocker increase risk myocardial infarction hypertensive patient diabetes mellitus,,Park L,1998,Can Fam Physician,,9839057,Park L; Por CP; Evans MF,article,D016428: Journal Article,"D002121: Calcium Channel Blockers; D003924: Diabetes Mellitus, Type 2; D005194: Family Practice; D006801: Humans; D006973: Hypertension; D009203: Myocardial Infarction; D012107: Research Design; D012307: Risk Factors",,,https://openalex.org/W284248629,119,17,1,0,0,0,en,
false,isradipine prediabetic hypertensive subject,investigator multicenter isradipine diuretic atherosclerosis study midas previously report isradipine group high incidence cardiovascular disease cvd event diuretic group ultimate objective analysis present assess index glycemia specifically serum glucose serum insulin hba c might influence effect two agent blood pressure control cvd events inclusion criterion include men woman year age ultrasonographically confirm carotid atherosclerosis diastolic blood pressure mmhg although insulin dependent diabetic patient exclude three glycemia index wide enough range include patient may classify prediabetic total patient randomize either dihydropyridine calcium antagonist ca isradipine mg twice day diuretic hydrochlorothiazide mg twice day follow double blind fashion years treatment group achieve comparable control diastolic blood pressure statistically significant difference glycemia index either baseline follow however excess isradipine event note cluster among patient elevated baseline level hba c also experience great blood pressure reduction follow increase cardiovascular risk associate dihydropyridine ca prediabetic patient may explanation overall ca debate,Byington RP,1998,Diabetes Care,https://doi.org/10.2337/diacare.21.12.2103,9839101,Byington RP; Furberg CD; Craven TE; Pahor M; Sowers JR,article,D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,D000959: Antihypertensive Agents; D001786: Blood Glucose; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002318: Cardiovascular Diseases; D003327: Coronary Disease; D003925: Diabetic Angiopathies; D004311: Double-Blind Method; D004656: Enalapril; D005260: Female; D005500: Follow-Up Studies; D006442: Glycated Hemoglobin; D006801: Humans; D006852: Hydrochlorothiazide; D006973: Hypertension; D007328: Insulin; D017275: Isradipine; D008297: Male; D011236: Prediabetic State; D013997: Time Factors,,,https://openalex.org/W2009438838,47,5,1,1588,253,5,en,en
false,verapamil hypertension atherosclerosis study vhas,unclear whether carotid intima media thickness influence antihypertensive treatment whether antihypertensive agent calcium antagonist may great effect parameter others diuretic present paper report principal result ultrasound substudy randomize prospective control verapamil hypertension atherosclerosis study vhas hypertensive patient eight italian centre randomize either verapamil mg day chlorthalidone mg day b mode ultrasound scan perform accord standardized procedure baseline month treatment maximum intima media thickness far wall common bifurcation internal carotid artery measure bilaterally following index calculate mean thickness six measure site mean thickness common bifurcation site single maximum thickness primary endpoint treatment efficacy slope change year rate change mm year correct use initial mean six site baseline month covariate mm year per mm patient also classify three stratum accord baseline single maximum thickness normal carotid artery single maximum mm thickened carotid artery single maximum mm carotid plaque single maximum mm among patient satisfactory baseline ultrasound reading classify normal carotid artery thickened carotid artery plaque intention treat population patient ultrasound measurement take least three different occasion period least year rate change mean thickness six site measure rather small mm year significantly p small patient plaque mm year patient thickened normal carotids mm year respectively relate initial value rate change mean thickness six site negative slope mm year per mm p although rate change carotid intima media thickness unstratified patient different treat verapamil chlorthalidone change mean thickness six site relate initial value slope relationship significantly different two treatment group verapamil versus chlorthalidone mm year per mm p blood pressure lowering effect two randomize treatment similar take fatal nonfatal major minor cardiovascular event together event verapamil group chlorthalidone group significantly p great incidence patient plaque among patient plaque randomize chlorthalidone p accord evidence animal model atherosclerosis calcium antagonist verapamil effective diuretic chlorthalidone promote regression thicker carotid lesion change carotid intima media thickness small group difference change two treatment consequently small observation small difference carotid wall change parallel difference incidence cardiovascular event well intima media thickness regression verapamil parallel low cardiovascular event rate suggest even small effect carotid plaque may clinical prognostic relevance,Zanchetti A,1998,J Hypertens,https://doi.org/10.1097/00004872-199816110-00014,9856368,Zanchetti A; Rosei EA; Dal Palù C; Leonetti G; Magnani B; Pessina A,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000328: Adult; D000889: Anti-Arrhythmia Agents; D000959: Antihypertensive Agents; D001161: Arteriosclerosis; D001481: Basal Metabolism; D001794: Blood Pressure; D017536: Carotid Artery, Common; D002752: Chlorthalidone; D005260: Female; D006339: Heart Rate; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D011446: Prospective Studies; D012016: Reference Values; D016896: Treatment Outcome; D017539: Tunica Intima; D017540: Tunica Media; D014463: Ultrasonography; D014700: Verapamil",,,https://openalex.org/W1994748801,62,10,1,3823,672,11,en,en
false,recommend article month effect intensive blood pressure lowering low dose aspirin patient hypertension principal result hypertension optimal treatment hot randomise trial,,Maldonado J,1998,Rev Port Cardiol,,9865094,Maldonado J,article,D016430: Clinical Trial; D016421: Editorial; D016449: Randomized Controlled Trial,D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D001241: Aspirin; D002561: Cerebrovascular Disorders; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009203: Myocardial Infarction,,,https://openalex.org/W2407105395,212,34,1,0,0,0,en,
true,quality life calcium channel blockade nifedipine git versus amlodipine hypertensive patient spain,objective compliance hypertension treatment affect treatment related factor complexity side effect efficacy compound specific effect impact quality life study examine difference quality life produce two daily calcium channel blocker use different delivery system nifedipine gastrointestinal therapeutic system git amlodipine design double blind double dummy randomized clinical trial compare nifedipine git mg amlodipine mg week follow placebo run clinical laboratory evaluation quality life data assess screening baseline randomization three time active therapy set study conduct medical clinic spain patient sample comprise screen randomized patient mild moderate hypertension diastolic blood pressure mmhg main outcome measure change systolic diastolic blood pressure health related quality life main outcome measure result significant difference active treatment group blood pressure change systolic blood pressure nifedipine git mmhg amlodipine mmhg spontaneous adverse event consistent calcium channel blockage different nifedipine git group improve quality life measure except sexual symptom distress show significantly great improvement amlodipine overall quality life p general perceive health p subscale vitality p amlodipine group decline overall quality life general perceive health vitality sleep disturbance significantly sexual symptom distress p however group improve self reported cognitive functioning p mental acuity p detachment disorientation p conclusion result suggest compound specific effect quality life may due difference delivery system nifedipine git short acting h half life deliver continuously h period amlodipine half life h may produce sustained low level effect beneficial profile observe nifedipine amlodipine demonstrate potential positive effect cognitive functioning,Testa MA,1998,J Hypertens,https://doi.org/10.1097/00004872-199816120-00018,9869019,Testa MA; Turner RR; Simonson DC; Krafcik MB; Calvo C; Luque-Otero M,article,"D003160: Comparative Study; D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000293: Adolescent; D000328: Adult; D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D016503: Drug Delivery Systems; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011788: Quality of Life; D013030: Spain,,,https://openalex.org/W84312996,117,17,1,2403,398,15,en,en
false,calcium channel blocker use risk prostate cancer,recent study suggest risk cancer include prostate cancer increase use calcium channel blocker objective study determine whether prostate cancer associate calcium channel blocker use case control study conduct massachusetts use case diagnose december february case men identify tumor registrar less year old newly diagnose prostate cancer control men history prostate cancer symptom undiagnosed prostate cancer match case precinct residence half decade age total case prostate cancer community control include analysis data collect telephone interview multiple logistic regression use estimate relative risk calcium channel blocker use control confound relative risk prostate cancer use calcium channel blocker relative nonuse confidence interval ci evidence trend accord duration use analysis confine symptomatic men relative risk estimate overall among age year relative risk estimate use class antihypertensive drug among symptomatic men close corresponding estimate among asymptomatic men generally finding suggest calcium channel blocker increase risk prostate cancer difference relative risk estimate symptomatic asymptomatic men compatible detection bias widespread use prostate specific antigen test early detection prostate cancer potential detection bias need consider future study prostate cancer,Vezina RM,1998,Am J Hypertens,https://doi.org/10.1016/s0895-7061(98)00176-9,9880123,Vezina RM; Lesko SM; Rosenberg L; Shapiro S,article,"D016428: Journal Article; D013485: Research Support, Non-U.S. Gov't; D013487: Research Support, U.S. Gov't, P.H.S.",D000328: Adult; D000368: Aged; D000959: Antihypertensive Agents; D002121: Calcium Channel Blockers; D016022: Case-Control Studies; D006801: Humans; D008297: Male; D008875: Middle Aged; D011471: Prostatic Neoplasms; D012306: Risk,,,https://openalex.org/W2119200592,60,10,1,1919,327,15,en,en
false,outpatient management congestive heart failure,,Massin EK,1998,Tex Heart Inst J,,9885099,Massin EK,article,D016428: Journal Article; D016454: Review,"D000319: Adrenergic beta-Antagonists; D000806: Angiotensin-Converting Enzyme Inhibitors; D000925: Anticoagulants; D001685: Biological Factors; D002121: Calcium Channel Blockers; D004071: Digitalis Glycosides; D004232: Diuretics; D006333: Heart Failure; D006801: Humans; D018487: Ventricular Dysfunction, Left",,,https://openalex.org/W154104348,50,7,1,0,0,0,en,
false,study population treatment titration international nifedipine git study intervention goal hypertension treatment insight,ascertain baseline characteristic high risk hypertensive patient enter international nifedipine git study intervention goal hypertension treatment insight determine success single combination therapy achieve target blood pressure population insight double blind prospective outcome trial compare efficacy calcium channel blocker nifedipine git thiazide co amilozide prevent myocardial infarction stroke recruit men woman age year blood pressure placebo run mmhg isolate systolic blood pressure mmhg nine country treatment allocation nifedipine git mg daily co amilozide hydrochlorothiazide mg amiloride mg daily perform minimization rather randomization balance additional risk factor follow four optional increase treatment dose doubling primary drug addition atenolol mg enalapril mg hypotensive drug exclude calcium blocker diuretic target blood pressure mmhg fall mmhg blood pressure randomization mmhg thirteen per cent patient previously untreated proportion additional risk factor smoking day cholesterol mmol l family history premature myocardial infarction stroke diabetes mellitus left ventricular hypertrophy previous myocardial infarction presentation coronary heart disease peripheral vascular disease proteinuria fifty five per cent patient one additional risk factor whereas two three additional risk factor respectively blood pressure fall blood pressure end titration year minimization mmhg patient still randomize treatment number require four treatment increment respectively mean almost patient randomized treatment insight receive primary drug one year patient blood pressure mmhg insight one first double blind comparison active antihypertensive treatment require high risk patient achieve sufficient power despite requirement possible achieve good blood pressure control patient without addition multiple additional treatment may dilute difference primary agent,Brown MJ,1998,J Hypertens,,9886905,Brown MJ; Castaigne A; de Leeuw PW; Mancia G; Rosenthal T; Ruilope LM,article,D016430: Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial,"D000368: Aged; D000369: Aged, 80 and over; D000959: Antihypertensive Agents; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D002318: Cardiovascular Diseases; D004311: Double-Blind Method; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011446: Prospective Studies; D012307: Risk Factors",,,https://openalex.org/W2409746009,144,23,1,2671,466,12,en,en
false,long term efficacy adverse event nifedipine sustained release tablet cyclosporin induced hypertension patient psoriasis,thirteen psoriatic patient hypertension course cyclosporin therapy treat month calcium channel blocker sustained release nifedipine study clinical antihypertensive effect adverse event treatment drug seven patient exhibit subclinical hypertensive state cyclosporin therapy systolic diastolic blood pressure patient decrease significantly week nifedipine therapy blood pressure maintain within normal range thereafter month adverse event combined therapy cyclosporin nifedipine include increase blood urea nitrogen level patient development gingival hyperplasia patient finding indicate sustained release nifedipine useful hypertensive psoriatic patient long term treatment cyclosporin patient monitor gingival hyperplasia,Nakayama J,1998,Eur J Dermatol,,9889429,Nakayama J; Koga T; Furue M,article,D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article,"D000328: Adult; D000368: Aged; D001795: Blood Pressure Determination; D002121: Calcium Channel Blockers; D016572: Cyclosporine; D003692: Delayed-Action Preparations; D004359: Drug Therapy, Combination; D005260: Female; D005500: Follow-Up Studies; D005885: Gingival Hyperplasia; D006801: Humans; D006949: Hyperlipidemias; D006973: Hypertension; D007677: Kidney Function Tests; D008134: Long-Term Care; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011565: Psoriasis; D016896: Treatment Outcome",,,https://openalex.org/W2099899253,143,18,1,1029,158,5,en,en
false,analysis arrhythmia circadian antiischemia program europe cape study,aim study analyze whether patient long standing year coronary artery disease cad addition long acting calcium channel blocker ccb amlodipine conventional treatment blockers bbl nitrate anginal attack would proarrhythmic effect test analyze data patient take part circadian anti ischemia program europe cape trial week single blind run period phase patient randomize amlodipine mg day first week mg day second week placebo week phase h holter data analyze amlodipine treated patient placebo patient base randomization scheme sixty three per cent amlodipine patient placebo patient receive concomitant bbl take sublingual nitrate anginal attack basic antiischemic therapy week therapy h holter monitoring repeat significant change frequency ventricular arrhythmia placebo amlodipine group patient subgroup patient without bbl also group comparison show significant difference arrhythmia amlodipine placebo patient summary amlodipine mg day give patient severe chronic cad receive conventional antiischemic therapy produce proarrhythmic effect,Lichtlen PR,1999,J Cardiovasc Pharmacol,https://doi.org/10.1097/00005344-199901000-00020,9890408,Lichtlen PR; Fisher LD,article,"D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D000328: Adult; D000368: Aged; D000369: Aged, 80 and over; D017311: Amlodipine; D001145: Arrhythmias, Cardiac; D002121: Calcium Channel Blockers; D003327: Coronary Disease; D004311: Double-Blind Method; D005060: Europe; D006801: Humans; D008875: Middle Aged; D015397: Program Evaluation; D016896: Treatment Outcome",,,https://openalex.org/W2316412515,84,14,1,1491,268,8,en,en
false,divergent effect ace inhibition calcium channel blockade activity systemic renal circulation essential hypertension,objective nitric oxide vasodilating blood pressure lower substance investigate whether calcium antagonist angiotensin converting enzyme ace inhibitor increase vascular nitric oxide activity assess systemic renal vascular sensitivity nitric oxide synthase inhibition hypertensive medication method ten essential hypertensive patient age year study time week medication week treatment enalapril mg twice day week nifedipine mg day time h blood pressure registration perform follow clearance study obtain h dose response curve intravenously infuse ng monomethyl l arginine l nmma respectively mg kg h result l nmma dose dependently increased mean arterial pressure mmhg systemic vascular resistance maximum dose whereas cardiac output decrease p enalapril nifedipine treatment decrease blood pressure l nmma induced increase systemic vascular resistance potentiate enalapril nifedipine p l nmma also dose dependently decreased renal blood flow maximum dose p neither drug potentiate effect conclusion result indicate essential hypertensive antihypertensive therapy enalapril nifedipine increase nitric oxide dependency systemic vascular tone may play role blood pressure lower effect drug however phenomenon observe renal circulation suggest different regulation endothelium dependent vasomotion hypertensive kidney,Dijkhorst-Oei LT,1998,Cardiovasc Res,https://doi.org/10.1016/s0008-6363(98)00124-2,9893735,Dijkhorst-Oei LT; Beutler JJ; Stroes ES; Koomans HA; Rabelink TJ,article,D016430: Clinical Trial; D016428: Journal Article; D016449: Randomized Controlled Trial,"D000328: Adult; D000806: Angiotensin-Converting Enzyme Inhibitors; D002121: Calcium Channel Blockers; D002302: Cardiac Output; D004305: Dose-Response Relationship, Drug; D004656: Enalapril; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D009569: Nitric Oxide; D019001: Nitric Oxide Synthase; D012079: Renal Circulation; D014655: Vascular Resistance; D019323: omega-N-Methylarginine",,,https://openalex.org/W1994242412,139,18,1,1726,287,9,en,en
false,improve tolerability felodipine compare amlodipine elderly hypertensive randomised double blind study patient focus vasodilatory adverse event international study group,primary aim double blind parallel group trial compare incidence newly occur vasodilatory adverse event elderly patient treat recommended daily dos felodipine extend release er amlodipine total patient year old sit diastolic blood pressure mmhg systolic blood pressure mmhg recruit centre worldwide patient randomise felodipine er mg amlodipine mg blood pressure mmhg three six week felodipine er increase mg amlodipine mg nine week average dos felodipine er amlodipine mg mg respectively newly occur vasodilatory adverse event report felodipine er patient amlodipine patient p treatment effectively reduce blood pressure hour post dose use low start dose individual titration felodipine er achieves good control blood pressure vasodilatory side effects,Schaefer RM,1998,Int J Clin Pract,,9894374,Schaefer RM; Aldons PM; Burgess ED; Tilvis R; Girerd X; Singh GP; Rehn L; Morgan TO,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D017311: Amlodipine; D000959: Antihypertensive Agents; D003692: Delayed-Action Preparations; D004244: Dizziness; D004311: Double-Blind Method; D004487: Edema; D015736: Felodipine; D005260: Female; D006261: Headache; D006801: Humans; D006973: Hypertension; D008297: Male,,,https://openalex.org/W69380414,208,31,2,1074,188,7,en,en
false,comparison hour ambulatory blood pressure data hypertensive patient switch nifedipine gits nifedipine cc,study objective evaluate hour blood pressure control frequency adverse effect patient mild moderate hypertension switch nifedipine gastrointestinal therapeutic system nif gits nifedipine coat core nif cc design open label prospective switch study set university affiliated outpatient cardiology clinic subject twenty patient mild moderate essential hypertension take nif gits mg day week long intervention patient stabilize nif gits mg monitor hour ambulatory blood pressure monitor switch equivalent dosage nif cc week week take nif cc monitor hour blood pressure monitor hour blood pressure load percentage value mm hg hr daytime blood pressure load percentage value mm hg p nighttime blood pressure load percentage value mm hg p diurnal blood pressure variation average hour blood pressure daytime blood pressure nighttime blood pressure mean blood pressure first hour last hour dose interval measure adverse effect headache dizziness edema also report measurement main result difference average hour blood pressure reading observe significant difference blood pressure control first last hour dose interval see systolic diastolic blood pressure high approximately hour patient switch nif gits nif cc although nif cc cause great initial response less effective nif gits hour could explain lack difference average hour blood pressure value formulation patient experience increased headache show sign increased peripheral edema report occasional dizziness switch agent three patient discontinue nif cc two order primary care physician one due headache conclusion study suggest patient switch nif gits nif cc could experience increase blood pressure night toward end dosing interval could also experience adverse effect headache edema dizziness could result physician visit put patient disease state coronary heart disease increase risk,Wurdeman RL,1999,Pharmacotherapy,https://doi.org/10.1592/phco.19.1.94.30512,9917082,Wurdeman RL; Mooss AN; Mohiuddin SM; Lucas BD; Ryschon KL; Hilleman DE,article,D016428: Journal Article,"D000328: Adult; D000368: Aged; D018660: Blood Pressure Monitoring, Ambulatory; D002121: Calcium Channel Blockers; D004304: Dosage Forms; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D011446: Prospective Studies",,,https://openalex.org/W1981314031,124,15,1,2608,458,23,en,en
false,hypertension elderly management issue,auniversity vermont college medicine burlington vermont usa ballegheny general hospital pittsburgh pennsylvania usa,Gennari FJ,1998,Coron Artery Dis,https://doi.org/10.1097/00019501-199809110-00003,9919418,Gennari FJ; Gennari AS,article,D016428: Journal Article; D016454: Review,D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D001581: Benzothiadiazines; D002121: Calcium Channel Blockers; D015897: Comorbidity; D018450: Disease Progression; D004232: Diuretics; D006801: Humans; D006973: Hypertension; D010353: Patient Education as Topic; D016032: Randomized Controlled Trials as Topic; D012078: Renal Artery Obstruction; D049993: Sodium Chloride Symporter Inhibitors; D016896: Treatment Outcome,,,https://openalex.org/W2017627478,46,7,1,127,21,1,en,en
false,improve efficacy maintained tolerability treatment primary hypertension comparison felodipine metoprolol combination tablet monotherapy enalapril,multicentre double blind parallel group study patients mild moderate primary hypertension randomise week single blind placebo run period combination tablet felodipine metoprolol mg logimax mobloc astra daily enalapril mg daily blood pressure bp remain suboptimally control week supine diastolic bp mm hg h post dose dose double week week felodipine metoprolol reduced supine bp significantly enalapril mmhg mm hg respectively mean difference change bp treatment mm hg favour felodipine metoprolol p p statistically significant difference advantage felodipine metoprolol also see stand bp even though dose increase large proportion patient enalapril group felodipine metoprolol group enalapril treated patient achieve adequate bp control vs felodipine metoprolol p treatment well tolerate three patient treat felodipine metoprolol four enalapril discontinue treatment due adverse event similar number patient report adverse event treatment group conclusion combination tablet felodipine metoprolol mg daily reduce bp effectively enalapril mg daily h post dose result expect important observation treatment tolerate similar degree obviously considerable bp reduction may well tolerate main purpose demonstrate study,Andersson OK,1999,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1000724,9928753,Andersson OK,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000319: Adrenergic beta-Antagonists; D000368: Aged; D000806: Angiotensin-Converting Enzyme Inhibitors; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004311: Double-Blind Method; D004338: Drug Combinations; D004656: Enalapril; D015736: Felodipine; D005260: Female; D006801: Humans; D006973: Hypertension; D008790: Metoprolol; D008875: Middle Aged; D013607: Tablets; D016896: Treatment Outcome,,,https://openalex.org/W2405509171,183,22,2,1744,306,12,en,en
false,verapamil sr trandolapril combination therapy elderly hypertensive patient,total elderly hypertensive patient men woman age year diastolic blood pressure dbp mm hg inclusive treat fixed combination verapamil sr trandolapril follow week single blind placebo run period treatment start response dependent step dose titration period patient initiate dose step verapamil sr trandolapril mg normalise dbp mm hg titrate weekly interval dose step verapamil sr trandolapril mg dose step verapamil sr trandolapril mg first week month treatment patient normalise exclude participation study total duration treatment period month routine safety investigation perform prior completion treatment period verapamil sr trandolapril highly effective reduce blood pressure individual last visit active treatment also take non responders account mean reduction sbp dbp mm hg ci mm hg reduction occur first month treatment month patient enrol showed normalisation dbp mm hg responder normalisation reduction dbp least mm hg normalisation responder rate appear comparable stratify age subgroup year great verapamil sr trandolapril well tolerate evidence clinically relevant change routine laboratory safety variable rest ecg conclusion fix dose combination verapamil sr trandolapril effective safe alternative treatment elderly hypertensive patient,Holzgreve H,1999,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1000728,9928754,Holzgreve H; Compagnone D; Zilles P,article,"D016430: Clinical Trial; D018848: Controlled Clinical Trial; D016428: Journal Article; D016448: Multicenter Study; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000369: Aged, 80 and over; D000806: Angiotensin-Converting Enzyme Inhibitors; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D004305: Dose-Response Relationship, Drug; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D006973: Hypertension; D007211: Indoles; D008297: Male; D008875: Middle Aged; D016896: Treatment Outcome; D014700: Verapamil",,,https://openalex.org/W2033615181,82,9,1,1910,342,15,en,en
false,randomised double blind study compare nifedipine git mg bendrofluazide mg administer daily mild moderate hypertension,multicentre randomise double blind parallel group comparison nifedipine git mg adalat la daily bendrofluazide mg daily patient mild moderate hypertension conduct two hundred patient diastolic blood pressure bp range mm hg randomise active treatment week per protocol efficacy population treatment result clinically significant mean reduction trough diastolic bp nifedipine git mm hg bendrofluazide mm hg systolic bp nifedipine git mm hg bendrofluazide mm hg study demonstrate nifedipine git least equivalent bendrofluazide reduction trough diastolic bp one sided upper confidence limit mm hg inequivalence pre defined difference mean diastolic bp mm hg drug well tolerate overall incidence adverse event nifedipine git treatment group bendrofluazide treatment group common event incidence headache constipation flu syndrome vasodilatation nifedipine git headache nausea bendrofluazide increased incidence elevation plasma urea glucose observe patient treat bendrofluazide respectively compare treat nifedipine git respectively nifedipine git mg daily least equivalent bendrofluazide mg daily reduction blood pressure patient mild moderate hypertension,Isles CG,1999,J Hum Hypertens,https://doi.org/10.1038/sj.jhh.1000757,9928755,Isles CG; Kitchin NR,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016448: Multicenter Study; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't",D000368: Aged; D001539: Bendroflumethiazide; D001794: Blood Pressure; D002121: Calcium Channel Blockers; D004232: Diuretics; D004311: Double-Blind Method; D004334: Drug Administration Schedule; D005260: Female; D006801: Humans; D006973: Hypertension; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D049993: Sodium Chloride Symporter Inhibitors; D016896: Treatment Outcome,,,https://openalex.org/W1983114004,146,19,1,1651,296,8,en,en
true,safety nifedipine angina pectoris,abstract objective compare cardiovascular event rate patient stable angina receive nifedipine monotherapy combination therapy active drug control medlars search publish article english french german italian spanish supplement manual search bibliography identify randomize control trial meet protocol criterion blind article extract physician pooled risk death withdrawal cardiovascular event compute express odds ratio nifedipine formulation relative study control drug regimen thirty cardiovascular event report nifedipine exposure event active drug exposure unadjusted nifedipine versus control ci major event death nonfatal myocardial infarction stroke revascularization procedure ci increase angina ci event major event plus increased angina episode increased angina frequent immediate release nifedipine ci nifedipine monotherapy ci immediate release nifedipine significantly high sustained release extended release nifedipine p nifedipine monotherapy high nifedipine combination therapy p increased risk cardiovascular event patient stable angina nifedipine due primarily episode increased angina confine immediate release formulation nifedipine monotherapy,Stason WB,1999,Hypertension,https://doi.org/10.1161/01.hyp.33.1.24,9931077,Stason WB; Schmid CH; Niedzwiecki D; Whiting GW; Caubet JF; Cory D; Luo D; Ross SD; Chalmers TC,article,"D003160: Comparative Study; D016428: Journal Article; D017418: Meta-Analysis; D013485: Research Support, Non-U.S. Gov't","D000319: Adrenergic beta-Antagonists; D000787: Angina Pectoris; D002121: Calcium Channel Blockers; D003692: Delayed-Action Preparations; D004304: Dosage Forms; D004359: Drug Therapy, Combination; D005260: Female; D006801: Humans; D008297: Male; D008875: Middle Aged; D009543: Nifedipine; D009566: Nitrates; D016017: Odds Ratio; D010919: Placebos; D011446: Prospective Studies; D016032: Randomized Controlled Trials as Topic; D012307: Risk Factors; D012449: Safety; D013997: Time Factors; D014665: Vasodilator Agents",,,https://openalex.org/W2000446588,39,6,1,1748,317,9,en,en
true,ventricular rate control chronic atrial fibrillation daily activity program exercise crossover open label study five drug regimen,objective compare effect five pharmacologic regimens circadian rhythm exercise induced change ventricular rate vr patient chronic atrial fibrillation caf background systematic comparison standardized drug regimen h vr control caf report method patient male yr caf effect vr standardized daily regimen mg digoxin mg diltiazem cd mg atenolol mg digoxin mg diltiazem cd mg digoxin mg atenolol study week treatment assign random order vr data analyze anova repeated measure circadian phase difference evaluate cosinor analysis result h mean sd value vr bpm digoxin diltiazem atenolol digoxin diltiazem digoxin atenolol circadian pattern significant treatment group p vr digoxin atenolol significantly low digoxin p diltiazem p atenolol p time peak vr holter significantly delay regimen include atenolol p exercise digoxin digoxin atenolol treatment result high low mean vr respectively exercise time vr plot group nearly parallel p n exercise duration similar treatment group p n conclusion study indicate digoxin diltiazem single agent dos test least effective control ventricular rate atrial fibrillation daily activity digoxin atenolol produce effective rate control reflect synergistic effect av node data provide basis test effect chronic suppression diurnal fluctuation vr left atrial ventricular function caf,Farshi R,1999,J Am Coll Cardiol,https://doi.org/10.1016/s0735-1097(98)00561-0,9973007,Farshi R; Kistner D; Sarma JS; Longmate JA; Singh BN,article,"D016430: Clinical Trial; D003160: Comparative Study; D016428: Journal Article; D016449: Randomized Controlled Trial; D013485: Research Support, Non-U.S. Gov't","D000368: Aged; D000889: Anti-Arrhythmia Agents; D001262: Atenolol; D001281: Atrial Fibrillation; D002121: Calcium Channel Blockers; D002940: Circadian Rhythm; D018592: Cross-Over Studies; D004077: Digoxin; D004110: Diltiazem; D004359: Drug Therapy, Combination; D015716: Electrocardiography, Ambulatory; D015444: Exercise; D005260: Female; D005500: Follow-Up Studies; D006339: Heart Rate; D006352: Heart Ventricles; D006801: Humans; D008297: Male; D008875: Middle Aged",,,https://openalex.org/W2138806529,153,22,1,1978,393,15,en,en
